<SEC-DOCUMENT>0001613103-25-000091.txt : 20250620
<SEC-HEADER>0001613103-25-000091.hdr.sgml : 20250620
<ACCEPTANCE-DATETIME>20250620064620
ACCESSION NUMBER:		0001613103-25-000091
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		166
CONFORMED PERIOD OF REPORT:	20250425
FILED AS OF DATE:		20250620
DATE AS OF CHANGE:		20250620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medtronic plc
		CENTRAL INDEX KEY:			0001613103
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		FISCAL YEAR END:			0425

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36820
		FILM NUMBER:		251059026

	BUSINESS ADDRESS:	
		STREET 1:		BUILDING TWO PARKMORE BUSINESS PARK WEST
		CITY:			GALWAY
		STATE:			L2
		ZIP:			H91 4K49
		BUSINESS PHONE:		01135314381700

	MAIL ADDRESS:	
		STREET 1:		BUILDING TWO PARKMORE BUSINESS PARK WEST
		CITY:			GALWAY
		STATE:			L2
		ZIP:			H91 4K49

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Ltd
		DATE OF NAME CHANGE:	20150112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Holdings Ltd
		DATE OF NAME CHANGE:	20140711

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kalani I Ltd
		DATE OF NAME CHANGE:	20140709
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mdt-20250425.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349,d:c14a750e81984b18a679ba753642023e-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:mdt="http://www.medtronic.com/20250425" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdt-20250425</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-92">0001613103</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-93">4/25</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-94">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-95">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-96">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-97">H91 4K49</ix:nonNumeric><ix:nonNumeric contextRef="c-72" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-513">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-709">http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet</ix:nonNumeric><ix:nonNumeric contextRef="c-209" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-722">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="c-210" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-723">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="c-211" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-724">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="c-212" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-728">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-213" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-729">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-214" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-730">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-293" name="us-gaap:DebtInstrumentTerm" id="f-990">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="c-296" name="us-gaap:DebtInstrumentTerm" id="f-994">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-299" name="us-gaap:DebtInstrumentTerm" id="f-998">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1005">http://fasb.org/us-gaap/2024#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1006">http://fasb.org/us-gaap/2024#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-293" name="us-gaap:DebtInstrumentTerm" id="f-1024">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="c-296" name="us-gaap:DebtInstrumentTerm" id="f-1030">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-299" name="us-gaap:DebtInstrumentTerm" id="f-1036">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-312" name="us-gaap:DebtInstrumentTerm" id="f-1042">P8Y</ix:nonNumeric><ix:nonNumeric contextRef="c-315" name="us-gaap:DebtInstrumentTerm" id="f-1048">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-318" name="us-gaap:DebtInstrumentTerm" id="f-1054">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="c-321" name="us-gaap:DebtInstrumentTerm" id="f-1060">P8Y</ix:nonNumeric><ix:nonNumeric contextRef="c-324" name="us-gaap:DebtInstrumentTerm" id="f-1066">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-327" name="us-gaap:DebtInstrumentTerm" id="f-1072">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-330" name="us-gaap:DebtInstrumentTerm" id="f-1078">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-333" name="us-gaap:DebtInstrumentTerm" id="f-1084">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="c-336" name="us-gaap:DebtInstrumentTerm" id="f-1090">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-339" name="us-gaap:DebtInstrumentTerm" id="f-1096">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="c-342" name="us-gaap:DebtInstrumentTerm" id="f-1102">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-345" name="us-gaap:DebtInstrumentTerm" id="f-1108">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-348" name="us-gaap:DebtInstrumentTerm" id="f-1114">P12Y</ix:nonNumeric><ix:nonNumeric contextRef="c-351" name="us-gaap:DebtInstrumentTerm" id="f-1120">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-354" name="us-gaap:DebtInstrumentTerm" id="f-1126">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-357" name="us-gaap:DebtInstrumentTerm" id="f-1132">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-360" name="us-gaap:DebtInstrumentTerm" id="f-1138">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-363" name="us-gaap:DebtInstrumentTerm" id="f-1144">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-366" name="us-gaap:DebtInstrumentTerm" id="f-1150">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="c-369" name="us-gaap:DebtInstrumentTerm" id="f-1156">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-372" name="us-gaap:DebtInstrumentTerm" id="f-1162">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-375" name="us-gaap:DebtInstrumentTerm" id="f-1168">P19Y</ix:nonNumeric><ix:nonNumeric contextRef="c-378" name="us-gaap:DebtInstrumentTerm" id="f-1174">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-381" name="us-gaap:DebtInstrumentTerm" id="f-1180">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-384" name="us-gaap:DebtInstrumentTerm" id="f-1186">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-387" name="us-gaap:DebtInstrumentTerm" id="f-1192">P30Y</ix:nonNumeric><ix:nonNumeric contextRef="c-390" name="us-gaap:DebtInstrumentTerm" id="f-1198">P29Y</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1203">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1204">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" id="f-1251">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1261">http://fasb.org/us-gaap/2024#InterestExpenseNonoperating</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1350">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1351">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1352">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1353">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-25" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1490">http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2354">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2355">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2358">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2359">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2362">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2363">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-2725" escape="true">Subsequent Events</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdt-20250425.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>mdt:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>mdt:plaintiff</xbrli:measure></xbrli:unit><xbrli:unit id="claim"><xbrli:measure>mdt:claim</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>mdt:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>mdt:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.250SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.000SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2.625SeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.125SeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.375SeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.000SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.650SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.625SeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.000SeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.125SeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.750SeniorNotesDue2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.375SeniorNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.875SeniorNotesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2.250SeniorNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.500SeniorNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.375SeniorNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4.150SeniorNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.750SeniorNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.625SeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4.150SeniorNotesDue2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:EnterpriseExcellenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:SimplificationRestructuringProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-27</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2015And2020CommercialPaperProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:TwoThousandTwentyOneStockAwardAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:ColibriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-08</xbrli:startDate><xbrli:endDate>2023-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-25</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-27</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-29</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic14a750e81984b18a679ba753642023e_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">April&#160;25</ix:nonNumeric>, 2025</ix:nonNumeric>.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.<br/>For the transition period from __________ to __________</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-36820</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><img src="mdt-20250425_g1.jpg" alt="mdtlogo2b05.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:448px" id="i-1"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Medtronic plc</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:38.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">Ireland</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">98-1183488</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">Building Two, Parkmore Business Park West</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Galway</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-12">Ireland</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">+<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-13">353</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">1</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">438-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Ordinary shares, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">MDT</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-19">0.250% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-20">MDT/25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-22">0.000% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-23">MDT/25A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-24">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-25">2.625% Senior Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-26">MDT/25B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-27">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-28">1.125% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-29">MDT/27</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-30">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-31">0.375% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-32">MDT/28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-33">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-34">3.000% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-35">MDT/28A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-36">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:Security12bTitle" id="f-37">3.650% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:TradingSymbol" id="f-38">MDT/29</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-39">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:Security12bTitle" id="f-40">1.625% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:TradingSymbol" id="f-41">MDT/31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-42">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:Security12bTitle" id="f-43">1.000% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:TradingSymbol" id="f-44">MDT/31A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-45">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:Security12bTitle" id="f-46">3.125% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:TradingSymbol" id="f-47">MDT/31B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-11" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-48">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:Security12bTitle" id="f-49">0.750% Senior Notes due 2032</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:TradingSymbol" id="f-50">MDT/32</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-12" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-51">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:Security12bTitle" id="f-52">3.375% Senior Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:TradingSymbol" id="f-53">MDT/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-13" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-54">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:Security12bTitle" id="f-55">3.875% Senior Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:TradingSymbol" id="f-56">MDT/36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-14" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-57">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:Security12bTitle" id="f-58">2.250% Senior Notes due 2039</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:TradingSymbol" id="f-59">MDT/39A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-15" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-60">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:Security12bTitle" id="f-61">1.500% Senior Notes due 2039</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:TradingSymbol" id="f-62">MDT/39B</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-16" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-63">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:Security12bTitle" id="f-64">1.375% Senior Notes due 2040</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:TradingSymbol" id="f-65">MDT/40A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-17" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-66">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:Security12bTitle" id="f-67">4.150% Senior Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:TradingSymbol" id="f-68">MDT/43A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-18" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-69">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:Security12bTitle" id="f-70">1.750% Senior Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:TradingSymbol" id="f-71">MDT/49</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-19" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-72">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:Security12bTitle" id="f-73">1.625% Senior Notes due 2050</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:TradingSymbol" id="f-74">MDT/50</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-20" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-75">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:Security12bTitle" id="f-76">4.150% Senior Notes due 2053</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:TradingSymbol" id="f-77">MDT/53</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-21" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-78">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-79">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-80">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-81">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-82">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"/><td style="width:18.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-83">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-84">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-85">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicate&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has &#64257;led a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting &#64257;rm that prepared or issued its audit report.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-86">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-87">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-88">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 25, 2024, based on the closing price of $90.59 as reported on the New York Stock Exchange: approximately $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-89">116.2</ix:nonFraction> billion. Number of Ordinary Shares outstanding on June&#160;17, 2025: <ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-90">1,281,264,703</ix:nonFraction></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-91" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for its 2025 Annual General Meeting are incorporated by reference into Part III hereof.</span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.600%"><tr><td style="width:1.0%"/><td style="width:2.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_13">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_16">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_19">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_19">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_22">1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_22">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_25">1C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_25">Cybersecurity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_25">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_28">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_28">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_31">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_31">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_34">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_34">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_37">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_40">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_40">Market for Medtronic&#8217;s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_40">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_43">6. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_43">(Reserved)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_43">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_46">7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_46">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_121">7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_121">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_124">8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_124">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_124">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_127">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-98">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_127">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_130">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_130">51</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_148">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_148">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_211">9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_211">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_211">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_214">9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_214">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_214">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_217">9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_217">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_217">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_220">9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_220">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_220">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_223">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_226">10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_226">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_226">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_229">11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_229">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_229">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_232">12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_232">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_232">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_235">13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_235">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_235">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_238">14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_238">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_238">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_241">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_247">15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_247">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_247">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_250">16.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_250">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_250">116</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_253">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_253">117</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, and other written reports of Medtronic plc, organized under the laws of Ireland (together with its consolidated subsidiaries, Medtronic, the Company, or we, us, or our), and oral statements made by or with the approval of one of the Company&#8217;s executive officers from time to time, may include &#8220;forward-looking&#8221; statements. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy and plans, objectives of management for future operations and current expectations or forecasts of future results, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Our forward-looking statements may include statements related to: our growth and growth strategies; developments in the markets for our products, therapies and services; financial results; product development launches and effectiveness; research and development strategy; regulatory approvals; competitive strengths; the potential or anticipated direct or indirect impact of public health crises, geopolitical conflicts, or changing governmental executive actions and regulations (including relating to global trade policies, enforcement priorities and compliance requirements), on our business, results of operations and/or financial condition; restructuring and cost-saving initiatives; intellectual property rights; litigation and tax matters; governmental proceedings and investigations; mergers, acquisitions, and divestitures; market acceptance of our products, therapies and services; accounting estimates; financing activities; ongoing contractual obligations; working capital adequacy; the value of our investments; our effective tax rate; our expected returns to shareholders; and sales efforts. In some cases, such statements may be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;looking ahead,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and similar words or expressions. Forward-looking statements in this Annual Report include, but are not limited to, statements regarding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our ability to drive long-term shareholder value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development and future launches of products and continued or future acceptance of products, therapies and services in our segments; expected timing for completion of research studies relating to our products; integration of new technologies, including artificial intelligence (AI) and data analytics, into our products, therapies and services; market positioning and performance of our products, including stabilization of certain product markets; divestitures and the potential benefits thereof; the costs and benefits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; our ability to meet growing demand for our existing products; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding the potential impact of changing governmental executive actions and regulations (including relating to global trade policies, enforcement priorities and compliance requirements), on our business; our expectations regarding healthcare costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; our human capital management with respect to our global workforce; and the potential impact of our compliance with governmental regulations and accounting guidance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the &#8220;Risk Factors&#8221; section and elsewhere in our Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled &#8220;Government Regulation&#8221; within &#8220;Item 1. Business&#8221; and &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K, as well as those related to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">competition in the medical device industry,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in regulatory approvals,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reduction or interruption in our supply,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to complete or achieve the intended benefits of acquisitions or divestitures,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse regulatory action,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">laws and governmental regulations,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation results,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">quality problems,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">healthcare policy changes,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">public health crises,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cybersecurity and privacy incidents,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">international operations, including the impact of armed conflicts,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">self-insurance,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">commercial insurance,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in applicable tax rates,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">positions taken by taxing authorities,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreasing selling prices and pricing pressure,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">liquidity shortfalls,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in currency exchange rates,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inflation, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disruption of our current plans and operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ic14a750e81984b18a679ba753642023e_16"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g2.jpg" alt="BusinessOverview.jpg" style="height:152px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-2"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company. Medtronic was founded in 1949 and today serves healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. We remain committed to a mission written by our founder in 1960 that directs us &#8220;to contribute to human welfare by the application of biomedical engineering in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Mission &#8212; to alleviate pain, restore health, and extend life &#8212; empowers us to engineer the extraordinary and deliver better outcomes for our world. We are a company of dedication, honesty, integrity, and service. Building on this strong foundation, we are embracing our role as a healthcare technology leader and evolving our business strategy in three key areas:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate innovation-driven growth: The combination of our attractive end markets, recent product launches and robust pipeline is expected to enable continued strong revenue growth. We aim to bring inventive and disruptive technology to large healthcare opportunities which enables us to better meet patient needs. Patients around the world deserve access to our life-saving products, and we are driven to use our local presence and scale to increase the adoption of our products and services in markets around the globe.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deliver superior outcomes and better experiences for patients and providers: We listen to our patients and customers to better understand the challenges they face. From the patient journey, to creating agile partnerships that produce novel solutions, to making it easier for our customers to deploy our therapies &#8212; what we do is anchored in deep insight, and creates simpler, superior experiences.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Turn data, artificial intelligence (AI), and automation into action: We are confident in our ability to maximize new technology, AI, and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Neuroscience Portfolio, the Medical Surgical Portfolio, and the Diabetes Operating Unit. For more information regarding our segments, please see Note 19 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_2631"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIOVASCULAR PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cardiovascular Portfolio is made up of the Cardiac Rhythm &amp; Heart Failure, Structural Heart &amp; Aortic, and Coronary &amp; Peripheral Vascular divisions. The primary medical specialists who use our Cardiovascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular, cardiothoracic, and vascular surgeons, and interventional cardiologists and radiologists. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><img src="mdt-20250425_g3.jpg" alt="CV Product Images.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-3"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiac Rhythm &amp; Heart Failure </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cardiac Rhythm &amp; Heart Failure division includes the following Operating Units: Cardiac Rhythm Management and Cardiac Ablation Solutions. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Our products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, and information systems for the management of patients with Cardiac Rhythm &amp; Heart Failure devices. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardiac pacemakers including the Azure MRI SureScan, Adapta, Attesta MRI SureScan, and the Micra transcatheter pacing system. Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity. The 3830 lead, with His-bundle and left bundle branch capabilities, effectively covers all current forms of conduction system pacing and sensing. The Micra transcatheter pacing system, which is leadless and does not have a subcutaneous device pocket like a conventional pacemaker, includes the Micra VR and the Micra AV device families. Both pacemakers treat patients with atrioventricular block.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardioverter defibrillators (ICDs), including the Aurora Extravascular-ICD, Visia AF MRI SureScan, Evera MRI SureScan, Primo MRI, and the Cobalt and Crome family of BlueSync-enabled ICDs, as well as defibrillator leads, including the Sprint Quattro Secure lead.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable cardiac resynchronization therapy devices (CRT-Ds and CRT-Ps) including the Claria/Amplia/Compia family of MRI Quad CRT-D SureScan systems and the Cobalt and Crome portfolio of BlueSync-enabled CRT-Ds, as well as the Percepta/Serena/Solara family of MRI Quad CRT-P SureScan systems. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cardiac ablation products include a full suite of electrophysiology solutions to treat patients with arrhythmias, including paroxysmal and persistent AF. The portfolio includes the Arctic Front Advanced Cardiac Cryoblation System, PulseSelect single shot Pulsed Field Ablation catheter, the Sphere-9 focal catheter, providing high density mapping capabilities combined with dual radio frequency and pulsed field energies to deliver ablation lesions, and Affera Mapping and Navigation System with Prism-1 software aimed at integrating clinical information to improve patient outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insertable cardiac monitoring systems, including the Reveal LINQ and LINQ II. These devices are for patients who experience transient symptoms such as dizziness, palpitation, syncope (fainting) and chest pain, as well as Cryptogenic Stroke patients, which may indicate a cardiac arrhythmia that requires long-term monitoring or ongoing management. Both portfolio devices have unmatched accuracy and a streamlined workflow with AccuRhythm AI algorithms to reduce clinic workload and data burden. LINQ II, the premium portfolio device, offers extended device longevity and remote programming capabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TYRX products, including the Cardiac and Neuro Absorbable Antibacterial Envelopes, which are designed to stabilize electronic implantable devices and help prevent infection associated with implantable pacemakers and defibrillators. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Remote monitoring services and patient-centered software to enable efficient care coordination as well as services related to hospital operational efficiency. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medtronic stopped the distribution and sale of the HVAD System in June 2021. We continue a support program for patients with HVAD devices, and for caregivers and healthcare professionals who participate in their care.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Structural Heart &amp; Aortic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Structural Heart &amp; Aortic division includes the following Operating Units: Structural Heart &amp; Aortic and Cardiac Surgery. The division includes therapies to treat heart valve disorders and aortic disease. Our devices include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, surgical ablation products, and a comprehensive line of products and therapies to treat aortic disease, such as aneurysms, dissections, and transections. Principal products offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CoreValve family of aortic valves, including the Evolut PRO, Evolut PRO+, Evolut FX, and Evolut FX+ TAVR systems for transcatheter aortic valve replacement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Surgical valve replacement and repair products for damaged or diseased heart valves, including both tissue and mechanical valves; blood-handling products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during arrested heart surgery; and surgical ablation systems and positioning and stabilization technologies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Endovascular stent grafts and accessories, including the Endurant II Stent Graft System for the treatment of abdominal aortic aneurysms, the Valiant Captivia Thoracic Stent Graft System for thoracic endovascular aortic repair procedures, and the Heli-FX EndoAnchor System. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transcatheter Pulmonary Valves, including Harmony Transcatheter Pulmonary Valve (TPV) and Delivery Catheter System and Melody TPV/Ensemble II Delivery System. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronary &amp; Peripheral Vascular</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Coronary &amp; Peripheral Vascular division includes the following Operating Units: Coronary &amp; Renal Denervation and Peripheral Vascular Health. The division is comprised of a comprehensive line of products and therapies to treat coronary artery disease as well as peripheral vascular disease and venous disease. Our products include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guide wires, diagnostic catheters, and accessories, peripheral drug coated balloons, stent and angioplasty systems, carotid embolic protection systems for the treatment of vascular disease outside the heart, and products for superficial and deep venous disease. Principal products offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Percutaneous Coronary Intervention products including our Onyx Frontier and Resolute Onyx drug-eluting stents, Euphora balloons, and Launcher guide catheters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat hypertension including our Symplicity Spyral Renal Denervation (RDN) system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Percutaneous angioplasty balloons including the IN.PACT family of drug-coated balloons, vascular stents including the Abre venous stent, directional atherectomy products including the HawkOne directional atherectomy system, and other procedure support tools. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat superficial venous diseases in the lower extremities including the ClosureFast radiofrequency ablation system and the VenaSeal Closure System.</span></div><div id="ic14a750e81984b18a679ba753642023e_2664"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROSCIENCE PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neuroscience Portfolio is made up of the Cranial &amp; Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The primary medical specialists who use the products of this group include spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, interventional radiologists, and ear, nose, and throat specialists.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><img src="mdt-20250425_g4.jpg" alt="NS Product Images.jpg" style="height:140px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-4"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cranial &amp; Spinal Technologies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Cranial &amp; Spinal Technologies division and Operating Unit develops, manufactures, and markets an integrated portfolio of devices and therapies for&#160;surgical technologies designed to improve the precision and workflow of neurological procedures, and a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. The division also provides biologic solutions for the orthopedic markets and offers unique and highly differentiated imaging, navigation, power instruments, and robotic guidance systems used in spine and cranial procedures. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Neurosurgery products, including platform technologies, implant therapies, and advanced energy products through the AiBLE spine technology ecosystem. This includes our StealthStation S8 surgical navigation system, Stealth Autoguide cranial robotic guidance platform, O-arm Imaging System, Mazor robotic guidance systems used in robot-assisted spine procedures, UNiD adaptive spine intelligence AI-driven technology for surgical planning and personalized spinal implants, and our Midas Rex surgical drills, including our MR8 high-speed drill system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. These products include our CATALYFT PL expandable interbody spacers, CD Horizon ModuLeX spinal system, and T2 STRATOSPHERE expandable corpectomy system. These products can also include titanium interbody implants and surface technologies, such as our Adaptix interbody system and incorporated Titan interbody fusion device with nanoLOCK technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products that facilitate less invasive thoracolumbar surgeries, including the CD Horizon Solera Voyager percutaneous fixation system and various retractor systems to access the spine through smaller incisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products to treat conditions in the cervical region of the spine, including the ZEVO anterior cervical plate system, the Infinity Occipitocervical-Upper Thoracic (OCT) System, and Prestige LP cervical discs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologic solutions products, including our Infuse Bone Graft (InductOs in the European Union (E.U.)), which contains a recombinant human bone morphogenetic protein-2, rhBMP-2, for certain spinal, trauma, and oral maxillofacial applications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Demineralized bone matrix products, including Magnifuse, GRAFTON/GRAFTON PLUS, and the Mastergraft family of synthetic bone graft products &#8211; Matrix, Putty, Strip, and Granules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Therapies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Specialty Therapies division includes the following Operating Units: Neurovascular; Ear, Nose, and Throat (ENT); and Pelvic Health. The division develops, manufactures, and markets products and therapies to treat patients afflicted with acute ischemic and hemorrhagic stroke, ENT diseases, and patients suffering from overactive bladder, and (non-obstructive) urinary retention. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Neurovascular products to treat diseases of the vasculature in and around the brain. This includes coils, neurovascular stent retrievers, and flow diversion products, as well as access and delivery products to support procedures. Products also include the Pipeline Flex and Pipeline Vantage embolization devices with Shield Technology, endovascular treatments for large or giant wide-necked brain aneurysms, the portfolio of Solitaire revascularization devices for treatment of acute ischemic stroke, the Riptide aspiration system, the Onyx Liquid Embolic System, and a portfolio of associated access catheters including our React aspiration catheters also for the treatment of acute ischemic stroke. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ENT products, including the Straightshot M5 microdebrider handpiece, the Integrated Power Console (IPC) system, NIM Vital nerve monitoring systems, Propel and Sinuva Sinus Implants, StealthStation ENT and StealthStation FlexENT navigation systems, as well as products for hearing restoration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelvic health products, including our InterStim X and InterStim II recharge-free neurostimulators, InterStim Micro rechargeable neurostimulators, and SureScan MRI leads. Our NURO System delivers Percutaneous Tibial Neuromodulation therapy to treat overactive bladder, (non-obtrusive) urinary retention, and chronic fecal incontinence. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuromodulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Neuromodulation division and Operating Unit develops, manufactures, and markets spinal cord stimulation and brain modulation systems, implantable drug infusion systems for chronic pain, as well as interventional products. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Spinal cord stimulation products, including rechargeable and recharge-free devices and a large selection of leads used to treat chronic back and/or limb pain and chronic pain resulting from diabetic peripheral neuropathy. This includes the Inceptiv spinal cord stimulation system which offers a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, Intellis (rechargeable) and Vanta (recharge-free) spinal cord stimulation systems, with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AdaptiveStim and SureScan MRI Technology, DTM (differential target multiplexed) proprietary waveform, and the Evolve workflow algorithm, and Snapshot reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Brain modulation products, including those for the treatment of Parkinson's disease, essential tremor, refractory epilepsy, severe, treatment-resistant obsessive-compulsive disorder (approved under a Humanitarian Device Exemption (HDE) in the U.S.), and chronic, intractable primary dystonia (approved under a HDE in the U.S.). Specifically, the Percept family of neurostimulators with proprietary adaptive BrainSense technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implantable drug infusion systems, including our SynchroMed III Implantable Infusion System, which deliver small quantities of drug directly into the intrathecal space surrounding the spinal cord, to help manage chronic pain, cancer pain, and severe spasticity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interventional products, including our full Kyphon portfolio of minimally invasive Kyphoplasty and Vertebroplasty solutions for the treatment of vertebral compression fractures, including bipedicular and unipedicular access options, bone access tools, inflatable balloon tamps, cement and delivery systems, as well as biopsy and specialty devices. The OsteoCool cooled radiofrequency ablation system with simultaneous, dual-probe capabilities and algorithms for the treatment of painful metastatic bone lesions. Emprint Microwave with Thermosphere technology for the treatment of non-resectable liver tumors. As well as the Accurian nerve ablation system, which conducts radio frequency ablation of nerve tissues.</span></div><div id="ic14a750e81984b18a679ba753642023e_2699"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAL SURGICAL PORTFOLIO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Surgical Portfolio includes the Surgical &amp; Endoscopy and Acute Care &amp; Monitoring divisions. Products and therapies of this group are used primarily by healthcare systems, physicians' offices, ambulatory care centers, and other alternate site healthcare providers. While less frequent, some products and therapies are also used in home settings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g5.jpg" alt="Med Surg Product Images.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-5"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surgical &amp; Endoscopy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Surgical &amp; Endoscopy division includes the following Operating Units: Surgical and Endoscopy. The division develops, manufactures, and markets advanced and general surgical products, including advanced stapling devices, vessel sealing instruments, wound closure products, electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, minimally invasive gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions that are typically, but not exclusively, addressed by surgeons. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced stapling and energy products, including the Tri-Staple technology platform for endoscopic stapling, including the Endo GIA reloads and reinforced reloads with Tri-Staple technology and the Endo GIA ultra universal stapler, the Signia powered stapling system, the LigaSure exact dissector and L-Hook Laparoscopic Sealer/Divider, and the Sonicision 7 curved jaw cordless ultrasonic dissection system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Electrosurgical hardware and instruments, including the Valleylab FT10 and FX8 energy platforms, the Valleylab FT10 vessel sealing generator, and the Force TriVerse electrosurgical pencils.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Robotic and digital surgery technologies, including the Hugo robotic-assisted surgery (RAS) system designed for a broad range of soft-tissue procedures, and Touch Surgery Enterprise, an AI-powered surgical video management solution for the operating room.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products designed for the treatment of hernias, including the AbsorbaTack absorbable mesh fixation device for hernia repair, MaxTack motorized fixation device designed for minimally invasive hernia fixation, the Symbotex composite mesh for surgical laparoscopic and open ventral hernia repair, and ProGrip laparoscopic self-fixating mesh, a self-gripping, biocompatible solution for inguinal hernias.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suture and wound closure products, including the V-Loc barbed sutures, the Polysorb braided absorbable sutures, and the Monosof absorbable monofilament nylon sutures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Endoscopy products, including the GI Genius intelligent endoscopy module, the PillCam capsule endoscopy systems, the Bravo calibration-free reflux testing systems, the Endoflip 300 Impedance Planimetry System, the Emprint ablation system with Thermosphere Technology, the ManoScan high-resolution manometry system, the Barrx platform through ablation with the Barrx 360 Express catheter, the Cool-tip radiofrequency ablation system, the Beacon delivery system, and the Nexpowder endoscopic hemostasis system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acute Care &amp; Monitoring</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Acute Care &amp; Monitoring division develops, manufactures, and markets products in the fields of patient monitoring and airway management. Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on blood oxygen management and remote monitoring, including Nellcor pulse oximetry monitors and sensors, Healthcast Connectivity Solutions, and the RespArray patient monitor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on reducing perioperative complications, including Bispectral Index (BIS) brain monitoring technology, INVOS cerebral/somatic oximetry systems, and WarmTouch convective warming. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products focused on airway management and respiratory monitoring, including Microstream capnography monitors, McGRATH MAC video laryngoscopes, Shiley endotracheal tubes, Shiley tracheostomy tubes, and DAR Breathing Systems.</span></div><div id="ic14a750e81984b18a679ba753642023e_2730"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIABETES OPERATING UNIT</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diabetes Operating Unit develops, manufactures, and markets products and services for the management of Type 1 and Type 2 diabetes. The primary medical specialists who use and/or prescribe our Diabetes products are endocrinologists and primary care physicians. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><img src="mdt-20250425_g6.jpg" alt="Diabetes Product Images.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-6"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal products and services offered include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insulin pumps and consumables, including the MiniMed 780G system, powered by SmartGuard technology. The MiniMed 780G system provides smartphone and Bluetooth connectivity, a meal-time detection system, an adjustable glucose target down to 100 mg/dl, and has the capability to continuously deliver background insulin and monitor sugar levels.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuous glucose monitoring (CGM) systems include the Guardian Connect CGM system and Simplera platform. Both systems are worn by patients capturing glucose data to reveal patterns and potential problems, such as hyperglycemic and hypoglycemic episodes. The Simplera platform's discreet design simplifies the insertion and wear experience through the integration of the Simplera CGM, as a Smart Multiple Daily Injections (MDI) system, and the InPen with the Simplera Sync sensor and the MiniMed 780G system, offering disposable capabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The InPen smart insulin pen system combines a reusable Bluetooth-enabled insulin pen with an intuitive mobile app that helps users administer the appropriate insulin dose. The InPen application integrates with our CGM data to provide real-time CGM readings alongside insulin dose information.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, we announced our intention to separate the Diabetes business, with the intention to create a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement. </span></div><div id="ic14a750e81984b18a679ba753642023e_2565"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic Workforce Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic&#8217;s employees deliver on our Mission every day. We empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. We strive to be the employer of choice for the best and brightest global talent, where employees can grow and develop fulfilling careers. We aspire to create an inclusive, diverse, and equitable workplace that fosters innovation and creativity, and where employees feel a sense of belonging and well-being. Medtronic has over 95,000 full-time employees, of which 44% are based in the U.S. or Puerto Rico. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inclusion</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that improving health for people from all walks of life depends on our ability to unleash the creative power of our global employees. By breaking down barriers, we open doors for everyone, driving opportunity, progress, and prosperity around the world. Our commitment to inclusion is a core element of the Medtronic Mission, and we integrate these principles throughout our Company to ensure every operating unit, team, and leader recognizes and celebrates the value of diverse experiences and backgrounds. Additionally, Medtronic employee resource groups (ERGs) and Networks are employee-led affinity groups that provide career development and networking opportunities to all employees and strengthen ties between employees of many different backgrounds, cultures, and interests.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pay Equity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our most recent reported period available, in the United States, we have achieved 100% pay equity for gender and ethnically diverse employees. Globally we have achieved 99% pay equity for gender. We are actively working to resolve any remaining pay inequities by continuing to expand the annual pay equity analyses for each country we operate in. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Workforce Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation framework is designed to provide market competitive pay for the value and contributions of our employees. We are committed to transparent communications on compensation. Our competitive approach to compensation reflects industry benchmarks and local market standards. Our programs include annual and long-term equity-based incentives that provide the means to share in the Company&#8217;s success, based on business and individual performance. To attract and retain the best leaders, we offer competitive benefits and cash and equity incentives. We reward high-performing employees with an ownership stake in the Company through restricted stock, and employees have the opportunity to purchase stock at a significant discount through our Employee Stock Purchase Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Learning &amp; Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skills and dedication of our employees drive our business performance. Our comprehensive professional development programs empower our people to build rewarding careers and help us attract world-class talent from global and diverse populations. Our suite of professional development programs ensures that our employees, regardless of level, location, language or learning preferences, have access to opportunities to develop and grow.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have shifted away from degree requirements to focus on skills-based certification for certain roles within Medtronic. Additionally, as members of the Multiple Pathways Initiative, we have used a skills-based approach to offering opportunities to expanded pools of external talent that have previously been held back due to lack of access to undergraduate education. Internally, eligible U.S. and Puerto Rico employees can now participate through MAPS (Medtronic Advancement Pathways and Skill-building) in undergraduate courses from top-tier universities to enhance or obtain new skills, at no cost to the employee. We have opened opportunities for employees who have been otherwise restricted from career advancement due to degree requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Engagement and Culture</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our Organizational Health Survey, we gain valuable insight into the Medtronic employee experience and identify where we can improve in key priority areas: 1) Employee Engagement, 2) Inclusion, 3) Innovation, 4) Ethics and 5) Quality culture as part of our commitment to Put Patients First in our everyday decisions and actions. In our most recent survey ending in the fourth quarter of fiscal year 2025, more than 88% of our employees responded. Medtronic carefully reviews and implements actions based on employee feedback in order to partner and create an inclusive, innovative and supportive environment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture is critical to achieving our vision. The Medtronic Mindset builds on our core values of integrity, quality, inclusion, and collaboration. It urges us to act boldly, compete to win, move with speed and decisiveness, foster belonging, and deliver results&#8230; the right way. Our culture helps us meet the needs of our patients and customers, and ensures our Mission endures for many years to come.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health &amp; Safety</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a large, global employer, our ability to attract and retain talent is based in part on our commitment to maintain a safe workplace and support the well-being of our employees. Medtronic has a comprehensive approach to providing robust support for our employees and their families in natural disasters, public health crises, civil unrest and armed conflicts, bereavement, and other challenging events. Along with other programs, the Medtronic Employee Assistance Program and the Medtronic Employee Emergency Assistance Fund have historically supported employees and their families when faced with difficult times by providing a variety of services such as mental health, safety, and financial resources and support at no cost. These programs have proven invaluable in navigating our employees through unique challenges, including in fiscal year 2025. The Medtronic Employee Emergency Assistance Fund is supported by donations from employees and the Medtronic Foundation, and over the last five years has provided $4 million in grants to employees experiencing unexpected events creating a financial hardship.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on Human Capital Management at Medtronic, please refer to our 2024 Impact Report available on our company website.</span></div><div id="ic14a750e81984b18a679ba753642023e_2598"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER FACTORS IMPACTING OUR OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which we participate are subject to rapid technological advances and innovations. Constant improvement of existing products and introduction of new products is necessary to maintain market leadership. Our research and development (R&amp;D) efforts are directed toward maintaining or achieving technological leadership in the markets we serve to help ensure that patients using our devices and therapies receive the most advanced and effective treatment possible. We remain committed to developing technological enhancements and new indications for existing products, and less invasive and new technologies for new and emerging markets to address unmet patient needs. That commitment leads to our initiation and participation in hundreds of clinical trials each fiscal year as the demand for clinical and economic evidence remains high. Furthermore, our development activities are intended to help reduce patient care costs and the length of hospital stays in the future. We have not engaged in significant customer or government-sponsored research.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D activities include improving existing products and therapies, expanding their indications and applications for use, developing new therapies and procedures, and entering into arrangements with third parties to fund the development of certain technologies. We continue to focus on optimizing innovation, improving our R&amp;D productivity, driving growth in international markets, generating clinical evidence, and assessing our R&amp;D programs based on their ability to address unmet clinical needs, produce better patient outcomes, and create new standards of care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements, including non-disclosure agreements, to protect our business and proprietary technology. In addition, we have entered into exclusive and non-exclusive licenses, and covenants not to sue, relating to a wide array of third-party technologies. In the aggregate, these intellectual property assets, agreements, and licenses are of material importance to our business; however, we believe that no single intellectual property asset, agreement, or license is material in relation to our business as a whole. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an industry characterized by extensive intellectual property litigation. Intellectual property litigation may result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products or result in significant royalty payments in order to continue selling the products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of intellectual property actions, the outcomes of which may not be known for prolonged periods of time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Distribution</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our medical devices and therapies through a combination of direct sales representatives and independent distributors globally. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals. Our medical supply products are used primarily in hospitals, ambulatory surgical centers, and alternate care facilities, such as home care and long-term care facilities, and are marketed to materials managers, group purchasing organizations (GPOs) and integrated delivery networks (IDNs). We often negotiate with GPOs and IDNs, which enter into supply contracts for the benefit of their member facilities. Our four largest markets are the U.S., Western Europe, China, and Japan. International markets are an area of increasing focus and opportunity, as we believe they remain under-penetrated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketing and sales strategy is focused on rapid, cost-effective delivery of high-quality products to a diverse group of customers worldwide. To achieve this objective, our marketing and sales teams are organized around physician specialties. This focus enables us to develop highly knowledgeable and dedicated sales representatives who are able to foster strong relationships with physicians and other customers and enhance our ability to support our customers and cross-sell complementary products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not dependent on any single customer for more than 10 percent of our total net sales. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition, Industry, and Cost Containment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in both the therapeutic and diagnostic medical markets in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> more</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our product lines face a mix of competitors ranging from large manufacturers with multiple business lines to small manufacturers offering a limited selection of products. In addition, we face competition from providers of other medical therapies, such as pharmaceutical companies, including those producing glucagon-like peptide-1s (GLP-1s).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major shifts in industry market share have occurred in connection with product corrective actions, physician advisories, safety alerts, results of clinical trials to support superiority claims, and publications about our products, reflecting the importance of product quality, product efficacy and quality systems in the medical device industry. In the current environment of managed care, economically motivated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, competitively priced product offerings are essential to our business. In order to continue to compete effectively, we must continue to create or acquire advanced technology, incorporate this technology into proprietary products, obtain regulatory approvals in a timely manner, maintain high-quality manufacturing processes, and successfully market these products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and private sector initiatives to limit the growth of healthcare costs, including price regulation, competitive pricing, bidding and tender mechanics, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements, are continuing in many countries where we do business, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, private healthcare insurance, managed-care plans, and volume-based procurement tenders in China, have attempted to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement to outcomes, shifting to population health management, and other mechanisms. Hospitals, which purchase our technology, are also seeking to reduce costs through a variety of mechanisms, including, for example, centralized purchasing, and in some cases, limiting the number of vendors that may participate in the purchasing program. Hospitals are also aligning interests with physicians through employment and other arrangements, such as gainsharing, where a hospital agrees with physicians to share any realized cost savings resulting from changes in practice patterns such as device standardization. This has created an increased level of price sensitivity among customers for our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Production and Availability of Raw Materials</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture products at facilities located in various countries throughout the world. We purchase many of the components and raw materials used in manufacturing our products from numerous suppliers in various countries. Certain components and raw materials are available only from a sole supplier. We work closely with our suppliers and have plans and measures in place to help ensure continuity of supply while maintaining high quality and reliability. Generally, we have been able to obtain adequate supplies of such raw materials and components. However, due to the U.S. FDA&#8217;s manufacturing requirements and those of other regulatory authorities, we may not be able to quickly establish additional or replacement sources for certain components or materials if we experience a sudden or unexpected reduction or interruption in supply and are unable to develop alternative sources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information related to our manufacturing facilities refer to &#8220;Item 2. Properties&#8221; in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and products are subject to extensive regulation by numerous government agencies, including the U.S. FDA, European regulatory authorities such as the Medicines and Healthcare products Regulatory Agency in the United Kingdom, the Health Products Regulatory Authority in the Republic of Ireland and the Federal Institute for Drugs and Medical Devices in Germany, the China </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">National Medical Product Administration (NMPA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other government agencies inside and outside the U.S. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and post-marketing surveillance of our products. Our business is also affected by data privacy, security and digital health laws, such as the European Health Data Space (EHDS) regulation, as well as government payor cost containment initiatives, and environmental health and safety laws and regulations. In addition, as a result of the release and availability of Artificial Intelligence (AI) technologies, including generative AI platforms, we have seen a global trend toward more comprehensive regulation of AI designed to ensure the ethical use, security, and privacy of AI and create standards for transparency, accountability, and fairness, including the EU AI Act, which may impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Approval and Monitoring</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many jurisdictions where we do business, including the U.S., the E.U., Japan, and China, our products are subjected to approval and other regulatory requirements regarding performance, safety, and quality. For instance, authorization to commercially distribute a new medical device in the U.S. is generally obtained in one of two primary ways. The first, known as pre-market notification or the 510(k) process, requires us to demonstrate that our medical device is substantially equivalent to a legally marketed medical device. The second, more rigorous process, known as pre-market approval, requires us to independently demonstrate that a medical device is safe and effective for its intended use. This process is generally much more time-consuming and expensive than the 510(k) process.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U., conformity with the marketing authorization requirements is represented by the CE Mark. To obtain a CE Mark, defined products must meet minimum standards of performance, safety, and quality (i.e., the essential requirements), and then, according to their classification, comply with one or more of a selection of conformity assessment routes. The competent authorities of the E.U. countries separately regulate the clinical research for medical devices and the market surveillance of products once they are placed on the market. The Medical Device Regulation was published by the E.U. in 2017, and it imposes significant additional pre-market and post-market requirements (EU MDR). The regulation provided an implementation period and became effective on May 26, 2021. The European Commission extended the implementation period to the end of 2027 for high-risk devices and to the end of 2028 for medium and low risk devices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global regulatory environment is increasingly stringent and unpredictable. While harmonization of global regulations has been pursued, requirements continue to differ among countries. We expect this global regulatory environment will continue to evolve, which could impact the cost, the time needed to approve, and ultimately, our ability to maintain existing approvals or obtain future approvals for our products. In addition, reported potential workforce reductions and agency reorganization at the U.S. FDA, if implemented, could have an impact on product approval timelines. Regulations of the U.S. FDA and other regulatory agencies in and outside the U.S. impose extensive compliance and monitoring obligations on our business. These agencies review our design and manufacturing processes, labeling, record keeping, and manufacturers&#8217; required reports of adverse experiences and other information to identify potential problems with marketed products. We are also subject to periodic inspections for compliance with applicable quality system regulations, which govern the methods used in, and the facilities and controls used for, the design, manufacture, packaging, and servicing of finished medical devices intended for human use. In addition, the U.S. FDA and other regulatory bodies, both in and outside the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the U.S. Department of Justice, and various state Attorneys General), monitor the promotion and advertising of our products. Any adverse regulatory action, depending on its magnitude, may limit our ability to effectively market and sell our products, limit our ability to obtain future pre-market approvals or result in a substantial modification to our business practices and operations. For additional information, see "Item 1A. Risk Factors" under, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement of products, services, technology, know-how, and investment across borders subjects us to extensive trade laws and regulations, including tariff regulations adopted by different countries or trading zones. These laws and regulations govern, among other things, our import, export and other international trade activities. We are subject to the risk that these laws and regulations could change in a way that would expose us to additional costs and burdens, as well as penalties if not complied with. Some governments impose economic sanctions and other trade restrictions against certain countries, persons or entities. We also sell and provide goods, technology and services to agents, representatives and distributors who may in turn sell or provide such items to customers and other end-users in their own countries or by means of their own cross-border transactions. If we, or the third parties through which we do business, are not in compliance with applicable import, export control or economic sanctions laws and regulations, we may be subject to civil or criminal enforcement action, and varying degrees of liability. Such actions may disrupt or delay sales of our products or services or result in restrictions on our distribution and sales of products or services that may materially impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Boycott Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. laws and regulations, U.S. companies and their subsidiaries and affiliates outside the U.S. are prohibited from participating or agreeing to participate in unsanctioned foreign boycotts in connection with certain business activities, including the sale, purchase, transfer, shipping or financing of goods or services within the U.S. or between the U.S. and countries outside of the U.S. If we, or certain third parties through which we sell or provide goods or services, violate anti-boycott laws and regulations, we may be subject to civil or criminal enforcement action and varying degrees of liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws and Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a business with a significant global footprint, compliance with evolving regulations and standards in data privacy and cybersecurity has resulted, and may continue to result, in increased costs, new compliance challenges, and the threat of increased regulatory enforcement activity. Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including personal information, protected health information, financial information, intellectual property and other sensitive information related to our products and therapies, customers, patients, and workforce.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operational footprint comes with the obligation for compliance and adherence to individual data security, confidentiality and breach notification laws at the State, Federal, and International levels. Examples of those laws include, in the U.S., the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended, the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and various State privacy laws. We also are subject to various other country-specific requirements around the world, such as the General Data Protection Regulation (GDPR) in the European Economic Area, the United Kingdom&#8217;s privacy laws, and China's Personal Information Protection Law (PIPL). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the laws and regulations continue to expand, differ from jurisdiction to jurisdiction, and are subject to evolving (and at times inconsistent) governmental interpretation and different cross border data transfer rules, compliance may require significant additional cost expenditures or changes in products or business that increase competition or reduce revenue. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities, withdrawal of noncompliant products from a market, and reputational harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations Governing Reimbursement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of our devices is subject to regulation by the U.S. Department of Health and Human Services (HHS) and comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare items and services. U.S. laws and regulations are imposed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily in connection with federally funded healthcare programs, such as the Medicare and Medicaid programs, as well as the government&#8217;s interest in regulating the quality and cost of healthcare. Other governments also impose regulations in connection with their healthcare reimbursement programs and the delivery of healthcare items and services. In addition, reported potential workforce reductions and agency reorganization at HHS, if implemented, could have an impact on reimbursement programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal healthcare laws apply when we or customers submit claims for items or services that are reimbursed under federally-funded healthcare programs, including laws related to kickbacks, false claims, self-referrals or other healthcare fraud. There are often similar state false claims, anti-kickback, and anti-self-referral and insurance laws that apply to state Medicaid and other healthcare programs and private third-party payors. In addition, as a manufacturer of U.S. FDA-approved devices reimbursable by federal healthcare programs, we are subject to the U.S. Physician Payments Sunshine Act (Open Payments), which requires us to annually report certain payments and other transfers of value we make to U.S.-licensed physicians, certain allied health professionals, and U.S. teaching hospitals. Similarly, other jurisdictions impose transparency reporting obligations relating to health care professional payments. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of legislative or regulatory reforms to reimbursement systems, or adverse decisions relating to our products by administrators of these systems in coverage or reimbursement, could significantly reduce reimbursement or result in the denial of coverage, which could have an impact on the acceptance of and demand for our products and the prices that our customers are willing to pay for them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Health and Safety Laws</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various environmental health and safety laws and regulations both within and outside the U.S. Like other companies in our industry, our manufacturing and other operations involve the use and transportation of substances regulated under environmental health and safety laws including those related to the use, storage, transportation, and disposal of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (Exchange Act) are made available under the &#8220;Our Company &#8211; Investors&#8221; caption and &#8220;Financials &#8211; SEC Filings&#8221; sub caption of our website as soon as reasonably practicable after we electronically file them with, or furnish them to, the Securities and Exchange Commission (SEC).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our corporate governance, including our Principles of Corporate Governance, Code of Conduct (including our Code of Ethics for Senior Financial Officers and any related amendments or waivers), Code of Business Conduct and Ethics for Members of the Board of Directors, AI Compass, and information concerning our executive officers, directors and Board committees (including committee charters) is available through our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the &#8220;Our Company &#8211; Governance&#8221; caption. Information relating to transactions in Medtronic securities by directors and officers is available through our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.medtronic.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the &#8220;Our Company &#8211; Investors&#8221; caption and the &#8220;Financial Information &#8211; SEC Filings&#8221; sub caption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website and the information contained on or connected to our website are not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a website that contains reports, proxy, and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC. The public may obtain any documents that we file with the SEC at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We file annual reports, quarterly reports, proxy statements, and other documents with the SEC under the Exchange Act.</span></div><div id="ic14a750e81984b18a679ba753642023e_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our securities involves a variety of risks and uncertainties, known and unknown, including, among others, those discussed below. Each of the following risks should be carefully considered, together with all the other information included in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and in our other filings with the SEC. Furthermore, additional risks and uncertainty not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Our business, results of operations, financial condition, and cash flow and prospects could be materially and adversely affected by any of these risks or uncertainties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and we may be unable to compete effectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in both the therapeutic and diagnostic medical markets in more than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. In the product lines in which we compete, we face a range of competitors from large companies with multiple business lines to small, specialized manufacturers that offer a limited selection of niche products. Development by other companies of new or improved products, processes, technologies, or the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">introduction of reprocessed products or generic versions when our proprietary products lose their patent protection may make our existing or planned products less competitive. In addition, we face competition from providers of alternative medical therapies, such as pharmaceutical companies, including those producing GLP-1s.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to compete depends upon many factors both within and beyond our control, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product performance and reliability,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product technology and innovation,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product quality and safety,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breadth of product lines,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product support services,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supplier and supply availability and performance,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer support,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effectiveness and price,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement approval from healthcare insurance providers, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the regulatory environment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may increase as additional companies enter our markets or modify their existing products to compete more directly with ours. In addition, academic institutions, governmental agencies and other public and private research organizations also may conduct research, seek patent protection and establish collaborative arrangements for discovery, research, clinical development and marketing of products similar to ours. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring necessary product technologies. From time to time we have lost, and may in the future lose, market share in connection with product problems, physician advisories, safety alerts and publications about our products, which highlights the importance of product quality, product efficacy and quality systems to our business. In the current environment of managed care, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, as recently experienced in China, competitively priced product offerings are essential to our success. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to differentiate our product and keep pace with emerging technologies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth and success depend on our ability to develop, acquire and market new and differentiated products, technologies and intellectual property, and as a result we also face competition for marketing, distribution, and collaborative development agreements, establishing relationships with academic and research institutions and licenses to intellectual property. In order to continue to compete effectively, we must continue to create, invest in or acquire advanced technology, incorporate this technology into our proprietary products, obtain regulatory approvals in a timely manner, and successfully manufacture and market our products. For example, data science, machine learning and AI are all impacting our products and operations and the competitive landscape in which we operate, and the application of these technologies is rapidly evolving at the same time as new laws and regulations of AI are being developed in jurisdictions around the world. Compliance with developing regulations may require significant expenditures or may limit our ability to effectively use these technologies. There can be no assurance that the application of AI in our products and operations will be successful, or that we will not experience data security and privacy incidents in connection with our use of these technologies. Given these factors, we cannot guarantee that we will be able to compete effectively or continue our level of success.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of our products requires the timely delivery of a sufficient amount of quality components and materials and is highly exacting and complex, due in part to complex trade and strict regulatory requirements. We manufacture the majority of our products and procure critical third-party services, such as sterilization services, at numerous facilities worldwide. We purchase many of the components, raw materials and services needed to manufacture these products from numerous suppliers in various countries. We seek to maintain continuity of supply by use of multiple options for sourcing where possible. We have generally been able to obtain adequate supplies of such raw materials, components and services, although global shortages of certain components such as semiconductors and resins have previously caused, and may in the future cause, disruptions to our product manufacturing supply chain. In addition, for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers. Although we work closely with our suppliers to try to ensure continuity of supply while maintaining high quality and reliability, the supply of these components, raw materials and services may, at times, be interrupted or insufficient. In addition, due to the stringent regulations and requirements of trade and regulatory agencies, including the U.S. FDA, regarding the manufacture of our products, we may not be able to quickly establish additional or replacement sources. Additionally, many regulatory agencies are imposing new and evolving regulatory requirements on safe use of chemicals, including ethylene oxides (EtOs) and polyfluoroalkyl substances (PFAS), and their potential impact on health and the environment which also may impact supply constraints. Furthermore, the prices of commodities and other materials used in our products, which are often volatile and outside of our control, and may be subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tariffs, could adversely impact our supply. We use resins, other petroleum-based materials and pulp as raw materials in some of our products, and the prices of oil and gas also significantly affect our costs for freight and utilities. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our products in a timely or cost-effective manner and could result in lost sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other disruptions in the manufacturing process or product sales, trade and fulfillment systems for any reason, including infrastructure, information and equipment malfunction, failure to follow specific protocols and procedures, supplier or Company facility shut-downs, defective raw materials, labor shortages, natural disasters such as hurricanes, tornadoes, earthquakes, or wildfires, property damage or facility closures from riots or public protests, and other environmental factors and the impact of epidemics, pandemics, or other public health crises, and actions by businesses, communities and governments in response, could lead to launch delays, product shortages, unanticipated costs, lost revenues and damage to our reputation. For example, in the past we were adversely impacted by the global COVID-19 pandemic, and may in the future be adversely impacted by other pandemics and the related responses of governments and of our partners, including suppliers, manufacturers, distributors and other businesses. Furthermore, any failure to identify and address manufacturing problems prior to the release of products to our customers could result in quality or safety issues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our products require sterilization before sale and several of our key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities. If an event occurs that causes damage to or closure of one or more of such facilities, we may be unable to manufacture or sterilize relevant products to the required quality specifications or at all. Due to the time required to approve and license a manufacturing or sterilization facility, a third-party may not be available on a timely basis to replace production capacity in the event manufacturing or sterilization capacity is reduced or lost.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises have had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition, and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations and interactions with healthcare systems, providers and patients around the world expose us to risks associated with public health crises, including epidemics and pandemics. Public health crises may continue to have an adverse impact on certain aspects of our Company and business, including the demand for and supply of certain of our products, operations, supply chains and distribution systems, and our ability to generate cash flow.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Mission is to provide a broad range of therapies to restore patients to fuller, healthier lives, which requires a wide variety of technologies, products and capabilities. The rapid pace of technological development in the medical industry and the specialized expertise required in different areas of medicine make it difficult for one company alone to develop a broad portfolio of technological solutions. In addition to internally generated growth through our research and development efforts, historically we have relied, and expect to continue to rely, upon investments and investment collaborations to provide us access to new technologies both in areas served by our existing businesses as well as in new areas. We expect to make future investments where we believe that we can stimulate the development or acquisition of new technologies and products to further our strategic objectives and strengthen our existing businesses. Investments and investment collaborations in and with medical technology companies and third-party funding sources are inherently risky, and we cannot guarantee that any of our previous or future investments or investment collaborations will be successful or will not materially adversely affect our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to maintain our working relationships with healthcare professionals, many of our products may not be developed and marketed in line with the needs and expectations of the professionals who use and support our products, which could cause a decline in our earnings and profitability. The research, development, marketing and sales of many of our new and improved products depends on our maintaining working relationships with healthcare professionals. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing and sale of our products. Healthcare professionals assist us as researchers, marketing and product consultants, inventors, trainers, and public speakers. If we are unable to maintain strong relationships with these professionals, the development and marketing of our products could suffer, which could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have debt obligations that create risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to use a portion of our operating cash flow to pay interest or principal on our outstanding indebtedness instead of for other corporate purposes, including funding future expansion of our business. We may also incur additional indebtedness in the future to supplement our existing liquidity and cash generated from operations to satisfy our needs for working capital and capital expenditures, to pursue growth initiatives, and to make returns of capital to shareholders. Changes in business and economic conditions will impact interest rates and can cause periods of tightened credit availability and volatility in borrowing terms. In addition, there can be no assurance that we will be able to maintain our credit rating. At the time we may incur such additional indebtedness, or refinance or restructure existing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indebtedness, we may be unable to obtain capital market financing with similar terms and currency denomination to our existing indebtedness, or at all, which could have a material adverse effect on our business and results of operations. At any time, the fair value of our debt outstanding will fluctuate based on several factors including foreign currency exchange rate and interest rate movements, credit conditions and our credit rating.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures and third-party funding arrangements, as well as liabilities or claims relating to such acquired businesses, divestitures, or arrangements could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy to develop and identify new products and technologies and optimize our portfolio of products, we have made several significant acquisitions, divestitures and third-party research and development funding arrangements in recent years, and may make additional acquisitions, divestitures and arrangements in the future. Our integration of the operations of acquired businesses, or a divestiture of part of our existing businesses, including our recently announced intention to separate our Diabetes business from the Company, requires significant efforts, including the coordination of information technologies, research and development, sales and marketing, operations, manufacturing, and finance. These efforts result in additional expenses and involve significant amounts of management&#8217;s time that cannot then be dedicated to other projects. Our failure to manage and coordinate the growth of acquired companies successfully could also have an adverse impact on our business. Further, acquired businesses may have liabilities, or be subject to claims, litigation or investigations that we did not anticipate or which exceed our estimates at the time of the acquisition. In addition, we cannot be certain that the businesses we acquire will become profitable or remain so. Factors that will affect the success of our acquisitions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to integrate information technology systems of acquired companies in a secure and reliable manner,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities, claims, litigation, investigations, or other adverse developments relating to acquired businesses or the business practices of acquired companies, including investigations by governmental entities, potential Foreign Corrupt Practices Act (FCPA) or product liability claims, intellectual property disputes, earnout or other contingent payment disputes, or other unanticipated liabilities,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any decrease in customer loyalty and product orders caused by dissatisfaction with the combined companies&#8217; product lines and sales and marketing practices, including price increases,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain key employees, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to achieve synergies among acquired companies, such as increasing sales of the integrated company&#8217;s products, achieving cost savings, and effectively combining technologies to develop new products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could experience negative effects on our business, results of operations, financial condition, and cash flows from acquisition-related charges, amortization of intangible assets and asset impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential exists that expected strategic benefits from any planned or completed divestiture, including our recently announced intention to separate our Diabetes business from the Company, or third-party funding arrangement, by the Company may not be realized or may take longer to realize than expected, and there can be no assurance that disputes will not arise under the Company's third-party funding arrangements, or transition service, or other agreements that have or may be executed as part of a divestiture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical devices and technologies, as well as our business activities, are subject to a complex set of regulations and rigorous enforcement, including by the U.S. FDA, U.S. Department of Justice, Health and Human Services Office of the Inspector General, and numerous other federal, state, and non-U.S. governmental authorities. To varying degrees, each of these agencies requires us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of our products. As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials or delays with a variety of study designs, patient populations, and trial endpoints. Unfavorable clinical data from existing or future clinical trials or delays by regulators in approving or authorizing reimbursement for new products may adversely impact (a) our ability to obtain product approvals, (b) our position in, and share of, the markets in which we participate, and (c) our business, results of operations, financial condition, and cash flows. We cannot guarantee that we will be able to obtain or maintain marketing clearance for our new products or enhancements or modifications to existing products, and the failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Even if we are able to obtain approval or clearance, it may:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant amount of time,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve stringent clinical and pre-clinical testing, as well as increased post-market surveillance,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve modifications, repairs or replacements of our products, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the proposed uses of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both before and after a product is commercially released, we have ongoing responsibilities under the U.S. FDA and other applicable non-U.S. government agency regulations. For instance, many of our facilities and procedures, and those of our suppliers, are subject to periodic inspections by the U.S. FDA to assess compliance with applicable regulations. The results of these inspections can include, and have in the past included, observations on the U.S. FDA&#8217;s Form 483, warning letters, or other forms of enforcement, such as a consent decree. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical products are ineffective or pose an unreasonable health risk, the U.S. FDA could detain or seize what it believes to be adulterated or misbranded medical products, order a recall, repair, replacement, or refund of such products, refuse to grant pending pre-market approval applications or require certificates of non-U.S. governments for exports, and/or require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health, and in certain rare circumstances, ban medical devices. In addition, the U.S. FDA has taken the position that device manufacturers are prohibited from promoting their products other than for the uses and indications set forth in the approved product labeling, and any failure to comply could subject us to significant civil or criminal exposure, administrative obligations and costs, and/or other potential penalties from, and/or agreements with, the federal government. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FDA and other non-U.S. government agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market clearances or approvals, and could result in a substantial modification to our business practices and operations. Furthermore, we occasionally receive subpoenas or other requests for information from various governmental agencies around the world, and while these investigations typically relate primarily to financial arrangements with healthcare providers, regulatory compliance and product promotional practices, we cannot predict the timing, outcome or impact of any such investigations. Any adverse outcome in one or more of these investigations could include the commencement of civil and/or criminal proceedings, substantial fines, penalties, and/or administrative remedies, including exclusion from government reimbursement programs and/or entry into Corporate Integrity Agreements (CIAs) with governmental agencies. In addition, resolution of any of these matters could involve the imposition of additional, costly compliance obligations. These potential consequences, as well as any adverse outcome from government investigations, could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental regulations in the U.S. and outside the U.S. are constantly changing and may become increasingly stringent. In the E.U, for example, the Medical Device Regulation (EU MDR) includes significant additional pre-market and post-market requirements. Penalties for regulatory non-compliance could be severe, including fines and revocation or suspension of a company&#8217;s business license, mandatory price reductions and criminal sanctions. Implementation of the EU MDR was extended to the end of 2027 for high-risk devices and to the end of 2028 for medium- and low- risk devices. The development and implementation of future laws and regulations may have a material adverse effect on us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality problems have in the past and could in the future lead to recalls or safety alerts, product liability claims, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is extremely important to us and our customers due to the impact on patients, and the serious and potentially costly consequences of adverse product performance. Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. In addition, many of our products are often used in intensive care settings with seriously ill patients, and some of the medical devices we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely. Component failures, manufacturing nonconformances, design issues, off-label use, or inadequate disclosure of product-related risks or product-related information with respect to our products, could result in an unsafe condition or injury to, or death of, a patient. These problems have in the past and could in the future lead to recall of, or issuance of a safety alert relating to, our products, as well as product liability claims and lawsuits, including class actions, which could ultimately result, in certain cases, in the removal from the body of such products and claims regarding costs associated therewith. Due to the strong name recognition of the Medtronic brand, a material adverse event involving one of our products could result in diminished market acceptance and demand for all products within that brand and could harm our reputation and ability to market products in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong product quality is critical to the success of our goods and services. If we fall short of these standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers, and our revenue and results of operations could decline. Our success also can depend on our ability to manufacture to exact specification precision-engineered components, subassemblies and finished devices from multiple materials. If our components fail to meet these standards or fail to adapt to evolving standards, our reputation, competitive advantage and market share could be harmed. In certain situations, we may undertake a voluntary recall of products or temporarily shut down production lines based on performance relative to our own internal safety and quality monitoring and testing data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing problems, including future product liability claims or lawsuits, brought either individually or in the aggregate, or recalls, regardless of their ultimate outcome, could harm our reputation and have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our devices, products and therapies are purchased principally by hospitals or physicians that typically bill various third-party payors, such as governmental healthcare programs (e.g., Medicare, Medicaid and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical because it affects which products customers purchase and the prices, they are willing to pay. As a result, our devices, products and therapies are subject to regulation regarding quality and cost by HHS, including the Centers for Medicare &amp; Medicaid Services (CMS), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of health care goods and services, including laws and regulations related to fair competition, kickbacks, false claims, self-referrals and healthcare fraud. Many states have similar laws that apply to reimbursement by state Medicaid and other funded programs as well as in some cases to all payors. In certain circumstances, insurance companies attempt to bring a private cause of action against a manufacturer for causing false claims. In addition, as a manufacturer of U.S. FDA-approved devices reimbursable by federal healthcare programs, we are subject to the Physician Payments Sunshine Act (Open Payments), which requires us to annually report certain payments and other transfers of value we make to U.S. licensed physicians, certain allied health professionals, and U.S. teaching hospitals. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to risks relating to changes in government and private medical reimbursement programs and policies, and changes in legal regulatory requirements in the U.S. and around the world. Implementation of further legislative or administrative reforms to these reimbursement systems, or adverse decisions relating to coverage of or reimbursement for our products by administrators of these systems, could have an impact on the acceptance of and demand for our products and the prices that our customers are willing to pay for them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are substantially dependent on patent and other proprietary rights and rely on a combination of patents, trademarks, tradenames, copyrights, trade secrets, and agreements (such as employee and non-disclosure) to protect our business and proprietary intellectual property. We also operate in an industry characterized by extensive intellectual property litigation. Intellectual property litigation can result in significant damage awards and injunctions that could prevent our manufacture and sale of affected products or require us to pay significant royalties in order to continue to manufacture or sell affected products. At any given time, we are generally involved as both a plaintiff and a defendant in a number of intellectual property actions, the outcomes of which may not be known for prolonged periods of time. While it is not possible to predict the outcome of intellectual property litigation, it is possible that the results of such litigation could require us to pay significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or that enforcement actions to protect our patent and proprietary rights against others could be unsuccessful, any of which could have a material adverse impact on our business, results of operations, financial condition, and cash flows. In addition, any public announcements related to litigation or administrative proceedings initiated or threatened against us could cause our stock price to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to defend against any threats to our intellectual property, our patents, trademarks, tradenames, copyrights, trade secrets or agreements (such as employee and non-disclosure agreements) may not adequately protect our intellectual property. Further, pending patent applications may not result in patents being issued to us, patents issued to or licensed by us may be challenged or circumvented by competitors and such patents may be found invalid, unenforceable or too limited in scope to protect our technology or provide us with any competitive advantage. In addition, our patents will expire over time, our ability to protect novel business models is uncertain, and infringement may go undetected. Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and such licenses may not be available on reasonable terms or at all. In addition, license agreements could be terminated. We also rely on non-disclosure and non-competition agreements with certain employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. We cannot be certain that these agreements will not be breached, that such provisions will be enforceable, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information, or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. Moreover, in the U.S. the Federal Trade Commission and various states have adopted laws and regulations that purport to ban or severely restrict the use of non-competition agreements, which may limit our ability to use and enforce non-competition agreements with employees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the laws of certain countries in which we market or manufacture some of our products do not protect our intellectual property rights to the same extent as the laws of the U.S., which could make it easier for competitors to capture market position. For example, business in China comprises approximately seven percent of our total revenues. This may increase our vulnerability to our technology being reverse engineered or our trade secrets being compromised. If we are unable to protect our intellectual property in China or other countries, it could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Competitors also may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harm our sales by designing products that substantially mirror the capabilities of our products or technology without infringing our intellectual property rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare policy changes may have a material adverse effect on us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been and continue to be actions and proposals by several governments, regulators and third-party payors globally, including the U.S. federal and state governments and the government in China, to control healthcare costs and, more generally, to reform healthcare systems. Certain of these actions and proposals, among other things, limit the prices we are able to charge for our products or the amounts of reimbursement available for our products, increase the importance of our ability to compete on cost, and could limit the acceptance and availability of our products. These actions and proposals could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on sophisticated information technology systems to operate our business. That technology includes systems that could be used to process, transmit and store sensitive data. Additionally, many of our products and services include integrated software and information technology that collects data regarding patients or connects to other internal systems. One of the most prevalent attacks on large organizations has been ransomware which can have a devastating impact on an organization&#8217;s operations. Our ransomware readiness program has required and will continue to require investment and will not guarantee that we will be immune from an incident or be able to respond rapidly enough to prevent a negative impact on our business. Like all organizations, we routinely experience attempted interference with the integrity of, and interruptions in, our technology systems via events such as cyber-attacks, malicious intrusions, or other breakdowns. The consequences could mean data breaches, interference with the integrity of our products and data, compromise of intellectual property or other proprietary information, or other significant disruptions. Furthermore, we rely on third-party vendors to supply and/or support certain aspects of our information technology systems and resulting products, and customers and payors use information technology systems to process payments relating to our products and services. These third-party systems could also become vulnerable to cyber-attack, malicious intrusions, breakdowns, interference, or other significant disruptions, and may contain defects in design or manufacture or other problems that could result in system disruption or compromise the information security of our own systems. In addition, our global profile and international operations expose us to geopolitical events or issues which may increase cybersecurity risks on a global basis. Lastly, we continue to grow in part through new business acquisitions and, as a result, may face risks associated with defects and vulnerabilities in acquired businesses&#8217; systems, or difficulties or other breakdowns or disruptions in connection with the integration of the acquisitions into our information technology systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide operations subject us to laws and regulations in many jurisdictions, including data protection and cybersecurity laws and regulations. The variety of U.S. and international privacy and cybersecurity laws and regulations impacting our operations are described in &#8220;Item 1. Business" &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Factors Impacting Our Operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Data Privacy and Security Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any data security breaches, cyber-attacks, malicious intrusions or significant disruptions could result in actions by regulatory bodies and/or civil litigation, any of which could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation, or competitive position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our information technology systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems. We experience continuing changes in information processing technology, legal and regulatory standards, patient and customer information use cases, techniques used to obtain unauthorized access to data and information systems, and the information technology needs associated with our changing products and services. We also face business and regulatory risks relating to our use of AI systems in our business operations and products. These systems are susceptible to flaws, biases, malfunctions or manipulations, which may disrupt our operations, result in erroneous decision-making, elevate our cyber risk profile, or expose us to penalties from non-compliance with emerging regulations. There can be no assurance that our efforts to keep pace with continuing changes in information processing technologies, including AI systems, and to deploy these technologies to our business operations and products will be successful or that additional systems issues will not arise in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our information technology systems, products or services or sensitive data are compromised, there are many consequences that could result. Consequences include, but are not limited to, patients or employees being exposed to financial or medical identity theft or suffering a loss of product functionality, losing existing customers or having difficulty attracting new customers, experiencing difficulty preventing, detecting, and controlling fraud, being exposed to the loss or misuse of confidential information, having disputes with customers, physicians, and other healthcare professionals, suffering regulatory sanctions or penalties under federal laws, state laws, or the laws of other jurisdictions, experiencing increases in operating expenses or an impairment in our ability to conduct our operations, incurring expenses or losing revenues as a result of a data privacy breach, product failure, information technology outages or disruptions, or suffering other adverse consequences including lawsuits or other legal action and damage to our reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FCPA, the U.K. Bribery Act, the Irish Criminal Justice (Corruption Offences) Act 2018, and similar anti-corruption laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business and to ensure adequate internal controls, books, and records. Because of the predominance of government-administered healthcare systems in many jurisdictions around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore potentially subject to such laws. We also participate in public-private partnerships and other commercial and policy arrangements with governments around the globe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global enforcement of anti-corruption laws has increased in recent years, including investigations and enforcement proceedings leading to assessment of significant fines and penalties against companies and individuals. Our international operations create a risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors. We maintain various controls aligned with legal requirements to prevent and prohibit improper practices, including policies, programs, and training for our employees and third-party intermediaries acting on our behalf. However, existing safeguards and any future improvements may not always be effective, and our employees, consultants, sales agents or distributors may engage in conduct for which we could be held responsible. In addition, regulators could seek to hold us liable for conduct committed by companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to government scrutiny, criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, adversely affect our reputation and result in a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international business operations could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (OFAC) and the U.S. Commerce Department&#8217;s Bureau of Industry and Security (BIS) administer certain laws and regulations that restrict U.S. persons and, in some instances, non-U.S. persons, in conducting activities, transacting business with, or making investments in, certain countries, governments, entities and individuals subject to U.S. economic sanctions or export restrictions. Our international operations subject us to these laws and regulations, which are complex, restrict our business dealings with certain countries, governments, entities, and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, certain of our subsidiaries have limited business dealings in countries subject to comprehensive sanctions, including Iran, Syria, Cuba, and the region of Crimea, as well as Russia and Belarus. Certain of our subsidiaries sell medical devices, and may provide related services, to distributors and other purchasing bodies in such countries or regions. These business dealings represent an insignificant amount of our consolidated revenues and income but expose us to a heightened risk of violating applicable sanctions regulations. Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. We have established policies and procedures designed to assist with our compliance with such laws and regulations. However, such regulations may impact our ability to continue operations in certain countries and require additional licenses which we may not be able to obtain or maintain. There can be no assurance that our policies and procedures will prevent us from violating these regulations in every transaction in which we may engage, and such a violation could adversely affect our reputation, business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere presents risks to our current and future operations. We face current and long-term operational risks and have in the past experienced business interruptions from severe weather events and other natural conditions, such as hurricanes, tornadoes, droughts, extreme temperatures, wildfires or flooding. Such severe weather events caused by or related to climate change or other conditions caused by natural disasters have in the past and could in the future increase our operational costs, pose physical risks to our facilities and adversely impact our supply chain, including: manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. The impacts of climate change on global water resources may result in water scarcity, which could impact our ability to access sufficient quantities of water in certain locations and result in increased costs. Although it is difficult to predict and adequately prepare to meet the challenges to our business posed by climate change, concerns over climate change also could result in new laws or regulations that are more stringent than current legal or regulatory requirements, and we may experience increased compliance burdens and costs to meet the regulatory obligations as well as adverse impacts on raw material sourcing, manufacturing operations and the distribution of our products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to environmental, health, and safety laws, and regulations concerning, among other things, the generation, handling, transportation, and disposal of hazardous substances or wastes, the remediation of hazardous substances or materials at various sites, and emissions or discharges into the land, air or water. We are further subject to numerous laws and regulations concerning, among other things, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chemical constituents in medical products and end-of-life disposal and take-back programs for medical devices. Our operations and those of certain third-party suppliers involve the use of substances subject to these laws and regulations, primarily those used in manufacturing and sterilization processes. If we or our suppliers violate these environmental laws and regulations, facilities could be shut down and violators could be fined, or otherwise sanctioned. New laws and regulations, violations of these laws or regulations, stricter enforcement of existing requirements, or the discovery of previously unknown contamination could require us to incur costs or could become the basis for new or increased liabilities that could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to our sustainability practices and initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is continued focus from our stakeholders, as well as regulatory authorities in the U.S., E.U. and other global jurisdictions in which we operate, on sustainability practices and disclosure. If we do not succeed in meeting or are perceived as not meeting goals and objectives relating to environmental stewardship, inclusion initiatives, supply chain practices, good corporate governance, workplace conduct and support for local communities, or if we do not effectively respond to new or revised legal, regulatory or reporting requirements concerning climate change, inclusion, or other sustainability concerns, we may be subject to regulatory fines and penalties, including potential loss of eligibility as a U.S. government contractor, our reputation or the reputation of our brands may suffer, we may be unable to attract and retain top talent, and our stock price may be negatively affected. In addition, enhanced and sometimes conflicting sustainability laws, regulations and expectations in the jurisdictions in which we do business may increase compliance burdens and costs for third parties throughout our global supply chain, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we have made several public disclosures of objectives and targets (targets) relating to product stewardship, inclusion, patient safety and product quality, access and innovation, and climate stewardship, including our ambition to be net carbon neutral in our operations by 2030 and to achieve net zero emissions by 2045. Although we intend to achieve these targets, we may be required to expend significant resources to do so, which could increase our operational costs. In addition, there can be no assurance of the extent to which any of our targets will be achieved, or that any future investments we make to achieve such targets will meet investor, legal and/or any other regulatory expectations and requirements. If we are unable to meet our targets, we may face litigation and could incur regulatory fines and penalties or adverse publicity and reaction from investors, advocacy groups or other stakeholders that may adversely impact our business, demand for our products and services, and/or our financial condition and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance program may not be adequate to cover future losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to self-insure most of our insurable risks across the Company, and we made this decision based on cost and availability factors in the insurance marketplace. We manage and maintain a portion of our self-insured program through a wholly-owned captive insurance company. We continue to maintain a directors and officers liability insurance policy with third-party insurers that provides coverage for the directors and officers of the Company. We continue to monitor the insurance marketplace to evaluate the value of obtaining insurance coverage for other categories of losses in the future. Although we believe, based on historical loss trends, that our self-insurance program accruals and our existing insurance coverage will be adequate to cover future losses, historical trends may not be indicative of future losses. The absence of third-party insurance coverage for other categories of losses increases our exposure to unanticipated claims and these losses could have a material adverse impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes, as well as non-income-based taxes, in the U.S., Ireland, and the other jurisdictions in which we operate.  The tax laws in any of these jurisdictions could change on a prospective or retrospective basis, and any such changes could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two Model Rules. A number of countries, including Ireland, have enacted legislation to implement the core elements of the Pillar Two Model Rules, which are effective for Medtronic in fiscal year 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to ongoing tax audits in the various jurisdictions in which we operate. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision. However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes of these audits could have a material impact on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded reserves for potential payments of tax to various tax authorities related to uncertain tax positions. However, the calculation of such tax liabilities involves the application of complex tax laws, regulations and treaties (where applicable) in many jurisdictions. Therefore, any dispute with a tax authority may result in a payment that is significantly different from current estimates. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities generally would result in tax </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits being recognized in the period when we determine the liabilities are no longer necessary. If our estimate of tax liabilities proves to be less than the amount for which it is ultimately liable, we would incur additional charges, and such charges could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of Medtronic, Inc.'s U.S. tax litigation could have a material adverse impact on our financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report for Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreements with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of our key manufacturing sites. The Tax Court issued its opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. Oral argument for the Appeal occurred in May 2025. An adverse outcome in this matter could materially and adversely affect our business, results of operations, financial condition, and cash flows. See Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medtronic plc is organized under the laws of Ireland, we would generally be classified as a foreign corporation under the general rule that a corporation is considered tax resident in the jurisdiction of its organization or incorporation for U.S. federal income tax purposes. Even so, the IRS may assert that we should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes pursuant to Section 7874 of the U.S. Internal Revenue Code of 1986, as amended (the Code). In addition, a retroactive change to U.S. tax laws in this area could change this classification. If we were to be treated as a U.S. corporation for federal tax purposes, we could be subject to substantially greater U.S. tax liability than currently contemplated as a non-U.S. corporation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various U.S. federal and state legislative proposals that would deny governmental contracts to U.S. companies that move their corporate location abroad may affect us. We are unable to predict the likelihood that, or final form in which, any such proposed legislation might become law, the nature of the regulations that may be promulgated under any future legislative enactments, or the effect such enactments and increased regulatory scrutiny may have on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Jurisdiction of Incorporation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction of the United States. It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be enforceable in Ireland.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an Irish company, we are governed by the Irish Companies Act 2014 (as amended), which differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions and shareholder lawsuits. Likewise, the duties of directors and officers of an Irish company generally are owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances. Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit Medtronic&#8217;s flexibility to manage its capital structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Irish law, our authorized share capital can be increased by an ordinary resolution of our shareholders and the directors may issue new ordinary or preferred shares, without shareholder approval, once authorized to do so by our articles of association or by an ordinary resolution of our shareholders. Additionally, subject to specified exceptions, Irish law grants statutory preemption rights to existing shareholders where shares are being issued for cash consideration but allows shareholders to disapply such statutory preemption rights either in our articles of association or by way of special resolution. Such disapplication can either be generally applicable or be in respect of a particular allotment of shares. Accordingly, at our 2024 Annual General Meeting, our Shareholders authorized our Board of Directors to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue up to 20% of our issued ordinary shares and further authorized our Board of Directors to issue such shares for cash without first offering them to our existing shareholders. Both of these authorizations will expire on April 17, 2026, unless renewed by shareholders for a further period. We anticipate seeking new authorizations at our 2025 Annual General Meeting and in subsequent years. We cannot provide any assurance that these authorizations will always be approved, which could limit our ability to issue equity and thereby adversely affect the holders of our securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of our shares effected by means of the transfer of book entry interests in the Depository Trust Company (DTC) will not be subject to Irish stamp duty. However, if a shareholder holds our shares directly rather than beneficially through DTC, any transfer of shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the shares acquired). Payment of Irish stamp duty is generally a legal obligation of the transferee. The potential for stamp duty could adversely affect the price of shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain limited circumstances, dividend withholding tax (currently at a rate of 25%) may arise in respect of dividends paid on our shares. A number of exemptions from dividend withholding tax exist such that shareholders resident in the U.S. and other specified countries that have a tax treaty with Ireland may be entitled to exemptions from dividend withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders resident in the U.S. that hold their shares through DTC will not be subject to dividend withholding tax, provided the addresses of the beneficial owners of such shares in the records of the brokers holding such shares are recorded as being in the U.S. (and such brokers have further transmitted the relevant information to a qualifying intermediary appointed by us). However, other shareholders may be subject to dividend withholding tax, which could adversely affect the price of their shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders entitled to an exemption from Irish dividend withholding tax on dividends received from us will not be subject to Irish income tax in respect of those dividends unless they have some connection with Ireland other than their shareholding in our Company (for example, they are resident in Ireland). Shareholders who are not resident nor ordinarily resident in Ireland, but who receive dividends subject to Irish dividend withholding tax, will generally have no further liability to Irish income tax on those dividends.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irish capital acquisitions tax (CAT) could apply to a gift or inheritance of our shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our shares will be regarded as property situated in Ireland. The person who receives the gift or inheritance has primary liability for CAT. Gifts and inheritances passing between spouses are exempt from CAT. Children currently have a tax-free threshold of &#8364;400,000 in respect of taxable gifts or inheritances received from their parents. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic and Industry Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the prices of our goods and services, customer purchasing patterns and stocking dynamics, and/or inflationary costs may have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had, and may continue to have, periods when prices for certain of our goods and services decrease due to pricing pressure from managed care organizations and other third-party payors on our customers; increased market power of our customers as the healthcare industry consolidates; periodic variation in timing, volume, and pricing associated with customer purchasing patterns and stocking dynamics; and increased competition among medical engineering and manufacturing services providers. We have also recently experienced, and may continue to experience, rising costs due to inflation. If the prices for our goods and services change for any reason or inflation continues to rise, we may be unable to sufficiently reduce our expenses or offset rising costs through increased prices to customers. As a result, our business, results of operations, financial condition, and cash flows may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture, distribute and sell our products globally. We intend to continue to expand our operations and to pursue growth opportunities outside the U.S., especially in emerging markets. Operations in different countries including emerging markets could expose us to additional and greater risks and potential costs, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare reform legislation,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to comply with different regulatory regimes worldwide that are subject to change and that could restrict our ability to manufacture and sell our products,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">local product preferences and product requirements,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer-term receivables than are typical in the U.S.,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic sanctions, export controls, trade protection measures, tariffs and other border taxes, and import or export licensing requirements,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">less intellectual property protection in some countries outside the U.S. than exists in the U.S.,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different labor regulations and workforce instability,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability, including as a result of armed conflicts and insurrections,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on local currency conversion or cash extraction,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially negative consequences from changes in or interpretations of tax laws, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic instability and inflation, recession or interest rate fluctuations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the international trade policy of the U.S. and other countries, including increased trade restrictions or tariffs, have the potential to adversely impact Medtronic. The ongoing global economic competition and trade tensions between the U.S. and China, including recent increased duties imposed by both countries, present risk to Medtronic. China, which comprises approximately seven percent of our total revenue, and the U.S., could impose other types of restrictions such as limitations on government procurement or technology export restrictions, which could affect Medtronic&#8217;s access to the markets. In addition, the tariffs imposed by the United States on many jurisdictions, including Mexico, Canada, the E.U. and other countries and regions in which we do business, increase uncertainties and associated risks on our global operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Russia-Ukraine conflict and resulting sanctions and export restrictions are creating barriers to doing business in Russia and Belarus and adversely impacting global supply chains. While we have no manufacturing, distribution or direct material suppliers in the region, we continue to closely monitor the potential raw material/sub-tier supplier impact in both Russia and Ukraine including materials like palladium and neon, which are both dependent on Russia supply. Additional sanctions, export restrictions, and potential countermeasures within Russia, along with geopolitical shifts in Asia and disruptions relating to Israel's conflict in Gaza, may lead to greater uncertainty that could cause additional adverse impacts on global supply chains and our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, several governments including the U.S. have raised the possibility of policies to induce &#8220;re-shoring&#8221; of supply chains, less reliance on imported supplies, and greater national production. Examples include potential &#8220;Buy America&#8221; requirements in the U.S. If such steps triggered retaliation in other markets restricting access to foreign products in purchases by their government-owned healthcare systems, the result could be a significant impact on Medtronic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant changes or disruptions to international trade arrangements, such as termination or modifications of other existing trade agreements, may adversely affect our business, results of operations, financial condition, and cash flows. In addition, a significant amount of our trade receivables are with national healthcare systems in many countries. Repayment of these receivables is dependent upon the political and financial stability of those countries. In light of these global economic fluctuations, we continue to monitor the creditworthiness of customers. Failure to receive payment of all or a significant portion of these receivables could adversely affect our business, results of operations, financial condition, and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, changes in currency exchange rates may impact the reported value of our revenues, expenses, and cash flows. In addition, the impact of currency devaluations in countries experiencing significant currency exchange fluctuations could negatively impact the Company's operating results. We cannot predict changes in currency exchange rates, the impact of exchange rate changes, nor the degree to which we will be able to manage the impact of currency exchange rate changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market disruptions resulting in diminished liquidity, or healthcare professional and staff strikes or other work stoppages, could adversely affect our revenues, results of operation, or financial condition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions in international markets and supporting financial services and uncertainty about economic conditions (for instance, resulting from credit scarcity, geopolitical risks and sovereign debt deterioration or default), have in the past caused periods of tightened credit availability and increased volatility in liquidity and borrowing terms. If these conditions were to recur or worsen, we may experience reduced demand for a number of our products. We also could experience reduced sales and profits due to delayed payments or the insolvency of healthcare professionals, hospitals and other customers, suppliers and vendors who experience liquidity issues, including as a result of cybersecurity incidents impacting private and government health insurance payors. In addition, healthcare professional and staff strikes or other work stoppages have in the past and may in the future cause reduced demand for our products. As a result, our business, results of operations, financial condition, and cash flows could be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation in the healthcare industry and the growing prevalence of ambulatory surgery centers (ASCs) could have an adverse effect on our revenues and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many healthcare industry companies, including healthcare systems, distributors, manufacturers, providers, and insurers, are consolidating or have formed strategic alliances. As the healthcare industry consolidates, competition to provide goods and services to industry participants will become more intense. Further, this consolidation creates larger enterprises with greater negotiating power, which can be used to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiate price concessions. In addition, the movement of procedures to ASCs could also create downward pricing pressure. If we must reduce our prices because of industry consolidation or ASC procedures, or if we lose customers as a result of consolidation or ASC procedures, our business, results of operations, financial condition, and cash flows could be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our customers, and the healthcare providers to whom our customers supply medical devices, rely on third-party payors, including government programs and private health insurance plans, to reimburse some or all of the cost of the procedures in which medical devices are used. The continuing efforts of governmental authorities, insurance companies and other payors of healthcare costs to contain or reduce these costs could lead to patients being unable to obtain approval for payment from these third-party payors. If third-party payor payment approval cannot be obtained by patients, sales of finished medical devices that include our components may decline significantly and our customers may reduce or eliminate purchases of our components. The cost-containment measures that healthcare providers are instituting, both in the U.S. and outside of the U.S., could harm our ability to operate profitably. For example, managed care organizations have successfully negotiated volume discounts for pharmaceuticals, and GPOs and IDNs have also concentrated purchasing decisions for some customers, which has led to downward pricing pressure for medical device companies, including us.</span></div><div id="ic14a750e81984b18a679ba753642023e_22"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic14a750e81984b18a679ba753642023e_25"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-100" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-99" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity regulatory based risk assessments for the Company&#8217;s systems and applications (where required),</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a formal incident response plan, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual information security training program for all employees, including phishing awareness training,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity works closely with application development and infrastructure &amp; operation teams to embed security considerations into the foundation of technology,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-101">engagement of third-party</ix:nonNumeric> service providers to conduct assessment of the Company&#8217;s cybersecurity risk management program, penetration testing, and vulnerability testing,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-102">a third-party risk assessment</ix:nonNumeric> process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-103">Risks from cybersecurity threats are integrated into Medtronic&#8217;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#8217;s business and operation.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-104">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#8217;s business or operations.</ix:nonNumeric> However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. See Item 1A. Risk Factors under, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.&#8221;</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-109" continuedAt="f-109-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-108" continuedAt="f-108-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-107" continuedAt="f-107-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-106" continuedAt="f-106-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-105" continuedAt="f-105-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-110">Chief Information Security Officer (CISO)</ix:nonNumeric>. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-111" continuedAt="f-111-1" escape="true">Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><ix:continuation id="f-107-1"><ix:continuation id="f-106-1"><ix:continuation id="f-105-1"><ix:continuation id="f-111-1"><ix:continuation id="f-109-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-108-1">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes</ix:continuation>.</span></div></ix:continuation></ix:continuation><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-112" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-113">Board</ix:nonNumeric> of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.</span></div></ix:nonNumeric></ix:continuation></ix:continuation></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_28"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic's principal executive office is located in Ireland and is owned by the Company, while its main operational offices are located in the Minneapolis, Minnesota metropolitan area and are owned by the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's total manufacturing and research space is approximately 9.9 million square feet. Approximately 36 percent of the manufacturing and research facilities are owned by Medtronic and the remaining balance is leased. The Company&#8217;s largest manufacturing facilities are located in the U.S., Puerto Rico, Mexico, China, Ireland, Dominican Republic, Switzerland, France, and Italy. Many of these facilities serve more than one of our divisions and also perform research activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic also maintains sales and administrative offices outside the U.S. at approximately 110 locations in over 60 countries. A majority of these locations are leased. The Company is using substantially all of its currently available productive space to develop, manufacture, and market its products. The Company's facilities are well-maintained, suitable for their respective uses, and adequate for current needs.</span></div><div id="ic14a750e81984b18a679ba753642023e_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Item 103 of Regulation S-K, we have adopted a $1 million disclosure threshold for proceedings under environmental laws to which a governmental authority is a party, as we believe matters under this threshold are not material to the Company. A discussion of the Company&#8217;s legal proceedings and other loss contingencies are described in Note 18 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div id="ic14a750e81984b18a679ba753642023e_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ic14a750e81984b18a679ba753642023e_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Medtronic&#8217;s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ordinary shares are listed on the New York Stock Exchange under the symbol &#8220;MDT.&#8221;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the shares repurchased by the Company during the fourth quarter of fiscal year 2025: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price<br/>Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased as a Part of<br/>Publicly Announced<br/>Program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/25/2025-2/21/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273,048,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2025-3/28/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148,048,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/29/2025-4/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127,728,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127,728,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company's Board of Directors authorized $5.0 billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. For additional discussion, see Note 11 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;17, 2025, there were approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,895 shareholders of record of the Company&#8217;s ordinary shares. Ordinary cash dividends declared and paid totaled $0.70 per share for each quarter of fiscal year 2025 and $0.69 per share for each quarter of fiscal year 2024. On May&#160;21, 2025, the Company announced an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Medtronic's cash dividends for the first quarter of fiscal year 2026, raising the amount to $0.71 per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total shareholder return on Medtronic&#8217;s ordinary shares with the cumulative total shareholder return on the Standard &amp; Poor&#8217;s (S&amp;P) 500 Index and the S&amp;P 500 Health Care Equipment Index for the last five fiscal years. The graph assumes that $100 was invested at market close on April&#160;24, 2020 in Medtronic&#8217;s ordinary shares, the S&amp;P 500 Index, and the S&amp;P 500 Health Care Equipment Index and that all dividends were reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g7.jpg" alt="1723" style="height:330px;margin-bottom:5pt;vertical-align:text-bottom;width:613px" id="i-7"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Company/Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic plc</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.80&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.87&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.66&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care Equipment Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on the Company's equity compensation plans, see "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters" in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Irish Restrictions on Import and Export of Capital </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as indicated below, there are no restrictions on non-residents of Ireland dealing in Irish domestic securities, which includes ordinary shares of Irish companies. Except as indicated below, dividends and redemption proceeds also continue to be freely transferable to non-resident holders of such securities. The Financial Transfers Act, 1992 provides that the Irish Minister for Finance can make provision for the restriction of financial transfers between Ireland and other countries. For the purposes of this Act, &#8220;financial transfers&#8221; include all transfers which would be movements of capital or payments within the meaning of the treaties governing the E.U. if they had been made between Member States of the E.U. To date, the Irish Minister for Finance has restricted financial transfers between Ireland and a number of third countries and the list is subject to on-going change.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any transfer of, or payment in respect of, a share or interest in a share involving the government of any country that is currently the subject of United Nations or E.U. sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Irish Taxes Applicable to U.S. Holders </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid by Medtronic will generally be subject to Irish dividend withholding tax (currently at a rate of 25 percent) unless an exemption applies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to U.S. residents will not be subject to Irish dividend withholding tax provided that:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of a beneficial owner of Medtronic shares held in the DTC, the address of the beneficial owner in the records of his or her broker is in the United States and this information is provided by the broker to the Company&#8217;s qualifying intermediary; or</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of a record owner, the record owner has provided to the Company&#8217;s transfer agent a valid U.S. Certification of Residence (Form 6166) or valid Irish Non-Resident Form V2.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irish income tax may also arise with respect to dividends paid on Medtronic&#8217;s ordinary shares. A U.S. resident who meets one of the exemptions from dividend withholding tax described above and who does not hold Medtronic shares through a branch or agency in Ireland through which a trade is carried on generally will not have any Irish income tax liability on a dividend paid by Medtronic. In addition, if a U.S. shareholder is subject to the dividend withholding tax, the withholding payment discharges any Irish income tax liability, provided the shareholder furnishes to the Irish Revenue authorities a statement of the dividend withholding tax imposed.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the U.S./Ireland Double Tax Treaty contains provisions regarding withholding, due to the wide scope of the exemptions from dividend withholding tax available under Irish domestic law, it would generally be unnecessary for a U.S. resident shareholder to rely on the treaty provisions.</span></div><div id="ic14a750e81984b18a679ba753642023e_43"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ic14a750e81984b18a679ba753642023e_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDERSTANDING OUR FINANCIAL INFORMATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on focuses on our financial results for the fiscal year ended April&#160;25, 2025 (fiscal year 2025) and the fiscal year ended April&#160;26, 2024 (fiscal year 2024). A discussion on our results of operations for fiscal year 2024 as compared to the year ended April&#160;28, 2023 (fiscal year 2023) is included in Part II, Item 7. "Mana</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gement's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;26, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on June </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20, 2024, and is i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncorporated by reference into this Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You should read this discussion and analysis along with our consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for fiscal years 2025, 2024, and 2023, which are presented within "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Management&#8217;s Discussion and Analysis, we present certain financial measures that facilitate management's review of the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, financial measures presented in accordance with U.S. GAAP. We believe that non-GAAP financial measures provide information useful to investors in understanding the Company's underlying operational performance and trends and may facilitate comparisons with the performance of other companies in the medical technologies industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As presented in the GAAP to Non-GAAP Reconciliations section on the following pages, our non-GAAP financial measures exclude the impact of amortization of intangible assets and certain charges or benefits that contribute to or reduce earnings and that may affect financial trends and include certain charges or benefits that result from transactions or events that we believe may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and reported. Because the effective rate can be significantly impacted by the Non-GAAP Adjustments that take place during the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the income tax provision, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income before income taxes, excluding Non-GAAP Adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the &#8220;GAAP to Non-GAAP Reconciliations," "Income Taxes," and "Free Cash Flow" sections for reconciliations of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with U.S. GAAP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE LEVEL OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a summary of revenue, diluted earnings per share, and operating cash flow for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><img src="mdt-20250425_g8.jpg" alt="Executive Level Overview Infographic Q4 FY25.jpg" style="height:421px;margin-bottom:5pt;vertical-align:text-bottom;width:750px" id="i-8"/></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GAAP to Non-GAAP Reconciliations </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The tables below present reconciliations of our Non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with U.S. GAAP for fiscal years 2025 and 2024. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year ended April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to Medtronic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain)/loss on minority investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year ended April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Income Taxes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income Attributable to Medtronic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain)/loss on minority investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (9)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company recognized $151 million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. </span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, asset write-offs, and for the fiscal year ended April 25, 2025, contract terminations. </span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges primarily include exit of business-related charges, changes in fair value of contingent consideration, business combination costs, and gains related to certain business or asset sales.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The charges predominantly include $439 million of charges related to the February 2024 decision to exit the Company's ventilator product line, which primarily includes long-lived intangible asset impairments and inventory write-downs. In addition, other charges primarily consist of changes in fair value of contingent consideration and associated costs related to the previously contemplated separation of the Patient Monitoring and Respiratory Interventions businesses. </span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Free Cash Flow </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Summary of Cash Flows section for drivers of the change in cash provided by operating activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Looking ahead, a number of macroeconomic and geopolitical factors could negatively impact our business, including without limitation: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitive product launches and pricing pressure, geographic macroeconomic developments including changes in global trade policies and fluctuations in currency exchange rates, general price inflation, changes in interest rates, reimbursement challenges, impacts from changes in the mix of our product offerings, delays in product registration approvals, national and provincial tender pricing for certain products, particularly in China, replacement cycle challenges, and supply chain challenges from time to time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recent developments in global trade policy have introduced new uncertainties for our business. During and subsequent to the reporting period, the U.S., China, and other jurisdictions imposed or proposed additional tariffs on imported goods. Based on current imposed or proposed rates as of May 21, 2025, we estimate the net tariff impact to be $200 million to $350 million in fiscal year 2026, with the majority recognized in the consolidated statements of income in the second half of the fiscal year. The lower end of the range assumes that the current U.S. (30%) and China (10%) tariffs persist, while the higher end of the range assumes tariffs revert to higher rates (U.S. 145%, China 125%) after the 90-day pause. The actual amount could vary based on changes in tariff rates, duration of tariffs, scope of tariffs, and potential countermeasures or mitigation actions. The impact of the tariffs on the financial results for fiscal year 2025 were not material. While we are taking proactive steps to mitigate the effects of these tariffs, the evolving nature of international trade policy continues to present a risk to our cost structure and financial performance. Further escalation or expansion of trade barriers could have a material adverse effect on our results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sanctions and other measures being imposed in response to the Russia-Ukraine conflict are having and could continue to have impacts on revenue and supply chain. The financial impact of the conflict in fiscal year 2025, including on accounts receivable and inventory reserves, was not material. For fiscal year 2025, the business of the Company in these countries represented less than 1% of the Company's consolidated revenues and assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial and operational impact of the conflict in fiscal year 2025, including on accounts receivable and inventory reserves, was not material. As of April 25, 2025, the Company had 6 facilities and approximately 1,500 employees in Israel. For fiscal year 2025, the business of the Company in Israel represented less than 1% of the Company's consolidated revenues and assets.</span></div><div id="ic14a750e81984b18a679ba753642023e_55"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NET SALES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation. The charts below illustrate the percent of net sales by segment for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g9.jpg" alt="613" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-9"/><img src="mdt-20250425_g10.jpg" alt="614" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-10"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes net sales by segment and division and market geography for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Sales by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.18pt">Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net sales for fiscal year 2025 was driven by growth in most businesses, including strong growth in Cardiac Ablation Solutions, Cardiac Pacing Therapies, TAVR, Diabetes, Neuromodulation, Spine, and Advanced Energy. The net sales increase was partially offset by declines in Stapling and a $90 million incremental Italian payback accrual resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><div id="ic14a750e81984b18a679ba753642023e_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiovascular </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular products include pacemakers, insertable cardiac monitors, cardiac resynchronization therapy devices, implantable cardioverter defibrillators, leads and delivery systems, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm &amp; Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents and related delivery systems, balloons and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, open heart and coronary bypass grafting surgical products, and renal denervation systems for the treatment of hypertension. Cardiovascular also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm &amp; Heart Failure division. Cardiovascular's net sales for fiscal year 2025 were $12.5 billion, an increase of 5 percent as compared to fiscal year 2024. The net sales increase was primarily due to the strong performance of Cardiac Ablation Solutions, Cardiac Rhythm Management, Structural Heart, and Cardiac Surgery.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of Cardiovascular net sales by division for fiscal years 2025 and 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g11.jpg" alt="1196" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-11"/><img src="mdt-20250425_g12.jpg" alt="1197" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-12"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac Rhythm &amp; Heart Failure (CRHF) net sales increased 7 percent in fiscal year 2025 as compared to fiscal year 2024. The net sales increase was driven by growth in Micra transcatheter pacing systems, Aurora extravascular implantable cardioverter defibrillator (EV-ICD) system, and TYRX, partially offset by declines in CRT-Ds. Cardiac Ablation Solutions experienced strong growth in PulseSelect and Affera Sphere-9 pulsed field ablation with partially offsetting declines in cryoablation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Structural Heart &amp; Aortic (SHA) net sales increased 6 percent in fiscal year 2025 as compared to fiscal year 2024. The net sales increase was driven by continued growth in Structural Heart from adoption of Evolut FX+ TAVR system and in Cardiac Surgery driven by growth in Perfusion and Surgical Valves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronary &amp; Peripheral Vascular (CPV) net sales increased 2 percent in fiscal year 2025 as compared to fiscal year 2024. The net sales increase was driven by growth in Coronary and Renal Denervation led by guide catheters, balloons, and the Symplicity Spyral renal denervation system, partially offset by a decline in stents and impacts from tender pricing in China in Peripheral Vascular Health. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the macro-economic and geopolitical factors described in the Executive Level Overview section, looking ahead, we expect Cardiovascular could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued global penetration of our Micra transcatheter pacing portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth from the Azure XT and Azure S SureScan pacing systems and the 3830 lead.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global adoption of Aurora EV-ICD.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth of the Cobalt and Crome portfolio of ICDs and CRT-Ds. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Growth of the CRT-P quadripolar pacing system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued growth, adoption, and utilization of the TYRX Envelope for implantable devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued use and acceptance of Reveal LINQ and expansion of the LINQ II cardiac monitor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance, adoption, and growth of our innovative portfolio of products in the electrophysiology (EP) segment, including the PulseSelect pulsed field ablation system and the Affera mapping and ablation system with Sphere-9 catheter. The Affera mapping and ablation system and Sphere-9 catheter received U.S. FDA approval in late October 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform. This includes Evolut PRO which provides enhanced hemodynamics, reliable delivery, enhanced durability, advanced sealing, and Evolut FX, a system designed to improve the overall procedural experience through enhancements in deliverability, implant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">visibility, and deployment stability. The Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access. The system was approved by the U.S. FDA in March 2024 and received CE Mark in late October 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and reimbursement for the Symplicity Spyral renal denervation system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Onyx Frontier drug-eluting stent (DES) platform. Onyx Frontier is a DES that introduces an enhanced delivery system and is used for complex percutaneous coronary intervention (PCI).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance and growth of IN.PACT 018 drug-coated balloons (DCB). IN.PACT 018 adds to the existing IN.PACT Admiral DCB portfolio and is used to treat femoropopliteal disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of, and commercialize the products within our pipeline.</span></div><div id="ic14a750e81984b18a679ba753642023e_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuroscience</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience's products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems, robotic guidance systems used in the robot-assisted spine procedures, and systems that incorporate advanced energy surgical instruments. Neuroscience's products also focus on therapies to treat the diseases of the vasculature in and around the brain, including coils, neurovascular stents, and flow diversion products, as well as products to treat ear, nose, and throat (ENT), and the treatment of overactive bladder and urinary retention. Neuroscience also manufactures products related to implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, and epilepsy. Neuroscience&#8217;s net sales for fiscal year 2025 were $9.8 billion, an increase of 5 percent as compared to fiscal year 2024. The net sales increase was primarily due to growth in Neuromodulation, Spine and Biologics, and Neurosurgery.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of Neuroscience net sales by division for fiscal years 2025 and 2024:</span></div><div style="margin-top:8pt;text-align:center"><img src="mdt-20250425_g13.jpg" alt="1102" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-13"/><img src="mdt-20250425_g14.jpg" alt="1103" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-14"/></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cranial &amp; Spinal Technologies (CST) net sales for fiscal year 2025 increased 5 percent as compared to fiscal year 2024. The net sales increase was driven by the continued adoption of the AiBLE ecosystem of spine implants and enabling technology with growth in Core Spine, Biologics, and Neurosurgery.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Specialty Therapies (Specialty) net sales for fiscal year 2025 increased 1 percent as compared to fiscal year 2024. The net sales increase was driven by growth on continued adoption of the Interstim X system and ENT, partially offset by impacts from tender pricing in China in Neurovascular.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Neuromodulation (NM) net sales for fiscal year 2025 increased 11 percent as compared to fiscal year 2024. The net sales increase was driven by growth in Pain Stimulation due to the continued launch of the Inceptiv closed-loop spinal cord stimulator, Brain Modulation driven by the Percept RC deep brain neurostimulator, and Interventional.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the macro-economic and geopolitical factors described in the Executive Level Overview section, looking ahead we expect Neuroscience could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued adoption and growth of our integrated solutions through the AiBLE offering, which integrates spinal implants with enabling technologies (StealthStation, O-arm Imaging Systems, and Midas), Mazor robotics, and UNiD Adaptive Spine Intelligence AI-driven technology for surgical planning and personalized spinal implants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and continued global adoption of innovative new spine products and procedural solutions within our CST operating unit, such as Catalyft PL, ModuLeX, CD Horizon Voyager System, and our Infinity OCT System, as well as continued growth from Titan spine titanium interbody implants with Nanolock technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued growth of commercially available Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Solitaire X revascularization device for treatment of acute ischemic stroke and our React Catheter and Riptide aspiration system.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our Pelvic Health therapies, including our InterStim therapy with InterStim X and InterStim II recharge-free neurostimulators and InterStim Micro rechargeable neurostimulator for patients suffering from overactive bladder, (non-obtrusive) urinary retention, and chronic fecal incontinence. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our ENT therapies, including capital equipment sales of the StealthStation ENT surgical navigation system and intraoperative NIM nerve monitoring system, and the Propel sinus implants used in the treatment of chronic rhinosinusitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth from spinal cord stimulation (SCS) therapy for treating chronic pain and Diabetic Peripheral Neuropathy (DPN) on the Inceptiv closed-loop rechargeable neurostimulator, Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator. The Inceptiv closed-loop rechargeable SCS received U.S. FDA approval in April 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of our Percept family of deep brain stimulation (DBS) devices with proprietary BrainSense technology for objectifying and personalizing the treatment of Parkinson's Disease, epilepsy, and other movement disorders. In August 2024, the U.S. FDA approved Asleep DBS surgery for people with Parkinson's and people with essential tremor. BrainSense Adaptive DBS and BrainSense Electrode Identifier received CE Mark in January 2025 and U.S. FDA approval in February 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of, and commercialize the products within our pipeline, which include the hemorrhagic stroke intravascular device, our next-generation spine enabling technologies, and the percutaneous tibial neuromodulation system.</span></div><div id="ic14a750e81984b18a679ba753642023e_64"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Surgical&#8217;s products span the entire continuum of patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, obesity, and preventable complications. The products include those for advanced and general surgical products, surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, interventional lung, airway products, and sensors and monitors for pulse oximetry, capnography, level of consciousness and cerebral oximetry. Medical Surgical&#8217;s net sales for fiscal year 2025 were $8.4 billion, flat as compared to fiscal year 2024, with performance outlined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below illustrate the percent of Medical Surgical net sales by division for fiscal years 2025 and 2024:</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><img src="mdt-20250425_g15.jpg" alt="940" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-15"/><img src="mdt-20250425_g16.jpg" alt="941" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-16"/></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical &amp; Endoscopy (SE) net sales for fiscal year 2025 were flat as compared to fiscal year 2024. Net sales were impacted by declines in Stapling, due to U.S. bariatric segment declines and continued shifts to robotic surgery, and Endoscopy. Partially offsetting these declines was strong growth in Advanced Energy, due to continued adoption of LigaSure vessel sealing technology.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acute Care &amp; Monitoring (ACM) net sales for fiscal year 2025 were flat as compared to fiscal year 2024. Net sales were impacted by growth of the BIS Advance monitoring system offset by declines in Medtronic Care Management Services.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the macro-economic and geopolitical factors described in the Executive Level Overview section, looking ahead we expect Medical Surgical could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance and continued growth of Open-to-MIS (minimally invasive surgery) techniques and tools through our efforts to transition open surgery to MIS. Open-to-MIS initiative focuses on capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, advanced instrumentation, or robotics. Through our approach, in parallel, we also expand our presence and optimize open surgery in current open surgery markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued global acceptance and future growth of powered stapling and energy platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to execute ongoing strategies addressing the pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to create markets and drive products and procedures into emerging markets with our high quality and cost-effective surgical products designed for customers in emerging markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth in patient monitoring and airway management. Key products in this area include Microstream Capnography, Nellcor pulse oximetry system with OxiMax technology, Shiley tracheostomy and endotracheal tubes, and McGRATH MAC video laryngoscopes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceptance of less invasive standards of care in chronic and colorectal, as well as hepatology products, including products that span the care continuum from diagnostics to therapeutics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding. Our expanded and strengthened surgical offerings complement our global gynecology business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global adoption of robotic-assisted surgery and the safe and effective use of the Hugo robotic assisted surgery (RAS) system, including system reliability and acceptability, for urologic, bariatric, gynecologic, hernia, and general surgery procedures. This </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes continued integration and adoption of Touch Surgery Enterprise with the first artificial intelligence powered surgical videos and analytics platform to make it easier to train and discover new techniques within the robotics platform. The Hugo RAS system, which received CE Mark in October 2021, as well as secured additional regulatory approvals outside the U.S., is designed to help reduce unwanted variability, improve patient outcomes, and, by extension, lower per procedure cost.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of, and commercialize the products within our pipeline, which include our Hugo RAS system in the U.S., the adoption of AI in Endoscopy and Digital Surgical Technologies, Signia powered stapling devices, and our next-gen Ligasure and Sonicision vessel sealing devices.</span></div><div id="ic14a750e81984b18a679ba753642023e_67"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diabetes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diabetes' products include insulin pumps, continuous glucose monitoring (CGM) systems, and consumables. Diabetes' net sales for fiscal year 2025 were $2.8 billion, an increase of 11 percent as compared to fiscal year 2024. The increase in net sales was primarily driven by strong U.S growth as a result of the continued adoption of the MiniMed 780G automated insulated delivery (AID) system, and strong international growth in CGM systems from increased attachment rates and adoption of Simplera Sync.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the macro-economic and geopolitical factors described in the Executive Level Overview section, looking ahead we expect Diabetes could be affected by the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The pending separation of the Diabetes business from the Company. In May 2025, the Company announced its intent to separate the Diabetes Operating Unit into a new standalone company, and its expectation to complete the separation within 18 months from the announcement date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth for the MiniMed 780G insulin pump system, which is powered by SmartGuard technology and features the added benefits of meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The global adoption of our AID systems has resulted in strong sensor attachment rates. The MiniMed 780G insulin pump system with the Guardian 4 Sensor is available in the U.S., and the MiniMed 780G insulin pump system with Simplera Sync received U.S. FDA approval in April 2025 and CE Mark in early January 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and growth of our sensor Simplera, which received U.S FDA approval in August 2024 and CE Mark in September 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued acceptance and growth of the Guardian Connect CGM system, which displays glucose information directly to a smartphone to provide patients access to their glucose levels seamlessly and discretely. The Guardian Connect CGM system is available on both Apple iOS and Android devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and growth of our InPen smart pen system, which allows users to have their Medtronic CGM readings in real-time alongside insulin dose information, all in one view. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued pump, CGM, and consumable competition in an expanding global market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in medical reimbursement policies and programs, along with additional payor coverage on insulin pumps.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval, manufacture and commercialize the products within our pipeline, including our partnership with Abbott to expand CGM options for people living with diabetes, our next generation insulin delivery options, as well as expanded labeling in Type 2 diabetes, and fast acting insulins.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSTS AND EXPENSES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of cost of products sold, research and development, and selling, general, and administrative expenses as a percent of net sales:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="mdt-20250425_g17.jpg" alt="179" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:600px" id="i-17"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of products sold for fiscal year 2025 was $11.6 billion as compared to $11.2 billion for fiscal year 2024. Cost of products sold as a percentage of net sales was flat as compared to the prior fiscal year. Cost of products sold increased primarily driven by increases in net sales and unfavorable currency impact partially offset by lower costs for quality remediation and excess and obsolete inventory charges. Fiscal year 2024 included $70 million of inventory write-downs associated with our February 2024 decision to exit our ventilator product line. For additional information about the ventilator inventory write-down, refer to Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. Looking ahead, we anticipate incurring additional costs related to current imposed and proposed tariffs. Refer to the Executive Level Overview section for further information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to deliver the best possible experiences for patients, physicians, and caregivers we serve; to create technologies that expand what&#8217;s possible across the human body to transform lives; to turn data and insights into real action to serve patient needs, improving care; and to expand healthcare access and deliver positive outcomes. Research and development expense for fiscal years 2025 and 2024 was $2.7 billion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General, and Administrative Expense  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our goal is to continue to leverage selling, general, and administrative expense management initiatives. Selling, general, and administrative expense primarily consists of salaries and wages, other administrative costs, such as professional fees and marketing expenses, certain acquisition and divestiture-related costs, and restructuring associated expenses. Selling, general, and administrative expense for fiscal year 2025 was $10.8 billion as compared to $10.7 billion for fiscal year 2024. The increase in selling, general, and administrative expense is primarily due to new product launches and commercialization activities.</span></div><div id="ic14a750e81984b18a679ba753642023e_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other costs and expenses (income):</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ic14a750e81984b18a679ba753642023e_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of customer relationships, purchased technology and patents, trademarks, tradenames, and other intangible assets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for fiscal year 2025 includes $151 million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio.</span></div><div id="ic14a750e81984b18a679ba753642023e_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges, Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In fiscal years 2025 and 2024, restructuring costs primarily related to cost reduction initiatives, which predominantly included employee termination benefits, facility consolidations, and asset write-downs, and specifically for fiscal year 2025, contract terminations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our restructuring programs, refer to Note 4 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div id="ic14a750e81984b18a679ba753642023e_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Litigation Charges, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We classify specified certain litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. For additional information, refer to Note 18 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div id="ic14a750e81984b18a679ba753642023e_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating (income) expense, net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating (income) expense, net primarily includes expenses associated with royalties paid for the in-license of intellectual property from third parties, currency remeasurement and derivative gains and losses, changes in the fair value of contingent consideration, certain acquisition and divestiture-related items, and income from funded research and development arrangements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2025, the change in other operating (income) expense, net was largely driven by a decrease in acquisition and divestiture-related expenses as well as insignificant gains from certain business or asset sales in the Cardiovascular and Neuroscience Portfolios during fiscal year 2025. In fiscal year 2024, acquisition and divestiture-related expenses included $369&#160;million of charges related to the Company's decision to exit the ventilator product line, which primarily included intangible asset impairments of $295&#160;million and other charges for contract cancellation costs and severance. In addition, the change in fair value of contingent consideration for fiscal year 2025 was $42&#160;million of expense as compared to $156&#160;million of expense for fiscal year 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in other operating (income) expense, net was partially offset by the net impact of currency remeasurement and our hedging programs. The currency impact for fiscal year 2025 was a net loss of $3 million as compared to a net gain of $68&#160;million in fiscal year 2024.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information on the charges associated with the ventilator product line exit is described in Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div id="ic14a750e81984b18a679ba753642023e_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Non-Operating Income, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Other non-operating income, net includes the non-service component of net periodic pension and postretirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $511&#160;million and $597&#160;million for fiscal year 2025 and 2024, respectively. Income from the non-service component of net periodic pension and postretirement benefit cost was $107&#160;million and $124&#160;million for fiscal year 2025 and 2024, respectively. Net losses on minority investments were $213&#160;million and $308&#160;million for fiscal year 2025 and 2024, respectively. </span></div><div id="ic14a750e81984b18a679ba753642023e_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Interest expense, net includes interest incurred on our outstanding borrowings, global liquidity structures, amortization of debt issuance costs and debt premiums or discounts, and amortization of amounts excluded from the effectiveness assessment of certain net investment and fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense, net was primarily driven by the &#8364;3.0&#160;billion debt issuance in June 2024, partially offset by lower borrowing balances in our global liquidity structures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCOME TAXES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.035%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income tax provision</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Nominal Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference between the effective tax rate and Non-GAAP Nominal Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two Model Rules. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two Model Rules, which were effective for Medtronic in fiscal year 2025. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for fiscal year 2025 was 16.6 percent, as compared to 23.4 percent in fiscal year 2024. The decrease in our effective tax rate was primarily attributable to the establishment of a valuation allowance on certain net operating losses and an income tax reserve adjustment made in fiscal year 2024 associated with the Ventor court decision noted above, which was partially offset by the Swiss Cantonal tax rate change on previously recorded deferred tax assets in fiscal year 2024 and the implementation of the Pillar Two Model Rules noted above in fiscal year 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Non-GAAP Nominal Tax Rate for fiscal year 2025 was 16.7 percent, as compared to 16.0 percent in fiscal year 2024. The change in our Non-GAAP Nominal Tax Rate was primarily due to the implementation of the Pillar Two Model Rules and year-over-year changes in operational results by jurisdiction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2025 and 2024, operational tax costs were not significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increase in our Non-GAAP Nominal Tax Rate of one percent would result in an additional income tax provision for fiscal years 2025 and 2024 of approximately</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$85 million and</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$83 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Tax Adjustments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, the cost from certain tax adjustments of $62 million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, included amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $299 million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $124 million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $50 million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $33 million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain tax adjustments will affect the comparability of our operating results between periods. Therefore, we consider these Non-GAAP Adjustments. Refer to the "Executive Level Overview" section of this Management's Discussion and Analysis for further discussion of these adjustments.</span></div><div id="ic14a750e81984b18a679ba753642023e_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in a strong financial position, and we believe our balance sheet and liquidity as of April&#160;25, 2025 provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity and capital structure are evaluated regularly within the context of our annual operating and strategic planning processes. We consider the liquidity necessary to fund our operations, which includes working capital needs, investments in research and development, property, plant, and equipment, and other operating costs. We also consider capital allocation alternatives that balance returning value to shareholders through dividends and share repurchases, satisfying maturing debt, and acquiring businesses and technology.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of cash provided by (used in) operating, investing, and financing activities, the effect of exchange rate changes on cash and cash equivalents, and the net change in cash and cash equivalents:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The $257 million increase in net cash provided was primarily driven by an increase in cash collected from customers due to an increase in sales, partially offset by an increase in cash paid to vendors, annual incentive payouts, and cash paid for taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $429 million decrease in net cash used was primarily attributable to an increase in net sales and maturities of investments of $576 million and decrease in cash paid for acquisitions of $113 million, partially offset by an increase in net additions to property, plant, and equipment of $272 million. For more information on the acquisitions, refer to Note 3 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was an $89 million decrease in net cash used compared to the prior fiscal year. In the current period, there was a decrease in total short-term borrowings of $1.1 billion, compared to an increase of $1.1&#160;billion in the prior year. Additionally, in June  2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;3.0&#160;billion, or $3.2&#160;billion, which was partially offset by an $873 million increase in net share repurchases during fiscal year 2025. For more information on Senior Notes issued, refer to the Debt and Capital section below.</span></div><div id="ic14a750e81984b18a679ba753642023e_100"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Capital</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital structure consists of equity and interest-bearing debt. We primarily utilize unsecured senior debt obligations to meet our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt at April&#160;25, 2025 was $28.5 billion, as compared to $25.0 billion at April&#160;26, 2024. The increase in total debt was primarily driven by issuance of Euro-denominated Senior Notes and fluctuations in exchange rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchase our ordinary shares on occasion as part of our focus on returning value to our shareholders. In March 2019, the Company's Board of Directors authorized $6.0&#160;billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an additional $5.0 billion for repurchase of the Company's ordinary shares. There is no specific time period associated with these repurchase authorizations. During fiscal years 2025 and 2024, the Company repurchased a total of 38 million and 25 million shares, respectively, under this program at an average price of $83.36 and $83.04, respectively. At April&#160;25, 2025, we had approximately $2.1 billion remaining under the share repurchase program authorized by our Board of Directors. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on credit arrangements, refer to Note 6 of the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our liquidity sources at April&#160;25, 2025 included $2.2 billion of cash and cash equivalents and $6.7 billion of current investments. Additionally, we maintain commercial paper programs and a Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments primarily include available-for-sale debt securities, including U.S. and non-U.S. government and agency securities, corporate debt securities, mortgage-backed securities, and other asset-backed securities. Refer to Note 5 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K for additional information regarding fair value measurements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain multicurrency commercial paper programs for short-term financing, which allow us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $3.5 billion. At April&#160;25, 2025 and April&#160;26, 2024, we had no and $1.1 billion of commercial paper outstanding, respectively. The issuance of commercial paper reduces the amount of credit available under our existing line of credit, as explained below.</span></div><div style="margin-bottom:7.7pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a $3.5 billion five-year syndicated credit facility (Credit Facility), which expires in December 2029. At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides backup funding for the commercial paper programs and may also be used for general corporate purposes. The Credit Facility provides us with the ability to increase our borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. At April&#160;25, 2025 and April&#160;26, 2024, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:7.7pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances of our Credit Facility are determined by a pricing matrix based on our long-term debt ratings assigned by Standard &amp; Poor's Ratings Services (S&amp;P) and Moody's Investors Service (Moody&#8217;s). Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. We are in compliance with all covenants related to the Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our S&amp;P and Moody's long-term debt ratings and short-term debt ratings:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agency Rating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard &amp; Poor's Ratings Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Moody's Investors Service </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P-2</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Agency ratings are subject to change, and there may be no assurance that an agency will continue to provide ratings and/or maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S&amp;P and Moody's long-term debt ratings and short-term debt ratings at April&#160;25, 2025 were unchanged as compared to the ratings at April&#160;26, 2024. We do not expect the S&amp;P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, Credit Facility, and related commercial paper programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Cash Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business, some of which are recorded in our consolidated balance sheet. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows.  </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is a summary of our off-balance sheet contractual obligations and other minimum commercial commitments at April&#160;25, 2025, as well as long-term contractual obligations reflected in the balance sheet at April&#160;25, 2025.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2030</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Contractual obligations related to off-balance sheet arrangements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to fund minority investments, milestone payments, and royalty obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Contractual obligations reflected in the balance sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-114">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-115">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-116">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-117">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-118">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-119">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commitments related to the funding of minority investments, estimated milestone payments, and royalty obligations. While it is not certain if and/or when payments will be made, the maturity dates included in the table reflect our best estimates. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the contractual interest payments on our outstanding debt and excludes the impacts of debt premium and discount amortization. See Note 6 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K for additional information on our debt agreements.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes inventory purchase commitments, research and development, and other arrangements that are legally binding and specify minimum purchase quantities or spending amounts. These purchase commitments do not exceed our projected requirements and are in the normal course of business. Excludes open purchase orders with a remaining term of less than one year.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes defined benefit plan obligations, guarantee obligations, uncertain tax positions, non-current tax liabilities, and litigation settlements for which we cannot make a reliable estimate of the period of cash settlement. For further information, see Notes 13, 15, and 18 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the current and non-current portion of our contractual maturities of debt, excluding deferred financing costs and debt discounts, net. See Note 6 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K for additional information on our debt agreements.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the fair value of our current and non-current portions of contingent consideration. While it is not certain if and/or when payments will be made, the maturity dates included in this table reflect our best estimates. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the tax obligations associated with the transition tax that resulted from U.S. Tax Reform. The transition tax will be paid over an eight-year period and will not accrue interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into agreements that require us to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of our products or the negligence of our personnel or claims alleging that our products infringe third-party patents or other intellectual property. Our maximum exposure under these indemnification provisions is unable to be estimated, and we have not accrued any liabilities within our consolidated financial statements or included any indemnification provisions in the table above. Historically, we have not experienced significant losses on these types of indemnification agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K provides information regarding amounts we have accrued related to legal matters. In accordance with U.S. GAAP, we record a liability in our consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. Actual settlements may be different than estimated and could have a material effect on our consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record tax liabilities in our consolidated financial statements for amounts that we expect to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts we consider to be permanently reinvested. We expect to have access to the majority of our cash flows in the future. In addition, we continue to evaluate our legal entity structure supporting our business operations, and to the extent such evaluation results in a change to our overall business structure, we may be required to accrue for additional tax obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. (collectively, "Blackstone") to receive funding related to the development of certain products, which may give rise to potential regulatory or commercialization milestone payments and royalties based on a percentage of sales of such products. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones or relevant product sales, which may span several years and which may never occur. These contractual obligations are not included within the table above. Refer to Note 3 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the contractual obligations and other minimum commercial commitments outlined above, we have recurring cash requirements arising from the normal operation of our business that include capital expenditures, research and developments costs, and other operational costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our balance sheet and liquidity provide us with flexibility, and our cash, cash equivalents, current investments, Credit Facility and related commercial paper programs, as well as our ability to generate operating cash flows, will satisfy our current and future contractual obligations and cash requirements.&#160;We regularly review our capital needs and consider various investing and financing alternatives to support our requirements.</span></div><div id="ic14a750e81984b18a679ba753642023e_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITIONS AND DISPOSITIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding acquisitions and disposition activity is included in Note 3 of the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" within this Annual Report on Form 10-K. In May 2025, we announced our intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement. </span></div><div id="ic14a750e81984b18a679ba753642023e_112"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 1 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect our best judgment about economic and market conditions and the potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting estimates include the following:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Revenue recognition on our products varies depending on the amount of consideration we ultimately receive due to return terms, sales rebates, chargebacks, discounts, and other incentives, which are accounted for as variable consideration. The estimate of variable consideration for rebates and distributor chargebacks is considered critical due to the materiality of the balances and use of estimates. Estimates for rebates are based on sales terms, historical experience, and trend analysis. The Company considers the lag time between the point of sale and payment of the rebate claim, the stated rebate rates, and other relevant information to estimate rebates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue adjustments related to distributor chargebacks are the difference between distributor sales price and the end-customer negotiated price. A provision for outstanding chargebacks is recorded when we recognize revenue from our sale to the distributor and requires estimates for the distributor chargeback rate, expected sell-through levels by the distributors to contracted customers, as well as estimated distributor inventory levels. </span></div><div style="margin-bottom:8pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025 and April&#160;26, 2024, there were $1.7 billion and $1.6 billion of rebates and chargebacks recorded in the consolidated balance sheets, respectively. During fiscal year 2025, adjustments to rebate and chargebacks recorded in prior periods were not material.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   We are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder-related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. Estimating probable losses from our litigation and governmental proceedings is inherently difficult, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines, or punitive damages, or could result in a change in business practice. We base our judgments on the best information </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available at the time. Our estimates related to our legal and product liability accruals may change as additional information becomes available to us, including information related to the nature or existence of claims against us, trial court or appellate proceedings, and mediation, arbitration or settlement proceedings. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results. Our significant legal proceedings are discussed in Note 18 to the consolidated financial statements in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Reserves  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions across our global operations. We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when there is (i) a completion of a tax audit, (ii) effective settlement of an issue, (iii) a change in applicable tax law including a tax case or legislative guidance, or (iv) the expiration of the applicable statute of limitations. These reserves are subject to a high degree of estimation and management judgment. Although we believe that we have adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Intangible Assets and Goodwill   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we acquire a business, the assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. Intangible assets primarily include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development. Determining the fair value of intangible assets acquired as part of a business combination requires us to make significant estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, the discount rate used to discount those cash flows to present value, and the assessment of the asset&#8217;s life cycle. The estimates could be impacted by legal, technical, regulatory, economic, and competitive risks.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four goodwill reporting units with goodwill assigned to them. We assess the impairment of goodwill at the reporting unit level annually as of the first day of the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment of goodwill requires us to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. We estimated the fair value of these reporting units using the income and the market approaches, weighted 50 percent each. Fair value under the income approach was determined by discounting to present value the estimated future cash flows of the reporting unit. Fair value under the market approach utilized revenue and earnings multiples using comparable public company information, which uses valuation indicators determined from other businesses that are similar to our reporting unit. We use estimates that are consistent with the highest and best use of the assets based on a market participant's view of the assets being evaluated.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most critical assumptions used in the calculation of the fair value of each reporting unit are the projected revenue, projected earnings, projected future cash flows, and discount rate. Our forecast of future cash flows is based on estimates of projected revenue and projected earnings, based primarily on pricing, raw material costs, market share, industry outlook, general economic conditions and strategic actions to improve our earnings. The fair value of the reporting unit&#8217;s goodwill is sensitive to differences between estimated and actual cash flows, including changes in the projected revenue, projected earnings, and discount rate used to evaluate the fair value of the reporting unit. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights the sensitivities of the most critical assumptions used in the goodwill impairment test as of the date of our annual testing:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assumption:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate % by which the fair value exceeds the carrying value based on annual impairment test</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20% - 312%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate % by which the fair value exceeds the carrying value if the discount rate was to increase 1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12% - 282%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate % by which the fair value exceeds the carrying value if the future cash flows in the income approach and revenue and earnings in the market approach were to decrease by 5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13% - 290%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe our estimate of fair value is reasonable, actual results may differ from our estimates due to a number of factors including, among others, changes in competitive conditions, timing of regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates.</span></div><div id="ic14a750e81984b18a679ba753642023e_115"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding new accounting pronouncements is included in Note 1 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL GUARANTOR FINANCIAL INFORMATION </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Senior Notes (Medtronic Luxco Senior Notes). The following is a summary of these guarantees:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of Medtronic Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - Medtronic, Inc.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantor - Medtronic Luxco</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of Medtronic Luxco Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - Medtronic Luxco</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantor - Medtronic, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees of CIFSA Senior Notes</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parent Company Guarantor - Medtronic plc</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Issuer - CIFSA</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present summarized financial information for the fiscal year ended April&#160;25, 2025 for the obligor groups of Medtronic and Medtronic Luxco Senior Notes, and CIFSA Senior Notes. The obligor group consists of the parent company guarantor, subsidiary issuer, and subsidiary guarantors for the applicable senior notes. The summarized financial information is presented after elimination of (i) intercompany transactions and balances among the guarantors and issuers and (ii) equity in earnings from and investments in any subsidiary that is a non-guarantor or issuer.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized results of operations information for the fiscal year ended April&#160;25, 2025 was as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medtronic &amp; Medtronic Luxco Senior Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CIFSA Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Medtronic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized balance sheet information for the fiscal year ended April&#160;25, 2025 was as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medtronic &amp; Medtronic Luxco Senior Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CIFSA Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The CIFSA Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, CIFSA, and CIFSA Subsidiary Guarantors. Refer to the guarantee summary above for further details.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes receivables due from non-guarantor subsidiaries of $14.2&#160;billion and $1.3&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes loans receivable due from non-guarantor subsidiaries of $5.2&#160;billion and $5.2&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes payables due to non-guarantor subsidiaries of $16.0&#160;billion and $4.6&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes loans payable due to non-guarantor subsidiaries of $11.3&#160;billion and $7.7&#160;billion for Medtronic &amp; Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENCY EXCHANGE RATE RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, we are exposed to currency exchange rate changes, which may cause fluctuations in earnings and cash flows. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. The gross notional amount of all currency exchange rate derivative instruments outstanding at April&#160;25, 2025 and April&#160;26, 2024 was $23.6&#160;billion and $23.7&#160;billion, respectively. At April&#160;25, 2025, these contracts were in a net unrealized loss position of $68&#160;million. Additional information regarding our currency exchange rate derivative instruments is included in Note 7 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at April&#160;25, 2025 and April&#160;26, 2024 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by approximately $1.6&#160;billion and $1.7&#160;billion, respectively. Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTEREST RATE RISK</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio at April&#160;25, 2025 was comprised of debt predominantly denominated in U.S. dollars and Euros, which is primarily fixed rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of the impact on our interest rate-sensitive financial instruments of a hypothetical 50 basis point change in interest rates, as compared to interest rates at April&#160;25, 2025 and April&#160;26, 2024, indicates that the fair value of these instruments would correspondingly change by $74&#160;million and $64&#160;million, respectively.</span></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of current market conditions and the impact on our financial condition and results of operations, see the &#8220;Liquidity&#8221; section of the Management's Discussion and Analysis in "Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. For additional discussion of market risk, see Notes 5 and 7 to the consolidated financial statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div id="ic14a750e81984b18a679ba753642023e_127"></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Medtronic plc</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Medtronic plc and its subsidiaries (the "Company") as of April 25, 2025 and April 26, 2024, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended April 25, 2025, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended April 25, 2025 appearing under Item 15 (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of April 25, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of April 25, 2025 and April 26, 2024, and the results of its operations and its cash flows for each of the three years in the period ended April 25, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of April 25, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Reserve for the Uncertain Tax Position Related to Puerto Rico Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 13 and 18 to the consolidated financial statements, management records reserves for uncertain tax positions related to unresolved matters with the Internal Revenue Service (IRS) and other taxing authorities. A remaining unresolved issue with the IRS relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's manufacturing sites. These reserves are subject to a high degree of estimation and management judgment. Total reserves relating to uncertain tax positions as of April 25, 2025 were $2.902 billion, of which the Puerto Rico manufacturing reserve makes up a significant portion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the income tax reserve for the uncertain tax position related to Puerto Rico manufacturing is a critical audit matter are (i) the significant judgment by management when determining the reserve, including a high degree of estimation uncertainty relative to the unresolved issue with the IRS involving one of the Company&#8217;s manufacturing sites; and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management&#8217;s measurement of the income tax reserve for the uncertain tax position related to Puerto Rico manufacturing, as the nature of the evidence is often highly subjective. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the recognition of the income tax reserves for uncertain tax positions, as well as controls over measurement of the reserve for the uncertain tax position related to Puerto Rico manufacturing. These procedures also included, among others (i) testing management&#8217;s process for determining the reserve, (ii) evaluating the status and results of the related U.S. Tax Court case, and (iii) evaluating the consistency of the reserve calculation with the relevant documents related to the U.S. Tax Court case. Evaluating the reasonableness of the measurement of the reserve included evaluating whether the methodology and assumptions used by the Company were consistent with the U.S. Tax Court&#8217;s ruling.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.466%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-120">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-121">Minneapolis, Minnesota</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1963.</span><span style="background-color:#ffffff;color:#000000;font-family:'Georgia',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-122">33,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-123">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-124">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-125">11,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-126">11,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-127">10,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-128">2,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-129">2,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-130">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-131">10,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-132">10,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-133">10,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-134">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-135">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-136">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-137">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-138">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-139">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="f-140">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="f-141">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="f-142">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-143">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-144">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-145">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-146">5,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-147">5,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-148">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-149">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-150">412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-151">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-152">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-153">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-154">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-155">5,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-156">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-157">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-158">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-159">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-160">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-161">4,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-162">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-163">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-164">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-165">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-166">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Medtronic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-167">4,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-168">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-169">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-170">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">2.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172">2.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174">2.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-176">1,285.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-177">1,327.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-178">1,329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-179">1,289.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-180">1,330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-181">1,332.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-182">4,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-183">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-184">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-185">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-186">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-187">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-188">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-189">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-190">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-191">1,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" scale="6" id="f-192">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" scale="6" id="f-193">596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in retirement obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-194">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-195">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-196">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-197">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-198">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-199">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-200">964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-201">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-202">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income including noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-203">3,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-204">3,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-205">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-206">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-207">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-208">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income attributable to Medtronic</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-209">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-210">3,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-211">2,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-212">2,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-213">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-214">6,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-215">6,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowances and credit losses of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-216">199</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-217">173</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-218">6,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-219">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-220">5,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-221">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-222">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-223">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-224">23,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-225">21,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-226">6,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-227">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-228">41,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-229">40,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-230">11,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-231">13,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-232">4,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-233">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-234">3,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-235">4,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-236">91,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-237">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-238">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-239">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-240">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-241">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-242">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-243">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-244">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-245">1,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-246">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-247">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-248">12,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-249">10,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-250">25,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-251">23,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued compensation and retirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-252">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-253">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-254">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-255">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-256">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-257">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-258">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-259">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-260">43,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-261">39,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies (Notes 3, 16, and 18)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-24" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-262"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-27" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-263"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-264"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-265">0.0001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="9" id="f-266"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="9" id="f-267">2.6</ix:nonFraction></ix:nonFraction> billion shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-268"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-269">1,281,934,628</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-270"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-271">1,311,337,531</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-274">20,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-275">23,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-276">31,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-277">30,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-278">4,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-279">3,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-280">48,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-281">50,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-282">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-283">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-284">48,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-285">50,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-286">91,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-287">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Equity</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.309%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>&#160;Shareholders&#8217;<br/>&#160;Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-288">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-290">24,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-291">30,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-292">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-293">52,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-294">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-295">52,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-296">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-297">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-298">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-299">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-300">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-301">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-302">1,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-303">2.72</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-304">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-305">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-306">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-307">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-308">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-309">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-310">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-311">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-312">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-313">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="f-314">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-315">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-316">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-317">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-318">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-319">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-320">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-321">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-322">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-324">24,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-325">30,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-326">3,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-327">51,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-328">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-329">51,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-330">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-331">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-332">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-333">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-334">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-335">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-336">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-337">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-338">2.76</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-339">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-340">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-341">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-342">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-343">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-344">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-345">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-346">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-347">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-348">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-349">2,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-350">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-351">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-352">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-353">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-354">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-355">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-357">23,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-358">30,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-359">3,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-360">50,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-361">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-362">50,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-363">4,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-364">4,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-365">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-366">4,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-367">966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-368">966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-369">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-370">964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-371">2.80</ix:nonFraction> per ordinary share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-372">3,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-373">3,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-374">3,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under stock purchase and award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-375">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-376">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-377">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-378">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-379">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-380">3,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-381">3,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-382">3,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-383">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-384">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-385">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes to noncontrolling ownership interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-386">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="f-387">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-388">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-390">20,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-391">31,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-392">4,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-393">48,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-394">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-395">48,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-396">4,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-397">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-398">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-399">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-400">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-401">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-402">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-403">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-404">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-405">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-406">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-407">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-408">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-409">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-410">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-413">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and related inventory write-downs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-415">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-417">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-418">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-419">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-420">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-421">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable" scale="6" id="f-422">576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-423">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-424">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-425">939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-426">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-427">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-428">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-429">538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-430">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-431">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-432">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-433">6,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-434">6,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-435">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-436">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-437">1,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-438">1,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-439">1,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-440">1,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-441">8,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-442">7,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-443">7,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-444">8,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-445">7,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-446">7,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-447">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-448">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-449">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-450">1,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-451">2,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-452">3,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in current debt obligations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-453">1,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-454">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:fixed-zero" scale="6" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings (maturities greater than 90 days)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-458">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments from short-term borrowings (maturities greater than 90 days)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-461">2,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-462">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-464">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-467">6,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-468">3,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-469">3,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-470">3,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-471">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-472">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-473">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-474">3,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-475">2,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-476">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-477">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-478">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-479">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-480">4,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-481">4,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-482">4,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-483">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-484">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-485">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-486">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-487">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-488">2,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-489">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-490">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-491">3,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-492">2,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-493">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-494">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-495">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-496">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-497">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-498">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-499">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-500">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_148"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-501" continuedAt="f-501-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-501-1" continuedAt="f-501-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company &#8211; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Galway, Ireland. In May 2025, the Company announced its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-502-1"> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-503" escape="true">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-504" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible assets, equity investments, and liability valuations. Actual results may or may not differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FiscalPeriod" id="f-505" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for each of the three fiscal years ended April&#160;25, 2025 (fiscal year 2025), April&#160;26, 2024 (fiscal year 2024), and April&#160;28, 2023 (fiscal year 2023).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-506" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-507" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-508" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-501-2" continuedAt="f-501-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-509" continuedAt="f-509-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-509-1"> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-510" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div></ix:nonNumeric><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-511" continuedAt="f-511-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-511-1">  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-512" continuedAt="f-512-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-513">three</span> to <ix:nonNumeric contextRef="c-73" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-514">20</ix:nonNumeric> years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-512-1">When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the asset group's carrying value to its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group is estimated by utilizing a discounted cash flow analysis.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-515" escape="true">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="mdt:ContingentConsiderationPolicyTextBlock" id="f-516" continuedAt="f-516-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-501-3" continuedAt="f-501-4"><ix:continuation id="f-516-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:SelfInsuranceReservePolicyTextBlock" id="f-517" continuedAt="f-517-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-517-1"> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="f-518" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. Refer to Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-519" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-520" continuedAt="f-520-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency exchange rate contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-501-4" continuedAt="f-501-5"><ix:continuation id="f-520-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-521" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For certain of our capital equipment, control is transferred upon installation. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-522">322</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-523">341</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-524">351</ix:nonFraction> million in fiscal years 2025, 2024, and 2023, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-525" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-526" continuedAt="f-526-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-526-1">  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-527" continuedAt="f-527-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-527-1">  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.</ix:continuation>&#160;See Note 13 for more information on the Company's uncertain tax positions and tax policies.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-501-5"><ix:nonNumeric contextRef="c-1" name="mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock" id="f-528" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating (Income) Expense, Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating (income) expense, net primarily includes royalty expense, currency remeasurement and derivative gains and losses, changes in fair value of contingent consideration, certain acquisition and divestiture-related items, income from funded research and development arrangements, Puerto Rico excise taxes, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock" id="f-529" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-530" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-531" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-532" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements but did require additional disclosures. Refer to Note 6 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company retrospectively adopted this guidance beginning in the fourth quarter of fiscal year 2025. The adoption of this standard did not have a material impact on the Company's consolidated financial statements but did require additional disclosures. Refer to Note 19 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Revenue </ix:nonNumeric></span></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-534" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-535">6,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-536">5,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-537">5,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-538">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-539">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-540">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-541">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-542">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-543">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-544">12,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-545">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-546">11,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-547">4,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-548">4,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-549">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-550">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-551">2,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-552">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-553">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-554">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-555">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-556">9,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-557">9,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-558">8,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-559">6,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-560">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-561">6,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-562">1,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-563">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-564">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-565">8,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-566">8,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-567">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-568">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-569">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-570">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-571">33,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-572">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-573">30,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-574">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-575">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-576">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-577">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-580">33,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-581">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-582">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-583">5,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-584">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-585">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-586">6,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-587">6,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-588">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-589">6,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-590">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-591">6,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-592">3,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-593">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-594">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-595">3,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-596">3,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-597">3,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-598">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-599">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-600">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-601">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-602">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-603">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-604">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-605">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-606">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-607">17,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-608">16,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-609">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-610">16,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-611">15,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-612">14,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-613">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-614">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-615">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-616">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-617">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-618">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-622">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-625">17,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-626">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-627">16,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-628">16,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-629">15,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-630">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;25, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-631">983</ix:nonFraction>&#160;million of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-632">680</ix:nonFraction>&#160;million of reba</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-533-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tes were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. At April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-8" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="9" id="f-633">1.0</ix:nonFraction> billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="f-634">574</ix:nonFraction> million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. During fiscal year 2025, adjustments to rebate and return reserves recorded in prior periods were not material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue at April&#160;25, 2025 and April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-635">446</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-636">453</ix:nonFraction>&#160;million, respectively. At April&#160;25, 2025 and April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-637">354</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-638">352</ix:nonFraction>&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-639">92</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-640">101</ix:nonFraction>&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. During the fiscal year ended&#160;April&#160;25, 2025, the Company recognized&#160;$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-641">320</ix:nonFraction> million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;26, 2024. During the fiscal year ended April&#160;26, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-642">324</ix:nonFraction> million of revenue that was included in deferred revenue at April&#160;28, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;25, 2025, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="f-643">0.3</ix:nonFraction>&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="f-644">three years</ix:nonNumeric>.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_154"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-645" continuedAt="f-645-1" escape="true">Acquisitions, Dispositions, and Funded Research and Development Arrangements </ix:nonNumeric></span></div><ix:continuation id="f-645-1" continuedAt="f-645-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had acquisitions during fiscal years 2025 and 2024 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#8217;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2025 and 2024 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2025 and 2024 business combinations were not significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during fiscal year 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-646">128</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="f-647">159</ix:nonFraction> million of assets acquired and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="f-648">31</ix:nonFraction> million of liabilities assumed. Based on preliminary valuations, assets acquired were primarily comprised of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-649">108</ix:nonFraction>&#160;million of goodwill and $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-650">50</ix:nonFraction>&#160;million of IPR&amp;D. The goodwill is not deductible for tax purposes. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-651">20</ix:nonFraction>&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2025, which comprised of other milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during fiscal year 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-652">335</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="6" id="f-653">338</ix:nonFraction>&#160;million of assets acquired and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-654">3</ix:nonFraction>&#160;million of liabilities assumed. Assets acquired were primarily comprised of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-655">131</ix:nonFraction>&#160;million of goodwill, $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-656">150</ix:nonFraction>&#160;million of IPR&amp;D, and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-657">29</ix:nonFraction>&#160;million of technology-based intangible assets with estimated useful lives of <ix:nonNumeric contextRef="c-182" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-658">10</ix:nonNumeric> years. For tax purposes, $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:GoodwillImpairmentLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-659">51</ix:nonFraction>&#160;million of goodwill is deductible while $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:GoodwillNotAllocatedAmount" format="ixt:num-dot-decimal" scale="6" id="f-660">80</ix:nonFraction>&#160;million is not deductible. The IPR&amp;D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-661">30</ix:nonFraction>&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2024, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disposal Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ventilator Product Line Exit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-662">439</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-663">369</ix:nonFraction>&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-664">70</ix:nonFraction>&#160;million recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income in fiscal year 2024. The charges included $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" format="ixt:num-dot-decimal" scale="6" id="f-665">371</ix:nonFraction>&#160;million of non-cash impairments and write-downs primarily related to $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-666">295</ix:nonFraction>&#160;million of long-lived asset impairments to write-down the value of related intangible assets to zero and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-667">70</ix:nonFraction>&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-645-2" continuedAt="f-645-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Care Solutions (RCS) Disposition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale was part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#8220;Mozarc Medical&#8221; or "Mozarc") with equal equity ownership. At closing, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-668">45</ix:nonFraction>&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-669">195</ix:nonFraction>&#160;million, made an additional cash investment of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-670">224</ix:nonFraction>&#160;million, and retained a <ix:nonFraction unitRef="number" contextRef="c-188" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-671">50</ix:nonFraction>% non-controlling equity interest in Mozarc valued at $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="f-672">307</ix:nonFraction>&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-673">300</ix:nonFraction>&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-674">136</ix:nonFraction>&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#8217;s retained <ix:nonFraction unitRef="number" contextRef="c-192" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-675">50</ix:nonFraction>% equity investment in Mozarc as a result of this transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration liabilities at April&#160;25, 2025 and April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-676">81</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-677">149</ix:nonFraction> million, respectively. At April&#160;25, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-678">31</ix:nonFraction> million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-679">50</ix:nonFraction> million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. At April&#160;26, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-680">96</ix:nonFraction> million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-681">53</ix:nonFraction> million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-682" continuedAt="f-682-1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-683">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-684">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" scale="6" id="f-685">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:BusinessAcquisitionPriceContingentConsideration" scale="6" id="f-686">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:BusinessAcquisitionContingentConsiderationMilestonePayment" scale="6" id="f-687">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:BusinessAcquisitionContingentConsiderationMilestonePayment" scale="6" id="f-688">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-689">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-690">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-691">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-692">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-693" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:26.766%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-694">54</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-695">16.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-195" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-696">28.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-697">23.1</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="padding:0 1pt"/><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-698">27</ix:nonFraction>&#160;</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-198" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-699">5.5</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-199" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-700">5.5</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-645-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at April&#160;25, 2025 and April&#160;26, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-701">13</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-702">58</ix:nonFraction>&#160;million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. </span></div><ix:continuation id="f-682-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-703">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-704">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" sign="-" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" scale="6" id="f-705">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" sign="-" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" scale="6" id="f-706">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-707">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" scale="6" id="f-708">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funded Research and Development Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. (collectively, "Blackstone") to receive funding related to the development of certain products within the Cardiovascular Portfolio and Diabetes Operating Unit. As there is substantive and genuine transfer of risk to Blackstone, the development funding is recognized by Medtronic as an obligation to perform contractual services. The Company recognizes the funding as income within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-709">other operating (income) expense, net</span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the research and development costs are incurred and funding payments become due. Under these arrangements, the Company recognized income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-710">181</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-711">174</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-712">202</ix:nonFraction>&#160;million in fiscal years 2025, 2024, and 2023, respectively. As of April&#160;25, 2025, the Company is eligible to receive additional funding of $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="6" id="f-713">391</ix:nonFraction>&#160;million under these arrangements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following potential U.S. regulatory approval and commercial launch of each product covered by the Blackstone agreements, Blackstone will be eligible to receive a combination of fixed regulatory and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-8" name="mdt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-714">1.2</ix:nonFraction>&#160;billion and royalties based on percent of sales of such products. Under certain termination provisions, the Company's payment obligation will survive, and in certain termination circumstances, a payment to Blackstone of a multiple of the funded amounts may be required. At the time of executing these contracts, the occurrence of such circumstances was deemed to be remote.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_157"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-715" continuedAt="f-715-1" escape="true">Restructuring Charges </ix:nonNumeric></span></div><ix:continuation id="f-715-1" continuedAt="f-715-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal years 2025 and 2024, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-716">303</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-717">389</ix:nonFraction> million, respectively, of restructuring and associated costs primarily related to cost reduction initiatives, which predominantly included employee termination benefits, facility consolidations, and asset write-downs, and specifically for fiscal year 2025, contract terminations. In fiscal year 2023, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#8217;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="f-718">1.8</ix:nonFraction> billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="f-719">0.5</ix:nonFraction> billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-8" name="us-gaap:RestructuringCharges" scale="9" id="f-720">0.3</ix:nonFraction> billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and, specifically for fiscal year 2023, voluntary early retirement benefits. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting fees, asset write-offs, and contract terminations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-721" continuedAt="f-721-1" escape="true"><ix:continuation id="f-715-2" continuedAt="f-715-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-722"><span style="-sec-ix-hidden:f-723"><span style="-sec-ix-hidden:f-724">Cost of products sold</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-725">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-726">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-727">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-728"><span style="-sec-ix-hidden:f-729"><span style="-sec-ix-hidden:f-730">Selling, general, and administrative expenses</span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-731">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-732">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-733">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-734">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-735">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" scale="6" id="f-736">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-737">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-738">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-739">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-740">94</ix:nonFraction>&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-741">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-742">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-743">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-744">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-745">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-746">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-747">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-748">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-749">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-751">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-752">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-753">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:fixed-zero" scale="6" id="f-754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-755">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-756">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-757">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-758">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-759">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-760">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:RestructuringChargesIncludingAccrualAdjustments" scale="6" id="f-761">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-762">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-763">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-764">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-766">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-767">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-768">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:fixed-zero" scale="6" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="f-770">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-771">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-772">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-773">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-721-1" continuedAt="f-721-2"><ix:continuation id="f-715-3" continuedAt="f-715-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:continuation id="f-721-2"><ix:continuation id="f-715-4">Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.</ix:continuation></ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-774" continuedAt="f-774-1" escape="true">Financial Instruments </ix:nonNumeric></span></div><ix:continuation id="f-774-1" continuedAt="f-774-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-775" continuedAt="f-775-1" escape="true">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;25, 2025 and April&#160;26, 2024:</ix:nonNumeric></span></div><ix:continuation id="f-775-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-776">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-778">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-779">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-780">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-782">3,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-783">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-784">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-785">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-786">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-788">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-790">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-791">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-792">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-794">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-795">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-796">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-797">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-798">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-800">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-803">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-804">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-806">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-807">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-808">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-809">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-810">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-812">6,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-813">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-814">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-815">6,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-816">6,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-818">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-820">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-821">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-823">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-824">6,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-825">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-826">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-827">6,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-828">6,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-829">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-830">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-832">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-833">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-834">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-836">3,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-837">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-838">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-839">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-840">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-842">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-844">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-845">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-846">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-848">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-849">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-850">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-851">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-852">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-854">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-857">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-858">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-860">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-861">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-862">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-863">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-864">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-866">6,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-867">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-868">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-869">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-870">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-872">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-874">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-875">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-877">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-878">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-879">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-880">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-881">6,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-882">6,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-883">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of debt securities excludes accrued interest, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-774-2" continuedAt="f-774-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-884" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;25, 2025 and April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-885">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-886">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-887">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-888">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-889">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-890">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-891">641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-892">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-893">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-894">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-895">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-896">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-899">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-900">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-903">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-904">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-905">814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-906">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-907">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-908">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-909">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-910">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-911">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-912">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-913">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-914">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-915">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-916">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-919">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-920">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-921">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-923">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-924">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-927">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-928">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-929">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-930">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-931">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-932">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-933" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company&#8217;s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-934">8,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-935">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-936">7,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-937">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-938">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-939">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-940">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-941">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-942">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-943" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-944">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-945">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-946">3,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-947">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="f-948">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="f-949">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-950">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-951">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-952">6,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-953">6,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-774-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, which includes income on marketable debt securities and the global liquidity structures, is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of income. For fiscal years 2025, 2024, and 2023 there was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="f-954">511</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-955">597</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-956">386</ix:nonFraction>&#160;million of interest income, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities, Equity Method Investments, and Other Investments</span></div><ix:nonNumeric contextRef="c-1" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" id="f-957" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;25, 2025 and April&#160;26, 2024, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-958">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-959">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="f-960">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="f-961">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-962">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-963">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-964">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-965">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" scale="6" id="f-966">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-967">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="mdt:ScheduleOfInvestmentsTableTextBlock" id="f-968" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="f-969">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:GainOnInvestments" scale="6" id="f-970">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:LossOnInvestments" scale="6" id="f-971">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="6" id="f-972">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, there were $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-973">181</ix:nonFraction>&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;25, 2025. During fiscal year 2024, there were $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-974">291</ix:nonFraction>&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mozarc Medical Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a <ix:nonFraction unitRef="number" contextRef="c-188" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-975">50</ix:nonFraction>% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During fiscal year 2025 and 2024, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="6" id="f-976">171</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="6" id="f-977">220</ix:nonFraction>&#160;million, respectively, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-978" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-979">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-980">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" scale="6" id="f-981">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" scale="6" id="f-982">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-983">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-984">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-985" continuedAt="f-985-1" escape="true">Financing Arrangements </ix:nonNumeric></span></div><ix:continuation id="f-985-1" continuedAt="f-985-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="f-986" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-987">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-988">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-989">0.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-990">six</span>-year 2019 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-991">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-993">0.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-994">five</span>-year 2020 senior notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-995">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-997">2.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-998">three</span>-year 2022 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-999">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-1000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1001">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1002">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="f-1003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-1004">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">Current debt obligations</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1007">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1008">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In January 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and in January 2020, Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-8" name="mdt:CommercialPaperMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1009">3.5</ix:nonFraction>&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-302" decimals="INF" name="us-gaap:DebtCurrent" format="ixt:fixed-zero" scale="0" id="f-1010">no</ix:nonFraction> commercial paper outstanding at April&#160;25, 2025. During fiscal year 2025, the weighted average original maturity of the commercial paper outstanding was approximately <ix:nonNumeric contextRef="c-303" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1011">13</ix:nonNumeric> days and the weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="c-303" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" format="ixt:num-dot-decimal" scale="-2" id="f-1012">5.02</ix:nonFraction> percent. There was $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="f-1013">1.1</ix:nonFraction>&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately <ix:nonNumeric contextRef="c-305" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1014">20</ix:nonNumeric> days and the weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="c-306" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" format="ixt:num-dot-decimal" scale="-2" id="f-1015">5.45</ix:nonFraction> percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Line of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In October 2024, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2029.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility provides for a $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-1016">3.5</ix:nonFraction> billion&#160;<ix:nonNumeric contextRef="c-308" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1017">five-year</ix:nonNumeric> unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a <ix:nonNumeric contextRef="c-308" name="mdt:LineOfCreditFacilityLengthOfExtension" format="ixt-sec:durwordsen" id="f-1018">one-year</ix:nonNumeric> extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="INF" name="mdt:LineOfCreditFacilityAdditionalBorrowingCapacity" scale="9" id="f-1019">1.0</ix:nonFraction> billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;25, 2025 and April&#160;26, 2024, <ix:nonFraction unitRef="usd" contextRef="c-309" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-1020"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-1021">no</ix:nonFraction></ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#8217;s long-term debt ratings, assigned by Standard &amp; Poor&#8217;s Ratings Services and Moody&#8217;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-985-2" continuedAt="f-985-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1022" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.238%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1023">0.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1024">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1027">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1028">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1029">0.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1030">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1033">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1034">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1035">2.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1036">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1039">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1040">2.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1041">1.125</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1042">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1043">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1044">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1045">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1046">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1047">4.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1048">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1049">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1050">4.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1051">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-316" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1052">4.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1053">3.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1054">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1055">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1056">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1057">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-319" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1058">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1059">0.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1060">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1061">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-320" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1062">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1063">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1064">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1065">3.650</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1066">five</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1067">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1068">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-325" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1071">1.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1072">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1073">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1074">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1075">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-328" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1076">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-329" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1077">1.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1078">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1079">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-329" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1080">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1081">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-331" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1082">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-332" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1083">3.125</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1084">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1085">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-332" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1086">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1087">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-334" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1088">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-335" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1089">0.750</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1090">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1091">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-335" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1092">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1093">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-337" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1094">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-338" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1095">4.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1096">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1097">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-338" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1098">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1099">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-340" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1100">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-341" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1101">3.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1102">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1103">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-341" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1104">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1105">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-343" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1106">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-344" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1107">4.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1108">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1109">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-344" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1110">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1111">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-346" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1112">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1113">3.875</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1114">twelve</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1115">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1116">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-349" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-350" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1119">6.550</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1120">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1121">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-350" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1122">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1123">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-352" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1124">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-353" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1125">2.250</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1126">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1127">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-353" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1128">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1129">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-355" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1130">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-356" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1131">6.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1132">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1133">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-356" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1134">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1135">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1136">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1137">1.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1138">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1139">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1140">1.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1141">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1142">1.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1143">5.550</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1144">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1145">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-362" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1146">5.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1147">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-364" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1148">5.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-365" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1149">1.375</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1150">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1151">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-365" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1152">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1153">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-367" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1154">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-368" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1155">4.500</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1156">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1157">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-368" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1158">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1159">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-370" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1160">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-371" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1161">4.000</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1162">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1163">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-371" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1164">4.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1165">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-373" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1166">4.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1167">4.150</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1168">nineteen</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1169">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1170">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-376" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-377" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1173">4.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1174">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1175">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-377" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1176">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1177">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-379" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1178">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-380" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1179">4.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1180">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1181">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-380" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1182">4.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1183">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-382" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1184">4.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-383" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1185">1.750</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1186">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1187">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-383" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1188">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1189">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-385" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1190">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-386" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1191">1.625</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1192">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1193">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-386" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1194">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1195">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-388" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1196">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-389" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1197">4.150</ix:nonFraction> percent <span style="-sec-ix-hidden:f-1198">twenty-nine</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1199">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-389" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1200">4.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-391" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1203"><span style="-sec-ix-hidden:f-1204">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1205">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1206">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1207">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1208">10.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="f-1209">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="f-1210">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1211">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1212">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-1213">25,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-1214">23,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, Medtronic Inc. issued <ix:nonFraction unitRef="tranche" contextRef="c-392" decimals="INF" name="mdt:DebtInstrumentNumberofTranches" format="ixt-sec:numwordsen" scale="0" id="f-1215">four</ix:nonFraction> tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1216">3.0</ix:nonFraction>&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-8" name="us-gaap:ProceedsFromRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1217">3.2</ix:nonFraction>&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-985-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Agreements   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#165;<ix:nonFraction unitRef="jpy" contextRef="c-394" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1218">300</ix:nonFraction>&#160;billion with a term of <ix:nonNumeric contextRef="c-395" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1219">364</ix:nonNumeric> days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-395" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1220">0.40</ix:nonFraction>% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#165;<ix:nonFraction unitRef="jpy" contextRef="c-395" decimals="-9" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1221">297</ix:nonFraction>&#160;billion, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-8" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1222">2.3</ix:nonFraction>&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1223">1.9</ix:nonFraction>&#160;billion of Medtronic Inc.'s <ix:nonFraction unitRef="number" contextRef="c-397" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1224">3.500</ix:nonFraction>% Senior Notes due 2025 for $<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-8" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-1225">1.9</ix:nonFraction>&#160;billion of total consideration, and $<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1226">368</ix:nonFraction>&#160;million of Medtronic Luxco's <ix:nonFraction unitRef="number" contextRef="c-400" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1227">3.350</ix:nonFraction>% Senior Notes due 2027 for $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1228">376</ix:nonFraction>&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1229">53</ix:nonFraction>&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1230" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1231">2,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1232">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1233">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1234">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="f-1235">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1236">19,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1237">28,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. For fiscal years 2025, 2024, and 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1238">913</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1239">916</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1240">743</ix:nonFraction>&#160;million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the estimated fair value of the Company&#8217;s Senior Notes was $<ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-8" name="us-gaap:LongTermDebtFairValue" scale="9" id="f-1241">26.2</ix:nonFraction> billion compared to a principal value of $<ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="f-1242">28.6</ix:nonFraction> billion. At April&#160;26, 2024, the estimated fair value was $<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-8" name="us-gaap:LongTermDebtFairValue" scale="9" id="f-1243">21.2</ix:nonFraction> billion compared to a principal value of $<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="f-1244">24.0</ix:nonFraction> billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplier Financing Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a supplier financing program that provides participating suppliers the ability to finance payment obligations from the Company with third-party financial institutions in order to receive earlier payment. The Company&#8217;s standard payment term is 90 days. The Company&#8217;s outstanding payables to its suppliers, including amounts due and payment terms, are not affected by a supplier&#8217;s participation in the program. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025 and April&#160;26, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:SupplierFinanceProgramObligation" scale="6" id="f-1245">100</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:SupplierFinanceProgramObligation" scale="6" id="f-1246">96</ix:nonFraction> million of outstanding payables, respectively, associated with the supplier financing program recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplierFinanceProgramTableTextBlock" id="f-1247" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of outstanding payables confirmed as valid associated with the program during fiscal year 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:SupplierFinanceProgramObligation" scale="6" id="f-1248">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invoices confirmed during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationIncrease" scale="6" id="f-1249">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confirmed invoices paid during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationDecreaseSettlement" scale="6" id="f-1250">517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1251">Ending Balance</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:SupplierFinanceProgramObligation" scale="6" id="f-1252">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1253" continuedAt="f-1253-1" escape="true">Derivatives and Currency Exchange Risk Management </ix:nonNumeric></span></div><ix:continuation id="f-1253-1" continuedAt="f-1253-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair Value Hedges</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of a fixed-rate debt obligation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a straight-line basis over the term of the hedge and were not significant for the fiscal year ended April&#160;25, 2025. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cash Flow Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash flow hedges will mature within the subsequent <ix:nonNumeric contextRef="c-404" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durwordsen" id="f-1254">two-year</ix:nonNumeric> period. At April&#160;25, 2025 and April&#160;26, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1255">149</ix:nonFraction> million in after-tax unrealized losses and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1256">229</ix:nonFraction> million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company expects that $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" scale="6" id="f-1257">62</ix:nonFraction> million of after-tax net unrealized losses at April&#160;25, 2025 will be recognized in the consolidated statements of income over the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instruments that are designated as net investment hedges, the gains or losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the term of the instrument. For fiscal years 2025, 2024, and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-1258">198</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-1259">197</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-1260">107</ix:nonFraction> million, respectively, of after-tax unrealized gains related to excluded components in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1261">interest expense</span>, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Undesignated Derivatives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward exchange contracts to offset the Company&#8217;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#8217;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1253-2" continuedAt="f-1253-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1262" continuedAt="f-1262-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1263">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="9" id="f-1264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1265">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1266">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1267">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1268">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1269">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1270">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1271">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1272">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1273">1.0</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1274">1.1</ix:nonFraction> billion, designated as hedges of a portion of our fixed-rate debt obligations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1275">5.0</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1276">5.7</ix:nonFraction> billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;<ix:nonFraction unitRef="jpy" contextRef="c-416" decimals="-9" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1277">322</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1278">2.3</ix:nonFraction> billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2026 through 2033. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1279">18.0</ix:nonFraction> billion, or $<ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-1280">20.6</ix:nonFraction> billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.</span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments</span></div><ix:continuation id="f-1262-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.704%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="f-1281">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="f-1283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="f-1284">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1287">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1288">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1289">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1290">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1291">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1292">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1293">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1294">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1295">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1296">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1297">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1298">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1299">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1300">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1301">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1305">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1306">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1307">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1311">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-1312">1,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-1313">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1314">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1315">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1316">706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1317">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1318">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1319">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1253-3" continuedAt="f-1253-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1320" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;25, 2025 and April&#160;26, 2024. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1321">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1322">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1323">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1324">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1325">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1326">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1327">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1328">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1329">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1330">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1331">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1332">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1333">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1334">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1335">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1336">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-1337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-1338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1339">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="f-1340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1341">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1342">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1343">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1344">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1345">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1346">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1347">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1348">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1349" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"/><td style="width:47.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.220%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1350">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1351">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1352">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1353">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1354">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1355">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1356">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1357">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1359">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1362">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1363">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1364">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1365">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1253-4" continuedAt="f-1253-5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OffsettingAssetsTableTextBlock" id="f-1367" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:OffsettingLiabilitiesTableTextBlock" id="f-1366" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1368">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="f-1369">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="f-1370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" scale="6" id="f-1371">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1372">401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="f-1373">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="f-1374">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" scale="6" id="f-1375">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1376">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" format="ixt:fixed-zero" scale="6" id="f-1377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="f-1378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" scale="6" id="f-1379">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1380">417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="f-1381">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="f-1382">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" scale="6" id="f-1383">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability" scale="6" id="f-1384">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" format="ixt:fixed-zero" scale="6" id="f-1385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1386">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet" scale="6" id="f-1387">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1388">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="f-1389">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="f-1390">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" scale="6" id="f-1391">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1392">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="f-1393">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="f-1394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" format="ixt:fixed-zero" scale="6" id="f-1395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability" scale="6" id="f-1396">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" format="ixt:fixed-zero" scale="6" id="f-1397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1398">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet" scale="6" id="f-1399">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="f-1253-5" continuedAt="f-1253-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;25, 2025 the Company posted net cash collateral of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1400">125</ix:nonFraction> million to its counterparties. Cash collateral posted is recorded as a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the offset recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. As of April&#160;26, 2024, the Company received net cash collateral of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" scale="6" id="f-1401">101</ix:nonFraction> million from its counterparties. Cash collateral received is recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the offset recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1253-6"> in the consolidated balance sheets.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-1402" continuedAt="f-1402-1" escape="true">Inventories </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-1403" escape="true"><ix:continuation id="f-1402-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1404">3,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1405">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-1406">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-1407">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-1408">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-1409">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1410">5,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1411">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ic14a750e81984b18a679ba753642023e_175"></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1412" continuedAt="f-1412-1" escape="true">Goodwill and Other Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="f-1412-1" continuedAt="f-1412-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1413" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1414">7,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1415">11,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1416">19,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1417">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1418">41,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1419">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1423">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1424">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1428">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1429">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1430">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1431">458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-1432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1433">565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1434">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1435">11,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1436">19,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1437">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1438">40,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1441">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-1442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1443">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1444">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1446">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1449">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1450">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1451">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1452">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-1453">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1454">8,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1455">11,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1456">19,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1457">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1458">41,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1459"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1460">no</ix:nonFraction></ix:nonFraction>t recognize any goodwill impairment charges during fiscal years 2025 or 2024. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="6" id="f-1461">208</ix:nonFraction>&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1462">61</ix:nonFraction>&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1412-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-1464" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-1463" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1465">16,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1466">9,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1467">16,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1468">8,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1469">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1470">7,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1471">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1472">6,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1473">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1474">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1475">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1476">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1477">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1478">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1479">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1480">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1481">28,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1482">17,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1483">28,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1484">15,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1485">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1486">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1487"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1488">no</ix:nonFraction></ix:nonFraction>t recognize any definite-lived intangible asset impairment charges during fiscal years 2025 and 2023. During fiscal year 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-1489">295</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-1490">definite-lived intangible asset impairment charges</span> in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1491">no</ix:nonFraction> indefinite-lived intangible asset impairment charges during fiscal year 2025. Indefinite-lived intangible asset impairment charges were <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1492"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-1493">not</ix:nonFraction></ix:nonFraction> significant for fiscal year 2024 and 2023. Due to the nature of IPR&amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-1494">1.8</ix:nonFraction> billion for fiscal year 2025, including $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="mdt:AcceleratedAmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1495">151</ix:nonFraction>&#160;million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-1496"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-1497">1.7</ix:nonFraction></ix:nonFraction> billion for fiscal years 2024 and 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1498" continuedAt="f-1498-1" escape="true">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;25, 2025, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1498-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1499">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1500">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1501">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1502">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1503">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1504" continuedAt="f-1504-1" escape="true">Property, Plant, and Equipment </ix:nonNumeric></span></div><ix:continuation id="f-1504-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1505" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1506">7,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1507">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally <ix:nonNumeric contextRef="c-486" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1508">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-487" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1509">10</ix:nonNumeric>, up to <ix:nonNumeric contextRef="c-484" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1510">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1511">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1512">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-490" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1513">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-1514">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="f-1515">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-493" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1516">20</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1517">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1518">2,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="c-496" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1519">40</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1520">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1521">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1522">15,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1523">14,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1524">8,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1525">7,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1526">6,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1527">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:Depreciation" scale="9" id="f-1528">1.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-1529">954</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-1530">999</ix:nonFraction> million was recognized in fiscal years 2025, 2024, and 2023, respectively.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_181"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1531" continuedAt="f-1531-1" escape="true">Shareholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-1531-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Capital   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="9" id="f-1532">2.6</ix:nonFraction> billion Ordinary Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1533">0.0001</ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="mdt:DeferredStockSharesAuthorized" scale="3" id="f-1534">40</ix:nonFraction> thousand Euro Deferred Shares, &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-24" decimals="INF" name="mdt:DeferredStockParorStatedValuePerShare" scale="0" id="f-1535">1.00</ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-1536">127.5</ix:nonFraction> million Preferred Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1537">0.20</ix:nonFraction> par value; and <ix:nonFraction unitRef="shares" contextRef="c-499" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="f-1538">500</ix:nonFraction> thousand A Preferred Shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-499" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1539">1.00</ix:nonFraction> par value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Euro Deferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="mdt:DeferredStockSharesAuthorized" scale="3" id="f-1540">40</ix:nonFraction> thousand Euro Deferred Shares, with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-24" decimals="INF" name="mdt:DeferredStockParorStatedValuePerShare" scale="0" id="f-1541">1.00</ix:nonFraction> per share. At April&#160;25, 2025, <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="mdt:DeferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1542"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="mdt:DeferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1543">no</ix:nonFraction></ix:nonFraction>&#160;Euro Deferred Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-1544">127.5</ix:nonFraction> million of Preferred Shares, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1545">0.20</ix:nonFraction> per share. At April&#160;25, 2025, <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1546"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1547">no</ix:nonFraction></ix:nonFraction>&#160;Preferred&#160;Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes <ix:nonFraction unitRef="shares" contextRef="c-499" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="f-1548">500</ix:nonFraction> thousand A Preferred Shares, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-499" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1549">1.00</ix:nonFraction> per share. At April&#160;25, 2025, <ix:nonFraction unitRef="shares" contextRef="c-499" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" scale="0" id="f-1550">no</ix:nonFraction> A Preferred Shares were outstanding. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Share Repurchase Program   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares are repurchased on occasion to support the Company&#8217;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2025 and 2024, the Company repurchased approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-1551">38</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-1552">25</ix:nonFraction> million shares, respectively, at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="mdt:StockRepurchaseProgramAveragePurchasePrice" scale="0" id="f-1553">83.36</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="mdt:StockRepurchaseProgramAveragePurchasePrice" scale="0" id="f-1554">83.04</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors authorized $<ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1555">6.0</ix:nonFraction>&#160;billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an additional $<ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1556">5.0</ix:nonFraction>&#160;billion for repurchase of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations. At April&#160;25, 2025, the Company had used the $<ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1557">6.0</ix:nonFraction>&#160;billion authorized in March 2019 and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="9" id="f-1558">2.9</ix:nonFraction> billion of the $<ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1559">5.0</ix:nonFraction>&#160;billion authorized in March 2024, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="f-1560">2.1</ix:nonFraction> billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_184"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1561" continuedAt="f-1561-1" escape="true">Stock Purchase and Award Plans </ix:nonNumeric></span></div><ix:continuation id="f-1561-1" continuedAt="f-1561-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2025, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;25, 2025, there were approximately <ix:nonFraction unitRef="shares" contextRef="c-502" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1562">67</ix:nonFraction> million shares available for future grants under the 2021 Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1561-2" continuedAt="f-1561-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense   </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1563" continuedAt="f-1563-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:</span></ix:nonNumeric></div><ix:continuation id="f-1563-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1564">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1565">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1566">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1567">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1568">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1569">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1570">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1571">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1572">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1573">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1574">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1575">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1576">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1577">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1578">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1579">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1580">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1581">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1582">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1583">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1584">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1585">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1586">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1587">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1588">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1589">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1590">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1591">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1592">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1593">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1594">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1595">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1596">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Options are granted at the exercise price, which is equal to the closing price of the Company&#8217;s ordinary shares on the grant date. The majority of the Company&#8217;s options are non-qualified options with a <ix:nonNumeric contextRef="c-503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1597">ten-year</ix:nonNumeric> life and a <ix:nonNumeric contextRef="c-503" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1598">four-year</ix:nonNumeric> ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#8217;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#8217;s ordinary shares. Implied volatility is based on market traded options of the Company&#8217;s ordinary shares.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1599" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1600">16.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1601">18.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1602">17.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1603">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1604">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1605">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1606">4.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1607">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1608">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1609">24.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1610">24.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1611">24.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1612">3.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1613">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1614">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1615" continuedAt="f-1615-1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2025:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-518" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1616">32,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-518" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1617">93.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-503" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1618">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-503" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1619">80.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-503" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1620">6,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-503" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1621">77.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-503" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1622">1,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-503" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1623">96.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-519" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1624">27,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-519" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1625">95.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1626">5.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-1627">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-519" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1628">7,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-519" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1629">88.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1630">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-1631">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-519" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-1632">19,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-519" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1633">97.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1634">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-1635">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1561-3" continuedAt="f-1561-4"><ix:continuation id="f-1615-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1636">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1637">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1638">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1639">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1640">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1641">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1642">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1643">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1644">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to outstanding stock options at April&#160;25, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1645">66</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-503" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1646">2.3</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a <ix:nonNumeric contextRef="c-520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1647">four-year</ix:nonNumeric> ratable vesting term or cliff vest after <ix:nonNumeric contextRef="c-521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1648">three years</ix:nonNumeric>. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-1649" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-522" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1650">6,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-522" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1651">92.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-523" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1652">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-523" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1653">82.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-523" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1654">2,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-523" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1655">99.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-523" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1656">636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-523" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1657">88.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-524" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1658">7,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-524" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1659">85.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-523" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1660">82.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-525" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1661">82.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-526" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1662">91.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1663">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1664">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1665">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1666">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1667">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1668">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to restricted stock as of April&#160;25, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1669">414</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-523" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1670">2.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance share units typically cliff vest after <ix:nonNumeric contextRef="c-509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1671">three years</ix:nonNumeric>. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on invested capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the <ix:nonNumeric contextRef="c-509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1672">three-year</ix:nonNumeric> period will vary, based on only actual performance, from <ix:nonFraction unitRef="number" contextRef="c-527" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1673">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-528" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1674">200</ix:nonFraction>% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1561-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-1675" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-529" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1676">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-529" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1677">106.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-509" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1678">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-509" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1679">98.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-509" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1680">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-509" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1681">147.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-509" decimals="-3" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" scale="3" id="f-1682">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-509" decimals="2" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" scale="0" id="f-1683">97.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-509" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1684">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-509" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1685">103.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-530" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1686">3,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-530" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1687">100.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-509" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1688">98.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-510" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1689">104.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-511" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1690">98.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1691">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1692">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="6" id="f-1693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1694">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1695">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:fixed-zero" scale="6" id="f-1696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to performance share units as of April&#160;25, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1697">90</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-509" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1698">1.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees Stock Purchase Plan (ESPP)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Medtronic plc 2024 Employee Stock Purchase Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#8217;s ESPP is equal to the <ix:nonFraction unitRef="number" contextRef="c-531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" format="ixt:num-dot-decimal" scale="-2" id="f-1699">15</ix:nonFraction> percent discount the employee receives. Employees purchased <ix:nonFraction unitRef="shares" contextRef="c-531" decimals="-6" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" scale="6" id="f-1700">3</ix:nonFraction> million shares at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-531" decimals="2" name="mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" scale="0" id="f-1701">72.27</ix:nonFraction> per share in fiscal year 2025. At April&#160;25, 2025, approximately <ix:nonFraction unitRef="shares" contextRef="c-532" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="f-1702">26</ix:nonFraction> million ordinary shares were available for future purchase under the ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1703" continuedAt="f-1703-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-1703-1" continuedAt="f-1703-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision is based on income before income taxes reported for financial statement purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1704" continuedAt="f-1704-1" escape="true">The components of income before income taxes, based on tax jurisdiction, are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1704-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1705">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1706">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1707">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1708">4,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1709">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1710">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1711">5,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1712">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1713">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1714" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1715">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1716">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1717">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1718">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1719">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1720">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1721">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1722">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1723">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1724">322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1725">435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1726">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1727">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1728">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1729">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1730">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1731">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1732">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1733">936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1734">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1735">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1703-2" continuedAt="f-1703-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1736" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1737">11,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1738">11,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1739">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1740">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization" format="ixt:num-dot-decimal" scale="6" id="f-1741">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization" format="ixt:num-dot-decimal" scale="6" id="f-1742">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1743">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1744">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="f-1745">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="f-1746">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1747">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1748">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1749">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1750">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-1751">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-1752">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsLeaseObligations" scale="6" id="f-1753">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsLeaseObligations" scale="6" id="f-1754">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" scale="6" id="f-1755">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" scale="6" id="f-1756">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsInterestLimitation" scale="6" id="f-1757">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsInterestLimitation" scale="6" id="f-1758">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" scale="6" id="f-1759">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" scale="6" id="f-1760">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1761">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1762">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1763">17,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1764">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1765">12,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1766">13,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1767">5,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1768">5,006</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1769">1,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1770">1,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="f-1771">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="f-1772">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1773">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="f-1774">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1775">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1776">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries" scale="6" id="f-1777">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries" scale="6" id="f-1778">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" scale="6" id="f-1779">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" scale="6" id="f-1780">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1781">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1782">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1783">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1784">1,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-1785">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PrepaidTaxes" scale="6" id="f-1786">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="f-1787">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:IncomeTaxReceivable" scale="6" id="f-1788">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1789">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1790">3,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsNetofValuationAllowanceOther" format="ixt:num-dot-decimal" scale="6" id="f-1791">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:DeferredTaxAssetsNetofValuationAllowanceOther" scale="6" id="f-1792">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1793">4,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1794">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-1795">403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-1796">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1797">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1798">3,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred taxes have been provided on the approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" scale="9" id="f-1799">88.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" scale="9" id="f-1800">86.3</ix:nonFraction> billion of undistributed earnings of the Company&#8217;s subsidiaries at April&#160;25, 2025 and April&#160;26, 2024, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-8" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1801">10.8</ix:nonFraction> billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="9" id="f-1802">4.8</ix:nonFraction> billion have no expiration, and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="9" id="f-1803">6.0</ix:nonFraction> billion will expire during fiscal years 2026 through 2045. Included in these net operating loss carryforwards are $<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-8" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1804">3.9</ix:nonFraction> billion of tax effected net operating losses generated in fiscal year 2008 as a result </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1703-3" continuedAt="f-1703-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1805">4.9</ix:nonFraction>&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-8" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="9" id="f-1806">2.0</ix:nonFraction> billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1807">53</ix:nonFraction> million of tax effected U.S. federal net operating loss carryforwards, of which $<ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1808">35</ix:nonFraction>&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2026 through 2036. For U.S. state purposes, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1809">84</ix:nonFraction> million of tax effected net operating loss carryforwards at April&#160;25, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1810">12</ix:nonFraction>&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2026 through 2044.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company also had $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1811">313</ix:nonFraction> million of tax credits available to reduce future income taxes payable, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" scale="6" id="f-1812">136</ix:nonFraction> million have no expiration. The remaining credits will expire during fiscal years 2026 through 2042. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has established valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="9" id="f-1813">12.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="9" id="f-1814">13.3</ix:nonFraction> billion at April&#160;25, 2025 and April&#160;26, 2024, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The decrease in the valuation allowance during fiscal year 2025 is primarily related to a decrease in the Luxembourg tax rate applied to previously recorded deferred tax assets and associated valuation allowances and current year utilization of attributes with a full valuation allowance due to certain intercompany transactions. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1815" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1816">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1817">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1818">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1819">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1820">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1821">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1822">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1823">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1824">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" format="ixt:fixed-zero" scale="-2" id="f-1825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" format="ixt:fixed-zero" scale="-2" id="f-1826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" scale="-2" id="f-1827">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1828">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1829">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1830">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1831">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1832">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1833">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1834">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1835">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="f-1836">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" format="ixt:fixed-zero" scale="-2" id="f-1837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" scale="-2" id="f-1838">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" format="ixt:fixed-zero" scale="-2" id="f-1839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1840">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1841">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1842">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1843">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1844">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1845">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1846">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1847">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-1848">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1849">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1850">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1851">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1852">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1853">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1854">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two Global Minimum Tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which were effective for Medtronic in fiscal year 2025. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="f-1855">187</ix:nonFraction>&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, the cost from certain tax adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1856">62</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, relates to amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1857">299</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, included the following:</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1703-4" continuedAt="f-1703-5"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-1858">187</ix:nonFraction>&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1859">124</ix:nonFraction>&#160;million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1860">95</ix:nonFraction>&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1861">50</ix:nonFraction>&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" format="ixt:num-dot-decimal" scale="6" id="f-1862">33</ix:nonFraction>&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the net benefit from certain tax adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="6" id="f-1863">910</ix:nonFraction>&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" format="ixt:num-dot-decimal" scale="6" id="f-1864">764</ix:nonFraction>&#160;million associated with the August 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#8217;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" format="ixt:num-dot-decimal" scale="6" id="f-1865">55</ix:nonFraction>&#160;million related to the disallowance of certain interest deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:num-dot-decimal" scale="6" id="f-1866">30</ix:nonFraction>&#160;million related to the change in reporting currency for certain carryover attributes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1867">28</ix:nonFraction>&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-1868">33</ix:nonFraction>&#160;million primarily associated with the sale of half of the Company&#8217;s RCS business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company&#8217;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions, inclusive of Pillar Two global minimum tax impacts, as compared to the local statutory rate favorably impacted earnings by $<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" format="ixt:num-dot-decimal" scale="6" id="f-1869">294</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" scale="6" id="f-1870">229</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxHolidays" scale="6" id="f-1871">115</ix:nonFraction> million in fiscal years 2025, 2024, and 2023, respectively, and diluted earnings per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="c-537" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1872">0.23</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-538" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1873">0.17</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-539" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1874">0.09</ix:nonFraction>, in fiscal years 2025, 2024, and 2023, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2026 and 2049. The tax incentive grants which expired during fiscal year 2025 did not have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1703-5" continuedAt="f-1703-6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="f-1875">2.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="f-1876">2.8</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="f-1877">2.7</ix:nonFraction> billion of gross unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1878" continuedAt="f-1878-1" escape="true">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2025, 2024, and 2023 is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1878-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1879">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1880">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1881">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1882">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1883">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1884">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1885">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1886">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1887">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1888">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1889">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1890">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1891">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1892">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1893">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1894">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1895">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1896">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1897">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1898">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1899">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1900">934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1901">934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:CashAdvancePaidinConnectionWithProposedSettlements" scale="6" id="f-1902">918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" format="ixt:num-dot-decimal" scale="6" id="f-1903">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" format="ixt:num-dot-decimal" scale="6" id="f-1904">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid" format="ixt:num-dot-decimal" scale="6" id="f-1905">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all of the Company&#8217;s unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023 were recognized, $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="f-1906">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="f-1907">2.7</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="f-1908">2.5</ix:nonFraction> billion would impact the Company&#8217;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#8217;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="9" id="f-1909">1.9</ix:nonFraction> billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1910">17</ix:nonFraction>&#160;million, net as a result of statute of limitation lapses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to income tax matters in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income and records the liability in the current or noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets, as appropriate. During fiscal years 2025, 2024, and 2023, the Company recognized gross interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" scale="6" id="f-1911">55</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" scale="6" id="f-1912">134</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:IncomeTaxExaminationInterestIncomeExpenseGross" scale="6" id="f-1913">86</ix:nonFraction> million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-1914">74</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-1915">19</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-1916">61</ix:nonFraction> million of accrued gross interest and penalties at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#8217;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1703-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfIncomeTaxExaminationsTextBlock" id="f-1917" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for additional information regarding the status of current tax audits and proceedings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_190"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1918" continuedAt="f-1918-1" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="f-1918-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-1919" escape="true">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1920" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1921">4,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1922">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1923">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1924">1,285.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1925">1,327.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1926">1,329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-503" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1927">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-504" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1928">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-505" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1929">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-506" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1930">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-507" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1931">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-508" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" scale="6" id="f-1932">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-509" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1933">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-510" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1934">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-511" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1935">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1936">1,289.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1937">1,330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1938">1,332.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1939">3.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1940">2.77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1941">2.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1942">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1943">2.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1944">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of weighted average diluted shares outstanding excludes stock awards of approximately <ix:nonFraction unitRef="shares" contextRef="c-540" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1945">26</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="c-541" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1946">28</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="c-542" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-1947">23</ix:nonFraction> million ordinary shares in fiscal year 2025, 2024, and 2023, respectively because their effect would have been anti-dilutive on the Company&#8217;s earnings per share.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1948" continuedAt="f-1948-1" escape="true">Retirement Benefit Plans </ix:nonNumeric></span></div><ix:continuation id="f-1948-1" continuedAt="f-1948-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="6" id="f-1949">466</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="6" id="f-1950">451</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="6" id="f-1951">494</ix:nonFraction> million in fiscal years 2025, 2024, and 2023, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#8217;s post-retirement benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025 and April&#160;26, 2024, the funded status of the Company&#8217;s benefit plans was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1952">440</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overfunded and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1953">484</ix:nonFraction> million overfunded, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1954">94</ix:nonFraction>&#160;million, primarily related to U.S. pension benefits. The charges were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">restructuring charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. See Note 4 for additional information on restructuring charges. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-2" continuedAt="f-1948-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="f-1955" continuedAt="f-1955-1" escape="true">The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1955-1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1956">3,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1957">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1958">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1959">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1960">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1961">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1962">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1963">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1964">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1965">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1966">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1967">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1968">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1969">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1970">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1971">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1974">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1975">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" scale="6" id="f-1978">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" scale="6" id="f-1979">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss (gain)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1980">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1981">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1982">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1983">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1984">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1985">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1986">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1987">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="f-1989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1990">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1991">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1992">3,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1993">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1994">1,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1995">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1996">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1997">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1998">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1999">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-2000">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-2001">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-2002">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-2003">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2004">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2005">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2006">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2007">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-2008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-2009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-2010">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-2011">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-2014">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-2015">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2016">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2017">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2018">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-2019">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-2022">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-2023">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2024">3,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2025">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2026">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2027">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2028">3,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2029">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2030">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2031">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2032">3,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2033">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2034">1,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2035">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over funded status of the plans</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2036">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2037">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2038">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-2039">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2040">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2041">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2042">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2043">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2044">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2045">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2046">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-2047">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2048">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2049">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2050">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-2051">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2052">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2053">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2054">289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="f-2055">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2056">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2057">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2058">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="f-2059">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2060">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2061">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2062">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2063">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2064">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2065">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2066">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-2067">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2068">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2069">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2070">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-2071">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In April 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-3" continuedAt="f-1948-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;25, 2025 and April&#160;26, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="f-2072" continuedAt="f-2072-1" escape="true">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:</ix:nonNumeric></span></div><ix:continuation id="f-2072-1"><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="f-2073">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="f-2074">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="f-2075">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="f-2076">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="f-2077">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="f-2078">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="f-2079" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2080">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-2081">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="f-2082">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="f-2083">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="f-2084" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2085">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2086">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2087">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2088">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2089">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2090">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2091">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2092">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2093">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2094">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2095">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2096">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2097">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2098">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2099">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2100">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2101">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2102">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2103">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2104">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="f-2105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="f-2106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2107">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-2108">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2109">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2110">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2111">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2112">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2113">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2114">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2119">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2120">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="f-2123">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-2126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2127">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2128">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2129">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2130">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2131">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2132">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost other than the service component are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="f-2133" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2025 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-2134">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-2135">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2136">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" scale="6" id="f-2138">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" scale="6" id="f-2139">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" format="ixt:fixed-zero" scale="6" id="f-2140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" scale="6" id="f-2141">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2142">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2143">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2144">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-2145">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-4" continuedAt="f-1948-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-2146" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-557" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2147">5.24</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-558" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2148">5.76</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-559" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2149">5.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-560" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2150">5.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2151">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-562" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2152">4.99</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-563" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2153">1.21</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-564" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2154">24.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-565" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2155">1.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-566" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2156">26.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-567" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2157">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-568" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2158">10.70</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-543" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2159">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-544" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2160">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-547" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2161">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-545" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2162">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-546" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2163">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-548" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-2164">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2165">5.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2166">5.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-571" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2167">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-572" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2168">4.99</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-573" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2169">4.23</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2170">4.48</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-575" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2171">1.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-576" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2172">26.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-577" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2173">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-578" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2174">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-579" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2175">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-580" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2176">25.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2177">5.53</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2178">5.82</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-571" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2179">4.68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-572" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2180">5.07</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-573" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2181">4.12</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2182">4.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-575" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2183">1.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-576" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2184">26.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-577" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2185">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-578" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2186">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-579" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2187">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-580" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" scale="-2" id="f-2188">25.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2189">5.51</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2190">5.63</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-571" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2191">4.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-572" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2192">4.90</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-573" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2193">3.90</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2194">4.23</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-575" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2195">1.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-576" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2196">26.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-577" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2197">1.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-578" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2198">10.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-579" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2199">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-580" decimals="4" name="mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-2200">25.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2201">6.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-570" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2202">8.10</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-571" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2203">6.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-572" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2204">8.10</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-573" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2205">5.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-574" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2206">7.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-551" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2207">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-552" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2208">4.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-556" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2209">3.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-549" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2210">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-550" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2211">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-555" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2212">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-551" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2213">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-552" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2214">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-556" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-2215">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#8217;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Investment Strategy  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;25, 2025 for the plans are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-581" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2216">42</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity securities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-582" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2217">35</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> debt securities, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-583" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2218">23</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plans did not hold any investments in the Company&#8217;s ordinary shares at April&#160;25, 2025 or April&#160;26, 2024.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-5" continuedAt="f-1948-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="f-2219" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;25, 2025, compared to the U.S. plans actual asset allocations at April&#160;25, 2025 and April&#160;26, 2024 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-584" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2220">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-584" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2221">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-585" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2222">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-586" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2223">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-586" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2224">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2225">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-588" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2226">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-588" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2227">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-589" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2228">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-543" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2229">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-543" decimals="INF" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2230">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-544" decimals="INF" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-2231">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Asset Fair Values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mutual funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity commingled trusts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed income commingled trusts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership units:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered investment companies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#8217;s general portfolio and participate in the insurer&#8217;s profit-sharing policy on an excess yield basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-6" continuedAt="f-1948-7"><ix:nonNumeric contextRef="c-1" name="mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" id="f-2232" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;25, 2025 and April&#160;26, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2233">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2234">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2238">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2239">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2243">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2247">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2248">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2252">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2253">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2257">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2258">3,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2259">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2262">3,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2263">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2264">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2268">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2269">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2273">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2277">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2278">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2282">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2283">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2287">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2288">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2289">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2292">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2293">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2297">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2298">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2301">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2303">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2306">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2307">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2308">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2312">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2313">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2316">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2318">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-2320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2321">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2322">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was $<ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2323">48</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2324">42</ix:nonFraction>&#160;million as of April&#160;25, 2025 and April&#160;26, 2024, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on an annual basis. There were no transfers into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-1948-7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Funding  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is the Company&#8217;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2025, the Company made discretionary contributions of approximately $<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2325">31</ix:nonFraction> million to the U.S. pension plan. Internationally, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-2326">45</ix:nonFraction> million for pension benefits during fiscal year 2025. The Company anticipates that it will make contributions of $<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="f-2327">29</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="f-2328">55</ix:nonFraction> million to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2026. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2026 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="f-2329" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-2330">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-2331">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-2332">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-2333">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-2334">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-2335">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-2336">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-2337">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-2338">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-2339">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 &#8211; 2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="f-2340">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="f-2341">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-retirement Benefit Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net periodic benefit cost associated with the Company&#8217;s post-retirement benefit plans was income of $<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2342">16</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2343">16</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2344">11</ix:nonFraction> million in fiscal years 2025, 2024, and 2023, respectively. The Company&#8217;s projected benefit obligation for all post-retirement benefit plans was $<ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-2345">231</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-2346">235</ix:nonFraction> million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The Company&#8217;s fair value of plan assets for all post-retirement benefit plans was $<ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2347">303</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2348">308</ix:nonFraction> million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The post-retirement benefit plan assets at both April&#160;25, 2025 and April&#160;26, 2024 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Savings Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions and Company performance. Expense recognized under these plans was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2349">478</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2350">471</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2351">390</ix:nonFraction> million in fiscal years 2025, 2024, and 2023, respectively.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_196"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-2352" continuedAt="f-2352-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-2352-1" continuedAt="f-2352-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically do not provide an implicit rate, the Company&#8217;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the leases that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2025, 2024, and 2023 were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;25, 2025 or April&#160;26, 2024 or for fiscal year 2025, 2024 and 2023. Finance lease right-of-use assets are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">propert</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2352-2" continuedAt="f-2352-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">y, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and finance lease liabilities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">current debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="mdt:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-2353" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-2356">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-2357">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2358"><span style="-sec-ix-hidden:f-2359">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2360">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2361">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2362"><span style="-sec-ix-hidden:f-2363">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2364">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2365">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-2366" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-24" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2367">8.7</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2368">8.8</ix:nonNumeric> Years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2369">4.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2370">3.4</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2025, 2024, and 2023: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2371">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2372">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2373">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2374">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2375">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-2376">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2377">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2378">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2379">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2380">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2381">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2382">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2383">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2384">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2385">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2352-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-2386" escape="true"><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;25, 2025:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-2387">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-2388">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-2389">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-2390">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-2391">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-2392">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="f-2393">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-2394">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-2395">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and the Company's net investments in sales-type leases are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Lessor income for fiscal year 2025, 2024, and 2023 and the related assets and lease maturities at April&#160;25, 2025 and April&#160;26, 2024 were not material to the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_199"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-2396" continuedAt="f-2396-1" escape="true">Accumulated Other Comprehensive Loss </ix:nonNumeric></span></div><ix:continuation id="f-2396-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-2397" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2398">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2399">2,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2400">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2401">773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2402">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2403">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2404">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2405">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2406">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2407">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2408">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2409">704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2410">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2413">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2414">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2415">530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2416">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2417">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2418">596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2419">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2420">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2421">1,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2422">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2423">2,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2424">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2425">741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2426">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2427">3,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2428">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2429">846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2430">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2431">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2432">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2433">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2434">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2437">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2438">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2439">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2440">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2441">846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2442">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2443">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2444">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2445">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2446">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2447">3,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2448">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2449">529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2450">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2451">3,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2452">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2453">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2454">1,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2455">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2456">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-2457">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2458">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2461">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2462">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-2463">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2464">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2465">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2466">1,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2467">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2468">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2469">966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2470">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2471">2,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2472">597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2473">640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-2474">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2475">4,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was an expense of $<ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2476">25</ix:nonFraction> million, an expense of $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2477">4</ix:nonFraction> million, and a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2478">21</ix:nonFraction>&#160;million, respectively. During fiscal years 2025, 2024, and 2023, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-2479">3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2480">5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2481">9</ix:nonFraction>&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 5 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2025, 2024, and 2023, the income tax on cumulative translation adjustment was an expense of $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2482">4</ix:nonFraction> million, an expense of $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2483">3</ix:nonFraction> million, and a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2484">5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, the income tax on net investment hedges was a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2485">47</ix:nonFraction> million. During fiscal years 2024 and 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-688" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="0" id="f-2486"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="INF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="0" id="f-2487">no</ix:nonFraction></ix:nonFraction> tax impacts on net investment hedges. Refer to Note 7 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 resulted in a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2488">32</ix:nonFraction> million, an expense of $<ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2489">79</ix:nonFraction>&#160;million, and an expense of $<ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2490">6</ix:nonFraction>&#160;million, respectively. During fiscal years 2025, 2024, and 2023, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-2491">3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2492">2</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2493">9</ix:nonFraction>&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 15 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was&#160;a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-2494">33</ix:nonFraction> million, an expense&#160;$<ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2495">103</ix:nonFraction>&#160;million, and an expense of $<ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-2496">56</ix:nonFraction>&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-2497">52</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2498">66</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-2499">133</ix:nonFraction>&#160;million for fiscal years 2025, 2024, and 2023, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 for additional information.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-2500" continuedAt="f-2500-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-2500-1" continuedAt="f-2500-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder-related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. With respect to intellectual property disputes, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. With respect to commercial disputes, antitrust and competition issues have gained increased prominence, enforcement and private litigation have increased globally, and the Company is involved in or at risk for antitrust litigation, investigations or enforcement actions regarding a range of commercial activities, including challenges to mergers and acquisition transactions, joint ventures, co-development or co-marketing arrangements, contracting practices, distribution agreements and employment agreements. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek significant monetary damages and/or royalty payments, as well as other civil or criminal remedies (including injunctions barring or restricting the sale of products that are the subject of the proceeding, placing restrictions on competitive strategies or practices, or unwinding consummated transactions), any or all of which could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. During fiscal years 2025, 2024, and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2501">317</ix:nonFraction>&#160;million of certain litigation charges, net, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2502">149</ix:nonFraction>&#160;million of certain litigation charges, net, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-2503">30</ix:nonFraction>&#160;million of certain litigation income, net, respectively. At April&#160;25, 2025 and April&#160;26, 2024, accrued litigation was approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-2504">0.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-2505">0.2</ix:nonFraction>&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Colibri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#8217;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $<ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-2506">106</ix:nonFraction>&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hernia Mesh Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of June 11, 2025, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately <ix:nonFraction unitRef="plaintiff" contextRef="c-717" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-2507">9,325</ix:nonFraction> individual plaintiffs, and certain plaintiffs&#8217; law firm</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2500-2" continuedAt="f-2500-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s have advised the Company that they may file additional cases in the future. Approximately <ix:nonFraction unitRef="plaintiff" contextRef="c-718" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-2508">6,950</ix:nonFraction> plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately <ix:nonFraction unitRef="plaintiff" contextRef="c-719" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="f-2509">500</ix:nonFraction> plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately <ix:nonFraction unitRef="claim" contextRef="c-720" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="f-2510">1,875</ix:nonFraction> actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than <ix:nonFraction unitRef="lawsuit" contextRef="c-720" decimals="INF" name="mdt:LossContingencyLawsuitsNumber" format="ixt-sec:numwordsen" scale="0" id="f-2511">ten</ix:nonFraction> one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diabetes Pump Retainer Ring Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 28, 2025, after a number of recent dismissals, there are <ix:nonFraction unitRef="lawsuit" contextRef="c-721" decimals="INF" name="mdt:LossContingencyLawsuitsNumber" format="ixt-sec:numwordsen" scale="0" id="f-2512">nine</ix:nonFraction> lawsuits filed on behalf of <ix:nonFraction unitRef="plaintiff" contextRef="c-722" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="f-2513">20</ix:nonFraction> individuals. Plaintiffs&#8217; firms previously notified the Company that they may file additional lawsuits in the future on behalf of several thousand additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applied Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation in the U.S. District Court for the Central District of California, alleging that the Company has engaged in anticompetitive and monopolistic conduct relating to its sales of advanced bipolar devices, including under contracts with group purchasing organizations. The Company has substantial legal and factual defenses and intends to defend itself vigorously. The court recently deferred trial from June 2025 until after it rules on the parties' summary judgment motions. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in other countries regarding certain activities in different global markets. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2500-3" continuedAt="f-2500-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Italian Payback</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, &#8220;payback&#8221; legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy&#8217;s medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by $<ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-2514">90</ix:nonFraction>&#160;million during the three months ended July 26, 2024, as a reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company&#8217;s liability could differ from the amount currently accrued.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Termination with Blackstone</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, the Company is party to various research and development funding arrangements with Blackstone, which are subject to certain termination provisions. During fiscal year 2025, the parties negotiated a contractual dispute resolution under one of the funding arrangements. As a result, the Company recognized certain litigation charges in connection with the resolution. The Company included this accrued litigation charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#8217;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. Oral argument for the Appeal occurred in May 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic, Inc.&#8217;s fiscal years 2017 through 2023 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2021. Covidien LP&#8217;s fiscal year 2023 federal income tax return is currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 for additional discussion of income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#8217; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#8217;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2500-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into standby letters of credit agreements, bank guarantees, and surety bonds with financial institutions to support various performance and other obligations, as well as ongoing tax matters. As of April 25, 2025, the aggregated amount outstanding under these instruments was approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-8" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-2515">0.9</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div></ix:continuation><div id="ic14a750e81984b18a679ba753642023e_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-2516" continuedAt="f-2516-1" escape="true">Segment and Geographic Information </ix:nonNumeric></span></div><ix:continuation id="f-2516-1" continuedAt="f-2516-2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2517">four</ix:nonFraction> reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The chief operating decision maker (CODM) is our Chief Executive Officer (CEO) and has chosen to organize the entity based upon therapy solutions provided by each segment. The <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2518">four</ix:nonFraction> reportable segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM measures and evaluates segment performance and allocates resources based on net sales and segment operating profit. Net sales include end-customer revenues from products developed, manufactured, and distributed by the segments. Significant expense categories include cost of products sold excluding amortization of intangible assets, research and development expense, and selling, general, and administrative expenses. Segment operating profit excludes certain corporate and centralized expenses not allocated to the segments, including interest income and expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. The CODM uses segment operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The CODM is not regularly provided with expenditures for additions to long-lived assets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-2519" continuedAt="f-2519-1" escape="true"><ix:continuation id="f-2516-2" continuedAt="f-2516-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2520">12,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span id="i8b8636ab5d4d4004bd25d54153027b58_1-2-1-1-411492"></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2521">9,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2522">8,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2523">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2524">33,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2525">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="f-2526">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2527">33,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2528">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2529">2,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2530">3,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2531">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2532">10,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2533">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2534">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2535">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2536">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2537">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2538">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2539">2,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2540">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-2541">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2542">7,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2543">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2544">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2545">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2546">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2547">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2548">4,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2549">4,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2550">3,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2551">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2552">12,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2553">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2554">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2555">729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2556">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2557">1,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2558">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2559">1,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2560">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2561">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2562">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2563">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2564">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="f-2565">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2566">5,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2519-1" continuedAt="f-2519-2"><ix:continuation id="f-2516-3" continuedAt="f-2516-4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2567">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2568">9,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2569">8,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2570">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2571">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2572">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2573">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2574">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2575">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2576">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-2577">963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2578">10,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2579">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2580">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2581">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2582">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2583">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2584">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2585">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2586">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-2587">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2588">7,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2589">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2590">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2591">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2592">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2593">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2594">4,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2595">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2596">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2597">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2598">11,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2599">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2600">1,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2601">719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2602">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2603">1,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2604">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2605">1,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" sign="-" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2606">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2607">389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2608">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2609">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2610">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2611">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2516-4" continuedAt="f-2516-5"><ix:continuation id="f-2519-2" continuedAt="f-2519-3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2612">11,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2613">8,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2614">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2615">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2616">30,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2617">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2618">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2619">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2620">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2621">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-2622">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2623">9,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2624">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2625">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2626">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-2627">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2628">2,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2629">2,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2630">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2631">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-2632">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2633">7,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2634">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2635">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2636">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2637">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2638">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2639">4,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2640">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2641">3,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2642">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2643">11,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2644">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="mdt:CorporateOverhead" format="ixt:num-dot-decimal" scale="6" id="f-2645">1,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-2646">636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2647">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2648">1,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-2649">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="mdt:CentralizedDistributionCosts" format="ixt:num-dot-decimal" scale="6" id="f-2650">1,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" sign="-" name="mdt:ForeignCurrencyCosts" scale="6" id="f-2651">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2652">647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-2653">345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-2654">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="mdt:MedicalDeviceRegulations" scale="6" id="f-2655">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="mdt:CommitmentsToTheMedtronicFoundationAndMedtronicLABS" scale="6" id="f-2656">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2657">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-2519-3" continuedAt="f-2519-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:continuation id="f-2519-4">Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medtronic plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2516-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="f-2658" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2659">16,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2660">16,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2661">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2662">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2663">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2664">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2665">18,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2666">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2667">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2668">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2669">33,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2670">33,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2671">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2672">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2673">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2674">4,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2675">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2676">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2677">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2678">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2679">72,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2680">71,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2681">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2682">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2683">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-6" name="us-gaap:Assets" scale="6" id="f-2684">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-6" name="us-gaap:Assets" scale="6" id="f-2685">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2686">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:Depreciation" format="ixt:fixed-zero" scale="6" id="f-2687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2688">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2689">18,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2690">17,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2691">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2692">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2693">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2694">91,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2695">89,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-2696">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2697">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2698">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="f-2699" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April&#160;25, 2025 and April&#160;26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2700">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2701">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2702">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-2703">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-2704">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2705">17,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2706">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2707">16,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2708">5,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2709">4,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2710">16,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2711">15,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2712">14,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2713">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2714">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2715">33,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2716">32,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2717">31,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2718">6,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2719">5,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2720">33,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2721">32,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2722">31,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2723">6,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2724">6,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer represented over 10 percent of the Company&#8217;s consolidated net sales in fiscal years 2025, 2024, or 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic14a750e81984b18a679ba753642023e_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company (as defined in Exchange Act Rule 13a-15(f)). Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that the Company&#8217;s internal control over financial reporting was effective as of April&#160;25, 2025. The effectiveness of the Company's internal control over financial reporting as of April&#160;25, 2025 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April&#160;25, 2025, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. </span></div><div id="ic14a750e81984b18a679ba753642023e_217"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Director and Officer Trading Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April 25, 2025, <ix:nonNumeric contextRef="c-779" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2726"><ix:nonNumeric contextRef="c-779" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2727"><ix:nonNumeric contextRef="c-779" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2728"><ix:nonNumeric contextRef="c-779" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2729">none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement,"</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act Section 3(r) Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reported in our Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025, Medtronic has engaged in certain activities that it is required to disclose pursuant to Section 13(r)(1)(D)(ii) of the Securities Exchange Act of 1934, as amended. In particular, during the first quarter of fiscal year 2025, Medtronic engaged in certain regulatory activities involving Russia&#8217;s Federal Security Service (&#8220;FSB&#8221;) related to its medical devices that were expressly authorized by the U.S. Government under applicable economic sanctions regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal year 2025, in the normal course of business and consistent with the OFAC authorizations as in effect at the time, Medtronic Russia filed a total of one notification with the FSB, as required under local Russian law for the import of medical devices that make use of encryption functionality. These activities did not directly result in any revenues or profits for Medtronic. Medtronic did not engage in these activities during the second, third, and fourth quarters of fiscal year 2025. To the extent that notifications with the FSB remain permissible under U.S. law, Medtronic may decide to continue engaging in such activities for the limited purposes of complying with local law requirements in Russia.</span></div><div id="ic14a750e81984b18a679ba753642023e_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ic14a750e81984b18a679ba753642023e_226"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part III of this Annual Report on Form 10-K incorporates information by reference from the Company's 2025 definitive proxy statement, which will be filed no later than 120 days after April&#160;25, 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections entitled &#8220;Proposal 1 &#8212; Election of Directors &#8212; Directors and Nominees&#8221; and &#8220;Corporate Governance &#8212; Committees of the Board and Meetings&#8221; in the Company's Proxy Statement for our 2025 Annual General Meeting of Shareholders, which will be filed no later than 120 days after April&#160;25, 2025, are incorporated herein by reference.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-2730">adopted</ix:nonNumeric> an insider trading policy which governs the purchase, sale, and/or any other dispositions of our securities by directors, officers and employees and other covered persons and is designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of our insider trading policy is filed with this Annual Report on Form 10-K as Exhibit 19.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are the names and ages of our Executive Officers of Medtronic, as well as information regarding their positions with Medtronic, their periods of service in these capacities, and their business experiences. There are no family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the name, age, and position as of June 15, 2025 of each of our Executive Officers:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Position with the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivan K. Fong</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Secretary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skip Kiil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Cardiovascular Portfolio</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Marinaro</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Medical Surgical Portfolio and Americas</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thierry Pi&#233;ton</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory L. Smith</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Enterprise Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett Wall</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and President, Neuroscience Portfolio</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Walter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Human Resources Officer</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geoffrey S. Martha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 55, is Chairman and Chief Executive Officer of Medtronic. Mr. Martha assumed the role of CEO on April 27, 2020 and became Chairman of the Board on December 11, 2020. He served as President from November 2019 through April 2020 and joined the Board of Directors in November 2019. Previously, Mr. Martha was Executive Vice President and President, Restorative Therapies Group, a role he held since August 2015, and he was Senior Vice President of Strategy and Business Development of the Company beginning in January 2015 and of Medtronic, Inc. beginning in August 2011. Prior thereto, he served as Managing Director of Business Development at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November 2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February 2002 to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998 to January 2001.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ivan K. Fong</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 63, has been Executive Vice President, General Counsel and Secretary of Medtronic since February 2022. Prior to that, he held several leadership positions at 3M Company from 2012 to 2022, including Executive Vice President, Chief Legal and Policy Officer and Secretary. Prior to joining 3M Company, Mr. Fong served as General Counsel of the U.S. Department of Homeland Security from 2009 to 2012. Prior to his role with the U.S. Government, he was Chief Legal Officer and Secretary for Cardinal Health, Inc from 2005 to 2009.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skip Kiil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 51, became Executive Vice President and President of Medtronic's Cardiovascular Portfolio in May 2025. Prior to that role, he was Senior Vice President and President of the Cranial &amp; Spinal Technologies operating unit since joining Medtronic in 2022.  Previously, Mr. Kiil served as President of Global Orthopaedics at Smith &amp; Nephew from 2018 to 2021 and Executive Vice President and President of Global Commercial Operations at NuVasive from 2017 to 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Michael Marinaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 54,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been Executive Vice President and President of Medtronic&#8217;s Medical Surgical Portfolio and Americas since February 2024. He became Executive Vice President in January 2023, and he served as President of the Surgical Operating Unit from February 2023 to February 2024. Mr. Marinaro previously served as Senior Vice President and President of Surgical Robotics and, prior thereto, as President of the Cardiac Rhythm Management operating unit. Mr. Marinaro joined Medtronic in 2000 and has led numerous businesses across the company during that time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Thierry Pi&#233;ton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 55, has been Executive Vice President and Chief Financial Officer of Medtronic since March 2025. Previously, he served as Chief Financial Officer of Renault Group (Paris) from March 2022 to February 2025, and he was Senior Vice President, Deputy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Group Controller, Renault Group and Chief Financial Officer, Renault Brand (Paris) from June 2016 to February 2022.  Prior thereto, he was Senior Vice President Administration and Finance Europe, Nissan Motor Co, Ltd (Switzerland) from 2014 to 2016, and Chief Financial Officer of Energy Management/Power Conversion, General Electric (Paris) from 2011 to 2014. He served as Chief Financial Officer, GE Oil and Gas Global Services (Florence, Italy) from 2007 to 2011.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gregory Smith,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> age 61, is Executive Vice President, Enterprise Operations, a position he has held since April 2021. Prior to joining Medtronic, he was Executive Vice President of U.S. Supply Chain at Walmart. In addition, Mr. Smith served as Senior Vice President, Global Operations at The Goodyear Tire &amp; Rubber Company, and held leadership roles at ConAgra Foods, United Signature Foods, VDK Frozen Foods and Quaker Oats.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brett Wall, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">age 60, is Executive Vice President and President of Medtronic&#8217;s Neuroscience Portfolio. Mr. Wall previously served as Senior Vice President and President of the Brain Therapies division of Medtronic within the Restorative Therapies Group from March 2016 to November 2019. Prior to that, Mr. Wall served as Senior Vice President and President of Medtronic&#8217;s Neurovascular business. Prior to joining Medtronic, he served as Covidien&#8217;s Senior Vice President and President of Neurovascular as well as Senior Vice President and President of the International Vascular Therapies business for Covidien. Mr. Wall also served as Senior Vice President and President, International at ev3, Inc. From 2000 to 2008, Brett held various marketing and sales positions with ev3, Inc. and Micro Therapeutics, Inc. Mr. Wall has also worked at Boston Scientific as Director of Marketing, Cardiovascular, Asia Pacific and Marketing Manager, Japan, from September 1995 to September 2000.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Matthew Walter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, age 46, has been Senior Vice President, Chief Human Resources Officer of Medtronic since June 2023. He served as Vice President Human Resources of Global Operations and Supply Chain from 2021 to 2023, and previously as Vice President Human Resources of the Diabetes operating unit from 2018 to 2021, and the Coronary and Structural Heart division from 2016 to 2018. Mr. Walter led Talent Management, Organizational Effectiveness, and Executive Development from 2015 to 2016, and he served as Senior Director, Talent Management and Leadership Development upon joining Medtronic in 2014. Prior thereto, he held various leadership roles at Best Buy and Bank of America.</span></div><div id="ic14a750e81984b18a679ba753642023e_229"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 11 will be included in our Proxy Statement for the 2025 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Director Compensation,&#8221; &#8220;Corporate Governance &#8212; Committees of the Board and Meetings,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Compensation and Talent Committee Report,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;25, 2025.</span></div><div id="ic14a750e81984b18a679ba753642023e_232"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by Item 12 will be included in our Proxy Statement for the 2025 Annual General Meeting of Shareholders under the headings &#8220;Share Ownership Information &#8212; Significant Shareholders,&#8221; &#8220;Share Ownership Information &#8212; Beneficial Ownership of Management,&#8221; and &#8220;Executive Compensation &#8212; Equity Compensation Plan Information,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;25, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</span></div><div id="ic14a750e81984b18a679ba753642023e_235"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 13 will be included in our Proxy Statement for the 2025 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Director Independence&#8221; and &#8220;Corporate Governance &#8212; Related Party Transactions and Other Matters,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;25, 2025.</span></div><div id="ic14a750e81984b18a679ba753642023e_238"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 14 will be included in our Proxy Statement for the 2025 Annual General Meeting of Shareholders under the headings &#8220;Corporate Governance &#8212; Committees of the Board and Meetings&#8221; and &#8220;Audit and Non-Audit Fees,&#8221; and is incorporated herein by reference. The Proxy Statement will be filed no later than 120 days after April&#160;25, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic14a750e81984b18a679ba753642023e_244"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.866%"><tr><td style="width:1.0%"/><td style="width:3.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1. Financial Statement Schedule</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule II. Valuation and Qualifying Accounts &#8212; fiscal years ended April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-2731" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDTRONIC PLC AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Changes (Debit) Credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at End of<br/>Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for doubtful accounts and credit losses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 25, 2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2732">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2733">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2735">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2736">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2737">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2738">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2740">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2741">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2742">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2743">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-2744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2745">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-2746">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 25, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2747">13,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-2748">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2749">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2750">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2751">12,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="f-2752">567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2753">11,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="6" id="f-2754">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2755">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2756">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2757">13,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" scale="6" id="f-2758">545</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" sign="-" name="mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" scale="6" id="f-2759">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2760">6,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="6" id="f-2761">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-2762">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-2763">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-2764">11,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" scale="6" id="f-2765">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="f-2766">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a) Primarily consists of uncollectible accounts written off, less recoveries.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b) Reflects the impact from acquisitions.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c) Primarily reflects carryover attribute utilization and expiration.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d) Primarily reflects the effects of currency fluctuations.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(e) Primarily reflects the impacts from tax rate changes.</span></td></tr></table></div></ix:nonNumeric><div id="ic14a750e81984b18a679ba753642023e_247"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.600%"><tr><td style="width:1.0%"/><td style="width:4.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2. Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020681/d859999dex31.htm">Certificate of Incorporation of Medtronic plc (incorporated by reference to Exhibit 3.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312517030983/d338710dex32.htm">Amended and Restated Memorandum and Articles of Association of Medtronic plc (incorporated by reference to Exhibit 3.2 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on February 6, 2017, File No. 333-215895).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000095013709001623/c49806exv4w1.htm">Form of Indenture between Medtronic, Inc. and Wells Fargo Bank, National Association regarding 2009 offering (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Registration Statement on Form S-3, filed on March 9, 2009, File No. 333-157777).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000095013709001761/c50013exv4w1.htm">First Supplemental Indenture, dated March 12, 2009, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 12, 2009, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000095012310025103/c56981exv4w1.htm">Second Supplemental Indenture, dated March 16, 2010, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 16, 2010, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000095012311025816/c63508exv4w1.htm">Third Supplemental Indenture, dated March 15, 2011, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current report on Form 8-K, filed on March 16, 2011, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312512123407/d318842dex42.htm">Fourth Supplemental Indenture, dated March 19, 2012, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 20, 2012, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513126071/d508677dex41.htm">Fifth Supplemental Indenture, dated March 26, 2013, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Forms of Notes thereof) (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on March 26, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312514072613/d684319dex42.htm">Sixth Supplemental Indenture, dated February 27, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (including the Form of Global Note thereof) (incorporated by reference to Exhibit 4.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on February 27, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex42.htm">Seventh Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312514439048/d835649dex41.htm">Indenture, dated December 10, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.1 to Medtronic, Inc.&#8217;s Current Report on Form 8-K filed with the Commission on December 10, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312514439048/d835649dex42.htm">First Supplemental Indenture, dated December 10, 2014, between Medtronic, Inc. and Wells Fargo Bank, National Association (including Form of Floating Rate Senior Notes due 2020, Form of 1.500% Senior Notes due 2018, Form of 2.500% Senior Notes due 2020, Form of 3.150% Senior Notes due 2022, Form of 3.500% Senior Notes due 2025, Form of 4.375% Senior Notes due 2035 and Form of 4.625% Senior Notes due 2045) (incorporated by reference to Exhibit 4.2 of Medtronic, Inc.&#8217;s Current Report on Form 8-K filed with the Commission on December 10, 2014, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex43.htm">Second Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.3 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex44.htm">Third Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic Global Holdings S.C.A. and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 4.4 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312523060059/d449390dex49.htm">Fourth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of February  22, 2023, among Medtronic Global Holdings, S.C.A., Medtronic, Inc. and Medtronic plc and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, N.A.), as trustee (incorporated by reference to Exhibit  4.9 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on March 3, 2023)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312524152334/d811133dex41.htm">Fifth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of June  3, 2024, among Medtronic, Inc., Medtronic plc, Medtronic Global Holdings S.C.A., Computershare Trust Company, N.A., as trustee, and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc&#8217;s Form 8-K, filed on June 3, 2024)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312507222875/dex41a.htm">Indenture, dated as of October 22, 2007, by and among Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1(a) to Covidien plc&#8217;s Current Report on Form 8-K filed on October 22, 2007, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312507222875/dex41e.htm">Fourth Supplemental Indenture, dated as of October 22, 2007, by and among Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1(e) to Covidien plc&#8217;s Current Report on Form 8-K filed on October 22, 2007, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312509125706/dex41.htm">Fifth Supplemental Indenture, dated as of June 4, 2009, by and among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K12G3 filed on June 5, 2009, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312510148405/dex41.htm">Sixth Supplemental Indenture, dated as of June 28, 2010, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on June 28, 2010, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312512253576/d359452dex41.htm">Seventh Supplemental Indenture, dated as of May 30, 2012, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on May 30, 2012, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1385187/000119312513224369/d540273dex41.htm">Eighth Supplemental Indenture, dated as of May 16, 2013, among Covidien International Finance S.A., Covidien Ltd., Covidien plc and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.1 to Covidien plc&#8217;s Current Report on Form 8-K filed on May 16, 2013, File No. 001-33259).</a></span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex45.htm">Ninth Supplemental Indenture, dated as of January 26, 2015, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Covidien public limited company, Covidien International Finance S.A., Covidien Ltd. and Deutsche Bank Trust Company Americas (incorporated by reference to Exhibit 4.5 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312517099886/d290589dex41.htm">Senior Indenture, dated as of March 28, 2017, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., and Wells Fargo Bank, N.A. (incorporated by reference to Exhibit&#160;4.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 28, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312517099886/d290589dex42.htm">First Supplemental Indenture, dated as of March 28, 2017, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., and Wells Fargo Bank, N.A. (incorporated by reference to Exhibit&#160;4.2 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 28, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312519066295/d710754dex41.htm">Second Supplemental Indenture, dated as of March 7, 2019, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., Wells Fargo Bank, N.A., and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit&#160;4.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on March 7, 2019, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312519187797/d762838dex41.htm">Third Supplemental Indenture, dated as of July 2, 2019, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC (incorporated by reference to Exhibit 4.1 to Medtronic plc' Current Report on Form 8-K, filed July 2, 2019, File No. 001-36820)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001613103/000119312520257811/d19681dex41.htm">Fourth Supplemental Indenture, dated as of September 29, 2020, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2023 Notes, the 2025 Notes, the 2028 Notes, the 2032 Notes, the 2040 Notes and the 2050 Notes) (incorporated by reference to Exhibit 4.1 to Medtronic plc' Current Report on Form 8-K, filed September 29, 2020, File No. 001-36820)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312522248112/d406839d8k.htm">Fifth Supplemental Indenture, dated as of September 21, 2022, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes) (incorporated by reference to Exhibit 4.1 to Medtronic plc&#8217;s Current Report on Form 8-K filed on September 21, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312523060059/d449390dex42.htm">Sixth Supplemental Indenture, dated as of February 22, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Registration Statement on Form S-3, filed on March 3, 2023, File No. 333-270272).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312523085642/d490503d8k.htm">Seventh Supplemental Indenture, dated as of March 30, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (including the forms of the 2028 Notes and the 2033 Notes) (incorporated by reference to Exhibit 4.2 to Medtronic plc&#8217;s Current Report on Form 8-K filed on March 30, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#4.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex430.htm">Description of  Registrant's Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312518348880/d672316dex101.htm">Amended and Restated Credit Agreement, dated as of December 12, 2018, by and among Medtronic Global Holdings, SCA, certain subsidiaries named therein, Medtronic, Inc., Medtronic PLC, the lenders from time to time party thereto, and Bank of America, N.A. as Administration Agent (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 13, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000007/exhibit101amendedandre.htm">Amendment No. 1 and Extension Agreement to the Amended and Restated Credit Agreement, dated as of December 12, 2019, among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic PLC, the Lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 10-Q, filed on February 28, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000016/exhibit1001termloanagr.htm">Term Loan Agreement, dated as of May 12, 2020, among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic PLC, the Lenders party thereto and Mizuho Bank, LTD., as Administrative Agent (incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000016/exhibit1001termloanagr.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000016/exhibit1001termloanagr.htm">1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on May 12, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000119312522135320/d347836d8k.htm">Term Loan Agreement, dated as of May 2, 2022, by and among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic plc, and Mizuho Bank, Ltd., as administrative agent and as lender (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on May 2, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex101.htm">Form of Deed of Indemnification (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021837/d859367dex102.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Current Report on Form 8-K12B, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1014.htm">Change of Control Severance Plan - Section 16B Officers (as amended and restated as of January 26, 2015) (incorporated by reference to Exhibit 10.14 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310322000046/mdt-20220729.htm">Letter Agreement by and between Medtronic, Inc. and Ivan K. Fong dated November 19, 2021 (incorporated by reference to Exhibit 10.1 to Medtronic, plc&#8217;s Quarterly Report on Form 10-Q, filed on September 1, 2022).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310325000022/ex101-letteragreementbyand.htm">Letter Agreement by and between Medtronic, Inc. and Thierry Pi&#233;ton dated December 24, 2024 (incorporate by reference to Exhibit 10.1 to Medtronic, plc's Quarterly Report on Form 10-Q, filed on February 25, 2025).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310319000056/officeofchairmanandchi.htm">Office of Chairman and Chief Executive Officer Letter Agreement (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q, filed on December 3, 2019, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-3.htm">1998 Outside Director Stock Compensation Plan (as amended and restated effective as of January 1, 2008) (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 25, 2008, filed on, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021907/d858587dex102.htm">Amendment to the 1998 Outside Director Stock Compensation Plan (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-4.htm">2003 Long-Term Incentive Plan (as amended and restated effective January 1, 2008) (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2008, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515021907/d858587dex103.htm">Amendment to the 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000110465905009815/a05-4434_1ex10d3.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2005, filed on March 7, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710105001490/med052766_ex10-20.htm">Form of Restricted Stock Units Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.20 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 29, 2005, filed on June 29, 2005, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-24.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.24 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710106001326/medtronic062430s1_ex10-25.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan effective June 22, 2006 (incorporated by reference to Exhibit 10.25 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 28, 2006, filed on June 28, 2006, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710107002582/medtronic074976_ex10-3.htm">Form of Restricted Stock Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 26, 2007, filed on December 4, 2007, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710107002582/medtronic074976_ex10-4.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 26, 2007, filed on December 4, 2007, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001392/medtronic082604s1_ex10-40.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.40 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 25, 2008, filed on June 24, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001392/medtronic082604s1_ex10-41.htm">Form of Restricted Stock Unit Award Agreement under 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.41 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 25, 2008, filed on June 24, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108000478/medtronic080932_ex10-5.htm">Israeli Amendment to the 2003 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 25, 2008, filed on March 4, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710109002528/medtronic095603_ex10-2.htm">2008 Stock Award and Incentive Plan (as amended and restated effective August 27, 2009) (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2009, filed on December 9, 2009, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex104.htm">Amendment to the 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-2.htm">Form of Restricted Stock Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-3.htm">Form of Restricted Stock Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-4.htm">Form of Restricted Stock Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108001858/medtronic083633_ex10-5.htm">Form of Restricted Stock Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended July 25, 2008, filed on September 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710112001054/medtronic122599_ex10-42.htm">Terms of Non-Employee Director Compensation under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.42 to Medtronic, Inc.&#8217;s Annual Report on Form 10-K for the year ended April 27, 2012, filed on June 26, 2012, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-3.htm">Form of Non-Employee Director Deferred Unit Award Agreement under 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000028/mdt-20150425xex1065.htm">Form of Non-Employee Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.65 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2015, filed on June 23, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1010.htm">Israeli Amendment to the Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.10 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310317000027/mdt-2018q1xex101.htm">Form of Restricted Stock Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc's Quarterly Report on Form 10-K for the quarter ended July 28, 2017, filed on September 1, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.35</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310317000055/exhibit101medtronicplcamen.htm">Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan (as amended and restated generally effective December 8, 2017) (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 12, 2017, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1050.htm">Form of Non-qualified Stock Option Agreement Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.50 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1051.htm">Form of Restricted Stock Unit Award Agreement Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.51 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.38</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1052.htm">Form of Restricted Stock Award Agreement Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.52 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310318000024/exhibit1053.htm">Form of Long Term Performance Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.53 to Medtronic plc&#8217;s Annual Report on Form 10-K, filed June 22, 2018, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1031.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.31 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex101-formofperformanc.htm">Form of Performance Share Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000089710108002439/medtronic084960_ex10-3.htm">Form of Non-Employee Director Deferred Unit Award Agreement under the 2008 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 24, 2008, filed on December 3, 2008, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex102.htm">Form of Non-Qualified Stock Option Agreement under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex103.htm">Form of Restricted Stock Unit Award Agreement (U.S. Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex104.htm">Form of Restricted Stock Unit Award Agreement (Non-U.S. Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex105.htm">Form of Restricted Stock Unit Award Agreement (Time-Based) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.5 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64670/000119312513348043/d589902dex108.htm">Form of Restricted Stock Unit Award Agreement (Israeli-Employees) under 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.8 to Medtronic, Inc.&#8217;s Current Report on Form 8-K, filed on August 27, 2013, File No. 001-07707).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1048.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.48 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1049.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.49 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1050.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.50 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1051.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.51 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1053.htm">Form of Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.53 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310315000008/mdtplc-2015q3xex1054.htm">Form of Restricted Stock Unit Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.54 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 23, 2015, filed on February 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000021/mdt202010k-ex1069.htm">Form of Restricted Stock Award Agreement under Amended and Restated 2013 Stock Award and Incentive Plan  (incorporated by reference to Exhibit 10.69 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2020, filed on June 19, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000021/mdt202010k-ex1070.htm">Form of Non-Qualified Stock Option Agreement under Amended and Restated 2013 Stock Award and Incentive Plan (incorporated by reference to Exhibit 10.70 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 24, 2020, filed on June 19, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1011.htm">Medtronic plc Incentive Plan (as amended and restated effective January 26, 2015) (incorporated by reference to Exhibit 10.11 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1015.htm">Medtronic plc Supplemental Executive Retirement Plan (as restated generally effective January 26, 2015) (incorporated by reference to Exhibit 10.15 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex103-medtronicnonxqua.htm">Medtronic Non-Qualified Retirement Plan Supplemental (restated November 6, 2020, and formerly known as the Supplemental Executive Retirement Plan) (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515023510/d859659dex422.htm">Medtronic plc Savings and Investment Plan (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 4.22 to Medtronic plc&#8217;s Registration Statement on Form S-8 filed on January 28, 2015, File No. 333-201737).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515023510/d859659dex423.htm">Medtronic plc Puerto Rico Employees&#8217; Savings and Investment Plan (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 4.23 to Medtronic plc&#8217;s Registration Statement on Form S-8 filed on January 28, 2015, File No. 333-201737).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000119312515020690/d858587dex1013.htm">Medtronic plc Capital Accumulation Plan Deferral Program (as amended and restated generally effective January 26, 2015) (incorporated by reference to Exhibit 10.13 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on January 27, 2015, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.62</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310316000123/exhibit101-medtronicplccap.htm">Capital Accumulation Plan Deferral Program (as amended and restated generally effective January 1, 2017) (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 28, 2016, filed on December 5, 2016, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex102-amendedandrestat.htm">Amended and Restated Covidien Supplemental Savings and Retirement Plan (restated November 6, 2020) (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310320000051/ex104-medtroniccapital.htm">Medtronic Capital Accumulation Plan Deferral Program (restated November 6, 2020) (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended October 30, 2020, filed on December 3, 2020, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.65</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001613103/000161310321000065/exhibit1001-amendmentno3an.htm">Amendment No. 3 and Extension Agreement to the Amended and Restated Credit Agreement, dated as of December 13, 2021, by and among Medtronic Global Holdings S.C.A., certain subsidiaries of Medtronic plc from time to time party thereto, Medtronic, Inc., Medtronic plc, the lenders from time to time party thereto and Bank of America N.A., as administrative agent. (incorporated by reference to Exhibit 10.01 to Medtronic plc&#8217;s Current Report on Form 8-K, filed on December 14, 2021, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.66</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex101.htm">Medtronic Capital Accumulation Plan Deferral Program (as restated generally effective January 1, 2017) (Conformed through the Amendment generally effective as of January 1, 2022)  (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex102.htm">2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.68</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex103.htm">Performance Share Unit Agreement 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex104.htm">Non-Qualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.70</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex105.htm">Restricted Stock Unit Award Agreement for awards vesting 100% on the third anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.5 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310322000011/mdt-2022q310qxex106.htm">Restricted Stock Unit Award Agreement for awards vesting ratably on the first, second, third, and fourth anniversary of the grant date - 2021 Medtronic plc Long Term Incentive Plan  (incorporated by reference to Exhibit 10.6 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q for the quarter ended January 28, 2022, filed on March 3, 2022, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.72</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1613103/000161310323000008/mdt-2023q310xqxex101.htm">Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022 (incorporated by reference to Exhibit 10.1 to Medtronic plc's Quarterly Report on Form 10-Q for the quarter ended January 27, 2023, filed on March 1, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000008/mdt-20230127.htm">Annex I to Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022 (incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000008/mdt-20230127.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000008/mdt-20230127.htm"> to Medtronic plc's Quarterly Report on Form 10-Q for the quarter ended January 27, 2023, filed on March 1, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000040/mdt-20230428.htm">Amendment No. 2 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2020 (incorporated by reference to Exhibit 10.85 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 28, 2023, filed on June 22, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000040/mdt-20230428.htm">Medtronic Nonqualified Retirement Plan Supplement dated as of April 28, 2023 (incorporated by reference to Exhibit 10.86 to Medtronic plc&#8217;s Annual Report on Form 10-K for the year ended April 28, 2023, filed on June 22, 2023, File No. 001-36820)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Performance Share Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.78</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.79</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1613103/000161310323000128/mdt-20230728.htm">Non-Qualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Medtronic plc&#8217;s Quarterly Report on Form 10-Q filed on August 31, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001613103/000161310323000132/mdt-20231019.htm">Medtronic plc 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to Medtronic plc&#8217;s Current Report on Form 8-K filed on October 23, 2023, File No. 001-36820).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#10.81</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm">Medtronic Nonqualified Retirement Plan Supplement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm">(as amended and restated effective</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm">March 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510xkxex1081.htm">5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex19.htm">Medtronic plc Global Insider Trading Policy</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex21.htm">List of Subsidiaries of Medtronic plc. </a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex22.htm">List of Senior Notes, Issuers and Guarantors.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex23.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex24.htm">Power of Attorney.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex321.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#32.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex322.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mdt-202510kxex97.htm">Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation</a></span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.LAB </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#101.PRE </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document </span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"/><td style="width:3.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.403%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Exhibits that are management contracts or compensatory plans or arrangements.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#Filed herewith</span></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div id="ic14a750e81984b18a679ba753642023e_250"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has not elected to include such summary information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="ic14a750e81984b18a679ba753642023e_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic14a750e81984b18a679ba753642023e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medtronic plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">/s/ Geoffrey S. Martha</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medtronic plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Geoffrey S. Martha</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Thierry Pi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#233;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ton</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thierry Pi&#233;ton</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Denise L. Blomquist</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denise L. Blomquist</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vice President, Global Controller and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Craig Arnold*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott C. Donnelly*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lidia Fonseca*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrea J. Goldsmith, Ph.D.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Randall J. Hogan*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gregory P. Lewis*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevin E. Lofton*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geoffrey S. Martha</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Elizabeth G. Nabel, M.D.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kendall J. Powell*</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Ivan K. Fong, by signing his name hereto, does hereby sign this document on behalf of each of the above named directors of the registrant pursuant to powers of attorney duly executed by such persons.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: June 20, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ Ivan K. Fong</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ivan K. Fong</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.30
<SEQUENCE>2
<FILENAME>mdt-202510kxex430.htm
<DESCRIPTION>EX-4.30
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6daa3c0925fc4096b7f73150c0166167_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit 4.30</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the &#8220;Ordinary Shares&#8221;), of Medtronic plc, a company incorporated under the laws of Ireland (&#8220;Medtronic&#8221; or &#8220;Medtronic plc&#8221;), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Senior Notes due 2028, 1.625% Senior Notes due 2031, 1.00% Senior Notes due 2031, 3.125% Senior Notes due 2031, 0.750% Senior Notes due 2032, 3.375% Senior Notes due 2034, 2.250% Senior Notes due 2039, 1.500% Senior Notes due 2039, 1.375% Senior Notes due 2040, 1.750% Senior Notes due 2049, and 1.625% Senior Notes due 2050, issued by Medtronic Global Holdings S.C.A., an entity incorporated and existing under the laws of Luxembourg (&#8220;Medtronic Luxco&#8221;), and (iii) the 3.650% Senior Notes due 2029, 3.875% Senior Notes due 2036, 4.150% Senior Notes due 2043, and 4.150% Senior Notes due 2053, issued by Medtronic Inc., a Minnesota corporation, which are all of the securities of Medtronic and its subsidiaries registered pursuant to Section 12 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF MEDTRONIC ORDINARY SHARES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of Medtronic&#8217;s share capital is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (as amended) (the &#34;Irish Companies Act&#34;) and the complete text of Medtronic&#8217;s memorandum and articles of association, as they may be amended from time to time (the &#8220;Articles of Association&#8221;). Copies of the Articles of Association have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibit 3.1 to Medtronic&#8217;s Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Capital Structure </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized Share Capital </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc is authorized to issue 2.6 billion ordinary shares, $0.0001 par value&#59; 40 thousand euro deferred shares, &#8364;1.00 par value&#59; 127.5 million preferred shares, $0.20 par value&#59; and 500 thousand A preferred shares, $1.00 par value.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic may issue shares subject to the maximum authorized share capital contained in the Articles of Association. The authorized share capital may be increased or reduced by a resolution approved by a simple majority of the votes of Medtronic&#8217;s shareholders cast at a general meeting (referred to under Irish law as an &#8220;ordinary resolution&#8221;). The shares comprising the authorized share capital of Medtronic may be divided into shares of such nominal value as the resolution shall prescribe. As a matter of Irish company law, the directors of a company may issue new ordinary or preferred shares without shareholder approval once authorized to do so by the Articles of Association or by an ordinary resolution adopted by the shareholders at a general meeting. The authorization may be granted for a maximum period of five years, at which point it must be renewed by the shareholders by an ordinary resolution. Medtronic's shareholders adopted an ordinary resolution at the 2024 annual general meeting of Medtronic on October 17, 2024 authorizing the board of directors to issue up to an aggregate nominal amount of $25,652.00 (being equivalent to approximately 20% of the aggregate nominal value of the issued share capital of Medtronic as of August 5, 2024) for a period of 18 months from October 17, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights and restrictions to which the ordinary shares, euro deferred shares and A preferred shares are subject are prescribed in the Articles of Association. The Articles of Association entitle the Medtronic board of directors, without shareholder approval, to determine the terms of the preferred shares issued by Medtronic. Preferred shares may be preferred as to dividends, rights upon liquidation or voting in such manner as the directors of Medtronic may resolve. The preferred shares may also be redeemable at the option of the holder of the preferred shares or at the option of Medtronic, and may be convertible into or exchangeable for shares of any other class or classes of Medtronic, depending on the terms of such preferred shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of the A preferred shares are entitled in priority to any payments of dividends on any other class of shares in Medtronic to be paid a dividend in the amount per A preferred share equal to twice the dividend to be paid per ordinary share and in addition on a return of assets, whether on liquidation or otherwise, the A preferred shares entitle the holders to repayment of the capital paid up on those shares (including any share premium) in priority to any repayment of capital to the holders of any other shares. The holders of the A preferred shares are not entitled to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any further participation in the assets or profits of Medtronic, nor are the holders of the A preferred shares, which are non-voting shares, entitled to receive notice of, attend, speak or vote at any general meeting of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of euro deferred shares are not entitled to receive any dividend or distribution and are not entitled to receive notice of, attend, speak or vote at any general meeting of Medtronic. On a return of assets, the euro deferred shares will entitle the holder only to the repayment of amounts paid up on such shares after repayment of the capital paid up on the ordinary shares plus the payment of $5,000,000 on each ordinary share. There are no euro deferred shares in issue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish law does not recognize fractional shares held of record. Accordingly, the Articles of Association do not provide for the issuance of fractional shares of Medtronic, and the official Irish register of Medtronic does not reflect any fractional shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Whenever an alteration or reorganization of the share capital of Medtronic would result in any Medtronic shareholder becoming entitled to fractions of a share, the Medtronic board of directors may, on behalf of those shareholders that would become entitled to fractions of a share, arrange for the sale of the shares representing fractions and the distribution of the net proceeds of sale in due proportion among the shareholders who would have been entitled to the fractions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Preemption Rights, Share Warrants and Share Options </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law certain statutory preemption rights apply automatically in favor of shareholders where shares are to be issued for cash. Medtronic initially opted out of these preemption rights in the Articles of Association as permitted under Irish company law. Because Irish law requires this opt-out to be renewed every five years by a resolution approved by not less than 75% of the votes of the shareholders of Medtronic cast at a general meeting (referred to under Irish law as a &#8220;special resolution&#8221;), the Articles of Association provide that this opt-out must be so renewed. If the opt-out is not renewed, shares issued for cash must be offered to existing shareholders of Medtronic on a pro rata basis to their existing shareholding before the shares can be issued to any new shareholders. The statutory preemption rights do not apply where shares are issued for non-cash consideration (such as in a stock-for-stock acquisition) and do not apply to the issue of non-equity shares (that is, shares that have the right to participate only up to a specified amount in any income or capital distribution) or where shares are issued pursuant to an employee stock option or similar equity plan. Medtronic's shareholders passed a special resolution at the 2024 annual general meeting of Medtronic on October 17, 2024 authorizing the Medtronic board of directors to opt out of preemption rights with respect to the issuance of equity securities up to an aggregate nominal value of $25,652.00 (being equivalent to approximately 20% of the aggregate nominal value of the issued ordinary share capital of Medtronic as of August 5, 2024) for a period of 18 months from October 17, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association of Medtronic provide that, subject to any shareholder approval requirement under any laws, regulations or the rules of any stock exchange to which Medtronic is subject, the board is authorized, from time to time, in its discretion, to grant such persons, for such periods and upon such terms as the board deems advisable, options to purchase such number of shares of any class or classes or of any series of any class as the board may deem advisable, and to cause warrants or other appropriate instruments evidencing such options to be issued. The Irish Companies Act provides that directors may issue share warrants or options without shareholder approval once authorized to do so by the Articles of Association or an ordinary resolution of shareholders. Medtronic is subject to the rules of the NYSE and the U.S. Internal Revenue Code of 1986, as amended, which require shareholder approval of certain equity plan and share issuances. Medtronic&#8217;s board of directors may issue shares upon exercise of warrants or options without shareholder approval or authorization (up to the relevant authorized share capital limit). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividends </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, dividends and distributions may be made only from distributable reserves. Distributable reserves generally means accumulated realized profits less accumulated realized losses and includes reserves created by way of capital reduction. In addition, no distribution or dividend may be made unless the net assets of Medtronic are equal to, or in excess of, the aggregate of Medtronic&#8217;s called up share capital plus undistributable reserves and the distribution does not reduce Medtronic&#8217;s net assets below such aggregate. Undistributable reserves include the share </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">premium account, the par value of Medtronic shares acquired by Medtronic and the amount by which Medtronic&#8217;s accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed Medtronic&#8217;s accumulated unrealized losses, so far as not previously written off in a reduction or reorganization of capital. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The determination as to whether or not Medtronic has sufficient distributable reserves to fund a dividend must be made by reference to &#8220;relevant financial statements&#8221; of Medtronic. The &#8220;relevant financial statements&#8221; will be either the last set of unconsolidated annual audited financial statements or other financial statements properly prepared in accordance with the Irish Companies Act, which give a &#8220;true and fair view&#8221; of Medtronic&#8217;s unconsolidated financial position and accord with accepted accounting practice. The &#8220;relevant financial statements&#8221; must be filed in the Companies Registration Office (the official public registry for companies in Ireland). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association authorize the directors to declare dividends out of funds lawfully available for the purpose without shareholder approval. The board of directors may also recommend a dividend to be approved and declared by the Medtronic shareholders at a general meeting. The board of directors may direct that the payment be made by distribution of assets, shares or cash and no dividend issued may exceed the amount recommended by the directors. Dividends may be declared and paid in the form of cash or non-cash assets and may be paid in U.S. dollars or any other currency. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors of Medtronic may deduct from any dividend payable to any shareholder any amounts payable by such shareholder to Medtronic in relation to the shares of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors may also authorize Medtronic to issue shares with preferred rights to participate in dividends declared by Medtronic. The holders of preferred shares may, depending on their terms, rank senior to the Medtronic ordinary shares in terms of dividend rights and&#47;or be entitled to claim arrears of a declared dividend out of subsequently declared dividends in priority to ordinary shareholders. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on dividend rights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share Repurchases, Redemptions and Conversions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Overview </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that any ordinary share which Medtronic has agreed to acquire will be deemed to be a redeemable share, unless the board resolves otherwise. Accordingly, for Irish company law purposes, the repurchase of ordinary shares by Medtronic may technically be effected as a redemption of those shares as described below under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Share Repurchases, Redemptions and Conversions&#8212;Repurchases and Redemptions by Medtronic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#8221; If the Articles of Association did not contain such provision, all repurchases by Medtronic would be subject to many of the same rules that apply to purchases of Medtronic ordinary shares by subsidiaries described below under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;Purchases by Subsidiaries of Medtronic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; including the shareholder approval requirements described below and the requirement that any on-market purchases be effected on a &#8220;recognized stock exchange.&#8221; Except where otherwise noted, references to repurchasing or buying back ordinary shares of Medtronic refer to the redemption of ordinary shares by Medtronic or the purchase of ordinary shares of Medtronic by a subsidiary of Medtronic, in each case in accordance with the Articles of Association and Irish company law as described below. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Repurchases and Redemptions by Medtronic </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, a company may issue redeemable shares and redeem them out of distributable reserves or the proceeds of a new issue of shares for that purpose. Medtronic may only issue redeemable shares if the nominal value of the issued share capital that is not redeemable is not less than 10% of the nominal value of the total issued share capital of Medtronic. All redeemable shares must also be fully-paid. Based on the provision of the Articles of Association described above, shareholder approval will not be required to redeem Medtronic shares. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic may also be given an additional general authority by its shareholders to purchase its own shares on-market, which would take effect on the same terms and be subject to the same conditions as applicable to purchases by Medtronic&#8217;s subsidiaries as described below. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors of Medtronic may also issue preferred shares which may be redeemed at the option of either Medtronic or the shareholder, depending on the terms of such preferred shares. Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on preferred shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Repurchased and redeemed shares may be cancelled or held as treasury shares. The nominal value of treasury shares held by Medtronic at any time must not exceed 10% of the aggregate of the par value and share premium received in respect of the allotment of  Medtronic shares together with the par value of any shares acquired by Medtronic. Medtronic may not exercise any voting rights in respect of any shares held as treasury shares. Treasury shares may be cancelled by Medtronic or re-issued subject to certain conditions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that Medtronic may not, directly or indirectly, purchase or agree to purchase any shares entitled to vote from a person who beneficially owns more than five percent of the voting power of Medtronic for more than the market value thereof if the shares have been beneficially owned by the person for less than two years, unless the purchase or agreement to purchase is approved at a meeting of shareholders by the affirmative vote of the holders of not less than a majority of the issued and outstanding shares of Medtronic entitled to vote or Medtronic makes an offer, of at least equal value per share, to all holders of shares of the class or series and to all holders of any class or series into which the securities may be converted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Purchases by Subsidiaries of Medtronic </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Irish law, an Irish or non-Irish subsidiary may purchase shares of Medtronic either on-market or off-market. For a subsidiary of Medtronic to make on-market purchases of Medtronic ordinary shares, the shareholders of Medtronic must provide general authorization for such purchase by way of ordinary resolution. However, as long as this general authority has been granted, no specific shareholder authority for a particular on-market purchase by a subsidiary of Medtronic ordinary shares is required. For an off-market purchase by a subsidiary of Medtronic, the proposed purchase contract must be authorized by special resolution of the shareholders before the contract is entered into. The person whose shares are to be bought back cannot vote in favor of the special resolution and, from the date of the notice of the meeting at which the resolution approving the contract is to be proposed, the purchase contract must be on display or must be available for inspection by shareholders at the registered office of Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order for a subsidiary of Medtronic to make an on-market purchase of Medtronic&#8217;s shares, such shares must be purchased on a &#8220;recognized stock exchange.&#8221; The NYSE, on which the shares of Medtronic are listed, is specified as a recognized stock exchange for this purpose by Irish company law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The number of shares held by the subsidiaries of Medtronic at any time will count as treasury shares and will be included in any calculation of the permitted treasury share threshold of 10% of the aggregate of the par value and share premium in respect of the allotment of Medtronic shares together with the par value of any shares acquired by Medtronic. While a subsidiary holds shares of Medtronic, it cannot exercise any voting rights in respect of those shares. The acquisition of the shares of Medtronic by a subsidiary must be funded out of distributable reserves of the subsidiary. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lien on Shares, Calls on Shares and Forfeiture of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that Medtronic has a first and paramount lien on every share for all debts and liabilities of any shareholder to the company, whether presently due or not, payable in respect of such share. Subject to the terms of their allotment, directors may call for any unpaid amounts in respect of any shares to be paid, and if payment is not made, the shares may be forfeited. These provisions are standard inclusions in the articles of association of an Irish company limited by shares such as Medtronic and will only be applicable to shares of Medtronic that have not been fully paid up. See also &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;Transfer and Registration of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; below. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consolidation and Division&#59; Subdivision </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Articles of Association, Medtronic may, by ordinary resolution, consolidate and divide all or any of its share capital into shares of larger nominal value than its existing shares or subdivide its shares into smaller amounts than is fixed by its memorandum of association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reduction of Share Capital </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic may, by ordinary resolution, reduce its authorized but unissued share capital in any way. Medtronic also may, by special resolution and subject to confirmation by the Irish High Court, reduce or cancel its issued share capital in any manner permitted by the Irish Companies Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Annual Meetings of Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic is required to hold an annual general meeting at intervals of no more than 15 months, provided that an annual general meeting is held in each calendar year no more than nine months after Medtronic's fiscal year-end. Any annual general meeting may be held outside of Ireland, provided that technological means are provided to enable shareholders to participate in the meeting without leaving Ireland.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notice of an annual general meeting must be given to all Medtronic shareholders and to the auditors of Medtronic. The Articles of Association provide for a minimum notice period of 21 days, which is the minimum permitted under Irish law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The only matters which must, as a matter of Irish company law, be transacted at an annual general meeting are (i) the consideration of the statutory financial statements and reports of the directors and auditors, (ii) the review by the members of the company's affairs and (iii) the appointment or re-appointment of the auditors and the fixing of the auditor&#8217;s remuneration (or delegation of same). If no resolution is made in respect of the reappointment of an existing auditor at an annual general meeting, the existing auditor will be deemed to have continued in office. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Extraordinary General Meetings of Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Extraordinary general meetings of Medtronic may be convened by (i) the board of directors, (ii) any two directors, (iii) the chief executive officer, (iv) the chief financial officer, (v) on requisition of the shareholders holding not less than 10% of the paid up share capital of Medtronic carrying voting rights or (vi) on requisition of Medtronic&#8217;s auditors. Extraordinary general meetings are generally held for the purposes of approving shareholder resolutions as may be required from time to time. At any extraordinary general meeting, only such business will be conducted as is set forth in the notice thereof or is proposed pursuant to and in accordance with the procedures and requirements set out in the Articles of Association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notice of an extraordinary general meeting must be given to all Medtronic shareholders and to the auditors of Medtronic. Under Irish law and the Articles of Association, the minimum notice periods are 21 days&#8217; notice in writing for an extraordinary general meeting to approve a special resolution and 14 days&#8217; notice in writing for any other extraordinary general meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of an extraordinary general meeting convened by shareholders of Medtronic, the proposed purpose of the meeting must be set out in the requisition notice. Upon receipt of any such valid requisition notice, the Medtronic board of directors has 21 days to convene a meeting of Medtronic shareholders to vote on the matters set out in the requisition notice. This meeting must be held within two months of the receipt of the requisition notice. If the board of directors does not convene the meeting within such 21-day period, the requisitioning shareholders, or any of them representing more than one half of the total voting rights of all of them, may themselves convene a meeting, which meeting must be held within three months of Medtronic&#8217;s receipt of the requisition notice. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the board of directors becomes aware that the net assets of Medtronic are not greater than half of the amount of Medtronic&#8217;s called-up share capital, the directors of Medtronic must convene an extraordinary general meeting of Medtronic shareholders not later than 28 days from the date that they learn of this fact to consider how to address the situation. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quorum for General Meetings </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that no business may be transacted at any general meeting unless a quorum is present. One or more shareholders present in person or by proxy at any meeting of shareholders holding not less than a majority of the issued and outstanding shares entitled to vote at the meeting in question will constitute a quorum for such meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Voting </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association provide that all votes will be decided on a poll and that the board or the chairman may determine the manner in which the poll is to be taken and the manner in which the votes are to be counted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Every shareholder is entitled to one vote for each ordinary share that he or she holds as of the record date for the meeting. Voting rights may be exercised by shareholders registered in Medtronic&#8217;s share register as of the record date for the meeting or by a duly appointed proxy, which proxy need not be a shareholder. Where interests in shares are held by a nominee trust company, this company may exercise the rights of the beneficial holders on their behalf as their proxy. All proxies must be appointed in the manner prescribed by the Articles of Association, which provide that the Medtronic board may permit shareholders to notify Medtronic of their proxy appointments electronically. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish company law requires special resolutions of the shareholders at a general meeting to approve certain matters. Examples of matters requiring special resolutions include&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:3.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amending the objects or memorandum of association of Medtronic&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amending the Articles of Association&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approving a change of name of Medtronic&#59;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Variation of Rights Attaching to a Class or Series of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Articles of Association and the Irish Companies Act, any variation of class rights attaching to the issued shares of Medtronic must be approved by an ordinary resolution of the shareholders of the affected class or with the consent in writing of the holders of the majority of the issued shares of that class of shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of the Articles of Association relating to general meetings apply to general meetings of the holders of any class of shares except that the necessary quorum is determined in reference to the shares of the holders of the class. Accordingly, for general meetings of holders of a particular class of shares, a quorum consists of one or more shareholders present in person or by proxy holding not less than a majority of the issued and outstanding shares of the class entitled to vote at the meeting in question. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisitions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An Irish public limited company may be acquired in a number of ways, including&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a court-approved scheme of arrangement under the Irish Companies Act. A scheme of arrangement with shareholders requires a court order from the Irish High Court and the approval of a majority in number representing 75% in value of each class of shareholder present and voting in person or by proxy at a meeting called to approve the scheme&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">through a tender or takeover offer by a third party for all of the shares of Medtronic. Where the holders of 80% or more of Medtronic&#8217;s shares have accepted an offer for their shares in Medtronic, the remaining shareholders may also be statutorily required to transfer their shares. If the bidder does not exercise its &#8220;squeeze out&#8221; right, then the non-accepting shareholders also have a statutory right to require the bidder to acquire their shares on the same terms. If shares of Medtronic were to be listed on the Irish Stock Exchange or another regulated stock exchange in the European Union, the &#8220;squeeze out&#8221; threshold would be increased to 90%&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">by way of a merger with a company incorporated in the European Economic Area (&#8220;EEA&#8221;) under the EU Cross-Border Mergers Directive (EU) 2017&#47;1132 (as amended) or with another Irish company under the Irish Companies Act. Such a merger must be approved by a special resolution. Shareholders also may be entitled to have their shares acquired for cash. See the section entitled &#8220;Description of Share Capital&#8212;Appraisal Rights&#8221;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Appraisal Rights </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, under Irish law, shareholders of an Irish company do not have statutory appraisal rights. If  Medtronic is being merged as the transferor company with another EEA company under the EU Cross-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Border Mergers Directive (EU) 2017&#47;1132 (as amended) as implemented in Ireland by the European Union (Cross- Border Conversions, Mergers and Divisions) Regulations 2023 or if Medtronic is being merged with another Irish company under the Irish Companies Act, (i) any of Medtronic's shareholders who voted against the special resolution approving the merger or (ii) if 90% of Medtronic's shares are held by the successor company, any other of Medtronic's shareholders, may be entitled to require that the successor company acquire its shares for cash. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclosure of Interests in Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Companies Act, Medtronic shareholders must notify Medtronic if, as a result of a transaction, the shareholder will become interested in 3% or more of the shares of Medtronic or if, as a result of a transaction a shareholder who was interested in more than 3% of the shares of Medtronic ceases to be so interested. Where a shareholder is interested in more than 3% of the shares of Medtronic, the shareholder must notify Medtronic of any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an increase or a reduction. The relevant percentage figure is calculated by reference to the aggregate nominal value of the shares in which the shareholder is interested as a proportion of the entire nominal value of the issued share capital of Medtronic (or any such class of share capital in issue). Where the percentage level of the shareholder&#8217;s interest does not amount to a whole percentage, this figure may be rounded down to the next whole number. Medtronic must be notified within five business days of the transaction or alteration of the shareholder&#8217;s interests that gave rise to the notification requirement. If a shareholder fails to comply with these notification requirements, the shareholder&#8217;s rights in respect of any Medtronic shares it holds will not be enforceable, either directly or indirectly. However, such person may apply to the court to have the rights attaching to such shares reinstated. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to these disclosure requirements, Medtronic, under the Irish Companies Act, may, by notice in writing, require a person whom Medtronic knows or has reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued to have been, interested in shares comprised in Medtronic&#8217;s relevant share capital to&#58; (i) indicate whether or not it is the case and (ii) where such person holds or has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during that time held an interest in the shares of Medtronic, to provide additional information, including the person&#8217;s own past or present interests in shares of Medtronic. If the recipient of the notice fails to respond within the reasonable time period specified in the notice, Medtronic may apply to court for an order directing that the affected shares be subject to certain restrictions, as prescribed by the Irish Companies Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Medtronic is in an offer period pursuant to the Irish Takeover Rules, accelerated disclosure provisions apply for persons holding an interest in Medtronic securities of 1% or more. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the beneficial ownership disclosures of the U.S. federal securities laws will apply with respect to beneficial ownership of Medtronic shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-Takeover Provisions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business Combinations with Interested Shareholders </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic's Articles of Association provide that, subject to certain exceptions, Medtronic may not engage in certain business combinations with any person that acquires beneficial ownership of 10% or more of Medtronic's outstanding voting shares for a period of four years following the date on which the person became a 10% shareholder unless prior to the person becoming a 10% shareholder, a committee of Medtronic's disinterested directors approve the business combination or the acquisition of shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Control Share Acquisition</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain exceptions, Medtronic's Articles of Association restrict the ability of persons who acquire between twenty percent and thirty percent of the voting rights of Medtronic to exercise the voting rights of the acquired shares in excess of twenty percent absent approval by an ordinary resolution of the disinterested shareholders. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Irish Takeover Rules and Substantial Acquisition Rules </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A transaction in which a third party seeks to acquire 30% or more of the voting rights of Medtronic will be governed by the Irish Takeover Panel Act 1997 and the Irish Takeover Rules made thereunder and will be regulated by the Irish Takeover Panel. The &#8220;General Principles&#8221; of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described below. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General Principles </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Takeover Rules are built on the following General Principles, which will apply to any transaction regulated by the Irish Takeover Panel&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the event of an offer, all holders of securities of the target company should be afforded equivalent treatment and, if a person acquires control of a company, the other holders of securities must be protected&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the holders of the securities of the target company must have sufficient time and information to enable them to reach a properly informed decision on the offer&#59; where it advises the holders of securities, the board of the target company must give its views on the effects of implementation of the offer on employment, conditions of employment and the locations of the target company&#8217;s places of business&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the board of the target company must act in the interests of the company as a whole and must not deny the holders of securities the opportunity to decide on the merits of the offer&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">false markets must not be created in the securities of the target company, the bidder or of any other company concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a bidder must announce an offer only after ensuring that he or she can fulfill in full, any cash consideration, if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a target company must not be hindered in the conduct of its affairs for longer than is reasonable by an offer for its securities&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a substantial acquisition of securities (whether such acquisition is to be effected by one transaction or a series of transactions) shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Mandatory Bid </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under certain circumstances, a person who acquires shares or other voting rights in Medtronic may be required under the Irish Takeover Rules to make a mandatory cash offer for the remaining outstanding shares in Medtronic at a price not less than the highest price paid for the shares by the acquirer (or any parties acting in concert with the acquirer) during the previous 12 months. This mandatory bid requirement is triggered if an acquisition of shares would increase the aggregate holding of an acquirer (including the holdings of any parties acting in concert with the acquirer) to shares representing 30% or more of the voting rights in Medtronic, unless the Irish Takeover Panel otherwise consents. An acquisition of shares by a person holding (together with its concert parties) shares representing between 30% and 50% of the voting rights in Medtronic would also trigger the mandatory bid requirement if, after giving effect to the acquisition, the percentage of the voting rights held by that person (together with its concert parties) would increase by 0.05% within a 12-month period. Any person (excluding any parties acting in concert with the holder) holding shares representing more than 50% of the voting rights of a company is not subject to these mandatory offer requirements in purchasing additional securities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Voluntary Bid&#59; Requirements to Make a Cash Offer and Minimum Price Requirements </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a person makes a voluntary offer to acquire outstanding ordinary shares of Medtronic, the offer price must be no less than the highest price paid for Medtronic ordinary shares by the bidder or its concert parties during the three-month period prior to the commencement of the offer period. The Irish Takeover Panel has the power to extend the &#8220;look back&#8221; period to 12 months if the Irish Takeover Panel, taking into account the General Principles, believes it is appropriate to do so. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the bidder or any person acting in concert with it has acquired ordinary shares of Medtronic (i) during the period of 12 months prior to the commencement of the offer period which represent more than 10% of the total ordinary shares of Medtronic or (ii) at any time after the commencement of the offer period, the offer must be in cash (or accompanied by a full cash alternative) and the price per Medtronic ordinary share must not be less than the highest price paid by the bidder or any person acting in concert with it during, in the case of (i), the 12-month period prior to the commencement of the offer period or, in the case of (ii), the offer period. The Irish Takeover Panel may apply this rule to a bidder who, together with any person acting in concert with it, has acquired less than 10% of the total ordinary shares of Medtronic in the 12-month period prior to the commencement of the offer period if the Irish Takeover Panel, taking into account the General Principles, considers it just and proper to do so. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An offer period will generally commence from the date of the first announcement of the offer or proposed offer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Articles of Association provide that an offeror who has completed a tender offer for Medtronic may not, within two years after the last purchase in the tender offer, acquire additional shares, whether by purchase, merger, exchange or otherwise, unless the shareholders in those additional acquisitions are given terms that are substantially equivalent to those provided in the earlier tender offer or unless the proposed additional acquisitions are approved by an independent committee of Medtronic&#8217;s board of directors prior to the tender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">offer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Takeover Timeline</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Takeover Rules, in certain circumstances a strict 42-day deadline will be imposed within which a person with whom we are in talks, or from whom we have received an approach, regarding a possible offer is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">required to make a firm offer for Medtronic, or announce they will not be making an offer. The Irish Takeover Panel may agree to extend this deadline at our request. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Substantial Acquisition Rules </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Takeover Rules also contain rules governing substantial acquisitions of shares and other voting securities which restrict the speed at which a person may increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of the voting rights of Medtronic. Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or more of the voting rights of Medtronic is prohibited, if such acquisition(s), when aggregated with shares or rights already held, would result in the acquirer holding 15% or more but less than 30% of the voting rights of Medtronic and such acquisitions are made within a period of seven days. These rules also require accelerated disclosure of acquisitions of shares or rights over shares relating to such holdings. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shareholder Rights Plan </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association expressly authorize Medtronic&#8217;s board of directors to adopt a shareholder rights plan, subject to applicable law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Irish law does not expressly authorize or prohibit companies from issuing share purchase rights or adopting a shareholder rights plan as an anti-takeover measure and there is no directly relevant case law on this issue.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Frustrating Action </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Takeover Rules, the Medtronic board of directors is not permitted to take any action which might frustrate an offer for the shares of Medtronic once the Medtronic board of directors has received an approach which may lead to an offer or has reason to believe an offer is or may be imminent, subject to certain exceptions. Potentially frustrating actions such as (i) the issue of shares, options or convertible securities, (ii) material acquisitions or disposals, (iii) entering into contracts other than in the ordinary course of business or (iv) any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any time during which the board has reason to believe an offer is or may be imminent. Exceptions to this prohibition are available where&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the action is approved by Medtronic&#8217;s shareholders at a general meeting&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Irish Takeover Panel has given its consent, where&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">it is satisfied the action would not constitute frustrating action&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic shareholders that hold 50% of the voting rights state in writing that they approve the proposed action and would vote in favor of it at a general meeting&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the action is taken in accordance with a contract entered into prior to the announcement of the offer&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the decision to take such action was made before the announcement of the offer and either has been at least partially implemented or is in the ordinary course of business.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Governance </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association of Medtronic allocate authority over the day-to-day management of Medtronic to the Medtronic board of directors. The Medtronic board of directors may then, by resolution approved by the affirmative vote of a majority of the board, delegate any of its powers, authorities and discretions (with power to sub-delegate) to any committee, consisting of one or more directors, or delegate to any director, officer or member of management of Medtronic or any of its subsidiaries such of its powers as it considers desirable to be exercised by him or her, but </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regardless, the directors will remain responsible, as a matter of Irish law, for the proper management of the affairs of Medtronic. Committees may meet and adjourn as they determine proper. Unless otherwise determined by the board of directors, the quorum necessary for the transaction of business at any committee meeting shall be a majority of the members of the committee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic has a standing Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, Quality Committee, Finance and Financial Risk Committee and Technology and Value Creation Committee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Appointment of Directors </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Irish Companies Act provides for a minimum of two directors. Medtronic's Articles of Association provide for a minimum of three directors and a maximum of fifteen. The board of directors has sole authority to determine its size within these parameters.  Directors of Medtronic will be elected by way of an ordinary resolution at a general meeting. This majority voting standard could result in the number of directors falling below the prescribed minimum number of directors due to the failure of nominees to be elected. If the number of the directors is reduced below the fixed minimum number, the remaining director or directors must appoint, as soon as practicable, an additional director or additional directors to make up such minimum or must convene a general meeting of Medtronic for the purpose of making such appointment. In the event of a &#8220;contested election&#8221; of directors, directors shall be elected by the vote of a plurality of the votes cast at any meeting for the election of directors at which a quorum is present. Each director of Medtronic must retire from office at each annual shareholder meeting and shall be re-eligible for re-election. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No person may be appointed director unless nominated in accordance with the Articles of Association. The Articles of Association provide that, with respect to an annual or extraordinary general meeting of shareholders, nominations of persons for election to the Medtronic board of directors may be made by (i) the affirmative vote of the Medtronic board of directors or a committee thereof, (ii) any shareholder who is entitled to vote at the meeting and who has complied with the advance notice procedures provided for in the Articles of Association, (iii) with respect to election at an extraordinary general meeting requisitioned in accordance with section 178(3) of the Irish Companies Act, by a shareholder who holds ordinary shares or other shares carrying the general right to vote at general meetings of the company and who makes such nomination in the written requisition of the extraordinary general meeting in accordance with the Articles of Association and the Irish Companies Act relating to nominations of directors and the proper bringing of business before an extraordinary general meeting, or (iv) any shareholder who is entitled to vote at the meeting and who has complied with the &#34;proxy access&#34; provisions contained in the Articles of Association. Medtronic&#8217;s Articles of Association contain &#8220;proxy access&#8221; provisions which give an eligible shareholder (or group of up to 20 such shareholders) that has owned 3% or more of the voting power continuously for at least three years, the right to nominate up to 20% of the directors and to have those nominees included in Medtronic&#8217;s proxy materials, subject to the other terms and conditions of Medtronic's articles of association.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Removal of Directors </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Irish Companies Act, the shareholders may, by an ordinary resolution, remove a director from office before the expiration of his or her term at a meeting held on no less than 28 days&#8217; notice and at which the director is entitled to be heard. The power of removal is without prejudice to any claim for damages for breach of contract (e.g., employment contract) that the director may have against Medtronic in respect of his or her removal. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The board of directors may fill any vacancy occurring on the board of directors. If the Medtronic board of directors fills a vacancy, the director shall hold office until the next election of directors and until his or her successor shall be elected. A vacancy on the board of directors created by the removal of a director may be filled by the Medtronic board of directors. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Duration&#59; Dissolution&#59; Rights upon Liquidation </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic&#8217;s duration is unlimited. Medtronic may be dissolved and wound up at any time by way of a shareholders&#8217; voluntary winding up or a creditors&#8217; winding up. In the case of a shareholders&#8217; voluntary winding-up, a special resolution of shareholders is required. Medtronic may also be dissolved by way of court order on the application of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">creditor, or by the Companies Registration Office as an enforcement measure where Medtronic has failed to file certain returns. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights of the shareholders to a return of Medtronic&#8217;s assets on dissolution or winding up, following the settlement of all claims of creditors, may be prescribed in the Articles of Association or the terms of any preferred shares issued by the directors of Medtronic from time to time. The holders of preferred shares in particular may have the right to priority in a dissolution or winding up of Medtronic. If the Articles of Association contain no specific provisions in respect of a dissolution or winding up then, subject to the priorities of any creditors, the assets will be distributed to shareholders in proportion to the paid-up nominal value of the shares held. The Articles of Association provide that the ordinary shareholders of Medtronic are entitled to participate pro rata in a winding up, but their right to do so may be subject to the rights of any preferred shareholders to participate under the terms of any series or class of preferred shares. Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of Medtronic Ordinary Shares&#8212;Capital Structure&#8212;Authorized Share Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional information on rights upon a liquidation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertificated Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Irish Companies Act, a shareholder is entitled to be issued a share certificate on request and subject to payment of a nominal fee. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock Exchange Listing </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic ordinary shares are listed on the New York Stock Exchange under the ticker symbol &#8220;MDT.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">No Sinking Fund </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic ordinary shares have no sinking fund provisions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transfer and Registration of Shares </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent for Medtronic maintains the share register, registration in which is determinative of membership in Medtronic. A shareholder of Medtronic who holds shares beneficially is not holder of record of such shares. Instead, the depository or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who also holds such shares beneficially through a depository or other nominee will not be registered in Medtronic&#8217;s official share register, as the depository or other nominee will remain the record holder of any such shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A written instrument of transfer is required under Irish law in order to register on Medtronic&#8217;s official share register any transfer of shares (i) from a person who holds such shares directly to any other person, (ii) from a person who holds such shares beneficially to a person who holds such shares directly or (iii) from a person who holds such shares beneficially to another person who holds such shares beneficially where the transfer involves a change in the depository or other nominee that is the record owner of the transferred shares. An instrument of transfer is also required for a shareholder who directly holds shares to transfer those shares into his or her own broker account (or vice versa). Such instruments of transfer may give rise to Irish stamp duty, which must be paid prior to registration of the transfer on Medtronic&#8217;s official Irish share register. However, a shareholder who directly holds shares may transfer those shares into his or her own broker account (or vice versa) without giving rise to Irish stamp duty provided there is no change in the ultimate beneficial ownership of the shares as a result of the transfer and the transfer is not made in contemplation of a sale of the shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any transfer of Medtronic ordinary shares that is subject to Irish stamp duty will not be registered in the name of the buyer unless an instrument of transfer is duly stamped and provided to the transfer agent. The Articles of Association allow Medtronic, in its absolute discretion, to create an instrument of transfer and pay (or procure the payment of) any stamp duty, which is the legal obligation of a buyer. In the event of any such payment, Medtronic is (on behalf of itself or its affiliates) entitled to (i) seek reimbursement from the buyer or seller (at its discretion), (ii) set-off the amount of the stamp duty against future dividends payable to the buyer or seller (at its discretion) and (iii) claim a lien against the Medtronic ordinary shares on which it has paid stamp duty. Parties to a share transfer may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assume that any stamp duty arising in respect of a transaction in Medtronic ordinary shares has been paid unless one or both of such parties is otherwise notified by Medtronic. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Articles of Association delegate to Medtronic&#8217;s secretary (or such other person as may be nominated by the secretary for this purpose) the authority to execute an instrument of transfer on behalf of a transferring party. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to help ensure that the official share register is regularly updated to reflect trading of Medtronic ordinary shares occurring through normal electronic systems, Medtronic intends to regularly produce any required instruments of transfer in connection with any transactions for which it pays stamp duty (subject to the reimbursement and set-off rights described above). In the event that Medtronic notifies one or both of the parties to a share transfer that it believes stamp duty is required to be paid in connection with the transfer and that it will not pay the stamp duty, the parties may either themselves arrange for the execution of the required instrument of transfer (and may request a form of instrument of transfer from Medtronic for this purpose) or request that Medtronic execute an instrument of transfer on behalf of the transferring party in a form determined by Medtronic. In either event, if the parties to the share transfer have the instrument of transfer duly stamped (to the extent required) and then provide it to Medtronic&#8217;s transfer agent, the buyer will be registered as the legal owner of the relevant shares on Medtronic&#8217;s official Irish share register (subject to the matters described below). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The directors may suspend registration of transfers from time to time, not exceeding 30 days in aggregate each year.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of Medtronic&#8217;s registered debt securities is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Medtronic Luxco, and Medtronic Inc., Base Indenture and Supplemental Indentures (each as hereinafter defined). Copies of the Medtronic Luxco Base Indenture and Medtronic Luxco Supplemental Indentures and the Medtronic Inc. Base Indenture and Medtronic Inc. Supplemental Indentures have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibits </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, to our Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Copies of have been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibits 4.10, 4.11, 4.12, 4.13, 4.14, 4.22, 4.23, 4.24, 4.25, 4.26, 4.27, 4.28, and 4.29, respectively, to our Annual Report on Form 10-K for the fiscal year ended April 26, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic Luxco series of notes was issued as a separate series of senior debt securities, under a Senior Indenture, dated March 28, 2017 (the &#8220;Medtronic Luxco Base Indenture&#8221;) among Medtronic Luxco, as issuer, Medtronic and Medtronic, Inc. as guarantors, and Computershare Trust Company National Association (as successor to Wells Fargo Bank, National Association) as trustee, as supplemented by the Second Supplemental Indenture, dated as of March 7, 2019 (the &#8220;Second Supplemental Indenture&#8221;), the Third Supplemental Indenture, dated as of July 2, 2019 (the &#8220;Third Supplemental Indenture&#8221;), the Fourth Supplemental Indenture, dated as of September 29, 2020 (the &#8220;Fourth Supplemental Indenture&#8221;), the Fifth Supplemental Indenture, dated as of September 21, 2022 (the &#8220;Fifth Supplemental Indenture&#8221;), the Sixth Supplemental Indenture, dated as of February 22, 2023 (the &#8220;Sixth Supplemental Indenture&#8221;), and the Seventh Supplemental Indenture, dated as of March 30, 2023 (the &#8220;Seventh Supplemental Indenture&#8221; and together with the Second, Third, Fourth, Fifth, Sixth, and Seventh Supplemental Indentures, (the &#8220;Medtronic Luxco Supplemental Indentures&#8221;). The Medtronic Luxco Base Indenture, together with the Medtronic Luxco Supplemental Indentures, shall be referred to throughout this description of debt securities as the &#8220;Medtronic Luxco Indenture.&#8221; Each series of notes is a general unsecured senior obligation of Medtronic Luxco and is fully and unconditionally guaranteed by Medtronic and Medtronic, Inc., on a joint and several basis. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic, Inc. series of notes was issued as a separate series of senior debt securities, under a Senior Indenture, dated December 10, 2014 (the &#8220;Medtronic Inc. Base Indenture&#8221;) among Medtronic Inc., as issuer, Medtronic and Medtronic Luxco as guarantors, and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association) as trustee, as supplemented by the Second Supplemental Indenture, dated as of January 26, 2015 (the &#8220;Medtronic Inc. Second Supplemental Indenture&#8221;), the Third Supplemental Indenture, dated as of January 26, 2015 (the &#8220;Medtronic Inc. Third Supplemental Indenture&#8221;), the Fourth Supplemental Indenture, dated as of February 22, 2023 (the &#8220;Medtronic Inc. Fourth Supplemental Indenture&#8221;), the Fifth Supplemental Indenture, dated as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of June 3, 2024 (the &#8220;Medtronic Inc. Fifth Supplemental Indenture&#8221;) and together with the Second, Third, Fourth, and Fifth Supplemental Indentures, the &#8220;Medtronic Inc. Supplemental Indentures&#8221;). The Medtronic Inc. Base Indenture, together with the Medtronic Inc. Supplemental Indentures, shall be referred to throughout this description of debt securities as the &#8220;Medtronic Inc. Indenture.&#8221; Each series of notes is a general unsecured senior obligation of Medtronic Inc. and is fully and unconditionally guaranteed by Medtronic and Medtronic Luxco, on a joint and several basis. The Medtronic Luxco Indenture, together with the Medtronic, Inc. Indenture, shall be referred to throughout this description of debt securities as the &#8220;Indentures.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The notes of each series are Issued only in registered form, without coupons, in minimum denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. The notes of each series are issued in the form of one or more global securities that are deposited initially with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear Bank SA&#47;NV (&#8220;Euroclear&#8221;) and Clearstream Banking S.A. (&#8220;Clearstream&#8221;). U.S. Bank National Association acts as registrar for the notes. The notes may be presented for registration of transfer and exchange at the offices of the registrar. Medtronic Luxco entered into agency agreements with Elavon Financial Services DAC, UK Branch (&#8220;Elavon&#8221;) as paying agent and&#47;or calculation agent with respect to each series of notes. Medtronic Luxco may change any paying agent, calculation agent and registrar without notice to holders of the notes and may act as a paying agent, calculation agent or registrar. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Maturity</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each series of notes will mature and bear interest as provided in the following table&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Issuer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Maturity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Payment Dates</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Record Dates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.250% 2025 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.250%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.000% 2025 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2025</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.000%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.625% 2025 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.625%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.125% 2027 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2027</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.375% 2028 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2028</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.375%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.000% 2028 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2028</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.000%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.650% 2029 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2029</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.650%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.625% 2031 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2031</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.000% 2031 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2031</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.000%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.125% 2031 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2031</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.125%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.750% 2032 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2032</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.750%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.375% 2034 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2034</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.875% 2036 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2036</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.250% 2039 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2039</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.250%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.500% 2039 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2039</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.500%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.375% 2040 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2040</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.150% 2043 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2043</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.150%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.750% 2049 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2, 2049</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.750%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.625% 2050 notes</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2050</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625%</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr><tr><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Inc.</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.150% 2053 notes</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2053</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.150%</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15</font></td><td colspan="3" style="background-color:#d3dfee;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Close of business on the business day immediately preceding the interest payment date.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes are not subject to any sinking fund. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interest </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fixed Rate Notes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 1.125% 2027 notes, the 1.625% 2031 notes, and the 2.250% 2039 notes bear interest from the date of issuance, payable annually in arrears on March 7 of each year. The 0.250% 2025 notes, the 1.000% 2031 notes, the 1.500% 2039 notes, and the 1.750% 2049 notes bear interest from the date of issuance, payable annually in arrears on July 2 of each year. The 0.000% 2025 notes, the 2.625% 2025 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes bear interest from the date of issuance, payable annually in arrears on October 15 of each year. The Interest is payable to the persons in whose names such notes are registered at the close of business on the business day (for this purpose, a day on which Clearstream and Euroclear are open for business) immediately preceding the relevant interest payment. Interest on the fixed rate notes will be computed on the basis of the actual number of days in the period for which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes, to, but excluding, the next scheduled interest payment date. This payment convention is referred to as Actual&#47;Actual (ICMA) as defined in the rulebook of the International Capital Market Association. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any interest payment date would otherwise be a day that is not a business day, such interest payment date will be postponed to the next date that is a business day and no interest will accrue on the amounts payable from and after such interest payment date to the next business day. If the maturity date of any series of fixed rate notes falls on a day that is not a business day, the related payment of principal, premium, if any, and interest will be made on the next business day as if it were made on the date such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the next business day.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantees </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of Medtronic and Medtronic, Inc. (each, a &#8220;Luxco Guarantor&#8221; and together, the &#8220;Luxco Guarantors&#8221;) fully and unconditionally guarantee, on a joint and several basis, the due and punctual payment of all obligations of Medtronic Luxco under the Medtronic Luxco notes, whether for the payment of principal of, premium, if any, or interest or certain additional amounts on the notes, when and as the same shall become due and payable, whether at maturity, declaration of acceleration, upon redemption, repurchase or otherwise. Each of Medtronic and Medtronic Luxco (each, a &#8220;Medtronic, Inc. Guarantor&#8221; and together, the &#8220;Medtronic, Inc. Guarantors&#8221;) fully and unconditionally guarantee, on a joint and several basis, the due and punctual payment of all obligations of Medtronic, Inc. under the Medtronic, Inc. notes, whether for the payment of principal of, premium, if any, or interest or certain additional amounts on the notes, when and as the same shall become due and payable, whether at maturity, declaration of acceleration, upon redemption, repurchase or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, each Guarantor will be automatically and unconditionally released from all obligations under its guarantee, and such guarantees shall terminate and be discharged and be of no further force and effect upon the occurrence of certain circumstances. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The guarantees of the notes may be subject to review under United States federal or state fraudulent transfer law or similar laws in other applicable jurisdictions, which could limit their enforceability. The guarantees will provide that the obligations of each Guarantor will be limited as necessary to prevent that guarantee from constituting a fraudulent conveyance or fraudulent transfer under applicable law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ranking </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic Luxco notes are unsecured senior obligations of Medtronic Luxco and rank equally in right of payment with each other and with all of Medtronic Luxco&#8217;s other existing and future unsecured senior obligations, including its outstanding guarantees of senior notes of other indebtedness of Medtronic, Inc. and other subsidiaries of Medtronic, including Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. Additionally, the notes are effectively subordinated to any existing and future secured indebtedness of Medtronic Luxco, to the extent of the assets securing such indebtedness. The notes rank senior in right of payment to any existing and future subordinated indebtedness of Medtronic Luxco. The notes are also structurally subordinated to all existing and any future obligations of Medtronic Luxco&#8217;s subsidiaries (other than Medtronic, Inc. because of its guarantee of the notes).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The guarantees are unsecured senior obligations of each of Medtronic and Medtronic, Inc., and rank equally with all other unsecured senior obligations of Medtronic and Medtronic, Inc. as applicable. The guarantees of the notes rank equally in right of payment with all other existing and future unsecured senior obligations of Medtronic and Medtronic, Inc.&#59; be effectively subordinated to any existing and future secured indebtedness of Medtronic plc and Medtronic, Inc. to the extent of the assets securing such indebtedness&#59; and be structurally subordinated to all existing and future debt and other obligations of Medtronic&#8217;s and Medtronic, Inc.&#8217;s subsidiaries, respectively, including, with respect to Medtronic, Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medtronic, Inc. notes are unsecured senior obligations of Medtronic, Inc. and rank equally in right of payment with each other and with all of Medtronic Inc.&#8217;s other existing and future unsecured senior obligations, including its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">outstanding guarantees of senior notes of other indebtedness of Medtronic Luxco. The notes rank senior in right of payment to any existing and future subordinated indebtedness of Medtronic, Inc. The notes are also structurally subordinated to all existing and any future obligations of Medtronic, Inc.&#8217;s subsidiaries.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The guarantees are unsecured senior obligations of each of Medtronic and Medtronic Luxco, and rank equally with all other unsecured senior obligations of Medtronic and Medtronic Luxco as applicable. The guarantees of the notes rank equally in right of payment with all other existing and future unsecured senior obligations of Medtronic and Medtronic Luxco&#59; be effectively subordinated to any existing and future secured indebtedness of Medtronic and Medtronic Luxco to the extent of the assets securing such indebtedness&#59; and be structurally subordinated to all existing and future debt and other obligations of Medtronic plc&#8217;s and Medtronic, Inc.&#8217;s subsidiaries, respectively, including, with respect to Medtronic, Covidien International Finance S.A., a wholly-owned indirect subsidiary of Medtronic Luxco. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Optional Redemption </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic Luxco and Medtronic, Inc. may redeem any series of the fixed rate notes, in whole or in part, in the case of the 0.250%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes at any time prior to the applicable Par Call Date at a redemption price equal to the greater of&#58;  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100% of the principal amount of the fixed rate notes of the applicable series being redeemed&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the sum, as determined by a Quotation Agent (defined below), of the present values of the Remaining Scheduled Payments (as defined below) of principal and interest on the notes of such series to be redeemed (excluding any portion of such payments of interest accrued as of the date of redemption and assuming, in the case of the 0.250% 2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes, that such notes matured on the applicable Par Call Date), discounted to the redemption date on an annual basis (ACTUAL&#47;ACTUAL(ICMA)) at the Comparable Bond Rate (defined below), plus 15 basis points, in the case of the 0.250% 2025 notes, the 0.000% 2025 notes, and the 3.650% 2029 notes, 20 basis points, in the case of the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 1.000% 2031 notes, the 0.750% 2032 notes, the 3.875% 2036 notes, and the 4.150% 2043 notes, 25 basis points, in the case of the 3.000% 2028 notes, the 1.625% 2031 notes, the 3.125% 2031 notes, the 3.375% 2034 notes, the 1.500% 2039 notes the 1.750 % 2049 notes, and the 4.150% 2053 notes, and 30 basis points, in the case of the 2.250% 2039 notes the 1.375% 2040 notes, and the 1.625% 2050 notes&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">plus, in each case, accrued and unpaid interest to, but not including, the date of redemption. These notes may be redeemed in part in the minimum authorized denomination or in any integral multiple of such amount. Unless Medtronic Luxco or Medtronic, Inc. defaults in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the fixed rate notes or portions thereof called for redemption.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, at any time on and after the applicable Par Call Date, the 0.250% 2025 notes, the 0.000% 2025 notes, the 2.625% 2025 notes, the 1.125% 2027 notes, the 0.375% 2028 notes, the 3.000% 2028 notes, the 3.650% 2029 notes, the 1.625% 2031 notes, the 1.000% 2031 notes, the 3.125% 2031 notes, the 0.750% 2032 notes, the 3.375% 2034 notes, the 3.875% 2036 notes, the 2.250% 2039 notes, the 1.500% 2039 notes, the 1.375% 2040 notes, the 4.150% 2043 notes, the 1.750% 2049 notes, the 1.625% 2050 notes, and the 4.150% 2053 notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">will be redeemable at Medtronic Luxco&#8217;s or Medtronic, Inc.&#8217;s option, in whole or in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of redemption. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco, or Medtronic, Inc., will provide notice of any optional redemption to each holder of notes of the series to be redeemed at least 15 days, but not more than 60 days, before the redemption date. A notice of redemption may, at the discretion of Medtronic Luxco, or Medtronic, Inc., be subject to one or more conditions precedent, including, but not limited to, completion of an equity offering, a financing, or other corporate transaction. In addition, if such redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in Medtronic Luxco&#8217;s, or Medtronic, Inc.&#8217;s, discretion, the redemption date may be postponed until up to 60 days following the notice of redemption, and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the redemption date (including as it may be postponed). Medtronic Luxco, or Medtronic, Inc., will give notice of such redemption to the trustee at least 10 days prior to the date Medtronic Luxco, or Medtronic, Inc., mails the notice of redemption to each holder (or such shorter time as may be acceptable to the trustee). Unless Medtronic Luxco, or Medtronic, Inc., defaults in payment of the redemption price on the redemption date, on and after the redemption date, interest will cease to accrue on the fixed rate notes or portions thereof called for redemption. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If Medtronic Luxco, or Medtronic, Inc., does not redeem all of the fixed rate notes of a particular series, the trustee shall select the fixed rate notes of that series to be redeemed in any manner that it deems fair and appropriate consistent with the applicable procedures of the despositary. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any notice to holders of fixed rate notes of a redemption hereunder shall include the appropriate calculation of the redemption price, but does not need to include the redemption price itself. The actual redemption price, calculated as described above, will be set forth in an officers&#8217; certificate delivered to the trustee no later than two business days prior to the redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Bond Rate&#8221; means, for any redemption date, the rate per annum equal to the annual equivalent yield to maturity or interpolated yield to maturity (on a day count basis), computed as the third business day immediately preceding that redemption date, of the Comparable Government Issue (as defined below), assuming a price for the Comparable Government Issue (expressed as a percentage of its principal amount) equal to the Comparable Price (as defined below) for that redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Government Issue&#8221; means the euro-denominated security issued by the German federal government selected by a Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the fixed rate notes to be redeemed (assuming that the notes to be redeemed matured on the applicable Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the notes to be redeemed. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Comparable Price&#8221; means, with respect to any redemption date, (1) the average of the Reference Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest of the Reference Dealer Quotations, (2) if Medtronic Luxco, or Medtronic, Inc., obtains fewer than four Reference Dealer Quotations, the arithmetic average of those quotations or (3) if Medtronic Luxco, or Medtronic, Inc., obtains only one Reference Dealer Quotation, such Reference Dealer Quotation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Par Call Date&#8221; means&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the case of the 0.250% 2025 notes, April 2, 2025&#59; in the case of the 0.000% 2025 notes, September 15, 2025&#59; in the case of the 2.625% 2025 notes, September 15, 2025&#59; in the case of the 1.125% 2027 notes, December 7, 2026&#59; in the case of the 0.375% 2028 notes, July 15, 2028&#59; in the case of the 3.000% 2028 notes, July 15, 2028&#59; in the case of the 3.650% 2029 notes, September 15, 2029&#59; in the case of the 1.625% 2031 notes, December 7, 2030&#59; in the case of the 1.000% 2031 notes, April 2, 2031&#59; in the case of the 3.125% 2031 notes, July 15, 2031&#59; in the case of the 2032 notes, July 15, 2032&#59; in the case of the 3.375% 2034 notes, July 15, 2034&#59; in the case of the 3.875% 2036 notes, July 15, 2036&#59; in the case of the 2.250% 2039 notes, December 7, 2038&#59; in the case of the 1.500% 2039 notes, April 2, 2039&#59; in the case of the 1.375% 2040 notes, April 15, 2040&#59; in the case of the 4.150% 2043 notes, April 15, 2043&#59; in the case of the 1.750% 2049 notes, January 2, 2049&#59; in the case of the 1.625% 2050 notes, April 15, 2050&#59; and in the case of the 4.150% 2053 notes, April 15, 2053&#59;. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Quotation Agent&#8221; means the Reference Dealer appointed by Medtronic Luxco, or Medtronic, Inc. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference Dealer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> means (1) each of Barclays Bank PLC and Merrill Lynch International and their respective successors in the case of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the 1.125% 2027 notes, the 1.625% 2031 notes, and the 2.250% 2039 notes, and each of Barclays Bank PLC, Goldman Sachs &#38; Co LLC and Merrill Lynch International, in the case of the 0.250% 2025 notes, the 1.000% 2031 notes, the 1.500% 2039 notes, and the 1.750% 2049 notes, each of Barclays Bank PLC, BofA Securities Europe SA, Mizuho Securities Europe GmbH and Deutsche Bank Aktiengesellschaft in the case of the 0.000% 2025 notes, the 0.375% 2028 notes, the 0.750% 2032 notes, the 1.375% 2040 notes and the 1.625% 2050 notes, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">each of Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> in the case of the 2.625% 2025 notes, the 3.000% 2028 notes, the 3.125% 2031 notes, and the 3.375% 2034 notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and each of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc in the case of the 3.650% 2029 notes, the 3.875% 2036 notes, the 4.150% 2043 notes, and the 4.150% 2053 notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59;, provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and&#47;or a market maker in, German government bonds (a &#8220;Primary Bond Dealer&#8221;), Medtronic Luxco, or Medtronic, Inc., shall substitute another Primary Bond Dealer and (2) any other Primary Bond Dealers selected by Medtronic Luxco, or Medtronic, Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference Dealer Quotations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> means, with respect to each Reference Dealer and any redemption date, the average, as determined by the Quotation Agent, of the bid and asked prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by that Reference Dealer at 11&#58;00 a.m., London time, on the third business day preceding that redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Remaining Scheduled Payments&#8221; means, with respect to each fixed rate note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption (assuming that the fixed rate notes to be redeemed matured on the applicable Par Call Date)&#59; provided, however, that, if such redemption date is not an interest payment date with respect to such note, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Redemption Upon Changes in Withholding Taxes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic Luxco, or Medtronic, Inc., may redeem all, but not less than all, of the notes of any series in the event of certain changes in the tax laws, regulations, rulings or treaties of Luxembourg, Ireland, the United States or any other jurisdiction in which Medtronic Luxco, Medtronic, Inc., or any Guarantor is then organized (or any taxing authority thereof or therein) (a &#8220;Taxing Jurisdiction&#8221;) if, in the written opinion of independent counsel chosen by Medtronic Luxco, Medtronic plc or Medtronic, Inc., there is a material probability that Medtronic Luxco, Medtronic plc or Medtronic, Inc. will become obligated to pay certain additional amounts with respect to the notes. This redemption would be at a redemption price equal to 100% of the principal amount of the notes of such series being redeemed, together with accrued and unpaid interest, if any, to, but not including, the redemption date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Payment of Additional Amounts </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain exceptions and limitations, all payments made by Medtronic Luxco, Medtronic, Inc., or any Guarantor under or with respect to the notes and guarantees will be made free and clear of and without withholding or deduction for or on account of any present or future taxes, duties, levies, imposts, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction, unless Medtronic Luxco, Medtronic, Inc. or any Guarantor, as the case may be, is required to withhold or deduct taxes by law or by the interpretation or administration thereof. In the event that Medtronic Luxco, Medtronic, Inc., or any Guarantor is required to so withhold or deduct any amount for or on account of any taxes from any payment made under or with respect to the notes or the guarantees, as the case may be, subject to certain exceptions and limitations Medtronic Luxco, Medtronic, Inc., or the applicable Guarantor, as the case may be, will pay such additional amounts (&#8220;Additional Amounts&#8221;) as may be necessary so that the net amount received by each holder of notes (including Additional Amounts) after such withholding or deduction will equal the amount that such holder would have received if such taxes had not been required to be withheld or deducted. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Events of Default </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the following events will constitute an event of default for each series of notes under the Indentures&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay any interest on the notes of that series when due and payable and such failure continues for 30 days&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay principal of or any premium on the notes of that series at its maturity, acceleration, redemption or otherwise&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to perform or the breach of any other covenant or warranty in the Indenture applicable to such series and such failure continues for 60 days after written notice as provided in such Indenture&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to pay principal when due at maturity or a default that results in the acceleration of maturity of Medtronic plc&#8217;s or any Restricted Subsidiary&#8217;s (defined below) indebtedness for borrowed money in an aggregate amount of $150 million or more&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc&#8217;s, Medtronic, Inc.&#8217;s, or Medtronic Luxco&#8217;s guarantee ceases to be in full force and effect or is declared to be null and void and unenforceable or such guarantee is found to be invalid or Medtronic plc, Medtronic, Inc., or Medtronic Luxo denies its liability under its guarantee (other than by reason of release of a Guarantor in accordance with the terms of the Indenture)&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">certain events in bankruptcy, insolvency, examinership or reorganization, voluntary or involuntary, relating to Medtronic Luxco, Medtronic or Medtronic, Inc.&#59; and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any other event of default provided with respect to notes of such series.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an event of default, other than an event of default specified in the sixth bullet point above, occurs with respect to notes of any series and is continuing, either the applicable trustee or the holders of at least 25% in principal amount of the outstanding notes of that series may declare the principal amount of all notes of that series to be due and payable immediately&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that under certain circumstances the holders of a majority in aggregate principal amount of outstanding notes of that series may rescind and annul such declaration and its consequences. If an event of default specified in the sixth bullet point above occurs and is continuing, the entire principal amount of, and accrued interest, if any, on each series of notes then outstanding shall become immediately due and payable. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The applicable trustee, after the occurrence of a default with respect to any series of notes, shall give to the holders of notes of that series notice of all uncured defaults known to it (the term default to mean the events specified above without grace periods)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that, except in the case of default in the payment of principal of (or premium, if any) or interest, if any, on any note, the trustee shall be protected in withholding such notice if it in good faith determines that the withholding of such notice is in the interest of the holders of the notes of such series. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of a majority in principal amount of the outstanding notes of any series affected will have the right, subject to certain limitations, to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the notes of such series, and to waive certain defaults. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In case an event of default shall occur and be continuing, each trustee shall exercise such of its rights and powers under the Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. Subject to such provisions, the trustees will be under no obligation to exercise any of their rights or powers under the Indenture at the request or direction of any of the holders of notes unless such holders shall have offered to the applicable trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture requires us to deliver to the trustees annual statements as to the performance of our obligations under the Indenture and as to any events of default thereunder. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A default in the payment of any of our notes or under any related guarantee, or a default with respect to our notes or any related guarantee that causes such notes to be accelerated, may give rise to a cross-default under our other indebtedness. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Restricted Subsidiary&#8221; means (i) each of Medtronic Luxco and Medtronic, Inc. and (ii) any other subsidiary of Medtronic which owns or leases a Principal Property, except any subsidiary substantially all of the assets of which are located, or substantially all of the business of which is carried on, outside the United States and its territories and possessions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Principal Property&#8221; means any plant, office facility, warehouse, distribution center or equipment located within the United States (other than its territories or possessions) and owned by Medtronic or any subsidiary, the gross book value (without deduction of any depreciation reserves) of which on the date as of which the determination is being made exceeds 2% of the Consolidated Net Tangible Assets of Medtronic, except any such property which Medtronic&#8217;s board of directors, in its good faith opinion, determines is not of material importance to the business conducted by Medtronic and its subsidiaries, taken as a whole, as evidenced by a certified copy of a board resolution.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Modification of the Indentures </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Modifications and amendments of the Indentures may be made by us and the applicable trustee with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding notes of each series affected by the modification or waiver&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that no such modification or amendment may without the consent of the holder of each noteholder affected thereby, extend the stated maturity of the principal of, or any installment of principal of or interest on, any note, reduce the principal amount of, or premium or interest on, any note, change the place of payment where coin or currency in which the principal of, or any premium or interest on, any note is payable, impair the right to institute suit for the enforcement of any payment on or with respect to any note, reduce the percentage in principal amount of outstanding notes, the consent of the holders of which is required for modification or amendment of the Indentures or for waiver of compliance with certain provisions of the Indentures or for waiver of certain defaults or modify any of the above provisions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holders of not less than a majority in aggregate principal amount of the outstanding notes of each series may, on behalf of the holders of all notes of that series, waive compliance by us with certain restrictive provisions of the Indentures that may be amended by such majority. The holders of not less than a majority in aggregate principal amount of the outstanding notes of each series may, on behalf of the holders of all notes of such series, waive any past default under the Indenture, except a default (1) in the payment of principal of, or any premium or interest on, any note or (2) in respect of a covenant or provision of the Indentures which cannot be modified or amended without the consent of the holder of each note of the affected series. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Modifications and amendments of the Indentures may be made by us and the trustee without the consent of any holders of any series of notes for any of the following purposes&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to evidence the succession of another person to us or any guarantor and the assumption by any such successor of our or such Guarantor&#8217;s covenants under the Indentures and in the notes&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add to our covenants or the covenants applicable to any guarantor for the benefit of the holders or to surrender any right or power in the Indentures conferred upon us or any Guarantor&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add any additional events of default for the benefit of the holders&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to secure the notes or any related guarantee&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to cure any ambiguity, to correct or supplement any provision in the Indentures or in any supplemental indentures which may be inconsistent with any other provision of such indenture or supplemental indenture, or to make any other provisions with respect to matters or questions arising under the Indentures&#59; provided such action shall not adversely affect the interests of the holders in any material respect&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to conform the Indentures or any supplemental indentures to the description of the notes set forth in any prospectus or prospectus supplement related to such series of notes&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to comply with the requirements of the SEC in order to effect or maintain the qualifications of the indenture under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;)&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add to or change any of the provisions of the Indentures to such extent as shall be necessary to permit or facilitate the issuance of notes in bearer form or to facilitate the issuance of notes in uncertificated form&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to provide for the issuance and establish the forms or terms and conditions of notes of any series as permitted by the Indentures&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to add or release a Guarantor as permitted by the Indentures&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to comply with the rules of any applicable securities depositary.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes will not be considered outstanding, and therefore will not be eligible to vote on any matter, if we have deposited or set aside in trust money for their payment or redemption. Notes will also not be eligible to vote if they have been fully defeased. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will generally be entitled to set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the Indenture. In certain limited circumstances, the trustee will be entitled to set a record date for action by holders. If we or the trustee set a record date for a vote or other action to be taken, that vote or action may be taken only by persons who are holders of outstanding notes on the record date and must be taken within 180 days following the record date or a shorter period that we may specify (or as the trustee may specify, if it set the record date). We may shorten or lengthen (but not beyond 180 days) this period from time to time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Provisions of the Notes</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Indentures contain provisions that restrict our ability, and the ability of certain of our subsidiaries, to incur secured debt and to engage in sale and leaseback transactions. The Indentures do not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. The Indentures contain no other restrictive covenants, including those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Medtronic Luxco, Medtronic, Inc., or any affiliates or other events that may adversely affect our creditworthiness or the value of the notes. The Indentures also do not contain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any covenants relating to total unsecured indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regarding the Trustees </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture trustee&#8217;s current address is Wells Fargo Bank, National Association, 600 South 4th Street, 6th Floor, Minneapolis, Minnesota 55415. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture provides that, except during the continuance of an event of default, the trustee will perform only such duties as are specifically set forth in the Indenture. During the existence of an event of default, the trustee will exercise such rights and powers vested in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#8217;s own affairs. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indenture and certain provisions of the Trust Indenture Act contain limitations on the rights of the trustees, should a trustee become a creditor of us, Medtronic plc or Medtronic, Inc. to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claim as security or otherwise. A trustee is permitted to engage in other transactions with us or any affiliate of ours. If there arises any conflicting interest (as defined in the Indenture or in the Trust Indenture Act), it must eliminate such conflict or resign. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain ordinary banking relationships and credit facilities with Wells Fargo Bank, National Association. In addition, Wells Fargo Bank, National Association is the trustee for certain of our affiliates&#8217; other debt securities, is the transfer agent for Medtronic plc&#8217;s ordinary shares, and from time to time provides services relating to our investment management, stock repurchase and foreign currency hedging programs. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Listing </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes are listed on the New York Stock Exchange. Medtronic Luxco and Medtronic, Inc. will use commercially reasonable efforts to maintain such listing and satisfy the requirements for such continued listing as long as the notes are outstanding. The New York Stock Exchange is not a regulated market for the purposes of MiFID II. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Governing Law </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Indentures and the notes are governed by and construed in accordance with the laws of the State of New York. For the avoidance of doubt, the applicability of Articles 84 to 94-8 of the Luxembourg law dated August 10, 1915 on commercial companies, as amended, shall be excluded. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No holder of notes may initiate proceedings against Medtronic Luxco or Medtronic, Inc. based on Article 98 of the Luxembourg law dated August 10, 1915 on commercial companies, as amended. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Book-Entry System&#59; Delivery and Form </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Global Clearance and Settlement </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notes of each series are issued in the form of one or more global notes in fully registered form, without coupons, and deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as set forth below, the global notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beneficial interests in the global notes are be represented, and transfers of such beneficial interests will be effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. Investors may hold notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have been advised by Clearstream and Euroclear, respectively, as follows&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clearstream </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream has advised that it is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and facilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby eliminating the need for physical movement of certificates. Clearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries. Clearstream has established an electronic bridge with the Euroclear Operator (as defined below) to facilitate the settlement of trades between the nominees of Clearstream and Euroclear. As a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector. Clearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers and trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions with respect to notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Euroclear </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Euroclear has advised that it was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash. Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator. Euroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly or indirectly. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related operating procedures of Euroclear, and applicable Belgian law (collectively, the &#8220;Terms and Conditions&#8221;). The Terms and Conditions govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and Conditions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Euroclear and Clearstream Arrangements </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">So long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes, Euroclear, Clearstream or such nominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the Indenture and the notes. Payments of principal, interest and additional amounts, if any, in respect of the global notes will be made to Euroclear, Clearstream, such nominee or such common depositary, as the case may be, as registered holder thereof. None of us, the trustee, any underwriter and any affiliate of any of the above or any person by whom any of the above is controlled (as such term is defined in the Securities Act) will have any responsibility or liability for any records </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">relating to or payments made on account of beneficial ownership interests in the global notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions of principal, premium, if any, and interest with respect to the global notes will be credited in euro to the extent received by Euroclear or Clearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system&#8217;s rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such interest, may be affected by the lack of a physical certificate in respect of such interest. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Initial Settlement </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We understand that investors that hold their notes through Clearstream or Euroclear accounts will follow the settlement procedures that are applicable to conventional eurobonds in registered form. Subject to applicable procedures of Clearstream and Euroclear, notes will be credited to the securities custody accounts of Clearstream and Euroclear participants on the business day following the settlement date, for value on the settlement date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Secondary Market Trading </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser&#8217;s and seller&#8217;s accounts are located to ensure that settlement can be made on the desired value date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We understand that secondary market trading between Clearstream and&#47;or Euroclear participants will occur in the ordinary way following the applicable rules and operating procedures of Clearstream and Euroclear. Secondary market trading will be settled using procedures applicable to conventional eurobonds in global registered form. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors will only be able to make and receive deliveries, payments and other communications involving the notes through Clearstream and Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United States. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions will not be performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream or Euroclear will credit payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system&#8217;s rules and procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, will take any other action permitted to be taken by a holder under the Indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are under no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange of Global Notes for Certificated Notes </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of &#8364;100,000 principal amount and multiples of &#8364;1,000 in excess thereof if&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the common depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for the global notes and we fail to appoint a successor depositary within 90 calendar days&#59;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Luxco or Medtronic, Inc., at its option, notifies the trustee in writing that it elects to cause the issuance of certificated notes&#59; or</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">there has occurred and is continuing an Event of Default with respect to the notes.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments (including principal, premium and interest) and transfers with respect to notes in certificated form may be executed at the office or agency maintained for such purpose in London (initially the corporate trust office of the paying agent) or, at Medtronic Luxco&#8217;s or Medtronic, Inc.&#8217;s option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on notes in certificated form, for which the holders thereof have given wire transfer instructions, will be required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge will be made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with that registration may be required. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.81
<SEQUENCE>3
<FILENAME>mdt-202510xkxex1081.htm
<DESCRIPTION>EX-10.81
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie6a413843b994d6ca51efdd917ee77eb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:258pt;padding-left:3.17pt;padding-right:3.17pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2025 MEDTRONIC</font></div><div style="padding-left:3.42pt;padding-right:3.42pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.70pt">NONQUALIFIED RETIREMENT PLAN SUPPLEMENT</font></div><div style="padding-left:3.57pt;padding-right:3.57pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.70pt">(as amended and restated effective March 3, 2025)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 1 DEFERRED COMPENSATION ACCOUNT</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Establishment of Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Property of Company.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 2 DEFINITIONS, GENDER, AND NUMBER&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Definitions..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gender and Number.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 3 PARTICIPATION&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Who May Participate..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Time and Conditions of Participation&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination and Suspension of Participation.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Missing Persons.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Relationship to Other Plans.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 4 RETIREMENT PLAN SUPPLEMENTAL BENEFIT&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calculation of Retirement Plan Supplemental Benefit.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Establishment of Nonqualified Retirement Plan Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interest Credited to Nonqualified Retirement Plan Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment of Nonqualified Retirement Plan Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 5 ESOP SUPPLEMENTAL BENEFIT&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonqualified ESOP Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gains Credited to Nonqualified ESOP Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment of Nonqualified ESOP Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 6 PERSONAL INVESTMENT ACCOUNT SUPPLEMENTAL BENEFIT&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calculation of Personal Investment Account Supplemental Benefit.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Establishment of Nonqualified Personal Investment Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Crediting Gains and Losses to Nonqualified Personal Investment Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vested Interest in Nonqualified Personal Investment Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment of Nonqualified Personal Investment Account.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 7 MEDTRONIC CORE CONTRIBUTION ACCOUNT <br></font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SUPPLEMENTAL BENEFIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calculation of Medtronic Core Contribution Account <br>Supplemental Benefit.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Establishment of Nonqualified Medtronic Core Contribution Account.&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Crediting Gains and Losses to Nonqualified Medtronic Core<br> Contribution Account. &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vested Interest in Nonqualified Medtronic Core Contribution Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment of Nonqualified Medtronic Core Contribution Account&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 8 ARTICLES. DEATH BENEFITS&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Form and Time of Payment..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Beneficiary&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 9 CHANGE IN CONTROL PROVISIONS&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Application of Article&#160;9.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payments to and by the Trust&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Legal Fees and Expenses.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Late Payment and Additional Payment Provisions.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 10 FUNDING&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Source of Benefits.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Claim on Specific Assets&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 11 ADMINISTRATION&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Administration.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Powers of Committee&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Actions of the Committee&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delegation.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reports and Records&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Claims Procedure..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disability Benefit Claims.</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional Claims Procedure Requirements.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 12 AMENDMENTS AND TERMINATION&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendments.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 13 MISCELLANEOUS&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Guarantee of Employment.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Release..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notices..&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonalienation.  &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Withholding.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Captions.&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Applicable Law.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Invalidity of Certain Provisions.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Other Agreements&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Incapacity.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Electronic Media&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delay of Distributions Upon Certain Events&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acceleration of Distributions Upon Certain Events.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Small Account Balances&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When a Plan Payment is Deemed to be Made&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restricted Period.&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE A </font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CREDITING RATE </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE B </font><font style="color:#8e8e8e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SPECIAL BENEFITS </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie6a413843b994d6ca51efdd917ee77eb_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MEDTRONIC<br>NONQUALIFIED RETIREMENT PLAN SUPPLEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Medtronic, Inc. (the &#8220;Company&#8221;) previously established the Medtronic, Inc. Executive Nonqualified Supplemental Benefit Plan (the &#8220;Plan&#8221;) for the benefit of the Eligible Employees of the Company and certain of its Affiliates, effective May 1, 1986. The Plan was amended and restated effective May 1, 2005, and again restated effective January 1, 2008, to comply with the requirements of the final regulations issued under Section 409A of the Code (&#8220;Section 409A&#8221;). At the time of that restatement, the name of the Plan was the Medtronic, Inc. Supplemental Executive Retirement Plan. The Plan has been amended in other respects, including changing the name of the Plan to the Medtronic, Inc. Nonqualified Retirement Plan Supplement in June of 2011. The Plan was further restated effective May 1, 2017, and was restated again effective April 28, 2023. The March 3, 2025 Restatement implements certain changes to Schedule B.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Provisions in the April 28, 2023 Restatement apply to amounts deferred under the Plan on or after April 28, 2023 (the &#8220;Restatement Date&#8221;), and to the payment of all amounts deferred under the Plan (whether such amounts were deferred before, on, or after the Restatement Date) for which distributions have not commenced as of the Restatement Date. No amount deferred under the Plan is intended to be &#8220;grandfathered&#8221; under Section 409A. The April 28, 2023 Restatement does not change the time or form of any payment required under the Plan, and does not reduce vested amounts credited to a Participant&#8217;s account prior to the date of execution of the restated Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of the Plan is to provide Eligible Employees with benefits that supplement those provided under certain of the tax-qualified plans maintained by the Company. More specifically, the Plan is intended to provide certain benefits on a nonqualified basis that are not otherwise provided under the Company&#8217;s tax-qualified plans as a result of the application of certain legal limitations on contributions, benefits and includible compensation and as a result of elections made by Eligible Employees under other plans maintained by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan is intended to be (and shall be construed and administered as) an employee benefit pension plan under the provisions of ERISA, which is unfunded and maintained primarily for the purpose of providing deferred compensation for Eligible Employees who constitute a select group of management or highly-compensated employees, as described in Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan is not intended to be qualified under Section 401(a) of the Code. The Plan, as restated herein, is subject to, and intended to comply with, Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The obligation of the Company to make payments under the Plan constitutes an unsecured (but legally enforceable) promise of the Company to make such payments and no person, including any Participant or Beneficiary, shall have any lien, prior claim or other security interest in any property of the Company as a result of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>DEFERRED COMPENSATION ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Establishment of Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Company shall establish one or more Accounts for each Participant which shall be utilized solely as a device to measure and determine the amount of deferred compensation to be paid under the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Property of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any amounts set aside for benefits payable under the Plan are the property of the Company, except, and to the extent, provided in the Trust. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>DEFINITIONS, GENDER, AND NUMBER </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Whenever used in the Plan, the following words and phrases shall have the meanings set forth below unless the context plainly requires a different meaning, and when a defined meaning is intended, the term is capitalized. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a bookkeeping account established by the Company on its books and records to record and determine the benefits payable to a Participant or Beneficiary under the Plan. The Company shall establish a separate Account on behalf of each Participant for&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The benefit the Participant is entitled to receive pursuant to Article&#160;4, if any, referred to as the &#8220;Nonqualified Retirement Plan Account&#8221;&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The benefit the Participant is entitled to receive pursuant to Article&#160;5, if any, referred to as the &#8220;Nonqualified ESOP Account&#8221;&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The benefit the Participant is entitled to receive pursuant to Article&#160;6</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if any, entitled the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Supplemental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Personal Investment Account&#8221;&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The benefit the Participant is entitled to receive pursuant to Article&#160;7, if any, entitled the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Supplemental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Medtronic Core Contribution Account.&#8221; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Committee may establish any number of sub-accounts on behalf of a Participant or Beneficiary as the Committee considers necessary or advisable for purposes of maintaining a proper accounting of amounts to be credited under the Plan on behalf of a Participant or Beneficiary </font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company and any entity with which the Company would be considered a single employer under Section 414(b) of the Code (employees of controlled group of corporations) and Section 414(c) of the Code (employees of partnerships, proprietorships, etc</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under common control)</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficiaries</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the persons or trusts designated by a Participant in writing pursuant to Section 8</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1 as being entitled to receive any benefit payable under the Plan by reason of the death of a Participant, or, in the absence of such designation, the persons specified in Section 8.2.2</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company as constituted at the relevant time. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Accumulation Plan</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Medtronic, Inc</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capital Accumulation Plan Deferral Program, as amended or restated from time to time or any successor thereto</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time and any successor statute. References to a Code section shall be deemed to be to that section or to any successor to that section, and to all guidance issued under that section. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.7</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Committee or individual appointed by the Compensation Committee of the Board (or any person or entity designated by the Committee) to administer the Plan pursuant to Section 11.4. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Medtronic, Inc</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and its successors and assigns, by merger, purchase or otherwise. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Domestic Relations Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 414(p)(l)(B) of the Code. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an elected or appointed officer of the Company, or any other key employee of the Company or an Affiliate, excluding any individual who is neither a United States citizen nor a United States resident. In order to be an Eligible Employee an employee must be a member of a select group of management or highly compensated employees within the meaning of Sections 201(2), 301(a)(3) and 40l(a)(l) of ERISA and rules established by the Committee. The Company may make such projections or estimates as it deems desirable in applying the eligibility requirements, and its determination shall be conclusive. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Employee Retirement Income Security Act of 1974</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as amended from time to time and any successor statute. References to an ERISA section shall be deemed to be to that section or to any successor to that section, and to all guidance issued under that section. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ESOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Medtronic, Inc. Employee Stock Ownership Plan, as in effect prior to April 30, 2001. (As of April 30, 2001, the ESOP was amended to permit elective deferrals under Section 401(k) of the Code and renamed the Medtronic, Inc</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Stock Ownership and Supplemental Retirement Plan</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of May 1, 2005, the Medtronic, Inc. Employee Stock Ownership and Supplemental Retirement Plan was amended and renamed the Medtronic, Inc. Savings and Investment Plan. As of January 26, 2015, the Medtronic, Inc. Savings and Investment Plan was amended and renamed the Medtronic Savings and Investment Plan.) </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;ESOP Supplemental Benefit&#8221; means the benefit under the Predecessor Plan that was commonly referred to as the &#8220;ESOP restoration benefit&#8221; and previously called the &#8220;Defined Contribution Supplemental Benefit.&#8221; Under the Plan, this benefit </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equals the difference between</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) the allocation due to Company contributions the Participant would have received under the ESOP prior to May</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1, 2005</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">but for the Section 401(a)(17) Limitation and Section 415 Limitation&#59; and (b) the allocation actually received by the Participant under the ESOP</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an event of change in control of the Company, as defined in the Trust. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an annual rate of two percent (2%) or such other reasonable rate of interest as is selected by the Committee, in its sole discretion, except that Interest Rate shall mean an annual rate of six percent (6%) for the following Participants&#58; (i) any Participant who has a Separation from Service on or before April 28, 2023&#59; or (ii) any Participant who was identified by the Committee as having a Separation from Service on or before May 12, 2023 due to either (x) restructuring activity, or (y) a delayed retirement date under the 2023 Medtronic Voluntary Early Retirement Plan&#59; or (iii) any Participant who has a separation from Service on or before April 30, 2027 and who (x) was actively employed on April 29, 2023, and (y) satisfied the age and service requirements for the 2023 Medtronic Voluntary Early Retirement Plan but was excluded from participation in such program due to the Participant&#8217;s job classification.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Medtronic Core Contribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the same meaning as in the Savings and Investment Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Medtronic Core Contribution Account Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Article&#160;7</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who has commenced participation in the Plan</font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.19</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Investment Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the same meaning as in the Savings and Investment Plan. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Investment Account Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Article&#160;6. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the &#8220;Medtronic Nonqualified Retirement Plan Supplement&#8221; as set forth herein and as amended or restated from time to time</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.22</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the 12-month period commenc</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ng May 1 and ending the following April 30</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Predecessor Plan</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Plan</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as in effect prior to May 1, 2005</font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restatement Date</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means April 28, 2023, the effective date of this restatement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Medtronic Retirement Plan, as amended from time to time, and any successor(s) thereto. Effective May 1, 2019, the Company established the Medtronic Retirement Plan for Certain Participants &#38; Beneficiaries and transferred to such plan the portion of the Medtronic Retirement Plan attributable to certain individuals, who, on December 31, 2018, were actively employed with the Company or its Affiliates and accruing pension benefits under the Medtronic Retirement Plan. Accordingly, effective as of May 1, 2019, &#8220;Retirement Plan&#8221; shall also mean the Medtronic Retirement Plan for Certain Participants &#38; Beneficiaries. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">In general, the Retirement Plan includes a final average pay benefit for individuals employed by the Company or an Affiliate prior to May 1, 2005. Effective May 1, 2005, the Retirement Plan provides a personal pension account benefit for individuals who become employed on or after May l, 2005 and before January 1, 2016. Individuals participating in the Retirement Plan prior to May 1, 2005, could elect a personal pension account benefit in lieu of the final average pay benefit for Plan Years commencing May 1, 2005. Alternatively, an individual employed before January 1, 2016, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and otherwise eligible to participate in the Retirement Plan could elect not to participate in the Retirement Plan and receive a contribution to a Personal Investment Account under the Savings and Investment Plan. The Retirement Plan is now closed to new entrants and, effective April 30, 2027, will be frozen</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement Plan Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth m Article&#160;4. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Savings and Investment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Medtronic Savings and Investment Plan, as amended from time to time, and any successor thereto. The Savings and Investment Plan includes a salary reduction benefit under Section 401(k) of the Code and a matching contribution benefit under Section 401(m) of the Code. Effective May 1, 2005, the Savings and Investment Plan also includes a Personal Investment Account for those individuals who elected this retirement benefit option. Individuals who become participants in the Savings and Investment Plan on or after January 1, 2016, can no longer elect a Personal Investment Account, but instead are covered under the Medtronic Core Contribution Account. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Section 401(a)(17) Limitation&#8221; means the limitation on the dollar amount of compensation that may be taken into account under qualified retirement plans under Section 401(a)(l7) of the Code. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 415 Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the limitation on benefits for qualified defined benefit pension plans and the limitation on allocations for qualified defined contribution plans, which are imposed by Section 415(b) and (c), respectively, of the Code. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separate from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; with respect to a Participant, means the Participant&#8217;s separation from service with all Affiliates, within the meaning of Section 409A(a)(2)(A)(i) of the Code. Solely for this purpose, a Participant will be considered to have a Separation from Service when the Participant dies, retires, or otherwise has a termination of employment with all Affiliates. The employment relationship is treated as continuing intact while the Participant is on military leave</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sick leave</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other bona fide leave of absence if the period of such leave does not exceed six months, or if longer, so long as the individual retains a right to reemployment with the Affiliate under an applicable statute or by contract. For purposes hereof, a leave of absence constitutes a bona fide leave of absence only if there is a reasonable expectation that the Participant will return to perform services for an Affiliate. If the period of leave exceeds six months and the individual does not retain a right to reemployment under an applicable statute or by contract, the employment relationship is deemed to terminate, and the Separation from Service occur, on the day immediately following the end of such six&#173; month period. Notwithstanding the foregoing, where a leave of absence is due to any medically determinable physical or mental impairment that can be expected to last for a continuous period of not less than six months, where such impairment causes the employee to be unable to perform the duties of his or her position of employment or any substantially similar position of employment, the Company may substitute a 29-month period of absence for such six-month period</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whether a termination of employment has occurred is determined based on whether the facts and circumstances indicate that the Affiliate and the Participant reasonably anticipated that no further services will be performed after a certain date or that the level of bona fide services the Participant will perform after such date (whether </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as an employee or independent contractor) will permanently decrease to no more than 40 percent of the average level of bona fide services </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">performed (whether as an employee or independent contractor) over the immediately preceding 36-month period (or the full period of services if the Participant has been providing services for less than 36 months).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything in Section 2.1.2 to the contrary, in determining whether a Participant has had a Separation from Service with an Affiliate, an entity&#8217;s status as an &#8220;Affiliate&#8221; shall be determined substituting &#8220;50 percent&#8221; for &#8220;80 percent&#8221; each place it appears in Section 1563(a)(l),(2), and (3) and in Treasury Regulation Section 1.414(c)-2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall have discretion to determine whether a Participant has experienced a Separation from Service in connection with an asset sale transaction entered into by the Company or an Affiliate, provided that such determination conforms to the requirements of Section 409A, in which case the Company&#8217;s determination shall be binding on the Participant. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section 409A of the Code, as amended from time to time, any successor statute, and all guidance issued thereunder. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an employee of an Affiliate who is subject to the six-month delay rule described in Section 409A(2)(B)(i) of the Code. The Company shall establish a written policy for identifying Specified Employees in a manner consistent with Section 409A, which policy may be amended by the Company from time to time as permitted by Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, prior to January 20, 2015, the Company&#8217;s common stock $0.10 par value per share, and on or after January 26, 2015, ordinary shares of Medtronic Inc., par value $0.0001 per share (as such par value may be adjusted from time to time). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Medtronic, Inc. Compensation Trust Agreement Number One, as amended from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Gender and Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise indicated by context, masculine terminology used herein also includes the feminine and neuter, and terms used in the singular may also include the plural. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>PARTICIPATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Who May Participate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participation in the Plan is limited to Eligible Employees. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Time and Conditions of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. An Eligible Employee shall become a Participant on the date on which he or she first accrues a benefit under the Plan, provided that he or she is then in compliance with such terms and conditions as the Committee may from time to time establish for the implementation of the Plan, including, but not limited to, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any condition the Committee may deem necessary or appropriate for the Company to meet its obligations under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Termination and Suspension of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Once an individual has become a Participant, participation shall continue until payment in full of all benefits to which the Participant or Beneficiary is entitled under the Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Missing Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Participant and Beneficiary entitled to receive benefits under the Plan shall be obligated to keep the Company informed of his or her current address until all Plan benefits that are due to be paid to the Participant or Beneficiary have been paid to him or her. If, after having made reasonable efforts to do so, the Company is unable to locate the Participant or Beneficiary for purposes of making a distribution, the Participant&#8217;s or Beneficiary&#8217;s Plan benefit will be forfeited. In no event will a Participant&#8217;s or Beneficiary&#8217;s benefit be paid to him or her later than the date otherwise required by the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Relationship to Other Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Participation in the Plan shall not preclude participation of the Participant in any other fringe benefit program or plan sponsored by an Affiliate for which the Participant would otherwise be eligible. Notwithstanding anything in the Plan to the contrary, to the extent permitted by Section 409A, the Committee, or anyone to whom the Committee has delegated this authority pursuant to Section 11.4, may reduce the benefits payable to a Participant under the Plan if, and to the extent that, benefits are payable to the Participant under another similar plan or arrangement maintained by the Company or an Affiliate. The Committee (or its delegate) shall have complete and absolute discretion to determine whether another benefit plan or arrangement maintained by the Company or an Affiliate is similar to the Plan, whether the benefit under the Plan can be reduced in a manner that does not cause a violation of Section 409A, and the amount of the reduction to be applied. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Plan Benefits for Participants who Separated from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The benefits provided under the Plan with respect to any Participant who has incurred a Separation from Service shall, except as otherwise specifically provided in the Plan, be governed in all respects by the terms of the Plan as in effect as of the date of the Participant&#8217;s Separation from Service. A Participant&#8217;s reemployment by, or performance of services for, the Company or an Affiliate after incurring a Separation from Service shall not affect the payment timing or amount of his or her Account(s) under the Plan attributable to his or her service prior to his or her Separation from Service. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>RETIREMENT PLAN SUPPLEMENTAL BENEFIT </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Calculation of Retirement Plan Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. An Eligible Employee shall earn a Retirement Plan Supplemental Benefit as of any Determination Date, as defined in the following sentence, in an amount equal to the lump sum actuarial equivalent value of the difference between his or her Unrestricted Retirement Plan Benefit, as defined below in this Section 4.1, and his or her Actual Retirement Plan Benefit, as defined below in this Section 4.1, with both values determined as of the Determination Date. For purposes hereof, the Determination Date is the first day of the month. The lump sum actuarial equivalent value shall be determined in each case by use of the applicable interest rate of six percent (6%) and the applicable mortality table within the meaning of Section 417(e)(3) of the Code. Provided, however, the Retirement Plan Supplemental Benefit determined in accordance with this Section 4.1 shall not be less than the Retirement Plan Supplemental Benefit determined in accordance with the Plan as in effect on May 1, 2010.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes hereof, an Eligible Employee&#8217;s Unrestricted Retirement Plan Benefit as of any Determination Date equals the vested monthly benefit that such individual would have accrued under the Retirement Plan as of such date under the otherwise applicable provisions of the Retirement Plan, but determined for periods from and after May 1, 1986, without application of the Section 415 Limitation or the Section 40l(a)(17) Limitation and based upon the compensation that would have been paid to the Eligible Employee during the Plan Year but for his or her election to defer his or her compensation under the Capital Accumulation Plan.  For </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">purposes hereof, compensation that is reduced pursuant to such an election shall be taken into account for the Plan Year during which such compensation would have been paid to the Eligible Employee but for such election and only to the extent that such compensation would otherwise be taken into account under the Retirement Plan in calculating benefits thereunder had such compensation otherwise been paid directly to the Eligible Employee (but without regard to application of the Section 401(a)(17) Limitation). The Unrestricted Retirement Plan Benefit is determined without reduction for the Actual Retirement Plan Benefit. For the avoidance of doubt, to the extent required under Section 4.3 of the Retirement Plan, an Eligible Employee&#8217;s Unrestricted Retirement Plan Benefit shall reflect actuarial increases determined in accordance with the actuarial adjustment factors set forth for such purpose under the Retirement Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes hereof, an Eligible Employee&#8217;s Actual Retirement Plan Benefit as of any Determination Date equals the vested monthly benefit that the individual has actually accrued as of such date under the provisions of the Retirement Plan, after taking into account all applicable limitations on contributions, benefits and compensation. For the avoidance of doubt, to the extent required under Section 4.3 of the Retirement Plan, an Eligible Employee&#8217;s Actual Retirement Plan Benefit shall reflect actuarial increases determined in accordance with the actuarial adjustment factors set forth for such purpose under the Retirement Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An Eligible Employee&#8217;s Unrestricted Retirement Plan Benefit and Actual Retirement Plan Benefit shall be determined after giving effect to the exclusion of Eligible Employees hired or rehired on or after January 1, 2016 from the Retirement Plan under Section 3.1 of the Retirement Plan, and to the election a Participant makes under Section 3.2 of the Retirement Plan (i.e., the election to receive a contribution to a Personal Investment Account under the Savings and Investment Plan, the final average pay benefit under the Retirement Plan or the personal pension account benefit under the Retirement Plan) for benefits accruing under the Retirement Plan on or after May 1, 2005</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision of the Plan to the contrary, a Participant&#8217;s Nonqualified Retirement Plan Account shall be adjusted, pursuant to the terms of the Retirement Plan, to reflect participation, as applicable, in any voluntary early retirement program or such other similar program sponsored by the Company and&#47;or its Affiliates, subject to the following special rules for the 2023 Medtronic Voluntary Early Retirement Plan (&#8220;2023 VERP&#8221;)&#58; an Eligible Employee who is a Highly Compensated Employee for the Plan Year ending April 30, 2023, as defined in the Retirement Plan, shall have their 2023 VERP adjustment credited entirely to this Plan and not to the Retirement Plan except for (i) Participants who were not eligible to commence distributions under the Retirement Plan as of their Separation from Service pursuant to the 2023 VERP and (ii) Participants whose benefit under this Plan was equal to the Retirement Plan Supplemental Benefit determined in accordance with the Plan as in effect on May 1, 2010 when calculated without regard to the 2023 VERP. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Establishment of Nonqualified Retirement Plan Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Participant&#8217;s Retirement Plan Supplemental Benefit shall be determined as of the first day of the month following the month in which the Participant has a Separation from Service, and the lump sum value of such Retirement Plan Supplemental Benefit shall be credited as of such date to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bookkeeping account established for the Participant on the books and records of the Company, referred to as the &#8220;Nonqualified Retirement Plan Account.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event a Participant terminates employment as a result of death, the value of the benefits, if any, to be credited to his or her Nonqualified Retirement Account shall be based upon the lump sum actuarial equivalent value of the death benefits that would be paid under the Retirement Plan under the same assumptions as used under Section 4.1 hereof in determining the Participant&#8217;s Unrestricted Retirement Plan Benefit (that is, without regard to the Section 415 Limitation and the Section 401(a)(l7) Limitation and without regard to any election the Participant may have made under the Capital Accumulation Plan to defer his or her compensation) less the lump sum actuarial equivalent value of death benefits actually payable with respect to such Participant under the Retirement Plan, if any, taking into account all applicable limitations on contributions, benefits and compensation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Interest Credited to Nonqualified Retirement Plan Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All amounts credited to the Nonqualified Retirement Plan Account from time to time shall be credited with interest at a rate that is equal to the pre-retirement interest rate or rates used by the Retirement Plan during the period for which interest is to be so credited for purposes of determining actuarially equivalent benefits under the Retirement Plan. Interest as so determined shall be compounded monthly during the Plan Year. Notwithstanding anything in this Section 4.3 to the contrary, for Nonquali&#64257;ed Retirement Plan Accounts that are established on or after May I, 2010, the rate for crediting interest pursuant to this Section 4.3 shall be the Interest Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Payment of Nonqualified Retirement Plan Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Payment to a Participant of his or her Nonqualified Retirement Plan Account shall commence as soon as administratively feasible on or after the first day of the seventh month following his or her Separation from Service. All distributions of the Nonqualified Retirement Account will be made in cash. If the value of the Participant&#8217;s Nonqualified Retirement Account, determined as of the date on which such Account is established, is greater than $100,000, the Account principal together with interest based upon the applicable Interest Rate shall be paid to the Participant on a monthly basis over a 15-year period in 180 equal monthly installments. If the value of the Participant&#8217;s Nonqualified Retirement Account, determined as of the date on which such Account is established, is $100,000 or less, the Account together with interest thereon shall be paid to the Participant in a lump sum. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>ESOP SUPPLEMENTAL BENEFIT </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Nonqualified ESOP Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company previously established an Account on behalf of each Participant entitled to an ESOP Supplemental Benefit (defined as a Defined Contribution Supplemental Benefit in the Predecessor Plan and commonly referred to as the &#8220;ESOP restoration benefit&#8221;) now referred to as the &#8220;Nonqualified ESOP Account.&#8221; All contributions to the Nonqualified ESOP Account ceased effective April 30, 2005. A Participant&#8217;s Nonqualified ESOP Account, if any, will continue to vest according to the terms of the Predecessor Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Gains Credited to Nonqualified ESOP Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Participant&#8217;s ESOP Supplemental Benefit is expressed in the form of the right to receive Stock. Because of this, the Nonqualified ESOP Account is adjusted to reflect Stock splits, Stock dividends and recapitalizations in such manner as may be determined by the Committee. The Committee may also, in its discretion, adjust the Nonqualified ESOP Account to reflect dividends payable with respect to the Stock from time to time in such manner as it deems appropriate. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Payment of Nonqualified ESOP Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Payment to a Participant of his or her Nonqualified ESOP Account shall be made at the end of the Plan Year in which the Participant&#8217;s Separation from Service occurs. Payment shall be made in Stock in the form of a lump sum. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>PERSONAL INVESTMENT ACCOUNT SUPPLEMENTAL BENEFIT </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Calculation of Personal Investment Account Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. An Eligible Employee who, pursuant to Section 3.2 of the Retirement Plan, elects to participate in the Personal Investment Account Benefit under the Savings and Investment Plan, shall be credited with a Personal Investment Account Supplemental Benefit as of the end of each Plan Year commencing May 1, 2005, in an amount equal to his or her Unrestricted Personal Investment Account Allocation, as defined below in this Section 6.1, for such year less his or her Actual Personal Investment Account Allocation, as defined below in this Section 6.1, for such year&#59; provided, however, that for the year in which the Participant has a Separation from Service, the Participant&#8217;s Personal Investment Account Supplemental Benefit for such year shall be determined as of the end of the month in which the Separation from Service occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An Eligible Employee&#8217;s Unrestricted Personal Investment Account Allocation for a year equals the dollar amount that would have been allocated by the Company to his or her Personal Investment Account for the year, but without application of the Section 415 Limitation or the Section 40l(a)(l7) Limitation and based upon the compensation that would have been paid to the Eligible Employee during the year but for his or her election to defer his or her compensation under the Capital Accumulation Plan. For purposes hereof, compensation that is reduced pursuant to such an election shall be taken into account for the Plan Year during which such compensation would have been paid to the Eligible Employee but for such election and only to the extent that such compensation would otherwise be taken into account under the Savings and Investment Plan in calculating benefits thereunder had such compensation otherwise been paid directly to the Eligible Employee (but without regard to application of the Section 401(a)(l7) Limitation) </font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Unrestricted Personal Investment Account Allocation is determined without reduction for the Actual Personal Investment Account Allocation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An Eligible Employee&#8217;s Actual Personal Investment Account Allocation for a year equals the dollar amount that the Company actually allocates as a contribution to the Eligible Employee&#8217;s Personal Investment Account for such year. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision of the Plan to the contrary, a Participant&#8217;s Supplemental Personal Investment Account shall be adjusted, pursuant to the terms of the Savings and Investment Plan, to reflect participation, as applicable, in any voluntary early retirement program or such other similar program sponsored by the Company and&#47;or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Establishment of Nonqualified Personal Investment Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Personal Investment Account Supplemental Benefit to be credited to a Participant for a Plan Year under Section 6.1 shall be credited as of the last day of such year (except for the Plan Year in which a Participant has a Separation from Service, in which case it shall be credited as of the last day of the month in which the Separation from Service occurs) to an account established on the books and records of the Company, referred to as the &#8220;Nonqualified Personal Investment Account.&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Crediting Gains and Losses to Nonqualified Personal Investment Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee shall designate the manner in which a Participant&#8217;s Nonqualified Personal Investment Account is to be credited with gains and losses as described on Schedule A hereto, which Schedule may be amended from time to time in the Committee&#8217;s discretion. If the Committee designates specific investment funds to serve as an index for crediting gains and losses to a Participant&#8217;s Nonqualified Personal Investment Account&#58; (a) the Participant shall be entitled to designate which such fund or funds shall be used to measure gains and losses on his or her Nonqualified Personal Investment Account and to change such designation in accordance with rules established by the Committee&#59; (b) the Participant&#8217;s Nonqualified Personal Investment Account will be credited with gains and losses as if invested in such fund or funds in accordance with the Participant&#8217;s designation and the rules established by the Committee&#59; and (c) the Committee may, in its sole discretion, eliminate any investment fund or funds previously designated by it, substitute a new investment fund or funds therefore, or add investment fund or funds, at any time. If the Committee makes any such investment funds available for this purpose, the Company shall have no obligation to actually invest any amounts in any such investment funds. Unless the Committee adopts a different rule, investment designations may be changed, generally, on a business daily basis. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ested Interest in Nonqualified Personal Investment Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Participant&#8217;s vested interest in his or her Nonqualified Personal Investment Account shall be determined in the same manner as the Participant&#8217;s vested interest in his or her Personal Investment Account, and the Company may forfeit the non-vested portion of the Participant&#8217;s Nonqualified Personal Investment Account under the same rules and subject to the same limitations as provided for the Personal Investment Account under the Savings and Investment Plan. Notwithstanding the preceding sentence, a Participant shall not earn a fully-vested interest in his or her Nonqualified Personal Investment Account as a result of the termination or partial termination of the Plan in those situations where the Participant is not otherwise fully vested in such Account. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Payment of Nonqualified Personal Investment Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Payment to a Participant of his or her Nonqualified Personal Investment Account shall commence as soon as administratively feasible on or after the first day of the seventh month following his or her Separation from Service. All distributions of the Nonqualified Personal Investment Account will be paid in the form of cash. If the value of the Participant&#8217;s Nonqualified Personal Investment Account, determined as soon as administratively feasible following the date on which the Participant&#8217;s Separation from Service occurs, is greater than $100,000, the Account principal shall be paid to the Participant on a monthly basis over a fifteen-year period in 180 equal monthly installments. During the payout period, interest shall be credited on the declining balance based upon the applicable Interest Rate rather than pursuant to Section 6.3. If the value of the Participant&#8217;s Nonqualified Personal Investment Account, determined as soon as administratively feasible following the date on which the Participant&#8217;s Separation from Service occurs, is $100,000 or less, the Account shall be paid to the Participant in a lump sum. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>MEDTRONIC CORE CONTRIBUTION ACCOUNT<br></font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUPPLEMENTAL BENEFIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Calculation of Medtronic Core Contribution Account Supplemental Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. An Eligible Employee who, pursuant to Section 5.4 of the Savings and Investment Plan, is eligible to receive Medtronic Core Contributions under that plan, shall be credited with a Medtronic Core Contribution Account Supplemental Benefit as of the end of each Plan Year that ends on or after April 30, 2016, in an amount equal to his or her Unrestricted Medtronic Core Contribution Account Allocation, as defined below in this Section 7.1, for such year less his or her Actual Medtronic Core Contribution Account Allocation, as defined below in this Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1, for such year&#59; provided, however, that for the year in which the Participant has a Separation from Service, the Participant&#8217;s Medtronic Core Contribution Account Supplemental Benefit for such year shall be determined as of the end of the month in which the Separation from Service occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An Eligible Employee&#8217;s Unrestricted Medtronic Core Contribution Account Allocation for a year equals the dollar amount that would have been allocated by the Company to his or her Medtronic Core Contribution Account for the year, but without application of the Section 415 Limitation or the Section 40l(a)(17) Limitation and based upon the compensation that would have been paid to the Eligible Employee during the year but for his or her election to defer his or her compensation under the Capital Accumulation Plan. For purposes hereof, compensation that is reduced pursuant to such an election shall be taken into account for the Plan Year during which such compensation would have been paid to the Eligible Employee but for such election and only to the extent that such compensation would otherwise be taken into account under the Savings and Investment Plan in calculating benefits thereunder had such compensation otherwise been paid directly to the Eligible Employee (but without regard to application of the Section 401(a)(17) Limitation). In addition, compensation for the Plan Year commencing May 1, 2015, shall be taken into account only from January 1, 2016, through April 30, 2016. The Unrestricted Medtronic Core Contribution Account Allocation is determined without reduction for the Actual Medtronic Core Contribution Account Allocation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An Eligible Employee&#8217;s Actual Medtronic Core Contribution Account Allocation for a year equals the dollar amount that the Company actually allocates as a contribution to the Eligible Employee&#8217;s Medtronic Core Contribution Account for such year. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision of the Plan to the contrary, a Participant&#8217;s Supplemental Medtronic Core Contribution Account shall be adjusted, pursuant to the terms of the Savings and Investment Plan, to reflect participation, as applicable, in any voluntary early retirement program or such other similar program sponsored by the Company and&#47;or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Establishment of Nonqualified Medtronic Core Contribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Medtronic Core Contribution Account Supplemental Benefit to be credited to a Participant for a Plan Year under Section 7.1 shall be credited as of the last day of such year (except for the Plan Year in which a Participant has a Separation from Service, in which case it shall be credited as of the last day of the month in which the Separation from Service occurs) to an account established on the books and records of the Company, referred to as the &#8220;Nonqualified Medtronic Core Contribution Account.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Crediting Gains and Losses to Nonqualified Medtronic Core Contribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee shall designate the manner in which a Participant&#8217;s Nonqualified Medtronic Core Contribution Account is to be credited with gains and losses as described on Schedule A hereto, which Schedule may be amended from time to time in the Committee&#8217;s discretion. If the Committee designates specific investment funds to serve as an index for crediting gains and losses to a Participant&#8217;s Nonqualified Medtronic Core Contribution Account&#58; (a) the Participant shall be entitled to designate which such fund or funds shall be used to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">measure gains and losses on his or her Nonqualified Medtronic Core Contribution Account and to change such designation in accordance with rules established by the Committee&#59; (b) the Participant&#8217;s Nonqualified Medtronic Core Contribution Account will be credited with gains and losses as if invested in such fund or funds in accordance with the Participant&#8217;s designation and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the rules established by the Committee&#59; and (c) the Committee may, in its sole discretion, eliminate any investment fund or funds previously designated by it, substitute a new investment fund or funds therefor, or add investment fund or funds, at any time. If the Committee makes any such investment funds available for this purpose, the Company shall have no obligation to actually invest any amounts in any such investment funds. Unless the Committee adopts a different rule, investment designations may be changed, generally, on a business daily basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Vested Interest in Nonqualified Medtronic Core Contribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant&#8217;s vested interest in his or her Nonqualified Medtronic Core Contribution Account shall be determined in the same manner as the Participant&#8217;s vested interest in his or her Medtronic Core Contribution Account, and the Company may forfeit the non-vested portion of the Participant&#8217;s Nonqualified Medtronic Core Contribution Account under the same rules and subject to the same limitations as provided for the Medtronic Core Contribution Account under the Savings and Investment Plan. Notwithstanding the preceding sentence, a Participant shall not earn a fully-vested interest in his or her Nonqualified Medtronic Core Contribution Account as a result of the termination or partial termination of the Plan in those situations where the Participant is not otherwise fully vested in such Account. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Payment of Nonqualified Medtronic Core Contribution Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Payment to a Participant of his or her Nonqualified Medtronic Core Contribution Account shall commence as soon as administratively practicable on or after the first day of the seventh month following his or her Separation from Service. All distributions of the Nonqualified Medtronic Core Contribution Account will be paid in the form of cash. If the value of the Participant&#8217;s Nonqualified Medtronic Core Contribution Account, determined as soon as administratively feasible following the date on which the Participant&#8217;s Separation from Service occurs, is greater than $100,000, the Account principal shall be paid to the Participant on a monthly basis over a fifteen-year period in 180 equal monthly installments. During the payout period, interest shall be credited on the declining balance based upon the applicable Interest Rate rather than pursuant to Section 7.3. If the value of the Participant&#8217;s Nonqualified Medtronic Core Contribution Account, determined as soon as administratively feasible following the date on which the Participant&#8217;s Separation from Service occurs, is $100,000 or less, the Account shall be paid to the Participant in a lump sum. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>ARTICLES. DEATH BENEFITS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Form and Time of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If a Participant dies before all amounts in an Account have been distributed to him or her (whether the Participant&#8217;s death occurs before or after distributions have commenced to the Participant), the Account balance, to the extent then vested, shall be paid to the Participant&#8217;s Beneficiary in a lump sum within 90 days after the Participant&#8217;s death. Provided, however, to the extent permitted under Section 409A, such payment can be made on any date prior to December 31 of the calendar year immediately following the calendar year the Participant&#8217;s death occurs, the exact payment date to be determined by the Committee. The Committee may confer with the Participant&#8217;s Beneficiary in determining the payment date, but retains the discretion to determine the payment date, except that, after an Event, the Participant&#8217;s Beneficiary may, to the extent permitted under Section 409A, determine a reasonable payment date within the above-stated parameters, and the Committee shall honor such determination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Participant has the right to designate primary and contingent Beneficiaries </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">death benefits payable under the Plan. Such Beneficiaries may be individuals or trusts for the benefit of individuals. A Beneficiary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">designation by a Participant shall be in writing on a form acceptable to the Committee and shall only be effective upon delivery to the Company. A Beneficiary designation may be revoked by a Participant at any time by delivering to the Company either written notice of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">revocation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a new Beneficiary designation form</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Beneficiary designation form last delivered to the Company prior to the death of a Participant shall control. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Failure to Designate Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event there is no Beneficiary designation on file with the Company at the Participant&#8217;s death, or if all Beneficiaries designated by a Participant have predeceased the Participant, any benefits payable pursuant to this Article 8 will be paid to the Participant&#8217;s surviving spouse, if living&#59; or if the Participant does not leave a surviving spouse, to the Participant&#8217;s children, if any, in equal shares, except that if any of the children predecease the Participant but leave issue surviving the Participant, such issue shall take by right of representation, the share their parent would have taken if living&#59; for purposes of this provision, &#8220;children&#8221; shall not include stepchildren unless such stepchildren have been legally adopted by the Participant&#59; or, if there are no such surviving issue, to the Participant&#8217;s estate. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>CHANGE IN CONTROL PROVISIONS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Application of Article&#160;9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent applicable, the provisions of this Article&#160;9 relating to an Event of change in control of the Company shall control, notwithstanding any other provisions of the Plan to the contrary, and shall supersede any other provisions of the Plan to the extent inconsistent with the provisions of this Article&#160;9. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Payments to and by the Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to the terms of the Trust, the Company is required to make certain payments to the Trust if an Event occurs or if the Company determines that it is probable that an Event may occur. The obligation of the Company to make such payments shall be considered an obligation under the Plan&#59; provided, however, that such obligation shall at all times be and remain subject to the terms of the Trust as in effect from time to time</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Legal Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall reimburse a Participant or his or her Beneficiary for all reasonable legal fees and expenses incurred by such Participant or Beneficiary after the date of an Event in seeking to obtain any right or benefit provided by the Plan&#59; provided however, that&#58; (a) any such reimbursement shall be made during a period not to exceed 20 years following the date of the Event&#59; (b) the amount eligible for reimbursement during a taxable year of the Participant or Beneficiary shall not affect the amount eligible for reimbursement in any other taxable year&#59; (c) the reimbursement is made on or before the last day of the Participant&#8217;s or Beneficiary&#8217;s taxable year following the taxable year in which the legal fees and expenses are incurred&#59; and (d) the right to reimbursement is not subject to liquidation or exchange for another benefit. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Late Payment and Additional Payment Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If after the date of an Event the Company delays a payment required to be made under the Plan past the final date that the payment was due to be made, the amount of each such delayed payment shall be credited with interest at the rate of five percent per year, compounded quarterly, from the date on which the distribution was required to be made under the terms of the Plan until the actual date of the distribution. In the event that this interest is to be credited for some period less than a full calendar quarter, the interest shall be determined and compounded for the fractional quarter. This interest represents a late payment penalty for the delay in payment and is intended to supplement any other interest or gains credited to a Participant&#8217;s Account under the Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any benefit payments made by the Company after the date on which a benefit distribution was required to be made under the terms of the Plan shall be applied first against the first due of such benefit distributions (with application first against any applicable late payment penalty and next against the benefit amount itself) until fully paid, and next against the next due of such payments in the same manner, and so forth</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for purposes of calculating the late payment penalties hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that payment of benefits has commenced to a Participant or Beneficiary prior to the date of an Event, then the date on which distribution was required to be made under the terms of the Plan shall be determined with reference to the payment provision that was in effect prior to the date of the Event. No adjustment may be made to any payment form which was in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">effect prior to the date of an Event with respect to any Account which would have the effect of delaying payments otherwise to be made under the payment form or otherwise increasing the period of time over which payments are to be made.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participants and their Beneficiaries shall be entitled to benefit payment under the Plan plus the late payment penalty referred to hereinabove first from the Trust and secondarily from the Company, as otherwise provided in Section 9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.36pt"><br>FUNDING </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Source of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All benefits under the Plan shall be paid when due by the Company out of its assets or from the Trust. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">No Claim on Specific Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No Participant shall be deemed to have, by virtue of being a Participant in the Plan, any claim on any specific assets of the Company such that the Participant would be subject to income taxation on his or her benefits under the Plan prior to distribution and the rights of Participants and Beneficiaries to benefits to which they are otherwise entitled under the Plan shall be those of an unsecured general creditor of the Company. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.36pt"><br>ADMINISTRATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan shall be administered by the Committee. The Company shall bear all administrative costs of the Plan other than those specifically charged to a Participant or Beneficiary. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Powers of Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to the other powers granted under the Plan, the Committee shall have all powers necessary to administer the Plan, including, without limitation, powers to&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">interpret the provisions of the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">establish and revise the method of accounting for the Plan and to maintain the Accounts&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">establish rules for the administration of the Plan and to prescribe any forms required to administer the Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Actions of the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as modified by the Board, the Committee (including any person or entity to whom the Committee has delegated duties, responsibilities or authority, to the extent of such delegation) has total and complete discretionary authority to determine conclusively for all parties all questions arising in the administration of the Plan, to interpret and construe the terms of the Plan, and to determine all questions of eligibility and status of employees, Participants and Beneficiaries under the Plan and their respective interests. Subject to the claims procedures of Section 11.6, all determinations, interpretations, rules and decisions of the Committee (including those made or established by any person or entity to whom the Committee has delegated duties, responsibilities or authority, if </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made or established pursuant to such delegation) are conclusive and binding upon all persons having or claiming to have any interest or right under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Delegation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee, or any officer designated by the Committee, shall have the power to delegate specific duties and responsibilities to officers or other employees of the Company or other individuals or entities. Any delegation may be rescinded by the Committee at any time. Each person or entity to whom a duty or responsibility has been delegated shall be responsible for the exercise of such duty or responsibility and shall not be responsible for any act or failure to act of any other person or entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Reports and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Committee, and those to whom the Committee has delegated duties under the Plan, shall keep records of all their proceedings and actions and shall maintain books of account, records, and other data as shall be necessary for the proper administration of the Plan and for compliance with applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided in Section 11.7 with respect to disability claims for benefits, the Committee shall notify a Participant in writing within a reasonable period of time, not to exceed ninety (90) days, following the Plan&#8217;s receipt of the Participant&#8217;s written claim for benefits, of the Participant&#8217;s eligibility or noneligibility (i) for benefits under the Plan or, (ii) if the claim is for different or greater benefits, for the benefits claimed by the Participant. If the Committee determines that a Participant is not eligible for benefits or for the benefits claimed, the notice shall set forth&#58; (a) the specific reasons for the adverse determination&#59; (b) a reference to the specific provisions of the Plan on which the determination is based&#59; (c) a description of any additional information or material necessary for the claimant to perfect the claim and an explanation of why it is needed&#59; and (d) a description of the Plan&#8217;s claims review procedure and the time limits applicable to such procedures, including a statement of the Participant&#8217;s right to bring a civil action under Section 502(a) of the ERISA, following an adverse benefit determination on review. If the Committee determines that there are special circumstances requiring additional time to make a decision, the Committee shall notify the Participant of the special circumstances and the date by which a decision is expected to be made, and may extend the time for up to an additional ninety (90) day period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Participant shall have the opportunity to have a full and fair review of the claim and the adverse benefit determination by the Committee. The Participant must exercise this opportunity by filing a petition for review with the Committee within sixty (60) days after receipt by the Participant of the notice issued by the Committee. Said petition may state the specific reasons the Participant believes the Participant is entitled to benefits or greater or different benefits and may be accompanied by written comments, document, records and other </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relating to the claim </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits. The Participant or the Participant&#8217;s representative shall be permitted, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the claim for benefits. Whether information is &#8220;relevant&#8221; shall be determined by the Committee taking into account guidance from the Department of Labor. If a Participant does not appeal within the Plan&#8217;s required time period, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant will lose the right to appeal and the Participant will have failed to exhaust the Plan&#8217;s internal administrative appeal process. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within a reasonable period of time</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">not to exceed sixty (60) days, following receipt by the Committee of said petition, the Committee shall review the petition, taking into account all comments, document, records and other information submitted by the Participant relating to the claim</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without regard to whether such information was submitted or considered in the initial benefit determination</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Committee</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s determination is adverse to the Participant, the Committee shall notify the Participant of its decision in writing, setting forth</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) the specific reasons for the adverse determination&#59; (b) a reference to the specific provisions of the Plan on which the determination is based&#59; (c) a statement that the Participant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the claim for benefits&#59; and (d) a statement of the Participant&#8217;s right to bring a civil action under Section 502(a) of ERISA. If the sixty (60) day period is not sufficient, the Committee shall not</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">fy the Participant of the special circumstances that cause sixty (60) days to be insufficient and the date by which a decision is expected to be made, and may extend the time for up to an additional sixty (60) day period</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of the death of a Participant, the same procedure shall be applicable to the Participant&#8217;s Beneficiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Disability Benefit Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For claims for benefits under the Plan where the disability of the Participant is in dispute, special claim rules apply. In the case of a disability benefit claim, the time periods for filing and appealing a claim set out in this Section 11.7 apply instead of the time periods under the general claims procedure described in Section 11</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6. There are also additional rules that apply, such as information that must be provided in certain cases when a disability benefit claim is denied. Where there is not an additional rule or a substitute rule that applies</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the general claims procedure described in Section 11.6 applies</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Committee will notify the Participant of its determination regarding the availability of benefits within a reasonable period of time, but not later than forty-five (45) days after receipt of the claim by the Plan</font><font style="color:#676767;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This period may be extended by the Plan for up to thirty (30) days, provided that the Committee both determines that such an extension is necessary due to matters beyond the control of the Plan and notifies the Participant, prior to the expiration of the initial forty-five (45) day period, of the circumstances requiring the extension of time and the date by which the Plan expects to render a decision. If, prior to the end of the first thirty (30) day extension period, the Committee determines that, due to matters beyond the control of the Plan, a decision cannot be rendered within that extension period, the period for making the determination may be extended for up to an additional thirty (30) days, provided that the Committee notifies the Participant </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the expiration of the first thirty (30) day extension period, of the circumstances requiring the extension and the date as of which the Plan expects to render a decision. In the case of any such extension, the notice of extension shall specifically explain the standards on which entitlement to a benefit is based, the unresolved issues that prevent a decision on the claim, and the additional information needed to resolve those issues, and the Participant shall be afforded at least forty-five (45) days within which to provide the specified information. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If a claim is denied, a Participant has one hundred eighty (180) days following receipt of the denial within which to appeal the determination. The Participant&#8217;s appeal will be reviewed in a manner that does not afford deference to the initial adverse benefit determination and that is conducted by an appropriate arbiter who is neither the individual who made the adverse benefit determination that is the subject of the appeal, nor a subordinate of such individual. In deciding an appeal of any adverse benefit determination that is based in whole or in part on a medical judgment, the arbiter will consult with a health care professional who has appropriate training and experience in the field of medicine involved in the medical judgment. Such professional may not be an individual who was consulted in connection with the adverse benefit determination that is the subject of the appeal nor a subordinate of such individual. If the Participant requests, the Plan will furnish the Participant with the identity of any medical or vocational experts whose advice was obtained on behalf of the Plan in connection with a Participant&#8217;s benefit denial (without regard to whether the advice was relied upon in making the benefit determination). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Committee will notify a Participant of the Plan&#8217;s benefit determination on appeal within a reasonable period of time, but not later than forty-five (45) days after receipt of the Participant&#8217;s request for review by the Plan, unless the Committee determines that special circumstances (such as the need to hold a hearing) require an extension of time for processing the claim. If the Committee determines that an extension of time for processing is required, written notice of the extension shall be furnished to the Participant prior to the termination of the initial forty-five (45) day period. In no event will such extension exceed a period of forty-five (45) days from the end of the initial period. The extension notice will indicate the special circumstances requiring an extension of time and the date by which the Plan expects to render the determination on appeal. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The period of time within which an initial benefit determination or benefit determination following an appeal is required to be made will begin at the time the claim or appeal is filed in accordance with the procedures of the Plan, without regard to whether all the information necessary to make a determination accompanies the filing. In the event that a period of time is extended as permitted in Section 11.7(a) or (c) due to a Participant&#8217;s failure to submit information necessary to decide a claim, the period for making the determination will be tolled from the date on which the notification of the extension is sent to the Participant until the date on which the Participant responds to the request for additional information. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective for disability claims filed on or after January 1, 2018, but only to the extent that applicable claims regulations so require, the Committee can issue an adverse benefit determination on review only if the Committee has provided the Participant, free of charge, with any new or additional evidence considered, relied upon, or generated by or at the direction of the Plan or such person making the benefit determination in connection with the claim. Such </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:90px"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">evidence must be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the Participant a reasonable opportunity to respond before that date. Likewise, effective for disability claims filed on or after January 1, 2018, but only to the extent that applicable claims regulations so require, before the Committee can issue an adverse determination on review based on a new or additional rationale, the Committee must provide the Participant, free </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of charge, with the rationale. The rationale must be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the Participant a reasonable opportunity to respond before that date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">In the case of any benefit denial, including denial after appeal, if an internal rule, guideline, protocol, or other similar criterion was relied upon in denying the benefit, the Participant will be furnished with either</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) the specific rule, guideline, protocol, or other similar criterion&#59; or (2) a statement that such rule, guideline, protocol, or other similar criterion was relied upon in making the denial and that a copy of the rule, guideline, protocol, or other similar criterion will be provided free of charge to the Participant upon request. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">These special rules for disability claims described in this Section </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7 apply only if the Plan or someone acting on behalf of the Plan must make the disability determination. They apply to a Participant&#8217;s Beneficiaries if the Participant dies, and the Plan is nevertheless required to make a disability determination. They do not apply if the Plan pays a benefit based on a disability determination made by someone else for purposes of another benefit plan or program</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For example, if the Plan pays a disability benefit only to Participants who are determined to be disabled by Social Security or who are determined to be disabled by an insurer under the employer&#8217;s disability insurance policy, these special rules do not apply. Instead, the rules for other claims, described in Section 11.6, apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Additional Claims Procedure Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The following provisions apply to all claims under the Plan. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Plan shall comply with applicable Department of Labor regulations regarding the manner in which claims shall be processed. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To be considered timely under the Plan&#8217;s claims procedures, a claim must be filed under Section 11.6 or 11</font><font style="color:#646464;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7 within one year after the claimant knew or reasonably should have known of the principal facts upon which the claim is based</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Knowledge of all facts that the Participant knew or reasonably should have known shall be imputed to every claimant who </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or claims to be a Beneficiary of the Participant or otherwise claims to derive an entitlement by reference to the Participant for the purpose of applying the previously specified periods. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The exhaustion of the claims procedures is mandatory for resolving every claim and dispute arising under this Plan. As to such claims and disputes</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) no claimant shall be permitted to commence any legal action to recover Plan benefits or to enforce or clarify rights under the Plan under Section 502 or Section 510 of ERISA or under any other provision of law, whether or not statutory, until the claims procedures have been exhausted in their entirety&#59; and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) in any such legal action all explicit and all implicit determinations by the Committee and any other person or entity (including, but not limited to, determinations as to whether the claim, or a request for a review of a denied claim, was timely filed) shall be afforded the maximum deference permitted by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">No legal action to recover Plan benefits or to enforce or clarify rights under the Plan under Section 502 or Section 510 of ERISA or under any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other provision of law, whether or not statutory, may be brought by any claimant on any matter pertaining to this Plan unless the legal action is commenced in the proper forum before the earlier of&#58; (i) 30 months after the claimant knew or reasonably should have known of the principal facts on which the claim is based, or (ii) 12 months after the claimant has exhausted the claims procedure under this Plan. Knowledge of all facts that the Participant knew or reasonably should have known shall be imputed to every claimant who is or claims to be a Beneficiary of the Participant or otherwise claims to derive an entitlement by reference to the Participant for the purpose of applying the previously specified periods</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The exclusive venue for any legal action arising out of or relating to this Plan, including, but not limited to, actions under Section 502 or 510 of ERISA, is a state or federal court in Hennepin County, Minnesota</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The Committee and all persons determining or reviewing claims have full discretion to determine benefit claims under the Plan. Any interpretation, determination or other action of such persons will be overturned only if it is arbitrary or capricious or otherwise an abuse of discretion. Any review of a final decision or action of the persons reviewing a claim shall be based only on such evidence presented to or considered by such persons at the time they made the decision that is the subject of review. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.36pt"><br>AMENDMENTS AND TERMINATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company, by action of the Compensation Committee of the Board, or the Chief Executive Officer of the Company or the Senior Vice President of Human Resources, to the extent authorized by the Compensation Committee of the Board, may amend the Plan, in whole or in part, at any time and from time to time. Any such amendment shall be filed with the Plan documents. No amendment, however, may be effective to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reduce </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the vested amounts credited to a Participant&#8217;s Account (or that would be so credited with respect to a Participant who is actively employed immediately prior to the date of amendment had the Participant had a Separation from Service and had his or her Account been established  </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately prior to such date), as determined immediately prior to such amendment</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except that the Company may change the investment funds or funds that it may make available for crediting gains and losses pursuant to Section 6</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3 or Section 7.3 at any time in its discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company reserves the right to terminate the Plan at any time by action of the Compensation Committee of the Board. Upon termination of the Plan, all accruals and contributions shall immediately cease. Termination of the Plan shall not be effective to reduce the vested amounts credited to a Participant&#8217;s Account (or that would be so credited with respect to a Participant who is actively employed immediately prior to the date of such termination had the Participant had a Separation from Service and had his or her Account been established immediately prior to such date). If the Plan is terminated, payments from the Accounts of all Participants and Beneficiaries shall be made at the time and in the manner otherwise specified in the Plan, except as otherwise determined by the Company at the time of termination, subject to Article&#160;9 and the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.36pt"><br>MISCELLANEOUS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">No Guarantee of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither the adoption nor the maintenance of the Plan shall be deemed to be a contract of employment between any Affiliate and any Participant. Nothing contained herein shall give any Participant the right to be retained in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employ of an Affiliate or to perform services for an Affiliate, or to interfere with the right of an Affiliate to discharge any Participant at any time&#59; nor shall it give an Affiliate the right to require any Participant to remain in its employ or to perform services for it or to interfere with the Participant&#8217;s right to terminate his or her employment or performance of services at any time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any payment of benefits to or for the benefit of a Participant or a Participant&#8217;s Beneficiary that is made in good faith by the Company in accordance with the Company&#8217;s interpretation of its obligations under the Plan shall be in full satisfaction of all claims against the Company for benefits under the Plan to the extent of such payment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice permitted or required under the Plan shall be in writing and shall be hand-delivered or sent, postage prepaid, by first class mail, or by certified or registered mail with return receipt requested, to the principal office of the Company, if to the Company, or to the address last shown on the records of the Company, if to a Participant or Beneficiary. Any such notice shall be effective as of the date of hand-delivery or mailing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Nonalienation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No benefit payable at any time under the Plan shall be subject in any manner to alienation, sale, transfer, assignment, pledge, levy, attachment, or encumbrance of any kind by any Participant or Beneficiary, except with respect to a Domestic Relations Order. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may withhold from any payment of benefits or other compensation payable to a Participant or Beneficiary, or the Company may direct the trustee of the Trust to withhold from any payment of benefits to a Participant or Beneficiary, such amounts as the Company determines are reasonably necessary to pay any taxes or other amounts required to be withheld under applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Article&#160;and section headings and captions are provided for purposes of reference and convenience only and shall not be relied upon in any way to construe, define, modify, limit, or extend the scope of any provision of the Plan</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan and all rights hereunder shall be governed by and construed according to the laws of the State of Minnesota, except to the extent such laws are preempted by the laws of the United States of America</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">Invalidity of Certain Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of the Plan is held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provision of the Plan and the Plan shall be construed and enforced as if such provision had not been included. The Plan is intended to comply in form and operation with Section 409A, and shall be construed accordingly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt;text-decoration:underline">No Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The terms and conditions set forth herein constitute the entire understanding of the Company and the Participants with respect to the matters addressed herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any Participant is unable to care for his or her affairs because of illness or accident, any payment due may be paid to the Participant&#8217;s spouse, parent, adult child, brother, sister or other person deemed by the Committee to have incurred expenses for the care of such Participant, unless a duly qualified guardian or other legal representative has been appointed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Electronic Media</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything in the Plan to the contrary, but subject to any applicable requirements of ERISA, the Code, or other law, any action or communication otherwise required to be taken or made in writing by a Participant or Beneficiary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or by the Company or Committee shall be effective if accomplished by another method or methods required or made available by the Company or Committee, or their agent, with respect to that action or communication, including e-mail, telephone response systems, intranet systems, or the Internet. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Delay of Distributions Upon Certain Events </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay in Distributions</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as set forth in Section 13.13, if a Participant is a Specified Employee as of the date of his or her Separation from Service, any distributions that under the terms of the Plan are to commence to the Participant on his or her Separation from Service (&#8220;separation distributions&#8221;) shall commence on the Participant&#8217;s &#8220;delayed distribution date&#8221; (as defined below). In this case, the Company shall, in its discretion, determine (i) whether the first separation distribution to the Participant shall include the aggregate amount of any separation distributions that, but for this paragraph (a), would have been paid to the Participant from the date of his or her Separation from Service until the delayed distribution date, or (ii) whether each separation distribution shall be delayed for six months. The Company&#8217;s discretion must be exercised without any direct or indirect election by the Participant as to whether payment method (i) or </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) in the foregoing sentence shall be selected. For purposes of this paragraph (a), a Specified Employee&#8217;s &#8220;delayed distribution date&#8217;&#8217; is the first day of the seventh month following the Participant&#8217;s Separation from Service, or if earlier, the date of the Participant&#8217;s death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">A payment under the Plan may be delayed by the Company under any of the following circumstances so long as all payments to similarly situated Participants are treated on a reasonably consistent basis&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Company reasonably anticipates that if such payment were made as scheduled, the Company&#8217;s deduction with respect to such payment would not be permitted under Section 162(m) of the Code, provided that the payment is made either during the first calendar year in which the Company reasonably anticipates, or should reasonably anticipate, that if the payment is made during such year, the deduction of such payment will not be barred by application of Section 162(m) or during the period beginning with the date of the Participant&#8217;s Separation from Service and ending on the later of the last day of the Company&#8217;s fiscal year in which the Participant has a Separation from Service or the 15th day of the third month following the Separation from Service. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">The Company reasonably anticipates that the making of the payment will violate Federal securities laws or other applicable law, provided that the payment is made at the earliest date at which the Company reasonably anticipates that the making of the payment will not cause such violation. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Upon such other events as determined by the Company and according to such terms as are consistent with Section 409A or are prescribed by the Commissioner of Internal Revenue. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Acceleration of Distributions Upon Certain Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company may, in its discretion, distribute all or a portion of a Participant&#8217;s Accounts at an earlier time and in a different form than otherwise specified in the Plan under the circumstances described below&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">As may be necessary to fulfill a Domestic Relations Order. Distributions pursuant to a Domestic Relations Order shall be made according to administrative procedures established by the Company&#59; provided, however, that the ESOP Supplemental Benefit shall not be eligible for assignment pursuant to a Domestic Relations Order. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the extent reasonably necessary to avoid the violation of ethics laws or conflict of interest laws to the extent permitted under Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">To pay FICA on amounts deferred under the Plan and the income tax resulting from such payment. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To pay the amount required to be included in income as a result of the Plan&#8217;s failure to comply with Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If the Company determines, in its discretion, that it is advisable to liquidate the Plan in connection with a termination of the Plan pursuant to Section 12.2, subject to Article&#160;9 and the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">As satisfaction of a debt of the Participant to an Affiliate, where such debt is incurred in the ordinary course of the service relationship between the Affiliate and the Participant, the entire amount of the reduction </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any calendar year does not exceed $5,000, and the reduction is made at the same time and in the same amount as the debt otherwise would have been due and collected from the Participant. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">As satisfaction of a debt to the extent reasonably necessary to comply with federal law regarding debt collection, but only to the extent permissible under Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To pay state, local or foreign tax obligations that may arise with respect to amounts deferred under the Plan and the income tax resulting from such payment. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything in this Section 13.13 to the contrary, the Company shall not provide the Participant with discretion or a direct or indirect election regarding whether a payment is accelerated pursuant to this Section 13.13. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Small Account Balances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If at any time the present value of any benefit under the Plan that would be considered a &#8220;single plan&#8221; under Treasury Regulation Section 1.409A-l(c)(2), together with the present value of any benefit required to be aggregated with such benefit under Treasury Regulation Section 1.409A-l(c)(2), is less than the dollar limit set forth in Section 402(g) of the Code, the Company may, in its discretion, distribute such benefit (or benefits) to the Participant in the form of a lump sum, provided that the payment results in the liquidation of the entirety of the Participant&#8217;s interest under the &#8220;single plan,&#8221; including all benefits required to be aggregated as part of the &#8220;single plan&#8221; under Treasury Regulation Section 1.409A-1(c)(2). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">When a Plan Payment is Deemed to be Made</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any payment that is due to be distributed as of a particular date pursuant to the provisions of the Plan, will be deemed to be distributed as of that date if it is distributed on such date or a later date within the same calendar year, or, if later, by the 15th day of the third calendar month following the date, and the Participant is not permitted, directly or indirectly, to designate the calendar year of payment. Further, a payment will be treated as made on a date if it is made no earlier than 30 days before the date, and the Participant is not permitted, directly or indirectly, to designate the calendar year of payment. For purposes of the foregoing, if the payment is required to be made during a period of time, the specified date is treated as the first day of the period of time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During any Restricted Period, no assets shall be set aside, transferred, or otherwise restricted in a way that would result in such assets being treated, for the purposes of Section 83 of the Code, as property transferred in connection with the performance of services by reason of Section 409A(b)(3) of the Code with respect to an Applicable Covered Employee. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Section, &#8220;Restricted Period&#8221; means&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">any period during which any defined benefit plan to which Section 412(a&#125; of the Code applies (&#8220;Defined Benefit Plan&#8221;) of an Affiliate is in at-risk status, as defined in Section 430(i) of the Code&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any period the Company is a debtor in a case under title 11, United States Code, or similar federal or state law&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the 12-month period beginning on the date which is six months before the termination date of a Defined Benefit Plan if, as of the termination date, the Defined Benefit Plan is not sufficient for benefit liabilities, within the meaning of Section 4041 of ERISA. </font></div><div style="padding-left:78pt"><font style="color:#282a28;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Section, </font><font style="color:#464848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#282a28;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Applicable Covered Employee&#8221; means any&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">covered employee of an Affiliate&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">former employee who was covered&#160;&#160;&#160;&#160;at the time of termination of employment w</font><font style="color:#464848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th an Affiliate. </font></div><div style="padding-left:78.4pt"><font style="color:#282a28;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Section, &#8220;Covered Employee&#8221; means an individual who is&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">an individual described in Section 162(a)(3) of the Code&#59; or </font></div><div style="margin-bottom:24pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">subject to the requirements of Section 16(a) of the Securities Exchange Act. </font></div><div style="margin-top:3pt;padding-left:1.82pt;padding-right:1.82pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.82pt;padding-right:1.82pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE A </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manner of Crediting Gains and Losses to Personal Investment Account <br>and Medtronic Core Contribution Account<br>Pursuant to Sections 6</font><font style="color:#666666;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3 and 7.3, respectively </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Personal Investment Accounts and Medtronic Core Contribution Accounts of Participants shall be credited with gains and losses as if invested in one or more of the investments funds available under the Medtronic Savings and Investment Plan and as communicated to the Participants from time to time, in the proportions designated by the Participant on an investment election form submitted to the Company by the Participant. The investment election form shall be submitted to the Company in the form and manner specified by the Committee, which may be electronically pursuant to Section 13.11. Until and unless changed by the Committee, Participants shall be permitted to change investment elections, generally, on a business daily basis. </font></div><div><font><br></font></div><div style="margin-top:3.45pt;padding-left:200.4pt;padding-right:200.4pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:200.4pt;padding-right:200.4pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE B<br>Special Benefits </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Schedule B describes special benefits for certain participants. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Benefit for Geoffrey S. Martha</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the terms of this Schedule 8.1, the Company will pay to Geoffrey S. Martha (&#8220;Mr. Martha&#8221;) the following amount as a Plan benefit, in addition to the benefit otherwise payable to him under the Plan&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The lump sum present value of the amount that Mr. Martha would have received under the GE Pension Plan as of the date of his Separation from Service with the Company, less the sum of&#58; (a) the value of Mr. Martha&#8217;s vested Personal Investment Account as of this date&#59; (b) the lump sum present value of the vested benefit that Mr. Martha is entitled to receive under the Plan (other than provided under this Schedule 8.1) as of this date&#59; and (c) the lump sum present value of the benefit that Mr. Martha is actually entitled to receive under the GE Pension Plan as of this date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The lump sum present value of the GE Pension Plan benefit as of the Date of Separation from Service with the Company will be determined based on the following assumptions&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Martha remained employed with the GE Company (&#8220;GE&#8221;) on a full-time basis and continued to accrue benefits under the GE Pension Plan until his Separation from Service with the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No benefit related to or derived from employee contributions, e.g., &#8220;Personal Pension Account&#8221; or &#8220;Voluntary Pension Account&#8221; under the GE Pension Plan, is included in determining the value&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Martha&#8217;s salary with GE increased at the rate of 3% per year starting with the date of his employment with the Company and ending with the date of his Separation from Service with the Company&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actuarial assumptions applicable to the Retirement Plan (rather than the GE Pension Plan) as of Mr. Martha&#8217;s Separation from Service apply. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes hereof, the &#8220;GE Pension Plan&#8221; means the qualified GE Pension Plan as in effect on the date that Mr. Martha first becomes employed by the Company (and assuming that the terms of such plan do not change thereafter). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Martha&#8217;s Plan benefit under this Schedule B.I will vest in, and be paid to him (or his Beneficiary) at the same time and in the same manner as his Plan benefit (other than the benefit provided under this Schedule B.I). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.&#160;&#160;&#160;&#160;Special Benefit for Hooman Hakami. Subject to the terms of this Schedule B.II, the Company will pay to Hooman Hakami (&#8220;Mr. Hakami&#8221;) the following amount as a Plan benefit in addition to the benefit otherwise payable to him under the Plan&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The lump sum present value of the amount that Mr. Hakami would have received under the GE Pension Plan as of the date of his Separation from Service, less the sum of&#58; (a) the value of Mr. Hakami&#8217;s vested Personal Investment Account under the Savings and Investment Plan as of the date of Mr. Hakami&#8217;s Separation from Service&#59; (b) the lump sum present value of the vested benefit that Mr. Hakami is entitled to receive under the Plan (other than the benefit provided under this Schedule B.II) as of the date of Mr. Hakami&#8217;s Separation from Service&#59; and (c) the lump sum present value of the benefit that Mr. Hakami is entitled to receive under the GE Pension Plan as of the date of Mr. Hakami&#8217; s Separation from Service. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The lump sum present value of the GE Pension Plan benefit as of the date of Mr. Hakami&#8217;s Separation from Service will be determined based on the following assumptions&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)Mr. Hakami remained employed with the GE Company (&#8220;GE&#8221;) on a full-time basis and continued to accrue benefits under the GE Pension Plan until the date of Mr. Hakami&#8217;s Separation from Service&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)No benefit related to or derived from employee contributions, e.g., &#8220;Personal Pension Account&#8221; or &#8220;Voluntary Pension Account&#8221; under the GE Pension Plan, is included in determining the value&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)Mr. Hakami&#8217;s salary with GE increased at the rate of three percent (3%) per year starting with the date of his employment with the Company and ending with the date of his Separation from Service&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)The actuarial assumptions applicable to the Retirement Plan (rather than the GE Pension Plan) as of Mr. Hakami&#8217;s Separation from Service apply. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes hereof, the &#8220;GE Pension Plan&#8221; means the qualified GE Pension Plan as in effect on the date that Mr. Hakami first becomes employed by the Company (and assuming that the terms of such plan do not change thereafter). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Hakami&#8217;s Plan benefit under this Schedule B.II will vest in, and be paid to him (or his Beneficiary) at the same time and in the same manner as Mr. Hakami&#8217;s Personal Investment Account Supplemental Benefit under the Plan, and the benefit provided under this Schedule B.II shall be added to that Account for purposes of calculation and payment of the combined Schedule B.II benefit and Personal Investment Account Supplemental Benefit. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">III.&#160;&#160;&#160;&#160;Special Benefit for Thierry Pieton. The Company will credit to the Account established for Thierry Pieton (&#8220;Mr. Pieton&#8221;) an amount equal to 8% of Mr. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pieton&#8217;s base salary (which shall not include severance pay) and actual MIP payout (&#8220;8% Credits&#8221;), subject to the terms of this Plan and the following rules&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">(1) The 8% Credit attributable to Mr. Pieton&#8217;s base salary shall be made for each fiscal year up to and including the fiscal year in which Mr. Pieton attains age 62 and shall cease after that fiscal year.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">(2) The 8% Credit attributable to Mr. Pieton&#8217;s MIP shall be made for each fiscal year MIP payment, if any, made up to and including the fiscal year in which Mr. Pieton attains age 62 and shall cease after that fiscal year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>mdt-202510kxex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6d4c71ba19494001a0480a688278fefa_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 19</font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:32px;margin-bottom:5pt;vertical-align:text-bottom;width:132px"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:24pt;font-weight:700;line-height:100%">Global Insider Trading Policy</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Purpose</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Scope</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This policy applies to all Medtronic employees and members of the Board of Directors.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#1010eb;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Policy Statement (Details)</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">BACKGROUND</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Summary</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The federal securities laws prohibit any employee of Medtronic plc or its subsidiaries (collectively, the &#8220;Company&#8221;) or any member of its Board of Directors from purchasing or selling securities on the basis of material nonpublic information about the Company and other companies that may have transactions or business relationships with the Company, and from tipping material nonpublic information to others. These laws impose severe sanctions, including the possibility of significant prison sentences, on individuals who violate them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">This insider trading policy is being adopted with the goal of helping&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to prevent inadvertent violations of the insider trading laws&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to avoid even the appearance of impropriety on the part of those employed by, or associated with, the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to protect the Company from controlling person liability&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">to protect the reputation of the Company, its Directors and its employees.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">What Type of Information Is &#8220;Material&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Information about the Company is considered material if a reasonable shareholder would consider the information important in making a decision to buy, hold or sell the Company&#8217;s securities. Any information that could be expected to affect the Company&#8217;s stock price, whether it is positive or negative, should be considered material. It is not possible to define all categories of material information, but information about any of the following subjects, including where applicable that the Company has plans or is in discussions with respect to any of these subjects, are examples of the type of information which is likely to be considered material&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the Company&#8217;s revenues or earnings&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant merger or acquisition involving the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">information concerning upcoming FDA actions or other significant legal or regulatory developments, including significant clinical trial results or a significant product recall&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in control or a significant change in management of the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the purchase or sale by the Company of a significant amount of its securities&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in the Company&#8217;s dividend or securities repurchase policies&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Insider Trading Policy 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a stock split&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a default on outstanding debt of the Company or a bankruptcy filing&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant product release, a significant development, invention or discovery, or significant legal or regulatory developments that affect the Company, including its intellectual property rights&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">significant licensing or collaboration discussions or agreements&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a significant cybersecurity incident, such as a data breach, or any other significant disruption in the Company&#8217;s operations, or loss, potential loss, breach or unauthorized access of its property, devices or information, whether at its facilities or through its information technology infrastructure&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a conclusion by the Company or a notification from its auditors that any of the Company&#8217;s previously issued financial statements should no longer be relied upon&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">a change in the Company&#8217;s auditors.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The above list is illustrative only and is not intended to provide a comprehensive list of circumstances that could give rise to material information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">When Is Information &#8220;Nonpublic&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Information concerning the Company is considered nonpublic if it has not been disseminated in a manner making it available to investors generally. Information will generally be considered nonpublic unless (1) the information has been disclosed in a press release, in a public filing made with the Securities and Exchange Commission (such as a Report on Form 10-K, Form 10-Q, or Form 8-K), on the Company&#8217;s Investor Relations website, or through a news wire service or broadly accessible news outlet, and (2) a sufficient amount of time has passed so that the information has had an opportunity to be disseminated within the marketplace, which will generally be upon the completion of one full trading day after the public disclosure. For example, if information is disclosed after-market on a Thursday, it would be considered broadly disseminated by the close of regular trading on Friday.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">What are &#8220;Securities&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#63;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The policy applies to transactions in Company common stock, options to purchase common stock, or any other type of securities issued by the Company, including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#8217;s Securities. This policy also applies to transactions in the securities of companies (1) with which the Company does business, such as the Company&#8217;s distributors, vendors, customers and suppliers, and (2) that are involved in a potential transaction or business relationship with Company.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">DEFINITIONS</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">As used in this policy, the following terms have the meanings specified below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Covered Persons</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all employees&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Directors&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all family members of Directors and employees who share the same address as, or are financially dependent upon, the Director or employee and any other person who shares the same address as the Director or employee (other than (1)&#160;an employee or tenant of the Director or employee or (2) another unrelated person whom the General Counsel, Corporate Secretary, an Assistant Secretary or another individual designated by the General Counsel or Corporate Secretary (each, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a member of the Corporate Secretary&#8217;s office) determines should not be covered by this policy)&#59; and</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all corporations, partnerships, trusts or other entities (other than the Company) controlled by any of the above persons, unless the entity has implemented policies or procedures designed to ensure that such person cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Designated Employees</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means a member of the Board of Directors of Medtronic plc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Executive Committee Members</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means employees of the Company who report to the Chief Executive Officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pre-Clearance Person</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Section 16 Officers</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> means employees of the Company subject to Section 16 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Trading Plan</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#8221;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> has the meaning given to such term in Section 6.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">GENERAL PROHIBITIONS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Prohibitions While Aware of Material Nonpublic Information</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Except as explicitly provided in Section 6, no Covered Person may&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">purchase, sell or donate any securities of the Company (or recommend to another person or entity that they do so) while aware of any material nonpublic information concerning the Company&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">disclose to any other person any material nonpublic information concerning the Company if such person may misuse that information, such as by purchasing or selling Company securities or tipping that information to others&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">purchase, sell or donate any securities of another company (or recommend to another person or entity that they do so) while aware of any material nonpublic information concerning such other company which the person or entity subject to this policy learned in the course of their service as a Director or employee of the Company&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">disclose to any other person any material nonpublic information concerning another company (which the person or entity subject to this policy learned in the course of their service as a Director or employee of the Company) if such person may misuse that information, such as by purchasing or selling that company&#8217;s securities or tipping that information to others.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Prohibitions on Short Sales and Derivative Transactions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Covered Person may&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">engage in short sales of Company securities, including short sales &#8220;against the box&#8221;&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">engage in purchases or sales of puts, calls or other derivative securities based on the Company&#8217;s securities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pledges, and Hedges</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Director or Section 16 Officer may (i) purchase Company securities on margin, borrow against Company securities held in a margin account, or pledge Company securities as collateral for a loan, or (ii)&#160;enter into hedging or monetization transactions or similar arrangements with respect to Company securities. The Company cautions and advises all other Covered Persons to seek their own legal counsel </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">in connection with purchasing Company securities on margin, borrowing against Company securities held in a margin account, or pledging Company securities as collateral for a loan, or (ii)&#160;entering into hedging or monetization transactions or similar arrangements with respect to Company securities.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reminder of Obligations After Cessation of Service</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">If a person ceases to be a Director or employee of the Company at a time when he or she is aware of material nonpublic information, the applicable prohibitions shall continue to apply to such person until that information has become public or is no longer material.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">TRADING PROHIBITIONS DURING RESTRICTED PERIODS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Quarterly Restricted Periods</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Except as explicitly provided in this policy, no person or entity listed below may purchase, sell or donate any securities of the Company during the period beginning the second Monday prior to the end of each fiscal quarter and ending upon the completion of one full trading day after the public announcement of earnings for such quarter (a &#8220;quarterly restricted period&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Persons Covered by Quarterly Restrictions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The quarterly restricted period prohibitions apply to&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Directors&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all Section 16 Officers, Executive Committee Members and employees who report to Executive Committee Members&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">such other employees as are designated from time to time by a member of the Corporate Secretary&#8217;s office as being subject to quarterly restricted period prohibitions (together with Section 16 Officer, Executive Committee Members and employees who report to Executive Committee Members, the &#8220;Designated Employees&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all family members of Directors and Designated Employees who share the same address as, or are financially dependent on, the Director or Designated Employee and any other person who shares the same address as the Director or Designated Employee (other than (1) an employee or tenant of the Director or Designated Employee or (2) another unrelated person whom a member of the Corporate Secretary&#8217;s office determines should not be covered by this policy)&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">all corporations, partnerships, trusts or other entities (other than the Company) controlled by any of the above persons, unless the entity has implemented policies or procedures designed to ensure that such person cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Corporate News Restricted Periods</font></div><div style="margin-bottom:12pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The Company may from time to time notify Directors and other employees that an additional restricted period (a &#8220;corporate news restricted period&#8221;) is in effect in view of significant events or developments involving the Company. In such event, except as explicitly provided in this policy, no such individual may purchase, sell or donate any securities of the Company during such corporate news restricted period or inform anyone else that a corporate news restricted period is in effect. (In this policy, quarterly restricted periods and corporate news restricted periods are each referred to as a &#8220;restricted period&#8221;.)</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">PRECLEARANCE BY DIRECTORS AND SECTION 16 OFFICERS</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Notice and Pre-Clearance of Transactions</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Pre-Transaction Clearance</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">No Director or Section 16 Officer (a &#8220;Pre-Clearance Person&#8221;) may purchase, sell, donate or otherwise acquire or dispose of securities of the Company (other than in a transaction that is excepted from this </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">policy under Section 6), or adopt, modify, or terminate any Trading Plan, unless such person pre-clears the transaction or plan with a member of the Corporate Secretary&#8217;s office. </font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">A request for pre-clearance shall be made in accordance with the procedures established by the Corporate Secretary. A member of the Corporate Secretary&#8217;s office shall have sole discretion to decide whether to clear any contemplated transaction or plan. (The Chief Financial Officer shall have sole discretion to decide whether to clear transactions by the General Counsel if the General Counsel is a Section 16 Officer.) </font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">All trades and plans that are pre- cleared must be effected (or adopted, amended, or terminated) within four business days of receipt of the pre-clearance unless a specific exception has been granted by a member of the Corporate Secretary&#8217;s office. A pre-cleared trade (or any portion of a pre-cleared trade) that has not been effected or a plan that has not been adopted, amended, or terminated during the four business day period must be pre-cleared again prior to execution. Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material non-public information or becomes subject to a restricted period before the transaction is effected, the transaction may not be completed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Post-Transaction Notice</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Each Pre-Clearance Person shall also ensure that a member of the Corporate Secretary&#8217;s office receives immediate notice of the occurrence of any purchase, sale or other acquisition or disposition of securities of the Company, and of the entry into, modification, or early termination of any plan that contemplates future transaction in Company securities. Such notification must be in writing (including by e-mail) and should include the identity of the covered person, the type of transaction, the date of the transaction, the number of shares involved and the purchase or sale price.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Deemed Time of a Transaction</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">  </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">For purposes of these notification obligations, a purchase, sale or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it (for example, in the case of an open market purchase or sale, when the trade is executed, not when it settles).</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">EXCEPTIONS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The prohibitions in Sections 3 and 4 on purchases, sales and donations of Company securities do not apply to&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations, in each case in a manner permitted by the applicable equity award agreement&#59; provided, however, that the securities so acquired may not be sold (either outright or in connection with a &#8220;cashless&#8221; exercise transaction through a broker) while the employee or Director is aware of material nonpublic information or, in the case of someone who is subject to a restricted period prohibition, during a restricted period&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">acquisitions or dispositions of Company common stock under the Company&#8217;s 401(k), employee stock purchase plan, individual account plan or dividend reinvestment plan which are made pursuant to standing instructions not entered into or modified while the employee or Director is aware of material nonpublic information or, in the case of someone who is subject to restricted period prohibition, during a restricted period&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">other purchases of securities directly from the Company or sales of securities directly to the Company&#59; or</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">transactions made pursuant to a binding contract, written plan or specific instruction (a &#8220;Trading Plan&#8221;) which is adopted and operated in compliance with Rule 10b5-1&#59; provided such Trading Plan complies with the Company&#8217;s Rule 10b5-1 Plan Guidelines included at the end of this policy.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The prohibitions in Sections 3 and 4 on donations of Company securities do not apply to bona fide gifts to family members or family trusts who are also subject to this policy under Section 3.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">PENALTIES FOR VIOLATION</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Violation of any of the foregoing rules is grounds for disciplinary action by the Company, including termination of employment for cause.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.43pt">OTHER MATTERS</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Regulation BTR</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">If the Company is required to impose a &#8220;pension fund blackout period&#8221; under Regulation BTR, each Director and Section 16 Officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with his or her service as a Director or officer of the Company, except as permitted by Regulation BTR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Limitation of Liability</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">None of the Company, the Chief Financial Officer, the General Counsel, members of the Corporate Secretary&#8217;s office or the Company&#8217;s other employees will have any liability for any action taken or inaction in connection with the administration of this insider trading policy. Notwithstanding any pre-clearance of a transaction described in Section 5 or review of a Trading Plan described in Section 6, none of the Company, the Chief Financial Officer, the General Counsel, members of the Corporate Secretary&#8217;s office or the Company&#8217;s other employees assumes any liability for the legality or consequences of such transaction or Trading Plan to the person engaging in or adopting such transaction or Trading Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Administration</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">The General Counsel is generally responsible for the administration of this policy, which includes authority to interpret and construe this policy and make determinations in connection with such administration. The General Counsel may select others to assist in such administration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:162%;text-decoration:underline">Questions</font></div><div style="margin-bottom:6pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:162%">Questions regarding this policy should be directed to a member of the Corporate Secretary&#8217;s office.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Rule 10b5-1 Guidelines</font></div><div style="padding-right:-6.75pt;text-align:center"><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MEDTRONIC PLC</font></div><div style="padding-right:-11.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 10b5-1 PLAN GUIDELINES</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 of the Securities and Exchange Act of 1934 provides a defense from insider trading liability for an insider of a publicly traded company (each a &#8220;Trading Individual&#8221;) who, at a time when they are not in possession of material nonpublic information (&#8220;MNPI&#8221;) and are not subject to any restricted period, sets up a plan or instruction to buy or sell stock that specifies in advance the amount, pricing and timing of transactions, or delegates discretion on these matters to an independent third party. The following guidelines have been adopted by Medtronic plc (the &#8220;Company&#8221;) to provide guidance on adopting and using trading plans under Rule 10b5-1 (each, a &#8220;10b5-1 Plan&#8221;) and apply to any Medtronic employee or director desiring to enter into a 10b5-1 Plan for Company securities.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The 10b5-1 Plan</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All 10b5-1 Plans must be in writing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Once a 10b5-1 Plan is adopted, a Trading Individual must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded, or the date of the trade. The 10b5-1 Plan must either specify in advance the amount, pricing and timing of transactions, establish in advance a formula or algorithm for determining the amount, price and timing of transactions, or delegate discretion on these matters to an independent third party who is not aware of MNPI when effecting purchases or sales.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Trading Individual must submit and receive approval from the Corporate Secretary or Assistant Secretary (or his&#47;her delegate) of a proposed Rule 10b5-1 Plan prior to adopting a 10b5-1 Plan or making any modification to an existing 10b5-1 Plan. No further pre-approval of transactions conducted pursuant to the Rule 10b5-1 Plan will be required.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">10b5-1 Plans should be for a minimum term of 6 months and include a specified expiration date, with a maximum term of two years.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Single transaction trading plans are strongly discouraged, and in no event may more than one single transaction plan be adopted in any 12-month period.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overlapping plans are not allowed, provided that Trading Individuals may enter into a &#8220;sell-to-cover&#8221; plan with respect to tax obligations that arise from the vesting of compensatory equity awards (but not the exercise of stock options) in addition to a traditional 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New and modified Rule 10b5-1 Plans must reflect a &#8220;cooling off&#8221; period before the first trade thereunder&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For directors and Section 16 officers, the first trade under a new or modified 10b5-1 Plan cannot occur until the later of (i) 90 days or (ii) or two business days after the filing of the next 10-K or 10-Q, but in any case, not longer than 120 days following the date of adoption of the 10b5-1 Plan or modification of the 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For persons other than directors or Section 16 officers, the first trade under a new or modified 10b5-1 Plan may not occur until 30 calendar days after the date of adoption of the 10b5-1 Plan or modification of the 10b-51 Plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trading plans must comply in all respects with the Company&#8217;s Global Insider Trading Policy and any other applicable Company policies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The 10b5-1 Plan must permit the Company to suspend trading for any Trading Individual who holds shares subject to an underwriting lockup, for the duration of such lockup. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The Trading Individual </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual may only adopt, modify or direct early termination of a 10b5-1 Plan at a time when he or she&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">is not in possession of MNPI regarding the Company or its securities&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">is not subject to any restricted period under the Company&#8217;s Global Insider Trading Policy.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and Section 16 officers must certify to the Company (either as part of the 10b5-1 Plan or by separate document) that (i) such individual is not in possession of MNPI at the time of entrance into </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or modification of the 10b5-1 Plan and (ii) such individual is adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions in Rule 10b-5. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When adopting, modifying, terminating earlier than the previously established expiration date or taking other action with respect to a 10b5-1 Plan, the Trading Individual must take any such action in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act or Rule 10b-5 promulgated under the Exchange Act. Therefore, although Trading Individuals are not prohibited from modifying or terminating existing Rule 10b5-1 Plans, a Rule 10b5-1 Plan should be adopted with the intention that it will not be amended or terminated prior to its expiration. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual should be aware that the Company will disclose the adoption, modification and termination of any 10b5-1 Plans by directors and Section 16 officers in its annual reports on Form 10-K and quarterly reports on Form 10-Q.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Trading Individual must agree to cooperate with the Company in any reporting and publicizing of the trading plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adoption of a trading plan does not preclude trading outside of the 10b5-1 Plan that otherwise is in accordance with the Company&#8217;s Global Insider Trading Policy. However&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trading Individuals may not enter into or alter corresponding transactions or positions, including hedging transactions, that reduce or eliminate the economic consequences of the transactions under the Rule 10b5-1 Plan.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trading Individuals may not engage in transactions outside of the 10b5-1 Plan if such transactions would affect the number of shares that can be sold under the 10b5-1 Plan (e.g., for Trading Individuals subject to Rule 144, an outside-the-plan transaction cannot reduce the pre-established volume of shares that can be sold under the 10b5-1 Plan).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Any Trading Individual who is a director or officer is cautioned to ensure that any trading outside of a 10b5-1 Plan does not create short swing profits with respect to potential transactions under the 10b5-1 Plan (i.e., if sales may occur under the 10b5-1 Plan, the Trading Person would generally want to avoid any purchases outside of the 10b5-1 Plan to avoid potential short swing profits if the purchase is at a lower price than any sale made within 6 months of the purchase).</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Insider Trading Policy 8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>mdt-202510kxex21.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if37c58e9c846410788a389b674116b50_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.489%"><tr><td style="width:1.0%"></td><td style="width:70.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Medtronic plc and Subsidiaries</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">At April 25, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2074417 Alberta ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products de Honduras S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honduras</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products do Brasil Ltda. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A&#38;E Products Group, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Medical Technologies GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affera, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AI Biomed Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aircraft Medical Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Airox </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arterial Vascular Engineering Canada, Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arterial Vascular Engineering UK Limited </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Suture do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avenu Medical, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batts LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Batts, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Between Investeringsgroep B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biostar Biomedikal M&#252;hendislik Anonim Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bo Yao (Shanghai) Medical Device Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CardioInsight Technologies Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlisle Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carmel Biosensors Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCI Istanbul Teknolojik Hizmetler Limited Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Chuangzhihui Incubator Management Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Kangdi Medical Stapler Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changzhou Kanghui Medical Innovation Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CircuLite, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comercial Medtronic Chile Limitada</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Medical, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien (China) Medical Devices Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien (Shanghai) Management Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Adhesives Italia Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien AG</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Argentina S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Canada Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Caribbean, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Delaware VI Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Eurasia LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien France Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Group Holdings Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Group S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Healthcare International Trading (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holding Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holdings International Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International (US) Holdings A, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International Finance S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien International S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Holdings Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Investments Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Israel Surgical Research Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Japan, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien llc</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien LP</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Manufacturing Grenoble</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Medical Products (Shanghai) Manufacturing L.L.C.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Peru S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Pty Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Sales LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Swiss Holding GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien UK Holding Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Uruguay S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien US Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covidien Ventures Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Davis &#38; Geck Caribe Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabeter Nederland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital Surgery Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epix Therapeutics, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ev3, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Lafayette Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floreane Medical Implants</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortimedix Assets II B.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortimedix Innovation B.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortimedix Surgical B.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortimedix USA, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GC Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia Packaging, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Given Imaging Vietnam Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Graphic Controls (Barbados), Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HBX, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartWare, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartWare International LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Egypt LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Lebanon Sarl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Health Services Pakistan (Private) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IHS Saglik Hizmetleri Ltd STI</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India Medtronic Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Health Solutions Chile S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Health Solutions International S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersect ENT, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invatec S.p.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invatec Technology Center GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kangaroo US HoldCo, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall de Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall de Venezuela, C.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KLHC, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Klue, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyphon South Africa (Proprietary) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Design Systems, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M-Smart Medical Technology (Shanghai) Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Makani II Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt DAR Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Holdings B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt Medical Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mallinckrodt US LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marblehead Medical LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mazor Robotics Ltd. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDT Sub Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDT Turkey Finansal Dan&#305;&#351;manl&#305;k Limited &#350;irketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Education Y. K.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Medtronic Nigeria Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicrea International </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicrea USA, Corp</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medina Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medinse S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic &#8211; Sequoia (Cayman) Innovation Investment Management Partners, Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Africa) (Proprietary) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Changzhou) Medical Devices Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Chengdu) Management Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Schweiz) A.G. (Medtronic (Suisse) S.A.)</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Shanghai) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Shanghai) Management Co. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Taiwan) Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic (Thailand) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ablation Frontiers LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Adriatic d.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Advanced Energy LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Advanced Energy Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic AF Luxembourg S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic AG</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Aktiebolag</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Arabia Regional Headquarter</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ardian Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic ATS Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Australasia Pty Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bakken Research Center B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bangladesh Pvt. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bangladesh</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Belgium S.A.&#47;N.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic BioPharma B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic BioPharma S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Bulgaria EOOD</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Canada ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Care Management Services, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Cash Pool LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Changzhou Medical Device Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China Kanghui Holdings</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China Venture Fund (Cayman), L.P.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic China, LLC.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Colombia S.A. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Comercial Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Comercial Panam&#225;, S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CoreValve LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Costa Rica. S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CryoCath LP</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic CV Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Czechia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Danmark A&#47;S</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Diabetes (Chengdu) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Dominican Republic S.A.S.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Dominicana (Manufactura), S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Egypt LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Empalme S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Engineering and Innovation Center Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Europe Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Europe S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Fabrication </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finance Holdings ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finance Hungary Kft.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Finland Oy</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic France </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Global Investments Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Global Holdings S.C.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic GP S.&#224; r.l. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Group Holding, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hellas Medical Device Commercial Single Member S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding Hungary Kft.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holding Switzerland G.m.b.H.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holdings France</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hong Kong Medical Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Hungaria Kereskedelmi Kft</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ib&#233;rica S.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Innovation Center (Israel) Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Integrated Health Solutions LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International, Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Holding LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Technology, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading Holding LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic International Trading S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Interventional Vascular, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Invatec LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic IP Holding International Luxembourg S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ireland Manufacturing Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Italia S.p.A.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Japan Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Jolife LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Kazakhstan Limited Liability Partnership</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic KL Holdings LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Korea Holdings Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Korea Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Labs PBC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Latin America, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Logistics LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Luxembourg Global Holdings S.&#224; r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Malaysia Operations Sdn. Bhd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic M E Trading LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Medical CR S de RL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Medikal Teknoloji Ticaret Limited Sirketi</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Mediterranean Offshore SAL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic META FZ-LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Mexico S. de R.L. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic MiniMed, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic MiniMed India Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Monitoring, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Navigation, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Navigation Israel Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic New Zealand Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Norge AS</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Oesterreich G.m.b.H.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Pacific Trading, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Pakistan (Private) Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Philippines, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Poland Sp. Z o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Poland Finance Sp.z.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Portugal, Lda</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic PS Medical, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Puerto Rico Operations Co.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic RCS Holding GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Romania SRL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic S. de R.L. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic S.A.I.C.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Saudi Arabia Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Servicios S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sequoia (Cayman) Innovation Investment Management Partners, Ltd. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Shared Services Americas S.A.S.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Shared Services SRL</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Singapore Operations Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Slovakia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek Deggendorf GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek USA, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sofamor Danek, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Srbija d.o.o. Beograd-Novi Beograd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Sweden Finance AB</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Trading Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Trading NL BV</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ukraine Limited Liability Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic ULN, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic USA, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vascular Galway Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vascular, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Ventor Technologies Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Vietnam Company Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic VT, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic World Trade Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Xomed, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic Xomed LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medtronic, trgovina z medicinsko tehnologijo in opremo d.o.o.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan Critical Care Consultants, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Micro Therapeutics, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Australia</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Canada ULC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Denmark ApS</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Distribution Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed France S.A.S.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Hellas Single Member LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Holding B.V.-</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Holdings Switzerland S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed International Trading S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Italy S.R.L. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Netherlands B.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Norway AS </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Philippines, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Portugal, Unipessoal Lda. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Pty Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Puerto Rico Operations Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Spain S.L.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Te Austria GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed Technologies Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiniMed (UK) Limited-</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMed Sweden AB</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMJ, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSCH LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N.G.C. Medical Srl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NayaMed International S&#224;rl</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N.O.K. Nederlandse Obesitas Kliniek B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederelandse Obesitas Kliniek Zuid B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederlandse Obesitas Kliniek West B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nederlandse Obesitas kliniek Zeeland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Ireland Holdings Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Ireland Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nellcor Puritan Bennett Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Wave Surgical, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Belgium B.V.                                                                                                 </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Finland Oy                                                                                                      </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Germany GmbH                                                                                          </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NPB Japan Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutrino Health Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesitas International B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesitas Nederland B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Old Colony State Insurance Company</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Capnography, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Medical 1987 Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oridion Systems Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteotech, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plastics Holding Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polyken Technologies Europe, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polysuture Industria e Comercio Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. Covidien Indonesia</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Medtronic Indonesia</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTB International LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raychem Tecnologias, S. de R.L. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail Group de Mexico S.A. de C.V. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RF Surgical Systems LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanatis GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sapheon LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MedTech Service Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Medtronic Zhikang Medical Devices Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Mei Jing Mwi Zhong Venture Capital Partnership (Limited Partnership) </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Mei Zhong Private Fund Management Co., Ltd. China</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MyanCor Medical Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherwood Medical Company I</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore MyanCor Medical Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Societe De Fabrication de Material Orthopedique En Abrege Sofamor</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sofradim Production</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SonarMed Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SpinalGraft Technologies, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Superdimension, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou Medtronic Venture Capital Partnership Enterprise (L.P.)</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou Medtronic-Sequoia Innovation Investment Management Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Titan Spine, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue Science Laboratories Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twelve, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.S.C. Puerto Rico, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.S.C. Puerto Rico (NY), Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Surgical Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USSC FSC, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USSC Medical GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valera Holdings S.&#224;.r.l.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valleylab Holding Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:70.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Medcure, Inc. </font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visionsense Corp.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visionsense Ltd.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitatron Holding B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VNUS Medical Technologies II, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warsaw Orthopedic Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEM Equipamentos Electronicos Ltda.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World Heart Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zephyr Technology LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zorginitiatieven B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr></table></div><div style="height:56.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>6
<FILENAME>mdt-202510kxex22.htm
<DESCRIPTION>EX-22
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie821e22ecdff496aa8b7656a1971f39a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 22</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Senior Notes, Issuers and Guarantors</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registered Senior Notes Issued Under</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuer</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantors</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of October 22, 2007</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covidien International Finance S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covidien Ltd., Covidien plc, Medtronic plc and Medtronic Global Holdings, S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of March 12, 2009</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic Global Holdings, S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indenture, dated as of December 10, 2014</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic Global Holdings S.C.A.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Indenture, dated as of March 28, 2017</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic Global Holdings S.C.A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc and Medtronic, Inc.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>7
<FILENAME>mdt-202510kxex23.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9f01955227414effb8e65f1de05f8eb2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">S-3 (No. 333-270272)</font><font style="color:#ff0000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">and Form S-8 (</font><font style="background-color:#ffffff;color:#242424;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">Nos. 333-201737, 333-221962, 333-261841, and 333-275959</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">) of Medtronic plc of our report dated June 20, 2025 relating to the financial statements,</font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">financial statement schedule</font><font style="color:#ff0000;font-family:'Georgia',serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">Minneapolis, Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>8
<FILENAME>mdt-202510kxex24.htm
<DESCRIPTION>EX-24
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5ad3ffc381fe4edc8b75d799caff7e08_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K. FONG and COURTNEY NELSON WILLS, acting individually or jointly, their true and lawful attorneys-in-fact and agents, with full power to act for them and in their name, place and stead, in any and all capacities, to do any and all acts and execute any and all documents which either such attorney and agent may deem necessary or desirable to enable Medtronic plc to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission in respect thereof, in connection with the filing with the Commission of Medtronic&#8217;s Annual Report on Form 10-K for the fiscal year ended April&#160;25, 2025, including specifically, but without limiting the generality of the foregoing, power and authority to sign the names of the undersigned directors to the Form 10-K and to any instruments and documents filed as part of or in connection with the Form 10-K or any amendments thereto&#59; and the undersigned hereby ratify and confirm all actions taken and documents signed by each said attorney and agent as provided herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned have set their hands this 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of June, 2025.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Craig Arnold</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Gregory P. Lewis</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Arnold</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory P. Lewis</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott C. Donnelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin E. Lofton</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott C. Donnelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin E. Lofton</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Lidia L. Fonseca</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lidia L. Fonseca</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Andrea Goldsmith, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Elizabeth G. Nabel, M.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrea Goldsmith, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth G. Nabel, M.D.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Randall J. Hogan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kendall J. Powell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randall J. Hogan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kendall J. Powell</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>mdt-202510kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5e8572fca17d41a09c3198e25527e7d6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Geoffrey S. Martha, certify that&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Medtronic plc&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:28.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>mdt-202510kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7701493a2009440da73e5a3185622031_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thierry Pi&#233;ton, certify that&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Medtronic plc&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thierry Pi&#233;ton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thierry Pi&#233;ton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>mdt-202510kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib1c476a09ed74ff3a9c6a6839e639397_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this annual report on Form 10-K of Medtronic plc for the fiscal year ended April&#160;25, 2025, the undersigned hereby certifies, in his capacity as Chief Executive Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey S. Martha </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey S. Martha </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>mdt-202510kxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieaa032c59cc242499706cc321fa6fe34_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this annual report on Form 10-K of Medtronic plc for the fiscal year ended April&#160;25, 2025, the undersigned hereby certifies, in his capacity as Chief Financial Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 20, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thierry Pi&#233;ton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thierry Pi&#233;ton</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>13
<FILENAME>mdt-202510kxex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie98bc1c70e314988ad2a1d2d76007c2a_1"></div><div style="min-height:62.64pt;width:100%"><div style="margin-bottom:1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97</font></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt solid #002855;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#002855;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:15.60pt">MEDTRONIC PLC</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#002855;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:15.60pt">POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Description</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Medtronic plc, an Irish public limited company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.  The Policy sets forth the circumstances under which the Company will recover certain incentive compensation paid to the Executive Officers of the Company in connection with certain financial restatements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">, pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy in exchange for adequate and reasonable consideration&#59; provided, however, that any failure by an Executive Officer to return a signed Acknowledgement Form does not affect the validity or enforceability of this Policy. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Definitions </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Clawback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means the three completed fiscal years immediately preceding the earlier of (i) the date the Company&#8217;s board of directors concludes, or reasonably should have concluded, that such a Covered Accounting Restatement is required to be prepared or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Clawback Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), and any transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means the Compensation Committee of the Board of Directors of the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Covered Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means an accounting restatement prepared due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial restatements (i.e., a &#8220;Big R&#8221; restatement), or that would result in a material misstatement if the error were corrected only in the current period or left uncorrected in the current period (i.e., a &#8220;little r&#8221; restatement).  For the avoidance of doubt, a Covered Accounting Restatement will not include changes to the Company&#8217;s financial statements that do not represent error corrections under accounting standards applicable to the Company at the time of the accounting restatement, including as a result of a (i) retrospective application of a change in accounting principle, (ii) retrospective revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization, (iii) retrospective reclassification due to a discontinued operation, (iv) retrospective application </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">of a change in reporting entity, and (v) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Covered Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means any Incentive-Based Compensation (i) received by a current or former Executive Officer after beginning service as an Executive Officer, provided that the current or former Executive Officer served as an Executive Officer at any time during the performance period applicable to such Incentive-Based Compensation and (ii) received on or after October 2, 2023 the (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;).  For purposes of this Policy, Incentive-Based Compensation is deemed to be &#8220;received&#8221; in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year, and regardless of whether the Incentive-Based Compensation continues to be subject to a service-based vesting condition.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:20.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; has the meaning assigned to it in Section 303A.14 of the New York Stock Exchange Listed Company Manual.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means (i) any measure determined in accordance with accounting principles used in the Company&#8217;s financial statements, whether presented in or outside of the Company&#8217;s financial statements and whether or not included in a filing with the Securities and Exchange Commission, (ii) any measures derived wholly or in part from such measures (including non-GAAP measures), and (iii) other performance measures affected by accounting-related information, including stock price, total shareholder return and relative total shareholder return.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221; means any compensation that is granted, earned or vested based wholly or in part on the attainment of any Financial Reporting Measure, which may include awards granted under the Company&#8217;s annual incentive plan as well as performance-based restricted stock units, and which may include Incentive-Based Compensation contributed to a plan, other than a tax-qualified retirement plan.  For the avoidance of doubt, Incentive-Based Compensation shall not include equity awards that vest solely based on continued service and were not granted based on the attainment of any financial reporting measure.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">General Rules</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event the Company determines it is required to prepare a Covered Accounting Restatement, the Committee shall review any Covered Incentive-Based Compensation received by a current or former Executive Officer of the Company during the Clawback Period. In the event the Committee determines that the amount of any such Covered Incentive-Based Compensation that was received during the Clawback Period exceeds the amount that otherwise would have been received had it been determined based on the restated results (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;), the amount of such Erroneously Awarded Compensation shall be recovered on a pre-tax basis.</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to the Covered Accounting Restatement. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">For purposes of this section, Incentive-Based Compensation is deemed to be &#8220;received&#8221; in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year.  </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Calculation of Erroneously Awarded Compensation</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event any applicable Covered Incentive-Based Compensation has been granted in the form of equity or equity-based awards, and such awards remain outstanding as of the Clawback Trigger Date, the Erroneously Awarded Compensation shall be calculated as the number of shares received in excess of the number that should have been received (or the corresponding value of such shares). In the event that any applicable Covered Incentive-Based Compensation is in a nonqualified deferred compensation plan, the Company shall calculate the amount contributed to the notional account based on the Erroneously Awarded Compensation and any earnings accrued to-date on that notional amount, and that sum shall be considered &#8220;Erroneously Awarded Compensation&#8221; with respect to that plan.   </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">For the avoidance of doubt, in the event Covered Incentive-Based Compensation is attained only partially based on the achievement of financial reporting measures, only the portion of such compensation based on or derived from the financial reporting measures shall be subject to recovery.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;In the event the Erroneously Awarded Compensation is not able to be calculated directly from information in an accounting restatement (e.g., equity awards subject to total shareholder return (&#8220;TSR&#8221;) or stock price measures), in order to determine the amount of such Erroneously Awarded Compensation that shall be subject to recovery, the Committee shall use a reasonable estimate of the effect of the Covered Accounting Restatement on the TSR or stock price upon which the Covered Incentive-Based Compensation was received.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Method for Recovery</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee shall, in its discretion, determine the appropriate means for recovery of any Erroneously Awarded Compensation, including but not limited to the cancellation of outstanding and future annual or long-term incentive compensation or requiring repayment by the applicable Executive Officer, provided that the recovery occurs reasonably promptly. The Committee may consider all applicable facts and circumstances in determining the appropriate means for recovery, including pursuing an appropriate balance of cost and speed.</font></div><div><font><br></font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Recovery shall be required in all circumstances unless the Committee determines that recovery would be impracticable and that one of the conditions set forth in Section 303A.14(c)(1)(iv)(A), (B), or (C) of the New York Stock Exchange Listed Company Manual are met.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Non-Exclusive&#59; Conflicts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;This Policy is in addition to any and all other rights the Company may have to pursue remedies against an employee or former employee in connection with an accounting restatement or for misconduct or similar behavior in the course of employment by the Company, all of which are expressly retained by the Company.  Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company pursuant to the terms of the Company&#8217;s Incentive Compensation Forfeiture Policy and any similar policy in any employment agreement, equity award agreement or similar agreement or any other legal remedies available to the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The Company will not enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company&#8217;s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The provisions of this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Indemnification Prohibition</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The Company is not permitted to indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company&#8217;s enforcement of its rights under this Policy. The Company is also prohibited from paying or reimbursing an Executive Officer for purchasing insurance to cover any such loss. To the extent of a conflict with any agreement with an Executive Officer that purports to provide indemnification rights to the Executive Officer that conflict with the foregoing, this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).  </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Amendment or Termination</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee may amend or terminate this Policy from time to time in its discretion, including as required to comply with any applicable law or regulation.  Any such amendment will be binding on employees who continue in employment after the effective date of such amendment.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Administration</font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. The Committee has full and final authority to make all determinations under this Policy, in each case to the extent permitted under applicable rules and regulations and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Committee hereunder shall be final, conclusive and binding on all persons. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Any action or inaction by the Committee with respect to an Executive Officer under this Policy in no way limits the Committee&#8217;s actions or decisions not to act with respect to any other Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Executive Officer other than as set forth in this Policy. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">This Policy is intended to comply with the requirements set forth in Section 303A.14 of the New York Stock Exchange Listed Company Manual (as such rule may be amended) and shall be construed and interpreted in accordance with such intent. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Successors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;This Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators, and other legal representatives.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Governing Law&#59; Venue</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">The validity, enforceability, construction and interpretation of this Policy shall be governed by the laws of the State of Minnesota.  Any dispute regarding this Policy shall be exclusively decided by a state court in the State of Minnesota&#59; provided that if such court declines to exercise jurisdiction, the dispute shall be decided by the U.S. District Court for the District of Minnesota.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt"> </font></div><div style="height:62.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="margin-bottom:1pt"><font><br></font></div></div></div><div id="ie98bc1c70e314988ad2a1d2d76007c2a_4"></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div style="margin-bottom:1pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Acknowledgement Form</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Medtronic plc </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">Policy for the Recovery of Erroneously Awarded Compensation</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Medtronic plc Policy for the Recovery of Erroneously Awarded Compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;). Capitalized terms used but not otherwise defined in this Acknowledgement Form (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">Acknowledgement Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#8221;) shall have the meanings ascribed to such terms in the Policy. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">By signing this Acknowledgement Form, the undersigned acknowledges and agrees that, in exchange for receipt of adequate and reasonable consideration, the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#8217;s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner permitted by, the Policy and the Committee&#8217;s determinations thereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Signature</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Printed Name</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:15.60pt">&#160;&#160;&#160;&#160;Date</font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>mdt-20250425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdt="http://www.medtronic.com/20250425" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.medtronic.com/20250425">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20250425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20250425_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20250425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20250425_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.medtronic.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.medtronic.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome">
        <link:definition>9952151 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952152 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952153 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>9952156 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.medtronic.com/role/Revenue">
        <link:definition>9952159 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements">
        <link:definition>9952160 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCharges" roleURI="http://www.medtronic.com/role/RestructuringCharges">
        <link:definition>9952161 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.medtronic.com/role/FinancialInstruments">
        <link:definition>9952162 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangements" roleURI="http://www.medtronic.com/role/FinancingArrangements">
        <link:definition>9952163 - Disclosure - Financing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagement" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement">
        <link:definition>9952164 - Disclosure - Derivatives and Currency Exchange Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.medtronic.com/role/Inventories">
        <link:definition>9952165 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>9952166 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipment">
        <link:definition>9952167 - Disclosure - Property, Plant, and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.medtronic.com/role/ShareholdersEquity">
        <link:definition>9952168 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlans" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlans">
        <link:definition>9952169 - Disclosure - Stock Purchase and Award Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.medtronic.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.medtronic.com/role/EarningsPerShare">
        <link:definition>9952171 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlans" roleURI="http://www.medtronic.com/role/RetirementBenefitPlans">
        <link:definition>9952172 - Disclosure - Retirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.medtronic.com/role/Leases">
        <link:definition>9952173 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>9952174 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.medtronic.com/role/CommitmentsandContingencies">
        <link:definition>9952175 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformation">
        <link:definition>9952176 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.medtronic.com/role/SubsequentEvents">
        <link:definition>9952177 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.medtronic.com/role/RevenueTables">
        <link:definition>9955512 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables">
        <link:definition>9955513 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesTables" roleURI="http://www.medtronic.com/role/RestructuringChargesTables">
        <link:definition>9955514 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.medtronic.com/role/FinancialInstrumentsTables">
        <link:definition>9955515 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsTables" roleURI="http://www.medtronic.com/role/FinancingArrangementsTables">
        <link:definition>9955516 - Disclosure - Financing Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementTables" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables">
        <link:definition>9955517 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.medtronic.com/role/InventoriesTables">
        <link:definition>9955518 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>9955519 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9955520 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansTables" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables">
        <link:definition>9955521 - Disclosure - Stock Purchase and Award Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.medtronic.com/role/IncomeTaxesTables">
        <link:definition>9955522 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.medtronic.com/role/EarningsPerShareTables">
        <link:definition>9955523 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansTables" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansTables">
        <link:definition>9955524 - Disclosure - Retirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.medtronic.com/role/LeasesTables">
        <link:definition>9955525 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>9955526 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationTables">
        <link:definition>9955527 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955528 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails">
        <link:definition>9955529 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails">
        <link:definition>9955530 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails">
        <link:definition>9955531 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails">
        <link:definition>9955532 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails">
        <link:definition>9955533 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails">
        <link:definition>9955534 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails">
        <link:definition>9955535 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails">
        <link:definition>9955536 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails" roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails">
        <link:definition>9955537 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesNarrativeDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails">
        <link:definition>9955538 - Disclosure - Restructuring Charges - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesClassificationofRestructuringCostsDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails">
        <link:definition>9955539 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails">
        <link:definition>9955540 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails">
        <link:definition>9955541 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails">
        <link:definition>9955542 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9955543 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails">
        <link:definition>9955544 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails">
        <link:definition>9955545 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDebtandEquitySecuritiesDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails">
        <link:definition>9955546 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails" roleURI="http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails">
        <link:definition>9955547 - Disclosure - Financial Instruments - Gains and Losses on Equity and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsCurrentDebtObligationsDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails">
        <link:definition>9955548 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsNarrativeDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails">
        <link:definition>9955549 - Disclosure - Financing Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsLongtermDebtDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails">
        <link:definition>9955550 - Disclosure - Financing Arrangements - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsLongtermDebtMaturitiesDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails">
        <link:definition>9955551 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingArrangementsSupplierFinancingProgramDetails" roleURI="http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails">
        <link:definition>9955552 - Disclosure - Financing Arrangements - Supplier Financing Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails">
        <link:definition>9955553 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails">
        <link:definition>9955554 - Disclosure - Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails">
        <link:definition>9955555 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>9955556 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails">
        <link:definition>9955557 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955558 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails">
        <link:definition>9955559 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1">
        <link:definition>9955559 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.medtronic.com/role/InventoriesDetails">
        <link:definition>9955560 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails">
        <link:definition>9955561 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>9955562 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails">
        <link:definition>9955563 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>9955564 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9955565 - Disclosure - Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails">
        <link:definition>9955566 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansNarrativeDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails">
        <link:definition>9955567 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails">
        <link:definition>9955568 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansValuationAssumptionsDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails">
        <link:definition>9955569 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansStockOptionsActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails">
        <link:definition>9955570 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansRestrictedStockActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails">
        <link:definition>9955571 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails">
        <link:definition>9955572 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails">
        <link:definition>9955573 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitProvisionDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails">
        <link:definition>9955574 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955575 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1">
        <link:definition>9955575 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955576 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955577 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" roleURI="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails">
        <link:definition>9955578 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails">
        <link:definition>9955579 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>9955580 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansNarrativeDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails">
        <link:definition>9955581 - Disclosure - Retirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails">
        <link:definition>9955582 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansNetPeriodicCostandAOCIDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails">
        <link:definition>9955583 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails">
        <link:definition>9955584 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansFairValueMeasurementDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails">
        <link:definition>9955585 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitPlansFutureBenefitPaymentsDetails" roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails">
        <link:definition>9955586 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails">
        <link:definition>9955587 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" roleURI="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails">
        <link:definition>9955588 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofTotalOperatingLeaseCostDetails" roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails">
        <link:definition>9955589 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>9955590 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeasesDetails" roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails">
        <link:definition>9955591 - Disclosure - Leases - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeasesDetails_1" roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1">
        <link:definition>9955591 - Disclosure - Leases - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossDetails" roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails">
        <link:definition>9955592 - Disclosure - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955593 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationNarrativeDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails">
        <link:definition>9955594 - Disclosure - Segment and Geographic Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationSegmentReportingDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails">
        <link:definition>9955595 - Disclosure - Segment and Geographic Information - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails">
        <link:definition>9955596 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails">
        <link:definition>9955597 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>9955598 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mdt_A0.250SeniorNotesDue2025Member" abstract="true" name="A0.250SeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A0.000SeniorNotesDue2025Member" abstract="true" name="A0.000SeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A2.625SeniorNotesDue2025Member" abstract="true" name="A2.625SeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.125SeniorNotesDue2027Member" abstract="true" name="A1.125SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A0.375SeniorNotesDue2028Member" abstract="true" name="A0.375SeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3.000SeniorNotesDue2029Member" abstract="true" name="A3.000SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3.650SeniorNotesDue2029Member" abstract="true" name="A3.650SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.625SeniorNotesDue2031Member" abstract="true" name="A1.625SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.000SeniorNotesDue2031Member" abstract="true" name="A1.000SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3.125SeniorNotesDue2031Member" abstract="true" name="A3.125SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A0.750SeniorNotesDue2032Member" abstract="true" name="A0.750SeniorNotesDue2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3.375SeniorNotesDue2034Member" abstract="true" name="A3.375SeniorNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A3.875SeniorNotesDue2036Member" abstract="true" name="A3.875SeniorNotesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A2.250SeniorNotesDue2039Member" abstract="true" name="A2.250SeniorNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.500SeniorNotesDue2039Member" abstract="true" name="A1.500SeniorNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.375SeniorNotesDue2040Member" abstract="true" name="A1.375SeniorNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A4.150SeniorNotesDue2043Member" abstract="true" name="A4.150SeniorNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.750SeniorNotesDue2049Member" abstract="true" name="A1.750SeniorNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A1.625SeniorNotesDue2050Member" abstract="true" name="A1.625SeniorNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_A4.150SeniorNotesDue2053Member" abstract="true" name="A4.150SeniorNotesDue2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" abstract="false" name="RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_IncomeTaxesandInterestPaidAbstract" abstract="true" name="IncomeTaxesandInterestPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" abstract="false" name="OtherOperatingIncomeExpenseNetPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" abstract="false" name="OtherNonoperatingIncomeExpenseNetPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" abstract="false" name="EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_ScheduleOfInvestmentsTableTextBlock" abstract="false" name="ScheduleOfInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" abstract="false" name="FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mdt_TotalReportableSegmentsMember" abstract="true" name="TotalReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_CardiovascularMember" abstract="true" name="CardiovascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_NeuroscienceGroupMember" abstract="true" name="NeuroscienceGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_MedicalSurgicalMember" abstract="true" name="MedicalSurgicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DiabetesGroupMember" abstract="true" name="DiabetesGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_CardiacRhythmandHeartFailureDivisionMember" abstract="true" name="CardiacRhythmandHeartFailureDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_StructuralHeartAndAorticDivisionMember" abstract="true" name="StructuralHeartAndAorticDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CoronaryAndPeripheralVascularDivisionMember" abstract="true" name="CoronaryAndPeripheralVascularDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CranialAndSpinalTechnologiesDivisionMember" abstract="true" name="CranialAndSpinalTechnologiesDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SpecialtyTherapiesDivisionMember" abstract="true" name="SpecialtyTherapiesDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_NeuromodulationDivisionMember" abstract="true" name="NeuromodulationDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SurgicalInnovationsDivisionMember" abstract="true" name="SurgicalInnovationsDivisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AcuteCareMonitoringMember" abstract="true" name="AcuteCareMonitoringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_OtherAccruedExpensesMember" abstract="true" name="OtherAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_VentilatorProductLineExitMember" abstract="true" name="VentilatorProductLineExitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_RenalCareSolutionsMember" abstract="true" name="RenalCareSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_MozarcMember" abstract="true" name="MozarcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" abstract="true" name="BusinessAcquisitionContingentConsiderationAtFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_BusinessAcquisitionPriceContingentConsideration" abstract="false" name="BusinessAcquisitionPriceContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" abstract="false" name="BusinessAcquisitionContingentConsiderationMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_RevenueMilestoneMember" abstract="true" name="RevenueMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_ProductDevelopmentMilestoneMember" abstract="true" name="ProductDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_BusinessAcquisitionContingentConsiderationRollForward" abstract="true" name="BusinessAcquisitionContingentConsiderationRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EnterpriseExcellenceMember" abstract="true" name="EnterpriseExcellenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SimplificationRestructuringProgramMember" abstract="true" name="SimplificationRestructuringProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" abstract="true" name="IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AssociatedAndOtherCostsMember" abstract="true" name="AssociatedAndOtherCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_RestructuringChargesIncludingAccrualAdjustments" abstract="false" name="RestructuringChargesIncludingAccrualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" abstract="true" name="DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_EquityInvestmentsMember" abstract="true" name="EquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" abstract="false" name="EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_GainOnInvestments" abstract="false" name="GainOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_LossOnInvestments" abstract="false" name="LossOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ScheduleOfDebtTable" abstract="true" name="ScheduleOfDebtTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20260250PercentMember" abstract="true" name="SeniorNotes2019Due20260250PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due20260.000PercentMember" abstract="true" name="SeniorNotes2020Due20260.000PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due20262.625PercentMember" abstract="true" name="SeniorNotes2022Due20262.625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_DebtLineItems" abstract="true" name="DebtLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_A2015And2020CommercialPaperProgramMember" abstract="true" name="A2015And2020CommercialPaperProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AmendedandRestatedRevolvingCreditAgreementMember" abstract="true" name="AmendedandRestatedRevolvingCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_MedtronicLuxcoSeniorNotesMember" abstract="true" name="MedtronicLuxcoSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due20253.500PercentMember" abstract="true" name="SeniorNotes2015Due20253.500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2017Due20273.350PercentMember" abstract="true" name="SeniorNotes2017Due20273.350PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_MedtronicLuxcoMember" abstract="true" name="MedtronicLuxcoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_CommercialPaperMaximumBorrowingCapacity" abstract="false" name="CommercialPaperMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_LineOfCreditFacilityLengthOfExtension" abstract="false" name="LineOfCreditFacilityLengthOfExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DebtInstrumentNumberofTranches" abstract="false" name="DebtInstrumentNumberofTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20271125PercentMember" abstract="true" name="SeniorNotes2019Due20271125PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2023Due20284.250PercentMember" abstract="true" name="SeniorNotes2023Due20284.250PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due20293.000PercentMember" abstract="true" name="SeniorNotes2022Due20293.000PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due20290375PercentMember" abstract="true" name="SeniorNotes2020Due20290375PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2024Due20303.650PercentMember" abstract="true" name="SeniorNotes2024Due20303.650PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20311625PercentMember" abstract="true" name="SeniorNotes2019Due20311625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20321000PercentMember" abstract="true" name="SeniorNotes2019Due20321000PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due20323.125PercentMember" abstract="true" name="SeniorNotes2022Due20323.125PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due20330750PercentMember" abstract="true" name="SeniorNotes2020Due20330750PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2023Due20334.500PercentMember" abstract="true" name="SeniorNotes2023Due20334.500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2022Due20353.375PercentMember" abstract="true" name="SeniorNotes2022Due20353.375PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due20354.375PercentMember" abstract="true" name="SeniorNotes2015Due20354.375PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2024Due20373.875PercentMember" abstract="true" name="SeniorNotes2024Due20373.875PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_CIFSASeniorNotes2007Due20386.550PercentMember" abstract="true" name="CIFSASeniorNotes2007Due20386.550PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20392250PercentMember" abstract="true" name="SeniorNotes2019Due20392250PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2009Due20396500PercentMember" abstract="true" name="SeniorNotes2009Due20396500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20401500PercentMember" abstract="true" name="SeniorNotes2019Due20401500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2010Due20405550PercentMember" abstract="true" name="SeniorNotes2010Due20405550PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due20411375PercentMember" abstract="true" name="SeniorNotes2020Due20411375PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2012Due20424500PercentMember" abstract="true" name="SeniorNotes2012Due20424500PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2013Due20434000PercentMember" abstract="true" name="SeniorNotes2013Due20434000PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2024Due20444.150PercentMember" abstract="true" name="SeniorNotes2024Due20444.150PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2014Due20444625PercentMember" abstract="true" name="SeniorNotes2014Due20444625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2015Due20454625PercentMember" abstract="true" name="SeniorNotes2015Due20454625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2019Due20501750PercentMember" abstract="true" name="SeniorNotes2019Due20501750PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2020Due20511625PercentMember" abstract="true" name="SeniorNotes2020Due20511625PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SeniorNotes2024Due20544.150PercentMember" abstract="true" name="SeniorNotes2024Due20544.150PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" abstract="false" name="UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" abstract="false" name="DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OffsettingAssetsandLiabilitiesTable" abstract="true" name="OffsettingAssetsandLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mdt_OffsettingAssetsandLiabilitiesLineItems" abstract="true" name="OffsettingAssetsandLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DerivativeAssetLiabilityAbstract" abstract="true" name="DerivativeAssetLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" abstract="false" name="DerivativeAssetLiabilityFairValueGrossAssetLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" abstract="false" name="DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_RenalCareBusinessRCSMember" abstract="true" name="RenalCareBusinessRCSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_AcceleratedAmortizationOfIntangibleAssets" abstract="false" name="AcceleratedAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_PurchasedTechnologyAndPatentsMember" abstract="true" name="PurchasedTechnologyAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_BuildingsAndLeaseholdImprovementsMember" abstract="true" name="BuildingsAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DeferredStockSharesAuthorized" abstract="false" name="DeferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_DeferredStockParorStatedValuePerShare" abstract="false" name="DeferredStockParorStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_DeferredStockSharesIssued" abstract="false" name="DeferredStockSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_DeferredStockSharesOutstanding" abstract="false" name="DeferredStockSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_StockRepurchaseProgramAveragePurchasePrice" abstract="false" name="StockRepurchaseProgramAveragePurchasePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneStockAwardAndIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_A2024EmployeeStockPurchasePlanMember" abstract="true" name="A2024EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mdt_EmployeesStockPurchasePlanMember" abstract="true" name="EmployeesStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" abstract="false" name="DeferredTaxAssetsResearchAndDevelopmentCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsLeaseObligations" abstract="false" name="DeferredTaxAssetsLeaseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsInterestLimitation" abstract="false" name="DeferredTaxAssetsInterestLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" abstract="false" name="DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" abstract="false" name="DeferredTaxLiabilitiesInvestmentInSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" abstract="false" name="DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" abstract="true" name="DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsNetofValuationAllowanceOther" abstract="false" name="DeferredTaxAssetsNetofValuationAllowanceOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" abstract="false" name="EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_IncomeTaxExaminationInterestIncomeExpenseGross" abstract="false" name="IncomeTaxExaminationInterestIncomeExpenseGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_IncreaseDecreaseInTaxRateAbstract" abstract="true" name="IncreaseDecreaseInTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" abstract="false" name="EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" abstract="true" name="UnrecognizedTaxBenefitsGrossIncreasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" abstract="true" name="UnrecognizedTaxBenefitsGrossDecreasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mdt_CashAdvancePaidinConnectionWithProposedSettlements" abstract="false" name="CashAdvancePaidinConnectionWithProposedSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" abstract="false" name="UnrecognizedTaxBenefitsNetofCashAdvancePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherPlanAssetsMember" abstract="true" name="OtherPlanAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" abstract="false" name="DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" abstract="false" name="DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" abstract="false" name="ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mdt_PartnershipUnitsMember" abstract="true" name="PartnershipUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_RegisteredInvestmentCompanyMember" abstract="true" name="RegisteredInvestmentCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_InsuranceContractMember" abstract="true" name="InsuranceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_HerniaMeshLitigationMember" abstract="true" name="HerniaMeshLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_ColibriMember" abstract="true" name="ColibriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_DiabetesPumpRetainerRingLitigationMember" abstract="true" name="DiabetesPumpRetainerRingLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mdt_OtherSegmentMember" abstract="true" name="OtherSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mdt_CorporateOverhead" abstract="false" name="CorporateOverhead" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_CentralizedDistributionCosts" abstract="false" name="CentralizedDistributionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_ForeignCurrencyCosts" abstract="false" name="ForeignCurrencyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_MedicalDeviceRegulations" abstract="false" name="MedicalDeviceRegulations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" abstract="false" name="CommitmentsToTheMedtronicFoundationAndMedtronicLABS" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_TotalOtherCountriesExcludingIrelandMember" abstract="true" name="TotalOtherCountriesExcludingIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" abstract="true" name="TotalOtherCountriesExcludingUnitedStatesandIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>mdt-20250425_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d7c2d61-9036-4a49-8d6d-13a25d164725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d7c2d61-9036-4a49-8d6d-13a25d164725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_26313634-ec9a-47ea-95e4-042ee3735f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_26313634-ec9a-47ea-95e4-042ee3735f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_55547362-56bb-455b-b694-a9cd0e021609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_55547362-56bb-455b-b694-a9cd0e021609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_20e4af3f-b73d-485e-bb4e-c2fee4416632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_20e4af3f-b73d-485e-bb4e-c2fee4416632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_604c57f3-a873-4acf-9589-06bab03407f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_604c57f3-a873-4acf-9589-06bab03407f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_2d535332-cde1-473a-86c8-ee2a4d78ca56" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_2d535332-cde1-473a-86c8-ee2a4d78ca56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_44ae5c5e-f559-40e7-a180-3a5411efd37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_44ae5c5e-f559-40e7-a180-3a5411efd37c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_79122ed2-7aa4-4bcf-9379-2bf6facf8438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b030edbf-3c7f-48a0-8c24-79a7372558b2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_79122ed2-7aa4-4bcf-9379-2bf6facf8438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b5ce5e9-24de-498d-8c72-60c3222f4f57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9be75f47-bd56-49a2-a91a-77784519c330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0b5ce5e9-24de-498d-8c72-60c3222f4f57" xlink:to="loc_us-gaap_ProfitLoss_9be75f47-bd56-49a2-a91a-77784519c330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9cc4802-ba37-4b61-81ae-d84b2f47eee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0b5ce5e9-24de-498d-8c72-60c3222f4f57" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9cc4802-ba37-4b61-81ae-d84b2f47eee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_36f54ec0-ff9c-4804-a3a0-54c6ebcfc6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0eb80da9-ce1a-48a8-b447-59cd84f2a16e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_36f54ec0-ff9c-4804-a3a0-54c6ebcfc6d3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0eb80da9-ce1a-48a8-b447-59cd84f2a16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3db6135f-55e5-475a-af11-14a9f204706f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_36f54ec0-ff9c-4804-a3a0-54c6ebcfc6d3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3db6135f-55e5-475a-af11-14a9f204706f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ad97b79-bfc7-46ce-ae07-47b52ad94eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f28e392b-03db-4b65-942b-6e6b3e2d5472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ad97b79-bfc7-46ce-ae07-47b52ad94eb1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f28e392b-03db-4b65-942b-6e6b3e2d5472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b722adcb-6017-4853-8fb9-cd3848ecd303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ad97b79-bfc7-46ce-ae07-47b52ad94eb1" xlink:to="loc_us-gaap_OperatingIncomeLoss_b722adcb-6017-4853-8fb9-cd3848ecd303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_776827b2-b8e8-42c1-8e9e-288a22cea496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ad97b79-bfc7-46ce-ae07-47b52ad94eb1" xlink:to="loc_us-gaap_InterestExpenseNonoperating_776827b2-b8e8-42c1-8e9e-288a22cea496" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b23a481b-0298-461b-b52d-3b59364a2730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1e5a0d3a-aabe-4c26-b37e-9686cbdc6154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b23a481b-0298-461b-b52d-3b59364a2730" xlink:to="loc_us-gaap_ProfitLoss_1e5a0d3a-aabe-4c26-b37e-9686cbdc6154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_eab59b6b-93e7-418f-bd12-5c816756ca44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b23a481b-0298-461b-b52d-3b59364a2730" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_eab59b6b-93e7-418f-bd12-5c816756ca44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a7006691-6e54-4b4e-99ac-c9a1ec43fba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a7006691-6e54-4b4e-99ac-c9a1ec43fba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7e221a98-9c2f-4002-a783-94a911f6fd97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7e221a98-9c2f-4002-a783-94a911f6fd97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_6669fbfa-cfd6-4801-acf8-af2225df69f4" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:to="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_6669fbfa-cfd6-4801-acf8-af2225df69f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b0e44aca-b8f8-4542-b6bd-5e98a7230789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b0e44aca-b8f8-4542-b6bd-5e98a7230789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3179e5b0-1df1-48ed-9872-606eeee72cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0f21f0aa-d707-46df-94df-0bc7cbf0cb5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3179e5b0-1df1-48ed-9872-606eeee72cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ddd12858-d9d7-445f-8d8e-74d4c496c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_36ac82c0-8a94-4487-a4a8-20b40b702333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ddd12858-d9d7-445f-8d8e-74d4c496c2f2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_36ac82c0-8a94-4487-a4a8-20b40b702333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1e5cd73d-ab4a-42f3-967a-c198068ecf61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ddd12858-d9d7-445f-8d8e-74d4c496c2f2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1e5cd73d-ab4a-42f3-967a-c198068ecf61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8d265df8-3cb7-4946-b674-483014fce5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8d265df8-3cb7-4946-b674-483014fce5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_895fd55c-0113-4f5c-a65f-277d71d22f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_Goodwill_895fd55c-0113-4f5c-a65f-277d71d22f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1e6342c9-e821-44f3-87f1-d52d6a9ff39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1e6342c9-e821-44f3-87f1-d52d6a9ff39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3db501b2-a592-4a58-b08f-61fb6e2d1938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3db501b2-a592-4a58-b08f-61fb6e2d1938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_faf7076a-9fc0-48dc-bcbe-d7f862058121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_AssetsCurrent_faf7076a-9fc0-48dc-bcbe-d7f862058121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c24bfaac-e250-43b7-859f-bc202744923a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4c44795-96d9-481b-9a13-653eda270b33" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c24bfaac-e250-43b7-859f-bc202744923a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_535c2ba2-2ba4-46ef-9559-f8e9af297a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:to="loc_us-gaap_OtherAssetsCurrent_535c2ba2-2ba4-46ef-9559-f8e9af297a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9359b75-8761-463b-8eb0-9856ffa9f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9359b75-8761-463b-8eb0-9856ffa9f5d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ab595c45-53a4-4905-82dd-3d9d45ca6aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ab595c45-53a4-4905-82dd-3d9d45ca6aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_86d91021-c5b3-4ed5-81f3-7289b4a77313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:to="loc_us-gaap_InventoryNet_86d91021-c5b3-4ed5-81f3-7289b4a77313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_954c233b-3285-47cc-b53e-6ea2bb314766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8740bd8b-fe73-47e2-984c-71f5a1aa3c92" xlink:to="loc_us-gaap_ShortTermInvestments_954c233b-3285-47cc-b53e-6ea2bb314766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c27821b-e625-4f18-a43b-bb9677c6320a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2937c322-2d86-4cb2-bdc3-dca91a357086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c27821b-e625-4f18-a43b-bb9677c6320a" xlink:to="loc_us-gaap_Liabilities_2937c322-2d86-4cb2-bdc3-dca91a357086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1fefbc3a-ba57-4c52-a78a-a309b7f91027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c27821b-e625-4f18-a43b-bb9677c6320a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1fefbc3a-ba57-4c52-a78a-a309b7f91027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52c9453f-c1bc-4d4c-a401-5b8a4af1da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c27821b-e625-4f18-a43b-bb9677c6320a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52c9453f-c1bc-4d4c-a401-5b8a4af1da7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_db363d20-ad13-43e2-bb8b-6db8528c1e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_LiabilitiesCurrent_db363d20-ad13-43e2-bb8b-6db8528c1e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9fd4aaed-ba76-4d16-9009-62a3d10f4adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9fd4aaed-ba76-4d16-9009-62a3d10f4adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c059c08a-ad3c-448c-9354-99e9a3dd2e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c059c08a-ad3c-448c-9354-99e9a3dd2e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_4aae80d8-5011-47b6-aafc-a5f451242eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_4aae80d8-5011-47b6-aafc-a5f451242eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d0413a7c-1320-4260-986d-3c2a585695c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d0413a7c-1320-4260-986d-3c2a585695c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0850a522-5737-4907-aa28-364c6f2925a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1d890-d469-459a-abf4-9ef30a21504c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0850a522-5737-4907-aa28-364c6f2925a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7260e511-bb79-4138-9b0c-489c8db3e28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7260e511-bb79-4138-9b0c-489c8db3e28a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_9c17f420-cdc3-4aa6-a9ab-8d9297041637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:to="loc_us-gaap_DebtCurrent_9c17f420-cdc3-4aa6-a9ab-8d9297041637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_71bfcfe3-cf53-40d2-a0cc-c0bf81d87d58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:to="loc_us-gaap_AccountsPayableCurrent_71bfcfe3-cf53-40d2-a0cc-c0bf81d87d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_0653fd0a-a568-48e0-97dc-c77f9ec7933f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_0653fd0a-a568-48e0-97dc-c77f9ec7933f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_90129551-37dc-446c-a8f5-c804ab180170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cb461579-2deb-41d2-83dd-e8c65a20e70e" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_90129551-37dc-446c-a8f5-c804ab180170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c231d274-c973-4529-bccb-7213874e1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4a55278e-c635-45c6-b1af-6a0bd1266070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c231d274-c973-4529-bccb-7213874e1f96" xlink:to="loc_us-gaap_CommonStockValue_4a55278e-c635-45c6-b1af-6a0bd1266070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d19127bd-b19e-4818-9efe-bf41662e8145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c231d274-c973-4529-bccb-7213874e1f96" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d19127bd-b19e-4818-9efe-bf41662e8145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db6f56b1-af4e-400b-8bf4-db4b28f980e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c231d274-c973-4529-bccb-7213874e1f96" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db6f56b1-af4e-400b-8bf4-db4b28f980e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96c2d692-8a25-4419-a5e1-42c426fabc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c231d274-c973-4529-bccb-7213874e1f96" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96c2d692-8a25-4419-a5e1-42c426fabc3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_193c5fa0-40c9-45f1-b5aa-c4db8a90bce0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c3189496-a4fa-4db9-bffc-5e0bbc2191e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_193c5fa0-40c9-45f1-b5aa-c4db8a90bce0" xlink:to="loc_us-gaap_StockholdersEquity_c3189496-a4fa-4db9-bffc-5e0bbc2191e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a00cf64c-c751-4889-9061-a75e4cbbc073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_193c5fa0-40c9-45f1-b5aa-c4db8a90bce0" xlink:to="loc_us-gaap_MinorityInterest_a00cf64c-c751-4889-9061-a75e4cbbc073" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2c90b018-4738-4e43-8bae-59311de2a988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2c90b018-4738-4e43-8bae-59311de2a988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d5b9930e-b796-48a5-83b8-a2261293a683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d5b9930e-b796-48a5-83b8-a2261293a683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf787b2e-46e2-457d-8a9b-31b305116b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_ProfitLoss_bf787b2e-46e2-457d-8a9b-31b305116b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a51f6752-2da6-4987-9cc0-aad742a71ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a51f6752-2da6-4987-9cc0-aad742a71ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_94cb9cb9-ad8e-4ed8-8fba-07aacf4aebe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_94cb9cb9-ad8e-4ed8-8fba-07aacf4aebe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_7b96d324-e8a8-4286-bd17-8c5ff98e9371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_7b96d324-e8a8-4286-bd17-8c5ff98e9371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efde5f25-88fd-47e1-be6e-8d8fc4297d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efde5f25-88fd-47e1-be6e-8d8fc4297d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4b00c834-a32e-480a-956a-ef8a62bdbf98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4b00c834-a32e-480a-956a-ef8a62bdbf98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8cb70c9e-b4df-4ef4-95e0-09351d587ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8cb70c9e-b4df-4ef4-95e0-09351d587ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a2d18228-5900-4437-997e-1e5d6491707f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_AssetImpairmentCharges_a2d18228-5900-4437-997e-1e5d6491707f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_256ab4da-1e46-4b9f-b933-4f9cf3d47067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_ShareBasedCompensation_256ab4da-1e46-4b9f-b933-4f9cf3d47067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2af57457-c92b-4330-a630-688481e873fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35140d68-1820-4d0f-8341-942f1b367c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2af57457-c92b-4330-a630-688481e873fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ee07f2e5-276c-40f6-b7b6-42ff019b8e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ee07f2e5-276c-40f6-b7b6-42ff019b8e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e78cb02a-e6e3-40dc-8e89-3c6b08f28fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e78cb02a-e6e3-40dc-8e89-3c6b08f28fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_760fa847-6a82-405f-9314-e589b72b98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_760fa847-6a82-405f-9314-e589b72b98ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f6099a5-674b-4117-a05c-c0b2afaad40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f6099a5-674b-4117-a05c-c0b2afaad40e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fe3639e9-4b90-4cb2-b01f-13fda4d48abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8376ed74-ae99-4493-aa3c-50b0c1c4e347" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fe3639e9-4b90-4cb2-b01f-13fda4d48abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70d707c0-b1fa-4f10-bdf6-2ecbbcac1117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d7bacb9-84f5-4933-96d8-c434f60ac9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70d707c0-b1fa-4f10-bdf6-2ecbbcac1117" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d7bacb9-84f5-4933-96d8-c434f60ac9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4062526-d164-4999-bcbc-9d116be855e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70d707c0-b1fa-4f10-bdf6-2ecbbcac1117" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4062526-d164-4999-bcbc-9d116be855e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbf8aeb8-eab6-4661-9b60-fbf62850f6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70d707c0-b1fa-4f10-bdf6-2ecbbcac1117" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbf8aeb8-eab6-4661-9b60-fbf62850f6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fd01cc4-7306-4e0b-abf0-4090d35ea502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70d707c0-b1fa-4f10-bdf6-2ecbbcac1117" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fd01cc4-7306-4e0b-abf0-4090d35ea502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b15dcf8d-8759-4f8c-aa0e-e223dc887073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b15dcf8d-8759-4f8c-aa0e-e223dc887073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3bd59334-081f-41ea-bbfd-de4e4e8adf11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3bd59334-081f-41ea-bbfd-de4e4e8adf11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_5cfb35dd-49a3-4cf3-b4b1-eceb1d1efcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_5cfb35dd-49a3-4cf3-b4b1-eceb1d1efcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_ce8d0656-4fde-4352-a230-42333722b3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_ce8d0656-4fde-4352-a230-42333722b3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5127ba63-c80d-4a09-944a-f16195664bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5127ba63-c80d-4a09-944a-f16195664bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8335f019-8768-4ee6-bfcf-7db04b0a8ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8335f019-8768-4ee6-bfcf-7db04b0a8ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0c384268-131b-4a2a-b0a2-1ddfee4d9a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0c384268-131b-4a2a-b0a2-1ddfee4d9a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_578503da-1687-44dd-b412-0aaa788ab08e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_578503da-1687-44dd-b412-0aaa788ab08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_43602151-24c1-4b21-b576-56e503b5ad24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08e3f601-bc76-4645-89c7-eda13b90d958" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_43602151-24c1-4b21-b576-56e503b5ad24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesClassificationofRestructuringCostsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_78b66f41-f947-4c01-a87a-927683deee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a7e7aa35-4396-4480-a161-11e36fd83fac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts_78b66f41-f947-4c01-a87a-927683deee1a" xlink:to="loc_us-gaap_RestructuringCharges_a7e7aa35-4396-4480-a161-11e36fd83fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_a9b0670a-173a-40b8-94c4-8e75e98f532c" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCosts_78b66f41-f947-4c01-a87a-927683deee1a" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_a9b0670a-173a-40b8-94c4-8e75e98f532c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1cc8864d-4746-44da-9996-861cecfde1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c3f1cce1-b76c-4480-9ecf-212da6b76b55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1cc8864d-4746-44da-9996-861cecfde1d1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c3f1cce1-b76c-4480-9ecf-212da6b76b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_10a18fb1-b775-4ae0-bc52-b2444195c574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1cc8864d-4746-44da-9996-861cecfde1d1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_10a18fb1-b775-4ae0-bc52-b2444195c574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d355da3-4a0b-49a7-9adf-b6934402ff96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1cc8864d-4746-44da-9996-861cecfde1d1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d355da3-4a0b-49a7-9adf-b6934402ff96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7539f3d0-ea4b-4f27-89d7-516e8222ce77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_584be093-8fbe-4108-896a-77297b2fd4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7539f3d0-ea4b-4f27-89d7-516e8222ce77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_584be093-8fbe-4108-896a-77297b2fd4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_76d82f30-9922-4f28-b055-ed546b273d38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7539f3d0-ea4b-4f27-89d7-516e8222ce77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_76d82f30-9922-4f28-b055-ed546b273d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_546f7897-617a-4ee1-bc54-1fd1f6fbc1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7539f3d0-ea4b-4f27-89d7-516e8222ce77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_546f7897-617a-4ee1-bc54-1fd1f6fbc1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_17d8cfb3-f5ba-47e7-a07a-2ca50dccd10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7539f3d0-ea4b-4f27-89d7-516e8222ce77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_17d8cfb3-f5ba-47e7-a07a-2ca50dccd10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5f9b3822-4232-4592-b53f-ae254aba2967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_53733b5e-5862-4eb4-93d1-77c2df93400b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5f9b3822-4232-4592-b53f-ae254aba2967" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_53733b5e-5862-4eb4-93d1-77c2df93400b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4f13f5ed-63e1-4223-b295-6f34fa680ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5f9b3822-4232-4592-b53f-ae254aba2967" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4f13f5ed-63e1-4223-b295-6f34fa680ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c5e40987-0541-49d8-9221-df46d934605b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5f9b3822-4232-4592-b53f-ae254aba2967" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c5e40987-0541-49d8-9221-df46d934605b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_31b052d8-0a70-4033-9a4d-91594e0b4109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5f9b3822-4232-4592-b53f-ae254aba2967" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_31b052d8-0a70-4033-9a4d-91594e0b4109" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_ed6a47fc-a005-4b21-bd72-0d6df0c012fd" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_eea90a9e-a80b-4a41-8381-c0a7d5a96321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_ed6a47fc-a005-4b21-bd72-0d6df0c012fd" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_eea90a9e-a80b-4a41-8381-c0a7d5a96321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6fc8445f-4cc7-48fd-a89a-dac764b15ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_ed6a47fc-a005-4b21-bd72-0d6df0c012fd" xlink:to="loc_us-gaap_EquityMethodInvestments_6fc8445f-4cc7-48fd-a89a-dac764b15ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4b9b0c29-5a16-47dc-bec8-3e4a3c759e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_ed6a47fc-a005-4b21-bd72-0d6df0c012fd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4b9b0c29-5a16-47dc-bec8-3e4a3c759e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_76e7780c-e372-44a6-aedc-12a3837d081e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_ed6a47fc-a005-4b21-bd72-0d6df0c012fd" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_76e7780c-e372-44a6-aedc-12a3837d081e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b034fab4-ae0b-409f-ad07-44b5ab676d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_7f3237a4-c19f-4a96-be65-3a5d9ba836a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_b034fab4-ae0b-409f-ad07-44b5ab676d25" xlink:to="loc_us-gaap_ShortTermBorrowings_7f3237a4-c19f-4a96-be65-3a5d9ba836a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_40bbb9e9-9e1e-4c41-8153-36ed7089a926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_b034fab4-ae0b-409f-ad07-44b5ab676d25" xlink:to="loc_us-gaap_LongTermDebtCurrent_40bbb9e9-9e1e-4c41-8153-36ed7089a926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0f88619a-4fc3-44b3-a491-d584f13603a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_b034fab4-ae0b-409f-ad07-44b5ab676d25" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0f88619a-4fc3-44b3-a491-d584f13603a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_0da7bdb2-5e0d-4ac3-bc98-c84573ce6a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_b034fab4-ae0b-409f-ad07-44b5ab676d25" xlink:to="loc_us-gaap_CommercialPaper_0da7bdb2-5e0d-4ac3-bc98-c84573ce6a60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c3c3f33-fd03-4509-88a0-d1a4545fc439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_d691ca8c-3065-4ae7-bcf9-7cbcf06240e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c3c3f33-fd03-4509-88a0-d1a4545fc439" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_d691ca8c-3065-4ae7-bcf9-7cbcf06240e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1e30b14a-0872-4de1-b58d-8a37ddb8b958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c3c3f33-fd03-4509-88a0-d1a4545fc439" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1e30b14a-0872-4de1-b58d-8a37ddb8b958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6bd99bf4-a170-4f97-ab2e-1a80891a2678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c3c3f33-fd03-4509-88a0-d1a4545fc439" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6bd99bf4-a170-4f97-ab2e-1a80891a2678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a571383c-80f6-4735-9c46-4b386b320b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c3c3f33-fd03-4509-88a0-d1a4545fc439" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a571383c-80f6-4735-9c46-4b386b320b5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsLongtermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b3db5395-cd3b-464d-89fe-dba85744fa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b3db5395-cd3b-464d-89fe-dba85744fa8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_db36173f-29ca-4d46-9353-cf86bb32666c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_db36173f-29ca-4d46-9353-cf86bb32666c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5f29d7fd-b9f4-4185-ac09-2a4a74f10ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5f29d7fd-b9f4-4185-ac09-2a4a74f10ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99c5232f-7050-4dcc-935d-019d666ed9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99c5232f-7050-4dcc-935d-019d666ed9d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_640e35b2-03f5-45a8-bd30-d7676287b975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_640e35b2-03f5-45a8-bd30-d7676287b975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6eac323d-42a6-49b7-bb04-80d988a61275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c07f8fbc-22de-445d-b547-364d27166e60" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6eac323d-42a6-49b7-bb04-80d988a61275" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0cf941e8-34d3-4c26-8ed1-b42ab9d4a762" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_b37d7447-40d0-42d0-adf5-81f1b84d35ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0cf941e8-34d3-4c26-8ed1-b42ab9d4a762" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_b37d7447-40d0-42d0-adf5-81f1b84d35ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_48815d98-96ac-4f69-92f4-53a4326284c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0cf941e8-34d3-4c26-8ed1-b42ab9d4a762" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_48815d98-96ac-4f69-92f4-53a4326284c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_923b4c12-735d-4e99-9fa0-5b6911154555" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_edafa785-9ab1-4dde-984e-26e05ef3417e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_923b4c12-735d-4e99-9fa0-5b6911154555" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_edafa785-9ab1-4dde-984e-26e05ef3417e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_0e075a42-3481-4cf3-a5f2-afc0aaf5f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_923b4c12-735d-4e99-9fa0-5b6911154555" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_0e075a42-3481-4cf3-a5f2-afc0aaf5f8db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_2aeaebee-4a41-4e2b-9d0e-f7b73d6fc56b" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_94974ee7-830d-482c-818e-8971903b37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_2aeaebee-4a41-4e2b-9d0e-f7b73d6fc56b" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_94974ee7-830d-482c-818e-8971903b37e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8021df15-4310-4857-b68b-c0fa46f69836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_2aeaebee-4a41-4e2b-9d0e-f7b73d6fc56b" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8021df15-4310-4857-b68b-c0fa46f69836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_e491a347-9f7b-495b-893a-21b697759d7c" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d8f23561-6d61-4111-89aa-2f3809fd661a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_e491a347-9f7b-495b-893a-21b697759d7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d8f23561-6d61-4111-89aa-2f3809fd661a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_69bcc1f8-a7c7-40f8-8227-ca5daa4ad9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_e491a347-9f7b-495b-893a-21b697759d7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_69bcc1f8-a7c7-40f8-8227-ca5daa4ad9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_d2a60fff-0d4e-483b-bd22-7b5526dd4935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_9a5cc30e-1e7d-480f-92ce-a55ceb0f5373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_d2a60fff-0d4e-483b-bd22-7b5526dd4935" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_9a5cc30e-1e7d-480f-92ce-a55ceb0f5373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_94787b79-3008-4e48-8381-0c00f233292a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_d2a60fff-0d4e-483b-bd22-7b5526dd4935" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_94787b79-3008-4e48-8381-0c00f233292a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_f97ab50d-179e-416e-b458-e941b386b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_3cae2bdd-22bc-4d4d-ad07-a4c5797cc1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_f97ab50d-179e-416e-b458-e941b386b30a" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_3cae2bdd-22bc-4d4d-ad07-a4c5797cc1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_858e6a3d-d860-4edb-a9cc-a64149206280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_f97ab50d-179e-416e-b458-e941b386b30a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_858e6a3d-d860-4edb-a9cc-a64149206280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_0d1fb96c-9ac4-4697-a671-6e1a3ecac17d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_f97ab50d-179e-416e-b458-e941b386b30a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_0d1fb96c-9ac4-4697-a671-6e1a3ecac17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_47204456-4f81-43d1-849b-0856ae18f623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e860fa97-4b8f-4859-ad48-6fe08c31e9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_47204456-4f81-43d1-849b-0856ae18f623" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e860fa97-4b8f-4859-ad48-6fe08c31e9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6c79d85f-5277-47e9-854a-6b82b80f4334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_47204456-4f81-43d1-849b-0856ae18f623" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6c79d85f-5277-47e9-854a-6b82b80f4334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_74e97e7b-e5f4-4401-a32f-679f9b9c5d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_47204456-4f81-43d1-849b-0856ae18f623" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_74e97e7b-e5f4-4401-a32f-679f9b9c5d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_45d5f397-33fd-491a-a845-f3cf9415275a" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_63a2b3c3-1b87-4b52-b874-cae4193bf22d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_45d5f397-33fd-491a-a845-f3cf9415275a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_63a2b3c3-1b87-4b52-b874-cae4193bf22d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_8eab87b5-f09b-4816-9ec1-c06b9e53f923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_45d5f397-33fd-491a-a845-f3cf9415275a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_8eab87b5-f09b-4816-9ec1-c06b9e53f923" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_7130415c-5ff8-4455-9004-66c7ef6f36ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_d95bbb1f-c6c2-47b3-805a-d92d3ec89f77" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_7130415c-5ff8-4455-9004-66c7ef6f36ab" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_d95bbb1f-c6c2-47b3-805a-d92d3ec89f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_4597a505-c218-428f-b384-5fe9c8e60343" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_7130415c-5ff8-4455-9004-66c7ef6f36ab" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_4597a505-c218-428f-b384-5fe9c8e60343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_5bb088d1-8702-424f-8f11-7a705fa55df2" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_7130415c-5ff8-4455-9004-66c7ef6f36ab" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_5bb088d1-8702-424f-8f11-7a705fa55df2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4090b3b8-80c9-46d7-a26f-1afac89e64bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9c3cef4f-f808-47ef-8cba-5d19bccb797e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4090b3b8-80c9-46d7-a26f-1afac89e64bc" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9c3cef4f-f808-47ef-8cba-5d19bccb797e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fefacdb7-4c72-421e-93e1-a674dec96dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4090b3b8-80c9-46d7-a26f-1afac89e64bc" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fefacdb7-4c72-421e-93e1-a674dec96dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8ae44ee3-917c-4a48-8877-c475c7e9f648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4090b3b8-80c9-46d7-a26f-1afac89e64bc" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8ae44ee3-917c-4a48-8877-c475c7e9f648" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_60b69c34-b7d4-4e41-9127-3176185938a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_9f3ed972-0668-4208-bc82-601b7662091d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_60b69c34-b7d4-4e41-9127-3176185938a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_9f3ed972-0668-4208-bc82-601b7662091d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1690a119-aff5-4284-b440-f3ed5faed721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_60b69c34-b7d4-4e41-9127-3176185938a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1690a119-aff5-4284-b440-f3ed5faed721" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_84dce032-e7c9-4748-a983-0ede2bc0e146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0a6e7476-b99b-4bdb-8bf1-a7e4aa29fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_84dce032-e7c9-4748-a983-0ede2bc0e146" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0a6e7476-b99b-4bdb-8bf1-a7e4aa29fc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_603e0a59-1102-4dfb-8888-09f1818c3256" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_84dce032-e7c9-4748-a983-0ede2bc0e146" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_603e0a59-1102-4dfb-8888-09f1818c3256" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_55c4f80e-e39a-4215-85e5-0b7ef59dc127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a1948474-a4d6-49f1-b3a5-ffcacfb0dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_55c4f80e-e39a-4215-85e5-0b7ef59dc127" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a1948474-a4d6-49f1-b3a5-ffcacfb0dbe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6c18791a-a487-4e8a-875f-fb9efb66d290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_55c4f80e-e39a-4215-85e5-0b7ef59dc127" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6c18791a-a487-4e8a-875f-fb9efb66d290" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b4e8c6f-bead-453e-8bd5-8913dd757072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_605384f5-179f-4495-adfc-496f2c465e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b4e8c6f-bead-453e-8bd5-8913dd757072" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_605384f5-179f-4495-adfc-496f2c465e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_55d44704-af44-485c-a614-23c2857bdabb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b4e8c6f-bead-453e-8bd5-8913dd757072" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_55d44704-af44-485c-a614-23c2857bdabb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09f40620-ab1e-4e15-a34d-2b081b494224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e2fac64e-3fd2-4e45-b140-d307bc88f297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09f40620-ab1e-4e15-a34d-2b081b494224" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e2fac64e-3fd2-4e45-b140-d307bc88f297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0707dfa3-8a76-4ac9-b9c1-be77e0bf9f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09f40620-ab1e-4e15-a34d-2b081b494224" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0707dfa3-8a76-4ac9-b9c1-be77e0bf9f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9a534c12-6f4f-471d-947a-a48f8be25d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_19bf68c5-499f-46fd-b153-075db2894c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9a534c12-6f4f-471d-947a-a48f8be25d7c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_19bf68c5-499f-46fd-b153-075db2894c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1b5d8d3a-ef76-4e74-a0b5-94cf97f4e1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9a534c12-6f4f-471d-947a-a48f8be25d7c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1b5d8d3a-ef76-4e74-a0b5-94cf97f4e1b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2464f313-8691-403b-9fee-a87c1a52673e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2464f313-8691-403b-9fee-a87c1a52673e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f35cbb68-89ff-4719-8d69-97e13c10ca23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_f35cbb68-89ff-4719-8d69-97e13c10ca23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8ae4f3c6-e86c-4459-b0b2-313ba93e3181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8ae4f3c6-e86c-4459-b0b2-313ba93e3181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_495230ab-11db-4659-b471-2b27fba38a84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_495230ab-11db-4659-b471-2b27fba38a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_7a9f4bd1-12d2-4829-9891-6a21d16746ac" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_7a9f4bd1-12d2-4829-9891-6a21d16746ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e1580cbd-3cf1-4649-9ace-449cb5539e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e1580cbd-3cf1-4649-9ace-449cb5539e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_6329f8f6-3c47-4b03-b46d-120596ec9452" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_402d3bd9-4b00-4456-b7e3-edfc6ba0fd0f" xlink:to="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_6329f8f6-3c47-4b03-b46d-120596ec9452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_636f770b-9517-4abc-a02e-2595eda3c7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b067ea49-d8c3-4278-8f4e-b02c0b34e333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_636f770b-9517-4abc-a02e-2595eda3c7b3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b067ea49-d8c3-4278-8f4e-b02c0b34e333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_6d92d24f-47f7-4bb1-ab19-af6df11c44b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_636f770b-9517-4abc-a02e-2595eda3c7b3" xlink:to="loc_us-gaap_PrepaidTaxes_6d92d24f-47f7-4bb1-ab19-af6df11c44b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_4b107579-7763-46b9-ac7e-404d02ee42f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_636f770b-9517-4abc-a02e-2595eda3c7b3" xlink:to="loc_us-gaap_IncomeTaxReceivable_4b107579-7763-46b9-ac7e-404d02ee42f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5cc0ef09-a317-4f95-94b3-8990a926324a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_636f770b-9517-4abc-a02e-2595eda3c7b3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5cc0ef09-a317-4f95-94b3-8990a926324a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d49b1084-615f-4983-bd9b-88c359f9a114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d49b1084-615f-4983-bd9b-88c359f9a114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_55f08732-bc7a-48b7-a9c3-b0d6fdc78950" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_55f08732-bc7a-48b7-a9c3-b0d6fdc78950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cc0d03f0-0275-465b-a3f7-f74ef1b8bce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cc0d03f0-0275-465b-a3f7-f74ef1b8bce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_77f6d51c-9883-4511-ac32-dde193485966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_77f6d51c-9883-4511-ac32-dde193485966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c8f1c287-4e56-46a4-958a-63cccef60990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c8f1c287-4e56-46a4-958a-63cccef60990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d6ce87b4-1df9-411d-8c80-ab223b3f75cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d6ce87b4-1df9-411d-8c80-ab223b3f75cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f3fd5314-d032-499d-92fd-bf9228337cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f3fd5314-d032-499d-92fd-bf9228337cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_137edc62-0c34-442f-ad78-5f150bb81aaa" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_137edc62-0c34-442f-ad78-5f150bb81aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation_ece4af20-da3e-437e-b758-9adaf217463f" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsInterestLimitation_ece4af20-da3e-437e-b758-9adaf217463f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations_0736674d-1c61-42cd-a1a1-9f09c5e5cbe7" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsLeaseObligations_0736674d-1c61-42cd-a1a1-9f09c5e5cbe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_ee2f4805-49ea-4723-9a82-ffd1ddd871b1" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_ee2f4805-49ea-4723-9a82-ffd1ddd871b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_e1334559-de2c-4029-b71d-59ef804158a9" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_e1334559-de2c-4029-b71d-59ef804158a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7edd744d-c156-4150-b256-5d642c9bc3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85f0e7ea-4801-42b6-a7a3-f0773d4964d8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7edd744d-c156-4150-b256-5d642c9bc3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b1312a0a-a159-41e3-b316-ff74863b8793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0d4a58ac-27a4-4b9a-ab76-93e0163f3f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b1312a0a-a159-41e3-b316-ff74863b8793" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0d4a58ac-27a4-4b9a-ab76-93e0163f3f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9e14a10-462e-428f-9a55-2a2c1dac12d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b1312a0a-a159-41e3-b316-ff74863b8793" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9e14a10-462e-428f-9a55-2a2c1dac12d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_30a56421-cfd4-48dc-8238-8f5c7329c7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_16a28f0c-c5f1-49fe-a684-3dc6fd46c7d7" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_30a56421-cfd4-48dc-8238-8f5c7329c7c9" xlink:to="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_16a28f0c-c5f1-49fe-a684-3dc6fd46c7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cd121b29-06cf-4dce-83d9-147ac0158081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_30a56421-cfd4-48dc-8238-8f5c7329c7c9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cd121b29-06cf-4dce-83d9-147ac0158081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8fab7d63-fc0f-42f4-b3cd-cffc35fbf4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_30a56421-cfd4-48dc-8238-8f5c7329c7c9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8fab7d63-fc0f-42f4-b3cd-cffc35fbf4d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_8532b00b-3368-44e4-bab9-53a32440d5c2" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_8532b00b-3368-44e4-bab9-53a32440d5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_cf019f00-b054-4c97-8c03-b67cd77e0f9f" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_cf019f00-b054-4c97-8c03-b67cd77e0f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_73cc9c1a-791d-418e-ba3b-9ed03bd09234" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_73cc9c1a-791d-418e-ba3b-9ed03bd09234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f9dedb1d-6828-4271-8eae-3d97a9da659a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f9dedb1d-6828-4271-8eae-3d97a9da659a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_76f1436b-bd1c-437e-949b-fff01f54f859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_76f1436b-bd1c-437e-949b-fff01f54f859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71385c3e-9e5f-4bab-a452-5b50f34126bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71385c3e-9e5f-4bab-a452-5b50f34126bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3b13b5b3-523d-4c8f-969f-6e441002f5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3b13b5b3-523d-4c8f-969f-6e441002f5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_f836b63c-de29-456e-bc5f-00644f7b6bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_f836b63c-de29-456e-bc5f-00644f7b6bb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8379d2b5-5277-4e80-9991-6072324f949d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8379d2b5-5277-4e80-9991-6072324f949d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_05f808eb-9e68-4f23-9b7d-80f878e9182e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_05f808eb-9e68-4f23-9b7d-80f878e9182e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_097c5586-5a45-42cf-b101-75174e4bbb20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_097c5586-5a45-42cf-b101-75174e4bbb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e3e67e08-baee-4c9d-be38-58f10355f4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83c47304-a19a-4c44-bb32-6b02f600794c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e3e67e08-baee-4c9d-be38-58f10355f4ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d21a1c7-79ad-433d-ab05-032b0d644b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_43fe48b3-2e39-4cb0-a78f-b305342be2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d21a1c7-79ad-433d-ab05-032b0d644b4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_43fe48b3-2e39-4cb0-a78f-b305342be2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1fd449be-a283-4b71-bb07-ad9fdd4305e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d21a1c7-79ad-433d-ab05-032b0d644b4a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1fd449be-a283-4b71-bb07-ad9fdd4305e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_8333cee9-238b-469d-b595-11643751e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d21a1c7-79ad-433d-ab05-032b0d644b4a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_8333cee9-238b-469d-b595-11643751e1be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_26fcf4a4-e99f-49c0-b680-484da200413e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_dedda43e-9865-4718-8b45-b29094aec104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_26fcf4a4-e99f-49c0-b680-484da200413e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_dedda43e-9865-4718-8b45-b29094aec104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_d2137931-92e4-476a-908e-4b80022eb07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_26fcf4a4-e99f-49c0-b680-484da200413e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_d2137931-92e4-476a-908e-4b80022eb07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ee48d539-6fee-4436-b45b-7b992e5eecac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_26fcf4a4-e99f-49c0-b680-484da200413e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ee48d539-6fee-4436-b45b-7b992e5eecac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_eb368c9b-ae90-470e-a3ea-82d90463ace4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_11430c6e-2039-4107-bc0a-ca2013d0d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_eb368c9b-ae90-470e-a3ea-82d90463ace4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_11430c6e-2039-4107-bc0a-ca2013d0d16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_90c669d5-ad30-48ab-8f88-a6b1ef1504ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_eb368c9b-ae90-470e-a3ea-82d90463ace4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_90c669d5-ad30-48ab-8f88-a6b1ef1504ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63f760c2-21e5-4e67-a7ff-e255a436d076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa97be85-b1b3-4e2e-9953-6c1f48d3a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63f760c2-21e5-4e67-a7ff-e255a436d076" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa97be85-b1b3-4e2e-9953-6c1f48d3a0de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_b3c5126a-b7a8-4dad-92e4-ea349c10c718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_63f760c2-21e5-4e67-a7ff-e255a436d076" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_b3c5126a-b7a8-4dad-92e4-ea349c10c718" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_25bda0f3-ce6c-4ec1-8201-7eef1c029b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_25bda0f3-ce6c-4ec1-8201-7eef1c029b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_00ddf2a3-c9df-43c0-a94e-bcead72ad17c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_00ddf2a3-c9df-43c0-a94e-bcead72ad17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_e2c7727b-b63d-4840-8aa8-10ff4b7099df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_e2c7727b-b63d-4840-8aa8-10ff4b7099df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e1935988-3532-483c-80f4-6053fbf0bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e1935988-3532-483c-80f4-6053fbf0bf37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_882a3531-0d06-41c9-99e7-455214f12976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_882a3531-0d06-41c9-99e7-455214f12976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5a5b6ee1-d5f9-42a2-b86a-302fe33245b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_5a5b6ee1-d5f9-42a2-b86a-302fe33245b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a297690e-3761-4e86-85bc-1fbf1c72bd28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5b8d59b5-78fa-49e8-b335-578a8cfc8fea" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a297690e-3761-4e86-85bc-1fbf1c72bd28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_92f1b894-95c1-4b3c-b9fd-e588c061a888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_176642d7-5a5f-4c83-bfdf-b3b31efe64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_92f1b894-95c1-4b3c-b9fd-e588c061a888" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_176642d7-5a5f-4c83-bfdf-b3b31efe64a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9e8e8bd4-3b52-40db-ad79-29f8b86c0188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_92f1b894-95c1-4b3c-b9fd-e588c061a888" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9e8e8bd4-3b52-40db-ad79-29f8b86c0188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_c7b1d16a-a345-460a-889a-cb95589b9daa" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_92f1b894-95c1-4b3c-b9fd-e588c061a888" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_c7b1d16a-a345-460a-889a-cb95589b9daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_599fc3b9-ea7e-485b-9269-4c924943d0a2" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_92f1b894-95c1-4b3c-b9fd-e588c061a888" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_599fc3b9-ea7e-485b-9269-4c924943d0a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesComponentsofTotalOperatingLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1a87ff6d-cde9-4eee-8aba-89d4be75bb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_794e7807-a113-4a21-89be-075200a3afee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1a87ff6d-cde9-4eee-8aba-89d4be75bb6d" xlink:to="loc_us-gaap_OperatingLeaseCost_794e7807-a113-4a21-89be-075200a3afee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_dfbe0986-214b-469b-9820-9d2b2b347ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1a87ff6d-cde9-4eee-8aba-89d4be75bb6d" xlink:to="loc_us-gaap_ShortTermLeaseCost_dfbe0986-214b-469b-9820-9d2b2b347ea0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesMaturitiesofOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afceb070-b47e-4e35-a4fc-1998805004af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afceb070-b47e-4e35-a4fc-1998805004af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94f5cc90-cbcd-49f9-81b1-e7eb0a3e16f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94f5cc90-cbcd-49f9-81b1-e7eb0a3e16f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2079028d-2694-46fc-afb9-685bd6a5b84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2079028d-2694-46fc-afb9-685bd6a5b84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc479a1a-72fe-49b9-9eb7-1fedea49935d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc479a1a-72fe-49b9-9eb7-1fedea49935d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e2271a96-efb6-483f-bde2-89b2a9779405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e2271a96-efb6-483f-bde2-89b2a9779405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54f6acec-62af-46c4-b3c9-47a9292ef107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e3821bb-4e39-4daf-882b-b1fad9c2597a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_54f6acec-62af-46c4-b3c9-47a9292ef107" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesMaturitiesofOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26386916-b96a-49a9-b33b-55cf3dd1d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8ee4bc1e-1250-4474-8534-dcb43ab99d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26386916-b96a-49a9-b33b-55cf3dd1d1ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8ee4bc1e-1250-4474-8534-dcb43ab99d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_25f76570-c308-4f52-8ff5-89220d0907fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26386916-b96a-49a9-b33b-55cf3dd1d1ca" xlink:to="loc_us-gaap_OperatingLeaseLiability_25f76570-c308-4f52-8ff5-89220d0907fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_effde06a-4c15-413b-ab76-135e7667a662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2351c952-87da-42d9-b703-07bacdd7fd55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_effde06a-4c15-413b-ab76-135e7667a662" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2351c952-87da-42d9-b703-07bacdd7fd55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ac931285-29ee-4f4d-8eff-f64a29b42eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_effde06a-4c15-413b-ab76-135e7667a662" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ac931285-29ee-4f4d-8eff-f64a29b42eaa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationSegmentReportingDetails"/>
  <link:calculationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b840719-25fa-45c7-940f-edf59c9babf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_OperatingIncomeLoss_2b840719-25fa-45c7-940f-edf59c9babf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_d748f084-016b-486e-bfa4-ec6bae164109" xlink:href="mdt-20250425.xsd#mdt_CorporateOverhead"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_mdt_CorporateOverhead_d748f084-016b-486e-bfa4-ec6bae164109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9d1da981-68bd-4c9d-8ed0-e30a0f20246a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9d1da981-68bd-4c9d-8ed0-e30a0f20246a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35af945b-145a-4e9c-88a3-e16083062fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35af945b-145a-4e9c-88a3-e16083062fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8defe339-9169-4eb3-b89c-c71c02f606ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8defe339-9169-4eb3-b89c-c71c02f606ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1280e77c-fc99-488a-a495-03f05e14cc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_ShareBasedCompensation_1280e77c-fc99-488a-a495-03f05e14cc3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_96037d40-2db0-45d7-92f4-40ba3456516c" xlink:href="mdt-20250425.xsd#mdt_CentralizedDistributionCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_mdt_CentralizedDistributionCosts_96037d40-2db0-45d7-92f4-40ba3456516c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_5429d681-20e4-4e0e-8c0d-4cdcaaa7103f" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_mdt_ForeignCurrencyCosts_5429d681-20e4-4e0e-8c0d-4cdcaaa7103f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2f0df34f-1e39-4da8-ad8a-b25a2d77b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_RestructuringCharges_2f0df34f-1e39-4da8-ad8a-b25a2d77b06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f08276b6-de27-4115-b14d-5092b685b040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f08276b6-de27-4115-b14d-5092b685b040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_31f570df-093c-49b9-823e-c8eb69882788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_31f570df-093c-49b9-823e-c8eb69882788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_97371532-528c-4367-b2f3-1a2b18e9225f" xlink:href="mdt-20250425.xsd#mdt_MedicalDeviceRegulations"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_mdt_MedicalDeviceRegulations_97371532-528c-4367-b2f3-1a2b18e9225f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_c1e016b2-e7a8-4a2e-9e6c-6235ba2a65a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_c1e016b2-e7a8-4a2e-9e6c-6235ba2a65a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_5af873a1-8ec1-44bd-abbf-754ba5ca7fc9" xlink:href="mdt-20250425.xsd#mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b77a4a8-3f70-4853-8217-d8164cce0112" xlink:to="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_5af873a1-8ec1-44bd-abbf-754ba5ca7fc9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>mdt-20250425_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.medtronic.com/role/Cover" xlink:type="simple" xlink:href="mdt-20250425.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d789e88-b3a8-451f-b8b6-64d7143e1e83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d789e88-b3a8-451f-b8b6-64d7143e1e83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.250SeniorNotesDue2025Member_f996c4d0-1c4f-4eea-8042-47ee2ff3a35c" xlink:href="mdt-20250425.xsd#mdt_A0.250SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.250SeniorNotesDue2025Member_f996c4d0-1c4f-4eea-8042-47ee2ff3a35c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.000SeniorNotesDue2025Member_eedcc502-cea4-4089-b390-6c283177923e" xlink:href="mdt-20250425.xsd#mdt_A0.000SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.000SeniorNotesDue2025Member_eedcc502-cea4-4089-b390-6c283177923e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.625SeniorNotesDue2025Member_3e296937-64ab-4d07-9a29-9afe43af5fe7" xlink:href="mdt-20250425.xsd#mdt_A2.625SeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A2.625SeniorNotesDue2025Member_3e296937-64ab-4d07-9a29-9afe43af5fe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.125SeniorNotesDue2027Member_f164da43-3a9a-435b-a2e0-0341411c5d9a" xlink:href="mdt-20250425.xsd#mdt_A1.125SeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.125SeniorNotesDue2027Member_f164da43-3a9a-435b-a2e0-0341411c5d9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.375SeniorNotesDue2028Member_dc220822-93de-4447-9675-8b7f8938d9b8" xlink:href="mdt-20250425.xsd#mdt_A0.375SeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.375SeniorNotesDue2028Member_dc220822-93de-4447-9675-8b7f8938d9b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.000SeniorNotesDue2029Member_ba9b7cde-17d3-44eb-9a12-873f70cdf928" xlink:href="mdt-20250425.xsd#mdt_A3.000SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.000SeniorNotesDue2029Member_ba9b7cde-17d3-44eb-9a12-873f70cdf928" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.650SeniorNotesDue2029Member_37f3fc08-3e45-4b32-9672-0cfd7d26dab4" xlink:href="mdt-20250425.xsd#mdt_A3.650SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.650SeniorNotesDue2029Member_37f3fc08-3e45-4b32-9672-0cfd7d26dab4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2031Member_89370b77-8eca-4e20-9682-af9208ca23a7" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.625SeniorNotesDue2031Member_89370b77-8eca-4e20-9682-af9208ca23a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.000SeniorNotesDue2031Member_1ff9a669-ce49-44f4-9a30-da02be59ea66" xlink:href="mdt-20250425.xsd#mdt_A1.000SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.000SeniorNotesDue2031Member_1ff9a669-ce49-44f4-9a30-da02be59ea66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.125SeniorNotesDue2031Member_4c4da889-dac0-44d9-9022-b9567c68e3d9" xlink:href="mdt-20250425.xsd#mdt_A3.125SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.125SeniorNotesDue2031Member_4c4da889-dac0-44d9-9022-b9567c68e3d9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.750SeniorNotesDue2032Member_0a1228d2-0222-45ba-8eb9-743dcdcd0837" xlink:href="mdt-20250425.xsd#mdt_A0.750SeniorNotesDue2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.750SeniorNotesDue2032Member_0a1228d2-0222-45ba-8eb9-743dcdcd0837" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.375SeniorNotesDue2034Member_8bf824c5-247b-4e63-a736-0234cbdf032a" xlink:href="mdt-20250425.xsd#mdt_A3.375SeniorNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.375SeniorNotesDue2034Member_8bf824c5-247b-4e63-a736-0234cbdf032a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.875SeniorNotesDue2036Member_715c7e62-5577-482f-b686-6bf00f20d5c1" xlink:href="mdt-20250425.xsd#mdt_A3.875SeniorNotesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.875SeniorNotesDue2036Member_715c7e62-5577-482f-b686-6bf00f20d5c1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.250SeniorNotesDue2039Member_110cd94f-1513-4fef-96f4-0de96d5faccd" xlink:href="mdt-20250425.xsd#mdt_A2.250SeniorNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A2.250SeniorNotesDue2039Member_110cd94f-1513-4fef-96f4-0de96d5faccd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.500SeniorNotesDue2039Member_c2f7d475-4e9e-4f8d-a861-67bf889b54c6" xlink:href="mdt-20250425.xsd#mdt_A1.500SeniorNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.500SeniorNotesDue2039Member_c2f7d475-4e9e-4f8d-a861-67bf889b54c6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.375SeniorNotesDue2040Member_62eb7362-9ab8-49bf-92ba-e751b8d6a8bb" xlink:href="mdt-20250425.xsd#mdt_A1.375SeniorNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.375SeniorNotesDue2040Member_62eb7362-9ab8-49bf-92ba-e751b8d6a8bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2043Member_69e76dfa-dd93-4665-a505-bd0a7ab7636c" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A4.150SeniorNotesDue2043Member_69e76dfa-dd93-4665-a505-bd0a7ab7636c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.750SeniorNotesDue2049Member_dd06279b-79e0-4a56-b68e-131360be7fb9" xlink:href="mdt-20250425.xsd#mdt_A1.750SeniorNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.750SeniorNotesDue2049Member_dd06279b-79e0-4a56-b68e-131360be7fb9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2050Member_9a6d23ff-261b-4368-b036-49eed7d16dc4" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.625SeniorNotesDue2050Member_9a6d23ff-261b-4368-b036-49eed7d16dc4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2053Member_4e0ee692-6b2c-4464-a731-cf860eb87887" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A4.150SeniorNotesDue2053Member_4e0ee692-6b2c-4464-a731-cf860eb87887" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ae56a456-93dc-43fc-9937-3d80a5eee35b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentType_ae56a456-93dc-43fc-9937-3d80a5eee35b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_94dae9cd-3c5e-4085-b06f-10db97348847" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentAnnualReport_94dae9cd-3c5e-4085-b06f-10db97348847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dda35b2a-2df8-431c-96e7-dae07be9a1d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentPeriodEndDate_dda35b2a-2df8-431c-96e7-dae07be9a1d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b9ae138f-89da-4843-879e-022adada33d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentTransitionReport_b9ae138f-89da-4843-879e-022adada33d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_02df10ec-357f-484d-a313-f2f53449b385" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityFileNumber_02df10ec-357f-484d-a313-f2f53449b385" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee18a787-ca7e-42f6-9e2c-b60e67c9916b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityRegistrantName_ee18a787-ca7e-42f6-9e2c-b60e67c9916b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1c635c05-452e-4290-82d9-f9b7ea6074ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1c635c05-452e-4290-82d9-f9b7ea6074ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6070dce9-3882-4cdf-a4fe-a66867f5465c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityTaxIdentificationNumber_6070dce9-3882-4cdf-a4fe-a66867f5465c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_203278de-cbee-4938-aa78-1950812b461a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressAddressLine1_203278de-cbee-4938-aa78-1950812b461a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_db807916-d998-4c2e-996b-316797b376bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressCityOrTown_db807916-d998-4c2e-996b-316797b376bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_bcb86cdb-e23e-4892-a57f-ec397908c1cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressCountry_bcb86cdb-e23e-4892-a57f-ec397908c1cc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_dd2ebf2e-2870-448c-b2c6-10559bc390d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CountryRegion_dd2ebf2e-2870-448c-b2c6-10559bc390d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82120515-d583-4ff7-ae9f-2c65af53509a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CityAreaCode_82120515-d583-4ff7-ae9f-2c65af53509a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9cc1e6ba-5823-4e50-9e62-7131a01b0559" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_LocalPhoneNumber_9cc1e6ba-5823-4e50-9e62-7131a01b0559" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76c9a852-c2ec-47cc-aef7-8513fb86fbc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_Security12bTitle_76c9a852-c2ec-47cc-aef7-8513fb86fbc1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5c4e3f7-a30c-4185-970a-ac5490406961" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_TradingSymbol_d5c4e3f7-a30c-4185-970a-ac5490406961" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1c30bde9-3e7c-4c89-b839-e8108ea831a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_SecurityExchangeName_1c30bde9-3e7c-4c89-b839-e8108ea831a1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_699730ee-9e77-4442-a144-5651f4f1b100" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_699730ee-9e77-4442-a144-5651f4f1b100" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_30d1f786-3695-4b4a-a87c-48fac522ea51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityVoluntaryFilers_30d1f786-3695-4b4a-a87c-48fac522ea51" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9fe79a93-d0ac-4365-a35f-d2061b8cb6e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCurrentReportingStatus_9fe79a93-d0ac-4365-a35f-d2061b8cb6e4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_823c3d39-88cf-4b20-bd68-435e4a81f7b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityInteractiveDataCurrent_823c3d39-88cf-4b20-bd68-435e4a81f7b7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0dd523d1-24ca-4ffb-93da-5b14fe302769" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityFilerCategory_0dd523d1-24ca-4ffb-93da-5b14fe302769" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a120dae2-e95e-48d3-a477-68c5ed4f6f73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntitySmallBusiness_a120dae2-e95e-48d3-a477-68c5ed4f6f73" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_761890a8-2bca-4d59-8dca-b28b560a99b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityEmergingGrowthCompany_761890a8-2bca-4d59-8dca-b28b560a99b6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_56eb669e-1206-4db0-95bf-516236730e83" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_IcfrAuditorAttestationFlag_56eb669e-1206-4db0-95bf-516236730e83" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_64ee5d47-1f52-4a3a-b9e1-99186f1ca5a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_64ee5d47-1f52-4a3a-b9e1-99186f1ca5a5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_41bc133e-e362-4415-a26f-d45d88f20ee1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityShellCompany_41bc133e-e362-4415-a26f-d45d88f20ee1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1499cf53-fae2-49ed-93e1-e8a38e2e2cd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityPublicFloat_1499cf53-fae2-49ed-93e1-e8a38e2e2cd5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc70a9eb-8bd0-4d11-b2b2-f005b8616b7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc70a9eb-8bd0-4d11-b2b2-f005b8616b7b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afd41a76-d72e-49ec-8211-ce5f26f98070" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afd41a76-d72e-49ec-8211-ce5f26f98070" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_db2c2e1f-2e85-4370-8d67-3af17ae23d41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCentralIndexKey_db2c2e1f-2e85-4370-8d67-3af17ae23d41" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2beb51e-28f8-4dcc-9233-9246622b4bbb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2beb51e-28f8-4dcc-9233-9246622b4bbb" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3de4750e-56fb-42f3-813d-0cb5b853b1be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_AmendmentFlag_3de4750e-56fb-42f3-813d-0cb5b853b1be" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5c87cba1-4923-42e6-b97d-c0d3b56311c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5c87cba1-4923-42e6-b97d-c0d3b56311c8" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_19aa15bb-77f2-4977-afe7-5da604416066" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFiscalYearFocus_19aa15bb-77f2-4977-afe7-5da604416066" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7b25fcb6-b42c-44e1-833a-028671043dac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressPostalZipCode_7b25fcb6-b42c-44e1-833a-028671043dac" xlink:type="arc" order="35"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:to="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:to="loc_us-gaap_EquityComponentDomain_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:to="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:to="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_85f5d0cd-0c90-4e13-be37-770f8c045e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_CommonStockMember_85f5d0cd-0c90-4e13-be37-770f8c045e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3a4e6b50-b8b7-445c-a780-d675ea707c52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3a4e6b50-b8b7-445c-a780-d675ea707c52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd2d1b7f-173a-47e2-b340-7be52449c042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_RetainedEarningsMember_dd2d1b7f-173a-47e2-b340-7be52449c042" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec1f9133-0558-4304-99b0-c4e3263378e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec1f9133-0558-4304-99b0-c4e3263378e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7004a40e-d174-4c66-85ed-b5f4aceb9ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7004a40e-d174-4c66-85ed-b5f4aceb9ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1774cfe-f14c-4a4e-b750-94a09d85fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1774cfe-f14c-4a4e-b750-94a09d85fa31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8293ca8d-b215-4aab-9d4b-c559c73d16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8293ca8d-b215-4aab-9d4b-c559c73d16d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69680062-d6c6-48bf-9375-b030bcb66fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_ProfitLoss_69680062-d6c6-48bf-9375-b030bcb66fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_246c751b-eb7f-4e5b-a1ec-2f73de3c815e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_246c751b-eb7f-4e5b-a1ec-2f73de3c815e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_44f99d67-2681-46c6-9942-cc3160a6e760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_DividendsCommonStockCash_44f99d67-2681-46c6-9942-cc3160a6e760" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8a7918ea-476c-4c1c-9d70-998d2e01bc52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8a7918ea-476c-4c1c-9d70-998d2e01bc52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0dac7b1d-7bca-4fed-84d1-cec2b4ca90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0dac7b1d-7bca-4fed-84d1-cec2b4ca90c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d2e7efa1-0539-4fcd-8717-c15793be4e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d2e7efa1-0539-4fcd-8717-c15793be4e5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_eb29e304-1e19-4898-b08e-b8607760eef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_eb29e304-1e19-4898-b08e-b8607760eef2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b12fd317-d123-4b5f-9832-577edd2d289b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b12fd317-d123-4b5f-9832-577edd2d289b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_84a25b88-861a-40c5-9fdb-d3592e794dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_84a25b88-861a-40c5-9fdb-d3592e794dd1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_762ff240-1bd1-4227-a4f3-777f2d7f3820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b89f0a1-d6ca-42fe-9c6c-f018e9a48163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:to="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6dfc470-4f20-47d8-9c1e-8fbb64012c32_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:to="loc_srt_RangeMember_a6dfc470-4f20-47d8-9c1e-8fbb64012c32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:to="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_27e32077-a61d-4a98-b1ff-049c1036a26f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:to="loc_srt_MinimumMember_27e32077-a61d-4a98-b1ff-049c1036a26f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfbb788a-d83e-43ee-baa5-187c227c9bc5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:to="loc_srt_MaximumMember_bfbb788a-d83e-43ee-baa5-187c227c9bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:to="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76306dbd-74d0-4d91-b342-571c9b511f8e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:to="loc_srt_ProductsAndServicesDomain_76306dbd-74d0-4d91-b342-571c9b511f8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:to="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_76aadd86-52de-41d2-88db-b55afab0fe41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:to="loc_us-gaap_ShippingAndHandlingMember_76aadd86-52de-41d2-88db-b55afab0fe41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2bd107da-3eef-42c2-b02c-eb252a8163c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2bd107da-3eef-42c2-b02c-eb252a8163c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2b8b8298-6775-4608-8eb3-b46200c82de7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2b8b8298-6775-4608-8eb3-b46200c82de7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5c334f13-81b5-481c-bafb-2c1fb2e5dec9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:to="loc_us-gaap_SegmentDomain_5c334f13-81b5-481c-bafb-2c1fb2e5dec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:to="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:href="mdt-20250425.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:to="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_982535ea-b9ee-4f98-a3a6-52ba865de119" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_CardiovascularMember_982535ea-b9ee-4f98-a3a6-52ba865de119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_29f00d38-70ff-4a81-8b40-0f78886c2a52" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_NeuroscienceGroupMember_29f00d38-70ff-4a81-8b40-0f78886c2a52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_8bc4dc54-c933-40b2-a0a7-b8a58f2aabd2" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_MedicalSurgicalMember_8bc4dc54-c933-40b2-a0a7-b8a58f2aabd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_3fd164a1-a031-49ee-aced-23dfd6afb211" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_DiabetesGroupMember_3fd164a1-a031-49ee-aced-23dfd6afb211" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_ec304322-9cb9-4b98-b045-6a80e317aae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_ec304322-9cb9-4b98-b045-6a80e317aae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_fc542e30-3ffd-438d-83f4-969c156db872_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:to="loc_us-gaap_SubsegmentsDomain_fc542e30-3ffd-438d-83f4-969c156db872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:to="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_1f1be70a-6808-424c-9427-feb9bb03d4e1" xlink:href="mdt-20250425.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_1f1be70a-6808-424c-9427-feb9bb03d4e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember_6bb4987c-c4bb-4110-ba30-d37e64ba34fd" xlink:href="mdt-20250425.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_StructuralHeartAndAorticDivisionMember_6bb4987c-c4bb-4110-ba30-d37e64ba34fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_ee1d3a6a-deac-4fac-9e2a-58158302f32a" xlink:href="mdt-20250425.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_ee1d3a6a-deac-4fac-9e2a-58158302f32a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_551ede04-6736-453c-afb7-20ee4fce0203" xlink:href="mdt-20250425.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_551ede04-6736-453c-afb7-20ee4fce0203" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember_a6f7f7e9-4903-43cb-b8a8-2d13bbea1522" xlink:href="mdt-20250425.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_SpecialtyTherapiesDivisionMember_a6f7f7e9-4903-43cb-b8a8-2d13bbea1522" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember_ce6ed77a-60b2-4099-afb5-a836ce4a3a7f" xlink:href="mdt-20250425.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_NeuromodulationDivisionMember_ce6ed77a-60b2-4099-afb5-a836ce4a3a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember_60df96f8-2f35-4af4-85ae-fe2026612e9c" xlink:href="mdt-20250425.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_SurgicalInnovationsDivisionMember_60df96f8-2f35-4af4-85ae-fe2026612e9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember_ae75933b-f625-4ae5-a77a-650534856a50" xlink:href="mdt-20250425.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_AcuteCareMonitoringMember_ae75933b-f625-4ae5-a77a-650534856a50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:to="loc_srt_ConsolidationItemsDomain_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:to="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_1253767c-1c45-4680-b0f1-d9e28af6ae68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:to="loc_srt_ConsolidationEliminationsMember_1253767c-1c45-4680-b0f1-d9e28af6ae68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d80f3a49-45cd-4ee2-9919-4d25a0882e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:to="loc_us-gaap_OperatingSegmentsMember_d80f3a49-45cd-4ee2-9919-4d25a0882e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11d281dd-8787-47d9-b5f6-2e2f0cbb0968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11d281dd-8787-47d9-b5f6-2e2f0cbb0968" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93876456-5a37-4990-a13c-632e0c5e2444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:to="loc_us-gaap_SegmentDomain_93876456-5a37-4990-a13c-632e0c5e2444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:to="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:href="mdt-20250425.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:to="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_5b1e368c-a171-4cbe-8ee6-7b67e2a105d6" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_CardiovascularMember_5b1e368c-a171-4cbe-8ee6-7b67e2a105d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_59f4b0d1-58ff-4af3-bc8f-d37d6fe92f5d" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_NeuroscienceGroupMember_59f4b0d1-58ff-4af3-bc8f-d37d6fe92f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_4ee5cbfe-fb02-48d8-a32a-2545dc5ea248" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_MedicalSurgicalMember_4ee5cbfe-fb02-48d8-a32a-2545dc5ea248" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_2a61c573-cfcb-46c0-9efb-b1274909f126" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_DiabetesGroupMember_2a61c573-cfcb-46c0-9efb-b1274909f126" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_19a16e2e-5883-4046-928c-6be8515b7080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_19a16e2e-5883-4046-928c-6be8515b7080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_39744c67-ca0c-4d12-a023-d96c529278a6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:to="loc_srt_SegmentGeographicalDomain_39744c67-ca0c-4d12-a023-d96c529278a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:to="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a00dc10a-4b16-4d38-81a8-e3299e9d38c2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:to="loc_country_US_a00dc10a-4b16-4d38-81a8-e3299e9d38c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InternationalMember_9675a08f-cbfb-4297-aa93-47017139f69b" xlink:href="mdt-20250425.xsd#mdt_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:to="loc_mdt_InternationalMember_9675a08f-cbfb-4297-aa93-47017139f69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_56e69ec4-abb8-4028-91e3-bae23f1fd051_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:to="loc_srt_ConsolidationItemsDomain_56e69ec4-abb8-4028-91e3-bae23f1fd051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:to="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0898b8f5-9cff-4472-a743-73dfc14ae94c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:to="loc_us-gaap_OperatingSegmentsMember_0898b8f5-9cff-4472-a743-73dfc14ae94c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_0fd10071-25b3-4fe7-b9e6-dba0d60cdd92" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:to="loc_srt_ConsolidationEliminationsMember_0fd10071-25b3-4fe7-b9e6-dba0d60cdd92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc451ef1-6dc1-40a1-a667-1959c02e85e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc451ef1-6dc1-40a1-a667-1959c02e85e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a3a7d0ae-0c10-44a9-9d07-4169c05198b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a3a7d0ae-0c10-44a9-9d07-4169c05198b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_d74e9860-330f-4037-9266-5088dd1bc037" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_mdt_OtherAccruedExpensesMember_d74e9860-330f-4037-9266-5088dd1bc037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_14140ed5-55bb-4907-affe-9adc602fdd30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_us-gaap_AccountsReceivableMember_14140ed5-55bb-4907-affe-9adc602fdd30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_e48c4b57-f2e5-4ad0-9121-122f3e084bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_us-gaap_OtherLiabilitiesMember_e48c4b57-f2e5-4ad0-9121-122f3e084bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_003b0cfd-cf35-4fab-ba03-c8f0e24bc08a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_003b0cfd-cf35-4fab-ba03-c8f0e24bc08a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1afb5a4f-53c5-44c2-8769-735d573d521b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1afb5a4f-53c5-44c2-8769-735d573d521b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6c040438-e00f-430e-85b0-45dff33f78a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6c040438-e00f-430e-85b0-45dff33f78a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d87aa77b-0a8b-4115-b1d3-a284c6c0a4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d87aa77b-0a8b-4115-b1d3-a284c6c0a4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_efd7acea-30ef-48d1-b49d-9a9f911ceb78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_efd7acea-30ef-48d1-b49d-9a9f911ceb78" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9283ab22-2161-4d4e-95dd-d863a7b7705c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9283ab22-2161-4d4e-95dd-d863a7b7705c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_744bb4d8-c85a-4c31-8a0b-cf34de31dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_744bb4d8-c85a-4c31-8a0b-cf34de31dc51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c559070-5b61-4a61-a421-744525f0cd9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c559070-5b61-4a61-a421-744525f0cd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eaa5fe6-cd54-4240-a22f-615f0ea3fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eaa5fe6-cd54-4240-a22f-615f0ea3fb2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bb5f9b24-4dda-403a-842c-b6f553bdcfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bb5f9b24-4dda-403a-842c-b6f553bdcfb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ede6d19a-c7aa-430c-bd41-eee4a97da8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ede6d19a-c7aa-430c-bd41-eee4a97da8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1288af2c-cf80-447c-b174-7095b2c37ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1288af2c-cf80-447c-b174-7095b2c37ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_29374653-82e6-475c-954b-619a8bdc6614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_29374653-82e6-475c-954b-619a8bdc6614" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db829829-78bc-4bb2-aa6f-0b374f7f6bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_Goodwill_db829829-78bc-4bb2-aa6f-0b374f7f6bf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_e7c00452-8f91-4183-bcac-d274a992d123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_e7c00452-8f91-4183-bcac-d274a992d123" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86a98154-973d-49e6-9524-89ad727860a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86a98154-973d-49e6-9524-89ad727860a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ee18a9fe-ae57-4189-9233-9cb4723e2468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ee18a9fe-ae57-4189-9233-9cb4723e2468" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d70bf2f-e255-43fa-bea8-f5bc6d824ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d70bf2f-e255-43fa-bea8-f5bc6d824ec1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_07a8c332-0380-4a1b-96c0-178cd9cfaf00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_07a8c332-0380-4a1b-96c0-178cd9cfaf00" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount_3fad4f88-20ad-4b86-a322-6c31541ba78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_GoodwillNotAllocatedAmount_3fad4f88-20ad-4b86-a322-6c31541ba78b" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5dc280a2-5302-43aa-b154-84e79945a590_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5dc280a2-5302-43aa-b154-84e79945a590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_db2d22d3-cc3e-4491-bd7d-4acacab9bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_db2d22d3-cc3e-4491-bd7d-4acacab9bbbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_531e8415-0929-4d23-b23f-2cef985a7603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_531e8415-0929-4d23-b23f-2cef985a7603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_98ab89f7-d003-470c-9ce1-940e99fc2150" xlink:href="mdt-20250425.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:to="loc_mdt_VentilatorProductLineExitMember_98ab89f7-d003-470c-9ce1-940e99fc2150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember_9c66c479-7e14-4d46-9da9-b989758aaed8" xlink:href="mdt-20250425.xsd#mdt_RenalCareSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:to="loc_mdt_RenalCareSolutionsMember_9c66c479-7e14-4d46-9da9-b989758aaed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_20783efd-8dff-4d22-af75-58c02f3fb10a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_20783efd-8dff-4d22-af75-58c02f3fb10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_cef4019a-8f5d-4d94-8a4b-cf1a635f5a76" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:to="loc_mdt_MozarcMember_cef4019a-8f5d-4d94-8a4b-cf1a635f5a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3095798d-6720-40af-8087-44dae0bb157c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:to="loc_srt_OwnershipDomain_3095798d-6720-40af-8087-44dae0bb157c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:to="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_ff41ffe7-b1c2-4b2c-a22a-1b78a0b7f2b6" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:to="loc_mdt_MozarcMember_ff41ffe7-b1c2-4b2c-a22a-1b78a0b7f2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87c28aa8-7119-4131-99c3-7212e7ce8412_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:to="loc_srt_RangeMember_87c28aa8-7119-4131-99c3-7212e7ce8412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:to="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed9289bd-c1ab-4371-9659-d2b7645787ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:to="loc_srt_MaximumMember_ed9289bd-c1ab-4371-9659-d2b7645787ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0025614a-64c1-4f46-a9a8-b70cf52239ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0025614a-64c1-4f46-a9a8-b70cf52239ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7aa49c3-1065-43ad-bce3-4626f35154d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7aa49c3-1065-43ad-bce3-4626f35154d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_14350522-c290-41e7-9ccd-6a774ddbbd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_BusinessExitCosts1_14350522-c290-41e7-9ccd-6a774ddbbd9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_f847a525-5117-487c-8706-b506e7bf7322" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_f847a525-5117-487c-8706-b506e7bf7322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c87b243e-33de-4a80-b0b4-554e2eebf514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c87b243e-33de-4a80-b0b4-554e2eebf514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_f66d6832-2212-42d5-9236-03df7f192982" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_f66d6832-2212-42d5-9236-03df7f192982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8c79c252-c4c8-4b95-9be8-1d6eefeb402f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8c79c252-c4c8-4b95-9be8-1d6eefeb402f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3a325c1c-5af9-4cbb-b228-ecbbb0dc78be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_InventoryWriteDown_3a325c1c-5af9-4cbb-b228-ecbbb0dc78be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_876bcd73-837d-470b-8445-001c35573647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_876bcd73-837d-470b-8445-001c35573647" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a9be2af6-b290-43a8-adb8-6f1b04262dd0" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a9be2af6-b290-43a8-adb8-6f1b04262dd0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_16d12c06-0ee8-4395-956c-ba967d3d5506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_16d12c06-0ee8-4395-956c-ba967d3d5506" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_12ae51b4-1f40-42f2-835c-8b133deb8794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_12ae51b4-1f40-42f2-835c-8b133deb8794" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b31b459c-a74d-45e8-9881-e69f873088a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_MinorityInterest_b31b459c-a74d-45e8-9881-e69f873088a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5993bdec-ab29-4682-aa34-b3977b526c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_AssetImpairmentCharges_5993bdec-ab29-4682-aa34-b3977b526c8e" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5fc552c4-5b4a-487f-9e21-2914f0343b34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5fc552c4-5b4a-487f-9e21-2914f0343b34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_696ecf1b-88ad-4a96-82dc-0f063db211fe" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:to="loc_mdt_OtherAccruedExpensesMember_696ecf1b-88ad-4a96-82dc-0f063db211fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_fc020682-498e-4ab8-b2c6-b67574a14930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:to="loc_us-gaap_OtherLiabilitiesMember_fc020682-498e-4ab8-b2c6-b67574a14930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4ab366f-fd18-43ee-99f7-e309168d66cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4ab366f-fd18-43ee-99f7-e309168d66cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d0400cca-e659-41fb-9375-239aeace7fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d0400cca-e659-41fb-9375-239aeace7fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a1eb8534-5e04-4342-81dd-7f2256ba882e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a1eb8534-5e04-4342-81dd-7f2256ba882e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b0087e6a-e4fe-4b25-a5e0-b43843062acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b0087e6a-e4fe-4b25-a5e0-b43843062acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71234605-c4b0-4bbe-80e7-39d18e8d18f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71234605-c4b0-4bbe-80e7-39d18e8d18f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_08b4d82d-fe7f-457d-8f49-16261d7cb6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_08b4d82d-fe7f-457d-8f49-16261d7cb6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ef53efa6-a5ba-4e6e-ba82-12a2567c035d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ef53efa6-a5ba-4e6e-ba82-12a2567c035d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_f4aff625-6ce3-4cef-8bca-7dc910a2614f" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_f4aff625-6ce3-4cef-8bca-7dc910a2614f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3d82543b-2280-407a-ade3-937924cd9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3d82543b-2280-407a-ade3-937924cd9bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_124e1890-7254-4b58-9026-6555bc180a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_DeferredIncome_124e1890-7254-4b58-9026-6555bc180a69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_09788039-6d8a-4078-a7e3-f9661fa36eda" xlink:href="mdt-20250425.xsd#mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_09788039-6d8a-4078-a7e3-f9661fa36eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b7c4dfbe-1c93-4618-b843-35918c90b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b7c4dfbe-1c93-4618-b843-35918c90b1fd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_07f63bb3-0811-4c71-8f48-8b5f58e604c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_07f63bb3-0811-4c71-8f48-8b5f58e604c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_873cb304-c7da-47e9-9a25-3cfb0ea92d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_873cb304-c7da-47e9-9a25-3cfb0ea92d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8edca598-3c96-4a5a-81e3-380afe5b8da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8edca598-3c96-4a5a-81e3-380afe5b8da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f963a96d-eed3-4cb1-b687-a1871bd220de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f963a96d-eed3-4cb1-b687-a1871bd220de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember_68d07cae-f380-4504-b14a-1af46c10845e" xlink:href="mdt-20250425.xsd#mdt_RevenueMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:to="loc_mdt_RevenueMilestoneMember_68d07cae-f380-4504-b14a-1af46c10845e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember_a2fdf4b2-617e-45ee-a1a9-95791ce97ace" xlink:href="mdt-20250425.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:to="loc_mdt_ProductDevelopmentMilestoneMember_a2fdf4b2-617e-45ee-a1a9-95791ce97ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4caa7305-b610-4d40-8474-d7c560e70923_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4caa7305-b610-4d40-8474-d7c560e70923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_15874dcc-f0e6-408e-9dd6-3d44c3dfd183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_15874dcc-f0e6-408e-9dd6-3d44c3dfd183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:to="loc_srt_RangeMember_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:to="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_35e12f75-c1eb-4ac5-b402-95688c995729" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_MinimumMember_35e12f75-c1eb-4ac5-b402-95688c995729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74073158-7051-4644-a09d-c601ee9878d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_MaximumMember_74073158-7051-4644-a09d-c601ee9878d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_04d99243-184c-4e82-91eb-8997df435457" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_WeightedAverageMember_04d99243-184c-4e82-91eb-8997df435457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1bef0898-4c47-4dba-994d-9792c07443d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1bef0898-4c47-4dba-994d-9792c07443d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8f8d69d1-28f7-4377-a771-5d4269e6bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8f8d69d1-28f7-4377-a771-5d4269e6bff4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab4324a-2989-4766-846b-22d24c4bd519_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab4324a-2989-4766-846b-22d24c4bd519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9909feb1-a40d-4414-9d60-ef6aa7ea0ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9909feb1-a40d-4414-9d60-ef6aa7ea0ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186a3c1-62a1-452f-8427-f09be081b81e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186a3c1-62a1-452f-8427-f09be081b81e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7b0fb1ac-b5b9-45f4-bc18-bf6a538db2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7b0fb1ac-b5b9-45f4-bc18-bf6a538db2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_89920aca-76c4-4f3d-b34b-354ffe046a10" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_89920aca-76c4-4f3d-b34b-354ffe046a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_da312d9f-adbb-4e8c-a2c8-1a202371a622" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_da312d9f-adbb-4e8c-a2c8-1a202371a622" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a213d7ce-3154-447c-b6a9-305b838f8d1d" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:to="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2ea61b59-b4e7-4312-8dc3-df371c8efd83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:to="loc_us-gaap_RestructuringPlanDomain_2ea61b59-b4e7-4312-8dc3-df371c8efd83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:to="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember_35afd5d7-f2ec-410a-9e56-19034bfe7293" xlink:href="mdt-20250425.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:to="loc_mdt_EnterpriseExcellenceMember_35afd5d7-f2ec-410a-9e56-19034bfe7293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember_3be1c778-41e0-42a1-b96b-75397090c3ea" xlink:href="mdt-20250425.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:to="loc_mdt_SimplificationRestructuringProgramMember_3be1c778-41e0-42a1-b96b-75397090c3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_4c676dac-d184-4af4-b8bb-f5f9e53b96b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringCosts_4c676dac-d184-4af4-b8bb-f5f9e53b96b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_59bbd055-ce98-4256-aa35-db1d4f6c77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringCharges_59bbd055-ce98-4256-aa35-db1d4f6c77fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d51c6234-6c34-4140-abdf-f1d7aefe0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d51c6234-6c34-4140-abdf-f1d7aefe0ba2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesClassificationofRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_499eb59d-2ba3-4dc1-aebf-457b99fdae64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:to="loc_us-gaap_CostOfSalesMember_499eb59d-2ba3-4dc1-aebf-457b99fdae64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f81330d0-b89b-4556-b370-8cd3fb829035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f81330d0-b89b-4556-b370-8cd3fb829035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a944a813-57dc-4d5c-a830-c8d7ea16933d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a944a813-57dc-4d5c-a830-c8d7ea16933d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_085670fc-eca5-404e-9020-3260efe6b575" xlink:href="mdt-20250425.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_085670fc-eca5-404e-9020-3260efe6b575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9e142ac9-6c4e-4977-8a56-ad0984dd1525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringCharges_9e142ac9-6c4e-4977-8a56-ad0984dd1525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_3a5734e4-1ae8-41f2-96cf-069a3d861fc6" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_3a5734e4-1ae8-41f2-96cf-069a3d861fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_1697f916-15a7-421a-84dc-cf0575c5d7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringCosts_1697f916-15a7-421a-84dc-cf0575c5d7ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_17b701f0-1415-4b15-939a-f7f38eb1064d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_17b701f0-1415-4b15-939a-f7f38eb1064d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_00c085eb-77d0-494c-af59-7e7d4f580291_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_00c085eb-77d0-494c-af59-7e7d4f580291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e3734406-f499-4ad8-bd7b-52764a47f8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e3734406-f499-4ad8-bd7b-52764a47f8b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember_393ec1fb-2558-46cd-89e6-8a1646a3a1ff" xlink:href="mdt-20250425.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:to="loc_mdt_AssociatedAndOtherCostsMember_393ec1fb-2558-46cd-89e6-8a1646a3a1ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6911d26d-9066-4065-b787-ea18d39e4567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserve_6911d26d-9066-4065-b787-ea18d39e4567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_5b4fdc6b-88b5-4d6a-be61-22e42124d81a" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_5b4fdc6b-88b5-4d6a-be61-22e42124d81a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7078002f-7376-4e90-bde8-b3c1f435e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_PaymentsForRestructuring_7078002f-7376-4e90-bde8-b3c1f435e7c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_6b940368-07e0-489b-ab49-13dc88de43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_6b940368-07e0-489b-ab49-13dc88de43a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9a84ca58-6449-4957-a7de-e4121f780ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9a84ca58-6449-4957-a7de-e4121f780ef4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_33a1d39f-0da3-4f63-94b9-4bcbc55b592c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b16b5b7d-b91a-4afa-9697-9a80fb4dec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:to="loc_us-gaap_RestructuringCharges_b16b5b7d-b91a-4afa-9697-9a80fb4dec9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39d9139b-d7e5-428f-8bf2-592b33d65539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39d9139b-d7e5-428f-8bf2-592b33d65539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_98e915b0-bd18-4e3f-9852-fc79fcd9b2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_98e915b0-bd18-4e3f-9852-fc79fcd9b2e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6b8456bc-7ea1-4f1a-9bfb-940ff08fe785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6b8456bc-7ea1-4f1a-9bfb-940ff08fe785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_97dba557-25bb-414e-8904-45c4490e5615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_97dba557-25bb-414e-8904-45c4490e5615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f3ed24b-7e20-463e-9592-ffab8ace563a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f3ed24b-7e20-463e-9592-ffab8ace563a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4bfb869a-1f90-451b-b410-62501f8106a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4bfb869a-1f90-451b-b410-62501f8106a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f7ba427d-0caf-4ec2-8041-9b1af87806db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f7ba427d-0caf-4ec2-8041-9b1af87806db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_0e218246-dde9-43a2-afc5-eb01eac0d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_0e218246-dde9-43a2-afc5-eb01eac0d20c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ed339ffc-b994-40da-854a-fe81c6a79183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ed339ffc-b994-40da-854a-fe81c6a79183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3d8f127c-6d92-4cae-8bbf-596a10f608e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3d8f127c-6d92-4cae-8bbf-596a10f608e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_c5cf9bc4-dbb8-45a2-8895-68a08b7ee1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_c5cf9bc4-dbb8-45a2-8895-68a08b7ee1ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a676bd02-10db-4e9c-bb55-542b9e4e6e79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a676bd02-10db-4e9c-bb55-542b9e4e6e79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f9d7264d-fead-4490-b031-807e050fdf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:to="loc_us-gaap_InvestmentsMember_f9d7264d-fead-4490-b031-807e050fdf0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_a9bc9841-72d9-49a5-881f-4ed8d25adada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:to="loc_us-gaap_OtherAssetsMember_a9bc9841-72d9-49a5-881f-4ed8d25adada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8fb8718e-d656-4807-b082-58b009e38bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8fb8718e-d656-4807-b082-58b009e38bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57f53781-3d3c-4a60-a009-6772bde6699e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57f53781-3d3c-4a60-a009-6772bde6699e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f675e827-cfc8-4408-984a-d53aac8d8bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f675e827-cfc8-4408-984a-d53aac8d8bdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7fecf764-7fea-457c-a3aa-32552df7503b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7fecf764-7fea-457c-a3aa-32552df7503b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e6ef800-2719-4671-9d2f-75ab48a82882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e6ef800-2719-4671-9d2f-75ab48a82882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_41a2aa50-73f8-43b7-aa37-dfff704e3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_41a2aa50-73f8-43b7-aa37-dfff704e3d6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b7986d1c-89b0-4bf1-ae0e-5678960d0075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b7986d1c-89b0-4bf1-ae0e-5678960d0075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_8ea8e4da-a674-45cd-86c7-2b9f53c3db09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_8ea8e4da-a674-45cd-86c7-2b9f53c3db09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_71126571-4ea6-4d8b-8f1c-27c0e35bf393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_71126571-4ea6-4d8b-8f1c-27c0e35bf393" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_7bd6a089-04f2-4032-9f74-f9fd63acb62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_7bd6a089-04f2-4032-9f74-f9fd63acb62f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:href="mdt-20250425.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:to="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_dd84adb0-d8e0-4f77-8076-20c4441a2026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_dd84adb0-d8e0-4f77-8076-20c4441a2026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0add706a-9874-4d77-9542-6b3cfcafe69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0add706a-9874-4d77-9542-6b3cfcafe69a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebad928f-68c9-40d5-8960-ec17f0db8bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebad928f-68c9-40d5-8960-ec17f0db8bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82184d43-d600-4904-b3f8-5c61116bc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82184d43-d600-4904-b3f8-5c61116bc5cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_abd05ea9-71ad-4484-bd51-00a95bf8dca1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_abd05ea9-71ad-4484-bd51-00a95bf8dca1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_40f329a3-3a44-4cd1-b244-3066c2eb1d92" xlink:href="mdt-20250425.xsd#mdt_EquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:to="loc_mdt_EquityInvestmentsMember_40f329a3-3a44-4cd1-b244-3066c2eb1d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:to="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0ec23f12-6a05-466a-800b-9e6fc49fd0e5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:to="loc_srt_OwnershipDomain_0ec23f12-6a05-466a-800b-9e6fc49fd0e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:to="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_6f3919e4-b2c1-4fda-9af7-8079eeb6c531" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:to="loc_mdt_MozarcMember_6f3919e4-b2c1-4fda-9af7-8079eeb6c531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_bb6227bd-00d0-4f14-89b0-683957184e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_bb6227bd-00d0-4f14-89b0-683957184e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_84249c53-1130-414d-9c92-a98d943198f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_84249c53-1130-414d-9c92-a98d943198f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f2f0831a-06d0-4d79-88d7-59846aaf0d51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f2f0831a-06d0-4d79-88d7-59846aaf0d51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5f9a6991-fe70-48bd-8463-d6e6343af523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5f9a6991-fe70-48bd-8463-d6e6343af523" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_27446573-efdc-4f5f-8bef-f0cfd4dfe6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:to="loc_us-gaap_OtherAssetsMember_27446573-efdc-4f5f-8bef-f0cfd4dfe6f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_01362a93-c16c-40bf-9db2-e8ddb0a57f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_01362a93-c16c-40bf-9db2-e8ddb0a57f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9035adf4-0b22-4c1a-bd61-cf4b8159a1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9035adf4-0b22-4c1a-bd61-cf4b8159a1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f6e41477-59e7-4762-b87d-3f90dc42b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f6e41477-59e7-4762-b87d-3f90dc42b8eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_34cdfa5a-9d3f-4798-8cb3-6dc5df1d8ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquityMethodInvestments_34cdfa5a-9d3f-4798-8cb3-6dc5df1d8ffc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_b5d88739-38c5-44d5-b90c-7fa055f3c9fb" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_b5d88739-38c5-44d5-b90c-7fa055f3c9fb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b1b5e67-a912-431b-8642-21396d167ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b1b5e67-a912-431b-8642-21396d167ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_1d98854c-2df1-4e9b-bf32-e233524f2a0c" xlink:href="mdt-20250425.xsd#mdt_EquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:to="loc_mdt_EquityInvestmentsMember_1d98854c-2df1-4e9b-bf32-e233524f2a0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4ab3f0f1-51ca-4720-b234-8e55ebbaeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4ab3f0f1-51ca-4720-b234-8e55ebbaeadc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_GainOnInvestments_1b28fb88-7d4a-4287-8c8f-dfd9373ac50b" xlink:href="mdt-20250425.xsd#mdt_GainOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_mdt_GainOnInvestments_1b28fb88-7d4a-4287-8c8f-dfd9373ac50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossOnInvestments_70e30c8d-46d9-419b-9a79-18d8417347b8" xlink:href="mdt-20250425.xsd#mdt_LossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_mdt_LossOnInvestments_70e30c8d-46d9-419b-9a79-18d8417347b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_bafc3205-872c-4ddc-b935-5e44df99d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_bafc3205-872c-4ddc-b935-5e44df99d0c5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:href="mdt-20250425.xsd#mdt_DebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:href="mdt-20250425.xsd#mdt_ScheduleOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_80a92efe-063e-4a72-9d35-9ce1a6d0860a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_80a92efe-063e-4a72-9d35-9ce1a6d0860a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_5f1d0bc5-797d-4fc5-991b-dc3c40aa600b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:to="loc_us-gaap_NotesPayableToBanksMember_5f1d0bc5-797d-4fc5-991b-dc3c40aa600b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5d215c88-d4a1-4d4d-a0ee-cd3f65621af1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:to="loc_us-gaap_SeniorNotesMember_5d215c88-d4a1-4d4d-a0ee-cd3f65621af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25f6bf34-0f28-42e9-912e-1156002c4c2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25f6bf34-0f28-42e9-912e-1156002c4c2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20260250PercentMember_55a8761c-3c25-489d-a856-0c9eb677b7d0" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20260250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2019Due20260250PercentMember_55a8761c-3c25-489d-a856-0c9eb677b7d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20260.000PercentMember_ae8cd4a7-135a-41bd-9488-42b0f815b89e" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20260.000PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2020Due20260.000PercentMember_ae8cd4a7-135a-41bd-9488-42b0f815b89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20262.625PercentMember_48047915-beda-440d-bc95-c548d274d5a8" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20262.625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2022Due20262.625PercentMember_48047915-beda-440d-bc95-c548d274d5a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_7dbe3ce1-2f15-4749-85be-9e0706d759ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_ShortTermBorrowings_7dbe3ce1-2f15-4749-85be-9e0706d759ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_04c565ce-3fce-4188-bae2-43da3f4a6f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtInstrumentTerm_04c565ce-3fce-4188-bae2-43da3f4a6f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8b0291b-13e2-4cf9-86ae-2a531ee289bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8b0291b-13e2-4cf9-86ae-2a531ee289bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f1786ed3-eaa3-4b47-ac2f-02e9fb39b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_LongTermDebtCurrent_f1786ed3-eaa3-4b47-ac2f-02e9fb39b0e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ecbc9730-cb08-411a-9065-a8ac6a23ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ecbc9730-cb08-411a-9065-a8ac6a23ac0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_2f09aca0-2332-4b75-84e7-ce6683aac428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_CommercialPaper_2f09aca0-2332-4b75-84e7-ce6683aac428" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_3558422c-e9af-4533-9f6d-71c994e0095d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtCurrent_3558422c-e9af-4533-9f6d-71c994e0095d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d29b7651-331e-4d62-ad3d-62720eea3e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d29b7651-331e-4d62-ad3d-62720eea3e9f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015And2020CommercialPaperProgramMember_eb14e342-9a0e-483f-9a64-8ecdf062fe0b" xlink:href="mdt-20250425.xsd#mdt_A2015And2020CommercialPaperProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_A2015And2020CommercialPaperProgramMember_eb14e342-9a0e-483f-9a64-8ecdf062fe0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_50e0177c-1184-498c-aecd-fd7b5b1be3f1" xlink:href="mdt-20250425.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_50e0177c-1184-498c-aecd-fd7b5b1be3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember_c7a3fcb1-32a1-435c-bf60-a58c1e9b63df" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_MedtronicLuxcoSeniorNotesMember_c7a3fcb1-32a1-435c-bf60-a58c1e9b63df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember_33361a75-3766-44a5-a266-ce2e07507bf1" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_SeniorNotes2015Due20253.500PercentMember_33361a75-3766-44a5-a266-ce2e07507bf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember_413e8851-8bf6-4b75-aae5-b5a476af6b62" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_SeniorNotes2017Due20273.350PercentMember_413e8851-8bf6-4b75-aae5-b5a476af6b62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_133c605d-f108-46bb-aa7c-9bf4ccc16bfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_133c605d-f108-46bb-aa7c-9bf4ccc16bfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2426fb9d-b2e5-42f3-9b9b-8e6358b04635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:to="loc_us-gaap_CommercialPaperMember_2426fb9d-b2e5-42f3-9b9b-8e6358b04635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e5bfba00-baa2-4996-a0c8-d80bc8c9c002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:to="loc_us-gaap_LoansPayableMember_e5bfba00-baa2-4996-a0c8-d80bc8c9c002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f402a99e-6153-4db7-bb62-98e609fee557_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:to="loc_srt_RangeMember_f402a99e-6153-4db7-bb62-98e609fee557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:to="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cb28d75-7bdf-4c66-8cfb-89cf13b96043" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:to="loc_srt_MinimumMember_7cb28d75-7bdf-4c66-8cfb-89cf13b96043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6bf856c5-4469-4840-a33a-501be291cd4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:to="loc_us-gaap_CreditFacilityDomain_6bf856c5-4469-4840-a33a-501be291cd4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:to="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c1046aa9-4c3a-4fb2-accb-a00376a39dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:to="loc_us-gaap_LineOfCreditMember_c1046aa9-4c3a-4fb2-accb-a00376a39dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_75b60502-6469-4775-b0af-dd945541c238_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_75b60502-6469-4775-b0af-dd945541c238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_de721465-63b0-4c7c-8d88-9d2cb4363240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:to="loc_us-gaap_SeniorNotesMember_de721465-63b0-4c7c-8d88-9d2cb4363240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5dc688d0-c543-4e45-bdbb-654a7b251bf1_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:to="loc_dei_EntityDomain_5dc688d0-c543-4e45-bdbb-654a7b251bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:to="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember_4b4b6e8c-0074-4726-a3d5-f23d4f82911e" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:to="loc_mdt_MedtronicLuxcoMember_4b4b6e8c-0074-4726-a3d5-f23d4f82911e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity_edda70f1-ed0a-457e-ab7e-3da9a246e3a3" xlink:href="mdt-20250425.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_CommercialPaperMaximumBorrowingCapacity_edda70f1-ed0a-457e-ab7e-3da9a246e3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6e4df90c-5d1d-47ab-beb8-50842608e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtCurrent_6e4df90c-5d1d-47ab-beb8-50842608e8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f56da9f1-00bf-4bc9-8f60-7a6191b6b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_f56da9f1-00bf-4bc9-8f60-7a6191b6b8b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_1385902c-e419-4699-b299-b32f694ca033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_1385902c-e419-4699-b299-b32f694ca033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_90cde5df-52e9-4459-9699-c93037fd33c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_90cde5df-52e9-4459-9699-c93037fd33c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension_443baf1c-9067-4ceb-bba3-ac14c0992ab0" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_LineOfCreditFacilityLengthOfExtension_443baf1c-9067-4ceb-bba3-ac14c0992ab0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_a9a1b9b4-b8d3-45b9-b9ce-887b4e6afe46" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_a9a1b9b4-b8d3-45b9-b9ce-887b4e6afe46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3c0520f6-fc13-45ce-9f6f-416f0dc77eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LineOfCredit_3c0520f6-fc13-45ce-9f6f-416f0dc77eac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches_f82c8128-bb37-4b31-97ab-52fef02b7d82" xlink:href="mdt-20250425.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_DebtInstrumentNumberofTranches_f82c8128-bb37-4b31-97ab-52fef02b7d82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_acd27315-fa2a-470f-a0e8-b11416f00a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_acd27315-fa2a-470f-a0e8-b11416f00a12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_ee92dbf3-0766-4936-863b-500118a0cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_ee92dbf3-0766-4936-863b-500118a0cdad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_939a4549-00df-4437-b52a-5b1262e12f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_939a4549-00df-4437-b52a-5b1262e12f4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_32d23aa3-9eea-4c0b-8c05-d7838440ee65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_32d23aa3-9eea-4c0b-8c05-d7838440ee65" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ab693d87-44f1-45fb-97f0-4064cd1f8105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ab693d87-44f1-45fb-97f0-4064cd1f8105" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aa53318-8fee-4a20-9705-ba07da520f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aa53318-8fee-4a20-9705-ba07da520f0b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_65debc4e-7de9-456c-bc04-9d49ffea4a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_RepaymentsOfDebt_65debc4e-7de9-456c-bc04-9d49ffea4a7c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3e89053d-5e51-4b71-9ae2-9ca5a8d74bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3e89053d-5e51-4b71-9ae2-9ca5a8d74bef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_db5586b5-1ba1-4ad8-9bd1-2aed4d573775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_InterestExpenseBorrowings_db5586b5-1ba1-4ad8-9bd1-2aed4d573775" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1d20fc70-36bd-4a9c-8fbc-7d9e90b0701b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LongTermDebtFairValue_1d20fc70-36bd-4a9c-8fbc-7d9e90b0701b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation_79b84ed0-7e92-43ff-90b7-3a47f03e0ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligation_79b84ed0-7e92-43ff-90b7-3a47f03e0ac9" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c3a2961c-ef5b-4873-978b-1c6064d10b14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c3a2961c-ef5b-4873-978b-1c6064d10b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d93eb3ea-a38a-4175-863b-0d2d49ae3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:to="loc_us-gaap_SeniorNotesMember_d93eb3ea-a38a-4175-863b-0d2d49ae3a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff6430a4-eba5-44a0-ab23-78f7564cfc81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff6430a4-eba5-44a0-ab23-78f7564cfc81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20260250PercentMember_0f583ba5-fadc-4fd4-b1b8-e4e4df0cf767" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20260250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20260250PercentMember_0f583ba5-fadc-4fd4-b1b8-e4e4df0cf767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20260.000PercentMember_08a6fe94-147e-4ed2-bcf1-38a7d10cf75b" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20260.000PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20260.000PercentMember_08a6fe94-147e-4ed2-bcf1-38a7d10cf75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20262.625PercentMember_a948f633-042e-4246-8d60-322868c61a50" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20262.625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20262.625PercentMember_a948f633-042e-4246-8d60-322868c61a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20271125PercentMember_727b1842-e6d4-41dc-bfa9-d5f119c31b5b" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20271125PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20271125PercentMember_727b1842-e6d4-41dc-bfa9-d5f119c31b5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20284.250PercentMember_237c0bc5-ff0e-419d-8de7-30fc94598c19" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20284.250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2023Due20284.250PercentMember_237c0bc5-ff0e-419d-8de7-30fc94598c19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20293.000PercentMember_08d0a516-119a-4407-8447-f04beab52337" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20293.000PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20293.000PercentMember_08d0a516-119a-4407-8447-f04beab52337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20290375PercentMember_b92255aa-8152-48b1-964f-08f57584299d" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20290375PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20290375PercentMember_b92255aa-8152-48b1-964f-08f57584299d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20303.650PercentMember_bfd026e4-2855-4f02-8575-7d37f5dc13a4" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20303.650PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20303.650PercentMember_bfd026e4-2855-4f02-8575-7d37f5dc13a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311625PercentMember_2e51671a-20cc-4b3a-868e-26b030918388" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20311625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20311625PercentMember_2e51671a-20cc-4b3a-868e-26b030918388" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20321000PercentMember_efac4d6f-9bb4-4ae4-8896-64f2d983a408" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20321000PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20321000PercentMember_efac4d6f-9bb4-4ae4-8896-64f2d983a408" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20323.125PercentMember_81d5b866-77f6-4854-8598-437519e4b7d1" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20323.125PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20323.125PercentMember_81d5b866-77f6-4854-8598-437519e4b7d1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20330750PercentMember_23345ebb-81e6-4d58-b0eb-6f85b82eabc4" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20330750PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20330750PercentMember_23345ebb-81e6-4d58-b0eb-6f85b82eabc4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20334.500PercentMember_40d2887b-cbd3-4c81-807b-24664a619d1f" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20334.500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2023Due20334.500PercentMember_40d2887b-cbd3-4c81-807b-24664a619d1f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20353.375PercentMember_8dc254a5-51e8-4410-93c8-762e883ac844" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20353.375PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20353.375PercentMember_8dc254a5-51e8-4410-93c8-762e883ac844" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20354.375PercentMember_835d26c1-0b7b-492c-a907-b8d7b311cb1c" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20354.375PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2015Due20354.375PercentMember_835d26c1-0b7b-492c-a907-b8d7b311cb1c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20373.875PercentMember_4ccb6c89-126f-4706-bd72-e59700217fff" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20373.875PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20373.875PercentMember_4ccb6c89-126f-4706-bd72-e59700217fff" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_48d43649-05a4-4a9d-a11c-bf39055d93c8" xlink:href="mdt-20250425.xsd#mdt_CIFSASeniorNotes2007Due20386.550PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_48d43649-05a4-4a9d-a11c-bf39055d93c8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392250PercentMember_4eea14c6-850e-45ff-8d02-9ca2510853de" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20392250PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20392250PercentMember_4eea14c6-850e-45ff-8d02-9ca2510853de" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due20396500PercentMember_781e96c6-928a-442e-b297-e825a2162262" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2009Due20396500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2009Due20396500PercentMember_781e96c6-928a-442e-b297-e825a2162262" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20401500PercentMember_86fb27e1-d2ba-44b4-af19-4361879b6579" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20401500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20401500PercentMember_86fb27e1-d2ba-44b4-af19-4361879b6579" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due20405550PercentMember_940b857b-b0fd-4d4e-87a5-26513d433ea0" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2010Due20405550PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2010Due20405550PercentMember_940b857b-b0fd-4d4e-87a5-26513d433ea0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20411375PercentMember_b551f39b-c251-405d-b824-6813937293a9" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20411375PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20411375PercentMember_b551f39b-c251-405d-b824-6813937293a9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due20424500PercentMember_6a894967-18ce-460f-8d21-0c565e4c9109" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2012Due20424500PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2012Due20424500PercentMember_6a894967-18ce-460f-8d21-0c565e4c9109" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due20434000PercentMember_aa337d05-ec4c-4077-9a5b-880105c74096" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2013Due20434000PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2013Due20434000PercentMember_aa337d05-ec4c-4077-9a5b-880105c74096" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20444.150PercentMember_b1c73c12-3771-4cf5-99ac-927d20db28bb" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20444.150PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20444.150PercentMember_b1c73c12-3771-4cf5-99ac-927d20db28bb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due20444625PercentMember_799257c6-eca5-4118-8564-6cc32ea36a6c" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2014Due20444625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2014Due20444625PercentMember_799257c6-eca5-4118-8564-6cc32ea36a6c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20454625PercentMember_11d486af-1916-4eef-823f-ef610013da77" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20454625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2015Due20454625PercentMember_11d486af-1916-4eef-823f-ef610013da77" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20501750PercentMember_4d025354-2b86-4a52-ae9e-656143c30ced" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20501750PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20501750PercentMember_4d025354-2b86-4a52-ae9e-656143c30ced" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20511625PercentMember_916e845b-2d00-4360-abfe-35169816b383" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20511625PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20511625PercentMember_916e845b-2d00-4360-abfe-35169816b383" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20544.150PercentMember_b0291378-c2ab-4788-b35e-94c7bb71aebf" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20544.150PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20544.150PercentMember_b0291378-c2ab-4788-b35e-94c7bb71aebf" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e559cea-9fea-43e4-b631-242ed5032668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e559cea-9fea-43e4-b631-242ed5032668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c07b8ddc-4782-4bf7-8cff-fce947110774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentTerm_c07b8ddc-4782-4bf7-8cff-fce947110774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bdc0ea13-3a76-44be-ad91-ce2606a094b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bdc0ea13-3a76-44be-ad91-ce2606a094b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e6210382-6e7b-4d8a-98c6-3ade3376ea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e6210382-6e7b-4d8a-98c6-3ade3376ea9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_02ee9f9a-8579-425f-b144-0cb3695a00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_02ee9f9a-8579-425f-b144-0cb3695a00a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_51e2529a-686f-4b13-bbf7-3db3402364ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_51e2529a-686f-4b13-bbf7-3db3402364ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8d009ffb-30e1-4161-845b-3af8f2c7f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8d009ffb-30e1-4161-845b-3af8f2c7f66f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_e5305a8e-5700-4303-a62b-127e0b34f367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_e5305a8e-5700-4303-a62b-127e0b34f367" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_661dc5bb-b15c-424a-8344-453f6039da17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_661dc5bb-b15c-424a-8344-453f6039da17" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_27ddc182-968c-4066-8c62-88b296a3710e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_27ddc182-968c-4066-8c62-88b296a3710e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_03113da8-7752-4239-b33f-6d08249a362d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_03113da8-7752-4239-b33f-6d08249a362d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6818ab7f-1741-4734-aefd-52c48179715f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:to="loc_us-gaap_HedgingDesignationDomain_6818ab7f-1741-4734-aefd-52c48179715f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:to="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5fdc974c-4499-430c-b740-de22b2caf4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5fdc974c-4499-430c-b740-de22b2caf4d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0d684a42-373a-4c27-b217-718d6c4f790e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0d684a42-373a-4c27-b217-718d6c4f790e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_cbbe2ea7-9287-4eef-9b18-4e3d3815c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:to="loc_us-gaap_CashFlowHedgingMember_cbbe2ea7-9287-4eef-9b18-4e3d3815c9f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_af913113-1a47-4a3e-affe-925c0b60e660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:to="loc_us-gaap_FairValueHedgingMember_af913113-1a47-4a3e-affe-925c0b60e660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_67f76514-3a73-4165-bc12-3abe5ececf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_67f76514-3a73-4165-bc12-3abe5ececf0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_73b59308-b068-425e-a1a4-af28d2408f53" xlink:href="mdt-20250425.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_73b59308-b068-425e-a1a4-af28d2408f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0775d011-9548-40b0-b336-13fdbea237a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0775d011-9548-40b0-b336-13fdbea237a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42cf7574-0c62-44ec-8b65-b3f451d90267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42cf7574-0c62-44ec-8b65-b3f451d90267" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e850e9ed-c682-4a8d-859f-990b71603c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e850e9ed-c682-4a8d-859f-990b71603c4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_7edbc2da-8bec-45ec-9dfc-6f38e24cfde3" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_7edbc2da-8bec-45ec-9dfc-6f38e24cfde3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6090b5ba-c846-411e-bc3e-ab666819ff6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6090b5ba-c846-411e-bc3e-ab666819ff6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c1a54b5a-d2d9-4481-aeb3-d61330ec5d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c1a54b5a-d2d9-4481-aeb3-d61330ec5d8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_4a4de204-f0f3-4392-bac9-4c4d3c3208ef" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_4a4de204-f0f3-4392-bac9-4c4d3c3208ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_282b8ecb-028f-4342-906f-aefc33a1458c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_282b8ecb-028f-4342-906f-aefc33a1458c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a5821145-05d5-4196-9f48-6990bbce9e85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_CashFlowHedgingMember_a5821145-05d5-4196-9f48-6990bbce9e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e6f06dba-0028-46d7-95c4-8bb6d902ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e6f06dba-0028-46d7-95c4-8bb6d902ce24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_d3deab26-1aa9-4bd9-8682-cdd1db87880c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_FairValueHedgingMember_d3deab26-1aa9-4bd9-8682-cdd1db87880c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3acb390a-4ec3-406a-8ffb-f7ae305495ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:to="loc_us-gaap_HedgingDesignationDomain_3acb390a-4ec3-406a-8ffb-f7ae305495ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:to="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6947f059-1625-4676-93ba-b641f74fd193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6947f059-1625-4676-93ba-b641f74fd193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_45eb887d-f548-4776-9b9b-c221911a6d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:to="loc_us-gaap_NondesignatedMember_45eb887d-f548-4776-9b9b-c221911a6d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bb0430d6-3faa-4b0b-a21c-8a361ec30434_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:to="loc_srt_SegmentGeographicalDomain_bb0430d6-3faa-4b0b-a21c-8a361ec30434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:to="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_491fb396-de1d-48ac-b0c0-eae82844429a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:to="loc_srt_EuropeMember_491fb396-de1d-48ac-b0c0-eae82844429a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_827a579f-a38a-4e9e-8257-e6659fb18d8a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:to="loc_country_JP_827a579f-a38a-4e9e-8257-e6659fb18d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7631fcfb-c935-43f3-937c-a130dbcecabb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7631fcfb-c935-43f3-937c-a130dbcecabb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c48be9ae-3286-43aa-9d25-fcd847b07cbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c48be9ae-3286-43aa-9d25-fcd847b07cbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_441a9838-181c-4d2c-93c1-c1a93cbea81c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:to="loc_us-gaap_ForeignExchangeContractMember_441a9838-181c-4d2c-93c1-c1a93cbea81c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_324a3c26-f886-4b9d-9a97-eaefd938678f" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_324a3c26-f886-4b9d-9a97-eaefd938678f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c82dc3bc-c286-4d49-9323-6f303f2b85fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c82dc3bc-c286-4d49-9323-6f303f2b85fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_9688f0dc-c312-48e3-b5bb-b5166a809793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_9688f0dc-c312-48e3-b5bb-b5166a809793" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_79ffdeef-3d56-4087-a317-ddb754fd2e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:to="loc_us-gaap_CostOfSalesMember_79ffdeef-3d56-4087-a317-ddb754fd2e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_67ba7e7d-6311-4e36-814a-e9278ac22806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_FairValueHedgingMember_67ba7e7d-6311-4e36-814a-e9278ac22806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e0b731e7-49df-4d73-b423-da307cfcceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_CashFlowHedgingMember_e0b731e7-49df-4d73-b423-da307cfcceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_bb6516c0-6a6f-439d-b101-adc82a7e57cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_bb6516c0-6a6f-439d-b101-adc82a7e57cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c81f67a2-f9c4-4076-9110-16d0458053e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c81f67a2-f9c4-4076-9110-16d0458053e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_641459b4-b1df-4459-b6f5-46b7f958b267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_641459b4-b1df-4459-b6f5-46b7f958b267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e91cc38f-fe55-4f36-bedb-408c88e6a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e91cc38f-fe55-4f36-bedb-408c88e6a0c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da073b02-e61c-49fa-9e41-9040b91441e8" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da073b02-e61c-49fa-9e41-9040b91441e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_932406e2-7206-4b4d-86be-e8920fcf4396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_932406e2-7206-4b4d-86be-e8920fcf4396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ddd8511b-46da-4668-8a22-d6dda8fe2f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ddd8511b-46da-4668-8a22-d6dda8fe2f0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_7804844e-7d56-4b12-ae52-83daa656c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_7804844e-7d56-4b12-ae52-83daa656c0ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_fa1b0410-80aa-443e-bc54-a7b36e12eddc" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_fa1b0410-80aa-443e-bc54-a7b36e12eddc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bb1a8b39-5bca-4149-bee4-fc7751ca9241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bb1a8b39-5bca-4149-bee4-fc7751ca9241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_be8ecbec-762e-4b21-b20f-aff0ac4ed19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_be8ecbec-762e-4b21-b20f-aff0ac4ed19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_df27f162-28bf-4eb7-9f87-2747f72e2443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_df27f162-28bf-4eb7-9f87-2747f72e2443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44223cfe-7fb7-4320-8aeb-5bd5b6b6f069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44223cfe-7fb7-4320-8aeb-5bd5b6b6f069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_20e0829f-39f0-4ed2-a589-b0391e792561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_20e0829f-39f0-4ed2-a589-b0391e792561" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:to="loc_us-gaap_HedgingDesignationDomain_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:to="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4fa00581-56ae-4f95-ab38-c005b6302b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4fa00581-56ae-4f95-ab38-c005b6302b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6e6c1a33-e77f-46cf-b740-6ed2fe4cdc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:to="loc_us-gaap_NondesignatedMember_6e6c1a33-e77f-46cf-b740-6ed2fe4cdc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_068f84a4-0bc8-4ade-8271-e92d22be9eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:to="loc_us-gaap_ForeignExchangeContractMember_068f84a4-0bc8-4ade-8271-e92d22be9eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TotalReturnSwapMember_3b3bce31-87e3-4175-b3ea-e23288e7d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TotalReturnSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:to="loc_us-gaap_TotalReturnSwapMember_3b3bce31-87e3-4175-b3ea-e23288e7d4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b25c514b-8726-4d8e-9f9a-ef92fedd4c72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b25c514b-8726-4d8e-9f9a-ef92fedd4c72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_82db147c-f81e-403c-8101-19a0123e4987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_82db147c-f81e-403c-8101-19a0123e4987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_732a3557-df44-4316-8f67-c95f1443e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_OtherAssetsMember_732a3557-df44-4316-8f67-c95f1443e9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_c759e19e-430a-4410-b174-59cb984f4476" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_mdt_OtherAccruedExpensesMember_c759e19e-430a-4410-b174-59cb984f4476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_4254c65a-49b8-432b-b080-e7ad8e5f41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_OtherLiabilitiesMember_4254c65a-49b8-432b-b080-e7ad8e5f41a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7337f0eb-d6f4-4897-8e44-2f6292569c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7337f0eb-d6f4-4897-8e44-2f6292569c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2ff7bec1-98fc-44e4-bbe9-b311dbc9bd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2ff7bec1-98fc-44e4-bbe9-b311dbc9bd8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_927ae524-9f94-400c-885e-252efb3d1c3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_927ae524-9f94-400c-885e-252efb3d1c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_44a0c1ac-6ac5-4a24-b916-b3a0dff3d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_44a0c1ac-6ac5-4a24-b916-b3a0dff3d3ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9cbf8b92-65bf-4225-a5c6-0b758367eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9cbf8b92-65bf-4225-a5c6-0b758367eca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2213748d-b908-4802-ad66-2f34598e8c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeAssets_2213748d-b908-4802-ad66-2f34598e8c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a64c8f93-e458-4dde-8732-cb1c1c74aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeLiabilities_a64c8f93-e458-4dde-8732-cb1c1c74aafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_739286b0-c8b2-4882-9966-9cabd595032f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_739286b0-c8b2-4882-9966-9cabd595032f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4cb31c17-2da6-4dfe-bf89-9d69c573b144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4cb31c17-2da6-4dfe-bf89-9d69c573b144" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d11abb2a-1247-450b-93ba-3918df3559c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d11abb2a-1247-450b-93ba-3918df3559c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7bb8c250-6839-4b92-a219-fdf4491342a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7bb8c250-6839-4b92-a219-fdf4491342a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TotalReturnSwapMember_2913865e-10e7-48fc-900e-77deb6673397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TotalReturnSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:to="loc_us-gaap_TotalReturnSwapMember_2913865e-10e7-48fc-900e-77deb6673397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2c00d41b-ec81-4f05-abf1-2da0a9285688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2c00d41b-ec81-4f05-abf1-2da0a9285688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8f3d9bf2-6f9c-439a-877e-9444984c8085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8f3d9bf2-6f9c-439a-877e-9444984c8085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_d2fdb324-1cf4-4321-99db-b848c4c913ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_d2fdb324-1cf4-4321-99db-b848c4c913ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_4745ecde-60dc-47f4-b5b5-732b990ff71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_4745ecde-60dc-47f4-b5b5-732b990ff71a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47a7be69-974f-4097-b38f-82ed36e40c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47a7be69-974f-4097-b38f-82ed36e40c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_13d7c0ec-3bb5-4e67-83ce-17886f96a576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_13d7c0ec-3bb5-4e67-83ce-17886f96a576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_71980a13-7d02-41c8-b30c-535eafe581c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_71980a13-7d02-41c8-b30c-535eafe581c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_32624c1e-72bf-402d-b226-fba9141b260e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_32624c1e-72bf-402d-b226-fba9141b260e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_9150d6be-6447-426e-a5f3-680d18458244" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_9150d6be-6447-426e-a5f3-680d18458244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_fb27c983-2214-4b29-82df-feb490e8dbad" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_fb27c983-2214-4b29-82df-feb490e8dbad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_ce3fda2e-7058-47a3-95f2-59b10ece4d00" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_ce3fda2e-7058-47a3-95f2-59b10ece4d00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_93b39945-ffd8-4673-99f9-35fe7b9ba5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_93b39945-ffd8-4673-99f9-35fe7b9ba5c9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8f5ba00-aaaa-4932-a4b5-984a47523d31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:to="loc_us-gaap_SegmentDomain_d8f5ba00-aaaa-4932-a4b5-984a47523d31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:to="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_ca0d3c0b-817e-4239-b4da-cf058df55523" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_CardiovascularMember_ca0d3c0b-817e-4239-b4da-cf058df55523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_f9d5455d-edc3-4b58-8043-84895505637f" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_NeuroscienceGroupMember_f9d5455d-edc3-4b58-8043-84895505637f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_9ce78ede-589e-49dc-becb-6b7caeb5e69f" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_MedicalSurgicalMember_9ce78ede-589e-49dc-becb-6b7caeb5e69f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_04b83de5-3ec7-44a3-b195-056cb541cce3" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_DiabetesGroupMember_04b83de5-3ec7-44a3-b195-056cb541cce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:to="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_639ead96-ca20-4aa1-8194-5a69067e8ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_Goodwill_639ead96-ca20-4aa1-8194-5a69067e8ff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3945ef4-b016-42cc-a186-ad46993d96f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3945ef4-b016-42cc-a186-ad46993d96f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e25c6621-0db8-4c97-89c1-8e56686923d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e25c6621-0db8-4c97-89c1-8e56686923d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_67ce1012-bf88-473a-9d4e-0fe257d5522e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_67ce1012-bf88-473a-9d4e-0fe257d5522e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9d6635f-c24a-4c25-b325-dea2e44439d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_09741a8a-848b-4835-82e6-14cb59b038af" xlink:href="mdt-20250425.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:to="loc_mdt_VentilatorProductLineExitMember_09741a8a-848b-4835-82e6-14cb59b038af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember_1886258b-c144-4b5c-b596-5ef4b59f9eec" xlink:href="mdt-20250425.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:to="loc_mdt_RenalCareBusinessRCSMember_1886258b-c144-4b5c-b596-5ef4b59f9eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_84572e04-fb4b-4b5e-9ef0-e85df4bdf616_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:to="loc_us-gaap_SegmentDomain_84572e04-fb4b-4b5e-9ef0-e85df4bdf616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:to="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_230f863e-7efd-4d37-9c8a-fd220cfd0616" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:to="loc_mdt_MedicalSurgicalMember_230f863e-7efd-4d37-9c8a-fd220cfd0616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_c8973f03-2b74-4c50-bd3c-38b7d3d1dd18" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:to="loc_mdt_CardiovascularMember_c8973f03-2b74-4c50-bd3c-38b7d3d1dd18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_105068bc-36c1-4dc7-bf0c-e9d68c985d46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_105068bc-36c1-4dc7-bf0c-e9d68c985d46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_a8b69049-1c1e-4fee-9773-5e67f3388ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_a8b69049-1c1e-4fee-9773-5e67f3388ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c35ae4e3-2727-48b7-b9f6-406016da09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c35ae4e3-2727-48b7-b9f6-406016da09c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ffe58385-b26c-4b43-ba39-33a9b000811d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ffe58385-b26c-4b43-ba39-33a9b000811d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ead610b4-23f8-4b8d-8d36-952e8573fc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ead610b4-23f8-4b8d-8d36-952e8573fc7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c73dc435-5c27-4d3b-a788-4bc661d6ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c73dc435-5c27-4d3b-a788-4bc661d6ffc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5b747c19-c08c-49fc-bbda-915cacfc1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5b747c19-c08c-49fc-bbda-915cacfc1f86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_34bb30b1-cbc0-4c44-8c92-ecbf5b4579b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_34bb30b1-cbc0-4c44-8c92-ecbf5b4579b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcceleratedAmortizationOfIntangibleAssets_9ebe5a64-a2b1-40af-9a33-37181805b45e" xlink:href="mdt-20250425.xsd#mdt_AcceleratedAmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_mdt_AcceleratedAmortizationOfIntangibleAssets_9ebe5a64-a2b1-40af-9a33-37181805b45e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_edbf0988-0922-4241-bf1b-de83127d1b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_edbf0988-0922-4241-bf1b-de83127d1b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_1365d28c-51a2-4119-9c13-f753bc08cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_1365d28c-51a2-4119-9c13-f753bc08cdd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember_aa6c8843-0327-48b8-ab4f-b8fae3eb797a" xlink:href="mdt-20250425.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_mdt_PurchasedTechnologyAndPatentsMember_aa6c8843-0327-48b8-ab4f-b8fae3eb797a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_75c53b46-2983-466b-9ab3-9f9f8d870ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_75c53b46-2983-466b-9ab3-9f9f8d870ee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e26cbe1f-8818-44a9-8f7f-f4d62e53cde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e26cbe1f-8818-44a9-8f7f-f4d62e53cde6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_049e1f53-ae9a-4060-a053-42f676887139_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_049e1f53-ae9a-4060-a053-42f676887139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9420425d-c079-4121-9ffb-82ad632db161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9420425d-c079-4121-9ffb-82ad632db161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6a0bba35-2460-4e2c-9b82-f5496072ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6a0bba35-2460-4e2c-9b82-f5496072ad11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_239e497b-ea19-4cad-8615-77c993b9bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_239e497b-ea19-4cad-8615-77c993b9bf6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87243ebb-7018-4a3c-8ad2-ca694c07e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87243ebb-7018-4a3c-8ad2-ca694c07e9a6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ef3bf8f6-f913-46ff-a70d-64329e039427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_EquipmentMember_ef3bf8f6-f913-46ff-a70d-64329e039427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_3b80bc98-47d6-406e-a1f6-eab9fd7e13da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_3b80bc98-47d6-406e-a1f6-eab9fd7e13da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_99b6b095-8622-4a10-b12b-5cb2159d149b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_99b6b095-8622-4a10-b12b-5cb2159d149b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember_6e00b330-90dd-4de9-ae0b-9e05e62762d9" xlink:href="mdt-20250425.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_mdt_BuildingsAndLeaseholdImprovementsMember_6e00b330-90dd-4de9-ae0b-9e05e62762d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c9b036e8-6493-47ed-a0d8-3d3ab86e7b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_ConstructionInProgressMember_c9b036e8-6493-47ed-a0d8-3d3ab86e7b67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:to="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_642cfa09-f995-40c2-8601-9a54f1457205_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:to="loc_srt_RangeMember_642cfa09-f995-40c2-8601-9a54f1457205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:to="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51265c05-61a0-45a5-893b-2b442fa6457c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:to="loc_srt_MinimumMember_51265c05-61a0-45a5-893b-2b442fa6457c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d4bceb5-e182-406a-912c-55bdc0f1dab9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:to="loc_srt_MaximumMember_0d4bceb5-e182-406a-912c-55bdc0f1dab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4eff7cf3-2c2f-43df-bc20-7b828dcaa978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4eff7cf3-2c2f-43df-bc20-7b828dcaa978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b5a6d944-9b36-482b-bb36-32dd25fc4818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b5a6d944-9b36-482b-bb36-32dd25fc4818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_af0b78c1-37ef-4647-95c5-4e5edd83eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_af0b78c1-37ef-4647-95c5-4e5edd83eba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1278b364-74ff-4d6e-a9d8-c97463fb994b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1278b364-74ff-4d6e-a9d8-c97463fb994b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_999ce9d5-ca85-4d9b-8aa6-5e506a42a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_Depreciation_999ce9d5-ca85-4d9b-8aa6-5e506a42a95f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:to="loc_us-gaap_ClassOfStockDomain_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:to="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b49abf54-61b9-41a0-80e9-1e4006340bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b49abf54-61b9-41a0-80e9-1e4006340bbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6f382d09-a69f-48d5-850d-649f152ec36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6f382d09-a69f-48d5-850d-649f152ec36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1471f481-93f4-4dfd-b11d-795079f043e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1471f481-93f4-4dfd-b11d-795079f043e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized_b3d9fb0d-55ad-4a72-8f0f-a80cc72f49d7" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesAuthorized_b3d9fb0d-55ad-4a72-8f0f-a80cc72f49d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare_dbdfb66b-fdbe-4915-9af2-488d183be3b9" xlink:href="mdt-20250425.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockParorStatedValuePerShare_dbdfb66b-fdbe-4915-9af2-488d183be3b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_99f73602-1430-44ed-a2b4-87b2c3807be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_99f73602-1430-44ed-a2b4-87b2c3807be7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2f7fe786-b117-4a35-804e-a7f5bda076c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2f7fe786-b117-4a35-804e-a7f5bda076c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued_a659eb96-8d58-4d88-890d-8890c66d02e2" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesIssued_a659eb96-8d58-4d88-890d-8890c66d02e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding_abc8bc30-d60b-4dcd-acee-55089a41d2c4" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesOutstanding_abc8bc30-d60b-4dcd-acee-55089a41d2c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e0eeb79f-8b94-41eb-a5af-643ac9ee4591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e0eeb79f-8b94-41eb-a5af-643ac9ee4591" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e7398aaf-088a-4883-9b0b-a65833f342d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e7398aaf-088a-4883-9b0b-a65833f342d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_67f67d03-760f-4cf9-a1e9-1f3e461e5334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_67f67d03-760f-4cf9-a1e9-1f3e461e5334" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_2bc861d9-9266-46c0-8389-0e0a9616e7ba" xlink:href="mdt-20250425.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_2bc861d9-9266-46c0-8389-0e0a9616e7ba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_2846a9ab-ac31-4a85-9f20-946d00c16e7b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_2846a9ab-ac31-4a85-9f20-946d00c16e7b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_dd6a8187-5b1e-4946-a836-b90c47ae7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_dd6a8187-5b1e-4946-a836-b90c47ae7ce8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c676afb5-c3b4-4ef3-89bf-d2cc2102544b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c676afb5-c3b4-4ef3-89bf-d2cc2102544b" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_60b8a8de-e486-4bc9-b57f-75948df7a4a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:to="loc_us-gaap_PlanNameDomain_60b8a8de-e486-4bc9-b57f-75948df7a4a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:to="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_5fb1ffaa-ea0a-47b9-bbd8-d0644ec6f9cf" xlink:href="mdt-20250425.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:to="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_5fb1ffaa-ea0a-47b9-bbd8-d0644ec6f9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember_feb8ce91-d77f-4c52-b532-29302611b289" xlink:href="mdt-20250425.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:to="loc_mdt_A2024EmployeeStockPurchasePlanMember_feb8ce91-d77f-4c52-b532-29302611b289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7708779-4898-45fa-8d00-138900b220a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7708779-4898-45fa-8d00-138900b220a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7556ab26-fb0e-4c0c-a848-afed2abcf7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7556ab26-fb0e-4c0c-a848-afed2abcf7bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4eb0c11e-83ca-44c7-80cf-a51538905563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4eb0c11e-83ca-44c7-80cf-a51538905563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3b2e1f1c-781c-4b6a-8692-cf95b898a235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_PerformanceSharesMember_3b2e1f1c-781c-4b6a-8692-cf95b898a235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_39cfb822-d256-4827-a4d5-d8f9f73148aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_EmployeeStockMember_39cfb822-d256-4827-a4d5-d8f9f73148aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b99f7625-da82-4baf-9e25-4b41e72b8a87_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:to="loc_srt_RangeMember_b99f7625-da82-4baf-9e25-4b41e72b8a87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:to="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6492806c-a176-4d59-aabd-39f6361e2cfb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:to="loc_srt_MinimumMember_6492806c-a176-4d59-aabd-39f6361e2cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0bd080cc-8430-4aad-a482-8f0caebd3a3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:to="loc_srt_MaximumMember_0bd080cc-8430-4aad-a482-8f0caebd3a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c2e477a5-d7af-4b0c-b0f6-a1a039348f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c2e477a5-d7af-4b0c-b0f6-a1a039348f0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b771f3f4-6335-4557-b869-25c43804a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b771f3f4-6335-4557-b869-25c43804a96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_037bf5f1-2573-4f9f-b50b-62ecc742c62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_037bf5f1-2573-4f9f-b50b-62ecc742c62f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f2d17630-29af-4d4e-9f63-8ee7f4b9c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f2d17630-29af-4d4e-9f63-8ee7f4b9c490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5beee867-f923-4594-a972-84e09ab19aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5beee867-f923-4594-a972-84e09ab19aa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_504da25f-3205-4ec0-90c0-f879c7ffa57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_504da25f-3205-4ec0-90c0-f879c7ffa57d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5b9f1f90-6804-41b2-b275-9c6ba1eacd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5b9f1f90-6804-41b2-b275-9c6ba1eacd43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_80f4682c-c798-4fa9-b423-87ec3867581a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_80f4682c-c798-4fa9-b423-87ec3867581a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b8beb39e-d0c2-48a8-a7c1-0e423cf7c95a" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b8beb39e-d0c2-48a8-a7c1-0e423cf7c95a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_386750e5-adc4-4116-ba28-2c84f69c944b" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_386750e5-adc4-4116-ba28-2c84f69c944b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbdca680-0990-4d6c-ada3-fc598e6e2934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbdca680-0990-4d6c-ada3-fc598e6e2934" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:to="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12379bac-fc78-4fed-b4a9-c813276f0bad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12379bac-fc78-4fed-b4a9-c813276f0bad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef00693a-89dc-4d34-93e4-b56e1e9244b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef00693a-89dc-4d34-93e4-b56e1e9244b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e406c891-848e-49bf-94d3-6361262247ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e406c891-848e-49bf-94d3-6361262247ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad590d54-92a8-4fe9-a191-63265e236d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_PerformanceSharesMember_ad590d54-92a8-4fe9-a191-63265e236d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember_9027689e-365f-4f0b-bc1f-c9ee4c129512" xlink:href="mdt-20250425.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_mdt_EmployeesStockPurchasePlanMember_9027689e-365f-4f0b-bc1f-c9ee4c129512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_362a3ef0-98ec-4515-b408-29cf4f98860a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_362a3ef0-98ec-4515-b408-29cf4f98860a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a24fad6f-9698-40bd-9794-e68435292acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_CostOfSalesMember_a24fad6f-9698-40bd-9794-e68435292acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_87b1ceb1-3333-4db4-a3ae-9501e432a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_87b1ceb1-3333-4db4-a3ae-9501e432a7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00fa66b0-d9cd-4968-8c39-61cb769f448f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00fa66b0-d9cd-4968-8c39-61cb769f448f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ebee109-aae8-4a05-b4c0-cea423f3ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ebee109-aae8-4a05-b4c0-cea423f3ff9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_970325c9-c722-414c-ad9b-0e26b1c9e7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_970325c9-c722-414c-ad9b-0e26b1c9e7d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_48234e91-061a-4780-9bf0-f6a5504e6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_48234e91-061a-4780-9bf0-f6a5504e6da6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:to="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1dedb3b-e9ef-405c-81e3-aed312289e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1dedb3b-e9ef-405c-81e3-aed312289e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5269438a-e61f-4f3c-908f-59b9005b3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5269438a-e61f-4f3c-908f-59b9005b3c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0efdb408-dd36-4bbd-9d11-9b2b7043043d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0efdb408-dd36-4bbd-9d11-9b2b7043043d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90621379-ba66-49fc-93f1-05f2b3edda0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90621379-ba66-49fc-93f1-05f2b3edda0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f83241a7-be12-423b-8794-b6f116704f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f83241a7-be12-423b-8794-b6f116704f55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcde5c8c-d112-4bd6-86aa-a892631663f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcde5c8c-d112-4bd6-86aa-a892631663f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cc4989b-fb04-47df-b490-e6a6bd3ce286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_484e6b22-20f2-43b6-adfc-3e88fcc3211e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_484e6b22-20f2-43b6-adfc-3e88fcc3211e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e6da262a-605a-4c5d-8128-337e913caa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e6da262a-605a-4c5d-8128-337e913caa26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_383e0e07-0fa2-464f-b2c5-57cd9fd2e39d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_383e0e07-0fa2-464f-b2c5-57cd9fd2e39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6188823-c4d3-423c-9953-f84c29ef350d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6188823-c4d3-423c-9953-f84c29ef350d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76577ce9-200f-49f5-9c68-d866bdb8b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76577ce9-200f-49f5-9c68-d866bdb8b21b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c407bdac-67d6-4501-bb38-d8dd2e7950e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c407bdac-67d6-4501-bb38-d8dd2e7950e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cca4d5c8-caa2-4195-bc79-108bbe04f777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f47359e9-5b92-48dc-a31c-1994f969e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f47359e9-5b92-48dc-a31c-1994f969e12e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e99dbb60-4ed1-4c61-80f6-eca7893b6695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e99dbb60-4ed1-4c61-80f6-eca7893b6695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f60d4d88-9188-48ec-8b33-64ed5528ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f60d4d88-9188-48ec-8b33-64ed5528ed6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39a234ac-ef64-400e-b5bd-1c8295c9010a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39a234ac-ef64-400e-b5bd-1c8295c9010a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140c0908-7a29-4057-8259-9e0677c8d5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140c0908-7a29-4057-8259-9e0677c8d5b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5fb967d4-1622-4479-abcc-648b026a78b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5fb967d4-1622-4479-abcc-648b026a78b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9452e098-88aa-46fc-aab1-bb2ce1ac3fff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9452e098-88aa-46fc-aab1-bb2ce1ac3fff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20718f05-54fa-41cd-ac8b-c4d6ec39d543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20718f05-54fa-41cd-ac8b-c4d6ec39d543" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0f0c1de5-7fc5-4752-9603-43645e7c6841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0f0c1de5-7fc5-4752-9603-43645e7c6841" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0cc3292-8ed7-4b35-95bf-588ecafab7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0cc3292-8ed7-4b35-95bf-588ecafab7f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_e2e5991c-cc58-43fb-b6bd-b137f62aa625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_e2e5991c-cc58-43fb-b6bd-b137f62aa625" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:to="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92077a95-2b3f-40e4-9203-e45eb7d2fd9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92077a95-2b3f-40e4-9203-e45eb7d2fd9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f271782c-83b9-4b6d-82bb-abb8fa2a799c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:to="loc_us-gaap_RestrictedStockMember_f271782c-83b9-4b6d-82bb-abb8fa2a799c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bed4df3a-eef6-40b1-9e82-692ec1ab8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bed4df3a-eef6-40b1-9e82-692ec1ab8d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c5e7f6d-b88b-4f48-baab-4b709bb64238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c5e7f6d-b88b-4f48-baab-4b709bb64238" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_795fada7-92a7-4565-b4e5-63c2f9e78afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_795fada7-92a7-4565-b4e5-63c2f9e78afc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dcba480d-dd11-41ed-a6e8-6adc476929be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dcba480d-dd11-41ed-a6e8-6adc476929be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505bf984-3580-44f4-9c09-03f02756075e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d904a207-cb46-4408-978e-5f5d3e62936e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d904a207-cb46-4408-978e-5f5d3e62936e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f45a1235-a292-4d97-b0de-ff54dbad2aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f45a1235-a292-4d97-b0de-ff54dbad2aaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f44a53d2-f5d0-4891-80a9-43b7605502a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f44a53d2-f5d0-4891-80a9-43b7605502a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ff2f38b-fafb-4feb-9387-f0d9140bf00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ff2f38b-fafb-4feb-9387-f0d9140bf00b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_846a7f6e-b998-443b-acb2-47ad2ef7fbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47e7e4f1-e95f-4b14-8899-2ccef41a3319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47e7e4f1-e95f-4b14-8899-2ccef41a3319" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_1f18eec0-0713-493c-8c5a-96b40c69d753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_1f18eec0-0713-493c-8c5a-96b40c69d753" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:to="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_debb7cd7-5e5d-44df-8d92-0a1a05216fcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_debb7cd7-5e5d-44df-8d92-0a1a05216fcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_80bc1113-df13-46c3-89e0-68a272e33452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:to="loc_us-gaap_PerformanceSharesMember_80bc1113-df13-46c3-89e0-68a272e33452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_632fc0f4-8301-45c5-9382-4e6454eaba33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_632fc0f4-8301-45c5-9382-4e6454eaba33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7403a16-4da7-4373-bceb-0e21e707a52a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7403a16-4da7-4373-bceb-0e21e707a52a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0542124b-c8c9-4be9-b1a8-3f557e631785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0542124b-c8c9-4be9-b1a8-3f557e631785" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_f961ae75-ec29-46d8-a91b-7b4890753b03" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_f961ae75-ec29-46d8-a91b-7b4890753b03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3d8a1951-c1c0-48dd-9001-44ac4bae03ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3d8a1951-c1c0-48dd-9001-44ac4bae03ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94146e31-18d8-4a24-9e98-2d2f045e7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_37be375e-b164-4156-9919-0430951674f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_37be375e-b164-4156-9919-0430951674f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9cc72660-c31f-4630-b1df-18e2dd383717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9cc72660-c31f-4630-b1df-18e2dd383717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be981ad2-ac8f-47e0-862c-5324a9b360e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be981ad2-ac8f-47e0-862c-5324a9b360e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_12ef1a43-91be-48c1-9203-7665cfdeaf33" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_12ef1a43-91be-48c1-9203-7665cfdeaf33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5a44abe1-b9ea-47c7-a57e-489c0e47001e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5a44abe1-b9ea-47c7-a57e-489c0e47001e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c274ce0-922d-4444-847b-c77cc81cbcac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0216b599-0d61-46c6-9f54-a9846863387e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0216b599-0d61-46c6-9f54-a9846863387e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_420733c2-42d0-4225-8913-fc14e9e131b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_420733c2-42d0-4225-8913-fc14e9e131b6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0e762f23-49e7-48fb-a11f-916edbcf1083_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0e762f23-49e7-48fb-a11f-916edbcf1083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1f280c18-fbf4-4333-bf1e-747321f104ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_ForeignCountryMember_1f280c18-fbf4-4333-bf1e-747321f104ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bc9a2e36-fd06-48cf-af9e-2577dc3f01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_DomesticCountryMember_bc9a2e36-fd06-48cf-af9e-2577dc3f01b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f8346931-ce2d-4632-bdac-d069bbf136e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f8346931-ce2d-4632-bdac-d069bbf136e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:to="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_cb93923f-277a-424d-8902-e73dbfb83803_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:to="loc_srt_ConsolidatedEntitiesDomain_cb93923f-277a-424d-8902-e73dbfb83803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:to="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_1c50126b-0dc0-43bf-a83c-27fcb60ad52e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:to="loc_srt_SubsidiariesMember_1c50126b-0dc0-43bf-a83c-27fcb60ad52e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_c5258d9c-6438-4c54-b4c0-6798a4b5eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_c5258d9c-6438-4c54-b4c0-6798a4b5eb5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_679469f5-037a-4141-b6c9-558983b9b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_679469f5-037a-4141-b6c9-558983b9b8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_470b106b-7738-4574-a391-1926ecbde87f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_470b106b-7738-4574-a391-1926ecbde87f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_22360058-2731-4991-8870-fe3ab08c73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_22360058-2731-4991-8870-fe3ab08c73d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_c479e4af-b8c0-4271-940d-86454b7bebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_c479e4af-b8c0-4271-940d-86454b7bebe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e74e88df-ee9e-443c-9aac-1105c1356b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e74e88df-ee9e-443c-9aac-1105c1356b31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_57578597-f643-4232-b0a3-7bf74ecdea58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_57578597-f643-4232-b0a3-7bf74ecdea58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_10ea8a14-6958-4a7f-b264-e3f9eb33939d" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_10ea8a14-6958-4a7f-b264-e3f9eb33939d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b335800-9276-4152-8eb3-01fccf3c80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b335800-9276-4152-8eb3-01fccf3c80e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c6c8f2fa-75d4-4c0f-890b-d293a0e640e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c6c8f2fa-75d4-4c0f-890b-d293a0e640e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_135387f6-9918-455e-90ae-fc441cb3441d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_135387f6-9918-455e-90ae-fc441cb3441d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_83960f3c-bcda-4e2a-8657-deb4400fe41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_83960f3c-bcda-4e2a-8657-deb4400fe41a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_246d33a8-7c1d-4724-b5da-c9c6da191610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_246d33a8-7c1d-4724-b5da-c9c6da191610" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7faa0de1-eab8-4b7e-afab-b6bde98a8ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7faa0de1-eab8-4b7e-afab-b6bde98a8ae6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9d8919ee-2ef8-4dc2-8f21-fe9b34a33830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9d8919ee-2ef8-4dc2-8f21-fe9b34a33830" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_32def2f1-62e7-44df-bacc-b63af7f9a8f6" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_32def2f1-62e7-44df-bacc-b63af7f9a8f6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_1324e950-9cdb-43c5-b3e6-cc957ec4c7c4" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_1324e950-9cdb-43c5-b3e6-cc957ec4c7c4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_0930cdc2-0290-4471-96b2-8133a5e817ab" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_0930cdc2-0290-4471-96b2-8133a5e817ab" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a2099bb-f199-4d78-8f59-99ece0b8f947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a2099bb-f199-4d78-8f59-99ece0b8f947" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_7589c17b-577a-4825-b532-b7db5efcc379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_7589c17b-577a-4825-b532-b7db5efcc379" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_da5c669f-98dc-474a-a66a-df9fdaebd404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_da5c669f-98dc-474a-a66a-df9fdaebd404" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_37f7e64c-1da5-4617-98dc-7f7a72f40b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_37f7e64c-1da5-4617-98dc-7f7a72f40b7f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5b854cf8-42f7-444b-adda-967b570c9d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5b854cf8-42f7-444b-adda-967b570c9d7c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5b94051c-5068-4eef-872c-0f3b8a8da6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5b94051c-5068-4eef-872c-0f3b8a8da6a9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3981d71e-0e96-4118-b9c2-b1a88cbd07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3981d71e-0e96-4118-b9c2-b1a88cbd07c3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_e1751d35-26a5-4dc6-89d8-e5ea775f29d6" xlink:href="mdt-20250425.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_e1751d35-26a5-4dc6-89d8-e5ea775f29d6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5a422a6d-aef0-47df-baa7-d258ca795e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5a422a6d-aef0-47df-baa7-d258ca795e16" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:to="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5655e55b-68ea-434c-ac34-97b16a8727bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5655e55b-68ea-434c-ac34-97b16a8727bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_323ea425-dbca-4d44-9755-0567793f0b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_323ea425-dbca-4d44-9755-0567793f0b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5dd539e8-6498-4b6b-941d-b402664c79cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_PerformanceSharesMember_5dd539e8-6498-4b6b-941d-b402664c79cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fc71915-3da7-4d23-bd16-1a521ceea23e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:to="loc_us-gaap_NetIncomeLoss_5fc71915-3da7-4d23-bd16-1a521ceea23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae32bd2e-40a1-46d9-a1a4-7678069af3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae32bd2e-40a1-46d9-a1a4-7678069af3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f38e0298-3b70-4edc-8c9f-64c9178b4b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f38e0298-3b70-4edc-8c9f-64c9178b4b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_c216fc15-b25f-46e7-aba3-3554973b427a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_c216fc15-b25f-46e7-aba3-3554973b427a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_677dae2c-5d71-49fa-964e-2eaf4a7b0ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_677dae2c-5d71-49fa-964e-2eaf4a7b0ef4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cb22cd43-e514-4576-b1aa-ff5d2f086270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_EarningsPerShareBasic_cb22cd43-e514-4576-b1aa-ff5d2f086270" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fedc64fa-e530-483d-bcd1-050982d801c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fedc64fa-e530-483d-bcd1-050982d801c2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ffcfea24-63c3-48e6-866a-3da7589fc808_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ffcfea24-63c3-48e6-866a-3da7589fc808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_405a57c6-c782-41db-ab9d-b49262621831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:to="loc_us-gaap_EmployeeStockOptionMember_405a57c6-c782-41db-ab9d-b49262621831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a6e3264c-2523-44c8-a6b0-a055f8dd49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a6e3264c-2523-44c8-a6b0-a055f8dd49f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_37d10585-b896-45ea-956c-42fcfa289ce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_37d10585-b896-45ea-956c-42fcfa289ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f8401978-8863-40b3-8145-b4d7fcf84c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f8401978-8863-40b3-8145-b4d7fcf84c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5b7511e5-9efa-4296-b424-a0a5451df41e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5b7511e5-9efa-4296-b424-a0a5451df41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f07695fb-af8d-49fc-8a09-c8ed8fb29776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f07695fb-af8d-49fc-8a09-c8ed8fb29776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:to="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d17576e3-8f76-4be6-a3c8-f60223e63b6b" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:to="loc_country_US_d17576e3-8f76-4be6-a3c8-f60223e63b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d9533771-c8e2-40c9-909a-1513b6dd3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:to="loc_us-gaap_ForeignPlanMember_d9533771-c8e2-40c9-909a-1513b6dd3b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b485f8ee-c7e0-4058-bb89-6b5d773afc4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b485f8ee-c7e0-4058-bb89-6b5d773afc4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_032fbfe0-612d-4c9d-bee9-f493b70ddc69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_032fbfe0-612d-4c9d-bee9-f493b70ddc69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_e995361e-8c74-45bf-b73e-5ef7af5b2538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_e995361e-8c74-45bf-b73e-5ef7af5b2538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_e35ed134-e0ee-486e-b33f-a0c3904455cb" xlink:href="mdt-20250425.xsd#mdt_OtherPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_mdt_OtherPlanAssetsMember_e35ed134-e0ee-486e-b33f-a0c3904455cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:to="loc_srt_RangeMember_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:to="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c44f92cc-f138-4c00-ab8a-4248e4732ade" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:to="loc_srt_MinimumMember_c44f92cc-f138-4c00-ab8a-4248e4732ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f27151d-418d-4523-a706-6f600e048df4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:to="loc_srt_MaximumMember_9f27151d-418d-4523-a706-6f600e048df4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2780f45-27ba-45c6-b1d7-178d412db16e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2780f45-27ba-45c6-b1d7-178d412db16e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_95c5550d-30dc-4eb9-a4f4-70c70be14c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_95c5550d-30dc-4eb9-a4f4-70c70be14c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ed0208f2-a878-4d30-8c9e-497f4ec5d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ed0208f2-a878-4d30-8c9e-497f4ec5d16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_94ad5d20-2069-4b3b-ad5c-384093246a11" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_94ad5d20-2069-4b3b-ad5c-384093246a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4da62a93-ceb2-40e2-a45b-2a7efc351029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4da62a93-ceb2-40e2-a45b-2a7efc351029" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_035d9f78-6332-46b0-9cdb-e15ee1f779fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_035d9f78-6332-46b0-9cdb-e15ee1f779fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_d842e967-87e7-47fa-b097-91e2668202e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_d842e967-87e7-47fa-b097-91e2668202e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_95a21133-9eb6-4f10-8708-65374cc090ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_95a21133-9eb6-4f10-8708-65374cc090ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e37b491-b226-4086-968f-bea0e6b67cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e37b491-b226-4086-968f-bea0e6b67cd1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7d8e87ab-bb4a-48dc-87c9-9de90b789ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7d8e87ab-bb4a-48dc-87c9-9de90b789ca0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_60a0ce27-fd46-402d-9083-230a1db4324a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_60a0ce27-fd46-402d-9083-230a1db4324a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:to="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5c41c0fc-6c6e-4a46-90ca-e2f9ab959aa2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:to="loc_country_US_5c41c0fc-6c6e-4a46-90ca-e2f9ab959aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_aec031d1-a4fb-43ea-9570-dd5c9e1474a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:to="loc_us-gaap_ForeignPlanMember_aec031d1-a4fb-43ea-9570-dd5c9e1474a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b2be62e1-bea0-4b1d-baea-af96ea160bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b2be62e1-bea0-4b1d-baea-af96ea160bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a98c8301-119d-40d7-89cb-d7b1b881d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a98c8301-119d-40d7-89cb-d7b1b881d88d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d8a9ecf3-e2b7-4dba-8c65-cabfe6d6aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d8a9ecf3-e2b7-4dba-8c65-cabfe6d6aa9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_d8ffbcf3-b99d-4b7e-8357-0f4bdf865444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_d8ffbcf3-b99d-4b7e-8357-0f4bdf865444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ff77ceb4-1cd8-4a7f-b8c7-805acca0de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ff77ceb4-1cd8-4a7f-b8c7-805acca0de2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b477d639-8b69-49d7-87cd-7fc6c328fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b477d639-8b69-49d7-87cd-7fc6c328fdf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_b2d2256c-3396-4e8f-988d-95057c232250" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_b2d2256c-3396-4e8f-988d-95057c232250" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ced64759-3b78-4217-bf59-2d6b5bdcdb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ced64759-3b78-4217-bf59-2d6b5bdcdb6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7be798f5-ec19-4cd8-a33b-ed96a076935f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7be798f5-ec19-4cd8-a33b-ed96a076935f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_366bece2-e81a-4df5-a46c-5115ecc10c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_366bece2-e81a-4df5-a46c-5115ecc10c19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_af9df1ca-47d8-4e56-9590-29618da2717a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8277e4e5-029d-4138-9484-03f54f283b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8277e4e5-029d-4138-9484-03f54f283b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_db064e7f-4301-423a-94fe-fc4666b94f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_db064e7f-4301-423a-94fe-fc4666b94f3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_433ada24-24ae-4ace-bf84-50efd9055cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_433ada24-24ae-4ace-bf84-50efd9055cc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_488c46e4-b544-4030-b434-44de6c77a595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_488c46e4-b544-4030-b434-44de6c77a595" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f77585f1-0fc2-438e-b6d4-615499d48364" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f77585f1-0fc2-438e-b6d4-615499d48364" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_a1600a55-dad1-4cf5-83db-fd0c15a7e342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_a1600a55-dad1-4cf5-83db-fd0c15a7e342" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_86f56e4c-678c-4787-8eff-247be3e21715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_86f56e4c-678c-4787-8eff-247be3e21715" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0b1009ca-42f7-41d8-9ffe-72ebf0f65814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edc37bb6-3480-4c6f-a9be-adef24919eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_11545699-6e05-424f-aed9-541eb261a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_1278dcf8-c3d7-439f-b6bf-b47247f7acc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_1278dcf8-c3d7-439f-b6bf-b47247f7acc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_5d406ba0-2f59-4659-bf21-ac68d4a9d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_5d406ba0-2f59-4659-bf21-ac68d4a9d3c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c0a2d8bb-06e4-45ec-bc08-942bf6ad875b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c0a2d8bb-06e4-45ec-bc08-942bf6ad875b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_236ce513-b8c5-4682-957f-21ea6088b101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_236ce513-b8c5-4682-957f-21ea6088b101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bdc1bd99-3738-4418-83ef-ee12d37a4938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bdc1bd99-3738-4418-83ef-ee12d37a4938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_481f39db-c96e-464f-be37-13fe0fcd0ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c3f55d48-5b9b-4dae-82d4-77856ca855b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c3f55d48-5b9b-4dae-82d4-77856ca855b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_645ad3a5-81d3-46d9-ba91-b345e6bde1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_645ad3a5-81d3-46d9-ba91-b345e6bde1c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_d22a6979-755d-42bd-8486-30b3848b5422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_d22a6979-755d-42bd-8486-30b3848b5422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_2bcdea4f-0a7f-4224-aa0c-ec0cc2f551ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_2bcdea4f-0a7f-4224-aa0c-ec0cc2f551ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_cc9819c5-5777-41c3-a6d3-478add79ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_cc9819c5-5777-41c3-a6d3-478add79ca06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0d7536f3-06c1-4860-a110-9c8855e03851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0d7536f3-06c1-4860-a110-9c8855e03851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_f63f96a0-3661-4f73-88bf-da6f89f81f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_f63f96a0-3661-4f73-88bf-da6f89f81f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_ca37b8a8-5b3f-4a08-937b-f3fb02616692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_ca37b8a8-5b3f-4a08-937b-f3fb02616692" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_49a61f78-2bf0-4392-b25c-2f43fc23d1ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_49a61f78-2bf0-4392-b25c-2f43fc23d1ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:to="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7cda5aa1-54a8-465e-9b80-4f69feb81b3a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:to="loc_country_US_7cda5aa1-54a8-465e-9b80-4f69feb81b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_2392fbd2-4d57-40aa-94c5-741037d459a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:to="loc_us-gaap_ForeignPlanMember_2392fbd2-4d57-40aa-94c5-741037d459a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_71446a95-9fd6-40e2-b292-a46e9413546f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_71446a95-9fd6-40e2-b292-a46e9413546f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5aeb2f3d-8a79-42c8-9666-b1a37fff799e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5aeb2f3d-8a79-42c8-9666-b1a37fff799e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_b8f6ac62-d280-4e5f-ad98-5fadba36fb14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_b8f6ac62-d280-4e5f-ad98-5fadba36fb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d1388c97-c001-43eb-807f-7f9f52534950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d1388c97-c001-43eb-807f-7f9f52534950" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cb45b300-d330-42ba-a104-13d3e7778903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cb45b300-d330-42ba-a104-13d3e7778903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b003c85f-78df-492f-883b-25d08aa9f350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b003c85f-78df-492f-883b-25d08aa9f350" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_88de392c-c8b0-45c2-b795-986721d801f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_88de392c-c8b0-45c2-b795-986721d801f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b8f57f70-6140-472c-b84b-2e503929d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b8f57f70-6140-472c-b84b-2e503929d14c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89deee2-5d00-4631-a462-db2e11e36f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89deee2-5d00-4631-a462-db2e11e36f5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7d0615be-122b-4003-9682-a7500b93677e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7d0615be-122b-4003-9682-a7500b93677e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8cbc73e-fe81-41cd-856a-bed91fcc315a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8cbc73e-fe81-41cd-856a-bed91fcc315a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9aeee88d-50d1-4de2-bb3f-b4415732860b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9aeee88d-50d1-4de2-bb3f-b4415732860b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_15a3e4d3-e012-4183-9c85-4abfcc37c93c" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_15a3e4d3-e012-4183-9c85-4abfcc37c93c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_43c31601-8958-42f7-952d-e0131558539a" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_43c31601-8958-42f7-952d-e0131558539a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a844534d-2feb-437f-95a9-09ddd253f052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a844534d-2feb-437f-95a9-09ddd253f052" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f0f37447-aa24-4630-a74f-daf55978f554" xlink:href="mdt-20250425.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f0f37447-aa24-4630-a74f-daf55978f554" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6ba2f03b-d8ba-4c65-b260-c886a4f65fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6ba2f03b-d8ba-4c65-b260-c886a4f65fcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c899fbf4-1b1b-4491-b8b3-764fc49b7196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c899fbf4-1b1b-4491-b8b3-764fc49b7196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:to="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70ecbd6a-5e60-48b6-984c-4ed77b11504d" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:to="loc_country_US_70ecbd6a-5e60-48b6-984c-4ed77b11504d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ff20d294-6b63-4712-a3ae-875d4a4cb8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:to="loc_us-gaap_ForeignPlanMember_ff20d294-6b63-4712-a3ae-875d4a4cb8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3c82eb0-a18a-4bf3-87cf-49ca184adb24_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:to="loc_srt_RangeMember_f3c82eb0-a18a-4bf3-87cf-49ca184adb24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:to="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_640c67c6-ea36-4e82-85ee-401f0e118b7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:to="loc_srt_MinimumMember_640c67c6-ea36-4e82-85ee-401f0e118b7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d37f8f-6f45-4a21-94be-e6dc4bae56c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:to="loc_srt_MaximumMember_d5d37f8f-6f45-4a21-94be-e6dc4bae56c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7239e1e2-50c3-4ca9-8cab-19fbf9328c92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7239e1e2-50c3-4ca9-8cab-19fbf9328c92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b0a1586e-6ebe-47f0-98c1-8d67e5270ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b0a1586e-6ebe-47f0-98c1-8d67e5270ff6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_8ef93792-4d2f-47ee-a310-f24c2a240e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_8ef93792-4d2f-47ee-a310-f24c2a240e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_ad39b86c-d08d-485f-aa02-50f688ef0336" xlink:href="mdt-20250425.xsd#mdt_OtherPlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_mdt_OtherPlanAssetsMember_ad39b86c-d08d-485f-aa02-50f688ef0336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f84f57ce-80ec-4c33-9260-dc45f078a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f84f57ce-80ec-4c33-9260-dc45f078a83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06e7b307-07ca-406a-8f86-368970fb11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06e7b307-07ca-406a-8f86-368970fb11b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_2beec47a-cbdf-4423-b540-2e3a46c8b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_2beec47a-cbdf-4423-b540-2e3a46c8b30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_807e8ba5-bd13-4bc0-aa48-547946ef8d6d" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_807e8ba5-bd13-4bc0-aa48-547946ef8d6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_f437f6cd-853c-4343-a040-3bdb051891b2" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_f437f6cd-853c-4343-a040-3bdb051891b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_726934cc-e1fe-44b0-b08c-2bb462151d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_726934cc-e1fe-44b0-b08c-2bb462151d07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_357bfb51-99c5-4f88-a381-c1ba9dd98083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_357bfb51-99c5-4f88-a381-c1ba9dd98083" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4271f84e-6028-4fd9-ad68-56ac33b5ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4271f84e-6028-4fd9-ad68-56ac33b5ecb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_4a55d9b2-7715-4ec7-9bec-64c88aa2284e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_4a55d9b2-7715-4ec7-9bec-64c88aa2284e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dcdda6e6-dec9-48e6-816e-ccf846f27a2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dcdda6e6-dec9-48e6-816e-ccf846f27a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_50a9678e-2efd-4332-b7d9-2b7d8dfbc8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_50a9678e-2efd-4332-b7d9-2b7d8dfbc8a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8fc6bb08-3fbd-444c-8906-0da4a904b328_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8fc6bb08-3fbd-444c-8906-0da4a904b328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:to="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8d4a0c33-fc98-48d1-a90a-ae745a0d2ce1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:to="loc_country_US_8d4a0c33-fc98-48d1-a90a-ae745a0d2ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_3a0fa4bf-c7d2-45ab-9f0b-3785f3c03875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:to="loc_us-gaap_ForeignPlanMember_3a0fa4bf-c7d2-45ab-9f0b-3785f3c03875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a1184446-ba7e-479b-b02b-ef70016356a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a1184446-ba7e-479b-b02b-ef70016356a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_61c064e0-b48d-4ae0-a368-74bcf8fe3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_61c064e0-b48d-4ae0-a368-74bcf8fe3b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_814fc05f-57b4-4bb3-8272-32dc8b41007f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_MutualFundMember_814fc05f-57b4-4bb3-8272-32dc8b41007f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_f1ddefb7-d066-4d32-874f-f255a8c2e408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_EquityFundsMember_f1ddefb7-d066-4d32-874f-f255a8c2e408" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_361dad50-f859-43a1-833d-d5395d67e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_FixedIncomeFundsMember_361dad50-f859-43a1-833d-d5395d67e39b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_f837699d-dcca-4bb6-ad43-04e680572251" xlink:href="mdt-20250425.xsd#mdt_PartnershipUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_PartnershipUnitsMember_f837699d-dcca-4bb6-ad43-04e680572251" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember_8519d4d1-b39e-4f44-bb76-0be5432aa619" xlink:href="mdt-20250425.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_RegisteredInvestmentCompanyMember_8519d4d1-b39e-4f44-bb76-0be5432aa619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember_b91a5263-d844-4a93-a712-f338ef2179e2" xlink:href="mdt-20250425.xsd#mdt_InsuranceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_InsuranceContractMember_b91a5263-d844-4a93-a712-f338ef2179e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51814bff-ec7a-40aa-8551-ce56905b44b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51814bff-ec7a-40aa-8551-ce56905b44b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4a0cf007-66dd-4b10-85b9-4b3b1ff63c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4a0cf007-66dd-4b10-85b9-4b3b1ff63c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5bf07e82-c42a-4952-8000-281d5200e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5bf07e82-c42a-4952-8000-281d5200e51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b9b45976-b4de-41dc-a0e9-762824d364a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b9b45976-b4de-41dc-a0e9-762824d364a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_21c14b19-944b-497c-9590-88065506335d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_21c14b19-944b-497c-9590-88065506335d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c15e2db-2477-479b-8f46-4d6fa2660e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c15e2db-2477-479b-8f46-4d6fa2660e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_db183742-7ab5-489c-b09b-9881b1cef5ef" xlink:href="mdt-20250425.xsd#mdt_PartnershipUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:to="loc_mdt_PartnershipUnitsMember_db183742-7ab5-489c-b09b-9881b1cef5ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ff1f72d3-41d9-4879-8651-fc72537ace23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ff1f72d3-41d9-4879-8651-fc72537ace23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansFutureBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9375cb02-f662-4403-a682-fb80bf456703_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9375cb02-f662-4403-a682-fb80bf456703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_84f2026f-4a39-46a7-a696-47ae9000d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_84f2026f-4a39-46a7-a696-47ae9000d6dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7641fd7e-52f6-4440-8c20-24862b966220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7641fd7e-52f6-4440-8c20-24862b966220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:to="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_18843fe1-791a-49b6-bf65-b30b00c6fe8f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:to="loc_country_US_18843fe1-791a-49b6-bf65-b30b00c6fe8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_931a5bd2-70f5-4910-a319-779b8ab65997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:to="loc_us-gaap_ForeignPlanMember_931a5bd2-70f5-4910-a319-779b8ab65997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c284638a-9462-4df1-a2e2-98507d8064cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c284638a-9462-4df1-a2e2-98507d8064cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_7cf4363c-ecf5-453f-9536-e98a664df362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_7cf4363c-ecf5-453f-9536-e98a664df362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_91a7d931-144f-4614-a8d9-92598e33d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_91a7d931-144f-4614-a8d9-92598e33d62d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2160a5f3-0197-4416-82b9-ea0223d8423f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2160a5f3-0197-4416-82b9-ea0223d8423f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_0686ab17-4105-4290-96c6-f993ef526554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_0686ab17-4105-4290-96c6-f993ef526554" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_01ab5059-9065-4bdc-ada3-91988e1b5034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_01ab5059-9065-4bdc-ada3-91988e1b5034" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_929d3dd6-5923-43f3-9769-6a2333e4ed4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:to="loc_us-gaap_EquityComponentDomain_929d3dd6-5923-43f3-9769-6a2333e4ed4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:to="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_119617e2-ef9e-4f79-a20b-89a4845cb192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_119617e2-ef9e-4f79-a20b-89a4845cb192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f43b0d28-cd59-4913-b421-c67fe58a5773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f43b0d28-cd59-4913-b421-c67fe58a5773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_ef0e899a-a3df-4262-b1d8-9c70586fb2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_ef0e899a-a3df-4262-b1d8-9c70586fb2a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2dc75ff-8d42-4e25-a753-75f6b308a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2dc75ff-8d42-4e25-a753-75f6b308a24c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_63580552-0c4e-4b8b-893a-ceb1c506eb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_63580552-0c4e-4b8b-893a-ceb1c506eb03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501f9623-2454-4a9d-9162-237defc91586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501f9623-2454-4a9d-9162-237defc91586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5e16cfa8-22ad-40a1-a308-2af5c34e6871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5e16cfa8-22ad-40a1-a308-2af5c34e6871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a7e41915-6f40-4494-b362-8624a5ad92e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a7e41915-6f40-4494-b362-8624a5ad92e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e28cf1c-16e9-488e-a853-4506a1fb2572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e28cf1c-16e9-488e-a853-4506a1fb2572" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1735d20-e79f-415a-b252-9ae02f0a6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_d23150a4-4303-4bcc-ae62-7ab7333ce0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_d23150a4-4303-4bcc-ae62-7ab7333ce0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9ead1d0b-1f8d-4389-969f-a41c00d8fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9ead1d0b-1f8d-4389-969f-a41c00d8fcab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_506882ab-3fe6-4884-8cd8-3b4608a20563_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:to="loc_srt_LitigationCaseTypeDomain_506882ab-3fe6-4884-8cd8-3b4608a20563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:to="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember_810f818e-acb2-45af-befc-d61568a12f79" xlink:href="mdt-20250425.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_HerniaMeshLitigationMember_810f818e-acb2-45af-befc-d61568a12f79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember_e6538396-2daa-4758-9945-ce001ad8e903" xlink:href="mdt-20250425.xsd#mdt_ColibriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_ColibriMember_e6538396-2daa-4758-9945-ce001ad8e903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember_4d9eae5c-5d49-48d9-b0c0-95138f3fc563" xlink:href="mdt-20250425.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_DiabetesPumpRetainerRingLitigationMember_4d9eae5c-5d49-48d9-b0c0-95138f3fc563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2ed27bd6-35b9-4be0-a602-e44196984336_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:to="loc_us-gaap_LitigationStatusDomain_2ed27bd6-35b9-4be0-a602-e44196984336_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:to="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_ec6cd1c3-3a83-465e-9fc1-a3c187d827d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:to="loc_us-gaap_PendingLitigationMember_ec6cd1c3-3a83-465e-9fc1-a3c187d827d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_786f2b93-531a-4539-9953-2de46559a5a7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:to="loc_srt_SegmentGeographicalDomain_786f2b93-531a-4539-9953-2de46559a5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:to="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_fa2bd9ad-5609-4f5e-b299-0ab693e10517" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_MA_fa2bd9ad-5609-4f5e-b299-0ab693e10517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_6a8c79b0-6e4e-43c7-8ed5-53ba2c7a2db5" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_MN_6a8c79b0-6e4e-43c7-8ed5-53ba2c7a2db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_e58b5e34-3353-46dc-9146-fa18472b3d87" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_CA_e58b5e34-3353-46dc-9146-fa18472b3d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_395886a7-5b20-4aa8-ba94-4b5d887bbee6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_395886a7-5b20-4aa8-ba94-4b5d887bbee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ec3abaed-5180-4b8d-9413-3220c89ca5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:to="loc_us-gaap_SubsequentEventMember_ec3abaed-5180-4b8d-9413-3220c89ca5f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_d1758001-b36e-4755-b1d5-efcc00fae3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_d1758001-b36e-4755-b1d5-efcc00fae3f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3c2c1608-9d13-4885-8696-2a6f0288f58b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3c2c1608-9d13-4885-8696-2a6f0288f58b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3632ee23-f112-4f2e-a8a8-f4ee346366f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3632ee23-f112-4f2e-a8a8-f4ee346366f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_009680af-c84b-436c-a498-9224006253b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_009680af-c84b-436c-a498-9224006253b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_106d3aef-30b9-4bde-b145-d05c78717eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_106d3aef-30b9-4bde-b145-d05c78717eba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber_f395d352-68a4-48d0-92e4-8f09e5c1f12d" xlink:href="mdt-20250425.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_mdt_LossContingencyLawsuitsNumber_f395d352-68a4-48d0-92e4-8f09e5c1f12d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8bafbf32-de57-481d-92d8-031242fa85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8bafbf32-de57-481d-92d8-031242fa85b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_5f438fce-e053-45b0-a133-86fabe32523f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_5f438fce-e053-45b0-a133-86fabe32523f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationSegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e9d00d24-0444-41ab-8199-8dc61a5f9f04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:to="loc_us-gaap_SegmentDomain_e9d00d24-0444-41ab-8199-8dc61a5f9f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:to="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_aecc0ca5-e03d-4e8d-b486-ab759be4c932" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_CardiovascularMember_aecc0ca5-e03d-4e8d-b486-ab759be4c932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_f9c4c492-ab72-42fc-bea3-e3e750f86ac4" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_NeuroscienceGroupMember_f9c4c492-ab72-42fc-bea3-e3e750f86ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_b03a9602-770f-4139-979a-56b1bb3a5e28" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_MedicalSurgicalMember_b03a9602-770f-4139-979a-56b1bb3a5e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_7a2c582a-d958-4bd3-8b64-c22a61b20f4d" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_DiabetesGroupMember_7a2c582a-d958-4bd3-8b64-c22a61b20f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherSegmentMember_3039e7a8-378d-4a56-bf88-64d91d848d41" xlink:href="mdt-20250425.xsd#mdt_OtherSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_OtherSegmentMember_3039e7a8-378d-4a56-bf88-64d91d848d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:to="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fbb63f4e-ef93-48a8-9768-60aea734b0ef_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:to="loc_srt_ConsolidationItemsDomain_fbb63f4e-ef93-48a8-9768-60aea734b0ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:to="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e028369b-3821-4ac1-936b-e381b0db64b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e028369b-3821-4ac1-936b-e381b0db64b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2e1c2c6b-cf0c-4f68-ac1f-b9c3e6065911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2e1c2c6b-cf0c-4f68-ac1f-b9c3e6065911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08b66625-2666-4979-a975-ab71ee727097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08b66625-2666-4979-a975-ab71ee727097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_519539da-86be-4a90-b9d7-7c4cceb27775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_519539da-86be-4a90-b9d7-7c4cceb27775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77736b56-015e-4b65-b972-6408d88a75bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77736b56-015e-4b65-b972-6408d88a75bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53c8c518-bbae-4244-8ab4-7182859a05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53c8c518-bbae-4244-8ab4-7182859a05c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0cacbc4b-e220-427e-a2cf-c2da99244c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0cacbc4b-e220-427e-a2cf-c2da99244c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dd130059-6226-44a5-80a0-7ff2d5d993a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_dd130059-6226-44a5-80a0-7ff2d5d993a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_be137497-6262-49dc-8dc0-adc0e366c6e1" xlink:href="mdt-20250425.xsd#mdt_CorporateOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CorporateOverhead_be137497-6262-49dc-8dc0-adc0e366c6e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a3b1ddf-5d67-4733-8f8f-1ef54cc02d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a3b1ddf-5d67-4733-8f8f-1ef54cc02d24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3b31251c-bc89-40d7-9b28-462b88ec3f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3b31251c-bc89-40d7-9b28-462b88ec3f74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5f5897c7-567a-4fb5-b4f1-e8ee4613ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5f5897c7-567a-4fb5-b4f1-e8ee4613ea03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8f352764-af8f-481b-89a5-06986483ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_ShareBasedCompensation_8f352764-af8f-481b-89a5-06986483ae37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_b8279c0f-7d19-439a-b079-216bc423c82d" xlink:href="mdt-20250425.xsd#mdt_CentralizedDistributionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CentralizedDistributionCosts_b8279c0f-7d19-439a-b079-216bc423c82d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_d1afd951-daa8-4638-9242-674a5e2a4804" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_ForeignCurrencyCosts_d1afd951-daa8-4638-9242-674a5e2a4804" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_63881001-ad28-4029-8e9a-7008cc7a6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_RestructuringCharges_63881001-ad28-4029-8e9a-7008cc7a6b92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1eadba33-b819-48b7-8c50-9682cb9dcf02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1eadba33-b819-48b7-8c50-9682cb9dcf02" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_3295d42e-35d4-4b0f-a21a-80a846a996a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_3295d42e-35d4-4b0f-a21a-80a846a996a7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_1a5b63f5-5dd6-4c34-82df-3f325c99d27a" xlink:href="mdt-20250425.xsd#mdt_MedicalDeviceRegulations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_MedicalDeviceRegulations_1a5b63f5-5dd6-4c34-82df-3f325c99d27a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_bb6a4e0f-fe75-4bd1-a359-063ed2c00a00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_bb6a4e0f-fe75-4bd1-a359-063ed2c00a00" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_9b750bac-4e23-415d-bc52-064ace52fa8a" xlink:href="mdt-20250425.xsd#mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_9b750bac-4e23-415d-bc52-064ace52fa8a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78b0a4d6-233f-4eff-9fd8-e695e77b3891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78b0a4d6-233f-4eff-9fd8-e695e77b3891" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:to="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8db1241f-71b1-4a83-ba60-e0cdadfdb817_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:to="loc_srt_ConsolidationItemsDomain_8db1241f-71b1-4a83-ba60-e0cdadfdb817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:to="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c4e2def0-b54f-46e0-b482-2228394361ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:to="loc_us-gaap_OperatingSegmentsMember_c4e2def0-b54f-46e0-b482-2228394361ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9b5026f8-7ec8-4e17-8664-1b81e8ad1a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9b5026f8-7ec8-4e17-8664-1b81e8ad1a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_12cbc570-e433-4788-a9e1-13e4de0ad269_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:to="loc_us-gaap_SegmentDomain_12cbc570-e433-4788-a9e1-13e4de0ad269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:to="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_59166231-a003-4f63-aeb6-d470d255fd37" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_CardiovascularMember_59166231-a003-4f63-aeb6-d470d255fd37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_c5b124b8-7211-469b-9826-da704783e68c" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_NeuroscienceGroupMember_c5b124b8-7211-469b-9826-da704783e68c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_fba72199-1854-42b6-8b02-e72d03c22b27" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_MedicalSurgicalMember_fba72199-1854-42b6-8b02-e72d03c22b27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_495a8e69-2b7d-4ca5-a7d4-fa49bdac3e7a" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_DiabetesGroupMember_495a8e69-2b7d-4ca5-a7d4-fa49bdac3e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_797c58c0-d238-4cd9-bc61-ffa64874c202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_us-gaap_AllOtherSegmentsMember_797c58c0-d238-4cd9-bc61-ffa64874c202" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e7470f9-3d1c-4ec6-b4ed-d1090f69e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:to="loc_us-gaap_Assets_9e7470f9-3d1c-4ec6-b4ed-d1090f69e20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2e55cc84-e288-4010-ad66-cacf26e6031a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:to="loc_us-gaap_Depreciation_2e55cc84-e288-4010-ad66-cacf26e6031a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:to="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:to="loc_srt_SegmentGeographicalDomain_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:to="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_3ea14ab3-9c68-4526-9187-8218ec46c2e9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:to="loc_country_IE_3ea14ab3-9c68-4526-9187-8218ec46c2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:to="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_aaa03008-23d0-4eb0-8bcd-a129aba40cc1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:to="loc_country_US_aaa03008-23d0-4eb0-8bcd-a129aba40cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_17f1dee8-5cdd-48bd-ac1c-27404ddc7a76" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:to="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_17f1dee8-5cdd-48bd-ac1c-27404ddc7a76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a08cf5-9204-4654-b784-ab2bfdfb734d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a08cf5-9204-4654-b784-ab2bfdfb734d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7eab8c52-de62-40bd-928f-a2dba3beeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7eab8c52-de62-40bd-928f-a2dba3beeb36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a8dfb830-f8b4-415f-9793-513049f31d78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a8dfb830-f8b4-415f-9793-513049f31d78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_93488972-0d1e-4c5d-9d8f-c3e63b1ed299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_93488972-0d1e-4c5d-9d8f-c3e63b1ed299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_29f6e1f7-910d-4350-88ee-450baaff4052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_29f6e1f7-910d-4350-88ee-450baaff4052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_54d37547-93bd-4fc4-989a-a6435e5ff2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_54d37547-93bd-4fc4-989a-a6435e5ff2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_270fc9a4-cf7b-4237-bcb1-b8306bf395ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_270fc9a4-cf7b-4237-bcb1-b8306bf395ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_4f27e92e-be1f-434f-bd0b-93e3abc16d7b" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_4f27e92e-be1f-434f-bd0b-93e3abc16d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_efb62381-4157-407d-9c26-1fc95d52b766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_efb62381-4157-407d-9c26-1fc95d52b766" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_4f4801b9-1eca-4eda-90ee-9a880daeec84" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_4f4801b9-1eca-4eda-90ee-9a880daeec84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_73bb9ee7-7baa-4951-b684-86c9cb6469bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_73bb9ee7-7baa-4951-b684-86c9cb6469bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_fd5647f5-a8bc-49c8-847d-d1373ccd721b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_fd5647f5-a8bc-49c8-847d-d1373ccd721b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_20bcfb12-dbb0-4ded-acb2-0fea22237202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="691"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="692"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="102"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>mdt-20250425_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_e294ffd8-3d4b-4097-b7a5-cf5aa37a080d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_f2911561-91b1-45c5-b2e1-227d5b835fc8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c6d2b08f-6186-4ea6-acf8-aad90984317c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6bf7cd54-23e7-4174-a035-68b39d3287f6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f56a965a-4392-40ee-8336-06f455f7abc9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ba9f70e8-7ed6-4d89-9fe4-4e1d4a32c4dc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount available for future repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_46164245-7171-4257-9b62-71c972212c82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_label_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:to="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_991ede17-319d-49e6-8684-35fb61269516_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bd4f6dfb-7c1b-4e17-b623-3fcc474a43a6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3244caec-66ec-4b9d-85c7-2d2863493dbf_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A0.750SeniorNotesDue2032Member_6cd39f12-56cb-43de-91ac-cf4443e71f07_terseLabel_en-US" xlink:label="lab_mdt_A0.750SeniorNotesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.750% Senior Notes due 2032</link:label>
    <link:label id="lab_mdt_A0.750SeniorNotesDue2032Member_label_en-US" xlink:label="lab_mdt_A0.750SeniorNotesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.750% Senior Notes due 2032 [Member]</link:label>
    <link:label id="lab_mdt_A0.750SeniorNotesDue2032Member_documentation_en-US" xlink:label="lab_mdt_A0.750SeniorNotesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.750% Senior Notes due 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.750SeniorNotesDue2032Member" xlink:href="mdt-20250425.xsd#mdt_A0.750SeniorNotesDue2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A0.750SeniorNotesDue2032Member" xlink:to="lab_mdt_A0.750SeniorNotesDue2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9611cec1-81a5-4f2e-a715-7c7e5373938d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2036b025-821b-4358-b4ff-3126b8e0cf87_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_b4e74e26-1cc0-4fe1-b578-aaa007b79bec_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_63034e7d-ab46-46d3-8d4f-a1a96fa21cfc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Pension Benefits</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_2269ce02-02dd-4758-92e0-6af6cd1275a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b78941e9-b4c9-45ca-a191-d703d4e53e16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_12d6437f-560b-4891-9289-fcc865139d5d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ce50e4f5-2c7f-4bdc-9279-3fb76d2328d7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_11aaec15-e06c-4647-b2b6-57913ca1e09c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_93b75aae-27ec-47fe-adab-70944334b14c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income including noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_31a35991-55a7-4ab8-8f3a-5b9ca40a02ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_66c5fae1-3f78-4bc7-8e1b-f2e38f31c610_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_caac9be8-d80d-4849-bc97-f75b9b9866cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value - Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_5b2b14ba-76e4-40cb-86a8-1ba8c2f9d26b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_10b71196-8aad-4204-9ab3-8b0663428629_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_0969999d-7e78-45f7-8ae4-9f9975dde15f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2089464e-fdcf-4ea7-970b-20b1f3453d0b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_9b95886c-2c13-4599-ae64-be69eb4fa579_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_da119709-0d41-4577-9be9-1da36ff4e1fd_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances and credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_3ca87b77-00ee-4135-bd18-a6629a23948d_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state benefit on uncertain tax positions</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:to="lab_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51d5e451-1666-43a4-a7e4-652f7d7413d6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_a4182955-bfad-4908-bc15-9c149ca6c4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1e3ba4b5-803f-4a20-b0ab-5c1bb7f881ed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6d6d852e-fbfc-48dd-a7d1-93c5571eb375_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_5bb9098e-f4ac-4986-b492-a7fe36aa0cbb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_771646d8-e760-40c1-b160-a47ce7127964_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f30be96a-5afb-4c0d-b7ed-49a396a32509_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investment securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1d302387-9b9e-4c98-bd4d-6c59ad81ee5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20321000PercentMember_452e0a44-bbff-4c30-9e0f-0488399c365d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20321000PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000 percent twelve-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20321000PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20321000PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2032, 1.000 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20321000PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20321000PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2032, 1.000 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20321000PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20321000PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20321000PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20321000PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_8fdfd362-1e60-4683-8bc6-0686f6940590_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5cfe8fa5-3997-4fb3-93dd-4c85d379acc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_8906436d-552b-4f87-a2a7-659fed0e9af0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claimants (in claimants)</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7e00180f-6773-4774-a256-f293311a2acb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a769fe21-351c-4747-bc9d-9522269aaeae_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_8cee5c79-e5b1-4d56-9647-0c5a80bc11e2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_79ffcffb-4780-48e8-a6a6-626dffd32969_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_fbcaa700-fb2e-4a47-8004-7abe277710ad_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss, capital loss, and credit carryforwards</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating and Capital Losses, and Tax Credit Carryforwards</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:to="lab_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4281dc5b-27f8-45e4-9513-eddeab2d10a8_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Pension Benefits</link:label>
    <link:label id="lab_country_US_22f5edb3-4d55-4098-8838-0af40e6283a8_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_43e0255f-50e4-4f1e-bf5b-a3d50f78b674_netLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f4394484-ca30-4b55-86bf-b36a3cbd2404_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3db24e5f-8851-4534-95de-b3bf02744da9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cc440d91-5577-4dac-8499-8b6b87523d55_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_8d31d45f-6f7d-40a8-854e-6a487f59d3c5_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest limitation</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsInterestLimitation_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsInterestLimitation" xlink:to="lab_mdt_DeferredTaxAssetsInterestLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_845fc9a7-871e-48cf-a8a2-6d5b69ce38d7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_9546c222-a531-4097-b30c-685f73d66cda_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsLeaseObligations_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsLeaseObligations" xlink:to="lab_mdt_DeferredTaxAssetsLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_dfa8b297-7f17-45dc-89ee-894906b92fa2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_29d071b9-32ac-43e4-9ac7-265128e7f3a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d53e6fbf-549a-4cef-b066-5f3c34d87492_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a7aea83a-a28e-4673-b547-ab432b729998_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2053Member_1588530e-488a-4097-a92c-375cdcb26bc9_terseLabel_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2053</link:label>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2053Member_label_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2053 [Member]</link:label>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2053Member_documentation_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2053Member" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A4.150SeniorNotesDue2053Member" xlink:to="lab_mdt_A4.150SeniorNotesDue2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_43ba17f3-5469-40e1-930b-354002d41090_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Certain litigation charges, net</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_d51c5f75-30b5-4aec-ae9b-d42a705d085a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_35e95873-c5fc-403c-b69a-b88d303ba640_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, net periodic benefit cost, income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5838a28c-ebd9-4482-b84c-e0fc585070e2_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit (credit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_77eaefd6-9759-4f95-a95e-5d5b23436e5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense associated with the amortization of the previously established deferred tax assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_6e6c2893-56ff-4ffe-b246-751e6b407de3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_fb597778-dfa8-4a4c-9981-de16750437fb_terseLabel_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross interest expense</link:label>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_label_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Interest Income (Expense), Gross</link:label>
    <link:label id="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_documentation_en-US" xlink:label="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Interest Income (Expense), Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:href="mdt-20250425.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:to="lab_mdt_IncomeTaxExaminationInterestIncomeExpenseGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6eb95abf-e526-43ac-ba0e-3696746d3034_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f0db776a-8314-43ca-a23a-495606f018ce_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e24bd03f-b933-441e-8bfd-3276055a6341_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_b49c910a-8177-4119-a6de-974019595979_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cc39d75f-00c7-40d7-8efb-57e31d455952_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_1034965f-6051-4a2d-a7c6-6004fce421b8_terseLabel_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_label_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Including Accrual Adjustments</link:label>
    <link:label id="lab_mdt_RestructuringChargesIncludingAccrualAdjustments_documentation_en-US" xlink:label="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Including Accrual Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:to="lab_mdt_RestructuringChargesIncludingAccrualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_2df95b3d-aab0-44a4-af0b-1672cc3b1255_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_63ccac53-5af0-4313-ac2b-5f6e11593428_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_41211917-4386-45b2-8b01-5c573b47fa37_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_f752bae3-a04d-4be9-ab2f-fb4539a142eb_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental expense related to acceptance of voluntary early retirement packages</link:label>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_label_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:label id="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:to="lab_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fd41abe7-fd06-4576-918e-8a74087ffd8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_b560d799-0411-4463-ba14-eab994d313a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Changes (Debit) Credit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44dd09b8-41fb-4276-94c8-c47de7dc0fe2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3a2501b3-2d75-451e-aa7d-828cc8a1e3ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_96806ce1-0a0c-4907-89fb-e1af9cba1683_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_f59f857c-0389-40cc-a4a9-a7ed7e389d17_terseLabel_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation</link:label>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_label_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation [Member]</link:label>
    <link:label id="lab_mdt_HerniaMeshLitigationMember_documentation_en-US" xlink:label="lab_mdt_HerniaMeshLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hernia Mesh Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember" xlink:href="mdt-20250425.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_HerniaMeshLitigationMember" xlink:to="lab_mdt_HerniaMeshLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f24b408c-28db-44c6-958b-511b7c5c3dc9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9f424c02-45e7-44a6-b839-7ed1c20047eb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TotalReturnSwapMember_c424b843-e9a5-4807-96eb-03b730c22887_terseLabel_en-US" xlink:label="lab_us-gaap_TotalReturnSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total return swaps</link:label>
    <link:label id="lab_us-gaap_TotalReturnSwapMember_label_en-US" xlink:label="lab_us-gaap_TotalReturnSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Return Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TotalReturnSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TotalReturnSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TotalReturnSwapMember" xlink:to="lab_us-gaap_TotalReturnSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f7fc24af-9333-4bf4-b0af-463fec064c5f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b02fd60b-aed2-460c-9ba3-f1ce1feebc54_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_6b919613-866a-4f72-83b3-5429d13a3e25_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_656cb312-d286-447b-ac85-a33f71505fd7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_bfd69065-74fe-4dfd-9cf9-e90a1bb90502_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount authorized for repurchase</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5a66eb88-9b2b-4a47-b6c6-7153dfee94ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_4295cdb8-fd97-484a-a4cc-942c7a5c7728_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed income commingled trusts</link:label>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Income Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeFundsMember" xlink:to="lab_us-gaap_FixedIncomeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_d23ad2bc-1ab6-471f-a3af-4e7865b995c9_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bcadcd08-bf89-44cd-9574-7dd258821b39_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f7bef4d4-4d97-4f50-96b8-b53beaec2f59_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b5f402f5-40f7-4c82-ad62-988524126b97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_9be2583b-cee1-4204-8a19-e97603ec12d3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_9cc77c32-c5ce-4193-980e-313dfeed95ae_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation Expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb53767c-0ce7-4a78-b9ae-bfbf0b361ae3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_832c61f6-77d5-4d01-8999-cad23a831e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_6cc33fe7-1ec3-4180-bbb0-9e7c48680b1f_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions and interest</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c22718f8-aca9-492e-8a64-02d825a364d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_621a1a5f-22c2-452f-8543-1e6f493bcea8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Medtronic</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_179bfb34-d2c1-4eea-906c-70521579883a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_4454b121-d451-48b9-b486-95b6ff887d47_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a504d43-cbdf-4566-9c41-738b44de4f6b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_3fbf017c-4a15-4159-8069-09f2fcacd334_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_06a9d8a1-0d94-4031-98f0-b91d1b821f38_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Debt Securities Contractual Maturities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0944c6bd-07f2-4b92-a233-6d4c11adeac6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_54e26271-1982-448c-845d-034240574d39_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d7cd71bf-92d0-4522-a748-2df1928b1ebf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_f559ea3b-b53d-4667-ace3-333201718532_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d541a6f8-6848-4ae0-80f8-e05da2edd96a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21307e42-9d5c-4206-aea5-981e5dbb84bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1f186245-29dd-4f02-8a0d-619cc124cbe3_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_18b000c2-5c77-4c8d-8f38-4be46ef59184_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5f3c1afb-a9e3-458c-8c35-c84a8551b10e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_cbc3af0a-9cfa-4e5c-95a8-eae3161d0b81_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e15459d8-c59d-4d66-9251-fa22fe9990a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8057b963-bce7-4d9f-ad8f-3baa482b896e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd658a4-aa46-4bb3-a102-2bee66a23cb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_148d671d-2c1c-433c-9382-ad513cea2783_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14d96f03-f761-41b7-adcf-3bcc5ca7f549_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_758ae94c-fda6-4229-9a8f-0397752fecbd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_1b7f7a32-a813-4602-861d-83c660341345_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_229319e5-40e1-4039-8942-bc58e2e38d39_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_de6fe04f-38ee-45a2-bb8c-4c8f21305bee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_cbb0a308-51d9-4c1e-a948-dfcdb371019b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain tax adjustments, provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_f40a3762-ed16-48ce-80ff-dc44bdb41017_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dea93f08-9007-438b-bd7b-e88a0b9b4e20_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_6bdc643b-c717-450b-a17a-e8e252d49cbe_terseLabel_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Structural Heart &amp; Aortic</link:label>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_label_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Structural Heart And Aortic Division [Member]</link:label>
    <link:label id="lab_mdt_StructuralHeartAndAorticDivisionMember_documentation_en-US" xlink:label="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Structural Heart And Aortic Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember" xlink:href="mdt-20250425.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_StructuralHeartAndAorticDivisionMember" xlink:to="lab_mdt_StructuralHeartAndAorticDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_197b6f74-055b-4712-bcde-edbe05dc5f66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in AOCI, Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2d5e452b-a699-43dc-95ab-8a79d2028536_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9847d827-b877-4726-96cc-d61782a8f110_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a89da06-6807-47e1-9e4b-7c7a2a0eaa66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wtd. Avg. Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4c311883-e189-414d-ba92-b1f84cfcb135_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_d4bd4fd5-4f24-454b-9971-1ddaa9920766_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Statute of limitation lapses</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1c37f02e-feab-4938-aa42-7ade7336db8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b92bea6c-f3f0-45ed-96cd-98db8f19454d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f1e9b21-9f40-41a5-8c41-873367c4e4b1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted &#8211; weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_3e7acd3e-19f6-4a09-b3f1-7fe67ce1696b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated expected restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_6164c560-3346-44ba-8220-45394207fdca_terseLabel_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Simplification</link:label>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_label_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Simplification Restructuring Program [Member]</link:label>
    <link:label id="lab_mdt_SimplificationRestructuringProgramMember_documentation_en-US" xlink:label="lab_mdt_SimplificationRestructuringProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Simplification Restructuring Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember" xlink:href="mdt-20250425.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SimplificationRestructuringProgramMember" xlink:to="lab_mdt_SimplificationRestructuringProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_069ca692-9846-4c0e-b9d2-f197df9d3f73_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_cc4c0176-d622-4783-ab39-8ae440a10552_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_301aa2d2-8383-4f51-9345-b804145c1581_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_25e656fc-cdf0-45e7-9801-639446d4ab8d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2023Due20334.500PercentMember_225e0027-dd49-4832-99bb-64d06d104e6f_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.500 percent ten-year 2023 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2023Due20334.500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2023 Due 2033, 4.500 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2023Due20334.500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2023 Due 2033, 4.500 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20334.500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:to="lab_mdt_SeniorNotes2023Due20334.500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5ff3115f-db85-435b-940a-ab6000f8bc72_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_c6ddf766-e80c-432e-a331-8d234eafd918_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_52427ca5-6936-4c87-a62f-1cd6bd86a014_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3.875SeniorNotesDue2036Member_80e66e72-ae5e-42ce-8ea3-fa8ae2c30bcf_terseLabel_en-US" xlink:label="lab_mdt_A3.875SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.875% Senior Notes due 2036</link:label>
    <link:label id="lab_mdt_A3.875SeniorNotesDue2036Member_label_en-US" xlink:label="lab_mdt_A3.875SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.875% Senior Notes due 2036 [Member]</link:label>
    <link:label id="lab_mdt_A3.875SeniorNotesDue2036Member_documentation_en-US" xlink:label="lab_mdt_A3.875SeniorNotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.875% Senior Notes due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.875SeniorNotesDue2036Member" xlink:href="mdt-20250425.xsd#mdt_A3.875SeniorNotesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3.875SeniorNotesDue2036Member" xlink:to="lab_mdt_A3.875SeniorNotesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_06f3bd75-d83b-4eda-bef8-3bfba12256cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6207d595-6345-4f2a-b9be-6cead33c4930_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_40f7da6c-e4d8-4960-81ef-2f664eb145cb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to Other Accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f9802217-cd4e-4420-b398-d04fecdbbb6d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d3b1b86b-e7b3-483a-99fd-d96061825335_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plans with projected benefit obligations in excess of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5e4ff2d4-450e-477e-a7db-a9e253e60d7c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense under defined contribution plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_53138363-fed0-441a-8b67-a1cfe5402158_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_d4c9ff93-0a0f-4adf-9ed7-d198fe4440b3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_bfa280c3-caab-4537-a717-828a55754722_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f47decce-d13d-4efe-9d3a-cf8d60b33ec0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_570d2908-4b9e-4d77-962f-7c3b63ce375c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationIncrease_59d0b232-90e3-4dd3-b25f-4c3df8738482_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Invoices confirmed during the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationIncrease_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0d5bcabe-71c2-4edd-935f-1824baa815d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition and divestiture-related items</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a089ee8f-e996-4cba-b280-56b7fe0db567_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ce379063-584b-4a44-b1d3-6944786abbb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payments (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_9e1a822d-5fbf-4046-8b1c-6a3f5af6da1e_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, tax adjustments for reserves, amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Adjustments For Reserves, Amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4e451fd9-3c58-45a0-aaa5-cee432bff7d2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_39b287c0-8325-49ad-961e-580cedde1a34_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (Loss) Gain on Investment Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9e0495f-549a-49b8-9f99-4011dc0eb2c8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ada66348-2896-4472-bcfd-6fe8df1ad2a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_96a76687-9b73-46e3-88e3-75e8ca6523d5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes to noncontrolling ownership interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ea686b20-d5b9-4916-b741-d30256d2be86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_132665b9-837e-47fd-8fea-ff878c58ddab_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e4981c23-4ade-4b09-8805-c3971e5f8212_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which remaining performance obligations are expected to be recognized as revenue</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_af0cfb59-b0e3-4586-8b5b-f80c5bfceafa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b98dc5b1-23a5-4113-98f1-999e0232e9d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7abbf76-aa1e-4be6-b364-ce3e34806f00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b34266c8-8bc8-4254-8a98-19b43821cb2f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_f5bc0d3a-dd83-419e-9bb3-6c6e494ff396_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7e4cba01-9ebc-439f-903f-ff187085bcbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_6a18a743-c49f-4484-bac5-7c7bac7438bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial loss (gain)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_0f3dff46-3a32-4c2a-a10b-400cf72bfe20_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_1c1e1365-e9ad-4df6-aa64-c13aaa2b93b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_34b494a5-a390-47d4-a094-a114139ba855_terseLabel_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_label_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesLineItems_documentation_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Offsetting Assets and Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:to="lab_mdt_OffsettingAssetsandLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_3914bf8f-18f6-4be9-9c90-dc28a25ed33b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_d9a3c335-d3f0-4534-83de-207d0f6a76b7_terseLabel_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper, maximum borrowing capacity</link:label>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_label_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_mdt_CommercialPaperMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Paper, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:href="mdt-20250425.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:to="lab_mdt_CommercialPaperMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2842205e-8208-4e85-a411-19c4f7eb3e77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_d6eb12e7-64bc-4b82-bd6d-ba74bf94ac75_terseLabel_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_label_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mdt_EmployeesStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mdt_EmployeesStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember" xlink:href="mdt-20250425.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EmployeesStockPurchasePlanMember" xlink:to="lab_mdt_EmployeesStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_4dcb3238-54d8-48f3-916b-ee093e5bc76e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) Loss Reclassified into Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_015f83e6-3f97-48c9-8a7a-6139ebcd0064_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6355eff4-aa58-4efa-9623-0d2c55f2880f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_6b6e4a45-654c-4b7d-852c-8e8a18a3f62c_terseLabel_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise Excellence</link:label>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_label_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise Excellence [Member]</link:label>
    <link:label id="lab_mdt_EnterpriseExcellenceMember_documentation_en-US" xlink:label="lab_mdt_EnterpriseExcellenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enterprise Excellence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember" xlink:href="mdt-20250425.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EnterpriseExcellenceMember" xlink:to="lab_mdt_EnterpriseExcellenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_74c6b6b5-8e30-4b0a-b303-d31594205d9f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_08d9a323-e697-4bcb-b14e-68768f664461_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax charge</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_dd5ffef8-0cc1-45e8-9591-aca8c4f5f5ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_350c77c8-ab33-466f-a55f-80f1e469d337_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_19c69f5e-3349-4f97-984c-d0721665bedc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_ba0d1f67-14a1-45a6-bfeb-0428b3eae490_terseLabel_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_label_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_mdt_DebtInstrumentNumberofTranches_documentation_en-US" xlink:label="lab_mdt_DebtInstrumentNumberofTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches" xlink:href="mdt-20250425.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtInstrumentNumberofTranches" xlink:to="lab_mdt_DebtInstrumentNumberofTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingLiabilitiesTableTextBlock_923659b6-3520-4fb0-953d-9f33af1ad2a9_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Offsetting Liabilities</link:label>
    <link:label id="lab_us-gaap_OffsettingLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OffsettingLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_28995e67-660c-440c-8c37-f9fb58ddb67e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_27a16627-eb08-44f4-a30b-313cb33964e4_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_7b1760b2-f794-40a0-bd61-19ae5c4399a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The discount rate from market value on purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_ae12473f-e6ad-47f1-adf6-eec5c34f5773_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6cac613f-fb1d-4fd0-a26a-6438c1f2f523_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_6377f990-2d9b-4a7d-addd-7995dbbe8811_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier finance program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_c2fcd04b-1de2-490c-9fb8-5c8dcf893705_periodStartLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_82edb1bd-4871-4cbf-9eb8-42adf39bd13b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligation_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligation" xlink:to="lab_us-gaap_SupplierFinanceProgramObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e61686f-58cf-42d9-b197-dd0720155200_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3.375SeniorNotesDue2034Member_be88976a-afc2-4814-9b5b-22ef3694d239_terseLabel_en-US" xlink:label="lab_mdt_A3.375SeniorNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.375% Senior Notes due 2034</link:label>
    <link:label id="lab_mdt_A3.375SeniorNotesDue2034Member_label_en-US" xlink:label="lab_mdt_A3.375SeniorNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.375% Senior Notes due 2034 [Member]</link:label>
    <link:label id="lab_mdt_A3.375SeniorNotesDue2034Member_documentation_en-US" xlink:label="lab_mdt_A3.375SeniorNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.375% Senior Notes due 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.375SeniorNotesDue2034Member" xlink:href="mdt-20250425.xsd#mdt_A3.375SeniorNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3.375SeniorNotesDue2034Member" xlink:to="lab_mdt_A3.375SeniorNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_86cce632-49b8-4ed8-b8c2-e03090d14b39_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A0.250SeniorNotesDue2025Member_074dbfe1-998f-477b-901a-e0ad99367d1f_terseLabel_en-US" xlink:label="lab_mdt_A0.250SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.250% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_A0.250SeniorNotesDue2025Member_label_en-US" xlink:label="lab_mdt_A0.250SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.250% Senior Notes due 2025 [Member]</link:label>
    <link:label id="lab_mdt_A0.250SeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_mdt_A0.250SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.250% Senior Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.250SeniorNotesDue2025Member" xlink:href="mdt-20250425.xsd#mdt_A0.250SeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A0.250SeniorNotesDue2025Member" xlink:to="lab_mdt_A0.250SeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7cb0c0b5-5e00-4804-b757-215dd849fb6d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bdfbc4cc-ebd4-4a1f-bd32-bed3a222dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c1b7cd8b-1c91-4f90-b436-cbf111b54b48_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer to held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_9640a77b-bb3f-4f8a-9406-fba08ab46cb6_terseLabel_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency denominated debt</link:label>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_mdt_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_mdt_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20260250PercentMember_bd2ae031-88ec-4cee-831e-8355de6d154c_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20260250PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.250 percent six-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20260250PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20260250PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2026, 0.250 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20260250PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20260250PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2026, 0.250 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20260250PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20260250PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20260250PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20260250PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b3f34377-01f6-4b85-9944-4587d254540d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_fd7a4ec4-18ee-48c5-a4fc-03daaef80531_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_f755a13b-463f-42d3-8a31-3ead3a2da3f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_70648798-7f05-4223-8da9-f582d1322264_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b90741b0-4a4e-41a9-bd53-b32b2ff55b41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_7614e4b0-5001-4b31-a650-841ba2e4eda9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Future Benefit Payments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_75a4e91e-12d5-42b1-9150-e4c110ab0bf2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6240963e-a515-4d4a-a1a5-48057cf50ace_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Tax Authorities</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f86dd5ba-140c-43d3-bda4-410fd8a28c8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.125SeniorNotesDue2027Member_93f211a7-f2dc-4d27-a711-5c25848e96aa_terseLabel_en-US" xlink:label="lab_mdt_A1.125SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.125% Senior Notes due 2027</link:label>
    <link:label id="lab_mdt_A1.125SeniorNotesDue2027Member_label_en-US" xlink:label="lab_mdt_A1.125SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% Senior Notes due 2027 [Member]</link:label>
    <link:label id="lab_mdt_A1.125SeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_mdt_A1.125SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.125% Senior Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.125SeniorNotesDue2027Member" xlink:href="mdt-20250425.xsd#mdt_A1.125SeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.125SeniorNotesDue2027Member" xlink:to="lab_mdt_A1.125SeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f2be81a6-a2c5-48f7-8c42-1861540145df_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_b9b93c6a-220f-4be0-b8b0-947abb623b6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonrecurring (Income) Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:to="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_09393edf-f059-42e6-ba0a-dd0a1c34fe83_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f36bfba0-d23b-406d-8af1-65391622eb2d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ce60b7b2-e7e2-4db2-99f9-6f77c650f40d_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1ce194b5-e8b4-4ba7-9122-b9f925f9f2bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_733f5ef9-cfe2-485a-845f-5d63bb287e0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_1a438117-0e6a-485f-b5af-979f02f2f143_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; interest cost</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_84fbcc53-f7f8-46a9-9873-0e47676a3f78_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_a13fd418-fe06-44a9-b54b-d37d857b02ed_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense related to internal restructuring and intercompany sale of assets</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_317f0456-8cc6-4a4f-b18a-be56f2817015_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Self-Insurance</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Self Insurance Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:to="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_7a6b91c9-9a34-4bcc-9206-17c086959106_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_efcdd636-894b-49ac-9655-cebbcc0a8940_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fe199ed4-11d3-42ee-9777-8666776af60d_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_60bc1e0c-fd9e-4505-bdb6-d5b4e4ffa64a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f17499a7-df63-425b-9707-91aa1fd5ddf1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_97b344d7-0891-480e-bd6e-97e5907f57af_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_00001ece-4ac7-4b28-aab7-4010533c9d63_periodStartLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_78ce8ca6-8bcc-4fe9-86f3-cac42e34a45e_periodEndLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4511a728-7757-4ebb-912c-2a7498cdff09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments not designated as hedging instruments, (gain) loss, net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_06c7c94b-ae47-4db9-8aa3-db31f906b1e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_18e8ab69-cb59-4bc8-9801-3d5b80635114_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_5288d3c0-83fe-4618-9da5-7289119ec883_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_0c23cb56-f9b1-4edb-a07c-30da6fb2889d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_08e3d291-f58f-4612-acf0-7b3b94a6a463_terseLabel_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coronary &amp; Peripheral Vascular</link:label>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_label_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coronary And Peripheral Vascular Division [Member]</link:label>
    <link:label id="lab_mdt_CoronaryAndPeripheralVascularDivisionMember_documentation_en-US" xlink:label="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coronary And Peripheral Vascular Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:href="mdt-20250425.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:to="lab_mdt_CoronaryAndPeripheralVascularDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6af3d01-e5c3-45f7-bf42-241d1783cd03_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_b547fc52-9bc1-4ccc-a90d-8005e0fee245_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bc82bbd8-98dc-4863-8dab-cf3530c5604f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_3b82cabc-4016-4060-8553-1538d608ecae_negatedLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Plan curtailments, settlements, and amendments</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:to="lab_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fc0a3ea3-64a6-4320-be0b-f308fe239196_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period over which unrecognized compensation is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b8ee0f4e-7cc4-40d0-a2da-b509dfbb80f9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbb5d166-1fee-40b3-a3db-59e4961b1519_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_056b1eb9-3215-4b55-87b8-2024ee3f520e_negatedTerseLabel_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash advance paid to taxing authorities</link:label>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_label_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Advance Paid in Connection With Proposed Settlements</link:label>
    <link:label id="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements_documentation_en-US" xlink:label="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Advance Paid in Connection With Proposed Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:href="mdt-20250425.xsd#mdt_CashAdvancePaidinConnectionWithProposedSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:to="lab_mdt_CashAdvancePaidinConnectionWithProposedSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_NeuroscienceGroupMember_b535db94-98f7-4f09-9fbd-9b7079bb41c3_terseLabel_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_mdt_NeuroscienceGroupMember_label_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience Group [Member]</link:label>
    <link:label id="lab_mdt_NeuroscienceGroupMember_documentation_en-US" xlink:label="lab_mdt_NeuroscienceGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuroscience Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_NeuroscienceGroupMember" xlink:to="lab_mdt_NeuroscienceGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_89ac5905-b26e-49d3-a384-069d7a8e02f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_dea99df2-4edd-4e7e-b913-3eec0619a4ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_23bf2d0d-1ad0-4ae3-8c8f-454269fa9217_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts Recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d95d5d07-ea8f-4973-a3ab-49f472d6415b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3666c945-0ce3-48cc-8cff-b6a531ba905d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AuditInformationAbstract_label_en-US" xlink:label="lab_mdt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mdt_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mdt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AuditInformationAbstract" xlink:href="mdt-20250425.xsd#mdt_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AuditInformationAbstract" xlink:to="lab_mdt_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CorporateOverhead_3026bc8b-6969-4e85-8300-11a859f0acf0_negatedTerseLabel_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_mdt_CorporateOverhead_label_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Overhead</link:label>
    <link:label id="lab_mdt_CorporateOverhead_documentation_en-US" xlink:label="lab_mdt_CorporateOverhead" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate overhead expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead" xlink:href="mdt-20250425.xsd#mdt_CorporateOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CorporateOverhead" xlink:to="lab_mdt_CorporateOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_17193bc1-2055-4121-abe0-c611d514127e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6abd2296-659d-4b48-ab6e-596f9879ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7305e9ee-5470-4800-8727-e4df30fb42e3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_f1905f1d-84b6-40e2-8950-5bc4967b0894_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustments (in dollar per share)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_564de9ec-a22a-4f97-b01e-9240a41e43d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_f5e59432-6c8a-457f-b39e-8624880bfd20_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_22cd83b4-3c48-422e-8c7f-5e69a308fda2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, (Gain) Loss [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_ba07c6f2-bb40-42d9-8ecc-859721f7db24_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_13d6c931-baaa-4cc0-965f-ef7febe340fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and associated costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_62431922-bc30-4023-b2a6-b7e35b08af19_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3c48b3b9-4870-4120-af72-6d9ecc56a38e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_6a69fa30-fc72-4c14-ada1-341da43e9739_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d522bf96-161d-4110-87cc-9fa6ea68ff62_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due20411375PercentMember_259488fb-92d0-4eaf-9af7-3ccb6cac7d79_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20411375PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.375 percent twenty-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20411375PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20411375PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2041, 1.375 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20411375PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20411375PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2041, 1.375 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20411375PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20411375PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due20411375PercentMember" xlink:to="lab_mdt_SeniorNotes2020Due20411375PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2010Due20405550PercentMember_5d4dd981-a26a-45de-998f-f4cfa6a6873c_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2010Due20405550PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.550 percent thirty-year 2010 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2010Due20405550PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2010Due20405550PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2010 Due 2040, 5.550 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2010Due20405550PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2010Due20405550PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2010 Due 2040, 5.550 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due20405550PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2010Due20405550PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2010Due20405550PercentMember" xlink:to="lab_mdt_SeniorNotes2010Due20405550PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_351dad1d-f947-41fa-82c9-0453331e0b7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_5bf0b6d1-5dfe-410f-928c-39b83757bab8_verboseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Other</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:to="lab_mdt_DeferredTaxAssetsNetofValuationAllowanceOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d6c247cd-0d23-4927-9c4a-ec8a1ed5f6de_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_55de2390-33f7-46ab-9e9e-04568b810e13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_6895266f-b241-44da-a4d9-392ac85aafca_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_label_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_mdt_DeferredStockSharesOutstanding_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesOutstanding" xlink:to="lab_mdt_DeferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4388ce51-a023-4164-b483-7e67010c9c05_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_594202fa-af42-4571-8890-39bae65f790b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3bf081fd-1c91-4bdb-8724-72a17d3e9276_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_78a1e1b7-87c1-405f-8f98-710de07655e8_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization of research and development</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Development Capitalization</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Development Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:to="lab_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_fd1a96c3-3337-4775-ba38-3548a666ee82_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_8c00764d-0c18-417f-9faf-e3b3f2c099a8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_b6f019b0-5a7f-4d58-9c35-67f8862e0eac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_32045a50-0310-4ef9-a226-fc327c35d0b0_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base erosion anti-abuse tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2d2b363-bebd-4169-b4e1-35c80c317748_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_abf714cb-98df-49aa-b809-d1fe246fc1a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9d1616a6-d851-4cf0-8b52-0214727f8e39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83076318-bafd-4f75-9bdc-af58fc1ad210_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_5358723e-e779-4f06-92f7-076fe4eaad93_terseLabel_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_label_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:label id="lab_mdt_OffsettingAssetsandLiabilitiesTable_documentation_en-US" xlink:label="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offsetting Assets and Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable" xlink:to="lab_mdt_OffsettingAssetsandLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_1fb2a528-e8bd-45d1-9f9a-d7c2fa31aab2_terseLabel_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Length of extension from maturity date</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_label_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Length of Extension</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityLengthOfExtension_documentation_en-US" xlink:label="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Length of Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LineOfCreditFacilityLengthOfExtension" xlink:to="lab_mdt_LineOfCreditFacilityLengthOfExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_26060b08-e6bb-48d8-802c-d8cdbe137802_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_3fe140d0-fc5e-4acd-82f2-fdafc187117d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plaintiffs (in plaintiffs)</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57edc93a-e8e1-4873-91eb-25ae8854f068_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7500cb44-5eb9-4122-8239-98fbc1d8a05d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to Income</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ForeignCurrencyCosts_f138d64e-1177-471e-868f-7dac733f1de4_negatedTerseLabel_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency</link:label>
    <link:label id="lab_mdt_ForeignCurrencyCosts_label_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Costs</link:label>
    <link:label id="lab_mdt_ForeignCurrencyCosts_documentation_en-US" xlink:label="lab_mdt_ForeignCurrencyCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ForeignCurrencyCosts" xlink:to="lab_mdt_ForeignCurrencyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_bd9d2079-6353-480c-ba12-6abda8f2acee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_91f44274-343d-4bc7-9ff7-610a653abd86_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, par value (in euros per share)</link:label>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_label_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_mdt_DeferredStockParorStatedValuePerShare_documentation_en-US" xlink:label="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare" xlink:href="mdt-20250425.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockParorStatedValuePerShare" xlink:to="lab_mdt_DeferredStockParorStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cf488b47-3625-495a-9408-c90506fc030c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_233dd08d-2f08-4703-961a-8b971ab6c282_negatedTotalLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_1c63e6c9-38cc-4b40-91b3-ad265cfc9bce_terseLabel_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment net sales</link:label>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_label_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Reportable Segments [Member]</link:label>
    <link:label id="lab_mdt_TotalReportableSegmentsMember_documentation_en-US" xlink:label="lab_mdt_TotalReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember" xlink:href="mdt-20250425.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalReportableSegmentsMember" xlink:to="lab_mdt_TotalReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03680a91-ac4c-4d1c-89cb-732803c34eb1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a30919e-e864-44c5-bdd0-9dba5acc8cf2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_5734528e-7f63-4ddb-8f8e-8af5ffbf91fb_terseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8466d7b6-a109-4ede-b1e0-e0f268236f2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_a4422e87-b9fd-4df0-a660-f3c8c87cbc60_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, (Gain) Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f14105c-1193-4713-abc9-beb9c515d327_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41a99a19-7670-4062-83cd-e370cccec68c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxHolidays_b4747b44-d98b-469c-8bd4-bed630fbd24c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax reductions from tax holiday</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxHolidays_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Holiday, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxHolidays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_5218f1c0-9a6b-405d-a024-6e2278f829be_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5b632dc3-13b2-4ccd-906b-057a15aac620_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_9484d663-cb09-4dc1-ba85-552a36143270_terseLabel_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_mdt_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an entity's accounting policy for contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ContingentConsiderationPolicyTextBlock" xlink:href="mdt-20250425.xsd#mdt_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ContingentConsiderationPolicyTextBlock" xlink:to="lab_mdt_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_be6535b0-9072-4953-abca-2ebb7aed194a_terseLabel_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated and Other Costs</link:label>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_label_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated and Other Costs [Member]</link:label>
    <link:label id="lab_mdt_AssociatedAndOtherCostsMember_documentation_en-US" xlink:label="lab_mdt_AssociatedAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Associated and Other Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember" xlink:href="mdt-20250425.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AssociatedAndOtherCostsMember" xlink:to="lab_mdt_AssociatedAndOtherCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_99ff92e8-52c4-415b-95e2-724c42c21fa8_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A0.375SeniorNotesDue2028Member_5d78a420-3cc8-4cdb-9e8a-cc7172ba1a29_terseLabel_en-US" xlink:label="lab_mdt_A0.375SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.375% Senior Notes due 2028</link:label>
    <link:label id="lab_mdt_A0.375SeniorNotesDue2028Member_label_en-US" xlink:label="lab_mdt_A0.375SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.375% Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_mdt_A0.375SeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_mdt_A0.375SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.375% Senior Notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.375SeniorNotesDue2028Member" xlink:href="mdt-20250425.xsd#mdt_A0.375SeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A0.375SeniorNotesDue2028Member" xlink:to="lab_mdt_A0.375SeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2023Due20284.250PercentMember_f6211224-8c47-4a07-84c2-1e8385f24bef_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.250 percent five-year 2023 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2023Due20284.250PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2023 Due 2028, 4.250 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2023Due20284.250PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2023 Due 2028, 4.250 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20284.250PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:to="lab_mdt_SeniorNotes2023Due20284.250PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9de8d58e-72d7-4158-9b23-f298cad76002_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_75c5ad6c-32ad-4cae-bf8e-534e5b0bfd71_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_be357ee6-a350-4900-be3c-11cf05eaeafe_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_788d1eca-5a9f-4f08-b68b-5cf7b7684f81_terseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Foreign Exchange Adjustment</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:to="lab_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3cc8c80d-1ac4-4368-8b67-286a0d72c6f5_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_350198d2-857e-4820-a202-e884c38b9b85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2015And2020CommercialPaperProgramMember_80fa5c1b-fc07-49cc-a06f-6b20171d3b01_terseLabel_en-US" xlink:label="lab_mdt_A2015And2020CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 and 2020 Commercial Paper Program</link:label>
    <link:label id="lab_mdt_A2015And2020CommercialPaperProgramMember_label_en-US" xlink:label="lab_mdt_A2015And2020CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 and 2020 Commercial Paper Program [Member]</link:label>
    <link:label id="lab_mdt_A2015And2020CommercialPaperProgramMember_documentation_en-US" xlink:label="lab_mdt_A2015And2020CommercialPaperProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 and 2020 Commercial Paper Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015And2020CommercialPaperProgramMember" xlink:href="mdt-20250425.xsd#mdt_A2015And2020CommercialPaperProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2015And2020CommercialPaperProgramMember" xlink:to="lab_mdt_A2015And2020CommercialPaperProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_bbbef6ec-8e45-4453-91e2-5aaaeb7f0b9a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_378a6448-9f22-4009-be94-02a898ecdfc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_feb72cb0-dfdf-4441-8cf4-b11c0073dda5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_925768a3-48eb-4534-8a71-cfa3b0ac2d13_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98a7288d-0016-488b-8521-75f6fccb4e87_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_b510b9af-7acd-4701-9f92-add18bb1a51b_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net of Cash Advance Paid</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net of Cash Advance Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:to="lab_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_ea944646-ed60-442b-a0a9-76472667d124_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and tradenames</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_14a95c94-db48-49d3-8fd6-90bd770f6d10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value, option loss</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_31274d73-c16a-4fa1-a70e-717cf775504e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Confirmed invoices paid during the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_aa18cb5f-c5d4-4313-9e5b-0287395fcc21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net underfunded status of the plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6f383649-c4eb-400b-b9c1-321d47710448_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Over funded status of the plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_ad563298-aee1-4dc5-a79b-bcf781ee60fa_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_label_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:label id="lab_mdt_DeferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesAuthorized" xlink:to="lab_mdt_DeferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_97fdeb6c-f200-449f-8fa1-eeb3008f2e95_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases:</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Gross Increases [Abstract]</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:to="lab_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e3e71825-399f-40ab-af78-b6152227c80a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e33e2de8-c2ed-4c61-8410-931d937d2606_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_702f5b55-9033-4f70-b6d3-a840b184f876_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7c704c57-0408-4705-b880-6170786dd834_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ca8a37ee-066b-4caf-b0cd-58037c14f35f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_02da2af8-6459-488f-b22d-2681feba9759_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact on diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_341efada-1a91-4b90-989c-6c1952953674_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_b1d3d1ba-8e23-42c7-8ecc-67b8a3284b09_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_28c0978d-e1de-4f96-a559-b24a24377dec_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_9d795a7a-0351-45a0-b53d-0a9b6c18d95f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20401500PercentMember_e7fc0a26-9a6a-4ad7-bff1-674ceb63e00e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20401500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.500 percent twenty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20401500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20401500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2040, 1.500 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20401500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20401500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2040, 1.500 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20401500PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20401500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20401500PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20401500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ad8cba83-8c9e-42fa-a067-b49d381b4a8f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_12aa0266-91a8-45a8-9ba0-d4d90103171d_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_12de3ed2-08a5-46b9-92cf-a0d70a429167_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f2aeabb6-dd9b-4c2f-a202-0a5ec3f097f6_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2.250SeniorNotesDue2039Member_4737c0b2-a18e-45b8-9233-bb2cb5f1493d_terseLabel_en-US" xlink:label="lab_mdt_A2.250SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due 2039</link:label>
    <link:label id="lab_mdt_A2.250SeniorNotesDue2039Member_label_en-US" xlink:label="lab_mdt_A2.250SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due 2039 [Member]</link:label>
    <link:label id="lab_mdt_A2.250SeniorNotesDue2039Member_documentation_en-US" xlink:label="lab_mdt_A2.250SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.250SeniorNotesDue2039Member" xlink:href="mdt-20250425.xsd#mdt_A2.250SeniorNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2.250SeniorNotesDue2039Member" xlink:to="lab_mdt_A2.250SeniorNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c8e42e96-146f-4b45-baf8-0e5aee9d16b3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_9347a418-3a93-43a7-a0de-5aa0cd2d0e71_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0c8b5509-5c51-4770-ac76-ab0dd010b936_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_adbc959e-9294-43a0-8091-d252c99a12d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedtronicLuxcoMember_b7cb7e4d-bb8f-4143-b51a-c0a8b39a5f05_terseLabel_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medtronic Luxco</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoMember_label_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medtronic Luxco [Member]</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoMember_documentation_en-US" xlink:label="lab_mdt_MedtronicLuxcoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medtronic Luxco [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedtronicLuxcoMember" xlink:to="lab_mdt_MedtronicLuxcoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6625e2da-7b08-4ac4-9c56-ddfef8dec7d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a0197358-1643-424c-ac04-48fd71e67444_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MozarcMember_210d73de-8d3a-48be-818c-07a254e318e9_terseLabel_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mozarc</link:label>
    <link:label id="lab_mdt_MozarcMember_label_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mozarc [Member]</link:label>
    <link:label id="lab_mdt_MozarcMember_documentation_en-US" xlink:label="lab_mdt_MozarcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mozarc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MozarcMember" xlink:to="lab_mdt_MozarcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_7b6d854e-5067-466d-a194-597d943e2fa1_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ee532ad5-ee44-4873-a5c0-0de9d8c17843_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AcceleratedAmortizationOfIntangibleAssets_cbfc42ce-77e8-46fc-878c-f21106f3bb48_terseLabel_en-US" xlink:label="lab_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated amortization</link:label>
    <link:label id="lab_mdt_AcceleratedAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Amortization of Intangible Assets</link:label>
    <link:label id="lab_mdt_AcceleratedAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accelerated Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:href="mdt-20250425.xsd#mdt_AcceleratedAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:to="lab_mdt_AcceleratedAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_297c9b5f-a815-4d67-bf7b-e973b93b040c_negatedTerseLabel_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Pension and post-retirement benefits</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_label_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Pension And Post-retirement Benefits</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_documentation_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Pension And Post-retirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:to="lab_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_d0435145-0b1f-4657-a1f2-317949909efc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value - Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_e0cc3fa4-b78a-4f7e-a221-6d766fdae940_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_890ea19f-7a1d-4f42-9093-9da8f6ec1abb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7f0926d0-258c-4f5a-9317-1d4245880e8a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a566a12-422b-4d15-b11a-c026459eaabb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d150e176-dc5a-4ce3-b489-793a6dc2aa72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e0b49972-5bc2-493c-a700-46c132cc89a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6386de80-e075-488f-a758-801a797aba58_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_7806d530-8295-4870-b0a1-732d843fb541_terseLabel_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product development and other milestone-based payments</link:label>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_label_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Development Milestone [Member]</link:label>
    <link:label id="lab_mdt_ProductDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_mdt_ProductDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A milestone in achieving certain product development target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember" xlink:href="mdt-20250425.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ProductDevelopmentMilestoneMember" xlink:to="lab_mdt_ProductDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8126aac4-3953-4e7e-a0b4-7ded4501d2e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_96b2e171-90b4-4222-a45c-020b6fb2722d_terseLabel_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in tax rate resulting from:</link:label>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_label_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Tax Rate [Abstract]</link:label>
    <link:label id="lab_mdt_IncreaseDecreaseInTaxRateAbstract_documentation_en-US" xlink:label="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:href="mdt-20250425.xsd#mdt_IncreaseDecreaseInTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:to="lab_mdt_IncreaseDecreaseInTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_74198f0f-b0f1-431c-8627-fcc717534f3f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_6eb957b6-1ec2-40f6-b1dd-2f33b15a12b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf5dc431-b5f8-43fe-8ac1-3ee128ffc06a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1a218e4a-8017-4957-9cfe-f855ba0d2de9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_75874d2d-75a1-4a26-a333-6211b700b601_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_95a45d78-8933-4894-ad44-44d9d9259cb3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6b172650-67fe-4718-bdbf-22dd21807653_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_98ddb030-4be1-4120-acff-5905c2253c0e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fd8d651c-ef85-4d80-9245-43b67cb8ebe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Balances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_413c2489-521a-4a34-898f-08f1882f2c38_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income tax penalties and interest</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_28ed034d-9ce6-4949-b53c-72e86b9a3d40_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_b464df34-45e7-4921-9737-48c5b7a2e2ae_terseLabel_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges, net</link:label>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_label_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Net of Restructuring Reversals Including Cost of Product Sold Impact</link:label>
    <link:label id="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_documentation_en-US" xlink:label="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:to="lab_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3.650SeniorNotesDue2029Member_b6a68cec-2573-4872-914e-dc6beb3341e4_terseLabel_en-US" xlink:label="lab_mdt_A3.650SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.650% Senior Notes due 2029</link:label>
    <link:label id="lab_mdt_A3.650SeniorNotesDue2029Member_label_en-US" xlink:label="lab_mdt_A3.650SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.650% Senior Notes due 2029 [Member]</link:label>
    <link:label id="lab_mdt_A3.650SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_mdt_A3.650SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.650% Senior Notes due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.650SeniorNotesDue2029Member" xlink:href="mdt-20250425.xsd#mdt_A3.650SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3.650SeniorNotesDue2029Member" xlink:to="lab_mdt_A3.650SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ce60993d-caf0-437f-9164-ae053154e3f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_78dd14b5-aaa3-4b2d-ab02-bf59ed9ce516_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d61442c1-bb3f-4f61-a4dc-c16b7742f6ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_866682f1-944b-4111-8a4e-38d254b7a1a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_e6710d4b-c7f2-4040-8c18-1c043c74a84d_totalLabel_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and other investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_label_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_documentation_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:to="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_0b8dbedc-8b58-4798-bffe-bcba2fcc7023_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4cdd6797-46ed-4b07-95b5-b8624c685705_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_92d0cebe-0996-4814-9626-677eeaf712b1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_c389bd13-dc77-4279-b3fb-83292d70a724_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_527a3f82-58ba-44c9-b2ba-aae50dc3a018_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_abf40d85-fa03-4a35-8875-dbc5dff4662e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d24267a7-a888-44b0-8dfb-b6f4bfd20a29_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2050Member_5e34711b-517f-47aa-888f-310b338c4c6e_terseLabel_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2050</link:label>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2050Member_label_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2050 [Member]</link:label>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2050Member_documentation_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2050Member" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.625SeniorNotesDue2050Member" xlink:to="lab_mdt_A1.625SeniorNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_22a45981-95c3-4e44-88f8-2b565872f86c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Before Income Taxes, Based on Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a2232d79-1950-42b9-a923-a72a7196b142_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_84d1a5bd-e0a5-450e-b038-6487f97cec7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at beginning of fiscal year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_949990e8-8e4c-43d9-8ffa-bcd27c5a0574_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits at end of fiscal year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b3872cd7-88e2-4606-b15f-b0d99e1ee9e1_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_191b2874-18fc-431a-a296-80cd7c388b6f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e4d873ac-3412-4949-b3e4-71a43f0a8e54_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_7de4bc8b-3ed0-4a98-bc99-deac133d8651_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_116ff955-733e-498e-ab86-7fecb2b778e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_7aa88245-daaf-4c5f-b0b3-66a831175058_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_697e38e2-5e3c-4bf0-a18a-cd8f7b28609c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current debt obligations, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_dcc4bbad-f88b-4b96-b141-06fb5f91ba14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_722fb09b-7f7a-49f6-be3a-226e2c595d97_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8a6a54fb-e7e8-4a8a-9a91-72d0b9101899_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_dc2c8061-6241-4530-8efc-742eb46a2359_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_81d9938a-aafa-4e17-8995-ba7b24f7e437_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_235ef044-15d1-407e-b830-4a9e9bbcb3e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.500SeniorNotesDue2039Member_201f7bce-772a-43ec-8c19-6fb6397b9b85_terseLabel_en-US" xlink:label="lab_mdt_A1.500SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.500% Senior Notes due 2039</link:label>
    <link:label id="lab_mdt_A1.500SeniorNotesDue2039Member_label_en-US" xlink:label="lab_mdt_A1.500SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.500% Senior Notes due 2039 [Member]</link:label>
    <link:label id="lab_mdt_A1.500SeniorNotesDue2039Member_documentation_en-US" xlink:label="lab_mdt_A1.500SeniorNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.500% Senior Notes due 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.500SeniorNotesDue2039Member" xlink:href="mdt-20250425.xsd#mdt_A1.500SeniorNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.500SeniorNotesDue2039Member" xlink:to="lab_mdt_A1.500SeniorNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_fdae2d00-6794-4253-8b6e-275b607a0b11_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_cd7d8a64-c830-43e6-a5a8-92a83765fa4e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_9f8bf4e5-1bbb-4d77-a15c-5671d1ebe57c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4ad504f4-68cc-4c5c-8974-7e754204b544_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefit Plan Assumptions</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3d98b175-3705-4ea3-b5ad-14808d55147e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_bb3d2afc-b2e1-49c9-af0e-e540e7cfd2fe_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_94d1f113-caa2-42fc-95e3-7ba6af6fc41e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e88f8a8e-b961-4ff7-a131-f140cfebbdf5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1ea3c73d-a527-47eb-9ebc-8042c3cd4a06_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Restructuring Reserves</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c26e9e3b-3745-4881-b9d8-058cf2e80ae3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_d4f30803-b415-40a2-aaf6-8fb9f6507eb8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2dba6f6b-f920-4e4c-a3e6-d39398e70319_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_090375a4-fc2c-43e1-851c-f9d5ae66598e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_cf7b17e1-5ec1-4df2-9473-e7c2800c40fe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AFS Debt Maturities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9da39c70-c7b5-4237-be80-ed8ccb52981a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_e74df3b8-6156-4d81-adbe-1c0b94b9f07a_negatedTerseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities and derivative financial instruments</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:to="lab_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3.125SeniorNotesDue2031Member_07051801-dc32-4996-8ffb-6c64a2085319_terseLabel_en-US" xlink:label="lab_mdt_A3.125SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.125% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_A3.125SeniorNotesDue2031Member_label_en-US" xlink:label="lab_mdt_A3.125SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.125% Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_mdt_A3.125SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_mdt_A3.125SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.125% Senior Notes due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.125SeniorNotesDue2031Member" xlink:href="mdt-20250425.xsd#mdt_A3.125SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3.125SeniorNotesDue2031Member" xlink:to="lab_mdt_A3.125SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_264f885f-fc46-47eb-8dc8-4fc79228ce0a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_0e7b492f-d7eb-4bb4-876b-4b043c4c1755_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_ae9a6874-226f-466e-9071-2b87a4532f5a_terseLabel_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, lawsuits, number</link:label>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_mdt_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_mdt_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber" xlink:href="mdt-20250425.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LossContingencyLawsuitsNumber" xlink:to="lab_mdt_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_87d17305-2912-4d93-b789-7b3c141210ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_aaec2c82-17c6-4692-a6f7-f65e9e57d237_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedge unrealized gains to be reclassified over the next twelve months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_372a69eb-2fb1-4aca-887e-72e0eca1f114_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_b23ac6ff-3371-4e4b-8ac5-3b9a80b88afb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5da9629b-da13-42a8-be21-88bf475a518e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of settlement paid</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce3b6a4a-d41e-49f0-b3c5-6fcd1428deda_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_2f30d945-7275-419d-984d-0342f73b6d82_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_1ffb565a-b304-419e-8540-a8347a204625_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Current Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c4cd0ce5-54b8-4623-a9c1-ebc380751aa5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b6a529f5-e570-4e94-9be0-6a4584367e4b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0655664a-0f3b-4bff-a7a7-2f435ee7fb44_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_9a4d1efa-c0e7-4926-828e-0edb939d19e9_netLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Employee performance share units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_0e77d727-4e1d-4fab-8b9d-23c85c8ce6f1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Critical assumptions &#8211; net periodic benefit cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_493d6f76-4b3b-461e-95e7-6fbeba69aaa2_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_dab888b8-7250-4529-a4c1-a045c5292d96_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d900757d-24b2-4b10-a365-39acd7634e2a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_8177d818-326f-4efb-b72c-ac000a26c2de_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b790f016-225f-40fa-a1f2-515355dab79b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_878edd6e-8ca6-4832-b52f-b70b7e1c70fe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Assets Target Allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Allocations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_baf3e8b5-a746-4a87-8b5a-d7fc0fd5e8a2_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_b24ae974-013d-4b02-8cc6-65def7e24d3f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Debt Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_da63d38b-d865-4cef-a61c-169fbad664c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_148f994a-4b67-4dff-a72d-3700d6e59203_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_bb004c18-d11c-4975-9349-14933a5dd24e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a434f86f-e3b5-4fa1-a7c5-228a90eefa39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_bf82b8cf-8a5e-486b-8c89-dd296eb50f99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_1492b414-f71f-4fac-9de7-b51239e9bc18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, unrealized currency losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6cb8c43-8bb9-4069-b98a-b9c69531ad64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_21483542-1dc5-43bb-b237-98e934528a54_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_559bfd16-a876-4918-8072-b1cfca22647f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b7cda072-bcc7-43d4-b51c-d08d9bb19040_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_20b7c0ce-8323-49eb-95a6-bc294bf4c718_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_fd1152b1-5ea8-4d4e-8fb2-29124583c2fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term borrowings (maturities greater than 90 days)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_28d302ca-92e4-42e4-8a7e-bfedc5ae48b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7d99cf15-10d2-4863-8a11-325bf485f6ce_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_2150338c-69d8-43ae-8fbd-9a2ff5041acf_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, no expiration</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:to="lab_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_8a0afa98-cd69-4c56-8006-131587a4e263_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Year-End</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_0845ca54-620a-4e65-a407-566284ef6132_terseLabel_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_label_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses [Member]</link:label>
    <link:label id="lab_mdt_OtherAccruedExpensesMember_documentation_en-US" xlink:label="lab_mdt_OtherAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherAccruedExpensesMember" xlink:to="lab_mdt_OtherAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_82fcf002-14e4-4b94-b80b-026ff961a65d_terseLabel_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cranial &amp; Spinal Technologies</link:label>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_label_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cranial And Spinal Technologies Division [Member]</link:label>
    <link:label id="lab_mdt_CranialAndSpinalTechnologiesDivisionMember_documentation_en-US" xlink:label="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cranial And Spinal Technologies Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:href="mdt-20250425.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:to="lab_mdt_CranialAndSpinalTechnologiesDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd791e91-2531-420d-8d72-fa7a76892265_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_94cba940-8629-4e27-97d8-d50bb0aba5ad_totalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount of Recognized Assets (Liabilities)</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_label_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:to="lab_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_93985b65-920e-407b-b867-826f5eb1f11f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_2c799cc1-abad-4e4a-93b7-338f196217bd_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e8f340a7-3b12-426c-a449-b90f53642517_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d57fbc8e-9a61-4184-87cc-7010efdd1168_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_3e365ce2-1c35-4a46-a35a-867af2fdd75a_terseLabel_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:label id="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_documentation_en-US" xlink:label="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:href="mdt-20250425.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:to="lab_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_39850ac1-7c6b-4f87-a3a6-32ed66dc1fe4_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_8248953a-63ba-4459-8432-a1a16152549d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications from AOCI, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f093e09a-6659-4d84-abc4-4cb0189b1f53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d81f6e1c-2342-404e-a549-fede83e860a6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_27dca97f-916d-41e4-844f-34419314be64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due20354.375PercentMember_8477e5f5-6c65-431c-bc23-d774dcf5aee8_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.375 percent twenty-year 2015 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20354.375PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2035, 4.375 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20354.375PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2035, 4.375 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20354.375PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:to="lab_mdt_SeniorNotes2015Due20354.375PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b032105f-386c-4b20-81df-77c06b9e3672_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b541d848-d044-4d21-9343-1f613b283c13_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_62da1430-b811-41b6-938e-2573c1ed2e93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0d248d02-bf1f-4e1e-bf04-cf95fe206eb1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_d1edaab4-c7dc-48ee-b55d-474f50fdd215_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average purchase price (in dollars per share)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_679f6f1d-61fc-4aca-8cf8-46394a741463_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_33d0084c-0212-41ff-9e3e-b6ecddafa5d8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_0780b90a-7e96-43cc-826a-870732312643_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price contingent consideration</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Price Contingent Consideration</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionPriceContingentConsideration_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Price Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:to="lab_mdt_BusinessAcquisitionPriceContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_9c617418-24cc-495b-891f-69f4b3be6a26_terseLabel_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental defined benefit, defined contribution and post-retirement</link:label>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_label_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges [Member]</link:label>
    <link:label id="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_documentation_en-US" xlink:label="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:href="mdt-20250425.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:to="lab_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_fad63073-eba4-485c-bcfc-3226c2b87ad5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative assets:</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_9d53b613-19ca-4536-9663-1579ebe2c2d4_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_fdfdcdd6-2adf-43c3-827b-85b73d653374_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6e17f1a8-ecd9-4a3c-9255-8c4575393163_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_00826eef-c464-4518-a8da-8f3fa5921abf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_8bea3883-c4e6-43fa-8614-59b9c3f680ae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_13170ed8-e4d4-46e0-97fd-e2f9423be3f8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_23c05e85-c516-4cfd-9339-3fdbbcaa7d7a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_80f511ac-4141-4e07-873f-7a9931d6a56a_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2e96e526-4c18-4d19-9942-e28eaf066d6b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_91363061-fec7-4330-9bd9-6bd1c6282d8a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold, excluding amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_c7ea8579-219a-40d2-a5bd-1ed741fa9661_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquityInvestmentsMember_13e95f36-5718-410c-bc5e-84ef859c8bb5_verboseLabel_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity and Other Investments</link:label>
    <link:label id="lab_mdt_EquityInvestmentsMember_98abf835-6ebd-4b5e-b810-758df227fee6_terseLabel_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and Other Investments</link:label>
    <link:label id="lab_mdt_EquityInvestmentsMember_label_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments [Member]</link:label>
    <link:label id="lab_mdt_EquityInvestmentsMember_documentation_en-US" xlink:label="lab_mdt_EquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember" xlink:href="mdt-20250425.xsd#mdt_EquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquityInvestmentsMember" xlink:to="lab_mdt_EquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aeddeed3-876a-4b5b-896a-b8690373ecdd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d41b75cd-1729-4a98-bc81-0a66f77951ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6b5aae0a-3d40-436a-9d89-6bd53af86136_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e7f1141d-b85b-4df8-ade9-005aeef1fe64_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 3, 16, and 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8a231ed4-b2e0-4718-b526-d3d940c072c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c93f5228-5a80-4217-870e-b99b7f8bdeed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_f96ac340-5183-4d36-96a5-2806b4f55e3f_terseLabel_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average repurchase price (in dollars per share)</link:label>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_label_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Average Purchase Price</link:label>
    <link:label id="lab_mdt_StockRepurchaseProgramAveragePurchasePrice_documentation_en-US" xlink:label="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average purchase price of common shares under a stock repurchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:href="mdt-20250425.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:to="lab_mdt_StockRepurchaseProgramAveragePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1af76a3-7ae2-4ed9-ad64-225ca488cc2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_f4dd8b9a-e346-4ed4-85d6-dfa620913f42_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d556fb7-f82d-4033-9c8e-39bc4294b32d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bd42bdfd-e0b6-4d8e-95cf-daa0646d8aaf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_4f954d67-7284-4be8-be0c-b1476fb7cdd3_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_f630b1d0-e56b-4e88-b933-f79bf5e5940b_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_57a72d35-0cb7-409b-a195-0fcf308098ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_678bde8a-fc5d-4199-a4da-36458830b971_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_2a0a792a-b5c4-4b57-bac6-f35b591fa948_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status at end of year:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_e6b631ab-c96e-4afb-bd37-1b50766b609a_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_9aba1e90-39e8-4512-9d1b-c6200844a6f5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f822693a-8280-47fe-a4e6-44cb1cd02e59_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Medtronic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d61064e2-2f39-4ad8-a413-a7009fbd4246_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to ordinary shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_e9ccd18a-e91f-4f31-aa5f-b2ca373d75d9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_8914b3c0-28d1-40a2-bb7d-6cd9c4793231_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031 &#8211; 2035</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_GainOnInvestments_3a2d5f29-a231-46e2-9737-706379d813a8_terseLabel_en-US" xlink:label="lab_mdt_GainOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross gains</link:label>
    <link:label id="lab_mdt_GainOnInvestments_label_en-US" xlink:label="lab_mdt_GainOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain On Investments</link:label>
    <link:label id="lab_mdt_GainOnInvestments_documentation_en-US" xlink:label="lab_mdt_GainOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_GainOnInvestments" xlink:href="mdt-20250425.xsd#mdt_GainOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_GainOnInvestments" xlink:to="lab_mdt_GainOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="lab_us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsTableTextBlock_b0f454d7-81ed-4a4b-b3de-6b6a39f3de0a_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Offsetting Assets</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsTableTextBlock" xlink:to="lab_us-gaap_OffsettingAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_30b79bef-70d7-4156-8cea-a896556c59f5_negatedTotalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:to="lab_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_c323b214-503c-4d9d-bc93-ded4f0b445ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_37cd6b83-e0d4-4282-86ca-d3c9d09d7cab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ScheduleOfInvestmentsTableTextBlock_c458dcc7-3a53-41c9-b85d-376d1e8f3bb1_terseLabel_en-US" xlink:label="lab_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Investments</link:label>
    <link:label id="lab_mdt_ScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Investments [Table Text Block]</link:label>
    <link:label id="lab_mdt_ScheduleOfInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:href="mdt-20250425.xsd#mdt_ScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:to="lab_mdt_ScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_02abc183-95a0-4664-8f20-414a15718ddd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_4d944167-01ea-4992-a513-958f8fbf4ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_b868eab4-9331-4779-b77a-150eff9c0b9c_terseLabel_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Operating Income, Net</link:label>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_label_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net [Policy Text Block]</link:label>
    <link:label id="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:href="mdt-20250425.xsd#mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:to="lab_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_60ca6df5-d3bf-4d95-891f-5be88148646b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_21630e48-2843-4e11-b4d3-74c4cc4558c4_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1382e7cf-8c56-4d7a-995c-30f24e783250_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5dc88f42-df1f-46de-9081-702fbb9eca6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cd7cc891-9ad3-4290-8733-09abba5b667b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_a32aa2e3-ed7a-4fda-89c9-be5666eb8e7a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2dd46cff-0315-4fcd-a10f-5311592686cd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_2d34fc7a-79d7-483c-b730-4a0ecbce1b5a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_49cf0098-3f2a-4acf-8bf9-460f51dd2d3e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_71efa0a6-6dfe-4115-b122-d00b54a80074_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_41330540-faac-409b-8318-e457d02f81a6_negatedTerseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Performance adjustments (in shares)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_57325d3b-431d-490e-a6af-4971df552c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2031Member_764e4126-7769-4504-b71b-4cb681c0630f_terseLabel_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2031Member_label_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_mdt_A1.625SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_mdt_A1.625SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.625% Senior Notes due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2031Member" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.625SeniorNotesDue2031Member" xlink:to="lab_mdt_A1.625SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_79b6a76f-4b52-4640-8946-b5b7c4f7d95f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Changes (Debit) Credit, Adjustments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_4ee65c86-a912-4e35-b0c6-7a0cf16480e3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_6a2af452-688e-4c5e-a8f9-9aaa29f60ab8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_af044bda-24ed-41ba-ba1c-a5230e05492e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3d614f55-f171-4ba7-b5e7-cf576b15a731_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_cba68074-ae04-4bc8-911f-bcf86bccc314_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Performance Share Unit Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_7c71cced-4f5b-4a83-a900-2f2541430285_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_74c04ad8-0c47-4993-9c1b-c9ee3525b6d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4c00bd9f-dc17-437b-af8a-215af924de3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_8d0748d9-2b34-449a-9796-8adddb06d042_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_f8c724df-4cf0-4468-b7e7-d13e9bd04eed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain tax adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b17ac89b-b6a2-4ea1-bc98-93ea66556ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MN_1d737905-acac-46ba-bc46-11c039e416f7_terseLabel_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minnesota</link:label>
    <link:label id="lab_stpr_MN_label_en-US" xlink:label="lab_stpr_MN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MINNESOTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MN" xlink:to="lab_stpr_MN" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e413e9a8-9f8c-480a-9b9a-88e0fb983cf8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_547a80bc-9dda-4060-bd67-0f9837409538_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31ed0849-053a-414c-a6fe-a89aac4e43e3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90e34e8f-c75f-4f83-b3d5-1c8cb0186e72_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic - weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_67c7dfda-011b-4691-9091-4c67e35062c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">More than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fbdef58d-8527-4b5a-8c18-f5db2fe03651_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21157767-03b9-45fd-8f2b-39fbbebb3bd1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81088996-f5d2-4717-bdaa-431cc3bbdf21_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27030a7b-d4b3-4121-99c1-89116c4d3eba_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_22ec118b-c0b6-4de3-99e3-1bcc1487c912_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Target allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_a8eabc25-9367-4d90-bce8-c3efe1bf17ad_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c89967f2-b956-4d0f-b3bb-8bb2d68ba8bf_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets/(Liabilities):</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_d8586e7b-d727-422f-ae12-ccbe67242c07_negatedTerseLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization and settlement recognition of actuarial (gain) loss</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due20293.000PercentMember_b654df77-1eee-400a-820a-44b8b6c8788a_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.000 percent six-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20293.000PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2029, 3.000 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20293.000PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2029, 3.000 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20293.000PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:to="lab_mdt_SeniorNotes2022Due20293.000PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_b6d609c2-f860-4a5d-89ed-52dd59c4f29f_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33a419b6-8997-4fd5-93b7-3ef452c6f44d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_73d08ee5-7c1c-4729-974f-2b47b54559fe_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_55ecb845-b899-4e7b-a764-3911514a2a6c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_5f42433c-1bcb-4aa7-8096-f3796f7d1b31_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_11226996-3860-49c6-8d3a-7f36e1f81d12_terseLabel_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive loss</link:label>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax</link:label>
    <link:label id="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_documentation_en-US" xlink:label="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="mdt-20250425.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_44e7c475-f7f7-4811-92f1-9be1db93599b_terseLabel_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased technology and patents</link:label>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_label_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchased Technology and Patents [Member]</link:label>
    <link:label id="lab_mdt_PurchasedTechnologyAndPatentsMember_documentation_en-US" xlink:label="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchased technology and patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember" xlink:href="mdt-20250425.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_PurchasedTechnologyAndPatentsMember" xlink:to="lab_mdt_PurchasedTechnologyAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_921355a0-a8a4-47a9-a3be-54828ff74cb2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill as a result of acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_44286747-7f7c-4d56-b438-97be00a0bd9a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_d8086835-8923-4101-b320-cc3d2678a562_negatedTotalLabel_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">(Gain) Loss Reclassified into Income</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2024Due20444.150PercentMember_e07a6ffc-4600-42be-ac56-d0c236dcf2aa_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150 percent nineteen-year 2024 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20444.150PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2044, 4.150 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20444.150PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2044, 4.150 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20444.150PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:to="lab_mdt_SeniorNotes2024Due20444.150PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_13b2dc8b-bf16-419e-a8a0-bf73323216db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0f1112c6-2b11-4da9-b96c-0e390a0bac49_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_6ed4ef65-d739-4b46-9995-016ff85088b3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_1e32a3c3-90f1-4c51-ad7c-844fea825e6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wtd. Avg. Grant Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_62e10b5c-8456-4a53-b7a2-20d5217bfe2a_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0cd2b5bd-b53f-4b2f-95ad-98e004e604d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cfa5f5ff-0539-4ce5-9262-9dee84c159a2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_782c2d9e-6a63-4e41-8b99-571e19a6a480_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due20262.625PercentMember_92982fe3-facf-4937-bba0-bb186bc57d76_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625 percent three-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20262.625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2026, 2.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20262.625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2026, 2.625 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20262.625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:to="lab_mdt_SeniorNotes2022Due20262.625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_67c44524-1f21-44bd-8b32-8a3258318ac8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherPlanAssetsMember_a593f0c8-a756-4ff9-ae4d-1a6485dc97dc_terseLabel_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mdt_OtherPlanAssetsMember_label_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Plan Assets [Member]</link:label>
    <link:label id="lab_mdt_OtherPlanAssetsMember_documentation_en-US" xlink:label="lab_mdt_OtherPlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other categories of plan assets not specified in the taxonomy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember" xlink:href="mdt-20250425.xsd#mdt_OtherPlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherPlanAssetsMember" xlink:to="lab_mdt_OtherPlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0230a533-7b04-4e35-a040-6d8b423afa0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_bce46a21-02d8-4253-bf4d-234661700bf0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_457d3261-be0e-44db-ba27-4d01054a92e6_terseLabel_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares purchased by employees (in shares)</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_label_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</link:label>
    <link:label id="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_documentation_en-US" xlink:label="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:to="lab_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_36b1322e-f1ef-4938-8eb9-9aefa27d7332_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7d5998cd-4043-4006-ab01-cd7f4fb12ab7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_b159da6e-401b-436b-a69d-db23cf069c07_terseLabel_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings and leasehold improvements</link:label>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_mdt_BuildingsAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:href="mdt-20250425.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:to="lab_mdt_BuildingsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_97201fff-0e1f-4307-866f-490212317d9d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase accounting adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3d7dfdfb-8473-49b4-be36-4d3dc24d5a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RevenueMilestoneMember_55cbb839-b373-4219-b5c3-a04076149b82_terseLabel_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and other performance-based payments</link:label>
    <link:label id="lab_mdt_RevenueMilestoneMember_label_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Milestone [Member]</link:label>
    <link:label id="lab_mdt_RevenueMilestoneMember_documentation_en-US" xlink:label="lab_mdt_RevenueMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember" xlink:href="mdt-20250425.xsd#mdt_RevenueMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RevenueMilestoneMember" xlink:to="lab_mdt_RevenueMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_4dfade2c-40dd-4a22-926f-37260101e5cf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method and other investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_e7670be0-c892-49e1-b021-aac58631810e_terseLabel_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_label_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes [Member]</link:label>
    <link:label id="lab_mdt_MedtronicLuxcoSeniorNotesMember_documentation_en-US" xlink:label="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medtronic Luxco Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedtronicLuxcoSeniorNotesMember" xlink:to="lab_mdt_MedtronicLuxcoSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_444fd608-e79e-4910-886f-a608b70e0641_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax (benefit) expense:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_fc3c1a31-bffc-4d90-901b-3703e6353bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_9e28dba3-b450-4b93-85fb-c679e573f217_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7fbd2223-d1bb-4185-9ec7-f214a047d443_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0f81f749-11fd-4240-b789-66a231d4a4d0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2014Due20444625PercentMember_a46d367d-2ad0-42cd-a119-dc0b4e1d8f0d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2014Due20444625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.625 percent thirty-year 2014 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2014Due20444625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2014Due20444625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2014 Due 2044, 4.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2014Due20444625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2014Due20444625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2014 Due 2044, 4.625 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due20444625PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2014Due20444625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2014Due20444625PercentMember" xlink:to="lab_mdt_SeniorNotes2014Due20444625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e7b8aa37-a531-4723-8609-7a7d0552e617_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a8bfa81d-717e-4b6f-adca-811a3693119c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_f9047ae1-bc87-4f58-babf-fcc2a2a40bb8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6726e309-5d46-4aea-a3bb-0fca969f5f25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2683df0a-dcf1-4473-bbad-f69d20398e27_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_90d67e44-77b1-4995-8746-dee29a8cdcc9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_759c7c83-cc4c-48a1-b74b-4af2c7b4a706_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5048f664-d285-4040-9a63-81578a7caa44_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8418aa03-1e00-42ea-bb1a-ab29cd1b4071_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_fa229498-4ad6-49b4-93b5-d59819523c45_negatedLabel_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Outside basis difference of subsidiaries</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_label_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment In Subsidiaries</link:label>
    <link:label id="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_documentation_en-US" xlink:label="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment In Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:to="lab_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_458b8135-c911-4ead-bd13-c67a5ed299bd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad1d1747-6199-4aee-9293-097c4db5c898_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_cef702ef-887d-44ee-98c7-652f37fc2874_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1217255-20a6-43a1-92f6-71095e44a8e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_e06ebe1b-7dab-4c86-8478-0825a5225da8_negatedLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent milestone payments in business acquisition transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_fd243751-ac79-4049-aed6-dc9225c8409a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_270acb77-04ef-442a-916c-f15bc8c4571b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_3ece893f-22b5-4607-919e-b0ad6489ebad_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_855d384c-979a-45c1-bfe9-b69043d50615_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_19e234be-45e5-4d74-8eaa-9524261c7bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_39003fdf-5f64-44a2-ab60-5f9f48b11b77_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedicalDeviceRegulations_ca1f8aab-fa88-4474-8dd3-41b210d2154a_negatedTerseLabel_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Medical device regulations</link:label>
    <link:label id="lab_mdt_MedicalDeviceRegulations_label_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Device Regulations</link:label>
    <link:label id="lab_mdt_MedicalDeviceRegulations_documentation_en-US" xlink:label="lab_mdt_MedicalDeviceRegulations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Device Regulations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations" xlink:href="mdt-20250425.xsd#mdt_MedicalDeviceRegulations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedicalDeviceRegulations" xlink:to="lab_mdt_MedicalDeviceRegulations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_ba28db65-3630-4f16-a583-fc901dfb1a42_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment losses recognized</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_76d8e32d-2c58-4eb7-9aca-1e523ed3c271_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_cca24687-fc19-4309-829c-b07a232ff71a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_734eb77d-3c30-4b27-b6ee-3d6a49e30b71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_93df0fde-8086-48f1-a317-1fc0e7509354_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_bde60069-cfa0-447f-8e97-4ce0745c7935_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_3ddf512a-8a78-484e-a696-d3fdcea0c29e_terseLabel_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross decreases:</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_label_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Gross Decreases [Abstract]</link:label>
    <link:label id="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_documentation_en-US" xlink:label="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:to="lab_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_fc3c169e-afa6-4d66-944a-8766cb049eaf_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_919b3429-f1e0-4c1f-b8e9-382600671c41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_666bbe1d-b78a-4852-a312-92230117a2f5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_d933728d-e83e-4f30-a98b-3ecb229ab793_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c3b6cf9f-5230-452d-b779-d20ee0fa56d9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A0.000SeniorNotesDue2025Member_0e2c9fbb-e711-472c-8aba-b1c802f8eaca_terseLabel_en-US" xlink:label="lab_mdt_A0.000SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.000% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_A0.000SeniorNotesDue2025Member_label_en-US" xlink:label="lab_mdt_A0.000SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% Senior Notes due 2025 [Member]</link:label>
    <link:label id="lab_mdt_A0.000SeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_mdt_A0.000SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.000% Senior Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.000SeniorNotesDue2025Member" xlink:href="mdt-20250425.xsd#mdt_A0.000SeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A0.000SeniorNotesDue2025Member" xlink:to="lab_mdt_A0.000SeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_9e751f36-41fe-4333-9f2f-db7a1196e1b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_609e401c-ecba-4cad-aa92-15d623473d3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0f110c6f-f118-4b73-9042-fc9e71072559_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_ba229c0f-0abe-4d58-8c1a-793b93b2f79c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, excluded component, gain (loss), recognized in earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_117040a5-6e6c-4643-84d3-498dcd3e3f05_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_75d4749f-81b5-4170-ac21-8609746dfda0_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_2073fde9-8e00-4adf-b34b-769cc66c9656_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_c38abe0c-4a3d-472d-b172-d38acef4b7db_terseLabel_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS)</link:label>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_label_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS) [Member]</link:label>
    <link:label id="lab_mdt_RenalCareBusinessRCSMember_documentation_en-US" xlink:label="lab_mdt_RenalCareBusinessRCSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Renal Care Business (RCS)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember" xlink:href="mdt-20250425.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RenalCareBusinessRCSMember" xlink:to="lab_mdt_RenalCareBusinessRCSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_8a6ba795-7cb6-4e5c-b159-da0c56aa068c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b9476fee-a725-4c34-b956-d76f5d71ed90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_04b98a7a-9dac-4ebd-a628-63dfd36903ad_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4d051428-a9bf-4bf2-92c6-17145bac4ad3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2013Due20434000PercentMember_1214648f-0ed0-4c1f-8884-2ac68fa9a287_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2013Due20434000PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.000 percent thirty-year 2013 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2013Due20434000PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2013Due20434000PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2013 Due 2043, 4.000 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2013Due20434000PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2013Due20434000PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2013 Due 2043, 4.000 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due20434000PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2013Due20434000PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2013Due20434000PercentMember" xlink:to="lab_mdt_SeniorNotes2013Due20434000PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_17648710-da2d-49ae-ad17-28506bcf16ec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebate obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ecdfe43e-1b3b-4c6d-b321-dd2c526fd77b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_776855c4-14f8-42a3-86d5-1a8ed0ffcc30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_797e4ecb-bc0a-4207-aa06-cb8ec51f4386_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_757a7c59-2d19-496a-a3e4-965b614bed89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_02342828-d16a-496e-b8ac-ed97fa0d438d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DebtLineItems_aadd49a3-91d9-426b-8138-2c59cf4023a9_terseLabel_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt [Line Items]</link:label>
    <link:label id="lab_mdt_DebtLineItems_label_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt [Line Items]</link:label>
    <link:label id="lab_mdt_DebtLineItems_documentation_en-US" xlink:label="lab_mdt_DebtLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems" xlink:href="mdt-20250425.xsd#mdt_DebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DebtLineItems" xlink:to="lab_mdt_DebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_0ced8c41-b1de-43eb-9871-11ecf5eacbf8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_08e73f2e-8af3-4576-9185-ba20ae400be1_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_fb3468f9-954d-46c3-9240-c9b1c35dd61c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_8022dc72-b775-4531-a247-1a3f6b794f93_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_e6f47528-3c9c-4787-b657-1ceb343d45e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2043Member_82b6471a-3e9e-48fe-8294-20b841f5eef8_terseLabel_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2043</link:label>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2043Member_label_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2043 [Member]</link:label>
    <link:label id="lab_mdt_A4.150SeniorNotesDue2043Member_documentation_en-US" xlink:label="lab_mdt_A4.150SeniorNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.150% Senior Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2043Member" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A4.150SeniorNotesDue2043Member" xlink:to="lab_mdt_A4.150SeniorNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_7cde224b-b95a-4c52-a315-cfa57902937d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigations charges</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6eca11a1-eaa7-4b84-a753-003a560d2cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_134dbd26-9c8c-48f0-be55-9947459e772b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_PartnershipUnitsMember_c589254a-6238-47d8-8239-8e743bfa51eb_terseLabel_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partnership units</link:label>
    <link:label id="lab_mdt_PartnershipUnitsMember_label_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partnership Units [Member]</link:label>
    <link:label id="lab_mdt_PartnershipUnitsMember_documentation_en-US" xlink:label="lab_mdt_PartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partnership units include partnerships, private equity investments, and real asset investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember" xlink:href="mdt-20250425.xsd#mdt_PartnershipUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_PartnershipUnitsMember" xlink:to="lab_mdt_PartnershipUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_a8af60ca-17b5-424f-ad4a-182f8ed199ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_927f1e3c-e963-4f87-9141-9910548999d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_InsuranceContractMember_60ec7c34-54fa-4063-ab4c-c6a1e56af791_terseLabel_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_mdt_InsuranceContractMember_label_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Contract [Member]</link:label>
    <link:label id="lab_mdt_InsuranceContractMember_documentation_en-US" xlink:label="lab_mdt_InsuranceContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember" xlink:href="mdt-20250425.xsd#mdt_InsuranceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_InsuranceContractMember" xlink:to="lab_mdt_InsuranceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_519ae0fc-dffd-4d17-a663-f344372d4ed9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e01fceb7-68ee-4dd3-9816-2407b4505e4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_fd180ae9-45eb-4683-b730-2cc8e85af4b6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments with readily determinable fair value (marketable equity securities)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.750SeniorNotesDue2049Member_8aa8e696-f721-4ced-8144-2a9f359b3e3b_terseLabel_en-US" xlink:label="lab_mdt_A1.750SeniorNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.750% Senior Notes due 2049</link:label>
    <link:label id="lab_mdt_A1.750SeniorNotesDue2049Member_label_en-US" xlink:label="lab_mdt_A1.750SeniorNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.750% Senior Notes due 2049 [Member]</link:label>
    <link:label id="lab_mdt_A1.750SeniorNotesDue2049Member_documentation_en-US" xlink:label="lab_mdt_A1.750SeniorNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.750% Senior Notes due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.750SeniorNotesDue2049Member" xlink:href="mdt-20250425.xsd#mdt_A1.750SeniorNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.750SeniorNotesDue2049Member" xlink:to="lab_mdt_A1.750SeniorNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_b429ad63-c53e-44a1-8544-439ce2388e99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ef05e473-25e7-4c62-aabb-916a74645ceb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2012Due20424500PercentMember_78dad889-02e1-4da6-9767-3a6d5f67662c_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2012Due20424500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.500 percent thirty-year 2012 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2012Due20424500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2012Due20424500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2012 Due 2042, 4.500 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2012Due20424500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2012Due20424500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2012 Due 2042, 4.500 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due20424500PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2012Due20424500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2012Due20424500PercentMember" xlink:to="lab_mdt_SeniorNotes2012Due20424500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c3fe3227-87dd-462e-b156-cf1564448d86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_a91c55df-5282-48fb-ae50-9e9fd428c8bf_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_89f7dd39-f07f-4b04-bf78-63f65e3d6d25_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DiabetesGroupMember_e25418d4-b54c-4196-9b23-e05b95f2d725_terseLabel_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_mdt_DiabetesGroupMember_label_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diabetes Group [Member]</link:label>
    <link:label id="lab_mdt_DiabetesGroupMember_documentation_en-US" xlink:label="lab_mdt_DiabetesGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diabetes Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DiabetesGroupMember" xlink:to="lab_mdt_DiabetesGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_13a885ba-d589-4edf-9a03-95c0cfc938e6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_5175bf92-ee01-4463-9315-4eedbf1e6b43_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_8ffde320-48a7-44ab-b5b9-22d1a0222974_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_2351618b-7d1e-492f-a765-cac1492d20f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb0f46c7-ac30-426a-a7a4-8d4e02387c53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_4c4b6a2f-7fac-4a6f-ac4c-dad5339f79d6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_InternationalMember_292ce333-dd7d-432f-b3cd-556bd3883ab3_terseLabel_en-US" xlink:label="lab_mdt_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_mdt_InternationalMember_label_en-US" xlink:label="lab_mdt_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mdt_InternationalMember_documentation_en-US" xlink:label="lab_mdt_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InternationalMember" xlink:href="mdt-20250425.xsd#mdt_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_InternationalMember" xlink:to="lab_mdt_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_57b82b67-dc39-42ea-9926-080e0bfbfe5c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.375SeniorNotesDue2040Member_e4eb7765-0714-4d9b-aebb-6861cfadae3b_terseLabel_en-US" xlink:label="lab_mdt_A1.375SeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.375% Senior Notes due 2040</link:label>
    <link:label id="lab_mdt_A1.375SeniorNotesDue2040Member_label_en-US" xlink:label="lab_mdt_A1.375SeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% Senior Notes due 2040 [Member]</link:label>
    <link:label id="lab_mdt_A1.375SeniorNotesDue2040Member_documentation_en-US" xlink:label="lab_mdt_A1.375SeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.375% Senior Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.375SeniorNotesDue2040Member" xlink:href="mdt-20250425.xsd#mdt_A1.375SeniorNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.375SeniorNotesDue2040Member" xlink:to="lab_mdt_A1.375SeniorNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_918c4a56-54d2-463c-a159-aa263b6505ac_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4f805a35-bda5-42c7-829b-933cc0306581_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Margin added per annum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_392b0669-32bc-40ab-977d-d71f1cbfc79c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_bddbe2bf-5653-402b-aecd-58947a3b3da1_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value, Amount Offset Against Collateral, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:to="lab_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3c7b5fd8-d618-4262-9cd7-e5d6fbee08c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_db0892dd-2a8e-45a8-8262-c68354bb7bd5_terseLabel_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mdt_A2024EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember" xlink:href="mdt-20250425.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2024EmployeeStockPurchasePlanMember" xlink:to="lab_mdt_A2024EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_49e6a2c7-2934-4683-be0a-ce0c848e2349_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_75627b52-0cbe-48b0-a92d-d686c803516b_terseLabel_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities</link:label>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mdt-20250425.xsd#mdt_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mdt_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_cc728e68-346a-45f6-a95f-1b31b898a76d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b22f4bd5-e5a9-4afe-b584-5454a6158f64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_14a2842f-5be4-4427-ba79-d0aabc00248b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments by Category and Related Balance Sheet Presentation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_dfc41ba5-62cf-4c89-b408-2e172e25629d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_9f3ed7c9-ccce-4416-a6ab-650c56c56a9c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782b2f2b-c766-45eb-8ca1-f5a2221f6b5d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_22aa6b43-d506-4b55-b4eb-28e749407734_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_508fc4c4-6447-415b-aeb5-ffe6fd85c14f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_37f795e0-accc-4ca7-833e-8eaa2c0a2d5a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8a884ea0-0e83-4056-ac96-081f41ca70f0_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_01652abc-20e3-46da-a107-e82d0be3b236_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_5f0f2a28-de5f-4861-a137-7144f0365aef_terseLabel_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_label_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes and Interest Paid [Abstract]</link:label>
    <link:label id="lab_mdt_IncomeTaxesandInterestPaidAbstract_documentation_en-US" xlink:label="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes and Interest Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxesandInterestPaidAbstract" xlink:href="mdt-20250425.xsd#mdt_IncomeTaxesandInterestPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract" xlink:to="lab_mdt_IncomeTaxesandInterestPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e25628f6-9e77-412e-aaab-f3cf1b66ae2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_efb45784-d37f-41b2-ba75-56a587a0fa33_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_label_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ScheduleOfDebtTable_bf727282-48be-44a2-9e3c-7ccde8bcf272_terseLabel_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Debt [Table]</link:label>
    <link:label id="lab_mdt_ScheduleOfDebtTable_label_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Debt [Table]</link:label>
    <link:label id="lab_mdt_ScheduleOfDebtTable_documentation_en-US" xlink:label="lab_mdt_ScheduleOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable" xlink:href="mdt-20250425.xsd#mdt_ScheduleOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ScheduleOfDebtTable" xlink:to="lab_mdt_ScheduleOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_fe6d9c73-d6f9-4dc7-ba50-810db55d58b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_2f046fa8-b0d6-4b63-8510-8c08f401d80a_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operation, other operating expense, net</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_f0518d1c-ed44-4dbb-9308-51e6521fece1_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_617fb6b3-407e-4c89-ae29-5b0f62517d07_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_6f7bca51-1be0-4003-8c71-e84c7caa2cad_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plans with accumulated benefit obligations in excess of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationEliminationsMember_26a2ccfc-dfc4-41c4-98ce-c2c77bd59940_terseLabel_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Eliminations [Member]</link:label>
    <link:label id="lab_srt_ConsolidationEliminationsMember_label_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationEliminationsMember" xlink:to="lab_srt_ConsolidationEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ec7027ce-67e9-4f1d-8d6a-70b42c4ebf2c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_aef30e7d-55ac-4f32-922b-336da7b544c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_9e8cf686-7d32-44b6-833d-6df42a90ba26_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring and associated costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_24e657b4-2d3c-424e-a6e7-f2aa3bee290e_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total restructuring and associated costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fa785516-c2c4-475e-b8e3-4f13ae14a1d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Plan settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_06c4ad7b-58c2-4a1c-9866-b34af5454a39_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_36c5b643-4f4b-4134-a683-320f9699909f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_009a0b07-edc3-4c82-8eb0-237b99b2387b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of net actuarial loss (gain)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_ff197a6c-881c-4fba-9dbb-086f6cf010e3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_af562e7f-a8ba-4bcf-9d8d-4557ce73add7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_cf33eebf-6a3f-4779-92f3-5efc4b2d7d31_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77ecadd3-8977-4863-b182-7c65bfdb440e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_a8be3c7d-338f-4d9c-a522-a310e0b492f1_terseLabel_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surgical &amp; Endoscopy</link:label>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_label_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical Innovations Division [Member]</link:label>
    <link:label id="lab_mdt_SurgicalInnovationsDivisionMember_documentation_en-US" xlink:label="lab_mdt_SurgicalInnovationsDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Surgical Innovations Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember" xlink:href="mdt-20250425.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SurgicalInnovationsDivisionMember" xlink:to="lab_mdt_SurgicalInnovationsDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_430e0d89-ccd8-473b-95d7-eddbf3716b1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in income, cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fb51f1f3-14d9-4cdf-b061-5e6ea680b44c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3196d8b7-7993-4a89-816a-77a39a064f30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_ad79358d-16f3-46bc-8e7b-902de7541a17_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_c7eddba5-a862-4a34-bc0c-853c83cdfa2b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlement and curtailment (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_bd251161-b2ae-4647-8e00-e2aba5f97c17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_8e981480-243c-4556-9296-81ac7d381fc8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to options exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f8c7c29d-0c66-4b05-9a16-a2c7b8d6ae39_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to restricted stock vested</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_1ac1871f-d425-4d10-91c2-dfb48db6de60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_9239d172-10da-413f-9653-917791eb846e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4f545243-e4b0-49b8-a124-3b8a18c9d580_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a6cbf361-5bf8-4dac-a13e-5f5065cbfd54_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, less allowances and credit losses of $199 and $173, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_625b9e89-3288-4ab5-8a76-7b8c8b6eaa26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_637e1039-7865-4be6-b3fe-3ec0f03624b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0a86607f-f73d-42c3-9af0-fd8e7ea5a803_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f7f9b928-31e2-4dc5-9106-f8938accbb23_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_0bec914d-5586-4b66-a33e-dca45f6809fd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairments and related inventory write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_ebb1cfab-d506-41b3-aedc-77d529f578c4_terseLabel_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm &amp; Heart Failure</link:label>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_label_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm and Heart Failure Division [Member]</link:label>
    <link:label id="lab_mdt_CardiacRhythmandHeartFailureDivisionMember_documentation_en-US" xlink:label="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiac Rhythm and Heart Failure Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:href="mdt-20250425.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:to="lab_mdt_CardiacRhythmandHeartFailureDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_70b15714-f903-4140-9edb-60013c800702_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Post-retirement benefit plans, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a2a7173b-1251-4196-bcb1-6040048858b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_adc5f967-20d8-41b2-b27e-fcc589a8a8cd_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cacd60df-6f33-4771-8bed-2283fe3ebd83_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_64587b57-d3f7-44e2-96b6-b587eb99f1c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_5913fd0c-01b4-4ff0-a9a8-84c5a1ec2df6_terseLabel_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_label_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability) [Abstract]</link:label>
    <link:label id="lab_mdt_DerivativeAssetLiabilityAbstract_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract" xlink:to="lab_mdt_DerivativeAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_aecac8c3-11c4-46eb-94a8-6845ec4d3c80_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, Dispositions, and Funded Research and Development Arrangements</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b1dc30e7-4dd6-416e-a17f-19289733eed0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a0f05e14-ff5e-449f-a381-f3621e35906b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20271125PercentMember_5bccac66-b16c-4950-beac-d1781e39c430_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20271125PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.125 percent eight-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20271125PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20271125PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2027, 1.125 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20271125PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20271125PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2027, 1.125 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20271125PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20271125PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20271125PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20271125PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2024Due20544.150PercentMember_6fce13d4-1f6c-441d-b429-574b2a30adcd_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.150 percent twenty-nine-year 2024 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20544.150PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2054, 4.150 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20544.150PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2054, 4.150 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20544.150PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:to="lab_mdt_SeniorNotes2024Due20544.150PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_07e1ba11-d4ed-47f4-b484-520fea9b3946_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44a0d26a-5b93-4d20-9459-68c71cc7f844_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_ba435dd0-7e86-48b5-b987-5b60cb03ed0f_terseLabel_en-US" xlink:label="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_label_en-US" xlink:label="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:label id="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_documentation_en-US" xlink:label="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:href="mdt-20250425.xsd#mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:to="lab_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_b252f96a-8d92-409f-bfb1-fd90af133251_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb19f588-2091-4136-8c47-5dc0eea3fafd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_02ddb936-2583-4cc3-b4ef-ed5ae948a7fc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e6fb611a-fd3f-4e1f-a933-0fa1b8e4a2e0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b8d3ef14-125c-445a-b6ea-4f15581eb5bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1cbdd922-b9bd-450b-afa3-ff9069c57728_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A2.625SeniorNotesDue2025Member_c7f61974-b28d-4b98-ab80-e90aed87f635_terseLabel_en-US" xlink:label="lab_mdt_A2.625SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625% Senior Notes due 2025</link:label>
    <link:label id="lab_mdt_A2.625SeniorNotesDue2025Member_label_en-US" xlink:label="lab_mdt_A2.625SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.625% Senior Notes due 2025 [Member]</link:label>
    <link:label id="lab_mdt_A2.625SeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_mdt_A2.625SeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.625% Senior Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.625SeniorNotesDue2025Member" xlink:href="mdt-20250425.xsd#mdt_A2.625SeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A2.625SeniorNotesDue2025Member" xlink:to="lab_mdt_A2.625SeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_bd1072e2-430e-485c-9372-01d5362b0515_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2024Due20303.650PercentMember_93d575de-c257-4904-ab6c-531834e5bab9_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.650 percent five-year 2024 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20303.650PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2030, 3.650 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20303.650PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2030, 3.650 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20303.650PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:to="lab_mdt_SeniorNotes2024Due20303.650PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_15c45e16-74ad-4635-b5df-ff04546dd98e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0f10cd50-2057-4711-94f7-88fa9dab593c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e20d53d3-9c56-4be9-bf02-426ce846ebc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4997aca6-9c5d-4222-be2f-e10fbbef8c39_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c6ba207a-e0d4-4c25-83ca-6d45382be690_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ef069ebd-c36b-46e0-8b1d-83b6d29d9b94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_516b1888-225c-41b3-ac7f-203c454a4db5_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_8bf6867c-9975-45ff-b80d-d6028f01ea7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_863bcc6c-b3b6-489b-82d6-fb5f85b47bc2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d86a2ec-6d5d-4b4a-9f3d-e19c8b266948_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_44bed4c5-9c9a-4458-bc5b-6ac4c893824f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c1467398-ab35-4200-86d1-8a11eab4be7d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock purchase and award plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b2cff990-5163-47d0-999a-6cc4d4cdcec1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_24e27793-9f32-4f7a-846c-a940dbab3d07_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9431ede1-d553-4f7a-a9ef-41db1786228f_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and retirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_790c5c51-ac28-48f1-bba7-bc67de0be68c_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1c0035d7-447e-4e88-bef0-f88050628602_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_8be92ac8-504e-4266-96aa-9c3603c5677b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_231f6e8b-7b8a-40c4-a37f-cf482397ed26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_84c1aa76-fcad-473a-93c4-7f389c347dac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7fa31e5d-16ff-4296-9fb6-d2d02e740d99_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_62949fef-b933-495a-8369-d7180068e640_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_cb7759ff-b082-402a-b809-d73c798ff4ab_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_223b6c1a-5005-4b7a-94f6-dd4c431779da_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_cd2f7c60-fc90-4eee-9229-e0eee89dc6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_66e1a146-03eb-48dc-90d0-d105caadfc4b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_420e0b7a-b701-485b-bb1f-5f25f05a9183_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_015baa5a-1a12-4b61-bafa-8ae695a4c75f_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_82d2a06e-215a-407e-94bd-7c16b952ee4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_29081f2c-e9f3-4eb4-8a49-de6563973e93_terseLabel_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring</link:label>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_label_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring [Member]</link:label>
    <link:label id="lab_mdt_AcuteCareMonitoringMember_documentation_en-US" xlink:label="lab_mdt_AcuteCareMonitoringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acute Care &amp; Monitoring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember" xlink:href="mdt-20250425.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AcuteCareMonitoringMember" xlink:to="lab_mdt_AcuteCareMonitoringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_1cfa91c1-5a61-403a-a966-8ca1959c8ccb_terseLabel_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on interest rate cash flow hedges</link:label>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_documentation_en-US" xlink:label="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="mdt-20250425.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_92eb03f6-74a2-4c1b-b941-bf0b0a5a8066_terseLabel_en-US" xlink:label="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.550 percent thirty-year 2007 CIFSA senior notes</link:label>
    <link:label id="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_label_en-US" xlink:label="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIFSA Senior Notes 2007 Due 2038, 6.550 Percent [Member]</link:label>
    <link:label id="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_documentation_en-US" xlink:label="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CIFSA Senior Notes 2007 Due 2038, 6.550 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:href="mdt-20250425.xsd#mdt_CIFSASeniorNotes2007Due20386.550PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:to="lab_mdt_CIFSASeniorNotes2007Due20386.550PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e902756-601d-4d90-a208-da0ad029295f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e6a23e1-ab47-4b6a-8b9d-741ed1e24ec2_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_c29951e5-6976-4f86-b036-a7b51e118693_terseLabel_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impairments</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_label_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Non-cash Impairments</link:label>
    <link:label id="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_documentation_en-US" xlink:label="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Non-cash Impairments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:to="lab_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_cec07a09-edc8-47cf-b97e-92443c53fd8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1f5ff601-6d64-420a-85b9-5a4c5db13bd2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f17d9d97-19ef-4986-89a0-10de4b5839e6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_98d05bee-d73b-4100-9a23-9056c80f8f2c_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due20290375PercentMember_b9455da1-579f-4dcf-ab69-4d54228da08a_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20290375PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.375 percent eight-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20290375PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20290375PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2029, 0.375 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20290375PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20290375PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2029, 0.375 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20290375PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20290375PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due20290375PercentMember" xlink:to="lab_mdt_SeniorNotes2020Due20290375PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_356319e5-4632-4187-91cd-20ef741ddab0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, net of tax</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_a5266515-947d-42fd-8293-866a38e493bd_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3a032eb0-773f-4a20-9653-da3c013a7908_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_594751ff-8930-4b03-b9db-7a2d6b877ddc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign derived intangible income benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3448b7c0-7e3e-411d-ab67-df09c7fd7260_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_eded66f0-1c07-46c4-915e-d440f838e0ab_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_dbed816c-10c0-4365-972d-d7b8969511b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_39c95212-c757-46ef-bc90-a240d0bd2bad_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9f8d1739-e10d-48e6-98b5-ee732d075542_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_655f0902-b8d0-49ed-8eb9-8b17a161d034_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_afabf740-5c35-49c3-91ac-84e70360999c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CardiovascularMember_f607e63e-a4aa-4957-8150-27eaefb336fa_terseLabel_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:label id="lab_mdt_CardiovascularMember_label_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:label id="lab_mdt_CardiovascularMember_documentation_en-US" xlink:label="lab_mdt_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CardiovascularMember" xlink:to="lab_mdt_CardiovascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_435953b3-b4cd-4237-9c56-d13cfe4d6ea2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments measured at net asset value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_5a683386-46c5-4f34-8328-0d0807a4ae6d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_30bc2aae-e844-4360-9707-7beb890bdd99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intercompany sale of assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_f14be534-ab42-448d-821f-c55fe5db59fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_d66083cc-0d9a-4760-b6dc-081451cce8ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Change in Retirement Obligations</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e8544e41-132f-4c19-a4bd-d089e77cb6f5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9d48d9ad-438c-45a1-8f5b-56edfa9b357b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_5bfcbb08-b11f-4593-9160-f3b417b64ab1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_973a8718-6d58-435d-a307-559356447e54_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3cbe8482-a5b8-4ae2-876f-6442730c38c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_daebeb24-15cb-445f-bd91-90082a132819_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6d72a81b-945b-41db-acb8-7bec04b0667b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_a7b59769-dfae-4fc3-afb3-2f80083a7327_terseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax reconciliation, disallowance of interest deductions, amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:to="lab_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f55367df-e8fc-4817-8a82-1edba926c014_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of (Gain) Loss on Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_cfdb2e15-124e-40b5-a2e5-197e11125bd5_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c4673783-97fb-4bb0-b222-7bd03ff3a4f3_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_81192868-42c1-4731-80c5-71e16e85d25a_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_07051e28-debf-4142-a982-39fa342be0d3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_755679b9-f1c5-400b-99eb-0a5c14d53bb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_84c76970-abaa-4a42-b0a4-d60b236e4ad6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3106d457-0cbd-4ff2-8868-f47af6ecfb92_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b4ba3b68-843e-42c5-bd92-7bed7a2c8c2d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3e7731b9-d0c1-4695-8fe1-cc2c04dcf861_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2b41001b-1390-4486-bcfe-610242c47b33_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c67976ea-14db-44de-a654-e08e17012b95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_712493c1-de07-4f48-802c-f128a6cf4d79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_69a86524-d401-4575-9389-41c5cab2a314_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_50e04288-e87c-4998-86a3-59d28d60e55c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives and Currency Exchange Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4574c309-3315-4385-8682-c106b17f7cb9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_0ca3f86d-9501-446d-a6b4-0ee504363278_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. tax on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_83a5040c-9ac4-4b40-8887-5113d80b3fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ba4cfe8c-1223-4abe-90b6-ffb706d972f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6b89898d-1748-4067-8ac2-bc2551affd43_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_df8864c4-5e94-461e-8c74-ca6041590286_terseLabel_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating (Income) Expense, Net</link:label>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_label_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net [Policy Text Block]</link:label>
    <link:label id="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_documentation_en-US" xlink:label="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:href="mdt-20250425.xsd#mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:to="lab_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_509ab204-30d3-4bad-a833-3207a028e559_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_741ea464-d8aa-4e46-96cd-39f34b5aad3f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a740cad-0a13-432d-afb4-9008278c0980_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94b67b00-9ac4-40f4-a1f6-7051372074fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bf537e65-f6d2-421b-ad49-a4ae305971a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_499bc34d-b97a-4d75-8e55-89993aa65ddb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_aa10b3b8-ede4-4c89-ac87-8ec9ed89f187_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3cf8e642-cc90-4676-ab32-19d48460b285_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_974a4551-0a58-4c34-9309-9aabbeede3b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bbc36242-85e4-4c8d-b85e-8dc08fbea8ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_19386028-4728-4c00-81a8-d5aefaa79b0a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_ef449dd9-1071-40a7-87d3-bb71e8cb0832_terseLabel_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_label_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Stock Award and Incentive Plan [Member]</link:label>
    <link:label id="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_documentation_en-US" xlink:label="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Stock Award and Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:href="mdt-20250425.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:to="lab_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_10e5d786-8a25-4e79-a6e3-0842e29a7b46_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20311625PercentMember_62c3838e-7226-45b9-ac0c-905c73f66eca_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625 percent twelve-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20311625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20311625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.625 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311625PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20311625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20311625PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20311625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_da85c26e-e46f-4bb2-b59f-d034c5ba6e3c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d2256cd4-efca-45e9-9e42-496a4037fd62_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment Balances and Corresponding Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_340724e3-fc64-4cff-9e4e-da2a05117c3e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration for the transaction, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_28b84743-f98c-4a4c-b1b8-221d12ec9433_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a1e10f55-7d25-4e23-a811-6a7ec1673d0a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due20330750PercentMember_239d4250-3a69-4ffe-848f-d45d39c87e8d_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20330750PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.750 percent twelve-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20330750PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20330750PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2033, 0.750 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20330750PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20330750PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2033, 0.750 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20330750PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20330750PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due20330750PercentMember" xlink:to="lab_mdt_SeniorNotes2020Due20330750PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d2368414-ea2d-4057-9ee9-4dc99427c619_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_3c1d8a9e-de16-4e77-9c72-e5afb5599b29_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_2ab8b348-a765-4eed-8699-5b392772d3ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_954dd3e8-8cfc-4bc9-9010-b57e485cfbde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5161c26c-d7d3-422c-8c29-7750bebc9d0f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_2e01e23d-33e2-452b-a438-f814312dcca3_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20253.500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2025, 3.500 percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:to="lab_mdt_SeniorNotes2015Due20253.500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c1bb9517-6a83-4764-8dc1-26b7abccf313_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c639217b-ef84-4a2b-99ee-e83397a1c120_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_f23a4187-9a93-4fa7-ae79-ea9e660bc53b_terseLabel_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurements, Retirement Benefit Plan Assets</link:label>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Retirement Benefit Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:href="mdt-20250425.xsd#mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:to="lab_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7acb2c93-bc68-4b61-b806-abbc630d64e3_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_183cce8b-d971-4bff-a6e3-e24f9886029f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1c671eee-6af1-4655-9d92-d54cc5cadced_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_9968774a-047d-4f83-830e-cb2ba95b19ca_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total recognized in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a567881a-9adf-48b8-8052-6e3397f35840_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e5b89e37-ff6e-4136-af7f-3be7a7de62c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_11826f08-ae66-4173-a0be-6d67adb82d4c_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_24681c17-2ec9-4692-be6f-33c62a3b8b47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_202123f3-346f-444d-a4c1-b1f3394f0f8a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_0f3b7e86-ad24-4f5c-871b-07aa8f70771a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_85b8ff99-31e0-456b-b994-baef2032e210_terseLabel_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_label_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding United States and Ireland [Member]</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_documentation_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding United States and Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:to="lab_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_MedicalSurgicalMember_d8e64e56-edda-4496-b041-3fcd928f3494_terseLabel_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Surgical</link:label>
    <link:label id="lab_mdt_MedicalSurgicalMember_label_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Surgical [Member]</link:label>
    <link:label id="lab_mdt_MedicalSurgicalMember_documentation_en-US" xlink:label="lab_mdt_MedicalSurgicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Surgical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_MedicalSurgicalMember" xlink:to="lab_mdt_MedicalSurgicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2e44a51c-ae1a-44cb-a087-8bdd8811f052_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_83a2db1f-c01a-4196-b0a7-5d204f64023a_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_30bc56d9-7fd8-4ddc-b936-dd714ae4169c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity commingled trusts</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75248875-ef1b-47cb-84a8-9f6255a85bbb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_99882dda-a87f-4280-a31c-50e118b95c51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_8bb32676-d3e0-492d-838a-1b788e442d64_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_742bf32f-5be7-4d0b-9fe4-056ca4912248_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9b1241b0-ad7e-43af-8f8a-28b49e119266_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f9cf608d-1969-4785-8e1e-1d0934c111bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bd8fe2d4-bdee-4a05-9eb7-a53c9df29278_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_17fb6fbf-fbaf-4ffd-bb02-7e587badce70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-retirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_875d2347-512e-4542-936f-54aab913e5dd_terseLabel_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported as (after valuation allowance and jurisdictional netting):</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_label_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets and Liabilities, Balance Sheet, Reported Amount [Abstract]</link:label>
    <link:label id="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_documentation_en-US" xlink:label="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:to="lab_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5bf11830-d11a-4b3f-939b-c531b5698127_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd8ff4d8-4a33-44c1-babb-79020eddfd07_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3e27d9fb-d86c-4737-a084-dff193eb6419_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in AOCI, net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_d3af8c17-8901-437b-8e5a-aeba5966a85c_terseLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash collateral received</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_86412d33-f1b3-4b28-850c-ff21630b9626_negatedTotalLabel_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_label_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</link:label>
    <link:label id="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_documentation_en-US" xlink:label="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:to="lab_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f49f6784-b1fe-4bb7-ad08-0f7403609e70_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_b3d133e3-ec00-41bc-81e9-550523afae81_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settled non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_739da959-55f2-4a2d-abf9-57b93ee3ce2b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_f82cbca4-796b-4a0e-8095-a7bc61f28336_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed earnings from non-U.S. subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cf4885bc-561a-42ec-a8fb-3fdaa3684cc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_e274db6b-8959-42ba-885b-27de72b95f62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_15c8df1d-9dcd-4b1c-b36d-0232f5c904ee_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_ddbfc1de-8e6e-4cb8-b691-553933fc59a8_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating segment</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1101c56e-da90-4b22-91fb-00fafd3a1abe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A1.000SeniorNotesDue2031Member_acc42aba-84bb-49bb-ad57-9671b16bda97_terseLabel_en-US" xlink:label="lab_mdt_A1.000SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.000% Senior Notes due 2031</link:label>
    <link:label id="lab_mdt_A1.000SeniorNotesDue2031Member_label_en-US" xlink:label="lab_mdt_A1.000SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.000% Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_mdt_A1.000SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_mdt_A1.000SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.000% Senior Notes due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.000SeniorNotesDue2031Member" xlink:href="mdt-20250425.xsd#mdt_A1.000SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A1.000SeniorNotesDue2031Member" xlink:to="lab_mdt_A1.000SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_c7373f3c-1a01-4fb2-87d6-5b43a9b04715_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_b3f28a62-99bc-49f8-8e43-c1af551ae17b_terseLabel_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; service cost</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_label_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</link:label>
    <link:label id="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_documentation_en-US" xlink:label="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:to="lab_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1b9e5f39-9212-4503-b886-8e53f53f7e1e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CentralizedDistributionCosts_db8563f2-dc79-40ad-bb92-6776f67fdbdc_negatedTerseLabel_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Centralized distribution costs</link:label>
    <link:label id="lab_mdt_CentralizedDistributionCosts_label_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Centralized Distribution Costs</link:label>
    <link:label id="lab_mdt_CentralizedDistributionCosts_documentation_en-US" xlink:label="lab_mdt_CentralizedDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Centralized Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts" xlink:href="mdt-20250425.xsd#mdt_CentralizedDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CentralizedDistributionCosts" xlink:to="lab_mdt_CentralizedDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_4a51f2a5-0635-4574-a662-9273a1988bfd_terseLabel_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registered investment companies</link:label>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_label_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registered Investment Company [Member]</link:label>
    <link:label id="lab_mdt_RegisteredInvestmentCompanyMember_documentation_en-US" xlink:label="lab_mdt_RegisteredInvestmentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember" xlink:href="mdt-20250425.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RegisteredInvestmentCompanyMember" xlink:to="lab_mdt_RegisteredInvestmentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_43257a3c-85fc-4820-87a7-dd2c56430536_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantee obligations</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3f5394f0-c47d-42d5-8b0c-4dd3ad3dc9de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_267f6c28-fa46-41d4-8c26-15a2fb509c60_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_114ecfab-2478-40c5-aafb-ed6106aa81e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_9eb47026-9583-41f8-821a-2d7c69ce52cd_terseLabel_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation</link:label>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_label_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation [Member]</link:label>
    <link:label id="lab_mdt_DiabetesPumpRetainerRingLitigationMember_documentation_en-US" xlink:label="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diabetes Pump Retainer Ring Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:href="mdt-20250425.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:to="lab_mdt_DiabetesPumpRetainerRingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_36da5582-e134-4ab1-873f-39fb406a1865_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized losses on equity and other investments still held</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5cffb5af-ecea-4e31-96d5-384d7118088d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2d4fbb68-4a1c-4bc7-8fdc-81252ef797db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_cb13832c-7885-491b-a0fa-ec6fffe9857a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d627c319-a09a-4815-9882-228a6fdec568_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_32f05b94-2251-4a02-a920-fe13969a0da1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_459ec1e4-6304-4c5f-832f-ac422944ae2f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_4fa21f8d-5c13-4de3-a2fe-1c1473599b76_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f5c75d1c-44f1-4834-925b-6654eec3d961_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0ee15ceb-52a1-4b14-8098-29b13c234ea3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net change in retirement obligations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_25cd949d-5949-4368-a0af-ffd1ca11a15f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2009Due20396500PercentMember_88806734-c07b-413d-830b-eb96012d722e_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2009Due20396500PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.500 percent thirty-year 2009 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2009Due20396500PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2009Due20396500PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2009 Due 2039, 6.500 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2009Due20396500PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2009Due20396500PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2009 Due 2039, 6.500 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due20396500PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2009Due20396500PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2009Due20396500PercentMember" xlink:to="lab_mdt_SeniorNotes2009Due20396500PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20392250PercentMember_c97df903-e4db-4ce2-90d2-5f8e8f1ec0c3_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392250PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250 percent twenty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20392250PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392250PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2039, 2.250 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20392250PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20392250PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2031, 1.625 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392250PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20392250PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20392250PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20392250PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due20323.125PercentMember_f67964ae-84bc-4066-acb6-4185962363b9_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.125 percent nine-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20323.125PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2032, 3.125 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20323.125PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2032, 3.125 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20323.125PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:to="lab_mdt_SeniorNotes2022Due20323.125PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f2b94154-aa0a-4400-987e-c850cfd48e85_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3f250707-71b1-4438-941b-12233a9d46ee_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6e26831b-7d63-4c67-8789-e42e41ddc90e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c4f67397-4258-4d3f-aebb-a829e3ee2455_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in projected benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_c129244c-9328-45c4-9475-46f933b5b5e6_terseLabel_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.5 Billion Revolving Credit Facility</link:label>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_label_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated Revolving Credit Agreement [Member]</link:label>
    <link:label id="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember_documentation_en-US" xlink:label="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated Revolving Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:href="mdt-20250425.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:to="lab_mdt_AmendedandRestatedRevolvingCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c2717769-bbfe-411a-8b88-2b3e1e911f16_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares under stock purchase and award plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8b5e331d-099c-4430-9bcd-02e987f919a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4442d12d-1d8c-4460-a4b3-e75db22e12e0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_2e140dc5-9b63-42a4-b64f-289bc758e7aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_65a1b125-5231-4003-9002-1327da1ea1ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9d6cf9b1-74fe-488a-8ce4-006a9f66e23b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_e6d104ee-4fb5-4af5-8b12-3209a511f0f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassified into Income, net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncome_0ec39621-6c04-4660-8f5d-0bf72c1d2a22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional funding</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncome" xlink:to="lab_us-gaap_DeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c4325a9e-34d2-4eee-bbf9-5e1b4212d882_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2022Due20353.375PercentMember_13c50689-4258-4d0c-962e-e79cbf246cf4_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.375 percent twelve-year 2022 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20353.375PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2035, 3.375 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2022Due20353.375PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2022 Due 2035, 3.375 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20353.375PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:to="lab_mdt_SeniorNotes2022Due20353.375PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dc7dfa87-6142-4496-a0d3-53bf53058140_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2fc758ba-ba44-4e65-960a-7acaabb8d3eb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2abf43d1-3965-4f02-a817-eaaacc56195d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2024Due20373.875PercentMember_23cac891-8773-4b4e-b0ed-e77d20b5d0dc_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.875 percent twelve-year 2024 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20373.875PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2037, 3.875 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2024Due20373.875PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2024 Due 2037, 3.875 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20373.875PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:to="lab_mdt_SeniorNotes2024Due20373.875PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c03d6014-b72e-444b-9590-4c8b638e45d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_91f3bde0-a9a2-4f3d-a4e0-9021ac311bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold, excluding amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_ce6df9e5-693c-4f78-95d1-bc1bed344583_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b6d1d4b9-1356-4e53-8544-c21d657dff66_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3feba331-26e2-4f28-9eac-93ad19825c40_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9b4f0985-3ff2-4c4d-963f-46a1f91ebfa7_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Recognized asset</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_4385968e-40ef-46d8-87e7-387c814c5330_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1fa3ef21-4de4-441f-b619-4c205d1a2979_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ecbf74b1-7d31-4d7b-86f2-560caaae220e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_93bccbc8-ba3f-4c2a-b4ee-8613c0aaa7c0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fede01f1-a348-4d77-8986-c634320cc6e3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_35cf9189-3488-481a-b90a-442ffa62fa4d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e9a5a555-dc5d-4029-87db-8a1a57057b8f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_fcacea2e-4504-47e9-9c95-a37bd866a234_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of senior notes, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_6cb7cc62-b4f6-4c14-af23-ee15cc54861d_terseLabel_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillNotAllocatedAmount_d9076383-418b-428c-9037-ba2cd9168018_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, non deductible amount</link:label>
    <link:label id="lab_us-gaap_GoodwillNotAllocatedAmount_label_en-US" xlink:label="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Not Allocated, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillNotAllocatedAmount" xlink:to="lab_us-gaap_GoodwillNotAllocatedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4c620700-8eda-49b0-aa15-41ce6775daf5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_22c88af1-f8f0-4768-9c8f-7eaaba051b1c_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_cceee972-ffb4-42f2-9d26-93191d7e6e2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fe301fc2-54f8-47fa-920e-622acb5a6b60_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_a8fee2b5-2808-4c70-b82f-14149746d3e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_4935021b-3d7f-4eba-884e-924a5a1fdcbd_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent</link:label>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2017Due20273.350PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2017 Due 2027, 3.350 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:to="lab_mdt_SeniorNotes2017Due20273.350PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_88cd1251-da8a-46f5-b4a1-68723083d219_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due20511625PercentMember_69dadb32-ea03-4f70-b82b-1f233267a7c0_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20511625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625 percent thirty-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20511625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20511625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2051, 1.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20511625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20511625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2051, 1.625 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20511625PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20511625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due20511625PercentMember" xlink:to="lab_mdt_SeniorNotes2020Due20511625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_8de1b32a-73b3-434c-961c-6c254756d21c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6cedc8e8-bfde-4f74-b3eb-3d9ef7129e1b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_669956b5-d397-4836-a84b-e5d247944b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_db2e3dc3-9416-4c4a-a1a4-4bb7909c1b1d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fa6a6fab-3f3c-475e-a46d-1d85db4454ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_933891c2-8b1f-4c7c-b561-0ba3cbfa7e69_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_0eee00c3-bf57-4da5-a3ec-46892a48647f_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Major Tax Jurisdictions Which Remain Subject to Examination</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Examinations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_14217594-ad66-4d47-9ad6-3a959ef57331_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_OtherSegmentMember_73a94992-8551-4b50-b7d3-92fe57641b8b_terseLabel_en-US" xlink:label="lab_mdt_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment</link:label>
    <link:label id="lab_mdt_OtherSegmentMember_label_en-US" xlink:label="lab_mdt_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment [Member]</link:label>
    <link:label id="lab_mdt_OtherSegmentMember_documentation_en-US" xlink:label="lab_mdt_OtherSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherSegmentMember" xlink:href="mdt-20250425.xsd#mdt_OtherSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_OtherSegmentMember" xlink:to="lab_mdt_OtherSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c4ec4f4a-3f2f-4ff2-b54e-306728a53c22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07256961-f586-4526-94c7-f1e86bd08134_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4a4eb31a-b9ab-4314-974b-484d6c6e24ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_4a20b9c1-b571-4720-8f4d-2a9bfade81c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6732ff0f-7a4a-4af8-81fa-dbdbb405e7c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fcb73c6b-19c5-4c0e-9b30-f5a64b843115_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c94a0e2b-90d3-410b-a7ab-1fcee0cee8ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_3cad652b-0790-44b3-aa82-f3290249eb39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5e894ab1-77b2-4f08-89a5-db9ea2359f36_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_aea0cae9-6a78-4e63-ab10-63dec23b8f39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_738dcd11-37f6-43e0-9484-35f0c93b0848_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c11241e9-0a09-4ddb-b08c-56f82b3a4233_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c36dabbf-03b1-44fa-94aa-6fa331d5ffaf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_daf893ec-b7d5-40d6-9431-269c03756ff8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits, net of cash advance, noncurrent liability</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_9548a6cc-eb59-4069-858a-70b16d7a4209_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_2823e2a5-da09-4e52-914d-8f79968db5a3_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_2019e5cc-7e91-4aad-9afd-2d01e057c424_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:to="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0dac11a5-5a59-46aa-931f-9e39007f8b4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_f6d7b064-5878-4e3d-b838-0f2e6fb13049_terseLabel_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity and Other Investments</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_label_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</link:label>
    <link:label id="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:to="lab_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8efe65c6-a8ca-42ad-8f59-6d41aaa5d1a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2e402cbc-45ef-4fda-be6f-4dd06867da4a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a6ff14ba-583a-4b1f-99de-ec7a5e76f4be_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_0f4a0be3-5ed3-4133-803d-0665a581f86a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of senior notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_eb9bd42a-d952-41e0-b289-1065cdc94994_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_adce1638-ab27-4b4f-b97d-6e4a3cde6618_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_9b7a1d08-6ff2-4c62-a5b6-c8eb9eedf2a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_db884c59-b93a-4d79-8bb7-160310275561_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_3923f16a-a222-45a7-adfd-1e7e35004a67_terseLabel_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuromodulation</link:label>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_label_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuromodulation Division [Member]</link:label>
    <link:label id="lab_mdt_NeuromodulationDivisionMember_documentation_en-US" xlink:label="lab_mdt_NeuromodulationDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuromodulation Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember" xlink:href="mdt-20250425.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_NeuromodulationDivisionMember" xlink:to="lab_mdt_NeuromodulationDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_46b69015-3911-49c8-9f80-64ee57038c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ea5f0597-80de-47f6-860b-91910fbd1433_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_f1c17fbc-6f9e-4eb8-81a0-b2f7cef4d9a5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer-related</link:label>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9958007b-b677-4eb3-8be2-a3daac1456b4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2cfbc172-d20f-45db-9844-eb3c12a4e82a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_LossOnInvestments_d7911327-d182-48d4-be55-bdca36b60289_negatedTerseLabel_en-US" xlink:label="lab_mdt_LossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross losses</link:label>
    <link:label id="lab_mdt_LossOnInvestments_label_en-US" xlink:label="lab_mdt_LossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Investments</link:label>
    <link:label id="lab_mdt_LossOnInvestments_documentation_en-US" xlink:label="lab_mdt_LossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossOnInvestments" xlink:href="mdt-20250425.xsd#mdt_LossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_LossOnInvestments" xlink:to="lab_mdt_LossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_18e609a4-a600-491c-89d6-d2b3744f1c60_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aacb7e3d-93a8-44d4-aa8c-869613199b07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f2f8a23-57fd-49aa-a272-d50dcbcdd692_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bbf72503-9483-4302-8b7f-ab214eb0fcc4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_da1681a5-b674-426e-8174-440c69f7715a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bfd7883c-cdaf-4934-a0cf-a755f7a43bb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares&#8212; par value $0.0001, 2.6 billion shares authorized, 1,281,934,628 and 1,311,337,531 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_0749a692-a92d-4898-985b-20c047f27a49_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_b1bdb6b4-e8da-46a0-bcb2-2b58a8b20b99_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_11fcb78c-c261-4631-ad7b-cc8df5b4abea_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized loss on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_27aadd97-e243-41e6-a47d-f9c65467ea69_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future employer contributions in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2020Due20260.000PercentMember_9dbeb956-25ef-4b1f-88a1-f4b3f36dd858_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.000 percent five-year 2020 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20260.000PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2026, 0.000 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2020Due20260.000PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2020 Due 2026, 0.000 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20260.000PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:to="lab_mdt_SeniorNotes2020Due20260.000PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_04efffc6-5088-4130-9662-10f5265cac53_negatedTerseLabel_en-US" xlink:label="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Commitments to the Medtronic Foundation and Medtronic LABS</link:label>
    <link:label id="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_label_en-US" xlink:label="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments to the Medtronic Foundation and Medtronic LABS</link:label>
    <link:label id="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_documentation_en-US" xlink:label="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments to the Medtronic Foundation and Medtronic LABS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:href="mdt-20250425.xsd#mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:to="lab_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_1a4b6ba6-5d91-4acb-b6dd-f77e0b827bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized on the consolidated balance sheets consist of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7354b426-b8ea-45e3-b274-71a53d8b686b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dc018a32-26e2-4494-9d9b-b903c196a868_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_e359d453-a42b-4450-828e-5d08538f8756_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments for which the fair value option has been elected</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0b37c58c-69f8-404e-8e24-bbb2706c15f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. state taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_adb0da80-eae1-49ce-ac0b-92b16e4ebd19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bdc722-0358-47af-89a7-64a04638c805_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_1a26f7ec-2ec7-45a4-97b5-ec88ebbef7d1_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6c12b265-7f2a-4a81-b8fe-840435ed5655_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_717191e3-d5de-4da7-b3e5-c40e5b9ccdfd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_edcdff8e-f471-49e7-abae-8bb8d07effda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_286cb9b7-8686-4729-9b7a-5c73ab34ba14_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification, Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_73267d84-89c5-49cf-983f-017c47206b53_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_29c94ff1-56d2-4d66-8db8-435ee7b35b47_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_79024db1-d05d-414c-b3d9-0668c07557b6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_528b1461-180f-4855-90ec-4779e8badd69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4b57ffe3-65ca-425c-abcf-82fdf854e454_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_1c59f237-60a3-42fd-81c5-76ea428fa5a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities Related to Debt Securities Portfolio</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2015Due20454625PercentMember_9ebf26a8-5204-4c25-9504-db764e3e4af6_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20454625PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.625 percent thirty-year 2015 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20454625PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20454625PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2045, 4.625 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2015Due20454625PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2015Due20454625PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2015 Due 2045, 4.625 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20454625PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20454625PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2015Due20454625PercentMember" xlink:to="lab_mdt_SeniorNotes2015Due20454625PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_e050de03-8b45-43f2-a419-dcb94669df14_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_3ba2f053-d0c0-4c5e-8290-dbc41411d372_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_8958558d-d6a6-4b34-acd0-c9afcc3d4267_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_23fbebe8-5cd3-494e-975c-31973d201877_terseLabel_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Specialty Therapies</link:label>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_label_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Therapies Division [Member]</link:label>
    <link:label id="lab_mdt_SpecialtyTherapiesDivisionMember_documentation_en-US" xlink:label="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Therapies Division [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember" xlink:href="mdt-20250425.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SpecialtyTherapiesDivisionMember" xlink:to="lab_mdt_SpecialtyTherapiesDivisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_268f6125-c581-4524-8e1a-1b507a732d1e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42749065-365d-4812-8aeb-5ba76caf27a9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e28770ef-af9a-4c8e-a599-1a9603809ac0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_01a310c7-74a0-4a53-8172-eb078f3caad3_terseLabel_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other countries, excluding Ireland</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_label_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding Ireland [Member]</link:label>
    <link:label id="lab_mdt_TotalOtherCountriesExcludingIrelandMember_documentation_en-US" xlink:label="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Other Countries, Excluding Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:to="lab_mdt_TotalOtherCountriesExcludingIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2053c74-c83c-46a6-8bef-bbe1616b06b5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b68a7831-58fe-46d9-9c64-ec92ec000767_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_c7df04c2-8faf-4280-b9bc-b2370a77a386_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Committed line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_061e3306-2e36-4c16-ae42-c74c3b8d75ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_bbba235d-b57a-4f09-b956-af12b7538b76_terseLabel_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charge to adjustments</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_label_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_documentation_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:to="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SeniorNotes2019Due20501750PercentMember_83e3802d-ecb9-4321-ba95-690a12d9b139_terseLabel_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20501750PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.750 percent thirty-year 2019 senior notes</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20501750PercentMember_label_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20501750PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2050, 1.750 Percent [Member]</link:label>
    <link:label id="lab_mdt_SeniorNotes2019Due20501750PercentMember_documentation_en-US" xlink:label="lab_mdt_SeniorNotes2019Due20501750PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 2019 Due 2050, 1.750 Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20501750PercentMember" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20501750PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SeniorNotes2019Due20501750PercentMember" xlink:to="lab_mdt_SeniorNotes2019Due20501750PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_A3.000SeniorNotesDue2029Member_b4baa71a-d999-4a0d-8f07-e7214749869f_terseLabel_en-US" xlink:label="lab_mdt_A3.000SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.000% Senior Notes due 2028</link:label>
    <link:label id="lab_mdt_A3.000SeniorNotesDue2029Member_label_en-US" xlink:label="lab_mdt_A3.000SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.000% Senior Notes due 2029 [Member]</link:label>
    <link:label id="lab_mdt_A3.000SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_mdt_A3.000SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.000% Senior Notes due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.000SeniorNotesDue2029Member" xlink:href="mdt-20250425.xsd#mdt_A3.000SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_A3.000SeniorNotesDue2029Member" xlink:to="lab_mdt_A3.000SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_62a033b5-303a-43ee-872e-9832e7a56b3f_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_f7b899d1-1159-45be-ae20-2f82c6dbd721_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate &#8211; benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_RenalCareSolutionsMember_4368b82d-9b76-4de2-b7ef-25afdeaca74a_terseLabel_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renal Care Solutions</link:label>
    <link:label id="lab_mdt_RenalCareSolutionsMember_label_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Renal Care Solutions [Member]</link:label>
    <link:label id="lab_mdt_RenalCareSolutionsMember_documentation_en-US" xlink:label="lab_mdt_RenalCareSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Renal Care Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember" xlink:href="mdt-20250425.xsd#mdt_RenalCareSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_RenalCareSolutionsMember" xlink:to="lab_mdt_RenalCareSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_03f984e6-b7bc-443b-b6fb-813171cd9623_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments from short-term borrowings (maturities greater than 90 days)</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_b171b4c5-f176-4127-9980-7f1241093c82_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank borrowings</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ab89c0d-ff75-42bd-97f7-39405bbccab2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase and Award Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cbd5fe0e-3c3b-4ddb-93f9-2e096e9d9bde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e6981f4d-ec56-4ecf-9d88-ff56368389d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3e514d3d-e408-4da7-89ef-c231032469d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_17c4bfb2-eccc-4d50-83cd-a4abee31887c_negatedTerseLabel_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Puerto Rico excise tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_label_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Puerto Rico Excise Tax</link:label>
    <link:label id="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_documentation_en-US" xlink:label="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:to="lab_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c3fdf66d-3171-4914-bf91-953322b2aa4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3e4dc98a-f586-4c0e-a3e8-387e4b22858e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_1e4a26ac-a347-40b8-a010-a139cb4edad0_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, at Fair Value [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_739285ff-c736-4b2e-ad67-e551a47b60f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_989d6313-f601-420e-a043-82734b3c2dd8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_59c908d4-6403-42d5-a31d-440cbd20efef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf9ba96a-8dfe-4d74-949f-d6cc57e7e880_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_84cbe9ed-97e3-4587-a877-787cc6ecef8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Critical assumptions &#8211; projected benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e363c339-0519-4a75-afae-5c1db35633fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ff277844-e0d4-44f8-a645-c996861e22de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_0f972703-6e96-4df9-b58b-68747ac38055_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_cc700fcb-c21b-456e-aa5e-947a5494ae92_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Tax Authorities</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0c363560-1941-4f05-93d2-2757e396908e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use leases</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2ade8359-1bf4-4851-b053-3a7b379f17d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e2218ee1-a94a-4e67-b61d-11dffafd5ba9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_51f2a267-41fa-4464-9b17-1ca1a8e07eeb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_776aada1-b2a8-4895-a874-b04c9c6ebf5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5e4aeb7d-3915-47d4-aafd-02317a65d79c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_47801073-fe80-4158-9d39-67dca7b9ff32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7ce65554-44aa-4163-9fd7-ac6d863c19ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8fc30369-b0d9-4b6b-af76-5e46185e4ec9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_88f45d21-f23a-4d8e-a8be-1114e77d7f73_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation charges (income)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_d3b20f4f-d809-435c-a325-c252456646dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Certain litigation charges, net</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_853c8ae8-24e7-4c06-955e-9b04958e4db6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_acf5c363-f33f-4323-bdc6-b279e1594341_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AuctionRateSecuritiesMember_7cc4a9a7-b2d8-4928-9a93-2429ed9a2824_terseLabel_en-US" xlink:label="lab_us-gaap_AuctionRateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auction rate securities</link:label>
    <link:label id="lab_us-gaap_AuctionRateSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AuctionRateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auction Rate Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionRateSecuritiesMember" xlink:to="lab_us-gaap_AuctionRateSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2fc7f61-f245-469a-8bbd-a2eea3c48b06_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expected lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dfab7b95-f064-4e58-bd35-2704c71371e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_caef90a9-5f4d-44e9-82ea-59a874f80ae6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_DeferredStockSharesIssued_15535f0b-7da4-4cc5-8794-1e6130ad86f8_terseLabel_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock, issued (in shares)</link:label>
    <link:label id="lab_mdt_DeferredStockSharesIssued_label_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:label id="lab_mdt_DeferredStockSharesIssued_documentation_en-US" xlink:label="lab_mdt_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_DeferredStockSharesIssued" xlink:to="lab_mdt_DeferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_62493b79-f58b-470a-8730-259c10b53d21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_bac51ef0-dfe6-4c8e-8218-7611d1e02d5a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_cda41f46-4034-44b6-b437-00a43b865370_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment reconciling items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0033491c-d01f-4804-a942-7c853f6405e8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa1b27e8-4417-4dfc-9655-2b5492668276_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_1606c5ce-f6ef-4866-b744-f37be83ed601_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_937cdf7c-fae7-4a56-81d0-33f04d41c673_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fdd0b418-53e1-40c8-b7d6-be2b2f4bc27a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was previously included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_10323ca2-cc36-44e8-8fdf-1cf47e4d3afd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency exchange rate contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a7409634-2df6-4ead-8409-31c919f80563_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4d5cbff1-b26e-49e1-a89f-b5e3cc259837_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ff1d79f1-e400-4fdf-b928-0e68789fd39e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_97b7de19-81cc-44dd-9497-0fa4dc37203d_terseLabel_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges to Other Accounts, net</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_label_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</link:label>
    <link:label id="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_documentation_en-US" xlink:label="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:to="lab_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c91bab31-4490-4775-9ffd-9faef64f4f14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_83c61265-dbce-4349-848a-4dc83a6f8692_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_6033b0de-6ff4-47cb-acd5-16596a5e6123_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity Related to the Company's Available for Sale Securities Portfolio</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_924c63bc-ba0a-46bc-a275-6cc58ace972c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_69f0042a-6f3a-4518-a82f-f81f7f25275d_terseLabel_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning and Ending Balances of Contingent Payments [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_label_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward_documentation_en-US" xlink:label="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:to="lab_mdt_BusinessAcquisitionContingentConsiderationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_bcc381d3-9a84-465a-9bd7-079436be0519_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_57254c46-0480-412e-978a-2aae99d3c82b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_ColibriMember_cd205491-7d51-42c8-90ad-e921d8d109f4_terseLabel_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colibri</link:label>
    <link:label id="lab_mdt_ColibriMember_label_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colibri [Member]</link:label>
    <link:label id="lab_mdt_ColibriMember_documentation_en-US" xlink:label="lab_mdt_ColibriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colibri</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember" xlink:href="mdt-20250425.xsd#mdt_ColibriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_ColibriMember" xlink:to="lab_mdt_ColibriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_12277c87-5fcc-4478-adf3-9992b079614d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_3dac6085-827e-4e99-a7e4-0f6d748216b8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized in accumulated other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_16666018-deb4-402f-9fc5-07e51d02eeef_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_677dbefa-df1f-4662-a038-0e5096e37a05_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_dd188c5b-a1eb-4c77-8810-88280227e469_terseLabel_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit</link:label>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_label_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit [Member]</link:label>
    <link:label id="lab_mdt_VentilatorProductLineExitMember_documentation_en-US" xlink:label="lab_mdt_VentilatorProductLineExitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ventilator Product Line Exit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember" xlink:href="mdt-20250425.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdt_VentilatorProductLineExitMember" xlink:to="lab_mdt_VentilatorProductLineExitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6f6b5fea-aefe-4604-babf-2d4961877c31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationRollForward_4db3f051-9bd4-423b-a67c-d94460e07a55_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationRollForward_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_3895f8c8-576f-43f5-8bc5-fd6561c6dbd3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_df3ad760-11a6-4a74-ab7d-e4c492f3de9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax (Benefit) Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_100997e3-619b-4c83-b94a-1b62b4b85c72_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_268b99b5-9e6c-4250-882e-ed1e69f3e012_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_46747d88-4b11-4cb9-8d63-d21fce1ba91d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_68276fec-e291-446f-b7f1-b52726ab8640_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, expiring in future years</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_172734e0-1b80-447d-9e85-d9e0f11ef6d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>mdt-20250425_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:643f1b39-463f-4341-b210-521f3c41ac51,g:09f6b732-636a-49bf-91c5-640ce9c55349-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medtronic.com/role/Cover" xlink:type="simple" xlink:href="mdt-20250425.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ea617f71-7762-4a57-adbd-8382ad4bfff5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ea617f71-7762-4a57-adbd-8382ad4bfff5" xlink:to="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d789e88-b3a8-451f-b8b6-64d7143e1e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.250SeniorNotesDue2025Member_f996c4d0-1c4f-4eea-8042-47ee2ff3a35c" xlink:href="mdt-20250425.xsd#mdt_A0.250SeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.250SeniorNotesDue2025Member_f996c4d0-1c4f-4eea-8042-47ee2ff3a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.000SeniorNotesDue2025Member_eedcc502-cea4-4089-b390-6c283177923e" xlink:href="mdt-20250425.xsd#mdt_A0.000SeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.000SeniorNotesDue2025Member_eedcc502-cea4-4089-b390-6c283177923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.625SeniorNotesDue2025Member_3e296937-64ab-4d07-9a29-9afe43af5fe7" xlink:href="mdt-20250425.xsd#mdt_A2.625SeniorNotesDue2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A2.625SeniorNotesDue2025Member_3e296937-64ab-4d07-9a29-9afe43af5fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.125SeniorNotesDue2027Member_f164da43-3a9a-435b-a2e0-0341411c5d9a" xlink:href="mdt-20250425.xsd#mdt_A1.125SeniorNotesDue2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.125SeniorNotesDue2027Member_f164da43-3a9a-435b-a2e0-0341411c5d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.375SeniorNotesDue2028Member_dc220822-93de-4447-9675-8b7f8938d9b8" xlink:href="mdt-20250425.xsd#mdt_A0.375SeniorNotesDue2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.375SeniorNotesDue2028Member_dc220822-93de-4447-9675-8b7f8938d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.000SeniorNotesDue2029Member_ba9b7cde-17d3-44eb-9a12-873f70cdf928" xlink:href="mdt-20250425.xsd#mdt_A3.000SeniorNotesDue2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.000SeniorNotesDue2029Member_ba9b7cde-17d3-44eb-9a12-873f70cdf928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.650SeniorNotesDue2029Member_37f3fc08-3e45-4b32-9672-0cfd7d26dab4" xlink:href="mdt-20250425.xsd#mdt_A3.650SeniorNotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.650SeniorNotesDue2029Member_37f3fc08-3e45-4b32-9672-0cfd7d26dab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2031Member_89370b77-8eca-4e20-9682-af9208ca23a7" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2031Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.625SeniorNotesDue2031Member_89370b77-8eca-4e20-9682-af9208ca23a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.000SeniorNotesDue2031Member_1ff9a669-ce49-44f4-9a30-da02be59ea66" xlink:href="mdt-20250425.xsd#mdt_A1.000SeniorNotesDue2031Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.000SeniorNotesDue2031Member_1ff9a669-ce49-44f4-9a30-da02be59ea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.125SeniorNotesDue2031Member_4c4da889-dac0-44d9-9022-b9567c68e3d9" xlink:href="mdt-20250425.xsd#mdt_A3.125SeniorNotesDue2031Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.125SeniorNotesDue2031Member_4c4da889-dac0-44d9-9022-b9567c68e3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A0.750SeniorNotesDue2032Member_0a1228d2-0222-45ba-8eb9-743dcdcd0837" xlink:href="mdt-20250425.xsd#mdt_A0.750SeniorNotesDue2032Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A0.750SeniorNotesDue2032Member_0a1228d2-0222-45ba-8eb9-743dcdcd0837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.375SeniorNotesDue2034Member_8bf824c5-247b-4e63-a736-0234cbdf032a" xlink:href="mdt-20250425.xsd#mdt_A3.375SeniorNotesDue2034Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.375SeniorNotesDue2034Member_8bf824c5-247b-4e63-a736-0234cbdf032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A3.875SeniorNotesDue2036Member_715c7e62-5577-482f-b686-6bf00f20d5c1" xlink:href="mdt-20250425.xsd#mdt_A3.875SeniorNotesDue2036Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A3.875SeniorNotesDue2036Member_715c7e62-5577-482f-b686-6bf00f20d5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2.250SeniorNotesDue2039Member_110cd94f-1513-4fef-96f4-0de96d5faccd" xlink:href="mdt-20250425.xsd#mdt_A2.250SeniorNotesDue2039Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A2.250SeniorNotesDue2039Member_110cd94f-1513-4fef-96f4-0de96d5faccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.500SeniorNotesDue2039Member_c2f7d475-4e9e-4f8d-a861-67bf889b54c6" xlink:href="mdt-20250425.xsd#mdt_A1.500SeniorNotesDue2039Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.500SeniorNotesDue2039Member_c2f7d475-4e9e-4f8d-a861-67bf889b54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.375SeniorNotesDue2040Member_62eb7362-9ab8-49bf-92ba-e751b8d6a8bb" xlink:href="mdt-20250425.xsd#mdt_A1.375SeniorNotesDue2040Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.375SeniorNotesDue2040Member_62eb7362-9ab8-49bf-92ba-e751b8d6a8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2043Member_69e76dfa-dd93-4665-a505-bd0a7ab7636c" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2043Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A4.150SeniorNotesDue2043Member_69e76dfa-dd93-4665-a505-bd0a7ab7636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.750SeniorNotesDue2049Member_dd06279b-79e0-4a56-b68e-131360be7fb9" xlink:href="mdt-20250425.xsd#mdt_A1.750SeniorNotesDue2049Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.750SeniorNotesDue2049Member_dd06279b-79e0-4a56-b68e-131360be7fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A1.625SeniorNotesDue2050Member_9a6d23ff-261b-4368-b036-49eed7d16dc4" xlink:href="mdt-20250425.xsd#mdt_A1.625SeniorNotesDue2050Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A1.625SeniorNotesDue2050Member_9a6d23ff-261b-4368-b036-49eed7d16dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A4.150SeniorNotesDue2053Member_4e0ee692-6b2c-4464-a731-cf860eb87887" xlink:href="mdt-20250425.xsd#mdt_A4.150SeniorNotesDue2053Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_248a49b2-7426-4eab-b4e3-271dfff33b19" xlink:to="loc_mdt_A4.150SeniorNotesDue2053Member_4e0ee692-6b2c-4464-a731-cf860eb87887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_59d19d40-564d-4366-b6fe-e23eb5ce11be" xlink:to="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ae56a456-93dc-43fc-9937-3d80a5eee35b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentType_ae56a456-93dc-43fc-9937-3d80a5eee35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_94dae9cd-3c5e-4085-b06f-10db97348847" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentAnnualReport_94dae9cd-3c5e-4085-b06f-10db97348847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dda35b2a-2df8-431c-96e7-dae07be9a1d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentPeriodEndDate_dda35b2a-2df8-431c-96e7-dae07be9a1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b9ae138f-89da-4843-879e-022adada33d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentTransitionReport_b9ae138f-89da-4843-879e-022adada33d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_02df10ec-357f-484d-a313-f2f53449b385" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityFileNumber_02df10ec-357f-484d-a313-f2f53449b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee18a787-ca7e-42f6-9e2c-b60e67c9916b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityRegistrantName_ee18a787-ca7e-42f6-9e2c-b60e67c9916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1c635c05-452e-4290-82d9-f9b7ea6074ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1c635c05-452e-4290-82d9-f9b7ea6074ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6070dce9-3882-4cdf-a4fe-a66867f5465c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityTaxIdentificationNumber_6070dce9-3882-4cdf-a4fe-a66867f5465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_203278de-cbee-4938-aa78-1950812b461a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressAddressLine1_203278de-cbee-4938-aa78-1950812b461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_db807916-d998-4c2e-996b-316797b376bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressCityOrTown_db807916-d998-4c2e-996b-316797b376bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_bcb86cdb-e23e-4892-a57f-ec397908c1cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressCountry_bcb86cdb-e23e-4892-a57f-ec397908c1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_dd2ebf2e-2870-448c-b2c6-10559bc390d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CountryRegion_dd2ebf2e-2870-448c-b2c6-10559bc390d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_82120515-d583-4ff7-ae9f-2c65af53509a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CityAreaCode_82120515-d583-4ff7-ae9f-2c65af53509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9cc1e6ba-5823-4e50-9e62-7131a01b0559" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_LocalPhoneNumber_9cc1e6ba-5823-4e50-9e62-7131a01b0559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76c9a852-c2ec-47cc-aef7-8513fb86fbc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_Security12bTitle_76c9a852-c2ec-47cc-aef7-8513fb86fbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5c4e3f7-a30c-4185-970a-ac5490406961" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_TradingSymbol_d5c4e3f7-a30c-4185-970a-ac5490406961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1c30bde9-3e7c-4c89-b839-e8108ea831a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_SecurityExchangeName_1c30bde9-3e7c-4c89-b839-e8108ea831a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_699730ee-9e77-4442-a144-5651f4f1b100" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_699730ee-9e77-4442-a144-5651f4f1b100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_30d1f786-3695-4b4a-a87c-48fac522ea51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityVoluntaryFilers_30d1f786-3695-4b4a-a87c-48fac522ea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9fe79a93-d0ac-4365-a35f-d2061b8cb6e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCurrentReportingStatus_9fe79a93-d0ac-4365-a35f-d2061b8cb6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_823c3d39-88cf-4b20-bd68-435e4a81f7b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityInteractiveDataCurrent_823c3d39-88cf-4b20-bd68-435e4a81f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0dd523d1-24ca-4ffb-93da-5b14fe302769" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityFilerCategory_0dd523d1-24ca-4ffb-93da-5b14fe302769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a120dae2-e95e-48d3-a477-68c5ed4f6f73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntitySmallBusiness_a120dae2-e95e-48d3-a477-68c5ed4f6f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_761890a8-2bca-4d59-8dca-b28b560a99b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityEmergingGrowthCompany_761890a8-2bca-4d59-8dca-b28b560a99b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_56eb669e-1206-4db0-95bf-516236730e83" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_IcfrAuditorAttestationFlag_56eb669e-1206-4db0-95bf-516236730e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_64ee5d47-1f52-4a3a-b9e1-99186f1ca5a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_64ee5d47-1f52-4a3a-b9e1-99186f1ca5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_41bc133e-e362-4415-a26f-d45d88f20ee1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityShellCompany_41bc133e-e362-4415-a26f-d45d88f20ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1499cf53-fae2-49ed-93e1-e8a38e2e2cd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityPublicFloat_1499cf53-fae2-49ed-93e1-e8a38e2e2cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc70a9eb-8bd0-4d11-b2b2-f005b8616b7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc70a9eb-8bd0-4d11-b2b2-f005b8616b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afd41a76-d72e-49ec-8211-ce5f26f98070" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afd41a76-d72e-49ec-8211-ce5f26f98070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_db2c2e1f-2e85-4370-8d67-3af17ae23d41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityCentralIndexKey_db2c2e1f-2e85-4370-8d67-3af17ae23d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e2beb51e-28f8-4dcc-9233-9246622b4bbb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_CurrentFiscalYearEndDate_e2beb51e-28f8-4dcc-9233-9246622b4bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3de4750e-56fb-42f3-813d-0cb5b853b1be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_AmendmentFlag_3de4750e-56fb-42f3-813d-0cb5b853b1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5c87cba1-4923-42e6-b97d-c0d3b56311c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5c87cba1-4923-42e6-b97d-c0d3b56311c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_19aa15bb-77f2-4977-afe7-5da604416066" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_DocumentFiscalYearFocus_19aa15bb-77f2-4977-afe7-5da604416066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7b25fcb6-b42c-44e1-833a-028671043dac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_447a379b-027a-413d-a673-c61205b4f196" xlink:to="loc_dei_EntityAddressPostalZipCode_7b25fcb6-b42c-44e1-833a-028671043dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AuditInformation" xlink:type="simple" xlink:href="mdt-20250425.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AuditInformationAbstract_e77ac734-bcef-4ff7-8ae2-7a300a3616a6" xlink:href="mdt-20250425.xsd#mdt_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_05a12dff-b9c6-45fe-aa21-bb876a825a06" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_e77ac734-bcef-4ff7-8ae2-7a300a3616a6" xlink:to="loc_dei_AuditorFirmId_05a12dff-b9c6-45fe-aa21-bb876a825a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_d4965cb6-eaf1-4d00-a2ce-dfa3dc0ecb96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_e77ac734-bcef-4ff7-8ae2-7a300a3616a6" xlink:to="loc_dei_AuditorName_d4965cb6-eaf1-4d00-a2ce-dfa3dc0ecb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_74be6edf-e1b2-4342-8a11-1d3ced2136b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_AuditInformationAbstract_e77ac734-bcef-4ff7-8ae2-7a300a3616a6" xlink:to="loc_dei_AuditorLocation_74be6edf-e1b2-4342-8a11-1d3ced2136b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8fea12c-6876-402a-9055-c3579bb4ade6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8fea12c-6876-402a-9055-c3579bb4ade6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4aa5eacd-8c7b-4451-9d9c-6e0894b3f339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4aa5eacd-8c7b-4451-9d9c-6e0894b3f339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_98ec7534-829b-4c60-aad7-8b5621735517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_98ec7534-829b-4c60-aad7-8b5621735517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32f7141-a84e-4fec-92b8-27c3efdad218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32f7141-a84e-4fec-92b8-27c3efdad218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_86bbbf2e-0270-4569-9c2f-c18d9d87c256" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_86bbbf2e-0270-4569-9c2f-c18d9d87c256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_b4244e57-25bc-4403-b42a-4acc1fcbbcbe" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_b4244e57-25bc-4403-b42a-4acc1fcbbcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_911c168f-08f1-48cd-bf41-4e5d5ddbe038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_911c168f-08f1-48cd-bf41-4e5d5ddbe038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5fa63695-f859-4e3c-8d17-b27e0e845175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_77e06463-44d3-4a32-ab84-a332929e0fa5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5fa63695-f859-4e3c-8d17-b27e0e845175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e424c17c-8f60-4970-a5b5-e36e5b78923e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_OperatingIncomeLoss_e424c17c-8f60-4970-a5b5-e36e5b78923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c6031b1e-e6c6-40a0-aba6-b99cc7ccd3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c6031b1e-e6c6-40a0-aba6-b99cc7ccd3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_89e40cd7-459f-454e-b7c9-c8f349d52c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_InterestExpenseNonoperating_89e40cd7-459f-454e-b7c9-c8f349d52c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e00d8205-56fb-4ef1-b7fe-3e3c836065bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e00d8205-56fb-4ef1-b7fe-3e3c836065bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70025edd-0025-4f7f-9ab4-17a973d6edf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70025edd-0025-4f7f-9ab4-17a973d6edf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2fbc975c-f8ee-4774-83aa-307c688b8292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_ProfitLoss_2fbc975c-f8ee-4774-83aa-307c688b8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07c0cab2-76d7-4781-afc1-4b9a97318a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07c0cab2-76d7-4781-afc1-4b9a97318a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e616ee38-1a60-4249-b8aa-2e52cd67515b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_NetIncomeLoss_e616ee38-1a60-4249-b8aa-2e52cd67515b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_066d490e-fad7-403c-9132-e3955b228fff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_EarningsPerShareBasic_066d490e-fad7-403c-9132-e3955b228fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_521beabd-de88-428d-90f2-b65b17162768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_521beabd-de88-428d-90f2-b65b17162768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ec3b179-9e8e-4e2c-b76b-8b38bf086825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ec3b179-9e8e-4e2c-b76b-8b38bf086825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96e5ab25-17a4-40ce-957d-ddd8913931b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_03c27729-80ac-450f-a10f-934f358720c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96e5ab25-17a4-40ce-957d-ddd8913931b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4eff1add-5df4-4e0f-8e32-751152f04fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:to="loc_us-gaap_ProfitLoss_4eff1add-5df4-4e0f-8e32-751152f04fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f9ab0a9-7133-4856-a9dd-42011dc7ebb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f9ab0a9-7133-4856-a9dd-42011dc7ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7eeee43d-f84f-423e-8abb-a87afc1e7289" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_7eeee43d-f84f-423e-8abb-a87afc1e7289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_1e98685c-3006-483f-a7d1-d8afbd245733" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax_1e98685c-3006-483f-a7d1-d8afbd245733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_18327e03-75b4-4a8c-b61e-8c1c2bee1e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_18327e03-75b4-4a8c-b61e-8c1c2bee1e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5f48bebd-c5bb-4cbc-842d-8e62c40da47e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5f48bebd-c5bb-4cbc-842d-8e62c40da47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f942b5eb-950b-4063-ac0c-d0b4abe634bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b060c21a-ff6e-43fa-9e39-71027ee43393" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f942b5eb-950b-4063-ac0c-d0b4abe634bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e82d5d1-05fd-44cf-b586-86e0c107b2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e82d5d1-05fd-44cf-b586-86e0c107b2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_571b0ed0-0185-4f8e-9f2d-48fb2986edb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_571b0ed0-0185-4f8e-9f2d-48fb2986edb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_15f12cc0-6570-46e2-b23a-048213e60494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_317bc841-f79d-4f02-91c8-afaaaa8a9530" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_15f12cc0-6570-46e2-b23a-048213e60494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_955a208d-6182-4111-9a6d-63bcf8e8110e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_955a208d-6182-4111-9a6d-63bcf8e8110e" xlink:to="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1aa596a3-8ace-4ee6-ae15-d03fa20a2bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1aa596a3-8ace-4ee6-ae15-d03fa20a2bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_6a6c54cf-1daf-4ff4-8cb3-3f1ae0ffe23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_ShortTermInvestments_6a6c54cf-1daf-4ff4-8cb3-3f1ae0ffe23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_14d8810f-bb8a-4ec4-a6a7-cfcfc399e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_14d8810f-bb8a-4ec4-a6a7-cfcfc399e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_424a605e-8cc0-4669-aec1-04e8d42c1031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_InventoryNet_424a605e-8cc0-4669-aec1-04e8d42c1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5647842d-6303-440e-8e1b-3f48eb44b92c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_OtherAssetsCurrent_5647842d-6303-440e-8e1b-3f48eb44b92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b2a055a0-25f1-4c8e-abd5-d45afa495b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5b1b103-0877-48d0-9b27-7adc26a19f40" xlink:to="loc_us-gaap_AssetsCurrent_b2a055a0-25f1-4c8e-abd5-d45afa495b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45eb3fdb-d4a7-49b1-b010-50bcbe6b7405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45eb3fdb-d4a7-49b1-b010-50bcbe6b7405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7cc1ce60-2e49-44b4-a48b-fe6b62b00d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_Goodwill_7cc1ce60-2e49-44b4-a48b-fe6b62b00d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69c40eeb-66c5-4d49-b585-62510c66c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69c40eeb-66c5-4d49-b585-62510c66c03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b5b2e413-ca63-4ca5-be03-eef64b1f6718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b5b2e413-ca63-4ca5-be03-eef64b1f6718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_248f8085-84c8-46c4-91a9-45132db41223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_248f8085-84c8-46c4-91a9-45132db41223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_50093cf0-bc1c-4133-b43c-a4fc0f3b6e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3aecd9b0-ba76-4d98-9372-dc6cafb84843" xlink:to="loc_us-gaap_Assets_50093cf0-bc1c-4133-b43c-a4fc0f3b6e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_955a208d-6182-4111-9a6d-63bcf8e8110e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f1b96ba1-5459-4365-8b6e-02e8c5d04a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_DebtCurrent_f1b96ba1-5459-4365-8b6e-02e8c5d04a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3f98aa02-ae24-48b1-bfbc-86574e9d8296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_AccountsPayableCurrent_3f98aa02-ae24-48b1-bfbc-86574e9d8296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_38522e63-35a7-4be7-bdea-8719177e458a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_38522e63-35a7-4be7-bdea-8719177e458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f617b487-b5fb-4bee-b400-1aea0b602a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f617b487-b5fb-4bee-b400-1aea0b602a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e197d0be-372b-4ed8-8b60-6aa07d94eccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e197d0be-372b-4ed8-8b60-6aa07d94eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b864d6f9-dfe9-4cb8-ae76-d4a7871cfd94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a587aff-3412-4389-868a-bb77e1488633" xlink:to="loc_us-gaap_LiabilitiesCurrent_b864d6f9-dfe9-4cb8-ae76-d4a7871cfd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d93c8e30-0d75-4f3f-8976-464d4253e193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d93c8e30-0d75-4f3f-8976-464d4253e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_c918f6e2-90b3-4ee6-9086-a16d7fe330b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_c918f6e2-90b3-4ee6-9086-a16d7fe330b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ece3ef42-f4a1-4af4-be2e-2969af1f15ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ece3ef42-f4a1-4af4-be2e-2969af1f15ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9766554b-abf1-4320-a467-d49aeef6c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9766554b-abf1-4320-a467-d49aeef6c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4266a259-58a0-4496-bad0-90381e469c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4266a259-58a0-4496-bad0-90381e469c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f7de7c52-f50e-40a5-8bad-830355bab20a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_Liabilities_f7de7c52-f50e-40a5-8bad-830355bab20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d3e511cb-0d4d-4235-88c8-603d2bb1bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d3e511cb-0d4d-4235-88c8-603d2bb1bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_35a53bf7-2b34-4e2f-8b4c-43344a114c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_CommonStockValue_35a53bf7-2b34-4e2f-8b4c-43344a114c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6a26c72c-a240-4c29-b75f-741e68c8601f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6a26c72c-a240-4c29-b75f-741e68c8601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abb6e363-c6b9-434b-8f28-187f71ff8f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abb6e363-c6b9-434b-8f28-187f71ff8f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1b3baae-51ec-4199-8bef-022191bae208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a1b3baae-51ec-4199-8bef-022191bae208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_306e4594-8e4f-432c-a305-924c0875d56b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_StockholdersEquity_306e4594-8e4f-432c-a305-924c0875d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_391fd09d-5af5-4eee-add9-6b5b35850286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_MinorityInterest_391fd09d-5af5-4eee-add9-6b5b35850286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_643d5449-63ba-40f5-b574-f194e549d262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08ff4636-4ad0-4434-824a-dacf7cfbb1bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_643d5449-63ba-40f5-b574-f194e549d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_557cf7f3-ee8c-4a66-aa99-186b48410a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bf6d7d7-9bde-402c-842b-a7d91fc71155" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_557cf7f3-ee8c-4a66-aa99-186b48410a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_028ca00d-d61a-4a29-b8c0-ac2ed1f3a280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_028ca00d-d61a-4a29-b8c0-ac2ed1f3a280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_27fb1bda-3a5c-465e-8fd3-4b4cfcc93f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_27fb1bda-3a5c-465e-8fd3-4b4cfcc93f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5ceb5baa-be2e-4927-af22-0ecdbcc29f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5ceb5baa-be2e-4927-af22-0ecdbcc29f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f285566f-5b7e-40e4-a83f-a6c61f6e3619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:to="loc_us-gaap_CommonStockSharesIssued_f285566f-5b7e-40e4-a83f-a6c61f6e3619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5d98447c-c0e6-479a-a0fe-7e1298f85320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2271da0e-9222-407f-8aa8-69734cf9a16f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5d98447c-c0e6-479a-a0fe-7e1298f85320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9d22611d-ef5e-48c4-ad96-08ddf77b8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9d22611d-ef5e-48c4-ad96-08ddf77b8bb3" xlink:to="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_478c5bd9-8de5-4eae-a6a6-9c8e5d2c30db" xlink:to="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:to="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_85f5d0cd-0c90-4e13-be37-770f8c045e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_CommonStockMember_85f5d0cd-0c90-4e13-be37-770f8c045e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3a4e6b50-b8b7-445c-a780-d675ea707c52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3a4e6b50-b8b7-445c-a780-d675ea707c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dd2d1b7f-173a-47e2-b340-7be52449c042" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_RetainedEarningsMember_dd2d1b7f-173a-47e2-b340-7be52449c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec1f9133-0558-4304-99b0-c4e3263378e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e8e5a82b-1374-45b9-9a3a-499208584f29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec1f9133-0558-4304-99b0-c4e3263378e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7004a40e-d174-4c66-85ed-b5f4aceb9ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3540222-d74d-48a7-855e-f0737bafbeea" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7004a40e-d174-4c66-85ed-b5f4aceb9ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bb430bf-c0c1-4d24-b03f-2b90cac3983a" xlink:to="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c4518019-c217-42cc-81ac-6d4cadb71dd5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1774cfe-f14c-4a4e-b750-94a09d85fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1774cfe-f14c-4a4e-b750-94a09d85fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8293ca8d-b215-4aab-9d4b-c559c73d16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8293ca8d-b215-4aab-9d4b-c559c73d16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69680062-d6c6-48bf-9375-b030bcb66fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_ProfitLoss_69680062-d6c6-48bf-9375-b030bcb66fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_246c751b-eb7f-4e5b-a1ec-2f73de3c815e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_246c751b-eb7f-4e5b-a1ec-2f73de3c815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_44f99d67-2681-46c6-9942-cc3160a6e760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_DividendsCommonStockCash_44f99d67-2681-46c6-9942-cc3160a6e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8a7918ea-476c-4c1c-9d70-998d2e01bc52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8a7918ea-476c-4c1c-9d70-998d2e01bc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0dac7b1d-7bca-4fed-84d1-cec2b4ca90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0dac7b1d-7bca-4fed-84d1-cec2b4ca90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d2e7efa1-0539-4fcd-8717-c15793be4e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d2e7efa1-0539-4fcd-8717-c15793be4e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_eb29e304-1e19-4898-b08e-b8607760eef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_eb29e304-1e19-4898-b08e-b8607760eef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b12fd317-d123-4b5f-9832-577edd2d289b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b12fd317-d123-4b5f-9832-577edd2d289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_84a25b88-861a-40c5-9fdb-d3592e794dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_84a25b88-861a-40c5-9fdb-d3592e794dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_762ff240-1bd1-4227-a4f3-777f2d7f3820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_762ff240-1bd1-4227-a4f3-777f2d7f3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b89f0a1-d6ca-42fe-9c6c-f018e9a48163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b079e274-806b-4a04-8fcc-76eaf66791b5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b89f0a1-d6ca-42fe-9c6c-f018e9a48163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59c970f1-d841-4366-924e-e66e7781c562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d0919cdf-a63b-400f-a788-5ecfc20d52cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59c970f1-d841-4366-924e-e66e7781c562" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d0919cdf-a63b-400f-a788-5ecfc20d52cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mdt-20250425.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5917defd-6f43-48c6-aed3-32aa5263ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5917defd-6f43-48c6-aed3-32aa5263ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_15797cb1-c4a1-427c-a314-027597e3bc46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5917defd-6f43-48c6-aed3-32aa5263ce9c" xlink:to="loc_us-gaap_ProfitLoss_15797cb1-c4a1-427c-a314-027597e3bc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5917defd-6f43-48c6-aed3-32aa5263ce9c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_57a9648f-d532-499f-a773-c08c7d848670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_57a9648f-d532-499f-a773-c08c7d848670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fb6be1ca-31b8-41d1-96ab-5339fc4d74e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fb6be1ca-31b8-41d1-96ab-5339fc4d74e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a532e745-6fbb-4d5c-955a-843ac63abf91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a532e745-6fbb-4d5c-955a-843ac63abf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b39e71df-9b62-4861-8de7-bc484f3cb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_ShareBasedCompensation_b39e71df-9b62-4861-8de7-bc484f3cb4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ff31e8c-bafc-4139-b77a-2ffae4eeb691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ff31e8c-bafc-4139-b77a-2ffae4eeb691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_04a1d8f3-19d9-415c-8d27-ea752f25cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_AssetImpairmentCharges_04a1d8f3-19d9-415c-8d27-ea752f25cd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8237205d-f606-49b0-8882-97f7000788af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8237205d-f606-49b0-8882-97f7000788af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497737b2-3e77-4677-97f4-49dfb8489d25" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_3aaee583-5685-4744-a307-b1fe93300afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable_3aaee583-5685-4744-a307-b1fe93300afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_879476e4-a933-4e09-b6aa-6e422a885dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_879476e4-a933-4e09-b6aa-6e422a885dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_712cb9d2-0b67-4786-ac81-fba9aac0c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_712cb9d2-0b67-4786-ac81-fba9aac0c07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f526011e-f4dc-484d-97bd-adaab3808d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_302db679-653a-4b0b-983b-fc911dea2eba" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f526011e-f4dc-484d-97bd-adaab3808d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05c912c0-9a3a-4fa2-8882-6b9da9504284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5917defd-6f43-48c6-aed3-32aa5263ce9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05c912c0-9a3a-4fa2-8882-6b9da9504284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8058c065-ef41-4c18-bffa-7b2437c1ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8058c065-ef41-4c18-bffa-7b2437c1ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1d9fc35-26b8-4cdb-8a94-3322da9e0b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1d9fc35-26b8-4cdb-8a94-3322da9e0b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_de440efe-221c-4efa-8dbd-5d13a44e4885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_de440efe-221c-4efa-8dbd-5d13a44e4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e83c55bf-8d4f-4b68-b761-8c5b228814dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e83c55bf-8d4f-4b68-b761-8c5b228814dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c728184b-0fe4-423d-9986-a1e6882909f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c728184b-0fe4-423d-9986-a1e6882909f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_436899ea-32c6-45c9-8189-201931559e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5b771985-1892-4236-b083-93e0134132ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_436899ea-32c6-45c9-8189-201931559e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_355fb18a-50ae-4b34-968f-97264e7cd462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_355fb18a-50ae-4b34-968f-97264e7cd462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_1244b638-dbc9-4948-a927-3f3c3115eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_1244b638-dbc9-4948-a927-3f3c3115eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_88e76627-63ab-45d2-ad94-f7a23b94259d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_88e76627-63ab-45d2-ad94-f7a23b94259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1662f13-e56d-4dc8-aab8-6fca5a8703e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1662f13-e56d-4dc8-aab8-6fca5a8703e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_03d4ead2-7aa5-4a33-8626-08ce79ed93b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_03d4ead2-7aa5-4a33-8626-08ce79ed93b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_d866eaf8-0558-4bcb-832d-3cd4f557c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_d866eaf8-0558-4bcb-832d-3cd4f557c0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_282296fe-88a9-4f12-a2b7-efc56e8962fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_282296fe-88a9-4f12-a2b7-efc56e8962fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2edf9191-14b5-4e65-8f8d-1ed0e8059a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2edf9191-14b5-4e65-8f8d-1ed0e8059a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_763a9182-a166-4368-b26e-6f4c5320c4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_763a9182-a166-4368-b26e-6f4c5320c4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5feee347-f379-43b7-913b-53292cd90a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8572f5b2-4e3e-47f9-9db8-4936253f5fe3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5feee347-f379-43b7-913b-53292cd90a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_266feb33-8958-4378-955e-ee4ce0ef2d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_266feb33-8958-4378-955e-ee4ce0ef2d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab80ecc-bead-43c4-9b96-b61abc9ce027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab80ecc-bead-43c4-9b96-b61abc9ce027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c245cf83-e1e7-413d-af0a-0568df27f161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c245cf83-e1e7-413d-af0a-0568df27f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23f499df-56aa-455f-9c82-452227576bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23f499df-56aa-455f-9c82-452227576bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c501df62-713d-4087-a954-1963e1c3a7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4c0595c6-4205-4772-83dd-cc18be949210" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c501df62-713d-4087-a954-1963e1c3a7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxesandInterestPaidAbstract_68800e0f-8bc2-4038-89f7-87b7ad2c63f5" xlink:href="mdt-20250425.xsd#mdt_IncomeTaxesandInterestPaidAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c501df62-713d-4087-a954-1963e1c3a7ff" xlink:to="loc_mdt_IncomeTaxesandInterestPaidAbstract_68800e0f-8bc2-4038-89f7-87b7ad2c63f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_907a65e3-a1e1-42a2-8d7c-d0dc9d95cedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract_68800e0f-8bc2-4038-89f7-87b7ad2c63f5" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_907a65e3-a1e1-42a2-8d7c-d0dc9d95cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1f52d90d-2fff-4412-a8b9-cd0dbe19cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncomeTaxesandInterestPaidAbstract_68800e0f-8bc2-4038-89f7-87b7ad2c63f5" xlink:to="loc_us-gaap_InterestPaidNet_1f52d90d-2fff-4412-a8b9-cd0dbe19cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mdt-20250425.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1ecd1807-a0ac-4f6f-94ea-db9d6de869c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3c1614c5-a46f-4639-bee3-622e3b05f058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1ecd1807-a0ac-4f6f-94ea-db9d6de869c3" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3c1614c5-a46f-4639-bee3-622e3b05f058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Revenue" xlink:type="simple" xlink:href="mdt-20250425.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0b7f3937-479c-4ce4-bf4e-3980491e7b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8ff7e122-3eb6-4664-aa6c-d75d1df84717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0b7f3937-479c-4ce4-bf4e-3980491e7b8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8ff7e122-3eb6-4664-aa6c-d75d1df84717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed8d49bb-705d-4e21-9745-e043f77dd017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_29905caa-8ee7-463b-aa8e-d83170e228d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed8d49bb-705d-4e21-9745-e043f77dd017" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_29905caa-8ee7-463b-aa8e-d83170e228d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringCharges" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringCharges"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ca13b8a-72ab-4914-a26f-daea59089227" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1e1bae41-d1b0-4e6b-aca4-9d9de6b2c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ca13b8a-72ab-4914-a26f-daea59089227" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1e1bae41-d1b0-4e6b-aca4-9d9de6b2c2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6ef0f71a-f4c7-4489-86b4-f065d699ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_72a38cb0-72d1-4168-bc0a-d2e6ac847012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6ef0f71a-f4c7-4489-86b4-f065d699ed86" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_72a38cb0-72d1-4168-bc0a-d2e6ac847012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangements" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangements"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d7091017-ab4f-4a20-8e23-d5f289c82344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7b388716-85e2-4f15-baba-c362ebe9953e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d7091017-ab4f-4a20-8e23-d5f289c82344" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7b388716-85e2-4f15-baba-c362ebe9953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagement"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_509ea9ba-1400-4462-a57b-699eab13078a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a7e606ed-6861-471d-b110-744c290a822a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_509ea9ba-1400-4462-a57b-699eab13078a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a7e606ed-6861-471d-b110-744c290a822a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Inventories" xlink:type="simple" xlink:href="mdt-20250425.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a5e35b93-1b9d-4897-af3c-fc987508c432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9a06fe69-6ae5-4b7e-a502-c616ba98c20b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a5e35b93-1b9d-4897-af3c-fc987508c432" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9a06fe69-6ae5-4b7e-a502-c616ba98c20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91df4058-034e-499a-88d6-a6f133caefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_37f76bc4-0efe-4a2f-b23e-68eae48efa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91df4058-034e-499a-88d6-a6f133caefe1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_37f76bc4-0efe-4a2f-b23e-68eae48efa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="mdt-20250425.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de6843b6-f0a7-47cd-971e-07d0279d81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b4d51132-abc1-4cd3-8bac-8a4d1936fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de6843b6-f0a7-47cd-971e-07d0279d81ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b4d51132-abc1-4cd3-8bac-8a4d1936fc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="mdt-20250425.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1ed2bac4-0914-47c8-a734-5a0ca8586eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_829db513-61b9-4f75-a1d5-c49713cb0306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1ed2bac4-0914-47c8-a734-5a0ca8586eae" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_829db513-61b9-4f75-a1d5-c49713cb0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlans" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlans"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a797f71d-3e0b-4177-9d03-7c77796db040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5ce5e4a4-8521-4182-a2c6-d1fd087af148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a797f71d-3e0b-4177-9d03-7c77796db040" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5ce5e4a4-8521-4182-a2c6-d1fd087af148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b9a50d8-804d-4037-85df-7aeffc1ab22d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c11a669e-4d6c-4760-941e-2c4eb222ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b9a50d8-804d-4037-85df-7aeffc1ab22d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c11a669e-4d6c-4760-941e-2c4eb222ccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c982abe1-1d33-4909-bc5e-0b636a76d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_94243c7f-1c17-41d3-9c3f-013805f3d686" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c982abe1-1d33-4909-bc5e-0b636a76d19e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_94243c7f-1c17-41d3-9c3f-013805f3d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlans" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4cb29c19-0e08-4746-8ce4-f3776eda45fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_752ee32b-5024-4285-b7d1-d310b061e1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4cb29c19-0e08-4746-8ce4-f3776eda45fb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_752ee32b-5024-4285-b7d1-d310b061e1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/Leases" xlink:type="simple" xlink:href="mdt-20250425.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ada13901-4507-4540-a0f8-bf61a0dbf64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6656a32e-43ef-4df2-8b9f-309330610ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ada13901-4507-4540-a0f8-bf61a0dbf64f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6656a32e-43ef-4df2-8b9f-309330610ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="mdt-20250425.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6fac08b5-8568-4f96-a9bc-f562cb7e80b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2decbdfa-b850-42cd-821a-26da38ab542e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6fac08b5-8568-4f96-a9bc-f562cb7e80b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2decbdfa-b850-42cd-821a-26da38ab542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mdt-20250425.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0115d9bf-0477-4979-b1cc-4652fcec38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_5cbcc66c-1a97-40ce-8574-403e6f63d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0115d9bf-0477-4979-b1cc-4652fcec38d6" xlink:to="loc_us-gaap_LossContingencyDisclosures_5cbcc66c-1a97-40ce-8574-403e6f63d8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cc17504c-c9fa-4f97-b0d5-8d9f250761bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2d481859-11c2-4f9a-b3f4-72add3a873ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cc17504c-c9fa-4f97-b0d5-8d9f250761bb" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2d481859-11c2-4f9a-b3f4-72add3a873ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mdt-20250425.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_857b1b47-ff02-4d2a-9348-32bce18cda7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8fd89d12-59fe-4441-880e-7deb6c06b375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_857b1b47-ff02-4d2a-9348-32bce18cda7c" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_8fd89d12-59fe-4441-880e-7deb6c06b375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="mdt-20250425.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_10fa4d91-8ac1-4696-9aeb-dfe204a47062" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_441af248-ace5-4fd4-87ab-8126f17168cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_10fa4d91-8ac1-4696-9aeb-dfe204a47062" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_441af248-ace5-4fd4-87ab-8126f17168cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mdt-20250425.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_18b78a09-3d5b-433e-bb16-b92455cfd528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_18b78a09-3d5b-433e-bb16-b92455cfd528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9f76c9e7-fb84-4ae6-8a82-6e13ec971ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9f76c9e7-fb84-4ae6-8a82-6e13ec971ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9d39ad30-46c8-4c3d-a7f2-d8280f9291a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_UseOfEstimates_9d39ad30-46c8-4c3d-a7f2-d8280f9291a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_7f7e6d9e-fa58-4123-bb79-e1e67ac651c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_FiscalPeriod_7f7e6d9e-fa58-4123-bb79-e1e67ac651c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4758fad7-4d72-427c-a53d-538e6aa673a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4758fad7-4d72-427c-a53d-538e6aa673a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1eb47167-a529-495d-8e55-e7ff99fe19fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1eb47167-a529-495d-8e55-e7ff99fe19fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6b0a4ac3-cc05-40b3-bb81-b74f4054a331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6b0a4ac3-cc05-40b3-bb81-b74f4054a331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6b8cacd4-981d-4805-816d-848d6c79d349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6b8cacd4-981d-4805-816d-848d6c79d349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1f708c84-b311-4d90-9e92-91eda757b90f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1f708c84-b311-4d90-9e92-91eda757b90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_83a9521a-1240-4736-b55d-3f8a74c3dece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_83a9521a-1240-4736-b55d-3f8a74c3dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1f259328-3d4c-4534-afed-bfe61d40626d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1f259328-3d4c-4534-afed-bfe61d40626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_652a1bbd-7ad0-4b99-8209-b1ec26d460ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_652a1bbd-7ad0-4b99-8209-b1ec26d460ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ContingentConsiderationPolicyTextBlock_dec982ec-2d9b-4bea-838a-7de60a4ac355" xlink:href="mdt-20250425.xsd#mdt_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_mdt_ContingentConsiderationPolicyTextBlock_dec982ec-2d9b-4bea-838a-7de60a4ac355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_07a10207-cabd-4e77-912c-05a5d78a49a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_07a10207-cabd-4e77-912c-05a5d78a49a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_8dfab3c8-a9c9-4a19-a46a-348b29d01a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_8dfab3c8-a9c9-4a19-a46a-348b29d01a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_da0a874e-0d66-4080-ab25-8d155b9f8113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_da0a874e-0d66-4080-ab25-8d155b9f8113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_97ec7e7d-2748-41f9-8dde-a495ecc14db8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_97ec7e7d-2748-41f9-8dde-a495ecc14db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9a8c8239-1d5f-411c-a382-5228085036cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9a8c8239-1d5f-411c-a382-5228085036cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b4894068-e438-4ada-9891-b291887ed2da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b4894068-e438-4ada-9891-b291887ed2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_79631430-8dfd-42bf-99ec-9bb678f5088b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_79631430-8dfd-42bf-99ec-9bb678f5088b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_830932ed-fc44-42a3-8667-ac587de4289e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_830932ed-fc44-42a3-8667-ac587de4289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_b2c7c579-b3f4-46c6-a585-e4ec4ac8779e" xlink:href="mdt-20250425.xsd#mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock_b2c7c579-b3f4-46c6-a585-e4ec4ac8779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_0c5b496d-9f27-4b7e-97a7-d4bca07987c3" xlink:href="mdt-20250425.xsd#mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock_0c5b496d-9f27-4b7e-97a7-d4bca07987c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_96bb0861-0ee5-4291-a8ec-99e77478eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_96bb0861-0ee5-4291-a8ec-99e77478eb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e8fd8f2c-718c-4308-8f4e-92ea9b092a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e8fd8f2c-718c-4308-8f4e-92ea9b092a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d2dd2d35-c087-4aee-8acf-154e46bf3445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d2dd2d35-c087-4aee-8acf-154e46bf3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_77f8ad39-df51-4c98-ac2a-7eed4033dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbacc252-331f-46ce-b740-0259576ab5cb" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_77f8ad39-df51-4c98-ac2a-7eed4033dab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e718312-9d5e-4408-9c85-78e73ba7bdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f2340a72-4515-41f8-ae36-d39a2ed27c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e718312-9d5e-4408-9c85-78e73ba7bdc3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f2340a72-4515-41f8-ae36-d39a2ed27c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_34db895b-267f-44d0-b7ec-936c833ca59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_587714ab-bd10-4f42-9609-dbc784377c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_34db895b-267f-44d0-b7ec-936c833ca59f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_587714ab-bd10-4f42-9609-dbc784377c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_385191a5-1e14-46f0-97dc-a19c8733fd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_34db895b-267f-44d0-b7ec-936c833ca59f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_385191a5-1e14-46f0-97dc-a19c8733fd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_364924f9-af51-42b3-8f25-96785a2d7245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_88c89dca-a0bc-47ce-a573-58707559de27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_364924f9-af51-42b3-8f25-96785a2d7245" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_88c89dca-a0bc-47ce-a573-58707559de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9ded83a2-e771-470a-ba27-72448cb6231a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9ded83a2-e771-470a-ba27-72448cb6231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5b2b6247-6995-4cd0-bc97-7b3f5025a306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5b2b6247-6995-4cd0-bc97-7b3f5025a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_c0854a59-3729-4f67-bb20-ac2485ba6d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_c0854a59-3729-4f67-bb20-ac2485ba6d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82e5fe17-8cd9-4be8-b36a-a5884bdcef24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82e5fe17-8cd9-4be8-b36a-a5884bdcef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_e1c9081e-9a02-403f-93a7-7cb303a9b9dc" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock_e1c9081e-9a02-403f-93a7-7cb303a9b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_098906b4-d065-4ef3-879d-75dd78a78c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_098906b4-d065-4ef3-879d-75dd78a78c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfInvestmentsTableTextBlock_877d7552-a59c-4662-bfb5-0cba72fae30b" xlink:href="mdt-20250425.xsd#mdt_ScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c5ad627-108a-494d-b87e-8383d622ff86" xlink:to="loc_mdt_ScheduleOfInvestmentsTableTextBlock_877d7552-a59c-4662-bfb5-0cba72fae30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_751b5fbe-5e58-4b88-af1c-a5d4fb53ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_ceebe590-caad-467d-83b4-1a2e5c5c2fac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_751b5fbe-5e58-4b88-af1c-a5d4fb53ce62" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_ceebe590-caad-467d-83b4-1a2e5c5c2fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_714c99f2-0094-4afb-bb88-2c2fc90881a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_751b5fbe-5e58-4b88-af1c-a5d4fb53ce62" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_714c99f2-0094-4afb-bb88-2c2fc90881a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4b483f58-c915-45b7-8093-6c4a07b8a715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_751b5fbe-5e58-4b88-af1c-a5d4fb53ce62" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4b483f58-c915-45b7-8093-6c4a07b8a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock_b1441c72-14cd-41ca-8eb2-386a294b9b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_751b5fbe-5e58-4b88-af1c-a5d4fb53ce62" xlink:to="loc_us-gaap_SupplierFinanceProgramTableTextBlock_b1441c72-14cd-41ca-8eb2-386a294b9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c4e18568-9188-4280-93e4-d8857cac124f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c4e18568-9188-4280-93e4-d8857cac124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1289cdbf-1a32-45bc-a973-5bf2bd50c3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1289cdbf-1a32-45bc-a973-5bf2bd50c3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bf03739e-f49c-48d0-8171-3fcaff2a36d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bf03739e-f49c-48d0-8171-3fcaff2a36d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTableTextBlock_f6c2362e-b392-47ea-9c7c-9fa5b8d8ddab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:to="loc_us-gaap_OffsettingAssetsTableTextBlock_f6c2362e-b392-47ea-9c7c-9fa5b8d8ddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingLiabilitiesTableTextBlock_1c52993e-007c-4ba6-8616-e5bb7122b845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8d294426-e37d-47f2-90ba-2645389b8cf2" xlink:to="loc_us-gaap_OffsettingLiabilitiesTableTextBlock_1c52993e-007c-4ba6-8616-e5bb7122b845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e14f23f4-c8b5-4ed1-ae8f-5c8b01f72d36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4b9ceb42-a1dc-4da7-9b63-e0b9817c1727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e14f23f4-c8b5-4ed1-ae8f-5c8b01f72d36" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4b9ceb42-a1dc-4da7-9b63-e0b9817c1727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6e7687f3-89d6-437b-a7fb-48d91b652147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_87f6e508-ef0e-478b-8f40-f47aa979ab14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6e7687f3-89d6-437b-a7fb-48d91b652147" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_87f6e508-ef0e-478b-8f40-f47aa979ab14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e09e641a-e8c0-4267-a5b3-0905a539dc28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6e7687f3-89d6-437b-a7fb-48d91b652147" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e09e641a-e8c0-4267-a5b3-0905a539dc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_95d5f1ca-1316-4754-aecb-e2e60d592277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6e7687f3-89d6-437b-a7fb-48d91b652147" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_95d5f1ca-1316-4754-aecb-e2e60d592277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6cb0ad7f-1a74-43de-909f-7c50b6c99811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6e7687f3-89d6-437b-a7fb-48d91b652147" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6cb0ad7f-1a74-43de-909f-7c50b6c99811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a0dd7ecd-827a-4c5c-b28c-bda4c0a5cb36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f8db23bf-6117-4a82-9531-4f9aada23612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a0dd7ecd-827a-4c5c-b28c-bda4c0a5cb36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f8db23bf-6117-4a82-9531-4f9aada23612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d2daa243-f609-46a3-b9e8-505dc5fbf0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d2daa243-f609-46a3-b9e8-505dc5fbf0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_58b9b78f-182f-455f-b679-ee2e13321e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_58b9b78f-182f-455f-b679-ee2e13321e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34a78fef-5285-4710-ab11-4b2371af730b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34a78fef-5285-4710-ab11-4b2371af730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_839f44ef-9d6e-4127-adbe-69baf9511b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_839f44ef-9d6e-4127-adbe-69baf9511b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_7c30f61e-fd73-42bf-840b-4958e1fd3f10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cb94f5b-3df7-41b0-88bc-ded0aefdb5da" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_7c30f61e-fd73-42bf-840b-4958e1fd3f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7dd52855-d8a1-4b58-b351-065d32f31d47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7dd52855-d8a1-4b58-b351-065d32f31d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_60dc4d92-5361-4a3e-a672-dd1fb16f5130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_60dc4d92-5361-4a3e-a672-dd1fb16f5130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4b9b94df-9673-499b-8090-5ae4daaf5749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4b9b94df-9673-499b-8090-5ae4daaf5749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_314f5533-3a1c-4cf8-83c5-65b67fe7fe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_314f5533-3a1c-4cf8-83c5-65b67fe7fe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_573dc2f7-09ac-4a82-99ef-200949f30930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_573dc2f7-09ac-4a82-99ef-200949f30930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_ee30200f-9aa7-41ca-8b4b-65952d52b19f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13145aad-b7b3-4d98-bf35-33ce13af3ad6" xlink:to="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_ee30200f-9aa7-41ca-8b4b-65952d52b19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9b0be865-d0be-44c9-b4de-30b14ba34154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1fe04774-4b40-4858-8e3e-bb1fbd2d7774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b0be865-d0be-44c9-b4de-30b14ba34154" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1fe04774-4b40-4858-8e3e-bb1fbd2d7774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_ce7a5248-417b-4fdf-9785-d574b601e550" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_ce7a5248-417b-4fdf-9785-d574b601e550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_743db9f2-7b13-48be-8bc9-54863901d957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_743db9f2-7b13-48be-8bc9-54863901d957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_2db0bbbf-2435-4607-b56e-17786b09c732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_2db0bbbf-2435-4607-b56e-17786b09c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_5e3369bc-194b-4561-afc5-8532010a1a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_5e3369bc-194b-4561-afc5-8532010a1a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_f16b1f26-cf54-4bb1-9c0c-ed5691d45fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_f16b1f26-cf54-4bb1-9c0c-ed5691d45fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_c39443d2-99fa-46c4-926d-4cb8a04ecba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_c39443d2-99fa-46c4-926d-4cb8a04ecba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_1b8269b3-d039-46b8-84db-9c825e26780e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_1b8269b3-d039-46b8-84db-9c825e26780e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_333934cd-446d-43e4-9afc-8d3eadb9c387" xlink:href="mdt-20250425.xsd#mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock_333934cd-446d-43e4-9afc-8d3eadb9c387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_0d50f6fd-45f2-438a-92d4-42354d292b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f562ced0-5145-4be2-b737-44575f29b924" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_0d50f6fd-45f2-438a-92d4-42354d292b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_da5fc1d7-f362-4aa5-9af3-6acae9ee5c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_9128210d-f447-4f19-85b5-171f341399d5" xlink:href="mdt-20250425.xsd#mdt_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da5fc1d7-f362-4aa5-9af3-6acae9ee5c0f" xlink:to="loc_mdt_AssetsAndLiabilitiesLesseeTableTextBlock_9128210d-f447-4f19-85b5-171f341399d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_0c78ee77-a462-4241-b077-1d5792045636" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da5fc1d7-f362-4aa5-9af3-6acae9ee5c0f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_0c78ee77-a462-4241-b077-1d5792045636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9bf91c96-d001-45c5-b873-fe4013c45282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da5fc1d7-f362-4aa5-9af3-6acae9ee5c0f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9bf91c96-d001-45c5-b873-fe4013c45282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a2aba88f-cdcc-4158-8fbb-9e72c94eb637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7ca35269-f494-4704-8e70-3e739053830c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a2aba88f-cdcc-4158-8fbb-9e72c94eb637" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7ca35269-f494-4704-8e70-3e739053830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2f400dfa-0630-44c2-93e2-a85b0ac8da90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_576ee19f-5cdc-4f6b-82c4-a4ae727c8329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2f400dfa-0630-44c2-93e2-a85b0ac8da90" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_576ee19f-5cdc-4f6b-82c4-a4ae727c8329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_b905247a-f72d-4971-b507-1919b297bc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2f400dfa-0630-44c2-93e2-a85b0ac8da90" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_b905247a-f72d-4971-b507-1919b297bc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_7062d62b-7abd-4dcb-aae5-ee66ca0bc848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2f400dfa-0630-44c2-93e2-a85b0ac8da90" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_7062d62b-7abd-4dcb-aae5-ee66ca0bc848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5081177b-b697-4fe6-870a-c33e0d979ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5081177b-b697-4fe6-870a-c33e0d979ff9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:to="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a6dfc470-4f20-47d8-9c1e-8fbb64012c32" xlink:to="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_27e32077-a61d-4a98-b1ff-049c1036a26f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:to="loc_srt_MinimumMember_27e32077-a61d-4a98-b1ff-049c1036a26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfbb788a-d83e-43ee-baa5-187c227c9bc5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85286966-a477-469a-9aad-aeaf44a1ec31" xlink:to="loc_srt_MaximumMember_bfbb788a-d83e-43ee-baa5-187c227c9bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:to="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_76306dbd-74d0-4d91-b342-571c9b511f8e" xlink:to="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_76aadd86-52de-41d2-88db-b55afab0fe41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_36143c17-52f1-49dc-bc48-c22199ad696f" xlink:to="loc_us-gaap_ShippingAndHandlingMember_76aadd86-52de-41d2-88db-b55afab0fe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fd9abe2e-ab01-48f1-8119-30369641b1cf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2bd107da-3eef-42c2-b02c-eb252a8163c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_51cb8eb9-9603-4688-b7fc-5e1b00290a4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2bd107da-3eef-42c2-b02c-eb252a8163c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_69fba0fc-f640-4e4f-b1c6-c0154574e80b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2b8b8298-6775-4608-8eb3-b46200c82de7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba19c6ae-72c7-4153-869b-413a445ada29" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2b8b8298-6775-4608-8eb3-b46200c82de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed803ee8-0614-4e08-bd6f-d0a3f3124abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed803ee8-0614-4e08-bd6f-d0a3f3124abe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c334f13-81b5-481c-bafb-2c1fb2e5dec9" xlink:to="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:href="mdt-20250425.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:to="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_982535ea-b9ee-4f98-a3a6-52ba865de119" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_CardiovascularMember_982535ea-b9ee-4f98-a3a6-52ba865de119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_29f00d38-70ff-4a81-8b40-0f78886c2a52" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_NeuroscienceGroupMember_29f00d38-70ff-4a81-8b40-0f78886c2a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_8bc4dc54-c933-40b2-a0a7-b8a58f2aabd2" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_MedicalSurgicalMember_8bc4dc54-c933-40b2-a0a7-b8a58f2aabd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_3fd164a1-a031-49ee-aced-23dfd6afb211" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_52167c46-8af5-4bd9-a657-f04cffb1cd58" xlink:to="loc_mdt_DiabetesGroupMember_3fd164a1-a031-49ee-aced-23dfd6afb211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_ec304322-9cb9-4b98-b045-6a80e317aae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e804a546-787a-4d2c-9c51-e60fd97e290e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_ec304322-9cb9-4b98-b045-6a80e317aae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_fc542e30-3ffd-438d-83f4-969c156db872" xlink:to="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_1f1be70a-6808-424c-9427-feb9bb03d4e1" xlink:href="mdt-20250425.xsd#mdt_CardiacRhythmandHeartFailureDivisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CardiacRhythmandHeartFailureDivisionMember_1f1be70a-6808-424c-9427-feb9bb03d4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StructuralHeartAndAorticDivisionMember_6bb4987c-c4bb-4110-ba30-d37e64ba34fd" xlink:href="mdt-20250425.xsd#mdt_StructuralHeartAndAorticDivisionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_StructuralHeartAndAorticDivisionMember_6bb4987c-c4bb-4110-ba30-d37e64ba34fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_ee1d3a6a-deac-4fac-9e2a-58158302f32a" xlink:href="mdt-20250425.xsd#mdt_CoronaryAndPeripheralVascularDivisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CoronaryAndPeripheralVascularDivisionMember_ee1d3a6a-deac-4fac-9e2a-58158302f32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_551ede04-6736-453c-afb7-20ee4fce0203" xlink:href="mdt-20250425.xsd#mdt_CranialAndSpinalTechnologiesDivisionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_CranialAndSpinalTechnologiesDivisionMember_551ede04-6736-453c-afb7-20ee4fce0203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SpecialtyTherapiesDivisionMember_a6f7f7e9-4903-43cb-b8a8-2d13bbea1522" xlink:href="mdt-20250425.xsd#mdt_SpecialtyTherapiesDivisionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_SpecialtyTherapiesDivisionMember_a6f7f7e9-4903-43cb-b8a8-2d13bbea1522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuromodulationDivisionMember_ce6ed77a-60b2-4099-afb5-a836ce4a3a7f" xlink:href="mdt-20250425.xsd#mdt_NeuromodulationDivisionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_NeuromodulationDivisionMember_ce6ed77a-60b2-4099-afb5-a836ce4a3a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SurgicalInnovationsDivisionMember_60df96f8-2f35-4af4-85ae-fe2026612e9c" xlink:href="mdt-20250425.xsd#mdt_SurgicalInnovationsDivisionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_SurgicalInnovationsDivisionMember_60df96f8-2f35-4af4-85ae-fe2026612e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcuteCareMonitoringMember_ae75933b-f625-4ae5-a77a-650534856a50" xlink:href="mdt-20250425.xsd#mdt_AcuteCareMonitoringMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_c3e23e56-0820-49b8-889b-ceba4311a8ea" xlink:to="loc_mdt_AcuteCareMonitoringMember_ae75933b-f625-4ae5-a77a-650534856a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_6af8f5f9-4f14-4ea5-9f8c-cc6f20736cd1" xlink:to="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_1253767c-1c45-4680-b0f1-d9e28af6ae68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationEliminationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:to="loc_srt_ConsolidationEliminationsMember_1253767c-1c45-4680-b0f1-d9e28af6ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d80f3a49-45cd-4ee2-9919-4d25a0882e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ecc8b725-a8da-4e14-a77f-fb12d0e3d36e" xlink:to="loc_us-gaap_OperatingSegmentsMember_d80f3a49-45cd-4ee2-9919-4d25a0882e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_08fe805b-a909-441e-b0ac-5c2f432cdff5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11d281dd-8787-47d9-b5f6-2e2f0cbb0968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79e02a71-6448-4bf3-b021-efa9b7630a72" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11d281dd-8787-47d9-b5f6-2e2f0cbb0968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4de363d7-50f7-493a-b159-f4ed5323e0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4de363d7-50f7-493a-b159-f4ed5323e0d1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_93876456-5a37-4990-a13c-632e0c5e2444" xlink:to="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:href="mdt-20250425.xsd#mdt_TotalReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:to="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_5b1e368c-a171-4cbe-8ee6-7b67e2a105d6" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_CardiovascularMember_5b1e368c-a171-4cbe-8ee6-7b67e2a105d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_59f4b0d1-58ff-4af3-bc8f-d37d6fe92f5d" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_NeuroscienceGroupMember_59f4b0d1-58ff-4af3-bc8f-d37d6fe92f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_4ee5cbfe-fb02-48d8-a32a-2545dc5ea248" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_MedicalSurgicalMember_4ee5cbfe-fb02-48d8-a32a-2545dc5ea248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_2a61c573-cfcb-46c0-9efb-b1274909f126" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalReportableSegmentsMember_c08955c6-b7cb-4ded-9d3b-d3e946c275ba" xlink:to="loc_mdt_DiabetesGroupMember_2a61c573-cfcb-46c0-9efb-b1274909f126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_19a16e2e-5883-4046-928c-6be8515b7080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_138f5a87-2022-44f1-a040-1907bbc1a87e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_19a16e2e-5883-4046-928c-6be8515b7080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_39744c67-ca0c-4d12-a023-d96c529278a6" xlink:to="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a00dc10a-4b16-4d38-81a8-e3299e9d38c2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:to="loc_country_US_a00dc10a-4b16-4d38-81a8-e3299e9d38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InternationalMember_9675a08f-cbfb-4297-aa93-47017139f69b" xlink:href="mdt-20250425.xsd#mdt_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f099fd1-97b6-48bd-bcf6-75da092ff3f9" xlink:to="loc_mdt_InternationalMember_9675a08f-cbfb-4297-aa93-47017139f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_56e69ec4-abb8-4028-91e3-bae23f1fd051" xlink:to="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0898b8f5-9cff-4472-a743-73dfc14ae94c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:to="loc_us-gaap_OperatingSegmentsMember_0898b8f5-9cff-4472-a743-73dfc14ae94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_0fd10071-25b3-4fe7-b9e6-dba0d60cdd92" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fc81c3cd-726c-425f-85ab-13d1d199ee21" xlink:to="loc_srt_ConsolidationEliminationsMember_0fd10071-25b3-4fe7-b9e6-dba0d60cdd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b31665f2-678e-46d5-b3a0-69aa9c23d7a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc451ef1-6dc1-40a1-a667-1959c02e85e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e7bd1fc0-4c7f-4160-bc19-f632ba87a412" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc451ef1-6dc1-40a1-a667-1959c02e85e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d5b13fb-faed-44c5-a350-9eea4cbdb93b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d5b13fb-faed-44c5-a350-9eea4cbdb93b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a3a7d0ae-0c10-44a9-9d07-4169c05198b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_d74e9860-330f-4037-9266-5088dd1bc037" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_mdt_OtherAccruedExpensesMember_d74e9860-330f-4037-9266-5088dd1bc037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_14140ed5-55bb-4907-affe-9adc602fdd30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_us-gaap_AccountsReceivableMember_14140ed5-55bb-4907-affe-9adc602fdd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_e48c4b57-f2e5-4ad0-9121-122f3e084bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be7133b2-12f8-4add-a186-083e7f7ee83a" xlink:to="loc_us-gaap_OtherLiabilitiesMember_e48c4b57-f2e5-4ad0-9121-122f3e084bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2625db91-c2b5-40b3-9c7a-157572e8c785" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_003b0cfd-cf35-4fab-ba03-c8f0e24bc08a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_003b0cfd-cf35-4fab-ba03-c8f0e24bc08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1afb5a4f-53c5-44c2-8769-735d573d521b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1afb5a4f-53c5-44c2-8769-735d573d521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6c040438-e00f-430e-85b0-45dff33f78a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6c040438-e00f-430e-85b0-45dff33f78a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d87aa77b-0a8b-4115-b1d3-a284c6c0a4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d87aa77b-0a8b-4115-b1d3-a284c6c0a4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_efd7acea-30ef-48d1-b49d-9a9f911ceb78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a82369cc-a672-4cca-a294-7dfcb29f25a5" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_efd7acea-30ef-48d1-b49d-9a9f911ceb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1684f633-d0a6-40ee-8b38-f88d66cd30b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1684f633-d0a6-40ee-8b38-f88d66cd30b1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9283ab22-2161-4d4e-95dd-d863a7b7705c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_744bb4d8-c85a-4c31-8a0b-cf34de31dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa9baf95-ee11-4cf5-922a-a8c4f7397edf" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_744bb4d8-c85a-4c31-8a0b-cf34de31dc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9c559070-5b61-4a61-a421-744525f0cd9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eaa5fe6-cd54-4240-a22f-615f0ea3fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eaa5fe6-cd54-4240-a22f-615f0ea3fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bb5f9b24-4dda-403a-842c-b6f553bdcfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15a3bdf3-5fa0-4ed2-bcf9-dfd6d6211dc6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bb5f9b24-4dda-403a-842c-b6f553bdcfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_437dbfd5-f21c-472b-9561-36b37bad4eb5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ede6d19a-c7aa-430c-bd41-eee4a97da8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ede6d19a-c7aa-430c-bd41-eee4a97da8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1288af2c-cf80-447c-b174-7095b2c37ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1288af2c-cf80-447c-b174-7095b2c37ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_29374653-82e6-475c-954b-619a8bdc6614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_29374653-82e6-475c-954b-619a8bdc6614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db829829-78bc-4bb2-aa6f-0b374f7f6bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_Goodwill_db829829-78bc-4bb2-aa6f-0b374f7f6bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_e7c00452-8f91-4183-bcac-d274a992d123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_e7c00452-8f91-4183-bcac-d274a992d123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86a98154-973d-49e6-9524-89ad727860a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_86a98154-973d-49e6-9524-89ad727860a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ee18a9fe-ae57-4189-9233-9cb4723e2468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ee18a9fe-ae57-4189-9233-9cb4723e2468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d70bf2f-e255-43fa-bea8-f5bc6d824ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0d70bf2f-e255-43fa-bea8-f5bc6d824ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_07a8c332-0380-4a1b-96c0-178cd9cfaf00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_07a8c332-0380-4a1b-96c0-178cd9cfaf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillNotAllocatedAmount_3fad4f88-20ad-4b86-a322-6c31541ba78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillNotAllocatedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34c701d1-eaa2-44c7-91ff-32435bbfe45a" xlink:to="loc_us-gaap_GoodwillNotAllocatedAmount_3fad4f88-20ad-4b86-a322-6c31541ba78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c9ea889-49ba-4edb-8e60-1d71642772d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c9ea889-49ba-4edb-8e60-1d71642772d7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5dc280a2-5302-43aa-b154-84e79945a590" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_db2d22d3-cc3e-4491-bd7d-4acacab9bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7942ea74-b4d0-44df-a182-e7d897273f33" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_db2d22d3-cc3e-4491-bd7d-4acacab9bbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_531e8415-0929-4d23-b23f-2cef985a7603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_98ab89f7-d003-470c-9ce1-940e99fc2150" xlink:href="mdt-20250425.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:to="loc_mdt_VentilatorProductLineExitMember_98ab89f7-d003-470c-9ce1-940e99fc2150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareSolutionsMember_9c66c479-7e14-4d46-9da9-b989758aaed8" xlink:href="mdt-20250425.xsd#mdt_RenalCareSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b49b9814-e574-4e4f-853a-02f9b1a65d87" xlink:to="loc_mdt_RenalCareSolutionsMember_9c66c479-7e14-4d46-9da9-b989758aaed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_20783efd-8dff-4d22-af75-58c02f3fb10a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_cef4019a-8f5d-4d94-8a4b-cf1a635f5a76" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f0295e8f-53ca-44b7-802a-d426006f88e0" xlink:to="loc_mdt_MozarcMember_cef4019a-8f5d-4d94-8a4b-cf1a635f5a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3095798d-6720-40af-8087-44dae0bb157c" xlink:to="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_ff41ffe7-b1c2-4b2c-a22a-1b78a0b7f2b6" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_bc66adb8-a5a5-4801-a865-b42546645f92" xlink:to="loc_mdt_MozarcMember_ff41ffe7-b1c2-4b2c-a22a-1b78a0b7f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87c28aa8-7119-4131-99c3-7212e7ce8412" xlink:to="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed9289bd-c1ab-4371-9659-d2b7645787ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e4e2a10-6ab8-4b2a-8b58-264189a72207" xlink:to="loc_srt_MaximumMember_ed9289bd-c1ab-4371-9659-d2b7645787ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0025614a-64c1-4f46-a9a8-b70cf52239ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7aa49c3-1065-43ad-bce3-4626f35154d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c7b6ca74-2552-4ad4-b462-e60707dc88e1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_d7aa49c3-1065-43ad-bce3-4626f35154d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_748bf261-3627-4182-aff1-5b6068e2183d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_14350522-c290-41e7-9ccd-6a774ddbbd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_BusinessExitCosts1_14350522-c290-41e7-9ccd-6a774ddbbd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_f847a525-5117-487c-8706-b506e7bf7322" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet_f847a525-5117-487c-8706-b506e7bf7322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c87b243e-33de-4a80-b0b4-554e2eebf514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c87b243e-33de-4a80-b0b4-554e2eebf514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_f66d6832-2212-42d5-9236-03df7f192982" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments_f66d6832-2212-42d5-9236-03df7f192982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8c79c252-c4c8-4b95-9be8-1d6eefeb402f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8c79c252-c4c8-4b95-9be8-1d6eefeb402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3a325c1c-5af9-4cbb-b228-ecbbb0dc78be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_InventoryWriteDown_3a325c1c-5af9-4cbb-b228-ecbbb0dc78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_876bcd73-837d-470b-8445-001c35573647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_876bcd73-837d-470b-8445-001c35573647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a9be2af6-b290-43a8-adb8-6f1b04262dd0" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a9be2af6-b290-43a8-adb8-6f1b04262dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_16d12c06-0ee8-4395-956c-ba967d3d5506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_16d12c06-0ee8-4395-956c-ba967d3d5506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_12ae51b4-1f40-42f2-835c-8b133deb8794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_12ae51b4-1f40-42f2-835c-8b133deb8794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b31b459c-a74d-45e8-9881-e69f873088a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_MinorityInterest_b31b459c-a74d-45e8-9881-e69f873088a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5993bdec-ab29-4682-aa34-b3977b526c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_16f5208a-bf12-4007-975d-ec3b54e4dc36" xlink:to="loc_us-gaap_AssetImpairmentCharges_5993bdec-ab29-4682-aa34-b3977b526c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6f99f5f6-1399-4a5b-ae4c-8be0b479cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6f99f5f6-1399-4a5b-ae4c-8be0b479cf46" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fc552c4-5b4a-487f-9e21-2914f0343b34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_696ecf1b-88ad-4a96-82dc-0f063db211fe" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:to="loc_mdt_OtherAccruedExpensesMember_696ecf1b-88ad-4a96-82dc-0f063db211fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_fc020682-498e-4ab8-b2c6-b67574a14930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b82cdc4a-9ed6-44d7-9f12-58d6c8f9894b" xlink:to="loc_us-gaap_OtherLiabilitiesMember_fc020682-498e-4ab8-b2c6-b67574a14930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4ab366f-fd18-43ee-99f7-e309168d66cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d0400cca-e659-41fb-9375-239aeace7fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34880c8e-8565-403d-bfbd-7ead5136f45c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d0400cca-e659-41fb-9375-239aeace7fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a1eb8534-5e04-4342-81dd-7f2256ba882e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b0087e6a-e4fe-4b25-a5e0-b43843062acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6a8d0346-f29a-484c-84c5-3d58a3a0facb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b0087e6a-e4fe-4b25-a5e0-b43843062acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_71234605-c4b0-4bbe-80e7-39d18e8d18f1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_08b4d82d-fe7f-457d-8f49-16261d7cb6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65ec5b00-df78-4617-843d-e93aa64f08b6" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_08b4d82d-fe7f-457d-8f49-16261d7cb6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38aff65e-a35a-41d6-8589-bd548dfb0446" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ef53efa6-a5ba-4e6e-ba82-12a2567c035d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ef53efa6-a5ba-4e6e-ba82-12a2567c035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_f4aff625-6ce3-4cef-8bca-7dc910a2614f" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_f4aff625-6ce3-4cef-8bca-7dc910a2614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3d82543b-2280-407a-ade3-937924cd9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3d82543b-2280-407a-ade3-937924cd9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_124e1890-7254-4b58-9026-6555bc180a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_DeferredIncome_124e1890-7254-4b58-9026-6555bc180a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_09788039-6d8a-4078-a7e3-f9661fa36eda" xlink:href="mdt-20250425.xsd#mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_09788039-6d8a-4078-a7e3-f9661fa36eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b7c4dfbe-1c93-4618-b843-35918c90b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_66887dcb-caf9-40bf-b986-ea82a5c77389" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b7c4dfbe-1c93-4618-b843-35918c90b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_387a56d4-9169-48ea-8986-3ea2bb28c761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_387a56d4-9169-48ea-8986-3ea2bb28c761" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66a3af55-acc0-40c2-9b81-2c8aad93d834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_66a3af55-acc0-40c2-9b81-2c8aad93d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionPriceContingentConsideration_50ce7bba-2d64-46dc-aabe-ed91d6809e3a" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionPriceContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:to="loc_mdt_BusinessAcquisitionPriceContingentConsideration_50ce7bba-2d64-46dc-aabe-ed91d6809e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_7909cfaf-4a93-4af2-a914-5b30d67d406c" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment_7909cfaf-4a93-4af2-a914-5b30d67d406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2370baa7-579d-4a25-91f6-bb0e13850005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2370baa7-579d-4a25-91f6-bb0e13850005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16bec714-4e34-4ce9-9fbd-38e0d07dc325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward_e32258ef-aa30-4c56-a166-21004ee5d9c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16bec714-4e34-4ce9-9fbd-38e0d07dc325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7654540e-c684-4dff-8a22-db62a9b8ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7654540e-c684-4dff-8a22-db62a9b8ff2b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07f63bb3-0811-4c71-8f48-8b5f58e604c5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_873cb304-c7da-47e9-9a25-3cfb0ea92d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_94d7a63c-cea9-47c2-a453-bc3f06d4ca2a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_873cb304-c7da-47e9-9a25-3cfb0ea92d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_03ca058b-9bcc-40a6-9a3b-34ef97f6ff1d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8edca598-3c96-4a5a-81e3-380afe5b8da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a0f1107-dba0-4827-a2b3-1e9662ee9224" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8edca598-3c96-4a5a-81e3-380afe5b8da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_f963a96d-eed3-4cb1-b687-a1871bd220de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RevenueMilestoneMember_68d07cae-f380-4504-b14a-1af46c10845e" xlink:href="mdt-20250425.xsd#mdt_RevenueMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:to="loc_mdt_RevenueMilestoneMember_68d07cae-f380-4504-b14a-1af46c10845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ProductDevelopmentMilestoneMember_a2fdf4b2-617e-45ee-a1a9-95791ce97ace" xlink:href="mdt-20250425.xsd#mdt_ProductDevelopmentMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_680b509f-6349-42c6-afdf-4cdf05e19252" xlink:to="loc_mdt_ProductDevelopmentMilestoneMember_a2fdf4b2-617e-45ee-a1a9-95791ce97ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4caa7305-b610-4d40-8474-d7c560e70923" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_15874dcc-f0e6-408e-9dd6-3d44c3dfd183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6651a870-630e-476f-bcde-e65f6cce850b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_15874dcc-f0e6-408e-9dd6-3d44c3dfd183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_70fb9a3f-2f9f-437f-ad09-e9d0fa820ae9" xlink:to="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_35e12f75-c1eb-4ac5-b402-95688c995729" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_MinimumMember_35e12f75-c1eb-4ac5-b402-95688c995729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74073158-7051-4644-a09d-c601ee9878d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_MaximumMember_74073158-7051-4644-a09d-c601ee9878d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_04d99243-184c-4e82-91eb-8997df435457" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4043512e-5fc7-4c08-a649-206e9794e579" xlink:to="loc_srt_WeightedAverageMember_04d99243-184c-4e82-91eb-8997df435457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e32b4728-3395-49f4-b083-43f7121fe6fd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1bef0898-4c47-4dba-994d-9792c07443d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1bef0898-4c47-4dba-994d-9792c07443d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e19ca3e9-53ad-4e2e-8c17-a7d51e2227ed" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8f8d69d1-28f7-4377-a771-5d4269e6bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_5690c0f7-eb8f-417c-a0f8-20f8b38c8df2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8f8d69d1-28f7-4377-a771-5d4269e6bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0f08a0e6-5a44-48d3-8c5d-44c97abf680d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0f08a0e6-5a44-48d3-8c5d-44c97abf680d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ab4324a-2989-4766-846b-22d24c4bd519" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9909feb1-a40d-4414-9d60-ef6aa7ea0ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97affc79-baad-498e-9baa-bcba37795a83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9909feb1-a40d-4414-9d60-ef6aa7ea0ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8186a3c1-62a1-452f-8427-f09be081b81e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7b0fb1ac-b5b9-45f4-bc18-bf6a538db2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_41872f04-20dd-4349-909d-51b097aaa5de" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7b0fb1ac-b5b9-45f4-bc18-bf6a538db2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_09839fc7-7e3e-4eb2-b5ad-300081095058" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:href="mdt-20250425.xsd#mdt_BusinessAcquisitionContingentConsiderationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8416d9c0-4630-47d9-afcf-0d6834e15bf9" xlink:to="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_89920aca-76c4-4f3d-b34b-354ffe046a10" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_89920aca-76c4-4f3d-b34b-354ffe046a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_da312d9f-adbb-4e8c-a2c8-1a202371a622" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue_da312d9f-adbb-4e8c-a2c8-1a202371a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a213d7ce-3154-447c-b6a9-305b838f8d1d" xlink:href="mdt-20250425.xsd#mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_BusinessAcquisitionContingentConsiderationRollForward_fb09ce22-5edb-4245-8f4c-a593a246bf44" xlink:to="loc_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable_a213d7ce-3154-447c-b6a9-305b838f8d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_20655937-2359-43ec-a3e9-65b0f542e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_20655937-2359-43ec-a3e9-65b0f542e16b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:to="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_2ea61b59-b4e7-4312-8dc3-df371c8efd83" xlink:to="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EnterpriseExcellenceMember_35afd5d7-f2ec-410a-9e56-19034bfe7293" xlink:href="mdt-20250425.xsd#mdt_EnterpriseExcellenceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:to="loc_mdt_EnterpriseExcellenceMember_35afd5d7-f2ec-410a-9e56-19034bfe7293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SimplificationRestructuringProgramMember_3be1c778-41e0-42a1-b96b-75397090c3ea" xlink:href="mdt-20250425.xsd#mdt_SimplificationRestructuringProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e39f8c16-3cad-4b33-8271-f88999fc26f1" xlink:to="loc_mdt_SimplificationRestructuringProgramMember_3be1c778-41e0-42a1-b96b-75397090c3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c964e8f-6c28-4541-91ca-fe5adef4efad" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_4c676dac-d184-4af4-b8bb-f5f9e53b96b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringCosts_4c676dac-d184-4af4-b8bb-f5f9e53b96b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_59bbd055-ce98-4256-aa35-db1d4f6c77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringCharges_59bbd055-ce98-4256-aa35-db1d4f6c77fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d51c6234-6c34-4140-abdf-f1d7aefe0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9db1a6e2-0759-409f-b28a-1bf028410a0c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d51c6234-6c34-4140-abdf-f1d7aefe0ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesClassificationofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_221e81e6-dbcd-4f13-ad14-dfac82758d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_221e81e6-dbcd-4f13-ad14-dfac82758d94" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5324fea6-cc1d-419e-a2e5-c57a5f5bb7f2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_499eb59d-2ba3-4dc1-aebf-457b99fdae64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:to="loc_us-gaap_CostOfSalesMember_499eb59d-2ba3-4dc1-aebf-457b99fdae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f81330d0-b89b-4556-b370-8cd3fb829035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1667b2a2-54a3-4508-bb90-d4342278fc6c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f81330d0-b89b-4556-b370-8cd3fb829035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a944a813-57dc-4d5c-a830-c8d7ea16933d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_085670fc-eca5-404e-9020-3260efe6b575" xlink:href="mdt-20250425.xsd#mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4094fc05-ade2-4687-b4c2-d91c2fbe5892" xlink:to="loc_mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember_085670fc-eca5-404e-9020-3260efe6b575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b348be49-85b1-4e1b-ba45-11385d5eb5c0" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9e142ac9-6c4e-4977-8a56-ad0984dd1525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringCharges_9e142ac9-6c4e-4977-8a56-ad0984dd1525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_3a5734e4-1ae8-41f2-96cf-069a3d861fc6" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact_3a5734e4-1ae8-41f2-96cf-069a3d861fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_1697f916-15a7-421a-84dc-cf0575c5d7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringCosts_1697f916-15a7-421a-84dc-cf0575c5d7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_17b701f0-1415-4b15-939a-f7f38eb1064d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e6fafd57-849b-4ad4-aa9b-e936e23a042c" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_17b701f0-1415-4b15-939a-f7f38eb1064d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d1779579-356a-45c6-91d2-80796ae60f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d1779579-356a-45c6-91d2-80796ae60f19" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_00c085eb-77d0-494c-af59-7e7d4f580291" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e3734406-f499-4ad8-bd7b-52764a47f8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e3734406-f499-4ad8-bd7b-52764a47f8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AssociatedAndOtherCostsMember_393ec1fb-2558-46cd-89e6-8a1646a3a1ff" xlink:href="mdt-20250425.xsd#mdt_AssociatedAndOtherCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5c35a1ba-68c6-4975-b45f-2c41ce56d538" xlink:to="loc_mdt_AssociatedAndOtherCostsMember_393ec1fb-2558-46cd-89e6-8a1646a3a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_3661c506-fb4e-470a-957b-37785a0041fa" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6911d26d-9066-4065-b787-ea18d39e4567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserve_6911d26d-9066-4065-b787-ea18d39e4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_5b4fdc6b-88b5-4d6a-be61-22e42124d81a" xlink:href="mdt-20250425.xsd#mdt_RestructuringChargesIncludingAccrualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_mdt_RestructuringChargesIncludingAccrualAdjustments_5b4fdc6b-88b5-4d6a-be61-22e42124d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7078002f-7376-4e90-bde8-b3c1f435e7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_PaymentsForRestructuring_7078002f-7376-4e90-bde8-b3c1f435e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_6b940368-07e0-489b-ab49-13dc88de43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_6b940368-07e0-489b-ab49-13dc88de43a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9a84ca58-6449-4957-a7de-e4121f780ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9a84ca58-6449-4957-a7de-e4121f780ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_33a1d39f-0da3-4f63-94b9-4bcbc55b592c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b6588da4-8905-488c-a03f-87037bacefc7" xlink:to="loc_us-gaap_RestructuringReserve_33a1d39f-0da3-4f63-94b9-4bcbc55b592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b16b5b7d-b91a-4afa-9697-9a80fb4dec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b19621a9-8c3b-4cf3-90cb-d00257cf6118" xlink:to="loc_us-gaap_RestructuringCharges_b16b5b7d-b91a-4afa-9697-9a80fb4dec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_404c9555-5e27-4155-97e8-4d0a2c9bfd72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_404c9555-5e27-4155-97e8-4d0a2c9bfd72" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39d9139b-d7e5-428f-8bf2-592b33d65539" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_98e915b0-bd18-4e3f-9852-fc79fcd9b2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_98e915b0-bd18-4e3f-9852-fc79fcd9b2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6b8456bc-7ea1-4f1a-9bfb-940ff08fe785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6b8456bc-7ea1-4f1a-9bfb-940ff08fe785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_97dba557-25bb-414e-8904-45c4490e5615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7919ae6c-bd89-4d84-9915-75d81a3daaa4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_97dba557-25bb-414e-8904-45c4490e5615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2f3ed24b-7e20-463e-9592-ffab8ace563a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4bfb869a-1f90-451b-b410-62501f8106a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4bfb869a-1f90-451b-b410-62501f8106a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f7ba427d-0caf-4ec2-8041-9b1af87806db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f7ba427d-0caf-4ec2-8041-9b1af87806db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_0e218246-dde9-43a2-afc5-eb01eac0d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_0e218246-dde9-43a2-afc5-eb01eac0d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ed339ffc-b994-40da-854a-fe81c6a79183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_ed339ffc-b994-40da-854a-fe81c6a79183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3d8f127c-6d92-4cae-8bbf-596a10f608e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3d8f127c-6d92-4cae-8bbf-596a10f608e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_c5cf9bc4-dbb8-45a2-8895-68a08b7ee1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ad324c8-2b68-47d9-93f8-1b03b4f4a9b2" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_c5cf9bc4-dbb8-45a2-8895-68a08b7ee1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a676bd02-10db-4e9c-bb55-542b9e4e6e79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_f9d7264d-fead-4490-b031-807e050fdf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:to="loc_us-gaap_InvestmentsMember_f9d7264d-fead-4490-b031-807e050fdf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_a9bc9841-72d9-49a5-881f-4ed8d25adada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5674342d-3321-44c7-9b97-2bcf7a30f3bc" xlink:to="loc_us-gaap_OtherAssetsMember_a9bc9841-72d9-49a5-881f-4ed8d25adada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_711858d4-2e81-41f2-9186-9523f2e36031" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8fb8718e-d656-4807-b082-58b009e38bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8fb8718e-d656-4807-b082-58b009e38bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57f53781-3d3c-4a60-a009-6772bde6699e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57f53781-3d3c-4a60-a009-6772bde6699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f675e827-cfc8-4408-984a-d53aac8d8bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f675e827-cfc8-4408-984a-d53aac8d8bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7fecf764-7fea-457c-a3aa-32552df7503b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_49a30eba-5a5a-4f27-b3fa-9b277891b45d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7fecf764-7fea-457c-a3aa-32552df7503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6fe91618-bcac-4ce5-9d93-7ce919834b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6fe91618-bcac-4ce5-9d93-7ce919834b58" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e6ef800-2719-4671-9d2f-75ab48a82882" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_41a2aa50-73f8-43b7-aa37-dfff704e3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_41a2aa50-73f8-43b7-aa37-dfff704e3d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b7986d1c-89b0-4bf1-ae0e-5678960d0075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b7986d1c-89b0-4bf1-ae0e-5678960d0075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_8ea8e4da-a674-45cd-86c7-2b9f53c3db09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_8ea8e4da-a674-45cd-86c7-2b9f53c3db09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_71126571-4ea6-4d8b-8f1c-27c0e35bf393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_71126571-4ea6-4d8b-8f1c-27c0e35bf393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AuctionRateSecuritiesMember_7bd6a089-04f2-4032-9f74-f9fd63acb62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionRateSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_678e029d-39d3-4024-8f3c-ece44e3a67ec" xlink:to="loc_us-gaap_AuctionRateSecuritiesMember_7bd6a089-04f2-4032-9f74-f9fd63acb62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5048eb7d-86d0-4a94-82b4-d224b46c8f7c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:href="mdt-20250425.xsd#mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:to="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_dd84adb0-d8e0-4f77-8076-20c4441a2026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_dd84adb0-d8e0-4f77-8076-20c4441a2026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0add706a-9874-4d77-9542-6b3cfcafe69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract_66474988-4ab6-4a04-a6d8-6e5d933f5cc3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0add706a-9874-4d77-9542-6b3cfcafe69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_684b47ad-50a9-4986-86f4-b855c583b0d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebad928f-68c9-40d5-8960-ec17f0db8bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ebad928f-68c9-40d5-8960-ec17f0db8bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82184d43-d600-4904-b3f8-5c61116bc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_24cbc14f-6533-45cb-be1f-d0d91a6cba89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82184d43-d600-4904-b3f8-5c61116bc5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_7aeb96d5-fbbc-4c11-8556-de797f69dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_7aeb96d5-fbbc-4c11-8556-de797f69dda4" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abd05ea9-71ad-4484-bd51-00a95bf8dca1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_40f329a3-3a44-4cd1-b244-3066c2eb1d92" xlink:href="mdt-20250425.xsd#mdt_EquityInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_814fd7f0-948d-41c1-a2a6-c52434ea9fc3" xlink:to="loc_mdt_EquityInvestmentsMember_40f329a3-3a44-4cd1-b244-3066c2eb1d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:to="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0ec23f12-6a05-466a-800b-9e6fc49fd0e5" xlink:to="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MozarcMember_6f3919e4-b2c1-4fda-9af7-8079eeb6c531" xlink:href="mdt-20250425.xsd#mdt_MozarcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f67b5379-121b-4873-9aba-9357b735031f" xlink:to="loc_mdt_MozarcMember_6f3919e4-b2c1-4fda-9af7-8079eeb6c531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_56811328-b78e-4df2-879f-e829f7f4d3bb" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_bb6227bd-00d0-4f14-89b0-683957184e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_bb6227bd-00d0-4f14-89b0-683957184e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_84249c53-1130-414d-9c92-a98d943198f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_84249c53-1130-414d-9c92-a98d943198f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f2f0831a-06d0-4d79-88d7-59846aaf0d51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f2f0831a-06d0-4d79-88d7-59846aaf0d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5f9a6991-fe70-48bd-8463-d6e6343af523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_c194f8cb-ad95-4729-b184-e22feac6f5f7" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5f9a6991-fe70-48bd-8463-d6e6343af523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_20d43db7-ea98-4855-963b-397d1076e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_75ff9442-9b74-4d3c-a19c-536074501013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_20d43db7-ea98-4855-963b-397d1076e01b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_75ff9442-9b74-4d3c-a19c-536074501013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c2437f93-31ec-4d37-b1c9-c863c703e45e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_75ff9442-9b74-4d3c-a19c-536074501013" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c2437f93-31ec-4d37-b1c9-c863c703e45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_033abb6d-9881-441d-87df-652bbda40ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_75ff9442-9b74-4d3c-a19c-536074501013" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_033abb6d-9881-441d-87df-652bbda40ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_2f938cad-58dd-4d80-af80-a6fd854da2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_75ff9442-9b74-4d3c-a19c-536074501013" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_2f938cad-58dd-4d80-af80-a6fd854da2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_20d43db7-ea98-4855-963b-397d1076e01b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c0e6d25b-2e24-4203-a35d-e98762eec967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c0e6d25b-2e24-4203-a35d-e98762eec967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7287445a-0c95-4302-9511-211c5e633a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7287445a-0c95-4302-9511-211c5e633a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b723659b-ab07-4bcd-9be3-8a025971b272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b723659b-ab07-4bcd-9be3-8a025971b272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_3189f4fa-afc8-4b96-ad73-a0d5b776b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_3189f4fa-afc8-4b96-ad73-a0d5b776b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_ab207c74-acbd-4d1f-846c-6c40971ac347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_004bb6d8-606f-4cf8-910f-e79dcc958cbe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_ab207c74-acbd-4d1f-846c-6c40971ac347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_20d43db7-ea98-4855-963b-397d1076e01b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_75039162-bc6b-425d-95a9-db1637912a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_75039162-bc6b-425d-95a9-db1637912a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb3c3113-0198-4ce2-9ce3-f442bdef1784" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb3c3113-0198-4ce2-9ce3-f442bdef1784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1a597c7d-9ca2-40a4-b080-4c903e37f7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1a597c7d-9ca2-40a4-b080-4c903e37f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_fca72c82-c4a3-449d-ac32-fe916e346204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_fca72c82-c4a3-449d-ac32-fe916e346204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8949aa6b-dc36-41ce-b279-f0ef72a3da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_fd6aeb0a-11f5-4ce0-8baf-3b489bdddad8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8949aa6b-dc36-41ce-b279-f0ef72a3da8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_a47e083f-6516-47e2-8a5f-6430a37e525b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_a47e083f-6516-47e2-8a5f-6430a37e525b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34e1a4bc-ecab-4d6e-981d-2bd0bae8ab40" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_27446573-efdc-4f5f-8bef-f0cfd4dfe6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4f00245d-579e-4f0d-b44d-78e18ed78077" xlink:to="loc_us-gaap_OtherAssetsMember_27446573-efdc-4f5f-8bef-f0cfd4dfe6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0fa00ffd-189d-46f0-81bd-e7cd0ae394ee" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_01362a93-c16c-40bf-9db2-e8ddb0a57f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_01362a93-c16c-40bf-9db2-e8ddb0a57f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9035adf4-0b22-4c1a-bd61-cf4b8159a1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_9035adf4-0b22-4c1a-bd61-cf4b8159a1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f6e41477-59e7-4762-b87d-3f90dc42b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f6e41477-59e7-4762-b87d-3f90dc42b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_34cdfa5a-9d3f-4798-8cb3-6dc5df1d8ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_us-gaap_EquityMethodInvestments_34cdfa5a-9d3f-4798-8cb3-6dc5df1d8ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_b5d88739-38c5-44d5-b90c-7fa055f3c9fb" xlink:href="mdt-20250425.xsd#mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6f62bcda-7414-464c-99d7-8052958f6846" xlink:to="loc_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments_b5d88739-38c5-44d5-b90c-7fa055f3c9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsDebtandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_df3a8941-ca5c-47ad-8bc8-ca11c7828fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_dca9893e-21c5-478d-8bb4-e640cc3a989c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_df3a8941-ca5c-47ad-8bc8-ca11c7828fa8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_dca9893e-21c5-478d-8bb4-e640cc3a989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_dd5a36eb-a6ec-4db8-b678-f8a276745aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_df3a8941-ca5c-47ad-8bc8-ca11c7828fa8" xlink:to="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_dd5a36eb-a6ec-4db8-b678-f8a276745aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_44114521-726d-4dcd-9a57-141a57efe508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_df3a8941-ca5c-47ad-8bc8-ca11c7828fa8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_44114521-726d-4dcd-9a57-141a57efe508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsAbstract_4ab1e854-550c-40a0-b5b9-24e1edb4a67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsAbstract_4ab1e854-550c-40a0-b5b9-24e1edb4a67c" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3b1b5e67-a912-431b-8642-21396d167ae0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EquityInvestmentsMember_1d98854c-2df1-4e9b-bf32-e233524f2a0c" xlink:href="mdt-20250425.xsd#mdt_EquityInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad170666-2b51-472a-8972-d233bafe7fed" xlink:to="loc_mdt_EquityInvestmentsMember_1d98854c-2df1-4e9b-bf32-e233524f2a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_40ed7999-21ac-4411-aaa9-96232d9b5511" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4ab3f0f1-51ca-4720-b234-8e55ebbaeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4ab3f0f1-51ca-4720-b234-8e55ebbaeadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_GainOnInvestments_1b28fb88-7d4a-4287-8c8f-dfd9373ac50b" xlink:href="mdt-20250425.xsd#mdt_GainOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_mdt_GainOnInvestments_1b28fb88-7d4a-4287-8c8f-dfd9373ac50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossOnInvestments_70e30c8d-46d9-419b-9a79-18d8417347b8" xlink:href="mdt-20250425.xsd#mdt_LossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_mdt_LossOnInvestments_70e30c8d-46d9-419b-9a79-18d8417347b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_bafc3205-872c-4ddc-b935-5e44df99d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_5873d935-d684-4a0d-91dc-dd73ed862578" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_bafc3205-872c-4ddc-b935-5e44df99d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsCurrentDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b40a0abf-dc9c-45b2-a04e-a46350d6a444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:href="mdt-20250425.xsd#mdt_ScheduleOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b40a0abf-dc9c-45b2-a04e-a46350d6a444" xlink:to="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_80a92efe-063e-4a72-9d35-9ce1a6d0860a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_5f1d0bc5-797d-4fc5-991b-dc3c40aa600b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2fb9bd02-02d0-4296-bef7-b8bdc6f9d8b4" xlink:to="loc_us-gaap_NotesPayableToBanksMember_5f1d0bc5-797d-4fc5-991b-dc3c40aa600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1dec3b8-d689-4f1e-a4c1-de42a61ea65a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5d215c88-d4a1-4d4d-a0ee-cd3f65621af1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb055d6d-c2b0-4fb3-819e-ffe74bc0a7ed" xlink:to="loc_us-gaap_SeniorNotesMember_5d215c88-d4a1-4d4d-a0ee-cd3f65621af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_25f6bf34-0f28-42e9-912e-1156002c4c2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20260250PercentMember_55a8761c-3c25-489d-a856-0c9eb677b7d0" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20260250PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2019Due20260250PercentMember_55a8761c-3c25-489d-a856-0c9eb677b7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20260.000PercentMember_ae8cd4a7-135a-41bd-9488-42b0f815b89e" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20260.000PercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2020Due20260.000PercentMember_ae8cd4a7-135a-41bd-9488-42b0f815b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20262.625PercentMember_48047915-beda-440d-bc95-c548d274d5a8" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20262.625PercentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1d45926-f72d-4c1e-8dbc-81fe58befa9a" xlink:to="loc_mdt_SeniorNotes2022Due20262.625PercentMember_48047915-beda-440d-bc95-c548d274d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:href="mdt-20250425.xsd#mdt_DebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_ScheduleOfDebtTable_db4f585a-8b05-4199-bf91-a78f8e660891" xlink:to="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_7dbe3ce1-2f15-4749-85be-9e0706d759ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_ShortTermBorrowings_7dbe3ce1-2f15-4749-85be-9e0706d759ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_04c565ce-3fce-4188-bae2-43da3f4a6f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtInstrumentTerm_04c565ce-3fce-4188-bae2-43da3f4a6f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8b0291b-13e2-4cf9-86ae-2a531ee289bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8b0291b-13e2-4cf9-86ae-2a531ee289bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f1786ed3-eaa3-4b47-ac2f-02e9fb39b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_LongTermDebtCurrent_f1786ed3-eaa3-4b47-ac2f-02e9fb39b0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ecbc9730-cb08-411a-9065-a8ac6a23ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ecbc9730-cb08-411a-9065-a8ac6a23ac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_2f09aca0-2332-4b75-84e7-ce6683aac428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_CommercialPaper_2f09aca0-2332-4b75-84e7-ce6683aac428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_3558422c-e9af-4533-9f6d-71c994e0095d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_DebtCurrent_3558422c-e9af-4533-9f6d-71c994e0095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d29b7651-331e-4d62-ad3d-62720eea3e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DebtLineItems_30893037-e088-4747-9891-18c7212b823b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d29b7651-331e-4d62-ad3d-62720eea3e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a708a6de-d351-47ad-b5d7-11f0c0d7e44e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a708a6de-d351-47ad-b5d7-11f0c0d7e44e" xlink:to="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc49688b-6e97-47dc-a0cf-bdfb808ce4b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2015And2020CommercialPaperProgramMember_eb14e342-9a0e-483f-9a64-8ecdf062fe0b" xlink:href="mdt-20250425.xsd#mdt_A2015And2020CommercialPaperProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_A2015And2020CommercialPaperProgramMember_eb14e342-9a0e-483f-9a64-8ecdf062fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_50e0177c-1184-498c-aecd-fd7b5b1be3f1" xlink:href="mdt-20250425.xsd#mdt_AmendedandRestatedRevolvingCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_AmendedandRestatedRevolvingCreditAgreementMember_50e0177c-1184-498c-aecd-fd7b5b1be3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoSeniorNotesMember_c7a3fcb1-32a1-435c-bf60-a58c1e9b63df" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_MedtronicLuxcoSeniorNotesMember_c7a3fcb1-32a1-435c-bf60-a58c1e9b63df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20253.500PercentMember_33361a75-3766-44a5-a266-ce2e07507bf1" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20253.500PercentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_SeniorNotes2015Due20253.500PercentMember_33361a75-3766-44a5-a266-ce2e07507bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2017Due20273.350PercentMember_413e8851-8bf6-4b75-aae5-b5a476af6b62" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2017Due20273.350PercentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0ddd86e-adbd-41c0-8ed2-693637f2bcb8" xlink:to="loc_mdt_SeniorNotes2017Due20273.350PercentMember_413e8851-8bf6-4b75-aae5-b5a476af6b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_133c605d-f108-46bb-aa7c-9bf4ccc16bfa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2426fb9d-b2e5-42f3-9b9b-8e6358b04635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:to="loc_us-gaap_CommercialPaperMember_2426fb9d-b2e5-42f3-9b9b-8e6358b04635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e5bfba00-baa2-4996-a0c8-d80bc8c9c002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5e67d4b4-9e9c-431e-a5f7-dc5274c1c653" xlink:to="loc_us-gaap_LoansPayableMember_e5bfba00-baa2-4996-a0c8-d80bc8c9c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f402a99e-6153-4db7-bb62-98e609fee557" xlink:to="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cb28d75-7bdf-4c66-8cfb-89cf13b96043" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_113eae9f-912a-4c30-843b-10f66bd8c1a1" xlink:to="loc_srt_MinimumMember_7cb28d75-7bdf-4c66-8cfb-89cf13b96043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6bf856c5-4469-4840-a33a-501be291cd4a" xlink:to="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c1046aa9-4c3a-4fb2-accb-a00376a39dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_32a6d321-c74c-41f7-839c-de00d0beca0d" xlink:to="loc_us-gaap_LineOfCreditMember_c1046aa9-4c3a-4fb2-accb-a00376a39dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_75b60502-6469-4775-b0af-dd945541c238" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_de721465-63b0-4c7c-8d88-9d2cb4363240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff3d4266-eda2-43c0-8661-6e5c3b369d46" xlink:to="loc_us-gaap_SeniorNotesMember_de721465-63b0-4c7c-8d88-9d2cb4363240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5dc688d0-c543-4e45-bdbb-654a7b251bf1" xlink:to="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedtronicLuxcoMember_4b4b6e8c-0074-4726-a3d5-f23d4f82911e" xlink:href="mdt-20250425.xsd#mdt_MedtronicLuxcoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a4dda82c-1b68-4a34-b3cc-2463723da2f0" xlink:to="loc_mdt_MedtronicLuxcoMember_4b4b6e8c-0074-4726-a3d5-f23d4f82911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba4f8d3a-8b5a-48ac-b6c9-d6b0a72dd1b2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommercialPaperMaximumBorrowingCapacity_edda70f1-ed0a-457e-ab7e-3da9a246e3a3" xlink:href="mdt-20250425.xsd#mdt_CommercialPaperMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_CommercialPaperMaximumBorrowingCapacity_edda70f1-ed0a-457e-ab7e-3da9a246e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6e4df90c-5d1d-47ab-beb8-50842608e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtCurrent_6e4df90c-5d1d-47ab-beb8-50842608e8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f56da9f1-00bf-4bc9-8f60-7a6191b6b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_f56da9f1-00bf-4bc9-8f60-7a6191b6b8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_1385902c-e419-4699-b299-b32f694ca033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_1385902c-e419-4699-b299-b32f694ca033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_90cde5df-52e9-4459-9699-c93037fd33c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_90cde5df-52e9-4459-9699-c93037fd33c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityLengthOfExtension_443baf1c-9067-4ceb-bba3-ac14c0992ab0" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityLengthOfExtension"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_LineOfCreditFacilityLengthOfExtension_443baf1c-9067-4ceb-bba3-ac14c0992ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_a9a1b9b4-b8d3-45b9-b9ce-887b4e6afe46" xlink:href="mdt-20250425.xsd#mdt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity_a9a1b9b4-b8d3-45b9-b9ce-887b4e6afe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3c0520f6-fc13-45ce-9f6f-416f0dc77eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LineOfCredit_3c0520f6-fc13-45ce-9f6f-416f0dc77eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DebtInstrumentNumberofTranches_f82c8128-bb37-4b31-97ab-52fef02b7d82" xlink:href="mdt-20250425.xsd#mdt_DebtInstrumentNumberofTranches"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_mdt_DebtInstrumentNumberofTranches_f82c8128-bb37-4b31-97ab-52fef02b7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_acd27315-fa2a-470f-a0e8-b11416f00a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_acd27315-fa2a-470f-a0e8-b11416f00a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_ee92dbf3-0766-4936-863b-500118a0cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_ee92dbf3-0766-4936-863b-500118a0cdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_939a4549-00df-4437-b52a-5b1262e12f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_939a4549-00df-4437-b52a-5b1262e12f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_32d23aa3-9eea-4c0b-8c05-d7838440ee65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_32d23aa3-9eea-4c0b-8c05-d7838440ee65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ab693d87-44f1-45fb-97f0-4064cd1f8105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ab693d87-44f1-45fb-97f0-4064cd1f8105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aa53318-8fee-4a20-9705-ba07da520f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3aa53318-8fee-4a20-9705-ba07da520f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_65debc4e-7de9-456c-bc04-9d49ffea4a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_RepaymentsOfDebt_65debc4e-7de9-456c-bc04-9d49ffea4a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3e89053d-5e51-4b71-9ae2-9ca5a8d74bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3e89053d-5e51-4b71-9ae2-9ca5a8d74bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_db5586b5-1ba1-4ad8-9bd1-2aed4d573775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_InterestExpenseBorrowings_db5586b5-1ba1-4ad8-9bd1-2aed4d573775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_1d20fc70-36bd-4a9c-8fbc-7d9e90b0701b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_LongTermDebtFairValue_1d20fc70-36bd-4a9c-8fbc-7d9e90b0701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation_79b84ed0-7e92-43ff-90b7-3a47f03e0ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b56f8451-7883-4564-a41a-b41fa4995e1d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligation_79b84ed0-7e92-43ff-90b7-3a47f03e0ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ec04b603-b2cb-46b6-9bd6-530a676d1ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec04b603-b2cb-46b6-9bd6-530a676d1ffc" xlink:to="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c3a2961c-ef5b-4873-978b-1c6064d10b14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d93eb3ea-a38a-4175-863b-0d2d49ae3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_030a5fa2-7ae0-4a16-b182-659d7b88d4ec" xlink:to="loc_us-gaap_SeniorNotesMember_d93eb3ea-a38a-4175-863b-0d2d49ae3a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff6430a4-eba5-44a0-ab23-78f7564cfc81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20260250PercentMember_0f583ba5-fadc-4fd4-b1b8-e4e4df0cf767" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20260250PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20260250PercentMember_0f583ba5-fadc-4fd4-b1b8-e4e4df0cf767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20260.000PercentMember_08a6fe94-147e-4ed2-bcf1-38a7d10cf75b" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20260.000PercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20260.000PercentMember_08a6fe94-147e-4ed2-bcf1-38a7d10cf75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20262.625PercentMember_a948f633-042e-4246-8d60-322868c61a50" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20262.625PercentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20262.625PercentMember_a948f633-042e-4246-8d60-322868c61a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20271125PercentMember_727b1842-e6d4-41dc-bfa9-d5f119c31b5b" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20271125PercentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20271125PercentMember_727b1842-e6d4-41dc-bfa9-d5f119c31b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20284.250PercentMember_237c0bc5-ff0e-419d-8de7-30fc94598c19" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20284.250PercentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2023Due20284.250PercentMember_237c0bc5-ff0e-419d-8de7-30fc94598c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20293.000PercentMember_08d0a516-119a-4407-8447-f04beab52337" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20293.000PercentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20293.000PercentMember_08d0a516-119a-4407-8447-f04beab52337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20290375PercentMember_b92255aa-8152-48b1-964f-08f57584299d" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20290375PercentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20290375PercentMember_b92255aa-8152-48b1-964f-08f57584299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20303.650PercentMember_bfd026e4-2855-4f02-8575-7d37f5dc13a4" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20303.650PercentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20303.650PercentMember_bfd026e4-2855-4f02-8575-7d37f5dc13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20311625PercentMember_2e51671a-20cc-4b3a-868e-26b030918388" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20311625PercentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20311625PercentMember_2e51671a-20cc-4b3a-868e-26b030918388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20321000PercentMember_efac4d6f-9bb4-4ae4-8896-64f2d983a408" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20321000PercentMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20321000PercentMember_efac4d6f-9bb4-4ae4-8896-64f2d983a408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20323.125PercentMember_81d5b866-77f6-4854-8598-437519e4b7d1" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20323.125PercentMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20323.125PercentMember_81d5b866-77f6-4854-8598-437519e4b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20330750PercentMember_23345ebb-81e6-4d58-b0eb-6f85b82eabc4" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20330750PercentMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20330750PercentMember_23345ebb-81e6-4d58-b0eb-6f85b82eabc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2023Due20334.500PercentMember_40d2887b-cbd3-4c81-807b-24664a619d1f" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2023Due20334.500PercentMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2023Due20334.500PercentMember_40d2887b-cbd3-4c81-807b-24664a619d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2022Due20353.375PercentMember_8dc254a5-51e8-4410-93c8-762e883ac844" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2022Due20353.375PercentMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2022Due20353.375PercentMember_8dc254a5-51e8-4410-93c8-762e883ac844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20354.375PercentMember_835d26c1-0b7b-492c-a907-b8d7b311cb1c" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20354.375PercentMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2015Due20354.375PercentMember_835d26c1-0b7b-492c-a907-b8d7b311cb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20373.875PercentMember_4ccb6c89-126f-4706-bd72-e59700217fff" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20373.875PercentMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20373.875PercentMember_4ccb6c89-126f-4706-bd72-e59700217fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_48d43649-05a4-4a9d-a11c-bf39055d93c8" xlink:href="mdt-20250425.xsd#mdt_CIFSASeniorNotes2007Due20386.550PercentMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_CIFSASeniorNotes2007Due20386.550PercentMember_48d43649-05a4-4a9d-a11c-bf39055d93c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20392250PercentMember_4eea14c6-850e-45ff-8d02-9ca2510853de" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20392250PercentMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20392250PercentMember_4eea14c6-850e-45ff-8d02-9ca2510853de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2009Due20396500PercentMember_781e96c6-928a-442e-b297-e825a2162262" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2009Due20396500PercentMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2009Due20396500PercentMember_781e96c6-928a-442e-b297-e825a2162262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20401500PercentMember_86fb27e1-d2ba-44b4-af19-4361879b6579" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20401500PercentMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20401500PercentMember_86fb27e1-d2ba-44b4-af19-4361879b6579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2010Due20405550PercentMember_940b857b-b0fd-4d4e-87a5-26513d433ea0" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2010Due20405550PercentMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2010Due20405550PercentMember_940b857b-b0fd-4d4e-87a5-26513d433ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20411375PercentMember_b551f39b-c251-405d-b824-6813937293a9" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20411375PercentMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20411375PercentMember_b551f39b-c251-405d-b824-6813937293a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2012Due20424500PercentMember_6a894967-18ce-460f-8d21-0c565e4c9109" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2012Due20424500PercentMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2012Due20424500PercentMember_6a894967-18ce-460f-8d21-0c565e4c9109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2013Due20434000PercentMember_aa337d05-ec4c-4077-9a5b-880105c74096" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2013Due20434000PercentMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2013Due20434000PercentMember_aa337d05-ec4c-4077-9a5b-880105c74096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20444.150PercentMember_b1c73c12-3771-4cf5-99ac-927d20db28bb" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20444.150PercentMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20444.150PercentMember_b1c73c12-3771-4cf5-99ac-927d20db28bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2014Due20444625PercentMember_799257c6-eca5-4118-8564-6cc32ea36a6c" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2014Due20444625PercentMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2014Due20444625PercentMember_799257c6-eca5-4118-8564-6cc32ea36a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2015Due20454625PercentMember_11d486af-1916-4eef-823f-ef610013da77" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2015Due20454625PercentMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2015Due20454625PercentMember_11d486af-1916-4eef-823f-ef610013da77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2019Due20501750PercentMember_4d025354-2b86-4a52-ae9e-656143c30ced" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2019Due20501750PercentMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2019Due20501750PercentMember_4d025354-2b86-4a52-ae9e-656143c30ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2020Due20511625PercentMember_916e845b-2d00-4360-abfe-35169816b383" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2020Due20511625PercentMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2020Due20511625PercentMember_916e845b-2d00-4360-abfe-35169816b383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SeniorNotes2024Due20544.150PercentMember_b0291378-c2ab-4788-b35e-94c7bb71aebf" xlink:href="mdt-20250425.xsd#mdt_SeniorNotes2024Due20544.150PercentMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2441d582-bee8-4e97-9693-0c2c38341274" xlink:to="loc_mdt_SeniorNotes2024Due20544.150PercentMember_b0291378-c2ab-4788-b35e-94c7bb71aebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2f7cfca-1a8d-4811-9138-cab171ea1f51" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e559cea-9fea-43e4-b631-242ed5032668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e559cea-9fea-43e4-b631-242ed5032668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c07b8ddc-4782-4bf7-8cff-fce947110774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentTerm_c07b8ddc-4782-4bf7-8cff-fce947110774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bdc0ea13-3a76-44be-ad91-ce2606a094b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bdc0ea13-3a76-44be-ad91-ce2606a094b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e6210382-6e7b-4d8a-98c6-3ade3376ea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e6210382-6e7b-4d8a-98c6-3ade3376ea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_02ee9f9a-8579-425f-b144-0cb3695a00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_02ee9f9a-8579-425f-b144-0cb3695a00a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_51e2529a-686f-4b13-bbf7-3db3402364ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_51e2529a-686f-4b13-bbf7-3db3402364ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8d009ffb-30e1-4161-845b-3af8f2c7f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8d009ffb-30e1-4161-845b-3af8f2c7f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_e5305a8e-5700-4303-a62b-127e0b34f367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_e5305a8e-5700-4303-a62b-127e0b34f367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_661dc5bb-b15c-424a-8344-453f6039da17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e22b03e4-82bb-4bc0-bc50-cc8dff52b91f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_661dc5bb-b15c-424a-8344-453f6039da17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsLongtermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_47f05d4e-0d38-440d-b2a3-d15e158f9ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_47f05d4e-0d38-440d-b2a3-d15e158f9ea9" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_14b880a7-c28f-4512-aad4-9be251a6c160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_14b880a7-c28f-4512-aad4-9be251a6c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9e1901e-9934-4e05-94a3-d3f2a16759b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9e1901e-9934-4e05-94a3-d3f2a16759b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a585f61f-165a-4bb5-a713-5cf9924d82af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a585f61f-165a-4bb5-a713-5cf9924d82af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_077d52c1-1737-4c7f-bf76-83010336e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_077d52c1-1737-4c7f-bf76-83010336e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f4a8b236-8abe-43a7-b748-e28089e80353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f4a8b236-8abe-43a7-b748-e28089e80353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_83bb5762-55c6-4342-958a-3385eda78d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_83bb5762-55c6-4342-958a-3385eda78d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c62a4300-c3c7-4ef6-921f-797be70db1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_c14a93d0-9e5e-41a4-94af-328aab70933c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c62a4300-c3c7-4ef6-921f-797be70db1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#FinancingArrangementsSupplierFinancingProgramDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b283d8b1-3e2a-4944-a3b8-386bac3f03cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b283d8b1-3e2a-4944-a3b8-386bac3f03cd" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation_07e3550d-e63b-4b76-bb2f-5ccad6a4bb34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:to="loc_us-gaap_SupplierFinanceProgramObligation_07e3550d-e63b-4b76-bb2f-5ccad6a4bb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationIncrease_0f03bb5e-2853-4c16-a6e7-d7dc742e95ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationIncrease_0f03bb5e-2853-4c16-a6e7-d7dc742e95ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_9202afda-7586-402a-a95a-a129876cfbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_9202afda-7586-402a-a95a-a129876cfbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_a736f0d1-5279-4759-8786-604b9613444a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_a736f0d1-5279-4759-8786-604b9613444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligation_9042f14a-a3d5-4aad-b65f-a7909a646115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_8a822d5b-abc8-434c-b337-e241a60a3963" xlink:to="loc_us-gaap_SupplierFinanceProgramObligation_9042f14a-a3d5-4aad-b65f-a7909a646115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c14d08f-264f-4ba4-9d18-0ec076d40091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c14d08f-264f-4ba4-9d18-0ec076d40091" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_27ddc182-968c-4066-8c62-88b296a3710e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_03113da8-7752-4239-b33f-6d08249a362d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7e050d53-847f-45f4-8560-b5e08af6656d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_03113da8-7752-4239-b33f-6d08249a362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6818ab7f-1741-4734-aefd-52c48179715f" xlink:to="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5fdc974c-4499-430c-b740-de22b2caf4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3b7c289a-85f0-4842-a197-bc7bd2a4c5eb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5fdc974c-4499-430c-b740-de22b2caf4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0d684a42-373a-4c27-b217-718d6c4f790e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_cbbe2ea7-9287-4eef-9b18-4e3d3815c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:to="loc_us-gaap_CashFlowHedgingMember_cbbe2ea7-9287-4eef-9b18-4e3d3815c9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_af913113-1a47-4a3e-affe-925c0b60e660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_9c0b126c-35f4-4842-b428-97ec19bdc3a1" xlink:to="loc_us-gaap_FairValueHedgingMember_af913113-1a47-4a3e-affe-925c0b60e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_50af1220-0a63-4009-8f0c-01d78f8a6314" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_67f76514-3a73-4165-bc12-3abe5ececf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_67f76514-3a73-4165-bc12-3abe5ececf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_73b59308-b068-425e-a1a4-af28d2408f53" xlink:href="mdt-20250425.xsd#mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax_73b59308-b068-425e-a1a4-af28d2408f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0775d011-9548-40b0-b336-13fdbea237a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0775d011-9548-40b0-b336-13fdbea237a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42cf7574-0c62-44ec-8b65-b3f451d90267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42cf7574-0c62-44ec-8b65-b3f451d90267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e850e9ed-c682-4a8d-859f-990b71603c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e850e9ed-c682-4a8d-859f-990b71603c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_7edbc2da-8bec-45ec-9dfc-6f38e24cfde3" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ce303166-a862-47ad-91f3-421315c597d0" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_7edbc2da-8bec-45ec-9dfc-6f38e24cfde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_f83995ec-9bc2-4cff-9585-6abc2fdeadde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_f83995ec-9bc2-4cff-9585-6abc2fdeadde" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6090b5ba-c846-411e-bc3e-ab666819ff6a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c1a54b5a-d2d9-4481-aeb3-d61330ec5d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c1a54b5a-d2d9-4481-aeb3-d61330ec5d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_4a4de204-f0f3-4392-bac9-4c4d3c3208ef" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2533444-3539-4854-8623-7c167eb933de" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_4a4de204-f0f3-4392-bac9-4c4d3c3208ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_282b8ecb-028f-4342-906f-aefc33a1458c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a5821145-05d5-4196-9f48-6990bbce9e85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_CashFlowHedgingMember_a5821145-05d5-4196-9f48-6990bbce9e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e6f06dba-0028-46d7-95c4-8bb6d902ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e6f06dba-0028-46d7-95c4-8bb6d902ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_d3deab26-1aa9-4bd9-8682-cdd1db87880c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf4fa994-0bde-4463-977f-170f111d2421" xlink:to="loc_us-gaap_FairValueHedgingMember_d3deab26-1aa9-4bd9-8682-cdd1db87880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3acb390a-4ec3-406a-8ffb-f7ae305495ed" xlink:to="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6947f059-1625-4676-93ba-b641f74fd193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6947f059-1625-4676-93ba-b641f74fd193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_45eb887d-f548-4776-9b9b-c221911a6d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_011e1c60-73c1-4dec-9306-a2cdf3f892cf" xlink:to="loc_us-gaap_NondesignatedMember_45eb887d-f548-4776-9b9b-c221911a6d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bb0430d6-3faa-4b0b-a21c-8a361ec30434" xlink:to="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_491fb396-de1d-48ac-b0c0-eae82844429a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:to="loc_srt_EuropeMember_491fb396-de1d-48ac-b0c0-eae82844429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_827a579f-a38a-4e9e-8257-e6659fb18d8a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6cbf1b9-9f4c-4b11-86f7-e21a234a4f45" xlink:to="loc_country_JP_827a579f-a38a-4e9e-8257-e6659fb18d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_58e4eb69-932b-4dfe-9bea-d92842825cd8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7631fcfb-c935-43f3-937c-a130dbcecabb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_567b06b7-f234-449b-9d0e-2bfee3b6f211" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7631fcfb-c935-43f3-937c-a130dbcecabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_24bd129c-dac3-4a85-ac31-9cf9e9ee00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_24bd129c-dac3-4a85-ac31-9cf9e9ee00b8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c48be9ae-3286-43aa-9d25-fcd847b07cbc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_441a9838-181c-4d2c-93c1-c1a93cbea81c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:to="loc_us-gaap_ForeignExchangeContractMember_441a9838-181c-4d2c-93c1-c1a93cbea81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyDenominatedDebtMember_324a3c26-f886-4b9d-9a97-eaefd938678f" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d6c3200-df8f-4a61-8ffc-f56bbe150747" xlink:to="loc_mdt_ForeignCurrencyDenominatedDebtMember_324a3c26-f886-4b9d-9a97-eaefd938678f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c82dc3bc-c286-4d49-9323-6f303f2b85fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_9688f0dc-c312-48e3-b5bb-b5166a809793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_9688f0dc-c312-48e3-b5bb-b5166a809793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_79ffdeef-3d56-4087-a317-ddb754fd2e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d77e0b5-208e-41c1-ad8a-9f400efe5ac5" xlink:to="loc_us-gaap_CostOfSalesMember_79ffdeef-3d56-4087-a317-ddb754fd2e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a533f5f4-fd1b-4d92-92e4-d8d42d6a8418" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_67ba7e7d-6311-4e36-814a-e9278ac22806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_FairValueHedgingMember_67ba7e7d-6311-4e36-814a-e9278ac22806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e0b731e7-49df-4d73-b423-da307cfcceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_CashFlowHedgingMember_e0b731e7-49df-4d73-b423-da307cfcceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_bb6516c0-6a6f-439d-b101-adc82a7e57cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b82fed03-8147-4fbe-94c7-1b89afc9ef45" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_bb6516c0-6a6f-439d-b101-adc82a7e57cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d8ef69d6-3798-4294-b866-3e956e2a2737" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c81f67a2-f9c4-4076-9110-16d0458053e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c81f67a2-f9c4-4076-9110-16d0458053e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_641459b4-b1df-4459-b6f5-46b7f958b267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_641459b4-b1df-4459-b6f5-46b7f958b267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e91cc38f-fe55-4f36-bedb-408c88e6a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e91cc38f-fe55-4f36-bedb-408c88e6a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da073b02-e61c-49fa-9e41-9040b91441e8" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax_da073b02-e61c-49fa-9e41-9040b91441e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_932406e2-7206-4b4d-86be-e8920fcf4396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_932406e2-7206-4b4d-86be-e8920fcf4396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ddd8511b-46da-4668-8a22-d6dda8fe2f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ddd8511b-46da-4668-8a22-d6dda8fe2f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_7804844e-7d56-4b12-ae52-83daa656c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_7804844e-7d56-4b12-ae52-83daa656c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_fa1b0410-80aa-443e-bc54-a7b36e12eddc" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1a9a655d-9c9a-4b11-b409-3482251bdc59" xlink:to="loc_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax_fa1b0410-80aa-443e-bc54-a7b36e12eddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_250a3c76-4a86-4d7e-a73e-6369b51d26da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_250a3c76-4a86-4d7e-a73e-6369b51d26da" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb1a8b39-5bca-4149-bee4-fc7751ca9241" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_be8ecbec-762e-4b21-b20f-aff0ac4ed19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcc17318-c73a-4cc8-94fc-72d694132842" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_be8ecbec-762e-4b21-b20f-aff0ac4ed19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_df27f162-28bf-4eb7-9f87-2747f72e2443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44223cfe-7fb7-4320-8aeb-5bd5b6b6f069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_52997e05-1c2e-45c6-9daf-c0bd2e2234f1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44223cfe-7fb7-4320-8aeb-5bd5b6b6f069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e9b40928-7507-434e-bf02-c155372d258f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_20e0829f-39f0-4ed2-a589-b0391e792561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_afe6567b-be23-48e9-9651-7999f3fc1451" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_20e0829f-39f0-4ed2-a589-b0391e792561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a97f78c-eaa1-47af-bf64-8ae31a8ca8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a97f78c-eaa1-47af-bf64-8ae31a8ca8ff" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_44ff4dc5-771a-4baf-b5ed-ad69e9f325a2" xlink:to="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4fa00581-56ae-4f95-ab38-c005b6302b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4fa00581-56ae-4f95-ab38-c005b6302b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6e6c1a33-e77f-46cf-b740-6ed2fe4cdc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_437c714f-d9bd-4d0f-89ef-1b7de1129855" xlink:to="loc_us-gaap_NondesignatedMember_6e6c1a33-e77f-46cf-b740-6ed2fe4cdc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b915a3ce-efaf-43cc-9e55-2ad2b6de6cdb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_068f84a4-0bc8-4ade-8271-e92d22be9eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:to="loc_us-gaap_ForeignExchangeContractMember_068f84a4-0bc8-4ade-8271-e92d22be9eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TotalReturnSwapMember_3b3bce31-87e3-4175-b3ea-e23288e7d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TotalReturnSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_827d2c53-c733-4fec-88ec-d1a94d322971" xlink:to="loc_us-gaap_TotalReturnSwapMember_3b3bce31-87e3-4175-b3ea-e23288e7d4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b25c514b-8726-4d8e-9f9a-ef92fedd4c72" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_82db147c-f81e-403c-8101-19a0123e4987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_82db147c-f81e-403c-8101-19a0123e4987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_732a3557-df44-4316-8f67-c95f1443e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_OtherAssetsMember_732a3557-df44-4316-8f67-c95f1443e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherAccruedExpensesMember_c759e19e-430a-4410-b174-59cb984f4476" xlink:href="mdt-20250425.xsd#mdt_OtherAccruedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_mdt_OtherAccruedExpensesMember_c759e19e-430a-4410-b174-59cb984f4476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_4254c65a-49b8-432b-b080-e7ad8e5f41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77d353de-8275-432d-a022-4fd9c0effcdd" xlink:to="loc_us-gaap_OtherLiabilitiesMember_4254c65a-49b8-432b-b080-e7ad8e5f41a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_4d10e8ea-89fb-4cd0-8e17-5abf6b7f794a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7337f0eb-d6f4-4897-8e44-2f6292569c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7337f0eb-d6f4-4897-8e44-2f6292569c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2ff7bec1-98fc-44e4-bbe9-b311dbc9bd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ac89b9e2-f97e-4884-8979-de10824e6404" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_2ff7bec1-98fc-44e4-bbe9-b311dbc9bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4d038a4-0a51-4f14-a02d-387d6aabad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4d038a4-0a51-4f14-a02d-387d6aabad7d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_927ae524-9f94-400c-885e-252efb3d1c3d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_44a0c1ac-6ac5-4a24-b916-b3a0dff3d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_44a0c1ac-6ac5-4a24-b916-b3a0dff3d3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9cbf8b92-65bf-4225-a5c6-0b758367eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8d498d6-caab-4d30-852c-3bb4ab66303e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9cbf8b92-65bf-4225-a5c6-0b758367eca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd1ab0e-c50a-486c-a294-eebe3cc62fe8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2213748d-b908-4802-ad66-2f34598e8c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeAssets_2213748d-b908-4802-ad66-2f34598e8c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a64c8f93-e458-4dde-8732-cb1c1c74aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeLiabilities_a64c8f93-e458-4dde-8732-cb1c1c74aafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_739286b0-c8b2-4882-9966-9cabd595032f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_739286b0-c8b2-4882-9966-9cabd595032f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4cb31c17-2da6-4dfe-bf89-9d69c573b144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0cf6e2a3-1cb2-462e-934f-cba25c308af7" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4cb31c17-2da6-4dfe-bf89-9d69c573b144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e1c134a-c9dc-4d89-b5e8-7f8ce754f191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e1c134a-c9dc-4d89-b5e8-7f8ce754f191" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d11abb2a-1247-450b-93ba-3918df3559c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7bb8c250-6839-4b92-a219-fdf4491342a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7bb8c250-6839-4b92-a219-fdf4491342a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TotalReturnSwapMember_2913865e-10e7-48fc-900e-77deb6673397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TotalReturnSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7dc66d9e-9709-4cfd-bd8d-be6c0bce3a2d" xlink:to="loc_us-gaap_TotalReturnSwapMember_2913865e-10e7-48fc-900e-77deb6673397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:href="mdt-20250425.xsd#mdt_OffsettingAssetsandLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesTable_e9394d95-3a09-4094-86c5-aeecc406975a" xlink:to="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2c00d41b-ec81-4f05-abf1-2da0a9285688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2c00d41b-ec81-4f05-abf1-2da0a9285688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8f3d9bf2-6f9c-439a-877e-9444984c8085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_8f3d9bf2-6f9c-439a-877e-9444984c8085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_d2fdb324-1cf4-4321-99db-b848c4c913ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_d2fdb324-1cf4-4321-99db-b848c4c913ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_4745ecde-60dc-47f4-b5b5-732b990ff71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_99a4ca5f-4c5d-4bbe-8466-6acb62564e92" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral_4745ecde-60dc-47f4-b5b5-732b990ff71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47a7be69-974f-4097-b38f-82ed36e40c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47a7be69-974f-4097-b38f-82ed36e40c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_13d7c0ec-3bb5-4e67-83ce-17886f96a576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_13d7c0ec-3bb5-4e67-83ce-17886f96a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_71980a13-7d02-41c8-b30c-535eafe581c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_71980a13-7d02-41c8-b30c-535eafe581c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_32624c1e-72bf-402d-b226-fba9141b260e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_6e4a901e-556d-4f4d-84dd-545af670d707" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral_32624c1e-72bf-402d-b226-fba9141b260e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_OffsettingAssetsandLiabilitiesLineItems_616f370c-1613-4f77-833a-7ac0841403aa" xlink:to="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_9150d6be-6447-426e-a5f3-680d18458244" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability_9150d6be-6447-426e-a5f3-680d18458244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_fb27c983-2214-4b29-82df-feb490e8dbad" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction_fb27c983-2214-4b29-82df-feb490e8dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_ce3fda2e-7058-47a3-95f2-59b10ece4d00" xlink:href="mdt-20250425.xsd#mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash_ce3fda2e-7058-47a3-95f2-59b10ece4d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_93b39945-ffd8-4673-99f9-35fe7b9ba5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DerivativeAssetLiabilityAbstract_a80dfdf4-b010-4749-936a-9c991d644b3d" xlink:to="loc_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet_93b39945-ffd8-4673-99f9-35fe7b9ba5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/InventoriesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8dbe3a38-20dd-438a-9bf6-d49b9b0dea57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_24d42ccc-ddb5-4cdb-a8ab-8cd16d4ddab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8dbe3a38-20dd-438a-9bf6-d49b9b0dea57" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_24d42ccc-ddb5-4cdb-a8ab-8cd16d4ddab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5e30e5ee-b6b0-497c-84d0-552ebfcd4b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8dbe3a38-20dd-438a-9bf6-d49b9b0dea57" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5e30e5ee-b6b0-497c-84d0-552ebfcd4b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_725123af-bc66-46c4-839e-2e362c2ec8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8dbe3a38-20dd-438a-9bf6-d49b9b0dea57" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_725123af-bc66-46c4-839e-2e362c2ec8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_afdf56f8-c10b-48a8-9bc0-cca44aa71b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8dbe3a38-20dd-438a-9bf6-d49b9b0dea57" xlink:to="loc_us-gaap_InventoryNet_afdf56f8-c10b-48a8-9bc0-cca44aa71b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfacaeed-f24c-4ad8-92bd-b2cf53c672d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfacaeed-f24c-4ad8-92bd-b2cf53c672d0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d8f5ba00-aaaa-4932-a4b5-984a47523d31" xlink:to="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_ca0d3c0b-817e-4239-b4da-cf058df55523" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_CardiovascularMember_ca0d3c0b-817e-4239-b4da-cf058df55523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_f9d5455d-edc3-4b58-8043-84895505637f" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_NeuroscienceGroupMember_f9d5455d-edc3-4b58-8043-84895505637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_9ce78ede-589e-49dc-becb-6b7caeb5e69f" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_MedicalSurgicalMember_9ce78ede-589e-49dc-becb-6b7caeb5e69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_04b83de5-3ec7-44a3-b195-056cb541cce3" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2c6108bc-80f1-4b6c-bf0b-28c7f8c7399c" xlink:to="loc_mdt_DiabetesGroupMember_04b83de5-3ec7-44a3-b195-056cb541cce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7746ad1b-b7d9-42e8-9356-aea59e7248e8" xlink:to="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4b2351a2-1008-42f8-aa6a-225a3877ebf8" xlink:to="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_639ead96-ca20-4aa1-8194-5a69067e8ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_Goodwill_639ead96-ca20-4aa1-8194-5a69067e8ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3945ef4-b016-42cc-a186-ad46993d96f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3945ef4-b016-42cc-a186-ad46993d96f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e25c6621-0db8-4c97-89c1-8e56686923d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e25c6621-0db8-4c97-89c1-8e56686923d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_67ce1012-bf88-473a-9d4e-0fe257d5522e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_67ce1012-bf88-473a-9d4e-0fe257d5522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9d6635f-c24a-4c25-b325-dea2e44439d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ca3bf3f1-17d3-4d21-8dd0-ab4615760394" xlink:to="loc_us-gaap_Goodwill_d9d6635f-c24a-4c25-b325-dea2e44439d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_836b3e96-cbb4-4171-b3c3-ac32b95e0801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_836b3e96-cbb4-4171-b3c3-ac32b95e0801" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1b5f617b-a12d-49d3-982a-0ecaf7ab5fe5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_VentilatorProductLineExitMember_09741a8a-848b-4835-82e6-14cb59b038af" xlink:href="mdt-20250425.xsd#mdt_VentilatorProductLineExitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:to="loc_mdt_VentilatorProductLineExitMember_09741a8a-848b-4835-82e6-14cb59b038af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RenalCareBusinessRCSMember_1886258b-c144-4b5c-b596-5ef4b59f9eec" xlink:href="mdt-20250425.xsd#mdt_RenalCareBusinessRCSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_71330ed9-0945-43c6-84e3-9b6db5601f6c" xlink:to="loc_mdt_RenalCareBusinessRCSMember_1886258b-c144-4b5c-b596-5ef4b59f9eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84572e04-fb4b-4b5e-9ef0-e85df4bdf616" xlink:to="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_230f863e-7efd-4d37-9c8a-fd220cfd0616" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:to="loc_mdt_MedicalSurgicalMember_230f863e-7efd-4d37-9c8a-fd220cfd0616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_c8973f03-2b74-4c50-bd3c-38b7d3d1dd18" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f92715a-ff96-4210-94a9-80a925d5da49" xlink:to="loc_mdt_CardiovascularMember_c8973f03-2b74-4c50-bd3c-38b7d3d1dd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_105068bc-36c1-4dc7-bf0c-e9d68c985d46" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_a8b69049-1c1e-4fee-9773-5e67f3388ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_762e8c1a-8c10-411d-acb7-71df1b554192" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_a8b69049-1c1e-4fee-9773-5e67f3388ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8e55a2b0-2048-4217-b991-1646734c353f" xlink:to="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c35ae4e3-2727-48b7-b9f6-406016da09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c35ae4e3-2727-48b7-b9f6-406016da09c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ffe58385-b26c-4b43-ba39-33a9b000811d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ffe58385-b26c-4b43-ba39-33a9b000811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ead610b4-23f8-4b8d-8d36-952e8573fc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ead610b4-23f8-4b8d-8d36-952e8573fc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c73dc435-5c27-4d3b-a788-4bc661d6ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c73dc435-5c27-4d3b-a788-4bc661d6ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5b747c19-c08c-49fc-bbda-915cacfc1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5b747c19-c08c-49fc-bbda-915cacfc1f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_34bb30b1-cbc0-4c44-8c92-ecbf5b4579b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_34bb30b1-cbc0-4c44-8c92-ecbf5b4579b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_AcceleratedAmortizationOfIntangibleAssets_9ebe5a64-a2b1-40af-9a33-37181805b45e" xlink:href="mdt-20250425.xsd#mdt_AcceleratedAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_04f79424-05ed-461c-bd03-d01b4f0519c7" xlink:to="loc_mdt_AcceleratedAmortizationOfIntangibleAssets_9ebe5a64-a2b1-40af-9a33-37181805b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecd266f2-9f4e-49f1-8ca9-599576bb5139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecd266f2-9f4e-49f1-8ca9-599576bb5139" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_edbf0988-0922-4241-bf1b-de83127d1b23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_1365d28c-51a2-4119-9c13-f753bc08cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_1365d28c-51a2-4119-9c13-f753bc08cdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PurchasedTechnologyAndPatentsMember_aa6c8843-0327-48b8-ab4f-b8fae3eb797a" xlink:href="mdt-20250425.xsd#mdt_PurchasedTechnologyAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_mdt_PurchasedTechnologyAndPatentsMember_aa6c8843-0327-48b8-ab4f-b8fae3eb797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_75c53b46-2983-466b-9ab3-9f9f8d870ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_75c53b46-2983-466b-9ab3-9f9f8d870ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e26cbe1f-8818-44a9-8f7f-f4d62e53cde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e839f26b-3e91-4e0a-ad37-593ef74231d8" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e26cbe1f-8818-44a9-8f7f-f4d62e53cde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_049e1f53-ae9a-4060-a053-42f676887139" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9420425d-c079-4121-9ffb-82ad632db161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9f8f16bf-a646-4903-9170-f53b47c643a5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9420425d-c079-4121-9ffb-82ad632db161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6db7a231-4235-4b2e-9197-9bc3cc042845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6a0bba35-2460-4e2c-9b82-f5496072ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6a0bba35-2460-4e2c-9b82-f5496072ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_239e497b-ea19-4cad-8615-77c993b9bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_239e497b-ea19-4cad-8615-77c993b9bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87243ebb-7018-4a3c-8ad2-ca694c07e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ae1aa5a-6c6b-4b93-b302-9f8714fdb9f3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87243ebb-7018-4a3c-8ad2-ca694c07e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a0caa2b0-d51a-4d6f-97eb-d940f7de6ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a0caa2b0-d51a-4d6f-97eb-d940f7de6ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f799aea4-a744-4545-8732-cac137990e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f799aea4-a744-4545-8732-cac137990e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f1b5adb4-a271-441f-b100-3040370478ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f1b5adb4-a271-441f-b100-3040370478ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f5b9e008-af5e-4cba-8ad1-36ad6b49441e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f5b9e008-af5e-4cba-8ad1-36ad6b49441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_35f64bc0-a170-4ddd-b5c7-bcdd820b329e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4808d102-c40a-490b-88bb-56f3a1b4bea0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_35f64bc0-a170-4ddd-b5c7-bcdd820b329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d022dd6-20e0-44dc-9cd0-abb4698266d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d022dd6-20e0-44dc-9cd0-abb4698266d7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ce19cc0-2029-41e6-b37c-8e5a1b6c0f56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ef3bf8f6-f913-46ff-a70d-64329e039427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_EquipmentMember_ef3bf8f6-f913-46ff-a70d-64329e039427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_3b80bc98-47d6-406e-a1f6-eab9fd7e13da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_3b80bc98-47d6-406e-a1f6-eab9fd7e13da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_99b6b095-8622-4a10-b12b-5cb2159d149b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_99b6b095-8622-4a10-b12b-5cb2159d149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_BuildingsAndLeaseholdImprovementsMember_6e00b330-90dd-4de9-ae0b-9e05e62762d9" xlink:href="mdt-20250425.xsd#mdt_BuildingsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_mdt_BuildingsAndLeaseholdImprovementsMember_6e00b330-90dd-4de9-ae0b-9e05e62762d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c9b036e8-6493-47ed-a0d8-3d3ab86e7b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7eba4df8-4984-4a68-9990-b925c2db50ec" xlink:to="loc_us-gaap_ConstructionInProgressMember_c9b036e8-6493-47ed-a0d8-3d3ab86e7b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:to="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_642cfa09-f995-40c2-8601-9a54f1457205" xlink:to="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51265c05-61a0-45a5-893b-2b442fa6457c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:to="loc_srt_MinimumMember_51265c05-61a0-45a5-893b-2b442fa6457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d4bceb5-e182-406a-912c-55bdc0f1dab9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_184b7212-7e47-4007-a9a3-172b32632cc7" xlink:to="loc_srt_MaximumMember_0d4bceb5-e182-406a-912c-55bdc0f1dab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4e06c2aa-d1f7-4ca6-a769-60c6a300107f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4eff7cf3-2c2f-43df-bc20-7b828dcaa978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4eff7cf3-2c2f-43df-bc20-7b828dcaa978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b5a6d944-9b36-482b-bb36-32dd25fc4818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b5a6d944-9b36-482b-bb36-32dd25fc4818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_af0b78c1-37ef-4647-95c5-4e5edd83eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_af0b78c1-37ef-4647-95c5-4e5edd83eba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1278b364-74ff-4d6e-a9d8-c97463fb994b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1278b364-74ff-4d6e-a9d8-c97463fb994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_999ce9d5-ca85-4d9b-8aa6-5e506a42a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7cf341cf-5874-4443-b1bb-ec98efd459f2" xlink:to="loc_us-gaap_Depreciation_999ce9d5-ca85-4d9b-8aa6-5e506a42a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_16075429-b558-4ba0-b17f-5c9c98ffd56c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_16075429-b558-4ba0-b17f-5c9c98ffd56c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fa4e26b-cc8a-4cdd-94fb-3d7ef9278564" xlink:to="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b49abf54-61b9-41a0-80e9-1e4006340bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_007047ea-fa60-444c-9c6e-1506807dc073" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b49abf54-61b9-41a0-80e9-1e4006340bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aa328a9e-3bf5-4bd8-bef8-12133eaac3f9" xlink:to="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6f382d09-a69f-48d5-850d-649f152ec36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6f382d09-a69f-48d5-850d-649f152ec36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1471f481-93f4-4dfd-b11d-795079f043e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1471f481-93f4-4dfd-b11d-795079f043e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesAuthorized_b3d9fb0d-55ad-4a72-8f0f-a80cc72f49d7" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesAuthorized_b3d9fb0d-55ad-4a72-8f0f-a80cc72f49d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockParorStatedValuePerShare_dbdfb66b-fdbe-4915-9af2-488d183be3b9" xlink:href="mdt-20250425.xsd#mdt_DeferredStockParorStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockParorStatedValuePerShare_dbdfb66b-fdbe-4915-9af2-488d183be3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_99f73602-1430-44ed-a2b4-87b2c3807be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_99f73602-1430-44ed-a2b4-87b2c3807be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2f7fe786-b117-4a35-804e-a7f5bda076c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2f7fe786-b117-4a35-804e-a7f5bda076c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesIssued_a659eb96-8d58-4d88-890d-8890c66d02e2" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesIssued_a659eb96-8d58-4d88-890d-8890c66d02e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredStockSharesOutstanding_abc8bc30-d60b-4dcd-acee-55089a41d2c4" xlink:href="mdt-20250425.xsd#mdt_DeferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_DeferredStockSharesOutstanding_abc8bc30-d60b-4dcd-acee-55089a41d2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e0eeb79f-8b94-41eb-a5af-643ac9ee4591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e0eeb79f-8b94-41eb-a5af-643ac9ee4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e7398aaf-088a-4883-9b0b-a65833f342d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e7398aaf-088a-4883-9b0b-a65833f342d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_67f67d03-760f-4cf9-a1e9-1f3e461e5334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_67f67d03-760f-4cf9-a1e9-1f3e461e5334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_2bc861d9-9266-46c0-8389-0e0a9616e7ba" xlink:href="mdt-20250425.xsd#mdt_StockRepurchaseProgramAveragePurchasePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_mdt_StockRepurchaseProgramAveragePurchasePrice_2bc861d9-9266-46c0-8389-0e0a9616e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_2846a9ab-ac31-4a85-9f20-946d00c16e7b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_2846a9ab-ac31-4a85-9f20-946d00c16e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_dd6a8187-5b1e-4946-a836-b90c47ae7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_dd6a8187-5b1e-4946-a836-b90c47ae7ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c676afb5-c3b4-4ef3-89bf-d2cc2102544b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_167f0a14-e827-4a9d-9179-9bb56c3fc8e9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c676afb5-c3b4-4ef3-89bf-d2cc2102544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8218bc2-2ea2-41be-bc6c-7a339df1378b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8218bc2-2ea2-41be-bc6c-7a339df1378b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_60b8a8de-e486-4bc9-b57f-75948df7a4a1" xlink:to="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_5fb1ffaa-ea0a-47b9-bbd8-d0644ec6f9cf" xlink:href="mdt-20250425.xsd#mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:to="loc_mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember_5fb1ffaa-ea0a-47b9-bbd8-d0644ec6f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_A2024EmployeeStockPurchasePlanMember_feb8ce91-d77f-4c52-b532-29302611b289" xlink:href="mdt-20250425.xsd#mdt_A2024EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4ec65800-ccf7-42b5-abf1-deea7d9218fa" xlink:to="loc_mdt_A2024EmployeeStockPurchasePlanMember_feb8ce91-d77f-4c52-b532-29302611b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e7708779-4898-45fa-8d00-138900b220a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7556ab26-fb0e-4c0c-a848-afed2abcf7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7556ab26-fb0e-4c0c-a848-afed2abcf7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4eb0c11e-83ca-44c7-80cf-a51538905563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockMember_0e9ba5ca-8d66-4b41-b1b5-e7b8d0b1822b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4eb0c11e-83ca-44c7-80cf-a51538905563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3b2e1f1c-781c-4b6a-8692-cf95b898a235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_PerformanceSharesMember_3b2e1f1c-781c-4b6a-8692-cf95b898a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_39cfb822-d256-4827-a4d5-d8f9f73148aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5c03128-9144-40e2-8a92-92abdf131206" xlink:to="loc_us-gaap_EmployeeStockMember_39cfb822-d256-4827-a4d5-d8f9f73148aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b99f7625-da82-4baf-9e25-4b41e72b8a87" xlink:to="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6492806c-a176-4d59-aabd-39f6361e2cfb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:to="loc_srt_MinimumMember_6492806c-a176-4d59-aabd-39f6361e2cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0bd080cc-8430-4aad-a482-8f0caebd3a3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2996ef02-4258-4080-987e-1bc31b8a49fd" xlink:to="loc_srt_MaximumMember_0bd080cc-8430-4aad-a482-8f0caebd3a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42487bd1-b2a9-452b-8189-51e7847485e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c2e477a5-d7af-4b0c-b0f6-a1a039348f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c2e477a5-d7af-4b0c-b0f6-a1a039348f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b771f3f4-6335-4557-b869-25c43804a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b771f3f4-6335-4557-b869-25c43804a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_037bf5f1-2573-4f9f-b50b-62ecc742c62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_037bf5f1-2573-4f9f-b50b-62ecc742c62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f2d17630-29af-4d4e-9f63-8ee7f4b9c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f2d17630-29af-4d4e-9f63-8ee7f4b9c490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5beee867-f923-4594-a972-84e09ab19aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5beee867-f923-4594-a972-84e09ab19aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_504da25f-3205-4ec0-90c0-f879c7ffa57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_504da25f-3205-4ec0-90c0-f879c7ffa57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5b9f1f90-6804-41b2-b275-9c6ba1eacd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5b9f1f90-6804-41b2-b275-9c6ba1eacd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_80f4682c-c798-4fa9-b423-87ec3867581a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_80f4682c-c798-4fa9-b423-87ec3867581a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b8beb39e-d0c2-48a8-a7c1-0e423cf7c95a" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod_b8beb39e-d0c2-48a8-a7c1-0e423cf7c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_386750e5-adc4-4116-ba28-2c84f69c944b" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare_386750e5-adc4-4116-ba28-2c84f69c944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbdca680-0990-4d6c-ada3-fc598e6e2934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb21b2-82ff-4890-9993-8d55730cf06f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbdca680-0990-4d6c-ada3-fc598e6e2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_824d359b-b203-4875-83f0-a88fb6c5c9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_824d359b-b203-4875-83f0-a88fb6c5c9f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:to="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12379bac-fc78-4fed-b4a9-c813276f0bad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef00693a-89dc-4d34-93e4-b56e1e9244b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef00693a-89dc-4d34-93e4-b56e1e9244b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e406c891-848e-49bf-94d3-6361262247ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e406c891-848e-49bf-94d3-6361262247ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad590d54-92a8-4fe9-a191-63265e236d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_us-gaap_PerformanceSharesMember_ad590d54-92a8-4fe9-a191-63265e236d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EmployeesStockPurchasePlanMember_9027689e-365f-4f0b-bc1f-c9ee4c129512" xlink:href="mdt-20250425.xsd#mdt_EmployeesStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_871ae132-8e3d-41ee-ba8f-1017af987687" xlink:to="loc_mdt_EmployeesStockPurchasePlanMember_9027689e-365f-4f0b-bc1f-c9ee4c129512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_362a3ef0-98ec-4515-b408-29cf4f98860a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a24fad6f-9698-40bd-9794-e68435292acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_CostOfSalesMember_a24fad6f-9698-40bd-9794-e68435292acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_87b1ceb1-3333-4db4-a3ae-9501e432a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_87b1ceb1-3333-4db4-a3ae-9501e432a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00fa66b0-d9cd-4968-8c39-61cb769f448f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42965685-bd29-44f8-ab01-2a9d5ab62e1f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_00fa66b0-d9cd-4968-8c39-61cb769f448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5dd3d9d-b620-4e69-bfea-4214751f0f56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ebee109-aae8-4a05-b4c0-cea423f3ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ebee109-aae8-4a05-b4c0-cea423f3ff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_970325c9-c722-414c-ad9b-0e26b1c9e7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_970325c9-c722-414c-ad9b-0e26b1c9e7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_48234e91-061a-4780-9bf0-f6a5504e6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a488b21-2c25-4ab6-b590-89f850f2aa2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_48234e91-061a-4780-9bf0-f6a5504e6da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0acf20f8-8f7e-441d-aba4-5dd0513f440c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adf23d10-8276-4051-8cfc-d951fbb3a22c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0acf20f8-8f7e-441d-aba4-5dd0513f440c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adf23d10-8276-4051-8cfc-d951fbb3a22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0acf20f8-8f7e-441d-aba4-5dd0513f440c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ce1687bc-556f-4f3f-8996-ade4fbe2871d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ce1687bc-556f-4f3f-8996-ade4fbe2871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bedfb191-898b-484f-8005-863afdad8415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bedfb191-898b-484f-8005-863afdad8415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63ecdb3b-86c0-4c06-962b-fba522b28560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63ecdb3b-86c0-4c06-962b-fba522b28560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f426418e-aa0c-449c-9639-0d418de61a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_26f0c26f-1a15-45a7-b1a2-5e67237acd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f426418e-aa0c-449c-9639-0d418de61a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5074dbb0-5d4d-4439-ba92-10e153f2b3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5074dbb0-5d4d-4439-ba92-10e153f2b3aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:to="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e1dedb3b-e9ef-405c-81e3-aed312289e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5269438a-e61f-4f3c-908f-59b9005b3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c914d7b8-89cb-4678-8574-4218f4fde05f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5269438a-e61f-4f3c-908f-59b9005b3c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e63bfc04-1bff-4437-873a-98407384c6c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0efdb408-dd36-4bbd-9d11-9b2b7043043d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0efdb408-dd36-4bbd-9d11-9b2b7043043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90621379-ba66-49fc-93f1-05f2b3edda0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90621379-ba66-49fc-93f1-05f2b3edda0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f83241a7-be12-423b-8794-b6f116704f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f83241a7-be12-423b-8794-b6f116704f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcde5c8c-d112-4bd6-86aa-a892631663f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bcde5c8c-d112-4bd6-86aa-a892631663f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cc4989b-fb04-47df-b490-e6a6bd3ce286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_929602c1-a46e-44ba-b9d0-ffe8c0d608a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cc4989b-fb04-47df-b490-e6a6bd3ce286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_484e6b22-20f2-43b6-adfc-3e88fcc3211e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_484e6b22-20f2-43b6-adfc-3e88fcc3211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e6da262a-605a-4c5d-8128-337e913caa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e6da262a-605a-4c5d-8128-337e913caa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_383e0e07-0fa2-464f-b2c5-57cd9fd2e39d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_383e0e07-0fa2-464f-b2c5-57cd9fd2e39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6188823-c4d3-423c-9953-f84c29ef350d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6188823-c4d3-423c-9953-f84c29ef350d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76577ce9-200f-49f5-9c68-d866bdb8b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76577ce9-200f-49f5-9c68-d866bdb8b21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c407bdac-67d6-4501-bb38-d8dd2e7950e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c407bdac-67d6-4501-bb38-d8dd2e7950e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cca4d5c8-caa2-4195-bc79-108bbe04f777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb38406f-36bc-49ec-8d2a-f4475b41b427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cca4d5c8-caa2-4195-bc79-108bbe04f777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f47359e9-5b92-48dc-a31c-1994f969e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f47359e9-5b92-48dc-a31c-1994f969e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e99dbb60-4ed1-4c61-80f6-eca7893b6695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e99dbb60-4ed1-4c61-80f6-eca7893b6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f60d4d88-9188-48ec-8b33-64ed5528ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f60d4d88-9188-48ec-8b33-64ed5528ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39a234ac-ef64-400e-b5bd-1c8295c9010a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39a234ac-ef64-400e-b5bd-1c8295c9010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140c0908-7a29-4057-8259-9e0677c8d5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140c0908-7a29-4057-8259-9e0677c8d5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5fb967d4-1622-4479-abcc-648b026a78b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5fb967d4-1622-4479-abcc-648b026a78b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9452e098-88aa-46fc-aab1-bb2ce1ac3fff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9452e098-88aa-46fc-aab1-bb2ce1ac3fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20718f05-54fa-41cd-ac8b-c4d6ec39d543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_82d3aea6-b85a-4340-98fe-07d8e84a71ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20718f05-54fa-41cd-ac8b-c4d6ec39d543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0f0c1de5-7fc5-4752-9603-43645e7c6841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0f0c1de5-7fc5-4752-9603-43645e7c6841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0cc3292-8ed7-4b35-95bf-588ecafab7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0cc3292-8ed7-4b35-95bf-588ecafab7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_e2e5991c-cc58-43fb-b6bd-b137f62aa625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae59a56f-1137-4840-a339-e86df766bd16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_e2e5991c-cc58-43fb-b6bd-b137f62aa625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89037091-07cb-4220-aecb-9d7c77024be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89037091-07cb-4220-aecb-9d7c77024be7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:to="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92077a95-2b3f-40e4-9203-e45eb7d2fd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f271782c-83b9-4b6d-82bb-abb8fa2a799c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3966fd-b25e-4b51-b2a8-13b14c7ee062" xlink:to="loc_us-gaap_RestrictedStockMember_f271782c-83b9-4b6d-82bb-abb8fa2a799c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ddc4854-7604-4849-9ca4-a55df7d03e2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bed4df3a-eef6-40b1-9e82-692ec1ab8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bed4df3a-eef6-40b1-9e82-692ec1ab8d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c5e7f6d-b88b-4f48-baab-4b709bb64238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c5e7f6d-b88b-4f48-baab-4b709bb64238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_795fada7-92a7-4565-b4e5-63c2f9e78afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_795fada7-92a7-4565-b4e5-63c2f9e78afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dcba480d-dd11-41ed-a6e8-6adc476929be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dcba480d-dd11-41ed-a6e8-6adc476929be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505bf984-3580-44f4-9c09-03f02756075e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_09c39c72-5ac6-4998-ae03-6ab3902474ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505bf984-3580-44f4-9c09-03f02756075e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d904a207-cb46-4408-978e-5f5d3e62936e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d904a207-cb46-4408-978e-5f5d3e62936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f45a1235-a292-4d97-b0de-ff54dbad2aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f45a1235-a292-4d97-b0de-ff54dbad2aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f44a53d2-f5d0-4891-80a9-43b7605502a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f44a53d2-f5d0-4891-80a9-43b7605502a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ff2f38b-fafb-4feb-9387-f0d9140bf00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ff2f38b-fafb-4feb-9387-f0d9140bf00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_846a7f6e-b998-443b-acb2-47ad2ef7fbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4c0c4a5f-54e5-4ea0-b218-ff69e7763b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_846a7f6e-b998-443b-acb2-47ad2ef7fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47e7e4f1-e95f-4b14-8899-2ccef41a3319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47e7e4f1-e95f-4b14-8899-2ccef41a3319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_1f18eec0-0713-493c-8c5a-96b40c69d753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c04150-c9d1-44b1-be38-0ac3736c9cd2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_1f18eec0-0713-493c-8c5a-96b40c69d753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a11e1446-9f05-4d35-90ef-6002d9be96fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a11e1446-9f05-4d35-90ef-6002d9be96fd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:to="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_debb7cd7-5e5d-44df-8d92-0a1a05216fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_80bc1113-df13-46c3-89e0-68a272e33452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854b6f1-896e-4f84-96f7-b4ba161484e1" xlink:to="loc_us-gaap_PerformanceSharesMember_80bc1113-df13-46c3-89e0-68a272e33452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9d76f8b-36a2-4afa-8345-4e1de8854b51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_632fc0f4-8301-45c5-9382-4e6454eaba33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_632fc0f4-8301-45c5-9382-4e6454eaba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7403a16-4da7-4373-bceb-0e21e707a52a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7403a16-4da7-4373-bceb-0e21e707a52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0542124b-c8c9-4be9-b1a8-3f557e631785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0542124b-c8c9-4be9-b1a8-3f557e631785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_f961ae75-ec29-46d8-a91b-7b4890753b03" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments_f961ae75-ec29-46d8-a91b-7b4890753b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3d8a1951-c1c0-48dd-9001-44ac4bae03ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3d8a1951-c1c0-48dd-9001-44ac4bae03ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94146e31-18d8-4a24-9e98-2d2f045e7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66c9edd8-1ee1-490b-abd7-bace10b74046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94146e31-18d8-4a24-9e98-2d2f045e7c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_37be375e-b164-4156-9919-0430951674f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_37be375e-b164-4156-9919-0430951674f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9cc72660-c31f-4630-b1df-18e2dd383717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9cc72660-c31f-4630-b1df-18e2dd383717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be981ad2-ac8f-47e0-862c-5324a9b360e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be981ad2-ac8f-47e0-862c-5324a9b360e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_12ef1a43-91be-48c1-9203-7665cfdeaf33" xlink:href="mdt-20250425.xsd#mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments_12ef1a43-91be-48c1-9203-7665cfdeaf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5a44abe1-b9ea-47c7-a57e-489c0e47001e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5a44abe1-b9ea-47c7-a57e-489c0e47001e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c274ce0-922d-4444-847b-c77cc81cbcac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_24d42f0a-84d7-4913-899d-46fe9ecba133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c274ce0-922d-4444-847b-c77cc81cbcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0216b599-0d61-46c6-9f54-a9846863387e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0216b599-0d61-46c6-9f54-a9846863387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_420733c2-42d0-4225-8913-fc14e9e131b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc62d58c-dfe6-4232-93bd-9e7fb4f2eb48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_420733c2-42d0-4225-8913-fc14e9e131b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32d521ef-b9b4-44b7-9e53-525f3cfe503b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_53a61005-046d-42ac-bdbb-cca433f74e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d521ef-b9b4-44b7-9e53-525f3cfe503b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_53a61005-046d-42ac-bdbb-cca433f74e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_015889d0-50f9-4211-969c-af66fea8c09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d521ef-b9b4-44b7-9e53-525f3cfe503b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_015889d0-50f9-4211-969c-af66fea8c09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88b0fde8-11b1-41d3-a495-daf6742d7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d521ef-b9b4-44b7-9e53-525f3cfe503b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88b0fde8-11b1-41d3-a495-daf6742d7ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a2fd97bc-d329-45c9-918a-48ee165d2078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aadf3426-24ea-4eb7-814b-cdb9401b3afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a2fd97bc-d329-45c9-918a-48ee165d2078" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aadf3426-24ea-4eb7-814b-cdb9401b3afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7f9a8d98-f896-4c3f-918f-8a5a85a2ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aadf3426-24ea-4eb7-814b-cdb9401b3afb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7f9a8d98-f896-4c3f-918f-8a5a85a2ea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b25ff2db-3e4b-42e5-a5e4-1e01f44fe54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aadf3426-24ea-4eb7-814b-cdb9401b3afb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b25ff2db-3e4b-42e5-a5e4-1e01f44fe54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_833d3449-910c-4740-b653-4df7aa9d9f97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aadf3426-24ea-4eb7-814b-cdb9401b3afb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_833d3449-910c-4740-b653-4df7aa9d9f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b23b86a2-b19b-4783-9bfd-b86666fd0559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a2fd97bc-d329-45c9-918a-48ee165d2078" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b23b86a2-b19b-4783-9bfd-b86666fd0559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6dd9d69e-f10c-4b94-853c-6fb55271c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b23b86a2-b19b-4783-9bfd-b86666fd0559" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6dd9d69e-f10c-4b94-853c-6fb55271c88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d8ece431-5cd7-4716-96a0-f358004b7346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b23b86a2-b19b-4783-9bfd-b86666fd0559" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d8ece431-5cd7-4716-96a0-f358004b7346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ec20787e-92c6-4f04-b733-788b4649a367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b23b86a2-b19b-4783-9bfd-b86666fd0559" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ec20787e-92c6-4f04-b733-788b4649a367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b29bea39-a822-42f4-9839-c778007207d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a2fd97bc-d329-45c9-918a-48ee165d2078" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b29bea39-a822-42f4-9839-c778007207d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b7817c91-2d0a-49df-bbd5-b4edb5708f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7817c91-2d0a-49df-bbd5-b4edb5708f15" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_5f3b88b7-8c7c-4bf1-8ac5-af1437ed1ef6" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards_5f3b88b7-8c7c-4bf1-8ac5-af1437ed1ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d69b60fa-c67f-4c26-a246-f6107a28fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d69b60fa-c67f-4c26-a246-f6107a28fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_6ede833f-abdf-4cf7-8c50-d76db444c97e" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization_6ede833f-abdf-4cf7-8c50-d76db444c97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0204c52d-3cd6-4f62-9eb6-b6f9e398983c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0204c52d-3cd6-4f62-9eb6-b6f9e398983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_37bf66ae-4abc-4078-b112-34f45b0c1dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_37bf66ae-4abc-4078-b112-34f45b0c1dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_adf78833-7b8e-460c-bd7e-650d92271285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_adf78833-7b8e-460c-bd7e-650d92271285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_575143df-d7c9-437e-80a2-ae9416253d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_575143df-d7c9-437e-80a2-ae9416253d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_635896f3-cc58-495f-b11b-8a1c8da37b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_635896f3-cc58-495f-b11b-8a1c8da37b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsLeaseObligations_c63141bc-fd7e-4b1b-968d-34939604fff7" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsLeaseObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsLeaseObligations_c63141bc-fd7e-4b1b-968d-34939604fff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_c14d6c04-92bc-4041-a723-f3a21cd86890" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions_c14d6c04-92bc-4041-a723-f3a21cd86890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsInterestLimitation_2ef522c8-67fa-43ba-a467-cbac0e9337c5" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsInterestLimitation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsInterestLimitation_2ef522c8-67fa-43ba-a467-cbac0e9337c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_184e3ea0-f581-4a1c-9509-a823eff61e7b" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives_184e3ea0-f581-4a1c-9509-a823eff61e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e8618b1a-b5bf-4766-805d-fb04c0b90319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e8618b1a-b5bf-4766-805d-fb04c0b90319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ed8613db-6ff8-4b70-b718-3b5d22cf77d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ed8613db-6ff8-4b70-b718-3b5d22cf77d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e99d90e8-c480-4974-8286-6014939f1a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e99d90e8-c480-4974-8286-6014939f1a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b6fbbb72-e4df-43af-9938-bc8878d2d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_3491575f-2064-405f-9e56-62d903f41308" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b6fbbb72-e4df-43af-9938-bc8878d2d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_50908648-44c3-41dc-a3c0-a8bf3a52d1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_50908648-44c3-41dc-a3c0-a8bf3a52d1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_9a203ce2-7f76-4091-ada4-daac6a17d6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_9a203ce2-7f76-4091-ada4-daac6a17d6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_da3875bf-17e5-4165-be3a-cba96e1a6ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_da3875bf-17e5-4165-be3a-cba96e1a6ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_debd51ae-580a-4928-8844-aec3674b6d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_debd51ae-580a-4928-8844-aec3674b6d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_56c2c874-853b-4ac3-aa54-0569f37bd3f7" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries_56c2c874-853b-4ac3-aa54-0569f37bd3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_dc8b7260-2940-4c7b-86b1-e27eea83a43b" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits_dc8b7260-2940-4c7b-86b1-e27eea83a43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7cfefa39-c852-4448-91f2-c06f82199af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7cfefa39-c852-4448-91f2-c06f82199af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_15dd9866-70e4-4a53-a553-b271039ec609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_24cba04c-9dae-49c2-b913-712c460c37cd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_15dd9866-70e4-4a53-a553-b271039ec609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_cc911c59-0faa-45d1-bdd4-76254fa02d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_us-gaap_PrepaidTaxes_cc911c59-0faa-45d1-bdd4-76254fa02d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_eaebf995-12e0-47b9-93d6-3d71638e3548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_us-gaap_IncomeTaxReceivable_eaebf995-12e0-47b9-93d6-3d71638e3548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2270be1b-6449-4235-a793-987ad528a68a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2270be1b-6449-4235-a793-987ad528a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_2ad35e29-96c4-4d3f-aafa-51ffdb1aa817" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_551b30d8-b832-4ac9-ba36-1cc5adbbe2aa" xlink:to="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_2ad35e29-96c4-4d3f-aafa-51ffdb1aa817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_ba95cece-7e74-4524-9b27-9406ac6c2d70" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsNetofValuationAllowanceOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_2ad35e29-96c4-4d3f-aafa-51ffdb1aa817" xlink:to="loc_mdt_DeferredTaxAssetsNetofValuationAllowanceOther_ba95cece-7e74-4524-9b27-9406ac6c2d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8624128a-4437-4ae4-8045-1dc44d7ce1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_2ad35e29-96c4-4d3f-aafa-51ffdb1aa817" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8624128a-4437-4ae4-8045-1dc44d7ce1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_addbf18d-fa7d-48ed-862e-482de3950ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract_2ad35e29-96c4-4d3f-aafa-51ffdb1aa817" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_addbf18d-fa7d-48ed-862e-482de3950ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fd332bb1-fb75-4cd9-a38e-24b918c6f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd332bb1-fb75-4cd9-a38e-24b918c6f0d8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e762f23-49e7-48fb-a11f-916edbcf1083" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1f280c18-fbf4-4333-bf1e-747321f104ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_ForeignCountryMember_1f280c18-fbf4-4333-bf1e-747321f104ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bc9a2e36-fd06-48cf-af9e-2577dc3f01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_DomesticCountryMember_bc9a2e36-fd06-48cf-af9e-2577dc3f01b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f8346931-ce2d-4632-bdac-d069bbf136e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a1a681fc-4df8-4c64-a9f9-43328f95a9f0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f8346931-ce2d-4632-bdac-d069bbf136e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:to="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cb93923f-277a-424d-8902-e73dbfb83803" xlink:to="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_1c50126b-0dc0-43bf-a83c-27fcb60ad52e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_58ad92a2-6d86-4839-aba5-afc8b2547151" xlink:to="loc_srt_SubsidiariesMember_1c50126b-0dc0-43bf-a83c-27fcb60ad52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b3da0a02-4e10-4b00-889e-6b6de8f09225" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_c5258d9c-6438-4c54-b4c0-6798a4b5eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_c5258d9c-6438-4c54-b4c0-6798a4b5eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_679469f5-037a-4141-b6c9-558983b9b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_679469f5-037a-4141-b6c9-558983b9b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_470b106b-7738-4574-a391-1926ecbde87f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_470b106b-7738-4574-a391-1926ecbde87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_22360058-2731-4991-8870-fe3ab08c73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_22360058-2731-4991-8870-fe3ab08c73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_c479e4af-b8c0-4271-940d-86454b7bebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_c479e4af-b8c0-4271-940d-86454b7bebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e74e88df-ee9e-443c-9aac-1105c1356b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e74e88df-ee9e-443c-9aac-1105c1356b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_57578597-f643-4232-b0a3-7bf74ecdea58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_57578597-f643-4232-b0a3-7bf74ecdea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_10ea8a14-6958-4a7f-b264-e3f9eb33939d" xlink:href="mdt-20250425.xsd#mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration_10ea8a14-6958-4a7f-b264-e3f9eb33939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b335800-9276-4152-8eb3-01fccf3c80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4b335800-9276-4152-8eb3-01fccf3c80e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c6c8f2fa-75d4-4c0f-890b-d293a0e640e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_c6c8f2fa-75d4-4c0f-890b-d293a0e640e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_135387f6-9918-455e-90ae-fc441cb3441d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_135387f6-9918-455e-90ae-fc441cb3441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_83960f3c-bcda-4e2a-8657-deb4400fe41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_83960f3c-bcda-4e2a-8657-deb4400fe41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_246d33a8-7c1d-4724-b5da-c9c6da191610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_246d33a8-7c1d-4724-b5da-c9c6da191610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7faa0de1-eab8-4b7e-afab-b6bde98a8ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7faa0de1-eab8-4b7e-afab-b6bde98a8ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9d8919ee-2ef8-4dc2-8f21-fe9b34a33830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9d8919ee-2ef8-4dc2-8f21-fe9b34a33830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_32def2f1-62e7-44df-bacc-b63af7f9a8f6" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion_32def2f1-62e7-44df-bacc-b63af7f9a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_1324e950-9cdb-43c5-b3e6-cc957ec4c7c4" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount_1324e950-9cdb-43c5-b3e6-cc957ec4c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_0930cdc2-0290-4471-96b2-8133a5e817ab" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount_0930cdc2-0290-4471-96b2-8133a5e817ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a2099bb-f199-4d78-8f59-99ece0b8f947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_9a2099bb-f199-4d78-8f59-99ece0b8f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_7589c17b-577a-4825-b532-b7db5efcc379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxHolidays"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxHolidays_7589c17b-577a-4825-b532-b7db5efcc379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_da5c669f-98dc-474a-a66a-df9fdaebd404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_da5c669f-98dc-474a-a66a-df9fdaebd404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_37f7e64c-1da5-4617-98dc-7f7a72f40b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_37f7e64c-1da5-4617-98dc-7f7a72f40b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5b854cf8-42f7-444b-adda-967b570c9d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5b854cf8-42f7-444b-adda-967b570c9d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5b94051c-5068-4eef-872c-0f3b8a8da6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5b94051c-5068-4eef-872c-0f3b8a8da6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3981d71e-0e96-4118-b9c2-b1a88cbd07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3981d71e-0e96-4118-b9c2-b1a88cbd07c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_e1751d35-26a5-4dc6-89d8-e5ea775f29d6" xlink:href="mdt-20250425.xsd#mdt_IncomeTaxExaminationInterestIncomeExpenseGross"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_mdt_IncomeTaxExaminationInterestIncomeExpenseGross_e1751d35-26a5-4dc6-89d8-e5ea775f29d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5a422a6d-aef0-47df-baa7-d258ca795e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_962f2788-2c0f-422b-b08e-d0427bd3f0cd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5a422a6d-aef0-47df-baa7-d258ca795e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7047b0a9-617d-427c-b7ec-37b87b7bc58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abf49c78-6125-4b71-aee9-bd96b6c430c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7047b0a9-617d-427c-b7ec-37b87b7bc58a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abf49c78-6125-4b71-aee9-bd96b6c430c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:href="mdt-20250425.xsd#mdt_IncreaseDecreaseInTaxRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7047b0a9-617d-427c-b7ec-37b87b7bc58a" xlink:to="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d56e781-9849-4f5c-9960-2f59c95681bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d56e781-9849-4f5c-9960-2f59c95681bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b34c6815-db59-4895-9e6e-ae0b1569f167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b34c6815-db59-4895-9e6e-ae0b1569f167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_77862d61-60c5-4f54-b407-ad4d93706119" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax_77862d61-60c5-4f54-b407-ad4d93706119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7befc6ae-273f-4585-96a5-396742d9e316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7befc6ae-273f-4585-96a5-396742d9e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_240acf95-4fa7-4cd7-bc45-8fa6f43dd44c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_240acf95-4fa7-4cd7-bc45-8fa6f43dd44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_e941f63f-e91f-428f-86fe-ba5444e354e3" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_e941f63f-e91f-428f-86fe-ba5444e354e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_6d473d62-43ed-4401-8dbb-adf9d8033a65" xlink:href="mdt-20250425.xsd#mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent_6d473d62-43ed-4401-8dbb-adf9d8033a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_bef59e20-8137-4ff5-a281-2cc0816a5a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_bef59e20-8137-4ff5-a281-2cc0816a5a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_51ca7e25-22a8-4eea-8b54-637ce2ad37fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_51ca7e25-22a8-4eea-8b54-637ce2ad37fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_afef0c3b-e6b5-40d2-a92d-56382f3846a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_afef0c3b-e6b5-40d2-a92d-56382f3846a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_db78f615-55c4-4aa5-adb3-caa3a1c6cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_IncreaseDecreaseInTaxRateAbstract_876821a6-1454-42b7-bdf8-7b62e4c1fc11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_db78f615-55c4-4aa5-adb3-caa3a1c6cc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e66dd7d-3ab9-4863-aad5-2c60870e7663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7047b0a9-617d-427c-b7ec-37b87b7bc58a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e66dd7d-3ab9-4863-aad5-2c60870e7663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_89472813-aa32-4beb-983c-c06ee26e1f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89472813-aa32-4beb-983c-c06ee26e1f98" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_516bd620-0bae-4597-9ee7-72130ebda90b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_516bd620-0bae-4597-9ee7-72130ebda90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_7cfebfcb-cd71-4ab3-86bd-ad273f89231c" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_7cfebfcb-cd71-4ab3-86bd-ad273f89231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0acbbcc3-01ba-490a-9fa3-8f2eaf8287bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_7cfebfcb-cd71-4ab3-86bd-ad273f89231c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0acbbcc3-01ba-490a-9fa3-8f2eaf8287bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d6965bdb-e25f-46e1-a61d-6d1436085752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract_7cfebfcb-cd71-4ab3-86bd-ad273f89231c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d6965bdb-e25f-46e1-a61d-6d1436085752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_32d4e77a-ea36-4913-9b32-b38af2c2f43a" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_32d4e77a-ea36-4913-9b32-b38af2c2f43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_52d9cd69-bfe4-4a28-8883-89b79555c86a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_32d4e77a-ea36-4913-9b32-b38af2c2f43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_52d9cd69-bfe4-4a28-8883-89b79555c86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c11133e8-df2c-4b2a-8dda-cff7afdf0f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_32d4e77a-ea36-4913-9b32-b38af2c2f43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c11133e8-df2c-4b2a-8dda-cff7afdf0f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_9c32cba4-89ba-42a7-8e7c-53ca1acc46fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract_32d4e77a-ea36-4913-9b32-b38af2c2f43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_9c32cba4-89ba-42a7-8e7c-53ca1acc46fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_52e149b5-8ca0-47a0-b666-448df5e794a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_52e149b5-8ca0-47a0-b666-448df5e794a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements_b8906422-1c94-40fe-a38c-97ac9c3df1de" xlink:href="mdt-20250425.xsd#mdt_CashAdvancePaidinConnectionWithProposedSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_mdt_CashAdvancePaidinConnectionWithProposedSettlements_b8906422-1c94-40fe-a38c-97ac9c3df1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_9344493b-5ec8-4d34-8c73-8af93ec39693" xlink:href="mdt-20250425.xsd#mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4009f11a-15de-4e6f-ae2d-09123026fba6" xlink:to="loc_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid_9344493b-5ec8-4d34-8c73-8af93ec39693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b767312a-2865-4f87-9b96-e3820e13aad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b767312a-2865-4f87-9b96-e3820e13aad1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:to="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1c045e45-5d18-40d7-aa34-6aaaf08f3cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5655e55b-68ea-434c-ac34-97b16a8727bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5655e55b-68ea-434c-ac34-97b16a8727bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_323ea425-dbca-4d44-9755-0567793f0b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_323ea425-dbca-4d44-9755-0567793f0b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5dd539e8-6498-4b6b-941d-b402664c79cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f4aa5d5-014f-46ad-a030-be8bad3d6873" xlink:to="loc_us-gaap_PerformanceSharesMember_5dd539e8-6498-4b6b-941d-b402664c79cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f4c26443-8587-4b33-8f6b-c79e33bc87af" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fc71915-3da7-4d23-bd16-1a521ceea23e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d3cab4c6-4bd6-4355-ac79-51483ecc48a5" xlink:to="loc_us-gaap_NetIncomeLoss_5fc71915-3da7-4d23-bd16-1a521ceea23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_5b6a4b42-03e7-4df3-ab3b-4dd7614d0cc7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae32bd2e-40a1-46d9-a1a4-7678069af3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae32bd2e-40a1-46d9-a1a4-7678069af3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f38e0298-3b70-4edc-8c9f-64c9178b4b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f38e0298-3b70-4edc-8c9f-64c9178b4b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_c216fc15-b25f-46e7-aba3-3554973b427a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_97766529-3881-481a-8402-358db1c38e27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends_c216fc15-b25f-46e7-aba3-3554973b427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_677dae2c-5d71-49fa-964e-2eaf4a7b0ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_677dae2c-5d71-49fa-964e-2eaf4a7b0ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cb22cd43-e514-4576-b1aa-ff5d2f086270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_EarningsPerShareBasic_cb22cd43-e514-4576-b1aa-ff5d2f086270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fedc64fa-e530-483d-bcd1-050982d801c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13b9b2b6-7e3e-4188-ad9c-1b5ba18c905c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fedc64fa-e530-483d-bcd1-050982d801c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a01be7da-fd1f-402e-bf64-6a59c2d6b2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a01be7da-fd1f-402e-bf64-6a59c2d6b2c2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffcfea24-63c3-48e6-866a-3da7589fc808" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_405a57c6-c782-41db-ab9d-b49262621831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aee65aa1-d506-4e54-b095-f375d5539405" xlink:to="loc_us-gaap_EmployeeStockOptionMember_405a57c6-c782-41db-ab9d-b49262621831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d9d0df1-2031-4f57-b0fa-6366d5395989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a6e3264c-2523-44c8-a6b0-a055f8dd49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4ab1cbcc-d0d8-48e9-85b1-e0fb94c2795c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a6e3264c-2523-44c8-a6b0-a055f8dd49f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c0541f09-d971-4c92-9057-605fd6811ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c0541f09-d971-4c92-9057-605fd6811ff8" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_37d10585-b896-45ea-956c-42fcfa289ce5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f8401978-8863-40b3-8145-b4d7fcf84c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f8401978-8863-40b3-8145-b4d7fcf84c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5b7511e5-9efa-4296-b424-a0a5451df41e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_286b6361-090c-4ae0-ad4c-6d7d6677fb8e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5b7511e5-9efa-4296-b424-a0a5451df41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f07695fb-af8d-49fc-8a09-c8ed8fb29776" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:to="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d17576e3-8f76-4be6-a3c8-f60223e63b6b" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_222e5195-2ebe-4fa5-baec-cc1c5dec4567" xlink:to="loc_country_US_d17576e3-8f76-4be6-a3c8-f60223e63b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d9533771-c8e2-40c9-909a-1513b6dd3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d36ff39-6a7e-4205-8cb1-ce5068201436" xlink:to="loc_us-gaap_ForeignPlanMember_d9533771-c8e2-40c9-909a-1513b6dd3b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_b485f8ee-c7e0-4058-bb89-6b5d773afc4f" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_032fbfe0-612d-4c9d-bee9-f493b70ddc69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_032fbfe0-612d-4c9d-bee9-f493b70ddc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_e995361e-8c74-45bf-b73e-5ef7af5b2538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_e995361e-8c74-45bf-b73e-5ef7af5b2538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_e35ed134-e0ee-486e-b33f-a0c3904455cb" xlink:href="mdt-20250425.xsd#mdt_OtherPlanAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b4dbe8bd-33b4-46ff-b617-77195d5c2c95" xlink:to="loc_mdt_OtherPlanAssetsMember_e35ed134-e0ee-486e-b33f-a0c3904455cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bbb98dd0-0854-4cb7-b8af-a5b30c351eb4" xlink:to="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c44f92cc-f138-4c00-ab8a-4248e4732ade" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:to="loc_srt_MinimumMember_c44f92cc-f138-4c00-ab8a-4248e4732ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f27151d-418d-4523-a706-6f600e048df4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6abfa7ac-350a-4777-b8b9-017037c36975" xlink:to="loc_srt_MaximumMember_9f27151d-418d-4523-a706-6f600e048df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_276a1a6e-e535-46bc-a7ed-4cf8a18d17b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2780f45-27ba-45c6-b1d7-178d412db16e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9936316-3a27-4c2f-8bf4-4b6010c40e9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2780f45-27ba-45c6-b1d7-178d412db16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ed633b8-0a9d-4c68-95bf-e8b7b27bf933" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_95c5550d-30dc-4eb9-a4f4-70c70be14c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_95c5550d-30dc-4eb9-a4f4-70c70be14c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ed0208f2-a878-4d30-8c9e-497f4ec5d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ed0208f2-a878-4d30-8c9e-497f4ec5d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_94ad5d20-2069-4b3b-ad5c-384093246a11" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits_94ad5d20-2069-4b3b-ad5c-384093246a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4da62a93-ceb2-40e2-a45b-2a7efc351029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4da62a93-ceb2-40e2-a45b-2a7efc351029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_035d9f78-6332-46b0-9cdb-e15ee1f779fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_035d9f78-6332-46b0-9cdb-e15ee1f779fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_d842e967-87e7-47fa-b097-91e2668202e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_d842e967-87e7-47fa-b097-91e2668202e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_95a21133-9eb6-4f10-8708-65374cc090ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_95a21133-9eb6-4f10-8708-65374cc090ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e37b491-b226-4086-968f-bea0e6b67cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e37b491-b226-4086-968f-bea0e6b67cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7d8e87ab-bb4a-48dc-87c9-9de90b789ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7d8e87ab-bb4a-48dc-87c9-9de90b789ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_60a0ce27-fd46-402d-9083-230a1db4324a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_5853a7e7-5f03-421c-8031-88180837ff81" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_60a0ce27-fd46-402d-9083-230a1db4324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f8e47b2f-89c0-43e3-a199-0e13ad26eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f8e47b2f-89c0-43e3-a199-0e13ad26eb5d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7a8bcdbf-58c1-45b8-a031-4ae93ebc98e2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:to="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5c41c0fc-6c6e-4a46-90ca-e2f9ab959aa2" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_fa66f5d0-e9cb-47c4-8a83-51d99cf80954" xlink:to="loc_country_US_5c41c0fc-6c6e-4a46-90ca-e2f9ab959aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_aec031d1-a4fb-43ea-9570-dd5c9e1474a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b6d8203a-283d-4a6d-a64e-53696af29d57" xlink:to="loc_us-gaap_ForeignPlanMember_aec031d1-a4fb-43ea-9570-dd5c9e1474a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e56f9f8e-2ef4-4de9-8b6f-4f6e4b8090e3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b2be62e1-bea0-4b1d-baea-af96ea160bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0bd7c8b2-dafc-4738-b350-5204946b4914" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b2be62e1-bea0-4b1d-baea-af96ea160bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_79cdfc4b-3dcd-4540-b2c2-4ec6b93c55d9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a98c8301-119d-40d7-89cb-d7b1b881d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_a98c8301-119d-40d7-89cb-d7b1b881d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d8a9ecf3-e2b7-4dba-8c65-cabfe6d6aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d8a9ecf3-e2b7-4dba-8c65-cabfe6d6aa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_d8ffbcf3-b99d-4b7e-8357-0f4bdf865444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_d8ffbcf3-b99d-4b7e-8357-0f4bdf865444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ff77ceb4-1cd8-4a7f-b8c7-805acca0de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ff77ceb4-1cd8-4a7f-b8c7-805acca0de2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b477d639-8b69-49d7-87cd-7fc6c328fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b477d639-8b69-49d7-87cd-7fc6c328fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_b2d2256c-3396-4e8f-988d-95057c232250" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation_b2d2256c-3396-4e8f-988d-95057c232250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ced64759-3b78-4217-bf59-2d6b5bdcdb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_ced64759-3b78-4217-bf59-2d6b5bdcdb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7be798f5-ec19-4cd8-a33b-ed96a076935f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7be798f5-ec19-4cd8-a33b-ed96a076935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_366bece2-e81a-4df5-a46c-5115ecc10c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_366bece2-e81a-4df5-a46c-5115ecc10c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_af9df1ca-47d8-4e56-9590-29618da2717a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_55e96357-67e7-4274-a2ac-dc2cd187212d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_af9df1ca-47d8-4e56-9590-29618da2717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8277e4e5-029d-4138-9484-03f54f283b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8277e4e5-029d-4138-9484-03f54f283b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_db064e7f-4301-423a-94fe-fc4666b94f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_db064e7f-4301-423a-94fe-fc4666b94f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_433ada24-24ae-4ace-bf84-50efd9055cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_433ada24-24ae-4ace-bf84-50efd9055cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_488c46e4-b544-4030-b434-44de6c77a595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_488c46e4-b544-4030-b434-44de6c77a595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f77585f1-0fc2-438e-b6d4-615499d48364" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f77585f1-0fc2-438e-b6d4-615499d48364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_a1600a55-dad1-4cf5-83db-fd0c15a7e342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_a1600a55-dad1-4cf5-83db-fd0c15a7e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_86f56e4c-678c-4787-8eff-247be3e21715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_86f56e4c-678c-4787-8eff-247be3e21715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0b1009ca-42f7-41d8-9ffe-72ebf0f65814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_654678a6-1560-468a-aea7-27c12fa79b21" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0b1009ca-42f7-41d8-9ffe-72ebf0f65814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edc37bb6-3480-4c6f-a9be-adef24919eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edc37bb6-3480-4c6f-a9be-adef24919eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_11545699-6e05-424f-aed9-541eb261a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_11545699-6e05-424f-aed9-541eb261a47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_1278dcf8-c3d7-439f-b6bf-b47247f7acc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_1278dcf8-c3d7-439f-b6bf-b47247f7acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_5d406ba0-2f59-4659-bf21-ac68d4a9d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract_0a4c7f2e-a7d1-4236-8525-69208a2b7a52" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_5d406ba0-2f59-4659-bf21-ac68d4a9d3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c0a2d8bb-06e4-45ec-bc08-942bf6ad875b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c0a2d8bb-06e4-45ec-bc08-942bf6ad875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_236ce513-b8c5-4682-957f-21ea6088b101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_236ce513-b8c5-4682-957f-21ea6088b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bdc1bd99-3738-4418-83ef-ee12d37a4938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bdc1bd99-3738-4418-83ef-ee12d37a4938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_481f39db-c96e-464f-be37-13fe0fcd0ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8a9f0cf4-e9d8-4c12-8466-b16d4d0a9871" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_481f39db-c96e-464f-be37-13fe0fcd0ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c3f55d48-5b9b-4dae-82d4-77856ca855b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_c3f55d48-5b9b-4dae-82d4-77856ca855b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_645ad3a5-81d3-46d9-ba91-b345e6bde1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_645ad3a5-81d3-46d9-ba91-b345e6bde1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_d22a6979-755d-42bd-8486-30b3848b5422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract_15a3e880-8665-4ee3-a2ee-13916384fd98" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_d22a6979-755d-42bd-8486-30b3848b5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_2bcdea4f-0a7f-4224-aa0c-ec0cc2f551ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_2bcdea4f-0a7f-4224-aa0c-ec0cc2f551ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_cc9819c5-5777-41c3-a6d3-478add79ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_cc9819c5-5777-41c3-a6d3-478add79ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0d7536f3-06c1-4860-a110-9c8855e03851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_b067a540-f061-4015-8180-f63f1f58963b" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0d7536f3-06c1-4860-a110-9c8855e03851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_061f2101-7248-4399-92de-224ff1c69622" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_f63f96a0-3661-4f73-88bf-da6f89f81f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_f63f96a0-3661-4f73-88bf-da6f89f81f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_ca37b8a8-5b3f-4a08-937b-f3fb02616692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_ae0de478-c711-4442-8400-5a7f53e03f66" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_ca37b8a8-5b3f-4a08-937b-f3fb02616692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansNetPeriodicCostandAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4304417c-c40f-4d44-82e5-de414d55e0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4304417c-c40f-4d44-82e5-de414d55e0ef" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_49a61f78-2bf0-4392-b25c-2f43fc23d1ff" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:to="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7cda5aa1-54a8-465e-9b80-4f69feb81b3a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_4746503f-4a8f-45fd-b681-05a1d0b6d1cc" xlink:to="loc_country_US_7cda5aa1-54a8-465e-9b80-4f69feb81b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_2392fbd2-4d57-40aa-94c5-741037d459a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d8f9a64c-3642-4c47-959c-6eb86fc3f434" xlink:to="loc_us-gaap_ForeignPlanMember_2392fbd2-4d57-40aa-94c5-741037d459a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_71446a95-9fd6-40e2-b292-a46e9413546f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5aeb2f3d-8a79-42c8-9666-b1a37fff799e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_af0ebd27-3b8a-421a-9bc9-f95bbf6aae92" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5aeb2f3d-8a79-42c8-9666-b1a37fff799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1d0dad72-9136-4423-b2e2-3cd61f9d9728" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_b8f6ac62-d280-4e5f-ad98-5fadba36fb14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_b8f6ac62-d280-4e5f-ad98-5fadba36fb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d1388c97-c001-43eb-807f-7f9f52534950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d1388c97-c001-43eb-807f-7f9f52534950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cb45b300-d330-42ba-a104-13d3e7778903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cb45b300-d330-42ba-a104-13d3e7778903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b003c85f-78df-492f-883b-25d08aa9f350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_b003c85f-78df-492f-883b-25d08aa9f350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_88de392c-c8b0-45c2-b795-986721d801f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_88de392c-c8b0-45c2-b795-986721d801f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b8f57f70-6140-472c-b84b-2e503929d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b8f57f70-6140-472c-b84b-2e503929d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89deee2-5d00-4631-a462-db2e11e36f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_f89deee2-5d00-4631-a462-db2e11e36f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7d0615be-122b-4003-9682-a7500b93677e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_e6676bc2-7d10-49a2-92b0-3bcf20dac120" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7d0615be-122b-4003-9682-a7500b93677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3267253f-0a63-4ae0-81d2-037c0a6268e6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8cbc73e-fe81-41cd-856a-bed91fcc315a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8cbc73e-fe81-41cd-856a-bed91fcc315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9aeee88d-50d1-4de2-bb3f-b4415732860b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9aeee88d-50d1-4de2-bb3f-b4415732860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_15a3e4d3-e012-4183-9c85-4abfcc37c93c" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax_15a3e4d3-e012-4183-9c85-4abfcc37c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_43c31601-8958-42f7-952d-e0131558539a" xlink:href="mdt-20250425.xsd#mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment_43c31601-8958-42f7-952d-e0131558539a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a844534d-2feb-437f-95a9-09ddd253f052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a844534d-2feb-437f-95a9-09ddd253f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f0f37447-aa24-4630-a74f-daf55978f554" xlink:href="mdt-20250425.xsd#mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_8a0851f7-f04e-411b-bf5f-bcbac659c51b" xlink:to="loc_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f0f37447-aa24-4630-a74f-daf55978f554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fe7fa6f7-7c39-41a3-972d-938dd022be17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fe7fa6f7-7c39-41a3-972d-938dd022be17" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5c4fdf46-a4eb-4fac-98d9-c5740d4e3d3b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6ba2f03b-d8ba-4c65-b260-c886a4f65fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c74304ae-8235-4a99-8086-90c987ba61f0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6ba2f03b-d8ba-4c65-b260-c886a4f65fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c899fbf4-1b1b-4491-b8b3-764fc49b7196" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:to="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70ecbd6a-5e60-48b6-984c-4ed77b11504d" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_d6856223-d383-456d-9036-a24e2a365be5" xlink:to="loc_country_US_70ecbd6a-5e60-48b6-984c-4ed77b11504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ff20d294-6b63-4712-a3ae-875d4a4cb8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8b9ace37-7691-4f41-9b68-a815402c47cf" xlink:to="loc_us-gaap_ForeignPlanMember_ff20d294-6b63-4712-a3ae-875d4a4cb8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3c82eb0-a18a-4bf3-87cf-49ca184adb24" xlink:to="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_640c67c6-ea36-4e82-85ee-401f0e118b7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:to="loc_srt_MinimumMember_640c67c6-ea36-4e82-85ee-401f0e118b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d37f8f-6f45-4a21-94be-e6dc4bae56c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5178d3b-3bf9-4066-8404-97358db6766c" xlink:to="loc_srt_MaximumMember_d5d37f8f-6f45-4a21-94be-e6dc4bae56c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7239e1e2-50c3-4ca9-8cab-19fbf9328c92" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b0a1586e-6ebe-47f0-98c1-8d67e5270ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b0a1586e-6ebe-47f0-98c1-8d67e5270ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_8ef93792-4d2f-47ee-a310-f24c2a240e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_8ef93792-4d2f-47ee-a310-f24c2a240e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherPlanAssetsMember_ad39b86c-d08d-485f-aa02-50f688ef0336" xlink:href="mdt-20250425.xsd#mdt_OtherPlanAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b66a6758-cc20-493d-9aef-046e32f969d1" xlink:to="loc_mdt_OtherPlanAssetsMember_ad39b86c-d08d-485f-aa02-50f688ef0336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a853225c-5c9c-4d03-b865-59df8ac74f50" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f84f57ce-80ec-4c33-9260-dc45f078a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f84f57ce-80ec-4c33-9260-dc45f078a83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06e7b307-07ca-406a-8f86-368970fb11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_6d517b47-6d1c-4600-a604-6b5eec6d9529" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06e7b307-07ca-406a-8f86-368970fb11b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_2beec47a-cbdf-4423-b540-2e3a46c8b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_2beec47a-cbdf-4423-b540-2e3a46c8b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_807e8ba5-bd13-4bc0-aa48-547946ef8d6d" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate_807e8ba5-bd13-4bc0-aa48-547946ef8d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_f437f6cd-853c-4343-a040-3bdb051891b2" xlink:href="mdt-20250425.xsd#mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_f437f6cd-853c-4343-a040-3bdb051891b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_726934cc-e1fe-44b0-b08c-2bb462151d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_726934cc-e1fe-44b0-b08c-2bb462151d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_357bfb51-99c5-4f88-a381-c1ba9dd98083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_99d78dd7-c04d-4992-a5fe-fa01f08aa463" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_357bfb51-99c5-4f88-a381-c1ba9dd98083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e2f9994-a6d8-458a-a0b7-554c7b4aa1d6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4271f84e-6028-4fd9-ad68-56ac33b5ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4271f84e-6028-4fd9-ad68-56ac33b5ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_4a55d9b2-7715-4ec7-9bec-64c88aa2284e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract_e7444e67-8ece-4fbb-b38e-612f89f3ae16" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_4a55d9b2-7715-4ec7-9bec-64c88aa2284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ce74a9c-0338-4e5c-bd14-58704954ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ce74a9c-0338-4e5c-bd14-58704954ca9c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dcdda6e6-dec9-48e6-816e-ccf846f27a2c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_50a9678e-2efd-4332-b7d9-2b7d8dfbc8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_7b620ab7-b632-470f-9794-1f33d12249ec" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_50a9678e-2efd-4332-b7d9-2b7d8dfbc8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fc6bb08-3fbd-444c-8906-0da4a904b328" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:to="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8d4a0c33-fc98-48d1-a90a-ae745a0d2ce1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_bc17776a-5282-40c4-a5fc-a609c2effcfe" xlink:to="loc_country_US_8d4a0c33-fc98-48d1-a90a-ae745a0d2ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_3a0fa4bf-c7d2-45ab-9f0b-3785f3c03875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b9ff104a-09d1-4fe5-a82a-aada6c807436" xlink:to="loc_us-gaap_ForeignPlanMember_3a0fa4bf-c7d2-45ab-9f0b-3785f3c03875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a1184446-ba7e-479b-b02b-ef70016356a8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_61c064e0-b48d-4ae0-a368-74bcf8fe3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_61c064e0-b48d-4ae0-a368-74bcf8fe3b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_814fc05f-57b4-4bb3-8272-32dc8b41007f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_MutualFundMember_814fc05f-57b4-4bb3-8272-32dc8b41007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_f1ddefb7-d066-4d32-874f-f255a8c2e408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_EquityFundsMember_f1ddefb7-d066-4d32-874f-f255a8c2e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_361dad50-f859-43a1-833d-d5395d67e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_us-gaap_FixedIncomeFundsMember_361dad50-f859-43a1-833d-d5395d67e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_f837699d-dcca-4bb6-ad43-04e680572251" xlink:href="mdt-20250425.xsd#mdt_PartnershipUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_PartnershipUnitsMember_f837699d-dcca-4bb6-ad43-04e680572251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_RegisteredInvestmentCompanyMember_8519d4d1-b39e-4f44-bb76-0be5432aa619" xlink:href="mdt-20250425.xsd#mdt_RegisteredInvestmentCompanyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_RegisteredInvestmentCompanyMember_8519d4d1-b39e-4f44-bb76-0be5432aa619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_InsuranceContractMember_b91a5263-d844-4a93-a712-f338ef2179e2" xlink:href="mdt-20250425.xsd#mdt_InsuranceContractMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_dea6f80c-2e75-415c-830f-542a081bfd49" xlink:to="loc_mdt_InsuranceContractMember_b91a5263-d844-4a93-a712-f338ef2179e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_51814bff-ec7a-40aa-8551-ce56905b44b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4a0cf007-66dd-4b10-85b9-4b3b1ff63c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4a0cf007-66dd-4b10-85b9-4b3b1ff63c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5bf07e82-c42a-4952-8000-281d5200e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5bf07e82-c42a-4952-8000-281d5200e51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b9b45976-b4de-41dc-a0e9-762824d364a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b9b45976-b4de-41dc-a0e9-762824d364a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_21c14b19-944b-497c-9590-88065506335d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_052489a8-9163-445d-9fde-503f680c5481" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_21c14b19-944b-497c-9590-88065506335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c15e2db-2477-479b-8f46-4d6fa2660e53" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_PartnershipUnitsMember_db183742-7ab5-489c-b09b-9881b1cef5ef" xlink:href="mdt-20250425.xsd#mdt_PartnershipUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_925aabf2-9d99-4fb2-9960-dcdfa6069524" xlink:to="loc_mdt_PartnershipUnitsMember_db183742-7ab5-489c-b09b-9881b1cef5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_42f38ed6-5d33-44b5-9888-cebae584aedc" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ff1f72d3-41d9-4879-8651-fc72537ace23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1e2ad9b-9b06-4961-ab43-7f3cae41fafb" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ff1f72d3-41d9-4879-8651-fc72537ace23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#RetirementBenefitPlansFutureBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ee0571ad-dae5-4717-9bb0-fa04a147f94e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ee0571ad-dae5-4717-9bb0-fa04a147f94e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9375cb02-f662-4403-a682-fb80bf456703" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_84f2026f-4a39-46a7-a696-47ae9000d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f5d381a0-5852-4c89-a6dd-819e39b09821" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_84f2026f-4a39-46a7-a696-47ae9000d6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7641fd7e-52f6-4440-8c20-24862b966220" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:to="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_18843fe1-791a-49b6-bf65-b30b00c6fe8f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_d6f33c56-3561-4d17-9cf7-59538852be87" xlink:to="loc_country_US_18843fe1-791a-49b6-bf65-b30b00c6fe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_931a5bd2-70f5-4910-a319-779b8ab65997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cff272b5-2156-42ed-b33f-f9b8a5fbdabd" xlink:to="loc_us-gaap_ForeignPlanMember_931a5bd2-70f5-4910-a319-779b8ab65997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_964a5330-7996-4427-8f24-0ca14b6e0a59" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2cc5ab57-f9ed-4458-babc-5eb01e5b9f59" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c284638a-9462-4df1-a2e2-98507d8064cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c284638a-9462-4df1-a2e2-98507d8064cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_7cf4363c-ecf5-453f-9536-e98a664df362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_7cf4363c-ecf5-453f-9536-e98a664df362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_91a7d931-144f-4614-a8d9-92598e33d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_91a7d931-144f-4614-a8d9-92598e33d62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2160a5f3-0197-4416-82b9-ea0223d8423f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2160a5f3-0197-4416-82b9-ea0223d8423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_0686ab17-4105-4290-96c6-f993ef526554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_0686ab17-4105-4290-96c6-f993ef526554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_01ab5059-9065-4bdc-ada3-91988e1b5034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_907d06d4-c61d-4857-993c-b20dd42231fe" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_01ab5059-9065-4bdc-ada3-91988e1b5034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_497d3be0-b60e-41ef-8e01-0df2303c72de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_497d3be0-b60e-41ef-8e01-0df2303c72de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ef6dde08-6b4f-4670-99d0-859d5c39382d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ef6dde08-6b4f-4670-99d0-859d5c39382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_982419c1-bf70-49f6-9bef-9fcdacd58824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_982419c1-bf70-49f6-9bef-9fcdacd58824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_188b489f-7165-4642-8011-ca18bc082664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_188b489f-7165-4642-8011-ca18bc082664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_294a3c5c-d1cf-4040-bfe8-70a6a201bd25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_294a3c5c-d1cf-4040-bfe8-70a6a201bd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_24b57e92-17c3-4cc2-9292-b443f637edf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_790664aa-d6e4-45f3-ab9f-e9427be0334f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_24b57e92-17c3-4cc2-9292-b443f637edf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7e36c432-fce5-474e-a6e9-692fabb6efd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2f5a0b87-ebcd-4660-923e-399d125dfea6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7e36c432-fce5-474e-a6e9-692fabb6efd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2f5a0b87-ebcd-4660-923e-399d125dfea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3173423c-7e6b-4d8c-a052-5e39c764a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7e36c432-fce5-474e-a6e9-692fabb6efd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3173423c-7e6b-4d8c-a052-5e39c764a2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesComponentsofTotalOperatingLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d4106006-afb1-4e8e-859c-9a7fa0558d47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ef9e6ea7-1139-4f47-a293-fe2a3f86de1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4106006-afb1-4e8e-859c-9a7fa0558d47" xlink:to="loc_us-gaap_OperatingLeaseCost_ef9e6ea7-1139-4f47-a293-fe2a3f86de1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_e11b6d00-ea96-4083-bb63-5807f8896672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4106006-afb1-4e8e-859c-9a7fa0558d47" xlink:to="loc_us-gaap_ShortTermLeaseCost_e11b6d00-ea96-4083-bb63-5807f8896672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a61d3eaf-7ad8-412f-8891-5a4f83c5281a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4106006-afb1-4e8e-859c-9a7fa0558d47" xlink:to="loc_us-gaap_LeaseCost_a61d3eaf-7ad8-412f-8891-5a4f83c5281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_89cbc0e1-3562-453d-afd9-eb5662dc3ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2336cec9-01eb-4c65-8853-3e79084e459d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89cbc0e1-3562-453d-afd9-eb5662dc3ab9" xlink:to="loc_us-gaap_OperatingLeasePayments_2336cec9-01eb-4c65-8853-3e79084e459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_be43d099-5795-43f5-a7d8-a80fe0d83ada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89cbc0e1-3562-453d-afd9-eb5662dc3ab9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_be43d099-5795-43f5-a7d8-a80fe0d83ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#LeasesMaturitiesofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb286678-5c6e-47a3-a336-48dca11bae2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fb286678-5c6e-47a3-a336-48dca11bae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2a70fb4-4bf9-4460-88a3-65c39fac2561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2a70fb4-4bf9-4460-88a3-65c39fac2561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_818933ae-0e3c-4653-9379-4d364d6ce570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_818933ae-0e3c-4653-9379-4d364d6ce570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d73ffba4-9023-4a1c-91fc-cac3c258d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d73ffba4-9023-4a1c-91fc-cac3c258d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bfdcbbe3-f03b-4668-b3ec-0060dbf37d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bfdcbbe3-f03b-4668-b3ec-0060dbf37d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9ffd5a1f-5d59-45eb-a78c-261df106126d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9ffd5a1f-5d59-45eb-a78c-261df106126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e36a7ad2-0213-4dc8-a790-6231fc5c2db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e36a7ad2-0213-4dc8-a790-6231fc5c2db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76d4b703-c591-40cc-b8c2-c2ba6e17bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_76d4b703-c591-40cc-b8c2-c2ba6e17bcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_54effea3-9714-45c1-86aa-efd8715d139d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3dcce44-60f7-4360-90b7-49070c9d75f0" xlink:to="loc_us-gaap_OperatingLeaseLiability_54effea3-9714-45c1-86aa-efd8715d139d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#AccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae685592-fae9-4bcb-874b-c453c289534a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae685592-fae9-4bcb-874b-c453c289534a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929d3dd6-5923-43f3-9769-6a2333e4ed4a" xlink:to="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_442edd3d-5cfd-4da9-aca3-66593c75f7ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_119617e2-ef9e-4f79-a20b-89a4845cb192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_119617e2-ef9e-4f79-a20b-89a4845cb192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f43b0d28-cd59-4913-b421-c67fe58a5773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f43b0d28-cd59-4913-b421-c67fe58a5773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_ef0e899a-a3df-4262-b1d8-9c70586fb2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember_ef0e899a-a3df-4262-b1d8-9c70586fb2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2dc75ff-8d42-4e25-a753-75f6b308a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b2dc75ff-8d42-4e25-a753-75f6b308a24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_63580552-0c4e-4b8b-893a-ceb1c506eb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7dd99c08-aa9c-4be4-bb71-829ac8190966" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_63580552-0c4e-4b8b-893a-ceb1c506eb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_713d0acc-b65c-40f0-818c-1f0a5f906d67" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501f9623-2454-4a9d-9162-237defc91586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501f9623-2454-4a9d-9162-237defc91586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5e16cfa8-22ad-40a1-a308-2af5c34e6871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5e16cfa8-22ad-40a1-a308-2af5c34e6871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a7e41915-6f40-4494-b362-8624a5ad92e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a7e41915-6f40-4494-b362-8624a5ad92e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e28cf1c-16e9-488e-a853-4506a1fb2572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e28cf1c-16e9-488e-a853-4506a1fb2572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1735d20-e79f-415a-b252-9ae02f0a6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a98f62bd-247e-4811-9039-5314bf602de1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1735d20-e79f-415a-b252-9ae02f0a6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_d23150a4-4303-4bcc-ae62-7ab7333ce0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_d23150a4-4303-4bcc-ae62-7ab7333ce0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9ead1d0b-1f8d-4389-969f-a41c00d8fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c5aee429-0e76-4fac-9e6c-a6cfe09679a8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_9ead1d0b-1f8d-4389-969f-a41c00d8fcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2fc24c97-37d2-4215-af08-50e4d84bcfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2fc24c97-37d2-4215-af08-50e4d84bcfc5" xlink:to="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_506882ab-3fe6-4884-8cd8-3b4608a20563" xlink:to="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_HerniaMeshLitigationMember_810f818e-acb2-45af-befc-d61568a12f79" xlink:href="mdt-20250425.xsd#mdt_HerniaMeshLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_HerniaMeshLitigationMember_810f818e-acb2-45af-befc-d61568a12f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ColibriMember_e6538396-2daa-4758-9945-ce001ad8e903" xlink:href="mdt-20250425.xsd#mdt_ColibriMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_ColibriMember_e6538396-2daa-4758-9945-ce001ad8e903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesPumpRetainerRingLitigationMember_4d9eae5c-5d49-48d9-b0c0-95138f3fc563" xlink:href="mdt-20250425.xsd#mdt_DiabetesPumpRetainerRingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e438dc88-d9b2-487b-8147-767c1ca63c56" xlink:to="loc_mdt_DiabetesPumpRetainerRingLitigationMember_4d9eae5c-5d49-48d9-b0c0-95138f3fc563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_2ed27bd6-35b9-4be0-a602-e44196984336" xlink:to="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_ec6cd1c3-3a83-465e-9fc1-a3c187d827d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_03709a34-4372-43c9-9b06-6ee2826590bf" xlink:to="loc_us-gaap_PendingLitigationMember_ec6cd1c3-3a83-465e-9fc1-a3c187d827d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_786f2b93-531a-4539-9953-2de46559a5a7" xlink:to="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_fa2bd9ad-5609-4f5e-b299-0ab693e10517" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_MA_fa2bd9ad-5609-4f5e-b299-0ab693e10517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MN_6a8c79b0-6e4e-43c7-8ed5-53ba2c7a2db5" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_MN_6a8c79b0-6e4e-43c7-8ed5-53ba2c7a2db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_e58b5e34-3353-46dc-9146-fa18472b3d87" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32feab4d-8d1c-4995-b7cf-54dcc10f7f84" xlink:to="loc_stpr_CA_e58b5e34-3353-46dc-9146-fa18472b3d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_395886a7-5b20-4aa8-ba94-4b5d887bbee6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ec3abaed-5180-4b8d-9413-3220c89ca5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dad8d3d6-6cc2-4d96-ba99-b14b5e9deff8" xlink:to="loc_us-gaap_SubsequentEventMember_ec3abaed-5180-4b8d-9413-3220c89ca5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_110ea735-be73-4e5f-9565-4bf1b364a7ce" xlink:to="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_d1758001-b36e-4755-b1d5-efcc00fae3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_d1758001-b36e-4755-b1d5-efcc00fae3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3c2c1608-9d13-4885-8696-2a6f0288f58b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3c2c1608-9d13-4885-8696-2a6f0288f58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3632ee23-f112-4f2e-a8a8-f4ee346366f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3632ee23-f112-4f2e-a8a8-f4ee346366f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_009680af-c84b-436c-a498-9224006253b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_009680af-c84b-436c-a498-9224006253b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_106d3aef-30b9-4bde-b145-d05c78717eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_106d3aef-30b9-4bde-b145-d05c78717eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_LossContingencyLawsuitsNumber_f395d352-68a4-48d0-92e4-8f09e5c1f12d" xlink:href="mdt-20250425.xsd#mdt_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_mdt_LossContingencyLawsuitsNumber_f395d352-68a4-48d0-92e4-8f09e5c1f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8bafbf32-de57-481d-92d8-031242fa85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8bafbf32-de57-481d-92d8-031242fa85b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_5f438fce-e053-45b0-a133-86fabe32523f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_db676d10-376a-442c-9f63-03ed8bfdeff5" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_5f438fce-e053-45b0-a133-86fabe32523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f565c079-774c-4aea-805d-fdc298f27506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5dff99b2-a29e-47ed-ba49-68659fdcc86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f565c079-774c-4aea-805d-fdc298f27506" xlink:to="loc_us-gaap_NumberOfReportableSegments_5dff99b2-a29e-47ed-ba49-68659fdcc86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationSegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a9ad05c-8cd2-43b6-b547-68111621afde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a9ad05c-8cd2-43b6-b547-68111621afde" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e9d00d24-0444-41ab-8199-8dc61a5f9f04" xlink:to="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_aecc0ca5-e03d-4e8d-b486-ab759be4c932" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_CardiovascularMember_aecc0ca5-e03d-4e8d-b486-ab759be4c932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_f9c4c492-ab72-42fc-bea3-e3e750f86ac4" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_NeuroscienceGroupMember_f9c4c492-ab72-42fc-bea3-e3e750f86ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_b03a9602-770f-4139-979a-56b1bb3a5e28" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_MedicalSurgicalMember_b03a9602-770f-4139-979a-56b1bb3a5e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_7a2c582a-d958-4bd3-8b64-c22a61b20f4d" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_DiabetesGroupMember_7a2c582a-d958-4bd3-8b64-c22a61b20f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_OtherSegmentMember_3039e7a8-378d-4a56-bf88-64d91d848d41" xlink:href="mdt-20250425.xsd#mdt_OtherSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_237ea089-d6d3-4033-b7dc-eedfc007c856" xlink:to="loc_mdt_OtherSegmentMember_3039e7a8-378d-4a56-bf88-64d91d848d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:to="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_fbb63f4e-ef93-48a8-9768-60aea734b0ef" xlink:to="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e028369b-3821-4ac1-936b-e381b0db64b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e028369b-3821-4ac1-936b-e381b0db64b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2e1c2c6b-cf0c-4f68-ac1f-b9c3e6065911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e0be012a-20d5-4c46-a91a-863c35e89ca8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2e1c2c6b-cf0c-4f68-ac1f-b9c3e6065911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_864bceb3-c609-4c71-823f-2e489f29fc28" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08b66625-2666-4979-a975-ab71ee727097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08b66625-2666-4979-a975-ab71ee727097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_519539da-86be-4a90-b9d7-7c4cceb27775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_519539da-86be-4a90-b9d7-7c4cceb27775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77736b56-015e-4b65-b972-6408d88a75bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77736b56-015e-4b65-b972-6408d88a75bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53c8c518-bbae-4244-8ab4-7182859a05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53c8c518-bbae-4244-8ab4-7182859a05c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0cacbc4b-e220-427e-a2cf-c2da99244c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0cacbc4b-e220-427e-a2cf-c2da99244c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dd130059-6226-44a5-80a0-7ff2d5d993a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_dd130059-6226-44a5-80a0-7ff2d5d993a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CorporateOverhead_be137497-6262-49dc-8dc0-adc0e366c6e1" xlink:href="mdt-20250425.xsd#mdt_CorporateOverhead"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CorporateOverhead_be137497-6262-49dc-8dc0-adc0e366c6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a3b1ddf-5d67-4733-8f8f-1ef54cc02d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a3b1ddf-5d67-4733-8f8f-1ef54cc02d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3b31251c-bc89-40d7-9b28-462b88ec3f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3b31251c-bc89-40d7-9b28-462b88ec3f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5f5897c7-567a-4fb5-b4f1-e8ee4613ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5f5897c7-567a-4fb5-b4f1-e8ee4613ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8f352764-af8f-481b-89a5-06986483ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_ShareBasedCompensation_8f352764-af8f-481b-89a5-06986483ae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CentralizedDistributionCosts_b8279c0f-7d19-439a-b079-216bc423c82d" xlink:href="mdt-20250425.xsd#mdt_CentralizedDistributionCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CentralizedDistributionCosts_b8279c0f-7d19-439a-b079-216bc423c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_ForeignCurrencyCosts_d1afd951-daa8-4638-9242-674a5e2a4804" xlink:href="mdt-20250425.xsd#mdt_ForeignCurrencyCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_ForeignCurrencyCosts_d1afd951-daa8-4638-9242-674a5e2a4804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_63881001-ad28-4029-8e9a-7008cc7a6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_RestructuringCharges_63881001-ad28-4029-8e9a-7008cc7a6b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1eadba33-b819-48b7-8c50-9682cb9dcf02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1eadba33-b819-48b7-8c50-9682cb9dcf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_3295d42e-35d4-4b0f-a21a-80a846a996a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_3295d42e-35d4-4b0f-a21a-80a846a996a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalDeviceRegulations_1a5b63f5-5dd6-4c34-82df-3f325c99d27a" xlink:href="mdt-20250425.xsd#mdt_MedicalDeviceRegulations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_MedicalDeviceRegulations_1a5b63f5-5dd6-4c34-82df-3f325c99d27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_bb6a4e0f-fe75-4bd1-a359-063ed2c00a00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_bb6a4e0f-fe75-4bd1-a359-063ed2c00a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_9b750bac-4e23-415d-bc52-064ace52fa8a" xlink:href="mdt-20250425.xsd#mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS_9b750bac-4e23-415d-bc52-064ace52fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78b0a4d6-233f-4eff-9fd8-e695e77b3891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36ab9fc7-4179-42ce-ae13-53b7ec2fe7a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78b0a4d6-233f-4eff-9fd8-e695e77b3891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ca206d9a-9fd4-4a33-862c-767ee938f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ca206d9a-9fd4-4a33-862c-767ee938f65e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:to="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8db1241f-71b1-4a83-ba60-e0cdadfdb817" xlink:to="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c4e2def0-b54f-46e0-b482-2228394361ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:to="loc_us-gaap_OperatingSegmentsMember_c4e2def0-b54f-46e0-b482-2228394361ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9b5026f8-7ec8-4e17-8664-1b81e8ad1a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fca0004a-9873-4bb3-9881-dc30357ea362" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9b5026f8-7ec8-4e17-8664-1b81e8ad1a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_12cbc570-e433-4788-a9e1-13e4de0ad269" xlink:to="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_CardiovascularMember_59166231-a003-4f63-aeb6-d470d255fd37" xlink:href="mdt-20250425.xsd#mdt_CardiovascularMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_CardiovascularMember_59166231-a003-4f63-aeb6-d470d255fd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_NeuroscienceGroupMember_c5b124b8-7211-469b-9826-da704783e68c" xlink:href="mdt-20250425.xsd#mdt_NeuroscienceGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_NeuroscienceGroupMember_c5b124b8-7211-469b-9826-da704783e68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_MedicalSurgicalMember_fba72199-1854-42b6-8b02-e72d03c22b27" xlink:href="mdt-20250425.xsd#mdt_MedicalSurgicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_MedicalSurgicalMember_fba72199-1854-42b6-8b02-e72d03c22b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_DiabetesGroupMember_495a8e69-2b7d-4ca5-a7d4-fa49bdac3e7a" xlink:href="mdt-20250425.xsd#mdt_DiabetesGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_mdt_DiabetesGroupMember_495a8e69-2b7d-4ca5-a7d4-fa49bdac3e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_797c58c0-d238-4cd9-bc61-ffa64874c202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_74865704-af64-4169-b183-701604c8cd47" xlink:to="loc_us-gaap_AllOtherSegmentsMember_797c58c0-d238-4cd9-bc61-ffa64874c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d11ac39e-b7a4-4357-9b50-21de5dbc3d0b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e7470f9-3d1c-4ec6-b4ed-d1090f69e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:to="loc_us-gaap_Assets_9e7470f9-3d1c-4ec6-b4ed-d1090f69e20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2e55cc84-e288-4010-ad66-cacf26e6031a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7639ab26-9f77-41bd-afcf-3844cd3e9ca0" xlink:to="loc_us-gaap_Depreciation_2e55cc84-e288-4010-ad66-cacf26e6031a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_58bbfc90-176a-4166-8761-5725467779c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_58bbfc90-176a-4166-8761-5725467779c9" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:to="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3d8c1ab0-c529-45c8-8fb7-d6f82ddf5b1d" xlink:to="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_3ea14ab3-9c68-4526-9187-8218ec46c2e9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:to="loc_country_IE_3ea14ab3-9c68-4526-9187-8218ec46c2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingIrelandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_894494d4-e6c7-4dc0-abf0-4eaf63ea6188" xlink:to="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_aaa03008-23d0-4eb0-8bcd-a129aba40cc1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:to="loc_country_US_aaa03008-23d0-4eb0-8bcd-a129aba40cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_17f1dee8-5cdd-48bd-ac1c-27404ddc7a76" xlink:href="mdt-20250425.xsd#mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdt_TotalOtherCountriesExcludingIrelandMember_4294d25f-f7d1-4dd5-aabe-b5414b7a847d" xlink:to="loc_mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember_17f1dee8-5cdd-48bd-ac1c-27404ddc7a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a05782cc-58d3-445a-bfd2-7db911ced4b3" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a08cf5-9204-4654-b784-ab2bfdfb734d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41a08cf5-9204-4654-b784-ab2bfdfb734d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7eab8c52-de62-40bd-928f-a2dba3beeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_e9587f4a-204e-4b3f-b189-a8c0f612d8ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7eab8c52-de62-40bd-928f-a2dba3beeb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="mdt-20250425.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_7e59e00e-070e-4117-abfe-db0a7f51f1ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_7e59e00e-070e-4117-abfe-db0a7f51f1ba" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a8dfb830-f8b4-415f-9793-513049f31d78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_93488972-0d1e-4c5d-9d8f-c3e63b1ed299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_93488972-0d1e-4c5d-9d8f-c3e63b1ed299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_29f6e1f7-910d-4350-88ee-450baaff4052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d9d52987-3327-4a20-a71c-d4358bcf4e57" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_29f6e1f7-910d-4350-88ee-450baaff4052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b452e0c5-adad-476c-9a87-a57947851de1" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_729d24bb-76ca-461c-a49c-54683cba99a5" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_54d37547-93bd-4fc4-989a-a6435e5ff2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_54d37547-93bd-4fc4-989a-a6435e5ff2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_270fc9a4-cf7b-4237-bcb1-b8306bf395ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_270fc9a4-cf7b-4237-bcb1-b8306bf395ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_4f27e92e-be1f-434f-bd0b-93e3abc16d7b" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments_4f27e92e-be1f-434f-bd0b-93e3abc16d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_efb62381-4157-407d-9c26-1fc95d52b766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_efb62381-4157-407d-9c26-1fc95d52b766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_4f4801b9-1eca-4eda-90ee-9a880daeec84" xlink:href="mdt-20250425.xsd#mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet_4f4801b9-1eca-4eda-90ee-9a880daeec84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_73bb9ee7-7baa-4951-b684-86c9cb6469bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_73bb9ee7-7baa-4951-b684-86c9cb6469bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_fd5647f5-a8bc-49c8-847d-d1373ccd721b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_fd5647f5-a8bc-49c8-847d-d1373ccd721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_20bcfb12-dbb0-4ded-acb2-0fea22237202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_07a8c6bb-a58b-4169-a27b-87b186a4595d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_20bcfb12-dbb0-4ded-acb2-0fea22237202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_0.jpg
<DESCRIPTION>IMAGE 0
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   K4   "J" 8   "SO[<F    "7!(67,  $SE
M  !,Y0%USO"5   I\DE$051XVNR=^U].V1['YY\X,PQ.QCB&82X.QG!RF3-G
M!M41(C1%E$P.HA1FE/MM7DC&)5(Q@UQ"*F%RJ<C]/HR9<*)()=+]JN_IN\_Q
M'(VA/,_:S]YK/Y_WZ_7]K9Z]]G==]GOOO=;:;Q        "2\P92
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MJ>7(N)F%E@H@M9!: $ CS)Z[@3[]V]B7AI.S/Y($J=4^/N[J :D% %(+J04
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MW1,1+1G48H0[$-02U%HZU X:/%MQDQX\^XN9NUE.J(47G^02" OS7Q%*4"L
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M:3QG!P  0*@%    "+4    @U (   "$6@   (!0"P   !!J 0  0*@%
M"+4     H18   "$6IH     A%H   " 4 L    0:@$  $"H!0    BU
M *$6    (-0"  " 4 L    0:@$   !"+0   $"H!0   *$6    (-0"
MA%H   " 4 L   !"+0   $"H!0    BU     *$6  "$I?\!  #__^W6,0$
M  S"L/DWS20@@$1"KR;0G 0  )A:   PM0  8&H! #"U  !@:@$ P-0" ("I
M!0# U ( @*D%  !3"P  IA8  %,+  "F%@  3"T  )A:  !,+0  F%H  #"U
M  !@:@$ ,+4  &!J 0# U ( @*D% ,#4 @" J04  %,+  "F%@" 00_(*',N
04L,^9P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_0b.jpg
<DESCRIPTION>IMAGE 0B
<TEXT>
begin 644 image_0b.jpg
MB5!.1PT*&@H    -24A$4@   >     +" 8   "G(%Y@    "7!(67,  $SE
M  !,Y0%USO"5    3$E$051XVNW;L0D , P$L=M_:6>'$-Q$@EO S5=N (!U
M.0$ &&  ,,"5)$EZD &6),D 2Y)D@ VP)$D&6)*D3P<8 /"&!  && "X=P"7
3(M$FZXIT;     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mdt-20250425_g1.jpg
<DESCRIPTION>IMAGE 1
<TEXT>
begin 644 mdt-20250425_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>IZV5YY@\PYOJDK\MKZ-;W[^A-1117DGKA1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!L@R/QK\>?^#L$
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M+N#<QQN'CBJ/+RRVO*SWMV/E<PXQR_!XB6&K<W-'>RNMD^_F?T 45_/_ /\
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MW?%KQ"D_V>Y70)M.M9 <,D]WBTC88YR'G4\>E?R[=2>.Y)_'_P#4?PK]V_\
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MH?\ ;W_I$CY/C7_D35_^W?\ TN)^/5%%%?T$?@9[Q_P2[_Y2*_!7_L<-._\
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MJ&$I.OB)<L4?3/QH^/'@_P#9Z\$3>(_&_B?1_"VB6WW[O4+E848XSM7)R[$
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M7#F:5EJUIOT:/9RWB#'8"#IX2?*F[O1/7;JF?L'_ ,18G_5!1_X7'_WOH/\
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MR;SQE>V7A^W.?O>9,)IA^-O!,/QK\IRS"?6<72P_\TDOQU/U3-,5]7P=6O\
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M0]1]:6D/4?6OT%GY^C^JO_@G=_RC_P#@9_V3[0/_ $VV]>Q5X[_P3N_Y1_\
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M3SC_ .M_("OUSPWP"C1JXR6[?*O16_5GY'XCXYRK4\''9+F?J_\ @("<FE&
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MZII/\&?F?B/@H.C2Q:6J?*_1JZ_(^2J-N\A?[Q HI5.T],_@37[ ?D9^U/\
MP:L?%N75?A%\5/ TSL(]#U6TUNU1NI%U$T,@ ] ;1/Q?WK]8J_"G_@UH\1R6
MG[:7C_2!GRKWP4]XW/&8;ZS0<?\ ;=OS/K7[K5_/_&^'5+-ZMOM6?X+_ "/W
MS@G$.KE%._V;K\3X\_X+Z?\ *)?XL?\ <(_]/-C7\VW<_6OZ2?\ @OI_RB7^
M+'_<(_\ 3S8U_-MW/UK[_P ./^19/_KX_P#TF!\'XB_\C*'_ %[7_I4PI#U'
MUI:0]1]:_06?GZ/ZJ_\ @G=_RC_^!G_9/M _]-MO7L5>._\ !.[_ )1__ S_
M +)]H'_IMMZ]BK^7<=_O-3_$_P S^G<!_NU/_"OR,[Q;XCLO!WAC4-7U*=+7
M3M+MI+RZF<X6&*-"[L?8*I/X5_*7^U[^T3J'[6/[2_C/XA:IYJ3^*=3ENX8)
M!S:VX/EP0Y_Z9P)$G_ #7]"G_!;_ .,<OP7_ ."97Q+NK64QWVOVL/A^W .-
MXO)DAE'_ 'X:8_A7\TK?>X(VCD#/.#_G]:_4?#; )4JN,DM6^5>BLW^9^8>(
M^/DZM+"1V2YG\]%^0AY.>](YPI(/0$_7BEI" Q"D@;N!^5?J!^9'TQ_P2N_X
M)[ZC_P %#_VF8/#;O=:?X/T9!J'B/48<!X+4-@11D@CSI6^4?W06?!V8/])G
MP<^$OAWX&?#W2O"?A/1K+0?#NAVZVUE96R82%1UY/+$GEF;+,22Q))KY"_X-
M^_V6;;]G_P#8$T77;FT2/Q#\2W/B"^D9/G\ALI:QYZ[!" X'0&9R/O'/W*%
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MR>,O^_Z?_$4?\/@/VF?^BR>,O^_Z?_$5\UX'H*,#T%1_9."_Y\Q_\!7^1?\
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MQ]%%;55]-F2YMHI8V5TD0.K*00P/((JQ7\K2;;;EN?U'3244D%%%%(L****
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M97YMU^DO_!KE_P G_P#C#_LGU[_Z<M,K'BO_ )%%?_"='"O_ "-J'^(_>8*
M<@#-+117\YG]$A1110 C ,,$9K^>3_@XZ 7_ (*9ZI@8SX>TW/\ WPU?T.'I
M7\\?_!QW_P I,]4_[%[3?_0&K[KP\_Y&K_P2_.)\)XA?\BQ?XE^3/@^@C-%%
M?N1^)'Z2_P#!KD3_ ,-_>,.?^:?7G_IQTROWGK\&/^#7+_D__P 8?]D^O?\
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M@)QUP,X'>OVUL_%C[V\/_M5&V_X-Z/$7@-YD^U/\1X- BCW_ #K:2!=5#X[
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MN?>;/>OR;PWQ2IX^="7VXZ>JU_*Y^J>(F%<\#"M'[$M?1Z?G8^ Z#GL&)[
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M_P#$2,P_Y]P_\F_S/H?^(<X#_GY/_P E_P C^9W_ (<B_M4?]$AUC_P/L?\
MY(H_X<B_M4?]$AUC_P #['_Y(K^F+ ]!1@>@H_XB1F'_ #[A_P"3?YA_Q#G
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M +)]>_\ IRTRL>*_^117_P )T<*_\C:A_B/WGHHHK^<S^B0HHHH #TK^>/\
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M(55!)( R/Z6?^"7?_!/G1_\ @GI^SC:^&8_LVH>*]5VWOB75(X\"^NB/N(2
M?)B!9$!QU9L N:^1XQX@CE^$=.F_WL]%Y+J_ET/J^$,@EF&+52:_=PU?GV1]
M'VQ&XX&,C./3\.W6ICTI%14)P ,]<#K2GI7X(?O/0_G,_P"#A/\ Y2D^-O\
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M'_!+K]HL'GX*_$=?<:'/_P#$U^H_VGA/^?T/_ D?F']G8O\ Y]2_\!9^QO\
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M_$FDV&M:%K,)M[VQNXA)#<1D=&!]."",$$ @@BO$X>SZKE6*]M!7B])+NO\
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MF_#.!Q,,TH2G3DDI=8L_9RBBBOY_/WX****  ]*_GC_X.._^4F>J?]B]IO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mdt-20250425_g10.jpg
<DESCRIPTION>IMAGE 10
<TEXT>
begin 644 mdt-20250425_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO'OVJ_V^OV2_V']/L];_ &KOBO\ \(5IFH3+#9ZSJF@W[6$LS!V6 744
M#0^:5C=O*W[]JD[<<UY])_P6?_X)I0^!(_BE+^TLB^&)H#/%XC;PCK L'B!P
M7%Q]D\LKD$9W8H ^HJ*^<_B=_P %;O\ @G-\&_V??!?[5'Q)_:HT/3? 'Q#U
M$V/@SQ&;2[ECU297='V1Q0M(J(T;!Y'143 +,H(S]$6EW:7]K%?V%S'/!/&L
MD,T+ADD0C(92.""#D$4 24444 %%%<_\5OBEX(^"7PZUCXL_$K5)K'P_H%DU
MYK%_!IT]T;6W7[\S1VZ/)L099V"D(BL[$*I( .@HKR_]E#]M#]EW]N3P#??%
M']D[XQZ9XVT#3-8?2K[4]+CE6.&\2**9H2)40[A'-$W QAQS7J% !1110 44
M44 %%%% !15/Q!X@T'PEH-[XJ\5:W::9IFFVDEUJ.HZA<K#!:P1J7DEDD<A4
M15!8LQ  !)-?-/[.O_!:?_@EM^UC\:_^&=OV?_VRO#'B#QB\DD=GHXANK7[>
MZ EEM9KB&.*[. 6Q"[DJI(R 30!]145PW[07[2OP+_97\"I\2/C_ /$BQ\-Z
M3<:C!I]B]RLDL]_>S-MAM+6WB5YKJX<YVPPH\C8.%.#5+]GK]K7]GS]J>WUP
M_!#X@C4[WPOJ(L/%&A:AI=UINJZ)=$;EAO=/O8H;JT9@"5$L2;@"1G!H ]&H
MKYB_:=_X+-?\$P?V-?B]'\!?VD?VPO#?ASQ<WE_:-$^SW=Y)9>8 R"Z:UAE2
MTRI5OWS)\K!NA!/T;X2\6^%O'WA?3O&_@;Q)8:QHVKV45YI6K:7=I/;7EO(H
M>.:*1"5D1E(8,I((((H T**\V_:%_:__ &;OV5-2\$:-\?OBG9^'KWXC^,;3
MPMX(L9;:>>?5M5N7"101QP1NRKN90TK!8H]Z[W7<,^DT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@[V;(!XKW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOB1ID<C9]$>8,?RKH^J8KE4O9RL_)BNCW>BN<\#_ !C^$7Q-&[X;?%3PWXA
M&<Z'KEO=\=<_NG:NCK!Q<79H84444@"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>$XDMWQSLE56]J^3QN5X[+W^_@TN^Z^]%IIGH5%%%>>,**** "BBB@ HHHH
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M>-@&1E*L 017Y?FV3XC*JMI:P>TOT?9FL9)G7T445Y!04444 %%%% !1110
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M_P""SOB__@F1\9U^'_Q,U&\U+X,^+M00>*-*7=(VBW#80:I;(,G<H"B6-?\
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MS@C@_->.^):&38!>_4>LND(+XIR\HK[W:*U:,,3B(86BZD^GXGPI_P %_?\
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MLGQ ^,7AG0;^WMI?$.CVDLPM--FEGEBCCM)+BTE\_+Y*^64#,JHX!]Z_ /\
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MDLKR?2KU9?LMU'C?;S*#NAE4,I,;A6 8$CD4 =/1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X5_P4F_;'T?
M]@[]C'QM^TA>F&34=+T[[-X9LIN1=ZK.?*M8R/XE$C"1P.?+C<]J]UK\&_\
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M;#R_?-/^)57V?.-)Z6ZU+W7NQ9]7DV!]E3]O-:O;R7_!_(****_DT]T****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XK_P""
MW7_!)SP?_P %0/V8[BR\/Z?:VGQ3\(6TUY\/M;?:GFR8W/IT[G_EA/M R?\
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M&WQG^,NO?$7Q/8:'<O/9:/+J$B"+3X9G1&G6&&*,&4HNYV? VA20#Z<HHHH
M_!K_ (.V?C]_PDG[1'PS_9KTZ]W0>%?"]QK>HQQMQ]IOYA$BN/[RQ688>@G]
MZ_(ROJ[_ (+@?&3_ (7?_P %4/C'XFAN_-MM*\3?V!:@'*HNG0QV3A?8R02-
M]6-?*-?ZW^$>11X<\-<KP5K/V,9R7]ZI^\E]TI-'P6/J^VQDY>?Y:!1117Z*
M<@4444 =)\'/A9XJ^./Q:\,?!CP/;";6?%FOVFD:7&<X,]Q,L29QT4,X)/8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *K:QJUAH&D76NZK<"*ULK9Y[F5NB1HI9F_  FK->.?\%#_&C_
M  [_ &"/C5XV@G,<VG?"O7Y;5P<8F_L^81_^/E:[LLP<LQS*CA([U)QC_P"!
M22_4F<N2#EV/Y)/B1XTU#XD?$37OB)JQ)NM?UJZU&Y+')\R>9I6R?JQK%HHK
M_:.E3A1IQIP5DDDEY+8_.FVW=A1115B"BBB@#][?^#2;X)P^'?V7_B9^T!=6
M6RY\4^,X-'MY7'+6UA;"3*^BF2]D!]3'["OUKKXW_P"" GPS7X8?\$F?A-92
MVPCN=9L;[6;IMN#)]JO[B6-C_P!L6A'T45]D5_DGXOYQ+/?$[-L4W=>VG!?X
M:7[N/X01]YE]/V6"IQ\K_?J%%%%?FYV!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^,/_!Y!\ (];^ ?PC_
M &GK&T'G>'?%5WX<U"1%^9X;ZW^T1%O]E'L9 /0SGUK]GJ^%_P#@Y$^$@^+/
M_!'[XI&WMA)>>&3INO661G9]GOX/.;_P'>>O4R2L\/FM&7]Y+[]/U%+5'\H]
M%%%?L!@%%%% !7M'_!./XK/\#_V_/@Q\5OM9AAT7XG:+-?/G'^BF]B6=<]@8
MFD'XUXO4EI=7%C=17MG,T<T,BO%(AP58'((]P:BK!5:<H/9IK[P/[G**P?A9
MXTM_B1\,?#GQ$M,>5K^@V>HQ;>FV>%)1C\&K>K\/:<79G0%%%%( HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KY0_X+DZ]+X<_P""3WQKU"&789/#$5J3[3WEO 1^(D(_&OJ^
MOBO_ (.'KJ:T_P""//Q@D@."RZ"A/^RVO:<I_0D5]CX=TE7\0,HIO:6*PZ^^
MK!'/BW;"5'_=?Y'\O=%%%?[!GY^%%%% !1110!_7W^P!X17P#^PI\&/!8C"M
MIGPK\/V\N.\BZ= '/XMD_C7KM<O\#]/BTGX+>$-*@^Y;>%]/B3'HMM&!_*NH
MK_%S.,1+%YMB*\MYSG+[Y-GZ+37+32\@HHHKSBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\1_X*7>"?\
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M/KP#)'SV(8#NU? E%?+YYP=D/$%Y8FE:?\\=)?/H_P#MY,_2.#/%CC;@:U/
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M10 4444 %%%% !1110 4444 %%%% '(?&SX(^ _CYX(G\#>/=.\R)COM+N+
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M=6VR_DI_RQ[O>3U>EHHHHHKXP_6PHHHH **** "BBB@ HHHH **** "BBB@
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M\ET[4K.6WN(7*303QE'C8=0RGD'V-15^C)IJZ/P"491DXR5F@HHHIB"BBB@
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M:^<;=0L9(3GZ.!6;7T4)PJ1YH.Z\CX*K1K4*CA5BXR71JS^YA1115&84444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BOF7]IG_ (+)?\$Q?V.OB\GP%_:/_;#\,>&_%Q$9N-$>.YNI++S
M&3[2UM%(EH2K*P$S)\K!OND&OH7P_P"._!/BOP5:?$GPQXOTO4?#M_IJ:A8Z
M[97\<MG<6C)YBW"3*2C1%#N#@[2.<XH U:*\1\$_\%&_V,OB%XX\/^ /#?QE
M N_&$KQ>"M0U+P_J%CI?B>1024TO4;FWCL]3; + 6LTI8<C(YKVZ@ HKA/VA
M_P!IW]GK]DOX=7/Q:_:6^,GA[P3X=MLAM3\0ZDENLCXR(HE)W32''$<89V[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX9M6L;NXM$>6W/\ :EDV8W(RGS*IX(^Z/2O6O'/PP^('QM_X)):M\&OA/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4$ C!%%% &?\ \(GX5_Z%G3__  "3_"F:SX+\'>(_#\GA
M/Q#X3TR_TJ9E:;3+VPCEMW*N'4F-@5)#JK#(X*@]16G10!%96-EIEG%IVFV<
M5O;P1A(8((PB1J!@*JC@ #L*BOM"T34[^SU34M&M;BZT^1I+"YGMU>2V=E*,
MT;$90E25)&,@D=*M44 5[_2=*U3;_:>F6]SLSL\^%7VYZXR..@_*GV=A8Z=#
M]GT^RB@CSGRX8PHSZX%2T4 9^F^$O"NBZYJ7B?1_#.GVFI:R\3:QJ%M9)'/?
M-$@CB,TB@-*40!%+$[5&!@57\>_#OX?_ !4\+W/@?XG^!M'\2:+>;?M>CZ]I
MD5Y:S[2&7?%*K(V" 1D<$9K8HH H^&O#/AOP9H%GX4\'^'['2M+T^W6"PTW3
M;1(+>VB486..- %10.   !5ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **^3?\ @K%_P5B^'O\ P2>^'OA+XA?$+X3:SXMA\6:S/IUO;Z->
MPP- T</FEV,O!!''%?#?_$93^S/_ -&9^.O_  ?V7^%>EALGS+%TE5HTVXOK
M=?YB<DC]EJ*_&G_B,I_9G_Z,S\=?^#^R_P *_1?_ ()I_M^^#_\ @I7^R_:?
MM0>!_A_J7AFPN]9O-.72]6N8YIE:W8*7W1_+@YXI8K*<PP5+VE>GRQVO=?HP
M33V/?Z**\<\=?\%!/V,?AS\0+_X4^)?VAM ?Q+I./[:T/2))-1N=*SG'VN.T
M20VG3/[[9QSTKSAGL=%<1\*/VE?V>_CQ>W&G?!+XU^%_%TMIIEOJ%R/#>MPW
MJQ6T\D\4,C-"S !GMIU'.<Q,,<5V] !1110 45Y3KG[</[)OA[]J'0?V+-1^
M.6BM\4_$EO<3Z5X*M&DN+SRX+>2YD:;RE9;8"&)W'G,FX !=Q(!OZ'^UQ^SK
MXD_:CUO]BW1/B;;7'Q.\.^%H?$>L^%%L[@26VF2R)&EP93&(6R\D8**Y=1(A
M*@,"0#T>BBB@ HHHH **** "BBB@ HHKRGQC^W#^R;X!_:6\+_L=>*/CEHT/
MQ/\ &)F&@>"H&DN+V416LEV[2K$K"V7R(G<-,8PP "DEE! /5J*** "BBB@
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MT/\ #+2;95&C6MMXFOK:RU>SB0*BB)"J\XVL2A8)<;H?WE) &2< =2:^2O\
M@F-=_"KXX?L^?&7PI)<:)XIT+4/VA_B9I^MV!>*[MKF"?Q%?EH95Y5TDAE4X
M.0R2 \@U_*Q_I>1?M9?%/X5?M%:'^R3\:OA/XGT_Q)X7\1?M!:+JGA_6+,[X
MIXGT36F21<C*L,D%2 RL"I ((KUCXN?M5:IX>^,Z?LR_ ?X8KXZ^(:>&U\0:
MMIMSKJZ7IVBZ8\SP037MV8IFC>>6*9(8HX97?R)68(B%Z_*_0?V0/VFO^"4?
M_!3CX)_L3^"9+SQ#^RG\0OCLGB[X97=]+)-+X+U>+3=2%QHWF'.$D2=I%#?Z
MQ8@ZGS%N=W<_M;_%#]E/]B7_ (+Q^+_&7_!3WX0>&K_X3?'CX9Z%%X ^('C/
MPA#JNG:'JNE"2&:R9I8I/LXD\UWD91QYENSX5BZ 'U!\/_\ @LOI/Q"^!GQX
M\96W[-VIZ9\1OV9Y;MOC#\*M5\2P)<VEK;V]Q<&YL;R.-X;V.1+:0QDB+=L;
M.WY/,U_C-_P5JT[X5?\ !+/0/^"K>E_L^:CK7@_4O"VFZ]J_AQ/$$-OJ6GVU
M])!%%LW1F.<J\Z[QN3 &5W=!P%U<?L*?M _L8?M42_\ !,']G+P&-,U/X,ZW
MHUW\0OAOX,M=.@\4:Q)I=\%TV&2WMXS?F -$6D#-&KW:QJ2XE"?%/QS_ &T?
MV6_'/_!I)8_ WP-\;=!USQK:_!_P_INI>$M&OENM1TR6SU.P2X>\MXMSV<2,
MH'FS!(R9(E5BTL88 _1G]LC_ (*Z^$OV-?$WP1T/Q;^S5XXUFQ^-VLV6G:-K
M^DR6<EK:S3QI(;<1)*UU/<A9%V1+ J2D[5DR" [2/^"JVM^$/@[K?Q%_:L_8
ME^(OPK\0K\4K?P)X \ ZI<6-YJ/CC4KK9]C73Y(I1;OYA9]S^:8(Q#(WG.$8
MCY1_X*._';X+^+[[_@F9X]\,?%7P]?Z-=_'#0)X-3M-8AD@:-;.&)VWJQ "2
M.B-_=9@IP>*]!_X.&(/'7PG\7?LI_MXII-]J'P]^!WQTM=4^*$=A;O,VGZ;<
MM!%_:3HH)*0A)5SV:X0<!B0 >_>(_P#@I9J_P!_:5^'W[.7[;?[/K?#I/BU>
MMIWPZ\:Z1XK36M&O-5&W;I=W+]GMY+.[?>@C!C>*1B0LIVG'3^(/VUO&_B?X
M\?$;X _LP_ RQ\=ZM\(K;36\?)J7C6/2)%N;^U^V6UE9(;>87$QM]CEIFMH
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M^!FDW&@_!/X0^%_!UC=W!GN[+PMH%MI\4TIZR.D"(&;_ &B,UU%%% !1110
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MQ+)!'#JM_;1+&4U&P,X"PQ-);L?LI_>;2&8 ^Q?A_P#\%B_AO\??^"=OB_\
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MA^WU\ ?V2O$?[,6MZGJ/Q<DU67P+\2KPZ>+"T2VTW[3=FVQ+)="38\,3JT4
M(F!#N 17QA_P5L\0V?\ P7E^,7PS_P""9/[$-XWB[X<^&OB!;^)?CO\ &#0@
M9=!T6"WBEA73H+Y<PW5V\=Q.?+B9L.(1G"S&+U;_ (*FZWX5\/\ _!:[_@G+
MHLNKV5H;;6_'Z+;/.JF))=(LH8!@G@/(/+3^\P(&2* /HWQA_P % O%'B#]K
M#Q]^QE^RI\ X_'GC'X6>%]/UGQY)KOBP:%96QOXVELK&WE^S7#7%U+$I?YDC
MA0%=TP.0OR__ ,%$?VW?A?\ \%'?^#;+XO\ [5'PR\-ZII.GZUX2F@N]#UV)
M!=:;?6FJ10S02;"5;;+$2K _,I4X4DJ+^I?M^_"CXM_\%1?CU^R9^U5\?(/@
M]X7^%EGH%OX?\)Z9K+:+K/Q+FNK9IFN7O("E]=)$9(8H+&R=6D^T_.)=XC'Q
M=^RUX_\  WB[_@U)_:'^#'@G65O_ !+X<NO$=QK?A^UCDDN]+@DUM9(C<QXW
M0%HU9U63:S+'(P!",0 ?8L'_  6UU3]B?]G[X0>*OC9_P3[^*UC\"9/#'A_1
MKWXY/]E%O;3/:0Q"Y;3 QNTLR^ LTPB,HYB23=&'^T_BO^UUIGAWQ]X9^"/P
M.\(IX_\ 'GC#P[/XAT?2;;68[.QM=%B:)&U.\O"LGD6S23111F..:25W^2-E
M25X_C+]O/XM_";XW_P#!OYI/P4^$OB/1_'GBGXL_#/P_X3^'/AGP[J$-Y<ZS
MK3QVBB.%$8\VQC>>5C@0K;NSE=M>&_M-:=\$_P#@F%_P4I^ 'BO_ (*5_#'0
M_%_P5US]E71?A6/'/B/PHFKZ=H'B72KAY3*ZR12&)948_,%#$3LWW89" #[6
M^&'_  5A\0_%?4/CG^S[IW[+MYH_[07P.L8[K5?A9JWBNV-GJ=M/$LMM?6VI
MJH5[1HY(W=C$LJ"1!Y99@*\]_P""-O\ P47^+7C_ /X)7V?[:W[</A^+1?"\
M6G>)_%6M?$F;7XYXKH?V]J$DEO%8J&FA2)288H\L2L,:(#E17H'[+'C#_@FO
M\:O$OQ!UO_@FA\ ?AI>+;^![K3_%7Q3^&_@NSL(9KJ81M;Z,EW!;H;YRB&:5
M$=E@\NVW#=,FW\[OV7KZS_:Q_P"#1_4?V,/V:?%UEXB^+?AWPAJ&J:SX&T=_
MM.HV45EXR;4'M[B!,M%)/;HPABD :X#-Y:N%? !^B7[0?_!6?Q-^QU)\/_B/
M^U_^R#K/@;X5?$3Q);:':^-F\5VMY>^'+NZ1GMAK&G1H!:JRHY=H)[D1["&^
M;"GTWQ+^V?XQ\0_M#^._V:_V9O@OIWC?7OA;I.EWOCU=7\:)HX@DU&*2>TL[
M0?9IS<7#PQ&0F7[/ HDC'G%MX3XC^!'[=_\ P;Y?M@_ #PWJ'@W]D+X(^(OB
MEXEMX+:P^!<_PGTY]8EU]DQ]B\MK)PL*R;MUZ088X@TKLH5@.I_;._8N^#7[
M9O[;'Q/^*?[%7[9&L_L^?M7_  >L-.LM=UK2]87[%K^ER:9:WUI-J=BQQ-9@
M3&W,O(7[,?,CE"Q* #[V_9@^-T_[2'P \*_'*Z\ ZCX5F\2Z6MW-X;U=U:ZT
MQRS*UO,5X\Q"I# < @C)QFN\KYE_X([?M/?'/]L?_@G+\-_VA_VC_"5GI/C#
M7;*[74SIUOY-MJ(@O9[>+4(4Z+'<QQ).-OR'S=R?(RU]-4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >%?MT_P#!.K]FO_@HIX3T+P7^TGIFKW5CX<U&2]TQ=(U9K1EE>/RV
M+%0=PV]J^:?^(8;_ ()6_P#0I^-O_"RE_P#B:^M_VI_VI] _99T#2M?U_P *
MWFJIJMX]O''9S(AC*INR=W6O%/\ A[Y\./\ HC^M_P#@?#_A7V.4>(7''#^
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MOHJJ  /85S/BSX ? ?QYKDOB;QS\$_".M:E.JK-J&K>&[6YGD"J%4-))&6(
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M2/\ X)J:]\)?@[8B]\;^%=<M?%GA#3#($_M&ZM8YHI+56) #R6US<*F< R;
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M[_0;K5M(MKRYT+55476G22Q*[6TP0E1)&6*-M)&Y3@D5KT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\=_V<OAG^T9I-
MAHOQ+M;R6#3;AI[46=V82'9=IR0.>*\S_P"'7O[*?_0(UO\ \'+_ .%?1%%
M'SO_ ,.O?V4_^@1K?_@Y?_"O7O@W\&_!/P(\$Q_#_P"'\%Q'IT=Q).JW5P97
MWN<M\Q^E=510 5Y]\2?V2_V5OC+XGB\;?%_]F?X?>*]9@"B#5_$G@RQOKJ,*
M,+MEGB9Q@=,'BO0:* (=/T^PTFPATO2K&&VM;:)8K>VMX@D<2*,*JJ.%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mdt-20250425_g11.jpg
<DESCRIPTION>IMAGE 11
<TEXT>
begin 644 mdt-20250425_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO'OVJ_V^OV2_V']/L];_ &KOBO\ \(5IFH3+#9ZSJF@W[6$LS!V6 744
M#0^:5C=O*W[]JD[<<UY])_P6?_X)I0^!(_BE+^TLB^&)H#/%XC;PCK L'B!P
M7%Q]D\LKD$9W8H ^HJ*^<_B=_P %;O\ @G-\&_V??!?[5'Q)_:HT/3? 'Q#U
M$V/@SQ&;2[ECU297='V1Q0M(J(T;!Y'143 +,H(S]$6EW:7]K%?V%S'/!/&L
MD,T+ADD0C(92.""#D$4 24444 %%%<_\5OBEX(^"7PZUCXL_$K5)K'P_H%DU
MYK%_!IT]T;6W7[\S1VZ/)L099V"D(BL[$*I( .@HKR_]E#]M#]EW]N3P#??%
M']D[XQZ9XVT#3-8?2K[4]+CE6.&\2**9H2)40[A'-$W QAQS7J% !1110 44
M44 %%%% !15/Q!X@T'PEH-[XJ\5:W::9IFFVDEUJ.HZA<K#!:P1J7DEDD<A4
M15!8LQ  !)-?-/[.O_!:?_@EM^UC\:_^&=OV?_VRO#'B#QB\DD=GHXANK7[>
MZ EEM9KB&.*[. 6Q"[DJI(R 30!]145PW[07[2OP+_97\"I\2/C_ /$BQ\-Z
M3<:C!I]B]RLDL]_>S-MAM+6WB5YKJX<YVPPH\C8.%.#5+]GK]K7]GS]J>WUP
M_!#X@C4[WPOJ(L/%&A:AI=UINJZ)=$;EAO=/O8H;JT9@"5$L2;@"1G!H ]&H
MKYB_:=_X+-?\$P?V-?B]'\!?VD?VPO#?ASQ<WE_:-$^SW=Y)9>8 R"Z:UAE2
MTRI5OWS)\K!NA!/T;X3\6^%?'OA;3O''@?Q)8:QHNKV45YI6K:7=I/;7EO(H
M>.:*1"5D1E(8,I((((H T**^-K__ (.#_P#@C)IE]/IMY^W]X-$UO,T4H2&\
M<!E)!PRP$,,CJ"0>U?7OA_7M*\4Z!8^)]"N3-8ZC9Q75G,T3(7BD0.C;7 9<
MJ0<$ CN : +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y5?\'BB@_\ !(2,D=/B
MMHA'M^YO*PO^"//_  52_9D^'7["?['/[!'AOQG8:[\2O'RIHVI>&?L,L@TW
M3U>]GN9YV*B,96-8U7<26F!VE5;$G_!Y!\1_A_I__!+NP^&=[XWTF+Q'J'Q,
MT>YLM ?4(Q>S0)#>[IEASO,8Q@OC:#@9R17IW_!#3X>_L^_M4_\ !)3]EJ^B
M\2:#JOB3X02PZO:RV4T-S>:)?)<7D$L$@5M]OYL+RH0V,@AL':* /#_^"_.N
M_LA?\$Q/V3_@_P#![XL_\$Z?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_P!G
MB6TMG#VBQW/DA#(%985#QL #7U+^V=_P5^TK]FC]M'X,_P#!.WX:>'_!&E^+
M?B=X577!KWQ$U^73=#TBT;SXK.S0P0NTMQ<36LT*+^[52$^^9%2OAW_@]Y\6
M^%O^&?\ X(>!/^$CL?[;/C'4+_\ L@72?:1:_9!'Y_EYW"/?\N_&-V1G(KTO
M_@LI^SG_ ,$R?^"HWB'P1\"OBM^T%X>^&?Q+B^#5CXC^#WQDN];@_L?7+6:X
MNXYM)N'9EBE1&MEF4"02_OY6C!$<R2 'V=JW_!3F]_9X_8N^*W[7'[?7P7'P
MWF^%7BF[T;4/#&BZT=5.INJVPLVL[B2&W\\7C7431$QQA5E7S-NQR/ [+_@N
MA^T/\.?CC^R[X>_:6_8VTO2_!/[6EA9S>"-0\)>);F_O_#LUY) +:&^62UCC
MN&\N[M'E\HH8Q)(0'\O#_ /A3X-?\%'_ -O7_@UP\=>"/&T^L^.;[X:_%E;O
MX=7*O)=W7B7PSIJQQS"UD(WWL$4DMT\+\EUMC&F=B+7V[_P0J_X+?_LG?'[]
MC#X.?LKZG)KM_P#&WPAH.G^%+CP%I?A:YN;J9;.-+--26<(+>*W^S*LLLLLL
M8BQ(IYV;P#V#XE?\%A?%/CC]MOXN?\$^OV,OAOX7U+QU\&O <OB3Q#J'Q$UF
M\LK347C2!GL[..UMI"^S[3 KS221X9\)'(H+C*_8A_X*R^%?^"OW_!)KXP_'
M?3_AA/X.USP_X9\0:'XH\/O?B[ACN%TIIEE@FV(7B>.53AE5E974[@ [?'W[
M17_!123X^?\ !</XL?L-?&?P!XL\'^$?#WA&]TO1/#OPQ\&7;^(?B=K$<,'V
M./5+RPB-XVFLDLLR1;XK0I'%]H8H6SYE_P &QGQ?^''PX_X))_MA>!/B!XFC
MT34=*BU74-3&K0R6\-I#)HRVL8EG=1%'(\X:-8F82,RMM4X. #Z+_P"#*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU1>5L/VA?^"A.I_\$J)?^"Q*_&ZZ3Q4/"TGQ&M_@RFEV'_",#PLA-U_93/\
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MU,32AA8/K5G[UO\ !!3DGY2Y3RZV<X*EHFY/R_X)_37XD\4>&?!NDR:_XO\
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M'5]G6BXOS_3O\BTTPHHHKG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444CND2&21PJJ,LS'  ]: %KYO_P""@O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** $95=2CJ"",$$<$5^;7_!3[_@VK_9#_ &W+:_\
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MBBOX>;;=V?2A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:F3LM-1YX1<GR96X'EN';/DJ*_.BBN;%X6EC<-*C4VDOZ?R&G9G]T%%?G?\
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M=14?8KF,[?$VI)AQ:#UMX\JTQZ-E8QG<Y3Y1_P"">?[#WQ'_ ."A'[4OA_\
M9S^'RR6\-Y)]J\2:T(MR:1I<;+Y]TW8D!@B*<;I)(UR-V1_5Y\!O@9\,OV:/
M@]X>^!'P<\-QZ3X:\,::EEI=E'R0J\L[MU>1V+.[GEG=F/)-?S-](KQ<GP5E
M*R/*JEL;B(ZR3UI4GHY+M.>JAU23EHU&_LY1@/K-3VLU[J_%G5VMK;6-M'96
M5O'###&$BBB0*J*!@* .  . !3Z**_SD;;=V?7A1110 4444 %%%% !1110
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MQ((C<B'._P H2$)YF-NX@9R<5I4 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YI/\
M@[DO8;K_ (*DZ/!%(&:V^$6DQR ?PL;W47Q^3@_C7Y=5^AG_  =&>*1X@_X+
M"^-M)$H;^P_#>@V)&?N[M/BN<?\ DQG\:_/.OV+)HN.545_=7XJYA+X@HHHK
MTA!1110 5^Q/_!F[:%_VN?BY?8XC^'%O'_WU?Q'_ -EK\=J_:S_@S*T$W'Q=
M^/'B?R\BS\-Z':[\=/.N+M\?CY'Z5XO$+MDU;T7YHJ/Q'[Z4445^2FQP?[47
MCWXK?##]G;QGX^^!/PNN?&OC73/#US+X3\*VLD:-J6H["+>)FD=%6/S"I<[@
M0@8C)P#^07_!-1?^"3_B_P#:P\(?L_\ [?G_  3"\0_!_P#:N-U;ZY8^(?BV
M]Q<_\)OKL;B>74H+O,<,UQ-<I)-L,*Q,Q*1ESA*_8[XT?';X+_LY>!I/B=\?
M?BKH'@WP[#=P6LNN>)=5BL[5)II!'$AEE8*"S$ 9/J>@-?('_!8GX4?"[]LC
M0/@9\+_AGJNEZI\58_C+X;\3?#G4M'N8YKO2=-M;V*;4]5WQDM'9)9H^Z3(C
M>8VJ F1H@0#VK_@J?\(_AU\9/^">7QF\._$SPK;:Q96GPPU^]M;:\!9(KJ+3
M;AX9PN<;XW =&/*L PP0#7%?\$'_ /E#Q^SQ_P!DULO_ &:O5O\ @H/+'!^P
M/\;YII B)\(/$K.S'  &E7.2:\G_ ."#<L<W_!';]GAXI P'PWLU)4YY!<$?
M@010!]+?%GP;K?Q%^&'B#P!X<\<7OAF]UO2+BPM_$.FH#=::98S&;B#) $R!
MBR,<A7"D@@8/Y@_\%R/^"1__  3S^"7_  2V\3?$K]GC]FK0/ 7Q$^'\^E7/
MPY\7^#-/^SZ_<:P^HVT%O%)=Q_Z3?RS/*$!F>1][B12'4-7Z.>!/VM/V8_B=
M!XYNO /QY\*ZI#\,]4N-.^(,]MK,1C\/7,"EIH[MB0(=@5]S,0H\MP3E&Q\=
M:7_P4<_X)G_MA_&#1?CI\9?V^O@EH_P_^'FLM?\ PS\%Z[\5-(M[O5=6C#QK
MX@O[:2X$D/E!G%E:R*'3>US*HE,"6X!5_;!M/C/X<_;?_P""=7BS]I#4T/A7
M2+[Q#;?$?4;AE73H_&<WACRM-EF/^K#M<_;%@;C$CD#EA5/_ ()2?&G3/V?O
M@G^UM^T1XKENV^$S_M4>++[X5Q:; 9O[8AFN88/*TF->)TNM19X;=(_EDGD8
M+][-?=WP^\=?"3]J3X-:=\0/"\=IXD\&>++ 7.FRZAI^ZVU2S9CY<XCF7YX9
M%"R(Q&&1D8<$5XM\+M.T[]L3X_6WQ:M+"&/X/_!_5)].^&6GP1!;7Q!XAA#V
MMWK*H/E:VLAYME:8&UI3=S@$+:R  [7]D+X)>-_!6F:W\<?CU%;/\4_B1/#?
M^,!;3B:'1[>-6%EH=M)_%;643LFX8$T\MS<84W! ]DK\0/CK\:_B^W[ O[8W
M_!1;4_$^IVGQ[^%'[7\F@_#G4Q<R_:="TZQU?1[.TT*"('!LY[:ZF\V #9<F
MY,D@<A2/VYTZ>YN=/@N;VU\B:2%6F@+9\MB 2N>^#Q0!-1110 4444 %%%%
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M_P"SA'<0^,/VR/#.M7\ (&E^"7DUR:1Q_P L]UDLD2-_UT= #P2*_/;]J/\
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M.]/652A%:Q[RII;QZN"UC]F\=(_'%%*Z/&YCD4JRG#*1@@TE?LA_)>P4444
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MA5G_ *%/#GAOP]X.\/V/A/PEH5GI>EZ9:1VNG:;I]LL,%K!&H5(HXT 5$50
M%     KXW/>)(T$\/A'>767;R7GY]/7:XQOJRMX%\"^#/AAX,TOX=_#OPO8Z
M)H6B6,=GI&D:9;+#;VEO&H5(XT4 *H  P*UJ**_/FVW=FH4444@"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G7]K;]@;PG\;UN/'
M/PZ%MHOBL@O-\NVVU(_]-0!\DA_YZ <_Q \$? 7CWX?>-/AAXFN/!_C[P[<Z
M9J-L?WEO<IC([,I'#J>S*2#V-?L/7&_&GX"_#+X^^&3X:^(N@+<! 39WT.$N
M;1C_ !1R8R.V0<J<#(-?I?"7B)C,E4<+CKU*"T3^U!>7=>3VZ/H?SQXH^ F4
M\7RGF63M8?&/5K:G4?\ >2^&3_F2LW\2;?,OR1HKW3]I+]@SXK_ @S^(M%B?
MQ%X;3+?VG90GS;9/^F\0R5 _OC*]R5SBO"Z_?LMS3+\WPRQ&#J*<'U73R:W3
M\GJ?P[G_  YGG"V8RP.:T)4JJZ26C7>+6DEYQ;7F%%%%=YX@4444 %%%% !1
M110 4444 >X_\%JM9'@?_@W0U^P23RY=6\/>%K>'GKYVJV$SC\8P]?S'5_2!
M_P '-FM_\(1_P1)\$^%-^S^U/%OAG3-OKY>GW-QC_P EL_A7\W]?@&1OVD,1
M5_FJS?XG^L^0T/JN0X2C_+2IK[H)!1117MGJA1110 4444 %%%% !1110 44
M44 %%%?:W_!,3_@A1^V9_P %*]3L_%NBZ _@CX:M-_IGQ"\1V;B&9 <,+& E
M7O7ZC*E8@5(:13@'#$8FAA*3J5I*,5W!)L^3/A-\(OBA\=_B%I?PG^#7@+5/
M$WB36;@0:9HNC6;3SSOU.%4<*!DLQPJJ"20 37]"/_!&O_@V>^'?[+,ND_M)
M?MW66F^+_B-"4NM'\'*5N-(\.2]5>7JM[=*<?-_J8VR4$A5)1]M_\$Z_^"5/
M[(?_  3,\ MX9_9^\$>=KU];JGB#QQK02;5M5(P2KRA0(HL@$0QA8Q@$@MEC
M](U^?9QQ-5QB='#7C#J^K_R7X_D:QA;<****^3+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  @$8(R#U%?/7[
M0G_!.OX1?%UKCQ%X(5?"NNR9=I;*$&TN'Z_O(1@*3_>0KU)(8U]"T5Z.69OF
M638CV^#JN$O+9^36S7DTSP.(N%^'^+, \'FV'C6I]+K6+[QDK2B_.+3/R?\
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M(?\ QZ2OPJK^?^&D_P"R(2>\G)_^3,_UX4(TTH1V22"BBBO> **** "BBB@
MHHHH ***^MOV*_\ @A]_P4C_ &ZC::Q\+/@#>Z'X9N]K+XS\;[M+TTQGI)&9
M%\VY7W@CEK&OB*&&ASU9**\W8+7/DFO<OV*O^";_ .V5_P %!?%W_"+?LO?!
M74M;MX9A'J7B*X7[-I6G9P3Y]W)B-2!\WE@M(P!VHQXK]T/V$?\ @T\_8[^
MTEEXW_:_\77GQ;\10[9#HPC:PT*!^N#"C&:ZP>\DBHP^]%SBOU)\$^!?!/PT
M\*V7@7X<^#]+T#1--A$.G:/HNGQVMK:QCHD<42JB+[  5\GF'%U"G>.$CS/N
M]%]V[_ M0?4_+_\ X)K?\&LW[+/[,3:?\3_VR]0M/BUXU@*RIHSP,OAW3I1S
M@0. U\0?XIP(R/\ EB",U^J%C8V6EV4.F:99Q6]M;Q+%;V\$81(D48554<*
M   . !4M%?$8S'8K'U.>O)M_@O1=#1)(****Y!A1110 4444 %%%% !1110
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M/6I)5E^(?_!0&UA0'YK?1?ARTA;Z22WR[?\ O@U[;\-?^#/;]@KP^R7'Q/\
MV@?BCXDE3K%8W5AIT#_5?LTKX^D@KFJ<3Y-#:;?HG^J0<DC^<RK>@^']>\4Z
MM!H'AC1+S4;^Y?9;65A;/--*WHJ("S'V K^KOX0?\&['_!(#X.F*YLOV1['Q
M#>1XW7GB_6[W4O,Q_>AEF,'Y1BOJWX4_ +X%? C2O[#^"'P7\*>#K+8$-IX6
M\.VVGQE1T!6!%!KS:_&6%C_"I-^K2_S'R,_E+_9U_P""#/\ P5<_:7DM[CPE
M^R#XAT#3I\$ZOXZ":)"B'I)LNRDTB_\ 7.-R1R!BOT(_9<_X,X-6FDM]9_;/
M_:S@@CX-SX>^&NGEW;U OKU %/;_ (]F^OK^[-%>'B>*\TKZ4[07DM?O=_PL
M4H)'RQ^R'_P19_X)K_L3O;:M\'/V9=&NM>MB&3Q5XK4ZMJ0D'_+2.2YW+;M_
MUP6,>W)KZGHHKYZM7K8B?/5DY/NW<NU@HHHK( HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]5\-?LZ?M*>!_'.HZ%$DFM6'A3Q/:W\U@CDJC3)"[&,,5(!8#)!H ]*HHHH
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M[^%-W\=;3XY>%Y?!5C<SV]WXMBUF)M-B>!F2;-R&\O",C!FW;05//%1? ?\
M:U_9?_:DM+K4/V;/V@?!_CVVLF*WESX1\00:A% PVY5G@9E5OF7@G/S"@#T.
MBO(-,_X*!_L.:U\4S\#-(_:U^'USXV$GEMX0@\56K:HK;0V#:A_-!VD'E>A!
MZ5Z_0 45A?#_ .)OP^^*VDWFN_#?QA8:U9Z?K5]I%]<:?<"18+ZSN9+:ZMWQ
M]V2.:)T8'NOH0:W: "BBB@ HHHH ***\*_X**_MT^$_^"=?[-=U^TGXT\":C
MXCL;75[33VTS2[F.*5FG8J&W2<8&.:[\KRS'YUF-+ 8*'/6JR4815E>3=DKM
MI:ONR9SC3@Y2=DCW6BOR)_XBZOV<_P#HT/QM_P"#RS_PH_XBZOV<_P#HT/QM
M_P"#RS_PK]1_X@'XN_\ 0JG_ .!TO_DSA_M3 ?\ /S\_\C]=J*^6_P#@EQ_P
M5&\!?\%1? 7BGQ[X"^%NK^%H?"VKPZ?<6^KWD4S3M)%Y@93'P !QS7U)7YIG
M>29IPYFE7+<RI.G7IM*46TVFTFM4VMFGHSMIU(5H*<'=,***\<\=?\%!/V,?
MAS\0+_X4^)?VAM ?Q+I./[:T/2))-1N=*SG'VN.T20VG3/[[9QSTKRBSV.BO
M._!7[7'[+WQ*L=0U3X<_M >$?$%KI.DV^J:G=:'KT%W%:V<\LT44SO$S*JM)
M;SKR<YB8'&*\\M_^"N7_  2RN;@VL7_!1?X)!UE$3A_B;IBA')P%8F<!3D$<
MXZ4 ?0]%</\ $+]IC]G?X3_"^#XW?$SXX^%-"\&721O;>+-3UZ"'394D&49;
MEF\LJPZ'=@]J;\"?VGOV=/VH=!N?%/[.'QQ\*^.],LY1%=:EX2UR"_@BD.<(
M9(690WRGC.>* .ZHKS3QW^V9^R7\+OBS8? ;XD?M)>"="\;:JT:Z7X2U;Q);
MP:C>&0 IY5N[B23.>-H->ET %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R&_\%RO^4MWQX_[
M'J7_ -%15\HU]7?\%RO^4MWQX_['J7_T5%7RC7[3@/\ <:7^&/Y(YWN=U^R]
M_P G,?#O_L>M(_\ 2V*O[9J_B9_9>_Y.8^'?_8]:1_Z6Q5_;-7QO&G\6CZ2_
M0TI[!7Y3_L3^,F_X*B?\%Z_VA?BE\8%&K>#?V1;FW\(?"OPI?#S+/3M:FN+J
M"[U<1'Y7NO,TZ[592,HDD0',2,/U8K\A_@W?Z/\ \$1O^"WOQRUC]IFZ_P"$
M>^"/[7.H0>(/"?Q/U %-*T_Q&D]S<2Z=?7!^2T9I+Z^*LY"E?(.<%S'\0:'Z
M6_M@_LG_  =_;=_9Q\5?LR?'3PS;:GH'BC2I;5S/;J\EC.5(AO(2?N3PN1(C
MC!#*.V:_.W_@XXL;;X>?#G]B5/&>N68/A_\ :A\)Q:GK,["&)5BA?SIBSG]V
MG[O>23@ <GBOT0\<_M@_L\>"]!L]4L_B?H_B'4-9&SPOX=\,:I!?:CX@G(RD
M%E!&^9F/4OQ'&H:21TC1W7\[O^#F;QIX?T_0?V-(?B9>:1I-Y)^U!X<U'5],
MGU%)8X+>)6^U-O=4\R&,R*K2%5&&4D#=B@#B_P#@X&\3?#O]OKXG?L__  =_
MX)C^(=,\>?M)>&OBG9ZG:^,?AS<)?_\ "&Z*L4WFR:C?VI9+2(W)M)@DK@X@
M<@<X?[2_X+]0Q3_\$;/VA$FC5@/ $K ,,\B:(@_@0#^%?-__  4*^&OBC_@C
M=^V3;?\ !9?]ECPC-<_"/QBUIHW[5'P_T" >7]E+A+;Q';0KA/-B9P'QC+-U
M N)Y%]=_X+1?M'? ;XW?\$(OC9\9/A)\7?#_ (@\+^(/A^%T?6M,U..2&Y>>
M:$1Q @Y$I9@OED!PV5*@@B@!?^"8?_!3#_@FO\._^";'[/O@+QI_P4"^!VA:
MUHWP2\*V6LZ+JGQ6T>VNK&\CTBU2>":&2Y#Q2I('5T8!E8$$ @UXW_P;O^*_
M ?Q!_;?_ ."@GQ"^&GB;2=<T/6_C[%>:5KFAWL5S:7]O)+J<B3131$I+&V\L
M&4D'=D'FOLO_ ()":[HNO_\ !*?]FZ]T/5[:\AA^!?A2VEEM9U=4FATBVBEC
M)!X9)$=&7JK*0>17QO\ \&_WCGP9XD_X*(_\%#K;0/%6GWLEQ\?_ +5;I;7B
M.9H!<ZG&94 /S)N&W<,C..>10!RO[$/[3O[.7[+O_!?/]O>^^/GQ@\/>#;;5
MKCPD-.DUR^6W6Y=+!FEVD]2-ZD_[WO7Z ?L??$3]EO\ ;+U>\_;^_9]M;>Z?
M4$U'P8GBFS7:NNV&GZBZ)*V45G19HYS$3T29^H88^*?^"4/CGP9J_P#P<&?M
M_6&E^*M.N)[R3PL+2&&\1FG^RVKPW.P Y;RI"$?'W6(!P:_3GP/\._!WPWL]
M0T_P5HD5A!JFM7>K7L4/"R7EU*99Y<=B\C,YQU9B>] &U1110 4444 %8OQ(
M_P"2=Z__ -@6Z_\ 1+5M5B_$C_DG>O\ _8%NO_1+5OA?]YAZK\SCS'_D7UO\
M,OR9^/-%%%?VB?Y#GT%_P3+_ .3I+3_L"WG_ *"*_1ZOSA_X)E_\G26G_8%O
M/_017Z/5_./BK_R4Z_Z]Q_.1_?WT9O\ DW,_^O\ 4_\ 2:94U^TU._T*]L=%
MU(6=Y-:21VEX8P_D2E2%DVGKM)!QWQ7XT_\ !'C_ (*F_!__ ()R>%6_X(]?
M\%8/ LOPA^(N@:YJA;QKXH@+Z)XV%]>SSM?3WCC&Z7S67[1*3#*D:DRJW[L?
MLIXDU&?2/#M_JUJJF6ULI9HPXR"RH6&?;(KX?\&_$C_@EA_P7B_X)\:#XR_:
M/7X?^(K2;PU%=>*;'4-3BM-1\%:F8%^U!96=9[!DD#8DW!9(PK9>-N?S4_H8
M]S_9H_97^%O[)7[*'B;X1?!Q--_X0V_U+Q'KWAZRTM0;2VL]3N)[U;>+!*F)
M//*IM^78% XK\]O^#8G]O;]@W]G[_@D5X-^''QQ_;1^$?@GQ)!XEUV:]T'Q7
M\1M+TV^C62_E,;O!<3I( R;2I(Y7!'%=Y_P;T:3XV^"O_!.'XV:!XL^)U[K7
MP8\*_$SQ5;? _P 9>(YO+6_\)VZ;%OHF;"BS>1)9%(PN]IL87%:W_!I+KNBZ
MG_P1A\(:5IVK6T]SIOBW7HM0MX9E9[9VOY)%610<H2CJP!ZA@>AH X;]D/XR
M_ W]H/\ X.L?BA\2_@'\5O"GCC09/V3(HX_$'A#7;;4[-KA-5T='43VSNA=0
M0I&<@'!K]"OV[OC]XC_9P_9DU_QM\/+&*^\;:H]MX?\ AUI<W*WWB+49TL].
MB88.8Q<31R2'!VQ1R,>%)KX,^$'CGP8W_!W;\4=,7Q7IQN'_ &5(-,2#[8FY
MKT7^DW!M@,\RB%6D*?>"J3C ->Z_&.;P1_P47_X*-1?LV^$?V@=1T;2OV:M$
MA\2^()O!.M6R7W_"6:JMQ:V4?[V.5<6FGI?L_P G#ZG#\RLA% 'SQ_P1?TGQ
MA_P2[_X*7_&C_@C;\6?B%J/B#2?%>G6_Q/\ A-XDUM_WVKM-&D6J@D_>D:5"
M<#_GQG<Y+9K]9:_'C_@O)^S;X@_X)^:?\'O^"P/@7]HCQSXP\7? [XD6$-]9
M>.M=LY'O]!O7,-W90&*WA8M(6$97+8CGF8;<$G]7_@K\:/AE^T1\*= ^-GP;
M\86>O>&?$VEPW^CZI8S!TEAD0,N<'Y6&<,A^96!4@$$4 =11110 4444 %?G
MI_P<\_\ **W5O^QVT;_T:]?H77YZ?\'//_**W5O^QVT;_P!&O7Z)X1_\G/R?
M_L(I?^E(X\?_ +E4]&?S94445_K@?!G[Q?\ !HK_ ,FY_%[_ +':Q_\ 2,U^
MNU?D3_P:*_\ )N?Q>_[':Q_](S7Z[5_E7X^?\G=S7_'#_P!-0/N,K_W"GZ?J
MSX)_X.2/V]/B3_P3]_X)@:_X[^"^LSZ7XR\;:_:>#_#>M6K$2Z;+=QSS37$9
M'*RBVM;@1N,%)&1QRM?2G[!/['OPX_84_93\(?LX_#K1+> Z-I,)\0:BB SZ
MQJKHIO+^XDZRS33;W+,3@$*,*J@?/'_!Q3_P3[^(?_!1G_@F=K_PM^#6GM?>
M-?".N6GBWPGI*,%;4;JTCFBDMD)_Y:/;7-P(QT,FQ20#D>A?\$Z/^"JW[,W[
M</[/^B^*9_BEHOA[X@:=IL=M\1_A]XAOX[#5O#^KQ($NX9K6<K*L8E5]DFW:
MR^C!E7\?/0/1O /[&?PN^%7[8WC3]L#X<Z19Z3JGQ&\*V.F>-[2SM1&NI7=E
M/,]O?OMX,WEW$L3L1E@D7/RG/YQ_\$$O'?[,7@[X7?MO^'_VD?%W@K3O"Y_:
M@\6/X@T_Q?>VL=H^F[8U<S13G:T) 9>05.".M?IY\+_VB_!'QL\4:I;_  FN
M(-=\+:+ 4O\ QQ8WBOILU^'PUG:RKE;HQ*',TB-LB<I%EY/-6'\S?^#;;PI^
MSS\<Q^UO+XE\*>#_ !=/'^U7X@U"P;4=.M;YTLY_+,,\>]6(C<QOM8<,4.#Q
M0 O_  :Y_"3Q%X]_83^.?@/QYX9U2\_9^\9_$G6+/X3:+XFBEV7?A^>-XKD1
M++\WV:171>/E,HN"/FWFNL_X-U?%.N_LG>,?CK_P1.^*U^S:[\!O&MQJW@2>
MX 5]5\*ZE+Y\-PJCJ1)*DKGH#J"+_":_4.VMK:RMH[.SMTBAB0)%%$@544#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>mdt-20250425_g12.jpg
<DESCRIPTION>IMAGE 12
<TEXT>
begin 644 mdt-20250425_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6K?3/A?H7A6XMY)-?>6W-S]H2661(DM8[=3/).S;0F-H=G1&O?LB_MA?#O\
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MAHY$8%64C(((Z@U\3B\%BL#4Y*\7%_GZ/9EIICJ***Y1A1110 4444 %%%%
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MZ+UC2ZJ4UM*IV6T/.5G'Y;,LV=6]*B_=ZOO_ ,#\PHHHK^MCP0HHHH ****
M"BBB@ HHHH **** "BKOA_PUXC\6ZI'H?A70+W4[V7_56>GVKS2O]$0$G\J]
MN^'O_!+3_@H[\4HTG\&?L1_$N:&3'EW5[X2N;.%_=9+A40CW!KSL?G&495'F
MQN(A27]^<8_^E-%PIU*GPIOT/!*_0O\ X-AO^4J6D_\ 8DZS_P"BDKBO#/\
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M$:=OM2;1+9GH"95$98X5WKX[KZZAB*&*IJI2DI+NC-JP4445L 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK,%H?W,Z;J6G:SIUOK&D7\-U:7<"36MU;RAXYHV 975APRD$$$<$&IZ_*/\
MX-7?^"DLW[2O[+]Y^Q;\4-?\_P 8_":UC_L"2XDS+?\ AUF"0@9Y8VLA$!Z
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRJ+_ .?T7_X#[WZ'Z!T445_)I_J %%%% !1110 4444 %%%% !1110 4444
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M\??M(?\ "91?%TZ[9K:Z=X6EU.WU66"2V,HO'U-)(#;JB0&!]RR&=!E1^L%
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M%%?.'WX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M78QR!%;EE##E99X?6OY4J^]X/P+C">+DM_=7IU_&R^3,YOH%%%%?;F84444
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MV@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5%(CI(@DC<,K#*L#D$>M+7X@?V/N%%%% !1110 4444 %%%% !1110 4444
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MU4KJ?Q!U^!<_;M3= &C1B,^1"O[J,<9"ER TCY^&/^#8G_@C=/\  OPA:_\
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MT%_H.KVM[ WW9[2X61#^*DBK5?,RC*+LU9GZ'"<*D%*#NGU6P4444B@HHHH
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M7R'$>>K#1>%P[]][OLNWJ_P]2XQOJS31$C01QJ%51A5 P *6BBOSHU"BBB@
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MS/\ 5Y"6/YUF45V4Z%"C_#BEZ)(04445J 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2.13U5E8$$>QKYR^,_\ P3*^#'CYIM7^'%Y/X3U!\MY-NOG63-_UR8@I_P
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M6 ZCJH;NRW=T9)(LGDK&47T48%?1=%%?/U:U:O/GJ2<GW;N7L%%%%9@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSX&_MD_LF?M.:WJOAK]G3]I3P/XYU'0HDDUJP\*>)[6_FL$<E4:9(78QABI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/Y#?^"Y7_*6[X\?]CU+_ .BHJ^4:^KO^"Y7_ "EN^/'_ &/4O_HJ*OE&OVG
M?[C2_P ,?R1SO<[K]E[_ ).8^'?_ &/6D?\ I;%7]LU?Q,_LO?\ )S'P[_['
MK2/_ $MBK^V:OC>-/XM'TE^AI3V"ORG_ &)_&3?\%1/^"]?[0OQ2^,"C5O!O
M[(MS;^$/A7X4OAYEGIVM37%U!=ZN(C\KW7F:==JLI&422(#F)&'ZL5^0_P &
M[_1_^"(W_!;WXY:Q^TS=?\(]\$?VN=0@\0>$_B?J *:5I_B-)[FXETZ^N#\E
MHS27U\59R%*^0<X+F/X@T/TM_;!_9/\ @[^V[^SCXJ_9D^.GAFVU/0/%&E2V
MKF>W5Y+&<J1#>0D_<GA<B1'&"&4=LU^=O_!QQ8VWP\^'/[$J>,]<LP?#_P"U
M#X3BU/69V$,2K%"_G3%G/[M/W>\DG  Y/%?HAXY_;!_9X\%Z#9ZI9_$_1_$.
MH:R-GA?P[X8U2"^U'Q!.1E(+*"-\S,>I?B.-0TDCI&CNOYW?\',WC3P_I^@_
ML:0_$R\TC2;R3]J#PYJ.KZ9/J*2QP6\2M]J;>ZIYD,9D56D*J,,I(&[% '%_
M\' WB;X=_M]?$[]G_P"#O_!,?Q#IGCS]I+PU\4[/4[7QC\.;A+__ (0W15BF
M\V34;^U+):1&Y-I,$E<'$#D#G#_:7_!?J&*?_@C9^T(DT:L!X E8!AGD31$'
M\" ?PKYO_P""A7PU\4?\$;OVR;;_ (++_LL>$9KGX1^,6M-&_:H^'^@0#R_L
MI<);>([:%<)YL3. ^,99NH%Q/(OKO_!:+]H[X#?&[_@A%\;/C)\)/B[X?\0>
M%_$'P_"Z/K6F:G')#<O/-"(X@0<B4LP7RR X;*E0010 O_!,/_@IA_P37^'?
M_!-C]GWP%XT_X*!? [0M:T;X)>%;+6=%U3XK:/;75C>1Z1:I/!-#)<AXI4D#
MJZ, RL"" 0:\;_X-W_%?@/X@_MO_ /!03XA?#3Q-I.N:'K?Q]BO-*US0[V*Y
MM+^WDEU.1)HIHB4EC;>6#*2#NR#S7V7_ ,$A-=T77_\ @E/^S=>Z'J]M>0P_
M OPI;2RVLZNJ30Z1;12QD@\,DB.C+U5E(/(KXW_X-_O'/@SQ)_P41_X*'6V@
M>*M/O9+CX_\ VJW2VO$<S0"YU.,RH ?F3<-NX9&<<\B@#E?V(?VG?V<OV7?^
M"^?[>]]\?/C!X>\&VVK7'A(:=)KE\MNMRZ6#-+M)ZD;U)_WO>OT _8^^(G[+
M?[9>KWG[?W[/MK;W3Z@FH^#$\4V:[5UVPT_471)6RBLZ+-'.8B>B3/U##'Q3
M_P $H?'/@S5_^#@S]OZPTOQ5IUQ/>2>%A:0PWB,T_P!EM7AN=@!RWE2$(^/N
ML0#@U^G/@?X=^#OAO9ZAI_@K1(K"#5-:N]6O8H>%DO+J4RSRX[%Y&9SCJS$]
MZ -JBBB@ HHHH *Q?B1_R3O7_P#L"W7_ *):MJL7XD?\D[U__L"W7_HEJWPO
M^\P]5^9QYC_R+ZW^&7Y,_'FBBBO[1/\ (<^@O^"9?_)TEI_V!;S_ -!%?H]7
MYP_\$R_^3I+3_L"WG_H(K]'J_G'Q5_Y*=?\ 7N/YR/[^^C-_R;F?_7^I_P"D
MTRIK]IJ=_H5[8Z+J0L[R:TDCM+PQA_(E*D+)M/7:2#COBOQI_P""/'_!4WX/
M_P#!.3PJW_!'K_@K!X%E^$/Q%T#7-4+>-?%$!?1/&POKV>=KZ>\<8W2^:R_:
M)2894C4F56_=C]E/$FHSZ1X=O]6M54RVME+-&'&065"PS[9%?#_@WXD?\$L/
M^"\7_!/C0?&7[1Z_#_Q%:3>&HKKQ38ZAJ<5IJ/@K4S OVH+*SK/8,D@;$FX+
M)&%;+QMS^:G]#'N?[-'[*_PM_9*_90\3?"+X.)IO_"&W^I>(]>\/66EJ#:6U
MGJ=Q/>K;Q8)4Q)YY5-OR[ H'%?GM_P &Q/[>W[!O[/W_  2*\&_#CXX_MH_"
M/P3XD@\2Z[->Z#XK^(VEZ;?1K)?RF-W@N)TD 9-I4D<K@CBN\_X-Z-)\;?!7
M_@G#\;- \6?$Z]UKX,>%?B9XJMO@?XR\1S>6M_X3MTV+?1,V%%F\B2R*1A=[
M38PN*UO^#277=%U/_@C#X0TK3M6MI[G3?%NO1:A;PS*SVSM?R2*LB@Y0E'5@
M#U# ]#0!PW[(?QE^!O[0?_!UC\4/B7\ _BMX4\<:#)^R9%''X@\(:[;:G9M<
M)JNCHZB>V=T+J"%(SD X-?H5^W=\?O$?[.'[,FO^-OAY8Q7WC;5'MO#_ ,.M
M+FY6^\1:C.EGIT3#!S&+B:.20X.V*.1CPI-?!GP@\<^#&_X.[?BCIB^*].-P
M_P"RI!IB0?;$W->B_P!)N#; 9YE$*M(4^\%4G& :]U^,<W@C_@HO_P %&HOV
M;?"/[0.HZ-I7[-6B0^)?$$W@G6K9+[_A+-56XM;*/]['*N+33TOV?Y.'U.'Y
ME9"* /GC_@B_I/C#_@EW_P %+_C1_P $;?BS\0M1\0:3XKTZW^)_PF\2:V_[
M[5VFC2+502?O2-*A.!_SXSN<ELU^LM?CQ_P7D_9M\0?\$_-/^#W_  6!\"_M
M$>.?&'B[X'?$BPAOK+QUKMG(]_H-ZYAN[* Q6\+%I"PC*Y;$<\S#;@D_J_\
M!7XT?#+]HCX4Z!\;/@WXPL]>\,^)M+AO]'U2QF#I+#(@9<X/RL,X9#\RL"I
M((H ZBBBB@ HHHH *_/3_@YY_P"45NK?]CMHW_HUZ_0NOST_X.>?^45NK?\
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MXEUFTO3\-/B-X6L25.O66H[UTY7V]Q<.Z!CUD^QKD!10!];_  HT/1_VF_\
M@I'XU_:0OM,@NM%^!>C-\.O UW)$&_XG5XL%]K]U$QZ;(_[,L0PY#P7J9Y85
M]1UY;^Q;^S_>?LQ_LR^%?A#K^KKJ?B"VM)+_ ,8ZTH_Y"NO7LSWFIWI[_OKV
M>XD /0.!VKU*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#X3_:/_ .#=+_@FM^U3\<_$W[0_
MQ:\,>+YO$GBW4FOM8EL?%DD$+3%0I*1A2%&%'%<3_P 0J/\ P21_Z$_QU_X6
MTO\ \17Z145Z$<VS.$5&-:22\V+E1^=_@S_@U\_X)4> _&&E>./#_A+QLM_H
MVI07UDTOC*5E$T,BR(2-O(W*,CO7Z(445SXC%XK%M.M-RMM=W!)(*S?%W@WP
MA\0/#MUX/\>>%=-UO2;Z/9>Z7J]C'<VUPN<[7CD!5QGL0:TJ*YQG"_"+]E[]
MF?\ 9_NKJ^^ W[.W@7P3-?+MO9O"/A&RTUK@9!PYMXD+C(!YSTJYXL^ 'P'\
M>:Y+XF\<_!/PCK6I3JJS:AJWANUN9Y JA5#221EB   ,G@ "NNHH R++X?\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>mdt-20250425_g13.jpg
<DESCRIPTION>IMAGE 13
<TEXT>
begin 644 mdt-20250425_g13.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MT *  P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT34=*BU74-3&K0R6\-I#)HRVL8EG=1%'(\X:-8F82,RMM4X. #Z+_P"#*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M@U32],US3+C1=:TZ"\L[R!X+NTNH5DBGB=2K(ZL"&4@D$$8()!H Y;X>_M!?
M [XM^-/$_P ._A;\6O#_ (CUOP5-;P^+=-T358KJ31YIO,,45QY9(BD812'8
MV& 7D#(ROQA^/GP9^ &C6FO?&7XD:5X>@U&\^R:6E_<8FU"XVE_(MX5S)<2[
M59O+C5FVJQQ@$U\#?\$7_ O@SX:_\%/O^"@O@OX>^%=.T31[/XD>%3::7I-F
MEO;P>9IUW(X2.,!4!=V;  Y)J]X=^+UUJW_!T'K_ ,)OC%<B*'1_V8(V^#UI
M?G$3&>_@EU*>V5N#<2>7(C.OS&*R92=J$4 ?=GP6^/7P7_:,\''Q_P# OXG:
M-XJT>.]EL[B]T:^686]U$<2V\R@[H9D) :)PKKD9 KKJ_-3P7XIN/@+_ ,'1
MOBOX,?#:;R_#OQF_9NL_%7CG2+;Y81KME?36L%\RC@2FV@"%NK?:,G)Q7WC^
MT]\?O!W[*O[.GCG]I3X@*[Z-X$\*WVN:A#"P$DZ6T#2^2F>-[E0B_P"TPH M
M?%O]H'X(_ :#3I?C%\4]$\.R:S<FVT2TU*_1+G5)P,F&U@SYES)CG9$K-CG&
M*K_$+]I+X)?";P7I'C[XF^/(=!L-?N8K;0XM5M9H;S4+F1"Z6\-HR"XDF**S
M>4L9<*C$J I(_*__ ()R?\% OA%\'O@[_P /<O\ @I/X0^)%YXU^,FH$:A\3
ME^&FHW'AOX>>'Y;HQZ;HUI<&/]Q9%?+E>6W5UEFG"R222)7T;^VUKEMH_P#P
M5+_8]_;1\1^,+!O@A9>&?%]G_P )J]\@T;2=2U+2XWLKN>Y)\J*.Z@5HHIF8
M*6^3<#(H8 ^W/A=\5/AO\;? &F?%3X0^.-+\2>'-9M_.TO6M&O%GM[E Q4E7
M4D95E96'565E(!!%26?Q(\"ZA\1+_P"$UAXFMI_$>EZ3;ZGJ6D1,6EM+2XDE
MC@EDP,()'@G" D%O)<@$*2/SU_X)7?%#Q)^RI^Q1\;?CYXG\&:K>Z/\ $G]J
MCQAJ_P"SWX-6,P76OZ?JE[&FDVMI'(!Y4=S<+/,KL B0N]PQ$09Q]F?LG?!&
MY^!OA*\7XD>*['7/B;XTO6\0_$76[<[?M^H.J1[($8[TLK:-(K2W0_=A@CW$
MNSLP!ZS1110 4444 %%%% !1110 445X?^U#_P %)?V&_P!C6&:/]H?]I+PW
MHFH0IN.@0W1O-3;TQ9VX>8 ]-Q0+ZD5W9=E>99QBEAL!1G6J/:,(N4GZ**;)
MG.%./-)V7F>X45^/?[2?_!VS\(M"^T:/^R=^S-K/B&896+6_&U^FGVX(_C6V
M@,LDJGT:2)O7'2O@[X_?\'%'_!4[X[^?96/QML_ FG3YW:?X"T>.S*_[MS+Y
MMRN/:45^Y\.?1G\4,]2J8BC#"P?6M/WK?X(*<D_*2B>76SG!4M$W)^7_  3^
MFCQ#XD\.^$M)FU_Q7K]EIEA;KNGO=0NDAAC'JSN0H_$U\^?%?_@K_P#\$QO@
MMYJ>.?VV? ;20Y$UOH.K?VO*A'4&.P$S@^V,U_*Y\2OC-\7_ (SZO_;_ ,8/
MBKXD\5W^2?MOB37+B^ER>OSS.Q_6N:K]HR?Z(&5P2>:YI.;ZJE",/NE-SOZ\
MJ]#SJG$$W\$%\W_PQ_2%\1/^#HC_ ()=>"S(OAC4?'WBXK]PZ!X1\I7_ / Z
M6W('U%>.^,/^#NO]GBR+_P#" ?L@>--3P/W?]L:]:6.[Z^6L^/UK\'Z*_1,!
M]%_PHPB2JTJM;_'5DO\ TVH')+.L=+9I?+_.Y^SVO?\ !W_XDFW+X8_8)L;;
MJ$>_^)#SYZ\D)I\?MQGL>>>/=O\ @E/_ ,' OQ-_X*+_ +7EC^S7XE_9RT+P
MQ9W.A7VH2:G8ZY-<RAH$5E0*Z*,'/)K^>NOT+_X-AO\ E*EI/_8DZS_Z*2O+
M\0_!#PMR#@',\=@,N4*M*C4E"7M*TFI*+:?O5&G9]TT7A,RQU7%0C*>C:Z+_
M "/K[_@HW_P<^_&#]A;]MWX@?LHZ+^REX:\16/@[4K>WM-7NO$5Q;RW"R6<$
MY+HL; $&4C@] *\ST'_@] UR.15\3_\ !/&TF0_>>P^*#1$<]0'TUL\=LCZU
M\"_\'!__ "F-^.'_ &';#_TUV=?&E?QK@L@RBO@J4YTM7&+>LMVEV9]2Y2N?
MT'^"_P#@\F_9:OI%'Q$_8[\?Z6A/SMHNL6-^0/82FWS^8KV[X:_\'5__  22
M\=.B>)_%OCOP8'(W-XE\%2RA/K_9[W7Z9K^8*BG4X4RB>R<?1_YW#GD?V(?"
M#_@K_P#\$P/CJT</PY_;F^'4MQ,<0V6K^((]+N)#Z+#>^5(Q]@N:^A]'UG1_
M$.F0ZUH&K6U]9W"![>[LYUEBE4]U920P]P:_AHKLOA'^T3\?_@!J?]M? KXX
M>+O!EWO#&X\+>([FP9C[F!US^->96X,IO^#5:]5?\5;\BO:']MU%?RS_ +.O
M_!SM_P %8O@0]O9>)OBQHOQ&TR @?8/'F@1RN4[C[3:^1<,W^T\CX/8]*_0?
M]E[_ (/#/V</&$EMH?[6W[-GB/P5</A)=<\)WJ:O9;N\CQ.(9HE]D$S?7/'A
MXGAC-L/K&*FO[K_1V?W%*:9^R-%>+_LL?\%$_P!B+]M:R6X_9A_:6\+^*KEH
M_,?1[>^\C4HEQG<]E.$N$'NT8'!YXKVBO!J4JE&?+4BT^S5F4%%%%0 4444
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M6BBBN884444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $4E<3X8_P"#>+_@KSXGB6X7]E Z?$W235/&6CPD?5#=EQ_WS7W-_P $/O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_)W_ (./?^"ND_P \&W'[!W[._B?RO&OB;3@?'6L64W[S1-,
ME7BT1A]RXN$.2>J0G(&949?M'_@JC_P4(\&_\$X/V3M7^-.J&VN_$M]G3O V
MA3-_R$-3=3L+*"#Y,0!ED/'RIM!#.N?Y4_B1\1O&_P 7O'^L_%+XE>)+G6/$
M'B#4IK_6-4O'W27-Q*Q9W/89)Z#  P   !7]4_1M\)8\49G_ *R9K3OA</+]
MW%K2I56MWWA3T;Z2G9:J,D>'G&/]A#V,'[SW\E_P3$HHHK_0L^3"BBB@ HHH
MH **** "O3OV4/V.OVB_VVOBE!\(?V;OAK>^(-5?:]Y-&NRUTZ$G!GN9V^2"
M,>K'+'Y5#,0I^E_^"3'_  0_^.G_  4?UJW^(_B][SP9\)K:Y*WOBJ6W_P!(
MU4JV'@T]'&)&R"K3,#'&<_?93&?Z*_V5_P!DC]GW]B[X3V?P8_9S^'5GX?T:
MVPTYA7=<7\V,-<7,S?//*<<LQ.!A1A0%'\Z>+?T@LDX!<\LRM+$X]:-7_=TG
M_P!/&MY?].XM/^9QTOZ^ RFIBK3GI'\7Z?YGQ)_P37_X-POV8?V2H;#XF?M.
M1V'Q2^($6V9([VV)T/2I1SB"VD'^DLI_Y:S@C@,L<9&:_2*.-(D6*) JJ %5
M1@ >@I:*_P ^^*>,.).-,R>.SG$RK5.E_ABNT(KW8KRBEW=WJ?5T,/1PT.6F
MK(****^:-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH " 1@BOSD_X*??
M\&W7['W[=45_\3/@I9VGPH^)<P:4ZMH=@!I6JR]?],LTVJ&8YS/#M?+%G$N
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M7XOM_F=]X8\,^'?!7ARP\'^$-#M=,TK2K.*TTW3K&!8H;6"-0D<4:* %55
M X %7J**_P UI2E.3E)W;W9]CL%%%%2 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !221I*C12H&5@0RL,@CT-+10!_-?\
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M.SD^[CS)OJ?%8G#XKF=::NI:W6JU\UT/!Z***_6#B"BBB@ HHKZZ_P"")W[
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M_N@HKY1_X(D_M=2?MI_\$S_AE\6-8U7[7K^G:1_PC_BJ1WW2'4+ _9WDD/\
M?EC6*X/_ %W'3I7U=7XM7HSP]>5*>\6U]QT)W04445D 4444 %%%% !1110
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MUK4OW=_:6_C#P];L^ )(F2SOL ]697L3@<XB8\XX_>&OY%/^"%W[1C?LQ?\
M!57X/>.KF]\G3M7\3+X<U?<V$-OJ2M9;G_V4DFCE]C$#VK^NNOS'BO"^PS/V
MBVFD_FM'^2^\U@] HHHKYDL**** "BBB@ HHHH **** "BBB@ HHHH ****
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M**^9/T0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[LQ/_L]?)E?U9P--3X3PC_NV^Z31_F5XT4G2\4,SC_T\3^^$7^H4445]8?F
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M+_@HN"U/2J***_.S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^[O+TXY1G!-O$>#N>1U.8373@\+5QN)C0I[R?W=W\A-V1^,__!?W_@HC;?\
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M;_)EP6MSJZ***_.34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_';P=GD6(J<19+3_ -FF[U817\*3WDE_S[D]U]A_W6N7P:BBBOUD_E\****
M"BBB@ HHHH *]:^ _P"VE\</@(T.FZ+K_P#:FBQD Z'JY:6%5](VSNA[X"G;
MGDJ:\EHKCQV7X+,L.Z&*IJ<'T:O_ ,,_-:GJY-GF<</8Z.,RVO*C57VHMI^C
MZ-=T[I]4?I'\%?\ @HM\!?BF(=+\37[^%-5DP#;ZQ(/L[-_L7 PN/]\(?:O>
MK>XM[N!+JTG26*10T<D;!E93T((X(K\8J[/X7?M"?&?X,SJ_PY^(6H:?"&W-
M8^;YELY[YA?*$^^,\]:_*<Z\)L+5;J995Y'_ "SU7RDM5\U+U/Z;X1^E!F.%
MC&AQ%A557_/RE:,_5P?N2?\ A<%Y'ZVT5\/_  V_X*Q^)+,1V?Q9^&EM>J,!
M[_0YS#)CU,4A96/T91[5[OX$_P""@?[+?CD)$?B =&N'Q_H^NVCV^WZR<Q#_
M +[K\TS'@GB?+&_:8:4EWA[Z_P#);M?-(_H?(/&'PYXCBEA\?"$W]FJ_92OV
M]^R;_P +9[316?X>\6^%/%MJ+[PIXFT_4X",B;3[V.9<>N4)%:%?+3A.G)QD
MK-=&?I-*K2KTU.G)2B]FG=/YH****DT"BBB@ HHK!^('Q3^&/PFT8^(_BI\1
M]!\,Z>,YO_$&L064(QU^>9E7]::3D[(#>HKXH_:(_P"#AK_@DK^SI%-!?_M3
MZ?XPU&,$IIGP\M9-8:7'9;B$?91_P*9:_/S]J7_@\=U6[MKC1/V+_P!DZ.T=
MMP@\1?$G4/,90> ?L-FP 8=<FY89ZJ1U]7#9'FN+MR4FEW>B_']"7)(_=>>>
M"U@>YN9DCCC0M))(P"JH&223T '>OA#]N;_@XO\ ^";G[%UO?>'M(^)J_$[Q
MA;!D3PS\/Y4NHTE'&V>^S]GA ;A@K/(N#^[)XK^=W]KW_@K-_P %"?VYDN-,
M_:)_:9U[4-$N&RWA;2Y%T_2MN>%:UM@D<N.S2AV_VC7SG7T^!X/A%J6*G?RC
MM]^_X+U)<^Q]X?\ !0W_ (.'?V_OV]X=0\#6?BQ/AKX!O T3^$/!=P\;W4)X
MV7=Z<37&02&5?+B8=8J^#Z**^PP^%P^$I^SHQ45Y?UJ9MMA1116X!1110 44
M44 %%%% !7Z8_P#!O=_P1/U'_@H#\4(OVE?VA_#<T7P9\)Z@/]&N$*CQ9?QD
M'[&GK;(<&=QUXB7EG:/S3_@BC_P1B^)?_!4CXO#Q%XHCO="^$/AF^0>+O$Z)
MM>^D&&_LZS)&&G92-S\K"C!FRS1H_P#4W\*_A9\//@A\.-%^$?PF\(V6@^&_
M#NGQV.C:1I\6R*U@0850.I/<L268DL222:^2XBSU82#PV'?OO=_RK_/\ON+C
M&^K-JQL;+3+*'3=-LXK>WMXEBM[>",(D2*,*JJ.%    '  J6BBOS@U"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCXD\-Z#XPT&[\+^*-)@OM/
MOH3%=VERFY)$/4$?UZ@@$<U>HJHRE"2E%V:V9%2G3K4W3J).+5FGJFGNFNJ9
M^;'[8_[%?B+]GG5I/%OA.*?4/!]U-^XNL;I-/9CQ%-[9X63H> <'KX-7[,:M
MI&EZ]IEQHFMZ=!=V=U"T5S:W,0>.5&&"K*>"".QKX(_;'_X)_:Q\,'NOB5\&
M;*>_\-\RWNEKEY],'4D=Y(1Z_>4=<@%J_?>"/$*GF$8X#,Y6J[1F]I^3[2_"
M7KO_  _XQ>!.(R.=3.N':;GAM93I+65+NXK>5/NMX><=8_+U%%%?K)_+P444
M4 %%%% !1110 4444 %%%% $MG>WFG7*WFGW<L$R'*2PR%64^Q'(KM= _:=_
M:(\,*L>C?&OQ,D:#"12ZO+*BCV60E1^5<+17/7PF$Q2M6IQFO-)_F=^!S3,\
MLES8.O.D^\)2C^31[1IO_!0C]KC346+_ (6I]H1>BW.C6;G\6\K<?SKT7_@J
M5_P4&_:&_8__ ."1]A^UY\+-7TM/'-Y=:-"MUJ.EI-;G[3+^]_<\+]P-CTZU
M\I5TO_!Q]JP\/_\ !"/X8Z66V_VMXK\,P >O_$LO+C_VEG\*_+./<ER?#/!*
MAAX0<ZMGRQBKJVSLE=']8_1MXFXFSS/L;2S'&U:\(4DTJE2<TFYK5*3=G:Z/
MSXNO^#JC_@KE<0-#%X[\$P,>DL7@B LO/;<2/S%<;XD_X.5/^"SGB(-$G[7,
M>G1,,&/3? FB1]NSFS+C\&KX3HKQHY3E<=J$?_ 5_D?U[=GT1\1_^"MW_!3K
MXK^8OC3]O+XI/%+_ *VUTWQA<V$#CT,5J\:$>V,5X1XI\8>+?'.LR>(O&WBC
M4=8U";_77VJWLEQ,_P!7D)8_B:SJ*ZZ="C17[N*7HDA!1116H!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUVS*Q-/,L0<@#) +9('I7>^'\X2NZ3^]?YBYHGZ^T445XQ045S'Q>^-7P?\
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M6G@7X=_M-^$[_P 17U\MG:^%WU(0:J\S1O*H^Q3!+@ I%(P8QA2$8YX->R4
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M:'XV_P#!Y9_X5^N_\0#\7?\ H53_ / Z7_R9Y_\ :F _Y^?G_D?KM17Y_?\
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MRRZIYAA8#YG1#\"?MQ_L+_LZ?LW_ /!8+]EKXW?\$JWT[PO\5_&/Q,B7XG^
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MU/0B@#] M,L$TO3;?3(II)%MH$B624@LP4 9)  R<<\"IZ** "BBB@ HHHH
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M\+:Y/HVOZY.(+?\ M6RN-/6.S>9V$<8FBNYMI? 9XE0'<ZJW\_G]SGF'P/\
MCI_P3C_X+0>*/A-^UW^S#\3="U;QC\'/$[:RMM>6PM_$&DVUQ8W-G<6-S W[
MU(7-PK;ANA>2!2CMC-6OBK_P6+@^'W[='B3_ ()^>'OV)_B=XA\>:1\/'\3Z
M!:6$NG >)<WL-M"ELPN6C@MV#S2O<W<EOY0MF4QEV16^.O\ @IC^PO\ LV?
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M4A<:-YASA)$G:10W^L6(.I\Q;G=^AG[1OC;P?I7_  5<_9H\)ZEXGL(-4OO
MGQ!^R:?+=HLTN5T0C:A.3D12$<<^6^/NG !/_P $J?\ @H9X2_;U_P""<O@W
M]L'Q%K5E87T6AR6_Q&$KK%'I>K6*[+\N#Q%&2AG4'I%-&37YH?#&U\5_$W_@
MY*_98_;.^(T-Y%J'QM\&>+_$V@:3?AE.C^&TTC4K71+81M_JW:QBCNY1@$3W
MTP/05UL_[(?[0W[/O_!6OXL_\$LOA)X:G3]G[]KA8/B)K>H6[M'%X=TV"Y4>
M([*(*-JF]RM@0/\ 5Q7UGC[M>E?MJ>*_ GA__@Z4_8V\.'7],LC8_"GQ);&S
M%Q'&+<S6&K);1;<@(7*[47C<< 9R* /U7HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OA/]H_\ X-TO
M^":W[5/QS\3?M#_%KPQXOF\2>+=2:^UB6Q\6200M,5"DI&%(484<5]V45OA\
M5B,+)RHS<6^SL)I,_-W_ (A4?^"2/_0G^.O_  MI?_B*TO!G_!KY_P $J/ ?
MC#2O''A_PEXV6_T;4H+ZR:7QE*RB:&19$)&WD;E&1WK]$**ZGG&:-6=:7WL.
M5!1117G#,WQ=X-\(?$#P[=>#_'GA73=;TF^CV7NEZO8QW-M<+G.UXY 5<9[$
M&N7^$7[+W[,_[/\ =75]\!OV=O O@F:^7;>S>$?"-EIK7 R#AS;Q(7&0#SGI
M7=44 9'B;X?> O&EO=VGC'P1H^K1:A9"SOXM3TV*=;FW#%A#('4AXPS$[#D9
M)..:POA'^S=^SM\ /MG_  H?X">"_!/]HL&U#_A$?"UIIOVH@Y!D^SQIOZG[
MV>M=I10!C^-?A[X!^)6E1Z%\1O ^CZ_8Q7 GBL];TR*ZB24*RB0)*K ,%9AN
MQG#$=S5/P1\'/A%\,KJ>^^&_PK\-^'I[J,1W,VAZ';VCS(#D*QB12P!YP:Z2
MB@ HHHH **** "BBB@#S;XX_LI?"/]H;5;'6?B19W\L^G6[0VQM+XQ (S;CD
M <\UPW_#LS]EO_H$ZU_X.&_PKZ"HKVL+Q)GV"H1HT,3.,([)2:2Z['R&8^'_
M  1F^-GC,;EU&I5GK*4H1<G96U;6NB2/GW_AV9^RW_T"=:_\'#?X5[5\/_ N
M@?#/P9IW@+PM'*FGZ7;B&T6:7>X0$GECUZUL45CCL[S?,Z:IXNO*I%.Z4FW9
M]]3KR7@_A7ARO*OE>"IT)R7*W""BVKWLVNETF%97B+P-X)\81S0^+?!VE:HE
MQ9/9SKJ.GQSB2V=E9X6#J<QLR(2AX)521P*U:*\L^D.(^$G[,W[-_P  ;F]O
M?@3^S[X(\%3:E_R$9?"7A2STUKKG/[PV\:%^>?FS7P]X@_94^*?Q2_X+U>(?
MVC_C#^P_J'B/X)ZU^SO#\/7U7Q'!HM]8S:FFMPWXGDLI;II3;!$8!S$6# ?)
MCFOT8HH R? _@+P+\,?#%KX(^&W@O2?#VBV*E;+2-#TZ*TM;=222$BB5409)
M/ ')K%U#]GKX!:M\3X/C=JGP.\'W/C2U4+;>+[CPS:OJD( V@+=&/S5   X;
MIQ7844 8_CSX>^ ?BGX6NO WQ.\#Z/XCT2] %YH^O:9%>6LX!R \4JLCX(!Y
M!Y%5]!^$WPK\+> %^$_ACX:>'].\+);-;KX:L-&@AT\0MG=&+=$$80Y.5VX.
M37044 <MX5^!OP4\"K>+X)^#_A;1AJ-L;;4!I7A^VM_M4)ZQR>6@WH<_=;(J
MOIG[/'P T7PA:?#[1_@;X.M- L-374K#0[;PS:1V=M>J<K<QPK&$28'D2 !@
M>]=C10!R/B7]G[X#>-/$,WBWQC\$O".K:K<%#<:GJ?AJUGN)2BA%+2/&6;"J
MJC)X"@#I6OJOP^\!:[XJT[QUK?@C2+S7-'21-)UFZTV*2[LE<8<0S,I>,,."
M%(SWK7HH ^)?#R_\%'_VW/CP_P )OVM?V.- ^%'P=\ _$Q-=378?B!!J]UX^
MATZX,^D6\=K"@^S0BYCM;V:29@6\A(1&-TA7[:HHH **** "BBB@ K.\7>%]
M*\;^$]4\%ZZCM8ZOIT]E>+$^UC%+&T;@'L=K'FM&BJA.=.:G%V:U3\PW/ST_
MXAAO^"5O_0I^-O\ PLI?_B:/^(8;_@E;_P!"GXV_\+*7_P")K]"Z*_0O^(N>
M)_\ T.,1_P"#9?YG)]0P7_/M?<?(_P"QS_P1,_87_85^-4'Q]^ 6@>);?Q#;
MZ=<64<FJ>(GN8O*F #C85 S@#![5]<445\EG>?YWQ)C/K>:XB=>K91YIR<G9
M7LKOHKO[S>G2I48\L%9>14UW0="\4:/<^'O$VBVFHZ?>1&*[L;^V6:&=#U5T
M<%6!]",5B>"?@M\'/AIJ$NK?#CX3>&?#]U/#Y,]SHF@V]I))'D-L9HD4E<@'
M!XR!7345Y!H5M2T71M9^SG6-)MKO[)<K<VOVF!9/)F7.V1-P.UQDX8<C)KE_
M$'[/'[/_ (LUZ;Q5XI^!G@[4]4N9 ]QJ6H>&;2:XE8  ,TCQEF(  R3V%=C1
M0!$]C927L>IR6<37,43Q17!C!=$<J74-U 8HA(Z$HN>@KC-4_9C_ &;-<U.X
MUK6OV>_ ]Y>7D[SW=W=>$[.26>5V+,[LT9+,2222<DDDUW%% #+:VMK*VCL[
M.W2*&) D442!510,!0!P !QBGT44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>mdt-20250425_g14.jpg
<DESCRIPTION>IMAGE 14
<TEXT>
begin 644 mdt-20250425_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
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MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO'<6[.<XQ^\ '4ANA^8_P#@@9^U1\<_VUO^"5OPY_:8_:1\9C7_ !EXEO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO%$(HP%\QI)=PR(U^SZ** "BBB@ HIEQ<06L#W5U,D<4:%Y))& 55 R22>@
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MU!(H9)8Y$)5T92"&!((((K^&ROTD_P""&_\ P7L^('_!.SQ/9?L__M!ZE?\
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MM*,E)>7]:&;304445N 4444 %%%% !1110!^CO\ P0=_X+D^+/\ @G%X^@^
MOQWU2\U7X)^(=0S=1?-+-X5N9&^:^ME&2823F:!>O,B#>&63^G3PMXI\-^./
M#6G^,_!NO6>JZ1JUE%>:9J>GW"RP7=O(H>.6-U)5T92"&!P00:_ANK]<?^#<
M'_@N!+^RUXOL/V%?VK/&!'PUU^^\OP9X@U&?Y/"]_*_^HD=C\EE,YY/W89&W
MG"/(R_'<1Y"L1%XK#KWU\2[^:\_S]=[A*VC/Z+Z* 01D&BOSPU"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$42!54 *JC  ]*6BBOXG/I HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9<VUO>6\EI=P)+%*A26*10RNI&""#P01QBGT4 ?@[_P
M7G_X-QAX:BUC]M#_ ()W^!<Z<BO>>-?A=I-ODVH&6DO--C7K'U9[51\G)B&W
M]VGX@].M?W05^%7_  <8_P#! \6G]N?\%"OV)?!>(OWE_P#%#P-I=O\ <ZM+
MJUI&HZ=6GB4<<R@8\S'W?#W$+DUA<4_*,G^3_1_>9RCU1^&E%%%?<F84444
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MC]FHJ2<Z=.-FW**=X^TEW6JA%K<^8SZM4<XTK>ZM?5_\ HT445_8Y\\%%%%
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MXKU6*;?!97_]G6V#D!;=1$<>Q=7;_@5?H_A?ERQO$OMY+2E%R^;]U?FW\C\
M^DAG\LI\/7@Z;M+%5(P\^6/OR^7NQB_*1Y31117](G^?04444 :7A/QEXL\"
M:S'XA\%^)+[2KZ+[EU87+1.!Z94C(/<'@]Z^F_@O_P %3/B%X;\K2/C1X<B\
M06@PK:G8*MO>*/4KQ')],)[DU\I45XV;</Y/GE/EQM%2?1[27I):KTO8^MX7
MXZXLX-K^TRC%RIJ]W&]X2_Q0=XOUM==&CZV^-G_!/W_@D7_P53@N-8O/!NG:
M/XSO%9Y=<\+E='UM9#R7ECV^7=D=WDCF [,*]U_X)U_L%?#3_@G)^S9:?LZ?
M#36+C5HUU:[U+5-=O;9(KC4;F:3B214)4%(5AA&.JP@\9-?$'[(/PJF^,/[0
MGAWPL4?[)!=B^U)U)&VW@(=AD<C<0J9]7%?JI7XSX@X[.LFP=/AV.8U:N$=J
MBI3ES*#5U&S[:R]U66S:;LU_>?@SQOFOB#D=7,LPPL*4H2]FIPNE4=DY/E=^
M6UXZ\TKMNUK6"BBBOR8_9 HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y$_P""XO[#0_;X_P""
M='C;X7Z#H_VOQ9X?@_X23P0$CW2-J5FCMY"?[4\+3VX[9F![5_(T00<$8(ZB
MO[H*_D>_X+M_L@+^Q?\ \%.?B/\ #[1])%IX>\17X\4>%42/;&+*_+2F.,=D
MBN/M$ 'I!7W7!^-?OX27^)?D_P!/Q,YKJ?(%%%%?=&84444 %%%% '[F?\&;
M_P"U 4NOBW^QEK.H\.EMXQ\/6Q?H04L[X@>^=/Z>AK]U*_DE_P""!/[13?LU
M_P#!6'X1^);J]\K3O$FN'PMJJEL+)'J2&UBW'LJW$EO)Z?NZ_K:K\PXKPWL,
MTYUM-)_/9_E?YFL'H%%%%?-%A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!E^./$L'@SP7K'C"YQY>E:7<7DF
M[IMBC9S_ .@U^/%]>W6I7LVHWTQDGN)6DFD;JSL<DGZDU^G?[>7BW_A$/V5?
M%5Q'+MEOK>*PB&?O>=*B./\ OV7/X5^7]?O7A%@^3+<3BFOBFH_^ J__ +<?
MQ']*?-G6XAR_+4]*=*51^M27+^5/\?,****_7C^5PHHHH **** /MK_@DW\,
M_L^C^)OB]>V_S7,R:5I[D8.Q )9L>H):$?5#7V-7F/[&O@+_ (5U^S/X2T*2
M'9//I@OKH$8;S+@F8@^X#A?^ UZ=7\E\7YD\UXDQ->]US.*](^ZOOM?YG^HG
MA9P_'AGP_P OP5K2]FIS[\]3WY7]'+E]$@HHHKYL_0 HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K\6?^#QC]F&#7/@Y\+/VP-&TL?:_#^N3^%]<N(TRSVMW&US;%SV2.6WG
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M%=-6?=X$T)'^7&H3R+ZG_1U4_P#H7YU\85_3GAK05'A&C+^=S?\ Y,U^2/\
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M6+OQH=9  Z_VC;PZ@3^)N2?QKY+K]MPM7V^&A4_F2?WJYSO1A1116X!1110
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MHJOXE95%_P#/Z+_\!][]#]!****_DP_U!"BBB@ HHHH **** "BBB@ HHHH
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M04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ24BJJ*$10 !@ #I2U^.8S%5,;B95ZF\G_PR^2T-DK(****YAA1110 4444
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M;&$,P(@$3B1T<)*"GEL ?0OQ[^-?QO\ VC_V[OVH_P!GC3OC3XK\!:%^S_\
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M(-?F]^VC^QUK'[.WB-O$_A:":Z\(:C.19W!RS6,AY^SRG_T%C]X#!Y!S^_\
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M5\I+5?-/U/Z=X1^E#BZ$8T.(\+[1?\_*5E+U=-M1;[N,HKM$_6*BOBKX:?\
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MWT']JG]I#PUM&E?&[Q+M7[L=SJLDZCV"REAC\*X"BN;$8+!XM6KTXS_Q)/\
M-'H8'-\VRN5\'B)TG_<G*/\ Z2T>UZ=_P4._:XL $?XGI<JO1;C1+,_J(@3^
M=>G_ /!=']OWX^_\$^O^">VC_M#? ;4M+@\5ZCXMTK2VFU73%N82D]M<2R_N
MR0,GR>#VKY%KN/\ @[VU+^RO^":7P\\-(VUKCXQ:<2/5(M(U0$?FRU^1<>Y/
ME.%S'+X4,/""G*?-RQ2NER[V2ON?V+]&CB+B+/IYI_:6,JUU35'E]I4E/EYO
M:WMS-VORK[C\YI_^#JG_ (*XS0M%'XX\$1,1Q)'X(@)7Z;F(_,5R'B3_ (.7
M?^"S?B!6BM_VL+?3(WX:/3? 6B+^3/9LP_ U\'T5PQRG*XO2A'_P%']479]'
M_$;_ (*__P#!47XJ^8GB_P#;T^*'ERY\VWTGQ9<:=$X]#':-$I'MC%>">+_'
M'C7X@ZR_B/Q[XOU37-0E_P!9?ZOJ$ES,_P!7D8L?SK+HKKIT*%'^'%+T20@H
MHHK4 HHHH **** "BBB@ HHHH ***5$>1Q'&A9F.%4#))]* $K]1_P#@A'_P
M;^^+?VZ-:TW]J3]K#0KW1O@W9SB;3-,D+077C%U;[D9&&CL@1AYA@ORD9SND
MC]?_ ."(7_!M+K/Q'ETG]K'_ (*.>#[C3O#H*7?ACX6WR&.YU3HR3ZDO#0P=
M"+8X>3_EIL3Y)/WSTS3--T33;?1M&T^"TL[2!(;2TM8ECBAB10JHBJ %4
M 8 &*^+S[B2-)/#X1WEUEV\EY^?3UVTC#JROX6\+>&O _AK3_!O@S0+/2M(T
MJSCM-,TS3K98;>T@C4*D4<: *B*H "@  #%7Z**_/VVW=F@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4$ C!&0>HHHH ^4/VL_\
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M?9]T]4?Q/G61YOP[F$L#F5"5*K'>,E;YKHT^C3:?1A11178>4%%%% !1110
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M10 4444 %?R&_P#!<K_E+=\>/^QZE_\ 145?UY5_(;_P7*_Y2W?'C_L>I?\
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M)BZ_IE7SI^TI_P %#O@Q^RG^V-\,/V:OC[XST7PQHWQ3\+:Y/HVOZY.(+?\
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M6OB)XOF\3;=#\,VK(\TL,EI 5T[0EC*OB*18[HQ6SF5Y?)D< 'U[^W=#$O\
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MO_!6OXL_\$LOA)X:G3]G[]KA8/B)K>H6[M'%X=TV"Y4>([*(*-JF]RM@0/\
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M?$#P[=>#_'GA73=;TF^CV7NEZO8QW-M<+G.UXY 5<9[$&N7^$7[+W[,_[/\
M=75]\!OV=O O@F:^7;>S>$?"-EIK7 R#AS;Q(7&0#SGI7=44 9'B;X?> O&E
MO=VGC'P1H^K1:A9"SOXM3TV*=;FW#%A#('4AXPS$[#D9)..:POA'^S=^SM\
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MIT]E>+$^UC%+&T;@'L=K'FM&BJA.=.:G%V:U3\PW/ST_XAAO^"5O_0I^-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>mdt-20250425_g15.jpg
<DESCRIPTION>IMAGE 15
<TEXT>
begin 644 mdt-20250425_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT34=*BU74-3&K0R6\-I#)HRVL8EG=1%'(\X:-8F82,RMM4X. #Z+_P"#*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$8]VC X/I7L]>#4IU*4^6::?9Z,H****@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\V_:K_:Z_9]_8H^%$OQH_:0\?QZ!H@O8K&SV6DUU=:A>
MRY\JTM;:!'EN9WVL1'&K'"LQPJLP])KG/$/PF\">*_B1X<^*WB+0X[O6?"=K
M?0^'YI_F6S-V(5FF13PLNR$1B0?,J2S(#B5P0#PK]AO_ (*[?L+_ /!0KQAK
MOPP_9Z^)MZOC'PU#Y^M>"O%.@W.DZK;P;E4S""Y13(@9E#%"VPNF\+O7-/\
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MW>>";"2S/A;3?$\%WJ$(MW"7#SJ':6282OF>1LOYLI,AWOR >NT444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$PJO7J1@O[S2_,[\#E6:9G+EP="=5_W(RE^29PE?07_!,O\ Y.DM/^P+>?\
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MXL[J!MLUM=PM')&?1E8 @_6O7IUJ557A)/T=Q%>BBBM "BBB@ HHHH ****
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MZ_N7UC1M(\1:5<:%X@TJVOK&\A:&[L[R!98IXV&&1T8$,I'!!&#7YU?MV_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVW=G]H)**LM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3,DVCR!GTZ4^RHDML!V%HI/WJ^*XOR_GI1Q<%JM)>G1_)Z?,T@^A^E=%%%?
M&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8A&OB/&(]4@)M[U<#H!<12X_V2I[U[G7XM5ISHU94Y;IM/Y'0%%%%9@%%%%
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MH04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?@_9%SMC^'MTX7T+7S@G_P ='Y5^.-?K7#JY<FH^C_-F,_B"BBBO:)"BBB@
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M_#(PYSBOHNBM*-6="M&I'>+37R#<_A@='C<QR(593AE88(/I25]G_P#!??\
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M6L7;^O4V3N@HHHKG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'(H:.1&!5E(R"".H-.K\U-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJGXB\0Z#X1T"^\5^*M:M=-TS3+22ZU'
M4;ZX6*"U@C4O)+([$*B*H+%B0  2:$FV!P'[7_[5_P (OV(_V=?$W[2_QNUH
M6FA>&K!IFA1AYU]<'Y8;2!21NFED*HHZ9;)(4$C^0']MS]L/XL?MY?M->*/V
MG_C)>AM5\17NZVL(I"T&F6:?+;V<.>D<48"@]6.YVRS,3]4?\%[O^"Q&K_\
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MD8_+Q$3M\O;^[]?POU^XG_!!3_@XU@T*VT7]BG_@H9XXVV<2QV7@?XH:K/\
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M*-#]9PQG"PE;ZM5?N2>C[/\ R?Y_,B<;ZG\Z-%%%?I!D%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !117VK_P3&_X(4_MF_P#!2O4[/Q7HGA]_!/PU:4?;/B'XCLW6&9 <,+&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7UKGZ[!+BN=NO^#.S]OY)BME^T=\'I(\<-+J&JHWY"P;^==*S_)Y?\OE^/\
MD'+(_)"BOUMA_P"#.W_@H&TJK<?M&?!Q(R?G9-2U5B![ V S^8KI-"_X,V?V
MI+AD'B;]L3P!9@X\PV&C7USCCG&\19Y^GX4//\GCO67X_P"0<LC\;J*_=KP;
M_P &86BQ.D_Q"_X*"74ZG'F6VC?#=8B/4"66_?/_ 'Q7MOPX_P"#0C_@G'X8
MDBN_'_Q9^*OBB5"/,MWUJRL[:3_@,5IY@_"6N:IQ1D\-IM^B?ZV#DD?S<5I>
M$O!GC#Q_KL/A?P)X4U+6]3N#BWT[2+&2YGE/^S'&"S?@*_K&^$7_  ;_ '_!
M(3X,R0W6@_L6>']7N8L%KCQ=>W>LB0^K17DTD7X! /:OJ;X<_"'X3?!W1QX>
M^$?PO\.^%K   6/AS1(+&' Z?)"BK^E>;7XRPT?X-)OU:7Y7*5-G\J'[.O\
MP;[_ /!67]I"6"?1OV4-6\*:=-@OJOQ!F314B!Z,8;@BY8?[D35^@_[+O_!G
M!9PRV^L_MG?M:-,!@W'A[X:Z=L!/<"^O$)([8^S ^XK]RJ*\/$\59I7T@U!>
M2U^]W_"PU!(^9?V1?^".W_!./]B*2VU;X%_LQ:$NNVV&3Q5XA1M4U,./XTGN
MBY@)[B$1K[5]-445\_6KUL1/GJR<GW;N7:P4445D 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16-\1_&=
MK\.?A[KWQ"O;*2YAT'1KK49K>)@&E6"%I2@)X!(7 SZU^07_ !&4_LS_ /1F
M?CK_ ,']E_A7=A,MQN/3="'-;?;]6)M+<_9:BOQI_P"(RG]F?_HS/QU_X/[+
M_"O?_P#@FG_P<6?!?_@I7^U!:_LO^!_V<_%'AF_NM&O-175-5U6VFA5;=0Q0
MK&-V3G@UO5R/-:%)U*E)J*U;NO\ ,7-%GZ+T445Y1045XA\0?^"D_P"P9\*O
M'FI?#7XA?M5^#M+U?0[A;?Q EQJ@,&C3-C$5[<*##9/@@[9W0@$'&#7:6'[4
M'[.NJ?"ZZ^-^E_&SPS<^#;*YN+>Z\5V^KQ/IT;P,R39N%)CPC(P9L[05//%
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MS]A?X=KXD\0?$*W?X2^.O#*,4@U>[OHV71)[@J"=@N%C#R'@?8K9<_-7$_\
M!P_\)/ G[&7_  2#_9]_9_N_&T%S=Z/\?/#MSJVKW\RI<:U?&'4KK5-4D!.2
MTUS--<2-T#3]LB@#]E:*CM+NTU"TBO["ZCG@GC62&:%PR2(1D,I'!!!!!'6I
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+:$*-.[ERP2BKNUW9=79?<4?$OA?PUXST.X\,^,/#MCJVFW:A;K3]2M$G@F
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.1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>mdt-20250425_g16.jpg
<DESCRIPTION>IMAGE 16
<TEXT>
begin 644 mdt-20250425_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO'OVJ_V^OV2_V']/L];_ &KOBO\ \(5IFH3+#9ZSJF@W[6$LS!V6 744
M#0^:5C=O*W[]JD[<<UY])_P6?_X)I0^!(_BE+^TLB^&)H#/%XC;PCK L'B!P
M7%Q]D\LKD$9W8H ^HJ*^<_B=_P %;O\ @G-\&_V??!?[5'Q)_:HT/3? 'Q#U
M$V/@SQ&;2[ECU297='V1Q0M(J(T;!Y'143 +,H(S]$6EW:7]K%?V%S'/!/&L
MD,T+ADD0C(92.""#D$4 24444 %%%<_\5OBEX(^"7PZUCXL_$K5)K'P_H%DU
MYK%_!IT]T;6W7[\S1VZ/)L099V"D(BL[$*I( .@HKR_]E#]M#]EW]N3P#??%
M']D[XQZ9XVT#3-8?2K[4]+CE6.&\2**9H2)40[A'-$W QAQS7J% !1110 44
M44 %%%% !15/Q!X@T'PEH-[XJ\5:W::9IFFVDEUJ.HZA<K#!:P1J7DEDD<A4
M15!8LQ  !)-?-/[.O_!:?_@EM^UC\:_^&=OV?_VRO#'B#QB\DD=GHXANK7[>
MZ EEM9KB&.*[. 6Q"[DJI(R 30!]145PW[07[2OP+_97\"I\2/C_ /$BQ\-Z
M3<:C!I]B]RLDL]_>S-MAM+6WB5YKJX<YVPPH\C8.%.#5+]GK]K7]GS]J>WUP
M_!#X@C4[WPOJ(L/%&A:AI=UINJZ)=$;EAO=/O8H;JT9@"5$L2;@"1G!H ]&H
MKYB_:=_X+-?\$P?V-?B]'\!?VD?VPO#?ASQ<WE_:-$^SW=Y)9>8 R"Z:UAE2
MTRI5OWS)\K!NA!/T;X2\6^%O'WA?3O&_@;Q)8:QHVKV45YI6K:7=I/;7EO(H
M>.:*1"5D1E(8,I((((H T**\V_:%_:__ &;OV5-2\$:-\?OBG9^'KWXC^,;3
MPMX(L9;:>>?5M5N7"101QP1NRKN90TK!8H]Z[W7<,^DT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?"?QM^&">.]:O/".DZCXWNM!F\.7TMW<7_V>);2V</:+'<^2$,@5EA4/&P
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M/BC5;;XC>(=6\+7FG>&]!N,P&TT/1XEBCT^*"*""1@EDK;OO2MO(10#]UO\
M@N)_P6K\;_\ !'"3X<ZU!^S3I'CW0O']Q>VOVF;QK+IEQ87%MY+/F,64RO&4
MG4AMX.58%<8-=K^R?_P4:_; _:2_;NUGX'>)O^";_C+P/\&6\%-KO@WXO>('
M<)K"F2$0%T$?E0//'(SK:M)]IB5 947+*GYJ?\'G/Q?^%GQ+^%G[,,WAGQ9;
M72:IJ&L:S#9S*\%RVFS16*QW+02A98XGPP5F4!MIQG!K]Y_"GB/PKXN\-V/B
M;P/KNGZGH][;++INH:5=)-;3PD?*\<D9*LI'0J2* .2_:2_9O^&7[6'PMG^"
M?QHM+N^\*:A?6T^NZ);W9ABU>&"59EM+@J-[6[2(ADC5E\Q4V,2C.C?AY_P6
M7_X);? WPQ_P6D_9'^$O_!-GX1Z9X#\:^)[Y-:\6:=X*LQ9VFDV&GZA;R1:P
M88@$@*I'>EG4+O-LHY?K^T?[='[;/P,_X)[?LR^(_P!J7]H/7_L>AZ#;XMK.
M%E-SJMZX/D6-LA(WS2L, =% 9V*HC,/PG_92_P"#GK]FWP!\2_&_[2OB']D3
MQMXZ_:0^*SK8KJ]S?6<.F:9;!MNF^'[#YVE@L(F\O>X7S;B7?,XW%$0 ]X_X
M+3?&WQ'X[_X.6OV*OV9;F]D;PYX/U70=>BL6;]V=2O-6FWRE>A(BL;4*3R/F
MQC)S!X'^-WB+X,?\'K'C?X;^'KR2#2/BCX4M-(\06D;8BF,7A"TU"&1EZ%Q+
M9( W4"1^?F;/6_\ !<']E_QK\*/^"P'[''_!4OQ5;0+X)TCQ)X?\+?%+Q';1
MM'8>'YHM3:2*]N6<G[/;2"]E7S7.U/LZAF!9=U?]E/\ 9RN/VO?^#JSXP?\
M!1/X>W4&K?"GX5:/:V=IXWL9EETW4-;?PS9Z9)9P3J2DS1++>-(4)$9B4-@N
MF0#L_P#@O1_P2D_X)M_!G_@DI\7/C7J/P=TN+X@:4D>LVWQ3OPK>(M7UZYOX
ME:2ZNP UQ]HEG=7AQY2B0^7'&$39[S_P1%\+^)?^">O_  0W^'.H?MF:_/H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU>XN/L[I=1^!=,N=2GO;[4Y,%HV-E'>PP1IEHY;Z:%,F(NZ_6O[-GQ0_8L\
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M:.X2ZBP\N%N/M,>POO7/[AT@CC$AE$:AV4!FQR0,X&?Q/YF@!:*** "BBB@
MKA/CK^T=\+?V>?#_ /;/C_7 +B5";'2;7#W5V1_<3(POJ[84>N< ^.?M9_\
M!0[PW\+?M/@'X-RVVL>(EW1W6H\/::<W0CTFD']T?*I^\205KX/\7>,/%/CW
MQ!<^*O&>O7.I:C=ONN+N[E+NQ[#V Z #  X  K]0X3\.,7FZCBLPO3HO5+[4
ME_[:O-ZOHNI_.'BAX_Y7PO*>6Y%RXC%+24]Z=-_+XY+^5/E3W=TXGJ_[2/[<
M7Q:_:!DFT**Y.@^&V)"Z+83',Z_]-Y.#+_N\)T^7(S7BU%%?O67Y;@<JPRP^
M$IJ$%T7YM[M^;U/XCSWB#.N)LQECLTKRJU9=9/9=DMHI=(Q22Z(****[CQ@H
MHHH **** "BBB@ HHHH *^@O^"9?_)TEI_V!;S_T$5\^U]!?\$R_^3I+3_L"
MWG_H(KYWB[_DF,9_U[E^1]YX7?\ )QLI_P"O]/\ ]*1^)'_!P?\ \IC?CA_V
M';#_ --=G7QI7V7_ ,'!_P#RF-^.'_8=L/\ TUV=?&E?F&6_\BZC_@C^2/\
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M4 %%%% !1110 4444 %%%5=;UO2/#>D7.OZ_J4-G96<+375U<R!$B11DLQ/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0ZCJ%AI%A/JNJWL5M;6T32W%Q/($2)%&69F/
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M@]XXO99/"=ZQ:0Z-<\O)I4[G)RHRT3,<R1 \LT<AKX$K^U3]L+]DWX0_MO\
M[.GB;]FCXWZ*+O0_$EB8O.11Y]A<+\T-W Q^[+%(%=3T.,$%68'^0+]MO]CW
MXL?L'?M->*/V8/C)8A=5\.WI6WOHHR(-3LW^:WO(<]8Y8RK =5.Y&PRL!^G\
M.9Q_:%#V55_O(_BN_KW^_J8RC9GE%%%%?2DA1110 4444 ?2O_!)+]O#6?\
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MV<LN <U\M>%/^#@W_@@Y\<V6+X@^)[?0[F?HGC+X97+,"?6:W@G1#[EP/>O
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M_JI))604444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>OQ+8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR?D#+%HB6 65CD#XGK]!P^)H8NDJE&2E%]C)JP4445N 4444 %%%% !1110
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MEB)W,.#R!V-7K^_L=*L9M3U2]AMK:WB:2XN+B0(D2*,LS,>%  ))/ K\G_\
M@M'_ ,$G_P!BCPQ^RHGB7X;6T=E^U+XH\:Z/%\,/B;J?B][;Q)XA\42W]N'E
MDN7E4%1$9I650L5M&@,2QB.-1[1_P6!MOB79Z)^R!\,OB%J@U?P9K/[27A+2
M_B_=- %M-694<VT5W']PVLU\D;&-QL+B%3U (!]XZ!X@T#Q7H]OXA\+ZY9ZE
MI]VF^UOK"Y2:&9<XW(Z$JPR#R#VI]UK.CV6HVND7NK6T-W?;_L5K+.JR7&P;
MGV*3E]HY.,X')KX#_P"";_C'3OA#^WC^W]91:I9Z%\#O!?CKP]JNEW3,L&E:
M5JLF@"Y\1E#Q'%ME6"28# 5F+$98U]"?LE^$/%'QD\;ZA^WA\8= N]/U/Q-I
MIT[X9>&]3A,<_ACPJSK*GFQMS%>W[I'=W((#(JVELW-J68 ^@:*** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^'7_  4#D7GY+76OAN&S]98K\?\ HNO2I\49-/>;7JG^B9/)(_"NBOV,U_\
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MW;N7:P4445D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !16-\1_&=K\.?A[KWQ"O;*2YAT'1KK49K>)@&E
M6"%I2@)X!(7 SZU^07_$93^S/_T9GXZ_\']E_A7=A,MQN/3="'-;?;]6)M+<
M_9:BOQI_XC*?V9_^C,_'7_@_LO\ "O?_ /@FG_P<6?!?_@I7^U!:_LO^!_V<
M_%'AF_NM&O-175-5U6VFA5;=0Q0K&-V3G@UO5R/-:%)U*E)J*U;NO\Q<T6?H
MO1117E%!17B'Q!_X*3_L&?"KQYJ7PU^(7[5?@[2]7T.X6W\0)<:H#!HTS8Q%
M>W"@PV3X(.V=T(!!Q@UVEA^U!^SKJGPNNOC?I?QL\,W/@VRN;BWNO%=OJ\3Z
M=&\#,DV;A28\(R,&;.T%3SQ0!W=%>#:3_P %2O\ @FUK]B-3T+]N_P"$U[;,
M2!<6GCVQD0D=1N64CBO1?@9^T?\ L_\ [3OA6[\<_LY?&KPOXZT:PU-]-OM5
M\)ZY!?V]O>(D<CV[R0LRK(J2QL4)R!(IQR* .THHHH **** "BBJGB#5X_#^
M@WNO30M(EE:27#QJ<%@BEB!]<548RG)16[(J3A2@YR=DE=^B+=%?)/\ P]K^
M'?\ T2/6O_ Z&C_A[7\._P#HD>M?^!T-?6_ZA<7?] K^^/\ \D?EO_$;O"S_
M *&<?_ :G_R!];45X%^SQ^WSX0_:&^)$7PWT;P!J6G3RVDMP+FZN8W0", D8
M7GG->^UX&9Y5F&3XGV&,I\D[7L[/1^C?8^XX>XFR+BO /&Y3656DI./,DU[R
MLVO>2?5= HHK&^(GQ#\$?"3P#K7Q2^)?B>TT7P[X=TN?4M<U>_EV0V5I#&9)
M9G;LJHI)^E>>>Z;-%1VMU:WUK'?6-S'-#-&'AFB<,KJ1D,"."".015/Q9XM\
M*> _#5]XS\<^)M/T71],MFN-2U;5KV.VMK2%1EI)99"%C4#JS$ 4 :%%>&^%
MO^"EG[!OC*XM$T+]J/PJ;74)UATO6+N[:VTW4)&.$2VO9E6VN&8_=$<C%NV:
MVO'/[=W[%_PO^'^C_%?XE_M2>!/#OACQ N[0_$.N^);>TLK\;F7,4TK*DF2C
M8P3D*2,CF@#UBBJ7AKQ)X>\9>'-/\8>$=<M-4TG5;**\TS4M/N%F@N[>5 \<
MT<BDJZ,C*RL"0001UKE/CS^TQ^SM^RUX6M?''[2GQR\)^ =&OK];&RU3Q?K]
MOIT$]R4>00H\[JK.4C=MH.<(Q[&@#N**S/!_C+PK\0/#EKXO\$Z_:ZII=ZF^
MSO[*4213+G&Y6'##CJ*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU:U53+:V4LT8<9!94+#/MD5^.FY^-?\ P1X_X*F_!_\ X)R>%6_X(]?\%8/
MLOPA^(N@:YJA;QKXH@+Z)XV%]>SSM?3WCC&Z7S67[1*3#*D:DRJW[L?IG^R3
M^RO\+?V2OV;=9^$7P<33?^$-O]=U[7O#UGI:@VEM9ZG=37JV\6"5,2>>53;\
MNP*!Q7@'@WXD?\$L/^"\7_!/C0?&7[1Z_#_Q%:3>&HKKQ38ZAJ<5IJ/@K4S
MOVH+*SK/8,D@;$FX+)&%;+QMSYA_P;DZ3XU^"O\ P3^^+^@>+/B?>ZU\&/"O
MQ8\36WP/\9>))O+6_P#"=N BWT3MA5LWD2616&%WM,1A<4 >6_\ !L/^WO\
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MFZ^$'P=\$GXA>.O",IS:^)=9V*]FEVGW9X(#<6+B)P58M,&!##'$6>H>"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>mdt-20250425_g17.jpg
<DESCRIPTION>IMAGE 17
<TEXT>
begin 644 mdt-20250425_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,CT?\/"_P!C_P#Z*]_Y0-0_^1Z/]6N(_P#H"J_^"Y_Y!_Q$/@#_ *&^%_\
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MBBBL#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_"_P#X/2?^;:_^YQ_]P=?NA7X7_P#!Z3_S;7_W
M./\ [@Z]WAK_ )'=+_M[_P!)9,_A/POHHHK]7,0HHHH **** "BBB@ HHHH
M*_=#_@RV_P";E/\ N3O_ '.5^%]?NA_P9;?\W*?]R=_[G*\+B7_D25?^W?\
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M?NA_P9;?\W*?]R=_[G*\+B7_ )$E7_MW_P!*14/B/W0HHHK\H-CXO_X*\_\
M-/?^XM_[95\7U]H?\%>?^:>_]Q;_ -LJ^+Z_J+PZ_P"2-PO_ &__ .G)G^;G
MCY_R=K,?^X/_ *8I!1117VQ^/!1110 4444 %%%% !1110!]H?\ !(;_ )J%
M_P!PG_V]K[0KXO\ ^"0W_-0O^X3_ .WM?:%?R[XB_P#)98K_ +<_]-P/](_
M/_DTN7?]QO\ T_5"BBBOB3]A"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OPO_X/2?\ FVO_ +G'_P!P
M=?NA7X7_ /!Z3_S;7_W./_N#KW>&O^1W2_[>_P#263/X3\+Z***_5S$****
M"BBB@ HHHH **** "OW0_P"#+;_FY3_N3O\ W.5^%]?NA_P9;?\ -RG_ ')W
M_N<KPN)?^1)5_P"W?_2D5#XC]T****_*#8^+_P#@KS_S3W_N+?\ ME7Q?7VA
M_P %>?\ FGO_ '%O_;*OB^OZB\.O^2-PO_;_ /Z<F?YN>/G_ "=K,?\ N#_Z
M8I!1117VQ^/!1110 4444 %%%% !1110!]H?\$AO^:A?]PG_ -O:^T*^+_\
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M** "BBB@ HHHH **** "OPO_ .#TG_FVO_N<?_<'7[H5^%__  >D_P#-M?\
MW./_ +@Z]WAK_D=TO^WO_263/X3\+Z***_5S$**** "BBB@ HHHH **** "O
MW0_X,MO^;E/^Y._]SE?A?7[H?\&6W_-RG_<G?^YRO"XE_P"1)5_[=_\ 2D5#
MXC]T****_*#8^+_^"O/_ #3W_N+?^V5?%]?:'_!7G_FGO_<6_P#;*OB^OZB\
M.O\ DC<+_P!O_P#IR9_FYX^?\G:S'_N#_P"F*04445]L?CP4444 %%%% !11
M10 4444 ?:'_  2&_P":A?\ <)_]O:^T*^+_ /@D-_S4+_N$_P#M[7VA7\N^
M(O\ R66*_P"W/_3<#_2/P#_Y-+EW_<;_ -/U0HHHKXD_80HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K\+_\ @])_YMK_ .YQ_P#<'7[H
M5^%__!Z3_P VU_\ <X_^X.O=X:_Y'=+_ +>_])9,_A/POHHHK]7,0HHHH **
M** "BBB@ HHHH *_=#_@RV_YN4_[D[_W.5^%]?NA_P &6W_-RG_<G?\ N<KP
MN)?^1)5_[=_]*14/B/W0HHHK\H-CXO\ ^"O/_-/?^XM_[95\7U]H?\%>?^:>
M_P#<6_\ ;*OB^OZB\.O^2-PO_;__ *<F?YN>/G_)VLQ_[@_^F*04445]L?CP
M4444 %%%% !1110 4444 ?:'_!(;_FH7_<)_]O:^T*^+_P#@D-_S4+_N$_\
MM[7VA7\N^(O_ "66*_[<_P#3<#_2/P#_ .32Y=_W&_\ 3]4****^)/V$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP
MO_X/2?\ FVO_ +G'_P!P=?NA7X7_ /!Z3_S;7_W./_N#KW>&O^1W2_[>_P#2
M63/X3\+Z***_5S$**** "BBB@ HHHH **** "OW0_P"#+;_FY3_N3O\ W.5^
M%]?NA_P9;?\ -RG_ ')W_N<KPN)?^1)5_P"W?_2D5#XC]T****_*#8^+_P#@
MKS_S3W_N+?\ ME7Q?7VA_P %>?\ FGO_ '%O_;*OB^OZB\.O^2-PO_;_ /Z<
MF?YN>/G_ "=K,?\ N#_Z8I!1117VQ^/!1110 4444 %%%% !1110!]H?\$AO
M^:A?]PG_ -O:^T*^+_\ @D-_S4+_ +A/_M[7VA7\N^(O_)98K_MS_P!-P/\
M2/P#_P"32Y=_W&_]/U0HHHKXD_80HHHH **** "BBB@ HHHH **** "BBB@
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MKXD_80HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OPO_X/2?\ FVO_ +G'_P!P
M=?NA7X7_ /!Z3_S;7_W./_N#KW>&O^1W2_[>_P#263/X3\+Z***_5S$****
M"BBB@ HHHH **** "OW0_P"#+;_FY3_N3O\ W.5^%]?NA_P9;?\ -RG_ ')W
M_N<KPN)?^1)5_P"W?_2D5#XC]T****_*#8^+_P#@KS_S3W_N+?\ ME7Q?7VA
M_P %>?\ FGO_ '%O_;*OB^OZB\.O^2-PO_;_ /Z<F?YN>/G_ "=K,?\ N#_Z
M8I!1117VQ^/!1110 4444 %%%% !1110!]H?\$AO^:A?]PG_ -O:^T*^+_\
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M** "BBB@ HHHH **** "OPO_ .#TG_FVO_N<?_<'7[H5^%__  >D_P#-M?\
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M4444 %%%% !1110 4444 ?:'_!(;_FH7_<)_]O:^T*^+_P#@D-_S4+_N$_\
MM[7VA7\N^(O_ "66*_[<_P#3<#_2/P#_ .32Y=_W&_\ 3]4****^)/V$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^:A?]PG_ -O:^T*^+_\ @D-_S4+_ +A/_M[7VA7\N^(O_)98K_MS_P!-P/\
M2/P#_P"32Y=_W&_]/U0HHHKXD_80HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\+_ /@])_YMK_[G'_W!U^Z%?A?_ ,'I/_-M?_<X_P#N
M#KW>&O\ D=TO^WO_ $EDS^$_"^BBO?OV(?V*?!/[4.KOK7QS_:Q\%_!7P/%J
M"Z?_ ,)=XQ+2M>7I56-O:6J,K3F-7C>5V>.*%9(R[@R(&_4ZM6%&#G/9?/\
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MOGC!Y-#QW\;=<\2:/X:\'^&#=:1HOA""1-"@6\+3K++(9)9WE4+F1F/&T *
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ML(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8_"'B+PO\=_"?AO3?A);:1XBM;]_%,[>';NU?R(HG9_+AEN8EED*@1^6V>0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M%_\ P>D_\VU_]SC_ .X.OW0K\+_^#TG_ )MK_P"YQ_\ <'7N\-?\CNE_V]_Z
M2R9_"?C+^S=\"/%'[3_QZ\)?L]>"=<T;3-7\8ZY!I6G7_B&^-M90S2MM5I9
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M1110 4444 %%%% !7X7_ /!Z3_S;7_W./_N#K]T*_"__ (/2?^;:_P#N<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?A?_P 'I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^XW_ *?JA1117Q)^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^V/QX**** "BBB@ HHHH **** /M#_@D-_S4+_N$_\ M[7VA7Q?_P $AO\
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M^V_[&WR_XMWR[X;#5\975&BKR>RT6ROUTV$W8^Z**_"__B-)_P"L;'_F8_\
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M'/$_="BOPO\ ^(TG_K&Q_P"9C_\ O/7W1_P1:_X+2_\ #WW_ (65_P 8U_\
M"O/^%>?V-_S./]K?VA]O^W?].=OY6S[%_M[O,_AV_-AB<CS3!T'6K4[16[O%
M[NW1WW!239]T4445Y)045\7_ /!7G_FGO_<6_P#;*OB^OU'ASPV_M_)J6/\
MK7)S\WN\E[6DX[\ZO>U]C^;>/OI"?ZC\6XG)/[,]M['D]_VW)?GIQG\/LI6M
MS6^)WM?2]C]H**_%^BO;_P"(._\ 4=_Y2_\ NA\?_P 38?\ 4F_\N/\ [@?M
M!17XOT4?\0=_ZCO_ "E_]T#_ (FP_P"I-_Y<?_<#]H**_%^BC_B#O_4=_P"4
MO_N@?\38?]2;_P N/_N!^T%%?B_11_Q!W_J._P#*7_W0/^)L/^I-_P"7'_W
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M?U%X=?\ )&X7_M__ -.3/\W/'S_D[68_]P?_ $Q2"BBBOMC\>"BBB@ HHHH
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M,MO^;E/^Y._]SE>%Q+_R)*O_ &[_ .E(J'Q'[H4445^4&Q\7_P#!7G_FGO\
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MNE_V]_Z2R9_"?A?1117ZN8A1110 4444 %%%% !1110 5^Z'_!EM_P W*?\
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M44 %%%% !1110 5^%_\ P>D_\VU_]SC_ .X.OW0K\+_^#TG_ )MK_P"YQ_\
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M -N_^E(J'Q'[H4445^4&Q\7_ /!7G_FGO_<6_P#;*OB^OM#_ (*\_P#-/?\
MN+?^V5?%]?U%X=?\D;A?^W__ $Y,_P W/'S_ ).UF/\ W!_],4@HHHK[8_'@
MHHHH **** "BBB@ HHHH ^T/^"0W_-0O^X3_ .WM?:%?%_\ P2&_YJ%_W"?_
M &]K[0K^7?$7_DLL5_VY_P"FX'^D?@'_ ,FER[_N-_Z?JA1117Q)^PA1110
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MQ2"BBBOMC\>"BBB@ HHHH **** "BBB@#[0_X)#?\U"_[A/_ +>U]H5\7_\
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M4_[D[_W.5Y/$O_(DJ_\ ;O\ Z4BH?$?NA1117Y0;'Q?_ ,%>?^:>_P#<6_\
M;*OB^OM#_@KS_P T]_[BW_ME7Q?7]1>'7_)&X7_M_P#].3/\W/'S_D[68_\
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MK[0_X*\_\T]_[BW_ +95\7U_47AU_P D;A?^W_\ TY,_S<\?/^3M9C_W!_\
M3%(****^V/QX**** "BBB@ HHHH **** /M#_@D-_P U"_[A/_M[7VA7Q?\
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M;_FY3_N3O_<Y7B\2_P#(DJ_]N_\ I2*A\1^Z%%%%?E!L?%__  5Y_P":>_\
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MI'X!_P#)I<N_[C?^GZH4445\2?L(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^%__!Z3_P VU_\ <X_^X.OW0K\+_P#@])_YMK_[G'_W
M!U[O#7_([I?]O?\ I+)G\)^%]%%%?JYB%%%% !1110 4444 %%%% !7[H?\
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M]K[0K^7?$7_DLL5_VY_Z;@?Z1^ ?_)I<N_[C?^GZH4445\2?L(4444 %%%%
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M9X>_^3Z/^'2?[>G_ $2C0?\ PYGA[_Y/K^O/_A5WPS_Z)WH7_@HA_P#B:/\
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M9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 37J?\1:XC_P"?5+_P&?\
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M+_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\ T7K0?^_S_P#Q-=U_PJ[X9_\
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M?R&?\.D_V]/^B4:#_P"',\/?_)]'_#I/]O3_ *)1H/\ X<SP]_\ )]?UY_\
M"KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-'^N.9_R0^Z7_ ,D'
M(C^0S_ATG^WI_P!$HT'_ ,.9X>_^3Z/^'2?[>G_1*-!_\.9X>_\ D^OZ\_\
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M1NX_Z#F@_P#A2V7_ ,>K]<O^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\
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M?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\
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MFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\
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MZ?\ 1*-!_P##F>'O_D^OZ\_^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\
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M1_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
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M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !- '"_\-S_LC_\ 1>M!_P"_S_\
MQ-'_  W/^R/_ -%ZT'_O\_\ \37=?\*N^&?_ $3O0O\ P40__$T?\*N^&?\
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MJ'3].U"QUE8WMIED@1_-B>+[O[]""KG.&R%XR ?0U%%% !117SS\?_V][?\
M9[_:N^'_ .S#XB^%,M]_PL6\MX-'UZSUE0L'F3+"QFA:($%6.<*S K@Y!R
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M:,,J30ON&YP1N&X,/F0KD_36C6=]I^D6MAJ>K27]S!;)'<7TL2(UPX4!I"J
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M(_AVUG_9?B(:$T5M>+!;FWVR0>=(T99-C%@[?.G"@-@ '"?$CXO_ !;\,?\
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M_%OXE^%]1\/2>.[O6](U]_#\O]NZ%837LEP=.MY3*4D!C<1"1@H5<#RWV(:
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MVCO#7Q8TS3K;X8+:C3])U73I[N;4#%,)6,UQYP.6P%W88]6)8G%=K_P4)_9
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M?MK\2V1T&=$TR:XFDD1@WGDRJGFL"#M+8!RM 'A?[/G[37QZ^)__  1+\?\
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M)KT*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@^%GQ<MK2U^)OP_TG7!I\QFTY]2L4EDLY2,&2%R-T3X&-R$'WJ+P3\%/A/\
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M:V^!7QA\6P>!?!WBB[CU>^T./6M*L-8T6[T^34M,<E4O+87,:>?$2.JY(X)
M!!(!Z31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@I3^VE_P .\OV*
M?&G[87_"M?\ A+_^$0_L[_BG?[9_L_[7]KU*ULO^/CR9O+V_:?,_U;9V;>,[
MA^4?_$:3_P!8V/\ S,?_ -YZ^Z/^#E/_ )0I?&C_ +ES_P!232Z_E'K[;AO*
M,NS# RJ5X<S4FMVM+)]&NYG.33T/W0_XC2?^L;'_ )F/_P"\]>Z?\$UO^#G?
M_AX;^VMX+_8]_P"&(O\ A$/^$O\ [1_XJ+_A97]H?9/LFFW5[_Q[_P!FP^9N
M^S>7_K%QOW<XVG^;NONC_@VL_P"4UOP7_P"YC_\ 4;U2O6Q_#V44<#5J0I6<
M8R:]Z6Z3:ZB4I7/ZN***@U+3=.UBQETO5[""ZMIT*3V]S$'CD4]0RL""/8U^
M9FI/17Y+?\$XX/A#J/[;O[0&C?M!:GI[^$O"TVIMIT'B74B+33HXM4= 4\Q]
MJ!8QMX[#%?2'Q#^$G[/_ ,.?V0/B7\?='?QEH_PU^+?P]T"\O=/\-7YN+S1-
MZW#O<1)=2J%B=+JV5XD8YVO\H4\ 'VS17RA^SG^T_P#LY_LV_L2_!NS\):QX
MP\36/BRX30O =CJ$5LNL:M<-<2*5(EF2"%%;(&^541/+7<3@'V+PY^U=\.+_
M ,#^-/'WCO2M9\$V?P^OFM?%<7BVUCADM&6UAN2R^3)*LR%)T"M&S"1N$W94
MD ]-HKP#X??\%&_@GXY^+GA'X-:GX2\6^&M1^('A]=:\#W?B+3K=+;6K1@[(
MT;0W$KQ,R1LX298VQMX!90:GQ+_X*:? 7X>:)XQ\8:9X8\4>*?#WP^UR/2/&
MOB'PS!926^DW;R+%L=)[J*>50[JI>*-TSD!CM; !]%45^?/_  7*^(GAOQO^
MP'X&^.GPH\1,\.K>,=/ET;7=/=X97LKBPO)"FX;756V1ED./F1<C*\?='PKD
MDF^&'AR65RS-H-F69CDDF!,DF@#>HKPGX1_\%!/A)\8OVF-:_9+T?P1XNTOQ
MCX=@GGUFVURPMH(K>.(H"P=;AC*&,L6WRPVY7#?=RPVK[]M#X3^&?A/XN^-G
MQ,TW6?"7AWP;K%QI>H7FO009NKJ"4PR1VRV\TIF_?#RP1C<V0,[6P >N45Y/
M\+_VP?A]\1OBO_PHW6?"?B+PAXMF\-0^(-.T/Q7;6T<M_ILC%?/A:WGF0[6!
M5HV99%(.4P"1Y]XQ_P""K/[-GA'P5)\78-"\4ZSX @\5'P]=^/M$M+.?3[>^
M RP:,W2W90#D2+ 58$%2P9<@'TS17B'[5/[?GP1_9"\(>&_B%\2M.UZ_T'Q4
MX32-6\/6D%Q$[-'YJ AID8;H_F!"E<#KGBK/P0_;K^"?[0?QX\3?L_\ PYLO
M$,NH^%],34)]7O-(\G3[ZW=U17MI2VZ526!5RBI(OS1LZ\T >S45YE^T_P#L
M\7_[3OA*U^%VH_%/7O#'AF>1Y/$8\+72V]]J2@ 16WGLK". DLT@"[GVHN0I
M;/Q1_P $N?AM\3/V9O\ @I+\7_V3/!?Q!U;7_AIX7T59YCJ,V^."ZF-M+;<#
M"I<;)9XV*A0_E.2HVJ% /TDHK\I/ _Q/N_VQ_@W^UW^U%XZGDN]7\,!6^&VH
M-(1-X9MK87,L L7'-LYV1F1X]ID()8G)KZ6_9OC\9_\ !3K_ ()^?#^?XC_%
M[7M!MKV"YM?'D_A>X6VU#69K69[>-#,581Q2[/.E"KER5484L" ?8M%?FW_P
M2Y^&WQ,_9F_X*2_%_P#9,\%_$'5M?^&GA?15GF.HS;XX+J8VTMMP,*EQLEGC
M8J%#^4Y*C:H7QO\ :*^/_P"Q5^U;^U_XOOOC?^U9\4O YM-?DT719_#UDCZ*
MEC:XA24/&[RDR2++*6,8 $H[#- '[$45Y]^RK\+_  +\&_V>_"WP^^&OC.?Q
M)HMIIHEL?$-S>K<OJ:S,TQN#*I(<.9"01P%( X KT&@ HHHH **** /%_P!K
MW]KW_AE3_A'O^+>_V]_;WVO_ )BWV7R/(\G_ *92;MWG>V-O?/'B_P#P]Y_Z
MM[_\NS_[DH_X*\_\T]_[BW_ME7Q?7[UP7P7PUFW#5#%XNAS5)<UWS35[3DEH
MI);)=#^)?%WQ=\0^%_$/&Y9EF-]G0I^SY8^SHRMS4:<GK*G*3O*3>K>]EH?:
M'_#WG_JWO_R[/_N2O:/V0OVO?^&J_P#A(?\ BWO]@_V#]D_YBWVKS_/\[_IE
M'MV^3[YW=L<_F/7VA_P2&_YJ%_W"?_;VCC3@OAK*>&J^+PE#EJ1Y;/FF[7G%
M/1R:V;Z!X1>+OB'Q1XAX++,SQOM*%3VG-'V=&-^6C4DM8TXR5I13T:VL]#[0
MHHKQ'_@H]HVE:E^P_P#$[4KVPCDN=+\&:A>:;=%?WMI<1PLR2QOU1@0.00:_
M!3^VCVZBOS(_X)?)^S#K_P"P[H^L?M(V>GZYXB\3?$H>'--_M#57&I7+W5S;
M6\:1,'$N$$K2$J1M5&.1UKJ_VY/A1^SW^SK\&OA!\"/CO\0_B?8:7HWQ U"_
M\*:UX3GBNC.)-0FGAM;AYY5E$T4,T2K-M.W#;2V2  ?H917D?C[]L?P'X/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;S>';)H9X) Z./(3D$<$5JS>$_"UQ:P65QX:T^2&U39;0O9H5A7^ZH(PHX'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>mdt-20250425_g2.jpg
<DESCRIPTION>IMAGE 2
<TEXT>
begin 644 mdt-20250425_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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ME]171_Q!/@7_ *%E+[G_ )B_M+$_SL_4'_B+-_:,_P"A+^"G_@HU/_Y84?\
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M83^TQ_T(_P "_P#P3:K_ /+&C_B,)_:8_P"A'^!?_@FU7_Y8UG?\0B/[4/\
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MO_RQK\HZ*/[#P'_/I!S,_5S_ (C"?VF/^A'^!?\ X)M5_P#EC1_Q&$_M,?\
M0C_ O_P3:K_\L:_*.BC^P\!_SZ0<S/U<_P"(PG]IC_H1_@7_ .";5?\ Y8T?
M\1A/[3'_ $(_P+_\$VJ__+&ORCHH_L/ ?\^D',S]7/\ B,)_:8_Z$?X%_P#@
MFU7_ .6-'_$83^TQ_P!"/\"__!-JO_RQK\HZ*/[#P'_/I!S,_5S_ (C"?VF/
M^A'^!?\ X)M5_P#EC1_Q&$_M,?\ 0C_ O_P3:K_\L:_*.BC^P\!_SZ0<S/U<
M_P"(PG]IC_H1_@7_ .";5?\ Y8T?\1A/[3'_ $(_P+_\$VJ__+&ORCHH_L/
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M /)%?,=%'^I.1_\ 0-'\?\P_XC!QG_T,:GWK_(^G/^'KGQ$_Z O@O_P$N?\
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M_P#Y85^7U%'_ !!/@7_H64ON?^8?VEB?YV?J#_Q%F_M&?]"7\%/_  4:G_\
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M-H[,OQU>>(C&<FUK^3/TX_XC"?VF/^A'^!?_ ()M5_\ EC1_Q&$_M,?]"/\
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M"/\  O\ \$VJ_P#RQK\HZ*/[#P'_ #Z0<S/U<_XC"?VF/^A'^!?_ ()M5_\
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MM_\ @H%K_P#P3C_8H;QEX3L[6Z\4:]K=OX=TN6[B\ZWL998IYVG=,C=MBMI
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M+3/&F%4_>YP,D?3QC*64I15W[/3_ ,!)^T?TA?\ !8O]KOXX?L<_L\^&]<^
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M!_L;^S_^$<O;6W\[[9]O\WS?/MIMV/LL>W;MQELYR,=]_P $*/\ @@I\+O\
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M>,R["SY*E:E4A&7:4HN*;\KO5K5=-3_1K#U%"K&<MDTS^GG_ (+1?M%?&/\
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M/Q UG^S6\-VNEV\2:-#(&VRP3A5F/D@;V,CON17&,E=OZ*_\' GPST3XD?\
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M 4444 %%%% !1110!Q/B[_D8;C_@/_H(K-K2\7?\C#<?\!_]!%9M?YQ\<?\
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MRR2.,I$I.YVY)Z# ''_"GXK^)?@9\1=(\7>#]<U+PWXFT&<7-AJ5A,8;BVD
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MY"NNTEBH.,@G=C/&<#[*TE-,_9Y^"-G%J%\%TOPGI4<,MU(-N]8HPN<>K$<
M=20!FOD'2O\ @K3XD@TL)>^$]$N;S!'G0W$L,9/;Y#N/_CWY5XW\>OVOO&G[
M0\:VVM7D-KI4;!ETZQ0Q6Y8'(9LDLY''WB0,9 !S7YWB>&.)<ZG2P^<.,:5-
MZM-7?1O2^MN]EK>Q^]9?XC>'G"-+$X_A2-2IB:ZLHR4E&'5)N5K13U=N9NUK
MVU.;\)>';[X]_&FTT^-O)O/%6J_.ZIO$'FR%G?&1D*"S8XX6O8OVFOV!;7]F
MWX72^(KCQLNI3&XBM;:S.D^1]I=SD@/YS8PBNWW3G;CC.:/^"87P_P#^$J_:
M(?5Y(6:W\-V$MPKY^59I/W2 _56E(_W/I74?\%7?B>=4\<Z!X1@D;R=)MS?W
M2AAM,LIVH"/[RHI/TEKZ;'9QC9<2T,HP,^6E&*E-6B]%=VNTVM.5:6?O?,_/
M,FX5R>'A[C>*<YI>TQ%2HX46Y35F[+FM&23:DYR]Y->Y;NCLO^"5/Q=M]0\$
MZQX+N+C%]IUR=0LXV(&^"0*'"]SMD&3_ -=1^"_MG_L%>(/C1\7E\3>%9M+4
M:I#''J$=W,T1CE1=@D! .5*!00!D%<X.>/BCPAXQU3P#XDM-8T6^N--U*Q?S
M(;B%MK(?Y$$<$'(()!!!(KZ:\*_\%8/%>FZ6(=6\.:+JERH $\4CVV[W9?F&
M?I@>U>9G'#&;X/-YYQD7*W43YHNRU=K[V33:4M[W/HN%?$;A7-N%:7"O&G/%
M4&G"<4WI&_+\*;32;A\+3CU3/L#PKI>E_LW_  )LK6^O%73?">EJ+FY*[?,\
MM,NX7U9LD+R<L!R:_.GX(?'L>%?VM;/QUJ.;>WU#5I[B_56)6*.Y+B0_[03S
M"W3G:.]._:$_;*\8_M&6RV.J36NGZ-')YBZ?8HR1.03M,A8EG(]SMR,@ UY/
M7?PGP74PF&Q#S-J53$)J5NB=[Z]VVV^FUCQ/$[Q<H9GF& AP]%PH8%QE3<E9
MRE'EL[7;48J*2N[N[OT/U6_:D^"R_M(? Z^T.SN+5+R8QWNG7$GS1"5>5.1G
M"LI9=PS@/G!Z'S?]@W]CG6/V=M1UK6O$DFGMJFH0K9VT5LYD\F$,'<EL#[S!
M.!TV=><#YB^ O[?GC;X&Z+;Z/_HFOZ);?+#;7V[S+= .$CD!RJCC 8, !@ 5
MU_Q _P""J'C/Q+I+VNB:3I/A]I4*M<AFNIDSW3=A5/U5J^2_U/XFP^&J9+AW
M&6'G*_-=+M_V\KV5TD_)ZN_ZA_Q%;P[Q^8T.+L?&I#'48<JIJ+:;L^J]R5N9
M\LG*+M9M72M>_P""J?Q9M_$OQ#T7PK9S+(/#T+W%YM8%1/-MVH?]I44'_MI7
MT/\ L"?%NU^)_P"SEHMLLB?VCX;B72KN$'YHQ&,1-]&C"\],AAV-?F??7TVI
MWLUS<S2W%Q<.TLLLKEWE=CDLQ/)))))/6NG^#_QL\2? KQ2NK>&]0>SG("S1
M,-T%TG]R1.C#K[CJ"#S7UV:\!QK9#3RJA)<]+5-[.3OS7WLG=][:'Y;PSXUU
M,'QMB.)<;3;HXCW9P6KC!64+7LFXJ*OLG>6S9].>.?\ @F;KGB/]H:[OK>\T
MU?!NI:B;Z5C,5N(8G??)$$"_>&653G&,$D'BOH[]K/XLVOP4^ .O:DTL<-W/
M;-8:<F1F2XD4JFT'KM&7(_NH:^7;7_@K3XD31Q'-X3T22_VX,RW$JQ%O7R^3
MCVW_ (UX%\<OVA?%'[0WB./4/$=XD@MU*6UK OEVUJ#C.Q<GDXY))8X'.  /
MGZ/">?9IBL/_ &WRJE0VLTW*UNU]962;=M.ES[G%^)W!/#>68[_4Y3EB<9=N
MZDE!N]M9):0YI.,5S7;U=ML#PC\0_$'P_EFDT'7-8T22Z 69K"]DMC*!G 8H
M1G&3U]:^EO\ @G)\8/%OCC]H9K'6O%'B+6+/^RIY/L][J4UQ%N#1X;:[$9&3
MS[U\HUT?PN^+7B#X,>)CK'AG4/[-U(PM;^=Y$<WR,02-LBLO.!SC/%?H_$&2
MPQ^"K4:<8^TG%I2:Z]+NS9^ <#<75<DSC"XNO4J>PI34I0BWJKW:47)1=_-I
M'TS_ ,%,?BUXJ\!_'?2;/0_$WB#1;23089G@L-1FMXV<W%R"Q5& +$*HSUP!
MZ5\N^+_B1XB^(/V?^W]>UK7/L>[R/[0OI;GR=V-VW>QVYVKG'7:/2KOQ7^,G
MB3XW^(H=6\4:E_:FH6]LMI'+]GBAVQ*S.%Q&JC[SL<D9YZ]*YBHX=R..7X&C
M0JQC[2"LY)=?)M)FW'W&53/,YQ6,PU2HJ%65U"3V6EDXJ3CNKZ-A1117T)\&
M%%%% !1110 5XC_P4:_Y,T\9?]N7_I=;U[=7B/\ P4:_Y,T\9?\ ;E_Z76]>
MYPQ_R.,)_P!?:?\ Z6CZC@C_ )*+ ?\ 7^E_Z<B?EK7TE_P2P_X)W:C_ ,%+
M/VH[7P+;ZY8^'])L;<ZIK5Y),GVI+-'57%M"3NEE)=5! *INW-Q@-\VUM?#O
MXC^(/A'XUT[Q)X6UK5/#OB#29?.LM1TZY>WN;5\$$HZD$9!(//()!X)K^KL^
MPV.Q&75J&6552KRBU";CS*,FM&UI>WSMO9[/_1BE**FG-775'])7[*G_  09
M\#_L0?MYZ3\7OAKXBU*Q\.VNDW&G7'AG4$-VR220"+SHKHMNPQ&]D=6^9FVL
M%VHOJW_!.+]@G6/V*_$7QJUC6O$EOK-Q\6O'5_XIALK0/]ETN"6:5HERX!:9
MD<>80H&551N"[C^5/[ 7_!SE\5-/^,'@_P ._&[6/!MQ\/VF>+7?$LV@7#:K
M!$(G*.%LV",WF!%XMVX8DCN*?_!33_@Y+^)GC;XI>,O!_P #O$_A_3_AI)Y,
M.D^)M/T>YM=:NHFMXS-\]T<Q,)6E0,L,;@*"IS\Q_A/-/"GQ2S7,YY)F=6-1
M5*5-2K2NX.G2J-QBZG)=S4I.7*_WDHZO0^FIX[!0@JL%:S>G6[7:^WX'G/\
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MTK48[N**5=K-$SWSH& Z%D8>QKY7'<*1]I#ZJO=^U=^FWXEJ?<\@_P""X?\
MP4&\&?\ !2[]M6/XD>!-,\3Z3H:>';/23!KUM!!=^;"\S,VV&:5-I$BX._/!
MX'?X[HHK[+#T(4:4:4-HJR,S^RS_ (*A?\HT/VB/^R9>)/\ TU7-?QIU^F'Q
MY_X.J/VA/VA_@;XS^'^M>#?@S:Z-XYT*^\/W\UEI.I)=0V]W;O;R-$SW[*)
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M2("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOX@_\N?\ P/\
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M7[0_Q2C^./[0'CKQK#8_V7#XP\0W^MI9AMWV1;FYDF$60 #M#[<X'2OZ0O\
M@EQ^P/\  KX@_P#!.SX,ZYKWP5^$NN:UJGA2QN;V_P!0\(:?<W5W*T8+222/
M$6=B>2S$DU^&'P]_89U3]M;_ (*H^)OA#X-AL]#L[KQAJT<L\5MBUT/3H+J8
MR2"-  %2-0J)\JES&F5W9'I>#N;<(X+.\^Q>!IU:+I.4JTZLXR@HQG._(HQ3
M2NF_><I;)/OGF%/$2ITHR:=]K+TW/ENBOZGOA'^P'^RK_P $JO@W;ZQJ&B^!
M]#ATM$@N_&'B[[/-J%W*V!S<3#Y6<@'RH0BYZ)6C?? ?]DG_ (*K_#2\GL='
M^&/Q&T^%?LLFIZ,D,>I:6S ,%\Z';/ WW3M)7..01D45/I5Y?[5XBEEE>6#C
M+E=;3?\ PVY;O=)U$P_L.=K.:YNW]?Y'\J%%?4G_  5N_P"";&I?\$ROVHI/
M"8O;G6O"6N6W]J>&]4G3$MQ;%BC13$*$\^)AM;9P0T;X7?M'] 'PC_X)E_ /
MXE_L?^&+>7X-_":UU7Q!X.M8WU9/!NG->0SS62 W ?RMQD#-OW9SN&<YYK]"
MXV\<LFX?RS 9Q"$J]#&7Y91:5DDKMIZW5[-;IIIZG+ALMJ59RIO1Q/Y6Z*_J
MF_8[\(?L?_"W7[[X*_"EOA3>>)M$B>'5=,A:VOM5NVARDIN)&#//(AW!P22F
M2"%' _-__@Y>_P""5W@3]GSP5X=^-'PS\.Z?X4M=0U8:+XBTG3+;R;$O+$[P
M74<2X2#!A='"*%9I(S@-N+>%PG](C+\XXBIY!B<%5PSK?PI5+>]=-QYHV3BI
M6]UIS3=E?J:5\IG3H^U4D[;V/QYKZ"_9*_X)9?'C]NCP'J'B;X5^!?\ A*-#
MTN_;2[JY_MK3['RKA8XY2FRYGC<_)*AR 5^;&<@@:'[/7_!(C]HK]JOX3Z;X
MX^'_ ,-;SQ%X5U9IDM+^/5;"!9C%*T4@V2SHXPZ,.5&<9&1@U^XG_!NE^QM\
M2OV)OV2/&7AOXH>%YO"NM:GXOEU*VMI+NWN3+;FRM(P^Z&1U'SQN,$@_+TP1
M7L^+7C!A>&\GJU\FQ&'JXNG.,72E-2:UM*\(3C-./7:SW1G@,OE6J)5$U%K>
MWZV/YP/'_@75?A=X\UOPSKUK]AUSP[?SZ7J-MYJ2_9[B"1HI4WH2C;75AE25
M.,@D<UD5^AG[87_!#;]JGXF_M;_%+Q)H?PEOK_1?$'B_5M2T^Y&LZ;&+BWFO
M9I(GVM<!AN1E.& (SR :^(?CO\"/%G[,WQ8UCP/XXT>30?%6@M&E_8//%,UN
M9(DE0%XF9#E)$/#'KCKD5^B<,\993G-*$<'BZ56LX*4H4ZD9..BO>*DVDF[:
M[-I-W.2MAZE-^]%I7ZHY&BBBOK# **** "BBB@ HHHH XGQ=_P C#<?\!_\
M016;6EXN_P"1AN/^ _\ H(K-K_./CC_DH\P_Z_U?_3DC[C"?P(>B_(_63]E?
MPIX1_P"")/\ P31\+_M.^(/#ND^*_P!H?XSF1/AM9:M");7PQ8[<F_"9R7,3
M+(74AL7$$0V!I6;X3^*/_!4/]HSXR>.+CQ%K_P ;?B9-JEQ()<VFOW%A;P$
M#]S!;LD,(^4'$:*,\XR2:^YO^#D)[76/V6?V&]5T./;X3NOAMLTQHD*0(HM=
M,(15_@(C,8VX!& .W'Y0U^>Y72A6IO%55>4F]^B3:279*WWG5+L?8WQ4_P""
MU'Q*_:._8/U'X(_%C3=#^*$RZA;WFA>+M>5I-:\/+&#O6.5=K22-A0)9&+;&
ME1_-5U"?(F@Z!?>*M:M=-TNRN]2U&^E6"VM;6%IIKB1CA41%!9F)X  )-5*_
M5O\ 97\7V7_!)#_@A_I7[1O@S2M-O/CI\?/$%WX:T3Q#>VB7#>$]/@EN89#
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MTC.S%BLHW9VK7GT<RQ$J,,3."4)-)ZNZN[7VM:_3M]P[=#\E:***]TD****
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M_M0>-/&,E]IUAJ7A[38)3]@T[3M;L[>"VB'"(RK,!)@ 9W9!.< # &?^V/\
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MB#3-8UGPWK<.T0-'+!<2W#Y5W8M)GB,H6*RLI^$O^#?/X+>!["3X[_M&^.]
MM_%UI^S3X6CU[2=#N4#076IS)=/;RL#E<Q_8W"EE8(\JR##1J:TIYQ%TZDG:
M3A;X7=/FT5GTUT=]@Y3X]TW]@7X[:SX-C\16?P5^+5UX?FA%Q'J</A#4)+-X
MB,AQ,(=A4@@YSC!K[ ^)_P#RJU_#G_LO,W_IKU&O'/B%_P %U_VL/B%\:6\<
M'XU>,=%O%GDFMM*TF[-KHMJC%B(A8\P2H@;:#,LCX52S,PS7UU_P4>_; T_]
MN+_@W=\!^.ET/2-!\5S_ !LCM/&$6EVXM[6[UA-'U!I+M8P JM/"]O*X48WR
M/U.28Q4L3ST56BK<ZV;=M]'=+[_P#0_(ZM#PMX4U3QSXAM-(T33=0UC5M0D$
M5K96-N]Q<7+GHJ1H"S-[ $UGU]H?\$6+7]J74?C#XOL?V6]+M?\ A(-6TB.P
MUKQ!=:=:/%X<MGG5EE^UW"E8&?RW&Q<M(JN1&[1*T?K8FM[*DZBMIW=E\WJ2
M?/\ \2OV(_C1\&?"+>(/&'PA^*'A/04"EM2UGPK?6-FNX@#,LL2IR2,<\Y%>
M>^%_"^I^./$VG:+HNG7VL:SK%U%96%A96[W%U>W$KA(X8HT!9Y'=@JJH)8D
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M_P HA/B7_P!?6C_^G2UKYG_X-$?^2#_&3_L/V'_I/)4?_!:[_@LC^S?^UO\
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M=/?6$JQ[+>*1QE()3N*A?EQG) /J'_!R-_P42^#G[?'_  IG_A4OC#_A+/\
MA$_[;_M7_B57UC]E^T?V=Y/_ !\PQ[MWD2_<SC;SC(S^F9GP[FLO&["9M'#5
M'AHTVG5Y)>S3]A55G.W*G=I;[M+=G'"M#^S94[J]]KZ[KH?L7_P2*_Y1B? K
M_L3=/_\ 10K\M/\ @@EJ-I9?\%YOC['</&LUY8>)X;4-U>0:Y:.0OOY:2'Z
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M8>.O&VJ?V+X5\.ZA-/J%]]FFN?LZ-:S1@^7"CR-\SJ,*I//IFOTL_P""\?\
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M:4(X[R1,BU\^-IMEKYHPS;Y2JD;-Q)#5X+16\*%>TO:5-6K*R22\TG?7U?R
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MQ7]%>)^#KXKA',L-A8.=2=&HHQBG*4FXNR25VV^B6I_H]@I*->#EM='ZW_\
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MW+_TNMZ]SAC_ )'&$_Z^T_\ TM'U'!'_ "46 _Z_TO\ TY$_+6BBBO[$/]%
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M!_[/'_#XC_@C#\)_A[,LUYK'P&^+MGIVH%I2]Q)X>O9PUQM?.^-$BNVQCH+
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M'I]Q;0QVIB\F=WEC8" ;E=B0V[IT'CM?1T)3=.+J;V5[;7ZDA1116H!1110
M4444 %%%% '] %%%%?LA_D&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5XC_P4:_Y,T\9?]N7_ *76
M]>W5XC_P4:_Y,T\9?]N7_I=;U[G#'_(XPG_7VG_Z6CZC@C_DHL!_U_I?^G(G
MY:U]0?\ !&3]G;P;^UA_P4I^&_P_^(&C_P!O^$=?_M/[?8?:Y[7S_)TN\GC_
M 'D+I(N)8HV^5AG;@Y!(/R_7VM_P;M_\IB_@_P#]QK_TR:A7]*>(>*K8;A7,
M\1AYN$X8>M*,HMJ49*G)IIK5-/5-:IZH_P!',)%.O!/:Z_,ZSXK?M-?L8?"G
MXX>)O!]Y^Q3<3VOAK6[O1Y=0M_BYK/FRK!.\1E6%E R=F[87P,XW'K57]M;]
MA'X*_$3]A6/]I[]FNX\4:;X1TW7%T'Q5X2\02K-<:!,^Q4>.7<S,NZ2#Y2\A
M87*,&7:R#T3QG_P0.\5?M6_M>_$5_"GQX_9MU:>ZU_4M8O=*TSQ;-J.L:3;/
M>.6,UK%;$J\9D5&!8 .=N[I7+_MD?M _!O\ 8Z_X)M77[*WP>\<)\6-:\6>(
MHO$/C7Q5;6ICTL-&(72&U)8ACF"V&4+J DF6W-M7\BR[-,)4QF7T^%\7B*V)
MYZ7MX2J8BK35&2_>2J>V<XP=K^S<7&3E9135SOG"2C-UXI+6VB3OTM;?S/SK
MHK[>_8E_83^%_A+]DVZ_:6_:2O-<'PUDU)]%\*^%]$E$>I>,;U-P?]YD>7 I
MCE7AE8M$Y+*%42=[\!'_ &'_ /@H!XX3X5VGPC\5?L[^+O%5P-.\*^)[?Q?=
M^(;5[MB!;I<PW+!5,KX38H(); D0D,/TS'^(F%P]2O[#"UJU+#MQJU:<8N$'
M'XEK.,YN'V_90GRZIZIHXHX232O))O9/=_A97\VC\Y**^E/@G_P3@U_QC_P4
MZTO]FWQ5>1Z'JP\1R:/JEY"=RK!"CS230;A\WF01EHMP&2Z9 R17TA\2/'7[
M ?P9_:4UOX1:Y^S[\0_[%\+ZG<>'-4\>-XSNVU2.ZMYWMY;@:>C>0T89"^1A
MB.D.<)73F7'F%P^(AAL%0JXJ<J:K6HJ#M2;:C.\YP3YFGRJ/-)V=HA#"R:O)
MJ.MM;[_),_-NBO=+3]DG3?V@/V]5^$7P)\03^.-%\0:X;#PYK.I6K6+36VWS
M'GG0C<%AC$A9@@+K$66-2P0?4'QLN?V'?V"?&<GPQN?A/XM_:*\5>&KDZ?XG
M\3W'B^Y\/V<=TA*W"VD5J2'$;AE"N,<8,KX+';,>-:&'JT<+AL/5KUZL%45.
M$8J<8/[4_:RIQAK[J4I*3DFDFT[3##MIR;22=KO:_E:]S\ZZ*^WOV[OV'?A7
MXA_91TC]I;]G&XUN/X9WFJ#0/$OA?6)/.O\ P?J.U2H\W+%X7W)]YF(,L9#,
M)-L?F?[$GB']E[P#X&\0:_\ '3P_\1/'GBB&[2VT7PMHUPNGZ;<0-'N-Q/=J
MZRJRNI3:N,!T(63+>7>%XRP^*RR6982A5J.,G"5)17M8S3LX2BY**:O=MRY>
M6TE)Q:;)8=QGR2:76_2Q\VT5^DGP0^ O[,7_  5B\%^-/"/PE^%/B+X#_&;P
MWH5QXBT6$>*KGQ%I&NI;X#VTKW/SH6WH 552I(;+!61O!O\ @BG\ O O[4__
M  4=\"_#WXC>&QXH\+>)X-2CFM#?W%ELDAT^XNHY-]NZ2'#0 8W '=SG&#Q1
MX_PD<#CL7B:%6E/!0<ZM*2A[11Y7-.+C4E3DI*,N5JI:\6G9HKZK+FC&+3YM
M$];?E?\  ^5**^Y_VG8OV2/V.(?&7P=T_P"&_B?XO?$31;34-(N_B'=^)I]-
ML]*UD0LD;6=C 0EQ#!<$*WG%<F)C^\4@&W^Q9_P3\^$W@#]C;_AIK]IK4-?_
M .%?ZCJ#Z7X2\*:%((]0\5W"&1'+/E2D0:*7&UT/[EF+ ;5=5/$'"4LO68U\
M/6A"I*,:2<8\]=S3<?9P4W)72;M45-I)RDE%7#ZK)RY$UY]EZO\ RN?!M?HC
M_P $5_\ DRS]NC_LEDG_ *(OJR-#^*W[ ?[1VEZYX=U7X2^.?V=;Q89I-&\5
MZ;XFO?%",T:EHQ<6TQ.#)C;L12,G'FI]\>E?\&Z?PJM_CC\*OVM_!DVKQZ'8
M^*/!$&ES:I/'N73X9A>(\[+D9V*2VW<,[<9'6OC_ !$XF^L\+8N>+PM;#.C/
M#RDJL8ZQ]O3=XRIRJ0E:SNHR<EI=*ZOT82CRUXJ,E*]]O1]['Y=T5^AOP\^,
MO_!/4?%BQ^']]\#O'VH>$IIH]-_X65J'C.ZM]0=RZQF\ET]&C@CAZR$CY@O_
M "QS\H^=O^"H?["\_P#P3L_;(\2?#?\ M";6-'MTBU'1;^956:ZL9UW1^8%X
M\Q&#QL0%#-$6"J& K[G)^-:.-S!97B,-5P]64'4@JL8+VD(M*3CR3G9QYH\T
M)\LTI)N.]N6IAW&'.FFMG;I^"_R/GNBBOKS]G_XE?L;_  4_9[T>]\;_  V^
M(?QM^*6I+))J6F3ZV_AO0]((E94CCFMV,SDQA6W%7!R.$.5'N9UFT\!2C4IX
M>I7E)J*C346]F[MSE"$4K:N4DKV6[,Z=/G=FTO7^F?(=%??'QI_9F^ ?[87[
M!'C3XX?L_P#A/Q-\,?$GPCNK&/QAX+O=6DUJT:TNW*1W5M<2DRD!M^2VWY8)
M,HN S6/^"'W_  3^^&_[??@WX_:9X\@@L]0\.^'[2ZT/Q#->7$<?AJ1S<B6Y
M:*.5$F"JB,5ERO[O'&2:^7Q/B1EV&R?$YQBZ=2FL-.-.K3<8^TA*3@E=*3BU
M:I&=XRDG%WC=Z&T<'.514XM/F5T^CW_R/S_HK]#/AO\ &'_@GO<_%C3_ (>W
MWP/\?W/A.XFCTP?$O4/&ES!J!D9UB^V2V",EO'!R968'<JY_=9^4?.O_  5
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M\6^ =8U275K.\TP*[R75I=RLSGRU24_,02(2#&I=';Z9_P""ZG[=_B#]D/\
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M&">]C5((\C8S1VA/RLI8R,6+JBH/BO\ ;:_X*1?%C]O[6=/D\?:Y;_V+HO\
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M,\D\#^ ->^)WB.'1_#6B:OXAU>X222*QTRSDN[F140N[+'&"Q"HK,2!P%)/
MK[]_X(GW,EK^Q?\ MTM&VUC\*ID)]FM[]2/Q!(KB]<_X+X_%BS\)Z[I_@'P+
M\$/@WJ'B4$:EK?@3P@-,U2ZW'+EI7ED&]N?GV[ADE2K8(\*_9L_;Q\9?LO\
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MG4:3IN+C%RI\EU4Y6HM<W)S>\Y6]TZ_;4)5UB)-[IM6Z^O;\3Y]_;^_Y/O\
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M>.:]=_X*X?$7QQ#_ ,$0?V=M)^-&K:K>?&3XC^--2\>7D.J#;>BRVW21M(@
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M\$VOB9_P4D^*%SX?\ V-I;Z;H\0NM=\0ZI*;?2= @.<//+@G<VUML:!G;#'
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MFPY6?G_16]\+OA?XA^-?Q$T;PGX3T>^U[Q)X@NDLM.T^TCWS74SG 4#]23@
M DD $U]Y^+/^"*_P=_9TUBS\*?'+]LKX??#KXF3;4N_#FE>%[SQ''I,C ,L=
MU=0RQK;MM9"3(B@9R"PP3T5\92HM1F]7T2;?K9)NWF*Q^=U%?2?_  43_P""
M9/C#_@GIKOAV[OM7T/QQ\/?'5J;[PGXST&7SM,UV#"MP<G9(%=&*Y8$."K.,
MD>N_LL_\$,]:_:T_8:\*_&[0_B1H&BZ7?>)+S2?%2Z[:"QT[P;I]K%-++J4U
MX9B95Q'$HC6(?/<("P 9A,LPP\:2K.7NO1/S[?A]^FX[,^#Z*^A/VN_V5OA/
M\(?$G@W2_A'\?M&^-,GB*XGLM3N&\/R^&;70IT>%(]\MW*5>)S(Y\X[(PL1;
M)!./H/6_^"/_ , /@YJUGX;^*7[<7PV\,^/)B8;G2O#_ (5O/$MCI]P#AHI[
MZ&5$A*D@$RJF/FX^4T2Q]&,5)WUO9<LKZ>5KKYH+'Y\5M77PV\16/@2W\4S:
M!K4/AB\N396^KO8RK83S@,3$LY7RVDPCG:#GY6XX->_?MC_\$V-4_86_:1\%
M^%O'/C#19OAYX\%KJ.D_$#1()-2TV\TB:55DOHHT^:1HHVWM"K%C\NUF#HS?
MIU\7_P!ES]G'4?\ @WW^%?A&^_:G_L[X7V'Q,GO=.\?_ /"M=4F_M2^,6J V
M/]FK)Y\6!),?.9BI\C&/G6N?$YI3IJG*%Y*;M=)O37LGKY;^6@^4_"VBO=?"
MW[$=U^T9^VH?A#\ M<E^,%O?7:PZ3X@&D3:+#=V^Q&ENIH)BSVT,1+!BY/"9
M&2R@_3FI?\$=?V=_ ?C6/P/XQ_;K^&VA_$:-C;WNG6GA.[OM'L+E3MDADU7S
MT@0HP93Y@1@5Y4'@=%3,*--I2;NU>R3;MW:2;7SL*Q^=U%>W?M\?L!_$#_@G
M1\<Y/ _CZVLWDN+9=0TK5=/E,VGZW9N2%N('P"1D$%6 92.1@@GQ&NBG4A4@
MIP=T]F(****T **** "BBB@ HHHH **** "BBB@#^@"BBBOV0_R#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\1_X*-?\F:>,O^W+_P!+K>O;J\1_X*-?\F:>,O\ MR_]+K>O<X8_
MY'&$_P"OM/\ ]+1]1P1_R46 _P"O]+_TY$_+6BBO:_\ @G;^Q[_PWS^V-X/^
M$O\ PD7_  B?_"6?;?\ B:_8/MWV7[/8W%W_ *GS(]V[R-GWQC=GG&#_ %MF
M>98?+\'5Q^,ERTJ493F[-VC%.4G9)MV2;LDV^B;/]%H0<Y*$=WH>*45]V>*_
M^"<G[)G@?QSJ7AO5OVX4LM8T>_ETV\@?X/:N5@N(I#&ZF03E,*RD;@VWC.<<
MU'\9/^"&7BA?A/?^/_@3\1/!?[1G@_1P?[2/A9]FK:>0A=M]GO<G"[3L5S*=
MXQ'C)KY&GXE</N4(UJDZ2J6495:%>C!M[)3JTX0UZ>]KT.CZG5Z).W9I_@FS
MX7HHHK[PY0HHHH **** "BBB@ HK[-^+W[*'@#PO_P $/?A3\8+'0/(^(OB7
MQ]>:+J6K?;KEOM-I&M\4B\EI#"N##'\RH&.WKR<_&5>+D>?8?-(5IX=22I5*
ME)\R2]ZG)QDU9O1M:-V=MTC2I3<&D^J3^\****]HS"BBB@ HHHH **** "BB
MB@ HHHH ***FT_3[C5K^"UM8)KJZNI%BAAB0O)*['"JJCDL20 !R2:&TE=@0
MT5I>,/!FL?#WQ%<:/K^DZEH>K6>WS[+4+5[6X@W*'7=&X#+E65AD<A@>AK-J
M:=2,XJ<'=/5-;-=T 5S?Q!_Y<_\ @?\ [+725S?Q!_Y<_P#@?_LM?F'C1_R1
MN,_[A_\ IV!Z&5_[U'Y_DSFZ^PO^"8'_  2\\.?M]_"KXU>-O%_Q;_X5+X7^
M"=EI^HZI>_\ "+2Z]YT%R+PN_EQ3Q2+Y8M.BK(6\S@#;S\>U^IG_  09\%ZS
M\1O^":G_  4"T'P]I.IZ]KFK>$-&MK'3M.M7NKN\E:+60L<42 N[$\!5!)K_
M #\S2M.EAG.F^5WBKZ:7DD][K9GV,=SS?P#_ ,$J?V5_C;K2Z'X'_;T\)WOB
M.Z98K.V\0_#C4?#EK<R,<(GVFZG"@EL# #'GIT!^5_VW/V(_'_\ P3Z^/VH?
M#GXC:?:V>NV<,=W#-:3>=::C;2;@EQ Y +1L5<<JI!1@0""*]%^"_P#P1:_:
MG^./C>TT/3_@;\1]$>YE2-[WQ'H=SHMC;*S8,CS7*(NU>20NYL#A2< _17_!
MS#\7_#'B+]H+X3_#;1_$%IXT\0_!OP+:^&_$_B*%UD:]OU/SQ.R *7389&"@
M!7N77 *E1RTL1..*C1C5]HFG?X;QML[Q2T>VJ'T/S4HK[PT7_@DI\&?AO\._
M#FJ?&S]L;X9_#O7O$UI;W\&A^'-$N/&L]I%<1+-";A[.51&6C8'=@Q\C:[ @
MUYA_P4)_X)AZM^P[X=\(>,]%\:>&_BO\)?B )!X>\9: &6UN)8O]9;S1DMY,
MPPV$WMD(_.Y'5>ZGF%"<U"+U>VC2?HVK/Y,5CYXTWX;>(M9\$ZCXEL] UJZ\
M.:/(D-_JL-C+)8V3N55%EF"[$9BZ@!B"2P ZBL6OW._9<_9@_9UTK_@@K^T1
MX7TW]J+^U?AWKGB72+GQ!XV_X5OJ<'_",W*W6F-';?8&D\ZZWND2>9&0J^=D
M\(:_)WXQ_LN>&+O]IG1?AW\ /'U]^T!'XB2WAT^_M/"MUH,US>R,P:V%K<,S
M_( K&0D)AB> I-8X/,H5ISBTURMK522LDGJVDD]=GK;4;C8\3HK]$?%G_!%?
MX._LZ:Q9^%/CE^V5\/OAU\3)MJ7?AS2O"]YXCCTF1@&6.ZNH98UMVVLA)D10
M,Y!88)\!_P""B?\ P3)\8?\ !/37?#MW?:OH?CCX>^.K4WWA/QGH,OG:9KL&
M%;@Y.R0*Z,5RP(<%6<9(UHYAAZLE"#U>UTTGZ-I)_*XK,^;**^\/V6?^"&.N
M_M;_ +#/A?XV^'_B)H&DZ=>^([S2O%*:[:BPTWP;I]K%/++J4]ZTQ,B 1Q+L
M6$?-<*"P 9AU?@K_ ((6_#S]J/PUXHLOV=?VK/!?QC^)'A6VDNI/"4WAFY\/
MR:BL1 D^RSSS,)UYPLBIY19D#.@;<(EFF%BVG+9V>CLGMJ[67J] Y6?G5IVG
M7&L:A;V=G;S75U=2+###"ADDF=CA551RS$D  <DFKWC3P/K7PW\2W.B^(M'U
M30=8L]OVBPU&TDM;F#<H==\<@#+E65AD<A@>A%?3W_!)GX&?#/QS^USH/_"T
MOBY-\(M>\+^*M&?0M*F\'WNL2>)+P7OSVC-"RBS97CB0O*",S9Q\C5]??\'$
M?[-WP!UG]NSXW>,]6_:4_L7XLI9:=.GPY_X5[J-QYD\>D6:00?VHK_9QYT:Q
MR;]N$\W:<E34U,RC#%+#-/57NE)]5V5K:ZO9;,=M+GY'T5]Q_!/_ ((^^&(?
MV4?"_P 8_P!H#X_>&/@#X7\?"2;PM8S:#<Z_K.LP1N$:X6S@=)!'EXR&3?A)
M%9M@9<\5_P %!O\ @EZ?V,OAKX-^(WA'XH>#?C'\*/'DTEGI7B/16%M,MU&I
M9X)K1G=XV !Z,VTJ5?RV*AMHYA0E4]FGK=K9VNMTG:S?E<5CY1HHHKL$%%%%
M !1110 4444 %%%% !1110 4444 %?U<?\&UG_*%+X+_ /<<_P#3]J-?RCU_
M5Q_P;6?\H4O@O_W'/_3]J-?)\8?[E'_$ORD73W/CO_@\(_YMW_[F3_W$U^*=
M?M9_P>$?\V[_ /<R?^XFOQ3K_0+Z.7_)N\O_ .XW_I^J?'9O_O<_E^2/U#_X
M)%>$;']M[_@E/\?_ -F'P_X@TG1/BEX@UNU\4Z3;ZC)Y46K00M9,8U(Y.U[,
MJQ .SSHVP1G'PE^TI^PU\7OV/M2-O\2OA[XF\)IY@A2\NK4O83N02%CNH]T$
MAP#PCGI7FF@Z_?>%M:M=2TN]N]-U&QE6>VNK69H9K>13E71U(96!&0000:_0
M+_@GY_P7B^-'@SXB>&_ /Q,U2'XO_#/Q)>6VB:IIOB>!+V[6VF?RG9+AAOD8
M!P2LYD5@FWY<[AZV-RGB'A[%XS-,C5/$4*\O;3HS;A44^2,9.G42E%\R@GRS
MBDFM)*YG&I2JQC"K=-:)K5;]5_D?GO''-J=ZJ(LMQ<7#X50"SR.3T'<DD_C7
MW,G_  1P\*_ CX=:/J_[2G[0GA;X$Z]XAMTOK+PNN@7/B/6X;=_N/<V]NZ/"
M2=PQA@-N"P8,J^R>//V+/AY^RK_P<K^ /!=G#8V?@74_$.G:_IVFF0>5I\\L
M;2PVO4_+]M1=B''R/&N".3%_P4RUK]B[7?V]?BE)\6F_;&;Q]#KTUMJ8TY?#
MJZ>OEX2(6HE_>?9O)6,Q;_F,90MR37AYGXA8G-<5@L-DSK4Z-;#K$N5*G"I5
MM*2C&"512A&VO/)QGKRI6O<UAA(PC*52S:=M6TO737T/F3]M_P#X)5ZM^RU\
M(=%^*7@KQQX?^,WP=UR;[&GBO0(S&MA=9(\FZ@+.822" =Q&X;6V,4#+_P $
M^_\ @E-KO_!1GX(?$W7O!?B:WA\8?#V[TF"+P]<V.V#48KZ9T,[WAE @6)(I
MY"/+D)$6/EW U[=IG[=_[(?P)_8.^-WP?^&VF_M(:W_PM>QB:WA\;6^BS:?I
MNH09:"Y3[+*C1G>(F9MKG]Q%@#:<U_\ @D'XNO\ P1_P2^_;VU#3;B2UO/\
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MSX3\7?#"37[>^TZSL(8="M[&[N+<:?!9NLQD/D6EI!&V^*,%LD<8!V/V//\
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M;KN7PWXJ7Q'I%_XYATS_ $(.)A/&LEG,/E/GR$*8B,N23D+CIM9^(^J^!?\
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MK7G5YZ%&24E32@G2C[D>2$&XKHYN<^\F9X^2=>=E;5]]=?-_D%<W\0?^7/\
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MY;Z5%'+>2JUM-$!&LDD:$[I ?F=> ?I6JPT_JV(ARZR<[>=UH'4[?Q?$L/\
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M*-?\F:>,O^W+_P!+K>O;J\1_X*-?\F:>,O\ MR_]+K>O<X8_Y'&$_P"OM/\
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MN?)%*RC&^JBEHE^)5:M*K+FE:_D%<W\0?^7/_@?_ ++725S?Q!_Y<_\ @?\
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MI_@?P;XJ\97UJH>:VT+29]1FB4\ LL*,0#@\D=J^MO\ @C[\"_&_P(_X*_?
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_5Q_P;6?\
M*%+X+_\ <<_]/VHU_*/7]7'_  ;6?\H4O@O_ -QS_P!/VHU\GQA_N4?\2_*1
M=/<^._\ @\(_YMW_ .YD_P#<37XIU^UG_!X1_P V[_\ <R?^XFOQ3K_0+Z.7
M_)N\O_[C?^GZI\=F_P#O<_E^2"BBBOVX\T**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?%W_(PW'_
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M_C9_V/NN_P#IPGKR.O7/V_O^3[_C9_V/NN_^G">O(Z_I_A__ )%>&_Z]P_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q!_Y<_\
M@?\ [+725S?Q!_Y<_P#@?_LM?EWC1_R1N,_[A_\ IV!Z&5_[U'Y_DSFZ***_
M@P^P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_JX_X-K/^4*7P7_[CG_I^U&OY1Z_JX_X-K/^4*7P
M7_[CG_I^U&OD^,/]RC_B7Y2+I[GQW_P>$?\ -N__ ',G_N)K\4Z_:S_@\(_Y
MMW_[F3_W$U^*=?Z!?1R_Y-WE_P#W&_\ 3]4^.S?_ 'N?R_)!1117[<>:%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q/B[_ )&&X_X#_P"@BLVM+Q=_R,-Q_P !_P#016;7^<?''_)1
MYA_U_J_^G)'W&$_@0]%^04445\N= 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '] %%%%?LA_D&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0W]G?\+ \ >"?'/]C^;]@_X2#0[74_L7F[/,\KST;9O\N/=MQNV+G.!7%?\
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MY_\ 1 ?@I_X0^F?_ !BBBC_6;./^@NK_ .#)_P"8>QI_RK[@_P"':W[.?_1
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M._\ H0O!?_@DMO\ XBC_ (9O^'?_ $(7@O\ \$EM_P#$445M_:>,_P"?LO\
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M (=_]"%X+_\ !);?_$444?VGC/\ G[+_ ,"?^8?ZNY5_T#4__ (_Y!_PS?\
M#O\ Z$+P7_X)+;_XBC_AF_X=_P#0A>"__!);?_$444?VGC/^?LO_  )_YA_J
M[E7_ $#4_P#P"/\ D'_#-_P[_P"A"\%_^"2V_P#B*/\ AF_X=_\ 0A>"_P#P
M26W_ ,1111_:>,_Y^R_\"?\ F'^KN5?] U/_ , C_D'_  S?\._^A"\%_P#@
MDMO_ (BC_AF_X=_]"%X+_P#!);?_ !%%%']IXS_G[+_P)_YA_J[E7_0-3_\
M (_Y!_PS?\._^A"\%_\ @DMO_B*/^&;_ (=_]"%X+_\ !);?_$444?VGC/\
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M^,444?ZS9Q_T%U?_  9/_,/8T_Y5]P?\.UOV<_\ H@/P4_\ "'TS_P",4?\
M#M;]G/\ Z(#\%/\ PA],_P#C%%%'^LV<?]!=7_P9/_,/8T_Y5]P?\.UOV<_^
MB _!3_PA],_^,4?\.UOV<_\ H@/P4_\ "'TS_P",444?ZS9Q_P!!=7_P9/\
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M11]:K?SO[V ?\.O?V9_^C=_@7_X06E?_ !BC_AU[^S/_ -&[_ O_ ,(+2O\
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M^'7O[,__ $;O\"__  @M*_\ C%%%'UJM_._O8!_PZ]_9G_Z-W^!?_A!:5_\
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B&QM=\C2/Y<,2JB;I'=S@#+,Q/))HHK.=:I-6G)OU8'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>mdt-20250425_g3.jpg
<DESCRIPTION>IMAGE 3
<TEXT>
begin 644 mdt-20250425_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( ,H#[0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M9B\NI3J3HPE*3@FVW%7;?=GQN-QM>-><8S=KL_1K_B*/_:A_O?#O_P $+?\
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M_P#P0M_\>H_XBC_VH?[WP[_\$+?_ !ZOSEHH_P"(/<$_]"NC_P" (/[0Q/\
M._O/T:_XBC_VH?[WP[_\$+?_ !ZN;\0?\'6_[5>FZK)#&WPWV+C&?#[9Z?\
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M , #_P#%T?\ #S[XG>OA[_P /_Q=?.U%>E_J?DG_ $"P_P# 4?G7_$5N,/\
MH95O_ V?1/\ P\^^)WKX>_\   __ !='_#S[XG>OA[_P /\ \77A]C\.?$.I
MZ5]NMM!UFXL<;OM$5E(\6/7<%Q^M8U3'A3(I-J.'INV^BT-JOB;QK32E4Q]=
M*6JO*2NO+N?1/_#S[XG>OA[_ , #_P#%T?\ #S[XG>OA[_P /_Q=?/Z:->2Z
M7)?+:7+6,;B-[@1,8D8]%+8P#[9JM5+A'(WMAH?<C.7BEQE&W-F-97U7OO8^
MB?\ AY]\3O7P]_X '_XNC_AY]\3O7P]_X '_ .+KYVHH_P!3\D_Z!8?^ HG_
M (BMQA_T,JW_ (&SZ)_X>??$[U\/?^ !_P#BZ/\ AY]\3O7P]_X '_XNOG8#
M)K6U+P#KVC:8E]>:+JUK9R8*7$UG)'$V>F&(P<U,N$\BBTI8:FK[:+4VI^)W
M&M1.5/'UFH[VE)V]>Q[G_P //OB=Z^'O_  __%T?\//OB=Z^'O\ P /_ ,77
MC!^$'BU8T<^%_$6R0@(W]FS8;/3'R\UGW7@_5[&TNKB;2]2A@L9!%<R/;.J6
M[G&%<D84G(X.#S6<>&>'Y:1H4W\D;5/$3CJFKU,;B%ZN2\_RU/=_^'GWQ.]?
M#W_@ ?\ XNC_ (>??$[U\/?^ !_^+KY^TO2+O7+Q;>RM;B\N'^[%!&9';Z
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M\11_[4/][X=_^"%O_CU'_$4?^U#_ 'OAW_X(6_\ CU?G+11_Q![@G_H5T?\
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M*/\ B,9^.7_1+_A1_P!\ZA_\D5^0U%']@Y?_ ,^E^/\ F',S]>?^(QGXY?\
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MJ[^FCT^]?D?!-M^PG\8KSX91>,X_AOXM?PK.J/'J@L&^S.&("D-[D@5L7O\
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M%QX"\30^"I[87D>M/9L+-X22 X?IMR",^U?J5XX_X*D?#W7/@EHOB7PA\4/
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M^RSX@_9 _:2\"R_M!?#&ZT/P;KUT89T\4VLUO:RPC!=U9'0Y7*]\?-TKZ@\
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MIUWHL5K,B03RW+W*L)@R$LO[E,;2O4]:^G?^"N'_  49^$?B'5?AKH_P9L]
M\7>#X=2N?'/B/3[ZT=K:?5KR62::WFCD0!PIF8$\C(XSUKAOV>OV_O 5W^S_
M /M3-J6D^#?AGK'C;0-&M/#WA[0[ V]KJ$UO+>/)L6--JM^]3);&<CKBJC6Q
M4J#J<K3DU;R7,E:WFKM^H:7-;XG?L$?LN?L%6WAWPE^T!XH^)6I?%#5+&*_U
M:S\*2016N@I*@9%<20R-(PSC@KG!/%9W[/W[&?[+.H_LB_$;XS>-M2^*^J>$
M_#WCM?#.CG2+JWLIY+5[>VD5Y8Y+>0F0-,P." 0!P*[W]J'Q+^S)_P %9_%N
MB_%[QA\;U^#OCB\TRWLO$NB7^DSW@:2&,+YELT2LK G. VW@\XK+_9YD_9V\
M2_\ !/SXI_ O4OCYI?A*VNOB1'K&DZIK&E70EU*RCM+13,(X8Y N7CD4 L#Q
MDXKG]I5]DN=SY[KFT=EKK:R_*^@'AO[?/[ G@OX4_ [P?\:O@UXDU3Q-\)?&
M4\FG@:JBC4-(O8PK&"8J K$JV>%7&T]<\?(=?='_  4(_:G^%O@K]C?P3^S3
M\%];O?&7A?P_JDOB/6O$L\!MH]2OY%5!Y4;?,% #9R!U'7G'PO7KY?*HZ5ZE
M]W:^]KZ7\R6%%%%=H!1110!^D7_!$+_DD_C?_L+0_P#HFOMZOB'_ ((A?\DG
M\;_]A:'_ -$U]O5^G9'_ +C3]/U9_FKXU_\ );8__%'_ -(B%%%%>L?EI]<:
M-XO3]H/P7::?X/\ $VI^%?$&E:1Y<VD20K]CN44$N4.!\QXR>>U<G9_L^?#?
M0O"_@.77+CQ4VH^-+>,@6DD?E0NY"@\QGY<GIG/O7$']LGQLOAIM-BFTVW5K
M;[)]IALU2Z$?]WS!S7;^,?VN[CP7\._A_I_A6]TN\FTW2@MZD]IYK6EP" ,%
M@,-C/(S7YS+*<SPTU2PRY8SD](RU2Y9/WIJ%[<UK)IO=7U/Z!CQ-PWF%*6*S
M!^TJ4J<4W.GHVYTU[E)U6N;D4E)Q<5:SY=#?T[X;>&_AE\%_'/A[Q5=:E<:3
MIGB2&,26.U)I28XV3[P8#J,\53M_V)/#>E>-?%S:IK4T?AWP]%;RQ&2Y2UD<
M3Y*!I&5E& IR=O)QTKP[5_C?XBU[PYJFEWETMS;ZQ?+J-T\B;I'E& #NZX
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MO-5C^,%KXB^'/A,>(M>^S:O:);7+(R)(L"M:$J-S9 +,<>O6MK]G+_@C_P"
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MC0JU)UOK$:L^>"C4=244YVI^TA3DU;W>6JX<L[*^C(C&BZ[2M:RUTMTUM?\
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M_"O(_B)\.->^$GC.^\.^)M)OM#US2W$=W8WD1CFMV(# ,IZ<$'\:_1/XD_\
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MTW4OS\VJERM6459)[.3BWNHV,*V#]G#G3OK;8^5****_3#C"BBB@ KBO%_\
MR'YOHO\ (5VM<5XO_P"0_-]%_D*_!_I#?\DY2_Z_1_\ 2*A[&2_QWZ?JC,HH
MHK^,SZ@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,B7#(98U*\$(P!R:X/X8?#?6OC5\2='\+Z#"MYKOB*\2SLXI)EC$TSG"@NQ
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M110 5ZUX$\&W4/[,GC34OWD;226OE1A<^='YAWM]%&37DH&XXKZE^(.LZ?\
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M+=[#4-#O/,1F*GRX3Y?( VR')&?0UVO[4?\ P23^"O[2_P"V7\<O%5OXFO/
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MN:P:].,DU=$CC,S#EF/XT><Q7;N;;Z9IM%,!WF-Q\S?+TYZ4TG)HHH ****
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M##)?>'M'MED:0^=<&20GC)PJG\LUV6FZ9=?$C3!HMSXVA%S#$)8VL;(KB,X
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M_$WB@:)\$O%VM([;M0O;N126;D"1D7 ;IQC@<5[)\5/$O_".^"M4OMW^IMV
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MJ=E?6OF2NT#W$+1_:$W<.NX#(-?I!_P12_X* 6EMX0N_A+XLO(U909=$FF?
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M)\*>'_L<^L1V0ATC2(P/)TZ 9"RS ?Q,P9L'DYR1@UYK_P $IO MM\$/V/\
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M:'_T37V]7Z=D?^XT_3]6?YJ^-?\ R6V/_P 4?_2(A1117K'Y:%%%% !1110
M5\__ +9'CVXU*_T_P?IIWW%RX:95/5CPH/T^;\Z]ZU#5(-#T^>]NF"V]I&99
M"?[JC)KPO]DKP:WQN_: U3QCJREM/TEFGRX^4G/ _E^M?D7BKFTU1I9/A_CK
M-72[7T7S?Y']4?1GX7HO%8GBK'65+#1:BWMS-7E+_MV/_I1[-\+OAG#\$?A5
MI>@1J%O)XEN;YAU9V&0#^?YBM2K6LZI)K6J3W4GWIG+8_NY[55K]!X<R>&5Y
M=2P4/LK7SD]W]_X'X3Q_Q96XDS[$9M5;M.7NKM!:17W;^=PHHHKW#XT****
M"BBB@ HHHH **** "BBB@ KX-_X+!_\ (\>"O^O&Y_\ 1B5]Y5\&_P#!8/\
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M;"BBBO6.<**** "BBG;&Q]UORH ;1110 4444 ?JI_P<\_\ *5+5O^Q;TO\
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M0HHHKUC\M"BBB@ HHHH \L_:W\;?\(W\,FTV'F[UI_)0 \A>_P"><5Z'\!O
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MS26%XZ>%J/\ CTJB]6N62_!,\?C"C&>!4X_9:/ANBBBO]4S\M"BBB@ HHHH
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MDC3R]1M8^MU"/X@.[J.1CDX K^1/]E+]I#7/V3_COX?\<:!<20WFCW*R.BG
MGB/#H?JI/XXK^IO]BC]NWPS^V9\"]&\2Z1?0R-?0*)8]PW02@8>-O<'/U&*_
M.N),O=*O[9?#/6_9G7AZSB[_ 'KNCUK3?%UCXKTN'4+&99K>8=0?NGNI'8CT
MJOJ6KJ@/S?K7"^.?A_/IVLR:IX9OO[)OI3NGB9=]K=?[RY&#[@_A7(:K\9->
M\-02MKGA>^?R5W>?IS>>DGT4@<GTS7S2J6TD=$J*EK2>G;K_ ,'Y'I=[XA^^
M?E/'-8MQXBCNBV,?*:\GUC]I5;=[55\->)G>]X7%IQ&>P?GBN5U/XC>./&4S
M1V.EV_ANU;[UQ>.9)E'M&,<_C2]HGL1[&2WT/4/B=\7K/P1;QQ+F\U>[.RUL
MH_FDF;U('11U)Z5R>EWT/P\TN^\0:_=QR:SJ'SW$K'Y;= .(D[!0/S)-<K%-
MI'PRMKC4+J[>\U"1<W%]=,#(?7'8#Z5\1_MJ?M?^(/CIK?\ P@O@&*XO+BZ?
MR6EA!)8DXP,5A*75E\UERQ/-?VWOVL;[]IS]I2'2O#ZS7L=@YMK18P6RY."P
MQZ8K[2^!VM:/^PC^RC<7FMW44<^FVCZCJ,C,-TLQ!.SZEB%'UKB/V<_V -+_
M &&OA=_PEGC+9>>/-4B\Q(GZ:>A&23G^+I^5?F[_ ,%-OV[KCXTZ[-X1T'49
M)-#M9C]L=&^6YD4_='JH/YD5V97EM7&XA4H[=7V1G.2C&[/GK]J3X\:E^TM\
M>/$GC+4Y'DFUB[:2-2?]7&/E11Z?*!7G]%%?L=.G&G!0CLM#@"BBBK ****
M"BBB@#](O^"(7_))_&__ &%H?_1-?;U?$/\ P1"_Y)/XW_["T/\ Z)K[>K].
MR/\ W&GZ?JS_ #5\:_\ DML?_BC_ .D1"BBBO6/RT**** "H=1OETS3KBX;A
M;>-I.?8$_P!*FKB?VA/$?_"._"S4=K;9;P"WC^K$9_3->3GN.6"RZMBG]F+:
M];:?B?4<%9*\WS[!Y:MJE2*?I=<WW*YG?L$:*VJ?$3Q1XXNH]WV/S9XR>S#.
MW^5>EW,[7-Q)(V2TC%B3[U6_9T\++\/_ -E>.1EVW6O7  /JBX)_K4M? ^$^
M7^RRV>,E\563^Y?\%L_</I/9Y[?B"CE--^YAZ:T[2GJ__)5$****_5#^9PHH
MHH **** "BBB@ HHHH **** "BBB@ KX-_X+!_\ (\>"O^O&Y_\ 1B5]Y5\&
M_P#!8/\ Y'CP5_UXW/\ Z,2OOO#/_DH:/I/_ -)9^K^"?_)78?TJ?^D2/CFB
MBBOZB/[E"BBB@ HHHH **** /I#_ ()*>';?Q3_P4 ^'MG=*'A:^+$'V4D5_
M0[=3)<W*G=[FOP,_X(B>%VU__@H!X5N0,KI:R7+>P  _K7[V6=KNL]V?F[U_
MFO\ 3$Q7/Q=AJ2?PT(Z=FYS?XJQ]_P *QMA9/^]^B-"98UMNR^AK)AMUEF/F
M,&]!Z4U)9KQV3/RK^M17D3P$LO;FOY(E+R/J(HLZG!%%:,1M4XX-<C%:1O>,
MTS"20GC/I6A-?3:H2#PJ]JP?$$4UE%)-'D-&,BN:M-=C>G%HI>.)((+B$[L&
M,Y90>M?F[_P7UTNTU#P]X*U)%7SH9)(0P_NG<<?I7Z$QVTVMV[7$IW%OTKX'
M_P""V?AWS_@!H]]DLUCK/E'Z,CD5^O?1UQSH^(N6RVYIN/WPDK?,\_/Z5\NJ
M+LOU1^6]%%%?[%'Y"%%%% !1110 4444 9/CK_D6O^WF/_T&2N-KLO'7_(M?
M]O,?_H,E<;7\/^.W_)5S_P $/R/K,G_W?YL****_&SU HHHH **** "BBB@
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MNR\=?\BU_P!O,?\ Z#)7&U_#_CM_R5<_\$/R/K,G_P!W^;"BBBOQL]0****
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M\A&69$;<O0G&#BN/KZB$N:*DNO?0 HHHJ@"BBB@ HHHH **** /U4_X.>?\
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M7YYU_H!X1_\ )%97_P!>*?\ Z2CXO,/]YGZL****_1#C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBO%__ "'YOHO\A7:UQ7B_
M_D/S?1?Y"OP?Z0W_ "3E+_K]'_TBH>QDO\=^GZHS****_C,^H"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _2+_ ((A?\DG
M\;_]A:'_ -$U]O5\0_\ !$+_ ))/XW_["T/_ *)K[>K].R/_ '&GZ?JS_-7Q
MK_Y+;'_XH_\ I$0HHHKUC\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KX-_P""P?\ R/'@K_KQN?\ T8E?>5?!O_!8/_D>/!7_
M %XW/_HQ*^^\,_\ DH:/I/\ ])9^K^"?_)78?TJ?^D2/CFBBBOZB/[E"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R?'7_(
MM?\ ;S'_ .@R5QM=EXZ_Y%K_ +>8_P#T&2N-K^'_ !V_Y*N?^"'Y'UF3_P"[
M_-A1117XV>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>mdt-20250425_g4.jpg
<DESCRIPTION>IMAGE 4
<TEXT>
begin 644 mdt-20250425_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   2=%$2
M  0    !   2=        8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( .,$NP,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M]HS_ *$OX*?^"C4__EA1_P 19O[1G_0E_!3_ ,%&I_\ RPK\OJ*/^()\"_\
M0LI?<_\ ,/[2Q/\ .S]0?^(LW]HS_H2_@I_X*-3_ /EA1_Q%F_M&?]"7\%/_
M  4:G_\ +"OR^HH_X@GP+_T+*7W/_,/[2Q/\[/U!_P"(LW]HS_H2_@I_X*-3
M_P#EA1_Q%F_M&?\ 0E_!3_P4:G_\L*_+ZBC_ (@GP+_T+*7W/_,/[2Q/\[/U
M!_XBS?VC/^A+^"G_ (*-3_\ EA1_Q%F_M&?]"7\%/_!1J?\ \L*_+ZBC_B"?
M O\ T+*7W/\ S#^TL3_.S]0?^(LW]HS_ *$OX*?^"C4__EA1_P 19O[1G_0E
M_!3_ ,%&I_\ RPK\OJ*/^()\"_\ 0LI?<_\ ,/[2Q/\ .S]0?^(LW]HS_H2_
M@I_X*-3_ /EA1_Q%F_M&?]"7\%/_  4:G_\ +"OR^HH_X@GP+_T+*7W/_,/[
M2Q/\[/U!_P"(LW]HS_H2_@I_X*-3_P#EA1_Q%F_M&?\ 0E_!3_P4:G_\L*_+
MZBC_ (@GP+_T+*7W/_,/[2Q/\[/U!_XBS?VC/^A+^"G_ (*-3_\ EA1_Q%F_
MM&?]"7\%/_!1J?\ \L*_+ZBC_B"? O\ T+*7W/\ S#^TL3_.S]0?^(LW]HS_
M *$OX*?^"C4__EA1_P 19O[1G_0E_!3_ ,%&I_\ RPK\OJ*/^()\"_\ 0LI?
M<_\ ,/[2Q/\ .S]0?^(LW]HS_H2_@I_X*-3_ /EA1_Q%F_M&?]"7\%/_  4:
MG_\ +"OR^HH_X@GP+_T+*7W/_,/[2Q/\[/U!_P"(LW]HS_H2_@I_X*-3_P#E
MA1_Q%F_M&?\ 0E_!3_P4:G_\L*_+ZBC_ (@GP+_T+*7W/_,/[2Q/\[/U!_XB
MS?VC/^A+^"G_ (*-3_\ EA1_Q%F_M&?]"7\%/_!1J?\ \L*_+ZBC_B"? O\
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M_P#0-'\?\S\?_P"(P<9_]#&I]Z_R/IS_ (>N?$3_ * O@O\ \!+G_P"2*/\
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M@XS_ .AC4^]?Y'TY_P /7/B)_P! 7P7_ . ES_\ )%'_  ]<^(G_ $!?!?\
MX"7/_P D5\QT4?ZDY'_T#1_'_,/^(P<9_P#0QJ?>O\CZ<_X>N?$3_H"^"_\
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M ):&@_\ R%1_Q$I_MK?]%H_\M#0?_D*OA>BC^R\%_P ^8_\ @*_R#F9]T?\
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M7@_]G30_ 6E_#2VMYO#?PPMO NE:O)KWFS:9JEO;7-K%KENIMOW<BP7ETGE
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M[.OU K]$X:_W)>K/\^?I&?\ )93_ .O=/\F%%%%?0'X2%%%% !1110 4444
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M7PC\36.L^)-0\?>)KAM.\6VMU=6\NG6%\EG#/+#;!(5<>7)*8R7=^4/2LO\
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MO7X_^(/VX_V(_P!B7XN?$IM/U_XG:?\ M'Z?X8?Q$-/M[6ZN+'[0TPA(@C1
M@*0C:%Q^Y!ZDDYT\XJ.TI4TD[?:O\47)?97:S_"X<I^+E?7'Q5_8(\'^!O\
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M'B/PQ\8-;TJ+QOI=QX6O-*C\%K/?V-O]AO+E9"T<DWVIXU+"!]R':,]/._\
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M$?\ -N__ ',G_N)K\4Z_:S_@\(_YMW_[F3_W$U^*=?Z/?1R_Y-WE_P#W&_\
M3]4^,S?_ 'N?R_)!1117[<>:%%%% !1110 4444 ?K]_P4$_:"^!WP=_9?\
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M@_X,T5-3)7/F;FDVT](V5TWJUS:MWWT#F/Z0/A)\2K/_ (??75G:VM_;^//
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MBBBNX04444 %%%% !1110!]@?\$4O^3I]?\ ^Q4N/_2NSK]0*_+_ /X(I?\
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MPKH/B9X#C_X5;X5\;6]G;:;'XBEN+*XM86/EB>!86:6-#DJCK,O&<;U<* H
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MMW)]*\?/J<HTDI+J>WA\'B,-6]GB(.#M>TDT[=]>A^H(5L9P>F?PKQS]L_\
M9TU;]I+P'I.FZ3J-G:2Z;?-<RV]X7%M>*T+Q#>5R=T98.O!Y';K7QYXG^'7Q
M5/[1<GBV/XBZU%(NI)"MNDS^6),@\1YV&/:<!,8(Y-?H3\,O%K^/OAOH&NR0
M_9I-8T^&\>+/^K9T#$?F:^0HU^=W1ZU:@Z=KO<JP>&YO!WPMT'1[B]FU*XTN
MRBLY+N7[]TT<6TN>IR<9Y)K^8/\ X*:MG]HVS]O#>F#\H *_J2\9\Z5;C_;/
M_H)K^6O_ (*8_P#)QEK[>'M.'_D&OZM^B3_R56(_Z\O_ -*B?,Y_\$/G^A\]
MT445_H@?+A1110 4444 %%%% &)X\_Y \?\ UV'_ *"U<E76^//^0/'_ -=A
M_P"@M7)5_$'CQ_R5<_\ !#\F?69/_N_S84445^-'J'T1^S=_P32\=?M1_LR>
M,/BAX=U+PO#8>%;BZM8M*O+MXM1UN2TLOM]VMJH0H3#:YE(=T+ ,%W$8KYWK
M[Z_8]_:+UK]GC_@CIXZU31;Q%MY?BYINE:_9>3$\FHZ3>Z3<BYM@[*7B$RVQ
M1FC*L5R,X)%?%?QA\ CX8_$K5M%CF^UV=M*)+&Y_Y_+211+;S#VDA>-_^!5Q
M8:M4E5J1GLGI^%_S0P^#G@$?$_XG:-H<DWV6UO+C-Y<]K2U0&2>8^T<*2.?9
M:[KQC^V)K7C'Q=JGVJQTVX\&ZG=.TOAT6D5O;S0\)%O:)59KB*)45+@DR+M/
M)#.&]B^)_P#P3E^(W[#W[.?C'QIK@T/5-1FL]/T'5[31+[[7>>!3J4<=T%U)
M=H\EYK;;$I0NA%RZE@V%/Q[5TY4Z[<XV:6B_/_(1VGC_ .%]O8:$OB7PS<S:
MMX3N)!$TD@'VK29FR1;W2KPK<';(/DE )7!#HG%UO?#OXD:E\,==:^T]H9([
MB,V]Y9W,?FVNH0-C=#-&>'0X!QP00&4JRJPZ?QM\,=-\4^%[GQAX'6:31[;#
M:OH\LGFWGAUF( )/66U9B DV,J2$DVL5:3;F<7:7W_Y@>=5Z3X&\(Z7\-/"]
MKXR\6VMOJ#7@+Z!X?F9A_:K D?:;@+@K9HP(QD-,RE%^42,J> O NF^ _"]O
MXT\96KW%G<[FT#16.QM>D4D&63^);-&!#..9&!C0@B1XN-\=>.M4^)/BFZUG
M6;IKS4+PC>^T(J*H"I&B* J1HH"JB@*JJ    *3?.[+;K_E_G_GL$?B_Q=J7
MCSQ+>:QJUU)>ZC?2>9-,^!D]  !@*H "JJ@*J@    5L?"?XG-\-]:N%N;5=
M6T#6(?L>LZ6[[$U"W)!P&P=DB, \<@!*.JG!&5/*T5;BFN7H!UOQ;^&B?#_5
M+6XTZ\_M;PSKD1N]'U$+M^T19P4D7^">-ODD3LPR,JR,W)5WGPE^(.GVVEWG
MA'Q2\S>$=;E$K2QKYDFB78&U+Z%>Y PLB#'FQY7AEC9+6D_LXZE;_$34M,UZ
MYATS0_#\*W^JZU"?M%JEDV#%- W F,X91"H(,C.H^4;BN:J<ND_^'_X(%;X2
M^ M-_LFZ\8>*HY#X5T:41):K)Y4NO7F RV43=0,$-+(/]7&?[[QJW.?$+Q_J
M7Q-\67.L:I)&US<;42.)/+AM8D4+'#$@X2.- J*HX55 K2^+?Q._X6)JUK#8
MVITGPWHL1M-&TP/O6S@SDEFP-\TC9>23 W.3P%"JO)U48N_-+?\ +^NH&_\
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M_P#!9WX(_M<:Q#X?TV]OM,URZ.Z/2=5M_+N)#C+>4=S+*1@G"-OP"0IKJ/\
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MGQ<O/''A#Q)_PC/B1IYD\4742_;8KRX2*%8@8]ZK&X ^8K][=R,U\&?LL_\
M!/:UU+X8_%;1;KX<Z/\ $;XJ>!_$PTRVMKK6[JPLS!MBR2T,B8#*974D9.W'
MM7]#Y/\ 20X9Q/#\LWK<[JT8P=6E&/O1<I*%X\S490YGNI72:NDW8\JID]95
M?9JUG>S/@:BOIO\ X*I?LTZ%^S%\<_#NE^']%M?#MOJWAFUU"ZTZ"\FNEMKL
MR2I, \S,V-R8'."!GO7S)7[3PSQ#AL]RJAF^#35.M%2BI)*23Z-)M7]&_4\Z
MM1E2FZ<MT26]K+>2K'#&\TDC!$1!EG8G  '<U)I.GG7YVAL9$NKB(2--$JLK
M0"-69MVX # 5N_;'6G:,EB+[S+[[4%A1G@-NVV1)L$(P/L3D^WY5K_L\_;O"
MO]J1ZU=:;?6 M;B>1TC9YL^040%F&0#)L&.GS>YK\0\2O$3CC(<_5'*LO]M@
MK0O/V<Y.\G:2YE-16Z2NM][GHX/"8:K2;G*TNUU_6VISU;J>,FT[PQIEG8&:
MUNK.YFN99U;;YA?RPH'/11'W[L:PB<FK%IJVCVFF:E]N67[;:I$UNGVY+=;@
MNQ4@!HVR5 +'D<>^,_J?'W$V0Y%@*>.XB=J/.HKW7-.4HS5G%)W7+S;JU[=;
M'%A:-6I)QI;V_5'2:_96GC30I-:L5,.H6JAM4M@A$8RP43(>F&)&5Z@GTKDZ
MZRSU%C\&I(H[==-^T7$=Q*WF>;)J"G_5@M@!412&"C))?)Q@ <G7!X7YYA,U
MRNKB,LFY86-64:/,FI1A%1]U\R3LI<W(G=JFXQ;NFE>,IRA/EG\5M?7_ #[^
M84445^D'&<EX\_Y#$?\ UQ'_ *$U8E;?CS_D,1_]<1_Z$U8E?Y\>*'_)5X[_
M !O\D?:9?_N\/0****^".P**** "BBB@ HHK[X_X(@_L9VOQ8\0>*_BYK7A?
M_A-+'X;"-=$\/&2*-=9U5AO4,92(\1( ^'.TL\>> 0<ZU54X.;,<17C1@ZD]
MCSG]F3_@BQ\>/VG?#EIKEKH%CX2\/WR"6VO_ !)=&R^TQGH\<(5IV4CD-Y>T
M]B:^@I?^#:WQ%H7ANYU+7/C)X/TZ&Q@>YNGBTJZFA@C12SL6.PX !/W>U?L[
MH/AM;K2X[[4HII[BZ"OY1EVB!2,\D'YF]>W.!ZU+<Z)I<2';829_ZZG_ .*_
MSFOFYYM6E+W=/1+]3EP^*G4U:L?DS^P;_P $(;[X4_M6?#CXA:YX]\(^+OAW
M8R#6(I=*%Q'?3R>0TEE)#%+"4;$QBD&21A>01FOU"\*6.E^!OC=XJUJ;6/,@
MUC2=/LXI;P/]O8VT;AWF C49=FSE0%+,< =!K06]KIVIR21V?DF- $D,F[.<
MY &?EZ#GN#67XAU^:*^50S16LUG=1RN #ABJE!D@X)(./I7'B*M2M+GF^ECT
M*V%C.G[5;HXWXD>%AXI\7R7NF^/6TG2Y(8LVT+7BR>8K-NP49 %*D'.<YW5F
MQ?#UHA(S?$*Y:"20.J.;\QHHC$;1#]]C!'8< ;1C@8SY-3LDC9CJ&LX6.9N(
MF/W' _N=QT'5OX<U7U/5+."X:--2U;AV094XR4#+SLQCU/0'@D'BL/9BPNIN
M6'A&""XOKB[\7V^L":U,,4%Z]\%A?<SM*IW.0S$\X R>YR:_-C_@X%_X)^^+
MM#DTGXTV^K>'-7\+Z3H>DZ#JJ0WDC:A:W#F;RF9'7+0E2BJY<MT!48K[MU'Q
M7#!*K)?:L4W!\&%LXVYZ;,YW#[O7'.,<UQG_  72T>Q\6?\ !->ZMX_+AGM]
M+MM478H4SM!>XPV.N$=\>F!73@JDJ6(AR]7;Y'MSH\U%I_U9'\_%.AA>XF6.
M-6DDD(55499B>@ IM?I)_P $C/\ @FY#MM?BU\1K#_0X2)-#TN:/+3MGY9F0
M]<GA5[GZ,5^RVU/%UV2N]DENWT2\STC_ ()-?\$U;?X"^'K'XK?$/3/M7BK4
M /\ A']'>/<]L7'RMM/65L_11STX?]!OB%X]M/V0?#E]XA\07UM_PLB^MBTL
M[?O(O"5NP)$48/6Y8?BN2QYK2U37;7]F3P@WC?Q08(_%UQ:F32+.8!H_#ULW
M2X=>AF;^!>,GGA1Q^27_  4*_;[FUJ[DNVD:XFNV>71K"9_,\UB?FO[G/WAN
M&5!_UC#.-BXKCIT_K$G*7P+\?)>7?^9^6_Z%D^78?*,,\?CM9O3O_P!NQ[^?
M\VM_<3YN=_X* ?M_WVJZD;*S<BZD)GM+25_,:TW<_:KC/WYVZJK=!AB/NBOA
M+5=5N=<U*>\O+B:ZNKES)+-*Q9Y&/)))ZFC5]7NM?U2XOKZXENKR[D:6::5M
MSR.3DDGU-=Q^SC\'KSXP?$.UM8;=IK6WD1IL#AR3\L>?]H_D 3VKT+N;LCY?
M'9ABLVQ2YNKLET5_ZU9^DW_!$?X&W'B#6/!NDR1LD=YJ<5_=Y'$<4 ,CL?8>
M:W_?)KR'_@N;\:(?B7\>O$ES#)OAN+V3R^>QD+#\AQ^%?>W[.FCV?[$O[%7B
M3XA:@RPZEK=D^@>'@WRM(AYN;A>X!+%0?]OVK\5_VN/B?)\1?B5<R-)YG[QI
M7.?XF_SG\:SNI5936R7*O7>7Z+U3/T;/:T,'E3I_W5!?K^GS3/*:***#\?"B
MBB@#[ _X(I?\G3Z__P!BI<?^E=G7Z@5^7_\ P12_Y.GU_P#[%2X_]*[.OU K
M]$X:_P!R7JS_ #Y^D9_R64_^O=/\F%%%*JL[!55F9C@ #)-?0'X3OHA.IKU+
MPI^RUJ4_AJ/7O%6IZ?X,T.8;H9M0/[^Z';RHN"V?J*Z31_#^C_LF>&[/6/$%
MA;ZS\0-2A$^G:9. \&C1G[LTR]&D/9>V#SS7D?C[XAZS\3_$<VK:[J%QJ-],
M>9)6SM']U1V'L*\&.+Q..E;!ODIK[;5W+_ GI;^\[I]$UJ?H4LHRK(::>=1=
M;%-)^P3Y8TT]5[6:][F:U]G"S7VI)Z'97Y^%?AMFAA7Q-XDDCX,^]+&-S[+A
MSC\:SK;6?AY>7+"?1/$%G&>C1:@DA'X%!FN$HKMCEL4O>J3;[\S_ "5E^!Y\
MN,+.U/!8>,>WLK_^32;G_P"3'?7'PU\+^)FSX;\7P>=)]RSUFW^PR$_W58,P
M8^G S7)>)O">H^#M1:UU*UDM9AT##AAZ@]"*SF4.N",@]0:UM#\:7FB6'V%M
ME[IISFSN/GB!]5S]QO<5K3I5J>T^=>=D_O22^]?,'C,BS'W:]'ZK/^>FY2I_
M]O4Y-R2\XR=ND69-%;$VC6^N,TFC^9N1=TEI*?WJ>I4_QK^OM6.1M.#U'!'I
M75&29X>:Y-B,!*/M;2A+6,XN\)+O%_FG9K9I,?;V\EW<1PQ(TDDK!$11EF)X
M  ]37UM^SY_P3\L[32K?6_B#))YTRB6+1H7VLJGD&9NW'\./QKE/V$?A5NMO
M$'Q!FTS^UY/#%M(=*L3Q]MO A95&>,\$#T.*]9^"?QM\4?M!_"FUUWQEX2U#
MX?ZE)),+_1KF823@K(RH"RDC#*%;KT;%?EO&G$F+3GA,OERQ@TIR37->2;48
MJ][66LDM'9777^IO GP<P.-PD.(,]I^TY[^RIOX;)VYY+K=_"GI;6SNK>D^'
MKKP;\/8%M]$TO0=+6$X4QP!F'U)S6A+\8;4C_D)VZ^RJH_I7D^OZ_>P:JHM4
M1=/6!B\,: 9;G 'Z5CWOB69Y"ODS#) +<8^O7M7X7F$.>?-.3DWU;N_Q/[&P
MN H8>FJ5""C%;)))+T2-BY\7?%)_VQ[+6H/'/A=?@BFB&&ZT1[<'4FU'*XD#
M]-F,]JU/C'\1=+\;6<VF#2]'U*.1=MU>SVP(A']U"N,L?7M7G5WXGN"N[[-<
M#(!QQGGMU[5D6&N:E=I=IJ&U%CN&%N%Z-'DX-&$IRYU.'NN-MG;YZ=2JV%HU
M8N%:*E%[IJZ_$\Q^*/[-]CIFEWNJ>%;V^2:UB,S:9>.)HYU4981N "A"YP"&
MS@#WKR;3=0CU6PAN(L^7,H8 ]1['W'0CUKZ?O[XI#(5Y^1OQ^4U\E_#N5I?#
MC%B=WVNYSGJ/W[U^_P#A_F6,KQJ4,3-S44FF]6O*Y_%_TDN!<GRRCALVRVBJ
M4YS<)**M%Z73LM$U9K2U[^1N4445^DG\EA5C2=/_ +3N9 TL=O;VZ^9<W$AQ
M';IZGW/8=ZR;O5 U]]CADCCD5/,FF?\ U=JG]YO<]EZFK$H34+>")$DBL+<[
MXX7/S3/_ ,]9/5CV'.W)%:>R:C>6G]?U;[_7[;)^'L/1P:SK.KQH7M""TE6D
MND>T%]J?R5V=#JGCUYM%.D:*K:?H[',TWW;C4?=C_"A_NC\ZPT01KM48 I:*
MQC",5:"M^OF^[/!SC.J^8U5*I:,(Z1A'2,5V2_-[O=L*Z*PG;4_AY>P2#*Z?
M.DL3'^'?PP_':*YVNDTTM9?#747(7;>7,<:D^JY)_P#0A6.(V7>Z_/\ RN>;
M1GRM^C.;HHHKH,3Y:_X*X?\ )M^B?]C+!_Z2W5?G97Z)_P#!7#_DV_1/^QE@
M_P#26ZK\[*_IKPL_Y$4?\4OS/[9\"O\ DEH?XY_F@HHHK]&/V,**** "BBB@
M HHHH *Z.PBV^$MZKN9EZ>N):YRNHT>Y$/AB)L;C"0Y&<9_? ]1R.E?A7TC/
M^2+J_P#7RE_Z6CNR[^+\F?H+\2;KX3C]@%=)A^/]MJEG9QRZKIOAF/3K@:O+
M>R0[5M98& 2-$D9R6W%1N9@3D9_/F&)M@KT:;]H=M<EN&U#3=0O&E1HT8ZY<
M!E!Q@'CY@N!UYP *X&&+"XK^ *,JLOXOZ=?2Q]-G&=8O,91EBI\W+>VB6^KV
M2W&&"I-)CA&LV7VOSA:_:(_/\E-\@CW#<5'=MN<#N:>T6%HM;B;3KR&X@DDA
MG@<.CH=K*1T(/8ULUV/)IS<9*2Z'Z4_\% /VB/A_XU_8-FT?3_C9X4\77<]M
M90V6EZ5HCQZE?F *L0N%:-5M0BY:0@Y+*!SFOI/_ (-IM,CNOV?/%DTGSJT%
MA;/$PRKJWV@G/Y8Q7XS>*OC1>>(O#]U8R1WJ/<2&3S3J4KJ"1M8E",$LORGV
MK]GO^#9AMW[.7B[TW:=C\KFOF<X4HT$I=_+]#Z/^TZ^-K<]=IM+HDNM^B1]V
M7W[.]KJ.H[VO8EM]OE>8+0?;EAQM\H39Q]WY=^W>%XSGFO1+>WCLK:.&%%CA
MA01QHHX10, #Z 4Y#D4.*^81TRDWN9_C(_\ $LM_]\C]#7\MW_!3(;?VC;4>
MGA_3Q_Y"K^HWQ><6%K_UT_H:_ER_X*9?\G'V_P#V ;#_ - -?U3]$G_DJL1_
MUY?_ *5$^>X@^"'S_0^>J***_P!$CY8**** "BBB@ HHHH Q/'G_ "!X_P#K
ML/\ T%JY*NM\>?\ ('C_ .NP_P#06KDJ_B#QX_Y*N?\ @A^3/K,G_P!W^;"B
MBBOQH]0^KOV?]/L]?_X)!?M&QR3,MYHGC3P;JD48_B#+JML<_P#?X_D*Z;]@
MCP!X5^*VEV/QC^(2VUWX1_9JL6NO$MA,^UO$05]^AV"Y^\T]TSV[==L%N.U<
MW^QA;6NN_P#!.#]K[37;=?Q:=X3U2UB RTABUM(&P/\ M[4?\"KTSXU?V;^R
MQ\.?!7[(,CVMOJGB2V_MCXFWA /V?Q+>Q(VEVC-_"NGJ+=9,'&^XNAZUXM:3
M<ITX[N7W1Y8\S^YV7FT4<3IO_!<?X[>)?BS#JGQ#\2S?$+P3>37<.N^#-05(
MM*URPNR1<6DHC4,V(SMAD<LT!1"A 7!\W_;G_9-TGX(ZEH?CCX>7]SXC^"OQ
M(C>]\*:M+AI[1E(\_2[S'"7MJQ".#@.NR1<J_'@^I:=<:/J-Q:74,EO=6LC0
MS1.-K1NI(92.Q!!%?0G[#7[4_A_P%IVO?"CXJQ7FJ?!+XCN@U>.W0277AF_4
M%;?6K('I<09PZC FA+QMGY<=DL.J/[S#QMW2ZKR\UT[[=K(^=:]8^ \3?!>*
MU^)6K7$EM;V[R1:/I:2%)O$DF"DB.,?\>(R5F9N) 6B7)+F/:^-/[*L/[&G[
M0.I>'_B/,VL:38V::OH,^D$FS\;VDV&M)[>XZ):RH=[2#+*%= /,'RX?PX^&
M7Q&_;^^/-OH?AS3?[8UV\A^2*()::=H=C"O+,QQ%:V<"=68A5 Y))YUE4C.'
M-?W;7;\OZW_SV1N>*_"5W^VMXHM]:\#V,EUXVU*6"QNO!=H"\BL2L41TN/J]
MJ/E7[.,O  /OQ@NOT%\//#WP/_X)KSWWA_QUJL/BSX\ZI83V\VL:58V^O:'\
M)[G;^[3R)#Y6HWVX%)64F.VS\GF2(:XWQU^T=X+_ &!/ &J?#OX"ZO#XB^(&
MM6[V'C'XKP(T;-&PQ+INA[@'@M3RLEUA9;C'R[(\ ^ Z7X%TCXM>"H?^$9AF
ML_&6DVY-]I+2F5=<B7)-S:EN?.5>9(.<A2\?&Y$Y.256-I7C3Z=WZ]EY=?M:
M739]2?&OX-?"K_@I1)KFN_L]:?<Z#\4O#-MYNJ^#I[6*S'Q MX8@9]7TJVC)
M2"Y++))+IR%L(0T18AUKX9EB:"5HY%9)$)5E88*D=015_P (^+M4\ >*=/US
M0]1O-)UC2;A+NRO;29H9[69"&21'4@JP(!!%?9-WHOAW_@K_ *3+?:/#I/A/
M]JBUB,E[I4:I::9\6 HRT]L.$M]7(!+PC"7)RR;9"RG97PRM)WAWZQ]?+SZ>
MFQN?'_P_\!:E\3/%EKHVE1))=719B\CB.&WC52TDTKGA(T0,[.>%523TKVO4
M?B3X?^*W@JQ^#5GJ#6^DZ%(7\.>(+M_(74M0)?>MT&/[NUE9W$ 8@6Y;<<>=
M<,>!\6>([?X4^!IO!NDPWEOKFH@+XLN[JU:WN(Y$;/\ 9B*X#I'$Z@RD@&25
M0,;8T+><5NX>T]Y]-O\ /^N@BUK>BWGAO6;K3]0M9[.^L9GM[BWF0I)!(I*L
MC*>00000?2K/@SP9J_Q&\6Z;H.@:9?:SK6L7"6EC8V4+37%W,Y"K&B*"68D@
M  5Z7X?TK4/VP3H/AW2],U+6OBW)<0:3IL-E;-/+XH@/R1K)M'RSP* /,;Y7
MA'S%3%E_<O&7Q9\._P#!+7PIJ7@3X6ZMI_B/X[ZI;O8^,/B%82"6V\*(XVRZ
M3HD@_P"6N"4GOEY/S)$0N7,5,0U[D5>;Z=/5^7_#;@=5X+\._!K_ ()G1ZEX
M2\9ZM'J_[0FJV#+=^(-/TNU\1:/\*;@.C"S%K*?)OKUT$D<\@)6V+A4WL'-4
M_BW\.O@O_P %2_'>OWOP+TV/X7_%J*1C:>#+]H+/2_B#&O'G:=M(BLM0<#<;
M')C<G$3[@5;X61)M2O%55EN+BX?  !9Y&)_,DD_C7?>._!FD_!GPV-)OOM%S
M\0Y)DENECF,</AI5.?(;:<R7;'&\'Y80-N&D+>5S_5'&7.IOG?7I]W\OE?3H
M^9W;.Q\':Y>_L&^(Y+R\LED^**JUM)HNHPEK7P_$W#I>PMCS+E@.(6XAX9OW
MH41\G\6?"%MXUL+SQ]X8DU&]TB[N-^LVUY.;F]T*[E8G$TA^:6&1B?+G;!8Y
M5\.,M[YX;_:6\#_\%"O#=IX1_: U2'PO\2[."*R\-_%KR&<W"H D=GKZ)\UQ
M#@!5O5!FBP-_F(#CQ?XH_";XD?\ !/KXYSZ+XDTW^R]52#C=MNM+\1:?,.'C
M<9BNK.=.0RDJ1Z,.-*<GSVEI4_!KR\OQ77?5'D=?3_[$G[.WA?PSX U+X_\
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M_P#LT0_M??M=^#/A_=7$EK8ZW<R-=O']_P B&%YI%4]F98RH/8D'!QBO:/\
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M-_X#\!ZU\4?&6F^'?#NEWNM:YK%PMK96-I$9)KF5C@*JC_(')XK^F'_@F/\
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M P[EW.1P?[6G[;K?&?PKI?P[\ Z'_P *[^"OA6<S:/X9MY_,FO[C&TZCJ4X
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MR"#V(IUU=27MS)--))--*Q=W=BS.3U))Y)-8^R=[7T[?UT_K8#[2TKQ!HO\
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M#:VL,US=7,BQ0PQ(7DE=CA551R220 !R2:^QOCY>P_\ !,[]G6_^"FCS1?\
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MNC_V.+'3[N>*WU)?/DF,L\9<QM(6E.2% . 2">:X+PQYG@NRU*WTV:2VAU6
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M%/%\2YAC:<:T4HPY8\LY1]U-*6CO9RB[:N%T]'8G 8B#<:,(NW7M_7ZGR_\
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MC[\_X(@^$[CXQ_M@W=CXCGO+JWL]%-PD=V!,G-U;KG9(&4G:2 <<9KTS5O\
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MK@L$+8&X$XSR*_8O]DS_ ()RV?PK_9W/@KXX^";'X@7PO)9X]:BM9;^1(&1
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MY^T-H]W:3?9?.GOHXC(+?& <=\_W??%:OB2TT3Q%JYBOH[>:\BC#;9&P0A)
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M)/))KO\ ]K/]J'Q!^U_\;]3\:>($MK,W"QV>F:79C98Z%I\*[+:QMDZ)##&
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MFC4Y;452DYQV<I-?>)A1117H ?='_!M9_P IK?@O_P!QS_TPZC7]7%?RC_\
M!M9_RFM^"_\ W'/_ $PZC7]7%?F_&'^^Q_PK\Y&M/8_%/_@\(_YMW_[F3_W$
MU^*=?M9_P>$?\V[_ /<R?^XFOQ3K_1[Z.7_)N\O_ .XW_I^J?&9O_O<_E^2"
MBBBOVX\T**** &M&&J-[7/>IJ*RG1A)6:'S,S[C2I''RM78_#S]H[QI\!]/9
MO!M]K&@ZM)$;>>_L-3EA:YA/6-D7@CIC).",^F.>HKX+C#PSR3B7#QPV9P;4
M7S*S:L[6OIZ['5A\94HN\#T7X4+<?M9:GXB/BKQ#H?AV^M+.74)-6UQU:2\E
MR,J7+!R3DL6PW0UY+Y!%U+$H23RW*>9'RCX.,J>X/8UJT5X/ WA-'AF=:EA\
M7*>'FTXTW'X+*SM)RD_>WM9)=C7$X_VUFXZ]^YG#2V<T]=(]:O45^E1R;#+=
M7./VDBJFEJOI3O[-C-6**Z5E]!:**)YV4Y-'C?L*TOA_XJU_X1>+K?Q!X3UW
M5O#6N6@80WVGW#0S1AA@C*GD'N#P>]0T5YF9<,9;CZ$\-BZ,90FFFGLT]&C2
M%:<'S19]*>"/^"T'[4?@F5/,^)G]O6Z%3Y>I:5:RLP'8MY>>>_0GUKZ:^$/_
M  <<32V\-M\5OAQ;ZE$N!)?:&=L@_P!H02;E;Z!UK\T2,TFP5^(\0?1?X.S"
M-\)&>&EWA)M?.,^9?=8]*EG6(A\6OJ?K;\8_^#A/X$Z=HUYI'A?X>^,/%C7<
M#P2K-:0V5J"RE2"[-(6[\A2.F*_&9- FDE9EA:"-F)5"VXJ.PSWKJS&I_P#U
MT&!3V_6N_@7P!RSAF-3V>(G5E.UV[):7M9).V[ZD8K-9UK725CGH=*FB[U[[
M^R\OV;]G+XY--PQT:Q5?<F\7_P"M7D7V=?[OZULZ#XXU3PSX;UG2+&Z\C3_$
M"11W\7EHWVA8WWH,D$KAN?E(SWR*^VSS@.6*P7U7#32?/2EJW:T*L)RZ/7EB
M[=&[7:6JYJ>*Y9<S[/\ %6.:AR!S4JM5@Q*?X:! H[?K7VM/ SALSG<DR-6Q
M4D9XH\I?2E50O2NR-*2W)<A:***Z"3DO'G_(8C_ZXC_T)JQ*V_'G_(8C_P"N
M(_\ 0FK$K_/CQ0_Y*O'?XW^2/M,O_P!WAZ!1117P1V!5S0+S[!K%O)G;M;&?
MKQ5.C-5"3C)270RKTE5IRIRV::^\_6C]DE+_ .(W[)FN6^@RM+>:*MAXULK0
M#=Y_V;=;WJ@=V0E'([(":^:?^"IOP*E\32:7\7_#]K)/H.L0I::@R+DVLL?R
MKY@'0@80Y[J#T85D?\$U_P!M#5/@'\1M%DANH]^FW32017!_<2B1=DT#CIY<
MR?*WX5^B=YX6TGP_X8U+QCX0TO\ X3KX(^+I2OB7PRZ^;?>%9W!W)(N. .=D
MOW75<'## ^XQ+CC<-9?:LU_BM9Q[7=DXWW;E'1V/Y9HO$\+<1.NXNR<DUT<'
MK?Y=;?#9/5-V_#&KOASQ)J'@_7;75-)OKK3=2L9!-;W5M*8IH''1E9<$'Z5]
M_P#[2_\ P1)O/&>BW/CO]G;5(?'7A><F630C((]3TS/)C"L?FQZ'!]S7PCX]
M^%WB3X6:Q)I_B70=8T&]A8HT-_:/;L"/]X#/X5\14IN,G&6ZW\O5;KYG]*Y7
MG6#S&BJN'FG=;:7^[KZJZ\S[(^!G_!;_ ,5^'M-M]-^)'AVS\;6L("C4+=Q9
MZ@!ZM\IC<^X5">Y->R67_!8?X*7UMYTNF_$+3IF',(MHI,?1A/\ KQ7Y:UJ^
M%O VM>.+U;;1M)U+59V. EI;/,W_ (Z#7%+ TIO;[CL6%HT_>2M^1]^_$+_@
MM9X9T"SD3P'X#U*^OF!5;SQ!=A$7W,419F^GF+7QS\;?VB_B'^V-XZMIO$6H
M76M76XQV&FVL7EVMF"?NPPK\J^[<L<<DU[1\!/\ @CY\3OBC=03>(+4>$[&1
M1*8IE\Z^D3KE85R0,?Q-@#OBOT(_8N_X)G^'?AYJ*V'A#0IM>UV- ;J^#JWD
M^K3W7^K@0=UB)8?WQR*Z*.!ITDYO1+=O^M/P,XYBJLO887]Y+LMOF]CY'_87
M_P""35UJ5Q;^)/'=M'(]JRN-.E_X][0]OM#<;F](P0?4J"&K]3=&\&^!OV-O
MAO:^*O'2FW5X5DTS0B%COM5('R,R ?N8!V. <'Y0N23ROQ:_:D^'/[#FF/#I
MMUI/CCQ[:(0C1 #0?#[?],TZ2N#_ !MQGUK\QOVR_P!O35/B)XCNM;\2:O>Z
MIJ&HYD2(RE;BZ!Z8S_J8O]HC<P^Z,9(Z/9RJQUO"GWVE+TZI>;U[+J?69?@:
M6#2Q..E>?1+IZ?Y_=T9ZE_P4!_X*1:M\<==NM5UB_73]'L";:SM+8?N;11]V
MW@CZ-)CKV7.YCS@_G/\ %+XJW_Q1U@37'^CV-N6^RVBN66$'JQ)^](W!9SR?
M8  4?''CS4/B!J_VJ_D7;&-D$$0VPVR9SM1>P]^23R222:Q:52HK*G35HK9'
M+F6:U<7*TM(K9!11161Y84444 %%%% !1110 4444 %%%% 'V!_P12_Y.GU_
M_L5+C_TKLZ_4"OR__P""*7_)T^O_ /8J7'_I79U^H%?HG#7^Y+U9_GS](S_D
MLI_]>Z?Y,*]"^%\G_"4_#7Q1X<X:XV+J=HO=FC!W@>Y&VO/:TO"?B>Y\'^(+
M74;5MLUNX;'9AW!]C7JX[#NM2<8?$K->J=T?BN!Q7L*O,]FFGZ-69FT5TGQ$
M\,QZ=?)J6GC?H^JYFMV'_+(G[T1]U_K7-UM1K*K!37_#>7R.>K3Y).(4445J
M9A1110 51\2V_P!J\/7T?=H7Q]<9%7J1T$B,K?=88-)ZJQI2J.$U-=&F?7?P
MH\0MXJ_8P\#:CN+2PV<4+'N'11&W]17<:?<8\/6I4_\ +/']*\;_ &#-7B\2
M_ ;7/!4TRF^T>\DE@0GD1NYD3\,D"O0O#/B#R+5M/NF\J2-RB;N,/_$A]R<D
M>Q%?S1FU&=*O5H-:QD_N9_J!PKG4,9@\/C(.ZJ4X_>EJ9/CGP*WB;Q%)??;%
MAW6PMPN#E2"2&!]LUS6L_">YNH<1ZPR2QC*LH.Z3']X^IKM]6NS$6%85_K(@
M3[U+ 5*VD8?D?:.S5SD;CX1R7-E$]Q=0K<,%\Z)@7C &>![\]:R[F>S^'FG3
M>9<+($^Z[C+(JC@#/3'K5;XI?'FQ\$6LC2W4(F3@J6X0]@?<^G4UY[HGA35/
MCCJ$.I>)/M6G:']Y+$'RY[X=B_=$_P!G@GUK]1R7AM^Q6+S%\M/?7=^277^K
MZ'F8C%^][.BKR_+U*<^IZM^T5K3V]BTUCX9A?9/>=#<8ZI%ZYZ%NG7!J/]J[
MP5:^$_@)%I-G MM!<7,5M%$O ^^I)/J3U)/)->\>%-!M=.@BAMX(K>UMU"QQ
MHN%0#L*\9_;)\16MWK>AZ;(W[FRE%U,%&[D9P/Y&OI*&9/&8VEA<+'EIQ=U%
M>75]V_PZ'R7%6._L_+:U7XI\K]6^R_R.3TNW^R:9;P_\\HE3\@!5BN>'Q'LY
M6VPV]],W;; U:-GJUQ?LN+22%>_F<5];+"58J\U;UT/\YZO#N8J3G7@J:>MY
MRC'\VG]R-"M#3=!^T$27<T=C;]2\GWC_ +J]3^ K/MKB2WP5VJW]XC<P^G;]
M*'9I9-TC-(_JQS_^K\*YI1>R9P5*&&HZ2GSO^[>WWNWX+YG17GC*'2;!K/08
MY+6*0;9KI_\ CXN/49_A7V&/>N=HHK.G3C#X?^"SAG4<@HHHK0@**** /EK_
M (*X?\FWZ)_V,L'_ *2W5?G97Z)_\%</^3;]$_[&6#_TENJ_.ROZ:\+/^1%'
M_%+\S^V? K_DEH?XY_F@HHHK]&/V,**** "BBB@ HHHH *U-1E\KP7"W^T1_
MX^*RZT/$S^1\.+=O[TA'_CXK\'^DC*W!%9_]/*7_ *6CT,M5ZUO)_D9,6J%#
M]ZKD&LL[*J_,S$  =R:Y=;W'\0J>TU9[2XBF7:6A=7 /<@@_TK_/".*/6]BS
MZ>^(W[%?Q#^'WP5C\2:G'I_]EZ9&UY)%&A66)9-I;,FT;\;1QDXP<=3G]&O^
M"',OA_X)?LM:;>:T-4M9/B-<3S7K0S2+ 8A)BWN'1(R=R"%E4[P,2/QDYKX;
M^//_  5+\._$[]F2^\*V.BZA#K%_8BU/F+A+=BN&)?<0PZXP,GCI7ZA_L">'
M;?0/V-OAC9P,6CC\,6#!O=X0[?\ CS&OGLRQE>6&4*NEW^%CUL+0IJK>'8^G
M=:\=?!Z]>ZD;Q=)#]HOGN&074\>\+$43/[O'/&1T'UK%MOBO\-?@!X5U:X\.
M^,+'6IGMHII+8VPE\^16VE448/W78G(Z+7/26\:21J;J.%F/1@#OJ1[(/.RA
MX&PH&#M()]<5\_SL]+E/HKX>_&[P;XNCMX[#Q9H%_?NBYBANT5LD= F?T[5W
M41W?2OC34O ^C>)HO+U&QL[CRU&QE4+)&W7<K+\RGW!%=-J'[2GB+]G/X ZQ
M?V>AZAX\F\,[+A;9;N.&X:R+;9':24A?W)(+%B/D.>H.>K#\U6:IQ6KT1,DH
MJY])>*^+>V/83KFOY:?^"CZLG[05MNXSHEH?_0Z_4KXY?\%Z;WQG\,]4T^WT
MOP_\/89HFBN-9G\2V.J7ULC*V?LEG;R,\MP1D(6VQJQ!9E'-?C=^T+\8I/CI
M\5=0U_[+)I]BR16>G63SF9K*SAC6*"(N0-S!%&YL#<Q8X&<5_:GT5>"LXP><
M8G-L91E3I>S<$Y*UY.479=[).]MM+[J_RV=XJG4C&$'<XFBBBO[J/G HHHH
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M?RC_ /!M9_RFM^"__<<_],.HU_5Q7YOQA_OL?\*_.1K3V/Q3_P"#PC_FW?\
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M\SLO"/ACP]H]_'JVL7T>J:E&=T:[=T%H?]A>[>Y_*O1K/Q9_:$7F6=K(\?\
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MVF7_ .[P] HHHKX([ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^P/\ @BE_R=/K_P#V*EQ_Z5V=?J!7Y?\
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MQ"BBB@ HHHH **** "BBB@#$\>?\@>/_ *[#_P!!:N2KK?'G_('C_P"NP_\
M06KDJ_B#QX_Y*N?^"'Y,^LR?_=_FPHHHK\:/4"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[H_X-K/\ E-;\
M%_\ N.?^F'4:_JXK^4?_ (-K/^4UOP7_ .XY_P"F'4:_JXK\WXP_WV/^%?G(
MUI['XI_\'A'_ #;O_P!S)_[B:_%.OVL_X/"/^;=_^YD_]Q-?BG7^CWT<O^3=
MY?\ ]QO_ $_5/C,W_P![G\OR04445^W'FA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7CS_ )#$?_7$?^A-
M6)6WX\_Y#$?_ %Q'_H35B5_GQXH?\E7CO\;_ "1]IE_^[P] HHHKX([ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^P/^"*7_)T^O_\ 8J7'_I79U^H%?E__ ,$4O^3I]?\ ^Q4N/_2NSK]0
M*_1.&O\ <EZL_P ^?I&?\EE/_KW3_)A1117T!^$A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M?\%</^3;]
M$_[&6#_TENJ_.ROT3_X*X?\ )M^B?]C+!_Z2W5?G97]->%G_ "(H_P"*7YG]
ML^!7_)+0_P <_P T%%%%?HQ^QA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!B>//^0/'_ -=A_P"@M7)5UOCS
M_D#Q_P#78?\ H+5R5?Q!X\?\E7/_  0_)GUF3_[O\V%%%%?C1Z@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?='_  ;6?\IK?@O_ -QS_P!,.HU_5Q7\H_\ P;6?\IK?@O\ ]QS_ -,.HU_5
MQ7YOQA_OL?\ "OSD:T]@HHHKY,L**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>mdt-20250425_g5.jpg
<DESCRIPTION>IMAGE 5
<TEXT>
begin 644 mdt-20250425_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,$17AI9@  34T *@    @ ! $[  (
M   3   !2H=I  0    !   !7IR=  $    F   "UNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%R:6YE;&QA+"!!;G1H;VYY    !9 #  (    4   "K) $  (    4   "
MP)*1  (    #.3,  )*2  (    #.3,  .H<  <   $,   !H      <Z@
M  $
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ \<HHHK]^/*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^Y_X^
M&_#^515+<_\ 'PWX?RJ*OR['?[W5_P 4OS9Z$/A04445QEA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >M_"G_D5;G_ *_6
M_P#0$KMZXCX4_P#(JW/_ %^M_P"@)7;UZ]'^&C\GSC_?ZOJ%%%%;'E!1110
M4444 %%%% !15J'3;ZXA$T%E<2Q$X#I$Q4G.,9 ]>*CEM+F"/S)K>6--Y3<Z
M$#<.HSZCTJ>:-[7-'3FE=IV(:***HS"BBB@ HHHH **** "BBB@ HHHH ***
M* /(?''_ ".=]_VS_P#1:U@5O^./^1SOO^V?_HM:P*^XPO\  AZ+\C]/P/\
MNM+_  K\D%%%%=!UA1110 4444 %%%% !1110 45K6WA/Q'>6L-S9Z!JD]O/
M_JI8K*1DD_W2!@]#TJC<Z=?6=O!/=V=Q!#<;O)DEB95EVG#;21@X/!QTK-5:
M<G925_4=F5Z***T$%%%% !1110 4444 %%%% !1110!2O/\ 7#_=JO5B\_UP
M_P!VJ]?FF:?[[4]3OI_ @HHHKS30**** "BBB@ HHHH **** "BBB@ HHHH
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M(W@ KD''<CU-<3+\6&TY-%MO!FA0:%8Z3>&]$#SM<M/,5*$NY )&QF7'H>O
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M'N/$TMJ[2QR;5MQ Q*J%P=WRX'4=,\UQ5-0E+XP/JP^#O!J?$26\_L;2VBN
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MV<[-I3.>^.^:G$9O42Y%%1E>V_\ >L^6Z][3?:R'&FMSYNHKZ)T8:R4\)_\
M"&&P'@H6<7]K^9Y6W=D^?YV>=V.GO[4>$TEO-!N['P_'=Z%HWVV]DMM:M&MI
M+>2(NVPSI)\X"@!1WZ?A<\\Y4WR+3^]MOOI=/3X5=B]F?.U%>W:8/$@^&GA[
M_A4WDD%)?[9\OR?,\_C_ %GF=L9Q[8[8K6T%?$']G^#QX,^PKX<%O'_;^?*_
MU^[_ $CSMW/3.,>_;%:5,XY$WRK1M:RLU:^^FC=O=6MP5,^>Z*]]T<ZB?!/B
M8_"WR/,_X29_L?W,^5Y8SY._C..G^QFI;K4;+_A-[+PUK<ENFI>(]%%CKIA*
M!4NRO[IFV\>9DD<?WE]JG^V7S22I[7TO[R22;;5M-'IKJ] ]GYGS[77:K\-M
M:TCP+9^+)I+2;3[L1D)"[&2,.#M+ J !D8X)Y(J_\4YUTZYT?PA;LAB\/62Q
M3&,85KF0!Y6'XD?CFO2[26'4?#/A+PC?.J6WB+PZ\"LRY"3IM>)_P.[\2*K%
M9E5A2HUH*RDVWU]U)N_KRJ_X!&";:9Y')\.-9A^'8\932VD>GM@B%G<3D&38
M&V[<8)Y'/3FN3KW_ %S5=.U#P9XMLN1H>CWNG:;&$!!$,4BAR/4D[^1[5J7?
MV[^VM5.L_P!G_P#"LO[-_P!%"^5Y)78NSR]OS;]V<?I_#7+2SFM!2=6.MW;6
MVEHM16CO+WMM+V&Z:Z'SMI5E_:>L65AYGE?:KA(=^W.W<P&<=\9K0\7^'O\
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M*NT 8Z@"L_PXFNKX2\*)\+);.6S6X<>(95\H%I-Z[C+OYV%<D8_AQCM3]OY
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M_P"$=UC_ *!MS_W[-'_".:Q_T#;G_OV:^8SXY\6?]#-JW_@;)_C33XY\6?\
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M2T8!1113 **** "BBB@ HHHH **** "BBB@#Z%_97_YFK_MS_P#:U%'[*_\
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MIJ2NCY^47&3B]T%%%%,D**** "BBB@ HHHH *3Q7&+CX1^+8V/ TZ.0$>J2
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MZ#\0(%-E#<  2([+NQSM.,BO/J]_*FW0U[GQ/$T81QJ<=VE<\A\<?\CG??\
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M-#BZA.IRU:;C'O>_WJW^9J\.[:,^5:*TO$.@7WAG7+C2M415N(#@E3E7!Y#
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M[*^6YY#XX_Y'.^_[9_\ HM:P*W_''_(YWW_;/_T6M8%?IV%_@0]%^1]/@?\
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M ':KU8O/]</]VJ]?FF:?[[4]3OI_ @HHHKS30**** "BBB@#O?AG"S?VA(C
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M^UY44EQX)FR!::U I'_/RKU\R?HASRHL=P1'@@=&QC-7K-?D)[^6O]:UH8_
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M-2"-1T%/HKNAAZ5-6C%(TNQ-H%%+16]DA!1113$%%%% !1110 4444 %%%%
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M3M+7S[N<@RSN,/.P[GT4>G:N:OB(P5EN-(SO&OA:;Q+I=IH6G3)96]N1)([
ME44#"C KYXO8!8W-Q#/<1F.&0QLT+[O,(./E]?K7KOQ7^(::-I<N@:-<[M1N
M?^/J=#S&IZCV)Z#T%>!5CA:<G&[>@I),N'4IEF#VY\D+]T*>G^)JK)(\TC22
ML7=CEF8Y)--HKNC",=D 44450!1110 4444 ?0O[*_\ S-7_ &Y_^UJ*/V5_
M^9J_[<__ &M17C8G^*_ZZ#1X?1117[L>6%%%% !1110 4444 %%%% !1110
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M444 4KS_ %P_W:KU8O/]</\ =JO7YIFG^^U/4[Z?P(****\TT"BBB@ HHHH
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M\BK<_P#7ZW_H"5V]>O1_AH_)\X_W^KZA1116QY04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'D/CC_D<[[_ +9_^BUK K?\
M<?\ (YWW_;/_ -%K6!7W&%_@0]%^1^GX'_=:7^%?D@HHHKH.L**** "BBB@
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M%?+5_P"++U?YG0M@_P"%?^#?^A2T+_P6P_\ Q-'_  K_ ,&_]"EH7_@MA_\
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M_P# =/\ "C^PM(_Z!=E_X#I_A110 ?V%I'_0+LO_  '3_"C^PM(_Z!=E_P"
MZ?X444 ']A:1_P! NR_\!T_PH_L+2/\ H%V7_@.G^%%% !_86D?] NR_\!T_
MPH_L+2/^@79?^ Z?X444 ']A:1_T"[+_ ,!T_P */["TC_H%V7_@.G^%%% !
M_86D?] NR_\  =/\*/["TC_H%V7_ (#I_A110!4G\%^%KJ9IKGPWI$TK?>>2
MPB9CQCJ5J/\ X03PC_T*NB?^"Z'_ .)HHKW*7\./HCZ>A_"CZ+\@_P"$$\(_
M]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?_B:**T-@_P"$$\(_]"KHG_@NA_\
MB:/^$$\(_P#0JZ)_X+H?_B:** #_ (03PC_T*NB?^"Z'_P")H_X03PC_ -"K
MHG_@NA_^)HHH /\ A!/"/_0JZ)_X+H?_ (FC_A!/"/\ T*NB?^"Z'_XFBB@
M_P"$$\(_]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?_B:** #_ (03PC_T*NB?
M^"Z'_P")H_X03PC_ -"KHG_@NA_^)HHH /\ A!/"/_0JZ)_X+H?_ (FC_A!/
M"/\ T*NB?^"Z'_XFBB@ _P"$$\(_]"KHG_@NA_\ B:/^$$\(_P#0JZ)_X+H?
M_B:** #_ (03PC_T*NB?^"Z'_P")H_X03PC_ -"KHG_@NA_^)HHH /\ A!/"
M/_0JZ)_X+H?_ (FC_A!/"/\ T*NB?^"Z'_XFBB@ _P"$$\(_]"KHG_@NA_\
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M !_PK_P;_P!"EH7_ (+8?_B:/^%?^#?^A2T+_P %L/\ \3110 ?\*_\ !O\
MT*6A?^"V'_XFC_A7_@W_ *%+0O\ P6P__$T44 '_  K_ ,&_]"EH7_@MA_\
MB:/^%?\ @W_H4M"_\%L/_P 3110 ?\*_\&_]"EH7_@MA_P#B:/\ A7_@W_H4
MM"_\%L/_ ,3110 ?\*_\&_\ 0I:%_P""V'_XFC_A7_@W_H4M"_\ !;#_ /$T
M44 '_"O_  ;_ -"EH7_@MA_^)H_X5_X-_P"A2T+_ ,%L/_Q-%% &CI7A_1M"
B\W^Q-(L=-\['F_8[9(?,QG&[:!G&3C/J:***XJOQL9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>mdt-20250425_g6.jpg
<DESCRIPTION>IMAGE 6
<TEXT>
begin 644 mdt-20250425_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MS_H2_@I_X*-3_P#EA7Y?44?\03X%_P"A92^Y_P"8?VEB?YV?J#_Q%F_M&?\
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MG^VM_P!%H_\ +0T'_P"0J/\ B)3_ &UO^BT?^6AH/_R%7PO11_9>"_Y\Q_\
M 5_D',S[H_XB4_VUO^BT?^6AH/\ \A4?\1*?[:W_ $6C_P M#0?_ )"KX7HH
M_LO!?\^8_P#@*_R#F9]T?\1*?[:W_1:/_+0T'_Y"H_XB4_VUO^BT?^6AH/\
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M8U/O7^1].?\ #USXB?\ 0%\%_P#@)<__ "11_P /7/B)_P! 7P7_ . ES_\
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M_F'_ !&#C/\ Z&-3[U_D?3G_  ]<^(G_ $!?!?\ X"7/_P D4?\ #USXB?\
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M9^#O@W)9Z)J]W80/-I.I-(\<4SQJ6(OP"Q"C. !GL*YS_B+-_:,_Z$OX*?\
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M&I__ "PK\OJ*/^()\"_]"RE]S_S#^TL3_.S]0?\ B+-_:,_Z$OX*?^"C4_\
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M_P#*1CP7_P!DXL?_ $YZI7Y?5_H!X)_\D+EG_7I?FSXS,O\ >9^I]R_\$_\
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M'1_BYI^I?%C;\0OAUXNN/#>D>&/^$7N?^*GMX+H027OVM7:&UP!(_E.6)\O
M8[@:\-K];/BY_P HL?\ @H)_V7E__3Q:5]>?$?\ :_\ &6C_ /!8CX ? 6"3
M13\,/'GP^CN?$NE3:3;SG77>QU# FD="Y5/LD055(&-P.X' ^FCXMX_!T:EL
M/]8E#VTI.=6,$HT,/AZT^10H/XO:OEC*[YMZG*TH8_4(R:UMMTONVNK\O^ ?
M@[9_#3X?3?LRW?BF;XF>3\1X=4%I!X'_ .$=N6^T6GRYN_[0#>0N,M^[(W?+
M[U]/_P#!7/\ X(H:I_P2T\*>$=?A\=I\0M#\27L^F75RNBC2SI=TL:RQ1,OV
MB;=YL?FL#E<"(]<BO5_BGX1T_P"'_P#P0P_:"T'28?LVEZ'^TK>V%G#N+>5#
M%;VD:+D\G"J!D\\5]U?$S0_#?_!0G]NO]JC]DWQU=M':PZQX5\?:#(79I(HX
M=-TF/4(HCG]WNC"*-I!_TN9NN37FYUXI9GA,QI8^C.7U.C/$.O!JG)NE%X2"
M<>6G&453>(<[7E)\KYIR5DJIX*$H.+^)I6WW][SZVL?F?\;_ /@AGJ7P&_X)
M;6/[1NL_$%5U2ZTW3-4D\'G02DEO%?W,<4(:Z-QD,(Y5<@P#Y@R=MU?!-?MI
M^WG^U=%^U]_P3)_;1UW39A)X8\/?$+1/#'AY5V^6EC97&GQ*T>/X))/.F'M-
M^%?4FG_#^S^'?Q@^&O@WP#KVM3?L]WGA6-1X$T;X2+K/A[Q9:26LI>XN=<WF
M-9)-P<[R"Q500YER_#E'C-G&59=4J<04_;5Y5JK2U@J<(4:%7V5Z=*=YKVO+
M%S23M)SJ12N74R^G.=J3LK+SNVVKZM=NGW'\T]?97Q-_8 ^%'PW^#G[*_BCQ
M%\1/$7@73/C;HNL:CXHUJZTS^W+?1I+38(!;6=NL4K+([K&P:1R-X;("D'ZV
M_9_O==^ G_!+SQ_XU_8O\.WFI^/KKXLWVD:Q?6VA#5/$>CZ KR&RC2"9'E*F
M/[)NRCE3/.2 RLZ<3_P<1:CXTUG]G']D.\^(NBVOA_QU>^'-7N-<L(+9;98+
MMVL&D+1* L;L3N= /E=F':OKJGB!C,WXAPF583_9Z;K5Z4G[2+K-PPU25Y49
M4W&,5)QE!N4TW&+E&TDG@L+&G2E4EJ[)[::M=;_?L8=K_P $$_A[K/[:DWP,
MTS]I5KOQ;HVCS:WKYD^'LUO'H]N+>UN83N:]\N7S([I2=CY3;R,Y \_U_P#X
M(9^(O ?[+7QP^(_BCQ@VA7/PCUG4=,T_1Y-#+MXIM[.>&%[U)?/'DQ,\RA?D
MDS@X)'->=Z+_ ,%??B5H7[;?B[X]0Z'X&;QAXTT >';VS>SNCIL5N+2VM-T:
M"X$@D\NUC.6D8;BQVX( T?B9_P %K?C)\7_A-KO@[Q!#X3U#3?$7@NP\$W<S
M6EP+@P6LK2_; ?/V_;)F8>;(5*L$3"+CFZ.6^)5*KAX_6XSART'5<E2YN92O
M74.6E%<K3Y5=7Y4N5\S<A<^#:?NZZVW^74\4_9,^%7PU^+_Q&O=-^*?Q7_X4
M[X?@TU[FWUG_ (1BZ\0?:;H2Q*MKY%NRNNY'E?S"=H\G;U85]'_M-_\ !*CX
M9_";]@FX^/G@']H;_A8^@MKD6@:=:W'@2Z\._P!K7);]ZL+75QOD\M!(Y*1,
MI\J09!5L?)7P0^#>O?M#?&#PSX&\+VIO?$'BO48=,L8L-M\R5PNYRH)6-02S
M-@A55F/ -?9O_!<SXJ:#\/O%G@#]F'X?W2S>!/V>M)73KJ2,!?[2UR8![VXD
MVG:S@D;N 5EDN1WKZ?B+$9E_K-@<#EN,J1YVZE6GRT735&GI)MNDZJE4FXP5
MJBWDTO=,*,8>QE*<5V3UO=_.VBUV-3X;_P#!"O1=:G^&?A#QA\?-"\%_&GXN
M: OB+P[X+_X1>ZU"%K>1)9(1<7\<@CA9EBDSE#AD=5WX!;R3]F'_ ()7WWQ6
MO?C!JGQ'\=:3\)O /P-NWTOQ3XDN+"35%6^$[0+:VT,;(9W+KC"L#\\8 )<"
MOUT\,:MX^^"G[3W[+'PU^'WPCM?BI\)5\'VEJOQ8O;&74-5TRWGB99Y+;5%/
MEV*1QK$XB/$BLL:8RF/D?P]\(/\ A8__  3I_;?^!_POU#5_B7XN\)?%8:Y$
MBEKO5M>TY+J",S=-US(#:SLQ3)=AE03(@;\=RGQ,S_$0J>VQ5HU'0M.U)^QA
M4Q4J4YV4+4[0Y4H5_:24FVY-*2/0J8.DFK1VOIKJU&]O/7M8^,/VPO\ @F+X
M@_9S^(WPQT_P;KUG\5O#'QLM8;GP)K>F6C6;:XTC1(86MY&+0RJ\T0*LQ $B
MY(.Y5]H\:_\ !&;X3_LZZ]I?A+XT_M<>"/A[\2KZ%)+GP]9>%[O6X=+9U#*E
MS=QRHD)*LIS*J @Y7<N&/TKH_P 4M(_X)R^&O^"<GA/XM(FF^(O"=WKFN:_'
M>@)=>&;/4Y94M_M$;_/$J&Z4L#C;]B?@E0!P?QL_X)J>-?"7_!5WQEXH\>?
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M),3W3!7# B+S1V#G!-?"MW\"M6\;:MXZU'X;Z'XR\;>!?!4LD]SKD6@RXL;
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M/YAQN(W!,@=0&_ 'X]S?!?\ 8L\5-H?B'3]*\6-XACDM;=W@DN9(F2!7989
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MC^VOX?\ %7QA_P"$1^)WP_\ "&I:+/JND^&KBZF\.:,]O;W,6OVUPCJS.WF
M_9(]LJM;J=^=I'P5^V)^P3_PAG[%7A;]I=?BWJ7Q*C^*/C;5]"B?4-'EM[J]
MCMKF\C3499YKB21GG6V$AC= R&7!9BN3%'-*=2NZ?V=$G9ZMJ_:UK#Y3Y$HK
M]-]6_P"#<:;P_P#M??%?X>WOQ>D_X13X0>&M-\0ZOX@LO!-SJ&I7)OM_E0V^
ME6\\DDNT1REF64D!5^7DX;^S!^QQX@^!>M_M6:-\$_VF=&U#PUX5^#USXGUJ
M_L/!T5P_B*U6WFDDT>YANV+Z=<KAE<HSO&7 8!U9%IYMAW&]-WT3VDE9VMK9
M]UIN*Q^95%?<OPG_ ."0W@O2?V9_A[\2?C[^T'H?P)A^+C/)X/TM_"]UK]U?
MVJE0+JX\F2,6T)WHP9MRA'0D@DJ.U^%G_!O#X@UK]K;XO?"WQU\4?#_@6W^%
MOA>/QE#XF&FF_P!+UG2Y&)6YR9HC"@0.7)W[6C<?, '-RS3"QO>6WD^CL[::
MV;L[7"S/SEHKZ[_;H_X)A:#^S1^ROX ^-WPW^+EC\8OAAX\U2YT./4QX=N-
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MQY6G%JG.4.:+CIRRMS*W1DUZ4J<N6>]D_O5S-\7?\B]<?\!_]"%<37;>+O\
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M(KUS3/C1\.;/]H1O&*^(O#HU76+AO#4\@OX5BM[>'SYOM98M@K(B6L0;IN&
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M(@V0OS8R#X[7LG[!_P"Q1XH_X* ?M'Z3\.?"MQI^GW%Y%)>WVHWS[;?2[.(
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M:_MO)N#;%Q+)&EO$DID (SYP# EJX7_@N?\ ME?"7Q!^RII.A_!?Q-H^K/\
M'[Q0OQ(\90:9J,-Q)ILD>GVD*6=U&A+PN\H64QR!6$D$A(R37Y,T5YN6^"V5
M8/.(9Q"K-RA5J5%%VY>634H4_P#!2J+VE/JI-]"IYC.5/V=NB7_!^:T9^XWC
M#]KOX1ZQ_P %S_C%??\ "TO $/AGXA_!B;PAI?B0ZW!)H@U"5;5Q'+=HS11@
M"&3)9AR OWB ?D>\\7Z#\!/^"%_Q=^$*_$KP'J_C!?C.I:ST#Q%#=?VW8)9:
M?FYMU!62>T,D7$@386C/.17YXT5OE?A'AL"L/3AB9.%+ZMHXQ]Z6&OR._3F3
MLUKKJ@J8^4KMK>__ ),?<W_!>CXQ^&?C9\<_@OJ7ACQ5H/BZ.Q^$&AZ?J5UI
M>IQ7XM[U+B^:6"9XV;;,H=2R,0PW D<BNK_X)I?#;Q1\-OAGX;\;?"_]N#X3
M_"+4-4O))/$_A7Q)K3Z<NGJKA _V2X5H;^8Q*#S&BCA5E/+#\[J*]V7 :CP_
M1X?H5[0IZ-RITZBG'WO=E"<7&UW=6L[I=+IX_6OWKJM:OS:_(_9?QC^VA\"/
M'W[4O[=6M^#?$/A'0M'\5?!B_P!$L;N:[BTZ+Q?K/V6997M(Y"IEDD=E0! 6
MD*;QNW@GS3XT_M2>%?\ A&/^"9]OI'Q$\/;? <EG)XGCL]>A_P"*>87.EAS>
MA7_T<B-9@3+MPHD[;J_+.BO P?@]@,-4I2A7G)4TDE*TFTL-+#:OORRYMDKZ
M))&TLPFT]%K_ )\Q^K5Q^V!X=UG_ (*#_P#!02\O/B/X9F\+^.?A/XET_0KJ
M36;;[%KUW'#;06$%K)NVSR^6TRQI&2S#=@$@UU?Q\_9FC_:D_P""._['.B_\
M+N^'7PGFLK#4+Q+#QIKQT?3M;431*TZRX*M-;;AM4KDK=/@C&&_(WP9X*UGX
MC>*;'0_#VDZGKVMZI*(+/3].M7NKJ[D/1(XD!9V/HH)KUK]IW]KKQU\8/@W\
M,?A%XPT'2M"M_@-'J.D6$265Q:ZD'GEB^T)>B61AYB/;JN%2,J=P()Z>?C?#
M.I1QV 64XA0E1E3E)N,&XQI8:I0C)0>DN9N*?97<6FE:HXR\9>T6]^_62>Y^
MJG@7]NOX1:]_P5NU2^7XI^']1T/P7^SZ_@*Y\9:SJ%O86WBC5H;E)'ECE<HD
MKR>9_!PQC<H"@!KS;]D'XN_ ']JC_@E_\)/AGXG'P?3Q-\*M3OCJ&B?$#XB:
MGX+M";B>65=1MIK8[;J0J^"K@F,M(%* X?\ (>M[P9\*O%'Q'T[6KSP[X;U[
M7K3PW9-J6KSZ=I\MU'I5JOWIYVC4B*(=W?"CUIUO!K+J&'C[/&5*3A['EFI<
MC4J4:L+MQ</C5:2M%QL[*.ETQ9A-O6*>_P"-G^%C]D-=_P""B_@?QA\9?VZ-
M>TWQ]X%T/4)OAA;>'?#.KZ;K7V-O%%[;VMXHDLVF999IU:18@8RY/E(RLP*D
M^#_\$Y_A'^SEXE_85\/W_BGQ;X UCQO'XFN+[6O#GCOXJW_A"Q\/A3Y<5Y8V
MMH ]S.T"0DN"3GY=XV[1^9-%=]'PCP^&P<\'@,74H\SHOFB[2M1I*DHN47&5
MI?$[.-I:+W;Q<_V@W+FG%/?\7<^W/^#A'XG^#/C+_P %,/$7B7P+K_AOQ1HN
MJ:/IC/J>B7D-Y;W,R6RQMNEB)#.JHB$$[@% ., 5]%_\$P]%U/\ 90N_AOXH
M\._MW?!W3?A7,MMJ?C+P;JNMO!<P OYEU8V^F7*G<[\QF=1!)EBP4X ;\H-'
MT>\\0ZM:Z?I]K<7U]?3);VUM;Q&6:XD<A41$4$LS,0  "22!6[\5/@QXP^!?
MB*+1_&WA/Q+X.U:>W6\CLM<TN?3[B2!BRK*(YE5BA*, P&"5(SP:[\=P#0J9
M!A>%%B[0ITU"TH4IN<8QY;\LT[..ZE'9[W6A,<4U5E7Y=W?=JWW'Z\_\$VOC
M%\(OV]_VL/VE/@3'H*V_P1\;:]'\1_#UN+40V]M)I]U:_:7*,!Y,=TJ1$HR@
M*@9"!G:>+^#/_!2C0?C=XV_X*"?$#4/&VD^$[GQKX+DT[P-#>:LNGW5W#!!=
MP6D5HDC*YF,8B8I&-P>4G +5\-_ K_@I+XR_9M_9:\7?"[P;X;^'^C_\)Q!<
M66K^+8]'8^*+BSG"K):"[,FT0%5P%\OY=S,"&.ZOGFOFL+X0TZV,QLL2W"E-
M484TY<[M3=*52H[I)2K>QI*75\CD]9&LL>U&-M7K?IO>R^5V?J!\//VP_AW\
M(_\ @F7^Q5<ZUK7AWQ'JGPT^*UQK6N>'8]0AN-5TZQ6]O9!*UL&,B *4=-RA
M6.SL17,_\%-O@/X=^)WCCXX?&[0?VMOA?X@\.^.&AU;2O#,.ORRZ[K4;31O'
MIEQ8QC=$ML !%YBL!Y,6X1?,Z?G+17T^#\-88/,?[2P>)E"<IU927+"2<:M;
MV[@E)/EM+126MM]5%K"6,<H<DEI9=^BL=4_QT\;2-X49O&/BIF\!LK^&2=6G
M_P"*=99%E!L_G_T<B15<&+;AE!Z@&M>U_:U^*MEJMI?0_$SX@PWUA?WFJVUP
MGB*\66WO+P.MY<HPDRLTXDD$L@(:0.P8G)KSZBOT">68.:M.E%[[Q76]^G6[
MOWN[[LY>>7<]C_X)]:)X%\1?MH?#JU^)7BK4?!'@O^UDEO\ 7+&[-G<:<T:M
M) ZS@$PYG6)3*,% Q;*XW#]3/C??_L\_!;_@G3^U-X5\+^(O@79ZMXWM[6[L
M+/0_BM<>+[[Q(\%V9(KB5;LA4N@S;]MN&;(RQ.Q"/Q0HKXGBS@!Y[F%#&SQ=
M2G&FZ;]G%^Y)TZBJIM72;;23YE*R2<>5W;ZL/BO90<>5.]]?56/V0^(?[7W@
M>_\ ^"Q/[%VKP_$[PE-X'\&?#;3X-2OT\16[:7H=Z\&HQW,<THD\N"9E%LKJ
MY5L>6"/NUQ?A#XN_#W]IG]G;]KKX"6/Q<\#?#?Q-XM^+^I>,]$UK7]76Q\/^
M)M--S&HMQ>KN3;^Y\P#D,)$*AEWE?RCHKPZ?@_@Z=.DJ.(E&5*-.,'RQ=I4J
MTZT9---.\IM-/IJFGJ:?VA)MW6]_Q27Z'Z2?\%5=5\)^!O\ @EE^S7\+=,^-
M'@?XP>*/ >I:G%JL^@:VFH+9*^7CB0;C+]GB5A#&[*H98AM51A%_-NBBONN$
M^'%DF!>#]JZCE.I4<FE&\JDY3EI&R2O)V26QRUZWM)<UK:)?<K&;XN_Y%ZX_
MX#_Z$*XFNV\7?\B]<?\  ?\ T(5Q-?RW](C_ )*.C_UXC_Z<JGT62?P'Z_H@
MHHHK\%/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K] /\ @A?_ ,U2_P"X3_[>U^?]?H!_P0O_ .:I?]PG
M_P!O:]GA_P#W^G\__26?D'CU_P D)CO^X7_IZF?H!1117Z6?YQ!7I/[*?QMM
M/@-\6H]6U2UFOM%O+.?3]2MX8U>2:"1<X4,RK]]4)R>@->;45RXW!T\50GAJ
MRO&2:?S_ %['HY1FF(RW&TLPPCM4IR4E?573OJNJ>S75:'UEX,_X*+:=HWCO
MQ_JFH:5J=U::O<I>^';<)&WV*:. P(9,N @9!'G9NVG=C/4^2^&OCWI^G_LN
M^-/!M]'JEQKWB;58=0CN0J-!A7B9_,8ONW'8W13R1S7D]%>/A^%<NH-NE%K6
MF]_^?5N7\M>[U9];CO$S/L9%1Q-12M&O'5+;$7]I\];1_E5DM#Z8U']KOP1K
MOQ;^'WCNYT_Q5#KWANWBLM3MXTMWM'A2*8%H<N'+F20?>*C;GOUY7PK^TIH6
MAVGQJCFM-69OB/YO]F[(HSY&Z2=AYV7&WB5?N[NA]L^(T44^%\#"'(KVM%;[
M*,^=)>DOPT"MXD9S5J^VDX<W-.3:BE>52E[&<GYN'XZG4?"'5_"FB^,HY?&>
MD:CK6AM$Z/#97/D31N1\L@Z;L?W=RCD')QM/I7CCX]^!O#G[/^K> /A_IOBI
MK7Q#>QW>H7FOR0>:OELC*L:P_+R8UYXX!ZYX\-9E12S,JJO)). !7SSXO_X*
M%:/X5N_E\.WEY8R3>5!<"]6-I!G 8H4. >O4G!KDXBQ64X2M2KYG6<=4XQO)
MQ;@[I\J3V;6NB;M>YZG >6\49IA,3@^',+"I:,HSGRTU-1JKEE%3DU=22:MJ
MTN:UKGZ4:M^VSX5O_CQKWBA-/\0#3]4\%OX<BC,$/G+<,ZL&8>;CR\*>02?]
MFO)]9^,FEZC^REI'@5+>_&K:?K\FJR3,B?9C$T3H &W;MV6'!4#'>O#?A'\5
MM/\ C!X9EU&Q62!K>18YH)""R%@2I!'4':PS[5U%7DN5Y55H4\3@).4$XM.[
M^PI16^NEW<RXNXDXFPV-KY?G4%3JM34X\JVK.$Y6:;6O+%IINR/M?]GSXVZ/
M\;OVN;[6M.L]02QL_ CV4T-VJQR2-%)'OQL9AM.>#G/L*\>U'X\_#WX=?"3Q
M5H/P[TCQ2NH>- EO?76N/ 5M+<$DQQ",G=]YAE@#\V23@"O&?#7B[5O!E[)<
MZ/JFH:3<31-!)+9W+P.\;8RA*D$J<#(/!P*SZC#\)4*==R<G[.U-*-W;]VVU
MS=];->FIKC_%''5\%&G&$57<J[E4<8MI5E&+]F]X7BFF_/2S5SZ2N/VX]/T3
MX]>$_%FCZ;J,UAI7A:#PYJ=O<A(9I0KNSM$59AP2A4G&=I! SFH/VB/VP-)^
M)'PFO/#>CZE\0-2DU2[CEN)-=:TCCBA1MXB581\XWA3DX.5'.,@_.E%=%/A/
M+85J==0]ZG:SOV;:OZ-]+>=[(\^MXH<05<+B,%*JN2OS<R2M\45&5O*225G>
MVK5FVW]$>+OVL_"/B3]LBT^(,WA^_P!2\/PVR0M:7D,7VA'6(H)%3<R%E8@C
M+=NQP1J_&S]L_P -_$'X ^(?"-K=>.M6OM4N+>>VO-:@LXUB"2H[1[;<J%4!
M#C"L26[ "OF*BE_JEE_/1G9WHJ*CKMR.\?QWM:_7H5_Q%'/?98NCS1MBG4E4
M]VUW5CRSV?;X;WY7\-KNY1117TQ^=FAX2\4WO@CQ1I^L:;,;>_TNX2YMY!_"
MZ,&&?4<<CN.*]Z\8?';X,_&W68?$7C+PKXPT_P 2R*IOTT2>$V=^ZC&6\Q@R
MYP/N@'W.,GYUHKR\=E%#%5(UI.49Q32E&3B[/=.VZZZ[/56/I,EXIQF6T)X2
M$85*4VI.%2"G'FC=*23VDDVKIJZ=G='O'PZ_:F\*^#[OQ3X9N/!]Q<?"WQ--
MYW]DM>&6[L7"J!*DC8)8[%."V5(7#_+\U^W^/?PI^&7PF\;:%X)TOQU)?>,K
M3[+))K#VWEVX 8+M\MB<+O;J"3GDU\\45Q5.&<'.7->23<6US2M)QM9R3>KT
M5WN[:W/8P_B+FU*FH6IMQ4XPDZ<.:G&IS<T(-)<L?>ERQVC=J*2T/H32OVQM
M/\,Z]\'[[3[75E_X0.P;3]71T11=QR!5D$6'^;Y0Q&_;\P7\+R?MK:3?_M$^
M-O%E]9ZQ_8^M>&IO#VD6T441EM5)B*;QO"A24D8X9B"^!D=/FVBHEPGES;DX
MN[BXWOK:4^=_^3-Z]M#6'B=G\8QA&HN53C4M;3FA25)?+D2NMFTGN%%%%?2'
MY\%%%% 'X_?M,_\ )R'Q _[&74?_ $JDKB*[?]IG_DY#X@?]C+J/_I5)7$5_
M:65_[G2_PQ_)'^E&1_\ (NP_^"'_ *2@HHHKN/4"BBB@ HHHH ^N/^"&/[0'
MA7]FK_@IU\.?$GC2XT_3]!D:\TV34KPA8]+DN;26&*8L>$&]U1G. J2.20 :
M[#]LS_@C!^TQ)^VWXQT_2_AOXG\:V_BK7KW4]-\0V$0ET[4(9YFF666Z)$4#
MD.-RS,AW;@,C!/PO7I_AG]MOXS^"_!D7AO1_BY\3])\.P0BWCTNR\4WUO91Q
M 8$8A64(% XP!C%?G^<<-9K'.WGN25:<:DZ2I3C5C*46H2E*$HN,HM-.<E*.
MTE;6+5WU4ZT/9^RJ)VO=6_'\C]'3^R[XV_:Y_P""'NB? OP38B;XQ?L[^.[V
M7QCX)-S%%J$JRSWS)*BEMLFU;M=K [6\F55+,H4\?\6/V"O FB?\$3/%WQ*U
M[]FOQ-\&/BUX)FT71TU/7-:U9KCQ [3V<-UJ LK@QQP+,SS?NO+94S\K8VFO
MSA\ ?%3Q1\)_%2Z[X5\2:]X9UM0RKJ&E:A+9W0#<L!+&ROS@9YYQ72?%/]K?
MXK?'/15TWQM\3OB%XQTY65Q:ZYXCO-0A##D'9-(RY&3@XXKYNGX?YYA\7%87
M&QC0^L_69<OM83;E-3K4VHU.2=.;NHJHI<D96]ZR9L\52<?>CKRVZ-=D]KIK
MR/W(\6:YIO[2/QE;]DWQ/J%O9Z3\:OV>- O?#\]SB2/3]:L_M4D<J194NVU5
MF(# D6('<D8/Q<^.^D^//AS^W5\-?"+^7X!^ OPKTGP)HMM'(6ACDMHM06Y8
M#LXD'DL>2?LRG-?B3+^TK\1I_'^B^+)/'_C9_%/ANU2QTG66URZ.H:7;HK*D
M,$^_S(HU5W 5&  =@!R:IZ-\=_''ARS\46^G^,O%5A;^.%*^(XK?5KB)-?!+
MDB["N!< F20_O-W+MZFOE:/@15I\K6)5HJE)1L^55HU:4JE5+O*C2C379N3>
MYT/-$^G?[K.R^]W/8/\ @EOJGQT\-_M;Z;K7[/6CW&O>/]#L;F]>Q5$>"XL0
MH6=)U=T5HSO48W!BQ3:=^VOOCXZ^'K;3OV')OVK]:^ $?[+WQ\^%?C/2Y-&@
ML[:XT6T\9NUS!YP;3Y51EC99)V; +,L3#S&4NM?DCX+\<:U\-_$]IK?AW6-4
MT'6M/8O:W^G74EK=6S%2I*21D,I*DC((X)'>NVU_]I+Q1^T!XZ\-_P#"Y/'W
MQ*\:^&K&_B-Z;K6Y=3OK:T9U%P;7[5(R+,8P=N["E@N[BOON*^"<3F6;TLQI
MRA"$.7G<5/VLX1<G.C*TU"I"HGRVG%\O-)I-M-<E#$J%-P=[]-K)]^Z:/V"_
M:U;P5^RA\(?C9^VEX)OH[>]_::\&Z5H_@N%)!%<Z9J.I(QU,@*,+*J6\<Y/)
M$D<PR,UT6@Z?XZ^+W[!M[\.=&\/^+O@9_P ([\&@M[X9\9>"K2]\#ZL@M 7O
MX=37]Y#?,'#?Z1(SQLK%X'9'-?F'_P %%_VZ/ WQV^%'PG^$7P;T7Q=X=^$/
MPEL;@6<7B.6'^TM7O[F0R3W=PL#-%NR6(VG ,TN @8*/#)OVK_BE<_"]? \G
MQ*\?R>"UA%LN@-XANSI:Q 8$8MO,\K:!QMVXK\URKPBS'&970JUYJ%:-7FBZ
MT>:4*--1IT(N-Y0<E3CS233DIU)-3B[W[)X^$9M+:W3JWJ_/?\MC]<_VZOV@
M?B%^T7^QW^Q.WC#6=4U;X0_%!]/;XOZJFGQC3FVZEIHWW5S'&%M"',X 5X@2
MK#G;@?27QM\*6MAX]^,'@_QQJOBK6OV?]-\&W?E^ +'X.FST'0+2*")H[RSU
ME&(FFB"LZB+Y]S$JBF(;?YZ(OC[X[@^$TO@&/QKXM3P+-*)Y/#BZO<#29) X
MD#FUW^46W@-DKG< >O-:NI?M;?%;6?AFO@N\^)OQ"NO!JPK;C09O$5Y)I@B7
MA4^S&3RMHP,#;@8KJQ'@7B?94</A,13I0ISK-*-.*TJ58U(S5XOEK0BE34H<
MLN6,%&<4G%J.9J[<DVVEU[*UO1[_ *'ZU:1^V]X^_9&_8V_X)UZ+X'O-/TV'
MXB7DUCKLTNGPW$UW9QZA9QFU#R*2D;B\<L4*ME$PPP<^A>.?VD]9_: _X*%?
MM=?LV^)-.\.W/P;T'X<:GJ6G:!'I-O$MIJ$4%G-]M$BH)#,TMS+)N+9#;",%
M 3^'>H?'3QMJVF>%;*Z\8^*KJS\"LS^&X)=6G>+P\S.CL;-2^+<EHXV)BVY*
M*>H%7(?VE/B-;>/M:\5Q^/O&T?BCQ):O8ZOK"ZY=#4-4MW"J\,\^_P R6-@B
M J[$$(H(X%=U3P.I2E/$)T_;25=J?*^95*F)]M3J7WYJ<+TT]U=V:39/]I/1
M:VTT\DK-?-ZG$T445_01Y(4444 %%%% !5;6?^0/=?\ 7%__ $$U9JMK/_('
MNO\ KB__ *":\O//^1=B/\$__26:4?C7JC@****_S//O HHHH **** "BBB@
M HHHH **** "OK#_ ((X?\%"]#_X)N?M6:EXO\4:#K6O^&?%'AF]\*ZJNC7(
MM]3LH+AX)?/MF9E'FJUNH'SH<.Q# @9^3Z]I_8=_;J\6?L#?$O5/$OA71O!/
MB!M<TN71M2T[Q1HD>J65]:2$%XF!*R*K;1N".H8##;AQ7/C*7M:,J=KW6U[?
MCT!;GV#\9_\ @EOX/^-_[,_@_P =?LT_'#QCXP^#.M?$.P\)ZMH'C"%[:Z\+
MZU?O! +IT7RX)FVW-NKO'&IPPQ(XW;/L37_^"#7P5;XG>(O@[_PI6Z\,Z#I^
MAM#IGQMOOBM:S:A<:JMNCJ\VABX 6)I2R$>2I^7H@8,OY=_M<?\ !7[XF?M7
M_"SPYX#MM#^'?PE\!^%]4_MNS\._#G0SH-A]O&2ERP$COYBEG8;64;F+$%@I
M';>+O^"]_P 5/'OA/6%UCX?? ;4/'7B#0)/#FI?$&?P3&_BF^M9(?(?S)S)Y
M+,T?RG,&,<8P *\*I@\QE&/+.V_75;6;:LFUKNFO)[E:'U!\<?C%\,;+_@U]
M^#[77P=M[R/4/$EWH.G+_P )1?1_V5KJVE^DFO C_6L\J2R_9'_<KYVT<(*_
M'^OH_P"&?_!3KQI\/OV'=<_9]OO"_P .?&G@/4[JYO\ 3I/$FC/>:AX8NYX6
MB>YT^5946&8!W979'*L[$<,0?G"O5R_"RH>T4NLFUJWH_7;S$V%%%%>@(***
M* "BBB@ HHHH **** "BBB@ HHHH _8G_@[-_P"4C'@O_LG%C_Z<]4K\OJ_4
M'_@[-_Y2,>"_^R<6/_ISU2OR^K^\O!/_ )(7+/\ KTOS9\;F7^\S]0HHHK]2
M.$_HN_X*;?%K]HKPA^U;J%E\-_VO_P!FKX-^%UL+5HO#7C36=,M=6@D,?SRL
MD]A-)L<\J3(01T K\B?V5?\ @FQJW_!27X3>(?%'P_\ '%KK/Q>L=?@&N^#+
M_35LC]CO+C8=4ANEE82Q([AI4$*&,+)UQ&)/H#]NG]MK]A+_ (*"?M!7GQ(\
M9:?^UMIFN7UI;V4D&BP>'H;0)"FQ2%EEE?<1U^?'L*\]_99_X*@?#/\ X)N?
M!OQ$WP)\/^,;[XI>*?%:2W6M^+;2S$-KX;M[II(+!##*^9IHE19V$<8W2R%3
M^ZB(_EC@G)<^R/AJ-#)L(Z68-4(N^'I4X-Q;YU5J*\JD+-MSNIIVY7>33]S$
MU*56M>I*\->K?I9='^![W_P3(_X)[?LY^&_VI_C]X/U+XI:'\7+SP9X%U6TE
MBU+X>"2RT]D>U^T:O:2//,CO:R'R5"[)',DA0A!EOF#P)_P2U^'][\)=:^*W
MC+]H"S\%?!63Q&_AOPEXED\&WE[J'BV5%9GF33DD$D$0VN,L[',;@@8!;T;X
M7_\ !3;]GGX%?\%'?'GQ.\(^"_B/8?#/XO\ @V_\/^)=$6WLH;[1+N]DBEGD
ML )VCDB+P*0KM'M,KX&U52NF_8]_X+6_#S]FWX$:I\&8=0^/'A7P#X?UZXU#
MP9XE\,#2'\1M932-(]KJ$%R&M2?,=WWQ$GY@!C:2_H5(\<8:K6QV"]O.5:.&
M<E-48N*49*KRI49QC4C/E5E3FG"4I*,K1:S7U9I1E;3F[_+JM+>9Y]\.?^"#
MVL>,_P!O35O@K??$K1]/T_\ X04_$#0/%<.EM<V>N:<TD4<+F(S(T*LSN&8L
M^WRC@."#7#?M*?\ !*[1_!/[,FA?%GX-_%NQ^./A74/%0\%W_P!D\/3Z/<V&
MILH:*-8Y9',B/E0&.P_O8B 0Y*^Y>#/^"W?@>U_X*5>,/B]KEA\4-3\'WOPV
MF\!Z'#>/9WVKHS212B68;X8TC:47$C*KR%6EPORX5/G[X/?\%"-$^$'_  2S
MU+X/:?:^((/B-_PM*V\?:9J26T#Z9;Q06]HB!F:3S/-$EN3M\HJ1CYN2![^7
MXCQ =>A7Q+=DL,I4^2GR2YU45:4I*'.G"T&^244FW:+3LLY1PEFE_>UUOI:W
MEKJ?7O["G_!*#P+^R)_P4G^%/A_Q+^T5X6E^.'AZ\M=;O? EKX?N7MU/EF4V
MRZEYGE^?Y1WJC1JS#:< ,I/@GC'_ ()W6/[1'Q[_ &G/BUX_^)&F_"7X3^#/
MB7J^D7.N3:3-K%S>7\NH2,MO!:0LKN0LB,QW# =< C<5]9TG_@J_^R+XK_;7
M\/\ [37BSX<?&RU^+D*VTNJ:3IEQI]QX=^V1P+;_ &R(R2I.[K&J[4/EH2BD
M@'<QYW]D+_@N/X?^!NM_';P[JJ?$SP]X)^*'CO4/'&BZ[X0^PKXBT::YF&8Y
M(;HO;2*\*1!AN.TJV"VY63Y:BN/(U:N9PIU98GV-"$W.-&'++VLG6C0Y83C*
M,4[PE.%25FW[[LC9_5;*#:Y;MK?MI?7[[-?(\NU'_@B'XN\2?M4?"WP/X!\8
M:/XR\%_&'1#XE\.^-7LI=/MO[.C0/<R7%LY:6&2(,@\LDY,T0W*Q8)]/?L7_
M +)WPJ^ _P"RC^V5J/PR^/FC_&1K?X8:KH^K6]OX=GT=[&012LDL1DDD6YMW
MV2 2QG:2HQD,#7F7C?\ X+UPZ7_P4!^&OQ(\-P_$3Q9X#\#Z#/X>U"R\87EF
M-4UR.[ %Y<8MT\J"1S';OL1BA:W4 (K,*H^"?V^/V//V9?@)\>_#/PE\&_':
M/6OC-X5OM$ANO$8TV:#1S+'(L-K'Y=QO^SAI,M(YDE(C3ACDUTYS3XYS# 4L
M+F,*GO1HOEIPI.,I+$-S]O)QC*$HTHTY+V:IQ<N;3["5/ZM"3E"W7>_;2WSO
MO?\ 4\E_X-__ /E+W\&_^OK4?_37>5Z5??\ !+[PC^T!X?\ CM\>/'GQLL_A
M5X5\,_%_6O"]\D_AB;5W/[Q)DEB$,RO)(TERB>4$&%5G+\;:^:_^"7_[4WA_
M]BG]NWP!\3_%5GK.H:!X5FNY+NWTJ*.6\D$ME<0+Y:R21H<-*I.7' /4X!]5
M^*G_  48\$^./^"?GQ>^%-II?BJ/Q%\0/C+=_$33[B:V@%E#I\J0JL4K"8NM
MP#&V55&3D?.>WV/%66\0/BGZWE'/3A4IX:G*I&,)-15:LZME.,HWC&47=Q=K
MK1['/0G2]ARU-;.3MKV5MCZ=_P"">/\ P32\-?L0?\%KOAYX>\3?%+3]<FDT
MB+Q;X#^S>')GC\907-I?(2Y\PK8O"8))06,@?8F"&.!XW^W;^QG#\>?A=\>O
MVB[?]H'7OBI!\-_$]MH*QZMX>N+>24W-S%OMHWGN6:&*V>[=558RC;"5"AN-
M35O^"P'PTO\ _@IQ^SG\:$T/QT/"_P (?A_:^%-8M39VO]H7-U%;ZC&SVZ?:
M/+:(M>18+R(V%?Y1@ \-^RS_ ,%%/A-I?P%^/'P=^+^@_$&;X=_%OQ%'XELM
M0\)?9!K-A<1W"2JCK<N(=I$4/(+8PXPVX%?D\/E_&-/,*7$-=5)5E2PL:BY*
M-W%8BI[>,5R)J7L[3:C).\W;10C#>4L.X.DK6O*VK[*WXZ?+U+7A7_@AWJWC
MOQ[^S3H.D_$&SDE_:"\)S>+9YKC1S$OAN"&UCN)(U43LUV^)-JA1&20"0%W%
M>P_9U_X)\1_ G_@HY\#-(^#'[1\:>+_%=QJ\::A>_#^2QUKPC);V4Q9KG2+Y
MSE)XS(B&1ER"S*#MS5O]H?\ X*H?LY_%GXO?L\MI7A#XV:3X!^"_A>\\.HMC
MJ\.DZYI[M%#%:W-M<PSL97B$98AGAW,0264,C=GK'_!=7X41_M#_ +.&L+I?
MQ<\9:-\%;K5KG4_%7BR#3IO%VJ)=V<\$=NODRI"T:M*A8O(&81(3E@2T8S'>
M(&*PO)4HU)*I0Q"E3E3H<O,_K/L^=.,U-V]C'V=X)W3:JJ4[.,<+&5TUHUK=
M^5[=NNOY'@'A?_@F6/BW/\9_BM\8OC)I?PY\ ^$O'%_X<NO%-QX>DOKOQ)J_
MGLT@M]/@=?O;MY",0NX@ A&*Z%O_ ,$2'UO]J_X(^#M#^*VD>(OAK\?+6^NO
M#'CK3]&D((L[9YIXY;%Y59)%950H9>-YS\RL@?X"_P""E'PA^)OPJ^+'PC^-
MGA?X@:C\,/%WCZ\^(/A?5/#4MLNO>';R:1QL,,[^0RM"[ C>0IDEP&+JZ=MX
M2_X+*?"_X7_M2_LWP>$/!OC;1?@'^SK#J8M+25K>Y\0:W<W]K,DUW-&)4MPY
MFDW;1)@;Y6!&X1KZV+QG'M.5:&$C-2C"KRQ4*/LE%8=NC*#MSNLZ_*G"5X6Y
MER**4GG&.%=G*W3J[[Z^5K==SS[]H;_@COX<^'W[/?Q3\9?#GXZ:)\5=8^!^
MI0:=XYT.W\.7&FMI7F2M#OAGDE<7 617!(55(BE(8E0&YK_@AIX\^$OPX_;\
MT?5/C!+H-GH\6F70T6_UR/S-,TW5_D-O/< D*%51* S<*[(V5(#+H?"__@HQ
MX)\$_"']M#P_=:7XJDO/VB[RWN/#;Q6T!BLECO;Z=OMA,P*';<Q@>4)>0W0
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M 4444 %?H!_P0O\ ^:I?]PG_ -O:_/\ K] /^"%__-4O^X3_ .WM>SP__O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)J[5TT]-FCEQV3T8TG.EHUJ>L4445_?!\N%%%% !1110!F^+O^1>N/\ @/\
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M2V-S;S21R&0-Y;#YU<*&'(X8;!AN<9/!KZA_X)92K=1_%B18UA232"RQK]U
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M_P"X3_[>U[/#_P#O]/Y_^DL_(/'K_DA,=_W"_P#3U,_0"BBBOTL_SB"BBB@
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MHKE/J HHHH **** "BBB@ HHHH **** "BBB@#]B?^#LW_E(QX+_ .R<6/\
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M,GN<Y]J=^SY;6UA\2=1CL[G[7"-*D(DV;,DF/(Q['BO0X"DZ/%.7/JL11_\
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MV1X;"0^%T:*?KR1/OK]BCP^OAO\ X+._L>Q+"T/G_"/5[EB3GS&DMY7W>W!
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MI_P2L"K\/OC0?FWM\5M7^@ V_P"-?<>']_[?P]N\O_2)'Y3XZ-+@;'W[0_\
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MP'9S6GB6Q$D3KF=1R, U\GFE1*M47I^2/-Q,6ZJ9[_\ $^R9_ JLWWHVC/\
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M_@/_ *$*XFOXU^D1_P E'1_Z\1_].53ZC)/X#]?T04445^"GL!1110 4444
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MTGAY_P C_#_]O?\ I$C\C\>/^2%QWI3_ /3L#Z8HHHK^HC_-D**** "BBB@
MHHHH **** /Q^_:9_P"3D/B!_P!C+J/_ *525Q%=O^TS_P G(?$#_L9=1_\
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M$2F' ,@7Y@#QT# ''J!Z5]$?\$PM>O/%'_"W+_4+B2ZNY]&7?*Y^9L6EZH_
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M^Q:A]MC28HBE=^YL814&"<XY.223Z)7R<E*+Y9:,_2(R4E>.Q5_LS_IXNO\
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M?_2J2N(K^TLK_P!SI?X8_DC_ $HR/_D78?\ P0_])04445W'J!1110 4444
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ME1E:Z+D94["<[2?E! /)[5]Z?#[]C+X,_#WP/!:I\+F\7>)(8469-0>=_.E
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M]K_'I\MN:_?KX:_"'2?A:+_^S=1UV^-\07_M'5)K[R@,X5/,8[1R>>I[DU^
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MCW/UT_:1^,ECX5T&XA6XCEN@C'RU<#8!U+'^$#OFOPX_;H_X+-P:;XKO='\
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M$_MKQ9K=[R 8-$\+W$A<^@EN&B0?C7JO[)W_  2J?3OLM]XV^*GB1K?RP_\
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M#LW_ )2,>"_^R<6/_ISU2OR^K]0?^#LW_E(QX+_[)Q8_^G/5*_+ZO[R\$_\
MDA<L_P"O2_-GQN9?[S/U"KGA[0[CQ/KUEIMFGF76H3I;PI_>=V"J/S(JG5SP
MYXAN/"7B&QU6S;R[O3;B.ZA;&=KHP93^8%?IU9S5.3I_%9VOM?I?R.);ZG[/
M:#_P0X^#OPO^ [R>*]+U37M8T?3C>ZAJ<%^\+RS(NZ553[HB!RH')QCGFOS[
M_P""C/['?A[X/>.[/6/AE;:U<^$=:@^T?9)HVFDTML!MI<9)0@G!/]PU]U_#
MK_@X:^%/CSPW8V/BJSUSP_K%]&8[];BU%QID)."ZAT.\HS#(#*2N0,GK7BOQ
M*_;G\>?MW?&BWT/]F;X>SKH=K9BVU'4;_28=L\K'AW9\I"L8X4 ECEC@\ ?P
M1P/Q!XEY;Q/*MG567LX<[J*O4<:%G=:22G%/FMR<BTM;2+9]/BJ.$G1M26NE
MK+4_-BBOU$N_V!/VQK<R76K:E\+Y&<L\BWKVTA7GGCR,?D<5L>$_V:=8\(?#
MUM<\=Z#HGQ,UJ&X>*XT3P=I&EQI:J#A6>694>3<<C]V#@\8/6OZ+QGCEDV'@
MI1J4JK;24:55S;;]:44EYR:7GL>/]0E>ST];+]3$_P"#?#X#6\>@>//B;>1L
MUQN3P[IQ/10P\VX8>^T(OT<U^EOA:W6+2V8K,OFN7P_7';CM7A_[(_CKPY)\
M%K73]/\  >J?"FXAN;@S>'[K3Y+>=9#M'FD^6L;EU Y4GI7LT>K^5;QHGF*"
MH'S#I7\.>*G%57/^(L3CZL7&[2C%M/EC%))75T]KZ-J[9Z^'H^RBHFEJYA\K
MYMV['! KYC_X*'? >U_:._9!^('A:#?-?3::]_:?+S'<6_[U#^:U]$:S?HJ[
M8[D7#*=IVH1CW'J*Y^?]W/(XM9+E)(9$EB YE4J05'N1Q^-?G=.<>647U1T:
M\R:/Y]? MXMQX5LVRJEHPQ4GD9 -6M:T'3O$ENL.H0)<V^X%EW8)^AK[<\5_
M\$U_A1XQ\+W^HPZ-X[^"+1LYA/B34(6CE<L<!(&DDD=2>P"G!XKX)^(OA2\^
M$?CW5/#>O6]]9ZGI4QAE4(I#CJKCGHRE6&><-SS593PCG.9UI8?+L/*K.*NU
M%7=MKZ;J[5[;77<].IB*<%>;L;WB+X?>"[*XL9]'T^SCN+= "\,+0J,=W#$[
MG/?'R^@IXE5?XE_.J_P(^!GB[]J#Q[!X8^'_ (:\2>*M<N,8MK*V#")2<;Y'
M+;8T'=F(%?J5^RA_P:XSWUE;ZI\:?&D]K(V&?0?#I'[K_8DNF&6/KY8 ]S6&
M>\-YGDU14<UHNC)ZJ,M';O;>WG:Q5.M"HKP=S\E_%<GVFUU95^;=97(7W_=G
MI7QU+"\#[75D;T88-?U]?#[_ ((,_LK_  _TAK8_#&VUV1E*/<ZM=2W<[ C!
M&YFXX]*\R^-W_!L7^S3\2H)9/"]GXB^'NH,,(^E7IFMU/O#+N7'TQ7FX&GAJ
MT^2O4]GYN+:^=M?N3*E)K5*Y_+)X+T_2]6\56-OK6H2:3I4TH6YO(X#.UNG]
MX(""WTKUH_"/X)Y_Y*UK'_A,R_\ Q=?JO^TG_P &L7Q<^&EK=7W@#Q!H/Q M
M8=SQV906%_(HZ!5?*,W_  -?:OSB\=?"#6/AAXNU#0/$6FWNBZUI<Q@N[*\M
MO)FMW'564C(K]LX6\"\7Q'3=3),QP]:VZ4I*2]8N*DO5JQYM;,U1_B0:.$_X
M5)\$_P#HK6L?^$S+_P#%UY1X[TS2='\6WUKH6I2ZQI,,FVVO)+<V[3K_ 'BA
M)*_2O?/^$<7^\O\ WPO^%'_".+_>7_OA?\*^L_XE0XJ_Y_4?OE_\B8?VY1[,
M^?\ P;XFU'P7XKT[6-)FDM]3TNX2ZMI4&621&#*?S%?1NJ^&/ G[3.HW'B?7
M+/7_  7XCU:0W%_'9(D]K<2GEY41B&0,V3C/4U0/AJ-NK?D /Z5<T;28;&Y
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MK^B"BBBOP4]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OT _X(7_\ -4O^X3_[>U^?]?H!_P $+_\ FJ7_
M '"?_;VO9X?_ -_I_/\ ])9^0>/7_)"8[_N%_P"GJ9^@%%%%?I9_G$%%%% !
M1110 5\Q_P#!3O41%\/_  M:[FW3W\\A7L=J(,_^/?K7TY7R+_P5"U/-[X1L
MA)N*PW%P4_N;BJY_';^E?"^)%;DR"LOYG%?^3)_H?M7T?<+[;CC"R_D527_E
M.2_-GQ'XE.[6Q_LJ*_0;_@E5IS0?L^^++K/R3:U:1$>I2WF/Z;_UK\]]:;?K
MTG?'%?I!_P $R]/^R_LIW4W_ #^>(YEQZ^7;6^/_ $,U^*^'M/GX@PZ_Q/[H
M2/Z]\=ZWL^!L<^ZIK[ZL$>]?LM%Y_P#@L;^S+'M(5=)\:,'QQG^S[3C_ #ZU
M]R?MJ?#S]FKX9_%/PYJWQ.^']EJOB7XF:LEA'>P:;/<N\BB./SIC&P"HI>%,
M@%LNN >2/SE\??%1OV/_ -I3X ?'O4(;C_A$_AWXJN](\53QQF3[#I>KV@M'
MN64<[(I$C8X'85^OGBSP':_M-:7I7B;PS\0MNAW=HLNG7.E6VGZE:RAB&$\4
MLL4G7:O*MCY%. 1FMN+J_P!6XDQ$ZG-RWUY9<K:<5;6SZV>VMK&O@S6K2X&P
M/U2:C+E:OO:TY732:_/S-[X._LW>"?V?O#ESI'@WPQH^@:;>71OI[>WC)66<
MJ%\P[B3NVJ!GVK0\::_I/P]M;>:ZT^!EF<JGDVZDJ54M[=AQ]:Z/3+62QTVW
MAEGDNI88E1YG #3$  L<<9/7CUKDO'WBK1/#FK+#K'C;2M!EF42QVUY<VT+%
M,XW 2<D9!&?K7P]2I*<N:;NWU>Y^M2DY.[.LLKIKZSAFCVA)D5U!'(!&:J^(
MO$,?A?2Y+RZ>-8X^@'WG/H,GD\'\JY?1OCAX)TV!DF^(?A:]+-E6DU:T4J/0
M;6'^3576_BYX(UFZW?\ "Q_"\,6T#R1JEFZ;N?F^8DYYJ23NM.U!=7L(KJW>
M.2"=0Z-@C<#WJMKMW!H6G7%_<0PLD"[F*Q@L>P_G5;P)>6>I:7]HT_7(-<LF
MPB2P2121J1U :/CN./I5S5]$FU2X5EO[BWAV%6B15*O[G(/TH ;H>J1^)-(C
MO+=52.?CYE^88.#T.#R.QQ7\\'_!(>3=^RS\6(]KYA^,.J_,1\K9MH>GTV_J
M*_>WXL>(=>^%_P --?OO#<,GC#Q/;:?*=&T-Y8+5+RZQ^Z1I#M6--V-S,>%W
M<$X!_+S_ ()M_P#!&+XM?LV?LI:IH?C;6O![>,O$GBN[\3WT%E=RS6\1FBB0
M)YGE@;\HQ. 5&[AC7T_!N.H83.*%?$S48)N[?3W6OU/SGQ:RK%YEPEC<%@*;
MJ59QBHQ6[M.+TOV2;,:AE#KM;[K<&O4O'?[&GQ$\ QR2S:#+J%M'R9M/<72C
M\%^;\Q7F%Q;R6D[1RQO')&<,CKM93[BOZCP>883&PYL+4C4C_=:?WV/\V<TR
M+-,HK*GF-"=&?3GBX_==*_R/R"_X*D?L[>(/AM^V%X@\;0Z'J6I>'_$<*74M
MQ:0-,MM.442!P.54LI92V 0WKG'R%XMUR/5=:69=/DVJJJ?-5U88]@U?T8S^
M#M'\:W=O:ZSI\=[%NVQL&:*:$G^Y(A#ISC.TC/?-,;]ESP7(QS;ZXI]M=O?Z
MRU_,7&7"\LEQBI*7-":;B^MK[/S7?KOIL?Z.^$OB5'B[*'B)0Y*U)J-1:--V
MOS1\I:Z/5--:[O\ G=\:>,[?Q#HIMX+>Y63S%;+)@8&?<UE>#?AIXA^(>K16
M.AZ+JFK74S;5CM;9Y#^.!@#W/ K^C;_AECP2/^6.O?\ @\O/_CE7+']GKP7X
M:TN\U)=+N+V:S\L6ZW^H7%["LK-PQBE=D.%#$94\X-?/Y;E]7&XJGA*7Q3:2
MOY]7Z;GW/$6>4,IRVOFN*^"C%R:25W9;+97;T7FSQO\ 8%^ UQ^SW^R?X1T/
M45"ZDMBCR@,& =VDED;(X*EI%4'OY1(R""?8J=-,UQ*SR,SLQR68Y)IM?UCP
M[DL,JP%/ P?-RWN^[;NWY:O1=C_,#COBZMQ-G=;.:T%#VC5HK7EC%*,5?J[+
M5]7?1;!1117M'R!^/W[3/_)R'Q _[&74?_2J2N(KM_VF?^3D/B!_V,NH_P#I
M5)7$5_:65_[G2_PQ_)'^E&1_\B[#_P""'_I*"BBBNX]0**** "BBB@ HHHH
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M0**** "BBB@ HHHH *K:S_R![K_KB_\ Z":LU6UG_D#W7_7%_P#T$UY>>?\
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M$"V/PSTOQ)J$87=J'B9CJL\C#^+;)^Z4D\_)&HKNOC!\*?A#H%YIVCZM\'?
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M\G_<(3_Y8UB45WKZ*'!O6I7_ / X_P#R!/\ ;F([+[O^"7[CX)? VUW21_\
M"?77'RPKIL%N2?\ ?:]E ],[#C.<'H8M8UZ.^%O9Z=I\^EZ+81K#:6CW(F\M
M5SR2%5=QR22J+DDG&22:M%?8<'> ?"G#>/CF6"A*=6/PRFU+E\TK))^=KKHT
M<^(S2O6CR2V\@HHHK]K/-"BBB@ HHHH **** "JVL_\ ('NO^N+_ /H)JS5;
M6?\ D#W7_7%__037EYY_R+L1_@G_ .DLTH_&O5' 4445_F>?>!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '[$_P#!V;_RD8\%_P#9.+'_ -.>J5^7U?J#_P '9O\ RD8\%_\
M9.+'_P!.>J5^7U?WEX)_\D+EG_7I?FSXW,O]YGZA1117ZD<(4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB
M[_D7KC_@/_H0KB:[;Q=_R+UQ_P !_P#0A7$U_&OTB/\ DHZ/_7B/_IRJ?49)
M_ ?K^B"BBBOP4]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OT _P""%_\ S5+_ +A/_M[7Y_U^@'_!"_\
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MK_,\^\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>mdt-20250425_g7.jpg
<DESCRIPTION>IMAGE 7
<TEXT>
begin 644 mdt-20250425_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/CW5OASXD^$.K>$M3TC3HKR6VU:[A=VCD;:ORQDE<]<GK7JE !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'A?@'_E()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\ [$32O_1C5[I0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%^ ?^4@GC_P#[$32O
M_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C5[I0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$GU"9\\G%[?7 ;\X3FOVT\*:)+X:\+Z;X<GU:XU"33["&V>_N\>;<F- ID?
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M\?\ _8B:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI_'^I7VS/7%E9HEI^4@Z"OW8HK7^WITO]WHTX>:C=_>PY>YXG_P3J_9+U_\
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M)I7_ *,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/\ _L1-*_\ 1C5[I7A?@'_E()X__P"Q$TK_ -&-7NE !1110 4444 %%%%
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M>/\ _L1-*_\ 1C5[I7A?@'_E()X__P"Q$TK_ -&-7NE !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A
M?@'_ )2">/\ _L1-*_\ 1C5[I7A?@'_E()X__P"Q$TK_ -&-7NE !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ]TKYB_9M\>^)?B!^W!XZUOQ/\,M4\+W$G@C3U?3M5=&EC"2X4DH<8;<2/\
M=-?3M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_13)TKJ-(_X-J_^"+NDD2/^Q\]VZGA[SQ_KS=L?=%\%/KR.M'+PU'=U7_X
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M)C5_^#SCX6P@_P!@_L$^(+DXX%YX^@@R<_[-I)V_P]Z^O_\ @C+_ ,%MX?\
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M** "BBB@#POP#_RD$\?_ /8B:5_Z,:O=*\+\ _\ *03Q_P#]B)I7_HQJ]TH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBO%/VSO\ @H?^QY^P#X,_X3']J3XUZ7X?::%GTW0U?S]3U+&1
MBWM(\RR#/RE\"-21N91S5TZ52M-0IIMOHM6![77S]^W5_P %0?V*_P#@G/X9
M76?VG/B_:V&J7-J9]*\(Z8OVK6-27) ,5JIR$+*R^;(4BR""X->N_![XL^!/
MCQ\*O#OQI^%^N)J7AWQ5HUOJFC7T?_+6WGC$B$C^%L-@J>5((/(->&?MN?\
M!)/]BC_@H7\5_!'Q=_:B\ 7FLWW@:WN+>TM+34FM8-2MY'5U@O#&!)+'&ZLZ
M*KH 99,[@Q%;X:.&CB4L5=15[VW]-?/03O;0_*CXD_\ !93_ (+!_P#!9CQI
M?? C_@E+\!M8\ ^#C+]GU/Q393*+Z*)OX[K57VP:?E?G$<!$_!"R2=*_+/\
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M1117A%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<7\'
M?COX%^-_]O?\(5>>;_8&M2:?<Y8'S-OW9EQUC?YMI[[36]/#8BK1G6A%N,+<
MSZ*[LK^K..MF&!PV+I86K44:E7FY(MZRY5>5EULM6=I1116!V!1110 451UK
MQ-X;\-Q>?XB\0V-A'C.^]NTB&/7+$5Q'B']K?]F?PQN&J?&[P\Q7[RV5^MT1
M[8AW'-=>'P&.Q?\  I2G_ABW^2/,Q^=Y-E:OC<33I?XYQC_Z4T>BT5ROPE^-
M7PV^.6AW7B7X8>(3J5E9WS6DTYM98<2A$<@+*JL1AUYQCKZ5I?$+Q1<>"/ 6
MM^-+72OM\FD:3<WJ67G>7]H,43/Y>_:VW=MQG!QGH:F>$Q5/%?5ZD'&I=+E>
MC3?1WM;YFE+-,NQ&7?7Z%6,Z/*Y*<'S1<5>[3C?FV>U[]#8HKXM_X>*?M0^-
M^/A9^S0LH?[A&GWM_P#K$(P:V_AG\2?^"E/C3XBZ%=>)?A^=,\/?VO;G6H3I
MEM:_Z)YB^;_Q\,9.$W'Y3NXXKZJKP-FV%I2GBJM*E9-VE4C?3HK7U['YGAO&
M?A?,<3"EEN'Q6(YFES4\/-Q5W:[<N6R6[=MCZWJ*\OK+3K=KO4+R*")?O2S2
M!5'U)XJ6OGW]IW]@^U_:3^*%O\0+KXERZ/!#I45I+91:9Y[2.KR,7#&50N59
M1C:?NU\]E6&R[%8ODQM?V,+-\W*YZ]K+77OT/N^)<PS[+<L=;*,%]:K72]FZ
MD:6CWES236G;=]#TWQ!^T?\  'PMN&N_&;PS Z_>A&LPO(/^ *Q;]*V/AY\2
M_ WQ7\/?\)7\//$,6J:?]H>#[5"CJOF+C</F /&1VQS7S_X?_P""5'P%T[;)
MK_BWQ-J+C[RBZAAC/X+$6_\ 'J]S^#_P9\!? KPDW@KX=:=-;6#W;W+I/=O,
MS2LJJS9<G'"+P,#VY->EFN'X5H86V KU*E6ZU<5&%NO]Z_8^>X9Q_B7C<RYL
M[P>'H8;E>D*DIU>;2VJ7);>_7:Q/\7/B"OPI^&NL_$:31I-031K)KE[.*4(T
MBKC.&(.,#)Z=J^4I?^"H?Q3\6R&W^&'[.?G/G"[[J>])/^[%$GY9K[-GMX+J
M%[:ZA22.12KQR*"K ]00>HI8HHH(UA@C5$48547  ]A6>49GDN HR6+P2KS;
MT;G**2MMRK1Z]S?BKA[B[.\73>5YN\'14;2C&C"I*4KO53D[QTLK+M<^6/@G
M\>_V\/B'\5=$C\=_!AM'\,2W>W56'A^6UVQ%6 ;=<.6X.T\=<5]4T45RYOF6
M'S.O&='#PHI*UH7UU;N[[OS/3X5X?QW#V"G1Q6/JXN4I<W-5:NM$N6*25HZ7
MMW;/FK]I+]@[Q9^T)\6KOQK_ ,+C.DZ3=6\"C3FM)+G8Z1A&(3S$4 [0>.^:
MQ_#W_!)KX36NT^*?B;XAOB.HL8H+8'_OI9#C\:^K:*]2CQKQ-A\)#"T<1R0@
MDDE&*T6F]K_B?-XKP?\ #K'YK5S'%X%5:U63E)SG4:O)W=H\_*E?HD>/>,[O
MP-^PQ^S!?#PG).T&F)(FBP:A.)'FO)V)12<#(WDN0!]U6K\Q]2U&_P!8U&XU
M?5+MY[JZG>:YGE;+22,2S,3W)))K];/BW\"_A;\=-.M-(^*?AM]4M;&=IK6
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MU^#6HX//N/#>J>&)XKN&'(!D+*&@8!F4$)*Q^8<8YKV72?\ @H/^R3JVU?\
MA:?V9V_@N](NTQ]6\HK^M?E^/X)XPRNLZ.+R^M"2W3IROZ[;=GL^C/H,9QIP
MAEV,^JXO,*-*I9/EG4A%V>VDFMSVBBN0^'_Q]^#'Q4U$Z1\/?B1I6JWBPF9K
M2UN/WHC! +%#AL D#..XKKZ^=KX;$86I[.M!QEV::?W,]O!8_ YE05?"58U(
M/[4)*2^]-H****Q.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?@'_E()X__
M .Q$TK_T8U>Z5X7X!_Y2">/_ /L1-*_]&-7NE !1110 4444 %%%% !1110
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MH+/1D*I;G;E?/NB)L8)$HKVZ&2U%35;&25*'G\3]([DN78_:W]E[]KG]G/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&O$Z_P!.<@JY37R/#5,K45AI4XNFH)**@XIQ44M$K=.A\955156I[WU/:O\
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M*T'&79II_<S=-25T%%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%4 *989()64!5#R.% 7 KZ^K\T_^#5[P7KVG?\ !/7QM\9=3LYH=/\ BO\
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M^+R<=\=J_8^BOT/AGQ7\0^#L \#E&83IT=;1:A.*OORJI&7+=ZOEMKKN<E;
MX3$3YJD+O^NQX!^P1_P30_92_P""<G@>X\*?L\>#9AJ.I*@UWQ7K,RW&IZH5
M^Z))0JJB \B*-4C!R=NXDGW^BBOC,US;,\\Q]3'9A6E5K3=Y2DVY/YOLM$MD
MM%H=$*<*4%&"LD%%%%>>6%%%% $&HZ;IVKVCZ?JVGP75O(,207$0=&'NK @U
MYCXY_84_8F^)N]OB%^R#\,=:=_O3:EX$T^:0>X=H2P/N#FO5:*[,)F&/P$^;
M"U94WWC)Q?X-$RA&?Q*Y\C^./^"$?_!)CX@;SK/[&.@VK/G#Z'JE_INT^H%K
M<1C\,8]J\=\;_P#!KA_P2^\5[SH$?Q#\,[ONC1/%J2!?I]L@G_6OT:HKZ_ ^
M*'B/EMOJ^;XA)='5G)?=)M?@<\L%@Y[TU]R/R#\<_P#!HE\ M0W_ /"M?VQO
M&&DY_P!7_;GARUU';]?*>VS^E<8/^#9?_@H!\(>?V;/^"F*6GE?\>_[[5=#Q
MZ?\ 'K-/M_#-?M?17UE#Z0/BM3I^SK8Y5H?RU*5&:^]PO^)@\JP+=U&WHW_F
M?BA_P[X_X.AO@D?^*"_;9;Q:(?\ 5@?$R2_#X]M8@7/XT?\ "_?^#LSX(<>-
M/@P_BZ.'I_Q36A:AO4=/^04ZL?\ T+UYK]KZ*W_XC;B,5IF61Y=7[N6&49_^
M!1DK?<+^S5'X*LU_V\?BB/\ @O?_ ,%KO@_\G[0G_!+\"&'[]P?A_K^E%P._
MF2/+&?JHQ6KX6_X.ZM,L;O\ LKXN?L%:GIT\1Q</I7CA9'![_N9K.,K]"YK]
MF:RO%/@3P1XYM?L/C;P;I6L08QY.JZ=%<)CTQ(I%'_$0O"W'?[_PI33[T<36
MI6](I-?)A]4QT?@KOYQ3/S7\#_\ !UY_P3S\0!(/&/PO^*7A^8_?DDT2RN8%
M^C17>\_]^Z]B\#?\'$G_  2.\;;(9?VG9=%N'Z6^N>$=4AQ]9%MVB'_?=>T^
M./\ @F5_P3N^(^]_%_[$/PMN)9,[[J'P196\[?66*-7/YUX[XW_X-Z/^"1WC
M??*W[*RZ3.__ "\:'XKU2VV_2,7)C_\ '*/KWT?,?_%P>/PS_P"G=2C42_\
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M2:LUJNUTRBBBOAC]@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_!,GP8&.L?MU_#&78/F&E^++>^/Y6S29KX5\*_\ !HQ^S+9E?^$X_:T\=ZB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9&LGC_:N J_6DM?9N#IR?>\I*4$][<L[;79\S4R"K[3]W-<OGN?GY_P:]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#POP#_P I!/'_ /V(FE?^C&KW2O"_ /\ RD$\?_\ 8B:5
M_P"C&KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+\ _
M\I!/'_\ V(FE?^C&KW2O"_ /_*03Q_\ ]B)I7_HQJ]TH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% 'KW_!#O]N3X@_MZ?L$Z7X_^-<L$OQ!\&^(M0\&?$"YM8U2.ZU33W53<!5
M"F6&2"5E 50\CA0%P*^OJ_-/_@U>\%Z]IW_!/7QM\9=3LYH=/^*_Q[\3^+O#
MIF0KYMA)]FLUD /8R64N#W&.V*_2R@ HHKQ+5/ O[>DNIW,ND?'?P1#:-.YM
M8I?"\C,D98[5)W<D# )H @\ _P#*03Q__P!B)I7_ *,:O=*^8OV;=*^+6D_M
MP>.K7XO>+-+U?5%\$:>9[K2K V\3*9?W8"DG! #9]<CTKZ=H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\?\ _8B:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#POP#_ ,I!/'__ &(FE?\ HQJ]TKPOP#_RD$\?_P#8B:5_Z,:O=* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_RD$\?_ /8B:5_Z
M,:O=*\+\ _\ *03Q_P#]B)I7_HQJ]TH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /"_ /\ RD$\?_\ 8B:5_P"C&KW2O"_ /_*03Q__ -B)
MI7_HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO+_BW^VM^R;\!_&(^'
M_P 8/V@?#'A_6$M8[J\L=0U)5:PMI&V1W%V1D6D+L"JRSE$8J0&.#@ ]0HIL
M$\-S"ES;3+)'(H:.1&!5E(R"".H-.H **** /"_ /_*03Q__ -B)I7_HQJ]T
MKPOP#_RD$\?_ /8B:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\
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MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\
MH;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E
M<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\ A97/^-'_  [W
M^"?_ $-OCO\ \+*Y_P : /=**\+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_]
M#;X[_P#"RN?\: /=**\+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
M"RN?\: /=**\+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&@#W2
MBO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H ]THKXW^/
M_P"R'\./ WQ.^%_AS0_%7C V_B3Q5)9:D;CQ3<2.(A 7&PD_(V1U%>J?\.]_
M@G_T-OCO_P +*Y_QH ]THKPO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^._
M_"RN?\: /=**\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\
M&@#W2BO"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO
M"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P
M3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\
MA97/^-'_  [W^"?_ $-OCO\ \+*Y_P : /=**\+_ .'>_P $_P#H;?'?_A97
M/^-'_#O?X)_]#;X[_P#"RN?\: /=**\+_P"'>_P3_P"AM\=_^%E<_P"-'_#O
M?X)_]#;X[_\ "RN?\: /=**\+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OC
MO_PLKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_
M !H ]THKPO\ X=[_  3_ .AM\=_^%E<_XUY7X3_9#^'&J?M=^+OA5=>*O&']
MEZ5X5L+VU*>*;@3>;*[!MTF<LO' [4 ?9%%>%_\ #O?X)_\ 0V^._P#PLKG_
M !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\ PLKG_&C_ (=[
M_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C_AWO\$_^AM\=
M_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z&WQW_P"%E<_X
MT >Z45X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQW_X65S_C0![I
M17A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C0![I17A?_#O
M?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_ .%E<_XT >Z45X7_ ,.]_@G_ -#;
MX[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C0![I17A?_  [W^"?_ $-OCO\ \+*Y
M_P :/^'>_P $_P#H;?'?_A97/^- 'NE%>%_\.]_@G_T-OCO_ ,+*Y_QH_P"'
M>_P3_P"AM\=_^%E<_P"- 'NE%>%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?
M'?\ X65S_C0![I17QOX3_9#^'&J?M=^+OA5=>*O&']EZ5X5L+VU*>*;@3>;*
M[!MTF<LO' [5ZI_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E
M<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\ A97/^-'_  [W
M^"?_ $-OCO\ \+*Y_P : /=**\+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_]
M#;X[_P#"RN?\: /=**\+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
M"RN?\: /=**\+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&@#W2
MBO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H ]THKPO\
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M_P"AM\=_^%E<_P"- 'NE%>%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\
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MS6]"??H>L:QH-O<W6G-G=F"61"\)SSE".:Z>B@ HHHH **** "BBB@ HHHH
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M_P"$V_X2.P_L7[!]N_M?[8GV7[+L\SS_ #<[/+V?-OSMV\YQ7C/P$_X*=?\
M!/;]J3XFW'P:_9Y_;&^'_B_Q3;K(PT/1?$4,L]PL>2[0+G_2%4 DM%O ')..
M: /=:*H>*/%/ACP1X>O/%WC3Q'8:1I.G6[3ZAJFJ7B6]O:Q*,M)))(0J*!U8
MD 5F?";XN?#+X[_#W3?BS\&_'.F^)?#.LQO)I.NZ/<B:UO$21HV>*1>'7>C
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M#]I7_@I!^P;^QUXLT_P%^T_^UCX(\$ZYJ<2S6>CZYK<<=R86)59FB&6CB)!
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MBF^/1_9@B_;8^'#>/!J']G_\(Z/%$'FF]W;?L@?=Y9N-_P GD[O,W?+MW<4
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MNM1U+4;I(+>U@12SRR2.0J(J@DLQ  !)- %VBO.?@C^UW^S/^T?J5WHGP/\
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M'?#N/PMHOB_X'V^K:5X91HV72X7,#Q0 QHB80!0-J@# P!7TS_P4S\2>'O\
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MXT2'7;1KQ?V;=!C-JMPID#I=V[NNW.<A9(V(Z@.I[T ?H-\2O!\_Q#^'6O\
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M^(>I?$+0U\*:O:0P6DW@6QBG26ZO99H5S:F2W5H8UE9/.FN(6)"JTJ?K.""
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MY^TCX@B^#UA+<-);II]H_P!FN)K5F)W6QFC,*/D[OLC,2<[C\\?\'">H:O\
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M,RM?-/\ P2<\:^ _^"5O_!8+X\?\$=_$'Q5AG\'^.9[7Q[\)+C5]2A$JW]Q
MAO=/?8%5;ATP50*N5L-P&9%%>I?L7^/O!FA_\'*7[:'@#6?$UE:ZSKO@7P'<
M:/IUQ<*DM[';:/#YYB4G+[!-&6 R0&STS0!ZM^Q[_P %I/ G[6GP)^*WCBS_
M &7_ !_HOQ'^"%W+;?$OX+RM9'6K!U65@\+W,UO#-&1!. 6:-]T+J$.4WX_[
M(_\ P6@\??MGZ)\)OB-\&?\ @F[\4M3\"?$D:I'JOC>SO[)[/P]=6C7 6W?>
MT9EWB&,-,?*@62;R5DEDCE5?)_V</ ^D^)_^"B__  4%_;W\'WMK#\,K[P;I
MWA*S\2)*JV.L:KIVBJNJS129VNMM+&('D'RF0R $E6QZK_P;.:]HNN?\$1_@
M<FCZM;W366G:M:WBP3!C!,NL7Q:-P/NL 5.#SA@>A% 'J7_!-W]NSX?_ +;N
MI_&B'P3^SAJGPVO/AQ\6;WPMXHL-;-E]MO\ 58(HA<7$XLFDBWAOW>X2S;A&
M"'((QX/_ ,&S4,5O^Q5\3K>",(D?[2OC-411@*!<0@ 52_X(&>*?#6L_'7]N
MY-(U^SN2O[8'B.Y;R+E7Q"Y"K)P?N%HY &Z'8V.AIW_!L1XC\/\ B+]BSXI2
MZ#K=K>*O[2?C!V-M.KX626"2-C@]&1@P/<'(H ^W_P!HC]FKX9?M2:!H?@;X
MRZ1'K/AC2_$D&L:GX7O85EL=;:".7R+>\B;*S0).\5SY; JTEK%N!4%3\#?\
M%(OV*/A-I'_!5/\ 8G\<_LA?#31O!_Q.'Q%O;OQ1=>$=,BL?M7@VQMTDU)KP
M0*JL@61+9&<<F]\L$[@*^W/VW?VY/V=?^"?/P(O_ -H#]I+QQ;:3I5O(MMIE
MDT\:W.KWK@^59VRNRAY&(/)(1%#22,B(S#XZ_9U_X*V?\$M-&\;ZC\?OB!^V
M?X0\=_'#XABST:U\/>"5N=0EL[=IL6'AG2%,2ET\^7+S/Y?VFXE::3RHQ%'
M 'A7XAZI^TO_ ,'//B;X<>+9#<>'OV</V?UE\*Z;(<QVVN:Q)8R3WZ@\"5K*
MY-OG^ZHQU.6^%_'FO_ 7_@Y4^('[-/@S67T[0?CU^SG9>,KZVAC#1V_B.QN)
MK"._6,_+O:UM7#\?O"L>XG:*O7?PZN/V0?\ @XXN?VC/&S+9^"?VF/@TGAW2
MM>N&"6\?BS3'M2FGR.?E1Y;&U+Q!B#*P=4!*&J_P4\%6O[1__!P)\5?^"@%A
MJMJ_PT^"7P8M?AU;>*_M"BPN];>9K^^6*?.QULXIIHYR#B.215)!5@ #K_\
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MPR\#Z/X<T:TW?9=(T'3(K.UAR<G9%$JHN223@=:V*** "BBB@ HHHH ****
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M%^BW'AOQ9H%EJFG7:;+JPU&U2>"9<@X='!5AD X([5QO_#)_[+/_ $;5\/\
M_P (VQ_^-5W]% %:QT?2-,TB'P_INE6UO86]LMO;V4$"I#%"J[5C5 -JH%
M4#  Q6'\-_@U\'_@W:7EA\(?A3X:\*P:C<_:-0@\-Z%;V*7,W_/200(H=_\
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M *!@ 8JS10!S7PW^#7P?^#=I>6'PA^%/AKPK!J-S]HU"#PWH5O8I<S?\])!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U?\
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M5/!'B_QQ=Z)8:Y?WFJ-:":Y%M87GV^&VBC0+;RH(?,NVD8,\<)0 ^_*^=_\
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M7L/V>79<JHE+2KO9U&T@'ZAT5^5.G_LZV/Q;_P"#BCXR? 'Q?\8_B6_@6_\
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MV+_8^C_\(7HEW]G\_1+"YE_>W-E)*^Z::5_F<XW8&  !]Y_\%+/^#BSX+_\
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MBS/::Y+;K-G<+9]>U%X>O8QLA7_9*UYK_P '1/\ R1K]EW_L\#PI_P"D^H4
M?I?X7L_$6GZ!;6?BS78-3U&-"+N^M;'[-',V3RL1=]@Q@8W-TZU?K\TO^"_7
MA;Q(GQV_8RU_P3\7O&GAB^\0?M2>&_#M]_8GB>Y6R-O)*TJS'3Y':RDGCD0,
MLLD+G^%MR_+6+XM^!?AG]@/_ (+]_LQ>'OV<O%GC&TTOX^>$?&UI\4]/U_QQ
MJ6L)KD^F::;ZWO)3?SS'S_-V_,I  7"A0S;@#]0-2CU&73KB+1[J""[:!Q:S
MW-N98XY,':SHKH74'!*AE)'&X=1\6?\ !'K]J_\ :F_:3\>_M0>"OVH_B-I7
MB*Y^%7[0&I>$/#DVB^'(M,MHK"VC0*$B5GD^8Y<^;+,P+$;R *X/]A;5_!?_
M  5A_:G_ &G_ (E_M.Z#!XJ\+?"OXKW7PR^'/@/6B9=,TBVL(]MUJ8MB?+:\
MNIG+?:74RQ)&L<;( 0?E[]CCXRZ__P $S/V(_P#@IE\4?A#J-]J.J?#;X_Z_
M:>$KW7[I[^>.=A!:6<UQ),6:Y,32QLQD),GEG<>30!^V]%?EK\>O^"97[;_Q
MA^#/P]^)_P"Q9I?PP^'?QD\/7VFZW9?'*Y^.^OZC?^(HC&&N$U0?V"O]H17(
M8,8Y6:-1A$ CRAL?\%PO@-XB_93U;X=_\%E/@L(SXC^%7BK3[CXF_#1-=F32
M_&ME/(L+F"!R(VOX7D+Q2>7O8?O"&:"-2 ?J%17RC_P2=^&OPG\0? U?VZ/#
M'B;3_$7B/X[-)XJU?5M)OII=/TV.Z?>ND6,<F/(AMBHBD^2-Y9XI9)55CY:?
M5U !1110 4444 %%?*GB#_@JI\/_  _KU[H,WPIUB1[*[DMWD6]B 8HQ4D?7
M%9.N_P#!6CPI)HMW'X=^%.IQZ@ULXLI+J\B,:2E3L9@!DJ#@D#KBOKZ? 7%M
M6S6%=GUO'K_V\?E5?QM\+\/S*68QO&]TH5+W71>YN>F?\-E:%_PV-_PSOYD'
M]F?8OL?V[//]K??\O/\ =V_N\=?,XKW6OQL_X2/7?^$B_P"$M_M6?^T_MOVS
M[=O_ 'GG[]_F9_O;N<^M?H3>_P#!03PGX:_9^\)_&+5?#-QJ<^MRO9:C:6$R
M(;6\B0>:#N[$_,H_NLI[U]/Q=P!6P#PBRZ'.Y)0E;K-)OFUVYDGZ6\S\[\+/
M''"9XLTEG]54E3DZT&[OEHRDH\FB;?LVXZVN^>^R9]%45\D_\/:_AW_T2/6O
M_ Z&OJOP_J\?B#0;+7H86C2]M([A(V.2H=0P!^F:^"S7A[.<DC"6.HN"E>UV
MG>V^S?<_;.&>.N$^,9U89-BE6=-)RLI*RE>WQ16]GL?&]C^US^T/^V3^W_\
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M$,/@F^G21@(/$9NVR 1+_P )%J9;=^&.O;% '1>,_P#@MY\$M/\ ^"1>B?\
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MX$UO4_"G]J^)/&:VTK0RZB%GE2VTZT\U71(VBGF=HW+&/ ![#_@NW!XWN/\
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MVOX!_;T^$O[4_P"REX.^$_P:\+Z1<S6'QM\*:#\5=9U*V\::1*T05C9OHMO
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M>ZDU.XU*&Y>VG10K0S3!"JR$31%U)C)R?T2HH ^%OV0_V*O^"M%BWAOX:?\
M!0;]N7P1XR^'?@BZLY[&V\%^%YX-:\6M9NLEH-6O)\!(DDCBDDCA4M<&,++*
MRM()/NFBB@ HHHH **** .7\5_!#X+^/-7;Q!XX^$/A?6;]HU1KW5= MKB8J
MO12\B%L#L,\5_+!_P<6^%_#/@O\ X+)?&+PUX.\.V&DZ;;?\(]]FT_3+1(((
MMWA[37;;&@"KEF9C@<DD]37]8]?*/[2O_!$'_@E[^U_\:]:_:)_:)_9B_P"$
MA\9>(?LW]L:Q_P )IK=I]H\BVBMHOW5M>QQ)MAAB3Y4&=N3DDD^[D.:4LLQ;
MJ5KN+BU9:ZW3ZM=B9*Z/Y#:*_JX_XAK/^"*7_1EW_F1O$G_RQH_XAK/^"*7_
M $9=_P"9&\2?_+&OK/\ 7'+/Y)_='_Y(CD9'_P &T]K:V_\ P16^#DUO;1H\
M\GB)YV1 #(W_  D6I+N8CJ=JJ,GLH':ONRN%_9J_9J^"G[('P4T7]G;]G;P7
M_P (]X-\/?:?['T?^T;F[^S^?<RW,O[VYDDE?=--*_S.<;L#   [JOS_ !M:
M.)QE2K':4FU?LW<T6B/FS]K#]ES]K7Q_^U1\.?VI_P!E7]H/PUX2N? OA37-
M'UCPSXK\.3ZA8^*8=0N-/E%M,89XGM50V0=9TWNKA1L9"ZMPOQI_8:_:H_;\
M^*?PON_VY;CX;>'/AY\)_'MIXVLO!_P\U*^U:Z\1:W9I(EFUS>7EK:BUM8_.
MD9H$BE,F=ID YK[-HKF&?G9\<?\ @E=^W%\*?^"I?B+_ (*B?\$V/CU\/K/4
M?B/H%MI/Q+^'_P 6K&^?3;Q8(8(4F@FL@TJMMMH'"X4HZO\ .R2F,87[7/\
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ME#_@F'_P6!^"/A*R_8O^)7_!2CPIK?[/6DP?V9:7UAX1E3QG/H2_*-*2Y?\
M=V:M%^Y\\/-+"AQ$4VQE/JUOV=?C-XO_ &T+#XN_%.?P=>?#'P=X=EM/AMX2
MLC<"XTK4IE\J?5)D:/R9IFMB]M&!M^SQ23!2WGR9][HH ^)O^"9O_!/+]I[_
M ()W_&'XE^&- \>^"9O@)XV\87FO^$_AQ92WINO!$L[,S16<SQA)('.P- 51
M4(W(<[Q)]LT44 %%%% !1110!CR_#OX?S2---X&T=W=BSNVF1$L3U).WFO@3
M_@H_\3/"^N_%B+X6^!='L+2P\,J5OY+&U2/S[UP"X)4#(C7"^S&2OT3KQ[4O
MV!OV3=8U&XU?5/A8\]U=3O-<SR^(=0+22,2S,3]HY)))K[3@W/\ +LCS-XO,
M/:3Y5:"C9ZO1M\TH[+1;[^1^1>+/ ^?\9<.+*\C]C2YY)U95.:+<8ZJ,>2G/
M>5G*]OA2UN[?F!7TC_P3@^*^@Z%\3I/@]XZL;2[TGQ*P;3TOH%D2#4%7Y2 P
M(7S$RAQR6$8KZG_X=Z?L?_\ 1(?_ "OZA_\ )%3Z;^P-^R;H^HV^KZ7\+'@N
MK6=)K:>+Q#J :.12&5@?M'!! -?H&<^(_"^<995PDZ59<ZT?+#1]'_$Z.S/P
MWA'Z/_B1PGQ'ALUHXC"R]E)-QYZMI1>DHO\ <?:BVO)Z]#T?_A6_P[_Z$+1?
M_!7#_P#$UL111PQK##&J(BA411@*!T ':G45^'SJU:GQR;]6?V32PV'H-^R@
MHW[)+\CY+T3]F?\ X*%? ?\ :9^+GQS^!7QD^'7BKPC\3O%=MK,'PM\<6=]I
M_P#9$T.EV5BT\&K6PN&1IOL@+PM:2(-J%65C)N?\ _V!/B7JO[;WB#_@H[^V
M=XC\+WWQ OOA\G@7PGX6\#I<'2O#>A"X>YE4W5PJ37UU+-(Y,QBA"(2BI@Y'
MUC169L?F/^P1_P $KO\ @JK_ ,$KI/%7[.W['/[3GP7U_P""6N>)9]7\/'XH
M^'=5GUOPX\P565(K*6**Y&U(]P:=%=TWJ(=[@YC_ /!#']M?]C;]H^\_;%_X
M)6?MP:%IGC3QP'D^,OAKXI>&E7P]XIO))Y+A[N.WTV(?8PLDK^7"B;D!($_S
MR;_U+HH ^-OVL?V'?VT?VEO^"</BW]COQ#\>/">M^.?B=9S)XW\=:O;75KIV
MEF22 _9],TZ)9"MNL47E*'F5MRF9_,>5\>Q?\$_?@E\8OV9/V1/A_P#LS?&6
M^\-ZC>?#KP=IGANQUOPU<SF/4K>RMDMHYGAFB4P/LC3*AY 3DY7.T>ST4 %?
M-7QO\#_\%7;7]J7_ (3C]F3XY_!^Y^%5_HD%M=>"/B)X9O1=Z7>*6\RZMKFQ
M(>XW_*2DK*H V@ _/7TK10!Y9^S=^S6WP5U/Q7\3/'/C%?%/Q#^(%_;WGC;Q
M5'IHLH9_L\/DVMG:VV^0VUG;Q[A'$TDC[I)9'DDDE=S\]^ _^"=?[2W[*_PX
M^)W[+7[%GQ.\&:)\,?B1KVI:IX?O?$%O=-J?PY;4EQ?06%M"ODZA"KEYK99)
M;;R7D(<SJ #]KT4 ?*WCS_@D/^R]XK_X)C67_!+C0DO]&\(:)HEO!X:UZV96
MU#3=4@F^TQ:LK *#<&[W3R8VJYDD7Y5<BLWQC^PS^T7^U]XZ^$=W^WKXN\#W
M?ACX->);?Q3:Z+X)CNF_X3#Q);0O%::C>"X1!8P0F2646,9N TCC=.438WUW
M10 5\'V7_!/+]L^U_P""Q%S_ ,%4&\5?#,V%U\-QX);P$+_4/-2P$J3><+[[
M-@S>:F['D;=IV=?GK[PHH ^*O^"W'_!.O]HG_@J1^S?I_P"RW\)?'G@[PAI4
M/B>QUV_\0Z^;JYN99;83!;=+>*,*BYD1C(96)P5V#[QL?\%(O^":7Q5_X*-_
M SP)K4OQ7T_X5_'?X4^(U\0?#SQYX2FFO;.QO@%$B,LT<4GD3^7&63#%#&F3
M*H9'^S:* /D7]D3]E;_@H_J?B"S\=?\ !3K]J_PAXNNO#EI<0^$O#WPL\/2:
M;9QW4]O):R:K=3R*LDUU]GFFBCC1(X8_/D;:[%#'\R^!?^"'O[?_ (;_ ."8
M?CO_ ()+ZG^V=\._^%9M!J,?P^U:Q\#W(UJZ6XOFOT@U*:25H88?M#N7\B*2
M8AQME4)M;]5** /S\_;%_P""7_[:W[4O[ GPF_9$O/CQ\/#XB\"^)=!UW6O%
M,^BW=O9.VE1[(+*UM$+OL;",\\LY9F#E8T5U2+T#_@H)^P5^TK^U;\3?V>/V
MI/@G\2?!7@_XE_ OQ/?ZBFG^([&[U71;V#4+:.WNHBT)MYF(6)=G"9W,"5P#
M7V'10!\3?$?]@3]L'QC_ ,%*_@S^W?-\3? >JVGPF\$W_AZ]TV^2ZM+KQ ]_
M"Z7-X#%"\=EAW!C@ FPL>&D8MN74^'7["_[37A;_ (*\^+O^"CVM>)/ S^&O
M%GPWMO!3>$[6[O#>V=K!<Q3I>^>T 220M&V8=J*!( )#LW/]BT4 5=;T31O$
MVBWGASQ%I5O?:?J%K);7UC=PK)%<0R*5>-T8$,K*2"#P02*^#?V;/^";G[<W
M_!,+7-;^'G_!.GXQ_#_Q5\$=9UJ?5=+^%/QCDU"UN/"<\S;I8M.U2RCN&>W9
MB3Y<T#8/.2[222??E% 'D?PP^%?Q^\3>,M/^*G[4WC+P[)>Z,)&\.>#? \-P
MNEZ;/)&T3W4UQ<$2W]QY;R1HQC@CC25_W3.1(/AKX5?\$4OV\?AI^Q+\8_\
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M50MY*3N."/I2B@#\U?V3O^"7_P#P4B_X)X^%O%O[+?P3_;6\$7'[-!DU._\
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M?=K[0HH _+>1?V@+;_@YV^)NM_L^P^%-0O+3]E[2/[5T#Q??7%E;ZC;-J48
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>mdt-20250425_g8.jpg
<DESCRIPTION>IMAGE 8
<TEXT>
begin 644 mdt-20250425_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^5?VY_VY_P#ABW_A"?\
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MCJM]5_F%T?HS17YQZ#_P6:\.W!7^VOACJE@,\_8-5CNL#/\ M1Q]J^LOV?\
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M_$_CK^R_[:_L6V%Q]@^T>1YV75<>9M;;][.=IZ5\$?\ #Z3_ *H[_P"7/_\
M<=11PE;$1<J4;KU07/TVHKX,^''_  5Z^''BC6H;#Q3X:U?P?#,P1;\2)>P1
MDGK)M"NH]PK?UKZM^-OQCM_A'\$]?^(MG91^)+33;)+V&WANQ$ETC,@4K*%<
M $."" <U-3"UJ<E"<;-[!<]&HK\R?^'TG_5'?_+G_P#N.C_A])_U1W_RY_\
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MJ^'CS3CH%SVJBBBN$84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^5?\ P7._YHG_ -QO_P!L*_52ORK_ ."YW_-$
M_P#N-_\ MA0!N_L%^!?V8]8_9+\+WWQ+M?AR?%#-?F_G\07%I'>!!=S!"YD8
M. (PN">P&*_._P")EAX>M_VI]2M/@M+-<:&OB*-/#3VYD=B_FKY8B+9=@).$
M)R2 I[UU-Q^QGK4O[&^G_'_2]7_M.R:_DM=1T1;/:]C"LSPBX\WS#Y@WA 1L
M&W?G) )KZ>_X(V^&OA-XD\::Y/K.EFX^*^C?Z;I,U[/N@^R, CO!%@ 2HQY9
MLG$BE<8:@#Z!_P""U?\ R:SX6_['.U_](;ZODS_@G_JW[*NG_"G7H_CM'H3>
M*#K;M9_VI:7,LGV/R(=N#$I&WS/-X/.<U]9_\%J_^36?"W_8YVO_ *0WU?'_
M .P;_P $\/#O[7GPMUSQ5J_B[5/#]QI^LOIBV]C;QR(ZK!#)O);G.92/P% '
MW+\#+C]B/Q'\6/#ME\,K3PS-X[$SW&E+9V5W',)(HVE9E9T"@JB.W)[5\W?\
M%J_@C_9_B/P;\5K"#$.H1G0M4=1QYT8:2W<^[)YJ_2):^B_V</\ @ECX6_9Q
M^,_A[XB:;XXUC6+W1OM'EV5U:Q)')YUM+ <E>1@2D_4"O=OVR?@FO[07[-_C
M7P?% )M5ELS=Z7QR+R']Y" >VYEV$^CF@#QG_@DS\7S\2_V4=/T6ZG\W5/!]
MY+H\@8Y<VYQ+;M_NA)#&/^N)K\ROVNO%6I_M:?MT:[IV@-]L-[K47AC1@#F/
MRXG%NK@_W&??+GL')I?V'?VL)?V7?^%K1R3R0?VYX9G33U&>-5BS]D8CT'FR
MYKU__@CG\$3X\^/.K_$+4(/-T[P?:8MWD&0U]<AD0\]=L0F)]"R'TH ^@_\
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M?FG_ /I5'7@/_!%__D%_%O\ Z[:7_P"@W=?04)2CEM1Q=G?_ ")ZG5_M=?\
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+Y6TJ2BN1OW*O3"Y )Y^H/#,FJ2_\$>;TZJ9&D&E7"P&7.[R!J+"+\-H&/\
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MOU)HKTZF95)1<8Q46]VB;!1117CE!1110 4444 %%%% !1110 4444 %%%%
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M_7*BMXXZI&5222]_<+' ?'?X-Z-\?/A7KW@G7%"V^HPXAN0NY[6=>8IE]U8
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M2Z6>Y1A('+/LR@&!V<GGD"OOBBNBMF,ZM-TXQ44^P6"BBBO)&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'G7A_XB76OQ:;?R7=EI>GZIK]SI^FPRV,LLMY;PQS# =9
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M.,$\8^E=N#5"53_:/AL1*_0]\^$O[9VE?$S]FGQ=\9+GP[<:+IGAT7K2Z?\
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MM-(OT6!& ^E11P+JRJ*4K*&^@[G[WT4G3@4M>8,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAW202D8<+$))1SE2%#=06\KZAB%9RC:[L5='Q?\ M/>,[_\ ;*_;2.CZ#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&L:G8CA0=J*.!SBO;?"GAC3?!/A?2/#VC6XM-)TJTBL;2 ,6\N&- B+D\G
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M'XDQ<L)2HN#C%RNVNC2MIZGH]%%%?,'Z.%%%% !1110 4444 %%%% !1110
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MM]*LY)IHXB\CSW+AI9I7=I))7( !9W9F. !EC@ <5KUE)WDV@"BBBI ****
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MZ_\ !VO_ ,8KJ_U'XC_Z Y?A_F3]:H_S'Z(45^=__#W[3?\ HE]U_P"#M?\
MXQ1_P]^TW_HE]U_X.U_^,4?ZC\1_] <OP_S#ZU1_F/T0HK\[_P#A[]IO_1+[
MK_P=K_\ &*/^'OVF_P#1+[K_ ,':_P#QBC_4?B/_ * Y?A_F'UJC_,?HA17Y
MW_\ #W[3?^B7W7_@[7_XQ1_P]^TW_HE]U_X.U_\ C%'^H_$?_0'+\/\ ,/K5
M'^8_1"BOSO\ ^'OVF_\ 1+[K_P ':_\ QBC_ (>_:;_T2^Z_\':__&*/]1^(
M_P#H#E^'^8?6J/\ ,?HA17YW_P##W[3?^B7W7_@[7_XQ1_P]^TW_ *)?=?\
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MP>%DE)05@NS[H_X?"?&7_H6? O\ X 7O_P ET?\ #X3XR_\ 0L^!?_ "]_\
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M)=4_ZZP?^C5KTLL_WZA_CC^:/G^(O^1-C?\ KU4_](9\;T445^_'\.!1110
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MNHEWR0:5927+HOJ5C4D#WJEK>A:EX9U2XTW5]/NM*U&W;;-9WT#0S1GKAD8
M@_45]T_LGV>H_"?]F?XO77C2#Q)X5TV'5+:UF/AN![7Q'!/B$D N!L3;+%C=
MC >3^\*X?_@I5'?77Q.\&ZO(8VTB^\.6YT^20%;QD#,S&Y!&=^7^GXYK7"<4
M5,5GDLL5->RO)*:>[C&,M-+/XMNEKW8I45&ESWU/D"BBBOT$Y HHHH ^Y/\
M@DG_ ,EQ\6_]BX__ *4P5^J]?E1_P23_ .2X^+?^Q<?_ -*8*_5>OXF\2/\
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MA_ZZQ_\ HI*^VX2_WZ?^!_G$_'O%'_D34O\ K['_ -(F<%1117ZT?RZ%%%%
M!1110 4444 %?9'[.'_))=+_ .NL_P#Z-:OC>OLC]G#_ ))+I?\ UUG_ /1K
M5\3Q;_N,/\:_*1^Q>%O_ ".:O_7J7_I<#TZBBBOR4_J$**** "BBB@ HHHH
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M!WB['H_A[]HSXE>%?'^I>-=,\7ZA!XFU+_C]OI"LOV@=E>-U*,HP JE<*
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M7Y(?\%C/^2X^"O\ L7!_Z4S5ZV5_[U'Y_D1+H? =;?@?2]+USQIH&G:WJ/\
M9&C7E_!;WNH8!^S0-(JR2\_W5)/X5B5?T"?3;77+";6+2>_TJ.=&NK6UG$$L
ML08;D60JP4D9&=IQZ5]M+9V)/TB_:<_9R^&?PR^ \TV@_!F_U_2;..ZELO%^
M@Z]YTL9:.#9=W/7=$Q#Y&UD3R3C:),CAOV._@7\'?CEX3T^T;X5>(/$#6X:+
MQ+XTU#Q!'8PZ9.8BZ^1;QS@RQY& 2F1D$YY GA_;)^"GPE^"MWI'POTCQ8^J
M:E9:E8PZ%K$Z_9-/^TM&6>5@Q,@&/W>"S8#!BF[->>? ?X^?LZ?"^X\)>+;K
MX?>,-,^(7A]&+-HVHK-87\Q0IYDGG2AT!W$[%&!G!WCKX$8U_8RC:5[Z/6_S
M5_\ @>11\S_$C0]*\-?$/Q-H^@W[ZKHMAJ=Q:V-[)C=/"DK+&YP "2H!X 'M
M7V_=_P#!/N]\%_LG?VH/AW<>.OBSJP%PP2_> :#;LF<"%9D^T2J!]W:_SOC!
M5<-\\V_QH^''BOQ)\6_%_CCP9?W'B[Q!-)?^%Y-*N=EOI5VS2,&E&] X!,9)
M*ON*M\HW9KZ'7]OOX1WOC[3OB]J/@WQA_P +9L=(.G+96U_&NC2-M922Q?>%
M.YN/+('!VEANKJQ$L0U%4T]-_-]MUIW8M#Q/]B+X<_!SXB_$*+1OB=-K%[K-
MY>166E>'K2-XK>Z+AMSRSHP=0F/N@H>F"_*CR[]H[PCI/@+X\>//#NA6GV'1
MM,U>XM;2V\QY/+C5B%7<Y+' [DDUH_!WXRVG@_\ :2T7XF>(K6:2VAUF35KV
MVTN)2_SL[,L2NRCJ_ +#CO6%\=O'EA\4/C)XR\6Z5#<V^G:SJ<U[;Q7BJLRH
M[9 <*S 'Z$_6NJ,:BQ#DV[-?*X=#A*^FOV"?^1^\<_\ 8K-_Z<;"OF6OIK]@
MG_D?O'/_ &*S?^G&PKT*?\6G_BC_ .E(^>XA_P"1-C/^O53_ -(9]=T445]^
M?Q"%%%% !1110 4444 %=[\"?^2M>'O^NLG_ **>N"KO?@3_ ,E:\/?]=9/_
M $4]>;F?^XU_\$OR9]#P[_R.L%_U]I_^EH^V:***_ 3^X@HHHH **** "BBB
M@ HHHH **** "BBB@ KXF^.W_)6O$/\ UUC_ /125]LU\3?';_DK7B'_ *ZQ
M_P#HI*^VX2_WZ?\ @?YQ/Q[Q1_Y$U+_K['_TB9P5%%%?K1_+H4444 %%%% !
M1110 5]D?LX?\DETO_KK/_Z-:OC>OLC]G#_DDNE_]=9__1K5\3Q;_N,/\:_*
M1^Q>%O\ R.:O_7J7_I<#TZBBBOR4_J$**** "BBB@ HHHH **** "BBB@ KY
MX_X*#?\ )G/Q+_Z\X/\ TJAKZ'KYX_X*#?\ )G/Q+_Z\X/\ TJAK?#_QH>J_
M,F7PL_!NBBBOT8@**** "BBB@ HHHH **** "BBB@ HHHH _HQ^ _P#R0[X=
M_P#8N:=_Z31UW5<+\!_^2'?#O_L7-._])HZ[JOS27Q,N.R"BBBI*/Q@_X*1?
M\G=>+?\ KWL/_22*OF.OIS_@I%_R=UXM_P"O>P_])(J^8Z_O'@O_ ))W!?X$
M?+8C^++U"BBBOM# **** "BBB@ HHHH **** "BBB@#[D_X))_\ )<?%O_8N
M/_Z4P5^J]?E1_P $D_\ DN/BW_L7'_\ 2F"OU7K^)O$C_DJ,5_VY_P"FXGT6
M#_@H****_,SN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'S_@
ML)_R<QX9_P"Q1M?_ $MO:^%Z^Z/^"PG_ "<QX9_[%&U_]+;VOA>OO\#_ +M#
MT,WN%%%%=P@HHHH **** "BBB@ HHHH **** /IO_@FK_P GK?#G_N)?^FVZ
MK]T*_"__ ()J_P#)ZWPY_P"XE_Z;;JOW0KX_./\ >(^GZLN.P4445X11YO\
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M2X^+?^Q<?_TI@K]5Z_*C_@DG_P EQ\6_]BX__I3!7ZKU_$WB1_R5&*_[<_\
M3<3Z+!_P4%%%%?F9W!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% 'TW_P $U?\ D];X<_\ <2_]-MU7[H5^%_\
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MK_MU_G$_(/%#_D34O^OL?_2)FA1117UY_, 4444 %%%% !1110 5]D?LX?\
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M/XLO4****^T, HHHH **** "BBB@ HHHH **** /N3_@DG_R7'Q;_P!BX_\
MZ4P5^J]?E1_P23_Y+CXM_P"Q<?\ ]*8*_5>OXF\2/^2HQ7_;G_IN)]%@_P""
M@HHHK\S.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\?/^"PG_
M "<QX9_[%&U_]+;VOA>ONC_@L)_R<QX9_P"Q1M?_ $MO:^%Z^_P/^[0]#-[A
M1117<(**** "BBB@ HHHH **** "BBB@#Z;_ .":O_)ZWPY_[B7_ *;;JOW0
MK\+_ /@FK_R>M\.?^XE_Z;;JOW0KX_./]XCZ?JRX[!1117A%'F_[2G_)N?Q4
M_P"Q4U7_ -(Y:_ ROWS_ &E/^3<_BI_V*FJ_^D<M?@97]2^#_P#N.+_QK\CQ
M,P^*(4445_0!Y04444 %%%% !1110 4444 %%%% !7[6?\$[?^3.?A__ -Q#
M_P!.%S7XIU^UG_!.W_DSGX?_ /<0_P#3A<U^(^+G_(BH_P#7V/\ Z14/2P'\
M5^G^1]'T445_)![P4444 %%%% !1110 4444 %%%% !7Y(?\%C/^2X^"O^Q<
M'_I3-7ZWU^2'_!8S_DN/@K_L7!_Z4S5ZV5_[U'Y_D1+H? =%%%?;DA1110 4
M444 %%%% !7TU^P3_P C]XY_[%9O_3C85\RU]-?L$_\ (_>.?^Q6;_TXV%:4
M_P"+3_Q1_P#2D?/\0_\ (FQG_7JI_P"D,^NZ***^_/XA"BBB@ HHHH ****
M"N]^!/\ R5KP]_UUD_\ 13UP5=[\"?\ DK7A[_KK)_Z*>O-S/_<:_P#@E^3/
MH>'?^1U@O^OM/_TM'VS1117X"?W$%%%% '"_'C_DAWQ$_P"Q<U'_ -)I*_G.
MK^C'X\?\D.^(G_8N:C_Z325_.=7U.2_#/Y?J9RW"BBBOI!!1110 4444 %%%
M% !7ZB^%?^1!\#?]BMHO_INMZ_+JOU%\*_\ (@^!O^Q6T7_TW6]>IE?^]?\
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MLG_HIZX*N]^!/_)6O#W_ %UD_P#13UYN9_[C7_P2_)GT/#O_ ".L%_U]I_\
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MS_@I%_R=UXM_Z][#_P!)(J^8Z_O'@O\ Y)W!?X$?+8C^++U"BBBOM# ****
M"BBB@ HHHH **** "BBB@#[D_P""2?\ R7'Q;_V+C_\ I3!7ZKU^5'_!)/\
MY+CXM_[%Q_\ TI@K]5Z_B;Q(_P"2HQ7_ &Y_Z;B?18/^"@HHHK\S.X**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#\?/^"PG_)S'AG_L4;7_ -+;
MVOA>ONC_ (+"?\G,>&?^Q1M?_2V]KX7K[_ _[M#T,WN%%%%=P@HHHH ****
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M "BBB@ HHHH **** "BBB@ K\D/^"QG_ "7'P5_V+@_]*9J_6^OR0_X+&?\
M)<?!7_8N#_TIFKULK_WJ/S_(B70^ Z***^W)"BBB@ HHHH **** "OIK]@G_
M )'[QS_V*S?^G&PKYEKZ:_8)_P"1^\<_]BLW_IQL*TI_Q:?^*/\ Z4CY_B'_
M )$V,_Z]5/\ TAGUW1117WY_$(4444 %%%% !1110 5WOP)_Y*UX>_ZZR?\
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M8*_5>OXF\2/^2HQ7_;G_ *;B?18/^"@HHHK\S.X**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\?/^"PG_)S'AG_ +%&U_\ 2V]KX7K^FNBOH*&;
M>QI1I\E[>?\ P">4_F4HK^FNBM_[:_Z=_C_P!<I_,I17]-=%']M?]._Q_P"
M'*?S*45_3711_;7_ $[_ !_X <I_,I17]-=%']M?]._Q_P" '*?S*45_3711
M_;7_ $[_ !_X <I_,I17]-=%']M?]._Q_P" '*?A?_P35_Y/6^'/_<2_]-MU
M7[H445X^,Q7UNHI\MM+%)6"BBBN 9YO^TI_R;G\5/^Q4U7_TCEK\#*_H[HK]
M3X/XX_U3H5:'U;VO.T[\_+:RM_+(XL1AO;M.]K'\XE%?T=T5^@?\1D_ZE_\
MY5_^YG)_9_\ ?_#_ ()_.)17]'=%'_$9/^I?_P"5?_N8?V?_ '_P_P""?SB4
M5_1W11_Q&3_J7_\ E7_[F']G_P!_\/\ @G\XE%?T=T4?\1D_ZE__ )5_^YA_
M9_\ ?_#_ ()_.)17]'=%'_$9/^I?_P"5?_N8?V?_ '_P_P""?SB45_1W11_Q
M&3_J7_\ E7_[F']G_P!_\/\ @G\XE?M9_P $[?\ DSGX?_\ <0_].%S7T?17
MQ'%W'W^M6!A@OJOLN6:E?GYME)6MRQ_FWOT.G#X7V$N;FN%%%%?D9WA1110
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M[9HKT/\ 6W'?R0^Y_P#R1\)_Q"[)O^?M7_P*'_R!\3?\*)\>?]"]-_W^B_\
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MHQ_X4/\ #3_HG?A3_P $EM_\11_PH?X:?]$[\*?^"2V_^(KZ7^VH_P GX_\
M (Y6?SG45_1C_P *'^&G_1._"G_@DMO_ (BC_A0_PT_Z)WX4_P#!);?_ !%'
M]M1_D_'_ ( <K/YSJ*_HQ_X4/\-/^B=^%/\ P26W_P 11_PH?X:?]$[\*?\
M@DMO_B*/[:C_ "?C_P  .5G\YU%?T8_\*'^&G_1._"G_ ()+;_XBC_A0_P -
M/^B=^%/_  26W_Q%']M1_D_'_@!RL_G.HK^C'_A0_P -/^B=^%/_  26W_Q%
M'_"A_AI_T3OPI_X)+;_XBC^VH_R?C_P Y6?SG45_1C_PH?X:?]$[\*?^"2V_
M^(H_X4/\-/\ HG?A3_P26W_Q%']M1_D_'_@!RL_G.HK^C'_A0_PT_P"B=^%/
M_!);?_$4?\*'^&G_ $3OPI_X)+;_ .(H_MJ/\GX_\ .5A\!_^2'?#O\ [%S3
MO_2:.NZJ"QL;;2[&WLK*WBM+.WC6&&W@0)'$B@!551P%    X %3U\NW=MEK
M16"BBBD,_&#_ (*1?\G=>+?^O>P_])(J^8Z_H0USX2^!_$^J3:EK'@SP_JVH
MS;?-O+[2X)IGVJ%7<[(2<  #)Z "J'_"A_AI_P!$[\*?^"2V_P#B*_>LE\4H
MY/EU# ?4^;V<4K\]K_+D=OO/)J8%SFY<VY_/]17] /\ PH?X:?\ 1._"G_@D
MMO\ XBC_ (4/\-/^B=^%/_!);?\ Q%>W_P 1CC_T ?\ E3_[0S_L]_S'\_U%
M?T _\*'^&G_1._"G_@DMO_B*/^%#_#3_ *)WX4_\$EM_\11_Q&./_0!_Y4_^
MT#^SW_,?S_45_0#_ ,*'^&G_ $3OPI_X)+;_ .(H_P"%#_#3_HG?A3_P26W_
M ,11_P 1CC_T ?\ E3_[0/[/?\Q_/]17] /_  H?X:?]$[\*?^"2V_\ B*/^
M%#_#3_HG?A3_ ,$EM_\ $4?\1CC_ - '_E3_ .T#^SW_ #'\_P!17] /_"A_
MAI_T3OPI_P""2V_^(H_X4/\ #3_HG?A3_P $EM_\11_Q&./_ $ ?^5/_ +0/
M[/?\Q_/]17] /_"A_AI_T3OPI_X)+;_XBC_A0_PT_P"B=^%/_!);?_$4?\1C
MC_T ?^5/_M _L]_S'YQ?\$D_^2X^+?\ L7'_ /2F"OU7KF_#?PU\(>#;Z2]\
M/^%=$T.\DC,+W&FZ=#;R,A()4LB@E<JIQTR!Z5TE?B/$F=+B#-*N9*GR<_+[
MM[VM%1WLNU]CTZ%/V,%"]PHHHKY@W"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH PO'7C+3?AWX+UWQ1K,WV?2M&L9K^ZD](XT+MCU.!P.YKY._8
M1_;E\2?M*^*/$GACQ]X>T[POKL=E#KFB0V*21B[TV0X#'S)'+,NZ,[EP"'^Z
M,&NJ_P""@GPS^)WQP^%NB_#CX=Z89+/Q#JT*>(=8:[ABCT^Q1U8ED>5'DRQ5
MML88E8F'4C/A$W[&OQ_^#OQU^%'Q.TGQ9;?%R;0!#X?O=/LM,LM">WT559"F
M/-1)@JN^ 3N#!#R!P ?2?BS_ (*#?L_>!];U71]<^(MM8:KI>I2:3>6;:=>/
M)#<QDAU*K"<H""/,&4R/O5L_$+]M?X)?"RZTZW\3>/[&Q;4M)37+&2*WGN8K
MJS=RB21211LKDE3A5)8@$XQS7P-\.;/XH:C\3OVO])^'7PK\/?$=-?\ $][I
M%[/JE_#:RZ?YDET%<K,0)HL,3L5@=P'K7L/P/_8G\=_"G]HKX":CJVEVFN^&
M_!O@N?3]1UI+B%HK?4))KR4)%&["4A3<(JN$QWXY  )OVI/VIO'W@/5?CQ-X
M/^*6DJGAWP[H]]I/AZ'0G^W:7)/<V@>>62>W,,@>.<_+O<CS!\B%"3]A^"?&
MM_)\"/#_ (MU&WN]<U-_#EMJ=Q!I]N&N+R8VRR,L<:@ N[$@* !D@<"OAW]I
MS]D?XL_$+XK?M+ZQX?\ "G]H:;XP\/:/8Z'-_:-I']KF@GL'E3:\H*;5@E.7
M"@[>"<C/W#X,TWQ#X*^ FA:?;Z6ESXKTGPU;P1Z9),@62\BM540F0-MP9%V[
MMV.^<<T ?(5K^V]\>_!/CCX:W?Q0^%FA>'/ _P 0-9_LC3M)MY9UU^Q+2(B-
M.COAB X.T1+GOL) +OB-^VI\78_VF/B'\-O"6J_!GPSIWAJ>TAM9/B)?7-G<
M7S30H^(BLX$C!B<A5& 5ZYKB_A#X"_:BB_: C^)GQ2^!=KXS\2SW:6]GJUUX
MJL([7PW8LV'%G:+,_*JS'=DN?7<S%N@_:G_9]^+/Q.UOQ[X?T[]G3X8>((_$
MEP/[.^(]O<06NH6,9VCS;DR,)WE  _U?RC&,.." ??WA]M3;0=-.M?9/[8-M
M&;W[!N^S^?L'F>5N^;9NSMSSC&:\A_:>^+'Q)^'FF^'=*^%/@"3QMXMU^]^R
MQW5W%*=+TN,8+3W;H1M7D #<N?F.> K< OC?QA^SSKG[,WP'T>;3O$FJ:G9O
M:Z[J5[;RN8[*RMT,DL6V1-I/S*I?=T&5)X.W^W)-\?KKX=66B_ +1H[S5M4D
MDBU/5%O;>VN;" !<&!IY44.Y+#<-Q4 XP2& !RG[.W[:'B3Q);_&G2OBUX>T
MO1O$?PK1[C5;OPS(\MA<1!96Q'O9BK@0G@L2<]%(*CS7P5_P4 ^+]O)\-_'/
MC[X?>'-)^#_Q!UG^R-,GTVXG;4]/WOLBEN&9BCJ<,PVHI948_+\H;KOV7?@7
MXO\ ^%%^/OA)XO\ @W;?"?1M8TF6W.M+K]OJ]WJMW/&\<L\[1L3O7Y6^;CG"
M@ 8KR+PQ^RC^T3X\T'X2?!KQ[X8T'1OAM\/=<74;CQ1;ZG%.VK01.QCCBA4^
M8AV.ZY=%SN!.-N& /5?V@OVMOV@O >J>/_$/A+X5Z/8?##P-)&EYJ7C(7%M=
M:R-X5Y++#HNSG .'SP1ECY=5_CU^W?XU\/VOP'F\"VW@KPU%\2M(FU6>[^(\
MTT-II^V**15::.2,*#O8!B#N)3 &:XO]ISX?_M-?&'X]R/JWP=@\>_!W0;QG
MT;PPGB:RT^TU)U/[N[NPT_F2'D_NV"J!@;>7W^J_&[PK\5O%VF> M=D_9I^&
M_P 1771S!J7AC7+JU:^TBX8_ZJWN)2;?R1A<E,DXP,8!H ]Z_9T\4>-O&GPS
MMM9\=ZAX*U75+N>1[>\\ 7,MQI<MMP$*R2,Q9LA\X)'3WKTZOE[_ ()]_L[^
M*_V=?A+K=CXO6QTW4M>UN?65\/Z7*9;;2$=440(Y9MV G8L ,#<W)/U#0 44
M44 %?%G[='[=?B3]FGQQX<\->"/#NG^*+U+%M=\21WD<KM:::)5C5D*.H5F/
MF?,VX+A25(-?:7X9K\W+#]BGX_\ QH^(GQB\=^(O%]K\)9/&KS:(VBWFEV6N
M27&C;%6-/,69U@&T*I",&W(6X^4T ?:?BS]IKX;^ ?AEX9^('B3Q+#I'A/Q&
MUM'I^HR0RRH[SQF2,-Y2ML&U6)9L*,')%<_X%_;;^"/Q*A\42^&_']EJ8\,V
M4VHZG&MM<1R1VT0)EFC1XPTR*!R8@XY7^\,_G=\?OAS\4OA/^P?X7^&_Q$T6
M".XT#XCV]IH-]<74-S;:C8O'=-&66.1W50Q8;7"D(R#'! ]M\3?LZ_&_XZ_%
M'Q%XX\2_#30/AO\ V-X$U;PUI>FZ3JUO=2ZY<W%M/%%B1"JI$#+D"785R!SD
ME0#V/XI_ML>!?'7P%^(.L?"/XKZ3I6MZ'86ET^O7VC7EQ;:<+B98XC(GV=R6
M8[EVB-V0G+)@5D_LU?'[QWX^_:\\;^"-;\50:_X5TWP;I&JV:6VGQV\37$]M
M:/).A\M9MKM+(P1SP&Q@8P.:OOV7?'T?_!+;_A45CX4BB^(DEI$)M'BN[5-\
MPU%9G+3>8(BWEKG=OYQC.>*V_P!E;]GGX@_#?]JGQ7XP\1Z!_9WAR^\#Z+H]
MO>_;;>7?=V]I9QS1[$D9QM:&0;BH4[>"01D ]+_:.^+GQF\/^-O#G@KX-?#N
MUU_4]1@DO+WQ-XDBG71+"-<@1-)&5S*V#QNR/E^5LG;POP/_ &_[3Q'^S)XS
M^)OQ)TB#PY?>#=0ETC4H-+E\VWOKI%0HEH2QR79PH7>P'7<5.:A_X* :/^T=
MX[M])\'?!_PRVH>"[^#?XBOK'5[6PO;A2Y5K-))I5,:,G+,J$G(&<;E;R_QQ
M^RO\3/C)^R3I7@FT^$6A_"F_\&>(;?4]*\'RZY'?6>MP)$XD$\T3GYW:1N78
M$X.6&[< #Z%_8;_:,\1?M+?#6[\4>*;_ ,&QZA-<%K;0/"\YEN=.MLD)]M)G
MD(D?&0NU, 9(RV%^D'8(K,02 ,_*,G\J^#/V;?V=_'.A_M,7OQG\1?#3PW^S
M]X7TWP])I<GA;P[>07 U$_?:>3[-^Z51PW0-F).#RU?0G[&_QG\5?M!?!"S\
M>^*=/T_3'U6^NSIMOI\$D2_8HY3'$SB21R78HQ)& 01@=R ?-7Q4_;J^/_PP
MM+SXCZM\(=(T#X0V^O#1TT[7WGM?$5U&=P$Z*SA0&QD#RVQS]Y07'K?[1/[4
MWCW0_BYX%^$OP=\-:/J_COQ)IS:U/<>*C,EGI]F-V#(D3*^XE'S\WRX VL6X
M^<O$7@?]JWQO\?CX_P#'_P !;/X@Z?HL[-X6\/2^++"TTS2R&XG\GSV,LI"J
M=TG0\X&$">V?M&?!OXMZ7^T-X ^/OPM\+:=XJ\0V.B-HFN>%;O48K1G1P[!H
MYI"$^5I&!.[/R)@,"< $'@K]NCQYXU_9[\3:QI?PIO-:^,'A_7SX7O?"^DI)
M-;1W?_/R[#+) /FSD]5QO .\;'[.'[4WQ1U[]HGQ#\%?C%X6\.Z=XIL=(76X
M-0\(S2O:K"?+_=RK)(Y5OWOWB1R,;2"K'S[X>_!']HKX!_LY_$/7/"NB:1JW
MQU^(7B-]4O;2&YMQ#I4,H;+(TLBQ/(C,Y W,H,@X<*<X?[.7[/?QLC\$^._
MWB7X;GX;ZWXTTNX&M?%JX\1VVL:G=W;$<-%'+O5&#2 !6 7KDL<D ZOP[_P4
M+\1?$/\ ;,\.?#WPGH>DS_";5+^\TF'Q)<0S-<ZA<6MN9+A[=Q*(_+#M&H)1
MLCG/S87[MK\Q#^P!^T#\._B=\$K?PO\ $>UU7P]X2%Y%;:[;^'M/M$\/1R@%
M]UN\N^[:8E@6(=E.6)R:_3I<A0"<GN: %HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O!/A#^VM\./C9\:/%_PP\.RZ@OB'PV91)->0QI;7HBD\
MN4V["1F<*Q&=RKD'(R,U+^VU\>A^SI^SAXJ\56\ZQ:Y+%_9VCJV"6O)LK&0"
M>=@W2$>D9K\S+/P=\5OV/;?X+?$[6O@W<>#-,\%W9M]=\11Z]:WTFL6][+F0
M301-OB.UY%7<2 64'G&0#]J:*_(7XVZO\%M;_;T^+M]\8;G7+KX;WF@Z5=0R
MZ(UTUI+,UI:&W>?[-\Q!#-Y9/R[FYZBN3T7PKXD\<^'?V2/#OC6Y\26FAZIX
MPU>ST>2^N'M]2_L1S9+$OF#YE5E,B@C^ _+\NV@#]./C1^T#XD^$WBB_M;?X
M8ZIK_ABP\+7_ (ANO%$=VL-G#-;Q22+:-\C89_+ W9R-ZD*PSCIOV=/C%_PO
M[X)^%?B"=)_L$:Y;O<?V?]I^T>1ME=,>9L3=]S.=HZU\ ?M6^"=&^&_[4ND^
M%O#UI]@T/2/@=K=G9VV]G\N)+740H+,2S''<DDU];_\ !.G_ ),H^%F>G]GS
M?^E,U '+ZM_P4^^#FD^*)+$V_BJ[\,1:G_8\OCJUTC?H,=UC)C^T;PS$#GY4
M.1\PROS5U7QH_;D\*?!CXH6_@ ^"_'7CCQ#-I<>L"/P;I,5^HMW=D#$><K=5
MY(4CYEYYKX*^-/[67PH_:&^)4OPYUK5X/A-\ M U(7EY::9H\QO_ !+=H2IR
MMO&RPQ K_%\WW6(+8$7J'[96I?"+2?C9?>)-<\6_%_X4^*!X7M[/PWK?A:!;
M?2]4A"^;%! \2M*YWNNY':( J 2, T ?H;\-?'*_$KP-I'B9-#UKPVFHQ&4:
M7XAM/LM];X8KB6+<VTG&0,G@@]ZQOCC\=/!_[._P_N_&/C;46L-)A=8(TAC,
MD]S,V=D,2#[SM@^@ !)( )'BO[.GQ^U7X;_LB^ O%7[0VIW6B:[J%P-.CGOK
M.62\NVDD<6@>&&-G,CQJ#RN2!N;DFNY_;%^-7@_X!_!2\\7^,?#<7BRV@N(X
MM/TF:W259KUE;RLEP1&.&R^"0,X!. 0"I\ OVS_!/[0/C'6/!]EI/B;P=XQT
MN 7<WA_Q?IHL;QH#L_>JH=QM_>)P2&PP.,<UQFJ?\%+/A#I/CF]T.6#Q/)H=
MCJ?]C7?C6'22V@V]WG!B>XW[L@]PF"/F!*\UX/\ L _$CP=\=_CIXF^(/B;Q
M\NO?'3Q)H\D4.BZ?IEU!8Z!IZE,PQ/)'M9U_=Y(8_P 6"Y9F/S^OB:3PU^Q[
MXR_93O?#6L2_&NY\6A+31HM.D<W<9N891=+)LV[-L; -GD;6'RG( /T9^.O[
M=WP]^!/C"X\*W&F>)_&GB*RL3JFIZ?X/TP7K:9:8#>=<LSHL:893U) 92<!E
M)/'/[>/PV\&_!OP9\2[.WU[Q=H/BW4%TO2[;P]8I+>/<D29C:*22/#!HV3:"
M26Q@$'-?+?[9G[56F_!74M+^">AW&G^%?&E]HEKIOBWXDW>FM++:6C6Z*5A\
ME#++*ZJ.<87Y0,'YXX?&FE?L\0_LB_!JRLM9^)4GPLT?6I[J/QUX/T]8I+/4
M(V8/<7AEC,L(,DCE#'&WW0 >!D ^X_@/\?H?CU8:O=P>!/&_@==.ECB,?C31
MQI[W&\$YA D?>!CD\8R/6O5*^'_^";GC+QCXIU/XGQ?\)-XJ\=?""UO84\(^
M)?&(8WMSPWG*KN [H/DZX P,*I+*/N"@ HHHH **** "BBB@ HHHH **** /
M'_VG/VI/!O[)_@>S\3^,H]2N[:\O5L;:STB&.6YED*LQ(621%VJJDDEO3KFO
M1?!/C+2OB)X/T7Q/H5R+S1]7M(KVTG'\4<BAER.QP>1V((K\W?VC/$'B_P#:
M:_;4O]+\&?#1/B]X4^%=A+IEWI#:S;:;!]NO(V2:1I9CABNW8$ R&@)X[^6Z
M7X\US0?^">GQ]^!/C:TFTCQ?\/[NS,6G74R2RI93ZA;N%#J2KA)"WS+\NV6/
M'6@#]CZR/&&M7?AOPGK.K6&DW&O7UC9S7,&EVC!9KN1$++$A/ 9B H]S7Y+_
M  /?P=)\>/@$_P #6\;/\2&2)OB2VJ&[*&S,,)E-WYWRX^]LV?)]S'S>770_
ML5_!_P .S?L/_&7XE7*WEWXJATGQ-H]K+/>2-!:6K6H=TBASL4L_S%L9)[T
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M-/V6/V@]:^&/CF\^)?Q\\36]M?\ BRZL-+NK;RK1YB)+>R62)"P$1F'R@$@
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MM\;_ !^/C_Q_\!;/X@Z?HL[-X6\/2^++"TTS2R&XG\GSV,LI"J=TG0\X&$"
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MA31_!OASX4V#16QM=1ANYM8NO+"+,JQ,PC7,<+8;&-AQG=\H!%\5/VZOC_\
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M^RX!&BI9EX699MA5OWN26W>U>Z4 %%%% !1110 4444 %%%% !1110 4444
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M:$_Z*!_Y1=/_ /D>C_AXE^T)_P!% _\ *+I__P CT?\ $(\]_P"?U+_P*?\
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M_P K#Z_2[/\ KYG[645^*?\ P\2_:$_Z*!_Y1=/_ /D>C_AXE^T)_P!% _\
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M_P HNG__ "/1_P /$OVA/^B@?^473_\ Y'H_XA'GO_/ZE_X%/_Y6'U^EV?\
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MI?\ R17TW11]:Q'_ #\?WL+'S)_P[5_9P_Z)S_Y7-2_^2*/^':O[.'_1.?\
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M$?\ T&S_  _R#ZM1_E/BG_ATS\(O^AC\;?\ @=9__(M'_#IGX1?]#'XV_P#
MZS_^1:^UJ*/]=N(_^@V?X?Y!]6H_RGQ3_P .F?A%_P!#'XV_\#K/_P"1:/\
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M&/QM_P"!UG_\BU]*?%WX\^#?@;_PC?\ PE^H36'_  D.I)I.G>5;23>9</\
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M_H-G^'^0?5J/\I\4_P##IGX1?]#'XV_\#K/_ .1:/^'3/PB_Z&/QM_X'6?\
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MS_\  G_F'^KN3?\ 0%2_\%P_R/.?^&>?A_\ ] #_ ,G;C_XY1_PSS\/_ /H
M?^3MQ_\ '*]&HH_M/'?\_P"?_@3_ ,P_U=R;_H"I?^"X?Y'G/_#//P__ .@!
M_P"3MQ_\<H_X9Y^'_P#T /\ R=N/_CE>C44?VGCO^?\ /_P)_P"8?ZNY-_T!
M4O\ P7#_ "/.?^&>?A__ - #_P G;C_XY1_PSS\/_P#H ?\ D[<?_'*]&HH_
MM/'?\_Y_^!/_ ##_ %=R;_H"I?\ @N'^1YS_ ,,\_#__ * '_D[<?_'*/^&>
M?A__ - #_P G;C_XY7HU%']IX[_G_/\ \"?^8?ZNY-_T!4O_  7#_(\Y_P"&
M>?A__P! #_R=N/\ XY1_PSS\/_\ H ?^3MQ_\<KT:BC^T\=_S_G_ .!/_,/]
M7<F_Z J7_@N'^1YS_P ,\_#_ /Z '_D[<?\ QRC_ (9Y^'__ $ /_)VX_P#C
ME>C44?VGCO\ G_/_ ,"?^8?ZNY-_T!4O_!</\CSG_AGGX?\ _0 _\G;C_P".
M4?\ #//P_P#^@!_Y.W'_ ,<KT:BC^T\=_P _Y_\ @3_S#_5W)O\ H"I?^"X?
MY'G/_#//P_\ ^@!_Y.W'_P <H_X9Y^'_ /T /_)VX_\ CE>C44?VGCO^?\__
M  )_YA_J[DW_ $!4O_!</\CSG_AGGX?_ /0 _P#)VX_^.4?\,\_#_P#Z '_D
M[<?_ !RO1J*/[3QW_/\ G_X$_P#,/]7<F_Z J7_@N'^1YS_PSS\/_P#H ?\
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M K[*_P""8_[?WBWX[^*+SX9_$>:/5=<AL7OM,UU8TBDG2,HKPRJH 9\-N#@
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M]F7PWHVF>(-/\4MJ+2:M=ZOI,HEL[B>7 /DN/O(JHB9/)*$X&=H /HJBBB@
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M.!Q7V;^R=\)_VT_AO^T5I7AC7O$&M6OA"W"W6IW>NWC:OI,MH&YC@9G.)6/
M5&1QG<WR@Y^'?$7BKXO? RS\+> O&FD:EI&E^%=?7Q!INBZU8F%5N58%BDF
MSQOU.UBO.1U)/ZR?LA?\%0?!?[27B&S\'Z_I3^!O&MUE;2"6X$UE?,!G9%*0
MI60X.(V7G@!F)Q0!W_\ P4C\5:EX,_8N^(FJZ/J5UI.J1BP2"[L;AH)D+ZA;
M(VUU(8':S=#R,BOR+^!_A']JG]I#3]5O?AUXA\8>(K72Y4AO)/\ A+_LOE.X
M)48GN4)R >F>E?JS_P %1]-U37/V.?$VDZ/I]YJNH7]_I\,=G8P--+)BZC?
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M3^596NO6,Q;3V? 51,KG=""0!NW.,GG: 37Z1T ?B!_P[W_;)_OZA_X5\?\
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MU3P5?^&K58],L;C3Y-.B6WB 2WC:,QJ%08&%!& ,#C%?FW_PXYT/_HK>H?\
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M!XG^UQ^U)H?[)'PJ_P"$QUC3KC6I[B\33]/TRVD$;7-PRN^&<@[$"QN2V#T
MP217)?L2_MPZ-^V9H?B*2V\.S^%-<T&2(7>FR78NHS%+O\J1)=B;L^6X(*C!
M ZY!KTS]H;]GCP?^TY\.IO!GC2WN'TYIUNH+FRE$=S:3J&598F*L VUW7YE(
M(8@@US_[+W[(7@']DCP_JVF^"DU&YGU:5);[4]7G2:ZGV;O+0E$10J;WP H^
M\<Y- 'X[?M]> ]9_9V_;@\0:];*R)J&K1^+M)NF4JKM)+YS8(_N3B1?7Y0>]
M?6'[97_!3;X:_%;]D^^\->";N[F\8>*K>&UO]-EM9HO[*B)5YP\K($D)"F,>
M6QSOR<8P?O7]H/\ 9L\"?M.>#!X<\<Z6;N&)_-M+ZV817=E(>"T,F#C(X*D%
M3@9!P,?)&@_\$5_A'INN176H^*_%FKZ=&X;^SWE@A$@'57=(MV#_ +.T^_>@
M#S/_ ((F?""]A?QY\3[J-H;*:-- L"RX$Q#+-.P/HI6 <<$EO[M?(?[>%Y'I
M_P"W=\1+J8D0P:Y!*^T9.U8H2?T%?OIX)\$Z#\-_"NF^&O#&E6VB:%IL7DVM
MC:)MCC7))]R2226.22222237S!\7?^"7_P '?C5\2-=\;^(;GQ,FLZS.+BY6
MRU"..$,%5?E4Q$@84=S0!YC\9O\ @J_\ O$WPK\4:-:6&L>*+G4=/FM(]+N]
M+"03,Z%5\QG; 0$@DC)XX!-?%?\ P25\-Z_JW[9'A_4M*AG.E:58WLNKSHI\
MM(7MI(XU<]/FE:+ /]W/:OONQ_X([? "UG$DI\57B8_U4^JH%_\ '(E/ZU]2
M?!SX#^ O@!X=DT3P#X:L_#MA*RO/Y&YY;A@,!I97)=R!G&XG&3CK0!WU%%%
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M%GC>^^*L#>*O$OC_ .%6GZC!%X1\5>*TD^UWB_O1./-D16D VQYW ;<CA=Q
M^V*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P .>_@U_P!#-XZ_\#[+_P"1*/[0P7;\ LS\R?\ AJ'XR_\ 16_'7_A27O\
M\=H_X:A^,O\ T5OQU_X4E[_\=K]-O^'/?P:_Z&;QU_X'V7_R)1_PY[^#7_0S
M>.O_  /LO_D2C^T,%V_ +,_,G_AJ'XR_]%;\=?\ A27O_P =H_X:A^,O_16_
M'7_A27O_ ,=K]-O^'/?P:_Z&;QU_X'V7_P B4?\ #GOX-?\ 0S>.O_ ^R_\
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M=,_"+_H8_&W_ ('6?_R+1_K7P!_T!P_\$1_R#V&*_F_$^*?^'B7[0G_10/\
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M%?S?B?%/_#Q+]H3_ **!_P"473__ )'H_P"'B7[0G_10/_*+I_\ \CU]K?\
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M\$1_R#V&*_F_$^*?^'B7[0G_ $4#_P HNG__ "/1_P /$OVA/^B@?^473_\
MY'K[6_X=,_"+_H8_&W_@=9__ "+1_P .F?A%_P!#'XV_\#K/_P"1:/\ 6O@#
M_H#A_P""(_Y![#%?S?B?%/\ P\2_:$_Z*!_Y1=/_ /D>C_AXE^T)_P!% _\
M*+I__P CU]K?\.F?A%_T,?C;_P #K/\ ^1:/^'3/PB_Z&/QM_P"!UG_\BT?Z
MU\ ?] </_!$?\@]ABOYOQ/BG_AXE^T)_T4#_ ,HNG_\ R/1_P\2_:$_Z*!_Y
M1=/_ /D>OM;_ (=,_"+_ *&/QM_X'6?_ ,BT?\.F?A%_T,?C;_P.L_\ Y%H_
MUKX _P"@.'_@B/\ D'L,5_-^)\4_\/$OVA/^B@?^473_ /Y'H_X>)?M"?]%
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MC;_P.L__ )%H_P!:^ /^@.'_ ((C_D'L,5_-^)\4_P##Q+]H3_HH'_E%T_\
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M\)?]!'6O^_\ #_\ &J/^&4?"7_01UK_O_#_\:H_M7(/^?*_\ 7^0?ZL\<?\
M05+_ ,'2_P SQ?\ X:%^('_0?_\ )*W_ /C='_#0OQ _Z#__ ))6_P#\;KVC
M_AE'PE_T$=:_[_P__&J/^&4?"7_01UK_ +_P_P#QJC^U<@_Y\K_P!?Y!_JSQ
MQ_T%2_\ !TO\SQ?_ (:%^('_ $'_ /R2M_\ XW1_PT+\0/\ H/\ _DE;_P#Q
MNO:/^&4?"7_01UK_ +_P_P#QJC_AE'PE_P!!'6O^_P##_P#&J/[5R#_GRO\
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M ,/_ ,:H_M7(/^?*_P# %_D'^K/''_05+_P=+_,\7_X:%^('_0?_ /)*W_\
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MIZ_Q]X_TWX=:+%J&HQW=W)<W$=E96&GP&:YO;E\[(8D'5C@DEB%559F954L
M#I:*\ET7]HFTOO$FK^'=6\%^*O"VOZ9HDVORV.K0VC>9:QLJ9CF@N)879F)
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M_$&L10_9]7E2V$LFW;,\R,4220&XCBWA21GN >VT5R7Q#UX:!'X=8ZA?Z?\
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M&W+ 'N%%>)6?Q"DTWQ=I^L7.HZIJ&B0_#YM;FBEV+).RR1N96B0B(3%<_=P
M20"!7H ^)FF-#X)D%O>8\7.$L1L3,9-I)=?O?FX^2)A\N[YB.W( .MHKP_P)
M^T5J6J-X_N?%W@?6O">D^'-1:TBO+@V4WF?NK<I;%+>[FDDN7>?Y0B;"&10=
M^174:+\<+&;4KO3_ !-X?UGP!=PV,^J0KXC-IMNK. J)YHWMKB90(_,CW*Y5
MP'!VXR: /2**^?/&7QPO/$ND^$)K/PYXL\(V&J>)M%CL-4U-(;9-3@DNXRZ"
M..=IHPT>XE+B.(LI(P>171_M1>.+KP#X!TB^@\7?\(+;77B#3K"^U_\ T4?9
M+66<)*^ZZCDA7Y2?F=2!0![!17A7@'QIHU[X=\9:AX7^/3?%NYT_3))3#]LT
M2Z6P<([)(186L1!)4C]X64[3@5YQ\'OC5>:Y)\,9="^-3?%O6]=%JOB+PR$T
MJX&F126S233DV%M$]KY4@"YG9E.=F-[ T ?7E%?._P (?%FO>-?$EL^L_%67
M2_&2SR2ZE\-+FPL8H[6W61E*1QM$MXPV@8N?.>-R2RJ5( ^B* "BBB@ HHHH
M **** "BBB@ HKRKQMXG\0^*?B6OP\\*:S'X:DM=+36-8UM;>.XN8(997BMX
MK:.0&,2.T4S%Y%<*L8&QBX*Y-_JGC#X*>*/"D>L>*[SQ]X1\0:G'HTUQJ]G:
MPZCIUU*&\B4/:0PQ20,ZB,J8@ZF16WD K0![717D-W^T9%_;7B*QTGX?^,_$
M=KX=O7L=6U+3;6U^SVSJB.Q42W*23X1PV($D;MMW$*=C5OC=IOD:0?"VBZM\
M0;K5-/CU:WM?#OV8-]BDQY<[R74T$2*W.T%PS;6PIVM@ ]&HKR+5_P!I70K'
M3O"LVFZ!X@\1:AXDO+O3;/2=-MX!=1WEL'^T6\WG31I$Z>5*"S/L_=GYN5W:
MGCCXT-X##W%YX%\5WFDVEFM[JNK64%JUOID>"S>8&N%DF**"6%LDV,=S@4 >
MDT5X?;?'37]4^(WCWPU-X+UW2] T;2HKRW\20/IS[%=+EO/VF[=F63R5,2^3
MD'/FJH(J_/\ 'R'19O"?A^Q\-^*O'/B'6/#\>MP+I\-C%)-;CRUDDE:6>&&-
MP9$)7(!+X3."  >PT5Y>W[0F@7'A;P]JNDZ9K6OZCK\D\&G^'["U1;^26!F6
MY1Q*Z11>4RLKO)(J!L ,2R;KWPR^,UE\3-=\2Z&/#VN^&M;\._9AJ-AKD$2/
M&TZNR!'BED20;4SN1F3Y@ Q(8  ]"HKSKQ1\:(=$\3WF@:-X3\1^-=1TZ..7
M5!H$-OY>GK(-R>8]Q/"KN5&[RHC)(%*DH R[F>.OC4G@4R7,O@OQ5JFAVMH+
M[4=;L;2%;?3X2"Q9TFFCFD*J"S+!%*RXP1GB@#TBBO._%WQHMO#>OC1]-\,>
M(/%]W%90ZG>_V!#!)]BM)7D2*9A+-&TNXPS82 2R?NS\G*YXB[^,U_X5^-GQ
M TF'PYXJ\916ECIEZUKHRPM%IT#1R[I"+B>)<L5/[N+?(VPG8>* />Z*Y;4/
M'"7/PX_X2OPY87GB:&YL$OK&VT[R8Y[F.10R,OVAXD'RL&P[+P".O%>!_ 76
MM:N-)^"M_?-XLL;SQ%'=7NJKXCUHWIU"0Z>K^>B)<S1Q0LQW)$HC"?\ /-#0
M!]2T5Y"/VEM$\L:JWAWQ%'X&-RMHOC:2"!=++M*(0VTS?:?*\PX\\P>5CY]^
MSYJG\=?M*>$_ASX4\=:_K4&IPV_@_4(=.O[6*W5[B:298&B:! _SHPN$P<@_
M*^0-IH ]7HKF-+^(>EZUXWOO#%D)KBZL]+M=6ENXPIMO*N'E2)0P;.\^0[8Q
MC;@YYKDO%GQ@TSX;R?$C6M8N]9OM,\,VME=75C#:0,MM'(K9:WV[9)"<;F#D
MD;<(.<$ ]4HKS3P[\=M.U#5;_3O$'A_6_ =W:Z9)K2+XB6V"W%C&P66X1[>>
M95"%DW)(4D&\$I3-!^.0URSNM1?P+XNTO0UL)=1LM6U"TMXXK^)$WX2,3F:!
MF7E5N8X2>G!XH ].HKRGP[^T-IWB'P%9>+1X5\26&G:J\":';W<%O]JUKSDW
MQFWB2=F0%02?/\K:JECA06K3T'XS6^K6^O0WOA?Q#H7B+1K:.\N/#5Y#!/?R
M0R%UADB^S32Q2*[1R*"LGRE#OVT >AT5Y3'^T-IUGI^LG7O"WB/POK.F"S)T
M+4HK:2ZN1=S_ &>U\E[>>6!O,FS'S*-AY?8N&K<L_BQ;Q>"]4\1>(?#VN>#Q
MILODSZ;K%O$]RSG;Y8B^SR2QS;S(BKY3OEFV\,"H .ZHKS?1?CA8S:E=Z?XF
M\/ZSX NX;&?5(5\1FTVW5G 5$\T;VUQ,H$?F1[E<JX#@[<9-<)XR^.%YXETG
MPA-9^'/%GA&PU3Q-HL=AJFII#;)J<$EW&701QSM-&&CW$I<1Q%E)&#R* /H.
MBO,OV@O%VL>"_!-I>Z7=7&DVDNHP6^K:Y:V?VN72;%MWFW21%'!*D*NYD=$#
MEW4JC5Y3\/\ XF^(/#?[)=EXPT[Q[%\2=1OK/3;/3KO5A#,;?4+F6*WV3RVP
M3S426="591(-C!G8G( /J.BO'?#-]XJ^'GQ:T?PEX@\77GC?3/$>EW5Y:WFH
MV=K;W%E=6SP^9&/LT42M#(DX*AE9T,1R[;ACLOB!H?BWQ&VE6/AOQ$OA2P:5
MWU/4[>"*>_$80^6ELLT<D*DN06>1'PJD!26W* =A17EO[/\ XKUKQ1H?B)-4
MUA?%%AIFM3:=I7B588XCJMM&D>Z5EB C+),9X2T:JC&'(49KEO"_QDO]!U#Q
M_$?#GBKQK%IOB:ZBN9M)6&9=,MQ%$RKB:>-G !9O*MUD< CY/G7< >]T5Y-K
MWQ&L]>:\GT'7[Z>SOO!<^M6(M8XA:/&2/+N5EP)A)AA@9VX.<;A7.^'?%FIQ
MZEH<EUK&I+;_ /"M5U*9HY/-?SPT>9PDF4:7!."X.>AX)H ][HKRR3XU6^DZ
M7X7T_3=&\1^/O$FI:1#J@L=-@M([K[,54?:;AY98+:(LQQM\P%F#[%8(V&:O
M^TAX:TGP+;^)QI^LWJR:TOAV72;6U4W]MJ#2F(6\D3. &\S:,@E2'1P2AWT
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MU_4O,-AH6C0K->7*ICS' 9E2.-=R@R2.B NH+9900##^#OP[D\'OJ5[=^!/
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MA?+&OVF_G*#,UQ+C=+(<GYF)/;I7TW10!\RZA826&C^+_&UG 9]1\&>/+K6
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MX43_ &'_ &?Y=_\ \)9_PB/E?8?LWD#R_MOE?+]K^T>1LW_OMOG?P[Z^H**
M/GS]JW5_#[7'A30/%D7A&PT"^^U73Z]\0;<W6A6TT0C$<,MN9H8I9I/-9H_,
MD7 AD*Y:O-?#>BV7C[]G;P=HNI2F^T4?$<VEN(+>:RC:R34IA'%%%([O' T6
M$$9<_NFVC"\5]FT4 >'_  C\,Z1\._CU\1/"?A?3+3P_X831-%U2+1M-A6WL
MX+F66_CEDCA0!$+K!%NV@;BH)R:]PHHH *\S_:2_Y(CXI_ZXQ_\ HZ.O3**
M/G'5?@KX+^)'QK^+%]XI\/V6OS0Z;ID=J-0A69;-_(F)G@# ^5-]T>:N' 1
M",5P'AW7/"7B70/A?JWQXN=/O/!][X TJXL+GQ>RMHLNJ,&-V]PTW[DW)0VQ
MC,OS$&;R_P".OLVB@#YLL_AO\/OB'\;/!MPND0:WX:T[P?)-I-IJ4#RVW%['
MY,OE3@EB@SY3$?*KDIP0:\J\3:/INO>,O'%MXZ\7>#/"?Q!.MWL>A7.L^&YK
MGQ'#:%_]"FTB;[:CN!%Y>!;18$BN'5FWY^Z** /AC]J;6M#OM4\>#6I_!VC>
M-/#NDB+19]>TF:]\0:M(+,3+<Z,%N8FM0)GV[H!)AXI"^-O&]XZU;PEH'QDL
M-;U"Z\+^,?&%U?Z.UOH&JQS6WB>PW)!&TFE3+N>6VP#*T4<:QEC<B27!95^R
M:* /CGXP6>CZA\;O&$'Q-UGP'HVG8LSX5?X@:"]XDD)MU$G]GS->0HMP+CSM
MRQ+YPS$22"@&GK.G^#-)\0^$+/XZ:W9>(_!L'A&U32-7\;6PMM*N[\2O]IEN
MH[@F);HQ?8R@F.__ %VSG?7UG10!X9^REJ>C:QIOQ'N_#UQ-=Z')XON19S3A
MQNB%I:!2FX F/ ^1NA3802""?&?C!XN\.?#?XWS:K\/O'/\ 9GC5=.UFYD\"
MWG[]-3U'S;/$$5C(!.INRC8>W*JYC\U=_P"\+_;-5Y-/M9KZ"]>VA>]@C>**
MX:,&2-'*EU5L9 8HA('7:N>@H ^>[7XI>'_@E\4?BE/X^OH_#9U][#6-)%XW
M_(05;"*W>UM?^>\Z2P-^Y3+GS4(7Y@3TWP/UBR^%7PI^$G@OQ3,=(\2ZII8B
MM=-DAD)62*#SY8BP7:AC3(.XJ/EP/2O9J* /EO2?V@OAK^T'XZT99_B9X0M/
M"MCJ4+Z1X=;7+0:CKNH)(/(EE@9_,CC27:8H<"1Y%5F  56/B5X%\10>+KSX
M5>#/%%O#H?CR:\U77+";2S+=:-8S-_IL\-T)@J":1G6-)(9&\R>1E8+$0OU)
M10!YC\>K._T[X*ZG::"FI1QP?8XKA-$\S[:NGK<1"[%OY?[SS?LPFV^7\^<;
M?FQ7EO@/_A6W_"Y/!/\ PHG^P_[/\N__ .$L_P"$1\K[#]F\@>7]M\KY?M?V
MCR-F_P#?;?._AWU]044 >&?LF?#7PUX3^'<6NZ=I%K'KVJW%[]LU9HE-W-&+
MR8I"9<;O*0 *D>=J@# KGOCQ=?"/3?%^O:AKOC_7/!/Q!_LZ&&V72]?OM/N+
MH1AY(/LUDKB+4&#2M\@BG&6*,.2M?2E% 'G/PS^(D]UIGA#POXOG2W^)UWX9
M@UG4M-2W=%! CCG8$ HN)GV[=V>>!@9KYA\$:]I.GZ?H^IZ1XKU:']HK6/$-
MK)XA\)-J\[2O(]TB7D=SIA?RDMX[57"7)B&V.*%DD(*[ON2B@#YH^*WPU\.6
M_B;4K'PGH.I7FN"UN?$&J6]KJ=V;>UBD64.MI;&1H;>[O6\Z$211K)M>Y?.[
M&_HOV?\ XN77C37KC08]?\'^+-+M=,CN!<>"[26WAT:0,$&GW >:4>9M)(_U
M3 1-NB3BO=:* "BBB@ HHHH **** "BBB@#YN^-FD?#G4?C]I-Q\4+?3+CPQ
M:>%9Y&_X2+:=(CD-W&%>Y63]SD<A&E& 2<$,1GA6\*Z+XT\$R:/8QM-\*;KX
MCZ6GAF.%F6VDT_R8//2V/_/H\_VE%"_(49PGR%:^I6\&;OB5'XM^V?<TAM+^
MQ^5US,LOF;\_[.-N.^<]JZ:@#P'Q9X:TCPSXWU;1-'TJRTG1K;X=7T,&G6-N
MD-O%'YX^18U 55Y/ &.:\QT[]GGX>VMY^SQ:?\(Q8S)K=G*FNM-$&;7@FF&9
M1J!Q_I8$J+(!-N 91C%?9E% 'QSJM[HO@OP/XW\&76EZ+;^!(/B =(C.O*_]
M@Z#9O80WA-S"CHAMO.9D6%F2+?,@) QG#\/V^GZO^SI\=]"TS5-+O/#$6I6\
M.FW/A.PDTS3$1[:S9Y-/B::81Q^:78-&Y0ON9>N3]Q44 >+WW@;P]\._B-\)
MM&\,:)8:#I:7&J2"UT^W2%"[6AW.P4#<['DL>2>237F^EZM!\*_AEX$^*\D+
M/9:(^IZ7K1CW%O[/N;N0A@H!W%+F*V//17DY]?K"N&^(OP_U+XA7FBV<NM6]
MEX4M[N&]U'34LF:ZOI()5FA07'G!8XMZ+O0Q.74$;ER: .4\.>#_ !3X+_9I
MUBVTK+?$.^TO4-6++C)U>Z$MP0,\86:0(N>R**\,N-4^!=K:_#>S^'UQI\?C
M&Z\4:%_:4-H"VM2;;E"QUC(,X8'/S76#YA4 Y;!^UZ* /FSQ#\-?#6O?%[XR
M^)M4TBUU/5]-T.R_L^:\B6464GV2XW30A@?+E8;5,BX8JBC.!6+K&L7WPCT;
MPGXET:*1[OQKX.L_#D"*I93K,<:G320!QN$]T&8]HHQVKZMHH ^-_BIX'T7P
M)XJ\)>$?%NI^$--^%^E>%+>STR\^(VC'4=)DU".5UG,C-<P0I<M'Y#*9=S-^
M]V8P^=>U^%>A^*O^%*Z'KVI0>/?#HU'6KBW673Y+>SGMC#(T=J8)GD,EM'E0
M@=F5EBB.6 !/UC10!XS^SKI]MX;U;XJ^&-+@2Q\/Z'XJ^SZ9IT VP64,FG64
M[10H.(X_,FD8(H"C<<"O./&VJ?!^/]H'XBZ?\7YM#339-/TF6TB\8B(:3(X2
M8,8S/^Z:Y'R\'+A3\F 7S]6T4 ?)6DZM=_"OP'X8^*^HPZB^AZ)>ZKI;'4/-
M-[_PCES<L;)I%<%V*/%9E=_S")SN.[=GW7X(>$KSP3\+]-@U-3+KUZ9M7U3;
MU:]NI&N)E&3T5Y"B_P"RBBI_B+\/]2^(5YHMG+K5O9>%+>[AO=1TU+)FNKZ2
M"59H4%QYP6.+>B[T,3EU!&Y<FNYH ^$OA[XBT#5/C#\-/$&AR^#]'\5:WKDO
M]NZ#H>F3MXBL(Y+.[=X-9OC<EG(<1#9/ O[Q!L^Z"-O0_ACX9\$?!OP3XZTC
M2+>U\:'QK8QGQ J 7Q@N-=%O);&8#>;?R96C$.=@4#CBOM*B@#S/]I+_ )(C
MXI_ZXQ_^CHZ\]U7X*^"_B1\:_BQ?>*?#]EK\T.FZ9':C4(5F6S?R)B9X P/E
M3?='FKAP$0 C%?1U% 'QEX=USPEXET#X7ZM\>+G3[SP?>^ -*N+"Y\7LK:++
MJC!C=O<--^Y-R4-L8S+\Q!F\O^.NYM?AO\/_ (A_&KP=<1Z1!K?AO3O!TDVD
M6FI0/+;<7L?DR^5."6*#/E,1\JN2G!!KZ4HH ^$OA?H=CK>H>'&UWQIX,\-_
M&R/4HGU.)/#$Q\7&9+D&:-Y#>F5[20 KO\K[.89 5"KMPWXE^)=!U'XB76O0
M/X0\._$&U\8V=BFE-IDUUXP-O'J4,!N/M7VE7@LY80[[?):#RI0-S;L'[OHH
M ^1?BQ?>#_"_[0#:K=W'A?Q=XKEU?3!:>'M4CFMO$^GAA#$7TF8%GEML RM%
M'&L98W(DEP65>1\3:/INO>,O'%MXZ\7>#/"?Q!.MWL>A7.L^&YKGQ'#:%_\
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M)'A_7=&7P_XKT&*S-]8V]T;NVDBG=&BGMYS'&9(V*RI\T:,&B<%0-I;H+/\
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MO(W;?4_ NN^-M4N+J+Q=X2TWP\H19+:;2=;.HHX)Y23?;P,D@X.%#IU^?L>
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MWSY\S./EQC&:R+7X+"WL/A/;'6"P\"($++;;3?8T^2SS]_\ =?ZS?_%TQ[T
M<QIO[32'XO6/@G5;7PS;/J-_+IUK;Z;XLAOM7MY$CED4WE@L2^2K+!)RDLI!
M*@@9)70LOBUXC\67OQ$M6\'Q6'A;PS)>Z=/J_P#;DD-W=RQP+(#;1I!\JE7
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MO 5B\=XTM])?"-X+^2&%=EN6/FPK\L^1T#_=/S#FI]2^'_\ :'Q8T'QK]O\
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M-,@@,KQQ^7=26GFS.VQSA;< ;6W$?*6GTG]I3_A-?#_AH^"_#\/B'Q-KDU]
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MQ\1M(TSPMK&B^)/#%]HEYJ/]J:3=+=*T\-S;Q;%EC<I@"9\C!.0.1R#Y%>>
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M?;43 )<V^\R*O(.2.A'-,B^*7@R?QD_A&/Q=H,GBQ%+MH*ZE";Y5 R28-V\
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MKDO$G[/O@3Q9KE]JNHZ/.9=1P=2M+74[NVLM3(4)F\M(I5@NCL 7,R/E54=
M!7 ?#GQ1K-]_PIW[3JU]<?;KO7%N_-N7;[0(_.\L29/SA<#&<XP,5M0?'VS\
M,^%_!8-CXI\;ZIXGNKVTTV.WM+)+NXE@:5F20>9%#& D;X8E5Q'\S!CR >IW
M7A/2KW7K;69K0-J5M93:?%,)&&VWE:-I$V@[>3#'SC(V\$9.>7UKX%>#=>T+
M0-)ELM0L;;0;46.G2Z1K-[IUS!;[%3R?M%O,DK(0B95G(8HI() -0Z7\=?#M
MUX%U[Q/J<&H^'H] N6L=6TW4+</>6ER A$&R!I%E=A+%L\EI _F*%))Q69HO
M[04=YX\\/>$=:\">+O".J>(!.^FR:Q!:-!.D,32R,9+>YE$9  &Q]LF6'R8#
M$ &OJWP#\#:MI&A:<NC2:3%H5N;33+C0=0N=+NK2 A=T*7%K)'*(VVJ63?M8
MJ"P) -6=4^"_A'5O#NCZ))I]U:V>CW!N["73]2NK.ZMYB'#NMS#(LVYQ)(')
M?Y][;MV37<5X=XD_:QT;P[H%WXG_ .$+\8:EX'MY#"OBJQL[9K.9]_E@QQM<
M+<&,O\HF,(B.0P?80U 'IGC[X;^&_BEH"Z)XJTJ/6-+6>.Y%M,[J/-C.4?*D
M'*GD<]0#U%9W@_X3^&_AK-J.IZ-8ZE?ZK<0[)+S5=7NM4O9(UR5@2>\F=D3/
M(C#JFXYP.35/Q5\8!H.O7FD:1X1\1>,[K3UC;4FT%+798!UW*'-Q/%O?9AO+
MB\Q\,IV_,N<;5/VD-'_M7P[IOAGPYX@\=WGB#1O[?TY= CM526SW(K.9+J>%
M$(,D?RN03O &2"  2?!OP3>V_BKQSX^UKP^?#6M>*KN )ILTL4EQ;VEO"L<8
MG,,DD7FL_FN3&[#:T8)RO&_XW^"_A+XA:M%JFLV5X-06 6DEQINJW>GM<VX8
ML(+C[/+'Y\66<^7+N3YVX^8YRT^/>BZAX5T+5]$TG6?$%_K33QV>@6,$:7YD
M@8I<JXFDCBC\IU*,SR*FXJ QW+G.U;]I70M#\)2:Q>Z!X@BU&#6;?P_=^'4M
MX)-1M;Z<(88G59C&P<21$.DC)B13NP&*@':Z+\,O#/AVT\,6NFZ4EG;>&86M
M](ACD<+:1M'Y94#=R-G'S9QVK0T/PEI/AO4-<OM.M/L]UK=X+_4)/,=O.G$,
M<(?#$A?W<,:X7 ^7.,DD\MKGQ4U71M-TJ>/X9^,-4O[R%KBXTRQ&GF73T!QB
M:5[M8&;T2&61CZ5D7GCR+Q7XP^$&J:#J-R=!UZ.]N@@+PK<1FSWQ^9&<'()S
MM894^AH ]8HHHH **** "BBB@#ROQA\*5\<?%R'4=3M+H:*GA][--0L-1ELK
MF&X-RK8BF@D2:,E V60C()!/.*U9/@1X(D\'6WAD:/)#IUM=?;X9X+^YBODN
MR"#="]607'GL&8--YF]@S L034GCCXL0>$==M= T[P[K?C+Q)<6YO?[(T%(!
M)%;!MOG22W,T,,:EOE4-(&<AMJMM;$6N_%B\TO3=*NM/^'WC#Q#->P&XFL[&
MUMH);%1P1,;F>%"^<C9&SL<9 *X) ':+\"?!'A_PYK>A6>CR?V?KDRW.I_:+
M^YGGO9E5%$LL\DC2.Y$:98MD[>2:?XR^"/A#QYKG]M:E9ZA;:LT"VLU[HVL7
MNERW,*EBL4[6LT9FC!=\))N4;FP.36?JGQWTI=)\+W7AW0];\:7?B2PDU73M
M-T>*"*X>TC$7F2M]KE@1-IGA!1G#Y? 4X;')>)?C%?:-\9_#T.G^'O%7B(ZQ
MX3DOH/#5A%'!,C"XBW2S+=2PPQ,BN%/F.K9;:H)XH ]:\#>!=!^&OA:Q\-^&
M=-BTC0K'>+:QA+&.$.[.P7)) W.V!T&<#  %<]_PH?P0=+UW3)-(FGTO6;K[
M=<6%QJ%S+;PW'F-+YUM$TA6T?S6,FZW$9WX;[P!KH? WC33_ (@^%[/7=,6X
MBMK@R1M!>1&*:"6.1HY8I%/1TD1U.,C*G!(P3YA9?M4:7>:3-X@_X0CQA;^"
MK6>:"\\5SVMJEE:&*1HI7>/[1]I:-60YECA9 ,MNP&( /0? WPM\._#N2]FT
M>WO'OKU8TN=1U74KG4KV9$+&-'N;F225D0R/M4MM7>V ,FL[Q[\#?!WQ,U'[
M;K]A>S3O;BTN%LM6O+*.]MP21#=1P2HES'EF^28.N'<8PQS!\0?C(OP]N+B2
M;P=XGUC1+&V^V:EKVF6]NUI8PX)9V$DR2S;5!8BWCE( Z9XJUJ/CG3]+\?/'
M=ZW=6VG0^'9-6EADC@%@L*2J&N&EQYH<+QC.S;DXS0!7\7? /P-XXU0:AJFC
MS"=K--/GCL-1NK*&\M5W;+>YA@E2.YB7>X$<RNH#L ,,<\Y>? C3+KQUHUHF
MF7-GX0TKPJ-'LKC3]3FM+FT=)DV)%/%*MPA\I2"ZL,C().2#@^,OCA>>)=)\
M(36?ASQ9X1L-4\3:+'8:IJ:0VR:G!)=QET$<<[31AH]Q*7$<1921@\BMO]JK
MQ9KGAOP#IUKHFC>(]1.JZSIUA<W/AJ\M;2XAADO($>,2S7$+(\JLT:O&<J6R
M6C'S@ M^,O@GID'@_P ,>&O#FA1S:3;^(K34+^&XF,SS1AR9YII9F+S2'.69
MV9V]ZZWP7\)O#7@'4K[4M*M[Z;5+U1'-J&KZI=ZG=>6#D1+-=2R.D0))$:D(
M"2<9KET^+%OX5EMO"F@^#?&/BN_TJSMVU*WMIX+J;2ED0,B75U=W:B>;;R5C
MEFD(PQR'0M$G[2V@ZMK7A;3/#.A:]XPN/$>F'5[1M*A@C2.V658IFF-Q-%Y3
M1.RAXVP^25"LP90 =OI?PW\.:+_8?V/3O)_L1[B2P_?R-Y+3[O-/+'=NWM][
M.,\8K#L_@'X(T[Q(=;M=+NK:;[4;_P#L^'5+M=,%R7WF<6 E^S"4O\YD\K<6
M);.3FJ'QX^*VO?"G3?#MQH7@[4/%;ZEK%G83_8GM%6%)9XXRO[^Y@/F.'(C(
MW*&&7*KR9?&'QLD\$VXN[[P!XNETNVLEO]6U&V@M'ATF,KN<2YN0TS(H)86J
MSXQP2<9 .M7P%H TO7M-;3(IK#79II]2MYBTB7+RJ%DW!B< J ,# ]JX'4/V
M9?"G_",ZQI.F-?P/K1M+?4K_ %?4KS5[J>QAG61K,2W4[ND3KYB;5;8OFL=I
M.<ZWCCX]^%OASJ4]KX@:[L(?[(;6+2],2M#J"HP5X+?#%GG!>+]WM!;SDV[O
MFVPZG\;FM;@6NF^ _%?B&^M[>&XU6TTV.RWZ3YJ"013F6Y17E"G)C@,K %3@
MAER =SKGAK3?$B6"ZC;?:%L;N*^MQO9-DT9RC?*1G!['(/<5E:C\,?#6K>&O
M$WA^[TWS=(\2M.VJV_GRC[29D"2_,&W)N4 ?(1CMBN4OOVAM'F;3SX9T'7_'
M4%UI=MK<LWAZ"%A:V-P9!#.ZS2Q/)N\F7]W"LDO[LC9DJ#ZFK;E!&<$9Y&*
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M:212)$MH]NJ6^]HE#2">3 #;4!8;/H2B@#YP^(7P8^)FH>&_B9X.\*R>%HM
M\975Q?1ZQJ%[=1W=FTZ()H#;I"ZR!F1\2B5-HD'[MMGS[GQ\^$?B;XB7$0T/
M0O"5U<?V>UI9^)+[4+S3-7T.9B=TUO/;1.\J?<;RA)!DQX+L&^7TSXG>-O\
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MG2;MNQ*]C\/2:K+H.GOKL%G;:TT"&\AT^9YK=)L#>(W=$9DSG!90<=16C10
M5R'Q<\(7GC[X=:UH&GRP0WE[&B1O<LRQ@B16.2H)Z*>U=?10!Q.E>";ZQ\<>
M.=9DEMS:Z[;V<5LBLV]#%%(C;QMP 2XQ@GOTKS/P/\'?'WPAT/P9=^&_^$=U
MW6K'PEIOAC6=+U2^GL[6<V@<Q3P7202LNUIIP4: [PZG*%<-]!44 >?Z!X/\
M1_\ "PM.\4Z[/I;3KX?;3;J+3_,"B=KA9?D#@DH%&W<2"2,[5S@>5/\ LRSZ
M)XJ\1FR\!_#3Q=IFNZO<ZN-;\46G_$QT]KAS)+$T0MI!=J)&<J3- 0K!/X=Q
M]N^)WC;_ (5Q\/?$'B?['_:/]DVCW7V7S?*\W:,[=^UMN?7!KIZ /E[XT?LR
M^(?'U]XVM[70O OB.UUZS%KI&L>*O,>X\+I]D$'E6EJ+>1&3<'E#+)"0TIR'
MVC.[XU^"?B_7O&6EWNEZ7X1TN>WDT\CQK9WUW9ZS!! R-);20Q1;;Q&VR*!)
M.D>)N8CM._Z$KF/'_C;_ (073])N?L?VW[?K%CI6WS?+V?:;A(?,SM.=N_=M
MXSC&1UH \A\;?L[SR?%'Q)XLT[P3X!\>Q>)3;27,7C*/RI].FAA6#?#*+6X,
ML;1I&?)(CPRL0YW_ "^N'P>8/AG-X:L[?3=/E;2WLDAT^W^RV<<C1E?W<8W;
M(]Q) Y('K74U!?7+V=C<7"6TMX\4;2+;P;?,E(!(1=Q"[CT&2!D\D4 >>>"O
MAKJ?AOQ1X;U*YGM'@TWPG%H,RQ.Q9IU>-BRY4 IA#R2#TXJ]\&_ FH_#OP9>
MZ3?SVLMW-K6K:DDEL6>,1W5_<7,0.0IW!)5##ID$ D<UV>F7CZAIMI=26D]A
M)/$DK6MUM\V$LH)1]K,NX9P<$C(.">M07VJS6>K:;9IIEY=Q7AD$EY!Y?DVF
MU=P,NYPWS'Y1L5N>N!S0!\]:3^SAX@UC6/$%MK&F^&/!/AS6-$U+2-4@\&7]
MTT>LR76!]J>R>*.&UD7YWW SR$R%3)C);9^$WP+OO!^M:,-4^'GPMT]='C"C
MQ+H5EC4+YU0J)5@^S1BS8G#'$\_=1UW#W>ZNHK&UFN)FV0PHTCM@G"@9)P/:
MJN@ZY9>)]#T[6-,G^TZ;J%M'=VLVQD\R*10Z-M8 C*D'! /K0!YAX-^$.L^'
M?^%<_:;FQ?\ X1RXU26[\J1SO%SYOE^7E!DC>,YQWQFCP;\(=9\._P#"N?M-
MS8O_ ,(Y<:I+=^5(YWBY\WR_+R@R1O&<X[XS7KU8C^+M/;4];TNT\V_U?2+6
M*[N-/@CQ(5E$GE!6?:A9S$X W<$<XR#0!Y+XH^$=Q;^'_BQ<:EXATOP^NO>)
M++Q%I.IW+%H;.:VAT];?[2K; 1]HLQE5;YE8 ,">,[4M<\7ZI\;OA7I_BJS\
M/Z?J-I+J6HG3_#NHS:BSVJV,D)NY#)!"T2^9/'&$"N,N/WA/%>[0K#XCT&,:
MAIK1PWUNIGT[4$1V4.N6BE4%D)&<$ D<'DBL?P3\+?!?PT6Z7PAX0T'PJMTP
M:X71-,ALQ,1T+^6J[C]: &_#/6->\2> ]*U3Q/81Z5J]]&UQ)8)$\1MHW9FB
MC=7)82+&4#YQ\X;A>@^;/'4/BKP;^S-J'@^WU#PEK7@L6:Z#H.O6&I2/?WX:
M58+2S%IY7E-*<K&95N#DJ6$0S@?7M<A9_!_P'IOB^3Q9:>"/#EKXID)+ZY#I
M-NEZQ/4F<)O.?K0!Y3XV_9WGD^*/B3Q9IW@GP#X]B\2FVDN8O&4?E3Z=-#"L
M&^&46MP98VC2,^21'AE8ASO^7T'PQ\-;CP[XXTC5HHM)LM-L_#?]D-9Z7 ;:
M))C.DA,4(!"1<-@;B1D=>M>B44 ?,NH?LLZC)I?AZ_GT[PGXKUG0M;\07J:+
MXAC:33KVTU*^DN AE,+M!,@\@^8(I "KI@AMP['2O@S>P^'-$B@\-^#?!MY!
MXCL]9N=/\,1,EL(82,KYHAC,\O7#F*,8(&!C)]IHH \-^,7P;UWQIX^CUJ+0
M/"'CS2'TV*RAT?QM+(+;2+A)9':]@B%O,DSN'C#*1$W[A0)0&.+?P]^#.L>"
M/#GP<L+J[T^=O!.GRVE^UHKHLQ-KY(,"!>F[G:<8'3->ST4 <M\,=:U[Q'X%
MTG5?$UA'I6L7T;7,E@D3Q&V1W9HHW5R6$BQE ^<?.&X7H.IHHH **** "BBB
M@#S#QCX1\8Z1\1)/&O@B+1-6NKW2X=)U'1M>O)K&.1(9998)H[F*&<HRFXF#
M(8F#AE^9-GS<7\0/@UXS\:>)+#6M9T+P'X^\S2HK-]'\2O.FGZ/=K+)(UW:Q
M&"<3LP>)3N$+'[.I#H'*K]!T4 ?.\WP'\1:7\%_AWX/_ .$;\$>.+GPYIRV<
MRZQ<W&F>1.L81;FRNH8)7@(&\;5C5L.,2+MPW9?#/X6^(O".M>&+[7=;BUVX
MTWPJNB7=XSRM-/<"9'WYD+,RX7&]W+L>3DDFO5J* .$^#/@6_P#AWX/N])U*
M:VGN)M;U;4E:U9F3R[K4+BYC!+*#N"2J&&, @X)')\7\&^$?'WQ ^ /_  A=
MB/#\7A;Q!'J5C>:Y<W4RW]E;RW,Z2)%:+"8YGVE@LC31@;@2C;3O^HZJZ;I=
MGHUFEII]I!8VD98I!;1K'&I)+'"@ #)))]R: /F;XR?LQ^(O'EYXTM;;1?!/
MBBVUZR%KI.M>+WEEN_#*"T6 QVMO]GD1P6#R[UEA.Z9MP?:,^F>)O@O-XPU"
M^@U&ZBCT?4/!D_A>Y,#GSU:5AN= 5QM"YP2<YQQ7J]% '@FK>"_C+XPC\'Z1
MKB^"K?3=#UG3M1OM6LKV[>?5([:97(2U:W5;5B5#8\Z8<;<@'>/2_BCX/O?&
MV@Z;96,L$4MMK6F:D[7#,JF.WO(9Y , _,5C8 =,D9('-=A10!Y/?^$_'O@W
MQUXEUGP7;^'=<TSQ-/!=WEGKU_/826-S';QVYECDB@G$R-%##^Z81D,C'S#O
MPM?X2_!&_P#AGKFCW,VJ0:JD&BW-K>W.PQ//?7%\;N>1(\$)$7>3:NXE1M'.
M-U>P44 <+\9/"&L>,?"EI%H'V%M8T[5;#5K>#4IGAM[AK:Y28Q/(B.T88(1O
M"/C(.T]*\3^+W[.'C'XG2^,&O/#_ (!U^[\2V*Q6>J>);B:[E\*N;-89(;*)
MK0K*GF>9() UNV9261MH!^IJ* /"_BK\!M>^+%SHD%UJUGH]AX5M8=1\.W%L
M&FF77D#".ZG1E"F")0 (P3YGG2;MNQ*Y[5?V>]=N?&FJ>+[SP%\-/&>J^)H;
M.35K3Q$SD:7>10) [6MR;.5YX65$Q$Z0D%"=WSD+]*T4 ?/7Q8^!?B+Q)I&E
M:;X>\,> XYK72?L%IKD,]WH=]H$Y^_+9-;1R.T1.UA )(.8\,[;LKZ_8V_BV
MU\4V$,UQI-WX5CTG9<W#+(NHRZ@'4!P!^[$)3>2/O;B,<5TU% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-KOC3P9X;^-D>I1/J<2>&)CXN,R7(,T;R&],KVD@!7?Y7V<PR J%7;C[MHH
M^.+>32X/C[%J+R3#X&MXED6U;(%DOB[)1I#G_EU\T.JG[OVXL>I4U(VD? R#
MQ)\3M1^)]OHW_"03^*+J/3+C7,-><0P[4THM\XEW<[;;$F\J2,E"?L.N9\$^
M#/\ A#I/$3?;/M?]KZO-JF/*V>5YBHOE]3NQL^]QG/2@#Y&\30ZM<_\ "NH?
MC;J7A32M$;P39&2X^)>BG4-+.LAS]J68M=001W13R"OF;F.)?+QA\]=:_"O0
M_%7_  I70]>U*#Q[X=&HZU<6ZRZ?);V<]L89&CM3!,\ADMH\J$#LRLL41RP
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MQJB,6,B$1I\@(.[T!=)>7P^-,O;R:]D:V^SS7CJB22DKM9R%4*">3@ #G@4
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MWQ'\6>)_'UKXQTC0;/3=+UF2SM9-,UF2[DA(M[9Q $:R@#1XD9_-9MVYBNW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS9^!_%/AWPW\,]3E@\4:+X?\-ZKXD@NH= TB*\O[%);Z06-REI-;S/)&(D9
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M9)/+<[%X/S-@<5YGI=QJGP]N-%\2W'AK7-2BT?X;(DECIVGRS7,URCQ-]E1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>mdt-20250425_g9.jpg
<DESCRIPTION>IMAGE 9
<TEXT>
begin 644 mdt-20250425_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT34=*BU74-3&K0R6\-I#)HRVL8EG=1%'(\X:-8F82,RMM4X. #Z+_P"#*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#9/%/CKXH>+H_#7P^\*IJ*V4=[>&)YY9KBY97^S6L,,3R22B.5P JI'(S*I
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MOA\!?!WQ<_9:\*^-]+^,VH^ _B[X(^(5AJ'P!UG1;;[1>W_BR3=':Z5%;_\
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MK'X9WOA^*.6*VU=-%N]&GL=1D=U%E$AGBN5GDVPF'>H?S%"$ _2GPSXE\/\
MC3PWI_C'PEK-MJ.E:M8Q7FF:A9RB2&ZMY4#QRHPX9&5@P(X((-7J\L_8;^ ^
MO?LN?L8?"C]FWQ5K<6I:IX#^'6C:!J5] Q,4]Q:644$C1[@#Y>Y#MR,[<9KU
M.@ HHHH H^)?#'AKQGH5SX7\8>'K'5M,O(]EYIVI6B3P3KD':\;@JPR <$=J
M=X?\/:!X3T6V\-^%M#L],TZRB$5G8:?;)#! @Z*B( J@>@ %7** ,[P[X/\
M"7@];U?"7A;3M+&I:A+?ZB-.L8X/M5U)CS)Y-@&^5L#<[98X&2:K'X:_#HWW
M]J'P#HAN3-YIN#I4/F>9G._=MSNSSGKFMJB@"CXH\+^&?&_AK4/!GC3P[8ZO
MH^K64MGJNDZI:)<6UY;RH4DAEBD!62-U)5D8$,"000:M6EI:V%K%8V-M'#!#
M&L<,,2!4C0# 50.  !@ 5)10!Q]Y^SS\ -0^*\/QYO\ X&^#Y_'-O&([?QG-
MX9M6U:) AC"K=F/SE 0E<!ONDCI78444 %%%% !1110 4444 %%%% !1110
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M3M72U@XRB[-#"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !16?KWBK0/#4/FZSJ4<1(RL><NWT4<FN%U_XZW#EH?#>EA%Z">ZY
M/X*.!^)- 'I+R)$ADD<*H&2S' %8.L?$[P7HV5EUA9Y!_P L[4>8?S' _$UY
M#K7B?7_$,F_6-5FG&<A&;"#Z*.!^54* /1M3^/75-&\/_P"[)<R_^RK_ (US
M^H?%[QS?D^7J26RG^&WA4?J<G]:YFB@"]>^)?$.I9%_KEW,#_#)<,1^6<51)
M).2:** "O0O@%_Q^:G_URB_FU>>UZ%\ O^/S4_\ KE%_-J /Y=/^#@__ )3&
M_'#_ +#MA_Z:[.OC2OLO_@X/_P"4QOQP_P"P[8?^FNSKXTK]GRW_ )%U'_!'
M\D<[W'12RP2K/!(R.C!D=#@J1T(/8UZU\*OV_/VX_@:T8^$/[7_Q*\.Q1XQ:
M:7XUO8K=AZ-")?+8>Q4BO(Z*ZITZ=16FDUYZ@?H-\$O^#GG_ (*Y_!\PP:]\
M9="\>6<!&VS\:^%+:3(]&FM!;SM]6D)]Z^U_V>?^#RCP_<26^F?M7?L:W=JO
M'VG6OA]KRSY]=ME>!,?C<FOPBHKR\1D.4XCXJ27II^5AJ31_7#^R[_P7B_X)
M8_M92V^D^!OVJ-'T#6;C 70?':MHMQO/2-7N=L,SG^[%(]?7EK=6U[;1WME<
M1S0S('BEB<,KJ1D,"."".<U_#%7N_P"R9_P4U_;P_8?NX3^S1^TQXET#3XI-
M[>'I+H7FE2'.3NLK@/!D\@L$#<\$'FOGL7P=!ZX:I;RE_FO\F6I]S^RFBOPW
M_8F_X/!;"ZDL_!_[?O[/_P!E)*QR^-?AWED';?-I\[E@.[-%,QZ[8N@K]=_V
M6_VU?V5/VU?!G_">?LN?'30/&-@B*UW'IEWBZLBW1;BVD"S6['LLB*37RF-R
MK'Y>_P!]!I=]U]_^9:DF>HT445YPPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI'=(T,
MDCA5499F. !ZU^6W_!4[_@Y*^#_[-3:C\$_V)VTSQ[XZB+07WB=G\W1-%DZ'
M8R'_ $Z9?[J$1*<9=BK1U]5PAP5Q+QUFJP&34'4G]I[1@OYIR>D5ZZO:*;T,
M,1B:.%ASU'9'ZB/J.GQZA'I$E_"MW-"\T5J90)'C0JKN%SDJI= 3T!=<]17G
M'COXM^(([^XT/2+4V AD,<DKX,I(].RCZ9]<U_,E^SW_ ,%7/VJ_A=^WSX?_
M &\?B?\ $_6_&6N6M[Y'B.#4+TA=0TB4XN;!(QB.&,H2T:*HCCE6-PN4%?TL
MZ[KO@GXT_#7P]^T1\*=8CU/0/$>D6U]97\"D"XM9HU>&7! *G:P!! (. 0"#
M7V?BKX09SX63PGUJJJU.O'XXIJ,:B^*&NKLFG&3MS*_NJS.? YA3QRERJS73
MR[G+W%Q/=3-<74[R2.<N\C$DGW)IE%%?D1WA1110 4444 %%%% !7H7P"_X_
M-3_ZY1?S:O/:]"^ 7_'YJ?\ URB_FU '\NG_  <'_P#*8WXX?]AVP_\ 379U
M\:5]E_\ !P?_ ,IC?CA_V';#_P!-=G7QI7[/EO\ R+J/^"/Y(YWN%%%%=H!1
M110 4444 %=%\*OB]\5/@7XXLOB7\&/B+K7A7Q#I[[K+6= U*2TN8O4"2-@=
MIQ@KT(X((KG:*3BI*S6@'[1?\$Y?^#MCXF>"'L/AG_P49\$MXLTL%8E^(?A>
MTCAU.!>FZZM!MAN0.[Q>4X /R2L:_<']G']J+]GS]KOX:6OQ>_9L^+6C>+_#
MUU@"^TFYW-!)@$Q31MB2"4 C,<BJXR,@5_$Y7IW[*'[9/[2O[$/Q1@^,'[,/
MQ8U/PMK,6U;G[)(&MK^('/DW,#YCN(_]EU(!Y&" 1\KF?"V$Q2<\-[DNWV7\
MNGR^XM3:W/[4J*_+_P#X)-?\'+G[/7[:LFF_!/\ :NCTWX9_$ZX*06ES)<%-
M#UZ8\ 6\LA)M9F/ @F8@DJ$D=FV#]0*^ Q>"Q.!J^SKQL_S]'U-$TPHHHKE&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<U\7_C%\+_@#\-]6^+WQE\;Z?X=\-Z':FXU/5]2FV10H. /5F8D
M*J*"SL0J@D@5SG[5_P"UE\#/V*_@KJGQZ_:"\8Q:1H>FKMC08:XO[@@F.UMH
M\@RS/@X4<  LQ559A_,U_P %1O\ @K+\?O\ @IG\3FOO%=W-H/@'2KMF\)^!
M+2Y)@M1RHN+@C'VBY*DYD(PNXJ@4$Y_9?"3P;SOQ/S#VFM'!4W:I5MN_Y*:>
MDIVWZ06LM;1EYV/S&G@H6WD]E_F>\?\ !7/_ (."OBY^VQ)J?P'_ &99=1\%
M?"IV>"\G$GE:IXECZ'[0RG]Q;L/^7=3\P)\QF!V)^;E%%?Z5<*<(</<$Y1#+
M<GH*G3COUE)]93EO*3[OT5DDE\=7Q%7$U.>H[L*_;#_@UP_X*%VFN:)J_P#P
M35^+NL*^R.YU?X:M<R*/,B;,E]IRY()():Z10"<-=$D!%%?B?72_!KXN^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M17^H&3Y/EF0992R_+Z2IT:2Y8QCLE^K>[;NVVVVVSXJI4G5FYS=VPHHHKTB
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M,JKZ:PEL_P!'Y_F;1E='3T445XA04444 %%%% !1110 4444 %%%% !1110
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M3^*<N\I/[E9*R21\)B<14Q59U)[O^K!1117U)@%%%% !117MG["G[ /[1O\
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MU7[W;M_G^0V.**(%8HU4%BQ"C&2>2:=117\KGN!1110 4444 %%%% !1110
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MEXVR;_R_HKEQN#HX[#2HU5H_P\UYH:=F?W/JRNH=&!!&00>"*6OR=_X-AO\
M@K3+^U3\%C^PW\=/$9F^('P[TI6\,:A>39DUS0D*HJDG[\UKE(V[M$T3?,5D
M:OUBK\@QV#K8#%2H5-U^*Z/YFR=T%%%%<@PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%?R>>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B-X$U+P3I?Q$U_PI-J-N81KWA>2W2_M0>K0O<0S(C$9&[82,Y4@@$;]?/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2OLVOQ?,%RX^JO[TOS9NM@HHHKC&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+?_!;"(R_\
M$J?C<@4G'@UFX'I/$?Z5]25\]_\ !6/0SX@_X)F?'>P";O+^%NLW.,?\\;5Y
ML_\ D/-?3<%U51XQRVH]HXBB_NJ1,<2KX>:\G^1_)71117^QQ^>A1110 444
M4 ?V4?L]7\.J_ +P/JEN^Z.Y\'Z9*C>H:UC(/ZUV%>,_\$Y_%\7CW]@'X)^+
MHWW->_"G0&FP<XE&GPK(/P<,/PKV:O\ %[.\/+"9SB:$MX5)Q^Z31^BTGS4X
MOR04445YA84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<!^U=>VVF_LM_$K4;R39#;^ -9DE;T5;&8D_D*[^
MO!_^"I'BR+P1_P $U_CYXEDG$;0?![Q&D#DX_?2:;/'&/Q=U'XUMAX\^(A'N
MU^8,_C7HHHK]N.<**** "BBB@#^M3_@WNLS8_P#!''X'P,N-VAW\F#_MZK>/
M_P"S5]F5\O?\$5/#<GA7_@E!\ ],EBV&7X<6%X!CM<*;@'\1*#^-?4-?BV82
MYL?5?>4OS9NM@HHHKD&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<'^U/X,_X6/^S#\1_AYY
M/F?V]X#UC3O+QG=Y]E-%C_QZN\I'1)%*.H96&"",@BNC"8B>#Q5.O#>$E)>J
M=Q22E%IG\5%%=G^T?\-F^#7[0WCSX0/"8SX5\9ZIHY0]5^S7<L./_'*XRO\
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MIS):07G*S:UBI;&DXTZ&%EBL34C2HP5Y3FU&*7FWH?F#_P $[/\ @AK^V?\
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M 'E5*KVKV*OQ[-\=_:&83K+;9>BV_P _F;Q5D%%%%>:,**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR;<?,,P[C!^0M?.8+&T,?052D_5=4^S7<_M%-22:=TPHHK]6?^#;'_@C1/\
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M5Q(99IBD8 +N[$D_0= !715^'9QG%;-JR;5H+9?J_,_MN,>4****\8H****
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M=/LUT?\ PZNC_/;BGA//N#<UEE^:T73FMGO&2_FA+:47W6VS2::"BBBO4/G
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M_P"A7ACX4Y)X<X"\/WN+FOWE5K_R6"^S!/YR>LNB11117R!^J!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN6C]7=^9_2?"?AOP;P5#_A*PD8U.M27O5'W]^5VD^JC:/D%%%%?/GW(4444
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M71?%]U\*OB#!X \&>&O%.FQ7UKH.@Q1SH[P6\ZLD;7T\,LLLF-T@C12=D:J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?VE_P!IKX7?
MLJ?#G_A87Q,U0!KN]CT[P]HMO-&MWK>I2Y\FRMED95,CD$EF98XT5Y9'2.-W
M7T*O$/VM?^";_P"Q+^W;J>CZO^US\ M-\<S>'X)(=%75[Z[$=FLC!I"D<4JH
M&8JN6QN(503A0  <7^S3=_ SX5^.M5^/GQV^/7@?5/C+\8=5T_3+V/2/$,-V
MME"C,FG^'M,13YDEO;^9*[R!%,TLES=2+&AV1<9^UG^PM^RS^SE\8_'/_!6"
MQ_:N\?\ P U*7PTH^*NJ^![[3#8>)+> *L1N+/4K&[B>[.$BC:%5E9G 3,DA
M8]W^SY_P1I_X)A?LJ?%S2OCQ^S[^QUX7\,^+M#\[^R-=LY+EYK4RPO#(4$LK
M*"8Y'7.,X8XKU/Q+^R3\ ?''Q+LOBS\0/!=SXDU?2]06_P!'B\3:_?:E8:7>
M*,+<VEA<SO:6LR_PRPQ(ZY.",T ?&O\ P0%_9#^)GP5^'WQ?_;V_:6TK6= \
M7_M%>-&\2G1_&&HO-J.B>';<SG38;Z68EA<>7<2R."1M1HE(0J47UC_@H;X&
M_:M_;9^"7P^U#_@F_P#$#X'>*O#+>+(]9\3Q?$'7KZ;0O$]G:[FMK83:3'*;
MB%;Q$EDCW*LAMEC<LAEB?ZJ\6>%?#OCKPMJ?@CQ?I$.H:3K.GS6.J6%PN8[F
MWE0QR1,.ZLC,I]C7*?LT?LR_ O\ 8\^"FB_LZ_LV_#ZW\+>#/#RS#2-$MKF:
M98/-F>>4F2=WDD9I9'8L[,26ZT ?CS^W#/\ \%R3_P %;_V+6^+6F_LH+\20
M_CW_ (56GAV^\3'0V/\ 8\/]H?VJ9HA<+^XV>1]G!S)G?A<5^O/Q-^"?P-^*
MW@'3?$'[8GPD^'?B*?P[I+7.I7GB+0[>\L--?RE:[>%[Q"8H,QDDMC*(N_I6
MAX\_9M^!WQ.^,/@?X_\ CSX=66I>,?AL=0/@?7IWD$VD?;H5@N_+"L%/F1*J
MG<#P.,5=^-7P8\"?M _#VZ^%7Q.LKB\\/ZA<6[ZMID5TT4>H113)-]EGVX,E
MO(4"2Q'Y98R\;AD=E(!\U^'/$WB[Q-\//B!_P5-U;P3+-_8/PXU=O@#X*OK5
MHS9:%#;-<"]>'AH[K5)((9"N \5HEI%A)//#?)_[.G[2W[0?PR\,_P#!/S]H
MJ7XZ^+_%VN_M+ZS<Z=\8-,USQ)=7ECJJW]F]XL\%G([6^GFQE50GV2.$"(&-
MPRFOUM>&&2$V[PJT;+M,94%2N,8QZ5X3\(/^":W[('P,^(GA[XD_#WX=7<5Q
MX+CU)/ &EWWB"\NM-\)+J#E[X:9:32M#9><25/EJ-B$QQ[(R4H ]XHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHKS/\ ;)_:8T/]C?\ 9?\ &O[4'B;PS=ZS8>"]&;4;K2[&
M98YKE595V(S_ "@_-W]*J$)5)J$5=O1?,#TRBOQI_P"(RG]F?_HS/QU_X/[+
M_"C_ (C*?V9_^C,_'7_@_LO\*]C_ %>SG_GR_O7^9/-$_9:BOAO_ ()._P#!
M<?X5?\%8?B%XM^'OP]^!GB'PE-X3T:#4;BXUG48)UN%DE\H(HBY!!YYK[DKS
M,3AJ^$K.E6C:2Z#33"BO./CE^UW^S+^S7J&F:'\<?C9H'A[5-:W'1-#NKP/J
M.HA<[C;V<>Z><#!R41@.^*I^ ?VW?V1_B?KNG^$_ W[0GA>^UO4]3_L^T\/?
MVDL>I?:OL\USY+V<FV>)C!;S2 .BY6-B.*P&>IT444 %%%>4_M7_ +</[)O[
M#?@VV\>?M7?'+1?!FGWUP(-/%^TDMS>R9 VP6T*O-.1D9\M&QD9QF@#U:BO.
M/CG^UQ^SK^S5XO\  /@+XW_$VVT#5_BAXIC\.>!+*>SN)6U74W VVZF*-UBR
M64;Y"B;G5=V6 /H] !1110 4444 %%%% !1110 45Y;^UE^VQ^RI^PO\.O\
MA:W[67QOT;P5HC,RV\VI.[S73+C<L%O"KS7##<N5C1B-PR.17IUK<P7MK'>6
MS[HY8P\;8(RI&0>?:@"2BBB@ HHHH **** "BBB@ HHHH **YWXM?$2R^$OP
MWUCXD:CITMW!H]H;B2VA<*\@! P">!UKYK_X>U_#O_HD>M?^!T->YE?#>>9U
M1E5P5%SBG9M-+7>VK7<^-XD\0>#N$,5##9QBU1G./,DU-WC=J_NQ:W3/K:BO
MDG_A[7\._P#HD>M?^!T->H?LP?MF>&?VGM>U30=!\&7^EOI=HEQ))=W".'#-
MMP-O2NG&\'\29=A98G$X=QA'=WCIK;H[[L\_)_%;P^S_ #*GE^7X^-2M4;48
MJ,TVTFWJXI;)O5GLU%8_CSX@>"/A=X6NO''Q&\5V&B:/8IOO=3U.Y6&"!?[S
MNV H]SQ6%\"OVD/V??VH/",WC[]F_P"-OA3QYHEM?-97.K>$->M]1MXKE55V
MA:2!V57"NC%2<X=3T(KYH_0CM:*\_P#B[^U;^S1\ -<TOPU\</CQX4\(ZAKE
MREOHMGXBUN&TDU"9R0D4"RL#*Y(.$7+'TKN["_L]4L8=3T^X66WN85E@E0\.
MC %6'L00: ):*** "BBB@ HHHH **** "BO./@[^UQ^SK\?_ (I_$/X*?"#X
MFVVM^*/A1JMMIOQ TJ&SN(VTBZG1WBC9Y(U27<(Y/FB9U!1E)#*17H] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:S^S;X!N_$MK>-=VOB&Z\'64E]#<,YD:9)VB,BN78N6#9+$G.373^._A_P"
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M**R?'?CWP3\+_"&H?$#XC^+=.T'0]*MS/J6KZO>);VUM&"!N>1R%49(')Y)
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M_P#P:*_\G&?%[_L2;'_TL-?O#7X/?\&BO_)QGQ>_[$FQ_P#2PU^\#,J*7=@
M!DDGI7^8WTEO^3NXS_!1_P#343[/)O\ <(^K_,_"']F#5+__ ()8?\%4M"_;
M'>\DMOA%^U3\;/B3\.OB(7<BVTKQ#9^-]9BTFY;HL:F-8(USPL:WKFOU+_X*
M5^)-?\9^ O#/[$/P[U>>S\3?'O6W\-SWMG(5FTOPW'$9]>U!6'W"EB'MXWR"
M+F^M<<FOE5_V0_ /_!5+_@B_\:_V>?!.O:7J>M2_'+XGZKX(U*TO$<6>MP^-
M-9O=/?S%)$:S))&A;_GA=LPX85U?_!##QU\>_P!K;X06W_!2K]MS1VT/7[#P
M)!\/_#2ZO(8S%8:9)_Q.=8E\P+Y,M]J,)\T'A4TN'G%?@AZIY_\ \&GVK>$/
MAK_P2&\3>)]>U"TTG1=&^*WB:[U*_N9 D5K;016Q>61ST5(TR6/0+[5[W^T#
M_P %@=<_9O\ @!H?[<OQ _8Z\1+\ -8N[#S_ !M#XB@_MK3=.OI4BM-5N-&,
M8*VTK2PE5%P;A5F3?!&^8Q\._P#!#SP)XA_:=_X-L?VC/@-\$=4AOO%7B'4_
M'6FZ986UROF27%UIT1@@;GY!,&" G (?/3-=7^P'^WC_ ,$"_BG^Q-X1\&_M
M'?LS?"2R^+OA_1;+PWXP^$VM_!NSN?$&J^(+94MVAM;1K1GO)+B>,,@&2K2!
M9"C*V #]%OC)^W?X.\)?$KP#\ ?@9X8'Q%^(?Q,T277O#&AV&JI:65MH<2H7
MUF_NRDGV6RW21QHZQ2R2R2!(XWPY7XK_ &7?B+\1/'7_  <__$J?XI?!*;P9
MX@T7]D**QOM-@U>/4+;4-NOV4L=U9W02(SPO'*BAI(X75XW1D79D\]KWQ<T'
M_@GK_P '#/A7XK?M8Z'I?PT^''Q=_9@L/!7@74I)XX]"\,ZE:7-O/)HOVD*D
M,,<;0N 0$3_2(#A0W'0?"W]J/]G'Q9_P=*:YJ?A?XY>%=0LM:_9(@T#1=0L]
M=@DMM1U5?$4,K65O*&V7$X17)CC+$&.08RC  'U3^PO^W[\//VKOVA?V@_A;
MI7[-6J_#76?A!X@TRP\9WGB673Q=:K<S6\Y$LILI)HRL<5LNUS/)E'7[F,5Q
M?Q;_ ."Q=QX&_99U;_@H)\/?V4]8\7? /0[_ &7/C*V\2PVVJZEIZWHLY-5T
M_3'B/GV8D)*M-/;R/&AD$?EE7;YY_8MT&?XZ?ME_\%5_@S\,O%-F/$/B>XTW
M2M(>*\4&*ZET+4+17R#P$G.UC_"RD'!I/^",?_!9G]B+X1_\$Y/"'[+/[5WQ
M)@\ ?%;X06+>#/$WPRUO3I_[8O+FUE>"&.SLU0RWLLJ^6IBB5G$I9"OW2P!]
MD?$W_@I3X*L/BA\&O@+\ / DOC;QI\<_"\_B;P?;:CJ+:1IUIHD-LEPU[>W+
M032PAED14BC@ED+9#*@&:T_V&/V_=)_;'\4_%/X1Z_\ "J_\$>/_ (,^+U\/
M^.O#ESJ4=];K))&9+>ZM;J-4\^"9%9E+1QN-IW(."?FG]L;_ (*(W/AW]O\
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MN1O#%_9>GF\NDN;9HU>-N%1=K.K!U;(.Y5\>\=_\%L?%&F?M*?&#]D/X5?\
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M4H+A[7Q=XDCN4BE#&)VU6XD56 ^Z2CHV#V8'H:_1R@ HHHH **** ,7XC?\
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M.ZA#>7.LZT\=HHCA1&/-L8WGE8X$*V[LY7;7AO[36G?!/_@F%_P4I^ 'BO\
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MH+BXTV0D$O;R2(6A;('*$'@>E,E^#_PEG378YOA=X<=?%$R2^)5;1("-6D0
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M2MJB@#YW_P"'7O[*?_0(UO\ \'+_ .%'_#KW]E/_ *!&M_\ @Y?_  KZ(HH
M\S^!'[)7P>_9SU:_UKX:65_%/J5NL%T;R^,P**VX8!''->F444 <K\5_@7\$
MOCQHT7AWXX_!SPKXST^!R\-AXK\/6VHPQL1@E4N$=02.X%7?AW\+_AI\(?#4
M?@OX3?#O0O"^CPN7ATGP[I$-E;(QZD10JJ G Y [5NT4 9'BCX?> O&]WINH
M>-/!&D:O/HUX+O1Y]4TV*X>QN!TFA:128I!_>7!]ZQQ^SY\ QXI/CD?!#PA_
M;9OS?'6/^$:M?M1NB^\S^;Y>_P S?\V_.[/.<UU]% '(^%/V?_@-X#UR+Q/X
M'^"7A'1M2@5A!J&D^&[6WGC#*58+)'&&&5)!P>02*;/^SU\ KGXHI\<;GX'>
M#Y/&L2!8_&#^&;4ZHB[=N!=F/S0-O&-W3BNPHH Y#Q5^S[\!/'6NS>*/&_P1
M\(:SJ=R%%QJ.J^&K6XGEVJ%7=))&6;"J%&3P !VKKHXXX8UBBC5450%51@ #
MH *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
<th class="th"><div>Oct. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-36820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Medtronic plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1183488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Building Two, Parkmore Business Park West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Galway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">438-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,281,264,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Portions of the registrant&#8217;s Proxy Statement for its 2025 Annual General Meeting are incorporated by reference into Part III hereof.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001613103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--04-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H91 4K49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A0.250SeniorNotesDue2025Member', window );">0.250% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A0.000SeniorNotesDue2025Member', window );">0.000% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.000% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A2.625SeniorNotesDue2025Member', window );">2.625% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.125SeniorNotesDue2027Member', window );">1.125% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Senior Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A0.375SeniorNotesDue2028Member', window );">0.375% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.375% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A3.000SeniorNotesDue2029Member', window );">3.000% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.000% Senior Notes due 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A3.650SeniorNotesDue2029Member', window );">3.650% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.650% Senior Notes due 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2031Member', window );">1.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.000SeniorNotesDue2031Member', window );">1.000% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A3.125SeniorNotesDue2031Member', window );">3.125% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.125% Senior Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A0.750SeniorNotesDue2032Member', window );">0.750% Senior Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A3.375SeniorNotesDue2034Member', window );">3.375% Senior Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.375% Senior Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A3.875SeniorNotesDue2036Member', window );">3.875% Senior Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.875% Senior Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A2.250SeniorNotesDue2039Member', window );">2.250% Senior Notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.250% Senior Notes due 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.500SeniorNotesDue2039Member', window );">1.500% Senior Notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Senior Notes due 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39B<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.375SeniorNotesDue2040Member', window );">1.375% Senior Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/40A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2043Member', window );">4.150% Senior Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">4.150% Senior Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/43A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.750SeniorNotesDue2049Member', window );">1.750% Senior Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.750% Senior Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2050Member', window );">1.625% Senior Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Senior Notes due 2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2053Member', window );">4.150% Senior Notes due 2053</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">4.150% Senior Notes due 2053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A0.250SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A0.250SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A0.000SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A0.000SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A2.625SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A2.625SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.125SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.125SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A0.375SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A0.375SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3.000SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3.000SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3.650SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3.650SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.000SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.000SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3.125SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3.125SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A0.750SeniorNotesDue2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A0.750SeniorNotesDue2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3.375SeniorNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3.375SeniorNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A3.875SeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A3.875SeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A2.250SeniorNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A2.250SeniorNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.500SeniorNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.500SeniorNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.375SeniorNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.375SeniorNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.750SeniorNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.750SeniorNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 33,537<span></span>
</td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="nump">11,632<span></span>
</td>
<td class="nump">11,216<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">10,849<span></span>
</td>
<td class="nump">10,736<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact', window );">Restructuring charges, net</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Certain litigation charges, net</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">5,955<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, net</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,691<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Medtronic</a></td>
<td class="nump">$ 4,662<span></span>
</td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,285.6<span></span>
</td>
<td class="nump">1,327.7<span></span>
</td>
<td class="nump">1,329.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,289.9<span></span>
</td>
<td class="nump">1,330.2<span></span>
</td>
<td class="nump">1,332.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investment securities</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">853<span></span>
</td>
<td class="num">(848)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax', window );">Net investment hedges</a></td>
<td class="num">(1,474)<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="num">(596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change in retirement obligations</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized (loss) gain on cash flow hedges</a></td>
<td class="num">(381)<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(964)<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income including noncontrolling interests</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Medtronic</a></td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="nump">$ 3,856<span></span>
</td>
<td class="nump">$ 2,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,218<span></span>
</td>
<td class="nump">$ 1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">6,747<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowances and credit losses of $199 and $173, respectively</a></td>
<td class="nump">6,515<span></span>
</td>
<td class="nump">6,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,476<span></span>
</td>
<td class="nump">5,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">2,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">23,814<span></span>
</td>
<td class="nump">21,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,837<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">41,737<span></span>
</td>
<td class="nump">40,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="nump">13,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Tax assets</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,584<span></span>
</td>
<td class="nump">4,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">91,680<span></span>
</td>
<td class="nump">89,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="nump">2,874<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">2,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,879<span></span>
</td>
<td class="nump">10,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">25,642<span></span>
</td>
<td class="nump">23,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued compensation and retirement benefits</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,424<span></span>
</td>
<td class="nump">39,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 3, 16, and 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares&#8212; par value $0.0001, 2.6 billion shares authorized, 1,281,934,628 and 1,311,337,531 shares issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">20,833<span></span>
</td>
<td class="nump">23,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">31,476<span></span>
</td>
<td class="nump">30,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,284)<span></span>
</td>
<td class="num">(3,318)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">48,024<span></span>
</td>
<td class="nump">50,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">48,256<span></span>
</td>
<td class="nump">50,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 91,680<span></span>
</td>
<td class="nump">$ 89,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances and credit losses</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,281,934,628<span></span>
</td>
<td class="nump">1,311,337,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,281,934,628<span></span>
</td>
<td class="nump">1,311,337,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Shareholders&#8217; Equity</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 29, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Apr. 29, 2022</a></td>
<td class="nump">$ 52,722<span></span>
</td>
<td class="nump">$ 52,551<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,566<span></span>
</td>
<td class="nump">$ 30,250<span></span>
</td>
<td class="num">$ (2,265)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,784<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,234)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,616)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 28, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 28, 2023</a></td>
<td class="nump">51,665<span></span>
</td>
<td class="nump">51,483<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,590<span></span>
</td>
<td class="nump">30,392<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,666)<span></span>
</td>
<td class="num">(3,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(2,084)<span></span>
</td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 26, 2024</a></td>
<td class="nump">1,311,337,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 26, 2024</a></td>
<td class="nump">$ 50,420<span></span>
</td>
<td class="nump">50,214<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,129<span></span>
</td>
<td class="nump">30,403<span></span>
</td>
<td class="num">(3,318)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,691<span></span>
</td>
<td class="nump">4,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(964)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(966)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends to shareholders</a></td>
<td class="num">(3,589)<span></span>
</td>
<td class="num">(3,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares under stock purchase and award plans</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of ordinary shares</a></td>
<td class="num">(3,166)<span></span>
</td>
<td class="num">(3,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Changes to noncontrolling ownership interests</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 25, 2025</a></td>
<td class="nump">1,281,934,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 25, 2025</a></td>
<td class="nump">$ 48,256<span></span>
</td>
<td class="nump">$ 48,024<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,833<span></span>
</td>
<td class="nump">$ 31,476<span></span>
</td>
<td class="num">$ (4,284)<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends to shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,691<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="nump">2,647<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(433)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="num">(538)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">7,044<span></span>
</td>
<td class="nump">6,787<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant, and equipment</a></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(1,587)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(8,226)<span></span>
</td>
<td class="num">(7,748)<span></span>
</td>
<td class="num">(7,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales and maturities of investments</a></td>
<td class="nump">8,495<span></span>
</td>
<td class="nump">7,441<span></span>
</td>
<td class="nump">7,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,937)<span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
<td class="num">(3,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Change in current debt obligations, net</a></td>
<td class="num">(1,070)<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends to shareholders</a></td>
<td class="num">(3,589)<span></span>
</td>
<td class="num">(3,666)<span></span>
</td>
<td class="num">(3,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance of ordinary shares</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of ordinary shares</a></td>
<td class="num">(3,235)<span></span>
</td>
<td class="num">(2,138)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,361)<span></span>
</td>
<td class="num">(4,450)<span></span>
</td>
<td class="num">(4,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">188<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">934<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncomeTaxesandInterestPaidAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,819<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncomeTaxesandInterestPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes and Interest Paid [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncomeTaxesandInterestPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company &#8211; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Galway, Ireland. In May 2025, the Company announced its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible assets, equity investments, and liability valuations. Actual results may or may not differ from those estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for each of the three fiscal years ended April&#160;25, 2025 (fiscal year 2025), April&#160;26, 2024 (fiscal year 2024), and April&#160;28, 2023 (fiscal year 2023).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-513">three</span> to 20 years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the asset group's carrying value to its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group is estimated by utilizing a discounted cash flow analysis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. Refer to Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency exchange rate contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For certain of our capital equipment, control is transferred upon installation. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $322 million, $341 million, and $351 million in fiscal years 2025, 2024, and 2023, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.&#160;See Note 13 for more information on the Company's uncertain tax positions and tax policies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating (Income) Expense, Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating (income) expense, net primarily includes royalty expense, currency remeasurement and derivative gains and losses, changes in fair value of contingent consideration, certain acquisition and divestiture-related items, income from funded research and development arrangements, Puerto Rico excise taxes, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements but did require additional disclosures. Refer to Note 6 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company retrospectively adopted this guidance beginning in the fourth quarter of fiscal year 2025. The adoption of this standard did not have a material impact on the Company's consolidated financial statements but did require additional disclosures. Refer to Note 19 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;25, 2025, $983&#160;million of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$680&#160;million of reba</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tes were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. At April&#160;26, 2024, $1.0 billion of rebates were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $574 million of rebates were classified as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheet. During fiscal year 2025, adjustments to rebate and return reserves recorded in prior periods were not material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue at April&#160;25, 2025 and April&#160;26, 2024 was $446&#160;million and $453&#160;million, respectively. At April&#160;25, 2025 and April&#160;26, 2024, $354&#160;million and $352&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, and $92&#160;million and $101&#160;million was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. During the fiscal year ended&#160;April&#160;25, 2025, the Company recognized&#160;$320 million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;26, 2024. During the fiscal year ended April&#160;26, 2024, the Company recognized $324 million of revenue that was included in deferred revenue at April&#160;28, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;25, 2025, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.3&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions, Dispositions, and Funded Research and Development Arrangements</a></td>
<td class="text">Acquisitions, Dispositions, and Funded Research and Development Arrangements <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had acquisitions during fiscal years 2025 and 2024 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#8217;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2025 and 2024 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2025 and 2024 business combinations were not significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during fiscal year 2025 was $128&#160;million, consisting of $159 million of assets acquired and $31 million of liabilities assumed. Based on preliminary valuations, assets acquired were primarily comprised of $108&#160;million of goodwill and $50&#160;million of IPR&amp;D. The goodwill is not deductible for tax purposes. The Company recognized $20&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2025, which comprised of other milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of net assets acquired during fiscal year 2024 was $335&#160;million, consisting of $338&#160;million of assets acquired and $3&#160;million of liabilities assumed. Assets acquired were primarily comprised of $131&#160;million of goodwill, $150&#160;million of IPR&amp;D, and $29&#160;million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, $51&#160;million of goodwill is deductible while $80&#160;million is not deductible. The IPR&amp;D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized $30&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2024, which are comprised of revenue and product development milestone-based payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disposal Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ventilator Product Line Exit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $439&#160;million, including $369&#160;million recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70&#160;million recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income in fiscal year 2024. The charges included $371&#160;million of non-cash impairments and write-downs primarily related to $295&#160;million of long-lived asset impairments to write-down the value of related intangible assets to zero and $70&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Care Solutions (RCS) Disposition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale was part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#8220;Mozarc Medical&#8221; or "Mozarc") with equal equity ownership. At closing, the Company received $45&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $195&#160;million, made an additional cash investment of $224&#160;million, and retained a 50% non-controlling equity interest in Mozarc valued at $307&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $300&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $136&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#8217;s retained 50% equity investment in Mozarc as a result of this transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration liabilities at April&#160;25, 2025 and April&#160;26, 2024 was $81 million and $149 million, respectively. At April&#160;25, 2025, $31 million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $50 million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. At April&#160;26, 2024, $96 million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $53 million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 28.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at April&#160;25, 2025 and April&#160;26, 2024 was $13 million and $58&#160;million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funded Research and Development Arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. (collectively, "Blackstone") to receive funding related to the development of certain products within the Cardiovascular Portfolio and Diabetes Operating Unit. As there is substantive and genuine transfer of risk to Blackstone, the development funding is recognized by Medtronic as an obligation to perform contractual services. The Company recognizes the funding as income within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-709">other operating (income) expense, net</span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the research and development costs are incurred and funding payments become due. Under these arrangements, the Company recognized income of $181&#160;million, $174&#160;million, and $202&#160;million in fiscal years 2025, 2024, and 2023, respectively. As of April&#160;25, 2025, the Company is eligible to receive additional funding of $391&#160;million under these arrangements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following potential U.S. regulatory approval and commercial launch of each product covered by the Blackstone agreements, Blackstone will be eligible to receive a combination of fixed regulatory and commercial milestone payments up to $1.2&#160;billion and royalties based on percent of sales of such products. Under certain termination provisions, the Company's payment obligation will survive, and in certain termination circumstances, a payment to Blackstone of a multiple of the funded amounts may be required. At the time of executing these contracts, the occurrence of such circumstances was deemed to be remote.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text">Restructuring Charges <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal years 2025 and 2024, the Company incurred $303 million and $389 million, respectively, of restructuring and associated costs primarily related to cost reduction initiatives, which predominantly included employee termination benefits, facility consolidations, and asset write-downs, and specifically for fiscal year 2025, contract terminations. In fiscal year 2023, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#8217;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $1.8 billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $0.5 billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $0.3 billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and, specifically for fiscal year 2023, voluntary early retirement benefits. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting fees, asset write-offs, and contract terminations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-722"><span style="-sec-ix-hidden:f-723"><span style="-sec-ix-hidden:f-724">Cost of products sold</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-728"><span style="-sec-ix-hidden:f-729"><span style="-sec-ix-hidden:f-730">Selling, general, and administrative expenses</span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;25, 2025 and April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of debt securities excludes accrued interest, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;25, 2025 and April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company&#8217;s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, which includes income on marketable debt securities and the global liquidity structures, is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of income. For fiscal years 2025, 2024, and 2023 there was $511 million, $597&#160;million, and $386&#160;million of interest income, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities, Equity Method Investments, and Other Investments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;25, 2025 and April&#160;26, 2024, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, there were $181&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;25, 2025. During fiscal year 2024, there were $291&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mozarc Medical Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. During fiscal year 2025 and 2024, the Company recognized a loss of $171 million and $220&#160;million, respectively, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing Arrangements</a></td>
<td class="text">Financing Arrangements <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-990">six</span>-year 2019 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-994">five</span>-year 2020 senior notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-998">three</span>-year 2022 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">Current debt obligations</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In January 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and in January 2020, Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $3.5&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no commercial paper outstanding at April&#160;25, 2025. During fiscal year 2025, the weighted average original maturity of the commercial paper outstanding was approximately 13 days and the weighted average interest rate was 5.02 percent. There was $1.1&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Line of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In October 2024, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2029.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility provides for a $3.5 billion&#160;five-year unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;25, 2025 and April&#160;26, 2024, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#8217;s long-term debt ratings, assigned by Standard &amp; Poor&#8217;s Ratings Services and Moody&#8217;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-1024">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-1030">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-1036">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125 percent <span style="-sec-ix-hidden:f-1042">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250 percent <span style="-sec-ix-hidden:f-1048">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.000 percent <span style="-sec-ix-hidden:f-1054">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.375 percent <span style="-sec-ix-hidden:f-1060">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.650 percent <span style="-sec-ix-hidden:f-1066">five</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1072">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.000 percent <span style="-sec-ix-hidden:f-1078">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125 percent <span style="-sec-ix-hidden:f-1084">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750 percent <span style="-sec-ix-hidden:f-1090">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1096">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375 percent <span style="-sec-ix-hidden:f-1102">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375 percent <span style="-sec-ix-hidden:f-1108">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875 percent <span style="-sec-ix-hidden:f-1114">twelve</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.550 percent <span style="-sec-ix-hidden:f-1120">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250 percent <span style="-sec-ix-hidden:f-1126">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500 percent <span style="-sec-ix-hidden:f-1132">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500 percent <span style="-sec-ix-hidden:f-1138">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.550 percent <span style="-sec-ix-hidden:f-1144">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375 percent <span style="-sec-ix-hidden:f-1150">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1156">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000 percent <span style="-sec-ix-hidden:f-1162">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.150 percent <span style="-sec-ix-hidden:f-1168">nineteen</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1174">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1180">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750 percent <span style="-sec-ix-hidden:f-1186">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1192">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.150 percent <span style="-sec-ix-hidden:f-1198">twenty-nine</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1203"><span style="-sec-ix-hidden:f-1204">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,642&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#8364;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Agreements   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#165;300&#160;billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#165;297&#160;billion, or approximately $2.3&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9&#160;billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9&#160;billion of total consideration, and $368&#160;million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $53&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. For fiscal years 2025, 2024, and 2023, there was $913&#160;million, $916&#160;million, and $743&#160;million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the estimated fair value of the Company&#8217;s Senior Notes was $26.2 billion compared to a principal value of $28.6 billion. At April&#160;26, 2024, the estimated fair value was $21.2 billion compared to a principal value of $24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplier Financing Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a supplier financing program that provides participating suppliers the ability to finance payment obligations from the Company with third-party financial institutions in order to receive earlier payment. The Company&#8217;s standard payment term is 90 days. The Company&#8217;s outstanding payables to its suppliers, including amounts due and payment terms, are not affected by a supplier&#8217;s participation in the program. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025 and April&#160;26, 2024, the Company had $100 million and $96 million of outstanding payables, respectively, associated with the supplier financing program recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of outstanding payables confirmed as valid associated with the program during fiscal year 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invoices confirmed during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confirmed invoices paid during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1251">Ending Balance</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives and Currency Exchange Risk Management</a></td>
<td class="text">Derivatives and Currency Exchange Risk Management <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fair Value Hedges</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of a fixed-rate debt obligation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a straight-line basis over the term of the hedge and were not significant for the fiscal year ended April&#160;25, 2025. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cash Flow Hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash flow hedges will mature within the subsequent two-year period. At April&#160;25, 2025 and April&#160;26, 2024, the Company had $149 million in after-tax unrealized losses and $229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company expects that $62 million of after-tax net unrealized losses at April&#160;25, 2025 will be recognized in the consolidated statements of income over the next 12 months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instruments that are designated as net investment hedges, the gains or losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the term of the instrument. For fiscal years 2025, 2024, and 2023, the Company recognized $198 million, $197 million, and $107 million, respectively, of after-tax unrealized gains related to excluded components in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1261">interest expense</span>, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Undesignated Derivatives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency forward exchange contracts to offset the Company&#8217;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#8217;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;1.0 billion, or $1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;5.0 billion, or $5.7 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;322 billion, or $2.3 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2026 through 2033. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes &#8364;18.0 billion, or $20.6 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.704%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;25, 2025 and April&#160;26, 2024. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"></td><td style="width:47.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1350">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1351">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1352">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1353">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;25, 2025 the Company posted net cash collateral of $125 million to its counterparties. Cash collateral posted is recorded as a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the offset recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. As of April&#160;26, 2024, the Company received net cash collateral of $101 million from its counterparties. Cash collateral received is recorded as an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the offset recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span> in the consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text">Goodwill and Other Intangible Assets <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any goodwill impairment charges during fiscal years 2025 or 2024. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,547)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any definite-lived intangible asset impairment charges during fiscal years 2025 and 2023. During fiscal year 2024, the Company recognized $295&#160;million of <span style="-sec-ix-hidden:f-1490">definite-lived intangible asset impairment charges</span> in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no indefinite-lived intangible asset impairment charges during fiscal year 2025. Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024 and 2023. Due to the nature of IPR&amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $1.8 billion for fiscal year 2025, including $151&#160;million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $1.7 billion for fiscal years 2024 and 2023. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;25, 2025, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text">Property, Plant, and Equipment <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally 2-10, up to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense of $1.1 billion, $954 million, and $999 million was recognized in fiscal years 2025, 2024, and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Capital   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic plc is authorized to issue 2.6 billion Ordinary Shares, $0.0001 par value; 40 thousand Euro Deferred Shares, &#8364;1.00 par value; 127.5 million Preferred Shares, $0.20 par value; and 500 thousand A Preferred Shares, $1.00 par value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Euro Deferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 40 thousand Euro Deferred Shares, with a par value of &#8364;1.00 per share. At April&#160;25, 2025, no&#160;Euro Deferred Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 127.5 million of Preferred Shares, with a par value of $0.20 per share. At April&#160;25, 2025, no&#160;Preferred&#160;Shares were issued or outstanding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A Preferred Shares   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized share capital of the Company includes 500 thousand A Preferred Shares, with a par value of $1.00 per share. At April&#160;25, 2025, no A Preferred Shares were outstanding. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Share Repurchase Program   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares are repurchased on occasion to support the Company&#8217;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2025 and 2024, the Company repurchased approximately 38 million and 25 million shares, respectively, at an average price of $83.36 and $83.04, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company's Board of Directors authorized $6.0&#160;billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an additional $5.0&#160;billion for repurchase of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations. At April&#160;25, 2025, the Company had used the $6.0&#160;billion authorized in March 2019 and $2.9 billion of the $5.0&#160;billion authorized in March 2024, leaving approximately $2.1 billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Purchase and Award Plans</a></td>
<td class="text">Stock Purchase and Award Plans <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2025, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;25, 2025, there were approximately 67 million shares available for future grants under the 2021 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Options are granted at the exercise price, which is equal to the closing price of the Company&#8217;s ordinary shares on the grant date. The majority of the Company&#8217;s options are non-qualified options with a ten-year life and a four-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#8217;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#8217;s ordinary shares. Implied volatility is based on market traded options of the Company&#8217;s ordinary shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2025:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to outstanding stock options at April&#160;25, 2025 was $66 million and is expected to be recognized over a weighted average period of 2.3 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a four-year ratable vesting term or cliff vest after three years. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,644&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to restricted stock as of April&#160;25, 2025 was $414 million and is expected to be recognized over a weighted average period of 2.6 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on invested capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to performance share units as of April&#160;25, 2025 was $90 million and is expected to be recognized over a weighted average period of 1.6 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees Stock Purchase Plan (ESPP)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Medtronic plc 2024 Employee Stock Purchase Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#8217;s ESPP is equal to the 15 percent discount the employee receives. Employees purchased 3 million shares at an average price of $72.27 per share in fiscal year 2025. At April&#160;25, 2025, approximately 26 million ordinary shares were available for future purchase under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision is based on income before income taxes reported for financial statement purposes. The components of income before income taxes, based on tax jurisdiction, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred taxes have been provided on the approximately $88.6 billion and $86.3 billion of undistributed earnings of the Company&#8217;s subsidiaries at April&#160;25, 2025 and April&#160;26, 2024, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company had approximately $10.8 billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8 billion have no expiration, and the remaining $6.0 billion will expire during fiscal years 2026 through 2045. Included in these net operating loss carryforwards are $3.9 billion of tax effected net operating losses generated in fiscal year 2008 as a result </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $4.9&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $2.0 billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company had $53 million of tax effected U.S. federal net operating loss carryforwards, of which $35&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2026 through 2036. For U.S. state purposes, the Company had $84 million of tax effected net operating loss carryforwards at April&#160;25, 2025, $12&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2026 through 2044.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025, the Company also had $313 million of tax credits available to reduce future income taxes payable, of which</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$136 million have no expiration. The remaining credits will expire during fiscal years 2026 through 2042. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has established valuation allowances of $12.7 billion and $13.3 billion at April&#160;25, 2025 and April&#160;26, 2024, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The decrease in the valuation allowance during fiscal year 2025 is primarily related to a decrease in the Luxembourg tax rate applied to previously recorded deferred tax assets and associated valuation allowances and current year utilization of attributes with a full valuation allowance due to certain intercompany transactions. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two Global Minimum Tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which were effective for Medtronic in fiscal year 2025. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, the cost from certain tax adjustments of $62&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, relates to amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the net cost from certain tax adjustments of $299&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $124&#160;million related to a change in valuation allowance on previously recorded net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $50&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $33&#160;million associated with a change in the Company&#8217;s permanent reinvestment assertion on certain historical earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the net benefit from certain tax adjustments of $910&#160;million, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income, included the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $764&#160;million associated with the August 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#8217;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $55&#160;million related to the disallowance of certain interest deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $30&#160;million related to the change in reporting currency for certain carryover attributes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cost of $28&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A net cost of $33&#160;million primarily associated with the sale of half of the Company&#8217;s RCS business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Company&#8217;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions, inclusive of Pillar Two global minimum tax impacts, as compared to the local statutory rate favorably impacted earnings by $294&#160;million, $229 million, and $115 million in fiscal years 2025, 2024, and 2023, respectively, and diluted earnings per share by $0.23, $0.17, and $0.09, in fiscal years 2025, 2024, and 2023, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2026 and 2049. The tax incentive grants which expired during fiscal year 2025 did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $2.9 billion, $2.8 billion, and $2.7 billion of gross unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2025, 2024, and 2023 is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all of the Company&#8217;s unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023 were recognized, $2.7 billion, $2.7 billion, and $2.5 billion would impact the Company&#8217;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#8217;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $1.9 billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $17&#160;million, net as a result of statute of limitation lapses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to income tax matters in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income and records the liability in the current or noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets, as appropriate. During fiscal years 2025, 2024, and 2023, the Company recognized gross interest expense of $55 million, $134 million, and $86 million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. The Company had $74 million, $19 million, and $61 million of accrued gross interest and penalties at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#8217;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 for additional information regarding the status of current tax audits and proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of weighted average diluted shares outstanding excludes stock awards of approximately 26 million, 28 million, and 23 million ordinary shares in fiscal year 2025, 2024, and 2023, respectively because their effect would have been anti-dilutive on the Company&#8217;s earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefit Plans</a></td>
<td class="text">Retirement Benefit Plans <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was $466 million, $451 million, and $494 million in fiscal years 2025, 2024, and 2023, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#8217;s post-retirement benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;25, 2025 and April&#160;26, 2024, the funded status of the Company&#8217;s benefit plans was $440 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overfunded and $484 million overfunded, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $94&#160;million, primarily related to U.S. pension benefits. The charges were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">restructuring charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. See Note 4 for additional information on restructuring charges. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss (gain)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over funded status of the plans</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In April 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;25, 2025 and April&#160;26, 2024. U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost other than the service component are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2025 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24% - 5.76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21% - 24.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53% - 5.82%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 5.07%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12% - 4.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51% - 5.63%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.23%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30% - 7.20%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#8217;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Investment Strategy  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;25, 2025 for the plans are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity securities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> debt securities, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plans did not hold any investments in the Company&#8217;s ordinary shares at April&#160;25, 2025 or April&#160;26, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;25, 2025, compared to the U.S. plans actual asset allocations at April&#160;25, 2025 and April&#160;26, 2024 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Asset Fair Values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mutual funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity commingled trusts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed income commingled trusts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership units:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered investment companies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance contracts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#8217;s general portfolio and participate in the insurer&#8217;s profit-sharing policy on an excess yield basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;25, 2025 and April&#160;26, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was $48&#160;million and $42&#160;million as of April&#160;25, 2025 and April&#160;26, 2024, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the fair value hierarchy classification on an annual basis. There were no transfers into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Funding  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is the Company&#8217;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2025, the Company made discretionary contributions of approximately $31 million to the U.S. pension plan. Internationally, the Company contributed approximately $45 million for pension benefits during fiscal year 2025. The Company anticipates that it will make contributions of $29 million and $55 million to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2026. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2026 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 &#8211; 2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-retirement Benefit Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net periodic benefit cost associated with the Company&#8217;s post-retirement benefit plans was income of $16 million, $16 million, and $11 million in fiscal years 2025, 2024, and 2023, respectively. The Company&#8217;s projected benefit obligation for all post-retirement benefit plans was $231 million and $235 million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The Company&#8217;s fair value of plan assets for all post-retirement benefit plans was $303 million and $308 million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The post-retirement benefit plan assets at both April&#160;25, 2025 and April&#160;26, 2024 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Savings Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions and Company performance. Expense recognized under these plans was $478 million, $471 million, and $390 million in fiscal years 2025, 2024, and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">typically do not provide an implicit rate, the Company&#8217;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the leases that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2025, 2024, and 2023 were not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;25, 2025 or April&#160;26, 2024 or for fiscal year 2025, 2024 and 2023. Finance lease right-of-use assets are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">propert</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">y, plant, and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and finance lease liabilities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">current debt obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2358"><span style="-sec-ix-hidden:f-2359">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2362"><span style="-sec-ix-hidden:f-2363">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 Years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2025, 2024, and 2023: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;25, 2025:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and the Company's net investments in sales-type leases are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets. Lessor income for fiscal year 2025, 2024, and 2023 and the related assets and lease maturities at April&#160;25, 2025 and April&#160;26, 2024 were not material to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">Accumulated Other Comprehensive Loss <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,284)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was an expense of $25 million, an expense of $4 million, and a benefit of $21&#160;million, respectively. During fiscal years 2025, 2024, and 2023, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $3 million, $5&#160;million and $9&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 5 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2025, 2024, and 2023, the income tax on cumulative translation adjustment was an expense of $4 million, an expense of $3 million, and a benefit of $5&#160;million, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025, the income tax on net investment hedges was a benefit of $47 million. During fiscal years 2024 and 2023, there were no tax impacts on net investment hedges. Refer to Note 7 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 resulted in a benefit of $32 million, an expense of $79&#160;million, and an expense of $6&#160;million, respectively. During fiscal years 2025, 2024, and 2023, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$3 million, $2&#160;million, and $9&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Note 15 for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was&#160;a benefit of $33 million, an expense&#160;$103&#160;million, and an expense of $56&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $52 million, $66&#160;million, and $133&#160;million for fiscal years 2025, 2024, and 2023, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other operating (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder-related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. With respect to intellectual property disputes, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. With respect to commercial disputes, antitrust and competition issues have gained increased prominence, enforcement and private litigation have increased globally, and the Company is involved in or at risk for antitrust litigation, investigations or enforcement actions regarding a range of commercial activities, including challenges to mergers and acquisition transactions, joint ventures, co-development or co-marketing arrangements, contracting practices, distribution agreements and employment agreements. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek significant monetary damages and/or royalty payments, as well as other civil or criminal remedies (including injunctions barring or restricting the sale of products that are the subject of the proceeding, placing restrictions on competitive strategies or practices, or unwinding consummated transactions), any or all of which could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">certain litigation charges, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income. During fiscal years 2025, 2024, and 2023, the Company recognized $317&#160;million of certain litigation charges, net, $149&#160;million of certain litigation charges, net, and $30&#160;million of certain litigation income, net, respectively. At April&#160;25, 2025 and April&#160;26, 2024, accrued litigation was approximately $0.4&#160;billion and $0.2&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Colibri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#8217;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $106&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hernia Mesh Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of June 11, 2025, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 9,325 individual plaintiffs, and certain plaintiffs&#8217; law firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s have advised the Company that they may file additional cases in the future. Approximately 6,950 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,875 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diabetes Pump Retainer Ring Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 28, 2025, after a number of recent dismissals, there are nine lawsuits filed on behalf of 20 individuals. Plaintiffs&#8217; firms previously notified the Company that they may file additional lawsuits in the future on behalf of several thousand additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applied Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation in the U.S. District Court for the Central District of California, alleging that the Company has engaged in anticompetitive and monopolistic conduct relating to its sales of advanced bipolar devices, including under contracts with group purchasing organizations. The Company has substantial legal and factual defenses and intends to defend itself vigorously. The court recently deferred trial from June 2025 until after it rules on the parties' summary judgment motions. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in other countries regarding certain activities in different global markets. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Italian Payback</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, &#8220;payback&#8221; legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy&#8217;s medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by $90&#160;million during the three months ended July 26, 2024, as a reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company&#8217;s liability could differ from the amount currently accrued.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Termination with Blackstone</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, the Company is party to various research and development funding arrangements with Blackstone, which are subject to certain termination provisions. During fiscal year 2025, the parties negotiated a contractual dispute resolution under one of the funding arrangements. As a result, the Company recognized certain litigation charges in connection with the resolution. The Company included this accrued litigation charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#8217;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. Oral argument for the Appeal occurred in May 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic, Inc.&#8217;s fiscal years 2017 through 2023 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2021. Covidien LP&#8217;s fiscal year 2023 federal income tax return is currently being audited by the IRS.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 for additional discussion of income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#8217; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#8217;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into standby letters of credit agreements, bank guarantees, and surety bonds with financial institutions to support various performance and other obligations, as well as ongoing tax matters. As of April 25, 2025, the aggregated amount outstanding under these instruments was approximately $0.9&#160;billion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#8217;s consolidated earnings, financial position, and/or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The chief operating decision maker (CODM) is our Chief Executive Officer (CEO) and has chosen to organize the entity based upon therapy solutions provided by each segment. The four reportable segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM measures and evaluates segment performance and allocates resources based on net sales and segment operating profit. Net sales include end-customer revenues from products developed, manufactured, and distributed by the segments. Significant expense categories include cost of products sold excluding amortization of intangible assets, research and development expense, and selling, general, and administrative expenses. Segment operating profit excludes certain corporate and centralized expenses not allocated to the segments, including interest income and expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. The CODM uses segment operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The CODM is not regularly provided with expenditures for additions to long-lived assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span id="i8b8636ab5d4d4004bd25d54153027b58_1-2-1-1-411492"></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April&#160;25, 2025 and April&#160;26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer represented over 10 percent of the Company&#8217;s consolidated net sales in fiscal years 2025, 2024, or 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDTRONIC PLC AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Changes (Debit) Credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at End of<br/>Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for doubtful accounts and credit losses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 25, 2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 25, 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended April 28, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a) Primarily consists of uncollectible accounts written off, less recoveries.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b) Reflects the impact from acquisitions.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c) Primarily reflects carryover attribute utilization and expiration.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d) Primarily reflects the effects of currency fluctuations.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(e) Primarily reflects the impacts from tax rate changes.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to ordinary shareholders</a></td>
<td class="nump">$ 4,662<span></span>
</td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity regulatory based risk assessments for the Company&#8217;s systems and applications (where required),</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a formal incident response plan, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual information security training program for all employees, including phishing awareness training,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity works closely with application development and infrastructure &amp; operation teams to embed security considerations into the foundation of technology,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engagement of third-party service providers to conduct assessment of the Company&#8217;s cybersecurity risk management program, penetration testing, and vulnerability testing,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk assessment process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks from cybersecurity threats are integrated into Medtronic&#8217;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#8217;s business and operation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#8217;s business or operations. However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. See Item 1A. Risk Factors under, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity regulatory based risk assessments for the Company&#8217;s systems and applications (where required),</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a formal incident response plan, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual information security training program for all employees, including phishing awareness training,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity works closely with application development and infrastructure &amp; operation teams to embed security considerations into the foundation of technology,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engagement of third-party service providers to conduct assessment of the Company&#8217;s cybersecurity risk management program, penetration testing, and vulnerability testing,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk assessment process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks from cybersecurity threats are integrated into Medtronic&#8217;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#8217;s business and operation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </span></div>reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is engaged in the Company&#8217;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#8217;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#8217;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#8217;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation  </span> The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible assets, equity investments, and liability valuations. Actual results may or may not differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Year-End</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year-End</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for each of the three fiscal years ended April&#160;25, 2025 (fiscal year 2025), April&#160;26, 2024 (fiscal year 2024), and April&#160;28, 2023 (fiscal year 2023).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#8217;s investment and are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories  </span> Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant, and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Goodwill and Intangible Assets </span>  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#8217;s net assets exceeds the estimated fair value of the reporting unit.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from <span style="-sec-ix-hidden:f-513">three</span> to 20 years. Amortization is recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable.</span></div>When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the asset group's carrying value to its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group is estimated by utilizing a discounted cash flow analysis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text">Acquired IPR&amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#8217;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;D with no alternative future use acquired outside of a business combination is expensed immediately.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain of the Company&#8217;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#8217;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReservePolicyTextBlock', window );">Self-Insurance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance  </span> The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#8217; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Retirement Benefit Plan Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefit Plan Assumptions  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. Refer to Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs are unobservable for the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency exchange rate contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#8217;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other intangible assets, and IPR&amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Shipping and Handling</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For certain of our capital equipment, control is transferred upon installation. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general, and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income and were $322 million, $341 million, and $351 million in fiscal years 2025, 2024, and 2023, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span>  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span>  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#8217;s tax return but has not yet been recognized as an expense in the consolidated statements of income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock', window );">Other Operating (Income) Expense, Net</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating (Income) Expense, Net  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating (income) expense, net primarily includes royalty expense, currency remeasurement and derivative gains and losses, changes in fair value of contingent consideration, certain acquisition and divestiture-related items, income from funded research and development arrangements, Puerto Rico excise taxes, and commitments to the Medtronic Foundation and Medtronic LABS.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock', window );">Other Non-Operating Income, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Non-Operating Income, Net   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Translation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive loss, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther operating (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplier Finance Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#8212; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#8217;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements but did require additional disclosures. Refer to Note 6 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company retrospectively adopted this guidance beginning in the fourth quarter of fiscal year 2025. The adoption of this standard did not have a material impact on the Company's consolidated financial statements but did require additional disclosures. Refer to Note 19 for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Yet Adopted Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income (Expense), Net [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 60<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480576/715-80-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiac Rhythm &amp; Heart Failure</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart &amp; Aortic </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary &amp; Peripheral Vascular </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cranial &amp; Spinal Technologies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Therapies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical &amp; Endoscopy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Care &amp; Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Includes operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue and other performance-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 28.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and other milestone-based payments</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 - 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr></table></div><div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of restructuring costs in the consolidated statements of income: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-722"><span style="-sec-ix-hidden:f-723"><span style="-sec-ix-hidden:f-724">Cost of products sold</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-728"><span style="-sec-ix-hidden:f-729"><span style="-sec-ix-hidden:f-730">Selling, general, and administrative expenses</span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and associated costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the activity related to restructuring programs for fiscal years 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled non-cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments by Category and Related Balance Sheet Presentation</a></td>
<td class="text">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;25, 2025 and April&#160;26, 2024:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Level 2</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the gross unrealized losses and fair values of the Company&#8217;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;25, 2025 and April&#160;26, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auction rate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of Activity Related to the Company's Available for Sale Securities Portfolio</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company&#8217;s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Available-for-sale Debt Securities Contractual Maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of available-for-sale debt securities at April&#160;25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock', window );">Schedule of Equity and Other Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's equity and other investments at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;25, 2025 and April&#160;26, 2024, which are classified as primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated balance sheets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments with readily determinable fair value (marketable equity securities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the fair value option has been elected</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity and other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ScheduleOfInvestmentsTableTextBlock', window );">Schedule Of Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other non-operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Current Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt obligations consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bank borrowings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-990">six</span>-year 2019 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-994">five</span>-year 2020 senior notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-998">three</span>-year 2022 senior notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">Current debt obligations</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt obligations consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.238%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity by Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250 percent <span style="-sec-ix-hidden:f-1024">six</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.000 percent <span style="-sec-ix-hidden:f-1030">five</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625 percent <span style="-sec-ix-hidden:f-1036">three</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125 percent <span style="-sec-ix-hidden:f-1042">eight</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.250 percent <span style="-sec-ix-hidden:f-1048">five</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.000 percent <span style="-sec-ix-hidden:f-1054">six</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.375 percent <span style="-sec-ix-hidden:f-1060">eight</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.650 percent <span style="-sec-ix-hidden:f-1066">five</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1072">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.000 percent <span style="-sec-ix-hidden:f-1078">twelve</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125 percent <span style="-sec-ix-hidden:f-1084">nine</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750 percent <span style="-sec-ix-hidden:f-1090">twelve</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1096">ten</span>-year 2023 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375 percent <span style="-sec-ix-hidden:f-1102">twelve</span>-year 2022 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375 percent <span style="-sec-ix-hidden:f-1108">twenty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875 percent <span style="-sec-ix-hidden:f-1114">twelve</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.550 percent <span style="-sec-ix-hidden:f-1120">thirty</span>-year 2007 CIFSA senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250 percent <span style="-sec-ix-hidden:f-1126">twenty</span>-year 2019</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.500 percent <span style="-sec-ix-hidden:f-1132">thirty</span>-year 2009 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.500 percent <span style="-sec-ix-hidden:f-1138">twenty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.550 percent <span style="-sec-ix-hidden:f-1144">thirty</span>-year 2010 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375 percent <span style="-sec-ix-hidden:f-1150">twenty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500 percent <span style="-sec-ix-hidden:f-1156">thirty</span>-year 2012 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000 percent <span style="-sec-ix-hidden:f-1162">thirty</span>-year 2013 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.150 percent <span style="-sec-ix-hidden:f-1168">nineteen</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1174">thirty</span>-year 2014 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625 percent <span style="-sec-ix-hidden:f-1180">thirty</span>-year 2015 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750 percent <span style="-sec-ix-hidden:f-1186">thirty</span>-year 2019 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625 percent <span style="-sec-ix-hidden:f-1192">thirty</span>-year 2020 senior notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.150 percent <span style="-sec-ix-hidden:f-1198">twenty-nine</span>-year 2024 senior notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1203"><span style="-sec-ix-hidden:f-1204">Finance lease obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2054</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,642&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramTableTextBlock', window );">Supplier Finance Program</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of outstanding payables confirmed as valid associated with the program during fiscal year 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invoices confirmed during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confirmed invoices paid during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1251">Ending Balance</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of (Gain) Loss on Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of the Company's outstanding instruments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;1.0 billion, or $1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes derivative contracts with a notional value of &#8364;5.0 billion, or $5.7 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#165;322 billion, or $2.3 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2026 through 2033. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At April&#160;25, 2025, includes &#8364;18.0 billion, or $20.6 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.704%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Reclassified into Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Gain) Loss Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of (Gain) Loss in Income Statement</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;25, 2025 and April&#160;26, 2024. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"><tr><td style="width:1.0%"></td><td style="width:47.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1350">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1351">Derivative Liabilities</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1352">Derivative Assets</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1353">Derivative Liabilities</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsTableTextBlock', window );">Schedule of Offsetting Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingLiabilitiesTableTextBlock', window );">Schedule of Offsetting Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 25, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount Not Offset on the Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amount of Recognized Assets (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral (Received) Posted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory Balances</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as a result of acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,547)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology and patents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,925&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,547)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets</a></td>
<td class="text">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;25, 2025, excluding any possible future amortization associated with acquired IPR&amp;D which has not met technological feasibility, is as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment Balances and Corresponding Lives</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment balances and corresponding estimated useful lives were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives <br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally 2-10, up to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:</span><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions used:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during fiscal year 2025:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg. Remaining Contractual Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds from options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,644&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per restricted stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of restricted stock vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to restricted stock vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of Performance Share Unit Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit activity during fiscal year 2025:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wtd. Avg.<br/>Grant<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;26, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at April&#160;25, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per performance share units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of performance share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit related to performance share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Income Before Income Taxes, Based on Jurisdiction</a></td>
<td class="text">The components of income before income taxes, based on tax jurisdiction, are as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax (Benefit) Provision</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax (benefit) expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss, capital loss, and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease obligations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state benefit on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities and derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis difference of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and post-retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported as (after valuation allowance and jurisdictional netting):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base erosion anti-abuse tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign derived intangible income benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits</a></td>
<td class="text">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2025, 2024, and 2023 is as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of fiscal year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross decreases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute of limitation lapses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash advance paid to taxing authorities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock', window );">Schedule of Major Tax Jurisdictions Which Remain Subject to Examination</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earliest Year Open</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - federal and state</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxExaminationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the computation of basic and diluted earnings per share:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ordinary shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted &#8211; weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans</a></td>
<td class="text">The change in benefit obligation and funded status of the Company&#8217;s U.S. and Non-U.S. pension benefits are as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated benefit obligation at end of year:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in projected benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailments, settlements, and amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss (gain)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funded status at end of year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over funded status of the plans</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized on the consolidated<br/>balance sheets consist of:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts recognized in accumulated other<br/>comprehensive loss:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In April 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:<div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost of the plans includes the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss (gain)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement and curtailment (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit (credit) cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other changes in plan assets and projected benefit obligations recognized in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> other comprehensive (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for fiscal year 2025 are as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S.<br/>Pension<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and settlement recognition of actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial assumptions are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; projected benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24% - 5.76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21% - 24.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical assumptions &#8211; net periodic benefit cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> benefit obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.54% - 5.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.99%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23% - 4.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">service cost</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53% - 5.82%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 5.07%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12% - 4.51%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> interest cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51% - 5.63%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73% - 4.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% - 4.23%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40% - 26.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% - 10.70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 25.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% - 8.10%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30% - 7.20%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. plans target asset allocations at April&#160;25, 2025, compared to the U.S. plans actual asset allocations at April&#160;25, 2025 and April&#160;26, 2024 by asset category, are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Actual Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;25, 2025</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April&#160;26, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Category:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock', window );">Schedule of Fair Value Measurements, Retirement Benefit Plan Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;25, 2025 and April&#160;26, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pension Benefits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity commingled trusts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income commingled trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-U.S. Pension Benefits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements<br/>Using Inputs Considered as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered investment companies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-U.S. Pension Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031 &#8211; 2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (d)(5)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (f)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (h)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2354"><span style="-sec-ix-hidden:f-2355">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2358"><span style="-sec-ix-hidden:f-2359">Other accrued expenses</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2362"><span style="-sec-ix-hidden:f-2363">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;25, 2025 and April&#160;26, 2024: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 Years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 Years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of total operating lease cost for fiscal year 2025, 2024, and 2023: </span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2025, 2024, and 2023:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's operating leases at April&#160;25, 2025:</span></div><div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)<br/>Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expected lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized (Loss) Gain on Investment Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in Retirement Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 29, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 28, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,284)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 25, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Operating Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span id="i8b8636ab5d4d4004bd25d54153027b58_1-2-1-1-411492"></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated net sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit / (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-operating income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centralized distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and associated costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain litigation charges, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device regulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments to the Medtronic Foundation and Medtronic LABS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span>Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets and Depreciation Expense </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April&#160;25, 2025 and April&#160;26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant, and equipment, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 25, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other countries, excluding Ireland</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Shipping and Handling</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">$ 10,849<span></span>
</td>
<td class="nump">$ 10,736<span></span>
</td>
<td class="nump">$ 10,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Shipping and Handling</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 33,537<span></span>
</td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Consolidation, Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">33,489<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">33,489<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Cardiac Rhythm &amp; Heart Failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,392<span></span>
</td>
<td class="nump">5,995<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Structural Heart &amp; Aortic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Coronary &amp; Peripheral Vascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Cranial &amp; Spinal Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,973<span></span>
</td>
<td class="nump">4,756<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Specialty Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Neuromodulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Surgical &amp; Endoscopy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,498<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
<td class="nump">6,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Acute Care &amp; Monitoring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CardiacRhythmandHeartFailureDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CardiacRhythmandHeartFailureDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_StructuralHeartAndAorticDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_StructuralHeartAndAorticDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CoronaryAndPeripheralVascularDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CoronaryAndPeripheralVascularDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_CranialAndSpinalTechnologiesDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_CranialAndSpinalTechnologiesDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_SpecialtyTherapiesDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_SpecialtyTherapiesDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_NeuromodulationDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_NeuromodulationDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_SurgicalInnovationsDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_SurgicalInnovationsDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=mdt_AcuteCareMonitoringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=mdt_AcuteCareMonitoringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 33,537<span></span>
</td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">33,489<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Consolidation, Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">17,171<span></span>
</td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">16,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Pension Benefits | Consolidation, Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_InternationalMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">16,365<span></span>
</td>
<td class="nump">15,802<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_InternationalMember', window );">International | Consolidation, Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">33,489<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">17,104<span></span>
</td>
<td class="nump">16,471<span></span>
</td>
<td class="nump">16,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember', window );">Reportable segment net sales | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">16,386<span></span>
</td>
<td class="nump">15,671<span></span>
</td>
<td class="nump">14,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">5,804<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,234<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,713<span></span>
</td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">6,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">2,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,664<span></span>
</td>
<td class="nump">3,717<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,744<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">4,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | U.S. Pension Benefits | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other operating segment | International | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_TotalReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was previously included in deferred revenue</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Period over which remaining performance obligations are expected to be recognized as revenue</a></td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Rebate obligations</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Rebate obligations</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 41,737<span></span>
</td>
<td class="nump">$ 40,986<span></span>
</td>
<td class="nump">$ 41,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration for the transaction, net of cash acquired</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Assets acquired</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLossNetOfTax', window );">Goodwill, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillNotAllocatedAmount', window );">Goodwill, non deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business combinations | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillNotAllocatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of goodwill not yet allocated to reportable segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillNotAllocatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember', window );">Renal Care Solutions | Other operating (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and related inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember', window );">Renal Care Solutions | Mozarc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Disposal Group, Not Discontinued Operations | Ventilator Product Line Exit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit costs</a></td>
<td class="nump">$ 439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet', window );">Discontinued operation, other operating expense, net</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments', window );">Non-cash impairments</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Disposal Group, Not Discontinued Operations | Renal Care Solutions | Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to acquire long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Non-cash Impairments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other Operating Income (Expense), Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Additional funding</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Contingent consideration receivable</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward', window );"><strong>Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionPriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment', window );">Payments</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments in business acquisition transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionPriceContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Price Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionPriceContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Revenue and other performance-based payments | Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Product development and other milestone-based payments | Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Fair Value Inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, significant unobservable inputs</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdt_RevenueMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdt_RevenueMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdt_ProductDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdt_ProductDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationRollForward', window );"><strong>Beginning and Ending Balances of Contingent Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_BusinessAcquisitionContingentConsiderationRollForward', window );"><strong>Beginning and Ending Balances of Contingent Payments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Beginning balance</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable', window );">Ending balance</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_BusinessAcquisitionContingentConsiderationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_BusinessAcquisitionContingentConsiderationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring and associated costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember', window );">Enterprise Excellence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated expected restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember', window );">Simplification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated expected restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mdt_EnterpriseExcellenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mdt_SimplificationRestructuringProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Classification of Restructuring Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact', window );">Restructuring charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring and associated costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember', window );">Incremental defined benefit, defined contribution and post-retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cost of products sold, excluding amortization of intangible assets<span></span>
</td>
<td class="text">Cost of products sold, excluding amortization of intangible assets<span></span>
</td>
<td class="text">Cost of products sold, excluding amortization of intangible assets<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Selling, general, and administrative expense<span></span>
</td>
<td class="text">Selling, general, and administrative expense<span></span>
</td>
<td class="text">Selling, general, and administrative expense<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Activity Related to Restructuring Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember', window );">Associated and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Changes in Restructuring Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_RestructuringChargesIncludingAccrualAdjustments', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Accrual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_RestructuringChargesIncludingAccrualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Including Accrual Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_RestructuringChargesIncludingAccrualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mdt_AssociatedAndOtherCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">$ 6,826<span></span>
</td>
<td class="nump">$ 6,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,752<span></span>
</td>
<td class="nump">6,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,719<span></span>
</td>
<td class="nump">6,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">6,373<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">3,540<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-U.S. government and agency securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other asset-backed securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Auction rate securities | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">4,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember', window );">Auction rate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AuctionRateSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">$ 511<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Fair value, option loss</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=mdt_MozarcMember', window );">Mozarc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember', window );">Equity and Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized losses on equity and other investments still held</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mdt_MozarcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mdt_MozarcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mdt_EquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract', window );"><strong>Activities Related to Debt Securities Portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 8,213<span></span>
</td>
<td class="nump">$ 7,359<span></span>
</td>
<td class="nump">$ 7,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Total</a></td>
<td class="nump">6,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>AFS Debt Maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">3,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 6,752<span></span>
</td>
<td class="nump">$ 6,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments with readily determinable fair value (marketable equity securities)</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Investments for which the fair value option has been elected</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investments without readily determinable fair values</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method and other investments</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments', window );">Total equity and other investments</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="nump">$ 1,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Debt and Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Beginning Balance</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions', window );">Change in fair value</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Ending Balance</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Gains and Losses on Equity and Other Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales</a></td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_GainOnInvestments', window );">Gross gains</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LossOnInvestments', window );">Gross losses</a></td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment losses recognized</a></td>
<td class="num">$ (135)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_GainOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_GainOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Current Debt Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial Paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="nump">$ 2,874<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current debt obligations<span></span>
</td>
<td class="text">Current debt obligations<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.250 percent six-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.000 percent five-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.625 percent three-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Bank borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank borrowings</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20260250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20260250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20260.000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20260.000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20262.625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20262.625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Narrative (Details)<br> &#8364; in Billions, &#165; in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 26, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,874,000,000<span></span>
</td>
<td class="nump">$ 1,092,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,284,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense on outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,000,000<span></span>
</td>
<td class="nump">916,000,000<span></span>
</td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligation', window );">Supplier finance program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600,000,000<span></span>
</td>
<td class="nump">24,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Estimated fair value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,200,000,000<span></span>
</td>
<td class="nump">21,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Medtronic Luxco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin added per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings (maturities greater than 90 days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">&#165; 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_A2015And2020CommercialPaperProgramMember', window );">2015 and 2020 Commercial Paper Program | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CommercialPaperMaximumBorrowingCapacity', window );">Commercial paper, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember', window );">$3.5 Billion Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LineOfCreditFacilityLengthOfExtension', window );">Length of extension from maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Committed line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember', window );">Medtronic Luxco Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DebtInstrumentNumberofTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds from debt</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember', window );">Senior Notes 2015 Due 2025, 3.500 percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember', window );">Senior Notes 2015 Due 2025, 3.500 percent | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption of senior notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember', window );">Senior Notes 2017 Due 2027, 3.350 Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember', window );">Senior Notes 2017 Due 2027, 3.350 Percent | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption of senior notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CommercialPaperMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Paper, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CommercialPaperMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DebtInstrumentNumberofTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DebtInstrumentNumberofTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LineOfCreditFacilityLengthOfExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Length of Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LineOfCreditFacilityLengthOfExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mdt_MedtronicLuxcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mdt_MedtronicLuxcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_A2015And2020CommercialPaperProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_A2015And2020CommercialPaperProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_AmendedandRestatedRevolvingCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_MedtronicLuxcoSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20253.500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2017Due20273.350PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">$ 25,642<span></span>
</td>
<td class="nump">$ 23,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt<span></span>
</td>
<td class="text">Long-term debt<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.250 percent six-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.000 percent five-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.625 percent three-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125 percent eight-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.250 percent five-year 2023 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="nump">4.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.000 percent six-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.09%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.375 percent eight-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.51%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.650 percent five-year 2024 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625 percent twelve-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.000 percent twelve-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.06%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.125 percent nine-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.750 percent twelve-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.500 percent ten-year 2023 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.62%<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375 percent twelve-year 2022 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.44%<span></span>
</td>
<td class="nump">3.44%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375 percent twenty-year 2015 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.47%<span></span>
</td>
<td class="nump">4.47%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875 percent twelve-year 2024 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.550 percent thirty-year 2007 CIFSA senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250 percent twenty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.500 percent thirty-year 2009 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">6.56%<span></span>
</td>
<td class="nump">6.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.500 percent twenty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.550 percent thirty-year 2010 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">5.58%<span></span>
</td>
<td class="nump">5.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375 percent twenty-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.500 percent thirty-year 2012 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.54%<span></span>
</td>
<td class="nump">4.54%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.000 percent thirty-year 2013 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.150 percent nineteen-year 2024 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 685<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625 percent thirty-year 2014 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625 percent thirty-year 2015 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.69%<span></span>
</td>
<td class="nump">4.69%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.750 percent thirty-year 2019 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625 percent thirty-year 2020 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.150 percent twenty-nine-year 2024 senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">29 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Amount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective Interest Rate</a></td>
<td class="nump">4.19%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20260250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20260250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20260.000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20260.000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20262.625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20262.625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20271125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20271125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2023Due20284.250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2023Due20284.250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20293.000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20293.000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20290375PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20290375PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20303.650PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20303.650PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20311625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20311625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20321000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20321000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20323.125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20323.125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20330750PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20330750PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2023Due20334.500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2023Due20334.500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20353.375PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2022Due20353.375PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20354.375PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20354.375PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20373.875PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20373.875PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_CIFSASeniorNotes2007Due20386.550PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_CIFSASeniorNotes2007Due20386.550PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20392250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20392250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2009Due20396500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2009Due20396500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20401500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20401500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2010Due20405550PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2010Due20405550PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20411375PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20411375PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2012Due20424500PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2012Due20424500PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2013Due20434000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2013Due20434000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20444.150PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20444.150PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2014Due20444625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2014Due20444625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20454625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2015Due20454625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20501750PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2019Due20501750PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20511625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2020Due20511625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20544.150PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdt_SeniorNotes2024Due20544.150PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Arrangements - Long-term Debt Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">2,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2030</a></td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">19,824<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 28,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Arrangements - Supplier Financing Program (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationRollForward', window );"><strong>Supplier Finance Program, Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligation', window );">Beginning Balance</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationIncrease', window );">Invoices confirmed during the year</a></td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement', window );">Confirmed invoices paid during the year</a></td>
<td class="num">$ (517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligation', window );">Ending Balance</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in obligation for supplier finance program from settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationDecreaseSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on interest rate cash flow hedges</a></td>
<td class="num">$ (149)<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Cash flow hedge unrealized gains to be reclassified over the next twelve months</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Derivative, excluded component, gain (loss), recognized in earnings</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash', window );">Net cash collateral received</a></td>
<td class="num">$ (125)<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) recognized in earnings from excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)<br> &#8364; in Billions, &#165; in Billions, $ in Billions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Derivatives not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Cash flow hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges | Derivatives designated as hedging instruments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges | Derivatives designated as hedging instruments | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Fair Value Hedging | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember', window );">Foreign currency denominated debt | Net investment hedges | Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Gross notional amount</a></td>
<td class="nump">$ 20.6<span></span>
</td>
<td class="nump">&#8364; 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</a></td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="num">$ (1,173)<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">(Gain) Loss Reclassified into Income</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, net investment hedges</a></td>
<td class="nump">247<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Reclassified into Income, net investment hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Other operating (income) expense, net | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">(Gain) Loss Reclassified into Income</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Other operating (income) expense, net | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, Cash flow hedges</a></td>
<td class="nump">308<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Recognized in income, cash flow hedges</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts | Cost of products sold | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, Cash flow hedges</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Recognized in income, cash flow hedges</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember', window );">Foreign currency denominated debt | Net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Recognized in AOCI, net investment hedges</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Reclassified into Income, net investment hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mdt_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other operating (income) expense, net | Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, (Gain) Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, (gain) loss, net</a></td>
<td class="num">$ (91)<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember', window );">Total return swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Total return swaps | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Total return swaps | Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mdt_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other accrued expenses<span></span>
</td>
<td class="text">Other accrued expenses<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(417)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetLiabilityAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(84)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">125<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet', window );">Net Amount</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Currency exchange rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember', window );">Total return swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amount of Recognized Assets (Liabilities)</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross Amount Not Offset on the Balance Sheet, Financial Instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral', window );">Net Amount</a></td>
<td class="num">$ (16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset (Liability) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset (Liability), Fair Value, Gross Asset (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount as of the balance sheet date of the fair value of derivative assets and derivative liabilities that in accordance with the entity's accounting policy were offset against collateral under a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TotalReturnSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 3,779<span></span>
</td>
<td class="nump">$ 3,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 5,476<span></span>
</td>
<td class="nump">$ 5,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Changes in Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 40,986<span></span>
</td>
<td class="nump">$ 41,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">643<span></span>
</td>
<td class="num">(565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">41,737<span></span>
</td>
<td class="nump">40,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">7,966<span></span>
</td>
<td class="nump">7,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">8,017<span></span>
</td>
<td class="nump">7,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">11,644<span></span>
</td>
<td class="nump">11,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">72<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">11,716<span></span>
</td>
<td class="nump">11,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">19,121<span></span>
</td>
<td class="nump">19,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">521<span></span>
</td>
<td class="num">(458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">19,748<span></span>
</td>
<td class="nump">19,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation and other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 2,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Operating Income (Expense), Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,807,000,000<span></span>
</td>
<td class="nump">$ 1,693,000,000<span></span>
</td>
<td class="nump">1,698,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_AcceleratedAmortizationOfIntangibleAssets', window );">Accelerated amortization</a></td>
<td class="nump">$ 151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember', window );">Ventilator Product Line Exit | Disposal Group, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember', window );">Renal Care Business (RCS) | Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Transfer to held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_AcceleratedAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Amortization of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_AcceleratedAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_VentilatorProductLineExitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdt_RenalCareBusinessRCSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28,925<span></span>
</td>
<td class="nump">$ 28,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(17,547)<span></span>
</td>
<td class="num">(15,915)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">16,550<span></span>
</td>
<td class="nump">16,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,650)<span></span>
</td>
<td class="num">(8,689)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember', window );">Purchased technology and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">11,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,514)<span></span>
</td>
<td class="num">(6,868)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (101)<span></span>
</td>
<td class="num">$ (84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mdt_PurchasedTechnologyAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 15,636<span></span>
</td>
<td class="nump">$ 14,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(8,799)<span></span>
</td>
<td class="num">(7,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,837<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 7,156<span></span>
</td>
<td class="nump">6,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 3,295<span></span>
</td>
<td class="nump">2,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 2,685<span></span>
</td>
<td class="nump">2,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment</a></td>
<td class="nump">$ 2,340<span></span>
</td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdt_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesAuthorized', window );">Deferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockParorStatedValuePerShare', window );">Deferred stock, par value (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesIssued', window );">Deferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredStockSharesOutstanding', window );">Deferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">38,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_StockRepurchaseProgramAveragePurchasePrice', window );">Average repurchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 83.36<span></span>
</td>
<td class="nump">$ 83.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Amount authorized for repurchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Amount repurchased | $</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for future repurchases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockParorStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Par or Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockParorStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock, Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_StockRepurchaseProgramAveragePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average purchase price of common shares under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_StockRepurchaseProgramAveragePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Narrative (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to outstanding stock options | $</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards | $</a></td>
<td class="nump">$ 414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to restricted stock awards | $</a></td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares) | shares</a></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">The discount rate from market value on purchase date</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod', window );">Shares purchased by employees (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare', window );">Average purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 72.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future purchase (in shares) | shares</a></td>
<td class="nump">26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mdt_A2024EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefits</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Total stock-based compensation expense, net of tax</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mdt_EmployeesStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 16.43<span></span>
</td>
<td class="nump">$ 18.49<span></span>
</td>
<td class="nump">$ 17.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">24.47%<span></span>
</td>
<td class="nump">24.29%<span></span>
</td>
<td class="nump">24.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Stock Options Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">32,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(6,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/Forfeited (in shares)</a></td>
<td class="num">(1,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">27,766<span></span>
</td>
<td class="nump">32,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Expected to vest (in shares)</a></td>
<td class="nump">7,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable (in shares)</a></td>
<td class="nump">19,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Wtd. Avg. Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 93.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">80.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">77.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/Forfeited (in dollars per share)</a></td>
<td class="nump">96.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">95.04<span></span>
</td>
<td class="nump">$ 93.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expected to vest (in dollars per share)</a></td>
<td class="nump">88.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 97.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Expected to vest</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Expected to vest</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from options exercised</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to options exercised</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Restricted Stock Activity (Details) - Restricted stock - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">7,644<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg. Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 92.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">82.37<span></span>
</td>
<td class="nump">$ 82.80<span></span>
</td>
<td class="nump">$ 91.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">99.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">88.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 85.64<span></span>
</td>
<td class="nump">$ 92.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to restricted stock vested</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Purchase and Award Plans - Performance Share Unit Activity (Details) - Performance share units - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments', window );">Performance adjustments (in shares)</a></td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Wtd. Avg. Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 106.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">98.49<span></span>
</td>
<td class="nump">$ 104.78<span></span>
</td>
<td class="nump">$ 98.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">147.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments', window );">Performance adjustments (in dollar per share)</a></td>
<td class="nump">97.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">103.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 100.51<span></span>
</td>
<td class="nump">$ 106.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit related to restricted stock vested</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 1,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">4,591<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 5,628<span></span>
</td>
<td class="nump">$ 4,837<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S.</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax (benefit) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S.</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(435)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Net deferred tax benefit</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 936<span></span>
</td>
<td class="nump">$ 1,133<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards', window );">Net operating loss, capital loss, and credit carryforwards</a></td>
<td class="nump">$ 11,252<span></span>
</td>
<td class="nump">$ 11,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization', window );">Capitalization of research and development</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsLeaseObligations', window );">Lease obligations</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions', window );">Federal and state benefit on uncertain tax positions</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsInterestLimitation', window );">Interest limitation</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives', window );">Unrealized gain on available-for-sale securities and derivative financial instruments</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">17,946<span></span>
</td>
<td class="nump">18,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,668)<span></span>
</td>
<td class="num">(13,271)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,277<span></span>
</td>
<td class="nump">5,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,238)<span></span>
</td>
<td class="num">(1,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Realized loss on derivative financial instruments</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use leases</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries', window );">Outside basis difference of subsidiaries</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits', window );">Pension and post-retirement benefits</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,773)<span></span>
</td>
<td class="num">(1,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income tax receivables</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Tax assets, net</a></td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">3,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract', window );"><strong>Reported as (after valuation allowance and jurisdictional netting):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsNetofValuationAllowanceOther', window );">Other current assets</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Tax assets</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">$ (403)<span></span>
</td>
<td class="num">$ (515)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsNetofValuationAllowanceOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net of Valuation Allowance, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsNetofValuationAllowanceOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Research and Development Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Investment In Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Pension And Post-retirement Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings from non-U.S. subsidiaries</a></td>
<td class="nump">$ 88,600<span></span>
</td>
<td class="nump">$ 86,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration', window );">Tax credit carryforward, no expiration</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">12,668<span></span>
</td>
<td class="nump">13,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Income tax charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Certain tax adjustments, provision (benefit)</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization', window );">Tax expense associated with the amortization of the previously established deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets', window );">Intercompany sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion', window );">Tax expense related to internal restructuring and intercompany sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount', window );">Effective income tax rate reconciliation, tax adjustments for reserves, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount', window );">Effective income tax reconciliation, disallowance of interest deductions, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Deferred tax assets, unrealized currency losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">$ 1,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Gross unrecognized tax benefits, net of cash advance, noncurrent liability</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncomeTaxExaminationInterestIncomeExpenseGross', window );">Gross interest expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued income tax penalties and interest</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-U.S. Tax Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, expiring in future years</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Net operating loss carryforwards, valuation allowance</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxHolidays', window );">Tax reductions from tax holiday</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Impact on diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-U.S. Tax Authorities | Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Tax Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, no expiration</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncomeTaxExaminationInterestIncomeExpenseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Interest Income (Expense), Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncomeTaxExaminationInterestIncomeExpenseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482620/740-10-25-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_IncreaseDecreaseInTaxRateAbstract', window );"><strong>Increase (decrease) in tax rate resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. state taxes, net of federal tax benefit</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax', window );">Puerto Rico excise tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International</a></td>
<td class="num">(6.50%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent', window );">Uncertain tax positions and interest</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent', window );">Base erosion anti-abuse tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign derived intangible income benefit</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Certain tax adjustments</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">U.S. tax on foreign earnings</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">16.60%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_IncreaseDecreaseInTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_IncreaseDecreaseInTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of fiscal year</a></td>
<td class="nump">$ 2,824<span></span>
</td>
<td class="nump">$ 2,682<span></span>
</td>
<td class="nump">$ 1,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract', window );"><strong>Gross increases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Prior year tax positions</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Current year tax positions</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract', window );"><strong>Gross decreases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Prior year tax positions</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute of limitation lapses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of fiscal year</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CashAdvancePaidinConnectionWithProposedSettlements', window );">Cash advance paid to taxing authorities</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid', window );">Gross unrecognized tax benefits at end of fiscal year, net of cash advance</a></td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">$ 1,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CashAdvancePaidinConnectionWithProposedSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Advance Paid in Connection With Proposed Settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CashAdvancePaidinConnectionWithProposedSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net of Cash Advance Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to ordinary shareholders</a></td>
<td class="nump">$ 4,662<span></span>
</td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic - weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,285.6<span></span>
</td>
<td class="nump">1,327.7<span></span>
</td>
<td class="nump">1,329.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted &#8211; weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,289.9<span></span>
</td>
<td class="nump">1,330.2<span></span>
</td>
<td class="nump">1,332.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share based payments (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Employee restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends', window );">Employee restricted stock units (in shares)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Employee performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share based payments (in shares)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 68B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-68B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Cost of retirement benefit plans</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">(440)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits', window );">Incremental expense related to acceptance of voluntary early retirement packages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense under defined contribution plans</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">$ (341)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated future employer contributions in next fiscal year</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. Pension Benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Net underfunded status of the plans</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated future employer contributions in next fiscal year</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | Non-U.S. | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocations</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other post-retirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Post-retirement benefit plans, fair value of plan assets</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Post-retirement benefit plans, net periodic benefit cost, income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Post-retirement benefit plans, benefit obligations</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over funded status of the plans</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(1,158)<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Plans with accumulated benefit obligations in excess of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Plans with projected benefit obligations in excess of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES | Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation at end of year</a></td>
<td class="nump">3,235<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at beginning of year</a></td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation', window );">Plan curtailments, settlements, and amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss (gain)</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency exchange rate changes and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at end of year</a></td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Plan settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency exchange rate changes and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligations</a></td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over funded status of the plans</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract', window );"><strong>Amounts recognized in accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service credit</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Ending balance</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Pension Benefits | Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation at end of year</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at beginning of year</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation', window );">Plan curtailments, settlements, and amendments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss (gain)</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency exchange rate changes and other</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation at end of year</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Plan settlements</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency exchange rate changes and other</a></td>
<td class="nump">138<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract', window );"><strong>Funded status at end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligations</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Over funded status of the plans</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheets consist of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Recognized asset</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract', window );"><strong>Amounts recognized in accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Ending balance</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Net Periodic Cost and AOCI (Details) - Pension benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss (gain)</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement and curtailment (gain) loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit (credit) cost</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Amounts Recognized in AOCI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax', window );">Amortization and settlement recognition of actuarial (gain) loss</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in other comprehensive loss</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive loss</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss (gain)</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement and curtailment (gain) loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit (credit) cost</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Amounts Recognized in AOCI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax', window );">Amortization and settlement recognition of actuarial (gain) loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment', window );">Effect of exchange rates</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in other comprehensive loss</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive loss</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details) - Pension benefits<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Actual Allocation</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.24%<span></span>
</td>
<td class="nump">5.54%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">5.54%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">5.53%<span></span>
</td>
<td class="nump">4.68%<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.76%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">5.82%<span></span>
</td>
<td class="nump">5.07%<span></span>
</td>
<td class="nump">4.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">5.63%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract', window );"><strong>Plan Assets Target Allocations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Critical assumptions &#8211; projected benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">24.40%<span></span>
</td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Critical assumptions &#8211; net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate &#8211; benefit obligation</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate', window );">Discount rate &#8211; service cost</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Discount rate &#8211; interest cost</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_OtherPlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefit Plans - Fair Value Measurement (Details) - Pension benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 3,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Short-term investments | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Mutual funds | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Equity commingled trusts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Fixed income commingled trusts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES | Partnership units | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Registered investment companies | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits | Insurance contracts | Investments measured at net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_PartnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_PartnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_RegisteredInvestmentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_RegisteredInvestmentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_InsuranceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mdt_InsuranceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefit Plans - Future Benefit Payments (Details) - Pension benefits<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Estimated Future Benefit Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2027</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2028</a></td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2029</a></td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2030</a></td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2031 &#8211; 2035</a></td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Estimated Future Benefit Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2026</a></td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2027</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2028</a></td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2029</a></td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2030</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2031 &#8211; 2035</a></td>
<td class="nump">$ 483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other assets</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liability</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other accrued expenses</a></td>
<td class="text">Other accrued expenses<span></span>
</td>
<td class="text">Other accrued expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liability</a></td>
<td class="nump">$ 918<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Balance Sheet Classification, Other liabilities</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Total Operating Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total expected lease payments</a></td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 1,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 50,420,000,000<span></span>
</td>
<td class="nump">$ 51,665,000,000<span></span>
</td>
<td class="nump">$ 52,722,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(964,000,000)<span></span>
</td>
<td class="nump">178,000,000<span></span>
</td>
<td class="num">(1,234,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">48,256,000,000<span></span>
</td>
<td class="nump">50,420,000,000<span></span>
</td>
<td class="nump">51,665,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(3,318,000,000)<span></span>
</td>
<td class="num">(3,499,000,000)<span></span>
</td>
<td class="num">(2,265,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(808,000,000)<span></span>
</td>
<td class="nump">457,000,000<span></span>
</td>
<td class="num">(704,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="num">(158,000,000)<span></span>
</td>
<td class="num">(278,000,000)<span></span>
</td>
<td class="num">(530,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(966,000,000)<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="num">(1,234,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,284,000,000)<span></span>
</td>
<td class="num">(3,318,000,000)<span></span>
</td>
<td class="num">(3,499,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized (Loss) Gain on Investment Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(212,000,000)<span></span>
</td>
<td class="num">(258,000,000)<span></span>
</td>
<td class="num">(209,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">135,000,000<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
<td class="num">(78,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">149,000,000<span></span>
</td>
<td class="nump">46,000,000<span></span>
</td>
<td class="num">(49,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(63,000,000)<span></span>
</td>
<td class="num">(212,000,000)<span></span>
</td>
<td class="num">(258,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="num">(21,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(3,686,000,000)<span></span>
</td>
<td class="num">(2,839,000,000)<span></span>
</td>
<td class="num">(2,599,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">851,000,000<span></span>
</td>
<td class="num">(846,000,000)<span></span>
</td>
<td class="num">(240,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">851,000,000<span></span>
</td>
<td class="num">(846,000,000)<span></span>
</td>
<td class="num">(240,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,835,000,000)<span></span>
</td>
<td class="num">(3,686,000,000)<span></span>
</td>
<td class="num">(2,839,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember', window );">Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">878,000,000<span></span>
</td>
<td class="nump">245,000,000<span></span>
</td>
<td class="nump">841,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(1,474,000,000)<span></span>
</td>
<td class="nump">633,000,000<span></span>
</td>
<td class="num">(596,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(1,474,000,000)<span></span>
</td>
<td class="nump">633,000,000<span></span>
</td>
<td class="num">(596,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(597,000,000)<span></span>
</td>
<td class="nump">878,000,000<span></span>
</td>
<td class="nump">245,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="num">(47,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Net Change in Retirement Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(529,000,000)<span></span>
</td>
<td class="num">(741,000,000)<span></span>
</td>
<td class="num">(773,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(116,000,000)<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(110,000,000)<span></span>
</td>
<td class="nump">212,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(640,000,000)<span></span>
</td>
<td class="num">(529,000,000)<span></span>
</td>
<td class="num">(741,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="num">(32,000,000)<span></span>
</td>
<td class="nump">79,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gain (Loss) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">229,000,000<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="nump">474,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(204,000,000)<span></span>
</td>
<td class="nump">438,000,000<span></span>
</td>
<td class="nump">184,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications</a></td>
<td class="num">(177,000,000)<span></span>
</td>
<td class="num">(302,000,000)<span></span>
</td>
<td class="num">(565,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(381,000,000)<span></span>
</td>
<td class="nump">136,000,000<span></span>
</td>
<td class="num">(381,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(149,000,000)<span></span>
</td>
<td class="nump">229,000,000<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), tax expense (benefit)</a></td>
<td class="num">(33,000,000)<span></span>
</td>
<td class="nump">103,000,000<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassifications from AOCI, tax expense (benefit)</a></td>
<td class="nump">$ 52,000,000<span></span>
</td>
<td class="nump">$ 66,000,000<span></span>
</td>
<td class="nump">$ 133,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 28, 2025 </div>
<div>plaintiff </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>plaintiff </div>
<div>claim </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Feb. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Litigation charges (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued litigations charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantee obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs) | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claimants (in claimants) | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LossContingencyLawsuitsNumber', window );">Loss contingency, lawsuits, number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Massachusetts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs) | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember', window );">Hernia Mesh Litigation | Pending Litigation | Minnesota | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs) | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_ColibriMember', window );">Colibri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount of settlement paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember', window );">Diabetes Pump Retainer Ring Litigation | California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs (in plaintiffs) | plaintiff</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_LossContingencyLawsuitsNumber', window );">Loss contingency, lawsuits, number | lawsuit</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_HerniaMeshLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_ColibriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_ColibriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mdt_DiabetesPumpRetainerRingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 25, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Segment Reporting (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,537<span></span>
</td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,632<span></span>
</td>
<td class="nump">11,216<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,849<span></span>
</td>
<td class="nump">10,736<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,955<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and associated costs</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,489<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">30,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
<td class="nump">10,385<span></span>
</td>
<td class="nump">9,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,541<span></span>
</td>
<td class="nump">7,365<span></span>
</td>
<td class="nump">7,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,518<span></span>
</td>
<td class="nump">11,979<span></span>
</td>
<td class="nump">11,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CorporateOverhead', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
<td class="num">(1,784)<span></span>
</td>
<td class="num">(1,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(729)<span></span>
</td>
<td class="num">(719)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CentralizedDistributionCosts', window );">Centralized distribution costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
<td class="num">(1,609)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_ForeignCurrencyCosts', window );">Currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and associated costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition and divestiture-related items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Certain litigation charges, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_MedicalDeviceRegulations', window );">Medical device regulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpense', window );">Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS', window );">Commitments to the Medtronic Foundation and Medtronic LABS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember', window );">Cardiovascular | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,481<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">11,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,967<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,801<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember', window );">Neuroscience | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">2,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember', window );">Medical Surgical | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,042<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember', window );">Diabetes | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mdt_OtherSegmentMember', window );">Other Segment | Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Reportable segment operating profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (89)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CentralizedDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Centralized Distribution Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CentralizedDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments to the Medtronic Foundation and Medtronic LABS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_CorporateOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate overhead expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_CorporateOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_ForeignCurrencyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_ForeignCurrencyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_MedicalDeviceRegulations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Device Regulations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_MedicalDeviceRegulations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483613/220-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_OtherSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_OtherSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 91,680<span></span>
</td>
<td class="nump">$ 89,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">72,476<span></span>
</td>
<td class="nump">71,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,548<span></span>
</td>
<td class="nump">16,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,476<span></span>
</td>
<td class="nump">18,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Medical Surgical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">33,317<span></span>
</td>
<td class="nump">33,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Reportable segments | Other operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,906<span></span>
</td>
<td class="nump">17,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_NeuroscienceGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_MedicalSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mdt_DiabetesGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 33,537<span></span>
</td>
<td class="nump">$ 32,364<span></span>
</td>
<td class="nump">$ 31,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,837<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember', window );">Total other countries, excluding Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">33,421<span></span>
</td>
<td class="nump">32,251<span></span>
</td>
<td class="nump">31,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">6,547<span></span>
</td>
<td class="nump">5,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">17,171<span></span>
</td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">16,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">4,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">16,250<span></span>
</td>
<td class="nump">15,689<span></span>
</td>
<td class="nump">$ 14,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Fiscal Year</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charges to Income</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charges to Other Accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other Changes (Debit) Credit</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Fiscal Year</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Deferred Tax Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Fiscal Year</a></td>
<td class="nump">13,271<span></span>
</td>
<td class="nump">11,311<span></span>
</td>
<td class="nump">6,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charges to Income</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments', window );">Charge to adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charges to Other Accounts</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet', window );">Charges to Other Accounts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other Changes (Debit) Credit</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Other Changes (Debit) Credit, Adjustments</a></td>
<td class="num">(567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Fiscal Year</a></td>
<td class="nump">$ 12,668<span></span>
</td>
<td class="nump">$ 13,271<span></span>
</td>
<td class="nump">$ 11,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>793</ContextCount>
  <ElementCount>696</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>198</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Financing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangements</Role>
      <ShortName>Financing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Derivatives and Currency Exchange Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Property, Plant, and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant, and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Stock Purchase and Award Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlans</Role>
      <ShortName>Stock Purchase and Award Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Retirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlans</Role>
      <ShortName>Retirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Revenue</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/RestructuringCharges</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/FinancialInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Financing Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsTables</Role>
      <ShortName>Financing Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/FinancingArrangements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Inventories</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Stock Purchase and Award Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansTables</Role>
      <ShortName>Stock Purchase and Award Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/StockPurchaseandAwardPlans</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/EarningsPerShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Retirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansTables</Role>
      <ShortName>Retirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/RetirementBenefitPlans</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/Leases</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails</Role>
      <ShortName>Revenue - Disaggregation of Net Sales by Segment and Division (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails</Role>
      <ShortName>Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails</Role>
      <ShortName>Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Restructuring Charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesNarrativeDetails</Role>
      <ShortName>Restructuring Charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails</Role>
      <ShortName>Restructuring Charges - Classification of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails</Role>
      <ShortName>Restructuring Charges - Activity Related to Restructuring Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails</Role>
      <ShortName>Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails</Role>
      <ShortName>Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Summary of Equity and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Debt and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Financial Instruments - Gains and Losses on Equity and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Gains and Losses on Equity and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails</Role>
      <ShortName>Financing Arrangements - Current Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Financing Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails</Role>
      <ShortName>Financing Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Financing Arrangements - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails</Role>
      <ShortName>Financing Arrangements - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails</Role>
      <ShortName>Financing Arrangements - Long-term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Financing Arrangements - Supplier Financing Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails</Role>
      <ShortName>Financing Arrangements - Supplier Financing Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails</Role>
      <ShortName>Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/InventoriesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/ShareholdersEquity</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails</Role>
      <ShortName>Stock Purchase and Award Plans - Performance Share Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails</Role>
      <ShortName>Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Retirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Retirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails</Role>
      <ShortName>Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails</Role>
      <ShortName>Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails</Role>
      <ShortName>Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails</Role>
      <ShortName>Retirement Benefit Plans - Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails</Role>
      <ShortName>Retirement Benefit Plans - Future Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails</Role>
      <ShortName>Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Components of Total Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Leases - Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails</Role>
      <ShortName>Leases - Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9955592 - Disclosure - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9955593 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/CommitmentsandContingencies</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9955594 - Disclosure - Segment and Geographic Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails</Role>
      <ShortName>Segment and Geographic Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9955595 - Disclosure - Segment and Geographic Information - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails</Role>
      <ShortName>Segment and Geographic Information - Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9955596 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9955597 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails</Role>
      <ShortName>Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="mdt-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9955598 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>122</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mdt-20250425.htm">mdt-20250425.htm</File>
    <File>mdt-20250425.xsd</File>
    <File>mdt-20250425_cal.xml</File>
    <File>mdt-20250425_def.xml</File>
    <File>mdt-20250425_lab.xml</File>
    <File>mdt-20250425_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mdt-20250425_g1.jpg</File>
    <File>mdt-20250425_g10.jpg</File>
    <File>mdt-20250425_g11.jpg</File>
    <File>mdt-20250425_g12.jpg</File>
    <File>mdt-20250425_g13.jpg</File>
    <File>mdt-20250425_g14.jpg</File>
    <File>mdt-20250425_g15.jpg</File>
    <File>mdt-20250425_g16.jpg</File>
    <File>mdt-20250425_g17.jpg</File>
    <File>mdt-20250425_g2.jpg</File>
    <File>mdt-20250425_g3.jpg</File>
    <File>mdt-20250425_g4.jpg</File>
    <File>mdt-20250425_g5.jpg</File>
    <File>mdt-20250425_g6.jpg</File>
    <File>mdt-20250425_g7.jpg</File>
    <File>mdt-20250425_g8.jpg</File>
    <File>mdt-20250425_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="5">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="2472">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="100">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>167
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mdt-20250425.htm": {
   "nsprefix": "mdt",
   "nsuri": "http://www.medtronic.com/20250425",
   "dts": {
    "inline": {
     "local": [
      "mdt-20250425.htm"
     ]
    },
    "schema": {
     "local": [
      "mdt-20250425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mdt-20250425_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mdt-20250425_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mdt-20250425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdt-20250425_pre.xml"
     ]
    }
   },
   "keyStandard": 622,
   "keyCustom": 74,
   "axisStandard": 45,
   "axisCustom": 0,
   "memberStandard": 96,
   "memberCustom": 98,
   "hidden": {
    "total": 65,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://fasb.org/us-gaap/2024": 59
   },
   "contextCount": 793,
   "entityCount": 1,
   "segmentCount": 198,
   "elementCount": 1247,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 2472,
    "http://xbrl.sec.gov/dei/2024": 100,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5,
    "http://fasb.org/srt/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.medtronic.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.medtronic.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
     "longName": "9952151 - Statement - Consolidated Statements of Income",
     "shortName": "Consolidated Statements of Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
     "longName": "9952153 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Equity",
     "shortName": "Consolidated Statements of Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical",
     "longName": "9952156 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.medtronic.com/role/Revenue",
     "longName": "9952159 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements",
     "longName": "9952160 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.medtronic.com/role/RestructuringCharges",
     "longName": "9952161 - Disclosure - Restructuring Charges",
     "shortName": "Restructuring Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.medtronic.com/role/FinancialInstruments",
     "longName": "9952162 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.medtronic.com/role/FinancingArrangements",
     "longName": "9952163 - Disclosure - Financing Arrangements",
     "shortName": "Financing Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement",
     "longName": "9952164 - Disclosure - Derivatives and Currency Exchange Risk Management",
     "shortName": "Derivatives and Currency Exchange Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.medtronic.com/role/Inventories",
     "longName": "9952165 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets",
     "longName": "9952166 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipment",
     "longName": "9952167 - Disclosure - Property, Plant, and Equipment",
     "shortName": "Property, Plant, and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.medtronic.com/role/ShareholdersEquity",
     "longName": "9952168 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlans",
     "longName": "9952169 - Disclosure - Stock Purchase and Award Plans",
     "shortName": "Stock Purchase and Award Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.medtronic.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.medtronic.com/role/EarningsPerShare",
     "longName": "9952171 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlans",
     "longName": "9952172 - Disclosure - Retirement Benefit Plans",
     "shortName": "Retirement Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.medtronic.com/role/Leases",
     "longName": "9952173 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss",
     "longName": "9952174 - Disclosure - Accumulated Other Comprehensive Loss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.medtronic.com/role/CommitmentsandContingencies",
     "longName": "9952175 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformation",
     "longName": "9952176 - Disclosure - Segment and Geographic Information",
     "shortName": "Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.medtronic.com/role/SubsequentEvents",
     "longName": "9952177 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts",
     "longName": "9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-779",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-779",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.medtronic.com/role/RevenueTables",
     "longName": "9955512 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables",
     "longName": "9955513 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.medtronic.com/role/RestructuringChargesTables",
     "longName": "9955514 - Disclosure - Restructuring Charges (Tables)",
     "shortName": "Restructuring Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsTables",
     "longName": "9955515 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsTables",
     "longName": "9955516 - Disclosure - Financing Arrangements (Tables)",
     "shortName": "Financing Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables",
     "longName": "9955517 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)",
     "shortName": "Derivatives and Currency Exchange Risk Management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.medtronic.com/role/InventoriesTables",
     "longName": "9955518 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables",
     "longName": "9955519 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipmentTables",
     "longName": "9955520 - Disclosure - Property, Plant, and Equipment (Tables)",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables",
     "longName": "9955521 - Disclosure - Stock Purchase and Award Plans (Tables)",
     "shortName": "Stock Purchase and Award Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.medtronic.com/role/IncomeTaxesTables",
     "longName": "9955522 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.medtronic.com/role/EarningsPerShareTables",
     "longName": "9955523 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansTables",
     "longName": "9955524 - Disclosure - Retirement Benefit Plans (Tables)",
     "shortName": "Retirement Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.medtronic.com/role/LeasesTables",
     "longName": "9955525 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables",
     "longName": "9955526 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationTables",
     "longName": "9955527 - Disclosure - Segment and Geographic Information (Tables)",
     "shortName": "Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955528 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
     "longName": "9955529 - Disclosure - Revenue - Disaggregation of Net Sales by Segment and Division (Details)",
     "shortName": "Revenue - Disaggregation of Net Sales by Segment and Division (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
     "longName": "9955530 - Disclosure - Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)",
     "shortName": "Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.medtronic.com/role/RevenueNarrativeDetails",
     "longName": "9955531 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
     "longName": "9955532 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Acquisition Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-176",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
     "longName": "9955533 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Disposal Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:MinorityInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
     "longName": "9955534 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails",
     "longName": "9955535 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:BusinessAcquisitionPriceContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
     "longName": "9955536 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails",
     "longName": "9955537 - Disclosure - Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details)",
     "shortName": "Acquisitions, Dispositions, and Funded Research and Development Arrangements - Reconciliation of Level 3 Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-203",
      "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails",
     "longName": "9955538 - Disclosure - Restructuring Charges - Narrative (Details)",
     "shortName": "Restructuring Charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
     "longName": "9955539 - Disclosure - Restructuring Charges - Classification of Restructuring Costs (Details)",
     "shortName": "Restructuring Charges - Classification of Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-208",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
     "longName": "9955540 - Disclosure - Restructuring Charges - Activity Related to Restructuring Programs (Details)",
     "shortName": "Restructuring Charges - Activity Related to Restructuring Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
     "longName": "9955541 - Disclosure - Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)",
     "shortName": "Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
     "longName": "9955542 - Disclosure - Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)",
     "shortName": "Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9955543 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails",
     "longName": "9955544 - Disclosure - Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)",
     "shortName": "Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
     "longName": "9955545 - Disclosure - Financial Instruments - Summary of Equity and Other Investments (Details)",
     "shortName": "Financial Instruments - Summary of Equity and Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-251",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-251",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails",
     "longName": "9955546 - Disclosure - Financial Instruments - Debt and Equity Securities (Details)",
     "shortName": "Financial Instruments - Debt and Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
     "longName": "9955547 - Disclosure - Financial Instruments - Gains and Losses on Equity and Other Investments (Details)",
     "shortName": "Financial Instruments - Gains and Losses on Equity and Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
     "longName": "9955548 - Disclosure - Financing Arrangements - Current Debt Obligations (Details)",
     "shortName": "Financing Arrangements - Current Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
     "longName": "9955549 - Disclosure - Financing Arrangements - Narrative (Details)",
     "shortName": "Financing Arrangements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
     "longName": "9955550 - Disclosure - Financing Arrangements - Long-term Debt (Details)",
     "shortName": "Financing Arrangements - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FinanceLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FinanceLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails",
     "longName": "9955551 - Disclosure - Financing Arrangements - Long-term Debt Maturities (Details)",
     "shortName": "Financing Arrangements - Long-term Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails",
     "longName": "9955552 - Disclosure - Financing Arrangements - Supplier Financing Program (Details)",
     "shortName": "Financing Arrangements - Supplier Financing Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:SupplierFinanceProgramObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SupplierFinanceProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramObligationIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SupplierFinanceProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
     "longName": "9955553 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails",
     "longName": "9955554 - Disclosure - Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management- Outstanding Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-413",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-413",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
     "longName": "9955555 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "longName": "9955556 - Disclosure - Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-432",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-432",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
     "longName": "9955557 - Disclosure - Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-443",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955558 - Disclosure - Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
     "longName": "9955559 - Disclosure - Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)",
     "shortName": "Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OffsettingLiabilitiesTableTextBlock",
       "us-gaap:OffsettingAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.medtronic.com/role/InventoriesDetails",
     "longName": "9955560 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
     "longName": "9955561 - Disclosure - Goodwill and Other Intangible Assets - Changes in Goodwill (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "longName": "9955562 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
     "longName": "9955563 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails",
     "longName": "9955564 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9955565 - Disclosure - Property, Plant, and Equipment (Details)",
     "shortName": "Property, Plant, and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.medtronic.com/role/ShareholdersEquityDetails",
     "longName": "9955566 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "mdt:DeferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
     "longName": "9955567 - Disclosure - Stock Purchase and Award Plans - Narrative (Details)",
     "shortName": "Stock Purchase and Award Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-503",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-503",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
     "longName": "9955568 - Disclosure - Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)",
     "shortName": "Stock Purchase and Award Plans - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails",
     "longName": "9955569 - Disclosure - Stock Purchase and Award Plans - Valuation Assumptions (Details)",
     "shortName": "Stock Purchase and Award Plans - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
     "longName": "9955570 - Disclosure - Stock Purchase and Award Plans - Stock Options Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-518",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-503",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
     "longName": "9955571 - Disclosure - Stock Purchase and Award Plans - Restricted Stock Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-522",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-523",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
     "longName": "9955572 - Disclosure - Stock Purchase and Award Plans - Performance Share Unit Activity (Details)",
     "shortName": "Stock Purchase and Award Plans - Performance Share Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-529",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-509",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails",
     "longName": "9955573 - Disclosure - Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)",
     "shortName": "Income Taxes - Components of Income Before Income Taxes, Based on Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
     "longName": "9955574 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)",
     "shortName": "Income Taxes - Income Tax (Benefit) Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955575 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955576 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955577 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails",
     "longName": "9955578 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
     "longName": "9955579 - Disclosure - Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)",
     "shortName": "Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-503",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
     "longName": "9955580 - Disclosure - Earnings Per Share - Narrative (Details)",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-540",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-540",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
     "longName": "9955581 - Disclosure - Retirement Benefit Plans - Narrative (Details)",
     "shortName": "Retirement Benefit Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
     "longName": "9955582 - Disclosure - Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)",
     "shortName": "Retirement Benefit Plans - Change in Benefit Obligation and Funded Status (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-553",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails",
     "longName": "9955583 - Disclosure - Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)",
     "shortName": "Retirement Benefit Plans - Net Periodic Cost and AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-549",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-549",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
     "longName": "9955584 - Disclosure - Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)",
     "shortName": "Retirement Benefit Plans - Actuarial Assumptions and Plan Assets Target Allocations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
     "longName": "9955585 - Disclosure - Retirement Benefit Plans - Fair Value Measurement (Details)",
     "shortName": "Retirement Benefit Plans - Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-615",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
     "longName": "9955586 - Disclosure - Retirement Benefit Plans - Future Benefit Payments (Details)",
     "shortName": "Retirement Benefit Plans - Future Benefit Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails",
     "longName": "9955587 - Disclosure - Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)",
     "shortName": "Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdt:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails",
     "longName": "9955588 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)",
     "shortName": "Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails",
     "longName": "9955589 - Disclosure - Leases - Components of Total Operating Lease Cost (Details)",
     "shortName": "Leases - Components of Total Operating Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails",
     "longName": "9955590 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails",
     "longName": "9955591 - Disclosure - Leases - Maturities of Operating Leases (Details)",
     "shortName": "Leases - Maturities of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
     "longName": "9955592 - Disclosure - Accumulated Other Comprehensive Loss (Details)",
     "shortName": "Accumulated Other Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955593 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails",
     "longName": "9955594 - Disclosure - Segment and Geographic Information - Narrative (Details)",
     "shortName": "Segment and Geographic Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true,
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails",
     "longName": "9955595 - Disclosure - Segment and Geographic Information - Segment Reporting (Details)",
     "shortName": "Segment and Geographic Information - Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-728",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
     "longName": "9955596 - Disclosure - Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)",
     "shortName": "Segment and Geographic Information - Reconciliation of Assets and Depreciation Expense from Segments to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-753",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails",
     "longName": "9955597 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)",
     "shortName": "Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-762",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    },
    "R122": {
     "role": "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "longName": "9955598 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-780",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-785",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mdt-20250425.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "mdt_A0.000SeniorNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A0.000SeniorNotesDue2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.000% Senior Notes due 2025",
        "label": "0.000% Senior Notes due 2025 [Member]",
        "documentation": "0.000% Senior Notes due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A0.250SeniorNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A0.250SeniorNotesDue2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.250% Senior Notes due 2025",
        "label": "0.250% Senior Notes due 2025 [Member]",
        "documentation": "0.250% Senior Notes due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A0.375SeniorNotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A0.375SeniorNotesDue2028Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.375% Senior Notes due 2028",
        "label": "0.375% Senior Notes due 2028 [Member]",
        "documentation": "0.375% Senior Notes due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A0.750SeniorNotesDue2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A0.750SeniorNotesDue2032Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.750% Senior Notes due 2032",
        "label": "0.750% Senior Notes due 2032 [Member]",
        "documentation": "0.750% Senior Notes due 2032"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.000SeniorNotesDue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.000SeniorNotesDue2031Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.000% Senior Notes due 2031",
        "label": "1.000% Senior Notes due 2031 [Member]",
        "documentation": "1.000% Senior Notes due 2031"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.125SeniorNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.125SeniorNotesDue2027Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.125% Senior Notes due 2027",
        "label": "1.125% Senior Notes due 2027 [Member]",
        "documentation": "1.125% Senior Notes due 2027"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.375SeniorNotesDue2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.375SeniorNotesDue2040Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375% Senior Notes due 2040",
        "label": "1.375% Senior Notes due 2040 [Member]",
        "documentation": "1.375% Senior Notes due 2040"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.500SeniorNotesDue2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.500SeniorNotesDue2039Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.500% Senior Notes due 2039",
        "label": "1.500% Senior Notes due 2039 [Member]",
        "documentation": "1.500% Senior Notes due 2039"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.625SeniorNotesDue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.625SeniorNotesDue2031Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625% Senior Notes due 2031",
        "label": "1.625% Senior Notes due 2031 [Member]",
        "documentation": "1.625% Senior Notes due 2031"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.625SeniorNotesDue2050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.625SeniorNotesDue2050Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625% Senior Notes due 2050",
        "label": "1.625% Senior Notes due 2050 [Member]",
        "documentation": "1.625% Senior Notes due 2050"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A1.750SeniorNotesDue2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A1.750SeniorNotesDue2049Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.750% Senior Notes due 2049",
        "label": "1.750% Senior Notes due 2049 [Member]",
        "documentation": "1.750% Senior Notes due 2049"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2.250SeniorNotesDue2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A2.250SeniorNotesDue2039Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Senior Notes due 2039",
        "label": "2.250% Senior Notes due 2039 [Member]",
        "documentation": "2.250% Senior Notes due 2039"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2.625SeniorNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A2.625SeniorNotesDue2025Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.625% Senior Notes due 2025",
        "label": "2.625% Senior Notes due 2025 [Member]",
        "documentation": "2.625% Senior Notes due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2015And2020CommercialPaperProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A2015And2020CommercialPaperProgramMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 and 2020 Commercial Paper Program",
        "label": "2015 and 2020 Commercial Paper Program [Member]",
        "documentation": "2015 and 2020 Commercial Paper Program"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A2024EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A2024EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan",
        "label": "2024 Employee Stock Purchase Plan [Member]",
        "documentation": "2024 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3.000SeniorNotesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A3.000SeniorNotesDue2029Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.000% Senior Notes due 2028",
        "label": "3.000% Senior Notes due 2029 [Member]",
        "documentation": "3.000% Senior Notes due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3.125SeniorNotesDue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A3.125SeniorNotesDue2031Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.125% Senior Notes due 2031",
        "label": "3.125% Senior Notes due 2031 [Member]",
        "documentation": "3.125% Senior Notes due 2031"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3.375SeniorNotesDue2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A3.375SeniorNotesDue2034Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.375% Senior Notes due 2034",
        "label": "3.375% Senior Notes due 2034 [Member]",
        "documentation": "3.375% Senior Notes due 2034"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3.650SeniorNotesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A3.650SeniorNotesDue2029Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.650% Senior Notes due 2029",
        "label": "3.650% Senior Notes due 2029 [Member]",
        "documentation": "3.650% Senior Notes due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A3.875SeniorNotesDue2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A3.875SeniorNotesDue2036Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.875% Senior Notes due 2036",
        "label": "3.875% Senior Notes due 2036 [Member]",
        "documentation": "3.875% Senior Notes due 2036"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A4.150SeniorNotesDue2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A4.150SeniorNotesDue2043Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150% Senior Notes due 2043",
        "label": "4.150% Senior Notes due 2043 [Member]",
        "documentation": "4.150% Senior Notes due 2043"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_A4.150SeniorNotesDue2053Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "A4.150SeniorNotesDue2053Member",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150% Senior Notes due 2053",
        "label": "4.150% Senior Notes due 2053 [Member]",
        "documentation": "4.150% Senior Notes due 2053"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AcceleratedAmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AcceleratedAmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated amortization",
        "label": "Accelerated Amortization of Intangible Assets",
        "documentation": "Accelerated Amortization of Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r1415"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, less allowances and credit losses of $199 and $173, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1639"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r223"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r223"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Change in Retirement Obligations",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r24",
      "r43",
      "r169",
      "r1597",
      "r1598",
      "r1599"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Cash Flow Hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r362",
      "r363",
      "r896",
      "r1348",
      "r1597"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (Loss) Gain on Investment Securities",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r352",
      "r362",
      "r363",
      "r1597"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r170",
      "r335",
      "r1088",
      "r1135",
      "r1139"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Total Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r43",
      "r915",
      "r918",
      "r994",
      "r1130",
      "r1131",
      "r1597",
      "r1598",
      "r1599",
      "r1623",
      "r1624",
      "r1625",
      "r1626"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Translation Adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r43",
      "r167",
      "r168",
      "r362",
      "r363",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r1597"
     ]
    },
    "mdt_AcuteCareMonitoringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AcuteCareMonitoringMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acute Care &amp; Monitoring",
        "label": "Acute Care &amp; Monitoring [Member]",
        "documentation": "Acute Care &amp; Monitoring"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r1415",
      "r1856"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1780",
      "r1857"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r774"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1556"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1469",
      "r1480",
      "r1490",
      "r1523"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1472",
      "r1483",
      "r1493",
      "r1526"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1557"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1518",
      "r1527",
      "r1531",
      "r1539"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating segment",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r1359",
      "r1360"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r816"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stock-based compensation expense, net of tax",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForCreditLossMember",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Doubtful Accounts",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances and credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r469",
      "r518"
     ]
    },
    "mdt_AmendedandRestatedRevolvingCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AmendedandRestatedRevolvingCreditAgreementMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.5 Billion Revolving Credit Facility",
        "label": "Amended and Restated Revolving Credit Agreement [Member]",
        "documentation": "Amended and Restated Revolving Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r551",
      "r558",
      "r1368"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedges",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r352",
      "r362",
      "r363",
      "r1597"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value",
        "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions",
        "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r1384",
      "r1416",
      "r1651",
      "r1657",
      "r1658"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairments and related inventory write-downs",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r66"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r238",
      "r327",
      "r382",
      "r428",
      "r436",
      "r454",
      "r458",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r892",
      "r897",
      "r955",
      "r1083",
      "r1199",
      "r1359",
      "r1360",
      "r1415",
      "r1447",
      "r1713",
      "r1714",
      "r1808"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r340",
      "r382",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r892",
      "r897",
      "r955",
      "r1415",
      "r1713",
      "r1714",
      "r1808"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AssociatedAndOtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AssociatedAndOtherCostsMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associated and Other Costs",
        "label": "Associated and Other Costs [Member]",
        "documentation": "Associated and Other Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionRateSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AuctionRateSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auction rate securities",
        "label": "Auction Rate Securities [Member]",
        "documentation": "Debt instrument securities (for example, but not limited to, corporate or municipal bonds) that typically have long-term nominal maturities for which the interest rate is reset through an auction process."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.medtronic.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1654"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r1078"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1653"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r1077"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1655"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r1079"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AFS Debt Maturities",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1652"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r1076"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Activities Related to Debt Securities Portfolio",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1534"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1535"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1533"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1532"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1531"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1531"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r1821",
      "r1822"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r575",
      "r1821",
      "r1822"
     ]
    },
    "mdt_BuildingsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "BuildingsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and leasehold improvements",
        "label": "Buildings and Leasehold Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r879",
      "r1388",
      "r1391"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r879",
      "r1388",
      "r1391"
     ]
    },
    "mdt_BusinessAcquisitionContingentConsiderationAtFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "BusinessAcquisitionContingentConsiderationAtFairValueRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]",
        "label": "Business Acquisition, Contingent Consideration, at Fair Value [Roll Forward]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_BusinessAcquisitionContingentConsiderationMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "BusinessAcquisitionContingentConsiderationMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Business Acquisition, Contingent Consideration, Milestone Payment",
        "documentation": "Contingent milestone payments in business acquisition transactions."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_BusinessAcquisitionContingentConsiderationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "BusinessAcquisitionContingentConsiderationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning and Ending Balances of Contingent Payments [Roll Forward]",
        "label": "Business Acquisition, Contingent Consideration [Roll Forward]",
        "documentation": "Business Acquisition, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "mdt_BusinessAcquisitionPriceContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "BusinessAcquisitionPriceContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price contingent consideration",
        "label": "Business Acquisition, Price Contingent Consideration",
        "documentation": "Business Acquisition, Price Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition and divestiture-related items",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration for the transaction, net of cash acquired",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r21"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r1608"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofBeginningandEndingBalancesofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r211",
      "r883",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, significant unobservable inputs",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business exit costs",
        "label": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CIFSASeniorNotes2007Due20386.550PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CIFSASeniorNotes2007Due20386.550PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.550 percent thirty-year 2007 CIFSA senior notes",
        "label": "CIFSA Senior Notes 2007 Due 2038, 6.550 Percent [Member]",
        "documentation": "CIFSA Senior Notes 2007 Due 2038, 6.550 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CardiacRhythmandHeartFailureDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CardiacRhythmandHeartFailureDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiac Rhythm &amp; Heart Failure",
        "label": "Cardiac Rhythm and Heart Failure Division [Member]",
        "documentation": "Cardiac Rhythm and Heart Failure Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CardiovascularMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CardiovascularMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular",
        "label": "Cardiovascular [Member]",
        "documentation": "Cardiovascular"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CashAdvancePaidinConnectionWithProposedSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CashAdvancePaidinConnectionWithProposedSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash advance paid to taxing authorities",
        "label": "Cash Advance Paid in Connection With Proposed Settlements",
        "documentation": "Cash Advance Paid in Connection With Proposed Settlements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r323",
      "r1339"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r183",
      "r378"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r183"
     ]
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedge unrealized gains to be reclassified over the next twelve months",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "mdt_CentralizedDistributionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CentralizedDistributionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Centralized distribution costs",
        "label": "Centralized Distribution Costs",
        "documentation": "Centralized Distribution Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1509"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1506"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1504"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r332",
      "r333",
      "r334",
      "r382",
      "r414",
      "r418",
      "r420",
      "r422",
      "r430",
      "r431",
      "r507",
      "r610",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r651",
      "r652",
      "r655",
      "r658",
      "r665",
      "r955",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1186",
      "r1208",
      "r1226",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1561",
      "r1611",
      "r1630"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r430",
      "r651",
      "r652",
      "r653",
      "r655",
      "r658",
      "r663",
      "r665",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1376",
      "r1561",
      "r1611"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "mdt_ColibriMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ColibriMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colibri",
        "label": "Colibri [Member]",
        "documentation": "Colibri"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r1775"
     ]
    },
    "us-gaap_CommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaper",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper",
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r221",
      "r1818"
     ]
    },
    "mdt_CommercialPaperMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CommercialPaperMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper, maximum borrowing capacity",
        "label": "Commercial Paper, Maximum Borrowing Capacity",
        "documentation": "Commercial Paper, Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r609",
      "r1439",
      "r1440",
      "r1441",
      "r1444"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Notes 3, 16, and 18)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r226",
      "r1086",
      "r1185"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1320"
     ]
    },
    "mdt_CommitmentsToTheMedtronicFoundationAndMedtronicLABS": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CommitmentsToTheMedtronicFoundationAndMedtronicLABS",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Commitments to the Medtronic Foundation and Medtronic LABS",
        "label": "Commitments to the Medtronic Foundation and Medtronic LABS",
        "documentation": "Commitments to the Medtronic Foundation and Medtronic LABS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future purchase (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends to shareholders (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1435",
      "r1436",
      "r1437",
      "r1439",
      "r1440",
      "r1441",
      "r1444",
      "r1623",
      "r1624",
      "r1626",
      "r1780",
      "r1854",
      "r1857"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r1186"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r155",
      "r1186",
      "r1205",
      "r1857",
      "r1858"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares\u2014 par value $0.0001, 2.6 billion shares authorized, 1,281,934,628 and 1,311,337,531 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r1087",
      "r1415"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1515"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1514"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1516"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1513"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of deferred tax assets/(Liabilities):",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive loss",
        "label": "Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax",
        "documentation": "Before tax amount, net of reclassifications, of pension and other postretirement benefit plans (gain) loss included in comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income attributable to Medtronic",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r357",
      "r359",
      "r367",
      "r1073",
      "r1100",
      "r1102"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive income attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r106",
      "r357",
      "r359",
      "r366",
      "r1072",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income including noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r212",
      "r357",
      "r359",
      "r365",
      "r1071",
      "r1100"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r364",
      "r1070",
      "r1098"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r1333",
      "r1337",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1687",
      "r1689",
      "r1692",
      "r1693"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r386",
      "r892",
      "r893",
      "r897",
      "r898",
      "r995",
      "r1325",
      "r1584",
      "r1587",
      "r1588",
      "r1712",
      "r1715",
      "r1716"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r386",
      "r892",
      "r893",
      "r897",
      "r898",
      "r995",
      "r1325",
      "r1584",
      "r1587",
      "r1588",
      "r1712",
      "r1715",
      "r1716"
     ]
    },
    "srt_ConsolidationEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationEliminationsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Eliminations [Member]",
        "label": "Consolidation, Eliminations [Member]",
        "documentation": "Eliminating entries used in consolidating a parent entity and its subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r266",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r386",
      "r428",
      "r438",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r1359",
      "r1360",
      "r1585",
      "r1586",
      "r1713",
      "r1714"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r266",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r386",
      "r428",
      "r438",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r1359",
      "r1360",
      "r1585",
      "r1586",
      "r1713",
      "r1714"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r1349"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration [Policy Text Block]",
        "documentation": "Describes an entity's accounting policy for contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r687"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized that was previously included in deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebate obligations",
        "label": "Contract with Customer, Refund Liability, Current",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1723"
     ]
    },
    "mdt_CoronaryAndPeripheralVascularDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CoronaryAndPeripheralVascularDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coronary &amp; Peripheral Vascular",
        "label": "Coronary And Peripheral Vascular Division [Member]",
        "documentation": "Coronary And Peripheral Vascular Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1384",
      "r1386",
      "r1402",
      "r1416",
      "r1432",
      "r1851"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r1635"
     ]
    },
    "mdt_CorporateOverhead": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CorporateOverhead",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Corporate",
        "label": "Corporate Overhead",
        "documentation": "Corporate overhead expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold, excluding amortization of intangible assets",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r1032"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Cost of products sold",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_CranialAndSpinalTechnologiesDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "CranialAndSpinalTechnologiesDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cranial &amp; Spinal Technologies",
        "label": "Cranial And Spinal Technologies Division [Member]",
        "documentation": "Cranial And Spinal Technologies Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r1710"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r1710",
      "r1711"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1572",
      "r1614",
      "r1774"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1572",
      "r1614"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r858",
      "r1614"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelatedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelatedIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer-related",
        "label": "Customer-Related Intangible Assets [Member]",
        "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1687",
      "r1689",
      "r1692",
      "r1693"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1550"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1550"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1552"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1552"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1465",
      "r1554"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1552"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1456",
      "r1545"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1457",
      "r1546"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1457",
      "r1546"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1544"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1544"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1544"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1458",
      "r1547"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1549"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1549"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1550"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1464",
      "r1553"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1462",
      "r1551"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1548"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current debt obligations",
        "totalLabel": "Current debt obligations",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Arrangements",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r380",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r608",
      "r609",
      "r621",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r644",
      "r645",
      "r647",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.medtronic.com/role/Cover",
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r143",
      "r144",
      "r222",
      "r225",
      "r386",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1413",
      "r1612",
      "r1699",
      "r1700",
      "r1701",
      "r1801",
      "r1802"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Margin added per annum",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r225",
      "r648"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face value of debt",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r969",
      "r970",
      "r1372",
      "r1373",
      "r1413"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Interest Rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r649",
      "r969",
      "r970",
      "r1413"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r623"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1413",
      "r1612",
      "r1801",
      "r1802"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/Cover",
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r386",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1413",
      "r1612",
      "r1699",
      "r1700",
      "r1701",
      "r1801",
      "r1802"
     ]
    },
    "mdt_DebtInstrumentNumberofTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DebtInstrumentNumberofTranches",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number of Tranches",
        "documentation": "Debt Instrument, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of senior notes, face amount",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r75",
      "r78",
      "r127",
      "r199",
      "r200",
      "r386",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1413",
      "r1612",
      "r1801",
      "r1802"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt discount, net",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r1718",
      "r1800",
      "r1801",
      "r1802"
     ]
    },
    "mdt_DebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DebtLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt [Line Items]",
        "label": "Debt [Line Items]",
        "documentation": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r527",
      "r1365"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "More than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r527"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r527",
      "r1365"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r527"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments by Category and Related Balance Sheet Presentation",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1659"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r1365",
      "r1667"
     ]
    },
    "mdt_DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated reasonably possible decrease in uncertain tax positions excluding interest over the next 12 months",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Compensation Liability, Current",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r202"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1614",
      "r1773",
      "r1774"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred financing costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1718",
      "r1800",
      "r1801",
      "r1802"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1614",
      "r1773"
     ]
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional funding",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1565",
      "r1820",
      "r1850"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax assets",
        "verboseLabel": "Tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r262",
      "r1614"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax (benefit) expense:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r224",
      "r849"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r1084"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "mdt_DeferredStockParorStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredStockParorStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, par value (in euros per share)",
        "label": "Deferred Stock, Par or Stated Value Per Share",
        "documentation": "Deferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, shares authorized (in shares)",
        "label": "Deferred Stock, Shares Authorized",
        "documentation": "Deferred Stock, Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, issued (in shares)",
        "label": "Deferred Stock, Shares Issued",
        "documentation": "Deferred Stock, Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock, outstanding (in shares)",
        "label": "Deferred Stock, Shares Outstanding",
        "documentation": "Deferred Stock, Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsAndLiabilitiesBalanceSheetReportedAmountAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported as (after valuation allowance and jurisdictional netting):",
        "label": "Deferred Tax Assets and Liabilities, Balance Sheet, Reported Amount [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "mdt_DeferredTaxAssetsInterestLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsInterestLimitation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest limitation",
        "label": "Deferred Tax Assets, Interest Limitation",
        "documentation": "Deferred Tax Assets, Interest Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxAssetsLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsLeaseObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations",
        "label": "Deferred Tax Assets, Lease Obligations",
        "documentation": "Deferred Tax Assets, Lease Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1768"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1768"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsNetofValuationAllowanceOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsNetofValuationAllowanceOther",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Other",
        "documentation": "Deferred Tax Assets, Net of Valuation Allowance, Other"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss, capital loss, and credit carryforwards",
        "label": "Deferred Tax Assets, Operating and Capital Losses, and Tax Credit Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss, capital loss and tax credit carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, no expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expiring in future years",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxAssetsResearchAndDevelopmentCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization of research and development",
        "label": "Deferred Tax Assets, Research and Development Capitalization",
        "documentation": "Deferred Tax Assets, Research and Development Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, no expiration",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state benefit on uncertain tax positions",
        "label": "Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions",
        "documentation": "The tax effect as of the balance sheet date of the amount of estimated future tax deductions arising from the federal and state benefit on uncertain tax positions, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, unrealized currency losses",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized gain on available-for-sale securities and derivative financial instruments",
        "label": "Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives",
        "documentation": "Deferred Tax Assets, Unrealized Gains On Trading Securities And Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized loss on derivative financial instruments",
        "label": "Deferred Tax Liabilities, Derivatives",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxLiabilitiesInvestmentInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxLiabilitiesInvestmentInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outside basis difference of subsidiaries",
        "label": "Deferred Tax Liabilities, Investment In Subsidiaries",
        "documentation": "Deferred Tax Liabilities, Investment In Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use leases",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DeferredTaxLiabilitiesPensionAndPostRetirementBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DeferredTaxLiabilitiesPensionAndPostRetirementBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Pension and post-retirement benefits",
        "label": "Deferred Tax Liabilities, Pension And Post-retirement Benefits",
        "documentation": "Deferred Tax Liabilities, Pension And Post-retirement Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1771"
     ]
    },
    "mdt_DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental expense related to acceptance of voluntary early retirement packages",
        "label": "Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits",
        "documentation": "Defined Benefit And Contribution Plan, Cost of Providing Special and Contractual Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation at end of year",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ending balance",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r43",
      "r169",
      "r1728"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized in accumulated other comprehensive loss:",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net actuarial loss",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r737"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service credit",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r737"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial loss (gain)",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of net actuarial loss (gain)",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r732",
      "r758",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of prior service cost",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r733",
      "r759",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Recognized asset",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized on the consolidated balance sheets consist of:",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts Recognized in AOCI",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r691",
      "r692",
      "r715",
      "r1198",
      "r1386",
      "r1817"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsTargetAllocationsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Assets Target Allocations",
        "label": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of compensation increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 benefit obligation",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r763"
     ]
    },
    "mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 interest cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of compensation increase",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "mdt_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate \u2013 service cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Service Cost, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Post-retirement benefit plans, benefit obligations",
        "periodStartLabel": "Projected benefit obligation at beginning of year",
        "periodEndLabel": "Projected benefit obligation at end of year",
        "terseLabel": "Benefit obligations",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r766"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r1384",
      "r1385",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in projected benefit obligation:",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in plan assets:",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r719",
      "r762",
      "r1384",
      "r1385",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special termination benefits",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "mdt_DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Plan curtailments, settlements, and amendments",
        "label": "Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation",
        "documentation": "Defined Benefit Plan, Curtailments and Settlements, Benefit Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDebtSecurityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDebtSecurityMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "terseLabel": "Debt securities",
        "label": "Defined Benefit Plan, Debt Security [Member]",
        "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": [
      "r1726"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity",
        "terseLabel": "Equity securities",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Future Benefit Payments",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031 \u2013 2035",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future employer contributions in next fiscal year",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r731",
      "r757",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Post-retirement benefit plans, fair value of plan assets",
        "periodStartLabel": "Fair value of plan assets at beginning of year",
        "periodEndLabel": "Fair value of plan assets at end of year",
        "terseLabel": "Fair value of plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r719",
      "r720",
      "r1384",
      "r1385",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate changes and other",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net underfunded status of the plans",
        "totalLabel": "Over funded status of the plans",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r715",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funded status at end of year:",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r698",
      "r730",
      "r756",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Post-retirement benefit plans, net periodic benefit cost, income",
        "totalLabel": "Net periodic benefit (credit) cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r754",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Periodic Benefit Cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets at fair value",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plans with accumulated benefit obligations in excess of plan assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets at fair value",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1730"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r1732"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate changes and other",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Target allocations",
        "terseLabel": "Target Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r1386"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plans with projected benefit obligations in excess of plan assets",
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement and curtailment (gain) loss",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r735",
      "r761"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r729",
      "r755",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Plan settlements",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r1725"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Critical assumptions \u2013 projected benefit obligation:",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Critical assumptions \u2013 net periodic benefit cost:",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense under defined contribution plans",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation Expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r428",
      "r441",
      "r458",
      "r1359",
      "r1360"
     ]
    },
    "mdt_DerivativeAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DerivativeAssetLiabilityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Derivative Asset (Liability) [Abstract]",
        "documentation": "Derivative Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DerivativeAssetLiabilityFairValueGrossAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Asset (Liability), Fair Value, Gross Asset (Liability)",
        "documentation": "Derivative Asset (Liability), Fair Value, Gross Asset (Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r36",
      "r258"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r345",
      "r935",
      "r936",
      "r947",
      "r954",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1192",
      "r1193",
      "r1281",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1347",
      "r1402",
      "r1406",
      "r1437",
      "r1784",
      "r1785",
      "r1786",
      "r1855"
     ]
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets:",
        "label": "Derivative Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash collateral received",
        "negatedTotalLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash",
        "documentation": "Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction",
        "documentation": "Derivative Assets and Liabilities, Net, Not Offset, Policy Election Deduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeCollateralObligationToReturnCash",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r122",
      "r343",
      "r1346"
     ]
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeCollateralRightToReclaimCash",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Amount Not Offset on the Balance Sheet, Cash Collateral (Received) Posted",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r122",
      "r343",
      "r1346"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1177",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1281",
      "r1282",
      "r1285",
      "r1287",
      "r1435",
      "r1437",
      "r1787",
      "r1788",
      "r1789",
      "r1790",
      "r1791",
      "r1792",
      "r1794",
      "r1795"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, excluded component, gain (loss), recognized in earnings",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r1778"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) recognized in earnings from excluded component of derivative hedge."
       }
      }
     },
     "auth_ref": [
      "r1778",
      "r1779"
     ]
    },
    "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueAmountOffsetAgainstCollateralNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Amount",
        "label": "Derivative, Fair Value, Amount Offset Against Collateral, Net",
        "documentation": "The net amount as of the balance sheet date of the fair value of derivative assets and derivative liabilities that in accordance with the entity's accounting policy were offset against collateral under a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value - Assets",
        "verboseLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r165",
      "r216",
      "r217",
      "r341",
      "r1347"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Amount",
        "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction",
        "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r121"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value - Liabilities",
        "negatedTerseLabel": "Gross Amount of Recognized Assets (Liabilities)",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r165",
      "r216",
      "r217",
      "r341",
      "r1347"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net Amount",
        "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction",
        "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r121"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117",
      "r119",
      "r218",
      "r1175",
      "r1177",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1281",
      "r1282",
      "r1285",
      "r1287",
      "r1347",
      "r1435",
      "r1437",
      "r1787",
      "r1788",
      "r1789",
      "r1790",
      "r1791",
      "r1792",
      "r1794",
      "r1795"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives and Currency Exchange Risk Management",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r908",
      "r921"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "documentation": "Disclosure of information about derivatives and hedging activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, (Gain) Loss [Table]",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r114",
      "r117",
      "r119",
      "r123",
      "r124",
      "r907"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, (Gain) Loss [Line Items]",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derivative instruments not designated as hedging instruments, (gain) loss, net",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r1571"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r345",
      "r935",
      "r936",
      "r947",
      "r954",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1200",
      "r1202",
      "r1203",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1347",
      "r1784",
      "r1785",
      "r1786",
      "r1855"
     ]
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities:",
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Amount Not Offset on the Balance Sheet, Financial Instruments",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r36",
      "r258"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross notional amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1776",
      "r1777"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Fair Value [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r107",
      "r108",
      "r112",
      "r120",
      "r385",
      "r409"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives designated as hedging instruments",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "mdt_DiabetesGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DiabetesGroupMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diabetes",
        "label": "Diabetes Group [Member]",
        "documentation": "Diabetes Group"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DiabetesPumpRetainerRingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DiabetesPumpRetainerRingLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diabetes Pump Retainer Ring Litigation",
        "label": "Diabetes Pump Retainer Ring Litigation [Member]",
        "documentation": "Diabetes Pump Retainer Ring Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1722"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase and Award Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r777",
      "r808",
      "r809",
      "r811",
      "r1395"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value",
        "documentation": "Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold, excluding amortization of intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r319"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer to held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r129",
      "r136",
      "r191"
     ]
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationNonCashImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNonCashImpairments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash impairments",
        "label": "Disposal Group, Including Discontinued Operation, Non-cash Impairments",
        "documentation": "Disposal Group, Including Discontinued Operation, Non-cash Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operation, other operating expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net",
        "documentation": "Disposal Group, Including Discontinued Operation, Other Operating Income (Expense) Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operations",
        "label": "Disposal Group, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is not classified as discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1388",
      "r1391"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends to shareholders",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476",
      "r1519"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1497"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1450"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Tax Authority",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic plan",
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1733",
      "r1734",
      "r1735"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1508"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r414",
      "r420",
      "r421",
      "r422",
      "r427",
      "r877",
      "r889",
      "r932",
      "r933",
      "r1074",
      "r1103",
      "r1352"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r418",
      "r420"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r414",
      "r420",
      "r421",
      "r422",
      "r427",
      "r877",
      "r889",
      "r932",
      "r933",
      "r1074",
      "r1103",
      "r1352"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r424"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r423",
      "r425",
      "r426"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r1398"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r828",
      "r864",
      "r1398"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base erosion anti-abuse tax",
        "label": "Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Base Erosion And Anti-Abuse Tax, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign derived intangible income benefit",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1764",
      "r1766"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r1398",
      "r1615",
      "r1764"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions and interest",
        "label": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain tax adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1615",
      "r1764",
      "r1766"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense related to internal restructuring and intercompany sale of assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Reinvestment Assertion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1615",
      "r1764",
      "r1766"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1615",
      "r1764",
      "r1765"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Puerto Rico excise tax",
        "label": "Effective Income Tax Rate Reconciliation, Puerto Rico Excise Tax",
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to Puerto Rico excise tax from intercompany purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. tax on foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1615",
      "r1764",
      "r1765"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1398",
      "r1615",
      "r1764"
     ]
    },
    "mdt_EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, tax adjustments for reserves, amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Adjustments For Reserves, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1398",
      "r1615",
      "r1764",
      "r1766"
     ]
    },
    "mdt_EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax reconciliation, disallowance of interest deductions, amount",
        "label": "Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount",
        "documentation": "Effective Income Tax Reconciliation, Disallowance of Interest Deductions, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to restricted stock awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1762"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to outstanding stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1762"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefits",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit related to options exercised",
        "verboseLabel": "Tax benefit related to restricted stock vested",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Termination Benefits",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Employee stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EmployeesStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EmployeesStockPurchasePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employees Stock Purchase Plan [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EnterpriseExcellenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EnterpriseExcellenceMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise Excellence",
        "label": "Enterprise Excellence [Member]",
        "documentation": "Enterprise Excellence [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1560"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1502"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r313",
      "r361",
      "r362",
      "r363",
      "r393",
      "r394",
      "r395",
      "r398",
      "r405",
      "r407",
      "r409",
      "r429",
      "r511",
      "r517",
      "r567",
      "r666",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r878",
      "r888",
      "r889",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r920",
      "r931",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r972",
      "r975",
      "r994",
      "r1098",
      "r1130",
      "r1131",
      "r1132",
      "r1155",
      "r1226"
     ]
    },
    "us-gaap_EquityFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityFundsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity commingled trusts",
        "label": "Equity Funds [Member]",
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments."
       }
      }
     },
     "auth_ref": [
      "r1726"
     ]
    },
    "mdt_EquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EquityInvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity and Other Investments",
        "terseLabel": "Equity and Other Investments",
        "label": "Equity Investments [Member]",
        "documentation": "Equity Investments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment losses recognized",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1663"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method and other investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r446",
      "r458",
      "r503",
      "r1591",
      "r1664"
     ]
    },
    "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and other investments",
        "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments",
        "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity and Other Investments",
        "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]",
        "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFVNINoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments for which the fair value option has been elected",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments with readily determinable fair value (marketable equity securities)",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r953",
      "r1341"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsDebtandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r935",
      "r953",
      "r1081",
      "r1082",
      "r1402",
      "r1431",
      "r1434",
      "r1784",
      "r1785",
      "r1786"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails": {
       "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments without readily determinable fair values",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1512"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1469",
      "r1480",
      "r1490",
      "r1523"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1466",
      "r1477",
      "r1487",
      "r1520"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1859",
      "r1860",
      "r1861",
      "r1862"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r947",
      "r1402"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r947",
      "r1402"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r1406"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r1406"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Unobservable Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r1406"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r948",
      "r1404"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r948",
      "r1404"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r934",
      "r936",
      "r937",
      "r938",
      "r939",
      "r946",
      "r947",
      "r949",
      "r1002",
      "r1003",
      "r1004",
      "r1372",
      "r1373",
      "r1384",
      "r1385",
      "r1386",
      "r1402",
      "r1406"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r937",
      "r939",
      "r1402",
      "r1785",
      "r1796"
     ]
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r719",
      "r724",
      "r936",
      "r947",
      "r1002",
      "r1384",
      "r1385",
      "r1386",
      "r1402"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r719",
      "r724",
      "r936",
      "r937",
      "r947",
      "r1003",
      "r1372",
      "r1373",
      "r1384",
      "r1385",
      "r1386",
      "r1402"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r936",
      "r937",
      "r938",
      "r939",
      "r947",
      "r1004",
      "r1372",
      "r1373",
      "r1384",
      "r1385",
      "r1386",
      "r1402",
      "r1406"
     ]
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments measured at net asset value",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "documentation": "Fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r934",
      "r949",
      "r1402"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r937",
      "r939",
      "r1402",
      "r1785",
      "r1796"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r934",
      "r936",
      "r937",
      "r938",
      "r939",
      "r946",
      "r947",
      "r949",
      "r1002",
      "r1003",
      "r1004",
      "r1372",
      "r1373",
      "r1384",
      "r1385",
      "r1386",
      "r1402",
      "r1406"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsReconciliationofLevel3MeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1402",
      "r1782",
      "r1783",
      "r1784",
      "r1785",
      "r1786",
      "r1796"
     ]
    },
    "mdt_FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements, Retirement Benefit Plan Assets",
        "label": "Fair Value Measurements, Retirement Benefit Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure related to retirement benefit plan assets that are measured at fair value in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value, option loss",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115",
      "r123"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r526",
      "r528",
      "r529",
      "r646",
      "r663",
      "r921",
      "r950",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1099",
      "r1365",
      "r1402",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1416",
      "r1573",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1781",
      "r1784",
      "r1785",
      "r1786",
      "r1793",
      "r1796"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, estimated useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r534",
      "r557",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r561",
      "r562",
      "r1033",
      "r1037",
      "r1333"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r557",
      "r1037",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r557",
      "r561",
      "r562",
      "r564",
      "r1033",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r561",
      "r562",
      "r1333"
     ]
    },
    "us-gaap_FiscalPeriod": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiscalPeriod",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year-End",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_FixedIncomeFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FixedIncomeFundsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed income commingled trusts",
        "label": "Fixed Income Funds [Member]",
        "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments."
       }
      }
     },
     "auth_ref": [
      "r1726"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. Tax Authorities",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r829"
     ]
    },
    "mdt_ForeignCurrencyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ForeignCurrencyCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Currency",
        "label": "Foreign Currency Costs",
        "documentation": "Foreign Currency Costs"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_ForeignCurrencyDenominatedDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency denominated debt",
        "label": "Foreign Currency Denominated Debt [Member]",
        "documentation": "Foreign Currency Denominated Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rate contracts",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1384",
      "r1401",
      "r1402"
     ]
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. government and agency securities",
        "label": "Debt Security, Government, Non-US [Member]",
        "documentation": "Debt security issued by government not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1416",
      "r1726",
      "r1851"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-U.S.",
        "terseLabel": "Non-U.S. Pension Benefits",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1733",
      "r1734",
      "r1735"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1527"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1527"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1527"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1527"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1527"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1507"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Related to the Company's Available for Sale Securities Portfolio",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1600",
      "r1601"
     ]
    },
    "mdt_GainOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "GainOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross gains",
        "label": "Gain On Investments",
        "documentation": "Gain On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on debt extinguishment",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r71",
      "r72"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning balance",
        "periodEndLabel": "Goodwill, ending balance",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r536",
      "r1068",
      "r1360",
      "r1367",
      "r1403",
      "r1415",
      "r1671",
      "r1678"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill as a result of acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r1367"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Other Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1669",
      "r1681"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r548",
      "r1367"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r563",
      "r565"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation and other",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r537",
      "r543",
      "r548",
      "r1367",
      "r1403"
     ]
    },
    "us-gaap_GoodwillImpairmentLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLossNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, net of tax",
        "label": "Goodwill, Impairment Loss, Net of Tax",
        "documentation": "Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r1367"
     ]
    },
    "us-gaap_GoodwillNotAllocatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillNotAllocatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, non deductible amount",
        "label": "Goodwill, Not Allocated, Amount",
        "documentation": "Portion of goodwill not yet allocated to reportable segments."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase accounting adjustments",
        "label": "Goodwill, Measurement Period Adjustment",
        "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1677"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantee obligations",
        "label": "Guarantor Obligations, Current Carrying Value",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r907"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "mdt_HerniaMeshLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "HerniaMeshLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hernia Mesh Litigation",
        "label": "Hernia Mesh Litigation [Member]",
        "documentation": "Hernia Mesh Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IE",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ireland",
        "label": "IRELAND"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1453",
      "r1476"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible asset finite lived statement of income or comprehensive income extensible enumeration not disclosed flag",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r1333",
      "r1695"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of finite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r1609",
      "r1694"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of indefinite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r1609",
      "r1691",
      "r1694"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1689",
      "r1691",
      "r1692",
      "r1693"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r827"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r231",
      "r237",
      "r1075",
      "r1094",
      "r1354",
      "r1359",
      "r1632",
      "r1634",
      "r1636",
      "r1637",
      "r1638"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesComponentsofIncomeBeforeIncomeTaxesBasedonJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r827"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1388",
      "r1391"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r31",
      "r40",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r139",
      "r192"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r575",
      "r588",
      "r941",
      "r945",
      "r948",
      "r1125",
      "r1127",
      "r1211",
      "r1333",
      "r1405",
      "r1823"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r588",
      "r941",
      "r945",
      "r948",
      "r1125",
      "r1127",
      "r1211",
      "r1333",
      "r1405",
      "r1823"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r828",
      "r829",
      "r839",
      "r855",
      "r1398",
      "r1770"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r828",
      "r829",
      "r839",
      "r855",
      "r1398",
      "r1770"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r819",
      "r828",
      "r835",
      "r836",
      "r837",
      "r846",
      "r853",
      "r865",
      "r867",
      "r868",
      "r869",
      "r1152",
      "r1398"
     ]
    },
    "mdt_IncomeTaxExaminationInterestIncomeExpenseGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "IncomeTaxExaminationInterestIncomeExpenseGross",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross interest expense",
        "label": "Income Tax Examination, Interest Income (Expense), Gross",
        "documentation": "Income Tax Examination, Interest Income (Expense), Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r263",
      "r408",
      "r409",
      "r428",
      "r444",
      "r458",
      "r826",
      "r828",
      "r866",
      "r1105",
      "r1398"
     ]
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact on diluted earnings per share (in dollars per share)",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r822",
      "r823",
      "r846",
      "r847",
      "r852",
      "r857",
      "r1146"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r1595"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, benefit",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r1398",
      "r1764"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationDispositionOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany sale of assets",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory."
       }
      }
     },
     "auth_ref": [
      "r1764",
      "r1765"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense associated with the amortization of the previously established deferred tax assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization."
       }
      }
     },
     "auth_ref": [
      "r1764",
      "r1766"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain tax adjustments, provision (benefit)",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1764",
      "r1765"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax charge",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1398",
      "r1764"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxHolidays": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxHolidays",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax reductions from tax holiday",
        "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday."
       }
      }
     },
     "auth_ref": [
      "r1764",
      "r1766"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r377",
      "r854",
      "r855"
     ]
    },
    "mdt_IncomeTaxesandInterestPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "IncomeTaxesandInterestPaidAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for:",
        "label": "Income Taxes and Interest Paid [Abstract]",
        "documentation": "Income Taxes and Interest Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts and Notes Receivable",
        "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities, net of acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_IncreaseDecreaseInTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "IncreaseDecreaseInTaxRateAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in tax rate resulting from:",
        "label": "Increase Decrease In Tax Rate [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee restricted stock units (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends",
        "documentation": "Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r1627",
      "r1628",
      "r1629",
      "r1631"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payments (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r422",
      "r776"
     ]
    },
    "mdt_IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental defined benefit, defined contribution and post-retirement",
        "label": "Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges [Member]",
        "documentation": "Incremental Defined Benefit, Defined Contribution, And Post-Retirement Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r555",
      "r560",
      "r1368"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r560",
      "r1368"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r555",
      "r560",
      "r1368"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1518",
      "r1527",
      "r1531",
      "r1539"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1543"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1543"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1543"
     ]
    },
    "mdt_InsuranceContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "InsuranceContractMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance contracts",
        "label": "Insurance Contract [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1689",
      "r1691"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on outstanding borrowings",
        "label": "Interest Expense, Borrowings",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r1602"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Operating",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1634"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r1359",
      "r1602",
      "r1634"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r375",
      "r376"
     ]
    },
    "mdt_InternationalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "InternationalMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "International [Member]",
        "documentation": "International"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r1343"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r1340",
      "r1415"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r322",
      "r337",
      "r530",
      "r531",
      "r533",
      "r1031",
      "r1350"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r1345"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r1344"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1251",
      "r1253"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Debt Securities Contractual Maturities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "JP",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan",
        "label": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and land improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1414"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1803"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1804"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expected lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r153",
      "r382",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r893",
      "r897",
      "r898",
      "r955",
      "r1184",
      "r1353",
      "r1447",
      "r1713",
      "r1808",
      "r1809"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r228",
      "r1091",
      "r1415",
      "r1613",
      "r1665",
      "r1797"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r321",
      "r382",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r893",
      "r897",
      "r898",
      "r955",
      "r1415",
      "r1713",
      "r1808",
      "r1809"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits, net of cash advance, noncurrent liability",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed line of credit outstanding",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r225",
      "r1819"
     ]
    },
    "mdt_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional borrowing capacity",
        "label": "Line of Credit Facility, Additional Borrowing Capacity",
        "documentation": "Additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_LineOfCreditFacilityLengthOfExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "LineOfCreditFacilityLengthOfExtension",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Length of extension from maturity date",
        "label": "Line of Credit Facility, Length of Extension",
        "documentation": "Line of Credit Facility, Length of Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case Type [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of settlement paid",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1699",
      "r1700",
      "r1701",
      "r1705"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1699",
      "r1700",
      "r1701",
      "r1705"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r1085"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Fiscal Year Maturity",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of senior notes",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r1782",
      "r1784",
      "r1785",
      "r1786"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r1719"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r639"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r639"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r639"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r639"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r386",
      "r639"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r1699",
      "r1700",
      "r1701"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r70",
      "r1699",
      "r1700",
      "r1701"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r599",
      "r601",
      "r606",
      "r817",
      "r1370",
      "r1706",
      "r1707"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r599",
      "r601",
      "r606",
      "r817",
      "r1370",
      "r1706",
      "r1707"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigations charges",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r1564"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Certain litigation charges, net",
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r1705"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation charges (income)",
        "negatedTerseLabel": "Certain litigation charges, net",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1705"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r817"
     ]
    },
    "mdt_LossContingencyLawsuitsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "LossContingencyLawsuitsNumber",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, lawsuits, number",
        "label": "Loss Contingency, Lawsuits, Number",
        "documentation": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfPlaintiffs",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs (in plaintiffs)",
        "label": "Loss Contingency, Number of Plaintiffs",
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1706",
      "r1707"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claimants (in claimants)",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1706",
      "r1707"
     ]
    },
    "mdt_LossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "LossOnInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross losses",
        "label": "Loss On Investments",
        "documentation": "Loss On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MN",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minnesota",
        "label": "MINNESOTA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reconciling items",
        "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r456",
      "r459",
      "r1359",
      "r1360"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r280",
      "r309",
      "r310",
      "r599",
      "r601",
      "r602",
      "r603",
      "r770",
      "r817",
      "r939",
      "r1030",
      "r1124",
      "r1126",
      "r1140",
      "r1176",
      "r1177",
      "r1234",
      "r1255",
      "r1260",
      "r1261",
      "r1298",
      "r1331",
      "r1332",
      "r1364",
      "r1376",
      "r1394",
      "r1406",
      "r1407",
      "r1411",
      "r1412",
      "r1426",
      "r1717",
      "r1810",
      "r1811",
      "r1812",
      "r1813",
      "r1814",
      "r1815"
     ]
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1784",
      "r1785",
      "r1786"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r1406"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r1406"
     ]
    },
    "mdt_MedicalDeviceRegulations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "MedicalDeviceRegulations",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Medical device regulations",
        "label": "Medical Device Regulations",
        "documentation": "Medical Device Regulations"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedicalSurgicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "MedicalSurgicalMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Surgical",
        "label": "Medical Surgical [Member]",
        "documentation": "Medical Surgical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedtronicLuxcoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "MedtronicLuxcoMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medtronic Luxco",
        "label": "Medtronic Luxco [Member]",
        "documentation": "Medtronic Luxco [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MedtronicLuxcoSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "MedtronicLuxcoSeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medtronic Luxco Senior Notes",
        "label": "Medtronic Luxco Senior Notes [Member]",
        "documentation": "Medtronic Luxco Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions, Dispositions, and Funded Research and Development Arrangements",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r210"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r280",
      "r309",
      "r310",
      "r599",
      "r601",
      "r602",
      "r603",
      "r770",
      "r817",
      "r939",
      "r1030",
      "r1124",
      "r1126",
      "r1140",
      "r1176",
      "r1177",
      "r1234",
      "r1255",
      "r1260",
      "r1261",
      "r1298",
      "r1331",
      "r1332",
      "r1364",
      "r1376",
      "r1394",
      "r1406",
      "r1407",
      "r1411",
      "r1426",
      "r1717",
      "r1810",
      "r1811",
      "r1812",
      "r1813",
      "r1814",
      "r1815"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r227",
      "r382",
      "r507",
      "r610",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r955",
      "r1090",
      "r1188"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes to noncontrolling ownership interests",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBackedSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage-backed securities",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "documentation": "Securities collateralized by mortgage loans."
       }
      }
     },
     "auth_ref": [
      "r1384",
      "r1385",
      "r1386",
      "r1644",
      "r1651",
      "r1656",
      "r1657",
      "r1658",
      "r1851"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_MozarcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "MozarcMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mozarc",
        "label": "Mozarc [Member]",
        "documentation": "Mozarc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1726"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Medtronic",
        "terseLabel": "Net income attributable to ordinary shareholders",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r185",
      "r232",
      "r319",
      "r355",
      "r358",
      "r363",
      "r382",
      "r397",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r409",
      "r419",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r877",
      "r889",
      "r933",
      "r955",
      "r1097",
      "r1207",
      "r1224",
      "r1225",
      "r1445",
      "r1713"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r213",
      "r355",
      "r358",
      "r405",
      "r408",
      "r409",
      "r1096",
      "r1599"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment hedges",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "mdt_NeuromodulationDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "NeuromodulationDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuromodulation",
        "label": "Neuromodulation Division [Member]",
        "documentation": "Neuromodulation Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_NeuroscienceGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "NeuroscienceGroupMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuroscience",
        "label": "Neuroscience Group [Member]",
        "documentation": "Neuroscience Group"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r410",
      "r427",
      "r466",
      "r467",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r566",
      "r567",
      "r583",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r880",
      "r881",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r951",
      "r952",
      "r971",
      "r972",
      "r973",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1034",
      "r1035",
      "r1036",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1141"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r410",
      "r427",
      "r466",
      "r467",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r566",
      "r567",
      "r583",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r880",
      "r881",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r951",
      "r952",
      "r971",
      "r972",
      "r973",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1034",
      "r1035",
      "r1036",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1141"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1484",
      "r1494",
      "r1518",
      "r1527"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1501"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r666",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1857"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives not designated as hedging instruments",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_NotesPayableToBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableToBanksMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank borrowings",
        "label": "Notes Payable to Banks [Member]",
        "documentation": "A written promise to pay a note to a bank."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1355",
      "r1363",
      "r1633"
     ]
    },
    "us-gaap_OffsettingAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Offsetting Assets",
        "label": "Offsetting Assets [Table Text Block]",
        "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r344"
     ]
    },
    "mdt_OffsettingAssetsandLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OffsettingAssetsandLiabilitiesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets and Liabilities [Line Items]",
        "label": "Offsetting Assets and Liabilities [Line Items]",
        "documentation": "[Line Items] for Offsetting Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OffsettingAssetsandLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OffsettingAssetsandLiabilitiesTable",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting Assets and Liabilities [Table]",
        "label": "Offsetting Assets and Liabilities [Table]",
        "documentation": "Offsetting Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Offsetting Liabilities",
        "label": "Offsetting Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r344"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating profit",
        "terseLabel": "Reportable segment operating profit",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r1354",
      "r1632",
      "r1634",
      "r1636",
      "r1637",
      "r1638"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1414"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesMaturitiesofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other accrued expenses",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other liabilities",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r983"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.medtronic.com/role/LeasesBalanceSheetClassificationandAmountsofRightofUseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification, Other assets",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1414"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.medtronic.com/role/LeasesWeightedAverageRemainingLeaseTermandWeightedAverageDiscountRateforOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1414"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, valuation allowance",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r1769"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r1359",
      "r1360"
     ]
    },
    "mdt_OtherAccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherAccruedExpensesMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Expenses [Member]",
        "documentation": "Other Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1415"
     ]
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "verboseLabel": "Other assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r123"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r167",
      "r168",
      "r170",
      "r957",
      "r958",
      "r960"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of prior service cost",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r170",
      "r354",
      "r736"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r43",
      "r362",
      "r961",
      "r964",
      "r967",
      "r1098",
      "r1597"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), tax expense (benefit)",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r361",
      "r1098"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "(Gain)\u00a0Loss\u00a0Recognized in Accumulated Other Comprehensive Income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "(Gain) Loss Reclassified into Income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r351",
      "r1098"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Recognized in AOCI, Cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r351",
      "r900",
      "r901",
      "r909"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Recognized in income, cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r351",
      "r353"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) Loss Reclassified into Income",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r351",
      "r353",
      "r903"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain)\u00a0Loss\u00a0Recognized in Accumulated Other Comprehensive Income",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r351",
      "r902",
      "r906",
      "r909"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Recognized in AOCI, net investment hedges",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails": {
       "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassified into Income, net investment hedges",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive (loss) income",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r38",
      "r356",
      "r359",
      "r364",
      "r405",
      "r961",
      "r962",
      "r967",
      "r1070",
      "r1098",
      "r1597",
      "r1598"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total recognized in other comprehensive loss",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r169",
      "r170",
      "r1098",
      "r1386",
      "r1727"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net change in retirement obligations",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r169",
      "r170",
      "r1098"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Foreign Exchange Adjustment",
        "documentation": "Foreign exchange adjustment to pension and other postretirement benefit plans (gain) loss included in accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net actuarial loss",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r203"
     ]
    },
    "mdt_OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization and settlement recognition of actuarial (gain) loss",
        "label": "Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax",
        "documentation": "2012 Element. Before tax amount of the income statement impact of the reclassification adjustment for actuarial gain (loss) recognized as a component of net periodic benefit cost."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment hedges",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax",
        "documentation": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investment securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r351",
      "r501"
     ]
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1368",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1689",
      "r1691",
      "r1692",
      "r1693"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r1415"
     ]
    },
    "us-gaap_OtherLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Liabilities",
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other liabilities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r123"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-operating income, net",
        "terseLabel": "Other non-operating income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "mdt_OtherNonoperatingIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherNonoperatingIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Operating Income, Net",
        "label": "Other Nonoperating Income (Expense), Net [Policy Text Block]",
        "documentation": "Other Nonoperating Income (Expense), Net [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonrecurringIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonrecurringIncomeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other adjustments",
        "label": "Other Nonrecurring (Income) Expense",
        "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativeGainsLossesDesignatedasHedgingInstrumentsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementGainsandLossesonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating (income) expense, net",
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other operating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating (income) expense, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_OtherOperatingIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherOperatingIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating (Income) Expense, Net",
        "label": "Other Operating Income (Expense), Net [Policy Text Block]",
        "documentation": "Other Operating Income (Expense), Net [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "mdt_OtherPlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherPlanAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Plan Assets [Member]",
        "documentation": "Other categories of plan assets not specified in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other post-retirement benefits",
        "label": "Other Postretirement Benefits Plan [Member]",
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r741",
      "r742",
      "r744",
      "r747",
      "r750",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r768",
      "r769",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390"
     ]
    },
    "mdt_OtherSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "OtherSegmentMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Segment",
        "label": "Other Segment [Member]",
        "documentation": "Other Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1471",
      "r1482",
      "r1492",
      "r1525"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1474",
      "r1485",
      "r1495",
      "r1528"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1474",
      "r1485",
      "r1495",
      "r1528"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholders\u2019 Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_PartnershipUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "PartnershipUnitsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partnership units",
        "label": "Partnership Units [Member]",
        "documentation": "Partnership units include partnerships, private equity investments, and real asset investments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other investing activities, net",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1567",
      "r1603"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r1607"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends to shareholders",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire long-term investments",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1603"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1509"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1509"
     ]
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending Litigation",
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r1705"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of retirement benefit plans",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r716",
      "r718",
      "r724",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r764",
      "r765",
      "r767",
      "r1386"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current liabilities",
        "label": "Liability, Defined Benefit Plan, Current",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r691",
      "r692",
      "r715",
      "r1386"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and retirement benefits",
        "negatedLabel": "Non-current liabilities",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r691",
      "r692",
      "r715",
      "r1386"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefit Plan Assumptions",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r27",
      "r86"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefits",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r741",
      "r742",
      "r744",
      "r747",
      "r750",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r768",
      "r771",
      "r1386",
      "r1387",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1501"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance share units",
        "netLabel": "Employee performance share units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r1384",
      "r1385",
      "r1386"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1736",
      "r1737",
      "r1738",
      "r1739",
      "r1740",
      "r1741",
      "r1742",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1736",
      "r1737",
      "r1738",
      "r1739",
      "r1740",
      "r1741",
      "r1742",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1502"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1558"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1501"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r651"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r1186"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r651"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r1186",
      "r1205",
      "r1857",
      "r1858"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1366",
      "r1668"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1590"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of businesses",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r1147"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r1147"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financing activities",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1568",
      "r1604"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt",
        "label": "Proceeds from (Repayments of) Debt",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in current debt obligations, net",
        "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less",
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months."
       }
      }
     },
     "auth_ref": [
      "r1605",
      "r1606",
      "r1610"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsActivityRelatedtotheCompanysInvestmentPortfolioandDebtSecuritiesContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r1643"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term borrowings (maturities greater than 90 days)",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r30"
     ]
    },
    "mdt_ProductDevelopmentMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ProductDevelopmentMilestoneMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development and other milestone-based payments",
        "label": "Product Development Milestone [Member]",
        "documentation": "A milestone in achieving certain product development target."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r308",
      "r461",
      "r1032",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1335",
      "r1377",
      "r1425",
      "r1426",
      "r1427",
      "r1430",
      "r1433",
      "r1589",
      "r1708",
      "r1709",
      "r1722",
      "r1820",
      "r1824",
      "r1825",
      "r1826",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r308",
      "r461",
      "r1032",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1335",
      "r1377",
      "r1425",
      "r1426",
      "r1427",
      "r1430",
      "r1433",
      "r1589",
      "r1708",
      "r1709",
      "r1722",
      "r1820",
      "r1824",
      "r1825",
      "r1826",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity",
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "verboseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r355",
      "r358",
      "r373",
      "r382",
      "r397",
      "r405",
      "r408",
      "r409",
      "r507",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r877",
      "r889",
      "r891",
      "r894",
      "r895",
      "r933",
      "r955",
      "r1075",
      "r1095",
      "r1154",
      "r1207",
      "r1224",
      "r1225",
      "r1399",
      "r1400",
      "r1446",
      "r1599",
      "r1713"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Accumulated depreciation",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1569",
      "r1570",
      "r1698"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1570",
      "r1696"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1566",
      "r1592",
      "r1697"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r988"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r252",
      "r260",
      "r261"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r988",
      "r1080",
      "r1093",
      "r1415"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r252",
      "r260",
      "r1092"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment Balances and Corresponding Lives",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r988"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for credit losses",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r521"
     ]
    },
    "mdt_PurchasedTechnologyAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "PurchasedTechnologyAndPatentsMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased technology and patents",
        "label": "Purchased Technology and Patents [Member]",
        "documentation": "Purchased technology and patents."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r280",
      "r309",
      "r310",
      "r599",
      "r601",
      "r602",
      "r603",
      "r716",
      "r770",
      "r803",
      "r804",
      "r805",
      "r817",
      "r939",
      "r1005",
      "r1014",
      "r1030",
      "r1124",
      "r1126",
      "r1140",
      "r1176",
      "r1177",
      "r1234",
      "r1255",
      "r1260",
      "r1261",
      "r1298",
      "r1331",
      "r1332",
      "r1364",
      "r1376",
      "r1394",
      "r1406",
      "r1407",
      "r1411",
      "r1412",
      "r1426",
      "r1437",
      "r1703",
      "r1717",
      "r1785",
      "r1811",
      "r1812",
      "r1813",
      "r1814",
      "r1815"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r280",
      "r309",
      "r310",
      "r599",
      "r601",
      "r602",
      "r603",
      "r716",
      "r770",
      "r803",
      "r804",
      "r805",
      "r817",
      "r939",
      "r1005",
      "r1014",
      "r1030",
      "r1124",
      "r1126",
      "r1140",
      "r1176",
      "r1177",
      "r1234",
      "r1255",
      "r1260",
      "r1261",
      "r1298",
      "r1331",
      "r1332",
      "r1364",
      "r1376",
      "r1394",
      "r1406",
      "r1407",
      "r1411",
      "r1412",
      "r1426",
      "r1437",
      "r1703",
      "r1717",
      "r1785",
      "r1811",
      "r1812",
      "r1813",
      "r1814",
      "r1815"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassifications",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r43",
      "r362",
      "r961",
      "r966",
      "r967",
      "r1098",
      "r1597"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications from AOCI, tax expense (benefit)",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r354",
      "r361",
      "r1098"
     ]
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1466",
      "r1477",
      "r1487",
      "r1520"
     ]
    },
    "mdt_RegisteredInvestmentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RegisteredInvestmentCompanyMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered investment companies",
        "label": "Registered Investment Company [Member]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_RenalCareBusinessRCSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RenalCareBusinessRCSMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renal Care Business (RCS)",
        "label": "Renal Care Business (RCS) [Member]",
        "documentation": "Renal Care Business (RCS)"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_RenalCareSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RenalCareSolutionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renal Care Solutions",
        "label": "Renal Care Solutions [Member]",
        "documentation": "Renal Care Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1606"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r1150"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments from short-term borrowings (maturities greater than 90 days)",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1763"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1467",
      "r1478",
      "r1488",
      "r1521"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1468",
      "r1479",
      "r1489",
      "r1522"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1475",
      "r1486",
      "r1496",
      "r1529"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "verboseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock",
        "terseLabel": "Employee restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r585",
      "r587",
      "r590",
      "r595"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated expected restructuring costs",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r589",
      "r592",
      "r594"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "negatedTerseLabel": "Restructuring and associated costs",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r591",
      "r592",
      "r1704"
     ]
    },
    "mdt_RestructuringChargesIncludingAccrualAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RestructuringChargesIncludingAccrualAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges",
        "label": "Restructuring Charges, Including Accrual Adjustments",
        "documentation": "Restructuring Charges, Including Accrual Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails": {
       "parentTag": "us-gaap_RestructuringCosts",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges, net",
        "label": "Restructuring Charges, Net of Restructuring Reversals Including Cost of Product Sold Impact",
        "documentation": "Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r592",
      "r593"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total restructuring and associated costs",
        "totalLabel": "Total restructuring and associated costs",
        "label": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1562",
      "r1563"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r593"
     ]
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAccrualAdjustment1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual adjustments",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r593"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Restructuring Reserves",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveSettledWithoutCash2",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settled non-cash",
        "label": "Restructuring Reserve, Settled without Cash",
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r593"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r201",
      "r1089",
      "r1134",
      "r1139",
      "r1151",
      "r1187",
      "r1415"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r393",
      "r394",
      "r395",
      "r398",
      "r405",
      "r407",
      "r409",
      "r511",
      "r517",
      "r567",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r878",
      "r888",
      "r889",
      "r913",
      "r916",
      "r917",
      "r920",
      "r931",
      "r972",
      "r975",
      "r1130",
      "r1132",
      "r1155",
      "r1857"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r747",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r1733",
      "r1734",
      "r1735"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r747",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r1733",
      "r1734",
      "r1735"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r741",
      "r742",
      "r744",
      "r747",
      "r750",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r768",
      "r769",
      "r771",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r741",
      "r742",
      "r744",
      "r747",
      "r750",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r767",
      "r768",
      "r769",
      "r771",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r1775"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "verboseLabel": "Shipping and Handling",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r428",
      "r437",
      "r438",
      "r452",
      "r458",
      "r461",
      "r463",
      "r465",
      "r685",
      "r686",
      "r1032"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Shipping and Handling",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r1334"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r689"
     ]
    },
    "mdt_RevenueMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "RevenueMilestoneMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and other performance-based payments",
        "label": "Revenue Milestone [Member]",
        "documentation": "Revenue Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which remaining performance obligations are expected to be recognized as revenue",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1414"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "mdt_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge to adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments",
        "documentation": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges to Other Accounts, net",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net",
        "documentation": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Charges To Other Accounts, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1386",
      "r1730",
      "r1731"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Loss",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r1798",
      "r1799"
     ]
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Plan Assets",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Securities Reconciliation",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1386",
      "r1730"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails",
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r879"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax (Benefit) Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1772"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r75",
      "r78",
      "r127",
      "r199",
      "r200",
      "r1372",
      "r1374",
      "r1616",
      "r1801"
     ]
    },
    "mdt_ScheduleOfDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ScheduleOfDebtTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Debt [Table]",
        "label": "Schedule Of Debt [Table]",
        "documentation": "Schedule Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1768"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of (Gain) Loss on Derivative Instruments",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117",
      "r907"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1631"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1398",
      "r1764"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r504",
      "r505",
      "r506",
      "r507",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsSummaryofEquityandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r382",
      "r504",
      "r505",
      "r506",
      "r507",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Benefit Payments",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1782",
      "r1783"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r557",
      "r561",
      "r562",
      "r564",
      "r1033",
      "r1333",
      "r1368"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1368",
      "r1688"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r1367"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1367",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679",
      "r1680"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Before Income Taxes, Based on Jurisdiction",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1614"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1368",
      "r1691"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory Balances",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r161",
      "r162",
      "r163"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1252",
      "r1254",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1252",
      "r1254",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1289",
      "r1290",
      "r1291",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307"
     ]
    },
    "mdt_ScheduleOfInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ScheduleOfInvestmentsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Investments",
        "label": "Schedule Of Investments [Table Text Block]",
        "documentation": "Schedule Of Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Benefit Costs",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.medtronic.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r988"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r193",
      "r194"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r171"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r171"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r775",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r207"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Current Debt Obligations",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r197",
      "r199",
      "r200",
      "r201",
      "r332",
      "r333",
      "r334",
      "r430",
      "r651",
      "r652",
      "r653",
      "r655",
      "r658",
      "r663",
      "r665",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1376",
      "r1561",
      "r1611"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r1397"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r392"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1368",
      "r1690"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1448"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1451"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r428",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r465",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r564",
      "r589",
      "r594",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1356",
      "r1359",
      "r1360",
      "r1367",
      "r1429",
      "r1820",
      "r1824",
      "r1825",
      "r1826",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r276",
      "r279",
      "r281",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r463",
      "r464",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1169",
      "r1172",
      "r1174",
      "r1240",
      "r1256",
      "r1277",
      "r1304",
      "r1318",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1336",
      "r1378",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1428",
      "r1437",
      "r1722",
      "r1820",
      "r1824",
      "r1825",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment and Geographic Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r428",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r448",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r1355",
      "r1357",
      "r1358",
      "r1359",
      "r1361",
      "r1362",
      "r1363"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r450",
      "r451",
      "r458",
      "r1359"
     ]
    },
    "us-gaap_SelfInsuranceReservePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SelfInsuranceReservePolicyTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self-Insurance",
        "label": "Self Insurance Reserve [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails",
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2009Due20396500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2009Due20396500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.500 percent thirty-year 2009 senior notes",
        "label": "Senior Notes 2009 Due 2039, 6.500 Percent [Member]",
        "documentation": "Senior Notes 2009 Due 2039, 6.500 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2010Due20405550PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2010Due20405550PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.550 percent thirty-year 2010 senior notes",
        "label": "Senior Notes 2010 Due 2040, 5.550 Percent [Member]",
        "documentation": "Senior Notes 2010 Due 2040, 5.550 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2012Due20424500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2012Due20424500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.500 percent thirty-year 2012 senior notes",
        "label": "Senior Notes 2012 Due 2042, 4.500 Percent [Member]",
        "documentation": "Senior Notes 2012 Due 2042, 4.500 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2013Due20434000PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2013Due20434000PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.000 percent thirty-year 2013 senior notes",
        "label": "Senior Notes 2013 Due 2043, 4.000 Percent [Member]",
        "documentation": "Senior Notes 2013 Due 2043, 4.000 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2014Due20444625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2014Due20444625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.625 percent thirty-year 2014 senior notes",
        "label": "Senior Notes 2014 Due 2044, 4.625 Percent [Member]",
        "documentation": "Senior Notes 2014 Due 2044, 4.625 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due20253.500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2015Due20253.500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 2015 Due 2025, 3.500 percent",
        "label": "Senior Notes 2015 Due 2025, 3.500 percent [Member]",
        "documentation": "Senior Notes 2015 Due 2025, 3.500 percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due20354.375PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2015Due20354.375PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.375 percent twenty-year 2015 senior notes",
        "label": "Senior Notes 2015 Due 2035, 4.375 Percent [Member]",
        "documentation": "Senior Notes 2015 Due 2035, 4.375 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2015Due20454625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2015Due20454625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.625 percent thirty-year 2015 senior notes",
        "label": "Senior Notes 2015 Due 2045, 4.625 Percent [Member]",
        "documentation": "Senior Notes 2015 Due 2045, 4.625 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2017Due20273.350PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2017Due20273.350PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 2017 Due 2027, 3.350 Percent",
        "label": "Senior Notes 2017 Due 2027, 3.350 Percent [Member]",
        "documentation": "Senior Notes 2017 Due 2027, 3.350 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20260250PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20260250PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.250 percent six-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2026, 0.250 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2026, 0.250 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20271125PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20271125PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.125 percent eight-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2027, 1.125 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2027, 1.125 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20311625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20311625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625 percent twelve-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20321000PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20321000PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.000 percent twelve-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2032, 1.000 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2032, 1.000 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20392250PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20392250PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250 percent twenty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20401500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20401500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.500 percent twenty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2040, 1.500 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2040, 1.500 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20501750PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2019Due20501750PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.750 percent thirty-year 2019 senior notes",
        "label": "Senior Notes 2019 Due 2050, 1.750 Percent [Member]",
        "documentation": "Senior Notes 2019 Due 2050, 1.750 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due20260.000PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2020Due20260.000PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.000 percent five-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2026, 0.000 Percent [Member]",
        "documentation": "Senior Notes 2020 Due 2026, 0.000 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due20290375PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2020Due20290375PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.375 percent eight-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2029, 0.375 Percent [Member]",
        "documentation": "Senior Notes 2020 Due 2029, 0.375 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due20330750PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2020Due20330750PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.750 percent twelve-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2033, 0.750 Percent [Member]",
        "documentation": "Senior Notes 2020 Due 2033, 0.750 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due20411375PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2020Due20411375PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375 percent twenty-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2041, 1.375 Percent [Member]",
        "documentation": "Senior Notes 2020 Due 2041, 1.375 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due20511625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2020Due20511625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625 percent thirty-year 2020 senior notes",
        "label": "Senior Notes 2020 Due 2051, 1.625 Percent [Member]",
        "documentation": "Senior Notes 2020 Due 2051, 1.625 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due20262.625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2022Due20262.625PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.625 percent three-year 2022 senior notes",
        "label": "Senior Notes 2022 Due 2026, 2.625 Percent [Member]",
        "documentation": "Senior Notes 2022 Due 2026, 2.625 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due20293.000PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2022Due20293.000PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.000 percent six-year 2022 senior notes",
        "label": "Senior Notes 2022 Due 2029, 3.000 Percent [Member]",
        "documentation": "Senior Notes 2022 Due 2029, 3.000 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due20323.125PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2022Due20323.125PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.125 percent nine-year 2022 senior notes",
        "label": "Senior Notes 2022 Due 2032, 3.125 Percent [Member]",
        "documentation": "Senior Notes 2022 Due 2032, 3.125 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2022Due20353.375PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2022Due20353.375PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.375 percent twelve-year 2022 senior notes",
        "label": "Senior Notes 2022 Due 2035, 3.375 Percent [Member]",
        "documentation": "Senior Notes 2022 Due 2035, 3.375 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2023Due20284.250PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2023Due20284.250PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.250 percent five-year 2023 senior notes",
        "label": "Senior Notes 2023 Due 2028, 4.250 Percent [Member]",
        "documentation": "Senior Notes 2023 Due 2028, 4.250 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2023Due20334.500PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2023Due20334.500PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.500 percent ten-year 2023 senior notes",
        "label": "Senior Notes 2023 Due 2033, 4.500 Percent [Member]",
        "documentation": "Senior Notes 2023 Due 2033, 4.500 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2024Due20303.650PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2024Due20303.650PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.650 percent five-year 2024 senior notes",
        "label": "Senior Notes 2024 Due 2030, 3.650 Percent [Member]",
        "documentation": "Senior Notes 2024 Due 2030, 3.650 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2024Due20373.875PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2024Due20373.875PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.875 percent twelve-year 2024 senior notes",
        "label": "Senior Notes 2024 Due 2037, 3.875 Percent [Member]",
        "documentation": "Senior Notes 2024 Due 2037, 3.875 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2024Due20444.150PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2024Due20444.150PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150 percent nineteen-year 2024 senior notes",
        "label": "Senior Notes 2024 Due 2044, 4.150 Percent [Member]",
        "documentation": "Senior Notes 2024 Due 2044, 4.150 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2024Due20544.150PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SeniorNotes2024Due20544.150PercentMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.150 percent twenty-nine-year 2024 senior notes",
        "label": "Senior Notes 2024 Due 2054, 4.150 Percent [Member]",
        "documentation": "Senior Notes 2024 Due 2054, 4.150 Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsLongtermDebtDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Shares",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1593",
      "r1594",
      "r1720"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "negatedTerseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average purchase price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Average Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The discount rate from market value on purchase date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares purchased by employees (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Shares Purchased During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Grant Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance adjustments (in dollar per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average, Performance Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in shares)",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in dollars per share)",
        "periodEndLabel": "Nonvested at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791"
     ]
    },
    "mdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Performance adjustments (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of restricted stock vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions used:",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r775",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired/Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1742"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired/Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1742"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansPerformanceShareUnitActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansRestrictedStockActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails",
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockbasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r781",
      "r800",
      "r801",
      "r802",
      "r803",
      "r806",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Performance Share Unit Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1736"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1396"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1724"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank borrowings",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r222",
      "r1415",
      "r1818"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r1699",
      "r1700",
      "r1701"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsCurrentDebtObligationsDetails",
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r1699",
      "r1700",
      "r1701"
     ]
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtWeightedAverageInterestRateOverTime",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate",
        "label": "Short-Term Debt, Weighted Average Interest Rate, over Time",
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r1596"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1308",
      "r1309",
      "r1310",
      "r1338"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/LeasesComponentsofTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1414"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r379"
     ]
    },
    "mdt_SimplificationRestructuringProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SimplificationRestructuringProgramMember",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simplification",
        "label": "Simplification Restructuring Program [Member]",
        "documentation": "Simplification Restructuring Program"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SpecialtyTherapiesDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SpecialtyTherapiesDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Therapies",
        "label": "Specialty Therapies Division [Member]",
        "documentation": "Specialty Therapies Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Tax Authorities",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsChangesinGoodwillDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationReconciliationofAssetsandDepreciationExpensefromSegmentstoConsolidatedDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r317",
      "r428",
      "r433",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r465",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r564",
      "r569",
      "r589",
      "r594",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1356",
      "r1359",
      "r1360",
      "r1367",
      "r1429",
      "r1820",
      "r1824",
      "r1825",
      "r1826",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r332",
      "r333",
      "r334",
      "r382",
      "r414",
      "r418",
      "r420",
      "r422",
      "r430",
      "r431",
      "r507",
      "r610",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r651",
      "r652",
      "r655",
      "r658",
      "r665",
      "r955",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1186",
      "r1208",
      "r1226",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1561",
      "r1611",
      "r1630"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r155",
      "r158",
      "r159",
      "r313",
      "r361",
      "r362",
      "r363",
      "r393",
      "r394",
      "r395",
      "r398",
      "r405",
      "r407",
      "r409",
      "r429",
      "r511",
      "r517",
      "r567",
      "r666",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r878",
      "r888",
      "r889",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r920",
      "r931",
      "r961",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r972",
      "r975",
      "r994",
      "r1098",
      "r1130",
      "r1131",
      "r1132",
      "r1155",
      "r1226"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOutstandingInstrumentsDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r276",
      "r279",
      "r281",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r463",
      "r464",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1169",
      "r1172",
      "r1174",
      "r1240",
      "r1256",
      "r1277",
      "r1304",
      "r1318",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1336",
      "r1378",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1428",
      "r1437",
      "r1722",
      "r1820",
      "r1824",
      "r1825",
      "r1827",
      "r1828",
      "r1829",
      "r1830",
      "r1831",
      "r1832",
      "r1833",
      "r1834",
      "r1835",
      "r1836",
      "r1837",
      "r1838",
      "r1839",
      "r1840",
      "r1841",
      "r1842",
      "r1843",
      "r1844",
      "r1845",
      "r1846",
      "r1847",
      "r1848",
      "r1849",
      "r1852",
      "r1853"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r429",
      "r975",
      "r1032",
      "r1142",
      "r1166",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1186",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1206",
      "r1209",
      "r1210",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1438"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r429",
      "r468",
      "r975",
      "r1032",
      "r1142",
      "r1166",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1186",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1206",
      "r1209",
      "r1210",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1438"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1470",
      "r1481",
      "r1491",
      "r1524"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock purchase and award plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201",
      "r787"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under stock purchase and award plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r154",
      "r155",
      "r201"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount authorized for repurchase",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1721"
     ]
    },
    "mdt_StockRepurchaseProgramAveragePurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "StockRepurchaseProgramAveragePurchasePrice",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average repurchase price (in dollars per share)",
        "label": "Stock Repurchase Program, Average Purchase Price",
        "documentation": "Average purchase price of common shares under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount available for future repurchases",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of ordinary shares",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201",
      "r1150",
      "r1226",
      "r1314"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount repurchased",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r154",
      "r155",
      "r201",
      "r1155",
      "r1226",
      "r1314",
      "r1446"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r159",
      "r187",
      "r1188",
      "r1205",
      "r1227",
      "r1228",
      "r1415",
      "r1447",
      "r1613",
      "r1665",
      "r1797",
      "r1857"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossDetails",
      "http://www.medtronic.com/role/ConsolidatedBalanceSheets",
      "http://www.medtronic.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r104",
      "r313",
      "r314",
      "r362",
      "r393",
      "r394",
      "r395",
      "r398",
      "r405",
      "r407",
      "r511",
      "r517",
      "r567",
      "r666",
      "r859",
      "r860",
      "r873",
      "r874",
      "r875",
      "r878",
      "r888",
      "r889",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r920",
      "r931",
      "r961",
      "r963",
      "r967",
      "r973",
      "r994",
      "r1131",
      "r1132",
      "r1153",
      "r1188",
      "r1205",
      "r1227",
      "r1228",
      "r1316",
      "r1446",
      "r1613",
      "r1665",
      "r1797",
      "r1857"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r381",
      "r650",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r666",
      "r922",
      "r1229",
      "r1230",
      "r1317"
     ]
    },
    "mdt_StructuralHeartAndAorticDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "StructuralHeartAndAorticDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Structural Heart &amp; Aortic",
        "label": "Structural Heart And Aortic Division [Member]",
        "documentation": "Structural Heart And Aortic Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r997"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r997"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r997"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r998"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]",
        "documentation": "Entity in which controlling financial interest is held. Includes, but is not limited to, variable interest entity (VIE) consolidated by primary beneficiary. Excludes entity in which broker-dealer holds controlling financial interest but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r1729",
      "r1805",
      "r1806",
      "r1807"
     ]
    },
    "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfIncomeTaxExaminationsTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Tax Jurisdictions Which Remain Subject to Examination",
        "label": "Summary of Income Tax Examinations [Table Text Block]",
        "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded."
       }
      }
     },
     "auth_ref": [
      "r1767"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
      "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier finance program",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Supplier Finance Program, Obligation",
        "documentation": "Amount of obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r1369"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationDecreaseSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationDecreaseSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Confirmed invoices paid during the year",
        "label": "Supplier Finance Program, Obligation, Settlement",
        "documentation": "Amount of decrease in obligation for supplier finance program from settlement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1369"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationIncrease",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invoices confirmed during the year",
        "label": "Supplier Finance Program, Obligation, Addition",
        "documentation": "Amount of increase in obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r1369"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationRollForward",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation [Roll Forward]",
        "label": "Supplier Finance Program, Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsSupplierFinancingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]",
        "label": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_SupplierFinanceProgramTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramTableTextBlock",
     "presentation": [
      "http://www.medtronic.com/role/FinancingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program",
        "label": "Supplier Finance Program [Table Text Block]",
        "documentation": "Tabular disclosure of supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r1369",
      "r1702"
     ]
    },
    "mdt_SurgicalInnovationsDivisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "SurgicalInnovationsDivisionMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surgical &amp; Endoscopy",
        "label": "Surgical Innovations Division [Member]",
        "documentation": "Surgical Innovations Division [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsAcquisitionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology-Based Intangible Assets",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1687",
      "r1689",
      "r1692",
      "r1693"
     ]
    },
    "mdt_TotalOtherCountriesExcludingIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "TotalOtherCountriesExcludingIrelandMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other countries, excluding Ireland",
        "label": "Total Other Countries, Excluding Ireland [Member]",
        "documentation": "Total Other Countries, Excluding Ireland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_TotalOtherCountriesExcludingUnitedStatesandIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "TotalOtherCountriesExcludingUnitedStatesandIrelandMember",
     "presentation": [
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of world",
        "label": "Total Other Countries, Excluding United States and Ireland [Member]",
        "documentation": "Total Other Countries, Excluding United States and Ireland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_TotalReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "TotalReportableSegmentsMember",
     "presentation": [
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbySegmentandDivisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment net sales",
        "label": "Total Reportable Segments [Member]",
        "documentation": "Total Reportable Segments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TotalReturnSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TotalReturnSwapMember",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementClassificationandFairValueAmountsofDerivativeInstrumentsinBalanceSheetsDetails",
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementOffsettingAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total return swaps",
        "label": "Total Return Swap [Member]",
        "documentation": "Contracts in which one party makes payments at a fixed or variable rate while the counterparty makes payments based on an asset, including the income and capital gains derived therefrom."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r1442",
      "r1443"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1509"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1516"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r1640",
      "r1641",
      "r1642"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and tradenames",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1689",
      "r1691",
      "r1692",
      "r1693"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1537"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1539"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medtronic.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsGainsandLossesonEquityandOtherInvestmentsDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r646",
      "r663",
      "r921",
      "r950",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1099",
      "r1402",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1416",
      "r1573",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1781",
      "r1784",
      "r1785",
      "r1786",
      "r1793",
      "r1796"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1540"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1539"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1539"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1542"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1540"
     ]
    },
    "mdt_TwoThousandTwentyOneStockAwardAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "TwoThousandTwentyOneStockAwardAndIncentivePlanMember",
     "presentation": [
      "http://www.medtronic.com/role/StockPurchaseandAwardPlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Stock Award and Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty One Stock Award and Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.medtronic.com/role/RestructuringChargesActivityRelatedtoRestructuringProgramsDetails",
      "http://www.medtronic.com/role/RestructuringChargesClassificationofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r592",
      "r593"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.medtronic.com/role/RetirementBenefitPlansActuarialAssumptionsandPlanAssetsTargetAllocationsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansChangeinBenefitObligationandFundedStatusDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFairValueMeasurementDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansFutureBenefitPaymentsDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNarrativeDetails",
      "http://www.medtronic.com/role/RetirementBenefitPlansNetPeriodicCostandAOCIDetails",
      "http://www.medtronic.com/role/RevenueDisaggregationofNetSalesbyMarketGeographyforEachSegmentDetails",
      "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandPropertyPlantandEquipmentNetbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Pension Benefits",
        "terseLabel": "UNITED STATES",
        "netLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsAvailableForSaleSecuritiesinContinuousUnrealizedLossPositionDetails",
      "http://www.medtronic.com/role/FinancialInstrumentsInvestmentsbyCategoryandRelatedBalanceSheetClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1384",
      "r1816"
     ]
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undistributed earnings from non-U.S. subsidiaries",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r245",
      "r820"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1536"
     ]
    },
    "mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on interest rate cash flow hedges",
        "label": "Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net unrealized losses on equity and other investments still held",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails",
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "periodStartLabel": "Gross unrecognized tax benefits at beginning of fiscal year",
        "periodEndLabel": "Gross unrecognized tax benefits at end of fiscal year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r840",
      "r1397"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1397"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r1397"
     ]
    },
    "mdt_UnrecognizedTaxBenefitsGrossDecreasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "UnrecognizedTaxBenefitsGrossDecreasesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross decreases:",
        "label": "Unrecognized Tax Benefits Gross Decreases [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_UnrecognizedTaxBenefitsGrossIncreasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "UnrecognizedTaxBenefitsGrossIncreasesAbstract",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increases:",
        "label": "Unrecognized Tax Benefits Gross Increases [Abstract]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income tax penalties and interest",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r1397"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1397"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1397"
     ]
    },
    "mdt_UnrecognizedTaxBenefitsNetofCashAdvancePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "UnrecognizedTaxBenefitsNetofCashAdvancePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits at end of fiscal year, net of cash advance",
        "label": "Unrecognized Tax Benefits, Net of Cash Advance Paid",
        "documentation": "Unrecognized Tax Benefits, Net of Cash Advance Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Statute of limitation lapses",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r1397"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.medtronic.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r250",
      "r251",
      "r253",
      "r254"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Valuation Allowance",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other Changes (Debit) Credit, Adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment."
       }
      }
     },
     "auth_ref": [
      "r1622"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at Beginning of Fiscal Year",
        "periodEndLabel": "Balance at End of Fiscal Year",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r391"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges to Income",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges to Other Accounts",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other Changes (Debit) Credit",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.medtronic.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "mdt_VentilatorProductLineExitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20250425",
     "localname": "VentilatorProductLineExitMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsDisposalActivityDetails",
      "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ventilator Product Line Exit",
        "label": "Ventilator Product Line Exit [Member]",
        "documentation": "Ventilator Product Line Exit"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1505"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.medtronic.com/role/AcquisitionsDispositionsandFundedResearchandDevelopmentArrangementsFairValueMeasurementContingentConsiderationSignificantUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1014",
      "r1331",
      "r1332",
      "r1406",
      "r1810",
      "r1812",
      "r1815"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average shares outstanding (in shares)",
        "totalLabel": "Diluted \u2013 weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r422"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.medtronic.com/role/ConsolidatedStatementsofIncome",
      "http://www.medtronic.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average shares outstanding (in shares)",
        "verboseLabel": "Basic - weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r422"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "60",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "68B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-68B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(dd)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r1703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27"
  },
  "r1724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r1733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r1734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r1736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>168
<FILENAME>0001613103-25-000091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001613103-25-000091-xbrl.zip
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MYKLNZ?L<K.T#[7(POD.*XWF/9IC8:(-[(: 1O[L97$&T,*8W_,P?3S@=42^
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MV:R+HE[P=@G5FZ_Q3X*K%V\)WI3/O]#V5(O>T_[7A"#:G[R)T;=U8H6QSDT
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MYA'WGMHCSW?](:-!J>/HCLX$WMYAI!@[W]&9Q]L[C!3C:SHZTWF[Q4AO0FW
M2#B]QU1K4GH/HS.7MR?(*,BOZ,SA[0DR"O(F.G-WNT6&>-O8=W!Q!%Q=;E>B
M,V&W#[ HR(_HS!/N RP*<B(ZTY.;PD)3@[Y/#*6>QK5:V2>&4$]+5ZWHS-!]
MHPZSB=N+^!#_W6X>%;_DRO/\!^$"RTV^5"LZ\W+[@8RB[+K.O-Q^(*,H;Z(S
M+[=+9'3M**1GA--OOL="GY=U 6ZUHC,?5VY$%.4]=*;BRHV(HKR&SBS<9HC0
MU8KK3(CM5D)%656=^;#=2J@@*U?5F0T[9Z1/0QJ4EU"N5G5FPG8IGX(L7%5G
M/FJ7\BG*OBG'"N%^/F>^%_@N<P3[<@5B6M@C[P;Z"+]YPT1FN87TKX/BW@^)
M>T<G/@])WZ5KMD!7\ZH<-63@H9)U5XXG,O!0R;DH1QJI#(]T[V/7%7L>E]RS
M*$<?&6PHXU:4(ZX,-I3Q*<I19B]A8^FW"Y>-F2>KRN4T[#7E&#-5!520=:TI
M1YFI*J""3%Q-.<X,A9!ZH5^H/^1D,D+27\K(]B,OY-/3[[VW.SN5/>R>[+]2
MK2E)!AK@E7UCF6I-29K1 *_L.^94:TH2F"\ #P4CS@22$=#[)S,9%"K@=Y7D
M20T*]\P)*\G(&A3NF4=6DOO=\U!P/U8G5VM*<LL&>_NP[+JN)&UNL+</R\GK
M2E8$3.2W=PZXKEOEPP"QI-Y8MTJ( 6))7;.IC*B'O;U8/5K7K31BD%<6YZM;
M.<0@KRS>UI1 # P5<+VZU4 ,#$OIAW4KAQ@8EM$I-TQE1#WD[<'6(@W=JB(&
M=Z5PNPW=BB &=^7PLZ;F84!8N-/5K=YA0%A"#ZQ;Z<. L(3NV%1!U,/=7FW^
MUM"M&F(06#9'K%LAQ""P;%[8U$ ,'-5QR4W=:B$&CF7VSTW=2B0&CF5VUDU3
M.5$+@?NUI6U3MP**@5^IG+%NI1,#OU(Y7U,T,5A4Q1/K5CLQ6"RO6]:MBF*P
M6%X?;>HI\_#;P_WYF[I5-,J,@8)\4DNW,D*9,5"0+V@9[EY10!3D&%JZL>=[
M XBBO(1N?/;> *(HEU%"AEE78ZT;V[H#411E)G4C&W<@BJ(,5-FY-EVME6Z\
MTZ[E4I3ITHT+VK5<"K)C;>7XF80G_T)<XMFT-Z(T_.K;0@HST0@*O6O;/*+.
MQ=,$;J9;"(69!W* :Y>-5/++VP9=.4+D]4%/RQ>V<.K!';4I>\"9?OH,NW*T
M@Z)87S#\[QMTY5)[9;&>Z[ KET"O/^P"[U\9Z3.7A4PGNZY<JJSHH.>*=.62
MXG30XWD 7?N/B 5L><Q[T$\:W RN/(<],"<BKCN]&H\AF..,N"MN+VD]H*U<
M,JV5"+=ES91+I8N3RMI-NV0>"^E7]D =R!Z)-V00-72#@(;!E^DW\KO/SUP2
M+$P)NO)NN6]#B^YH0 FW1UW0)OI 77^"(Z,/8I1+\K728Q5XFA-U^0 =1+BE
M&.=$7<+ F&(U$:,NUU$RQ-Q3>^3YKC^<?B'!\HWZ($99HN:<!1,_(*[8@DM(
M !ZX*H>=N_#:#^$S=I)Y$77B:=\YHN7*L_TQG<WZSJ388#2ZCL-DX0!;X?I!
MQ"F@:*Z) 3S"C1SF#5>W=$8!_H:CZ)+0YV">G,@.OX(27#RQ+1BDQ82P=E1;
MJRJQ<.G[HA!EV2N#Q5UB<=[49>'U/E.G+$]GX%68J2LJX5*6OMRET.\H/.B,
M<-KSW2@7Z,Y/FJ3.!0XNQ)69(RW\_T" GY>*[%9S<P%[I;H.V!<N?1_8E25Z
M#=A+!?9,X+" W_<%#LI1XBCYFT>/\F#$)AN*6Z%Q58XXSDFCU!GBCK+$KC&]
MZ[[GCGA#.EL3\HT\L7$TU@>"RK+8"Q!\889$NGN O"6>CJ5CGK6Q*KPWYBQH
MAFM'.2:\.)^=9[&WHRQ??"9@/X2;T###$R7VOTSOIQ.:58 '"LKQC;DT"'TO
M-R6^)(S_1MR(?IFF?_X*'<)JTO0KUI+F[4IZT94WB<) 7%'?0F.^48(6 P?S
MDM,_(NK9TV=:DKD4)S]&G,-XZH-,9=GCW4GC3?$$\]:()XP:OJ$Q&1&*Q\^&
MX+DKA/N.O/ .')\^FJ<LL:ZXYJT5R1O-,YKWK.8I6T906_/^0=EP!&E[]P'P
M.<Q-!8P&[I\&*EO;6!.,<;DU.]NMU+C<R]1(N0*&'FZBF !MWS1R7SR%<M4N
M/92PV%C-*&,9E;%64;8NJA0:]C!8JE64K5<::+P!&CDNEH"G&6B4"!H+]>;W
M04/9NJB!QIOF+12S*4*MHD,5T^!(]04&M8JR-3G,*&X&7<XQS<-[YX5UYKLN
MZ?N8C3W0S%7W\%= ;,S1_L'"T2T,X_3>?^YJ?:)-92LX=Y#E<DA](U226Y=D
MMB:[P!T2)YP%].+)IJX+*J=1ZJ<L8__"B/?8&.Y.9MO/7\AQ$\OMS@?-=?RW
M3D:_P=57UW3UN9IH90G!M2;&GOE!>#/H$7<;NX8I,(6T5E66(U),/@6%.%5E
MB1K%Y%-0*E-5EBU92SX]"&S O?Y"/<AQ7#$1?\P\!IY7!)L76]N250G9*4MG
M:"2[HOR6LA2"1K(KRJ<IF[;/Y1SHNT RN%L6?\A42T' DEXA[CD=,(\Z7T",
M Q;&G[#HREE?+#R"^V_A,7<T9/*>LQ'AP](JI1YY_BK!)A=>0 KJ3RGM4:S$
M;SOESY.<K^J1\C^G5=T@\&V&RTSA5[$>$:_<P?KYO(9?V>EG*F%?"?>C+"6A
MEJ*H(*N:LO2$2EJUI9D -66Y![4495O#KRRUH!+V52 2:LH2"6HIBA*R4I8X
M4$FKME06J^F=^1?A47(=?F7S\SSFW51SFW?#/- J1MPK#T&Q/'WC>^\7'U3/
M$[\,*5Q+@W/:#WLXW4:K<YUJ-659 Z4@\?HA4U?> Y@0,>O*X/ -.%26/M$,
MA_)$Q77VYS<X7(5#9<FA/'!8VQDDSGP^P1F+5%,<U)4EGI3"@9I^47OP*4N\
M:0:^(IRA]N!3EG94"GS[%!35E>4WE8*$FLZP3#A4EKO5#(<F27P?#I6EL97"
MX:N0^.;S<$B&] NQ?U!'1R"4FE ON6/4'WVEYNY+[@[U1U^I&?O=.<%+GU,V
M]&;!D:Y!D6'.]?6%90%AP]#V^KK$TH#0T/>YX$' 3]OXJ&%X='W]H>;0,WR]
MOEY0<^CM-46OD!P,1;UK[Z.0\ TMO6O[KY#P2\T*Y[>YYJM^.!+[,.*.[SKZ
MX5*SL[FA0-'L0V_HE9H(WB'T"LD^M(9>4UGZMYR!9E-9IK.<L5VSU)SBWBS@
MS'.7B&:IN3ZS@%,;')::^#,+.+7!H2$^<X%$$<N8<L6!X4#U]8O:@Z_4'*R2
M!+P!7PJ^4E._>[. ,U=(E)J2+;DS+!$.6\KRLYKAT"2)[\.ALKRU4CA4<Q%3
MKD H-:%><L>H/_I*S=V7W!WJC[Y2,_;[L8 S5SP8YEQ?7U@:$!K:7E^76!H0
M&OH^G\F$.U_*E"L*#(^NKS_4''J&K]?7"^H-O?9>4_0*R<%0U+OV/@H)W]#2
MN[;_"@F_U*QPF1=PYHJ"4K.S9@&GRM K-1%L%G"J##UEZ=^2!IK*,ITEC>W4
MY115G!:=Y]K9MKJ<FN(S[_*4PHFZ])*2$SYR'7MU*27U.-5<!UY=.D>]<#+7
M@5>72E'1W>89Z9RHRU\H[FYSE8*ZJ;R2[C;7L5<VEU70W>8Z\,HFM0JZVUP'
M7K_L=NR$IQ=_1-#6K=(W,*@\/ >ISH:\G3XG_2T=.R>Y="$82GYYFW3T2X"+
MD$Y=#'EG'>DLZ,Z[I--1-C'NC< 3WU,^QACH?CJA\R;KV@]I<$NFI._2>_\+
M\7[HDQ]TE,V(%1OT/+U$1]EL&,=ZE0GJ48_Y7(QYK5+MG$<4AJ0%4*S<4F[#
MI7E5=[[ZWC!\5NB99NBC8<IFX/LL;!7"D8ZR!,$^(V-;-E]9'F(M8=<JB;"/
MH16EE':N1E]9YF.OI:V$U5>6F]EK:&S+["M+"*TG[5HL[=IQJ]8LI;1S-?O*
M$DQ[+6T%S'Z]HBR[M=?0V([9KU>4I=6>DW87$KIFUW/0PY_YXS%(F!'WED"W
M;[D_Y&2<E[1?(?867KY-D5=!P:NYB5Q94D^= <_3V=8KRA)K10^X$OY.67*K
M:.ELR^4H2S 5/> *%#?K%>4(H8"'IW?$&\;2P(_?F,?&46D<O1)RUX[MZ<)'
MASK$<^XHC%)(X=\'WWU@WO",4X>%W2&G=)QC^"\?>TELYL( S8/D*_/HS4!>
ML5537#^JUN#_\C'%VI$^^R3T!;,P)_:7S,+"I>\S"]H11?N$D"TE+%7M** ]
M%7J>87E5.R9H99&_7:V6E/;+5<.5Y8#V6=@JT"%59<FJ?4;&MFR^LMS7>K6>
MNA3V2>.XK#.[<C7ZRA)O>RUM):R^<JR?@<86S;YV7-_*$G^G7MJ97;F:?>U(
MOKV0MA)F7SMV;R^@L26S7]..UELYH;=3J;?+F=KE:?5K>M-Y)16V"D:_IC?W
M5U)D;,OFZTWGU1I"V/5*_;A5TL0N5Z.O.9]74FDK8?4U)_]*"HUMF7V]^;RX
MBE.O5LNZAB-7JZ\WG5=282MA]/6F_DJ*C&W9?+W)O$38M6I9N;P\;7Y=;RZO
MI,)6P>;7]2;^2HJ,+=G\NN9<7BT6=OVXK-.U<C7ZFI-Y)96V$E9?<^:OI-#8
MEMG7G,R3)1P(8MLEY?)RM?IZ<WDE%;821E]OXJ^DR-B6S=>;RXNGZ$*@<MPL
M:6*7J]'7F\PKJ[15L/H-O:F_LD)C2V:_H3>=ER1VS?IQ6:=KY6GV&^7@\\HF
M;27,?CG(O[)!8UMF7V\^K]J,I=THK;1S-?MZ\WEEE;829E]O]J^LT-B6V=><
MT8MGZ;;KQR<EE7:N9E]S2J^DTE;"[&O._Y44&ELR^TWM*+VSJ\M>=T[DE;84
M^4GKN%G2<DZ>MK^I':^W/R)7P0$TM6,"]P<?V_(">C-\R<S=3JVL>S#E:O\U
M)_C**6PE++_F9& YD;$MFZ\WO5=)A-TJ:RT_5YNO-[M74F$K8?/U9@)+BHQM
MV7R]N;W8P3<JU;(*.T^;W]*.VML'8:M@\UO:,8#[@(PMV?R6=G3>O+ KL;";
M927R<K7YFA-YY12V$C9?<]:OG,C8ELW7F\B+E^<UJM6RSMS*U>;K3>255-A*
MV'R]6;^2(F-;-E]O(J\J5VDT:HVR)G6YVGS-B;QR"EL%F]_6G/4K)S*V9//;
MFA-Y<D%VH]XHZXY[>=K\MN9$7CF%K83-UYSU*R<RMF7S]2;RXO49C4;CN%I2
M)B]7HZ\YDU=2:2MA]37G_4H*C6V9?;VYO&HJ[;(>J)"KU=><RRNGL)4P^IH3
M?^5$QI9L_HGF7)[<@:/1+*VP\[3Y)YIS>>44M@HV_T1SXJ^<R-B6S=><RY-S
M<YN5:EEWUL[5YNO-Y954V$K8?+UYOY(B8ULV7W,F3\[3:I;WL,Q<;;[>1%Y)
MA:V$S=>;]2LI,K9E\_4F\N+J3;/$U9L\C7Y';R:OK-)6P>IW].;]R@J-+9G]
MCG9<WC?JA-SWF/TU>K+]]<=</R&WCNJ5?(2L'8=79B$O&OFLF%\R\@N7OL_(
M*T?T.92=?J5#XEZ(]CP'A;SDWQOY/+Q_%@!??>(%MV1*^B[=JIK7A2T_R4?-
ME>/H]DFH<VI=0[&NI]8+"'B?6NM-W,65N5JS7MH#\7+5=[V9N[=(6Z'!UYL<
M*ZNJ*6&%]:;2JG*O\EJ[?EPO:0:=HR%H5/2FTMXB;84&7V^RJJRJIH 5;E24
M9;;4L($YEA,:%64))C7&.D?&ME%1CKJ9F3S.'DC('NC,\-VQX,?\F%_ZG+*A
M=_%DCX@WI&?0.T[LW*S>JD8$OQ#F??6#X,OT5^H,F3>\HRY<XWO!B$WFFW=&
M@M&EZS_&%^;5K/AQYS2 OHM7S[\V^8$ZW2"^=M;^4A::&A7EZ*I2 ?F2,/X;
M<2-:;B1ORZ,IS*09<&H(SEQ# (6)OQ* <S]"@&T93H5Y48--_;"9J]U4F)@M
M 3:O:7CE/= @Q!OW!J!Y&L^JPERR :BF ,W3@E85YMM? B@R[S$XSR+.J6=/
MSZGGCYF0")*#!J.E,:+*$O\&HSIC-%<[JFS!1 E'_QH(KGW/27&@CV$RE1L]
MA)ZKIBM7Y0AX>-H+81#Q^E^H/^1D,F(V<>5PX\\7$?<GK\V1U0M=QN<5;OZ4
M*ZF\H@FV'P$&IZ=_NS4Z8'0@'QTPE1L=RXI7GNV/:6HJOOKV"H3>A"/*;P .
M\!N"$V^Y>)K L[:]VJ2@"1Q54^HQ8,X=S'(.:&<=,"_$Z>\#LZD-&3"79>YS
MS=21-"S"*X[E@J*,FJ8E)X-EA;%<4)!1T[0T9;"L,):+BC%,":NL6#[S@_!F
MT"-N2?<X:]1,)<Y@5]<80KF"HL&N=M@M*F90K@1HIF9IZ\,U+:49+"GH4S6M
M9!DL*>CC3"&I9$ JR,'531&G9$ JR+O5306E9$ JR+75E2U?;)FB5P+0NKHQ
M9>L$!C3JNBQE"7H#&G7=DV'&BYIAOW8COA"7>#;MC2A]1G=N.9T0YL3J$G0]
M1VB3Y#?";A#04)^-,>N:$MX&DDI!,L\%B75->7,#R83Q%>#KVC:/:(I)?2RB
MIE2[@5]A\,O5^AEV7F/XS>57FH6"#4/G&^058O,:AO\O"_*^,M)G+@N91A%?
M0]FJ@8&?HO#+U?HI6W_8CRTO&LI2^>J.?Z[X-ZSX>T"PR:YC.9K;PBG'7$V
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M?P?X5[8D:#)3@_\=X%_9\J3)1XU*%*$2K8JIGFH-.3E9$R&G#?/1JIBBJ5&
MO58 4RLU"K#7"F!*I$8!]EH!3&74Z(31B7F=, 51K3%WR9ZH<^79_IAJ!CQ3
M%C5:8+3 %$>-%A@M,"52HP5&"TRAU"B&48QEQ:B:<JF6P,,%SK>$AQ[EP8A-
MOGM,GYGBK:JIEQH-V&\-, 53HP'[K0&F8FHT8+\UP)1,C5(8I5A0"F5KIB8U
MV((&* 2\4M=,342N+O!*7:8T@;"ZP"M?9=#$G[IB4=GZ7%EDO9U<([EIYQO7
MY+CA:JNF; W,Y!Q&$W:J":4NS)DDR&C"VII0Z@*=R<J,)JRM">4KU)DTT2A'
M3LJA; W/@$^A#6YRA9RID!G\[S/^3:'.X'^?\6_JA0;_^XQ_4[8T*F%48DXE
M3/54:\CM:G.;/#%7-T53HP![K0"F5FH48*\5P)1(C0+LM0*8RJC1":,3\SIA
M"J):8VZG&]GD"CQ3%C5:8+3 %$>-%A@M,"52HP5&"TRAU"B&48P5BF'*I5H"
M;^<;V^0)NH:IEQH-V&\-, 53HP'[K0&F8FHT8+\UP)1,C5(8I5A0"F5KIB8U
MV((&* 2\4M=,342N+O!*7:8T@;"ZP"M?9=#$G[IB4=GZW!JR3F'H<\J&0@[;
M09H6J<<=';(@I!SK8<DF-F?^>$*\Z5;AF.<6K UEJV*Z92%&-\JF&\U2%^]V
MF2@9W2B=;I2ZK+?+7,[H1NETHWP%/W723:,NI5,79:N#!HX;PO'* RM!/)N>
M@8@YL;=+R^0*0E.-,QIA-"*K$:9,:#3":$16(TS]TFB$T8BL1IC"JE$2HR2O
M*(FR%5^36J@^\R!7'):ZU&L">EUPV"IU6=6$T=K@L'PE3!.\E@2:RE802RKZ
M[>4M157H\IRSVE*V0F<R&*,;!>M&J0N')JLRNO$.W2AU"=%D>D8WWJ$;Y2LF
MFNS3J,O6U$792J.!H]*5O%Q!:"IY1B.,1F0UPM04C488C<AH1-M4-XU&&(W(
M:H2ILQHE,4KRBI(H6_$UJ87J,P]RQ6&I2[TFH-<&AZ4NJYHP6AL<EJ^$:8+7
MDD!3V0KB:X-_$XXHO_6#D*<79F+\K<L#QIR'YY ^S"323I^3_I8.K9-<NC##
M,_GE;<+3I)ZEMO#J0B*==82WH'GO$YZR=2"=A%=#B=0KZPA/RODD'^$I6[)0
M7'A;FNM^HBQAKH\\\@PK3I2E:WLA*#W><_%'!.W"*2R^!Q\73JCLVG8TCERX
MUH$ ][O'*7'9?[*37WXAS/OJ!]L]*Z0V[YO>)Q-EV<'-97+/03=<F04XOT=2
M(OI(0EE^;%U)^#8[AQX_@ 0>Z/]&H!N#*?.&W>!7Z@SIQ9/M1@YUTMMO(274
M23[*\D:;:\IR^2/046.495 VETCB.*ZQ_!2,+EW_46B-;DJB+'.@@8M7(8<Y
M498]4#8>4$)LRO(&F@4/2@A361Y!^4A#!?%UE*4=U ]+E)"?H2ERB2L79/*N
MN+)C: I5)&%H"K7E8V@*U21B: KE1&)H"KWKY!U#4V@I-D-3E$B8AJ;06'SM
MBJ$I]):?H2E4F^'2KAB:0A5)&)I";?D8FD(UB1B:0CF1&)I"Z[48[8JA*;04
MFZ$I2B1,0U/H++ZJH2GTEI^A*51;&-6N&II"%4D8FD)M^1B:0C6)&)I".9$H
M1U,$/#S]RD(V%'X!QI;.=G([\UW6YVS[1:':426=K?+*W-7LI>^+MI0E'&;B
M0#V)%I3B%GH-7F-VT2OB>1<"?J7<8^0;#4;YO2\U E$_H']$: 4>X#_+2[L7
M+M@R#)OK3Z%>N/1],%2.0$$\I ;Z%^H/.9F,F$WBK8R"<,)/OW7?+W\#\WV"
MN7+4TEHPOS8P-S#? .8U92DX \,=P7 Q<Y@AZUV90TTY<G = WKVCCCA)0B=
M,]*G(0UNH_'DCH:0'%)^ERN 5054,Z>)_>V:<LRF 50QCC(+J5<<93.GE:/M
MVM;9W"T6?>#2=EYS4VO*T::H)F>X4:S+'('\*]#(A7CA!OH(OWG#GGSL:P6=
M];4CT?\O40 Z& 3)"S*L%.$.\Q](8$<NX>4L!=:4HVY51\4UC;@?V(QZ-OV%
M^]&DI,!0DD!6&1C?J(,Q1"_B0_RWI+!0CLQ6'19)P%=F6Z$DM9PW*'05CI*$
MJ,H:*W;ZC;\N)R;JRK&'ZV#B&_27,^+>4>B.S5Q A[BJI#)2DH=366]WFJ\5
MM,*TKB29IC(J=IVO%04,Y68MJ@Z,W>9K1<'"L'X*YVM%@6(O2#]=A6.(-W7S
MM:(PH27K5E"^5I2,]H($TS9?*V;CXG;=L&^*YVL% :.A)06W/_E:4; PK)_"
M^5I1H-@+TD]7X1CB3=U\K2A,:,FZ%92O%26CO2#!=,K7MK04NF$(-74%G>?6
M? TM6;*2Y]K;4FK#MBDMZUSUVG!HJE$E6]+JIB'%%)9TGCK=-#R76CS7MC1Z
M+Z@K/>6<JS[O!0NFD%YIR3#M=KQSQ;=ABS:P8^F^>JZ;)7LU4B_#&:DN[ERU
M6TOFZ,SG$Q\$3J]];VOEE&TIF);\S:Y'/%>,:\FB[&3$55CNU=*2^MB]> J:
MW=G2DJ_8O7@**N:VE*097MACRO8C+^33TZN+TADR)9F 8D51E-%2DB0H5A1%
M&2@E^8.=BV)+V41+R72]R-'-,W-H*9D=KS&ZWWLZ8%?)3+C(T<T5NTIFO2^,
M+I: [OV02";M3(PUHX$\M(=YP^\>"ZDC'A 0S[GBU(5_RID3MY7,B7437D'!
M9UO)C%DWX144KK9URZ=5$=Z6@H2V;DFU@O+(,ZQHZY99OR:/<L<1NB7?:DBK
MJ,!!MV1>#6D5%2GH1@X4)JUMA0:Z\0<J""#76&#K%,.FI@#@5<W :U=N]D2Y
M=#VI@_Y&W$@>1^VZ_B/Q;!IT/>>.!I0_T&#Y9)3TLDN?GW'JL'#K9XGGB<@3
MY5)OU06A0I1ZHES.K;K4MN113Y1+MC42Q$)L^3Y!*)=EJRX(%?*W$^6R;=6E
MEE&?VKS,WJ<^RB72J@M"A83Z1+F$^JU26[[^9G!.!Y2#!._)4S<(J$9K!$Z4
MR[,UDXL2,;9RTP$T$^*60NY.::B#XN629P3>*0V3H(+1*R@@[Y2&6"A>N?*,
MSSNEX1E44*[MA^L?V=,IIX$?<1@/^7%$B2,:[["'SS_#?X1LF5UMD':S0D^J
MG9-&OWI"6NU.'[ZIMQKX>OIO-*NS>X)PZH*,Q\P[&E$V'(6G]>IQ<Q)^>F1.
M.#JM5BK_YT!<^?GG8$*\SS_W^4>X7_XM'[/TL EQL)ARY-)!>%H]@8<EWW#Q
M!O$5]NN(N&SHG=HPT)3+;YB'&#JMMR8AO#<D?9<FC^W['#I\9/NN2R8!/4W^
M^.2P8.*2*6B$RSQZ)&[Z-"9\")WJ^V'HCT^Q1P^4AU@*BM\J7B=_GG7VN"([
M',+ AD[RYOCG8_CIX_+WG9/C3F7U3Y7CJOC^HW@>3WY,1EKVT;&@)SB@?SVH
M'RQT-FY^=1):8K65]:>*^-^G^/?0GYS6EGZ,A_NT8L&-Z?L_BH%9)7PY5/BL
MUBK)'$C9)Y=#:WU^FKQK ! ]&I Q<Z>G?[D'?0ZL:_IHW?ECXOWE,"!>< 2J
MRP;RPH#]AYYVX"7BTZ,<AS8\1D@N'I=J#67P_?KJ_N+<ZMUW[R]Z\XC+M%V1
MQO8NSK[?7=U?7?2L[O6Y=?'/LU^[U[]<6&<WW[Y=]7I7-]>J]^ ?)!@!9D+?
M.[3.C\^.K5JEV>@\V^IY]4+8[!I%U?9:_;J\N?MF_0SVTO.]ZV@,#[&MV*S>
MT0$ZP^J!Y1%T= YEI^>^':$30$=S("SJ "[X7*T<_5U8W=E3/EOY#LYN;5T'
MK%FKM:FI:Q[7&[47+=W:1K-VW&B>K&,TG[.0B9&K39[0S&7'%!W/TA#XD_41
M^ ]X,#X\>*M*22^R,>JZGA?A)L@3GX<'UL#G8Q*"3W\*3P?LB3I'(8]25$)D
M_><_==J-UJ=%8*:X#)V<!D]")QL([,XZB:&4 V-Q,3+6).)!!+&O%?H6A*08
M_5G5NN5SJ]K\X/QD^0,K'%&K1^V(LY!!*RZ>[!'QAM3JVB'^7.W4&\=+^EM(
MURZAV=C: 0M@P*TI)=R"L) Z;[!:MR)\O)!!Y3R '/CF: R/&.%M1PZ9'N&K
MCJB7 *J^"6+/(@BPO?!2-/I?\*!U7SI[7P/$.N',_?.?JJW*)V1SYF%\:"'3
ML_CM@M0$Q@NT%&]#0F,E$N1 Y*^]*G5H#XWZ/8>W,312SQOV 7&#U+(W8\O>
MV*5E+\#RS09FE6'OO<.P8Y*:V-5P]A:975L#[H^M?Z?_PY?-/BVC=9V\J:Y.
MWG3FC\<L0%+%NF0045[[QQMXD@O!>>"-<'$?^A!CL@4Q\%&]=5*K/(O)EZ/@
MYT:(C8=6P&VXW F/T.!7&K7FOX?5X]\GPP.+N*'XQ?6'?JU?:<IOY]/H:J4Z
M>7I+#-QHG$R>9 <9C,+'O!.4RFM&LA8;R7;CTVNCJ!C(-@74'1VR #4QO(9?
M$E"U#SY_HT[(?0^>,7'M3:%5V*"LEN2'BR<"5@C[CJ:(IWVV2& %$VHC->I8
MS+-8&%A@MS@T]:>DDSKD?_63X]I),Y<$L-HY/JFW<WD4M*K9WE8N&9.3NP^I
MWAM^2,6[\NQX(R9P"&)FO)SU/CWSG?E@'1IDGU)G2/B$^P_Q2OM9M'YR\#F>
M'9]O4"(H894CUGU#S#UYNHKK.+9 S7P@T#GXW#DYJE9/ZHV3DQ>AH*'.K0;%
M!Z$W&(7ZN&S$^AV"S\!A,CP%0\^R.B8NXT/BL?^(SS\9]5!;N%?'=\>]8^MB
M/'']*4AW'OP8/O^D<$ZP%&3F$Z]U'8?3((C_^0K/JZ9L>.7@\Y>(N2A?Z_[1
M/[1N"?\Q]CFUDBUZQ3?6/V@0;LR9EV3@SN#/&W[O/Z;^LUH]^/P+<1_)=)GG
M>NM+I(]>]N*Q\\;;9@Z\6GO=@Q=>FWHFL(X[C,9VPL'<L@EQ+?I$[2AD#QAL
M@[K2X*?GT:5(VO0_&Q"L4H:8./DS&=8//M>;]66M6O^Q"!].B0S_XJ<V(+E_
MQS._^F#';T>^M\ 95)L'GQMU"!9@,+2#W"QC_4M@A=2E$^R@Y8D>'J+/ETM&
M+0*C":/CT)\V[M.JV13J@3;#MLF4EG+(8E=2=;4/_92DZ]KAZ49=TV*R1Z-^
MW'YELL?:&7 [MT?5F\?U]::@Z!2P/<,:L] 5_ HE]LBR71($F@:DS[+BPJ[T
MIN.^[Y:J:]<Q,R8D1Q/F'@S'XXC!-S/KLDD>F9D)M3Q-2I^Q6=_=QO9X6JWU
MA2ZD[K9U\/F&0W<)GUK!"/Q2<&A-"+<>B!M1Z[^%O:MB$43^^@8>9^_&.E9&
MJ8OI0"-O?7YOQF]]K"9E.LG^+[&.\.M"LG("U@+:^B\?$LE>Z-L_TDI?V3BG
M-PQQ;2UST#GX7#FN-2O_!^(SC_G<NO9#:)\#MF#5Q(I2>9KUAV^EAM<J0L,_
MFE%ZIQ[7JD:/GQ_B^CIZ7*NA'F.J8O3XA>%;K<?U1(^[9IC>I\@-H\C/#W%C
M+45N'GRN';=J3:/(+PW?:D5N)8K\Q0S3^Q2Y;13Y^2%NKJ7(D)Q4CZO/*7)[
M?Q':?%V1.[$BFU%ZGQ[7*T:/GQ_BUCIZ7*]B9%UO/Z/'+\]NV9_A6ZG']5JL
MQV:4WJG'=:/'SP]Q>RT]AMRD_GR&O,<(;;^NQ\U$C_<X0UZ)LHT5N644^?DA
M/EE+D=NHR*WG*.O._B+TY'5%/HD5V8S2._6X8_3X^2'NK*/'C0HFR,\Q7?6E
MN6;[@]#.JWK<J$H]-J/T3CUNU(P>OU"EKZRER'54Y.<BZWV&Z/SXK=;D1J+)
M>QQ:K\;9QKK<-+K\PABO-3VLT<+@^CG6>J]U^?4I7XUVHLM[7']:C;.-==E,
M[7IIC->:V]40<[O:SR3*]=H>8_3UR5W->'*7&:;WJG+3S.YZ:8S7FM[5K*%;
M?JX(56_L,49?G]_5C.=WF6%ZMRJ;^5TOC?%:$[R:353ED^=4N;7'&'U]AE<S
MGN%EANG=JFQF>+TTQFM-\6J>X%S-YQ9/U/>XQE)]?8Y7,Y[C5>_L,_&5RRRO
MEIGE]=(8KS7-JX7[=Q\WGR.Q]UF77Y_GU:HENKS/Q%<N,[U:9J;72V.\UE2O
M%FY5\FRVW'A^FY'R8_3UN5ZM>*Y7H[+/?CF7R5XM,]GKI3%>:[97"_*4QG'U
MF1B[L;3+T1YA]/7I7JUXNE>COL^ZG,N$KY:9\/72&*\UXZLM9GP]5Y!J['.,
M_?J4KW8\Y<L,TWM5N6WF?+VTH\-:<[[:]9<F;S;W.,2NO3[GJQW/^3+#]&Y5
M-E.^7AKCM:9\M5LO1=C+^XCN$49?G_+5CJ=\F6%ZMRJ_9\;7LSMM+PWI0;DV
M50UFFZH.W[ZI:@%=N_8]^FP;DRO%J<"^/)?I%'>EQHV<EPX=GNV;)S9VK<QN
M(?W =Z-P^9;7SBF6_QWQF:8.Z5&?4_+CB Q@S$[%'MT!;IFZK?.1YW>KQ9'(
M;'Z^<#;R[U$0LL%TVY)<O0GRE>?@-OC4ZD\M>T1!;\>XL3N36,R<;\,"BUB/
MU'6/?GC^(S23D@!0X, /083;)1-P.G3 /'G\S5WD4JM1::XXSPL OOEQ5?^
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M_^K>+TY<S<5PIO)D8[#>W(:[G? (!JQ9:=2:_Q[6CG^?# _ @X5_/4A>?/.
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MM_"ZQ>*L[S)?[I5Z32/N![8P$(N_?8N?WHM@E/&/S.^)73UG! PNO/A&%F8
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M+.>/J,S6COOQ(H"X>DX35C^]5H["X:PTO<2"Q1.\Q3HV3D?(\. !KK@Z:/%
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MDL662^5/L8%>][[[]5^7]];M5UQPB7OM8B0OLG4QC2K 557XJK-SZU>?L_^
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M[8?P^9;.N0[PXV[XQ"(W1/8(E=-X6#@XOH]^: %>ZJ:T@1K'LFC8+F^P(8C
M@UZQVQ_QB['WK0V!&%4^TAX*?UK4RY([L+E94N"+/WN4>O0KZ2^/N)W/X5'N
M!6[GT?S=$<3$O-\^>_?=6?%=U=3;WE%(;6+D?B/P$^T3>5TOEZ?E"K6S?@M1
MY?BMF*7'U[[MRJLV?&E93V55"9HT+*?E]GTAV:N+_"=XSL4RG,5_?/($Q?A*
MJ+%>+\O@(%2;J#JCW]9*VVC%+ZNW>0B5M"0W+?%5)*CJJGATA]%OY48^$?!M
MV77O'6^94F_$^_*&Z8M__/.3XOE[5EIC5Y5<"&7+X)"O[ZA9ZEVK<D:'*2N7
MIK/EQ^I]<-*!=G$)%C2<]IO@0_7_>OK@LTG2WU)INE=OMS]/_R&UM(_K75;L
MTP*=D;T4KMED[-NUF-:NNW!BNKCN,6M[OVS[Z]3[-F,5,JP4D3Y464,7LDM6
M-41EOFO/'P4_!M,_@[SY=@F=GO=J=?7+M@Z:GDU4WVL-M=_@O&^0M;RB/H?A
M49*M>E/UZY.N"PMML P?XZ+/;O&$K;V=D:@3G$-KHY5#I!N96OR:^;8&4H?1
M]5D8Z/?%P;=GYX>Q02E:FXT[A,]^_-NK<U#%$)CTAU[:)M*"2]"@L(!^+KN5
MI*O">7A524/==?@CL,F/:+?/;@'M'"EJ=Z37O$WV9&!\B)CJD9ZB;]FT%UVY
MODS69U*\G'WWYN3M]\7+DU/-1R[+[J:YH/=#R00 .&[H$ $M?,E>F^W4?21_
M#K<!B:!^1"W$DS?!8ZV"NY:X6O\%#-1?_OCD?F.@GIV=?/O\[?/SXM7KYV',
MSW[\KOCIQ[.W#\#? F+A&?O+PC5_05?FN%-DV56WZH/3]?9F715/)>&.?WZA
MG6W51TAU:/,<XHE95T^%=#.^0'J:3B*Q\)W&9#%45D_N(6"G")_ZU?N(]\"3
M_NS@2?&I/T02X\M? 9[TYWL#3QI?JX^N^'TZ#,^:?AN^&;SGU3IB:?KM"EFQ
MG8S+R[JI =?[RU=/OHNQO57=IL&+#A.T^6Y;=G/?7T*K,?+31/G?XW> E4NZ
M^]OEMMJT$&&?.1\=Q8Q5.!R/T(@:K%ZNX\D:H+2O,J%WL=S.T%ZDO6;S]KH!
M=NCIDR?%ZN(/\Z78QTL%)$=(-9D0A+A@VVY[: AH\P2:@B^$KJC6,:.%5>7V
M?GM1=L42MOBQ</)IE_1IG+ZX"IQ+?W#ZW<O#2"O@^9RX<(%*U\BP"-_T9+?G
MP+V!'M>R:L?%MUBD=BV<5==MUV G1'JTL+(V6][8GF5>;DJLLBZL%1C)<@.4
MKYY[[49;W #U7S*<,%YG"DU>+&]FB:GM9MW&/U3KNF_G=DCO/*LTTLVZ"IN!
MA4PT&(3H:%$KD#*L:IQ3IAY2E5"50SQ%8GXO76!B)HX'-MXOC!F;(THQ!L5+
M;?(LGI5 2)\U?Y=MVQ<'+Y^='>YD",^:UY7+3L;KHNM)P_A4J1HS1ZW1T877
M7;>]<'"[CHG'S?EIE>'C'-/H1UN*@K?N-2%RK835=2LS&(^$HZK!'^;9#X7*
MD#3FVYJA]JJ= A9?KM<""$5W&ND>D!":HW@/@D^N(K9A!H<3.'N[Z+R%5'-Z
M5L?XFJ1\%-I'/OE@*6Q?ZZE&T@0YJ_!I^"\,AE(Q4$K:WZP@;'#UKS _??DY
M.8%G3?$RQ--PJ2?!EH3):<+1"5@DAJMNE#B(I'O5NL1P<C*BMSW=]E@#1@]A
M9B?^:H:X-URW:,(#8[N%=3!G[\-Z.PUSM638C%HWX0Z-NB%Z,Y5MAWTC%V:X
MX%33195Q8X:9>?H53H[-9:0P!%NUJ'O+ZTCR^1='W%_^^<O['7%__]/+DQ^+
MTY/79V]/?G@()$_A.-E([^K/X!H@9/'5%4*7ZOI>O=[XMHRO1[+BOWP3MD!8
M\NU-154Q<71QJ%,T1YHN*Q;RYF780#^#T#+J9>&R)M:#.'WBW 6%X:^WX?^J
M%L?_HN[ZC1SS88/#]K;;3=APFH; '8/OM)P?!XLK]Y2L5K =\U9,"),%85@K
M.=^Q'R%[6[;!:P,?&1^PWW24/N"&YE?D!3NJDURVAOXBY6C5;Y28"B^#_[I8
MME,R5"QI2ZY9BDUCA/IK" *NM2F4B1>TQ2[J)6&O& ?IRE)VS,K;*NU< 5AL
MHE2E2@A<_2.<6SSH0'$1?+:94OHLVEZ),)OV*C%I\8H6%<%;&SSGH@*3H1 "
MX<6G%4X=JY^A%?-H6C$5G18\8B&POQ5??SD)JY#=OG)^Q>O"N]+FS#_]Z;\X
M(]/2"<&!M0 DI:^WP9-LBS?UK+TE9?.?B!#ZZA$A]#D\RB='"'TV!]Z96*0'
MP6?X,TSZ$J308CQ%&Q-63VD\8?CM/ )E&^@PKLOE._IW(11&6@E^9&^'H$L*
M;9ME5?;BB:KYK50\,OP87]:S(UK+X^+;FX+;F.$H,E#3L@L'),I"UY6 ?.<M
M:M1L.<*AUT)-!8<J.1?(1KUM:.;#JUQT=(@E0=[V.&S!KI XM/4$!3HC'*VK
M6B#3F];.'?%ZH??9L0'#:W:F@T!/?CU94KC/\Y3"54SP+JLH:!B.<@F#Q-7&
M'</)PS8D>@\)98^7F12;JM20'S1\802AWG'1A*G6%&1XMJF$6$(<'J(_DI7(
MF9DY&CR_8VX.7 -S:064UK_T6C8OJ.J%AYU5TL?=%P?/WWS7"X/=C]4&![!6
M)O0'1P@WRX5*U>B/Q+_14$^.?7,(8OFPD:OE4ZE-C%AZZ;P6X;(NN#?A?<-9
MBB\%-^FZ"O^1O@6F#0QO)-/R+SXI9MNE*_V0$[/Z-PB(?PHK]3K$DL_A(SV$
M)N<SL2T O6'A"YD]ED<U%_Q"6&U79;W$L3.)KE58.FB4A\R7F(]+\'24LTO8
MNSD2V_]5K,,PT944CHZ+2HBEX&!N+AOE>(R;*-FI[VBYPF<[E_WZZSU7%1<7
M^'1B&_!;7>I,;?;D:\-B[:I565.P$]<)@X$K<7W?6*)=?R6B>9*3:9HM<Z/Q
MSFQE[C5:J$H"*[8-<!?7UL4#2_4@F(93Z F#&BSI0R(<GKE7 J//JL+"P;GD
M9:W-LDH!6WZTD=0>%H5%<'(R:-4J1'Y3)172$]DM<5VM<BQNC/4UO,NZI"7%
M!]O&L$(X__V#QC,U/@6SAEB&K!>Y5P)6N!(TXSP,=EB@TW!07>)%Q,XOVQD5
MI?ABH*6;EYWQ>/.0+UU=0C>"_*ZY. HV?:5;XLA"+UB0\$B#,XF%_:IL1-CB
MLA31#4'T\I2.*8!^2T*DB<9RP.)I\DT/$J YY]R/5<<L)2F]WX9#;$-^.\7*
M4$(KQM5RLJNG@_,J&[XP)M6BUM+P#'Y5#(-OW"MQWKKJ&A5%XI[U"6 QTKEH
MZ=_@884[7M9K#.N[X?O&$@9.Q4XT</I-.WNG(7B\'"V@- =&_XMK,C@-(4BN
MY%<%I4^Q8DG0U[#9FC8IW@A+\+EY'>?\T6N[!O#A#^%D_J$J.UIWP0 _2R[0
MO7JY_;";_AV4HC7A,[<BP-# T&<7F$O</-EN,?O15<'!8[M@V*@+(383@HWH
M.D8C8,DV7%7#%N2UMO5RKIO"Y9R44F.Y+K9]W)@,"(YFRQ)\9\QI2>"CH8IT
M^8H[L&[72M:IMJC?HED1*.R['Y3.OAJ@;%S T7E1*F4 :;?#SR>T@=(C&;;!
MQ;84;9NEK:4P2G1P23FB#HERMNUZTI:&(S=+UU[?KUVUUT54S_ FC(GS]X)U
M6U I!VA%H1T/L1F#FF [NTH4@S:M8!MARV7]ZF$!H4.:J]CT:=*'7;M42QK^
M(P9-PVBJ[,.9LIIBN5G8:/7=U^7F$EFJXHPUD@V3G/;8A%F6^;/X$S06;7=F
M5YQ">,:@Z\-=PQR!%<N2M%K?*[FCJJM:4!M31$Z74%@BF?M\RZVSQ+^I"62K
MB2FAL(C#\186.U#$>MZ3$E'?N@HK@NVRS&^R_S8E. ?9X::]#AX*\%[U6D)F
M.0M>GKP^+PY2-*K$)=Q'<>B(,L 8'7&3AP$AO6S^D.&,Z>@(8_;#RCT*0]49
M9T@:M^:2?4C(K4\YPRB4R01,<'8U\%MZ9@=<FKSBB<O11'H"[D V(_2^T\%[
MV<IW.=PD+;NN^\J?L'Q*C8]+]\XZ(R.K]W[MW_%3,9[ZSYL+#R@^E1#]7KWA
MOJ,Q^3BONHNR44&QL"^EQP(\#5?5#6W !=8??'5566?M*)'-CN1H'/*$/BA*
MN^%EM=!Q77&O27Z/?MZ["GV"=:L9L:KL_UH\/2Q&YF%2?'%8Q*SGI/@C_LN*
M*Y/B3^%'P08J#=67A\7_!L<7%]7L"J6; %Q0#R#/L[W><C<+].<%2EYX.)Z(
M2(3-2^#)5/1:6IEF>N*.) 5Z#B  LL(3IG1GVRX,[C^VX1DD];@(;F<8=1P4
M6F]?M:((T11???5?NZX*4.TM;*JO_F"+HN*#@!W%3O7]41"7,T6?- 4)<:X6
M536GE<6KDD@;SG)XOD:3#Z/U+ZMH7<D,J_0>_K-JKNKP4*RM/X"=0L]/%T^(
M<F=AB1(W385TI%F,7E=:YA0NZ;*QS;P/D2)/A)B89@:7T2_/1$G1,D_\#UFO
MDY3S55+R=KDLIR8N5IQM"O"H !,C3Q+NT"[G..XD3J-YO@9E\ZHU0MA^72D)
MGJSBJTH@&E*E3%7&B2?-59V4'O'F'Y]\PU7,>FMQC:*R'QY#Z00GH]KPBTVX
M80SGDX@IWF>+?HC(F&DN:%:Z;D@>(WP=B #I3&G$7MVOM;4'?R&F5F*O\W)1
M/8@$Z4EOFCV305&EFPS+,F,I"/$+ZSX5I\5B-R,6&\E)_BIXIV'\7/W=624I
MKL2J^4AZ*2^CEX-0S[NZDI\1QJ$0*F[B/0P&D5<%PIWK3MC^X7_!CX/BCXC=
M4Z6Z-\B35;EFX$1"/:"^JI?!,>P,YE!V*^*A&DH (^$3#M/@OLFQF'AG9Y?@
M]A*\0'5%GZPXH8*0 -[X)0O^)H,C/!ZY)[VH+J 97KZ;@)N[WWX>MO(%&\O=
M[UYLB=$&MTX-843-8.N(5?/;Q^H:I91%.3.M8Y1-P N^H901$]!I,LI@3:&7
M($+?UJM@V%N,$(EQ,, 3KA2#7BR@.4]9>*LK]=G22:XV+3OK9QHV:]#2 D$#
M%J'H'T7M2#T9TFM:.!'\\7]LJSA3.50_7&#H% Q/E0\8=[3CQX$.8S4/SIU2
MML.GWQEZ=_47J$B521F0L!)\!>3OX=G":XLIOA0AS"N2TOR?/Q4KX&A$<RH,
MD8:RZ4[1*Y128H3OR2+5LBPG,\T*R.^0$WQDJO$F]NM'',KG\"C_B3B4\07Y
M CY:VV5 :)S85. I3LLUJ0A?NO[<33(XX00$.(-$+1)^P&J&@?L3&%G@'KRI
MQ!A;7=4Y ZP-7%=3<+/]\N;9+[_^ZGY#>5^]_?[YF^+%R>G;5V_.B[.7K\._
MT$'[ZJ<WUD_[ZL?S>^5=CK_HFW &E]U,*DX/KUYA+;_A"!6DYG65)22I3+"=
MH@V'I?JPLURWGM"E2Y[.RG^6' E>(-2U*:2EJ1<#$%7O:Z%&REH^(2+$_XQ:
M'=>.[*4/_XTT+/I\O2.NE5&M'^+D9HS8^6GS58B#-PQ_GAT6U2*8#FTK%DDC
MUGE9/;3+TZ7J7.2=OWJZJR5<;#RO*[J%5=0Z4H23%%TM,D7M1WPVKT":Z,N1
MVJFUO,A<3T8M'UY J2(2X67P+7HDG[44BO?(J]@Z%KOOHBG@50R9M54B%KF9
MS!W.G.&R^CXQ6]J//0,L?XT_2O&TZA@NV&@A,A-^]>"GK:HX0A+0PQLM-SX2
M$SE6-=RU5A 4[)Q6K[J&E^$ [30O, N[0-(I70VE4T)#O/>K'9[S,'*-4'?&
MG_#)0SC4LG\.3BB<7QGCGO7FX^ *=QO2<@'@KO.:0%[2FFJJ&FQ0F<NL<(F0
MEJ2*[RXZ'ZTUN=,A)N2+K*9M+V=<V& WB0N)-(LI*4\6>^8R&=?Z\K,E1+"\
M+^!Q,X-VA%Q?WW8D))<==+\2'_N3:KKO_2P8;"(A/\<MDY,7D *3-A347;9!
M&#2GUB]9\UN ]MVFX\9(ZBH"SLQXB^GH2V"&?=&1[%BVI38WU9TN<RG>+ S0
MZ1<;%KL6Z_P^Y-I0(%655?Z@>K6J_RDW3AGN-#:M&T0='NTI, 0JZJGA 6OI
M>NL:2_'K-I\8SS?KT+:M;"?)RY<])1=W;R<Q<$PGR^C[S$YF/^+5:4 F^KR5
M-9/8%K.FDHE//+/R94 ;CF/8B/=K%^P#;X/W,!P9 .>\[@"#4[FU'\)^N'@H
ML#$>?!"[;"2S-JV;B,* 3T,J>W;[$66E_VY*K@.0/#+=;'\/QWA8%W;0E:@_
M[K#A0\P,<!YEW/5?DA0>R =RM(=N_"BZZ0D0SD!-('7T5!.G5: 99YE;"R-R
MUH;;I[\$\T-A;\OC7X57@^W 60!LU[8"RF(INQ ;)U@50,?(72::5=W\".;E
M9F YSN20*2\N@-+8"%=F7RF?IJZK=5Q782=SV-QHT%?0Y^,92(PRS%WX9; T
MP1]C1DE/=ANM;\)Q=XV2&(<C ^TWX8W"BRQO?0KW$!,B1^01X%2FNS<Z*M(P
MFD\6<K37ERW<JH>Q01($5NILBCV$$GLX'RMA-)_>$#TA2>GQX5U&PW%<G-WQ
MC3#6-UK=&3HC\Q(L.8"I=',+!OZ^;69.HV?6;I=S8C8$Q5%Y_B))H9:2[RCI
M%E-I3<_PMMMSWZZ]H?SBNKR1 ];7).,IV5?2KK>Y3&S:Q\7)AH#E"W8TBMJ]
MMAVJY).0O0/9/*?N(\@?R+!0HSB]$'L2SNQ%\ (9),%>-5O@9:Q(-[*>9\I.
M1\2A]43&/CL,,3;ZM"K>-6@A80]+UR(='_'B@L:I'T9-Z[Q<JA_UK.XCIO=>
MO=C>78J%)W5^)<\:CQ(C6^_PM).HEAL#L23XM5"9$/BO@G6M$QX%(AD^=!A=
M*,1_!]%%)5?'Y*%HV=_W)"C!;H'BH;AY$<_3 L+!^ ([(OP/&?(TQ,;NV,1X
M1M&$D2UL&_SI&^>-[ZHH4I)0?YSI)$:]A$PK,:DD,KX*!D29/AQU"A0.9Z:
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M(@)UK%[DCO/POY5!R&<AJ#<N=T'7V3:8&ME!*IAIRZ=E%%S:*RV]A,NU/U1
MHY4SR=>:XY9X*;6!TX>)<?QBYHYC1M&;")E6E@!6B)2624M<3&"L0GQQ13?J
M$0_E5NK3)X^ J,_A41X!4;8B';X=Z99V6<^U)+YJ(Z.-\*/;836Q*%M9#Z,/
M&H9Z*="'KJI74_2/T51T0B;!DH/%[UK'N*H%/KD1#HEU5\\(['=-W$SCU+.4
MEXW'L/*G]+V2V0[2[]+MLI.5M4YZ-.)9B+N4!J(5@-+9%Z6R1R0'6\<2D,)K
M=H27:+MUJ^0U=>_%MYE!\16;9-"U8ZZK+BSU1 3W%0X,)G61:UU2+J)!#2-B
M5[(@/+DH6G\&VL7&6YONI>5&CT.CUU%?Y0$X -]%'(*N*YX]A6J2U[%3E.<P
M/3<>:UIVIM9K7.8$3GB7BHO/)HGK/*.)L!4[K>=S2UOH:EY5\(/K&?=6>$*6
M*H@TN5',33CP:ZD>KH0P],HMRD:;F9TKZ$7=6?!.J!L]C(\D_^B*_Q-EI(@<
M* 0_-3?.VX_M;O/6,:+FI.QL2GVK=;LTH.!>3.:@6JTOJ; FE?8L<\3P?)!9
MNC4_?5RX>4U] $X5A;_6=*O\![)7-OUN4L&!VY4$"V3CM%Z6IL5T%3R(5:5-
MP]A%6VD4U<GDCM2DI+2*;X('M=;D+5.C[5)1-],;660V=,&4;L5CRNTBDX_7
M]7(9R48$@Q066N?0'3 _$:B%17"S:V)I^@R30$]8J[2IW][Z-I(,AV_&T+7:
MK\*P?Y_2XI(+CI043*4XP\?!7_9@UZT2*P\1$S(4J<3@^A[2O=QL3A0G5B*?
M-6'NO0NV!6%E2H ;YU312ZJ==BX;ZU0'NX+D1Z=5P!7UM1(\41U?EUK7!>;>
M/KT=;9PB:X3M:B>W9R\J7031%,G@YMO1XCFTJR(TX7O)%BP3/HN5YY'[&,N*
MD![I"+'%NB^O>"@.HFZ)Q;E^UXC5:X&*"1N\/8MZ_@9?T1*#)E+1/B$GX5R[
M*W6[DV9!H@_^&B5?53H3]R&E+:WMZ'X>.WOHPA+L%'-](JAOR=^&07E37A<O
MK:ISKUYW;P;.E\Y3;6WC"C["N2$!-K8\Y!'N2BO]7"4+PY-):X34,F_B"=>%
M\4Q5LJWVW.7NCU]BLOR#0:@Z/ 6K6+5:\IU'.RY.%?5VZUVY\QRZ?ZGT&"4T
MSJMX#[X3":> [2%MF7&XI\<HK>N,IY <XF%?T>1CLPH];PX#MF-<&\BD,'<-
M_:X,>@P',0;[TK.XK'5I'D/.5G &"25$9@6K::A?6LZK?Y *0A^YEUL&@S$8
MDV;N!@T&5#$W2KX0O8<7STXB&U0^;1FMB#@!K5 *BP'U+O(V?-9I(14^>T(N
MV/.':\W>A7&I*-)2@_4I%J,%T\&QI9&V7CI/4N)6 %MZ[47K!6[H.0/"<,SG
MX*3H?)\83T#)"0H)?==MUX8JUCFS$O"VL:>.!#-::(9_I$]WS\H5^UMOW#SX
M!ARF?,23DAJ@7QO.ML2^&ZI.//GF##H.7QP;)C%\A1\\_4;.]W!TG0BQF?;E
MA%N]@$SQTR='_W//QG3\!'(.\IL8H-RK]]I?ME8V5RL*9% .UUF2D&8I1(,'
M'NW^A0L.T8*ZDS%/UFFB\(.RV6-QHK^DC:B(_31L^3[+E,BCODD7.9'NUYQF
M\W_" \Q;%;76)OO78S_6)XB_#^M9>K&#A3S#[FGF$>O_HII7HC@:9G #\638
MMF?=]J)W@=(2/4F,N<(EOZO 'Z8*X QRBL^R5/:C98_L'4PL[T2U5E1SX^#'
MEZ]/#C]E3<V'5B,+D.0T<PE<@S/4&Y.B!-DMW!,&><);A/8!])N(6P3=0[N,
MGIN&;B 80'V-9:GD*FE;V%ZP9>]@_Q-3G9_DUA?,:<#*R <*S9@DS%?LO5XC
ML$_@#9+*A,C6RA.9Z\]"7JRX@2J:09;!+]$$#I$;QO&SL"K[*@3CYLG,ZXLZ
M-<GS-2?9MHQ;6#?4,USK? UGZN#Y]\_.#[-<#N% (0(O,T,1XG'X ZVF [6*
M[A,?UG(1"R+ID02XPLK0V"0,BH.E"! 19:I^;]C0;#/EKAX$%2?"K%9S@P/H
M65_0%3DX.3O,8-?>QEG[1#"2)V=1J\OSO=']B[(47=6DCC9)VWB>"6=H\41G
M&:5J[%>KP ;,7<I6%IM$(Q;GW.KO71-%:J @R"Q2IV(=E#.ZZSH:RHM0UMU8
MNNKY3[CPR6PS<0C76KITLR3Q_3@M><6_8N'7LP^/3(L3S2>+X8_J=/?CG>^B
M+F2H^/>PJ/IP&(A]^]!$IIQTSX]_"O\BO%!A,Y+?RX)(YV[( B_]F.Z$)UDD
M(Z24*AAN))TYKX<&:<=P3'$J;.0KZG/\,_85H(FQZK#OR:VMYM>4J78*N.DT
MB;!:_% B.PF<(8,)@W/=1AU<5!F%PD-U= 0+3O:,2JT[@JW$[:A T"^?/CEX
M=VC%A\GP7)I7*W3T:GU$R3N'SPSG:LJV7WE)7.)*N1<!+UR&P4Q5C&H^N( )
M;P5[/5=NLJZ^:.D"QN<:>Q^;SYVG=B!G"G0.WJ$<>P-P^^0MMC!C-7$)VK6Y
M%<VW.CY6/D4K'&4"90O[Y4AD4JVP@!!3;# Q.[M#?T_,V5U;.^U.T B!B7ES
MDQ3:'$8TVR;9WJL==E.<"CJWSXN7X==TLBS-87]$ 7/!W1$W/PN"9 F#?[G:
MKO(&O[MV=7%0'U=J;%*9TC_F892D;.1\$W,A69,:3<1EW\?M-LD\/&Y@A3VB
M?27'(KF!2Z6B(FR'J+"M55"XI2["41\$H^\2=Z:>1^(^&CLYXB/.)?;-$XDY
M7M:)>)R!<YCZ;40"M"*WHB3 K&E3?QL)AEP(XT+?8,%Z =+TEVG2^2YAIK]X
M\O0O6D$@M4"+;C+?UN/2$]Y Y.YMOLP.@J/Q\MF;0WDPYQE%OB%AD%2,KGRD
MZ@L-1,IFY<K5_/"V5#3\\P3$(D_ELM&E/44KN[+.O;<N<,$"C=S .%=Q3BUP
MN;]P=E@]#J?FNWQ^AE_^*D[E=J4-#=>%_]DCU5$&[7GZ".WY'![E$=KC:5HT
MHG,.JL?PU;UKF 'CW0;1@=4NMTTP@G"M2^$%894!&-366I P<OD=Z(6C7LB"
MPGK;]=MJ/LE-I@?8B,:050M3,>;G2E53)8U[^VNPA.ZO6K%[TB(_Z0#5V$_J
M2O!MB1Z'[B!:_;UKKXP"J*&N>.3ML$%&($ZD?4C G<2$+:0:[J.=&FB>"4CJ
M/%&>^SI*M,2:@M)%2#JQJWQ'&"IQ>3JS7J2CH6)C#X9"\ M-#(>;B*R*L0V1
M1PB?CMWI&IT#N\%X".227.,)+CEZ7>:67DU=&@VSDU%OPU%^D<12<GC7VV$R
M#(S"RIY"Z7'%Q8S#HU)B"[)@W;QX5U7KB#'(@-]:M;)E/->IXGB4\W&Q,!D6
M7^5 2&$$T[L*[ I(M^ FK1$30"+,(N6]Y8RO9P@:UR9VSBI6&DQ1+!%F$1BZ
M'/[K]ZSM%<F!*2@X.(7S6&A-VNFN(".E/V)?](OA"2::7,04^'1BV%=AO;TK
M$W6O$& JU2F$S^BU#;W'&#G1>2%1&V.H;//<O2RG8;0P[VP=V;<T#_)<@>72
MWY+1(7E?<K]7@%97MBG.9![",VI]U3YX!M]Y8Z#I[U.24$CGSI4%U+U#_HO_
MQBEB/"=6N.ZAT%6<A$.H:ZJ;WNYY.+'=8UWG0&(K0(%+=5/WCEO6M:4W-W$M
M^\T\,VSG6AG"4<9$:%0&OWFSG1-2I8"GH9UT^,K".=.Q/3E!(4=_GMO1D9!]
MT*%?^@Q"&(=YRE,,F1D,"6,-HE9JDCS,>)D2.<RJ^!V+CD]/@F&$+_RBQ)3W
MOY/NT4GQNW]SU6%O(O#6'KK1>IG5[9?5^Y2H3DGPP:$N):9;U@B7@17+E_&+
M^!>7 2<@$:8B3U/'I1DGQDW%[^Y'+N,C4[-B2MRA>C_>\FY"0,?3E_9UGXR;
M@PTB#7=TV5X;G.^JZC?*=(;.UF"B.T(N==E:0BXM76'8&:NN9-G>8"L7BWP5
MS]NUU9BBO&5*<TC)@3_^9]M4T<>XI9@V4>=5SANJB??B,$J##JF_2 KJG +?
MR2[ODMC%XHGO-BVK0C WS#QN]C^3.'C:?D>3" 4?_NJ:'^%A^LKH^).=2WQQ
MTVT8?*)B4VDLV'YIK89'";2-.!E*>7U<G ..F4Q''UT\H[T+J\MYKSI6?'$3
M<9$/B8G<."2.SLP$_DY/+[ #-8$;*8&?+EU+P1S/TLX'>.GH;P@,'&ZC=%7M
MTEMDE!;H^&;Q*)PBV^ ;R>G5Q5NQ]EBSG0IY^JQ16UXT')Q'P6/IK-^J[J A
MER^[L"!%1B]R*? K;/2>:A,#BF%)R0-@I(DEX ?<;@I&C<R<63G$FJH5Z;3'
M5QRL7D,X8_AW)W5\)RHZ:YHM9:&+AY_:A3._(8$D0YQ(=6@EY4$17,23(XCM
MG"5?O3]N$R8-,"M<>EXMPQ^D@7_@Z.#CN PR[R%;B!IK^#JW(R3(<I;N>A%J
M[([!_YB:XTG8E4??MC>S\/#%#V%!W(^WO/5@^XE]'/3)QY<X/XJ=N!8BU1T]
MT7I>EYW]&<K.RYIBTSM1AX*&+NMI'<EO'!VI<LEB%QBJ/X>R;QO;BA(E50A^
MIS(5_5BKJ]G7Q%06CY]AN10K?A+QN1.Q0@NXNB"Y6.O#J5\G@06-;[8Q5/ M
MOC ,GNI.IT&@.QI-HHZ1SS@DDQ<9*F\W>T-3O?-@D^*J;I>B&A16KP[9KVW.
M[K9F]V.K?*1!(/#FM0(], 3GAN/YP<;W8;G!%)2)6TH.U*R^I&G,1=MNH&Z_
MF>P<P,Q<"B(Z#[U2W3$L>P^/DGUS [%$&U[D7^5<0\Y/LEDW68)4/IU(LWSJ
MY63G&_ $[K&\]H=E@,)&J\J-XUNJYGEN-M\!5SRP,] 7\.A5;!/CDP=O$>5+
MD?:@E8G)%HBR6//<92L95^JG2+])E4?IKG6//N,PBE=>S6IN@*WLTQ2A#BXZ
MRJH7?;S19QD"F_>1 [LF7*/XEL&.^=][8B'N!/7J#HA1OM\-A7 2QC)_ROT.
M\YJ2S+H4[5:%:IAX-/=& INA#"Y9U]0,@?I;." R((N8?,F?GV](4JK)/YF)
MG'V,C4_!"7\N[6KJM;<6E2D_],0#<3*0[YGU(Q:OP>&@*2\V$648-P#8<.VG
M7W_]Y^+@^[/7)R>' AE<,24ZN&A:>&]3X(.Q>VXN.U%.5K/7W^D]OGCRY&O<
MX^WST^\/\V0C!R0:'+QB"KT&D:K]1'FN>)[?')&<"WPN>:.'<'C%3J <QVE9
M5#U&N&?Q:J[:?_#=L]=O#FV48Y4\ONU)F.C)". Z=J'X5W(0L-_WQ6LS'7Y4
MW5.$(ZPX>'WV^H?#>]9(,+XWOZUF90A1.59[$@NNO$8N\XD5[^BN>AP>ON/_
M.Q$>^CRDG70'_-#4LM!*WT A*JR0PSP;R;3)&NIKT:ER.1R7.!(;8(YJT6V7
MUF.M]D,(9:6A?P_^@]A?PJW"GZP+-VNE3/%?/-48_]F1F-'],-)D7ZS271X7
M/[:-/V:9G4G1J#&\]+456@%-8AY$4S%TA#51AJ[0L*; Z&S7W&0^/8SJO"NO
MI2J1?2UOERLU43_1%;#>;LSHH?1[3\ZAC_14?8GSNPB1?^,[K._'>]^9I?4-
M^5X^I.[]WLP[:?:4I?86LL(A\OWY82POE!WS25*P(@=(VQQ)Q)<JMY2/H/CU
M@EO%][;GIFA UR")-Y_<.]X?KXM\!E.3C\1$.7KIBT?TTN?P*(_H)5N1&5'S
M,'^U$-<<W==;0@-RGB)E"MEIUAMRA;CONF('J6&BXQ%]1>-^*!)EC^7(?*<U
M'8?,1H70=] 'IAU/6B3Q!FKD726?Z%XPMXY1XL2"\XRM]W9#^>O#CX+E_W#4
MT?B+W!,7X_:\,4X@7:1^$N10TJ;]JD%*L?7DON$,!@Y": &U=0#3ME-DR-;!
M7, ':5<<W;8K4GJ$3^-2%._JV3OT>$)J.RS0*M(3]M5R<<3FZ\X@;ES1[OJ+
MKMP*0VA7J4('F,;[.HQNV>GIGU^5*5>[I\8(^%-V-ZT06[C,1Y81X"C2\<6E
MXY9.*9F1MT^]9QNMF:E@"1O^1EOS/! ,6\I 1D<*%IQ''\KF@U8Y^$TC\Y]F
MX7JTQLN+OXY<DZ]-7N)\"TKIIF*L?O JQ #QLT.#;@VZ5TIVOA.O+P4\39E'
MR8JL$,M(B6D,JKU+KOL=HST\TY$JGSC";414>LEPFSIET\([+BHF[H18/]R&
MK[5!TH7D%(FR_UR6!R&6?)2\G4L-I.\"U-<98@.],(WI4^N QX>)KRY@IT59
M+]FIF/?-WEE<MRG;RD9 ISIQ8$;FG424VU04X,G 4D'*+\9([B%8O+.\ P'5
MC>JB[L5CEO#7]<BQ_50B#7\$*"TI(UO#&04WJ>YWYCC+IDX!-HH-X&UG1?3P
M:T=T&BG8A@&&'5 N$\!MH^&Z?\"L8"R';5-+3&V7SU''NX<>"<%FLVH=J5N9
MR$BZ@6.)8B%8ZE/SG(,9H.&Q5J&9-C*)A1^M[DMFZB.C]>=9T[4+0\^EZ?J!
MU)[WX'XMP?I+6L\%^ZK%V%'\ZP^@B;;<K56UZT;U,HUB?I>D)1TFCK9#58QX
M]:WVLXLM1]+;[(1B-N4$E=8R<V@^Z!V'Y-?.H=$;QP+29'#[B:%]PC$CN_BR
M_&?9S3&^D?;G?EGG/=B,2%GET]GWZL5NX2339HS2Y+41B'PZ\H_;$@W7U]?'
M*Y,3/PX[[%-RE$A)-F-(ZC.*I$GQO]O@'8>'OQG[_'\GQ:D2@P\__0H_ID./
M.I7XF]R/LD'ERXMZB?;.$+=L.X7^LV&HE([O<PV"G_[QH#S$UYY^>3 _-$"(
M8@E@GIZ_5[QC+);]\4^^2%8<^&\<JO+2W!.YB;G!=959"B.C$E7\T].GWX2M
M YQJVT62J5FYCI4(_=T+\^[Z^+/SYZ?%BQKG<_QA,'GQQYJ(C4LW!(%MRQYU
M5!%:T(/=&%Q=5&J0>2,162R72R8$[5DX]FG@)VY@Y:^;=C(<.3QX'!O76WH0
MGOE!* .<#6OQSGU,E,V2F)$N[G2:X#NO._!36X7W-/[B._>+TW9N23CV4!WD
ME["/GX,,16+Z\^ TAO^):T4;2;H$LK<SS&V?\(/KD@I+A^F>WUKER6[.&4UW
M>DD]KMBW]6T+1I?P'\\H\-8"<'!R)@N][PV-G89LAH9L*8;@5:KW8>F(/Z\/
M/%&IN%:?76Y@NN$H!:3!B'^E: B$U0[)_1,WH<&WLNWP:,D_8)E_F/U*BW9@
MP(Z+??O$0X[A!KZT-S:$!:P(L?1^%<1X^'%Z?\/IO?5X<K]-9L?/^H>=5@_A
M3'CEUY\.S<#H*4F.U.TU'Y]07/''$4<?CQ*10*H6BDPB]_]=/)0/8$A16<;"
M,5>\=[ZXBO#JW]7W(PCO_<WNB<-DKA-]WNVB39Q*P5G9FAR% RSKOIC(G>D5
M#3REB# +SRP$&\JF"%R(L<*$G35O9UOU7=E 4\G5_,\_7PMVN=FL__J'/\"0
M!5M]''R<3QMK_*RC)WGIM!#^$4.,?&WL60II3K)I2!;2^_HC>ZN>_]_?W5U<
M??KU[^[)AAR/]T=[5!^ H9$S3D4LR*:=W!#--O6YU@"ZYGJEL]!ZA2"BE J,
M'_#?F1:!Z^EC8S;B5FC1;7L40:;5LKT^+IXG4L[@;2_#WXC<YAW[2^9_IR((
M+/HK1+:%=4K<9GM1<4$+3'RY%,CKCKE3*.G\ QB-A\%+TO-!5T@\]=.^BL>?
MA1OA-*M,X%DJ&WR>A?@# [OY8MOA4]!/33QR;FS$A:);&^U4=Y4P02FBF'E5
MG;'E3=+G;3&$]<JR<331@CL=:R].W! >;9XILZ7\Y&2L&UELS:P,4?,"A$?:
M5,C6?JL 3:NLS]DZZ]W#B".0J.S[2H>%1.%N'=ZOTW_<V,0@%"/QRB&[87SN
MB=7YR!($E+3YHMIDJW+"7A@HBA 2QQ];AQ+?^X@(U?U:#?\^G58OY?OYRY(J
M7V&N3!I>(K:AZ7@D(="2\J354+/4:96FXLL'Z91.3/Z:[YN+EDK-4&B6QF5+
M@U]\Z03!0*MGO- 8NV$Y"+\ SPX[W 4"D1K^'<%.SD:LC<J/J$N/NOSC(^KR
M<WB41]2EK<@:7?Y1O61!=@39T/.LY8%\M<$0PNVIE7FY,>C"CM1AL6REMZ2&
MQ-E&T7[62B,-\^\JS3$KHQK:=I<0/G0W7L+RN4/V%^DL>WV57UEM6325'\@I
M;B[X@)3)#G<AA.J+[;I5*NZ%A)D[((-I==,2:] 9BX0;P[_>-5@8FC_B0"BI
MKWBTK!:;O_[QSZ.#)7^J2=G\UZ.G840_T? Q=?KG;SYA9B@;KJ=_.OX28V$N
MBN,M5HA(;$6?/,[';S\? YJ:Y'@^SL8GF V/YE=2[\=I^.VF 9[N7&1YLY#J
M<1(^P5Z 6AWRC)$PY7$2?KM),*E(L42J&^CU@)B<=!H$CY/SVTV.(;!MBSP.
M_F\Y^)F,>$P^$R7_.!&_X40,.K6-/IQ1]YC^>@K%66AYG*K?<,\H>871B8YR
MZ3^$W,6I2_\(<:<2<@ 2[!D^+*'-%+ V-4@-@;(Z<Q"U2](J9J5B*LIE0EBL
M$ 2<$WK>:2:<E?-J)7SMU.64$F3&<!()$1+>09$IOF\Q2NWXYEMM*5:B+_IN
M]CWR5K\;2;RQ72UJ)(?I"8Y%JSJ!7K*>4%(K>=Q,W(6C_(^3DE3",9-H\ER9
MU@TJ0*K(KIOS)_KQB6/,4=WVTGL]Z[;UQKI.P <CHM>,VQ;H1'25&GF8IKS0
M)F/2^C35,NOX1J)JANY)7*:ID.]TZ<NLD'%<O&#-",(1V$GX7U-17%)7POC6
MM$-,V<N1 34)S:*_%*.XT^L=$S0J"C!)_98H3-5]*V2XVO]2+JM.R_BR3FPI
M3%$ARQG6I1K%0B7V2A\99KK8B#8(@"?Q#Q4 G<8UEXL(]$-J]5@/TV)^IM01
M;B*3,2<L8N(P"ER01%WD_;)V6GB>NKB_P4O/-4C&/'\4H3:KP*'(VA4)@J7F
M3U6!CDZ#8#X 3YL)_B"I.1 +H<* +O5,4'X]2]EI*;$1)X$G3W)?.C[]=D:!
MMGO2=?.1!?%7Z0UC9E@Y=%WN.-(U@0?5KT].#?0W"NJT"A5B<*XOF&7WV^]^
MC-Z= %2CTYH7%UU[;5UMV0".C9]8V8E:J\J96I9D,TJLNMQDE5D_C&IH1R@-
MM6W'B=)>:P_B;FFE[9*='],$SD^4[(@ !ZIB^^()))M86Q4OZ[51:-K!*=9>
MS[[LE, GVJ&NRHTC;T;#I$S:;<9G-H+$$+;7K>K_QB]2HW:BC/4$275I+@0X
M,,^8[ATV6.!;+M5+=/"^DMG$@*A>9R'*7A!T0HT>E,["&=)-_ H2N)F# ?B%
MDLM^0.ZB$A;#B7(GSFCW<%C-R#FP#"/>V'$+M5YVI2ZUI]G09EG+\D"[?7-9
M9=@8Z)7WLW)=93 )1=0DFE%E([=:I."HLF4,D4<@.V"QC4].21Q[Z.KQ> Z+
M&9MCM"%6]8<[E+N$G9>+5*Q^3D8P9"L\)M+8D[?JCX?TK?O8YH;L<A\DHZ(D
M?8.!,.*-<%V C)H6FH\:<9EDP' XPWO7S:U31UTMTAW;JIIXM!X_!JXO'98Y
M^V;R6F?TPLG#.<IQ@Z? FXW.\G'Q'8)\_42KC-R@X75Q_XMM&5X5G479HX4G
MOP5KI=!^V=NX/SD]I2%Y=H^D5#^:ZBY6]U6( J3Y@C2U'&/D=\E[O'&RU+.M
MZ$ 0ASD&P<Q_,S $!C2-Z670Z=^3@;Y; <79VZ'J0"1GV:CJ'!6%$U$3I(LP
MNC5/QQ4 ;_BS^=I8OVT3,;NQ-UW.\=[PA\&0SV)@I-(^P:IO:6=!=!/)3JKW
MICM";FGH'NQ3L29TW[\;Q<'*O[>=2M+OF!! 1O#%&9#9 J](3#N)>MV0%CU>
M9FDD4NGSL)6;;7 "T8WO-,=H?*^#+>&#&3&]0! 4C)V&*P2KY?5@O"*34A+^
M&[Q>G]!PDLJ*SV$I>5HQHV+(=0L9;'N10+4R.EJZQZ8W9O BMJ]=RT:!7]6'
M026D1!3-UVU/=D3>@+%F$HRFTJ(9.NM>F8<)A,^AS]NK7;O,AV,R7%AN\$,(
MQG8]96SN+Q$H7LB5DCQ+_'6<3+AJDH"P=L"P[&NJ0EY1Q.L*8P:P+ AGY_OB
M97XZ,5$/CDM.^S(P-#JL82W4S2#S(HR29:_G?2SOV@DY4;)7GTX6"AI7:YF,
MO/0O6%P[TO)1D9WK+,3"55ICQ\6)S<(UG8YWQ0QY!)=E<@N2[9KB+R#;6HVO
MNVNJ>-K:)!U3L!U9S=NC0<25TF/!#N</'($PJ9-([#LACM_.&^G[1U;8C-Y@
MSN;B<//N491TR(F?D4GCZ:)%&U&C'+:))9',U%&VN=V*1PD(.!W.NPA/,7L'
M\QMS:2[-R,5'*6NA.,+&AJ4XB5]!M+&2KN]=#<W(6"JI*8GQABH!0Y.-T)%2
M]&IB9I?8E=SP:1"JS64X(J$A_CX84RA9;U[U0MNZ;I<WB^6V[=IR^>YFZ2E:
M#EZ_.#E/JN4 ]$6ZP$1RY*A:-A25=F*M=/=CLE)_8]LW3&V8Q9K'3M9@XDB0
M!#6-_.PFSY6F=:B:E:,IL$1.=P7I#^E)2U0X.N<1J6;F*9?]>(0Q>QCSGQYA
MS)_#HSS"F&U%BO)?;\QN*5!Q:EQB<NA1;<E* R_%> A#M!AV?[5='4V9<\Z/
MN/5VN6:Z.#O\$$!!!V_GU!B0N.'S6K+1%Z76;7+N.1=.B2X?7)A%QS>4SKJ-
M>L/A'$G<K/M#.F/7#'_932=FB&@]G\0)A4]G%QB.I'O&3!E[CZ_C,U:MO%8J
MX&L.2\.6G @?196'$R<*$[#W:M7M'96I5NVJ%"I/G(^SV"X7]7+IB1,Y:^))
MP-WUIWW=++HRG*U;56+V/:9T*8+W(+G95;E<;!L5;G DF=+A6D0I#Q02VUF[
M3#%?6(>=!':*6VH32X4&<"'^N]P&\]5>8Z_-*UL @["$:>,4<TQ0P]F"2S6,
M7(EX,04<E]NNP[[AX+1A&<];_+,*P>9E\&K?:>_1=;V<+VH^7E3OF9<KY8.,
M3P?_FODXNN,AO)-BL%9A63OM\X;TG*/.,/"16$+MS:*HUC73V-3X:>R?,=6B
M=S#NTJ[NK7QE]"LA8K0:F\I9K+9-<H$R]<W&*/4KV[C+JF0PLBS#W%Z*0F*?
M*GQNJ+<-6'A%7"Z*0G$7JG2%:F3*X&E0EH0B!BEE7=[K,&L,8BK)E&?F6%KT
M2+LMP>;IJ[^=/3MZ^G4<J7U1XG3?Q710;:!W.IUM>'K1JW/$W.2O$=L5EE S
M()B(X58F;"Y$2$XS-"V/-&7#CNF<@C8JPTL[\;S#]M\Q"J(4'\Z1MDLXCB7!
M#;[.;@Q7D21T:%0MW,,FDU(RR30>A(G-XDC+"HTEXP:)IRE8:47O4./8*U-Q
MQZ_?53=YY.[FG]&L7:VBFDVI&HU;X!W,O$Q4?=&B');!PZ*UR-NZ,WTFR [G
MX>.FC!B%$<,X8W<&4S.;;:WKDTF4WF_5SBP<7ZNI!.DB_TF+FBX[&>U:S@YX
M]])<AU>9GDQ<H!QM!QS0$\1*,!W':[D\+IZEJ)^5F_A3\%D+W;:O]67LW-HS
M-CI(\'^R)*0/XB-!5>M<E.#UU4I0S-C=WHH$039E:HMDW.]XDO2C7JF%N6A@
M5^_)IOO(0L/KD0--<H"7Y1Y50GR*3R+W<Z4^9I.HQI6(03?EK\#P(+4S<3!D
M=5%FG&>VGC)RL,BNUTQ[)'%0HHMUATY"I'\>K%1? @UTYI+0FCFX3N3O3@V7
M] U5TW"GA)JKD2MQ2-^W,\$N""1JU#%R:2SSJ_16>N(?%Z,+<&S)^1674EA[
M5ISYLVQLC*LO3RTZ,F^'W'=Y\YT(T2]9G\D>R)&S/F)C7&I/I8N^I"BPJ=+J
MOB>+\1>@C2(2A"/DL"7!:)!>MF.Y?,TP&'"-Y-^E__80%0Z^DG6,%Y8Q[U;
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M$,Y*4;=!0G(9+(80*>K'HM9HXQ%[WF^K59NSEU"9)9HTG)9S2M??G7S'2W8
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MZ2!)XSZ.8A"_C*/H#O3%L6"[5=A4SD3>6:#PPX)@5UH75V=3@C#U'#;21U4
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M*:_+DVVN;2HOL\6URS&*DUQU3)PT3"E<PX3A^:_8GM:':Z,"0?U$(HK?PZ+
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M:8J=O%/X\>^ACY#[*">5P^L( >"4S+8:M-P<((ED%#O#R%L03XBC(.#I=V9
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M:6?'K3>>O"'%D>]NFZTG*=H#NQ 478NRV+IL=;VF :7I-PG*&2C2=I>]/C<
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MBU,YM 7_!E1WPXF/#C,W2804[5I^R4 -)C91!#V5#(JRH?PAR&)*4D/;SLL
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M"W2')E/G/<#Y05ZPQ?V74SGM?X3['\/^&X!#H9JA-D;Q!%@3@*WE)F!!-QR
M'MA<Z/1%5 )\3+(A64G$,27'3Z3_F/"BX0#3#5-V[XC_9/Z<B(2PBF@97PT_
MOO4]7M%0A'% -IT/;NA.2&MV,B03L+22^W=J)!!NY_?F==,I_RW84"@YF6(%
M^P[T'E@/APWD[\E)IE$6>&B_*;&$<@7,Q$"I]FG$9T;_AHOWQ+JY0/1OT%O
M# 9-#YXS6Y*O0_H$ZB<!C#9!%'O$08AV]5&:()_@[2,?3 @IE41Z)T2X_L4Z
MATBELPBY$E)WC%$<Z[+D%1VQ9S=_!6ARNDC-R."L*7M%S"]%=0H7Z=@8!RX!
MY0-WGH@WZA]O51F-'Q+BTD-O\U*UI$2#7LA?O[WSO72*8:MFBT)7*IM3OEE^
MW82O?EK^_*3?; \&I5^UFNW2SU<MU<9>"MV-EEK]^>E3;JI_[U(/9,#>&^D]
M6_I922AW)%"TO,Q8V-.U$F+?<^#BGV 5;S(_<\.<WVV>\- /E961+%6*E 7Z
M-YB+6FW88N#IJ0[\T$C)?;JTWO=-DGU<->-69T-_7%>$/MF0X<=E=^W)Y/ -
M\[>V>NJ31JOWU!.F'YD&]*1#PQ^]^=>.O#N&OX/&R>DCQV@\Z]S[%ZJVVNK=
MGZ]O([]\U_.MWLQANW':WZ!P^;O2)S?GFUM-;=TV8/JG)R\.F*<<M'[2/%EC
M!,)6;SGO7WHD7RY/#&_=EQO^NF3W4UQ0M:FUWVB?/K*AZM/=4;45V)I*:BII
M=%J/G+NT72I9J]BB<D&F+QA75%'YZVPVP^2%:&SB9HF3" H=4G#0BWVX@$0%
MYTV <[U@T<I(A-Q3K\/JP'+;)QTM^%.^AY8$=LL\X@X!KEFZ^I$EC]Z6KK[;
M+O2HLOX[C8WS>B*.A[%POQZ[8]CL&S>X<Q<)8IR-7H!;A3LL'G_E(<?C9\L5
MH*OVQ"CBG(XW0+,BYAY=?W&KLA5G&HOQ7P_^QQ^U>^Y)OR5.VV>GO6'[U!V<
MG WAD^Z@AQD(XE\G!S_?4'0,"0335M 4='\N V.E2+\\/O[!'<41ABFCF3]R
M;F(1>LF:"3-XCNT?JYRL?HNBK\1VIL+U*&J>S8; XP!FL]R)J:I!1/,(9YMA
M7&DL<XI'%$ .Q818#^9?S>98#(.1895=U)!)62H7.LI2SO)E[%HW\ZCD(G/Y
M-=W!EA*1UKQL[ '4&;Q]EFRDM;90R-OJ-:F'(N;8B=2GS&V=6N=FX6@J=(+Y
M"$&'V>Z<E0"8,(G=^100(X\FG@ <B.:<6&> ;N7%38)HB&D%L>O!ZP"=1JJR
M:QQ@S99, 4 IB5GCX0A3T*7HQ!R@!-\>@K@,:%\H3\>!+,NQ7D.9/B))U3.Q
M\&?#+$XX]P)^& 0BI/(?QE>9(&2M0!D%_C<D!<1E=3/1&'0 3%=NP&$#$"X.
M)2#SEYRBKU+[YBCBW0 ;0[HRF9FO$P0_YTFD6%$6ZPNF?'V=T\PI_@W.GZ("
M1<IN="ZF?NCBB>:!.Y+G68P"D3L5OHCR.!;XL1]:7\J4*\RG1U4&_G?=W-F:
M )^% +\(5*V*M%-"*0LN%P+<)N00'A64 *4RSE F#.*0S7N;SKM,)X)B^H[X
M3X9ODUHL)^\0=5-M18,^Q<R9AD(T4Q[R;U@I\7R9' >$$R6P!\[(Y7^K7"5*
MVH,+&E/U%/Z2,H0F4>3!CGYQZ3E%XFGI4D2XF)D#!/C!73B=MBJXO*-417^&
M:4ZIS*7DMRGAPR4I/X!QI-.0X:,?NGWS-Z;H6J6=L/*@83(I9^Z_N=;+JDV6
M/ $3I= 6XA1<$&%B5BCODC],D"MZ +)@K$P ZXU-!]- P6805%>J?A$3HW.!
MS\XH/8P+R?1%44K38;?U)TYE(@@YAVW\6]TWP!'3D2DQ.N +F@("WOL:^6@L
MT&##JY)/, P.Z:WM7O]/$B><=J>/.T 5FY8[:QU[ **YFR6"#^9R6J4[ ],S
ME4K"+9I+0PU[B]4R\"2K]C(KJ9EWUG"2$=A(N4^(E4:H5OI4=94AQU>Y<(A)
M,S.%5=4(T-:4@L(W8:$I0ZB8PX8$5<"4/B>V8DH<(F$,/V\Z?Z?K!MS$A++4
M_<H2,R*#CC-(*5@B=\6  4.<RFMX+XDPIZ-O;Z/@%I<!\8&%?X1A\#HM37*L
M@5/,,R%#,ER8YCI L5]5+2%FESNJ-EJPT-7G!;R!H\XP0:_IO,]BHGB!YY;0
MH*)%8'T*-/3RH1O'OM!ZH"QG5+<"_  M8'5054FIKA9%JZEAK-7 K4HA) U8
MT\I\9J:O26HH$!<5JP:RA0_G$1:Q2EGR)4L2WSW^_6OL8K<%0,AQ@.GF2!"
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M:^4J8RLSXV'/2W.O97X'&(*LHK"Z<HYI7B-GI8JWGT6?W4:_OVF/@[HB]\6
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ME^H3P,M%.)H":?K_92I,B=80^6_]$9'P;!ZXH;50A.J3 %$GQOXP!B)P><U
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M$-F" 'TU4%%""5#T93B7(6BPT5R0K]#VC,@P6TV#58%KEK#R8NDR ,@O8(&
M]/OMZN/_HV_!SG I0*>@3-]<717#R#6Y5@2L!IQ%DIUH]HOVAA^&T2W%XO(R
MTTHC('B3US".YM,%8$$031;.X>7G(]5EST[JP5_;GL9RKZ+E?2)5F5V1,W<^
MUPDUA9^2'U+[*I5QQ(Z3-1XGEU7Q:2<6(P%G]YS?F]=-Y_V[<P>6B.%& CPX
M!N*=3V"N#X5TT]3H737T+N T1<!%,#XFCD4(>1'%@GR4R@6:MZY==NDN)TW
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MP5"S!O5FH9\VT%$^10EZX6(GJW'J?/ZM0:+I-_&/AG/QSOE;%/O_A1W\$2U
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M0T>H[7B(+L@_<)A@*GL>#Z.8&ZT"H[J'KS3^?_:^M4EMI$GWKRAZO;MV!,V
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M_A?%0D26'^^&SK,R/"KAJ6BO+!J8@K?T6>Q"3[CUJMJ#'">&S[WX]L:&(05
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MNI)KY:'':6.M5CO>>+/"VC%A3:_HO>,-!2JL'1/6>D><#Z"0=DQ(J_<J7?U
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M3ZJUQ#J6(Q6%%4<W[;@0CWBC94M+.J2, 7!15?L/"VCM<:Q44JN#%P<<(0G
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M_8XI\0U49#SZK2&\247#C%C\*P4IZ# 66B3EYXFZ/$;?TOW,T..^"Z(B>2J
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M+^D]35C^?'=E3&IV,\6@]U4[&O,+[-(+UL+C)H$B;DT8)<T%<<9*Z,CUT%:
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MZK6JWFCDNM7BSYLGOZCEMRI6E=K-7*/N6II5]DRCZ)WJK75>BI^(AWFM.3%
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MKNGW'5-D8ON/0(#<8KIU<56O5]H-O2 Q70*-2.%H;86\0""U"4AZO:V =(I
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MFFX(2(R(NQUSE\Y26W^@</$;=$)2;_UZX[YC%N#Q:%]<]>J5=K>H\3W%4?5
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M7ZYMURO)MJO]=>5HX]_#U<IFF"MOV!JIYA]L]UG[Z/![A9MYT?34]*SC+ER
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M2G=25'X')F?-02HYP3TP\] )@)5_!;#-+.;_@!_^;E/S62DW.UP66T[(S/M
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MW"6R'U\!Y(9[;9.B"Q'Q!PO=JEP*Q"3<OPX2YH?3_A?DP]U[QZP !4M=(0P
M'_Z->*GU]=_Z7?@Q^PFX3?M%>8:*#-E(9(X9H'U\\( "$+FT>R!:0,"YL."
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MT_D3<OH./QJY<M%R=Z<8[:?-@/B8Q5-Z4!9BE;^]$8 C#1HCEAC>0ZC!OWV
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M9;_?X@SFWZFI=4!%!9A>&B645:?[FK]"J:#4P2H)V%.Q??*)J)1,#GY$<OD
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M,_'RJ!V@N@V*\B.52W\!?0 VH8765#-5UD]4R&UGGD+$'HVHTZF2 CB+>S&
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MLO<\RX_&F$=I>W:4-1AU ,CH@"K"F9XI'0JS<!F*O%)UF3AQJTG9KPH15RL
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MH!J(/9:LN06Z70 7:)%=:3G "BPS-&Q %->3\# >'ST&PA:P!.XHY<)73J-
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MD>]+;W7DHL9<Z*B-*4^'418C$0BB<V'8<RG\ )B1;Z8I.J/RRB2MPXO$FN1
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MT O/K#Q)/7:)XR\KNBG]:$7BZ,"\X"KQ=5TEOG_1]$5<[-E+Q"\.7+T:7$7
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M17N,]%S K4,#CXV@J1E A*"?F1EXKF/-M)4]J\B>_G #G#GH(C!)[-(LJ0_
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MRTK9TH>HH0_[>BW%:V*OB?UHQ-ZOPIS>D3XB:N^D.\O7U%Y3>TWMI5'[D3H
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MZ##R4NJZ.!!U#D0.Q$;=4F,PD=7TP2='5SO15=(MO2B\3KJEQAA[9_)(YR6
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M;^$/[CUJ,V6Y.W)#S9RX*CK5&.\N,:<@YIL@_Y)4,.=*Y[Z:M'_\F?QSN8T
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M@::Q%4AQNJYZ4OPP-3F'R#TA5K97I=[/M4-1'&C'@):B0JD':-)X,%%E^::
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M]RJI4>\OF!;?F=5YTJRZBP683/8+9CSW;.=K;"'] SN;(#\?,F,'-P-K8<Y
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MY@)O..R/Q)KHH$5#I($@6TXH,0SF #WL%F2'D, '[%Z>C\\\E/Z#)B==M5L
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M;6NGII5M43X>*L>]WB21#\%ZVY5SDO>TC'ZH99*+F=8S6WUA)/0%'AF/TC0
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M@/2 Q?F<N A* +?KK]>VX\5/-[@V<6'!( )O9NQG<_@;M5Q^-[+F&^1 @H<
MQGW'BI"#CXU=PW24C[Z#L$W<J(57:8,MI&XMEZSA93_8F(5-R]YCQ?V!#F),
MQ&_.3>?+!%UEV/I3\,"D#S'$EIWC; ?BA$#DH0O7$Q>*MQE[/!TWL!+BMY@@
M$#W8@4)>J$.>*9PTLO.I9L,6_=5XT&!G1P''W/&W/D:?PLM3M6J_-1WW.RDE
M9(=OEC,]LV%5BQVPQ7:3]^$[%\CUTO?I0N>+I?Q&@"# U;W)KOY)4WD;6SQ7
M/@".8D]-F7"=S/.*7G6WLGW+ZQV7OQ2['AR"AZUULGH.A'>$\-"8!#MH-724
M&,UV).%!FB&GZEQY@V#-2<&,I)-**0@._;!\"H)UQ[QHQ0+- PQE+(PYFGOT
M9LUDI$)<U\;L$" 9\XG@>6Y<+48T9?K-S?8WXFIJ2=AP.9U]6 /TCHY!;PQ<
M1IR7\Z?L',AIVJ?3F,^8N@?LF-1)2>.9;:)W)YS&)3AA<@PGI)\&2@F3DA>T
MJ;;MHWPY58-<)Q1L_1M=$0/=B T--M^)J)'<L(8M6_;DJ(')00R3S4]$_@\<
ML0V+<C:/F(_,Y_@J=T=8,$]EUR]#5X4[39M(R(K"ZGE7WN!;6U8GBPI9<VJ:
M5"\ULVM0I\PN-6]FUR:'ZV%Q'_,8OE&63'QONY[+K*^?D<R/W.]V4_*]M+1\
M+RTMWPM!JCQ&<APC8:^H,C'OV3TQYXN_*.W]JOBI8)F&6<S]2M%FP-L6ZD?F
M]"D$:0B<@].BV=?@!SUE.X?K5QNXZCMU5F#!X' ^L&(9U95W[,OXK^\YTT;_
MC9XC1E8XV^)SV6N1:>&0;O[C ZD6!N5\:41/Y6NRUTPYM\,EKF.)MRP%FOLR
M'IQSM)'D)TPDPC?!,F BV\)P!=LM#P;QD$7P"APK2]QEX /SK^TU#D!N\!&S
M1=S68?= &^(-"\69[,X!6CZS@,W/;PDN8UP!;#"CSL,B"#F'$O>S[?R"YY#F
M16H >2U9R[/C1:9+;W:X"10A$(Z2J0&+!#@>8-'@VG:9M7OKH$0!;"3FO4>)
M])PGNYN?D)EKF[Z7_9/$L,D+\>IHG#;.F_]SZ82K68/S>3-S*/GSAF#1QBTQ
M7\F;BZ4%<0D%PBAX^$B%M^_N/7.'%YE)/_T[$64IRM)!;OS+8:4.=O5WAGR0
M8CBNG7</)M.$.Y\]L/UBH^BW)+H@:\)D<!9XQVZ.6++#_+;/4;R:W2OQL/2[
M^U!'O\]![8/*7TU7_GWQE7]&'C@+Y#)MH,0UAO(IJ%?91*KS)?+/EU3WS1UC
M#ZT\T"A)#;313^Z="?8>^W:@C!+:C-F*/[/R-<9=:49B/^V<^DDC\6)73GS,
M//,^F(0 B\5EP&47+;!;VV+_R0P-D[@N1BY(>&&4&7\/RXQB!2NH=7?,I*0M
M%+=Y^-5W8 RQ\O;5VK3?:&AM1:&1-3/I/CT]/KX_JBSF-F*V7=-[/]OURZFS
MX(2.C !6  A';I*U2V_#?_F@&R[LZ^W6L-C!L1]]V'XAFAL[-77LA?S/&T6*
M"?>H3(/N",&;]T^#U]3.J-'3[H5=E+KW40?:7 C1VNGD$LSXGGK#>HY<_\RE
MS[] ^N3I3R+DP:7O$ ?'![Z5FVB*DU8P?.+85O'.%I5)61L^5&7=)*(-)-'R
M$ZU_=;W^GN+68743SAO6@N2*)[P/N_W]8<C B:-ZN@<7.)>I0<5!:ZI=RQ!V
MR5N2MY*\=:"Q5P'>PAZ+DK<D;UTO;QU(IRS 6QKP5N'&=N?@K6L8X_AM)\ I
M1S;NX8D##90*\ 0.5NPU<8:=A,VP>Z#+8 '88,^R<3(I6L*F"; Y,,"K &RP
M6K"XZU@2;*XA;O28?FEX9<,A\L%_4A7\1UULN%>X@:J /?0E;(:];F6PZ;6F
MD[+\%HD:L5!SH,JQ &I4\'8+6VAB#4P46M5^VI."(YW;/2QP(%^Z  OT6]-^
MLH96.BE-0$UEUUNC :!&%!]%HJ9<U%1V<3,:IC86J+5G6Y>!3]]M;%QQ*.&V
MM C_55\]-?7>J3H[7&M-!VI9@^6/.Y>ZW>=*CFH@1QWJBU. I4:@:R=]R5*2
MI:Z,I2J[!QZ-T54N["M7SE*!91NN(*3DD+59./-0K]@N4\:7E34R3*[N2J[J
ML&82"P?7CJW[<\]%MM&+!&H;*O6;*MLKO J8@ M25E)I#8PBR00B[2T?$U1V
MBSKNEG$9()E ,D'E3%!=!@K.IBQ^MR$OA?-D.5/6^(^W!W^AILWF.&<%I>5E
M3>RRIK( TEAM38>J()<U\HJO7-14%B,9]\&,+IR')5$C)&HJ2Y7'IJ']PM<_
M8ET,"ZURGZAILE$AS]2B#C%Y<R.BKPS+<#V'-1XLI'ZO(S51K2XO:XRY$GV9
M!]U,V%268C/6 #:]K*[;$C;UADUE^7QC+'$<BP*;DIS>9J=FY;%,"]R UYME
M*KLN&(]+R5C*=3XU<(&N%FC5)?*,)Z4D\DBD-05IE<5N)MU2\ELJ1]HU..A?
M++ !J.*1'\H,7/3%]=4CORM1SX=E9T_4>3'F-)TSOI,?/W-2?W;LU;$\TVM-
M1TF[.='75'I:M<+3(75>(:!P&DFR)%4"JN: .J"U*P14'P E@(223GV*4]]6
M+,H2&D'1GVA@!<W\4S)$K[8U8/D$$EL2G3TB\I5Z#PN01JGR!N_RAF55>99W
MAA?R:2472RX6-=RTEXWQ_K'L *=D8\G&DHW+CN7M96.M-54G)<?T+L3&S(/X
MB4VR.FJL9LW&URD/VY,KS@Q>MA!%"5?!)D2'(W.)Q^:YT1_4F1O8KLD!'[6M
MO"Z-^1*GTE.<:XL##=G4-]-FXZC9EW9FV_^_OXS5WNA#8L*] HRR&9:+\Q#Y
M7-T5^<-V#.\M\S&QQ6[/UPW_\FIX2X7LG_+,YD"D#*"='1Y .]L=0 L\:?!1
MFWS2^];<=#B6^:WN.Z^P?9=:,38=M:8>M6[>V-BG[;%R"NR(SWT^<1NGS-%E
M__@'!:8(1];WCMS)N#5=V+Z3OA6@#)M>]\*?K'C466V//?=QQ#D>]<\F2*&;
MI_G2-FEXT Q3^+N5K5-3>;?]'?;A>X2A3O'!@&[VI 4QPJ'HX<S!#7"\5-SM
M^\EFV&_*ZQ4'>,% 1 ,O$DYC7-&*_ EGZ+K^*GB*0Y\)\@#RB?T'93V^=P84
M!GN.N&Y&E^3%L!V<?&BX?]XL'/BJ@:.'@)I(6@I_>;%Q;+"YAV>"UFN<A=E<
M1% C[/T@.PV=6C@!^E/X6>QYP.@\DH&S[!4X1APFO5"6!CS108D=_S+#JZ48
ML"5C^S''282.\B7YT_@*0);_28&V#M%C['[DPQ-3TD\9"9K..4R6!T+T'X @
MSG&;D\^:]3F9)(9Z"J[+\DP%#8:BX]GP7Z-6 4T/+++#;.%)AKH'F"?D"SY&
M%)_!AF/C(V(<Y2,P#"N+,V^WSUR.X6S,Q$LA%R7'<*[E&$Y1]GC2T35T+J*<
MP'D"T>0$SA.(=GT3./^9R[23(SJKVG]](Z2/U&%NU=YK2[6T,$?@I_V"@'2_
M!"&;$,5W',3LCQ_!W?@,8$:/;I-FT8W<-ZV+<RNTSJ#RCGOGO!"1<PDELY[
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MA78?EGP'V^9 B1:0N.H9=7NMZ4CMJ,FKGEAZI&$E<K0[REUJ]5I;(>NU8_^
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M?92M&6:)PLE\XF5E095R5E9H;[";_BE4#G7.9%V@F&NX/&G5BT^5N W!(M-
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MNP>F:W%O39JN(J(D[Z54-DK4UK3?M"JON@P%^\6Q73>M7V,1 [1IHW.J;92
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MRIJ\L9_Z:^Q1',(G !0G>#JL.I$X9K*MEK+L+A7UVZ>R)'H1.3;L]_?+A0?
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M%WT\:-74+ U\"%9XN>8VO+(@+P!ZY@=@3:9O,L7FV*ND\09?P#\2WUO:#O.
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M;H('1RI/BVD\S'H89XU, 9B8_(!8CCNZT?,E$RXZ" B<NK6-Y 'CXX5A(@&
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MQJ%8X0"^]V6H.Q[L4"?VSZ43KF9-GNG-S*'DSQNR@,7>$O.5O+D8;XF+)9!
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M^]T"T6NB!7[OPQ^L^=NO+/J;'X\:^(:' B0[>-PXA@Y=8Y@$).8\6 83J2%
MY\1QWNP7"D+6\QQCYGLR/EU/@)[HE98?S\,\IK&,YTFD7\)Q.\/-N38^(E8'
MK@$ !LB8"G4P%IB9L"3F(H3Z;O3NV_V3,O/!=J=N(_(YN18$YZ*=NMVH',?=
M\0?;RA, AX 6HVWEHXU^U1Q6_XVR^ASP-G'4(,&ODC9S.^Z7AD5XH<@+' %(
M#R8FEBRT\\;GO^$'6 -C\9(7$ E>4"/#KL$B8RV(^+CXK:T2DI1Z'ZP_ 2S
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MH7PT>AY %:JS'8&^;2%5,D6S:68F<V;YQ,P,KR1N::(O"(R.[F]H::(CQ&3
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M!4P\>%>1N/RI(#CCM)92]*; S3PD*:^*E-=PP_R5>E&+=\]SC)G/O3O/WHE
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M=$69^'5ES1*""0)."1,$ZEN"6K'QMM,#.21Y*B\,0(HV*'XL@5/$=,L#G"$
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MI:EW=M=7V[J9LYY,7MX:FF/OM87;<VZ!W%B1FC]D$?;RBMW?NX"A $*I(G6
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M-D'M(],]Q[9 LUZ96DWF],GV8##/QLV,"KO>&99J43OZ;U&)UZM'SC28_KK
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M-M VL@"!5>1MO[>^M4)FAD!V8RR-?[F%/=*/F\!X@+\XL!R%_X8!DG1"6,0
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MY3/1K3@:-:9CJ8F>DH?VVE(3/2T/-9ZS]8<Q'$>W+"^75$3KA:,*>.@V'$V
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MD06XUW;PH7YC.NELN_)=-@N[:, <)K7V &;0F([[9?D^2A%<NUN\%"QA@YW
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M %AV/]WW1 +JT@$U/A.@AHWI '/O):#J#JAB>)KL*5LM&4;8@#:-(GD1SA5
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MS0VO^$+&>>L!#UU143XTQA;I6Y+/PD4#BULQ^.:9F>N6\FM.\.)S0-]_,KT
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MH&/!%J_E@XNML9W-,\!/*'+IKFR+G[$-'_S'-QP#P\V;1YN-V A<&^<4IR"
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MV=ZKYHNZ=G'+8XM:&E8P^J@+K]]<_-8ESN>'+'&28X4<.X!\F]/4/6"5.=P
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M=/\)R7W50M_'<0!OP%8(PR?'Y3:^%./]$'RV6!+4SJXTG4Q_.S+]^:'MN-(
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MQ-]A*'3L7A[C1*O(^LSRI'[V_7@X(_N9G3_YS/YY;O=@M)?VX-6>!"@QI$$
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MB'JB425C]SE66;92D;?5- J,*:>J)V[^N=;,*?3V9 =,E(J44L6BH[I^:_A
M3I?KC8*%!7+X73^[4BLS9.__ *G(4G7"I%0PC3Z'E(RS*R.GS321TFF2DJ)L
M&,-DHA^%R(G(*2*G4FZYM+6GY[RQ[OF_F>_EDEG[#(C*5!7U Q$;$5M$;)M:
M>C"7H?;D= HY#C>>/\*2\.NE&)](T*"QG11CT^*YHI9,4>K'23;;23&VL.96
MNZ$;%+]^G&2S8:*@Q:M)566D).*H%7&T-HQ?MU0@#H60XSB)8\,(*PN3&[2J
M2CG6Q(EQ4"%6E7;JQ/&>;"6PZA?H>(!B5;W*=053_>S*4AJMRH(TJ]N\/5F3
MB'V)?;? OMLQ1UC&V95I-2RS8J\"L2^Q+[%ORGJ^KJ.F" ^C4[ A&SOI!$\L
M3"Q\FBR\:15 "]/<B$F)28E)M\BD&P;86"8PZ>8EY6O!I-R6=L%3]U*-H^-!
M9YL.J]FFR_AG)JA7,;/L\[_C('1Z$W')<;O,#2_/E2WT:B[2Y_SL*A4LN_.W
M9Q>JW3147(6O;F<P[F*G[SZ+XY$]5_21]MQG#X.30Q_>R6.#)?O99U'7[Y[O
M#:6G<0"O 9U./.#&&\*T)E+?#B3VYF#'<,^78#=9 +\W9P*%,\V]#Z'3]A?F
M/?OVJ.]TI*^ND'YA4>9ZGA>=10ZA[AZZ1+-W!DP-& /[[C/)#D/?>1KC[H4>
MW]<.@$;H3R2,^T:ZX!<'7D?TN?5ZXDLP!0_V4@KMGT@V(P_I(DA]8^1[W7$'
M: >(PG&E5UC(/O\ AOWB=*+7^PSXU =RD5+K#;<"<8:3AC0:V&[8X 3*_AP[
M(Z3&,L,>]2<!+YTY.WZ;FR::4G8_2W6@?^CT67<\8-][/]@+<\>,=Y__]!8R
MW[4'-]$"!==N]QLPUS?@BZXPB'R<3.=J#ZY]9@>/"(B/;*Y'O65MTJ.^/C3W
M"$O>\P8#[Y5C#,_<AD,OX.#B)@0);";U'#P!I0FS_8#WW!6M8P418 M+\=MR
M&FGPA]JAQ/O/BH,R[N'+OYF^'C6GY6]/ =M?@X2F@&BZWM#I. /6B"XZ,-Q7
M)^Q+ :RNTX.=!,H$BL&VGQ&NBC'9@X'D\0R0Y,9+J6(8B5+AHY-?G-^PM0-[
M%+#+^)</72> M9I<.B[?('[3A^P+<](_^ O%QQ_BCNAR4Q924.05B]Z\O)&Z
M9C;;1]XH7M66-XJG0=5Z^PQ97_JH@OW<CZK)?2(M;-J[VSK,^=^O/F?*]%2N
M14ANL9F_ ZD-GCK H^Q]@=T_JD;9U))]C46CENQK+)JV*; >X[IP\5R*)78B
MJ_66+U)LRIQ/1Y%+\A6SVMWN]IHU'IGQ_I2;5;965.*(;#MHVKGQ4+7OA/\-
M:G]LWOGTAB956)AK;O]BW4?[+<>&#VR*Q4:W7@ZM"A-]!;'0Q&G$:?.<MJ+6
M8%6<IB"G;;UX%W$:<5IM.6U%6'55G*:>75E5)6D0H]6*WHC1"C':BO"KV'AX
MCZ;#:[?[*;8;WK$PEZ,P[\G:..R96(I8JD83+\=2*X*E2K.47DDKVUVP5&2:
MB0<1K:&H6UAE11FZG^XO>_\IF W_<'D0VT-HK]OEZS32NY6MZ!?E$DS:LL&+
MCRCMJJ2E&@A$1&,I&ELA6N^$QC")J=4P6E6)#T1C]:*Q%;+F3FBLS6E,:]>E
ME2?16+7ZS(H<Z>7Z3%EB,L^NC(:B$2T=)RVMJ.-6+2U9V'/5L.I"2Z?08O@'
M"T(,-G_U_,%<^$(A3LB9]%%RPHK2=+LXN169G]RJ49=6@%7:"(C&VNT5%>YV
M0F/HS#8:+;.J[$^BL7K1V(H:'#NA,15H3&^T#>J3?9PTMB+"K5*I4=&P[HNN
M4.ODXZ2E%3%<U=*2CK2DFG7!I5/P@8C^RC/YJ@V)Q0>-M""VNHR:OIE?_] Y
MJ :^$\4XN]*TAJZ>2J0)46=1ZJR!UT5I 76JH%<3=1)U9JFS!OX:I0W4J324
MROH:$'4>"W7NTM.CF&=7K48%?1R)"H^,"G?I(U(L]#>:[8/ 0FKC0 4NJ<#E
M'@I)[T(L4V6NTAI:Q8V-J98ML3JQ>O&"TSOA=84;"+06U:TF7B=>WUO=ZIWP
MNLK-+:I*YSKQ.O'ZWCJQ56HV4#4T7IDDJQ-/$T_OKSU;M3RM(T\KVG'T;,MI
M4[%!!X/ZU&&_\Z0 UF60*N#OLZ@0.U;-AP61%%D"LL"BAG&Q_*@@^E]^,56E
M_0'+HKM\N6V\9UJ]W7$7%V_W?%Z[/:<K!-*LXXYYR?3,JD8#U]'0.O)$3XI+
MC#X)G1<V+47^']F:^-$FR--;["<8[#A<?,M<*<<];8XB&S/+D_J)XT5><SJ*
M;K<-F9F*9>I/BFFWVM837 %U&%>8_4O%H.'HKGY236!D/[/S)Y_9/\_M'LSQ
MTAZ\VI, B3U-R4"T\;JKPL8]NVH+UZ;76V=M"G4SX3L$X..)ROJ78VP:@=^"
M(=EU&8K4]Q%W?UF]0^VS*][P ?D+-2?L@O"W"_LJ;_?KWRCE:\B&DM64;OJV
M^RQ@ &MDWSI!JH$,;Y5PW>$A939>@+,K^A.CRO"&SXYKNQT'X -N[0R\8.RS
MM?LD[ U?0\D>C09PJ,#^-N>'7Y2%];,Z3GH9 5PW.2W[( KS[03IHL.ZL(=!
M?3<Q?SY3\JM\1O61!+Z/?0D> J>"J&//&92WS+%1)G)&2;L<#[YYTW=83_KT
MQCIC/'VE[[V>TP%9 9=%?#;EWNBSAF@,]6(/QEQ.P&>S7H]U\ '81BJ6+KH,
M6ZB()E1Q3ZKXO=WI5G326S%*MD)Z!V_ILAY,L(O0\V,,N*IH]KEBO&/O)0[/
M_#4/,'8?) *XY=-;AV,5(!"7<11+P_XR\.@AMB/J2N_PAO2WWK_GK^U,(2Y/
M+G)<T?LG'JN0IWK)RH"HY?D<[Y8,NI<>=&8,.,)HS1@N5M1G"?;?0Q7T!?LH
M24\3N.H$T;N:TD?>#FD\X@V1[##>$%CCAIA#^9V%C7WA^\&[B77Y<QNE!F>[
M(/#%Z]&H9J>C-\ZLF)\BNAPXKC<0_9[P9T)BUV+E?O"5PT/T:TQS$51)WY'F
MIGOV(Z:Y(\"LZ7I(G,(#H.K 04$*6S>Q /4U)^C' L70!H:$__._N^Q/Q*$2
M/#K3#FJ6_#(@DF7@]TTI-51X$39"@[M@Q:;LEW#++"86'V&FU5G/!_1Z]?R?
M.+BM-!Z<[A)_XJ43 E%T"NS;'(UR<E8^<.)]]OGQ\#D9_CM55K3MM$XL2&=
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M%4-.?4:4%.]?#SM_MV%Y)*O!!S(#G(K1AO\0<!)PIH&31$H"SBQPMEO*1<>
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M+&=@63';;:L-L-Q23<U,P7*):F+CP4128Q J5D*L0!&;)8!<I@3"!G4/_EH
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MEH3)OQ8'R&E,KL'?:Q! $D!F 5*A]%Y"R!1"*A8.WFA=>%QC]GJ=ONWX,&!
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MLV\/=R-4HL]IB51)/B=2T[<%HI1!2B":SG)JX>^J=A%-"=LW)XXGP*2./1*
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MQK:H,/. GD?XNB:K<:GB!]M_LET6G']_&[ )2!M<)%%E625X(7C)P O9,$X
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M:((=X$H[Y.(1^9R&-EJC.#NA<ERA!(G2,@61A>)$AS;:1V0B5+1'!DBI_UP
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M3DT"3X2&,^)APG>7TW#34Z"74)M-XK;W8(?R8R.CQ2$94WI4+O2^<Q@I6-C
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MWS^_^_6'E[-T?H;3Q0\O.@P+S#]\&2].?UB<X@__F'7_''\./[R=A$69=6<
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M7&4/D[=A3%-L[7F.,O=<V)@)@L<:#.^J'XM #BTW1J#CJG6&X -0AF02-Z9
MB\%OV+M[$>J!YB^AFXZG'^>TZIZ?U:'&7(\ZT[A>NIFB3>00BL):/HTL]GK"
MD:.*PA7O&+8^-'P:U9#,YL;\:*R2EA;1!8Z-BO'4@@G9>-KR0XUV4-R3 5=[
MJ(JDA"DA)MGZ8GQ+B$,RK%LO,CTJ:VC!2]S+I$M@-!%2/8(M'*(. 9+*T07/
M8L+6%DL?P4MM;%+)G5?>0% E  U ;;90$FAD,29!6PRVWL&?LDF'9K_USK&G
M0[>V4E.SZ?;;>#KKE@.P%BHPEHI1U9/6M4J9\^"9H5W%:E2)@+#FZ72W,0S;
MSCLX5?92T9%:FZQKX^U;'^C^S^RWC<G]T!O5"ZII4/2 M]WL\Y@^[>=O?\SK
M<<9E@Z23M!A_7ETB2LT5R\8!=_5&.+,"3BI>FVT5'J6QJ7G4T.;H&I0K^3RN
M$16O9MW+V7E<E//)Q='P2"2:$(Q<'64E?4$ER9(-"-I+SC.*X%WSP)='\ QI
MY^J)/_>4-&FCGI8M';MZ!_X25_^^GE[DFZTNW*/WDI%?;'TM>1PTR1H=!"$,
M%UX&X]HG]#T":%#E[0[$F78:ZJ-!<RS6V2BPIJP+VH!MKA4>(T@2BVG.#<%K
MOZ9LT=CH4 <3AUM!=AGZMN&XU1@C66_VKPR:%V-U3=L*M?V\L^!38A!"MDH$
MRU/HI:+X?6 &51/\0,QHHYD>-Y8EP$NIUR>Q-4;/DW'MZ?\0:@50A=G5EI4!
MF TA%14P8NLXN,W1;7GK]UU0J2?=]<BM"R/J9)I_GRWP6H&$D8W>9"D48.V3
MKH0SM=F6!4>.8_$.O;0]-);>&-^6L9;?*;\:Z:]='<\PGL[K+HOS-]-?OE;9
MS\?ST^K+OBDUSFJ$):,N@LPM5W)-[^<0T6"M8ER2$MYFTSI \TE0FW#)?F=<
M:JNIAC%0GSI,X^5 T?<37#<L.#FKIUO_M7Q]I")CB22%(*L9YU@ KTT +"X8
M$7,D?C>/@7H:UR8T<M^76=U<7?VEF2P3GNG?%_3B>#$?N10M2YX\P-I]0V&-
MA]?(@'D:D*R=3=@Z,N8I3)L0R']O!&JHIK9%"E^??0KCKBZ(+TY#]Y$$#2*3
MB,*!]HP$59(< F\1..ILE.>6-:] <#^2C8X V??%E 8Z:5C9*73X,UE@-X)"
M1X)6-:)IH(<K<AACK:7I9:VY[5.165EF6D?HWX]D(WY\9V?$#71R $=K'6=>
MM\A5[.B-"CZA:*NTA>1%!"4E@V#HBW%..8[.RM+:-MX-Z4;\.M25Z-&=KV8Z
M;<:_!X9D517MYI X:0UF2\89>D_KIY=0:ZR!9I$EGA1*U7K-VAS=W@?NX=OR
M&O7#["3]Y_F8UH?S^7B*U>E91A4MBX:N?I-'B+15"-0@K$F@6"&'N:9$$S<*
MXSXZ5*VSZ[;!M^6UWU&<U'T)=N?4OB_]M;S228AY_HJ&Z'V8X&]A4;M=?UM6
MWII,<-D.>/ZF7"](B):,6B;( 3*X3"Y*X-!YD,G4,ON"W.W64VX'F$.*>CD4
MW7I69CO6W9X7UQ%9PTIPRH()3A B7<!+K@"U\]&*Z!TV[Z[R")XM+QN_SW5K
M5_WTQY@'N\2,1#',^Z#!6%43HKB%P/0R]Y&,F1"R:IY"OSFZYW!#V3N;VNBN
M.;=>S;KK*^CR[NN^L2@HC?3HJS?&UH5*&2_ 9<E!9>5";!UTOR7$YW!YV1?+
M^M!BT\X+MTK\OR-DW3@M,*]; -Q\X=H[5YWJ[_IQZ_C97[ZFTS#]B._" G\I
MA7;[D66U27-B$'D-@2Z<OLMD5PJL8:TA<9I@C9EZ6 E[<C3O\[U5MC'4&V^G
MB@95SV"\R0Z2DHI6K9!\:3WK=XT?/7)KXN%R_/::T9/ZCW$.@HH9H86!S$WM
M N%K(E-,X'.-"$.G=?,,PEW/08[KBSU_>NZK_K[I^6H\#=-T$U^.Q06,#C#4
M(PUC./AH&)18C'":%9,.%'U_#[HAQ9,^?WKNJ_YF]%R)^*9<%_O-=*\!'NF2
M&4])@96,!$$6:RFZFH?D698:@V:M8Q9[$&-(2;G/B/#')M0Q%F[F4))]PVD[
MJ<6?C=+@?+* .7!)GE/VS8MX[;IP[^[YORDOQ_59TSR_5CQD%+G.J;@,SFKR
M$XM+Y(XR!!1"YN2<;9^[^3BBYW"'LB^)'O+K&^BHEUN3U_/Y.0F,;[IZY$Z+
MPRK[6,:LR4E0P!POH#@&B+%DR*CH/Q=RX:W#CY]&-20[_%#T::NJ?B[>+MI^
M+>-6=2I1ZIS)B@\25"H2HHH<,&'DF6-)[>N4/P1F2);Q$0BSNV)ZX<D[_'2Y
M&-Z MKKHJ_GQ'X@1^-MLNCB=O^E^Q?E\E-!E9C0-0\D(2M:624+6FMA22BM$
ME*%UM8I],0_)/#T"ZWI7<R_DO';^OCQSOV^$="V^%8RL901I&@7FP2L5H'##
MO39&T;+;(Q<W@#BD8H]'H%YK)?9Q1T?3X[PC!VQ.._AU2]!)J6N@3.V-7//H
MT4 M@@LV1Z8B"RZ&UB6*GD;U'-*\^K+8&^FJ81V^JW7U>EN $4O2*5'#*B6/
MQ&A!!B + GC.!5%E'UCKJYV'L#R'5*[6?&FBEWY]NYNXM'6:R1J3;9P%I<@D
MC(H+8"$$ZUR(-!J'\.VV9LZ1L[<.XMOMKJI>%IJ;+H22A@FN.0B5.*@H:MTJ
MDEL;))A1ARS:U_E\ ,R6V5K?W5*SNV;Z+0*V/"L^3RM3?YTF]&(2YO-Q&:?E
MQ\_*S??,YHOYRUK1=+)+@;#]GM>D>%A#D1L5%KO[M)%UT9BB.!2O:N]A8F!P
M-H 79,/(C(B\=7S]713[+TUW1WH4+-H0:FEL68L)*<<@D#$/G*,T)3M90NL&
MF_?A&%(0RY[ZO[ON[#GL>^]--.WO1;',0[CQBW?X&;MYF,POK]&J_&\*K<V9
MWO-^-LDUC3$M1L%'9BRCS=7* (I%1YY@4N#0:O2N:"G2$XM/#["&=,C=B$;'
M5EZ_&]YZDP^3U],JR7)[OA9P'K^]" O\..N^A7J1NJRW_'.85&/O_2F2W7!C
MH]A]'^P%1I/ML?\!:K1K5DOJ/:::=%(;M'^F!]7,PE>SY87+NJA"37"=+W[Y
MNN;G90^25376DT+_GDPFLR\5/_WE*I%^6?F,I^2<4;681\V%K5FQWM/2Z0Q/
MF$I&GEO?J?4KT=YY_K?PW$)[59_\[QT][8]IAV%2X=;B*3]CF76U8L$HR4(C
M6\NC+!//ZC[D:3A!\%HXC%Z,NGE'BA; !W4;/B#JWZD\<'"6M"MDL2/T.F97
MT#D+W)58H5NRM@(R\AVU@"A4K<*OD[:MO>XFP(=DR7R'_-Z=)$W[8SX\J@\-
MY$AEJ76NE]"!Q7H=;<&'7" :+Y5BHK3OBK4;TB'%#PR8P0>@P>%-^/61W;>U
M1;J8+4ZQEC8)TV_7K-=:];_,)N,9V:XWA^%%K?M/GLIYF*P3F>G%MN9]KQ![
M,_T/-[##<0M6Z_0#4\]JZ8O,###4K-$B+#B?+6ANT DA$MH^.@OW*%)KN^D*
MZE4<R1)X7=#>3/'#:3<[_WCZ:OP9_P^&;GY#@)%V*B+SLI9X15"<.1I?$\!:
MX6T4):O<NL1S4P&&=+ XI+GPE"%U.-;TYC \),(_QHO3\91DJ,!OXK8F.U$D
MN3=>B#J"#B+3&C!K9:*P,LOF;:OW1OV=N0I'IW@C?AR<U\NI^0&G]\U'98IU
MWH+A-M28FWJ#JA7PDGDQ)2:>6T<M[(_Z.W,@CL[K1OPX#J_K1K/><^X7@=OL
M:I V%!U#+?E<RX>0,"(%S7)*F3?O\=14@"$%/G\W;&_*FF.?_.CBHW1UWQ&R
M-G_Q J*6!0(*K4(,PC<OT=KBY.?P'LRK,.Y6W;^UM%)&C:"=H2'#J,#+S,D.
M32(7+VMKWX%Y+Y?@GX_GTH2QK1V2W4@PF,WM"KXJ7!:-&8Q<-@P6$J+P&DR1
MJ@3C&(;6-Y_-P#\?U^3X'&Y&@N,ZU%>8DT;%:N<IIA5A]MD!>4T<<E$FT[0S
M3!]K\;T?\?-Q.([*U@;J/JYO?(59<G+?!2%EP=:Z"[6R4U 9/->^UF-0G!WU
M='.G!7487L+Q%]3]U'WX2[/W==R[;[-U;GJ8YFL%#)?O:'L#MOGS>KO.VE'D
M/>^F:DCEZH%7_'GU'[^_OOU:7>AFYXMW&/)X\HV08'=&0E3Z75 JK"J8+K[]
MAO3>?*.Z<C9!V9+(H61ZG560K0"632XL,2YN)[S>&R';.]"]2RUM#X9\\//I
M8H08/ L>(;AZAQUHVW#2<4@T/;,.WDC1VK+=&>P0O+'A\?9.E:2#<*%=E; '
MAL"4Y)32!51*%E3M(1><#Y!#LD9%KK'T0\PG)N=Q'*CG0KO]]-B85->&ZO/O
MXY&*/K(D/.C #2B;$T1,#B2J()/5'EWKB\7[< S!PWDN=-I#@_UQB<:I]GL^
M[[I:,MT:M-:Q!"A)-*6"(2N:@'$1I),V,\=;7^L]CF@([LDSY-?N6CV(ET(^
M7-?5HH=+T5^L8%:'ZTV<C#\N'[._:[+-0UKZ(SL+US! ;OW4463U-"_6&OC5
M"&*>O.+,:NYZU"$::[)HG8UQ[?'[=Q9<)U7_/.NZV1<:V?G(%BFD#0H2)V$4
MV7&U$:\&&73V,3AIFA]>WP-C",;[OOJ^VS-PO]%NMD==K[EP(9AB,<;:8,$C
M1[*^JC7/M0196SPP,L&\:!VD?@^,(1C/K=6^[V@W4_MJ^<1?:]'=BZ:!WRX0
ML>*<X;X6V4VRRB4A*,\A:U=O,@R3H76IY,?P#,'L;4V$9N/?KL')[.P,NWK"
M]S9\PF[$<K Q1P$:E\7""$E,W@'Y9-K*A":8UD6Y;D$8@CG:6N_[C/(1K,6Z
M7BW6ZU5C&_&^C^[/,GQ2D$;VX/4%OC;O"Y_&BS!93O-K%NE())EDD1)*9C3#
M-?/@7&"0>5!:Z9*4;'USM1FR%L%15S<$?TS#1;S6R_%\V;/V;8=GX_.SWW$Q
MRL;S%%P"R<PR;\\2]XL'F^@?9H1BS1N?; %O4#G*/=#JODRV/C37,.ZN("W
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M2)S964$]DJ8&DB=REV@S..^F;Z;7+#D4R5IA(T13D[^<8N ";<F<E:*B99Z
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M0JI_?M*-Y\2@ZSRZ=HULC5$B6Z"UM-3:(A)BR37Q)$J.!8T*K0,WCB3JH"K
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MU?4-!ZD:9YA :ELJ%EH<F>M01-%2D8$AG=Z)WL=/?/&T[B3"AJE6=UC>X_F
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M8%_U<6ACYB610YOJ("]NZ)Q*M%<5(VO.JPV*GU1]7)3<&%T$&.N0SN6L(<K
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M>^GB-!G@]%UY.\ID0.8K.MF_O+V\##/Z>1@NVV@7X7JK5(PJ.TA.!\(M.;C
M8@V^JHR2Y]2M>F<3@V=+K >X.6E+^Y/F4'O@K(<(^<]5[N0S?\;\=C0C-V9
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M"9]!^BQ!D5:!*[).Q4.E4 9CL?5Y>OR:NF4&_-$HZB:D]J"@ZS->%0\B!,W
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M7D \ +)0V"Y0-K%SNO)["/-D1R*6T;F#%!MNU\L@%6.CEM8#%SR"<E:"#S&
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MX)O/\ROR:D/*PDJNH82:OVE9J=.J"";G*^JQP/MV_;K#\K(YT%32CQG@]V7
M^\4\(>;E+R2%#_@E?%WUT[N>C'6&Z$6.10);%9U[:< 92>QDC',7R (-K9/>
MGL)S&DQH)O$-T:3&@P1^#,O9\H\O"PSYW<6_PV)6;Q*K#\O/O/1!:>6!L9J:
MK6CWBIH(K",71B 71;7N23H4VVG0I(LF-E!F[PCD?3Y_$P,YDR(+6=NC>\1:
M!, B.+)G(%LGG5(,T;0.-6\%<QJD:"/K#2S8.R[Y[6II7[M:I$]AB?G^41>-
ME]F1G:,*IY672,9.8:"842GSXCCK<?7P#*S38$9K^6_@2..IE$_.T" J:RFY
M U<0007!""K1.09F<Z@N4?,1],<XPV0ZQC33Q@;B[%V6\\A,,CIC3 K!YAK\
MU"9!3$R!S\J7@D$%VSK0<)K&Z%Z2W:#JO7.T_T&26/XV7RYQ^:[V4Y]=?+R:
M+3]=-UR_/NG0>:9E!HVT9A4MN<QU$)-/00>7K8K8VO)\%M1ID*&M[#>P8^]H
MXWJ7^OGO+WBQQ'L#V'+4VIFH@<?:'B]D!SYF#B)@5EE;:6UKVV(KF--@0QM9
M;V#!SE')^VG+:\/WES!;_#N<7^$9SW0.)<M FMJ#+?A$QU5,M)%Y]"PRRWAK
MDV$CD-/0_OXRWJ#YO>.5?UQ]^7(^P\7-@(Z;YKCOXOGL8Z@R/K,^.H69@45?
M4]=+ <)E009%EJY$%I)OG>WP#*;3X$-3R6^@AI]LVLG]HH?& T\V?72WF2?/
MKJ/SV!,4(I)>%3@18TV$8F0I:@8IN5R*%M'SOA' 6R@]QIXD46PJ*0 GNP:4
MXV3I<.D@A<@MQ\"+'M1H9?<DNF,8>S)&QT/&GHR1ZK&,/=E8$Y=D$+Z.=,>B
M23#.2O*(702>##,J<Q9YCX&:QUPM/$JW0ZJ%Q\AXN@+1(:A>:[7P*(T-JQ3=
M1=S3D8%)%G0) FQ 1O8P-Q"Y$V"TSS8ZEU7['A%'7BW<@0-CI#Q-M;"7&"4&
M"-(%4+S."*VWM"R+K'Q &>SKJ18>I9WGJX5'B+93I<R#.3ZE&$5+5( QU'XW
M@4&(0I(352RY4'3DN;Z6X"D=]'O*MT-!Q=:>_D-PO=899Z-T-G2VU2X"[UY1
M=0^?4(IG33M;1'2@ZE0O;[P$ED223BHN;-^ZJN.;<=:%!V/DW+BT^=MY'/YZ
M'H>I<9]OQW&PHIVL2RXA)U E*SKSH@-4M1J0I6+-@Z;( R:=;'W<H2.(N^IF
MZZ"3-H)M7"/]#43!UA!_8 ]'\3 73$&O@"N+)(-,TDB% QDLENQ;PJB'S+<;
M^KQ3TWXKT?9\]86XP2A^,$)_BS%XY8J1M&HE"*-0!EPV#*00SKAD>-!#ZIJ&
M/N_DU-](M U-P:T;E.7\(40K+'DW2@ :VIM('G4,6_"0=>'<)\GC^)=_^^-.
M3?F-!-NP&O8Q/^4U1*=^>'0Z"6D3BXE.IU+';W*?B9]H0;*2O-+>)>Y'O_K;
MGW=JVF\EVL;EK!NW)R\WG4Z9!<T-$"$#6;O,@E/*0F$J8HA:2#G:ZGOB>2>G
M_D:B;5S8NM$X\4S:!QM4]$)H'0(XK@4H%SG)0!5@KFBK:>?R/N]J]CU^W,DI
MOXU@&U:P/H:H5A EDS^8A]M3+)E,%E0@G"9'MS !3M?!!%G:HG/B,JC1RM_^
MO)/3?B/1-BYQW62;2,X?V:4":6NR/)!"4ZI5FL15XQ"$B;0FSYUT;D>C;\/C
M3DWYC03;L/QU*T3!'YU,6$)2V13P,9)=&FHRA/,&:(<2V3LB)]M9]X\?=ZJZ
MWU.P#0M?MYDE4L@?'CDECB00G3%@;1V[ZS1A)%L4%!UBW*.*-H\>:/W$\TY-
M^ZU$V[+2=9ME(F4=H_W0*9%*8XQDF2!A)'E 9!C!%$?8!1FF#[L>#3;Y-CSN
MY+3?1K M:U:WN:0$Y_'(=<6RJ%U4(,7:624Y#H[1'X4R1M5N;_EA@N-@;W_3
M\TY._8U$V[):=>L.I>4/C_P2EY/0*FC0O$I!<09>)@?6"'1T/B7R4'?=_#<\
M[^3TWTBT+2M1']LG^@:DV@!2ZBQ,XL B45-YD2!X9FNC)1O)FDV1I]&6W_;G
MG9K^6XFV94'I5L?4RA_<0Y JI6B2\\!%[;ADF8&8K0#4WC(FN"UE_/Z__7FG
MIO]6HFU99;KJV?SK+W^\^08IL]=(G?E!/[14E,M*FMI=0X?JI?@,@?@)L4C/
MM,YUVQI @E$//0$F]!-RR[+2K>YJC4@^Q(@8N$J&O)1Z0:%+ 9?9JO15:,Z<
MEGE(@_N!CSL!"O00;,MJTD<8V1JC>62O6O)3O"&,7M2LU'H['04) IW007 C
MA!G2[&[@XTY-^8T$V[*@=!M!%9DM#S$Z4Z*PR"&+6#%&!:'4CLW2<&=]--J.
MOO7=_KA34WXCP6XO&6VA?':#43\ZFKQBT6DR4B,K&516",Z2XR*,YI).+8EA
M=+;/]L>=G/+;"'9#KD_S^)_B_/'-I-:<3) (Y*URH%5D\E"$ N.X]-(*+\/X
M?(^MCSLUY3<2[ ;E-\SQO0Y2**$>[4XF.*^\L<!=(KO$L&J7"')9DS8:5?*<
MC=_VMS[NU)3?2+ ;E-\PS>\Z0JFD>G0Y%8*4-C,-F.K 8V9)!D%'<([V-)VL
M8GY(]_*!CSLYY;<1[ ;E-\SSNPY/**5^X(]2$GBR,G$!TEK:GE+1X'U(9*3:
M+%B.PL7Q&=[;GW=JZF\EV@WZ;Q?YX[<@'V4E6.^%MN248*I5+;PVOJO-4DQ*
M4F"0)ICQ@=^MCSLU[3<2[ ;EMTOSNXE-*_T8(^=9.1,*<,\-R0#I=!*R !;#
M&>UL.=CQI3U;'W=RRF\CV W*;Q[DTXP_NI=6F?0HM0(1'6$,6D! CV"TX4HF
MR1*.SO'<_KB34WX;P6Y0?KL@WXU3HC<DHQ$MT2FR141FK 8A:C%C09":&^^X
MB22(';V]#8\[->4W$NP&Y;<+\MT8)GJC8<*$)T?5D4L:(BCK'$2I$;Q*-D;+
M \9=;_LV/>_DU-](M!OTO_>,BQ&=C@5J[1,&\*6V4:^MKZ*1'(02F#63PI@'
MUWVOLN]TN[Y@S;31O1G(:OIG8C:Z7$N3+;TP*A8++I4"):%7EG/R9U_3;-6&
M_>'&2K=3DZ=US]/?YQ?I9L)OS(EAX!)DL*9>4R"$[#DD%(:9P+R*MK'.-R,Y
M#;TWD'*'-C W?4U_P[#$WV8AKN;NW8.'1G F:ULCK!E+V=&FY,B3E2&CE-9@
M\*V[73X#Z338T%+N#<N"-R_Y7Q?A\WQQ.?M?S#_-EJD.U7B_P,^SJ\^_X^49
M$XB^^%#+ESR045@@<J7(CHK2>!T8>WA;U/AL>!+>:="EESX:EA3?02U(',XW
M#'\[7UXN*RS-46A!L(RKN6^1MKQ83SJ9HU1,2*,P-*?)1BBG0HG]Y=RPI'C3
M,??F(K\-7V:7X7RUS]UUS5Z>.7*)?2D1)$->QWIR6+G*,A171++%F-;GRC!D
MIT&.#EIH6(+\O$OT<RF8+F=_X3VO"+5D.C@$;5?A%"8A&!&!_'1DQ.TB'S:?
MZNBC;@!X&LSIIY.&1<P#K:B58WT]QN6FE7PX?S]?KK1R,UP\GM,_7%Z>&<-S
MTB2MR'6J+7CH^)1T:"HMBV'2Y\!;DZL9^-,@WF%TN;6ZNNU$AI]P,?LKU)=G
M&6@[7BTI??WY[_2ISC7X,%O^SS_#1;B></![6"Q6O[K[E(:]'M=B<D.[]3:;
MYK &=,?;)9V,_P_FCW7 1-W8:*&XK ;U^7QY1;O>':\3TL[&C8'@C !E0P9B
MLB1N<4D<T][FUHV/]P*\_\$\_N'737(U"X4+P8 %0_(A\P)<80D8S]851S]L
M/B!@9[#339F8BGN/#_,I]'@L$RLVK;9N-:N6K<+FG&I_;F]<3< B@;I$ G4N
M"F^"M)SA!,1<XSE<8^M)&#& ASMIIDO?XS6VMT3+14CWF[P/P=:M&?9V7(=J
MB-U*BUOIT4@%4].$G!W-LI;D/=M2:[EJ4P]#QJ]&Y@)YT=KD%T^/9]MD'X(=
M8R3?@16_S!<X^WBQ-FS7 -?=_22O^5T.K*T=WH3T$*4L8#)S0OD@C6A-BR<!
M'<)1;*6[A]YB,\%WN$"_.4Q_PB5!7(7:5B^!<=R%2$OE5G&RY*2"@"6#%DDY
M;KWENG7,<S.2UV5\--!&AXO7QZANWHHAN#J9'-LP'<;<:*&W9ZFPA] ['"=;
M\<EHDW"K.[W"0-5^T8%["S'9F$5026/K(;_3DN$9XV)*+HR1=1=#\QH0YC?+
M&XQWN^7-^:9+3M[60B+E:]TP[831*D;OE!!1I%!4;G\5\BRLZ<V+-CI\9&^V
M54"7#+T-!VD=8U^GV/_X]0;U!SR_ON?[-/NR>EU8-DX%58N09 "5! E$< N6
MNVR2*M9/$@-Y'NGK,E FT&:'%*$-L-:3\08 ZVO!/ 9U/!&3UIK=?*PU4DL_
M&V<#0)]8Y,(DD-457&W:40D'WF+B/N8D0^N)@Q/S98<0RL'H,D8;'6CR-BP_
M_7(^_\\-P)MS-\6( H.M?7/L=3&=C[Q6;\@L'=?)%]&8(AN!',S4V5=1\]92
M[F#=_!)FBW^'\RO\%E4HGM>X#O"@"%60"*$4))":)& 8&M/Z$G8SDE-1?@,Y
M=WCQ_QG^GGV^^OP!Z_HJJG!YM9A=?GU7;F)^ZVR">SD&_,S88HWFJJ;1RYK)
MILG6K^7V] "-"1,98XW)L1/00X9@I[Y][J_)QJ,0_W6QP'!>TZK7A^Z[B_L9
M</=W2UR^2>GJ\]5Y=13?77["Q=OYYR\+_%3/^BKK-/^,]2-^Q\MWY<_P]YF5
M47O):LMOXVI>-KU7](K1RR5<%JJ.?1E29]L5Y&N@YW%INK/IA.OU_3G_$3]@
M.@_+Y:S,,/_7[/+3[.+/_^#Y7_C/^<7E)[(CK=69U;'66A%L%EF]-3' 9<D1
M@Y VF([&U0BHKX&F4VJSRWSQM<!^_CN=7V7,]:V97Y#<UHN@!<P_7M27\->+
MG\.B'A'+,R7JM%-;RU6JJ!0F<+&> ;(HS;-GHD.6]TY07Q,)I]!FES*V9V'?
MRRN^WLG?;=K>[S*,?[X@L2]69O@9UM:]'C,D4^MV@\MUE@LY2YY%RPV32;4O
M:>JYHN^4/@@W&@_VO%O9F^42+VL&]CJAG@1)5LK;^7DU9A;A_*X8Z'+^ <D\
MOZC'S9G%')/(@5Y6>F,5F=W@<TE@BG0H5"H9AYBJ>P-Y#7R<7F-;J_X.5_/P
M[NIR>4F_]<U=VW*: HBGGSUU-<0(2?0LC5AO@7?<UL:2.Q,M%"%5O?>,Q#"&
M(&)!E-$4P5M'YX<AF_XR]<>OUSO_[?GP6WT(_>6/7S=]6%7PS2VA0X71>/!2
MU*K^&E4C6QRR%TX))W3*[=OL3+6Z@Y93[,?7_6]D)Z'$BRBT,(PL'!T#)*=,
M;7:)$%.-(4=CC..^%-//*#[R0HLCH-"8RHPQJIPZY7X(MN^5&:.U.";W?A<5
M3$V3*+242BF06OJ;<:M&2+")&XO1RT?CBUX@/?:IS.C&CC&2G[PR(_&@5=2T
M1XI,X)3C$#!*R(9+R3#I[%KGT[ZDRHQ1NAM5F3%&\(UO]QY=.E[,/\]6>9ZU
MG<&Z86]0N39RAL*JWRZ]@!@2(4TJRR0%<SBD'>J09YV SKN(M>L1,2JQBFRG
MZ#!%8,(50JT$>&9*S3%/4@:NM&N=5' "^;(OP\AMK/Y^%4(;DGZ& /N>8-M*
MLX,S)G=1RZ0)MK&H$KQ7P&)&.GR-!&]7U3.L<,ZS4.)[@NUD=!FCC<D2;(-V
M@M."@.E<1Y5X [XH!Z;>6\6$'IU^;0FVHQ0U*,%VC)0[)-C^CI>_7OR%R\O*
M_V^1H2G,9'('&7$=E,D6O$YD"L9HZG5]0M&Z?\]V-*="@D;R[N$E;TX!SF3K
MAR@,\!#(2(_DJKEZC9URYCDZZUSS;-KC3[7>AP$-Y#Q)#?KJN),A1>E9 (6I
MUK*9 *XV"2TVH&1:>?UP&M!KZ%-P?&Y- _7UJPO<4),[ -=K;FPP2F^#B]EW
M$/J4C0T8Y\B385"G(Q+_:]Z*9 :"2+G(XKQ(_7NB'%]C@RY<&"/K S4V,%[9
MPK2'.DV+S"%+AK$DZR@:Q8M5)7,O&]/A934V&*7#'1H;C%% #\]D?I%O4:YC
MQQJC<S9#626RVPHIKF9H"^XY#R:[UF4)&V"<" ?V%7##?6&YN#R[M9?^@?./
MB_#ETRR%\]4.&"-3DF4#L@3:!B.+M#Z>P 5I.&V*=<KR$*W34^YIG/YTI^TG
M 7RW/3?:GNV4UC#I>07J.K7I/J2UWS8 U!B[\SE&;0,RK;'94%'S7E)NO9EL
M!8<FQ<*CKU&V5&>B</*SBP44/ BI@BIJ4%3SN%2_Q;2<6O-CA-M8XS]?+>9?
M<'V,>5[(:#;T3O ,RH4$D24&&-#1AJ:4\(,2#Y]1\OUG3F<4-%3!O('\&II^
MJ_%5BZ]G_^_[,R=LT-87"-)5U\<CT"E$RS!&^Q*YR^XI#2XQ_?!Q_M?_N?G$
M:R7>_.%.AW?/>\G:VU%J77,K?I]7Z=$^\[F".[-&\I+(:4U>DBLABR1#PR8(
MG/:?F#"%V#K':AN6(ZDCZI6DOH?@M[[(AZL%NOO=*J]E%1@N[WS7\-AWG:A0
M: ]@4U<1M9+AM"5&//A@M,[@DP_7&V%4S(-43@C-8TZZ_23)$RLQR@Z+\=6^
ML[[VGO *HC/T1_3:H C"RG[U\Z^LQ&@,7P]88C2&$B^BQ"@I%]$'!"F<H0..
M'!F?A8:2LE-TH-H4I\C+?$4E1J,H-*;$:(PJIZX=&8+M>XG1:"V.*2+91053
MTX1>BYK!SB"7FAT8ZA#54A(4;6)$KIE5_4[<EU!BU(T=8R0_>8F14F0>..F
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M::'V>MUT<S3-O=LP#%/?J>T@F3WORU:)1D\^]8[WAILB+4O #:_5$]:"DS*
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M:4#M@R9WD7-I03G%R L@\PV=R<6289?YY ,G7E+VJ9&Q)*: QYJ(KDB&SLH
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MN5W6Q=]&BI)8410",%JH3KJ^K%%8@$9IA2$&V0OW\?#%WR>]209 Z=&:9;M
M[(Q+&D>!]"WI@@95^["4M!)BP@@,!4?+;-#B?!YH7UBS[&GNI , =L9EAB.F
ME>!"14@N56(7]!!Y<""+UA:-Y-:=S'C9UV;9<]A(!P"L8>G?U[SH<8WW(K\W
M^;^OYXOEOQH5;WA JP%3'19ER#3!\PB6G&W/K):1/7#P'KU;'D/NUXVR8:.<
M/(#.JO;N<<NOS"YPKSDDGFI)<*;8E%6?586D8NU2QO-I#WMYG>6G>?<<!K-3
MFH7>.?+SBBN#D@-W9!45A */WH'(HK#E>!-V/OOI0CK+A<J*M!_ J3I?P_.:
M"/:Y#O1"CRD&?D8)G\OK+#_-'&D[2)U5@J=#=;ZT$:752(%$'7;,M0'ON0>F
M)*.CWEA5SF=;O7:6'PCR4^PL[X+0L]JE7;MU?4I6&,,@25[(?I*12G(A)P5%
MSM))R^W9;-77SO*SVJ]]8O6,4[[/*R)2W,!#%G7*)BG"(@-G1 (MA0H^2L/P
M7/NI7C?MB6_:/K%Z-NGE)T^N+:E#+K#PH"1X'A&42WPU:,(:HU/)&,K#6'/@
MW/,>BWK=C$]MQI,S5R<,GF/Z>K<&>AV4(N$X1(^!CJ1D(6A;]>$30V49X^>3
MB7NE>3B?N[,WE)YG8OQY'; DK$KD,G@A:M6Y4F10&R%9FY+C*:9SG/-RJ30/
M3' 3M?? LN&UK-J +UI!\$X99Z1T]GS.U8NC>3C-9'HS0)TTS8,2S$J9!*F]
MTFL)H>DZHCNI)*[H/N*2Q]8E^"^;YN$0L!_'[ /1//PVH=\B28_S=X$TNAA_
MP_U)')[ZM!84#3M+VXB X?U?6+]D\OGWZ7S^EK[Q>UF54\SOH.6-*,(Z!R*Q
M4HT:(3*'D$DK-F996&H]FG@'L0X]Z[9_Q:I/.LH<6&"U4)T3E"-CE7$'P423
MT15&#EKK,M1G1!J*[J U)AX>-RTU?RHL!;?[]LWUXLMT1B[ LHF4H:V*JHPW
M2%&9*Q$"YP4\-YAC*IRYUN_"FR4Y%F]!4UM/F^N\AY?.QU+=CD!]7JZ>J 6V
MR70<>H 6=GL6"@<H?4A0!!Z,XR6!RL6!2J;Z^J72T$KABM?TA]:4R<."X9F>
M^R&QT$77/6#@U^D,QY\G;Z?7D\7L^[HQFQ?A6*ITK+&H*HF$6#B"558*3NM4
MH;5OM4F.X4.>-E::-E9Q#\V\M"R*^,?I1Z%B\D&@-% R,_5=HD H=.\);6U.
MY#[QV)HU8:,@%V+XPY7<1\W3(BPJO\/O]"^O_K_KV7B>QZDJ]V:"N9/*>,DA
M8<WU&@K98PX4P3/C(T%4&FQ.4_"T2!>"AI:*;YAEF\\6H[?3R7QZ-<XD8/YE
MLB#MXGQYXZ7HI1>R@+ V4$"E,CA/?C%:F6.)3KJ'C5J;P4!?<@\(]*<[$#SU
M_9<4'S33\P"V7Z-]%ZFZQ 9[H. 8$4$[2SUC^@/4W/!B>$8Z[4+V(@@PV=7K
M2GH(,6BZLY*+0BO+=Z/B/#'C;XD AK9]%^TVMOG'ZS@?YW&8C6\)F7C2C L3
M@>7:!"8CN29.)EIO2=&PD+78Z>7P&5L__N;AKOB6]I@V4V8/'OZ?DSR>+V;C
M>%U7&683NL[F[\LZ&+DO[RAIH5WV"8R2U:O1"J(BF8WU+JBH,>K6)"&[2S>\
M]]=WIKDGR_2 H>V:&)$$Y*T6#4S6LY K#M$D#UH[[V3TT34O"=DNS>5AI)'F
M>X@??\:"LQGF&AW-Y[B8;Q?UW71!:/YO3(M/TU_^_FL\6S[9CI1ED3,Z&*VM
MH-:6@BCI.7 O#*9('K1MS99\L-"7A[!A[=A#64B'!6R27@AI&-.D.RMK8WX=
MM>8L@X(RD!(3^72M7U(/D_A%0_!0"_8P+&^[L+5J:E4K<W4U_5<M_AXE93VJ
M4""ZZ@P*R\$K1O%#I9N+-F)$-=AU^5B^R\-6;];IH1Z_PSX8H57H7"Z Z+%.
M7$O@0TC .=.)2VVB;$VEW4&\R\-17[;IH52<1'Q+DHX7]Z5Z\[4^/HRTU=9I
M;Z%0)+$JQ(LL2+"QD- I8]"MY]$\(<[EP:25[A_#PAS2>O<(O1OEO.?@+>Y?
ML)QA<($K,%Y7JAQ+!Z0P"E 6CU%*+_V#9^"-K7('"7$Y4!G6'H^!9)M?4QMN
M4D5B:,=JIX@UE=!!@"/1@/&24I')L>:OASN(=3D@ZLL6C^'BFE47?< TG:3Q
MU?BF8OOM=%)5@_3#FN,RR151 EB=%:BJ"U=ITK+P,I"(BF%OU8A/BW9YL.G#
M)H^AXWN"SK)IY?9'D\\K?9!C)9TM2^:8FH;0")X%A)*4XBE*^K5UL5(7^5X,
MB ZWSH9LY<$I["W"OIO6-H7KM!C'*Z0K%B=S)'=MMAC_>W77.ND-HT,28LH!
M%(I T:"VD#$JQ5A!Q5N_B>PIZHL!6%.;;<!:NWK:'^7^>3S_:SI?VN1]6=W6
M(Z%,EC(XL(EG4%8HB)J$3CZ9'+CGAO=68?NL="\&48=:9@.(#DYK/W;D'OIZ
M;[_4!KS?)NOPTI806$8.&"*=L-$BA!)(.29F](XBAN8N=U<9+P]0O5II ZP.
MSE9OV0$W4NX23_CL//>((+ 6/^9$\401' IZNL>#E$X.=&9UD/KRH#>P)3>
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M]4F^6<:;E&;7F"NMN1#!9 A8&/G^RVQ[L)"%=BE8KY&W?C4^0-S+@=G0MMN
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M %__Q% 7ON0X?"SO3<W6#L+VE,_M).AQ<KQ]6'P;J'HS5Y]GV$Y")^^ED=R
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M+B*^$B@=9-@]B'#VL<J1 !1-=H+) *(.-E3!9 AU#JJ6=&R'(GS6K1ERSI=
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M2I+KU@,XCK344X!^[\"<GA^J!MY,]P/)-_F_K^>+NMY?R7BU(6AGI?PZG>W
MCN@#.4T4H()F=;!$KD_;M0TL*L6UE<(9UOJ:.)6UOVZW,\%=PS>#KWGQI [(
M$%=A/A^7\:I4L,L1='/NW#?F9@_S3@U+GCZ5)2#C@FSI9.6-T.1?Q'H(V>3E
M@Q3+HR[&$UO22]I5)Z;Z3FAJ^&+RG!JZ'!VUJO:7O]-R%N;=(312DFYDPS@X
MK]UJK*/7(M>%TDVMG98^'+A/#I?R%?I'LWD/3S%-5G>WG+M=&IQ26JH,HF $
M)6VA=04/S.><:XC)FH_E[&LM+PGQ)X6+AL]$=2?WL9S"BK1*60A!J)J091"L
MJFPJ16MO'?VJ=CBR7U%[\#E];.MN?5@:@C3D37U&F(W#U9OY_/KK7TN2EC#)
M=W4FG\+L,R[>7%VMNX/FK0E%]I>@/[*11EH9E(B$H2C>>U7Y*LD?T'7N.8L6
M"&G)1A4"SR^ B"20WR-JB[%./E'@S.J$,*-!^UQ<2+0'F]<7G3$121?,'$9$
MTL4NITE$<MONHI,JN2@#055'I(0$WF4/25O%LD*9F]/<GW/38"?+[]8TV,4"
M0_:'[2+72VX:[&2W71O%]E'ZD* @A$NFEF.59,TU>0^..0.>)>]LK 09K6^D
M<V@:[ 4+771]C*9!$X,H3$;(+@90%)5 %(9!<LX$58PNS=E!SJAIL)/UNC8-
M=E%]#\U=SW/E).=]B44!CQ2Y*E7'5KDHP1I5DO+1<M_:?[\04K-V'L:A=NF=
MH6 S5<<N(KZ2FAUDV#W(J?:QRI%(S5ST(=41O];X2NVL./AH' 3'M6(B*9L&
M)50\&7?E&+CI8HQA2,VR<=H((2%+)T%ID^E.EN2Z"84B2*,CMB9).A=2LT[&
M>I[4K(NF>R(U8YAB-@$TDG>D7"3_RRFZ5C%;&SG73#TUSNPL2<TZ:7T#J5D'
ME0U":E9JL;?P"DRLQ;B6"PBR^M569Q54BJ[Y2+HS(34[9+L>IN>&AI_/%J,/
MRVJ >AT5F9S 6,?J5*J56"1]?ZK-F8E^HD*.8B=B"/K4>X:F/]T9^8<OO-R8
M8'^]-JP6NA7B!F,[B-'%M]_%S.UW\/-^^P'*?VB^ S37QRY=BY,TMR[+"#(6
M#XH94Z=;*/!6:I>CL<;LE/LYM@&W^,_M[==%88WM]D_2U-?KKS>I(\62L<D
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M#4I,6#B*0,@@.#!#GI[A$")%X;;(%%#Q$DK_HW:.3DRH1*&]EPWH+&4-M.J
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MTMG61*)G0DQXR'8]3,]')O )G#NZJ@S$8&M?OH\0F8B Q3+&C=0FM(XN+H[
MYY XHR];]5!*N;UW?!?!7@E\#C+GSN0L^]AB4 *?C,$4QQ((M!H4U^0F2U9
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M8&@-J!(2>#2543\59-Y8WYQNO*N,AYZ/.W[?ZC'=<IE92+0=C4Z@6&'@N$O
M2W4Q:+=DTSIWW$6^H>IG>\71PU.M-P.=2B7MQP6MK7[0BA2TKF\Z65X*RU(P
MX;/,M2'6"PE*DB/KK?%@@I!2HL*L0NN:[:<$.E;52W\P>%BZW<P<O;'RWLIT
MVX7UO% ]E;AL%.@X12T-#;>1K;>%U@>#A*K/=R0>Z%3G).;@(21RX8S1Y$Y:
M76QIG;X8$ K/E*D,C80NRNX! 3L<C>LW69NS]XDY",'3N1AQR5C*P0D?DN.>
MKN+6 ^)V%F[X(*V!,;O[*GM8HH?7RGN"OL/%GQ.*_*[&_[Y/=?L/TD6]4-?R
M<NX-MR@ RY+KUI)6!(O@?%!.Z12Y;_T>U%7&X0'4D[FW@ZJ]K?H]CC[-PF1^
MM:H.S/]]O9+VABA;R<BR<)!RI3SW7$)4@D,RMJ!V05O;NE-L-\E> (Y:V:6'
M)\,WTS3^&6?C;R3=-_S_KPGKY?MX\OG-_#\P?\9?_DY7UQGS[:G]1YC=R8Z%
MH?,^0)"Y@!)&0.39@4^6:6=*%*$YI@Z0]V*1-I0->W@OO*>A#>T5CW9+%+GZ
M! 5<5@(4"@W!:@GT,Q,E<T&HUF4[W22\6(SU9Z<>7@'O27MS6;^KI/;S+[]>
M3?^UW!4_; (CM6-:"V!)T14>7;V]9:@T:#QI9C V;Z/N*.(+P%5S2_7PO/?F
M_=O?WBP6LW&\7M34UZ?I2CJ2^7WY%/[^,+VZ^G4Z^U>8Y5'PKA@1<^5^(E$=
MY^"9]*!E)9DV3.0G9P+O!:K=Q3M)0#5,8_=DJ!Z"PX^+:?J_7Z97]&GS58Q,
MRJ ;FV[P/Z:SI4U^6,B[Z:2FQDGU](F??YO4H2GSQ4@S7KP1DE:AEQ,U<J4"
M%2"D)>LFS^DV;YZY;B'Y$9#8%S@>Y;8'MVP/ >93F_4G+-,9?L!42<K&9;QJ
M<)C?*'*DD=-F#0Z$"+DRZG/R,^FF$*'H).N,)MOZ##Q W,M%XE V[*7I^$?!
M?B4E[G"5O+V>547^07'1--^N)5A4G#8,F*(8*.7)59&TE9P1*NB0O<#6E$PM
MY;]<@![-RCW$M$]MMGN[2KA4> )NL-+G.83@*$)2Y,0&3F&WMJTSO+O(=;D(
M:VZ5'N+61@Y#YE;J+!B@]:4.:PM D@OP 9DH+)@<6M^Z?;B"@[@JU>I92*Y9
M(-]*,K)U3!1CH%G2HEHI94(66X]=W4_2"P_:!C!?+Z06&ZZN:1K_<#=5.3V&
MS#.+P$L=)RZ=!V]H@P;%$V/9E11:PVQ7V2X<6+V8:*NOV[84EQ3S=;P:2Q\F
MN8[1I ,3)ZG.YMR["'>'#VU1?MM5]D:%MQ4X/WS9'8IR--9DSD!:$RH_$Z&H
M& E,8G:QT$J+;KP'MTMSZ,GSZ)-7Y7B<,PSD 4!$2^<AZMJ%N*PL+SS6N3\V
MM6ZIWRS)4 6RC>S]\-1HH-YC%[W.9XO1[Z3SS\MC[VV8KP@/R9MU3H0(LJ"I
M;JX"E[(#&96ICS-,FYW>.^CC[Z&#_G2'C,W??*QRUA:FG#93:4,GY+$T]T@,
M=Y&I2Z%J)W,?B_>UA7VVFOI Y0YE>"3/)2?G(/LH*C=_!,>5!6MLXBF82C!T
M=@;?4H4ZE+V[Z+3QU)3_P-ED'/Z)\R]WTMU0B7)6'*]IBE2ETJ'065829,.U
M<8&+8OTSON#3WS!<9-!.^]/FJFOX[%>E>CN]&L?9^*8$QVCII#<@<B ?Q6H'
MWBL-%+@R'K)#_[#Z8*,-?_C0,S?;_@IJO/5^'M.?%SC_X_KK7Q]JR#+!V0?R
M(AZA266*'5$GT%G5S&'V$%EBY$]PZ8HLZ9%+M=&(NW[?F=NW%[7V\/AT)T]M
M<KA>=30(S,+&7"GZEA.9D4$P3  JQ;WQ3DG9^J5]DQP7X$LW4_, IE\C?A>I
M>FK^VBS1<;J_#K?8,Q X0-T]Y'BW2,>D93[(FGFV=/S)Y%<3MPRB<,)HSV+K
MMJ\A0?!,W]=0&.BBY7XF*>1-5Q,FDS)/$F1P=. 9C>!+JL41B3N;G;"Y=='H
M%E&&S]ZWL-3CJ0D'J[FAFU[=GMO&QG_@]/,L_/5EG,+5BG?;F2*BE_7E.52B
M-UJHUY(<5"0)M0\Z[,1,\$R O56 "[C[VRFX80G'4JA5RO6^2#<L^CL(U3"?
MME60X1-JC0PU[4O+C1-KVX63HF"(*H.C,PD4"0;1I@):Y90X*[:XG6B93LOT
M3Z36AK1\%^6VM/CBK]GHGV]&)8B8?<B@#:O3=>FFB<)[8"$:+Y$SS9\ZU&_H
MYNO'K6Q;?W?/KJNO&39R;Z3LZ?Z::GDG+[_^W<@$ERPY%N17U"80F2PXS)J
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M"ZGOQ+A +!RJ[(8U^BMRYQFME *]]]]P]@5#'D5:B25OFX0Q@MSNG&K9 H-
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M>E:9 >AL^8SS$4GA>.4Q"KDZ&TQX<$A(LXRYE&PPT;<>B+Y)C@NR?S-U;\#
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ML2$$5.+0!J0*M\2D"3%=G"".[R:(3$@UD$\!S=BI3!>-8S &J"JV+J3 .F2
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M]=C<>N [3_-NXSMFK#O(#1@8(H)J ZD[AI\? S\K?4>-=6L/^.,_F"VYEOX
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MSH+KH8?[=F?_D%TW(+F5QV\#?7$>*"Y>5BTJ+'^YHP+RD4R6^#GAP<SIYWL
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MBDYQ!)\/&&_?07_(?)*\M;2=01>U=VBNG9%8WX1N6,08+_LG*VTK**'(<J5
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M('RKPWD\CQ$;')5O\B:S<I9T?6G6UROZC;MEYC\L&/LO,+'II$QR-(9V 3M
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M!T4S66'(U<!"C@?)_G2?-E3=1Z"PQ79]I.H;2O"&_#Z]TR)N]UJ6^QO@Z:%
MR;>8;OLZ\O,:2888;<N$1GB^[JS,6_]=\OO0[=MWCA\0EO33*Y1+M&M3ERF4
M26;R0P(L=J(K"0ZR?PX:]+NY'L#L TT]J?QS8FC@:%%BX4Q!W6Y!WK-V3]!T
M\O#'LSJ('<XTM$;'3$R3R1OL\EQ9W/(VZ<[<+&ZE;D!&[99\7QQ[LMMU\YY(
M]E7%W3]WR?_A?<"\UH4]$O0L^/PZPJ*$N_-:U]G=S2@QQ,3O&]:X]^Z9@S*'
MRFA#YZ2\C0[L-&AIJ940-#,SV%$T+)\>L>M_;)>FX9$@Z=\_K@5*'LWSXR#*
MR,%?O.\/,HZ)M=GKM0#^,$-ZG;=EYW9]3!,$@;K6[[6]&$I&RVX5H+A*+GMH
M7\/KD[(-WZ1"MYZSC8EEM&V1]IXE,9PE6@X_XY)3L(J?\5S;C) _DJ"]$*.T
M9;F.$<!< "@#J?OF230+Y2N @HRX?:CJLJG6K;J*XLC'6^QI]//^E4'%D$O7
M-S:(/U88FGG&,2N;G70VTTC5F9+][#3ZK$Q-B0L*&$&VDKQ.1\7P2BK1TC"$
MT^ZR@^H83XKH'07SJG?,OZR-]VC@ =0!$B751^IH"%)CI59W*BVOPJA]TJ3=
M\<@VD"F-VI[65V*N4PZ<P:]!FNS[N '"+J,E?I9\X$7:I7"[]PTUJ*K",LNE
M,^='38,L[T7I]Y'>\%UM4MHAJB:C]FCP"9\$W@9CPE(55$_KX;XNN/6<N)H$
M"@6&O?IVY;*KWGGK*Z>91,9>DWGT;O!*!4.!_OX'3JUX9).T9^%0<M4=8S%G
MO[BKZ# [C/C4[)DRM;MNTMSZ2NN*7Z^'/B]SS%B;]WR<G#QRBKRPW&]=6MUY
M[/?'M)./]/B?QG.OOGTU5HE^[T><'-N,9F1I-2$'>7]"&JEO6ZBI_JR;=?]X
MA\_X">.>J2&\$7O8-)KJTFT"XXA3H*%6T](F1L"NIYO2[*,/JE6'K*6\U-I=
MP]0$EWG^W+XDQEMN?AF7P,P.>Q?PT4I8)_]&!89V>&P=8S0!UEEFOWQN$Z/'
M001]$7K^T+Z'D*7L NK0]%<:5E[Y\[XLZ;R2094T'+M<RN5C=WOR5CS>[)?2
M>DN+H<JU =3['RK7+&(6(3R) @>*7<"X*5!W"B=^IT4D*8!Z6$?OPF.3)8V@
M(LOD8T:?G\$,ZEA-4<I25'(+#1FZB)-BG#'N?-I\4=P[_)' BR_W@YK3#2ZB
MSN;RCENO1F43R_,!5=M"<^%7.:\2UUS9BU!R[8-$E,"5Y[A6TV5K0KL/*.)C
M*"X'"GM2OQ_[%N-W:NCU'4;D7&+4G\V1;U;-O5MRH(1Y9JH6M">8ZACU@E1R
M*DAC4D6]).B=+0<QZ$4; 0QHZ\RB7WJD"E0+BJRSKN.IN,!:!>M+<1%_=TM(
M)FW:@T+2-L]4=<."B?D)Y;9MC5-1SR9(PS_U%]9R:Z;A&.Q5ZM4#4+)'Q9]]
M6OL\NYWZC5E8$ND=C^8@YK<M[YH)NN3M(WWG( 3,?-T"*[)XV5.,6>"B!N9Q
M0/^J*\N2$8<5@WYC#WB%OW+4=!=V2OI25^ZN<:^529[ ]IWT%%N)K=T@3F*I
M+Z*^VS>,[1LR0R4IUV1Y'<S1J;N=(@ZRZF52[U[\/HAYC]YJR,'8GU=R;ELU
ME-SY4&*]22Z&1\@;#5HM-$W.Y(,[V95H5:BM9O_WSBJNB26?']_-EB;F#UK_
M^9YN?/*8X=TI\S.V%H2S^DK?.(BP6EP/9OVVWB,. H!ERROB>UW(+[-V7;A>
MKYA/1Z?CS9T@:_,U(U>]-I$KBOOR9)(N#H+OUK-!-/?F.PXBO65"E0410 ,4
MC8$<M(<BY:)(*]L 77C-AO=#!G?G#> AA33S"Z )0P8<A+,M,+-.HLE!]MV$
M__E\(:">@G$D;)](T^ @2'" ;+!J]Y4*B4*>,]J\P@\%-L'\#3N)&OPSQF2K
M@GP<Q+OUH"U0N'_SS>\36>6$"53D*/]SATS#5(37_7,H3WV6)U;;?J;NI]^D
MQUB:FKKAKMVU=5D;6]/?Y1_(=Y$*0Z)9,B3IM!J54N< QXH[E>YK>]3C])]@
MI!P^I.;>856MMS]-F=E0A6-G=^]4'T!) W;*);'OTRSC^718H_<R'0D-*LZK
MGI!@')U_!#<PNJ,[)K!2E<? >Y?O+N>%1LSV$:L%5?"@NZ$K-\2W1C,9/?^+
M@Z ]GUVE1+FN*1\+M!WR0+W &<%FUY5XH)'ES="8_72$4&L9JV2?=_SCYT04
M8QOR8N!Y?V(6A/)'O3&.U %3-C8BZ*/GFG6$/'$(WXA/)U'BT,C()A3M&B'T
M]+4/L0_H,B*4 P@!%_%)J2"J,!O3V"&HWM1'>F?.D#Y4>@A6WSQH!D9OS&/#
MITQB8CIQT 'FIU(>V)Z[%R0+L5&^"0#QFCD38XEK&O^!M<CM ^'911D(6<T8
MS?[=MH7[[C,N?7P6[B_#[43OB[S)?AZHG/?BG&>&;\>8H!'Z1EG2@S=!MV%?
MJS' Q<..OK 0 <(3&9JRL5L90TG]?E&C$.DW82KZ#P?AV)B_,+%ZO3U@6&6P
M_;/VRB]?O:OQK7G98#;ESND9/5M)^8\M&G&&PVO].M,14 PFU;*I"JA3@>7U
M,1(/L/BXA[3N;[4AC1K5!,O__7%&?SBP4@+4<1#EJ*^^[M"<%>C,01BC_NZ.
M=*T;<VY#F%FW?08CBJ$LJ#+E43!-643E ;-MUF \L8_,T&V#3'CK !;O_-BV
M1A])9F'[($SD)LTN='$0<Y<AW 2**6&Y@=TVV?/O5A:FY_^_;H[D_Q^+#,?8
M$U"0HS,S&M7#9?#_?IE!,?X;5YU>D(+\RK;5K NX#N61* 1(TIP/JL?PGEH?
MQ+514B7O!F\1%BU$,)$/(<V%WFF@T!U\M_6#P#I8@F<??5FM 5/& D9$-,P8
M0?+<XIXR\61L*^G(I[8M_]=!-6_FC;11;/]IW7?,%W"\-O5-&8":4<CU!T>Y
MK]+]1]Y C)<=4W[H=V\]L"_EXM,V6#[P65<<-4Q9IP,UJ@]?/@T=3^:=>=UM
MW5P_E&E'VJ^T%<-ERI(2\$F:QNUO<H61HQT=@7E]?2D?YJ0Q\J];3GP1WK?#
M5)V";*"^L]+3SRU[0>7GGS)7&[AKA!ZI\W&]_X?LEK!YW3O2OMGH*7!W3!"4
M=J4@N1V^"[_E=TS_<^X!@K^<3\@ILJG+P/5FT.F'%641MP;NR9R=;SVW%WDD
MHA#;VNU:-E7!-C*3%7IM82 4^??5E]CITY[=I#? $%#7%:C/+D$KSUXU[+HS
MA];H7?IP+<LXVMUN]^.@&PK$>2H%F@W^3<>V\8)"D??P#0#M*B;:Q\-5O3S:
MRR$V]*5@X4B;Z(/%\U%6<S;B6ANY;=F*(+D]T,1T_C?6QIXII73I\6YR@:X]
M4:@D]_%"3(7HC"CQ#[[98GL$CKI9C'?Y($#/-M20L+GE:-4F)L9!W)3M/D1V
MWZA?)P[T=).$,)1>20UCG&;@O<K#@7FN!WZ*Z9P);?%00KK%)K.)^DHT*1UC
M>TUE]M#V:L96#9_KY/K**';[^O]5EL?F%0G8VBQ1X'X0_Y,1"AGZXNEM:WO8
M,O#I=VLQY1Q$Y!H'<7%[BX.X8OT(Y]H_IPJ*3W$0L&:>0++D^DG;3WJ4I)3@
M-@P 6JH$_$':"47%^(4\>X)H5Q:R6GO'/O"7UTHCZG?:D=+,&=JSL)N&O)M_
M*TH.*QGF(,8$L)WC<U@R"I3P^>MJO9A%FQY@?1?Q.VT-,B2"!T!JH-PK[.H)
M+!4;CT9^B.HRP$WB9'!Q,((57.0@Z@'?>@(SNY^P[=&CM)5&VH6A]*LR,1R$
M**R?JCF(GL1WV*H-AODKU*I6$N,?W$PM9E4!2XVESX B/9"%*MT6&D=M^Q42
MIX<JMOO7_V9/K<-*RQ2\Q4%\,X+27)R99<NXTLT:":"Y"-B O7).#7VR <L4
MNP!5$]F*#R[YX_.5C\ZC2[?Y,1BC#:M_)]5>K)Y=Z*L*@/C@F9?G(!CP7#]D
MG84[YUH=L#/TR80V<6K8G=5N3L?\@E)K.8C*ZQS$'C"6F0T[V 7?Y'NJFX=I
MWLDO$KS,Q8=*R&E[FA[Y>D^PJ=GSI8QSS=)Z;F(_/:,\L-^QM*?Y*7C68=\=
MXU9J31/:$][K=H65BIA]^4RK<8>KU0@QXI OE^P;P[%V:;J;ONMT-^FA,F*)
M;),:(R#$(^B=%MT8E%F&UCA#Z,?4D7?4TYK&C5[J:;E$2DA)=;L^;>X]RV4I
M>DUMUYD'/$]++]1;E^A"+^P!EZ$E(B5F^CAYU.AJ+73QYC9D^=[-K"V \/MI
MW%63,[=@>1-_]M_L3<Z5A)K'.T%/  IEQ).%A?9D3\QJM=:;%G?G?UV\='=N
M<W7<Z 'KA^^R\[96/)??W"CI'8FA[ W/*1\*%#Y,9=?&3NUW>FT]59RPZI)/
M;>IT:1K'?O#UX)^^GN2 Z9";@:1-!IZ*^!%;"">Z^J."XW9=(OO+=W 1A_3-
M&\E]&(:FJ?%:C5K@@YJQDB%'\<##" HSWJ2NF(-PH6-+-1G_2B[]Z"A[BH.(
M\9E4,,[LI%R/.6>!,Y^I (YBOPK#H?7GVG2'$_,);!/R[*T06Y>T^)5V#B)+
M/8G_^S%U@KLU=.MOOA+<C/DBF^4=>(.67K\9< >Y[R[YD>C=W4MN$L.UO.RB
M=QA%*%L%H;Z6XM.(VP/4M9-VF0>3W)3Y&[\V'.AIDI)\D?5ZKU^Y=T%GRT:#
MX=!8K$U2V"V2_=O6T$$/T)*40%9MN"Q7TC9Q3_F!:MT<\P\XG@&R]6<S'-V>
MI7C5=O#ZLTN+Z;8K[DBHUW ($IBEBSP;?<BZ#AJ%GHW0YR!T!R^)W$3&U+;O
MS)@/6J"\?L+7=+T?,]._GM?EFP:I"I S^"M(Q2HJ&55Q0SK1GZ(E#YD7#(CB
M-(TD^G=Q<^T]F2,?5*$3-(/3DM0[_REK\UC&%D^0%^P%:HR3' 0_ =KSB+8A
M^[SMP7@8H<'JH<JX:%EX\G$T84X 0<X17E40XUW!23IO]$ "5@P-%? .W8HJ
M04.X?'$!S]BKC%79>7_[=I?E9SGVEHB)\"!8MN;=N#/8!HWV;.@+BM2Q[4]E
MF"T%D R(L[C6GVI_FIQNGU-JLDV^^N'T8XV [DN/2\&I3N@5AHM$F1Z1F"/0
MKK+%G^P3,*H[+<+M4*?]O1H_O8&I!//6OI.N_"V<O+=W".HG(4LQ\EQ^XURN
MI(I5HML=5%CJ=C+80)RM.4A 6YSC('Q6.R%?ZN<G=KW]6R0U8CY\Y0OQKUTD
M2BYLFY,N;Q*##(>C_[3$7ZZ$3\:K85X$QF(O G6R7H7CL/,K8.K>-;N/^B:/
M#BD.75KS%('(V_T?4^H)JD0I6M)DQ][TP+?;!^[)H=I1/:P'-U(\HJBD!-6A
MH5HS6OWF,*/B0XGR#L<:U=X#P@]"'FA=.Z7,0>R(?@TK9LO<9<33B6H 3:!Y
M]-?RX0X"=>=5 BV$JR(_!5[J5O:ZD>1V<$DM>\ N"BC9>;5BZ[W^PJJ[ -TD
M#?U4=G,B.[=_M6([^]5;*[V]2D:+IEBC[!E;BJY@P"ZYKS!:69RE3"(\R/I*
MF]F%C&Y]STTG=BCN!/1'UR;;C]93MX4[4=;U,$9IIKRR#+_804G8*Q.+/'I%
MNVG7?V1UWP"ZCO9A:&A8 L0IP2X<L@,W5$8H,E]Z^=3,?_$VPXCZJ,K:X%?'
MD&UQE2$<<%+Q9A7VKV:R4]-^DCXN&#F>58ZQTI8(7H=%7,QQZJ]ZI9\!HCUX
M::M(G_4 ],QLU<D?[W#VSS>[<V1/+<GD9]_L*02[@?I8P F_+:/;!/'^X2!6
M87DSB1W,@,(%"SF(X$T,&(OM.?0O@6/5 6N52[\P,\.85?<U=!ATM(,;PIES
M$+)P//O+S,*.0;VH]4M>>! )7SL9\3=!O]2(?4 29LK<BP#S&.G3">0Y0[@Q
MZ)CA PX"#4]T// 6:-"I!<@M\!6D29C]_:^W-P)U1#8_PPS]PA> $O0WP]UJ
MO3%X5KYV70CXS^X@&6':2"83 R:!^&F?_W4PY5&TBX3!Y&-B-?N=$=P$&+4*
MH20QL((XAW-_L_>^!'W%S"S_^*A@5\K^^$4@%47?OX9D;B'!]V ]=+2/"VAK
M@5"3GIA=>GO08H'':,27;UZ:(QT/)3O4-4M=5$#=)2Q/Y.,,@+I>W YG=TE0
MBG[^XEZ?,MW$I!/!?A>$7IM$F),(1[G9\=CB7Q^>VE0])3XC42:(S_!P7.4;
M]Z(J7=I;/B:X$>#J+%^9,H1><$SZ@]21D>M&.=&^73^\Z!EQ\Q-T'&; Y06D
MTP$I-X.]GD24W*\12H:/N&Y+,U?3$^J,35(>&<^-P7!K;0*%80A7)C8?,0I(
M.P"',2[?WJVW57+4PP+6-\]?,)80X9,F4G.-.I.AHO7*/Z5*\FY'$HZ'4-5/
M/)%VNRW\[&CPN@YQ8L-P(NI@':B]OK).G"V&=I]A/1["]:$*O?$?G:QJ[*-J
M#M=+A>482$^;1CX5+:G8N=K:^>P%7I;Z.BV=I$:74TF9N_:S#IM(Q\6T8TAK
M&%/:C'J4THVZ]J'D=G\8"I#-+%R$@4R,H_.J],:_-C\ODLS09+#A4&X1Z!A\
MHD8X\$S9.ZF)]DJZP.)]L$LQ=V@H?G&H %B)QQ;@%.F2^%!0)RC/*>GQ+<?O
M#Y%>/IXG>6)VQYJ>*=1'7#5&]X(DH.XRQD4'XX8=0C6FZ;WZ]5VF2"7UXX6C
M.J'FSXKJ$_1RXE75;=I/LJR&:;ONG#!\6*@<4-+CL^;4!I)?3@RWGM+8"C,?
M_;SD+@N+J5C*&PL#W#3NR/^KS6L[@PR4-3S+]+:M9GAG%\%__OUKWSLDRH*V
MI)X7S?):=EM<O=5-MX8OB2_"(#U2*NY2_SJ*!\,P_#@+<]=/ (8>5^9QVQ^8
MDU>:0S&D.0@PDTSI9T?QP7XS27R?-PLP9'[F[PJ'B=MQAKI^0X@V/CQ_?/@*
MVO&D.++QG=&$38?+^]H^4Z8L\V13:_*M01@O]8!3P-7(+3QS(^OS>+.V3KLQ
M]M<EZ!TL#]ZB%/\/VNS_4-F!ZQHG@9'S .S%KN$,\BL.8@7FD77;A0[+Z!*+
MX2#G=4.<+WF!>Q.^?3R: 1.\?[SA<S/5^C]9O8,:2:OV8WN Q;\;PZV_%%]O
MA>XTPKH>H +OV.=@T>J3#0DS>7;N@)6T4LH<>A<\JK$XL98)(N-XXVC.7C-I
M7ZT&?UP1RTI&VB_Q.<%]_8/Y5^),<?#JUA6DO@XFS0/;AUGRI&F@!FTW']')
MS^S5Y4!9?\T.PMZX)U^OT G'S1D[*P]#W-A6J>KT>PSG.Y4]*TL/BVH*W^7/
MA)PKI<3R&5GR?N3QB&D09R?51_V3MN>36+6M$IA*NH'3HJH(U!\V/Y 8%UWC
M#'$K6O1+BS7K@)\S8R,^UB%BZ\CF0#UQ')M1O%92 %S'T,S,8QY#7:2O_?4H
MX:;'*FXJZ_S.SC.\$%:YO[E"=(DU.\S>37Q*; 08I[,WF:4T^_!2;+"-=,V^
M.[XOQTO=][2<E$Q?N,\R^$ VF\T[%K-K,JG2:DD"68&_ZTUV@MRI>D6W]O[(
M.E3B1E\SWRYDB]2_2_$8"-+-8;7<9FJR[R9&R!/W;IV/4(A_*"?A>584$-8#
ML@,5&(Y$1L:MV ?=56>RR3GW*K2'A-1+HK<5B)-)/].4*N@S41O13S:V1A=$
MBK%7@AXF#!IA(G6VK99AW1+ \AX,E&:GV3*TTN=1]!O@V8'C>1+NB47=%D5U
MKR;%1LXC<*M?:NE1D%#XSO<QQC*AA'H0NLE2#;OM\GG</C*YO,3;)F(;'&",
MO;K]QOF?!R]"2<76VY6X2_+24W([)U*X0PT0#Y_Y'XPIW3[Y!UQ"E6%I3F/U
MCJ?((23AJOO-"X>J\ZT=U=5%]RH?]1/%_US;"2L/I0V'=>);@!+#013'0[^P
M-'-\V'?AJ:_E?5YG4$LCEX0'J0'U,XOW_48D7(7LH8J)TB ]?ZLU8/^$I=+)
M?!N5N39S@W00/SLJ45>E<MLPJMRBOW>>@SC)_/7OA>02X;^*3I+/.)DI_'<7
M'50S*/>?)03$;BQ#LPV"X^M/U*8Y$5B?^F0UW?L?D@Z["D!J?Y53  >1K:Q1
M2"4QA6!-Q=?U@[1Z^B,DO94&S]_,R6T96%8@D":0+TR^)DA,X[0<V*,VWW,0
M'S2!"V%9@!Y \QB#H>(&'! #S#B(3O&:A7HR4YQ$,UT+IZ4=!9H+@7#<908:
M;FX8WX#_-UU:T<?M!?Y+CTA^"[0T6%_&5I'J#VZAN>!/)AR$$!Z/H=005L.!
M2-36;EC9M4<#IT?(?:1, D,U&TS'4IO8/S#K:[;8]G+/#6(I;0(R@+4F$88
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M&U,R$!^3=F PP'TI*@Q3&3AH,N8E5<]H8)XK6>GE52CWRT]"AIY;]$*MK !
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MK_K(J904YK?\9XCY_^,'>#[S/P!02P,$%     @ Q3746M>I,-V?N@  A]$
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M$C->QG>'LD,_1!/MG/REK*#&8R5LI.A=F?/&D8L<:HN--;A+1%'XT(2#P3)
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M0-V+"F :;*E9 P_XM37>BWZQVEE#"L)P:["4(TAS61+,FQ/KO2:_O8/[CDZ
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MXO\G?R9NMY4]"#.G$_(!<R'I@6QJ4<I51HLM"$J3-$SA.4-CB29QWX@H)#,
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M'&=]NC:\(^U_*$ Y/V<)V.(3,7D#<L(:A=C#:C&QNR8M=]S$!W)OTG]R^-*
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MK9M;[I-3[]6Z8@6"3YJ9YCQJ&X0<_DC[O0G*%! DZ(E!%+X@LA#(7Y_6 *&
MBU:Z\TN*4<7*,J.+XH\I[Z0O^E-\FD85JHV&'^Y4Q3^+&Z9]1+;5#%L#"FW=
M=< >6:?ED[XZT=ALUGM:<S7-56ER<T9-/R"$(4DO53-=LY0A?E3'WNB!GL5&
M4U,]Y-1=NE^M_.+/'+BP)NS+$R6*IG7*2\=^9S"IQ/6.;/+_:!^$+UD3"@?0
M2U20JCX]@C19'4&2]\=#^B68X ((6])JJF91F(*FTH-*\^V6[U'F-0GC767(
M9ZX6#,$7= +RGRG&1CN;(/R)*!IKJ;XZ/AL+QT!;[1-JEB@FU'S-K[^"1)8
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M O(W8[X@(^_Y!-Y9XCB6_*0JR5.XQR73__5A65^0!%\>RI,2OII'@7^O ;=
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M>L)\T@7?M].W,@UV>_#V'9<@8V,H=WS$,@.^Z[EY*:&6Q2KU#G_?-<:*0$9
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MC(Q*EC'ZC!SWV$ED25*T^,Q>T<S6"^LN-&M*1L/N_S^"R)\4U^@ZZ1DC:5I
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M-F;_&N(%C6VFBBX@2HR+G(TR %JSNHFULZ$>-&>/*!6M.C9)%/7TR_4ALI3
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M3CT/2=+'S"CN8F<"[:PS+U)PP72.3Y6ULPA^*W=E]^&%N[6WS+1>E@AK-2?
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M+;0DG$U"!&/)!H'HO5L5\%@MQ=@VB9-+:J)'SVGU*G"_QDQ9]N;C"IG\*#9
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M]WF<C58-$BPZEVZ0  Q)0BW0D/'>* >*2YE6!@*1;=_,=JVO>3[%$7J(IUV
M3*#KFM$4]D%][X$5EJ:DPHGVR:+2/TN>)]DH3D2M^# ?/KW%2,["BV!(5[!C
M6&9T;SL<@)7N@XXQA%B=N3,)#7^]4SZ)V47%5G"\8D*6[86_LE!$<:Y_V^/=
M_'N;J:"4*4A7<.;YAZ7IS>R&XY9Y7>(XG[U+1IIQF*Q(2J\XIO$ZS!$2#CL!
M9?(#*=2P7Y"6FCNPRG+-,_I*HAFR5]O'9\OUN?-N,VFN8ELX5=>2OOMZ37'C
MEBQZI 1XYZ%X@1$B1LC0/==V6>AL\XM)E4*!\DUC_BL*-WZ"7"LS]*[^O'VY
MU7?KWSC>WJP8/0DK183C'XES4"\.HJ^Z%5&,6Y)W^);LCY6[RT,UJN5^?WN;
MNYF4/'KDH9_$LW,S(+N6EXA%3$7[Z@K)>#S.EA'UW#BB<@3"5Z=.=$/I?0%,
M'J\?2AYW*I5T?^)\^;4M5/)!UC<?WM,7V Y>TY3X[^2F;"?*D?:$V=%P@)%3
M!Z6)([-GDV/^>C'8R?=AKV;R10RCQFY:E-K5&I3(<CIOGO'COAQ]"71>*O$$
MV.(_S?DW0A2<YV(#+UUE6$ORD=KSJB=NU#"2H=M]V1\'V$"9'#:[.*;$"'F#
M&2%1L0]Z]6OD6Q)YVC_#).F^@)!JGLN H=U:H5UO#,GX!%(]Y/+=9M>3%;K/
MXJX8&4VK/&*NVDPIK#R2_8T% N#-^#W)%R-,#FW[C[1+Z+%,849>Q9K9]5\H
M84Q.0XI;"J^^WY-8,07/[Q/]-=YUD);WOH)6Z7?$VWBFIM4\O&)I9;T== LR
M#?:S8&X7K:4D>\]3]X*"47G:B^J<4H1%@)) W&SO:XDC@!W1 R>&TJ78A45D
MC^;2IHS-OED]>(6I6Q\]IMDK$$J6I;YA8#&/P$>Z9S?&\+.(4 W_+%NX4E)/
M$9'[!<&D*G+.W.ZC^RE?\R?%T??2B8-;9QK<&$?6W' PH)9FP>R&@)2ZH<UP
M,2T-I%F36MBWI\E[<MC7%=6>DH/GGM[0.=CYO?-W<,C]DJWB]29F[[V2<+.!
M=4';@'<65E+:S=D@\_"20R*@Y/\NKW_B@O%_C1'*/HB$;8$%88]HG9OP0,L
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M&:!BD;DY:SJ"4O#\.*7OIQ#5Y.449O5*^]GEYHH6^%7W["G<#"R8(+@/FDF
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M3S7Q3]*<%J<7Z;<+NEB"-7'Z/_DU#'MIZ)_)@5U0=1)VQ_Z\1S)[>P<ZO"/
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M_F/<>S=C9H0D.WO-->=\GF>NM<.88BR ^"X;FQF#F XQ@6X#?R#&)NC(>;<
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M:<#HE]!3Y23WIH\9K;H+-+OSDP55=VG38V@MKX9^NS?'522O%FT;^KHJG(P
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MXUHRF"G"I1,WF%\57*G5=.J5R;6F9A?7-*]L:MD=FX+OW;);88JOP5[#,!!
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M=A[1!Q"(.61FE#1.,7Q#X"4%3T)"?.(EX5;OC.LEG.?6&W18!6Z%WQQHH)S
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M)7IZJ%M>2W(MT%!IS5;P]HQC<W3SY9,_1Y1X#/6.W=R?/XZ>P1#L><E*MH^
M*<?2GFY270MG':V(S-V'G'1P]&QM21U'D^?WC\M\F"EG]S_Y==@X:-D-J>8L
M3U1X;.".!XA:E%QCWS169V%+<OQH?O7CLSZML6W=^_+A_O;/GU4I9)JAUP(*
MK6*KAJH&DFH<PCN'L\NZ*Y6OI^U$+5IL# ]1>:#LNKT4Q0<<9YWIYG3>'S9
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MA,H_^?45WHIKU3S<_5A?6NB26T/V>4E\C@:Q^8>[4[R) QV#O V9<<4%4(7
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M ==!$@#)"TT8D&_5R8PJ[\K[EGS/2^*6;UO4:)@<&T=24+.9[*W4:?#XRJ>
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ML*:!$MG>.$Q!MZU:FT==O>1Q+VS@&_^;$%NT@/?\Q0^%"E!Y>H]*!PN4>PO
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M;;RQ8YS(U8"CWPH"!"KWS>')5[&CD^!(%N@3NATZF@Y[ 11.&V90B!UUG"V
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MBGERB?&:!5KHH_NP8:D;0L[[#Z_@AM"D?< 7%NAJ$5N%/L'OJD;3+-AC!8%
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M!RA"M&GXAI[2FR62VE'MU-@>;MX=(DI2WK,WL[S)YCWVS+/1Q#EF.ZS?O"C
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M%#J_L.LH#V+(#KAF>U5O&%2\'MN 9<MH<X6S:% !I#!0PSJ.2*1BNUOQ8IX
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MID:WPR\@@V=ADE- ?N_P[^S&^V(GOE76=%PU+G%2;6IT;[[RMK^:0;9]7^G
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M?GC\(<XJ#,RCQ??_N"XF,64$F*"9S_6Q\CQ(@$&P*XL0Q,"DUSCQ(*^#4<?
MDZ"=S\)??V'GHHD$'J31!_4!2W>'I4SO;N_<_QNO,^K3U5:9U_6V(%LYQ%J-
M&.E'=F8%PT=K4!=[/*,N%ARN*<_97.!!]-@?+H!9IX,KT/\'B/WW2"]PAS:
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M_&=<IT$;PNFQ+:EHJMJ?W[I M'BL@&@F$CA[ O_1BCFIV3S(=9JEXS[V<^S
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MY+_*?Y7_*O\?173;BWZ'@_F#T#U0-Q0AHA-7P0;%X-PQ8DO:+-Y11XOZ$>6
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M+KCOU\W?VZ]QXMQ3[A.67\5Z9<X]*+I^003$:0444(AB",/)1(:P&RV,(I8
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M^;3)K!1YKO_WC1K.(5F)ZE./IW\_N]*[(=G).^NC*_5%;&F&9&P;AZM>6W6
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M@3'1EA^TLGB.('O@O(HONE4NK87P%L9*=I7I/RX@:VTL=*!!929 $Y'!U^=
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MZSE2,G.'OL ;&^_FEBQ)(Z5M,CSY*BK*E?EJ:YM.RR9H 4I*2>SG 8 ?$.M
MH+HQU==+R!&P"58[D!._1 MFBU<Q4GO>EM536E@F%",O\F1F7L6DP+EWSE21
MR]X$"+WS]T7C<#U')LR#2'1,T;3O_3W&PRF7'L%#@_ T^A&ZY0OBG?<*1G6[
M#3/^5=%()6R"K]]\]]*BM8CMDV#J9"WGZEY^_L^LK-'%YCU1ZKPDM#"Y^.I;
M%VUIQY*1[JF$-3U]4^5>Z[NN3T?;[=J,<PK+4_L#;KOW&YPH^ '&M>=T5&)*
MQL\,>B 0[BKG6Z23JC]4\;R!Q@>PO=A)3P:_UQ]"<GU)W> 025@9F]A\I/['
M_1J9^X$%)@<9](VR\((\#K9,6]F(')H)O1;"]A),7=PJM?)+)/4,S>,#QDPD
M/,M#8(#7U8<2IG<IZVNP+/^ Y;4,>B.)A]&-M\V/=7R8%&S@^"BD!/>N\,?E
MIB)#!75J:/K4A%&HV,M>CU7V0!W<%%161!50H9S0@L3A"Z",.7AIL9IV&<T2
M=A/_+I6?9B10\CJ)7&?UN'/>/47JW'T!^$%.,7)R1_OV[8_#0VLJ[QK"Y=(2
M3U3IR64,94P_,T%?^.FNU48[_O"B>PDOCRCUC)+.1H"_POPDRCO.J=9U8/[U
MD9FG$#JN/HOY^XXN*@8:_>W,>J:J J,]%R*P)O*H".=%!$V&#\I]]@/H%8L1
M]*:]\P)*#?WE;2]\Y0"6D=[;Q$E=A5] KD&4@),)?/5$Z:+'[K8Q >N[(>2B
MJ.Q_\V7TR_% 6F(IY'MXNM'P;R@^[M[[[S21Q>@9Q&?5"CBP!7XB$Y<F+=^Y
M77*S[/\B\N#QUZ^G[04.IOBOJ8_5,_BAC!"=@_H<X$N@1Q(?HD61ZH&U;L9@
M8O/ZG=0\(02'A%)PZUJX4)"1\4 S1WX#6?*<MMJ^VE>%3:-;EZT+=N_1'T*>
M7," "MA5;_GL!XSC?O4P3@.WV[5\V4EJCINOBPSSAYZH^!G^%A<XG4.7&@Q1
MU7<9?#6\&0FJK:KEN0145A0)FVG>T*@L+XRUYSJ8PJ5%.^$\B'MK2Q-C I3?
M?\Y\++\U(0D0:=M&4B[U4Z! ^P?L'?][-FZ"U:PWOT4T\<F\V%NUS_GS_+Y#
M-A9]W,KPN4CD2R801;<6I6+&]HOM0"R+;0+*GMFXJ]A)EW*C?<B@AD2"1+M,
M=-41#)%W*T#6[@F)O7:#W?&ZX>$7IN.7WW@9C"[M>=<89\HF!&6A!+#<24 D
M^O7*KPZ(8+H9X0X/GG-5S&^(_2_O9^+1]1B:: GE F2%$)#US^[$!&>74F/N
M#Y5=B8=W/E;[Y53O39TR3JO5..;UN-PO3#6=!>QB\,Q T2*%/$G/+AY&>_>-
M54;I0Q,7S)L)>!-6E-!7"*(\C)4\$[LS&8OT 1U^]S(31#1&'*6.M 77R)SV
M8!DYHRL"$X\T*>OU&@J)\E@JSG%:T4 MW[]7>NP-P , SENPAS.FM,E$65M-
MXH$;1D+CG3*.;S[\HND:K=[6(A7FI!$]-Q+NJ/.X=N-,&-XC:)(]&E1#KX9
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MRVZ\:X<;]NI>K^,^^1X=L;\1N^&!1M\V[S'L&U92S&^^\/:_IN?4!=XGL[;
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M533AX&99XK,JH$>#JS^[WENQ=!ZUYCPSV+W!HYB/J[0%_N4*^$O*<B3BMIB
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M7"OA6PD7O,J"JCA9W^ MSU"0'2_(PI?2CMF.(KY] J-()830UDO[PB()B+8
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M="L+2MIT.W$+/T9GQ%,;2%\3VL/BG[0P@>\F"MO6\.]T:0CS=R29@'WK?[B
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MM"KQ,J<-=[%S%.G]<R.IIYR2-+0M8$%"+>_+0S;#I)%J>]5E= \@Q_OIPN3
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M!41TJZT^;G3+SNZ^ZZ]O-SH&GY?R,?D,7VL,+T]P^*/;5G:RA% FC -E>^7
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M["+TTJONS6Y,@Q(I!H#S;V(;<QQ7X;U<2*KC^VM*C:MEU)X$WI9VT$S@"K9
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M%>:"<,]4A^:W\3-'LWNTJU5=*37[]Z"N>\14+Z*H-WP[V; XN#!B+@U7)_/
M:"\Z^[2$[5#^:)C0>?^!GF"APB/7^P)D,\-M)6^?(A=<>OXPN7?:86Z.\P<1
M.)(*VN;0%,"^2C8,?%Z3R- #!70@C^P!YJ%$J&%E7V658Y6P?=GA';."E_S?
M3J);CV.NJ6>%%&K_4JEOX*\+J7C[W*JCX]V[YJJKAWRT:'"F'(+2+_ 9^O86
MD#-WJ=G48VJ4V.5:OOTGH]$D1+$B^T+6GI!G&^_-^B43X;+J1^4^&NRT,6S
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M13'H5QNI?D\P!J5H-JPSAH\W%,Z[;0SB S._/MB4FL\["*U&$\(W1YD-HSX
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MC1C]B(W "#\YA+Y'EJRC44VE^A/:R;2GN2<&[=QQ8_=SS.GF# YH#<\CO'#
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M:> ^V>6'"8XXJZG\1&9OD4O&Z^,CZ;<CZG[-?EJU5/."7'>F_6]P-J0F$+E
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MW'BDT3,F3A@KT[V-=)QDP]*9H-G;C#]&V1"Q_9[T;R^X_0>$4.X_Y?Z@Z$I
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MR=HF(#_9^ZZR<&+ UOR:HQ-!Z&:GJQIZC"!320]=KJVM>S%6O^59-+USGG#
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MEI9IG B=]_F:GSN_IO;-_Y5TO9&G4:7M%_W*7Y61*"9'"N3MB:7^?WGV#%L
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M5ZG]W411?W?ND8I:$0'U_,#5T"3&U<%3MA2$@>(MY:PI-TPG%NM J07WH?M
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MU1 :$SBGRC.B(:&:?,=4X+XW#'[5]O]A[SW#FHJZ==&H($J5KJ!$*:)4Z:)
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M<209!+V<<6[OKI-2BF_J@JNKQ?O\JD5S.Q9B!%2FACH*6.^PPK'QYE^$?J^
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MM)_,JG_Z\9]*9NG0"_2$F*"F!8"#J,QF.[6;6O3(T_L;!\0U?"?AR]8OF,M
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MJ"@$K[]Y:(YLB]^[,Z3>JW5CR&/+0QP:--@WR!8V.#@J$W?NH3[GEZB/[+=
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MV?1HR,,70PQI)*(JFKC8(O^P]/,G(A>[O939VV<\1=$BEDZZ,N\[)FYU2.K
M_A[\^C7T%N@0B'>X'-9"+'GWW@/JZF .W9OPWA5)W&_O<N&_TM[E/SWJF"!B
M_$H%27"./W&N'<*S<K8N:=W-,L)CS7A;]<:]C#\3$B-_A& &HB>B&^_=>[HM
M<U2IQ /RX^2)N'LI+L==PMM_AMH@5OKD3-<2'P-S1 A-P,48TU,+F)*ON3_O
MC&N'5PDH!>K\>74:/:6IMTU Z=%?0]P@!]0Z\+QXJZJ;Q,4K'SQ] Z6.IS)!
M)[%#-?)K&^N"?IB#;]VZ-& [*3CD$P85$^W"!!G">9^'+8;EZ:CC:=346C2I
MU]BV2R=OSKF6T'\,< #^9LK\1'@O)U-'=T:Q7/$ URNW9%2WV^396.Q$Y8?B
MOR)5E:L['VNKK(_1[[T67D2=I\?@G/#'13QL9^OC!;5DRL<G>Q;'Z*<2Z_LY
MB!1.8P5+$19ZXGZ+X^C>Q20ZX_2?3&8@%'H>: S<#?D$M [CBE(_[=KJHR+]
M@AE'?:@:2_,8DQJRQ%OHM*VNV2E#.B.VD[8</[(?<I$XEA;Y$Z7N9MD,Z,\D
MG 28H/I'<?5AX9&_9*T#MF7XK"#TJG>  F*@OX4F[Y;,Z8-NM)1G@DQ_ZUG3
M4U890U0C0$#'F^P4S 3AU;+1)D 2@X]SV"F#P7EU5E?9=VV5<=3*B"-;#UMP
M:$]R;,6P"0J<M2PA%1#;@LG<2/N*X?L#%1?7,L?_]')U"2V"=@L/8-_A9BOW
M6[^!X\&DN_&3W8;T+-0)FC\I-6S%&W]P\C'?Y^715+/S?I[%BZJ'(ZT\(&YM
M%Z5<64:.Z'"V8U-"LIEX8?MM?MO[I!>)90AW]<SVK?A7=J(M[T^\F;NPVP:>
MN/OA[N!""%98".MG8AJP#<FX)$^YULW@GJ#G_[[F Y[B(]#,:E_SQ@>>EEJZ
M-F;V"=WX#G-L3>8V$3W%!.F7F?MJA#?G%QLM?@OX4X;_\5Q/LC.;"5).G5;>
M@/C/)P!)^N@K$EPL#*&. HUWY!%E5[_/\=P^L#NF3RHJ>@VYKE!UG!8;X-L,
M!]19M,)TUM=8!\;7@CXA?+K&+[R-BU/K"Q-T)6C\-; X\_VKE^5MGISY/YCE
M^[\3:!UCMTFUL^@V3)Q8!VF]$1'B($M&?;12'D>J?+2#]R;]?/+Z.".9_H3&
M(K]!BBQW)X<ZK/X,X* (DPYU'STL'L_O:FB3?.1/DYE^WOW QMY *4(_MQ^B
M<5)'3X(4'U[H7:0W_6)J_&]E))L*G_Z- W<#V?V3@;Y$!L]9NCV.'=V#=>Z?
MQU!\6._V&#=;! ;_KJH=J><81^H.*5U ES-.+WM-"IW:].#[X)WS4OWZ[MR6
M+,6>]<^74>S 0]/ YY1Z>EX%7KBGVM\;S#Y^-O6Q>(UNR\R3,MF:0L4M[,2D
M?'.KEX%[Q*#J+?@TO*"66JC!YN>[DLORBZ/T4,C#RX_'*(_H:4@50NUPO*-[
MUL]IMV?<]\-^5*O:'4/7XA"R43MBY["'<VTJ\GHMS.I7IU-8 -'Y_X_]3_]W
M_-_Q?\=_9@CONE/W3Z<;A!R .*(G@]MPI4Q0),X)([JLQ> :M36O&5'PR; B
M?'>ZY_&G6.O IN]6<>%9+N&XC- CFQI8Z+!9[O>]9'V4.A/4X@0I@]!/8.)P
M)+030[B,-,?@I=#?HZ20UW^B)"90'1*:E1D.HQ[>?SQEQIYTM0SUE'"<YG[#
M]>CU7_OU\,V0XK^0'^AWW[-0]2Q>-B<D!%,A!\S!&IF@"6K#&$103YMVZZ<.
MF+"L>>_[:)UQP76G)W%X'YU.Z[NU_*&W?%5F#[KWEJ\#YR$KLH%.7E_L44.9
M)P:S*X?RAB'$K.I Q;R*,#7ILBM5T>)VDJ<5;$[/\@9$@78XY6. ?NH-)#?]
M0QT;1I"AC83]I,E_[/42_E&96^1VE-.N7WGORQFVM738XI/')Z8X0&-2I (&
M)SM5&.E!=@IOQH<R0>6XD&VXP!*LW\65X#0\JGCOLZUU<5?%VUI/*0G]ND'/
M1YR6FJ?3010Q^9;]]N6FZ-E,.*=.P%>D I!!1=#D?NJ89IDXCGKS.+:_T-Q)
M40(]+&W:"(\AO"6\FHUJ26)P;K),:W'4@/+\?N4=3=A*1MI0#6DR=$W[U!6]
M%WS7=V]Q#-RUD)?_XGW_Z@DVB2.Y_P:=D3&3:$H/J7^E&>OZDO?';"W]]K:I
M876<J6G(E=>VGKQK%:P?)5%PX>@MHVTLC3>L/I6]D6;\CN 8V?S@UR?%#W/%
ME4OKWW?7O(A5X1.'G>XH]ZB0\VPR3&Y[9;B6IX_H%Z6_5%MVD_^- 0+@S;@]
MZ9=C#([K<!.D#!#I1'8GU,>3I<R'<LN#K<I%^:?,"9D7C(]+/WT)TW1M]I\Q
M-=#P*K>3DGTT!;6%9[M\:D:=)OF*$O/".LENY00)Y\3T<L]D^I_BHE/"0C!9
M<MY<52-FHKLA"6D.D,F0&Z24UVSDAKWB'U]DZLS4P_F;0B-4319#8Y^M^-TR
M\W.9..4D/(?F9J&G3^@2<!M8T,9/E(!?U2)<9H+XX7#%#]A0O,4Q-ZR:P<87
MJE"C$NB\4,SQ-J$0QTR> )G_$<R!O4?UX"K:5Y:IC_RN6Y/75X;(FE.M-H;A
MM#L!A%X'RF0?4;AJ>)73GP)DJCM/2E\[==4 9FEY_RK6D+7^&YACC%^04D0H
MS@W,AVI-Q[4KBC-$\J(>5*<:DLP*C+W\!AK=97[%7HBT]C!,$*Q64P]H.. K
M<BO0YG\*KA;&1^@I5P*!LXK/VZM2$%Z\D3EV2P)3+0WJ!=QF9VY!06^J:6Y_
MASZX11V#>4R\_.;9M?!#>%>0]:H^J#[TUF.4)DO-YS' [?_'%=@RC@RBL0#
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M28!!9/7_^'+J_[AD]CG_ E!+ P04    " #%-=1:&J8=1'1V   6C@  %
M &UD="TR,#(U,#0R-5]G,34N:G!G[+QW5%-?MRX<I-?0FT!00$":2I.66'Z
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MV0KLA;&9\Z<#;TYDFRVE<K% YXS# Y<3D^077R[>AQV >0[.G&;R\6(H>$L
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M+) L&@9@NU@@_F9HQ=/<6G)G>KX\ZI=83V95%RA-1G83%<W/Y3)#%&N50ED
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MWWZ<!3K1=.L]MVRG."*)\^:C]^[H" =WH/30?CF;D3(I-4;@S'>#:5B5WF0
M4^# WYY(_=4JB^\D3B61O.5?/Y"@^9YHZI0OQ*J =\*<.[/.G^3H_DGTGUSE
M"9@I 9XP<@A^&ZF0]]E=5XT7?%<I%*V+Y**$[:*!\J*"@>KWZ8*6!Q7RAXQ
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M(^RX>&N[3Z[\!J))4DS&:YOS^1H*QD;GD(?ZI0PK0)/D8DU+'\CO$S<>RA<
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M&R"]LU/=4BDJMI?^Y=N'GO4^B=A0"Q&!BL/]X$UNVBUT#PLD#?,$3_MV0:K
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M"U!GA]=OJ,Q^^_2B?KL\PXUMH6U?"'@&!:9\GB49RR7H52?O,X,<,W&#_1[
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MQ9!=\ _0:EF!26&DB:%/ZM&A@C:K(/J5[VC#3;50S#ZH.I$N#BS,#2;O.;-
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MCF5!YY_844.JK;)J9.7=<*BB=KG2FI17N=)\LLZEOW8-WC \%MUQ *>$)A1
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MG*">%70VH;;UPM<A=>WL$'L!Z&K2PQSCCQ/N4:B66]:67\Y!/#(F&]&<$<(
M@H!(,% "<$0$YP5O$D)"/PF)M14T_>T#=8_^6&LID9C;*WI#>'^Y\T34EZXU
M(/7<4(L]<9D)X?8=6]5(*?14*ELQ4^MQ4>#/*PHY_O29C+\EQQ*'^K[?:)J
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MV@?9PA:WB=..@^@39B(I"9B0<9UMARL@^]R)_0+<1P)U(I[D8A==_%"JG2:
M^JM-;Y2M@I7G[[?4O2W78# DVR FS]O)#>)N\CA^R J94"ZA&;Y4OQXOF>S:
M(/4SCIJF@8IF?,:1/=FR5?'+L+JP5:_A?=%!Q/78IKOM\$!E+'^ZKOM*.S61
M_BFW10\N?.O9G^BK+N:(UEERQ8B P4UZ&IJ0,DN^ IM(-/=S)"!6NM^>;O:+
MA0LC8\2NCW2FSIFM);W@7#M^"%L;J6$DO+'Y?JP+GE.:C;F[YKRG6#W^Z9F
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MM--^V+.RS0[C>^36X[Q /O?:%#X?VCK(9:^C">FP/W+ 7G;6&PTDTJ5RFRJ
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M)S/V^/^T./Z_;[ SO_\W4$L#!!0    ( ,4UU%J%-TWBOW4  '"-   4
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M)+\P8(-V&2AW)%0&_$=__LL%OW4J&SP$ZC-@MZ0(.@)6;O_F ,H?0X?^.3J
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M%UKA.:MXEP&KD%#:4-I=B=[Y,D;Q? EX5-9>PEQ"$^\Z]LZI4J R)^01.,&
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M6[$G, -!,A;LY .;D55Y+;UCF>+/^&_TH:YO 7XYG2JYDY\GQS+:-X^PEA3
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ME7#J"AZVNK$ED1@NKQ(GG?DPW>=.[8/U?8D[=:?X17E<(_-$V\L3$ZFI= ?
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MNX%6^D?*[1H)#8[=-XZ_G"]W"<AM(N&UUS$?]B"T8\6SXYU!GF94I0B5H"N
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M%I_C/HR$$Z'AGBC^N3T(FTO#K[B"3W>_G<^ZUZ66X58P=#OIY %=LP4M_IV
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MO6$],KC7K5N_<?T&GI47\M.FC3R;5OZS,LG_.'4-%R<G%P_W.FZ>_\<O^#/
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M:6"$]3*]!NJ#@;%0'5U!3#<*SR5H?/3O!\H!+-M%&GX#_I2! 7?G*1X&"=K
M"P/J&R$*FNF'=<#,S@239LVND*8:V!J<;$DJ'W16R0H&/$CS[',)H?+]1C^.
MA<J^7O-_RB A<=\W3UC*)S%?@(O<V$(A!A8&N),0R^3!P,\!Q#J'%GV=(;V;
MI*D9MG04^@%+&5'3@N>6WYRJAX^AV@VYG8<&9]C?,13_@%&P+(8\=X.P* -.
MWRA60E+L$VDLTP<&3NL>[T??1/R']?H'8B">.1A06X3ZR4Q;K$A'%XJ*(2RE
MD!:%$<O+,4I)[XH/P4"D!K)0=\3R7PG#(WC"K'<.BGD?!M[N1:R.=0G0$C36
M!?Y^^"/PN1;)+W$(*%TGL$N(N?((2C.D-%BMRLP',# UY?\&6U>Z&P:^VH;"
M0 %Z_B??//XS>DGMDP^[&@9:%A W((:@;1!WO?-?8_P:M0%F]Z"FZ@J^^KIZ
M?U?_*#\K[ZW>&$2M1$I Z#)I01XB(.!/8F=)M'R!1O]V%-U*7$80.!(&Z&53
M6OCI>Z&0R&@B^S0,(,Q@"8E(EW_INZ2;Z+XZ]Z5/1LPHTN)!RX.$3:#]Y91@
M^L^?^2TQW;D%P_[5*3Y7%U<4&J7PW\+>+$3^^\W@<!>"E1Y(F.P(&,500)8$
MPG .=" HB(?Z)GHHQ*4=S<BE2/,Q9Z"MU%)D_K9OOX'+'Y6'#5Q@(I*LLP#K
M:\&?+Q%0K:5^C(5.1(-39/9>(;Y@=B,2?;/WKZX()]_ :B$S'X%3T3@L%@$^
M:W#X%;(8"\0V:?W+4 )U CKU4YE-0DRV!XQ_I0U^[?H&3O-!SY(0C?EG,:C&
MNH+ WPT.!($%Q"$G$78Y2*>7-A*1+-[WF#QWCC2-T+J"/'H@J,1 CDG'R$,_
M$95=1S>C$?HQV#Q$7A2' :,V1#>E4NP'OR:)_ZPA3R5!? @]CG=&](C0F>M>
MS#=8Q#^HMXU8W5CV=S3S/M'G(6G0QP#J1;*3V7Z&4?DRDITP*K\9G-V(&%R1
M-#R$GC9$5#P4(-(Q'<02=84!#83(WO"!1N3+^[%+ @B7*0#GDRYH2_[-W6MY
M\2LZ)*+GC,!I11C(-Z7YKW@JURW$4Y'4ZN'.SB8^FEA^5$%<DKQ.HB,4Z\5S
MR,T78;XRSBH(]J*7KSPVUA6BUPR4Z0J>X_B[P8W$S2GWI7?8Q0U(W'0QCY6N
M9-3C8/TQY#0CJ+>C2XA5U*_,BKE$9"+LZNQG&#C%XH2!*(-8\*<[&WT!T1 C
MBOX;C*_RA?_?\H757+Z*[:O8OHKMJ]B^BNVKV+Z*[:O8OHKMJ]B^BNVKV+Z*
M[?_9F+Z*[:O8OHKMJ]B^BNVKV+Z*[?\6;"]ATG>Q0W%;F>?&9S)PGNQTG @5
M\YGFM#$%!LJM!@2:\X;&3*^Z.SJ%91P,M]:([AP(%8I4G=X4++YP*,_FY&;/
M3ARBJ?<A?6J8=I!ZD<B0:JC$,Z25JU"\C/.5H* :4=S7O3KN0@$D2+L8Z^!:
MVIJEJM#TE>.65CY6=0_7-2_;Z%,NTZ;O$6#XBJCF/.LR\O[4*>! &^MP/Q]#
MER5.A8$*C4,IP<56GLGB'ZO*C\WJ7!4,N!9PK?FI%*OO9.CW&]Z2?5D_] *7
M&]"?R-0%LH&[1V=O3>V\,?8M*KN#)1Z>"C6B<_3NDAQ B0#$AS:7[C@[D+'!
MRP^UB1%'=OUV@"@9?$TZ<ZNO;]NUM4K[&".BJ557]_V0W7LQ.JK%#@;D[YTE
M/)_']*!%T7T/P:W%2%;ADJ*B65O1%&Q-PV9&=Y6U<F-"VXQ7M_,&19>;SG9F
MPW;/8KW]\QM%J21? [%, XPTTPHLD_7"=R[2K:+H58RSM"AH*Y%SC+#5RV@-
M(]*Y 9G3UMJQZ^7+R@_I"?R>U[.[ZH9LK_5F;@K.V"83-O"L[VW?4TC>0J^=
M/I8\.>5?_FUI<^A"/1_=;)9TC1=++V0\&2 Q]-+M:9MNBU24;!D+P$&*I+-$
M7%.4W"WA]L?9HDH'OFS*T5UOF:-Z:X?7L:0]9/G.[A$V&-/_ST1-U;\M:JP:
MRAKN+Z,K'R7>&C *6=:[/V_[0H>=EB90[?AA0X1L&5?MO>1GT1<V?9*\SHVE
M)[!C63I,5=]8H^8%/OYN9S%OHE/+6-S+W)-HM;T<;8]S7"5OO!*]N^G@.'>S
M%EG)+.RZ$E@2Z2I_Q#4MIT#>T:G9QPK?D%C>.3\K.J*2B%,3,XE5<Y>P=_AT
M//[E22-=&8F+\V=FE^61?&!OU!E;!>8J?L_RLO%GQR>-FM^,U5A.CZDV%5BK
M\#AUVNK[CR.0Z=I7GY>2;YI44YS[G6S&OAYL*5"=JO<F-D_)=P<P$^]O?6IW
M2:OTX:$2#3'3I9(7+TNF3SY-+\AVE>^J[]DS.6F,/8%39]]1PGE19T[2A@MH
MI*.-*/-LD7-C7:%73H0\>^ 2*[KIM8;A0@.C@*Y"DWC$U!DEYY >XMQMTIUN
M9T3VG/7;SKO]P)/'TP:SE?UJY)ISM=Q[BE-QQH_;B"9ASGZ-)C>:]:7Y0GK2
MS&XOHXRP%0$'*OK>]8\\P$6_U*SH??LS&<-PCM:OG9UL=LY(;Q!)*#G?3YBL
M\NG#/IRB72V'%*&NIHQB7<^$<5XE MW,=7KWD\?[=*3N)KI^XGU\LH\GK&.O
M+;7#O3R-&!JPL[VT;",Y(^:NG6M!Z?M]%6<N3(M+AJSOV;/-S>NHJOZ.^?V6
MZ_:$IAGZ&%K&'YZS;L\C!A#/BA3/M])47JB_'&(4!%4:#T6F3/D\PN?D+7V*
M\G"<3%^(?DW<\Z0.0=91"?[5K+>:]?ZJK#?Q@<&CS8FN>BD$.GXJOOB*FVF.
MT%C"VAJW+D(4^:N(E%Y13QJ>F%+*A4.2VST7XJ0?R$1#+>0L& B5H4W>'BQ\
M^(CF_CE .E2<'9$JW.ZK%)W@$.NX#1@\<+*&JWM!;.ZIXYCPS-N8PKF.@MXK
M^$8B0ZE@TDIDJJ2?W(D>4)YTIO4:;6&@^NM?QM[3WN'KB?&*:*B@*1@_&PI^
M(# EF^W_QI;OT-=U/PN^"H)G$7%VP<"5AFX^NJ]1!'H]SHRI.1&P@>'N3FUA
M\E%LWV;X7^L06YAC)T[=?EG;W;#3HJY Y;";9JCT/2X[ R]UACOS6$#O*S2#
MT(</)'%I;\W/Z&M8@Q/.*@RB0 3AC\WC_#U6ENKUO6^._-07G@BQO1H>'"+
M=4*T=V8:\<@SR.)EJI1_.'7TWT1MPX=#>P@[?,W42D3S^"0,T5EV:RZ[;6TP
MNV$41_)Q7#JTC.N5E/\&9K>M5YO*=L:&CO6.86/!5X4Q<<.?:.A*0E# ?L9Q
M&I\UPYB&.A9E0.-[Z!7_4MZJ1?K)C@QEQ2&'M\'9 DGIP7714MNOGR):L^^6
MKF4$T6?81= VU@;:PRPOT#73.>9 X5#/4-U^BU'O?0\_<CQCA? &YJ1N"C0-
MOW"9PXH\B92<7&O9!$@8JL0BT6]/#"=GT:-H6_N5J^1#W-2PH;<':0;^R?4*
MIU]=U5=P/\"PY;L1%K$I\E098_@C^,.37D E3/J_Q9G13E'S$_T'C$18BB0J
M_IZZO'VX3=.U5E')HI(;AK3=W1L$5._,[?U^J..3B>][XW=/%:43;CO?S+.*
M]&=N?3.!P5(Q:'&<.N)#]4B<4\\3@\RY\G.<2I5*\&<:E:7VZ7I19G;E,A0U
MN+0--@H%RW/MVB&4_X'+*(4T=1?%$L10W%F'G?OX[D^SN*C=QHSX3!R&4814
M?\+6-=>[#CRSCQF_<5%Z?3[]B>:YRIE/SR^?VZV<13HPT5TSI=Y' @(J1^C7
M&/()3C&W82!"G5# LJ&ILSS>M"IF)'U_F63NXNV>E6@W;D(Q-_MV.?S#+I<T
MVWF,9 KJEIE,IWQG*:O >XZU,6=L1CC@ZRMY1 :\[YX6^IM&UGEG:@K]%C4V
M3(WP@+3VIO^QKS-N^J^&)"/T'A[0B8WLZ^GM$59HKI,-MY/=@O-GVD!?22)H
M&W+7X4H8R(:!&G'Q2S@]BE]NZ+#%AK#\#F-]L3K>2J5C,1&G7FZ_MD[\0VTZ
M#SX%O$)FR*64SR"8F*6.GU1FGO:5KXP:E1!G5"7Y(HSPT.(#Q:EI)0/SGN/J
MU2_5-+8>>R/-7_JUK3/1T?#J=8"(%*;WH@*Z>Y'(N1<"=5HKL].U="B7<J5H
M:QMUWSH\,1IF/ZSM77MO?=<9/A7Z2=%N0,3N,R=PDO?J^_YDP].M;5,,"ZON
M@+GH94@R#\_S)W7TA[\#6$V<WG0@4O\^%4>M(-$?ZSWF\5\*ZP61(.SL20HX
M!0/L@_M9/VESD&'[520A@/-5DA9EG&4R5<)7^^7'KYZ<T^N.B,B*#R=,W@IR
M"\A;T)M*H08&J(P3-FE94:.JZ\%$WX1M-UTYC0HO9UUZ9RI7]]EEB[BOR\=K
MU48\I7Q])'&HX3[E!+2.@:>FF/B[NIO[H05'XT*3F*>VA30?O?"N;*#4MVRP
MD4:N[O&LC$,_+$91[GLE.91NN7>B\;5%>4MZ]I=K,3[1QX9/7JUN7','V*$_
M7G-Y;KNWA]Y6G=/Q22,HO^BR:F/OIR:N/76Q2U:9+_,#W,[&#1Y4YKDRRW)Y
M8ZV9?-+Q//U)FFAY@MO6IPF)M:]'6#1/#X_23+1=0"UY?8""[WK?AO+"E IF
M/:J"QO"9M!8+'7<PZ/V&:SC0?S3BL\'>+D-?T_5W'M_I*)/8V>@%\DQTE&ZC
M<4598,<Z;ICW=N>LN1)S0&[\E-3V?9+W(^1_H.V-NI4K2>LD:6*^'R:T)0^U
MQREF;%KNQF=])#/+BC70^\8B7CKS419KC#A]W?M&PHJY!U"!PH40J=],S  M
MT'LHM_U[[;K^;\FS&<\YUKK9'22B93Z/?#II^RCC8N2[U$/Z-_P*FIMC2_:P
MNPOD)V12C_3*??=5#OT(RI51LE3?R/%7YJ?VXF)QK6/0] L,R58,5SHIF92G
M$L#-D&,.8*M)FWWE+Q;%^,XH[XJ@FUV3JK'EX921>7U*<J<WQ]',M]BN^$O4
MQ2EW?^;)46&5GFIUL\"\L'1CVP\_+I_*YOB!>_Q1L^_.]=L89:I]?\QS:@*Y
M2NQQBWT\I@VGKAV=:'GR@G2\H:GMLZCOE&VVECY7+77]A<Z4:OYTQ:8?F_]T
M),ZJ->]]@=ZT4EP5@5OOR/NHP1^8NQDN1OE>0]+%MD8]B7YI&L+C#:E.3FRC
MU_']V2P<M8.UGWPW]_U-(SY+WXC%2DBN0UT_NCXYRSMZ5O"RGL '8$15\^B:
MD769*532>?9K-8=2*3,G8X;]Y]O6:<X4D-O<\IA=E/).4SO=G==RGML]?1%C
MUR7NQOV"+[CP9! 5A(0Z'BA,VY2VN[%@0&A\?RI>6[/[ #WK<M00)[-:AHO@
MODWG%9G"-Z5"(?*R)(+Z2)6*J'-^.]!5,87#+_V2]<2_/AO$1/8T]0";A#[T
M12:73G"$TN2'?OSDU< HIS@;Z1:GDV?DG/UJ+^J[.R@J?FM:8"@@=.9[UD:^
M5QB3X43O-LIF!^+/QF*7-DVKVK,6<3F6]>_VH@\RB-2**NRZTIU.:%Z6_5K'
M=X[9@4]>^S=]27_3?$)J4YK\&E6.D;5KUF=Z%QEU;1V01D".].@VL9(YI>(2
MR$SH-DN;GK4)%^(WN.RF:1D5D33 &=H_,?Y!H*J.4[\_TM02HVJQU\("UU"_
M_XOMS;D79U2_'K2)UD]UL_CHJ7V2WE;=(Y*@W?@KA:*!?V3$PWA^<#"["NPF
M++MQ+Z/Z4*PXRR)H !Q;?J,KB*DD? C\I67ZGS9^96BDF[_3X6G$V2+&P&[R
MLL$>< ,#BS7$J2$:V(^<>2Y@'XO/J$N#TC#IW%]B4+[?S#_[^[S_*_E'=?Y%
M#_+I-TX7:*ROJ\TUWG==QW(04P^AVJ6HTZ2K_>O3%96ZJF?E _-(!5MU5/1X
MLT]H'=IN\Y2JLYOD@>[KXMN"S&X,*>",&(',*ZR3C)?]^.VL@X1R3&,%9>IJ
M==89KWHOV^/N7'G%+2X?Y"2CUZ9GG4P=?Q3]G=PXYV*%VRS4GE*7,H?%2N>_
MU;<BA&(W0EMP)HP.FN19!IH:]5FL(+C8.*V''7^V\6:\3-SPK:/23W>'A;_>
MKZ+)DZJ_<XUS.\G9B"'=,;7(W.3K;$1+F3)FJDU8"S7E'8P1M[+)="6Z:@US
MQ>S=DQMS(?08YY8(TXCVSYJ:C33[J4=,LX!O8%Y*-6$'X_CI6 JF$MS&2#$-
MJHQTI*D=(CQD31TSB$_;J)_-^T'5Y>03X''2+M,VJPKHN6\0?9E&KD0QU.,K
MM7>R"UDV,J%:I@-$@9^^6$I][\=R@RG7G27W3A1ZH]4R7!I[MJJ,L$4Y5>RX
M$D7"JAO?GSX79BDU()SY,V^\T PL$],G! O-*T^FP<#:Q)7?U0KHUE[WB?&<
MJ0+5%<Z$X(XXRU=Z)7HZV[JJA50DJ5K5"?Q4?<53>>E^65E_Z6UBFS)#HZZ2
M0#6!@:Y']$6J1DBI.,NN;;)4%'?XE*N668),<#M9+Z=I]_W+6?@S<\#CK[-W
M)K:B#K(6_9DOYNTNA?ZPE$IM\;B(622ZGU5,6V!6YMD/8\.U15AZ#"^: )."
MBF!M3!W3EFU1ETPA,P*6JP:*[XT>($LG2'JS^C@B;JB\"%U8*8NH9V:ZH_K0
M=]0)(01!B,-ZK OST/PK[N*N-I?,3):6NZ29*YB;H3CB%WZX7L^$Y!BA-<WY
M?DWI9W8AZ)!QG()E;2?8,PV@'S"P)A/'E\@ ^P_<O^69;)GN8[)C=[/FSH(V
MC6-F2AM.71S@C^G"U*[-M2O]S&A@FD'?")SJ>(9L38T1BG65&A1<K$PCEP>(
MMP0(6#A*[,XC@8+?>W<4Y8&[95\2ZAY:/(LQX[F+BND<!'SEAI]]K(X*5%M*
M%/4INA'J<=8QP95L5;3Y"TN)<9CJUX^=XJ#I'6/(4SW+10XMAFH9O*NYFN H
M''C\I^'(W4]?3IQ3_39MRG]\_Y;73Y[TXS<[!?#1E!(IBB[=_@4&I3'-,Y.8
MQI[CP]5#XG5QPK[)9]Y75'\+VW?AL0XQ2QOEN!S$VII"U[I?0[^X'RQGLQ-N
MBF13%5_P"Q=34^Y-;PAUU17$??5Y_[CQZ 4W"]OHMKO1SH/N2&@Q JD5E[!\
MN--4B1S*E,X;@8R(3\GUCBIA(YL%3"]V7;]5K4F\&.YS,2G#S2K6NWVF)25C
M^5*4V)^VXV<9?WT[W@?-K<TW"@,"2N$CX=HR8Q)\33$>W/3,= /1MY_W:":N
M%9'CB;EB>DYU,/SS#G*7 ?T<S7UR;N"(9,7&C#*B!>/>D2[IJ1?28I0"N:<J
MTRX'K%0>[@S:OL#9P-JB)8 SMM/>7?I6S5W-_^/HA.C'3JCFF??(!/846':"
MI9+@;+V=JEQ-6N/;Y7J\PCSB6;[8R9>R' H#X1SG41REE]=?7[I<=\\CT+K8
M^S#J0;^E.I\3.]I4W9ZK[EMT_].8XN[\^!P#@_UU7V==HM2HB_NJ%51]7^Q/
M6HK&3!V4UC;[=-X]MC.M>F^UTNFS![H^???5H&]^U*]\Q^N(YV<42NM@AF^0
M7L$<4HND['HBZ2*P=4J<6CFU<]^QP(><5^.69DL_()'NYP@#&XHQ%+(02ZVI
MV#'3(> @33B4ZO]1RMK<XKUT:7V'XA<E<=Y<6YZ^#TO.V*9IK2.9O:,B-R3K
MKOI(%Q-%:W,DA:3\KIE>\YUT/=,M>K^R]0;=;;-6HS$NVW#*3&K@9JOU\N%Y
MR;!LEU=!&X<.YF.#PM%NJ:DOHJU.S96?_OI>0_;".<=Z1]2M&\FI1W+ZE"?U
M4=56>SH7".%=W$$+X:=;?XY)B,>Z+.:4A==)5DM=##<+L+E3F5(?AD&]A>H0
MJQ)AP,&3J?XEIG'"T?=*G/?C9P*[4/$C(Z*R5RHB. YR B],9SHENN25']$)
MPL7G4X^\NMOW05W1WOB&89NN/&\A#-S61SG);3[5TWG62&3*IC_C,#TMGOZZ
MH(E_Z&.ICY6JXWI,CLK2FAU]7OR QIT V^]\I\N]-"-$8^2B>4*33/?TO[AP
M0:YHMIQMFH>KS[LY?V8R.:B/IQ@=<T7EV:US\97O6CU>O!VG),3FIO;//SJ/
MRQK4/WQ6ZJ<9]M_5M)/()@O%#HP\)%%>L7B3#1)\;P]4^I3*T"Y^2CV3Z:KX
M*)?X.'&-9O0=[H-/R@$1374O=. R88HC49>VN\X$7Z'-V;Q@@=W(.-3<OU7M
M^:TU::I[.:5?U*DE#>8<:.R^+BRN_FU?:[16.2[#<*H3^X1TXT"H\RO7(]&M
M6]V:<^11%0<E;(*C72*BTD1.U_*8&--3-=*,3[OJFR2]L!J2/YV>*%2_^9KO
M$:$FI":VZ2?>QVY11SV$]M]3:U7K//:E47MT\.*YL=T"ZTRC[XH"<_<XUF(.
M8RU.YBGH;FM+EJ_65VNO/W+>.F6(4;Q'AB/T_<-*G?(D\;"$>2?]SK=%;],;
M<M%_;"_BL+_=NEP*JL0N*61AZ2-0_%THG,$- WMBE1!^1EX.>&>L*T23F=SU
M2V?L'XY?^WX]O]^Y]"M6AP')0BQ]$8K\2B@/$&G2%5K^%/S+K4$ \VOCCUKZ
M1ZBT%A& @2^11'81#"3O?D-#%0H:ZP:<<UF1[I?&WQ3?'[&RU7H'^%4<66H!
M#,P/-LQYUC0L'3;#L\M@H$7P7J@L,1\M\6MO\L])ZQ#Y[TFKWG\OTEK'U,"M
MI^E-H6D3Y=B<CGM>]>)GVEA7,W62'3N@7:4'VL_5R[M>C#F:;NK);K.3X3 -
M :"' 66HK!F68!2T?@"QR07JVT0DK,V#'FKQ7GUW"^37 C<U@^62MRC9?%WV
M,4MMN[K2YFJV%TEO71][V=L4'5MRZ&)!L);_ $G83.<M(Z6ZL#3%U<G3U?V=
MD\FWQS1\M%6PM>9 7D!L:$5[9<IFVZ]2+6>Q >_)\ZJ&-:/">*8JXSZT>3UB
MM6:<'LWG<[Q\B0RE-*7_R3L&O@KO<,ZQ2THNINELWD.NMMJR9_U:,]X*!VHD
M^5)AH.\=F7J,W"4,!MU>G)*A3=##J-[WJ3Y]^(IX!H3"J5 OB+C=3)-WMC\0
M8_S50RRQP>/Z+J9N][W9PSFNGT]@*VKE(V]YRW25-6?4K9>*'"K*;[BXZ&S0
M;50ZU$1W36'Q-U1U$*BG6I&59=8P3_A:N22U!\8QQ"Z%?M]]B$#W/ML4=9E0
MSYYY?)YMU$!"2WM)K%0+2/:T0O?%DG-1=TJ5<-)4W5Y2@)*BE_(F!@Q0+%O&
M#YT^=;U>Z!MD&7#&8H. :-NNR-TCGJ]O: M /]I(V> ',$\IH(*.1T]:^]VR
M=NLIM?LVX-VK<56SGUB'&&=' Z6*>K-7O8U\ZMR:L;/O3[O>X9;D=^ON>/72
M^4UC=7YKJHQP;P3:=C+7V=7+[Z<2_A/8-XCNQE)$II 8XN+'\N,$VA7R7$7*
MM'ERJ,5Q4/S.R&Z3HM#^\>%;.Q^#&8'6HY69VIC91WOE:HV"$>\[0K)'!VD?
M;&?I,DV@EOQ(_'WL>D6;-JVK//I#I&#BR^ /5':13]RL;5<EF'9WS^/H+E[<
M@#E(C6-\\3T,"?V@N:7 P/JE5E*N82!]2;N&WJ!<QS2**K*/'V*]LM-P'=#L
M3WW%]^-RXL-D>:E(DH77$NFSLH_G A[B;6<GX&28%F"9"\Z,>11JP]P^\>H
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M_)J2X-HY+4*5@J&[PJ8LM:M8_KJ%:Y$W[A6_$$HU:S8Q<7S[*6;ZVP3H2I#
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M1Z+SLN%[YY$?$V(N?1M<E:YR&9RLNC!D9G7Z7CKO+5W!H9-/!Z1E>PS ?4=
M^CMV@;8ZU&%N?T]+FL8[7[_RD"C>8@V)P#[T>@?A6=V4T7:G=^F26_45LO5E
M8@*'8O2E;CR**;^C=2]4[GU+H*QLF=D_458I_YO*JLRQ "F:<)#@8X<X]E3<
M6>B3HMNK?3!P+LF>EGH!TW5:)2XWNFF)]U#T7H,XWI0>A[.V[\;%;+O(8QTM
M%M^?=ZL)//5X<O_>P<&M2ZU=1L'J4VLPA&/M,PJO=$(DFH<&%(YL,-E_833A
MW(.HL]8#@4ZM7=>C+K:93054O(US#HGK[[\8J7?E^W2G@I&)_KB3K_I+Z^XS
MA!/Y;6Y7LPN?2(PWR=@(?GO^X]L=2NBTBX#FUQKS#%V-;7EV@6)18?%GW\XP
M1J&%3U<-VKS.\IU[=+')2_[1X7>HFR('<M1NG.Q-K=7A_GE^H02THBF][BH(
M7D@K.3;VF<_3[T;SE\^; +,0F36IQ@:1VUGT#N>%#^P\6X-.3VV+WHYF]E0>
MJSQ4-G7_:@9:S4"K&6BUW;;:;OLWMMLD+$"F2T"MN=7\LMT;6MWQT/XNNU#?
M5Q=K#T6*&M6U;M%%$(*W@2D) TVW&\$9Q ]HZKT&U!9*Y6SN' O=M*/GT>'2
MZ U(!C'L/:L!"?E4H)=E;HM /+M@H-^!$Y'OX0C["0R,ECB@%Y<01(A#4Y @
MN08N*YOSL2$0VE-$9)B2-R'?>#F*9<@&P4!(XO^QT[ 2$4=]"4DXDZGGR P3
M%+6F,.+^RF\TGT!3I&'@P2-(+IX7/4EPAFJ9:%9  ]_SHLD6__H?G7-7Y0F=
M[G]V36<B9UA:;'^B==S9:N94JG-R44A:&NJ+/>N0$7T>!A*,7\, Y1MU$09D
MFF!@<Q2[!#WZU '-\-1"(/3K AOQZ/),ACT,G)A!7+#L!)IU%D5-*Q5%G.-P
M(XEJS <#6[''H8_#X%>^0BSKB58P=!Q-:08+4M@"X4@X;[8/(BUIXQDW"5-C
MR"2).C!0\9PR QD1)QI^50\,!%I1&Z"07D1-]X)!1,4=VQN6=BTB"31R\PEP
M%X$ZANYN@4).WH>!H/T59!9![Q^(T;$P @,\110">VL) J1<6Q#_50-_$V(B
MPI[UF(DDIZ_<N]&/&WY?8"*T0X9Y&VR2;02IP[Y(5$=-+,_]OD0*!K<?68#/
M&[ O 07MP2_4[(=.^3?#P.#])W^QGO66!YXCG$![#)S5^8(?W/_[ A=\(-Y@
MQBTBN/)$8Q]$$ANG0WP/T!0$#!\X0_QD1JJ+.E\>.XJ)F4+1AK3^_H'&:%O2
MKZ+\ZEN99WP$KN9L4GAW(<PD.M]P66VYX(?3AL,OE%D:Z$D\#.A.(,HC-<!
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M!@4C)M^E]3SC&7/XGWL2])2V/&L5KJG=\%EFXNA&7=P24P;J;4?E+M9@0]!
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M1!$N3=PJU3A5DF(W9O+]Z+&*$276?K$FZ[./#FIR!$[3\_N@=7Q;N;1A1A3
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MS3?15*%NT4[;N@\UDL%F![FY&(!&L9\1?,$R7,7RB"MUA%5[,?)T]EP+'9R
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M^JDZ,%_Z9]OH,5M9UY$ 0JBY0A%(:,]GOUU0/22E_1#3 \Z9Q[WE5B%]6ZY
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M5B\KR^W;$GA6DY(90U@JYNBPVV0H>7'W%X^-X^QS>KTM"WA%D_Q+TI+;)_+
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MC*P]^,V[KSFY^,NLSHIVX:4\%592]5J*;OV7P^ 3EP3?[T</[X*D.'+#RU
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M0H5\KY[W5%&&$&5==D$E"9H"\ "6X1?J/5"4Q,6@79"H&92E ,!I'T32, 9
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M3PE:69FK_T@P>GQ^9S09ZPF>*QJ BZL W11"-$9\$GV%-UGM 74MCC=?X\+
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M,.PUT<<,3-<9**GZ,AB@9KB)?-$R@?-(^?!1.\]=ON&1N2JOHL,7L[W &9H
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MR^%M6&*; &5%#"H,*7JXF_^,TE[KZ&ARZN*=YD"+GX8=]TF'5"Z"4\\;,+_
MCD2IT=48E:UGB! N3!?+>2T+C_02<4> X.O^<X>*QYX[>MFCVU.>F$N.NS[1
MN%;2O_DP^0*L5D_N280\J3HI%W<DU-ER=/Y#9N2/)IMKW:/-,/4L4-V/C8!O
MY1;\EY)GZCVHK_WV0&0@*0CL0?9;T_D#D//6\: H4^9DOCKE30MKE)4 <,6B
M'@.[V;7/0R0SX[5SXHK;689,Y=@LN^18.>Y\Q6TXL:?D;G6$%*6IK(R #_#3
MCO=!B1*?Z>EL"#PSX;"I(0A0&O$UPK:28J,_XKYJ.5RD>M@(,9<>JY9$MV]5
M9P<'AT76W_QNW\NAEBQSM4?(.IRMO9!_* U0X._")2!9TXVAQ%/_, I:U1@E
MU5ZHSY)"X]C2>TF50V<]T.0';#\];MN%'(M5[;QOJ<#28N$ HD@J=@B0S8\E
M%7 I#[)4[R R864;+N(XU6T^4Q6WZ.MWR^36N.T!]Q7M!@E.3#@ IW11>]:Y
M\7RWQZE5+ NPC3SXBZE?<(MR8_#Y 4<SWV/9?8-V-AP\M2*;R<EKI[)U>FY>
M\-H]8#IB[<%Z:]KC;$0YPL1 P#CUWCIDQ9QVA6Y%<5J]282+AU;TP(YATWC^
M:9ALJU+^_)ZOP6%0]O%O)86SF[(9.AV?TF=N:BLT8-IQ8N?UZ?K (HTWXA(R
M_KQ04GNV'K*[WR$)$DL0_G+&P=P\A*?B^IA*MPMT1/?H:9%4C8W:N@SKM"FG
M(RPD;SO:E-'?&24ZNO76-?-SMK)>GX[0+*U;"E00AJ1+YTO2A 9S&3&NU/!>
M]]9FFH+/J]PU]3>JW3MR:%"4+;+#L=69!!%"=F@@W=V'(RX@ E^PP]7^6"6_
MQY>]++O#+Z-(+]T:B*KRD"_B._V5KH5 ]:[4E>5.GL.Z"8&EK%J%V,MUR@F
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MHW.7I;_;ZND& =Y5+%H-E&M5=F'0 ?*PI"]C"I%QQ.(:D0+KO@^I[2.=H8
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MK[#ACX+?2?9_W4CJ_[3YWZ,-N1B"VLQG@ZPQ+B"(-(!37HK_IXKCY'B2(<D
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MXAEM3LPK)9^+OM]QN)+>6RW]JSJ6\1P3U]M3+$"P -#KV:P( +P:87_ VPZ
M=^"$V-L&IEX;?\-?QE3$/>:(2])4V7-[\"3=VK[C+Y?(K/\(=QJ(Z$AOR33X
M&C1W&WKX14.V?%1M?YW=KP"2R9VTC;L%#M]%K:MU9?6O?"_\;;WZ+AS*C*&+
M;B+QH16]Q!E^1BW[7)C6=)RIC.&JNHLTGA ;^7>6G48HH&Z.!>@)MQDA_S@+
MYO$ ]B[_,^1O%ANYCL-UP5@:/ \Y^H^=WR<5Q9&#(MX#S_NO*QXI_[2R8;U\
MR G[SWYC<1F2 $/\O=A_IL/D.6S-QG 'M@)&WLU?==M@_3N,1T!-_W&I[?]G
M.LN(]D PP=!M\8(GPB:1$70-.2V:!^%W#OI(-[0W]ZV:$"\A>T#<2DT!37ON
MSW-I2:*86J*K[GYG.94KK9\V:C#K^)%C<^)R\G>$D&/(R]['WI['2@>+9%%Z
MTB?(FCX>\*.1WM; 4"C_J]0=(;4&7\S?TJ(CGNB/^RL=^O]ENW8@'XLT O07
MU?(%%+F'_P!W)X/'M\,NHN89IQ/>67?S9 SYT;96WHR<=;(RVS.(U3K+Y?3
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MSPS,(=+'!=)^DRS^?C&OAL!*10'IO/HW: N@N\+_S5NI$-S^A)VD+ZU&A##
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MPZ%(C6$VF+Y%-Z)H!%M[K$G#S\6X79L*,]?FK'&#+YET2V>^Z=@+9JP^3W$
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M7ON66B'D98R.0F=W=L+<GK<:O<4Z^R>>?F)FZ3%N@#3>8"C6>.T4SNGU)LU
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MYGBS)S(W\:V9B%_BPA>(@MW%'W[*D^PM]G%$ZQ98&2$SRW[$-E>>*,A!L/=
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MRY#[;/>ZN(+Y4$* -0%10Q,;R7(YO-=^?&;*3@HQ)QZ9=V)!ZQ3J,L!/Y[@
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M.%:_S*$6PS[:2UKC$<CS$#VEW(D^LZMU*;=FG'Z1JD_"A>[^X$39;'S"AFW
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M<^?/]?<;R-XZR<7F2<!5'8$B2[JRIYQ$!S@#,3A,82 J[78/;,W">PYU]W"
M?E:-L8C,]"$L'_:^D@C"O5VCIXSHRX\X[-S7$+;3;%2=R/-T6^.+*LBV=3E'
M_W7EOE@PL^L_ZI(1> 6T*9ID@?X!QEMW;@'2[CW>_K< .5*:SF0-]BS,80JV
M2C\WME%>)FG39RN>*,8:RW'Q;:@<>8=^QN5OP^,(^EE;LK_5I*:CUEY")\>)
M9L@TVE7J^EY&VH!DYA.7,TT6->7L>U8WZZ\R00M)^C'J$'&"?*=Z^^TR82W9
MM(P2F:$GR;$6+J(&W8%FT9B99TU>E=^^ -$8@JF5=YG"1])S7IH#_ OJZ]_V
MYW,LQM\#Y="O("PN$[Q6T_,K+!X52N.\4-6!$RH?'@O:LK@T63,?.J#;P5BW
M(Q!PR;T]6'6!9=6)>T2U[,GLO$>K*BGVG]SABR?@ TM$N<]#WTO!"G47;842
MRSE6S=(:OQ<E#,#-.BR>QKD7HYY6F<Y9N$N5Y?K>,A;/*A,HE/Q.O_^YHAJ"
MS\!692 A?QM3 G($<#<'VZ^#3H]6B>;1P#@ELVK[ 98Q7DP[V_*WC(=1M?F1
MML'F<?$IAV5_?W>[_1+$%7T.H:,_V6Q&^DE(>$&]@G?\!Y%@V3BV"U=@%_HA
M5E>?\+6I/DK<MVKKO>3#6=[TDTSB%V@X4>!WRN-:]]<#O[]G>> ^%>L%3 >9
M/S$S?%XH+:):6W(OC275HH))9;2ZMG"[21=ME\.$%#J\@F)XT>.NH\T<! ;S
M<=( T(4#M&R*QM,4=]6XMY$GSE _O(MJN]_Y0@_?60[_PS@H%(=J3]>G<@]0
M5B>08$)J"E*\W/,[(N)VJ*>=YZ,--T_QR\IUWV:D0EW-#26/^TA6>6FJD@>8
MNFTQ#O&U7 B'.]Q)L7.;R=90@_H^1VVK[#3<K<6K4_]\*BZZI"2^E,Y0U@&:
M;?_?I'Z@,M'M7$>@95X(R4SID"L@@<9;BEO1^F___8><B6[$DG6.0,91%+-9
MZA0I(0R#CA25J!ZI$5$RG]R+NT4ML1=B<6]H:$!R8\1OVL8?4P?MEH\1<>O/
MR;YXOC#VDD5L.):SF;=@5J.7=Z6%T#1X;5[O$<%R)<XB.>P%AWI%"P0_ P-[
MS(/'(1Y*[+]0,J2ZT%8(8J"#<W6!537.+R]:O1P]RDK6EX]<$\F<JOW&Y\QY
M45C<Y=XB1W<"((.E<M<1(KI8(+$'X,A6,>1U,B9E**/(<)&K]?*(PMT""X?\
M(CG:.Q!'FE"5;EI?Y!>0KD-';E<CI]GHM)J['&.ULJ[MK?.-_ER!OM0&PQ=X
MFLW@'P%WG4E-W3*G)(5=FN*0\4#15X$;8K%\CT#0$Q_*\Q;YUS^2C2E!7VH;
M@9<D')'II;>OQ+;W"IDCHGSWZT\DWW2<II? E]+'U]NT4P[^AKO_(%JO'X'<
M(-/B[>"S5$="Q3'4A*A2:#M2I/BW?^^9IB_1-_?Y)LO$OMC61E6!)-+"27<D
MTS)H!:U7T.TW(<Y;4R6]\R> (Q!AF!,Q3%CH$KJN,H7A$,P%BL?TW^>;I/'M
M]\G'L+97+LN76UP3$)]]$2'?43CI>/[SK]'JI\FFTV778''9[=X<P^CC2"YR
M83>8'1%A0QI^A30C*DAW7,O==VP=W2W:4JBQ?R+R"G=5K\ Y@?-KD(&%LU V
MVY.]@T &7#%NXVT@NOTV=OV]_A$HOQ&#>H!S9-4ILBNXULJ7-I],NQ-P!.)K
M9<AJ/']T3]@BEJ'[VNT6;]:)F^)JBG9GJKFY^*"RKM;31E_88H7!1CD$_C:P
M*.J[1G=/#E[I)-#4,QU>S"Q5^UTE),[(PV+I>-_9*R#\MKX738#A+(J1UP,7
M.0"Y^81\F]R^Y\4(J'YUG=[]C_E)Q&4>+H2 Q!/XNN^,"X6-5H%UXPC//@=P
M'_( UPX[L:R[WJ*7J+K$#>FN9U8I94"%S1M./Y5D$W_>+L39"!GN9(Q!'*?^
MNYVWG\TSEF.+Y=;64^IP/W/7M.^18HA'H/6=Q2/0U)8YIIJ\_[+9&1\RL.Q6
M&]8EJ#KT7K+-X;1,M5CJB2<_1:YJP1,J?DE3;M+"T?"%:6,*$D@AZ5-&25D]
M#23Z3F?R @#M;ER(5!ETL27-U[&/G-"7Y^>:U;:<BS',%I>Q*2TM)"@!:L/X
MNI?K$L#6H1ZP=;..'%BX/D;PV-N0UFFX^=W1RU]R;*:_;=D?_&/VDNO]!-FO
MET>*RB[]Y Q8,YPVY0,<QU9&;'=Q^L_#W@+[)K27J!MP;;:$+BOT*92"(P+E
MH=OU+%/[W+A$-2+RJ]_E"&?S,]>'+L/7.:*.0-LEL,Z<0R5E]&J%684P$/YO
M(9I2[8M(3U]A<)S3E1%?OF"IVM&:C&IX[G0>G]A%EV]<N:>G60?$"1;5RJPX
M'(QDMC5S DJKQ^+G%HX!JP%:XK?(#D<@(?$:\BL[Q_HZ3-,DM_ZXH#$F%E0\
MUD'9KC>+VX;<2W+AE8=J\=K)SOYVFZL;F5/"DM@XOJY])]6%JT*%@==C!B,J
M<SHV$QCFDU:U5M>V_/R>_,S-]V!1#@&9N..FP23=&-ATFAG023P$3_D:,W3(
MJS"K4?$OD\VW @OM-)V$:X,G4F&8V4LV M0Z(7X%L9)$H1JCD8,?Z?/]R9_+
M"H-<=YXE(8] 9#F*.#!"<N]0('*<1UX$/A*T3AU/'<?DG%VPF2HG@KY5=17U
MB0OO)#J%$- L:RAU\K6LW%^-@93*TM_\9K8V-K;V+=T3&UWE7.H/XHZY)\Z%
M%G^6C (=-T$!J#;L*8B7;RBLUBTL'^E&JV@] QQV9E]M2N_L@K#O,<C)]F^[
MUW4G1QJ;KZ6JG>-E%^@1CTHTG<OW5H>D:;,#W@54-H9_V5IUXB!1O3US <CB
MN,:U#-%M.Z$0WW.1#X2B)-Y$YDDD]]KM?&G(^_R3R8W8D&Q=O= (*W(HC 2@
M%&6@?7%!Z+>3P'<Z#])HLMF0T*"9!3/\0NK>Z*:D'H'FLGDBFTW:"6V:UM)D
M<8)O%)T=4>S-TDT7QC7+E=L7-S>B*@L'7 +/:;'HRI:\"'GH#RO*(3UFHO*&
M$-,ZL#.+/3EG6SD1>;: -0'-/-?N5]1'R$@=\]74*1X\Z3\8Y.?'-Y5Q_$[D
MQ2<%SDPGSYU&;V21R[?H9\T8N+B/@"Q*=S%_G&B51TH!D?/L#>03=A)!=BFE
M;YB116?#ST_Y>76]>/(]>>+':-X[:[\"JWRN.&,%H<;&D1:%"L+CRC_V^9[\
MJ L398_D%7R4*BH^&8? X8AOR0X&2[*YLJ&V[R-!QY(,>%=AY]#.PW%H9J2(
M=&2S)0E-3'N-A)R-2+XWT7P)[>HNF 22LA6S "5=EZZO^ X%I%&5^0S2(8_&
MQ\U?HI66J3P'6P'=9.ZN#7S"<:<%NYC/NR>9I3.NAFH;G@G=2U!W9I5%N%G]
M"2(L4/F5*9])#,=.M53KX>!%Y&V,,@B5+OE4^WC C5\)"^&EL/TK/;]3Q'AC
M\9GG@LM295ML!_^)7H[!S'AM^,*EX=XHVLF00L8T]+MPRHDC4)4QF![YI6+P
M&<WJ+U77OH!P)]:U@W\L=+6R?5\D#8=CAD&S3JOIFEY\6E),AT(*Q>%X>=L?
MH,6S5[I1%J-]&0B#VK)2[.ZGZSX\9KK/7H7__RH?TII6C_:JI26B\2O@U\]F
M=P;8HX@0UM56_LGC+FS>(:I=1M\,SQO\W):2$":*1GPD@P$U9?I99P:T<@#&
M9"5CH&S1%]#U;;Y5,NUHHTM+0#^G1([R6SV:N77!X<H)UENJ.SE4_F%* Q!R
MZ$6?>P,,$-(B(00ITC3@-0!5RW%NJ.XB]UT/F/(3]FT+_.G#CI!.IY8G''>I
M5N+U#XKO&+?1U!48H\1GMF2L%)IJKT\O>ZMLN(>4_]I$?.X\ 4TU?J^R\3S(
M?;> F/-R7I"<UGT$8@9^FXT]J"<KA7I7E 6$U()5<YWDC;6UIIS-LMOJBBKZ
M8(#,UL9%[T/]OQH34HWM/+^B[ $YLT?3,.2[:DV7JNKC78]X^KB_A#=]4?BJ
M ?//$[-8-S"@?DAY=@1Z;4"*PW6!P28N9,7A3K(4IH#MA'E*(39:*Z'69F-:
M^.YJ"_1].!?(X,(B.8URC58N_X@AVHJS.8$)LK*5H'=*;^Q"5_H>*10>7KOS
M,%A"3MAK^VHH</9C)(A]@I3-B;#.(5P1R%96ZQR/_?+NV?CG2WK&Z?Z6O*N.
M(0.V,ZFKC5%E>VN]BT6&MU6F]]-]E[V/0.41FSBJ,$.HR;P"THY ,#L(/4L!
MOH(&5/3I!I >Z"''#_2J9@J8RM=$9Q$_5*-/_MNOU@DC. A;7;Z @:9MJ8-G
MA;L+[66Q77"'W&%P/FV)TG>^RZ,W5:#GM.DIA"]5Z/W?G^T&Q ^9J)) 6@'5
MBEQ'%:N;OS"QH5@J1N_%MA[>\60IN>;]X8WB^9>O+Z3/2.#7Z3EA[U];:[*Y
M1J9*78U3,_+*2]C46F9W<JMY5N -=C.YJRO]3L_+:')^;<Y4C<Y>PZ W;ST@
ME(N>1Z #6S2L"0;&+@U2&??WP'6?_J8/-M1+%>8X?("\3JO#>F^(]X!9J+J,
MIPV)\$:*NQ<,!%%82A3J.&?GFCX-1"[ZAZ<JOZF_T;@DC*K\^_8B] ^]#R5#
M2T>:$0[!,:*HBL^ VQ:T+HS.&>>*[)N?6+28G7RI9_,RZ>9^-PQ,0CV/)*!X
M.PDDU4*-*SDUL9XFC4$!94-O?86FJ%93%%9%L:0*QP8Y+8S=5N4?\O]%.N42
M%%#+H P!\$,VU+23--FW&\*%[E BT'3:K>UT6W"4YQ/[[P/V)[E*0Q2(B3WF
MS*;$CR@'=XD3:V#2$S4JCS'^YP;C>\ZZTWF58B$$>8:?A1[Z'EK3):TG(:Z'
M^I0@!AJ +_<V!24JS0Y=VXF-I;]_3]J$*PE]>5_S>$)44&4Z,%AR?8S":YFY
MT9\U;;\Y.I?YN(QC?>I>8PNEM:D\8AU&Y9*CFT61Y.A=<PR)J'N6^C>E@-GK
M6BJ,Y.2;4#FK"5==CH@B8-@FE@27\]ZTTNT,4"]P8Q"2*1I0A*U7D\ 4;@"*
M7^"E_D/O)_\_Q+UW5%-1]"8:145 1$! I 0%0;I*+Q(5 0$!$0&I40%I @+2
M)"0JTDND*RU*%2F1+C5TI$OO$((4J0E(N)#"7&?->FO>FM^\WUOSYJWY(UFP
MDMRRS][?_KYSS]E;+!2AX)B_9H8BQJSMTE+]%X\-(WR+8H)G'P>OPZ/$R+@Q
MY F0S2IL1V/.[#T>VQEH/XPMS['N83A0JAJVON^KS^>&DGEL+]'M6S4NO.2N
MT_J2,<QB3A%W'G_]PNM$C8J<@OX<L=-=%-W*YT,&-V5&__JI7G_<[?E()!51
M-WD@O&="/[M$9(NI1!^C7B:=C&G,]\$+<"\^"#-S4N*SDIQ$]DOG9-SNL#"S
MUQ%F]BNY_>$421:07VG24*RA?4<X$UQ9@AY"(2!*V<#,:KJL>+<M_06G..3"
M/CW2P[_1$W_Q082O<8\6C\,3MB<[R=G$FPV8V$HG)"\0[W1G_H_&I9"<X=\O
M>0(B5\4CLF=>JL]+][-US54W*J.:7\/LMR<EFZ090ZFFN4 )8>[&BPKH*8N
M@DMXNUY3*Z<PH8S^L\>:GEV'JX4,*/<P- \3IRRX="QV;S\R3D!+Y2TOY5A;
M&53DY7=7>+CY)JFKET*MR=]F&^%CR1IR8(9JJN33]<%-T@<%Y8+.7*0."U'6
M^:I2A<4FRG317[!C Y-;SX/)ZD3UN'*1"/ST*3.3=SD6.N]849+SQ =&T]7M
M\Z#\G#)Z!$00VD/[\K3*ARI^\#<THNU#HGU7.Y.%RN54& +KJLZ?R][W6&#\
MA^WZ1!S(DE%L\XC'.PI!:JV*J4%M4&*TJ_12?W(!G^A2A<3+INAW.HV2N+;M
M,]Y4MI/VO()05A-VL^!O:Q(/D@S-'^KY(@I6T]--)B<GTKD5$TL57!3C?2MG
MJWY1O4$7/.<B-PU"M77CF=[X'ZD&#S<%=I.?D'DD)C46PF&6-) ]!W^!+7&/
M8\CR?S#]EM1_JXL,J:^(V(U!$+7. D\7L7PNF(E&+N+6%_G#D/W)O!J*JD+1
M8/!2"UH8T9_-G+/[)Y7V;P,\Z5^A9Y@C9EJ-?+J&"&^%A\.)\?ZI!LB./1#%
MOU=*JK="/S74]T3Y#\>TQDRJX"_2A-O/\O=YVHK__A3+P_+PE?,WZSUA)F7M
MT>?S\O&>,0EU=6:&-$-U+B<=AH<<\76-*>/V_K)4SC#Z6>4C2!@2^=.6%S !
MX]J#SK$-Z#C4IU!,Z!P#WX.R-WD>SMAU4<[7^1[4(0_Z9TCI;.,>@$@^]7PG
M73"."&T35 0Q0(Q^#KXA'?075HIZ@7(^H+CAT_IVU<-]5_JGJYTI-0/*T.X@
M9!:J^2P.7X5BQN%3H>7FD>I\BS@VZNW12@./MB'7!_J?)R8'W#]4%E=<>MSG
MP\DXR\)_4OB$=_I;6R5_:-*SLB)MY]8)1O668BW11=681F=;CV23W^9UK[6L
M<H.E>_/ROIC9$FQ2>G('<AM!V&@>PQ&S-=3]IYMAQ"^H2M@"V_AV!:SJ"-+B
M]CL(NS'.H;E\@'KBEE;E/EU3FFZ_A_V) :XR;H+0R3I(L05Z"-5483 ]18$_
ML)&NP$VBW"E^D^IIC]U(*P&>VP-)=5LR2G;I]CL8$)S:IMEBX!78-ABO\\LY
MJS](:9)B;K%%NV]D-7NKMX_4S[*3SQ\L6!_G^LB0SJ%2<A%G\:]T1@G_0N;]
M5JD6BM3=/U_[=D>2MGO$)?6\(O>S,B/<'+XT1W::%6_UFYL/WP79&C++\__C
MYL.XPP *$WT4QPRR@"_P[S>Q&X&46_Y9XTT7YT-EIB@+?F@/0S<I4;6?976^
M3]B1 >SZ-[*UN]_DQ+7!NY&707O^0%6.OZ5:B&+R$0K5I.3,7HV>8G^4=1G&
M"/?PV#R?KHB7Q"YZKB/LG6>LZT+J!I6-HDV] ]A]44Q9P KZ#[1.V<5;#M\?
MVW(3>O$[/<>=)SUSM@\A.[+^,#TW)%[/<%/!QZ_.S+EPSQ*KF4<;*/NWA>H2
M@N\(<N((0HM%Z!+8IM0(YU^S=;(^NXI^AX3Z/]N:?E@?T9TQ4"!H^E3J91]?
MR&UN,UV;-LU?J*>@EH*>!6\T=YZHEX::9&F?D_O5>)'Z$ C &A"@H5,E-4J3
M?S/<\N,= WD=1#;C<FHS7I[:T&7)^FGW"O:Q>GS8Q:_<>J9/NKV]M:*L1S(E
MP";V7XD>79&$L:RLQ[PC^2Z5?$D'"7I="I.^6VE^=2,R2#0"C(-@)Z3"J@;,
M%1=CB7V+9*>*#_ZVBC%OWZ>+E<4S;73>4/A66.XQ/3SP.&69,3-I&?0O&]CT
M?@NN6F?3(GN:JK3;V3(0<G@2%Z)^8X!/6U8XO#1^5?CK*[;$6Q<<[4_?>W@/
M>G[0U(C19.K;Z$HO(=7,3(_2,(>#?8"6S5>F;#1@4<T!1Y"G'I,K!,:F8LU6
M6Q$@AHAKB0/T.VQ9$\RJ2T>DEV/L;DNYRD=&1I/NKR^K;L7>;7Y6Q AZ_0D:
M+5Q^'A#KW&"E./K#VFUEB/1*4ET;AG$OP\CJE[S^;UQPRVO$19^I9JZVKIVH
M OL?OE=9('&7^,_U :Y:7OKB7_\$V3S:EWU5XS-'=C\L/!!;UK#[FTUGM?E'
MJ-919*-*-(UY"J>PFM4@X8^TW"U&15QQ'\.M>!D-H0$91^K'\0U&D+@DPVCL
M3VV_$%W)'B0V*A>4SCH#>!.Q^+8I:(3&%:HP:7.NH,3?/>@A"U^SA]K:*24C
ME:1K/7Y\IWQ-+UTY%B4Z?,"FY7D$>5ZI?7Y1VD[&?C-OVP>EL>0-_0::VP/=
M+.U*!KG<NSS$2R(T?-K(+; %<X9Z.Q^>QA?G[2ZJNZ%Y(L[_"1NO0#.V._)J
M2:VR(W-9H9C?%:[**AS&BAKB_=>5#&:!I%>P9UC*!00HD?+UIS:/((X4]"DP
M2IQ1^$]P-IPC3;/#%DHTVF0E7B:LR9Y4Q/E*%U$M\HQV%;YI:%AP"4<PO^D]
M6>3QTW'RP$;+6[UZIBPI)^=W1I5;M:N/F6\0]=W*ZA&DE0U0TN^$,>_I#W#0
M1^:DB.@FCY#7G.5S:][K8WZUH47!6\71#RK>9AQ>1<!RW)&6!ZYD.5J:!C<=
M3#B5?S./DQP[3FOP Z(D[+,AA-4WYSO*VR+WH^ :BFD.V-1K?8T/OVGWM7T8
MQ5>8$;_8#I&3%%RZNT3JA_S&1ZEO:-&@E4 RWRP$>R$+B!U!-CT6L)R=B]BS
M@"Q^+JSH=B$0UN8[IQB"4"EQ'OQ!T5,H#1J2FRY\\SSD3OHU'XD+2-2_9*DA
M#? L5E//)RPR1B'Y.IT:6<<J5Y*[K1Z_?SGW(X:#\ >R)I;AD.9GMNL5(-KH
MG57>BL]GWF8WT^T>&[32G[>QF8!_68.6,E(S4UJ@%($*#YI,:&/8O\> 1Y E
M.3@?:GW;X @R;)"$,-9R)^ZW2>Q/25N-YJ.:9'/1H%^I1M$?FF2A)C5 B_R5
M3/W7MP8DJ(EW_^O\I2T11T]T,3WHT?+6D:WB4+;U"$NQ0DD:N>Y5>\Y;@?K8
M-N[2_[#C."B;$H#LFC^G(8_PMK%K564D)Z?*3[A1MZNM-'<+581?Q$MZQO5?
M[_//P1&-,%&_[O;/L;=\EC(BYZ9 4-,NI%3)I9V9?+GFI\X+XL_$?S2+8/7,
MR[9=NI",?_BUVOE5TI^;[MXW/%7O8I:08-PV;&Q -F*>;;#:NTFA,ZT?083G
MT; -W1'87X<&?];SYJ5A310IFQ?F"K1\F>3I)(6&O0:*)%0RMI]>GK3@-:<?
MR&B\:TN=&VS?=)/NF9VCL67#\%]1.][B1Y G@1XT9DMX*&XG!A:.(5\'O7K5
MS&<WB6MI:&'K/H[U+1G3G"BPB1,V'&M,J?;SD/MS73U@TWNF597,?3@CJ9F2
MAB>7>N*49!MZ J>Z*3;0^\B60\.P$NI9H,>1H-N7%^7MEJ?CZ<6)FO3:5Q/M
M#$)7@I"LT-\,C@&)M(4M*'3V]O=^].LY_(: E\!#V5)5P>B &Z^:%TZO%!1"
MRU:HJ;A.U"%Q&/57+9)X<9?XXX7]+O\+8E+B32 O5]"!*O&Z4$\:EF9D('^S
MON=:M[,][TVI@=-K]+7LAR%&CK+[J?2-M!"MJW]>Q4<GN ^-'#*02T@KH=0K
MQ+06'!-"LD +:P4\]\6-*BA_?_JC[@E5^[;0V^6N='O((_L/HV)HU!)?)HA'
MI5F+1Y#;-=C,5:P>AJTC0T)^47%&(E!7L61%K"]PJLNFFZYKV3E 4%[+?6$H
M4[^:>W&$Z[2V]-?A]]8J'+7NUM^8U"JFW0W^:J !I9)56 5LHP_:4FQB7D;<
MCI#G6\$1]_K6#WRK0R:[0M+*N9,Z5*D_;[D5282%X? 9]&MEXV<:K]4.(J07
MTLPXK-?*UQZ4J6LF7X?H]JMZ,*M ]0[HD4:B[4,91E_''X1H_QX.DWN(XHQ:
M-JL;Z].UJ78/Z8PJZS65@I'[F<8*[UQ_[W"QL4_OW!![@:#NKA?6EYBD2(CW
MT,]LICA1/8=!AS:H0+>"NG'A(G$VTCG5TT%R1>)WQ=M[)QB:(+OO&:/C;.,H
M7!-_<!5A+2 O"E7].UCPRT<-=<ZY3V@VRE,BZFOG_>-%K5B+W7[)912S__/=
MCL:KPZ^"-!3B*:8UL4.SO.]"X[69:\3>W- 1RPT2RP8D=LF"-$R]11"!26JC
M'K5X3SLN[[&65_R,A15TKRSYSJV?*C]%CI=ZQ]_:\9Z1@;*F/.S^'E_IVCFY
M'@!/LSB\TKN\Z:HT"S5N#LB#71L@J1NDFBRW_!@Y;"U_=, O4" V9/!5PK@N
M:<2VZL4.VU0^88 J@XZ=(E>>3_N[A]E(]3?K9G%JO-=-O,9WDC11@X7_&'J!
M<D>_HW-5#/NX"L (LN]>=&1<":$2KA=:?7U0IMU9B/A,X7[B+]&YU"TYW6;_
MX-75X9:>R>Z8FBNNTX9FJ4-_BO<,#_,^D7X(RG\K_=A]D*1@FWF#/L;CZ;;K
M7:"MJV&A#6<I-ZOU=,[<ST.V^F6>&)*I1$5:+F?@W60NV.\\Y6&WF;?IJ]AX
MO*@MT:K^@<\3@DY12XFGQ2.5IJG'@&F'8EOM76<>]JZG2*X;!*;KR0PW39/X
M^'^+"]Q36)8WPTSZN/XJU+Q6N,FEY7IU)Z=RTM;P<.LWV:PTF'!?D8TWM,/^
M,>JI!,?RP\19W7YSHWG$=[1$9:+=Z=79Z4:,IG\GG>D(0F [MU[\%:%6.T@U
M71"X8T-.>;EV7=+R;F?.EPG^?,UJD<7/ZF>A8%0TWV3 )Z=E_R$")>.V)#L/
M^GAEZ7$K?>C6UQ2A+0'FN,R<3;S2QT%]IC>]EY0#$4;R=H.WQ:2E:I;\D/2U
MF+G<Y4_+.I8Q\ ('>G^QOLM:3<?%/%KB>:'%0*OY#'VMBKK,I078Q(HQ$(-G
MY6F#GT7HY@-1ICO!:ZI.&2\\7DWN-MGT*O/'M)7X;EF'+M;2LK;VH&&8TB5T
M,%UHG;MV/S9O[.3H>[@KC[FJS7=;1&>_D2Y/P1'D,>2GK89)5HW+;__(B4B?
MZUR)V88(TCX'QDI,?M-AZ<348/E@JV<F ^-;K.:QX%=K9KD;>;3")-&,Q)P"
MY?F,J3_=.8E6]0^'VL\;P_60_O];BX0>@I^=ZD)UF_WK</*$U?P(<M=\938(
M3'<GI&D%5$8*/ZKYUE\4/^+>.&J!G]A0$H=RE=Z>*)%5[)*R,D;\$([73.BX
M@_=K1VGY8X*QD0O\/:PAP1FZ@U^S+^2+Z_ZH$TF:]LBRQ*R2F?44\$N5@X?S
M1Q#&FU0?$JX).E'7=)C_5MV!@#VQEH)4"!T*[&,T^S'L+OI^8NYZ3":/F;W4
MMVG=CD>"G\U[840WS&8"11<10/OF46%TWA_;::L.V)R*\Q/-#L3JRF2SADQ<
MOW!GSJ!F[*'5<5FYDP)I3Z=XD:L-8.)^?P2Q$]!3L$)'79N12'\K]MXG#T)7
M-$TAS ,J#&1-HF.8:)H^::N P"1->![9>I_8F'VF+&[P_,SM\T\RI]/9'DH"
MWB =>4RD"IB\7VK9<S$MZ'/9S99?[/WKK&IN>!.JJH\2_B,1R!-.ID^*U-J@
M,*O^**I )5Z >Y>L G@0(MS<< O"PU3[6M/*_L$5%MT-]Z5/Q]:K>ZO?+.;=
MVL.6P/#@T.U$PM_!R9 CR-3..!Y'Y6:A,V^"!-NX4?3/,]8;J#.(F\1L?5I$
MCB[LD_R *,.L==+!_:)O$..XB\D/^FH^X8Q@^&0<T0HS&4SV ID4$B%-A$73
MQ5!V_MFMJ3J3/GRR@(Z"*[J\:_GG-.)GL:WBPMON4O[Q81(VM-[@';%5JBOS
M8NZ+NZ[=7B'*W=GYO-K9NCOB;CZ^%0]]ZV87PSJ,DQ5]9.(K2_XV=K:"3&/^
MP.(;BG*5+G,$&7R=@8P#?>\79B?*=8!R\=7 BC12#]F)JQQO'0C!$*T/&J^O
MSPE1V%I]2=7AE9Z%M'?+UE.S5XC5"3_O]1Y!5%)A*3TS2EZGSFI,_2]-1E!D
MY!;2";CP=+68[/>%$H\*GHXL%_1UG%40G4J,K[ T4$PS,S+!L%FFMIA&Q=>Y
M=U-6T3DH_#CN0*L20XM1Q>Q&XF[\V^$ VRG=W*:A,[G!>[KH%J0#A@$_>$&U
MR %8*7J#W0V/BX"?PRWPD>1?T_;602K^U,7\8ZB1K%U ,GE'3,V(K^SZ3RYB
MYV8/Q1Q@6.2A<M>N$U9"][8WH6%E_M6W1\;-**R]*M55D5V.*-%[8QZ)K4(=
MO1GU#'$9RM!0[TA!8=)9U4:.(J?17)L[[NDCHK/WY+-%BT6'W$1FAWS/&+AX
M,&E+Z/TI+-S\ B;-(\A)'Y!9/D. [Z5*#\!+UOXW#Q&L[\.GBWH"$[04[O#X
M KSUEO^I<=AQZ)OYWR;""N>)QNC_.FU)6B1S J7X>6;$ _HH22RB7B$@_T_5
MOVE+8E!>@/ E3D3RMZB$V8_'UN'Q,*+NOPI_H)OB4XX@ EL*::Z*X_5<!-/8
M\;;:JR_1WA<Y[#*YU:5('EYUC6;F/LHS AH\;ZG2!/[.5L2P6.;%5YYG*R3N
M<#V5<$?$Q0RMZ/N\RIP9,\CUK2U]O/:@O27+N5!^LQBM#5X_FLJPZ,&":GY8
M[_@-R)HWH;>33C8DSO'68;RMC!P$<JX.-GG="5_F"+W]CC]9>.4DS@B\J+%M
M"/!OYL60IK?8KGB8FQE1 J0&:;9>FTO8M9 _)VG G) 4LFQQ[\*Q<#](V,Q<
M(7&%SF)%$:*/9)ZNKAU5#UJP4>L1ET\UCY9JSR%[48M.B9KPE:4C!M5*S$,)
M]7;D/?#*/C:>I3(#J*_.L%/N*02=6,%3[SJ<BJ^$W1T6:6(1*5/6O/%5A>GT
MI4@N6:AEIW*_<F<$8,>T0).*S56M:$AW>&@<'_EH-+%A]6O+H8IN5SY6MJW(
M)#\LV_)QM:G\=CYV&=&Z:* ]_ @\4^VE^*[%>*[Q%PMVT-N7_=U%/@3=C6RB
M!,-!H=G<[=W%1N4PZ5@KZ2Y;2]7[P7BL<_J+LD:V$/0K%^ -^NPXK?#50"B.
M^ C&0+4&B@GZX2_LQF7V4.=<3:9[?(1UU3FWDN+/.SX;NJ>L!0O\?!RG!UKP
M!YSX&#4Y0&X"'=X?2&O"G45>1K5H$8HU'PSG5Y?2FT8VU=LBUU1$-.S)71=:
MWKU\S!E[PW7#O_6M'$*6C]@NI2&8ZZ*L]]C2N_"BUTO##.VTQ'@751E'WZ+4
M%RNMA((>5HNJA(0$O<.U6$<Z*V2D!%9)U[ X& I*Z?J5MU.^$S;[E;7)5WEQ
MGN&7>2QXEY.XG3CTR2/(I'(I*+<R"TQA^!DVX*I."]N$F"U0I]2.YD&UB$,C
MI?\F#O-1),B43=%3]6 4=U;<<)M>[MPOS9AQ9!0$8X/Q#'URGA7E#I_6;Q64
M!BP(1H">.BP?D!B_]Z.6/E!;NK,5?T@W0SNT&=>T&+'/G,?V1?\^IY$OLS S
M)*A(*'<,_?I]*"^^L$OV^7QI7E&^N]E6ZORKL=46TR^TU()96PK<9EX3OW8U
M"U> /O<_U+CZU^#LOUL:5:OWWU> Q?;4.X$968GW"/(2E(L;;)J21Y#7Z($=
M1R5X/I1X%P0H(^IY?7I;AO 11,M5X0"MA3IF=VUN+J6\H=)HRYD>-I%OMX8#
MQ-BHG-A6&/%!,6-'J@B,IUX.CXHDLW?,<1+[:S'/JTC7*4,AM=*M$H7'+@HK
M76I<?8%,0C5+PYX/Q**(NC<Y"3KA,%?9\W\R^6B9F^K2@7F8TRYTB6"S*/BG
MJM-:23D>$E?CU%?),?$:>R:\_-@%4ZZ>Z*9';;8<F!^'7K-8'1^/5#=6-:@-
MJODFZ$D?4\6HYXWP^U%?B /M V# +#Y'![&1E=[NX:7LQHNJ.*6^S\H)#/FT
M7!;(-)ZO=#"'_QJ82,,/=*" *SH;7T@MB^16DFD,MN6F73-/*G<$<=N<=/=B
M^UCIU^]M+(X7]2_?+;Z0I)A=@AA]_N#R#"Y,WCBRZ5')C /,LV*SYUNUHX]'
M#>Y:S:$22&W("%>BQ!I4L/$8L-V6K,%22<M6YZ;S#^VM3YJI!>KOZ8=G142=
MJTNWJ9-9/I9ZY79RG!:L&4/TZ$3CGLM&&@-UY.0Q=4;B+CXLV./9B(*;Y]ZJ
M+#I2VD[#SO+/V.#U3%U'9F'3>.7I_1I3+T5H_T6);T]< BU&<C5,U>#Z#5PE
M&:,9=7GU(=Y_U^EG\TDB9!S1-(;O\?!R:O\:[*33?O)0MEL\(Z=U[37A;(9@
MC+$MFO*<WC<&)WKRA-4KD!;Q,G4+.,!Z[#578]PB+G0JLY U!OCQ1K%K\^*=
M;ZOMD85U$C=.',2-W<5VKDDJ.\1F2!CGJ^FEEOD.YM>Z4-1D<-=WH0C$?3"B
MKW12>)"]<S(D]*8T2:D5=8;J-&4'/0GPZ=<&6XY5!NZ]4LZX'!1U:OY#O7OS
MF6\;34*QC\&A#(%7.;9BWM)E@$*BWR+7HA..!>>$/8L^L_9ZZC<K]Q^S5U69
MVBOV_C49]T/NZ3A]JLJJ8WNW6IP;G&1Y(S<<HZ3DX&KEZE%N/MJ@A>Q<#8M&
MX2?14Q(#'9%S7+6 ]R);F-*+84M_\G2[F>\A;-+POO=]K%AZ78(K.X=>-I+A
M.U_A% R?"SU%YZ</'$&([KA6[&FJ(LDWC71\0 ?X%;>.%!U.# JS'#5,*%!H
MG?Y^!+%@9N"_2MUZ?*SK@L(!FY:C%&M -T>Q&;7XIK#KX=H1A$56Z(?YV@"5
MO7@3Y8(!1#HWN2C7 :6.5-E@I#PP;5$U^O=C)1B$&WLDUC=6<-5^E4?;B-SB
M%M4G,=7"+Z_VZRPI<(U&MU!>(R(F\U(#US+&,FY#L5"B/@P0@87C\)F8:L>6
M(T@XO**C? $>5J9)X N2;<GD0C^N&MG#<JSM>TEGE/PLSM32?Q48DO1;.NET
MS0,FX668P$1?/@AZ'8>)?N=Z3L10M-6_V-_)R0927BNR/3<[P_;R]JHK054R
M\\+%S"%3E_XMXZ5!"UD#^+(:YAFJ&74$6;HVSX_;N.YQ!,E1'%V;/P-;,L.%
MSY-MGX+8:9L!3Z\PI>GLRZ_.XY?&IG?HYNR'X#=/= $UQ'DR**S>N?E7D^6
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M(MDV!F5&7J*RTM)>Z7_=JL!.[C=Q6_H,1VC>FPKI->:]_^TS9/,,=]D*@T:
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MD+^Z=U^G1'N8O$3-V0>\%(\U74B*NON[+,18+)#(?@1Y>@0!KC+&<B[8Y+?
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M>_LRQQD7&X'&3Z =UY"S="':AR.(6V!/#WHRBFP A.#G!1Y;K-%Y2=B(1JC
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M.$/?8"Z'T8;<_[6S[5&W=SY >5DK.GC+.E:&\U*#-/?S$:'@165:V.?Z5=5
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MX%^'=\2Q5);!4CWJR\@4 -V!.C;\PKZ#J:B/PI3*]RP*DH98_ 6OJ#\M6'$
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M"8PO-L479>,8]CBWB!=^W@L.7$\IG)VM&#KR_OPP6=MEOQJ1*4@KJ$\-(@G
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M\5]-F'JFNV(.&FY&!XN/Y&98'94[8\.EGMG]J/;@N#H*8'0E6$_C8F!N#6S
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M!@G*<Y;M8S^:V]=V]=F(:3O2OA07J-H\+E+&Q'.MQS)"P;.8R\H[3[Q[K>>
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MMF(J"*_(IRG_RK>%W[6?D5W =/EG"FF-)M&P\2Q =%NO]@%F5^/S]X4,2.4
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M-3KD%7,3BBQ218?,@!>$>Y%! J#)O5N!4=^##FDUU?:@Y8&T!5-&A[S';&?
M=NJ24)^58=2]L#DHH0<, >B_)CBM,LI@R:#WJ0!(+3Z'36&I''8H(F@?*4,1
M0':!!J"^0K]]MZ1#+GP![PT"BF?_9/_0T4#<-D5N]VO/+ZC"&FO:/G/0%&$
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MRRV&GQGW<\BN^QM?V?YR]2]7_YM=Y>+JH!Z5(GG4C2T@<9A]\V/]J.![51W
MA<S(]BI4BE5HGMU1,],'>6>5\4[-2B_3^^#>T']^SK=F^Q4FC+S\-P,A_V]#
MJ+^L_^^T7FH X*/*$7!-Z/TC@>Y-@,#G>O'I'E74B%(Q7[,4/[_]NA)ZOH6C
M0&Q)8'R*I5Q>/=XELSS=+<$J+77S.HH^\A]02P,$%     @ Q3746LT**%D&
MFP  TJ\  !,   !M9'0M,C R-3 T,C5?9S,N:G!G[+P'5%-1MRZZ$1$$ >G=
M**"(-*6*(E$1$! 1D"(M*B(E @("04*B(+TI""A51)H(D1)02B)=FD@-TA.:
M-$DH(9#VXCFWG/__[WCOW#?>&^_=,>XB*]G 7'/-;ZVYYOPF>P^88\Q9X*BI
MD8D1P,;&!MQE?0%,/.!@"/-\" #FYL 9  "X  YV-H"#=<7&ZJ;L[/_V^;<#
MED?__?KOFZ4 </#??\[7:BGXWZ__R@%L4>\ H#*9.0$8  ?8V/Z^_DMCYV#_
MVPX=/,C.P7F(D_-OYSK,<YB+BYN+DY.;EYN;YPBK<1[FX^<]PO?W^J^2O\/_
MCF*]CG!Q<AWYGV[,;X  %]#-OL[.)@L<$&!C%V!CM@$@EJ4<;/_6@/_2V ZP
M'^0XQ#*)FX<E@#[*,I^=_0#+6(Z#+(AL8:S? P<%. 1/G+MR2,CR'J>LG[#Z
M\U?Y7')7*YM%K :(\AKW_<,/<XN*B4M(GCRE<%KQC*:6MLYYW0L&UPR-C*^;
MF%K?MK&UL[_CX/K [:&[AZ=7P)/ H&!8R-.(%Y%1T3&Q<2FIK]/2,]Z\S7Q?
M\*&PJ+BD]&-5=0VZMN[+U_J6UK;VCL[O7=V#0\,CH[BQ7^-XPMS\PN+2[^45
MTN;6]@YYE[*W_Q<7&\#.]E_;_Q"7  O7 =8>'.3\BXOM0/!? 8&#'"?.'1*\
M8LEYST](5OTYE_#55_F5S8?E-*R((O?]![A%Y37Q)TE_H?T;LO\<L/#_6\C^
M&[#_CFL<.,)RS ,"[ ( &-@%450L:&(\<\@U*:H?A 8F2L&NP1 SQE48BW69
MTY,6BZ8)$%5YE_.S]S$WF$!, 1/P FW +S*!9AXD:87U+:<>$^B^C?:EBFYC
MZ:(C>TN0Y;HH%U%BDLZ+S;6':JJ%%U(+#IO>/%P[:3,1]HOT9=(;ALMVU8%6
M;T,9LLGT$F03<8,)'%1A ITE_SH!;>$]9I5Q?/<@$_A9D<P DB#K1RRVL(UT
MR7^5!1-.,X'Q:.H,'Q,@7IVA/<7J>A3\A[$15 ,AVL8&V C[SX+)E#@P.9^Q
MVXJE':UC L=0/QQ8$C&7FL';2JQ)GAUG_&QC A>I_0.H?Y(L^&<,95OI<6 "
M_V,+.O=O)C#+!:XY!_[!V/K/@DVF1$P*,8&K]6#* ?[_#?7_(Z@5OFT@8B!V
MW:YHI<I "JXS]J4#KO]KF0DXE\UF$AHA3.#$'B:>%HG0F8N.UCN7-G^[4@)Q
M*$VWOM*\0_&B?]_$X')89^EK0MGM3W.ZVN7[!=M(AFP'O0S;1,0Q@<.+3&!N
M&-EF/X,.WL6P(./U_L+2\$ M6*PY\=/VDR?#Q#3 -[ $9=_Q!NH,+Y*8Z\NX
M9$PS3*3:(4/Q*(90W[\MOW8<N/(Q>&L%_#A 8[OG/S-# 56,G0GH%^QR_F_]
M_VOIWQUB'"YE AR_*22J#4RHK3XY+JL9ZS&(FJN-6'MJ<+5!\E*G7*^N+JH0
MB5^:$6J"7V)Y."<3B$=U)5-DQ6@I2"DF,.8 H@M!?.U^ZX*Y'^R<?9Q-_.E=
MOM9039%J1QVE9*D1)GWX.9)*;V:["1=(:&9\%7N_XSX )FYMQ$YCCC&!;RS;
MVP>8 +\^)6<5OT$#P#1G^+KA4\@*PH0)7/[,DK#<P]$,?<XR@?PT7QIOWC4F
MT-J/47A*"64" #\3$#.FZ5$)P:AH+!%@ J1 /!G,!S<H78;XU/X,S(J7]J%>
ML[72L]^9% .5N][NC%17U"Z(+EK'Q!MX84Z1RC4+K4'.BEXH1264ZM+_E6&,
M3*WY>J>,'D__T7-?$O\<O''?Z))P[5G^6B^T%5XZ<3TJ>C)A@9 A833Y*]$M
MS Y#UH]E M%Y\)L[Q%T& &*H)E-"=MLV(/S(638F0%A=\F)%#^M-BWV.:,8!
MEFA,>0=H6[V<"3RO_IWW#Z*__U$/)HC]%!JM!JR.:[_)P&6JED/=3W$[F;O+
M^VD_O1?3W'?CBX5LO*F]EQ?5 ZU=3 B6'+YYF[23F41^G=,4>FSI'V&!_A$T
M+@'TXIB*_4!_),VPZNH!'?*CL4?;G3U][E,PL%UE3?V7++/A_/".*R*]R8]6
MTO_X1?H;"6<G\?%K9</<HQ<^>%@CY;VMVVY>*$)92\6X5)CU;P[O(O]/P2 &
MM^.;_$G>:^4^:JJ@/^T''QK[O@,ROQ) !Z$N@K>]'8U'--M?XGFG/KW\HS_Q
MK,\1[Q1I]@J_/(-.ZW4EN$N99I5+AP6+-"RF9?2[3OV3LQ8PCH61+N):9R@
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M1R7GKXK\E$FMFE=DB%K1H9OZZ*8;&1=0AXT%;/<-/.\X^^N0GXR80;2*??3
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M':S[S"^<Q6#-1#(//(RDBOX(\YFQ<Z2K[X\M+VMV3]Q*KA**=).0JHX8Q6I
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M+J]5S)M?JIWH?:%D-)UP&(BCGZ-'8;V1ARC5Y$!*Y5Q80$NY3/(W;X?==A?
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MQGYF07WFN]ERVOM706L[*A;#;KQO=MMN[N(^%MY\S(7ZL7-0J+&^4:MML,N
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M'TABFO0,B]:23L2OVQ,L4R=<4EU316+RUI=,3;0D55TKON8?!].3C-LJ#"D
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MJJMN!4?S</3O@\&G-@;#+ZO*=[V6+YLV6MBD+V*W\DA<+<A)?YW#2WA@J+N
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MHXL. ,B;;ZF0=%.R&87>EN#YDPURTHONS_%?JMEOS]YW4\:9\6#:CA3[J6Q
M[638;U@%6XHRQ;[)\8LHJ61J)HB!Z_NF+Y&8\^8O-)]CAQA*W[0-*/ ,ACZ[
M._SY$ZJW=/(08>O'>GM0B)S#%2R3^QFFFTA0F:/EDKE(Z#C8N1*G;FCH&Q\U
MPJN J%L2>7!Y6[;Z&IILAIB2!$^*TIY5US>EC;<WKCCI&7.QBP1Y;_*4U%M'
M5H/SB60[-%U.MI I)#YO@.DDQL1"@D@;VIWFK/S+/#0FKUK5]U_<I_!Z#X]"
MEO*L'NP]2S-7&!T%QAX P+GH=A4;RL4X;,47S5;1T<UK+,.Q",4U!]4^[@_6
MQA,AW&>+P=9>0I?2?^"2H0DY#!/)EBI/1$71 JX4](MK+1IZ/ :2P?SE%[),
MWG$+-&HL=1W:2#(()*G>:A\*\1RF; OEIY=M0[GA'XBG6V6]!V:^ (]0E$LA
MH/T&O_7L-'9,*YX5BYB;AB82:[H*H)$D/A#=OE7L@[=_B#&2D._"N-##?HP9
M*T>P>5WSUHB5B!C8]?G'?L'.7WG,FR'"V_-1QB:&V[]TG7KU03*FU>5;T]HC
M7FFZVD^=*&\JL>>+=@K<U0"6WY\.X'A5S1$X*(FB?T:W[;$]%Y^"K8E.N3UN
MC.:U_U&*CV'&'72)FL<;Z >)6%G:=Y;\3&YB'SO'D&)WP,5C0S: XUV.B_*Z
M4^6." TCUW&?BP-'(R3&N\%DNWJ0!T( ICSJ0?[:WJ)Y8_0:_>N4CT;9?5G\
MC+W+]1/#XR@R-)XS0<@C?+$%-<Z>'1E3#_//8VMEPID=[#0*;N,TXTY8/.U%
MT^VM/VD_2N7;?&J)_2&1OWBEGK& 4>BF8Z]TX@62BM<5+F:9S)H_:AH$EZ=4
MBL5ERO*J%=Y0*]= +6<T"1%MTRMFE#]90U\$$%091S,*IW*&U$1<]TF[)?T4
MN=NA,[0TR399_';9647JQ+TOG8[CU%'6^EZ0OC-%8O;[4YDD[)T+G]P3-6HR
M\2[3;E1UM('PH%A1Q>UU#N^Q.[1?_'NII]S?RU*QGX1Q<(>,O<,!P$7A + B
M3V]N9RW#R^1=&[S>XO1]5O%GLA&>K:W9="V&,UVTG?CS1\3Q9H-\GV$?%/@%
M$1QE^O"M>/MB3W+IZZ?;3:5NN9-@+36>-2MU5"4F:J'B:+NG;62B@_QJ_FMG
M%*1Z+_M:Y4GQ4_3^#@>X-D6V*S>XK]%^SX$1/\&+\7ZW@%%"/;4NX5YQ;@ =
MFR?;YAH*U-Q/,:URXK7+DHZ9,+(>-(CTT[:*JK%XM"E\KB-B*/]MMK&"45K4
M0&&>6:-<;#!C17K'K;HAZ=%UINMM09"$PP@:B]AHF><G<'4*TE/;M#W*72M\
M&A_$H /]ZTH(1E#/$TTR$2:K@^G]8%2K>YCP*JA2I1;NS7&AN6I? UV#"$;&
MH,[%+/-BY1**Q:QS15+]_;MN/>Y&[L/&=QH\M.3&:I2"62TE(X]ZTLZ+8<IZ
MM\_:JGOUA#B)2[@>T8Y3_"(M+.Q^GQ-=;OTU7?@KY-?D^*O2.SC_;LP!("4P
M@P5'LI-OT=3 ))SEZ)E75@:(,^A;?PE2\&7$^T)PG5\^4(SB\)YE37&KC['<
MT-/0DMK*]?T!W!D-KV+:#&%TY3!&"XF2(O4IU[:IXK?W9VZ 7IS<S$M.L@!@
M%BUIUJQ\]?Y)$ GWG!GPYJ[)B65D8)6VPB\YTNVY^\6@),7]+%8<R)]XG#V)
M/KP+%5P1'?@P/B"?KM<>+/C3\\26]_TC]W':"V8M0YB-C'8]Z&1V6/@GY0-
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M='/R[_T"N2@>DNZV? 5Z?<7<Q*/YD1FS='_$(5F7NXJVC$N159%>O1"O_5K
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MS!]>#':R^$%XQ%G#$IZ2JPR_RQAM%0.*",:^7:V28*F-/HN*M,J\<%%+L]S
MZ=K[3MPA_>R@PJ@K7^0;[LRL:[<X4Y[AXII5" /'9Q#OB>WJFC9LR)[*>U,
M<DXJ_D4"8?9YRI,?W*Q'E(R+CR(OEYEP<:Q>3$F;344WCI@OI W5S&YL/7-[
M<)]VNIV@PC$A;59CH7TWNZ1LQ"P[?\W<H&_G87X6:BZQ.:5A?Q>_&2$F0PY
M"\REX#$GW=.KOSY,\##6=BM(ZI'2D7UM'7@XR5Z_#369T@D50"I/ 7J4?FL2
M+4YXTP5ME#1]^Z^XOBV] ,_C??R"9YVB'-)VO,-5-_F!38K2B"/@*.%:;S6G
MU)1^VEIQ:,RE1O[;V1CC-AWNU[3R2U4?CR2<*$6LKH%Q=T;[Z/+<>?)Q*"G=
MYI[]%")M:&TS^F1H\NFHXS<33H]D8[]IDXIC">N/TMPO^PM<IMY,]ORA]?JI
MF4^UI>?3RNSOWJ6"5G@OB]O66I::%E*&**O4PJ%XV=RQ\OLK[8%FOPRV6PK?
M%:YGFJ%4>DFR,-;OQ I8IPAW)_ONF6/7IIRZ(M]^&M5;L7!I.L$IJ?110#:H
M8\O'3A?78<)KC2A5X$!Q@\4M W*J9E_>R;;D$ONI5Y7;K]GG S#EC[5@!),3
M;MB:..T+'MV-&8;W*K0'?2F15#F#@(=3@>JC/;I$L; :+6$BUU4[P"V?%MB<
M.1?JTH8\U?#SMV-2]XJ:I%/,Y*O#D,9O"^0O2<$<GWTLQ3-4]RV,/G>I_LY>
M-+P49L__:-KDQ^RW5<#E>2=5TV[K':'T;G*J67*!"8]9CI7<FDP[QR6#S=/%
MM0.B@"<I"H\L(J$ZGRU%2P I+F4(F0W/W3+;P)I70</?R$>C)>,^3MWY?>*Z
MV.YP#Y5]N7'\!5)T]2"@I+3,X_74') RD*PBAG:3YU;Y+LP3_SSHT@=<4_+;
MO?W? P3+A@?X691! IW108@^EW57/_Y,Y9RTF\3#=<Y#PF]HA2Y:O^H'-I2)
MX7C<.GIC1>@VHX?QY6)%C2Q7!FU+\KS)>T+@?%)3BL-[.9GO],+BR$Z;K=:*
MFOSYM JOY*<>]@W^0SW?%IM-VTOC9)POBWG9!'@IQWCEE\G(7/&M.*-V6V%J
MSU^^UAA+00/V[VFG &(%PEL_\X!H/#PVF9=,'GWO?6E*YC:AM*SCBBA+M^9N
MY;$ZK6#BABT!%?.[]OO3S8VIHOEXYZR^6WLOXQWA:1#3"%W1$SZYS6/70A7A
MMVNU%#01T;[&>K(FS<E6H1K(6[0]K<X'<K\NQP!L3TU3?^&%"N)$L^)LC(M<
M)UUQ92!>-@[(7\B/@?RO?=^#P0'VS^=Q^:B)?E9&\JS5DA,R&JQ7=K"%Z1T3
MJO!])F3(MI2VCEG!<,(6=*%DHVU870@'$Y)L R6B?X7%7, ,)DZTMW;2*[#S
MF6.HXPP61G]F3X<M[ S0WXT[TZP16(9;)M]H#-\G]7B>[[^L,,^[P2E?KB/,
MQI[]_ 3R*F8V\05LRP8VGP:CG <Q_, U!BM#5HE1?BM*0C3+#88ZFR7T(0<X
M;0H=%>M^Q3P+N/K1S]$J\]+6OH,!-!XI1W_=*@]P&PYYUPY$,"$\JK9GGOV^
MRG6)0.T(3">[:_"*ZA^7)[^0C+O>+B/O\P7C3&]A0N93<U7I+QG\M(OD@#SN
M&#7[JST.(M5C:F\5M92U<[A?8G[S6*\$\E8W[B\;*4+[GMYAK/M!/1$>E 3R
M4D_B9#"#PX@[3LN>P'U29SX498(E$1P<FN(//1KU;JZK6;KXF"I5-RAVZ$WJ
M\Q.^RPQM(#R8((R]#XW3ODQ6&*LE"1F1?L4Z$:^9;=L+B3Q%)'G&=*BM&Y]3
M4K7R:/CEYRW?<R[ 3@0H=XD1ILO[2UGR$TI^^)2PU='+$-8/9=IY4\W-0VA)
M1O>,%887-27""@D;H9[>2L^^8R7(_03N]6*R/EXIW).F2\!$SFF3!J(V.<I%
MWE?@J4UR5_I#?U8;B!2XU'&KU<\/3%@16>,+!YVB\)@$^9IXG\<NX?=:?BJ=
M&R+6M;S6]PS8.Z80ZWD.)M\P]464#UX+K1O+\B?!P5:^K-F L,Q01L2V,Z[]
M_+WAUZOE1ISE-B7-=HUL:4P4#WH^[*S:-]-Z*GNR8K$;PBW^ 9,,FZ^ G]8*
M]:;*,;I@G#08T7;S.,*QBPEA5^7[8,.$>.2H&#>G&P7?2MM\-//A@7'I9.KZ
M7\*?%\;A)X#J3!>S/!TNO51[F^18M$HJOZ.N15IRT]/X&1O/\^NSM3$6'R\6
M!Y[?L0U9]\'66JWS4,\@N[2OC&OS(Z@$C9ZOK;*N(KPXDXI[KI;&^/[8GCH^
MW2-W+@IQ-:=!]L-@65R77G>%-!&$:#QKW3@VF"/F)1-R:K<"2E#8T58=J10G
M*T66T\YI:3 $JF,V\A)<TB8CO20XR,(/XPW2((ILTCME\\4=2@FO$7Q=N4+T
MQ@> %3%Q<OPF::-C"OC%8'03]HO83T6M:_!\LLM8_!(D?B^6Z)'R?(X_]RR0
M1[V%:A-@0ISC SMR9<BLT0HT/N+I:=2K+9!ZW+1Q]4RHQ#G%[#K<V;X0OT'1
MTQ&PC(O@#(=+I))_^QBM[N0EQ,-QPQ'NE86RINAK(D.&J6F7-<U\PWZ]IR\;
M#\5X&AK:CK0/!X;4#=94.)>/'31M8NU-!IB0*6Z*7DLSO5#+ H\*9T*.([6-
MB@#GL:E?FP9DERCA9H,B^22];J.OGH[3_(_M^!\>,_VY5QD*I@V:"1%S'%?8
MJ0.DR#[^<A]L")PZ\QOZ YE27USN;@5>BN]//G8,OP;_!!;%7Q6D:@9'P9\/
MY9*UPP,.D WX@7"2>Z;_$,1FBL!U:,BZ4)@HNUI,PKQEJ"#G8,(A,F"SQ0:<
M)GC""/"X"IIY:<A?K;7-X\?*E$<JW]4']XI'&H7-.;Z[_[*,ETV75589;IP"
MO$4_=)M?GE\><L]O;]^5UE!T!USLZT;\31<]FC$_N]^?2 W*SAK.>M1HV+.8
M^*KYR@>$CD/S4*T'YW>EN\/O@SV:KGX6X8R]=V?#=4&/)2TUC.,UFSC6 "F$
M:CM.DZ%Z(C3F$Q-;#P$%]F@0)6,K;6\#T6+84$^?#PBQ7T<NS>#SPZ3\+Y0G
M_8[C'?#J6<B2:4.U]6@^M$>UF?LW5#PFVG[WN#Y8Z6*+:/5X.S7(=UFT^F1I
MRP]^#NIIR@,RN@,.2"BUP:)0U3U=GW][:1E3#23'L;RW1N+N )>ZMV8W%'ZN
MP^0>E5XM.7(D9^]DU6&LL$^K9S2^N5[]:W9>7.?U[Z8QYF;AA8L6-3/>ZVE%
MK/Y!6S<&<ML[\"6EP\56>!NXIW<Q;KS?(>HK]I/+NC=5BC$"(YEYGPP1^#BF
M?=D>\#;#BGB'U4YSF1LZM7AX!)=X5RKF5/@L?'U@4KUOFGPW>>D72[#))(;!
M#B-Q4];H&=I*B#W\[2)R9K\9:;1C)??$<(A^T/O]S)P#M_:UWL\G;=/$#0Z+
M\R=I?M#:W>^@I -J9 T&6S$8!,?2H2?6>-T:]R(?I=PA%;\R+A2203WP$4V2
M)%Q)(C@K-R=]EKW1V*IY#',9$*(&T6SHF4@Q6$0(-V&EAHO#Y*0-HJB"\+$V
M+:' G=S,%Y1\<^C!WP9O]H(>LQPO9V<=[WQTY9=+9()3Q[TLOU7SCL:GV0O#
M/D_]G2Y\@!&NFP_OM^2["S7PE!ER)]>H&>-,FGZ/D[3CP,8A&RQU\LT2U*.,
M7C@;S=BQ'$BY0]Z+KCQ]F^Q9,3K:W.@?L76O0^OC])$(NZ"GAHY2L_LZ0Y^8
M$$?<!"M>;7,=BD$.HL\T7R>+0X], DE:2L6NC$/5=>B[F?.E*L:J]2QYD3#T
MX6^3R>^\%"1=F1!8R%-Z'>,"<@C)60ORZ7B:A6)+X>1:!D,B1EB^(M\)V_JZ
MWU_CK:C[4G#554Y^D%<\/QJ: B8&$D!1'1&.\T5[L5B7,[9MR/.D[I+REKK:
M^7@=Z^%?ES[I\<_,3,UH!EW0&VR02G!AB_+0K\G(T8?U I9RJM_<.G@VO&63
M2]:)%ZXTR+H7OJ-G^=28+P348BAAZ$\E\)GPVKK:W3I*:W$_JE9Z?6E^4BW>
MO!-L1F?@ EK^I%C=JMH,J_%:S(EF#SRUX:]9#U\?#K:G1:^]SK$XGPM\?J9Y
M[3H]2UL<*.MH/%%5!+!V-Z:G$,IZAG=LI^U/_/((?;BHL1DVI7NC^E:KW=N;
M4I'=7^>)%"M[()SD@0^D"829A*E3D *#?B931OAU!SX _1[A3%#[N;/)][?T
MR5/J\^63OH*CD]]'O% (AT_C!-PKK L*D'%I]YY<FJ>DS6^>DEY?(\UMWVH:
MK@UU1:"HJ+O-=0G!VTY/=8XTI[Y1/UD8&?RZRRH8,W _Q/I;"3XOJB#R:<;'
M@TXG&T.M$8LKYY=4"TZ@O HXJ55^BR*9=D/6IQPV=NMB*PX4*#0_F";H<"P@
MN=0%F[*B-),VV[%\@#F!M4.Y3%=ME%%6BKBQ@:W:&!(^(YTNK)6MMR7>*9RC
MMP(YDBVSC8H%&U#]3N\(=,U8%:E2Z1ABVH*LD+/8:>.?B7BV>G7#>>S*HYM-
MD=,>5W7%N^TN_;9S.>Z324\?W5U#3Y8Q.!2HHJTM9 F"T$M'\KGQQ_ZHJ-9+
MY#C-KIZHEX,77TBUQ+^9T?7Q>Z@<^_:19^])XR:.\]SK67CX2<152A[]HS:4
M]O=H<V 1S8/\S70&4*AA0@0F.@@*.AU8SQ8?S\(Y>]4DVP9[;-/#0ID;1YPT
M,%G<IZH1/]X[JMV^ZR#&%Z]6W++[=C!'5\&NX$CJZM.^.Z;5<>7[<^C)G=F\
MBDULKVIKJ"9#GZA=056B_?T3*3,!"%+QN(3R9L^2=\D#'</+&J:K]>Z!)P>G
M51]:026V2I'$9R*S#?3PUBOW5BCCOB'" (:K8J',VUL%T+]CO924,'K345 X
M>IZE5\MJ0ZPLU&U>:5J.<@;P)W!I])@09X5LQVK9-IN]"?$P>[):'5JA]L?]
MUN2?1*YS<9VW];X:_IZI9$VGJ=(;D I0-C"WC3#GP73V>D\RIB4AGGP/E4"U
M:XLQ&,-TONRVNE-$SL7YPR)UEU0<4K7N_ZCB+[!BCRCRLO&LOV+C,"P@KVHG
M>C=#[E-NO8?U6H$*8Z!8R,U@=V5*:PI4&=<%"T=>!(0)3H,AGG@X+P(&THL%
M:X_,1U.A@]'1G-(9E\H\I:R/=;.;+WMD85IA\Q^@ KN;"4P(R0@S$=4U)S_B
MY8_A@T\"W=V;9DUI[QN;$X;-:^M>]DLD_VB_W'TO6C+]VMK\,WK6R^IR/;<,
M^=NR' (2FC4+^=.):B+5A5.>TFZ7[>%W<VIGMLG\(]+]9\K1<RGT&R ?+U16
MU@IB0LXBF)"UCTS(3YL&V;60?PPPSI*)#,,&$ &A*=K5TDQ(X/['_!@Y<L&(
M=BDXZ ":[K(?'+B@-MXEA^&E_<V$1-CB!R+$!#.Z&BO+F!"V]<RE TG)MXDI
MHH.P7I%J6M9DU?/")'N-#5L0K-Z1!CJ\)P9;M4-. ?A\VE/ \_V:!Y[^=%'K
MJB]^>D-\I3THN*+R3$[JVY-\6^BY<RRI57 7)B3<5XTNU)[+1J^J->$%4 S>
M ;!'/>9_M<+J)M4O'3:M'BU:H8:9DCB*WW8\GOOP4&_3DP6.@PP&FS%88&Z1
M<-V;4WMM3 @+@R_D) G7!HV8NXTAG+'L/N-,=&@=\^IZ&W^\WHJM_*[,PD7G
MJQ(L:7?+0N8TSL04V12NS';G9#FL6M;.U?UJ6O&\FIH,8UO&3&,F RG+P"#5
M =4&T]8*"0:"WR^WBM-+M#0J[R%<_H[5)]%S?A3AN5D?V>EPQ>=W&GW(#2:W
M)"WX"$MBDYNN76W3=*@@X*;@#/99\F'B[2A'/'HJO$LSH297HC[1.-8$.^KW
M8:,RHG:4IOQB<:"^]^HM,Y&@#'<!Y??#/XJ.C<Q75I87!?J+>5;4&S%8^E#:
M.U8[YO-80<9/J C*$S[EB\=L2,U?/:-!,1CRLW=W?31"NW8L)V_%\O5'C]/]
M1GCHIK.K?O;&KRK]&5R3:_L)?0HW*03' 9M/15?_ /L0 NLKK:-!A+*L$IK;
M!\!C?AM!H7:*O,ERJVI5;FPIYWE M/_"^E>$O4]&%-I&XXG5L//4J$:9J=>!
MI\OPNZ?H##3)!#XA 5J\-F,]EFH*4#N?940_KDT,<Q"L&]NY[#?]2J*N*?-Z
MP#TORULY.:R3PX?4X[9F<I5W7-9Q8)2\IX/5UPWV:NXP:2*#L!>N']_*#>L<
M&U72LGV/:WL_HUU^8*>.$5FYDQ[QR$1M8:ZPS).C*1!=HN6+WSP"N'2B2!9&
MJ$/+&0XBPUE?IFZ.']P=$^]][,]:V^J1).KX/&&ACTW*(#7MZBU,V[-RK56B
MZ*+PYQ#UK68^VL3C4'LP9/SISYLU0$&6@7ZP%K<AH>.[W+SV[G/':D>;=0)]
M5)_>R&S'X2;F>CP_J4Y[)4^>C*'.A$SZ)B7J 8[@-"^2=CA5DZ9&WNP9F-+I
M@!WZ!71Q3X=(%/;BLW*>V3:95_=_;D@6-E5P?""N[++/8V]T\6H:DA,SJ30!
M4EU7[V@41^M1FAA II[5(??,HU\I;,R3ZJ,W58OM==H;=8??>;SXT-%LJ_<Z
MS=] *_J,1!SKEQMJ/7<Q47E'-]16Z2-3U=.9:XL3@L5+2B"5<4:_9!PC;78A
ME@!Z_FJK+$D;0T?C0S5ND49W%Q,3'IPHW5.&AU1-EX;U+%E:3@2HE,FA63&3
M)G&X:C#S4$XHX+PWC3\+O]=!-S2V:M<6(H]'*/CM/\J^35JZ,SQG%."S%W>I
MNMU@X4W#DMJN_BNL)^X,@I7!$4X5IK$.N0QN,$0!)@3O_#:4$"NL6N:V,$Z;
M-EI.ERE*$N[T"8T7%A ."IS]?))5\X?TJ7JV;:]=-]<\8;]$V_6#W;H>&1I^
M$/Y)?Q[LA6)A\Z]A=9L=\$@QH9':M4UNQL_AK@?XV6,_C*:_RC]LJHY12"<?
M>YU?_C<+!R(^45<R]!S!FQN!H<"!7:JJ_@>:#'DI3@T7Q81\6EW.+ /T33Z-
MU X<FOM07>^I-W0ZN^/:-_GD[JKGZP3]<Y)W^OQR@P3\"BJF:C=JS%MGO;VW
M)ZZ8+ 6TI@)5H(>W0=A[ +[V K94/50[G+()W$.>:_V)Q8LQ^K:PU<CO4D-!
M6+?MQ+=-ZY/3B^<U=B\OK9@ 5SB_("\-:TN%")-=8IKO>1,Y44((W86AW[M0
M=GT\5H#-,2M(I(;CV H*F7=*WE#],X\$J]NUV/DE6KX5@[V?"7$YACX(:JJ0
M=;[DYV85-966N65H8U^X9__:FN:?CRVX.@#(>'=RG69P/*!ZT:Z.*H2H$+BC
M8*RMPNZYUWYJP?P+;<M]W&W\!%6BW YY^:IF7+I:D_5C/B)@HVV_!0D#PBE$
M^BLFY"$\%LV;93+.D'9C0FJ0:'P4^>3PQH97I3SRYS#;K3#5OYX72KC:(1?$
M"E-RM @%-47&DAL4#%FW-S1M:H#T^2DZ-FVWI^L/!#".@45#E:9,SU=04^+M
M)<)%$(3-#HTQ<[N_INPL!Q56K!*43Z;>0GY[JR"GI+ 5%X<<1B3VP&K&078T
M7Y<K";(IDZB >O0GL:H'3_U=-YN5O+2N^3HJA!M(S61TJ[0N_NZUU'N=+/PB
M[G@CS9<("S.EV8%7U&5\;V4!X!I1F HU[RDKT^$0)<66V'A% HMO::QSPXGB
M[Q$%;/<,E9,,[ OKN&&4;Z7!&DYG'L[FC&:F)^JZO/]PQ:3[F=R!.CU?6PBH
M)V#6):CW75'"6IXH\B7<%X9PXTC--4WOEY< #5U29)YKQJ5S0TK.^YOBL[R5
MB_+J>L7!\@U($2)E%8B@*JU 24:;AP#U;<-A&HQL>YWT.Y'P^=?0_.<LJT]I
M.VOPZIK*HD$!K_=.;%9+]V_[Q P)K[^O8#O_^Z"F)E'#&M?OG1.>2GM,SV%"
M'L"$D,/0:G2W2?34B0)\OS'K?&A.!*7)&^6C&ICAAM@NO#%I)JU_WQ,7^(;\
MG&,^UX=02S]*.P9TD6'S":!%CXH!GB1GXITZ[Y>:WROS2+B. \6DHR.-JO7C
M@=MS"N6<?*HQM^STVMIEG[_CH!TA>S**2H$R\\8QK<T-CZP&I];M@JV%[<G>
ME*?SGIZ="_?O4P1F,X@NKW)N/RJO\/2OCGFVLG3@U_3W ,@81GCV]&FG[S$A
M,A5_OKSC,T"_N*I&M[/:2F1"CHVA^CR0G$S(C"\3\K=F/,I*8!]["M7:0Y/;
M3JJXEM@%^]^_LXX<0_WCL\-TL8,KJ-XF,"5^:S#0I2'.WHP]6,9"8FDK+]AB
MAURG7@9Q&^;5>CQ$9=@_D05 VY$OC._B1%>0XNF<5& TH*C<0-25LGKH!J?\
M]]?)7-B6QVX((0;'/M%>AW(=:"!%$<9I4E#A&MRK,<I&X2I(]&.*D]?:ZU^G
M^WV.?V^0>W=;D%69-0YZ(2Y1.3XD2A?YPO;YEDBE;TGD;?,/95<<[!B#AI?,
MS+%:CXFG+_3J2O5[V1:D/2RM0!L%V?ZD"X/0&D:=+J;QBV\3B\;_5$H;7,@U
M,9:L#API[<V>=':R6L]4Q'N]&VD3$D=<K@)=3V \L/ERY#'2^#J&B(E LX!@
M, N=+T)W=L7@.AL+@-*USHSQNE[TC,1,=X7(ZWO//II*1EC8UR=&7\"H1T7,
MJ.GY+1F^3'Y?4@3UL$TJO;VSG[=Q1?KK+&%)6'57AEBF.AR,RV]M6O,HVX<B
M$1D,CFG252*L#1OA( Q44"\P(>WM(ZW\@%Y'NZ4FAB:_H6.PC:\+N]R_KSZV
M6M:2@CS58#\QXY.)F1\ Y$S:>NBOFZ^0X#U8L"6F22-Y29$M)1[/5.&DJLT:
M[$=ZZ>HO5\(W=<:CW+M68I9+2?4;,W])'YYO_/.E#\<.QG=3T]("8>JMHNC.
M(G8J8T?!(EA]?Q%Y^^YFZ3/K@PU;G''%I^D!XX#59U$;+F0K/*8+G#=FD]$^
M$ $E%8? CF6FCXMHT"3W',Y2C7^F6WI@M/$6XT^U#!9?U 1=;:S"*.7'4!^?
M.)'+^_+)2';VP_+L(IG^I2L-AB8_C*MSS9X&HA;WQ=JH0HS!.6YZ9JOXJ@TZ
MGL$#6!%/1)6Y?7+[M/+L>V?==W?1,.?ZM,-L[XF'C./ZV*?N)'LLHP3!N#/Q
M,XE!<@(H$@P/;3\C,8_ND":W)&#+K-LJ9SPR&K]/Y)Z-M"T9%7W7GE-^BK%Z
M5MCB4&:F"^WD=)<I39:D%*ME0)ZF. $H#S)?!P4I-23?;$4TJ"E;45!\8'#G
MS4)MF],)@3J5"_?_<AQK-0 IRC"#?ZE+P;<=;"%>(UQ W TT]J!C\-.;]6[/
M(F&+1<U4JV]QE,?'QY=&2#2%SK<OJRX_2ZAP?T;S;\E,]190<EXHN7*]WNUI
M@W1IX,CJ+XR>H'OO 7QSAAX(1FD)JLU86Q39@R-90D^MHD@_D&?(^ET#D#9'
MP5BB <W(UT-LOZ8IR#']5YN$\HS!R<^NH[%ECV^RI):F ;;ZX +EJT/(/@<I
M(!B#@%-][<@N77EDN"F9;:0+F_4T)%P!._E2DFN34^.-Y)=MY8]$=/)R44<K
M_T*0UV'NB#)6RZ(+0[>?YAC5&P17RHQD5">JI+9DP\6]7>Y7))1=:5#@:\WT
MW_=8:]@KCL3.U\-(8!_59DX+IOZ-:J_:QN(U?EK=9$)>^C)X%; /NW)R,%D4
MS"<02LDK3=ZIV#5E=(:T$L4 E+*_ODUI,E$',"$?QO_.(W-W(+E;TK<[JE<<
M-$:TI%'%T?:%Z>S.-<>]SBFNWU"'#(26U>,/Y'Y6X-%<(WFB6A\9ZXZ&',,?
MBD[]C"LP2C=T-_6)6Q1[-%)8.)(=;=W7.T<_4&QBZ'] 3L)K-I8V(JAZ0"+A
MZ%S:L1=BM;*<QN?G5FW?^'WE$>"5#&)W_%G-4VO4]+J4S70-5ZU$$[#MA'Y*
M7'?A[H!R *$/R%Q1G5FH5W7:4IXW]Y_T'A<DT9,VCL";XSM9?8,ZY"04YY86
M17:@\2#/&4B$N7"QMFD6QZM"USV@KS)%M25).VC/^L\@=_IEX?JKT^Q*XI/[
M ;<$NH-,'7(?O%[P?_+Y<88P6Z./Q^1P:FYEYE#?'EK>/SEDW*;OET^9A<%(
M AV.60B-I=Y$M?GZX>)AG+0@EZ*0,\TD7#Q2W+HVO:#"@"QDB1U>CXM[[_:X
M9FQ:H/KC$:[$%\EL_O+QX?,X0)XU7,N"E(+_$4VNI@22>KJ]>4*DA[M3\"T!
MFYU\*[AE][R'85NS#Y,41]7C6,^*ND"JTP&'F*T+ +S#[^,:EV%<?FI#BH6'
M3''_UQ%WV>Q51;&UL.18&^M!HH?&-]Q\!<[#^B"% *7QIW.?9O3A#C.$IH!#
M.-U:0(G@J=-Y<::MO%?>:L7_@Q&BKD0TJ;JS*OK(@[E[;\-^:Z4XY!$W 84!
MFC14".9N(@"&$%6)IHJ)J-!2 UGDK7H0!*\LN+7W_\!13"DY$[CJQ];4IL0Y
M3-AR95^NV!.Z24+$;A:PZFU6(_>=!G<OEX#)/2W3K5E:\[<<J-<=O(<\?M#_
M%QALE1YS+/37VJPA&B1L5&0L@?L%0Q'=-:8MX6GTPVA?,I-@RCFU;U0+&^*H
MW[1]%G91PV=U"D,3.MWA(#0>XD_$16*K,1':8B%/@>@'"NEE1.N0ZSZA1WA-
M$FOLIE8&3L8(/Y) ;FR\U7;9OH3'7ELN)SN<)OT6]_)_<M!GGEJA&6T\@J[)
MS#0W?.*[UY(]\BYW\-8'HIP">KY1SFURNG)I;$X$%+(&2,'7K\]2KR)4VK7%
MHG3)0NM[E:N:B[E-:DS(U,,QKL5OVZJ7;/8-'1,?;? ]M)0O3/J8>TVE$TVR
M17,";HQS0 '>:GT3CXH$:<N%B?X'E8ANI9,S[G*\ ]\[T].]>?4?;VG\,*PZ
MVE[-*HZ%N1;PX+$GQDLV9!_L/LW.*3:5N3+B_^A]ZE#V&;V%/+4+YV?ST\,2
M+GVR-"'9"]1L%%N44,]1!4-D@32J+;(-=G2=!J=>I2G1"VBP^?U%,9$Q_<XW
M?K8#;#;L-V)#+:6..T??.'8QSW%1TIV\'W-]6?O\%("AM((=3D2(!M$D3&-.
M;$05]2*]42$C;A?POI]H,%S1DUO?*[8T*_[&*7>&K4T6_T*6_S/-)+]5O?BE
MOY@*7VQQ],O00KEV'HJ_Z-DJWML%3]+/M36=SZB./]6@[=;MK5/DS)FF6U$^
M5WK@68'9PWT]R&!PRE$=IAA3,-(=F @B1;\A@=BN>;HXDJ;^8'(A-&SX H;G
M[W#13V_?F],GHVZ'+Y9>P(P^E4=SIRZ.7/HF6ZMY,4XH6%<J\->>=UG39?>[
M_N>7%"9[__=_"&*)2X0M*$/I/M #/@ML).QHB!.YC@DQK26YO&PV)JQ5B/7N
MR@%^]HJA-XSD[IZ]UEG&6W4K]5/81L312!-Q;+B66;*=18+W_G]^&-17U0JD
M<1RG>V"D#V C=Q_5+D08 /YBC%*4  /8)T78)RT:L9=J.2#];>!TH,NULLE6
M061W&1[$713_IK8L389>6!YB7(!P'H>3:@Z@D2$MXMTRK4.">]8>;SIZ',]%
M\?0+'@XRWPH@[V_\??-L)<X6B2Z9")G6148APAEL<$+BY#"<GJIE0.12ZA:3
M #&#R]LPMOO OB<"H_J!)EB-FYBF1VXM/E(030DM(9JUL\Y$N0Z87 6#&'1P
MFZ8:=A)%:0<J-)ZW\B.(-P$)?(69G/U5:Q'G//\"6YG(D_V4_? RZ)6W2#>#
MXP&4+E^S;Q]WS^>Q!A=CC,]4K*'.3:*O,;ZC:C&=T$G63FWQ4>09()S!,\V$
M""QK:)\:=:)RU>*F:M8BX]^'\W7C U5-<Y8/QS=?[/TAU :/;Y6G9X.=E+8*
M21M;@G#L$A%M]4\H<#S?^^XA1])R7Y_AIX^R?;?.ANGZ9@;D^)2["U(" K;M
M[>UO?>PX?N%1LHMCA(5IO[(DA%4RDW[F3SU%M7&IPB>4*)=(WIU@14!;DC6B
M:Z[VVQ\F5**E1EM&L5%JMEFG@S^,G>-W)751?RK+!#SP\;I^NJ%Q]^/.JJR_
MPK-,SY8F.F6\Y67()-7@S]_TL:Z8J<V_?SY&GJ49-H^K,B%<[J9K@H));@'J
M@BM!PGTFD@$_]5(TDY\X<<6AS>TR8L#N[!W\5+,+U:Z73-CNT4R%"1:ELV=U
MJE^\[JCLZID\RIIVQ.T$3EPU/L-YW.XW5T-U/TV,GJ%]GO%SK'X8.(P?3Z#Y
MGDC_JR6EX^#HW/NZM\)B#R+5V9,&OL<<*#$X4%3^%=AA+4^J&N""QX7YQ\)X
M0VX ,G@,[]HSB\_-+:TC_M,%?HK9.A)7"^,>WGD0)UMB_M+!X^H#M^^F<6:-
MP5+YL[A>AL2X;RS]'78>@ZW)V- -Q0>C14(LQC#G20Z%:CD"Y?\7:^\9U52T
MM0M'45$147J/"@@2BH4N$!M-!*1W(B(B1$!ZD) H2)$J(" U2A&I$4E :J1+
MERXU) A(3P AD';C=[_[WG/N.>/]OO?>.T;FCYTQ=K+W6FL^\WG6FFLN>4]_
MU.?9%S=J@2XQ\D,O>MFJ;=B=4>\6\)@E&C_;;B*]LHFG:\X[&L^#_K-Y<MJ$
MKZ\?Q9_A4E2^EO1F,&-R\OBL9QG?BZ1W7I9/76^*FY,E=LTI^22_MDF%6.+F
MWR7VBDJBP1$-G<A*PFJ]2+EICVQ$F+J+56J-QJEST@KYQ7SU%8AO2#':%<*Z
MN?5(TTFX_?!.#J<C%C2%8E\Y,[5,..;0)W&+__)[[J"S+]1+XD5%@^WB_*=T
M*'#JL2(\C@4A%#7ISEPN,KBE[SJ++S;[>!*TI EIB870SW\C%8]\!9;'4>J;
MR3K'K14BS^&,\_LVAR(E1>'R5&UDLWZ3&J('(D@S(K,U@\\JYZBVSRH9\#@U
MU2>(Z4/%738??XU9EHK1FS8XW6T;I'+\E-\JF!TY%X<\JZV$;%:"&U%ON0=J
M*^4R 09CQ,]#\$O0.6I6<</MARV'#][RE"Z\ORWY_LNM96I43T(@&8?A6G,3
MZPQK$"J%2U#,J88&'# 5, ^E9+L=(=B7%)U7[Z'"!>4'5QV?;0DV5IG;6'5X
M9P<[KO,CS,3)5B5M%1*BX[,"WYL'\J^(:Y,#B]$>P['EUG8-F8PM9^'.)2-0
M>E+U^Y.UCZ5/ H2^ :P\_>N\FQ,%H6 .+%#4EF+25N/$,;@QQN+';6>64[H*
M)QQ4^C[W^ IT&W"]>Z?[P/C/?)(]0YV>I"T'5Z2$L,<V&)%P1.DH^*6 JJXQ
M+/BTDYW[MC=!94#RX;5Z"4&O$.O2]7.-4Q5XT@G-C<9W+/^YV71%L1T9V:0>
MU3&>EBM' 1.HX),4/5,LIKHF17]8WLHB;.IL![_K"<V2C@?K%[YW+T3QC;+N
MN_!WO? 4 \\*!P-1N!-PY]"*Y291LMMNXN2&OWM>Y &X:KDFR'T!4]D=?O7&
MBX73%I\%U216O%E(WZR >PR<Y-EUH+^'.Y*DVX 8_GBBXL3NF'V?/NUFS="O
MH0"D9/>CL%E#I2/Z5OP=N^R*P.^WN=4J;7HU94-D2PY8H_\M2J&I^O/H0";X
M"9@BAU\'4<UI4F3IE_!@LJR17XNV@KUIR7+L^^6T-].AF02OAZY;\F\Z6BQT
M'\>5:K>?MKW!QF7Q5R# GX\AH1 NN'\M>2F#;-Y2%SR$:?2F"AA#ODP)7GS1
MN>O#/C&U9\VCL!17,Y#]Z[":#=(%'"< Y$J,=:&8DV5-3E:D!525H2,5C7/E
M )(S^PSK]%^ $]M!3[]ICFAKT=\@Y.$@TA%M.;)>RV9TK@BIO/DF?U4)S&MK
MP.1-;8MGKO[8M:^DR].C'0F<"OH=6I9E=1/*VP:0II>?\.R,42=MDL :>9XK
M0L.X<=<$0-G:&*,Z#C':O:6G/F(#DH]M9UY3"K&U(*K>]_E^H?'ZWU>J1?R8
M'.]HA!*EQMN USJ<+I#"*5SW1\"?,:-4W9B-BK&F^S5;Z7(Q\'9312"2CZL=
M-Z'18T4"?J-"(EC8"7Y2BA:#WQA24 @0#-CD OV$)</F8TRNM:YZ [/\GI:X
MNCV>OO5N@$UY$<?-!#S:C$$=I8FX$14%:=<H+PE@KA7N:/D +;?6FD#^H*MG
M].]DVHP*15NI'<F^M%-BVFH1]-9R9N_N9CYUK6GAI[)V+X63ZDB3H+_ S;T%
M\FE>)S$!Q#3TO'<\!&.5Y5P M;L 0ZR:#-,$GO"[UNIF.DBU?02]GN=NZUQ,
MUCQG^=A[0(.N0?G !!QIIB<C'_1)$U"18'>N:)2H,R6")4!_4&(\39HG';-S
MA7[DO?MLZ:=DHM4Q5&@0[B=6'Z,KI ,_,8>>&&Y'BC>=6[4S:8&<@&T2=:I1
MFO'>]%3"\@8Z<SCD^,=,#J1J]^/[)QQ[#WT_];//;\[C!_S/ WS#QJ_1E-]E
M:ZFIY4S :95GO-8^>8Q>)'># 9G'AH3((>UU"D?%:H*]I6:+\^R?J)JM:#R]
MLHZ7VUV)U$\*^F@[<JC1-Y@7'P>L K<E3JS(JY@ X6!RS<MA6ZM0K8:;'QS=
MP_:M1>)T'T$N<_8DUW805D _=C_CY$>[U#)!/Q RC"XD'X*=8C;@1$:W@J.U
MN7[\.<$/<M2S)ZTOHMQ]USAD"ZIT/[5]D@08G..9S F@7J#9?*$8-VEE$:+:
MU. G2>4ME'B:.JS.\ X^\*:_RU9U=IS83_7\*7/L?OHL>ZZI#M][X -D,R_N
MU_(?)H#*IP#>J>C'W0=M,0'_MLA4WK-Q:O(?M_WMG3@F(+D;^6<#]:LE!C0%
M=@:SP?PZ47S8X\H]CF"+1NS0XM?!G9Y]>*GCK36^R83I7P]R+\.ZFJ?"EQ_;
M_)[[7-5NI)*'=L7]F6GD'J$E1OG:932YZLGG2PE9I*:DKC6M5E,EL[RZ/ 9X
M\AHWY\>2B%S<J^(BI#0L"=V"XZ+I%'L8'&W*+[++LK<O?%/F@:I7B.-[Q__
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M=Q-O.BU3CR'PZ> CK+XK ',QU&@.8W"?^792WUJZ<.I(NIO%F$*^RO"M$G3
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M\HG (9MO@I\HOL2S(UU9:HTQ3JQ98ZDYCA2S!LJU#STNH4S B=D/!/P:1:<
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M!P.+E&*9KDNSW.5'3U8(?!IO2IU,3H[U;-9S70-6F[0[\A!K8C0E5,(_J7R
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MVL@B1U'7D"TX=>'AGS1S)B"\!;PXPP1L/&("IHT0E\;7W?YE+GQP,S^=EM6
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MBE9(%%A_8%^.16^<EAGW6+KC@(WTYG^G)Q?0%% 4+>MO66(7.>"!80 D)_5
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MMZ[*LOLX;SXQ&/I(\;3L1DMY5M$ OP\4& < TF16?=^X D_[;[M>-FV=&^J
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M"M<M*#; -HH0W\Y&;_;>J9#U?%DD&Q%6F#P_LBMST)CW6%/'&YAM@])C^]=
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M@ S9WXJ#/IO)TV<)T[>.]WZ((J]Y-L%H"+?.0DEV-4V!G%>&8-+RX/,%!KY
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M^7,.,""%X/(.F&KFN4.(R[+>3V68X0B_V.OBGAP;]X@C:6Y(K]39_@%?E)E
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M+[.66&BV)%F*3A(>]AYJ[[DP"1]!FTU^OS9"KW:S^*33 I(H[/HK%ZHE$$^
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MPF^<UV6&>TA:S&NH#(U)]19V6/5IER"-PM]*@1YJ]<!Z'L6[J5F[#M0@O:F
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M;67G.OZ=T/+_UP&FCOQ?4$L#!!0    ( ,4UU%H@'(98H7   $^'   3
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M<(B\P-"\=A^X2<LIBN+:_8.TOU#VKQ'V[G]$V3\(^P^Z)H%;^'A7G8=/ 2@
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M8V''6;N0UX/U7WT]OM3/7+A?[Q#:V30:F=%(X\Z=PYRPRG,->&B%EY75CJF
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M- VF#:=+?DQ]%'JR&_<BL-A2-7[9>"M3GWE%,P325>-35.NWVQJQK&]"+2(
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MJVF[H3FU6W=(U)D8&Z+;+WBDNWW)GB7S6M5'HAZ7@@#<5'*%J1BB7B!9/(0
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ME<QW4E2$9^66\J\\6+^YO_%WUT/^%F']CL!AD)Y#R"FF-4ON5RS]5_K^9]F
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MP?9<+D@,:' WS7]5Y>^ZE@, ]\JQ]PCJIX02U/_Y!_5-T<*X4*Z;>,"UKWC
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M!GD#1!*LB8YXQJX+8-PJLAS^<(; @IV*KU97*0IRH'"&(('R[<66,WHAQ(:
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MD*XIH7YJ\@Q@=J>>T.HFG]_O4=;M$C2Y3LQT+VY-+/ITROB&HX,/-VAJD":
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MNK\N=(F ?/F;36O1OP19&:2&D6?;# 2[)?5;DY[R.WKM@Q>^P4=D<N!#D5]
MSTX^6V#HN/*$2 4UZ?:P:5D2>!*LPCXI&:KUFWYJ/C5>GA,,:2<50.2N\-0E
M.#"^L>'9WUKCC<@IT[[=QY4*3UGU,.SUJ0Y(QZ4UY;;8NH6\%3J-E:E3+F1]
M.N>D-KZ8V1#^RD'J2O::9XIO_?)B;CE,9]S*&Z$"3'4^S^P>X;9[TM+;@MFP
M8.<*>E4NH7G+J^U5^6+2JZFFL!_(VH3:L#'^IE<4 2!T.=KPQ^/QO"&Y@VLE
MW#=.O3NX.KNA'*XW<J)-MR_OO 8+07LUPY]-_@%)X!7)+M>;&&_YB5%2F/[9
M&M^?4QW?)CJN ,[@&4@_9@(=I\A3\PDODS&9.;IQ-?C:K/.)FJ*7'QT/C;@%
M\:'2TR,*K,Y"?N[8]MVY\1"#]('?E;-F:$M+%3]4]=H7O*=6VE(9#F\93G3?
MY!;)3KMP5ROS[+>T68^V1T7C#ZQ-/&1E]Z9Z8-.9_3#FRS^6IMIN^+MAOBVX
MU.X5)2T;R]WBC#A[A=VW*^?L,..I:J"?J /$+K(82"=:=_M::Y79]CN<K1KG
M*LO2>J7[<VWPZY+\RQ15U%V\2[+?3RK(<02T3JNQTEW5C)I*R+?BJ"#_GO!@
MOU_IE^R??3]ATR<8\5U2S#%AM94C,4\6;_<.R^(1:#K1QNN-^T(V]B@_B?=\
MO]?]H:\V.GC'XX!'3Y^/_6'&K'<KJ[:O08S"=8M(IMLJ0Q*MFE;3TXK-53P>
M?W*;:JWRTC48L)B?^I^^6.1 ZTI-I<Q=26VCJVF.$S>&]=9Y!@UO5J_D[P^5
M;DTO6>_&\I>^>CP:&!2MW:@2V(AT?Q%\]:2.+#JL#W?GNH5X7@[_'W<$Z,D!
MHC:Z2^ +6;ITD[^Q 1?[M#21V7)VX_W0-3$.'Y 3P_9]O:Y%O]Z04Q'!BR0P
MQJ4/S9G<XT6O5Q*4J:5,5(YXH-TR^_@5^.K#Q%?G/YGJW6AAY;1S6/2*X6<K
M_0QYJ>SK_OP.- N2Q+5#86Q+=*R-WO91R99:D\B^>R.;GE$5I=P1G-#7E[KL
MGC[F.>!]4*Q?D?5\?D!/5LFX:@3!V/G.R-B,$^Q6O"UJ=W4U79+TN@>;+EGL
MW%S*>'DG*V4J76?],)<*VAK%+<2"N=HL7;!>#%]+4=$[!5&[^H:FTJDE?#Z<
MZE//'/ET+D7= J7<6FV6CT.>A)O@#2R::@@ZJ<J9-Y?M_/C>7$IR&F:")KXS
MNO'"YYK".'3T>6GO!?;9L#$.#YSL)<>IK.^NB1?((0T\W[#D')7=4Y-KGD%>
MS_?1&./>(Y<8A#,5%$X,R"I.).87/X1IAS"H2,I,!C]1EHECDGQ=2E?S^?JZ
M71\TQUFAYT>A*<MTT_EM.2=2NDF3N+C_4- &:FX!D8;3./NE;.5G@BUS;5!,
M^3A0OJ=8D_*^(/^\SE#7Q,W)E'6><U7%>/%.NY-C$"<.KJ#-7B$.*NA5-4E_
MBJM/ MW@*8,(6&<_Y7!]L57H0>J84C$AFW@#P>>JP339P0\8/*RA#2XTRMHY
MT&]NF1-ZZW!U^[)KW"+DK?>GQ,YKC/<%\(Q+LPLGJ:#'(SS*T;@+$'V"0U"4
MJJS'W&+*ZMUWPE"GJ%LSF711 3F/CJ"Z> YB9BTP@A_LG><'XBM=6Z(:/ACS
M##5/^?,IM@I\,O/:40>\5SR<9)M 5WT[#VN6<!NKXU>5:G[+89FK+ =\VFP>
MUY<&=6?([OM*7L;4U;9JU$EWXSM4Y+L<WP[?':^*,C5]L'[[PYN<E>J+DA-K
MY><_P%-*Q5)-]4W=Q,-A84-"U\<TQ!\"RDNWL\"<;G<=ZQN#<2S/\BWC95K)
MM5<2AW=^;O8^!*))4N1;@!D6LCV$Z X\QV_5TK=_B!]<K@N=VTCZ]DZ,]2.]
M&'L1=#0:AX[\C< 8+,YGLE<LD@S!G<3,@I#X"[8[E5MMOQ[*7-YX>HKEXZ.=
M#>#SYQ$6+"SFR+:_>P&C/$^R&YLW]-R1K/]9VJXYM;;-RU OC)R_T&$YL);8
M,?'+%"<S"4_UPQ4^496SM-V?\/L-']*=TP\XJ)JK,F8\^QFN9&A1*'AG1<-M
M-,+\XB#8)2K1KRA727*^,%T:Y1*0NF)X':DTJLUST(]=6SK85J""Q"\2Z"E]
MMKI4D'Y1M4@K N-",=+",1XGM"13TO5LM!&N3H@=/W0W^"MX78<V2F0+ ERD
MU43O"^*D/_TYT>Y+-#V."),/FSEJ_X/L6CBQ,2_C<45^1CRVH+&^0?; PB V
M]Z*%^NOB3F&N4W0H4=0X>N9L+_]!)Q)0F2(^JP,,E?J0BS"^V7E(LO\%M0"]
M:B61_G-3K#EO,28^15?[CQ2EQTYTB"=>C^?+5!?BD+]/_/GA0YJ3*658:+ED
M-L7;)R#")#PMN.C'JJZ14(++D.0V3ZC*%MR<]) *ZE0(4POKSF)+JB 88'<*
ML8G2)I_.91QT[4T>391(V>@X-6;<L9"JO/68"?-SF%W]<@?NN( *>H1F_[6
M-SP=)D>K--(F-62#Q+LU+L??TA#*[IK":.>EEHVP^@R+\JHPG'J0(M.BU;"G
MX7D:;(HB<Z$7#1"=GZOP=X)8D9&;6(YMLT(V=Q/<TE8K>:0^F()86!-RGO_9
MS[/W6]V\<Q&O4/Y.;[+<Z'KLU[%"-4D92-U:?*D=G)!M;N\X$S\U;P&=6W22
MM.(7]\"$+'RP:(Q>ZN4Y^ON-0]=QDB(X#EV7DW=Y$NT$.P=W;6TCT&.H( ]8
MT)$\XR\+HE0,Q[1C<+[";"Q#?EK&[4B!EP/)<#R2S&6\R-'),7- +,:/)),A
M%4&%6&07%40GGO3[B>A$M3UZ[/U>9$]-=.S2/I_R(#^32G@^"U=/UN90F\W7
M/;*=.+W%V;1?ES$1Q>+21KG*:>90B0:I-[7E_/"!'96ZRWDP4V]3B[H_6PM>
M<ID0L/NZP2YPB:-W,)D+?G%4D<66L3=KMP_%C(HG0TK7,2G=8@'.D"N5NWX7
M8R^9,Z1#[?M9#4.UEXRC%FJ1G5X_X[O1]5'%)(U-(9$Z8 0U4A+D]7FM/^O5
M.0VNQAH.CQL->QP:P:59\Y8UPA?O;,2=Z+$RSJ<HDD&  0E&64!_A(9[JE\M
MMX4+$Z!=K=GQLASW._)8RBI3[[6TU,=9OG_CN,"7)%C[=9][^:,XY&9>4)T5
M5Z*-G%"QU/V'*%>IUZ5*0]'%DD:<"=*75YAZ>TG?7\U:1>J"@R;S3GI<SC[P
M</_S_&8+RJ*ED*#5,R_8AD?$*K&)FD9O'45E^E[*';>>()<[/$YJ34N__DCG
MMC!120>M [%'_DSM#KN&I\EW62.O:5@OC+^C<\DZ\7(7<;\_'LO!OGX$M^[/
MY/F6JK,_%WU>RG+*]5[ZHSMYH]AD0'275LQ%H?$67@E@=K)YP4:',.!01!9M
M 2**7)?,\Z3GSAG76UTTSQ.'J18.?3%6>)[N-W\AK>; >UY^^:?4GX]O8X:&
MTP07Y&M34Y)%4DS,;6C%4E#E!PEQEX$5!XF5/V)I&4,S*&1FI@$RQ8[UNP?<
M!)=]08-D-::NZAHHD61K;)*$,["^!.D7F>F5Z=4]5DB<^3DUK0+#WTZ.S\0T
M)=0OL =E8T<2&HSI-K*,$BNF77G57F?=J-(>UXF1DRG@.KWDEV5A:O[X\6UG
MJ/G4\2>(RVZXT W:)F<7Q$*, 8SQ:R: 22ABJ9S,5_8K$7<CUW-^6V/$6\UX
MU<8IXJ5GF[#V\6:X +-NS!,TWMPX>5Z0D->,8X/@+JTDU> ,#95R]7$+AK4)
M<W.7D<HYU0,?(T%6(R(,H,NX6H=O=_S7*[+7IE?!FW"52YH/5M1\2VUEI<S*
M3SJOD[1=P$^R$^:KV4*++AFEBP]:6T^7M"JM><GECF@<5Z"=JWR)-X_SU0WQ
M4SV961KYU4$6?DTMGWX4IUBK6N+T;B<6W9U-K&4O4QV9;!?];P^G&%!&P8V0
ME[R]8';*^0W,0K33F\)HDT]M]6,>.W$Y5V-WBF/T\VN+4Y^Q5BJD"P?#>KP2
M6M#;HH1AK_-PG4GQ<:4+87NG)OW/R]I'6<1JWK%TB#UW99 +!+K/)+B<"GN_
M@/=-CB=;8F$8W4XPAQ^QY4<8Z[H05VUJ5Y93[-5U%9 G](TF]L+8TR=J6[=>
M.03/E;@C7=X^-;)^/>J7(<W)-%"LUV=:DBO1C4SA3%=1D30BV!#JS;P^EO\H
M&M]HW2LMV*S:#BS'\VZ+TK:Z.\>OPX2IH"Y9@G37<]0K_^[3GY)8>DV;.+EN
MI4B>J?<IN2WPYNV)T\.W>=;^'/"2SR(6 R-I]385Q$)^"HP1]O;[P%SJ$+Q
MMW(@R_O&!K4Y=T.5O R\TJB#C 7AD/6TIO*NV:A^4\%MDC#\Y#%-3SBA07 O
MP N_9@I8>Y7"'XRI,^*H(*;9H(PU\YKQ[1VGQF\94PI@2-A,S$M0/EW1YT.>
M:7,"K<2V7?15\TE;'^#>,"_E+I>JBU9_E/9!+>^WS=-#)^[EM)*\KB[5ZB<W
MA<IO;N6B&I*'LJ2)$7UHO#%R&H)+WBXGH(DN^.0N-O<NC<MX^0@7 D]R8G*\
MUT['2)!(0[J]M:K8$PP/KW?X<.^,0]*U:G51;&DG:CJ5&$@C_"Z<#Y@C*"QV
M%!/D>X64"'+Y^0N7T/'RO]^NQ-UHS5^[$F?86A@U*R7"P#J4Z3#9MB6?H!IV
M.5(M[9G_[(9^2N0-T[64*B-_UZ]AI#<Z)J6RJT59DY(W,F4Z7%N_6L)LGRLB
M#?Y E,I0/V45**>M\0OW:/=,(3\?-3.<:#/'D["PJ*TVW<(@=??8DI&*V07-
M[9,)37NUA\]DWMQ3[\*^N.KIH^6UC'#S L3DP\GNV-V7:E$1B]FP%T)20 2!
M>>%SR^XK'*''3C9<('C2TF'<OOFLOH_HR_Z,NX,MU8PG,\!]PP)5,<4Z<A8Y
M%S5<OC0_6"<]+-="8B ^4VGV$I=_^!HFKC2D>#7]VL;,',Z2*ZKC<8%=X'/P
MLP2N)Q0%/#JF3;1"[X3MI8R&DB%:&=,1<%<TW3Q.F5W@_/7KZ[" L,GYJ\<)
M"*?D!,IU .9%4@1:>ZQ*NT.-9.78/'?[ XD^04FX>3^#3O\SAX\BQPUJ%DUA
M*U*B[,P'8+P?)*E--)1D%N1RNQXO8Z%Q);H[R_\W18*_MR?1]W$7UJ&&)!JV
MH@D964W.;1&2KJ/'71;ERWYTY0&>Q]Z ASG5++L(*<.CJJ.G4XF4-N>]YJJG
MG)(XWOSXH3:_3VI*FT<#F=R6/)@E48 VN1Y>X0[98VRA@JKEJ:#W677F#<A#
M^CG$%"\5]-TP.'B-'%\#7D124H8DR.X3@G^?2E@-/GBIS7V?3IN'*$X^0T\Q
M8\.K4+IYP4=:O@]QTB%2IA7N>R64E6<:-PK0GNC%<H@@VNT\686P:]!RW$A;
M"K8&V"6-)L=Y4/V48B9!8;U*;#111E,1JX*9%!&17O-B+UT;&8*)4(;0>"T#
M&&9P$=V]$-O!!@P5JG0GZ@@L$<0?CM>_JD-$UD[/'.Y5]>AL=WQ/>+_U;-33
M(C'F_H(\4E<YHGC;'2/]M>G'$:G";HYHE>[9OW;,<[1-DJ'T4$&UNW'HQ1B$
MH-*V%L[Y+:T\)>0H;Q-.D+"^>I5!MES$T]M56.UW:XYML?:O8XI9SK<[/=/7
M" L%%/X^AH;/7>A*?I4UU6>,H=<!(#CYI$U!RFG\$6"Q:9=%F7=)NA%<[13U
MP, \O5B3Q?'D(ST&M2I=Y?>S:=7-MHW/UT-Y4)LS@86W!T;"?Z$ZT"XCP$7;
MW42:KC-PA7!W2+I"F*R)3D@CRFQ;IDZJ15U'0XN*G*?#DY6D6^KQ_BF*G'4#
M+G=$%+(*"9F4T[Y5/^%/CY'P&_A4G'(TP;H;49];U3L2J7Y;[IURE.BY?,<V
M]_A@?FCBQ<A)K2B7&[;PCP/T[L?ED6O+J^0+C:OSDX#_@KU/W9)Q-/@TV9(0
M;]91BT^.4M?"50Q=Z[,UVF,#&V4=61O<K5FUN5LCS1VK(K?V5&J'3U1I!+K=
M3^8:(3(!NB09LL=Q 03+<%Q4#XFWD\,CNSG._-(0QI/M>#^-+M?)B"[<;/MA
M*&+;*_@QV&@47W+GJT!F8#<51$\%+:;.LV82'?#@7G#2 E@1]O(YK->]>1'O
MG]!QOF5*7NEZOK=@IIF,J8[L(BOT(/&3AY]#8M?'TFS3M.7<K2J/2P$8+W>8
M4VCC.+RTY\]W#%R4X$0%=4NC!&YCD\\,+<X(K(S)^?_ZO9Y]KZG5B;UQUX=W
MP%*_]J-F9XSPTJF.4;PN^8QO'Q@_B>:#TR_M"@(A6%H*ZJ!?)VP*21':B+5S
MF.+$'F=K5=GMM(IO^R(U/\^?O/JE-3Y2]\ K$0VB@,E,5%"$M_H3-"M%UI4*
M.D^61I&M:CL,[=C.>9S##3@U)O')>LI>#DR1Y!V "B1_2RFDJP]WJW;5T[]:
M=)B38S$\F9E;%>+N/JMJ_/6Y]&]WRFE5*NCR(<D/,7UJ"O([Z[EQ)!BO!8MN
MV=V:P<OC.)+1KE4JV%DT6,P:S/%K+^ARJ#YV-\M+TIZ-Y_NW6VD+-V)&66,X
MYD]]*''1S]4SJRC.,M#9]0]-^17IL&@<A691-R9D]Q+GP7A$M-+N.?>#EXD=
MV86N>PMVQO5.C=I<=8V@KY\7S;T$  %KP 4WIW6+<#GY X"P_>&L?-#B6>QZ
MJ7@N)^*#'O<+M2N_'[&%#?U]$ 3QN)V#2$](WD;1G,<#IRF%5[JXO_R>=K.2
M.:I.Q5;$E[>I%MYL;_]F==S0I59W(_C%<<K-V@KK\H7<(C@/Z7%8)P0?%=9K
M=^ZX> HW7TR0@L1I*$_\ED#>'UUI:FE/PJSN*8X[Y;G'BKGD>KR*4KGUQ:G3
M63J5VU??7[H%X7(G-Z^J@MA0J6&VK"_]>\'B+R4E-"VZ'4J 8;=W>]<A6&[@
M-K9*I4<-'2/3=M:WS UZF81(9^M(]U)/,:C7E72VU*.#KBQCT76,6]XXCI?/
M%[8M"^%GCTO\/+2Z[7B F[ZX4#=*=^>H#22FRF+>56QTQ[[U\9'_ #9]0*'-
MZ?.C"Y;G\CRBO=M50L]B]"PQF.D#*T]I\+L'T%DT+4(67\^S_$ X(Z+17&$:
ME._/P9_?ALDI?%T\EB7+^Z/F8)CR^W+5ZN]$SWW/_=69[?/*3RQ</VD*ZT(6
MZ,:QN1,;@79\4S^,&PY9M$9$=O F]]T'WKJ64$$&DW[-Y].;OV:),C.PV^22
MK%3 5^B&!A6[^@XRYHT+ZQJSIEMOV,B,#%M);Z)G"BE,D>\I0^!:] L-%;@*
MT.Q B,=&)RL9Y++?O!<4L'3K4UU']+=OSIC 0"GXNX_]KH=T&"UZF C4G/6.
MM&Y>]IAYG575F/$#85I]_(A9HN#%WP/R&+&XM7!XMS^<"MK*H96FZR,/4(,;
M?_\M,*(.L2(JQ$++MMX.5%#I35.T? 5IL!-R>-%GY.@W6AGNZ439AYAY4<Y!
M8Z@@K U-C8%IBNA4$RURDHF9Q!&B^$PQ98@4F+Y\7+%%:D-#!@[5AUH;R<W]
M/$V^)'VR3AL040BT>($!#(P'")B6^5WE^F>P9%SQRYEK1?>-8-]B>6P_/W@$
M"@#YN(\A*4Q0 @'A>E, RTR&9,%BA(1'HV.>*OYL"&$211J+:,II_*C+]M=:
MN2Y0Q/"1):$VXMOZ0HU\SR"$A:Q#,%^+F&Y3P3M8).L1<NHV AJ_ELX)1#!.
MOW35NK>J+4EZ>?%DVF\G\0UTXZ?GC34H'9NO2JYF\('*9I')E@^U-K';JG+F
M@?DC6YMRR81U%!80#%WKIX*$W(1X"*<BO9>\>(WS =K.2(+:C"U/RO%/6;;-
MBY$,OVD3#97_6.R+L<ZD"2Z;SZ QJ3C/?(*T/B&WOP=V86B)[=1/2]>6K:SC
M&3<K/SK;._=G^=2_?)=)8?OP^;'.^<,DQ-VP\XA.-D^(FS$F&^>?T8R'V0#T
M6"0CH+0\]EM6&L<3U2H-1#SELA9K.OON8;>ZZ=WMR >:<>KCZH*(EPB\_BXO
MV926$>_ ]?%AJ?BF6Q,=ZD&^2]+K"C;E8];W/]9'&]9D/(34&QRZG\AT%C;\
M6)?CV 1A-.MEYS*Q( :V7U)<T2[3:3'(,DTH9>3AX5'ANSZ3;EMQ 6:*6IN<
MV?3J_TY>&0]3"YJ!XNU*L:WH\\"'S>Z6R3+,:G[Q4(41$7H4 >+?>VBPE;(8
M>=_ID<VB;^\37=)]\KUX7-5:TA1./"FSGS\!XMQ*.#U5'57ASYM1$^QC&YSG
M+I\1DVW V?# #V2&?D(%3:?V(VOE>V^@3\)U\1,'D7!#%V[?]N)NL7@QHVLI
MNF)/1P>BWS3S94H-YI33[^Q.NQ-% 3/\ H4IE%9+)@N) 6>7DC'6=H3&YA"'
MD.(GF+F==QY8%G=73Q$N_:?IQ9?(Z:$_Y$;F)69S@I'F/8+:*4YO^:\O.%9H
M<5XRRBK=PI1MZ&;K&=TO'93HVAYPU7A8!9.Z6JQ3M+P48@T-6??J1SGL+Q@
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MD(_;'N4=5#3@Q]Z%B1<6)),&6HS+BU^]&VHE-'U/>\;^-Z:8:2Z&>@Q*@-;
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ME15 C=GS+1?N]WUEEOO!+%Z7=U"P[#&UR9GB/[I:IJ18:/]R'K\1''\,8A\
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MY?57T-Y8HZKZ=^>ATL^O>E0<@\26G\Q9-\IQHMM>T>0H+HN\I-M$4RZ$3J>
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M K2$HUO)E?;K7\^]WS<DE6T=@Y+!O@R0:,D#[HON/9#0@_0(3:O/0(,&.$Q
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M;VO#(RXM7"8/80K6H2YP;N?9F06)I,$"US3/B3S;D+AZ+7.%RI-Y (1V,9L
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M5:>W".-3?]_B;C[#K7(I=O=UX?WUE?<CCT&G>8\:--DHLP0&TL.@S+M07D0
M@;W=03#$G3=J.?+0R 9;_[;W]GQ[Z^"EC301SU9%H]<AH8GG,ZD8(-^7W(QD
M%^_$@'OQU6$.LJ\7KC:JVW<RGWH\.[!=$](]7X<9?($Y4RGD9J-=%EAD'>_L
MT3#R.T5BS*Q06U8U12A5;<= ::G0W-A$]N]&EA9GIA'LY=H"9AC=[[(W3%T[
M^HRZBAI!?\=MF"S<G/0S=B"P=[&,S1+I7S.0+B;>#6D9JO../7P.VD)#()LH
MKM);LR&[Z=VX<_:_$'\76=[0GG\%2NR/LG=QS//[*-!W0/WI[N63HQ+7/+:D
M]U(>BV5<*5V[MO]7_D;,8T%T5E2+%K#)'C8*,$,$@&I-5J6<0$VUAN;6T2=O
MU=[>JL8M7UI@>E(> 'JU8]^03O*F.-@!;BVL34 FY=QZ6\FYV7AF.*>S0<&9
M]'#32G[-LEPF)A]FJ1).O+/XM%D'09Y[5?OCNE*NB91AJHNYHDWL<MF9?&-#
MH8KE.&YW[H_V"6[E<\G>^5,5U<W"QZ O!Q-YJ-D%K:-W6!<X(.X<BP\:A!A'
M$J\O3:IOC*Z2YXP#W(6_N/-7LU]+>E?7]*+K7(W9S0X6K?#%[!E3NW]'P5^@
MU5,;LT1CC8Y_0\[!D0)9^84>G*LJ%)F"+]R7?(.K[A>)*BK5*O36U>@\%3E]
M A+Y*K+'5-!KQCW\:3DCOI>40$Y60B+PZ=:?B.0=Q=SOE>9 [?7<^.A8'T/)
MM=..D=04(-Y[D03K>@X<=H\ N9UI&)>2==9R)S8=R]IG7\G#6L<@!=M?UTZ6
M=W+$G,';^)DR%1M:=(J;SAK8>"$Q'RR+HZGC:U"4U[-FI;\V_IXJIM3D$9BW
MTK;A('*A\*(NM\TNYU(XM]F=T__*>A*]Q.['B//08]!=9;?_=3+#]L[P/N]C
M2!LCNV68 5-?U?ZU>0_L;/U/+?Q?JN4;@V+4T&W:NQ! ;(5D5XS =@E<J,8
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MOP=:)>FZ6DJX+@8.#Y2&T$\RX)J"O IDDDN(/>V0^"Q>(*2(=I,2D(C1N@)
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MM,#99^JL@/^7URDRRPF SH&F?AK*'"< .US'">")?Q8<8K+*1+F6<@(0YB1
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MK^$,7\9<SO\#H.3&E[ /75>:"XAAAMG5I;%'&6@.2$*SI[7$TB )(0=3(E0
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M2WI'$X77=-"^,T=8G+)E=9FR(,VN@ARH*YJ4F#V7YMQV92'M-HN#*Q#9%$2
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MD/.'6Z6$+SY\_)]Y[74M<C81PM/\)).]DIQQF[M43TCR=J]"S<=F3;MJ9,%
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M>Y)!CT\ !#!/)\4CIP.::VVN4U)0C#4-9[.,OC3/1T-#:S7KWI#-+R9[L2>
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MEA4-B;#MW7^$T1/0A7]36G/H/Z<U_U4&UW0*R _4.P4,%D,>^W<@=BPE$)O
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M"->?UA8<ULG<\N;=L@79-BXF[[EZ"R>]<#&R^"?:8HKO>=P97"Q4\XP;&\/
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M#@OI$725TRTJZNEQO:1T8]PRQ_]/NMJ@^U)Y.;$S0D)"P#+\_+W^-I>\O2M
M3E1\<4N,:X-H@F4R9N%G;@4H!\%)>4UP;E;E[M0C>H76@[ ?.-L.G16R_?C*
M%E< %V^4'@"2*7,G#9CY^0;AIX1AN/6\:3+9Q#X["'%]QOP[?C,BB0'VQJ5F
M\9R2UYF'BQ<W(+%F)6CODAF>\(VZPNZIHKB>(6F*EE#!N!53D+U>HJIQ_U(9
M;=NU8ZP-1YW0_;JX@P,<M*ZWV\QA):FW6[:T5U9ZL50P%JSGV'#=>"CVW]+.
M[O)^(H45<I!^DDH]:[;.CN%18^A=F-HHQ"B,FVJUX<;X?GBK#TY8O[LK4<V;
M]K?S+,:PD7;'9CN0->(R7%*"IV4\ <$D;DRUY&C!.Q:FZSYW-(@;5H4>'69@
MV!<@YUR=A%#BZK+,5I*ZE(+,]^ >5CWM05-O_@2@;/Y3LSM^G=O.[8BIW0,[
M4G!AN[<SL57G5Z3>@\'BAEX.J0A@77RG"J,R2FV(9B)^0LHP+6EZ?,]V<?[Y
MN,)P^L\UG\14V;UY7/F:SO841ARGQY-RG_IZ E<;8O2CRQ-DZJ*APY!H@;>]
MO-D@^[5"FN/J.Q$ZJ4?,XP9X?'6(Q9\1Y[&U!-W07.]PU;&?SC WM1)=A?(G
M71O7K%R"!%=2W5&,X53Z!K*N*)9BF=E_"K"4HQ>B60_#'4.VXXN0^6@Z[-T_
M+9T7+N?MIUK? 9G*>QU)Q"=\'I!!W7%SD]TPI:VY=JXB:V&9*!SLG]E:B: X
ME<LSD22B\=)Y^8;$T;0\)Y!+AFD.:(?-M^ZIIT;S+),N[5WN80@6B"[()-LI
M(.ED!04?IUZA)V)P-^/(^CB%6I6Y1IB"62G%VE!^T<M8=EVQ;,;20L?#XWW[
M4K*=C)8 ?_;W':U]N4FQ#1E_UAZ9W/[$UUB=R?$(/4]\[N,K\>O@!1@R>X[@
MG$AA$\,.;(+RX87-():;W/QI"V)Y3K!ZG>MJ=A-\UW/C7 *JG[A5WYWGSVSP
M;X2#.](5H*;RVU\:;Q(0'<[GYI1K@GZK/F4Y'C6/+>VY;,P?4!FS#>DI=L<P
M4&7A=?.-156SS$2U!FPA&C9KF^)WNQ%<K7>&0@N+=N=,(YXP6>ZD,<LP=^A(
M>6SL<J##;8^Q>[=G/#7W?W&-Y#W43W6*.=&9HD[Y\'\!35 <YI'\) 4B_+5+
MMI;<>;(VIRCBW)-30&50(B[8'!Q,O4J,#D??81PY!3R FANHH<0_BH91$;Y7
M3P$7<"<%]71O$P@4HQ&TR */,?G9I%A.YVBBW#8O+89]0(XHOK^J]<CK^U=E
ME"^.4?O10:.E^X;]_G2G ):X#K7QN*D_2]O]4KU?]S%5ORHQ8B!OZ@U?UV'0
M6SS[+DZJ<P!H[\]C@K4I'80M'MW0_]U%<\2F+M(=,@#^=#1E#]%LA'&ZJDB]
M0D>VWD!>D[.\6B'!KGES>%/OE=JHVW6Q7SK2O,Y.U9MW95RL^(@".%1HHS0\
M2L>Z/?W&F(I6@:86-$T=OR5(H6<-V%0JND+]3G!N$I>Z,.Z=+E17'/K-PJGB
MLSYZR+P27W<D"*])@(D_6PRK>/2O:N[.*Y>Z,L+$/[ZNC$#65A1RY\Z\N#-B
MY/B-M593D@8?]O][@Y[^O\B-/%BC47IAU/XBI!*T&9E#'9EC^A'5 0.I$W-2
M9$Z"C>MDCZ#O7-\&?#85E@@ZG]\\4.RSQ+:\?*0+E&GIO1QF'%%GOS<JY\=!
M3]0%!>]RVB9!GV5)00MSDLMU'-S'CY!((PQ! PC4R;N8TCE+'WGY"-DW8D(]
MUT-%'TIMG@((T> 3I-H%$J+YP$LGSV+-%IJRL8VTP?=E>]4&WX[WS'(\0UU3
MW?C)\/2F,BJ]&\XJWD,$F;6Z*6<-U36@&KN!7AW\\BX<+#;;XIT[HCHY([>&
M/4<M:U19Q[4=8X;,X1T=AZV'M6HU61,;W+JYY\QFS70#,FI"@[CX-&]\4H4N
M-7!0+Q/\KY.2CQ?^3VW7&=5DEH8_106""J(8 05'JA.:%%M"&!L(B#01J1$C
MBX 2Z2TD(D4ID@4I(RTB1@0A$0DU2!DZ*(B"@00E-"-*"Z)\IDZ8'WOV[-G9
M,[O'_?'^O><^][[WWN>VYYG0[QQ/,9,.R9M5LB^YTA _V"J-SO?2]&@)Z5&D
MW-<FCXW'+9?WNH-EX1F?\FR7$&E0CEM21%1><;8S585LF'JY6:&DS+=P3RA/
M!WLUOV:<Z3\UR47;-:KR@OR5'06I2&._-Y)U@BKA08^C=XK8C0UA$J^V'^$_
M^5@&:\5!IV/$'1>+;T&.QJC7#7R?75,T$?J\I/ @? ^OKODL3CZ>&4T0FCJA
MOLF"O6X$IM&4ED $-(B Z61N4#(13*C7$A-N%FH)(@*2,J?TQ'.?.$&N8H<E
MYU"<5=M;?51!'?*06^<1J1QZMYE&0P?NWIJNJ-DEC!RN%R51S&&G((VPWB!O
M2OFS1/2VMUB;:,V"@'AYM=I*PV>* *N1-O(4?GR%\JO_&^%&X=M"'7 ST?O-
M@EK3:^L ?YERZB^K/T<5(8=9',F$$$_5/&T,0XM:>"?L+,/, S'XK5%F):>C
M/+JD8_]1P_,.)3*':0O#3#\FTVG0:$$U :72N)U3^*+G/GBSW^TQT[NC?%EJ
MH6)Z]XYTY:R+$7N786*8\;C)4QL5'MH%07+!15?!@R:(\%7X@7<1JZV&OE&3
MVD[#Y=86D:J\6@/#,\"*.L'OU=K5_ALOKPE;QJ&NW"UY(=3F[/=+)TTE;"3%
MP&/@SE-@/[3_^K,92B*QS(;RW .G]76KXZ2^S-_LG PB$[1P:7Z&(J#%VU<_
M%TD>1C3+NIJ^)07N26@\$6QI='M(MI2B49G3@J].K"[5P>VNI5/A.PP.-KR*
M]$7PGCI(FRO6L&9B6P[O\>^MEC&+EWNO5S1%2&K2! N,):-<46.$RND@(TQ
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MHB>#QN2*'^4! C9&_[!_P03G9DE7K">A\V-K?31]>$@GQ961&6Y"]NX,+HM
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M8D@W)-9 F:R1G^-5S=><'^>C(FWZ^Z=JV=&>$_P;J3UBCYO>R#=K86;*_/G
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MJW"(XI7^+\TW[]G["8GXG)0?RI>4$<D3R9N0387+@A+R]H-_[Y<RI?[NWV[
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M5*5\6@;>X6[A>LLG@FZGDJ5YW<6M,F?48N/2>XW5&M2>CY'7,(-X0+&V&PW
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ME)!I]!UBE>;*>\8E<%Q/%--*K(INA0L@N]KV#W@UC.=4F/KTGQ_@S16\UO'
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M,>?_"X\#_SO%V%0\A WIO:J#9D/NG.:8:*Y$\_#_M%G]?^OQ_UOK?\:!&T0
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MV\7Y<XYOC.)\<?'&)5VC'%[@Z<LSSW"Y&[U&\VG#(?*:;T8/WWYDUG7<X"%
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M%UR6<1/,>HD*<7S?F?EQ)-KQNXKGHFV)[A+7U]7';\/[9/QN*7#&7V"H@.-
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M^+K/8[74!Z*.I<LKB3>\EV% $)3""XAWPX SZ1E19.G>I_N'[$$L&2EAO]R
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ML^)EV@[ZX^7?RQX7A-L%<<V.PA380=SIC&BP3F/(+X=D$MY&]!*$&'S4\HK
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M1%,CZ.8W79;A6J=<DT?0,4_'G^=SS4ZH)BFK9*Y?:OY)BSF67W[ZTP/DQG_
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M"[@[0+J,FZ 0G.FW'(X_^2+P6"=(1PJFQECS71J^HW =IJ>%U-];PS4-)")
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MC/QW)46/B23J/1TE 8L39RGPKYI;_=_Z0S,&% ,Q_WS:=(4,\@.Z4*D2&!Y
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MX)6B[7_\\FE$4CHB7?F0I8)9X^H[EBG[9R.OBHCC&/,GGX-J#E\19K1D^ W
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MXT1SI$ZU]CE,[DL5@ZHV>>D^!7F9GT-=5/"@(U<FE!VRM2@#2O-%VRMO<>7
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M7^&T(E9VZQQ&0<IEVM+3\XW\],6<AN%.N:'=4^HO$.D&M8[=KL<GB7:,5-!
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M ;*V#RDX(/S_E'?4\FSA1<UGYW=.:WJZ-_TK1I<G;WM4ILX9)_ KD0S%(?!
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M3P:N1VOMHW9!8.O10GI*-7'.U1>6?,CNWJY-'XBXC<D*6+.T;3.()6B60^W
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MN(:%E9V5E9V?BY.+_]\^Z#\ GA/'_K "S$R2P#$>)F8>)GH[  ( )E:F?QW
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MK8-/C3NX/5YR4QB."-8=N+AU32[S/"@"%@EOT86I,0K3!C4=JJ,SW8)P^&-
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MXW2W<R&)#MA<6?TP\9J\HMBNUO&9.\*>]:+%A^"6\OO46#KP>%IK%ARQY4I
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MC%8!@ &IW&XD2.91MHS.F!4M:*EGR51T:O=>S/I;!E5;5W[;MK#D+;J-E$<
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MH3!]YOX]3I40.DB[#;/F3H'\.\#TWEHX[1I2#OVXP2" 6O*<IV#<?BSR+>1
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M'_;>.ZS)M\L??! $I1BE%R$J*"@E"E*D!0M-%$1%!(2@B#0ATH/&A"*]1%%
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M-(3PQ#8&L15<]JV:J8,4ZIL;J+7^X!L&]RM9=*Q<JT[K[)P436^I/$.PZ_X
M"S^9H1I3Q0PZ3]M:(@UE)E-%+-+6KPRII&O:7789O^?W? =P358^POYTM8:^
M6(N90</^2*'#3",404F%=A#?FJ-.'HDO_ZK0C!;N^ZGK@A=M7QN]=D;Z2O.]
ML:3/NW-%Q(/[K(X8CS3 J!= R?0UI#ZM%U,'1@1;,Z T(2=.^X#J0("JOYW=
M%/- )NE9DN$+';%W^1FR++Q:0 W=E2%#Y@(,>Y0IPYKW2TP8<>>&OX=UYL22
M#6Y\\??=X@E:;5"OD47S*BRC+N!$8Z2@>GOM,:8:I\_4^#M*'"E/6XT[KJA
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M,<:;<H49NM2?([#!7[(JM5]I^HD'<D)L=HSL.]-OX:A="5+X9 K+^!1&Q?/
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MY&^=G-?%2#[F%8:J!0/.O+A@*DW]53!ZW$1Y.JS*R\O_*[8K43-T]\LR\>[
MB?3S]^$\\K; !1ZK,9QRL6/KZ(5S@WQ=BT3JI=68;+LDE5(]SI$::K,SEFY<
M9UC1K__CV*3'(6@Y7+1Y%^KR"?#13M;0$-*;76U\F.I!CL5'@J)9H13,[I[\
MMJ(=+(4W+:A7DY,/CRD%53G,Q"K/N47@HNN.<X9APE!O>.)%UHGA"H2I!'+;
M=]W]$1$^;[W7%;B ^&3>D:!*VJ>FW>HLF/[D#1%W\T5PY95\:K(U8^P^^7QP
M"UZ&(\EXB7";ZFVZ2XQ]Z7(?<OD!Y+GD;N.S_=532]6*KX!W BG\9N \O!@R
M""]>*_8&\>RXB5^3S[MF3WE8@K]IUWUXG'KBC8EQZU:SCNF8J=(Z U8(%;V\
M2N6LMIKJ#3HW6<<.[^B7[7X\T3TV)FIENEX)>@F(6P&/R/BR@K851Q)^.7D:
MPBN(A)SAQ))%&7[;M'M+)V[6UOBH!'HKR7IX:1O[@M33!>=FLG^B;\-2W4 ,
M(>K%]1;.,>J$FT9E--F@G'W(+R3CUE=/N/K!ACUI"I!HLV]\!@+;"NHAX] &
M:#DH)10C-.9C>H@:GA+R>?O$%)B&RM: R_.7_?Z0-^'/)M^QNGW4H$VWU1=+
MO=C[P- N#1YRPIUFG*V85L!.#:=<#4DGB'V=NG/C7BKS$^C.4^4Y 9SN-!?X
M"&K&""'#&0MD>(+I(=K:$E'1V/IUAZ2A%O:MZTF/ESZ+EXXVKUE6Y*##TV6Y
M@+1(YBTH%)?XACJR?(\"&;/]W>3<C)?_B706'[!(MGW4,W%K3LZ\OZ,LH*?T
MHUBNQ3#X<#O EF,L,<.1)@P)B@A&>,(G5Y56D%!49/O^_0('-+!]R2?SJ=C\
MM3)##9^X2X,/Y:SK/55HO2L4ZG@#7I E1]/Z1G2CA<60)T^&?-4:;QH^K$F9
M>'3(P_M-NO%1[S&]:.O;[KN#89J<,6S%E>=4QXO]G)T_PN71L4B?^Z^<%^HT
M&8_#WY9_(CCK?CE\%?E$NTO]0UI@[*99PR8EOC7;<9D&6DZF^G9V.3$R5!M[
MP,ZYBU!%!-3NZINR0>5;H$"$9TK7#FVK6=' JDE 2=#,E,( T;; F"OR7R>4
M!&CXJ!';3(,4U/&^UMS?"@TG'NP$(V1G:"D8YU]G&6C.SFH*1)91<(F!E6&I
M3!VAC32*N(Q>:C0]2$OPN!?<%-%9,FWT<M-P6E3T2'JGZ?2__H 2F%T ];43
MY'1PA,IHT)37@R4K.,B55D*O5=R) ,^'A<?VWWPDX_LAW1IN6XTSI]JEE.,2
M<D%]2+N\:\D]8,?R)'I_(,N^/2]+N;1A)FQ?$FN2_=KX)(^:$/SH@_A^EARU
MSQ2"N$1R??#%<^HAH:?RN= X3OEFMD6F1YQZE;N9MOPVQ.KL%QA&MT>(LW.!
M]GO:+K7X4+\QC,KYV=U2X'HNO3/STJ+T3TG#]!+Q4T1M5HTG1M&;GV[ZR?AZ
ML2L#WGCW6_'U-Q-^(\-ZP=<:\@E'G4IFSFB4[C<6O+$-$PQ+YP+\Q(9^)((A
MP/O-I;67MC_]$".=D%>C=KO[Z+/SQ)PURNKML;7[W<@IUQ!H*:R!"^SJ88)8
MGHR,H*HLU)%X:YH>QD_C=_IQZ<QB7\5^M>!2&VBWBYSJ5^!^U#1L7-6))M/Z
MYZY[4=9I:NMZPU9OLK&N?H+612YP:5+O:?MOD9GC;E;$1X!_R\.H?9W1ZGU<
MP!M"@#7@RP*2\]T0>14B*Y97JYG2CU[^J'R[=&'P;?OV?<G[Q/4A&F9=:M^<
M3K(6V,GHF5FT)YQY*#N>D[$8RN/$ZTP[1##=A;HK%3>%<.YM4=+YDFM5JY<U
MW$ES_I;G-!\!ZD["[V_<W7TJ!:?Q4O'W\BK3$:%.?U).$V(ITWP)ATI)FYS>
MPA^FRN726<,:-L!-L^Z7XIB^Q.U6MY4.H[9SAI2DV*]JK2EBT(;L@(KP-XA;
M/T9[R3YYL2%='0W,S&\'(:I@O3"^*B&H]OPZI3Z<7G><G0GU-O$C8=+@I@=9
M2)KN5UY[2=8J.EY3"#_2-W? YM[!=!4- 8OK:Y%6P/9K:J_IQX;)5%P;Y %'
MFL%'02LR:IHNN72H-BN"FJ_T*F7D&UF(?-)JN7IS"BP[87, \I24\!(TW+GI
M1<:Q).$D>"-6WJ].*>L\#98XT%1F"2>+>31E6WT9V/!QI0M4/WOC6G "K!9P
MTNVJE-+\- \9[69DD4'2WKGR0UR@0A<L/,4%O/SVY)>W9X[LG8,>^Z[\J'S^
M^NWP%A2<0P!75$6S+M$<F[';EG75H;%NHID_VB@XF98WUIKT A5X9F74/@M5
ME1<=A_0]XT[1U(0FT=)X/TP\6H@CRPANT_]=E3WWG.PA[*UW5ZJTNG;(V4$T
M6?0FSL@*>NR:N-#4OKU8 #4!%JD-IJZVND&J:P=K]\.GAT7(BCK-PYI^Z+>9
M*A8JL38WJ[=?WG_#9;85@7L*]3%@G9AV5:5;,FJF:VS8'M.XZ$.7L[TU;X97
ME#W:M\?5*E8_9<?3LJ-R[J\+A8NI,61H'*1.%34(+<\L?N6V"-X>4+2LN7)E
M_5SGDO8IY8NTIB.1HR$71-Q!Q[T$]@+W%:DPCC ?=8EBUWQ>O^&"-T>#FE91
M2+B/MU ZTA_[PKE6P>E!9O<GT]DC*?65W^L#'[?XLKS8GTWWLD",-A(TSK#1
MEU"05'M:8X^*\YD]-HI9.6I)RG=ZCTA-6!M<://NV%NRFL %;N$)$HWH<O3*
MP7SD*5I C9\,IGS)I5B?--*XHMU*TEC6:SK4H-N1<N:FI]##4RGO.U<NVQUE
MY)/ :6"QG[52Q2QSAEDA!;<;>>[3\ Q-LN[@IXR*>Q53FN4S:7KHLE,?K*[<
M.E)+KP? %8-78+&K%9IV3<X.<V5O4Q4</Y<GN?3H>CFU%'5'UKK=H#*O9DP8
M&/3X_GNW:F#CO/G)Q/'7]"6:ZO( !;,+X=>@I#C LK^;J5G"2#=JGPTK'SA3
M*/]),E2X&]G[K&I[8_H;^2V1%FSY2!,:8&E3>YM!XHA,1>5&E+*?]P;;PLHS
M0W$^I4,6?MC%G5!DHR?I/I/$^-1$/\RC%K379-56B"(CN86.WWF35MCS2B\Y
M(G_,+_V:][B4A]VQ6Z&1_L)OE 4G8C]OGH\ M:W&0R7K)#@-'!D&G"9A'FV4
MRD\V^?HVYGY@J%A/Y>L;M,GCGIDG%(=.2RM<.[RC_5@#P+]A68^O)#: $R\P
M7L'$&)RN2TIRGY[;#U)<_!)FT@C[SI598&1]'IG--.\-PD_)K:_^_=S<,0WQ
MG![*(-)&R)B$VD R+"Y;J F]#-_F.R7?OS&I>J7J2]:UZL^5N6JE!Z0N)\@%
M"=0(S^P*.OM+AOAI%?.:"T2[H!M?E5+?V"//I/?OU\-(37Z /_55U\E\WKU'
M>FW$J&H]Q<OX@I -4Q>)HA$Q>+]>!8:R"^VR/!>(#2$*+L@79[OXT,:;1R3&
MG8T?YZT-^Y?TMS?LI2K(RM9O@/]>?KY9L%S,-&:=Y"'<RPQ<JY+R=VA9[8G[
MT_=E+*N^,OUY+&1E18.2;9*H;$#XWJXO)1Q&M5+6XP)_)T>_RI^4S!$^3#$B
MCA:V$B4=&[_H8M)8JB4M)&:-S[DL^<OK<M<=T[73!=4K+ZTE[MHA%+Q-?8P+
MW,0F$R4Y6C#?D=QC/ [(!78C4"(WUYZ32O(#(P+%NG:?FH _&A+LF;@3)'1[
M)!?A15IM@3 \(VK!7DP#A%!3F3<AY5!;/>?0('GH=H6Z)]^4QX$3ETX$W;EE
M_*)4-3(([PD=&VF=$N.U R<:M@4*0AI1(4WQ)PUOHG91V1/Z._6$C2:LW$TO
M1LW.SPK;@2';G_+_K')/ZCZY3Y3U6G4-UXM/PE8Y\DASG'06=L\O^ -#BRAJ
M'-%-WM"'P.SU(ZN_^S:M:NXES.^Q+\(_#;4635F C1(IT"2\-R1:&F5"L\46
M+& ^$%US](AVT599R_:='HDOK)73E^T3E8'HHT;8-&/S:32AJI4+@#$8%IHJ
MW4O>A7WUK8<$!]F0NT3.Z]CL_XSM6!_M.BQ<$)(#,I UBP1;</J@%?J8$&AR
M[G:&#36\R=D41\&+^_04VP627VL[+= ]PD03)=1_'@1#];LB]4H#3J"WHR:5
MC&FXY=]D?P\;QJ6(8J0[E5.'A-PCW3^HDDTPPF]NALG=C$2.=2Q^GN*;4F6_
M-A5CN?3S&CX<0-YGN)#\C5K<]I?V*9SAT>[P=RW>W](48RR//U#M[#^J&H8Z
M4^]N:_#G(@T!M#<N$EV&;38);OQRZ%$A,I012]8?@OCOKZ[:O7"A4T$C52-9
MHCWEF]E$IVA,O' 0WSA2B%W$.0)#AM#"&T')'$GJ+";Y>+$ (WKJ=^.EL_3<
M"U=[,[1KTSK''B+'%(^51Q<AT&-@>CMCDFGMYR93_7F((S2V(#-B"V>9;/]%
M0*09>4\DRFFFK,8U_KS8)+OOA7 I4Y8%8?11IZ 2"Z@C#-6"'UOS"1I: :%P
M,"*FF;[U9JOUI>5/RF<KUS=7KY;=>:$FL-:F&EO!3J_30%HSBJD-JRA!'DKG
M]3GV+9-+%VCQ,?-5L!7=Q*$'%QHD(B+UB)NW=_8:/?&\RK_Q/P:"@'38^:;'
MQSB]:'Z6"V6I(LVK_W:7\WBG[=C/:P^B==+N]&OSI\6H5D1X+4.8CDOX\JQ8
MI)TGI5BIJPFV&ZF#W#=87B,[DW1,-/F+G)1*^/47AB]*Y:[]WE8-&^^=MFR!
M$> M6+%:,9+!I3-4Q>+QQ:V1)"VE*6_WS^;7 ^*&\L7/I^AW?7RO_=9.+ U*
MPBPWT8C3L)5'7C1Q+@"+)U<FDI?D-(Q="@G.SMYS@T<.-"@[)UZVNMP&[I'/
M)*A05.< NA^<H?9[F10:_G8<TJ*P8V[PH/>!]:(2\F7W<;L7/3MVIW !R?R3
M>^?WCCB2,>/JT_/1'&7K:1./UH_.B.H C16+3(V2-Q$J7X3==W3L<115W'G$
MRK4IT)G5Q<[F@%DP1@43C"@@C41Q9! >;E0ND%1K;ARN=!0_>"/:]5C?M(9G
M;.NF<.QV)9.6(-1%,Z'EWC$\W87&@T[C$BT<C>&0A)\LK;I=_>4FZLT7S_-_
M;:;3*Q]V7CDZ=W5]!J_Q<K=AKC;?+%@)ZH=.4MI92F.WQ:/4%^2+OJ";F6#0
M2;^W/TRO99]_WA8ZYWPNP#^ZO24/;'@<>^?1/E')^TNTF+:[\4W0N"]<(#$$
M*[KHICUT6[.+X.U\1O-@R\R;R(1MA;NU3]X"2"<-#!I8LXP,IA3K%@^=:N(^
M(O1[.9.,,A^ROQ'G4*;-_$('?65@_>@XQA#RZ",7T)^<IFS **;%%'\)$CH!
MCMK[H[)N/ZWV"J]]'AF >U[-R[Q1CUS^%@.(CVI5CZ>LFX'568?9.)3> KI<
M/PHES_*AJL9MH!FVY9N0#1S#8O;II _SHN7A<(5V5I32KFV104%W&D**T'!^
M"G%<A76$FHF;7M%ON*MV=$E^)$'K6.@[-R&"?\CL.F77^,>:2OR1>8'MH#DN
M\ G:R*,]_(U@Z9+0/S,%!#E$,ES"^*$?6@)2Z^!A,IGZ_O0G(S_O-]?EM^T)
M:S6!QIHIG=9G2:R2YW*H2Y<9)X0:B/R+N/ B]ELBY3@AY7#X]JJG)?P6Z/[@
M6(*#Q<0)A:NS[4)+J4@:TQ)YC=%#X@(*B. &F&"=(F%I*_>U0%96W2&:RJ62
MQ.OR,SNRK3KGKC10PBR[UBIM1S?0R5/J_6A?N#!R]T<_$S^+?J3T%WQ"14U7
MQ'G*.87V9+_$;8?#A&>D@DX:F+0)<8'MP!^BLJHXOF"ZBP$E90X:RZ %N< >
MV-5%>J5,E?"U0J<WC\^^/7YS]MF%QP]U4COKI3C2?R;R!^ABQ]1YU5X*Z4%"
MW Y=%7#K>.,VZO/XL==]A'%%RNG]Q JGN0L1]U_/=6T[@N'UJW%U\B]L"S:.
M1P.&IK$@[VQ8<X[):JW)?=((MKO2/>[D]DZKU6?"3\!:1V_:XH\Z+J#+"I)1
M1U'-G*,,DT*61G_=CE[9U.-BIHINFF</WTQ-#\WU>:45M/;^RJVN-9?L.5-I
MUG;&)LV/XM7P]1X%%'L<+<@()IV/,;_M'RH;,#>L5?LQ6;OH7*-N]YU*!=G1
MP!RBF@!,"AJ P_!(G2;$5'F1N",DE9\D5E=[/&2@XG?N2+.C?4Z];=(W2<%6
ML[7QO>S9[6WO../$RJ]<8'F)=%^^K?Z+254":K_O<+KOPEO?"^U]HPL/7UN;
M]#0JO]XEE6$QV[$K*,P?:HI(KN=Q$7@J!PH&\\#?M":V61%JGO.\<4HIJR53
M.OM6YNE Z./YTLR+4K8+ADIWCD8903#8CY@6+B#K1Y0V/8#P(%^&CJ-T^IQ;
MX<+G\\;/JX]OGA5\KKC<3Y;4R#N7^'&OX(D#D:9M;"QGGR]4JFX'0J;5L%RO
M<BNWYO6XK\S1,76-PRJ/XMRCGCW5LI.[<7\)CQ-A)W$4$+])^LOK)(P8\LQ0
M7%Z)4X.\Y2W-:0Q3BT_^B%-6[+-;HP[X>^DNX17W\O^O7YMT7&_B F*G:5F<
M)&(:GOJ&YQU*.;KI LN3"[RJHN!8AR%HQLI]&;JNW?R9=?#W7U(L7@G[Z]_!
MU$&H'/I',6.)"PC;$#E&EG_6G^Q&GQ[\CRD CPY!<X2.L4'VL%X02Q?4"MM2
M1QER@<;TWUP@K>]?D>!QF1.RMVU5OXD872?*<,0AJIRH=:GLK/>(3ZS%N]U$
MWVQXQ;7TYKHQQ>B@E<;M>S<67%O0QM"_,?1OE;%3+VU^#_XOM]4-$_/_7]E?
M2Y2N$V;H4-[&7'^-H%APQ@=N0RB#*R3FY6&FEH?HGM]G?MCR5PD\#&XO(>-S
MP0Q?< I^XPJ+5]1C#ZYR <77'/EX"H0MA5=$DZSO<8$V;T[K>]:/$Y@?=Y,X
M"#3I'4J;"_2YT$8XDEEX5ACF;P4PY0O67\Y!\Q;5-WE5/"[OSPU/YO V&..B
M&Z^+$:!_(V+9%_LMYBDG_AUN/OYOM/]K$DH_H UW>6PIO?K'!EAA=0E_OM-G
M13">4>P(Z_7.^@F\VEGFVJ^%(LXO;&56!0?"M29-9T=" F9=1#\T*4?SK3@-
M=GK9BC]/[[MV C/FJX;+PD_G8>58'E3]Z<ID'$+Y*J=YJ,3XI%A*%=@SCA*B
MZ1\T&]:9]GHN=9=9KV*$;D_&[% PTE]CN^"31:-#J_"<Q^C( EU;+;N\7V)2
MC (N !)GYT%_O$3/RMAQ@9F[4!(95J[*E@2Q7BUP 18&5L0%FI5[T?._("QA
M-*MH>HNMU;NUB:UXXDC&LHQMZ ]XB1/%!9ZX0KG HQ\\UI"(^H[=N !=2^8)
M7S,!TW:L$S?9-EQ@&Y8+J(-P_<M< />,Z62..LS+W&:\M]V6&GC3?( +;"IA
M&(BLE9T\]_-S ;4O:"Z@S,NUW1@3+H =Q%-YZ]<^_M=07U GPLY&DW:S/]2B
M:5B..+2"E]J.^>,^^%'L]3$Z[.!^5P[Z:?A\QT)I8,W[-E,B+ E-I4$($IPD
M(8Y]"!?@6+[F*!UDGD+WF7&!3BV>;>T;Z'_I9U.\31FGSFO%\S\2)$O6*>/?
M'/1%+E#/6]S9M+11 UV:0PW;_Z^JY96N-(X4PH7L.1]7@CR?SP5\;4@]MB9>
M-F*!&C[;9]PW@YY8",\&W=E[5&[!U?^_<RC_H?X_4WW&++Y\O@',\%Z-XAQB
MA/]YE6O';WI_/9X \V3:/9[MW4M<_/UV>1/!;)+KO>TX"_F_82MX&BK"2],]
MT_!=C. 5J#^G?:"XG N4;Z)@SV?/E*Z./ZXR"DYYX?6^F,"Z]+=2_R:1]BOQ
M"C[T/7J:MWCV^J\M5^RO=:B?&JX%^J_M_Z\I3-XSCU_?RN)LAW*N@&'Y8SPN
MKT/_E/2_KAG&4>11Q*K&>R8WQAL),/I-Y]8"TS*4,]EIBKQVPWC,:>;6[9S7
M*=,>D>K%_UDV_N=YY_]3FE&Q/()KS-%AM%&R&OS]W&AUI>RJ0A=&M)]LB6F7
M6-WH%<)8XTKB'KL>Y1>/<N]2U>>#?P(]!N$"-,:7)[,"_>77GH\,'T8=&BR]
M4*QU]>W]T^92:Y@55RYP4,*6"WR\C-XR]&44X?C8^8E740&N"E]Q53U*8'$O
M["*'C_(5:Y)]Y6O5>AD+4_@.]RU;?1D]N+K% S8=:*;'&IR1#/[%_[\_];_A
MG,1:>(7Y9<1Y!5V#<4:A9 WT(.B?'K(']?FJK[]-@O[S?[IS@812+G !^D_/
MT4/-"^,9%53'!JSB<04QA39Y??K4\^MHI0(XB/"V:BQ8UAWS1?74'<7/*C&Y
MYLC3YN#%</89] R>_1'=?)4+O .SWG,! OC5H./\>4GT>^*O/5P@G0O0>2Q_
MCP?G)7J-YT9O5+(]+.>X/:< /6C)X56+<2&6.6:+5U@ZL>R\+4US5$B?Y58.
M%[ ';T*XP&TP31JZ*,0%CJ#I\3\JI#8'_JMI3>$_+)1'QAN^>\WF1?$=AI7%
M!2I!_R(>*US@ 71[K0(5W/@) :__HD]72CXXF%7L1W]?HJ-#N1?P;+*:8/#-
M8,'UZW^WO?\_J17V:F@]HM6._9C71B)Z>E"9%<5S3.S+.UAI=+$2\;=2[]@:
MN\1O/1@=IE<%R?WSPFP/]N7_>/T>K(UNJD![@;94H9O7!O&;!S",,-R?<19G
MYGF]*9L7(A7'@1!'Q^%2\#J-O7S%]"8OVWTYW\ ;MNBUZO?H-7,P=04VUL1)
M[.4XZD(X5KBP(=.#",?3M+>/2(JGF^7O8Y-T$5.N4*MLTI6Y!<ECMU)W=@%[
M$MM^GP\IO^_'\P<4/-78UHW]GZ6\YB@6,@W0?2=X7ICCP;L.J8U)R7\L_\?R
M?RS_+[>\!$O"+9^D7IKF JGEJS((RP;TF.G^@=K>3U-HWZF>V<U'M79KUCK[
M.XUVG6P-.M& "WF53_;K<.H9'XITS$)])Y;UQD-]X-O'$![-O[_DQ\:^?9F=
M;OVF:V_0,^D3RL SY< J\2K9;V;S(X/>'QK)A=.%EA)Q61J4#WXA+6KOU4TP
M26C2 '0'_H<'K8HCY,0#()I@Z@+V 6SC&&.<"_ 7\3"_=-TPSH110YMOP/.C
M20J\1H._D-W$$5>T/IYCU%F9#M<F<19S(E>4YI.VB+_&>3W_AQXZ?E/VOC-F
M#:O+8Q!O47O0W]LH<-:N,AX8<H;^5>/]8G/P4A7/1=]O\Y#3&JC0GG.)C&6$
M]#9"MF19_EP@:AC-2K9D&7J19-BB*#T>%5Z"<LQQ%;QN&$:&;HEA29R3OWRA
MG4@>OMCUC&'.!4Z#4_%4PUX>A_#FU=QSK -<( _32F0H>O%H<06]0A)=,F')
M!4Z6L:#MIL66FW;_,3_P ,\_[T]HZ!T7.$RS^ZM9O!.@0TWFQ$$5T--_)J(=
M&"$,VG-J L%LP5XJ%]BW50&>-3W\MU:5H__J**9S$G0D0)D+O!SC@&? 5UZS
M"EJ@?V,5YJ^.@OG96VZM-*,W%*!-K)C%0?031L%?;>K[6T?YK?BJ<0'7SQA.
MC!<#_?"?HB?YC^C]OQZ]LTA7QOHT,0I/3>4Q6MB[\]>YP,Y=;[)M<V9=K/6?
MW>$"H;;U89C@EKM2__#[/[+FOW7T*C8@R^M,8T8PW8?JNAIG?.S>!]BHZR+H
MO7%V>6F'VJ/7:=I\:<<5 L5I*3.Y]TTLDM9+638O;CTQ+4YM[KPSU>OWBF+Q
M0I%<U%@-E4:J4_%INK*KO[[JK%39-^]S,NW30)C9\#UP-RQE+16]JD-E^#XY
MV'O6%O(E#!V5JRH2WWJ)?C7;-W!%)9OY;!Y*[?TS,.P''Q=X7 5F!6$87G_&
M&&\ O!X^CN&<<$N]IM\*3U629/!/VV!E$?U;KD8GJS(-5'(5PG-BVL<OWS:S
M4]ER]*+G&G'0O"!L0\]%0!=_GN<"9I?QU&O0=AX8$%W_,^TT$KQI%,@%VO[,
M[8CX,[+'#,3*^<P%*!D_I,,#?:7ON)X*/WW<[\ QV<Y'C]J^#PZB?2CX>187
MH*IRKG-*9H@;VWE,9WL3"W/BKQ*>H)N,_PQM?RG$L9U TSHW?-4X VWHWDTN
M,&W':F*[=N!_"&=Q1.(WE8+_ ^8,VK,+TK@ =IT79NQF_%;-8_1W*0A+!K1F
M/,^1^Z<[GP#H6AB%"Z39_U6<>M^[UTP[11[NX9&A*.@ZZ%?X(9YA1V ,+?!,
M1"]+Y\\DMBT /;/2Q@7VOOZ+.,?7]I;_PI/@?^G(=>Q?0F/Y%V$XBU>8%>-P
MGL>P' $NT T=FGC.B7R/GOZ,?O0?B+,YF(!8Y7D,^F? \U-T8;4^F^\B%VC@
M55[E;VA2[I^ID]]YM%LU ,J8!?]%W%?Y)&@YC;C.0?^9Y'B4"S@&P;>V\6(?
M3>)8ON 5AO\I/M"_2+NK*_F/8/\CV/\(]O\9'ZD>%RG8'KB_?>>X:]5F;IR$
M5H/[B;KW%L<WJV:34E<JEC-6PB3MS8.5_GEFMV,[F&H/&;\[3[>BHC %#-]O
M4\PVI?WK8L_=#M^[9Z!,4/*Z</)65V3R]YSF&:WA+0Y>#SJ-(WXBIIBJC3,<
MR?HQ&\^QN]$WG&T*%K_<3SI>M:<>UIUV,\4KZ+VV4)ORD0@@ V!X7:9YK4!I
M+A1(4Z_DI"LC>I4LC?/4)3XHL;]>GNUR(5VGX@N05/I$G,[78/#-;Q7#4$6W
M]1+0;5@)7;P@\GS?\PM4>G2-[GD7V"<]?;J$U"&U"Z_X=/1%3Q\V0OE/2XE1
M[1J)XW!G:E4K)'I*G1;W,+NGH$E3[_PN@HBX^^?<[TT:5GM+C[@*//U1O8.O
MH<MQ^??R /,Z4H]=>#PY&;-],?C0^UO)!^F)[\UGIIS?&XA>%B^II@3I[#)3
M45+C;\)/OT%7A14P-1;N6L8B903$$?/7HDIB?PW>L"I?<A\__<#8.*4A.N:A
M7OK)=J%U(D<</N[1/,6')4^@]C-2..)IAVK\+8B7TT6"0=W.#A6.KGU\CZL]
MCKSTVB?,'AG>$--I)MP;]9/W?UOHH4JLJ(NZE5CWH3X&E@&ML&1)G;Y G4"+
MFXHP[$AO<UY:YD_X*DE@'/PM>Q(UR1&:X2V^'U^UAFDYA'_"\<_Q/P19\_+)
M@T.<TF2LDI-[X]![YC .(_M+[ZWHN%[M/ZQJU:G>=.0='U;LLP'P$%>C*EBS
MRC@,7IE\S^DR='M$@FUO$,@],;+/+^]^J&RZIN&HWG<2"*1\U/WEC-B;AT%\
MFTV<';-,0X(KH\F>415.UCSPDV);GM[:>_I3C1-<,Q?^I.=.S-,H\U"S"/]N
MQ'CO(KWJI4_NH8&IIJL#_KHN<J;LX@V1X^=_71&0!_Z,XGKPG#Y*TX_T8E2!
M$U#*T >O$TO&[:N&5*(GFM:E,_P=1D+,;OZ\VOE.KGU;7>??N;/:<?J?ZVW>
M^2HI8,B6#>B=K.,#Y3LV:E)/-P8N%K_;+#U8:W>PA%%\1?+JMY;.$KK#-+(^
M&/9W[:]=:,G_ST>;<7AI: ":8#M/3Z+U/JB5H/C?6I%H)J2F/7Z]</>FC/C3
M]#GS-+7OI[XQS(%08P<\PPU,O0#>$F1=X)$6'M+;%*\U.DW[G<SB9SKYH7>S
M%%ZB&RV+%MQ4!B'[JK+[_=[)95M;?MOOZ1&Y28HW6&FY?X]*X8BX4-1!$N9P
MFFJ]O#'!EIVE2>HS*1[<BWFJLM9>8@D]K(ZU3S.#6M0JDT&234RU'U_F$Y1^
MCK1V3;^#A K5QG1\QER0%EY[IGQ$SR K[/*[!@'W$%RK'3]J E91U=R[NR4/
M8==*^)U0\<S^C8VBD4U%]BT'N1N2IU_P=> (7$ <T67!2&1"EW(/47^QG',3
M/S#"%A?[?TJL=2BX5 L-*C4KG110,D<!G YHN2-+>Z0U!\HK<50,;\MV=!N7
M9/CR:B7[<?ASN?-37EF'CKV@P$T'^5;O5JWT,3TXO:;[/J*57'TSWX>(/O*9
MTJ1NV)\,*QSQV_$Z2- "627T*'=HJX-YD-.W%;YB3W4\2^M)3?8)ARB/+<K?
MTR/!0Y7T/U31#HL6%93(>@D=P"MQ@=NX<<HE=F6Q\6'2(Y()M'[+%GLW -F5
M<VY2YUS7;%Q$2N"#5(<TBX&E7  WM#H*FB[)HD+HGM2IU+>(&#N:C:_FH>+P
MP@7MQ-L_5;. 32W3M2.O#MFIY!G($0#3I'_G:I-_\]J3.3N&FNJ*_3WF8:2H
MX7"\P"5&H5.-O-L3+[[754%IJW<Z451S6Z%3W<_:VW%M=G(_B(JFN@AX W%/
MK0?9U>[J@+$]&;Q\7WCI\N#H^]J)R[7V_ D>CMN#/KS<?<< -\(%&&H%RP4?
M4$,P ?<!Y'$J+CE$G;BB::@0MR,+K:R2.=O!)R(H<(P2I&8@\(@Q0H9((=T8
M<EXD.!]BP&JP/!72^&6+$7.^+[100KBX\Z/&Q7."".)[0DM$^Z(UP$RFVS+L
MF#XL??:K<IRHW]2^X6+D_@#II4LU(W %QW[/<K'N.SHGFHL0PBEI.M5U%X)_
M_5YAT^9Y)V$;1XQ'FL2,C[U?RE4;NN7G.:BQ,0;?WW]]9];GQ[X9H/0\?M:;
M=*O]9W-!]%.\1'[)@-#3:6+8F%_LPRPQBDM1\1OQB9U%N*>BRTD7)8OBA?9\
M6J\7;2;7C;P$-=CQ&N,G](HN$X:XPB1?-LSY628_T;%7 A'CC/@9,)N2$0@$
M1TK.:I]5V_?NA]DJ=#H77TEL1L<1%6NAU+96P[K79)"H7W:Z=US;U9Q\[+F:
M=#LMO<2)S LJ^YV-5YK$!<WOS:_,\N"'.*.%:<KRINE'(95?_3CZ0V\XLUBP
M*OQMKV:WG<:.Y=.;C>*GCP&R[;\$ZWC<-=J5I4NU; $1SC8UU^G0OGY!X,Y]
MN6]G0QTL;2];=+3)6N]N%C!2@,R^UVH)COP0Q,=,-9=\UJ8:9:8DQ/1##6:'
M+^=3'2_0E(_K,#*9H9DQ!1V]V!#'U8^K>SWFX2^O13?BCZ'=P8)(=W:)J8[U
M.S_B'N.;QB*OOE5]F6WTR[(O[DYI2>_3^PRTGYRL4KB@]* $B:5/LO-T,00F
M/;W&7TSKEZOX-PI3IDG>L\A?N4N)7=.OV^%S"/T\ZH4DC"0U[(W?#?6S&Q5I
M_&*L[3,R)4J-'>JR42RF9_B8Y#?WQGEFFA4U6NS\_J5NL+Y^+X"B'7EPX:4[
M7Z3Z.HQ.YFV_R 4AN.Y E6F82V,V9_ZD9W$.99L,T[4/'UD(2#FF$1FM_W'T
M6#V2ML$%ED\RW7RX0,7OQNK0,B_I1^34(]=]BA;NE'J3PP3:-&ZNS[;S*1M'
MEU0;A<N%PD<M2=)XYJE>6LPEZAIQ:>U-0,AFY7/^D#=<(+_<H.FL15_'>,9D
M5<2D&?@A^!.D#9V(.L0NY,@0EL"[D9?>N[@Q,OL"BG_^>OY,^>GQIJ O,@U"
MJOM2'#=VPGIA]>!-*]@#GD4O(9Q,>4[LOYW1N&?0Z9?8"O-57J2.+CGOW6-'
M+KZU['/7_H5@VF2GT=>FP\P&*0-%$6TOY0-USW&9T.E7V$^Y[YD.R#TQYZD#
MC76:WW'H\O(? ;('7%DIZ2Y9*@(:LKO;4MM?3HN;"<T(I6S T[#RM?K3JPE3
MQVA:!44^N6HT$-TT-O2#[^W+4P%'W-2BFH\51E<[7-AAL-=Q#/\IO!$];D?"
MKTCE(SS<:((5?B21.U7..5,U"$+=8\V7 1Y1S[X=]*B_?#,PIV<M!AN/-"?C
MDHG\&BS-:8B\CWSFHWR&(PRVV^>+5L6-ZP[55[8G64?V*OPRNHH[H6@-+<)^
MDF%)"36@R[,2;K/ N 6[:;C\I*?_OLSI\Y[(>J^;%Q_FWS0P2,W*!6ZI2O(1
M>73!BN7P'J%#UV(D?OBQE3'\^(.%AKA(C4)<]$W(.Q=E_]#]482>[VO:ZFN0
M:?0#M"^6<-IN"(Y21,2W*AVHZ)^U@JO\^5A]N>[2YX,6JM6G@O@6<C.VRGC)
M:#D0>CZ8?H*FQ^N[O[-+\M#H@B;%G!2QXY]N+.K7FPM@JT<=YQP;'C-OH+I,
MI8; ]9R=-'1<N4MU.A>XX%1[2$OTN:.WUJ&H'$G1>84[VG;%P'T9YCY.-^\8
MSD=#?4 "2]@]0HEHDFC9YXP*<!6B3J0]3%;%85)X\@3Z10&?'<Z7[8KKAHX&
M<X2+<<ASC-372&-&J4_!\YQ;GF4#QJ<+&J]KALSL(.7NS]@<7=GU_,[9Z#?B
M31MKD<)KO00/>N1W_"UXS-9(6NBP$ZHS]WQLV@KN7EC]Y@7(8+0U1^I*P-"B
MQ+E,FO&G+VWBAV^%&P@+J3P>=20+K?C3'C?#J/9@0LUI1CB539AO'';T?_OC
M<V\&Y$3U(,];'K[I)LHGZV^YFYD&TN KIVGQ+77[!I&G[].$6J0_+69=G-!V
M6JS2HW=VCQT65X]UN!8I&2(KQ>9#=1MF?'O/U$$>&M05>1^PJF6\_TUO8&CP
M_HB#89\2<R9'9TI5TJT[#N'W0:??X87*P9%U1Q@VT[!=YF7G^Y$'2B.Z7YHT
MO_T9K-*+H81KM"U%U4MM$9F0L9)\I@KR8'F86I:24/\!C:]F?COB+.?-P(_1
MY6TK%30O>CV#@.2G%MH/W3:&A*+I8C)6?7/,XX1$,"3'^,/)(Z.0BJ<'(*IY
MOK,H-4X/MKQM&9J_P#'!NM;V+[_YG.HY6&M2U'%DO'OBPS6(G,#,S;A3"-6'
MH#U4O-LP%W#'C\O8UM'<D@_V_'Z@*U>\6C3"5U"5*9.8_R!WUX_\]=TS_!D=
M0/96%YW.*UE/62:,=>HN)FD^<F/2;8YR+7-L%:=KXUEE<Y7\3%7XI9'TPUI?
M$#6JYK$9V W=P..BMVWPA":2ZQ8BT0.V%^%KM?++:7^*I6*_U=ZF.Q\,+C;J
M7[&OOZGB?I1_R9G5R-.@S#(8.DX495G16@8ANS(^V/F\O5HF&M$#9,Q=7^3+
MU&VG&,7[LDW^[1$J?][.DF9_Y +>_$QM3B_G(&U0NA2VF-EHY&HX[)$P4YW1
MN/]VD$/0M:CH4WL>O1CAL4R,%D<?U8<505ZB85J5#M6-&!_,]WTX>DUAG/R1
M_>'\T[2I(90YX=-^ P= /QCV&5HIM+P%]>F--%6FJC@&+FSEU*<MV=9D6%O]
MO''GAX*BU,<+C]+YT_E:U:E=Y/ H4P-.-T><)M2$EOFQ515?JUSDUF0RJ#VN
M\>7^;+/EL0ZQ^NTV[FC^;69-NXX"IH4,,/,H9PPOR-%B0,]]-[:Y?YW$MM+X
MY+OP3B_OU<D  #)_4E6A<OK(DRLJD44GE'\2&6HRC=!$L!P*("#"26_2\4G*
M0RLE-Q&0X?IR];UYW]86CU5GS?:NX7+1-_$,]<PH2NJE,U3'YAYA\ ZBW:R3
M\]*PCO3 &%7J3.=\R+Z'@BO?M",(?+I;EF;@!#!U%3VNRMR*YTC1N !M<?-Q
M<W95"T2$959'=>A-JNC"[7%:%+))'VYSRIS6;4=KM*:DG>9Q?(C .JP&6P5>
MD0(O]S"-&/'-U'/OR0H5G.X^Y=N>N(,7I6@3%GDSIG5N1B-S,BQQ#SKR,45H
M10B*J:@)J_G.4D@FZB$_8B\^Q.X31]'.&;^9WY]NS%X$V$7?_>?+OV_\T K2
M.E"9>K KP"@Z,F*U!_8J"6"E\8[0>]3XE&8%XUDX-:8^^U=K[.N%"ZVZ-5^U
M+TFU3'8G@=O7'>?VO-+>]L'"Z:E>6!3L*/(4&X,R1G7C01OPY*VD">^CKL;^
M!Z>RWGWQ-0SNZE1(_>S=M5<TSN"&U$<KP:H$!Z0?K[I*?HUW2.C:]9IVIL$8
MP@6,QQU&+U%A650< 3I>:%,Y#/583;[C:CEW)GM[2SVOWV^[#(UYA6V,-"[@
M[,0P77WQY2.-J7;G:*$SX;EZU-J^AM#02-P]OWV'Y,;,^%$.?1^AL=:SA>N.
M="IM)&4?N[Q.Q<<0EO@KV<#E2IJLYO2@9])Q35$S@-]=-/L7A''@;8$QN+PM
M64,FL.HS]<5:NY!91[BO%(9-;^)L=U-@HMRL"S@3,/&?>0X1+X</9$A%[?O4
MM >@3%P0RD-:LA^C_7K'>%1D*RNEI"(UXGB.UO[ B/MYC/PI&T1#1U"R6E!A
MI#4P'800P."@TQG0RK84CI&O(1=HPH#=*O&%/LX10T6ZU1]5TR<]TPX?>!JU
M_K"_U>'+]$<5&NP ,H07DQ=(!*.*.N)(3:O*\S:5Z0M%.'^C4VSZ2ZYG7GV*
M[(-G^P"BVKL  ]7L+3AGQP@)'+OE'Y]8T:/:@AV'2004*\=Q >OLR>+GMF53
M16?<'\^K6TF$Q$0Z",J<< <-)/T[5Q#\73\T&$&=7L?P86K51<FD541H_JQX
M'INDX*)6NTF.5S'I?A3S^51!M)E*KM35&(PO#^'XXABJQ"8[0MF%\\%.3'0\
MRV6O#3"\\5YPP0/V);UUNC!2)UJOBGE5]B7H(=ZGY_2T71MF?)RD^.U]"<++
M@0$O1-S8_/75=MP^;4IQ:?NZQ<"YE'R5*U<_RL:UVZ<-K0NQ)(8*RMAUM8KP
MZ><U!?TN]G6)*L]G?<I)HMW([P8=J2<;*'?<IAWS&5V<G9ID?Q%Z&A73- F!
M#55 =_IE!KM.(H:0NNK./N<2=7;<4C^<4B.;87'SW#/'M&=L*?;#/RV #]5>
M.KDH?_FWVP&:_S+4JWJD8OMES^1]3TFIB-2=PG8:S5&9K0 PA_>S8QR6B>$"
MGF!9_0>ZH)V(&#?:_HJTM8,)EG O%;L71Y\]+9UU0J2D%.X:LB0+-?>.B5"P
M]9,V+;FJ7ZC&E7?C<G]?*L)[G@\@>)WJ3BIDSE:+MOU<L^[=-[.5M>+$E&>
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MMO.%Q.QU90!X#%@[26+YLZ2[K5\*]]PZ!&<!8V+*%+]][/UJ+%O27E'6^UT
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MZH V8;#("3-Y5D5I._,C,<;0FV%PR<A7,T70O^C[:ZD"&4-T;[+(5';-:H-
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MW)OQ"!+SY%)ZH0\NWATW5@U]2$A'EUD_-]F*F;0T:!=IVQVAKLI\4=D0VG%
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MYN<3TM+IW%O?.3Q,P$\-:JA$(,!VP#="X))WIUT(J)8#LY!0G^5\!NCF.F]
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MC!V^7"W@G.3K=):.><K[LG\0;JRF__I;NVM?D[N<]3%O]>=&O]/I=0#_N$Y
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M=2S)WF%Q.\3I5XH9/IWX$LW%Y]E1S4SWH\7S2D7"SU;*G\_%VQ70G)!$+6+
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MH%DMX1W=QNZ1LH8LVI*?.9X+N]R\/W2U@H7H#_SXH%R))$Q;= 9X9LM)7]I
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M8N&2.)"-Z-^&:??',B #@X)<2K? &;=LW(PA._*]$X36K=<71WK[3J8TS*[
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MEZ.5D&^MY;RT4XUU9;>E36V?>&@DQ,6$E$[O#U>V*>]S4=ZVV,9/=I$9)M2
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M\^PL2,6?S #7:""^;:<3;L#OD6[K0?E25/1X)Y=?*;E6)]2<1_Y\RWHB\.N
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MO&1**-*^?)UN[QV)5N/&+R5W6?,35O_;S'I0C.%-Z=I@S NND ZV8^,!YG0
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M@I?8Z ->6J1S:>/ [TRWXJS\_]'65$W]:^1^8(MJ$)4[5JP63*+K4GEZI4_
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MIQ/)O)&ZZ/ C/5#?*,$@'&+W@MLW$RK0)U!JN<"YLO_Q!&&1R).2I#O)G"'
MT[/(63="2Y(?)VD5_VWC&JO<=9">S[X.:Q+EY?_#],<S<*59MX)-YBV@&_A5
M)YC6:7F'H=OB*.Z6&L_,]B&OAA#C3HF+G7%-8VR)2;0SO/]KR;#V@%%PGF!L
MR3Z$]LAN"L[AA(T98216/JTB2,1(E/#7S40\27_ <2!84\8N;?EDE-KY9VS9
M2M XC0Q4.(@+NQBM@.1H,<8G=/LF=@$4T0M?-\"P5 _ZG'!=>^GGV6)5*8]?
MX^E?T+]^:)Q10$8W72LI<4FM&L":PX6*,3T.4"%4#'\&B,^MDW,M4/[MB=W\
MKZ&HV,C0&FVZ-\H)%"3:1GPHAK>AC?"D:6<M]?LFNKRG>QI\PTH/,2Y;<?/'
M!\8(3MH@6EX7#"51"S<2(5KDS*T>#TG]R>W=7"XW4*LA7,"F?,Q@4\]%JKD:
M\@.9=_(!P.>(;0JZT:'.4R?)"]>>\E9F8GBJI):&]"K$Z,H?*K5^_5AS-R50
MI5NE0? ^HYNPDT.*R'YGE>@L7)\0UO<!#@PH0\^Y',O\?.5D.G7#H#J2G1)^
M+%:^FC,B9#SW\<K7&99B^(T9DB9!\Q%!N!'7*FL\H:)>;%#LX@*,L(LP28"_
M$YG%$)^^^DE5=C6?[O=-2F7;&.]V=C4>*[AF'9Z$=B^_EE#VE_O;)AH^4V\#
MJ75)N?=V3K4A299_)RURCE^F*8]FF8IRI+8=_9WIY=)>',G!)=^EZ=]EBA>:
M2;C!92MT2LPQ*?%<K] +9> U!V%+VKAK^%=!4GWO9I8+2["93B\FR (PUY'.
M<"::K>Z/EB[O:UR-53-K;C>8*X(Z!V3\JS*C!5]P8H?O\Z@'O6\="6N[;;:%
MD;8"F1'B5A11BJ,;2*?@J;QPNE"/CK4J%AQ%T#C[2;QY@D@^8:9CD#E2308U
M5:>?)YQV67W72K"#Y5+:7IXWM^8XH%**@W607\LN(VE?XUJ"_+/_A\<HY[S6
MP/_I\<A9&(#-6.M_?VX.P,T(6W!)HE<%L42NT0?UOW'VWEU-?=&[;R@"TB)(
M1PA(4WI'I(LT$;'2 @1%2@@A(BU(($CO54!!FC21)ET@]"9->J\)'0PDU%"$
MP_>.\?OOWG'.N6]@C['G7NMY/L_<>Z\YLK3?E4D9H"S)N*0HQN3?K>H0=>I1
M6H-I/TJ-Q(/(,6"VXUC?>DG2'TXW4?K J2%*+N-.!!O46FQ(/I.')&=,F*\-
M6_<Q$MU_-,F8%QD<8G >F0=S1!7(=/)3*2;1\5NUKTKTB'3%WD N+^V&HUX5
M(Q4P&MC?C^,LTD#, XPY[XE6)XPMW2X9C]]FV[GRVUO3WE&8:2?4=EA,QLA;
M.70NB%=-R@\"+1O7H@O,-D%O7-\-]5"G>]U-U5(I?O^;.CDNWS*A@)9U@.#@
MU>I]3O:O_**V_Q(0'CO] 5$G=PDH6IQ5\3MNK@:\)O4M(Z+DF[F0W0\)B_[B
MAWW&M%/@+=/ZX(OZ"3'YY]T")T_OU*2XM_>BDR*$:6_RS?LC*98GZG!P<"N\
ME"0+8MQ05ZSQB2;?48/@35%:1\$Q>T!^9FI'[9],?=*]-_2WK3XM,J#PD&ZO
MQ9E[5^OP6R^WAM3O2T L0I)38#Y]41W5O[S:)9/ZNYHD+O%7_>8LC\U/PFU*
M\9I9HR/Y$_']JYCO<5&))KIW-P+<N!!X^5#<86R !QA"/ZN>@Y9,AR'R217<
M>.N%AS'F+ MFXH8K1>+,[Q-ZM41I.(7<Q9LDD+&=*<U,$N!6HAD2W"YKO3FZ
M=0F83=#V\A)_)^X_JQN'^O&J19;S94Y@E;J<N37PWU>4-O:+ZK5\X^4B<.9U
MY.UCO(5U&BS;-V-K@T;8W[=F>=#N2\OG&A(NTLWNBUF&&M"0!/N7EDV:?'(Q
MO*^!%6QLP.RK1OEF#H;;SD8OJL_7_=%U&WI*G:P4N7-P%2XN1$;D8>DN6[/8
M@J,@KL>3?X_9.:Y$9*"]4(K_%N)ULDNCFW6F+?'Y*)BX'GJNEC,KF0<MW'B.
M#+ R$&X#SZ:$2UQ8%;A^Q@2]E^9W&W"8)BD9DFS5TW'IL([D9(LG'['NPY(N
MB+99S>\Q42Z\IK[?FT6T6P872DV/GA+<N31"%)IO@%7+\K:Y@LH=#>1?TW.)
M,_^N>99_3^;&B"'G[JT>31[=0J)*QTQH3#4"B%1J4_R ;PHBZ!4[6>3_=!:(
M,1<P1T5ZF G+/2I7==$^,3@;X[7W@N/\F/X[F"A(;VDWP$6C8C7M@AG(#H'Z
MO=Q=Z8&O;YE&-X9P"WDNE=W*P)C:EJ*DB%:Q4=4EZ)8%F9\$PB0F95Q<(9JI
M^HZ%XS(379BBI>9P[QO]N!U9?B;^*4;<=+)&Y>%:&L%-FQ!D+9GLBWXXSEAI
MAS-L5%>2\#BJDZ0P MB9F.R;WQ+@Y_]<&!7OSV#,>_YAY.*6%6GPS'Y,VQ8[
MH/2D2<GH?7QDN)1(!@WNY"@7K:JO5(G_M_9D*/>K<3"Z*KHL5O5]T\UF!&WZ
MDZT1V/9=50&<QR2?(^ZMJ<&4UO40R,)=NNHD?Y1&KXYF<Z5+-DZ/.#\9K6H_
M4Y.':[!2%'#]MIGSQ$@6S"F8?!W^:O5KE/ZFL*##R7BXD)GH\07-D*I;_J*A
M1B3J=?XV4=SZ)=O,DR#WE2W@E[L^X=,K2[%Q79DR)_=M*&(F55V)O)-'\2,H
MN=>YCC>1LG NGVG!7Q-O(U:31*KU,OO8C,)O]GN8!<U:*JZY\]%FH1U+7#3H
M8D%]2V$XDEFGD)7-5F>U<87\QVO$\ALL9^JC_WV^W)VVNK^Z<R)61]3P5[ R
MQ.F%HJQR8)ZI[LF*B=#:(Z\9-RNA\=R*=@&::?NH]CO2_K=.(D.4M3O?=1]Y
M3*P0?A$HFY1B(,$1SX6&_R28OCR[_?N661KVGG$EGM?TW.>D"<)KOYOAK^;5
M>7^L"428R/L!GLD[J*G9E6T5Z@7GV#BL)?U^^6RL?(/LGAHP$'H)J*%T(^EU
MIX8>&8>>:Q<C3=H6G\.,KY&R%2(-?^4EZP=!75=T>^XYYE(IA0'K0I2%?-&X
M[O9?%W>1;+OM)1]F8 9JU6-*Y$RRXC^-;Q'#;PM>%Y!B#HV*KS.D#WBO>KI\
MY$<4"1<F>EP"(C!NT$*G#+Z1XH,X^8$;T]/3W0C51#$].LO>E?*D6I=/>U32
MTED4N01$)XC)BG2J08/L:ZNQYAZ7<N_Q\+UO)&<&U[V;%6&6DR0D02FL_'*0
M:29[+.2>GQBD<Z;#1(,)<^T-<4&^=@1"LT!WPA_L"4Y6=Q;;&XP?TIC7D%XK
MN*K&)< 193:$@EVE4:DS*;VF$;_VE?6!L\<3%=YIQZZU?W_-5JW[O9<9N*(T
MN3.O+FO6R:;I%?1KM;Y_F;WSZR=#GXD- BYR&:%J][* =PB+> $<W-!H&'7%
MJAJUPQCVPFW#K,C52?K)X3_']B/*T>4U+Q7QTD]!?Q:K6_>V"RM();AF%F3
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M^TG$;2Y.WT\:17XP=T]_,&_G_68@<Y:RO(?3:Z9M)7;!(,GFI<0NT]6ML)6
M0CPBI3A+RF+<^=^'%UMN&BCDC2EQ/Y[8M\B-3V2S#2J=?M4:+(O?=P%TD0Q_
M.*46=.V&2Y1L/MLX+;8P">7IK&YLK:M=O$AUH^\4D!49:&?1CM-ZJBL6TV#E
M8CSCU;5P>U*5">MK,MO6Q%U3/X)8GQ!*W>DQ:.9?BOY;TRYXIFA889ST3!WJ
MMW%P"0@!T:.TL" V4EG'@C#QK;K(.$J+YZM+<BID2J*$;>X1^8,0<_#K?;=0
M3YO9&!P-7=YWE,*95SC*K@CM^/>*,R-U:H;/,P4T'/:B)W?E&M8&9YIVJ!0]
ME)<HHH8O5)$)Z]B)CS@CXQ9#NT+2#YBCJA+VS!?RI^X7-!L:.C.='2U1HYN@
M?_9XZJ&SBS-_(:YL1LZ2Y)9+2I9B0][F0+W(W:2PK!YU-S(O@WNHO+[??KOU
MW1%1^@OG<J_J(PT?7HZ 3A\&'^Q-IP5R0GXDM-0H;]N/77%T\\.8M-B)UXVV
MUW.$<OZ<!*5X'B5R$UW:WJG7 TZ9 (58+KV2+5X9(KRT  ?#R[C[P$JD]'U4
MN.E>WQ\427$^9J[SYA18&)#!"<ZPK]&3&34IH)Y >+26<@CMVA"F^<V!XEG]
M!8G$,S4XLTYTQS[=S=M/>);)Y4,>\H?OZR[XRF'1L=FDM"6X4L<S<X/\QM9D
MSK_Y[_ (5Y8R^N'D6XK3 N^ G(!;]+B<M!9U1&<:A-NW@5<W7#'Z""2RB\A0
MQ@R<-7C[>.)WOQ(CU-F0U!>LF4'HGQ>+__(N 3?ISG8U>O::E]=V8-%I7DKS
M^Y[KJO@_5.\ RFE2$0MB1+TPJ<%@%!/\!^F%T5CNR,XA&.]H864L_MS;BP&*
M6*GOC?_E+FR>+92#(I?NWXZ-OM!K;PZ[N'O1.7\)H/%=RX8=&5>CNQ>GK^CE
M3-UH>C.DNU$/3LCLS.":5+A&R(R!'R!HMU*CZO,FOGA_B^QK\+9/[/_%YL7[
M7M!0(.6]4 A*/C: BM6[+ Q4&1JN:IY'VFVOUXLM.0#1(-N\I:3$9Q^PL_\T
MOLT7I_U.Y"&3<A2;:7CF>IQX9)(H6:-&-\.C;=SJ8L"!+[4!YF(@>5IJ9+_C
M.O0'QUJTX)E127Q8.'[(("0^+VHGPN[5F\\NIJV7 .YS[V^SYX;C*&\L_NY!
MXTTP%SRX-O30$].0@'M8:2;^S4 </QS8\TY&/(&<RRCWFM7X*,J0)%!V_FC2
M.>&X\X/#^>V:F>", M;T[E#;M!<5J=1ZY'^._[P*DM.5':!/8-BAB"J=5M#X
MJ/2A<S+&N8 H'=KN)X2)-(O@!C.DQJ05ZDI@ZG!U4"[%AS"S>5M'X,#X%S\+
M0$/6^0NB1&Q4E3$C<K?-4YW[U^0$^F]:B8"9[Q/J!$%F!4S_!($C3^8DACST
MP6UTIHJV]][%F+4B@@&J+G1%-Z84CA8U/U$:;XMP&@>3&%AH381N<$F 1*5^
MYC9EOF9)0Z^:V) [*#A#J(F8'([3X"%5='>D<)$/_DN$Y3KNYFLF/ I0_/7%
M N<F_DU#ANQY&&79G@/4!/AQB@ *.E?Z5WT)X./YP(# 0]Y> B"K\]7=2;7H
MOO19K[?+G-U.@)ZTHR@$]8:?4DKWJ5!FJ$(LK<37%+93OV+)OSNV#6^22WCZ
MA\'X^3N.4[_#OK],[_0N;J:Y&&<[72LIW#B.1S[?-HDU:!C_R][F)V9EO_"R
MEM9:+/P:!H[@7\AEB,FEY@]_+O:=&-LB)G4+9GT/TSR^4X(E2H2DP$!3.2\S
MC5.[H/DA.&7N]Y77A73)$@&=?Y;>R;N749+6CHTFQ#'@92LELXB=+C"'P(@[
MA4UXH^NZ8=.:?8+6X)SC:.+> 1]%>.)1-)$QC5#;?B$SB>+)(3DBD]=F>(1Y
MP!TAW$@V).];7]VE&7R5B$V4Z/5]P?C2]W,?C@,.2PRM"9T9V<6;[S9FHB*Z
M8&#P>*/_ZS @2V_1FFX+E8EH20AWTA/-EC$,'8X;$EK/]A%;QCR]:7IJA6$;
M<"V$DI^.[,E']KU-71R(/JI=X!9Z0,,I+EO<3.7'7M!F3%'Z\:C/9]*G(6W3
M*"EB:D9/<*^J-/EHRTS[AH/*"S?>W$IF(P"RNW,QXD*8]/%,C=1G54NP5%P@
M'W,O;*X\5!PWW'K1U>UL*F'/-Q5WKSUDOR_(QD+F-^]\#NKAQ00Q)48>=*7(
M8A=,2=6(*N_9IM%U3;NS!C^C7]TO,C#N95*3&O:+G-8H-0S)(^_<L&94E7R8
MVP?LK:HJ,H8O:7<QA%3[YNH.?2?7."0W"OPO1]:7<9[S$B4+<(,WMII8B>FU
M(24H(UO6Y/)K?Z*D[/N=-BIG>H6C="1[%!-%'V?>OA'(\(M"I".SZB@SB\2.
MO?A!V*CWJUTV4O;@%I.ZL=V3/]42P+&2TM_@.(5]7/Y]^J8<&[4C6<2AQC4_
MV6F4S8B'5Q"T[VKY9+YNL@(]M]+M_-J5(#8[+RJ2QFE*X?K0IG?K)6LQA/0T
M)=4X6/V6-O9*#*/E.JVI1MD-R\=+Y2\!51;S;38Q=W-^U3#GR"-6ND@&SY)R
M'H  (0<:U- /1REYLLA$JT#(N&#<[_WI*3HQ9!=@F@6\8O<LP,^;IZ)[K0L
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MB(Y@8FB(^W:Z];)QQ?CN;K48#'8OLT\NKV1N:$W>7KQ#T&D@:BD!R<%R"8@
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M:HBZB:2$<PA2%Y#81AIW6HB$3W1IL0X/5W.X=#9\Q;[=FZ[) %+SB.66I6.
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MD<8J.P?ZQQ_]-('?-W[,O$WLRY]1&_A56><8U^=2S/&P4_<I4VOK[]\'1?*
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MWXW@[A9(ET!?%JAB(B^[N3&F@4F*RH3@\(/H'@(T[,3\HX<27+7NZ(3WM.S
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M(8OG/L>>IJ'Y3RXG-4L*I./'?;85)X.C>&$R..UHVCYJG2!<T$B+@P+\!2*
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MC.T?I>;6V3E*\@$RUF[V%:"__UP30G:UMB<HV8E6>5%,&L@\0)J-:J ,7(L
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MGF&"0SO1R5LB:/Z.W6QK\;^*2P,I.JF&;_UB)L-$"G&JFR$WZ)3'1&(?HM_
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MY.0K<4,>MF 0I9;M637@ OQH=TA[6"O^[<_(U' !.+W%$)@CE_,10/%Y*@L
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M6*[)(, /['=OC.7MD$!V>/TM))?](VHV-K#'#[_U;QC[>+UGO8NF\K87F.Z
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M]@>Q_W#&:-!H/(A@R!4\FH&\1Y!.()R#GDZ2E'!CY(,32]O-:AQ1* O]*)]
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MO,LOAM=[D;PZB&B1?]SXF+&F$L.4J,RW*BQ,W?+A/W/B?Q.'M?/,O?2XVLB
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M02N>?::$PL^VE AA8ZYV[6POYFSV;KB#9\7BPO?O_:L,6<WI@]^P5R'2@O?
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M>B?2FQ 0%)"F]!X5:2("BB UTIN(BDC0D"!(EZZ@*$0Z2I,N-=)51'H72(*
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M&ZX]M^"G 7D)C:1=RK$*&A>*+(] 4I\:\R*_'+[.W3X"]2^Q^^NC8E4-64H
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M2-G9GT_V3;3Q?2^V:V,Q\P1=-=U] A7M%$%$ J&E]&*AL9QGT)LO,>49H+D
MLWIM*=CFEC$]Z2;I)BG*:F[FP/ LBF%LU)4:WP<%!6($PM1B<OT23WP@JJ84
M.V_D-KWDOM+_;6K5TJLYPE6U5UU3(/A"U\S%KZP,6B/_[NW_>A%:AC:);"<7
MTKYL8D/8UI$\67W&^D !_B=%BT#N?EM>]2R\.4X^WZE:U0FV-?6^1^"S7*&>
M*^A=QJ>O[\X9Y2;]6;:@-E+N8J%S UW0VM_;=H1X,T)G!Q%J-AG2>3P(R4^\
MW_H-_6ZHM#\+=N.K7UU#]AQ>5\[IVN^0X^75X45J.3 3C=.*X3=!8G+YST -
MCFNP;3IC8:FG5M".P6WLJ.6==%!UHCUL&3P[;K%P-Y3HA@CS\$%%E+S]TQCD
MQE?T*+M.@?NM<I4H/.G+XM50]VUB.(T335#KAM0N]=C,+>.TT3I/L< D7H6M
M!\/1('-/&79C2BL"T1;DM.*#JF-64KK<=[Q?.IWY 8,%V_B$8Q3M,Z9I<FD@
M+14MC/(!)T'!RA1%HCSV%^WE$8B#]55)4,K;@,.XO+?.U-+^PS&\A<K"\V<6
MF6:CBDD6GP99'8RR:"-90;!&<>00!DQ1:*W[F0LFU?2J1-9<OO.3\5:*\5<%
ML_WJ'<Y!M>?/]][$?[UG."-\#GSYWR*):3\0DB!>LRU)!PHFF&Z4H(4O87?K
M%UEO^!T08I.^JALVY+#Z16_WG"&'^+<MD_Q!" 0^T8,7+B$;TBOYB#I"FM#1
ME7P.H)*UYX/<3XVGXTY.:[:U?0K>M?CIZN0L&CH1O[;SU G((1S0Z%7[SK=8
MLA]\#KYE+(4<@;#Z$"2'$W;E^.8"%A7K/S2W-$5'N'"(S*D$"\E\-W^I<-\U
MG<$FY@C$ZT+JI?/4)XCKY/MPU545<]Q?*A0]=00":P[S.UG(U4\:6MX-NQL6
M)M0^^.S5UHB;I6 ?QZS2"<B+,R!(X:\_%24 V\<E,!UK;E2XA# "4*O1P@F,
MIYY:"'ZL4K;9)3F;:)\PKOL4],U!DR5-3F$MB>Q(<J$V07W3YB^ 1;_3AC#\
M(KV66#51-[A7W\G[FZ]"Z@(? /LGI! !JS5?SYZX;;;&?2<(;Q2"S^DY3Q]*
MY_4SD 3]4[^HR2X6/K2)Y!03&G]$&5E^\0CDMH+<'R3/1_0K,(VA0E+8>E%@
M#+824Q>_';Q,S@HFE'4?0I\>&(7WBE@W]?0X5]'RH^=6=TSVY@?NU&JU?@7.
MX>Q>B GJT!$X<S?Q=\H1R!LV,[T,&X )4HPG=TX +>3K<(P+%8U@"Q5P=@]Z
M\+#J>U")<Y_@._%%O1])CS*W"CR;U%W?[TWF8LQWJJMN!7MW=K:DBGH\;1^_
MA+LNR)TM1P =SPQ:LYFM'MLD-0,=1R">>7Q% -N3 [)+B@;6..?.$Z;2P;T%
M>$KZ039%P>I>A)60F83UC_5SDFE;980R<X#IC0T.+(6X.-:XE(14:\WJQ1S[
M9;%V8VWRE]AUV0C/V%=?K73Y=:N"1WZ8L[1;6-[\NM@!>X(TF#26F?U+7FC*
ME(@/C;*DDCHJ)G/^/.9L3*7JA]:AO([2/*XC4*7VVB6_%.EK*XWU[SGM4E'A
M__>J4$T<%-L)84!($D-)SH2:E /,T[FT*)HJ((L7BBL@L#F-!G>./D+A/^N8
M!Y68TD&\2M_P@L=O+[X_8\@-109R?J<UW8VSD8,0"6,EQ#6 B>Q(81F1)5ZI
M(4#PDOV-*,*AFYF$&9$5'>$_%0[QS7Y@(4P2\I [X9>J;="5H<X#0E31W> +
M]2WE.OD*JNMR6L\1"% RCRTCP+8="6G=(LZH'AB32O3\3XWUYC/]6D8AUB\L
MY>?55"_JWA,UR_[<)!2<PXVI$-&>FFX:<UIT*7[_)?9DDCUW=?'-MVS1[,M"
MQ($^F]FL?FA3V?8O AOIW:0Q0Q $K&S,:E,5J(.4)EXD<;T+4HOP#?8<PZ9^
M67U UF\S'/NL<8*2E*&<?S\UOQY'K]--P=/;+D1'W!$H!>6=H$(3@L-ZLG70
M/.W!I4#IE-62\)(APXYR7T.F=+/'*6"RQ']$M,M/25J!P8K&J4=D58M#U38G
M&1\'P-UG@XQ5B#O)=[&8N$Z>QA1'LJ-#9U,FNS3'Z,U$KF$-0JV+RY"LA^UT
M+'R:QOZGRA]*N(*:'2"Y P9XJCI*C/:5ID]H3J'HA54,*HLCVRK6LPR;[US^
MF4HPN7=;M>F]^=GL-.E8K36D.$!7EJ5_'*F]N01!W*6/L?XXY1I>L9T*[6H6
M@3;L/ X*QE6)Y=UPGI]/D.L=>Y:R<]NP>[]5^L^))(6L'=C,+CU?-3JF&G,X
M _.D+X!/$0#I/ZPN"C.DL8_\\O_%?E_BO&+JXD*-[$G5XK.%7_=46=>_1#$R
MG(.H_83Q=BK1/D,:0@;4  5H+XP[P!$MB/*WMNI9Y 4,".C+D[G+K-V?\<U6
M%07B3]LX=F_G"65.34W.:,9:5*.[Z?V&;*W0-3X8HW@10OO"\Y6)1Z DBE!Q
MW_+PG-5 _O&1Y3S-Q##)KW.E;ZK46XO,F5Y4J63C;RA7R3*>%;2P*:<P A'+
MJ&3H\4;TO,AR6IR:YLNJS$VZ9W%0%-^9U@5S7>1_?+?<BDYH'2/*/W->^D@9
M=>X+XF,_ OGS[(EL"Y!5D>,0%IHZ;6$,4,)"$Q"H$+(S17>L$BFV"" 55I+F
M':V%=\WR!^PR%DR?6?@EK?AEW3HEN0'Y:ON$Z:"LQ_@D@>XIACIEP$"W\U!3
M44G@U%GW@-S8UX46MZM6SA&_/-7U]KGY,95=>G)C;W@F!&O<0>^R'\()]5T2
M"KH;Z%P619/TGV,MB602$/PMG&UW7M;\ ]/*CDFSK,'=W%_Z((7")% 1'L8-
M#^I_*#0<2_' ;4JZ7&Y/\UFE%UDYPI46MJ!^; 5WU!WSP/!XBM$;N(UI$V$I
MML' 2.-*78*IGT?9O-R9<S&%A=*<;QZ"6%P+HS3:#;#T\8$;A3AVNPN/-]2^
M#>1?VI"]4IL*;G2S3%./T&;H=/CX?3M;5^Q4!20.PYORFU1 X$VX?7DQX(.^
MO;'?R]>["\T&]=\>KC:5O^$T5B!@XA AN"J3KGQ-PG9J3='&U-79C=8K;_US
MA*>S]PHL9;(5&9QDPTXZB1[[F'Z>M<K9V7G&N<_+B\X%3<0'N,]*VZ> /EYG
MB@*)@NR?V;)!(LB&%-"$L5(/<95>!$-BUHA#[9X&*+$AW"N'R<)S<6<J'GCM
M/V,^>4=B)U/?T<-4$&3W_SHQO8OR"C@"01PS3.E55(Z+\I/164D;)@I<XK^8
M?^H]<Q@DZ (JS[H$B#>96E@>T[*X??F<&+-:V^V'MBQ?E#XB3Z.ZKF&P>6@F
MFMP&FHUV!CGCSD982CRP>A+C,!J6XGK>J#)-W**@AU<]4]:OE,<:AP%.FU,$
M'/O&E*4@5 R29TCY"?-CFEQ QJ=>$OL^*S1GOSKMG6>+?<?K2LJ+ZC1X84L-
M$\47@!(-:);-?2$\\'A963+8K;EM>?KWE<FQ*5[UY'H33H7"]'_E-W/_5(30
M-?"*<X0)X]OU;\WY9)6D[FT?V'VN%H$!FW=6"@B+V7P/.79:H-&I;'AKT$.K
M3QDRF>:<;[SKCS/<T!_HW67Y.>L4%IM/!SK*V^8O4&<_4JPC>!OQD:A>]9 I
M+:<RL4]FMZ0/%;#(ZQ>BC"2N ;\F-4/HX*OMY%<,^30]MD,/X_MVCR]EK6Q8
MWBH#@G%VAZ_14RVY"HR_=A,1)F^]89LYH4P4==>SD.R[]I9R/W(5WC!V<&%%
M*,A U*\O:JN3:XT_82#,\OZU(U"U'4K[#7AEG,9+[^%9/^7.$>C]=CPM=VMS
M^1)9[9^=I:)5CD 981""^9ZYP??[5P>9*PSYU?7/>-_7/6U^ >SEWDBH(%&H
M'VBL#5XX\#:*J-13:_[4.0"IU9&T$%]TX>3>S".A$^VI21MY^F%"I5GN#Q\?
M\A"L:+P1]&+>0H&<Z:I!^(RT1_@Q2-RB!.&L M2-Q(/.AQA$.E^(W-Q&S:[1
MP H$:F_VH=^V&UE\8:X&$C#5"0D:-(Y\,.O./+!\+XB0E+1'%..]E@"\/;E>
MMN+Q5A/E"JW;I8@DTSB\R$Y6(<6 !*E\](#'=YGA/D2RPK]98MAB<N=!CP9Z
MIT]V>CJ[V6&Z:71QUM5<4T,:7I+8H_16C)L=&ZTWA.*^OG,$JO.C"$Z3"-3X
M'1RTWGS[+-Z-R2;)>ANWKAJ[^ESFVY5-I2B"]QX7,\\PLU306BU"DJU:O*2]
MA!9$>1D8.;Q5FD31H29BL 07KK?*% @921L^ OG(5=X#IG&+3FS!^P'[+3<-
MZDTUI-H\?RK]6J(CZ4:4C\V\8Q>:D(\<1$MJ@D5G3BBY#92ZX3<^-9M^:$I7
MGMIZI)Q0//W%ZUXETOT(%,F:$SF]1/-Y>^IABJ"=^YWN)+H+_,O$_'X*=Z;N
M=;ML7UW0P^F59HJ0 8WW$@ E:VD7$6Q(\L$: YWZ"0TBB_)^^_>MA:_$>\D<
M@:Z\1+4^N5@F]N#TZ/3DG7B6NVJ2OA4,6;9A\J3\T6A:P.=UH<V*.<4.[K.B
MN;HW0B<>F&_(;N@C'CYY>#&'4/5]I'W4^>6YC.4+[W9$]$Z7C B,B+C^$EJ3
M,@":\>R[.YI&)R9FV+W/?E;"?K$XV"I:1[M.[Y\D&]'QLB,T$!.[U#P<?P0*
M@20>@01^8<2"LIL[S1.P$VH6;B86S_"K7;*BJ:)?^$<+RU/U''2XG@E1E3=;
M=Z.1FG32_7N;CU!V(^W:B*%YL0O,"?:QF"O9J<@QSO489UXE S,C+P,H!N:'
MKWDB-AR;U1T9^*[J2CM2M[1(/!D?U]IVZK7W]M>:G0H---.+:P.*]RJTQ@=;
M!K^[VH1IN+I=V;-84]T[*X>^%_#,#I8AB?L?5P+<8PE<-*@6]'!%9#]P?^Y
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MVOUJ5IW5$&:]0[CD@L!;+=&*I@B;Q^T<R[#$1;5Q"@-AK?MA:EMUX+122&F
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MYLKPCML59 MX&2D+J("[7".>*ASK\Z\33K9IA&5S6=2/Z19QQK1T>65[VFR
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M/]?"-QX^UW^V>>U:3.O#4D]ZD-WXRX(EE^C@R@QA2\TT-H:[D-( K:I78#[
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MR-;\,GC6"__KR3 .)?93??UA],R'U*"PF]RA%RQDO!,GY2Z<9RARC58'IU%
M?_^A )#<!6E8HW.Z(+4Y^>4?T&.(ZUB;V'4LC#'%H!LV0YH2-IW<";G-5[UC
MW4<A\SE?]_=D%U56:I-FVM#_!T?Y7\@?-M( _?F?$">HF9W202@>B@%9A1(*
M]#S"L5^%0=P1D@!\KC$MUJ2[/F&W.O]&86J(S%B(HE-2?Q?ZIBP4YGCV#IH3
MY;?+ (_IUZD+6!0G_$K>,)8AGBJY*Y_#;;IH53'8DI=V^:5DHB[HYDT0B$V&
M+$R;0]</4P292)%CT("TV:Q^U+RQV.0L_I0_MXZVCEWZR<8/B2U)WG(^$<SJ
M==EF#L8LY,OT.G$?XPN>?;6<DV#,Z$9A E:6\\Q[1,[.;8H/](3$W=N8\W:T
MYK]$ZE[QN1[@Q7_ZTQM$RG/#MTQ*]) B*P'C6)$M%!&,UY22E.+M -:((;UH
MOG857.0UFYN&.F6!RHFE+M:W*F,OS7<QUQSS]N&/\*Y0'/BJCTZ&8FN7""&[
M\2HT!0H*B,'!YJQ(@3;\PZ'+VR8FA-8 XY.$\4"=7:-O9;6L\N"P>WMG,RU_
M:\8Z%;!X@R#5-.%I2"]-=+S=\E1B9*EV@0?/8$!KL97D4$$&TY]KI^M9,D(;
MHSR9&!F,@F*I%4>@P*4GF-KX+J.@Y=_]!35Y3.??Y^[;'H&>A/;HY%:N"UJX
M+10UIGRU*Q<+*)[E#PNW&PI'BA%/Q2]#> -H:H3^$LF=5^]F^B+*W"\@+;'/
MF09.K-4K,1HWXI<(]HV.__6=SH0-=BBCH3N[T1$(;Q7^EW7TD"_ =4C5U#Q#
M(?)E"G0\3$*%:\!=O&%:\Y6;I\)R:]PB7N:$<H5$JU*L1WKE1ZDGTPF(OR^(
MMB._P?@IEEC%@V$VH&[X(UJH/0B%4XN#":E5;4U?) K7!HZ791QSR6Y-]'L4
M]*PY\P:?;U!X/Y.9-Q2;KL_2G(3!IF! [6H1AK4F;Q&\H]L^V:P]A9_+"OG+
M:D&$R* ?-D]0!.N0.1IL-IETD=[A??@ SO3;<_#6"MFD9QDEBK"BC33H7RDJ
M"7#,31E*K.70<#6<CB8)S8PJ1@WHO&RXI<IPZ$<^1PDEA&PM$]#V0.,RO'HG
M> M1?NM^E3J?RDY5I&$R3U5LI7>:.AX?(1NG^8GEAVNZNKECL1L,%J#=W)J?
M/:6CX5+TW<FP0M:EQ=99_<NEVFL9Z7?N9L#D8(A[@!W1"G^#^L%8'QB;OP1H
M$9;<@L'8@W"^SSJ4DU*R+^?Z(P/93SAD;B<;YB+1QRUV5<DM&=Y.V[/(-$"%
MN(^3W^;"S>\*4&2(T8'O YS;#QWJ0TX63S4_]*'(133E/&AFSYK[]NK9BY*+
M=R1=1&]:L'G0$0BCY8F+*<K50O;\7P= X&NPSW14LT\J1Y.^4=LZY1"1R79!
M>6IV1.[L3HF3G=?'MFM# AZ/AIN*ZS$!>6ER6;#1:8KP(U)6#ND&?4@#$5>!
ME-) LWE'S,B5F )];3F1\"T5DP+:08!R%OCPAS5*\3H5<V"*\^]/]>B][E41
M^ 22V; 1^;OLM\9J_>%A=](O5";U0I)"S?:UM7\P^8YA&@>&+ K/(?VAOJ?(
MD'5^1L,KM926&N%HNZA0C^*>^-971DRW_@@8BLFE/)J.<]S=I8BWD 5-",VD
M@&E,,%AX_7P8)N%W<!D0MI*V&F_6\*RB+NO3?O7S/7VAIL1X9TI/OY2>.X0@
M):]>NNT.:RLZ L'D'T')=Q6O+$0$3VP/$I9<^LS P4MEOPH.,[ UK' 7W'!,
M0TT\C6UD^V!(Q&2\X/W8_4W[>:&J!@795#G)Y]?/02Z-%]+)M+R\WN2KUPOS
MD\T5P;_\%HHSZ4FR^#^TL>A]IP)"DV#>'Q)W^+O;)M&96;\FGF)=[!J0.Y5W
M1SU'>+Q_]%/\^.F!C$^&J::W1ZUU1,(^0/IM*()0DCHQ;8N)[ F?)SD3'UGK
M X_LY2].K%ACYO2]WU@%W#O;[RYL_=%;*=[]75!?T"&8CFK;4!YP0Q1!H!O=
M7!/3$!46PK!P*@;_QS-M-<>B-8<J[FB<OM#Y$;K^IT/I#Z%F>@^!(J7".&OP
MLX=5-"K-E]^![DZ.Y?^%O3</A_+]^X>G%"D20M:I$&4KV<,D(5M*(>M4DBTI
M*MN8*96=B2PAIBPARV3?38PE(3L9RRRV[#-H7,SVC,_ON']_W+_[^1V_^_[>
MS_/\\_QQ'@=SS%S7=9[OY?5^O<_W^;[VMD<XAA'W?7%0*",>X0V-P%2N1^B.
M9K1DR5=AZL*$L4XXSG%_7Y3I7<_[^K^\:9?)-5&58#' ]3HE]6V5UOJS7I=6
M\2F=#<&D+.X;NGXJ_[@<NJ;=WWLL$.<4?-B:.00EFUEQ.'KA(G#JB C_/L+4
MC=2N(^YE)9PZ+Q6_5$']OC2KQ#[Y..Q)LEW<P)A\I:'F/;GZ:7M9MK[>_]3Z
M8RXB'ED!\NMM*&'FL CJ4.->\%W **+[DE^WB,5:MS;S A#%:KCFR*=4/_,G
M8ZI7'*_7) A<(QYNG;]1KLW?4=:]ZV8$@J%I^HB6*_!+]!! FV(XT]Y'%XPA
ML9=<49?O"R<9'09[FGL&1?(5<9$1Z--]08V?$] -S=+"]_C+(,^]Y+FKF44W
M97QIO,D.A.T9\;HW:2HP6082KAHH;0=D$AN01X'L3?;EL#&9G'VM&JE//RBO
M33M^*@Q5NUD9?L*'IV<SR)&>A#\=.F($"N1;Y:;@;S#"]"7HLD 0.8=J2V&!
MVIHNWJ(8(PD?"&0;) Z%'96R2ZI_.][9S>,M%OX"EP:YF"_J2Q?2W[9^S^2>
MHN2WN(B3[:(:C4J "J)[9"68SV-:D%RU5O(\ !&0-XD]X.*<:ZWF-:A3F$#M
MJ-OY8-=__ 97-PM$-G:C<$:PE[ ;N$#N[,#ST>V("/Y 3>)::G9@S%5*P%N5
MRHP8[^Z0Y_%7N0-XX%YSUV60?E+:I4AJ[0C=AX)JKX>N0,CEVS>''-N#@S!
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MR51U"(FMO)3KS2-LAQ&DKZ'Y?1U0P+3J&9.V?Y93SN3[$QMFIUZI3)2XA1V
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M\L*'#0J2%#N;@ESJ_F4(TV9K[3B;4\,J47P>N\A5&CN:QI&'[9A'F]Y604[
M]/M=C]9[G9_>#?\0M5T27)G2S<Q)B0VROQ8*;V8S_#!HX-A,1F#Y<HN#TFLH
M<.;\H%>BRS5;/1UK[EM'[M+7@CNTI!6?QH[-Z[ICA\DWLP+"$O.UEJV5<.HB
MB_KX'OHV,Y\LWEX\<>3##2*L515M[)N2E.B7J2(W,NB(V:%6 <^@82P0V6BO
M&8M5&Q(XY]NY5=8<O6T".!-C/LQ1%J*SD0?0/-7"Q<9B2S?Q"0*"TAP;TBR0
M+?1PLS!,#P"3\5<!0S*J]46Z2#A=^TO[O>Q%C0NKT;A#8X=SZO2Z!>RC9!)-
MU?#AD$-,89@0>:7Y&/OKZT;DCF3]''^$1N9GSS)<Z[:=@.C##[EW]Z^MF$(,
M^O<Y"\$E/[H+57AU57DHI2[1^U9K.Y/8SI$2_=^2O/T/AC8^&G&XD8^2T9+J
M<@!XE:,T]_;'CP4!@Y.T\HZIFQV!D!M^W%R;[M0\1B+].4T-0#+4H3?)?R=S
M/8,GGQ(=,<GRX*59CAIC4/*?RXQK;"L0"KR%A6N2&6-O8<[9$TLZSU>,+V68
M%V"ET4-E7.],3KXT/H0N(^I?Z'S2(9T<LO6 \0=>ML("<57\&9MER@=:)0)Q
MKQ9>Y,6$59[+8X$2+4,+X!>".[^FSH0*;6%6V6SAP"X%TJI91UEOO:;\',D3
M]J"V M3U_ OZUCOME%,,RD]DH]8DW .]J)NCW5W1(]9&6.@5P3RCJ0^P+:@H
MATXE90GVU6JJIT#3!Y[-5X=TF.]\5LH3F?*I,/V'+MS8^?Z?VR_=C:%>VR.?
M@:])]M7 *THI;L:,3+MO[BP_?ZG$(#ALBABYRYB7U @3:RR>T>DN5Q1OFY'K
MEHHI"LVNQW0'/ C5//PD'-&15NQ'_QKS<7K=HP6A-E=I1Z*:-DCW(=RL?K-
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M:'6:;P]QV/-1FI"9YHBX]G;7LMCK@A'RZUE/+L:F"Y; !\@4P5(AQYL57[%
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MYK'?X=\G]]EJ<_0?M>ED@:(1QYB'82>!#)\2((=H7.3SA7YY\'-%;5QE3.'
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M@'QAQPL\NE:%UZ3+=$H_*"4ZR_V"G;:8=FYKX3X8V_^2.^DP:!=!W6L G>!
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M3/8K"+GT:6D*R#[+- PO@ZX^UCB^L=S&\IX.57IN:K(WJGFDVUU#1JQV/RX
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M3)O8<_1J@$X/L%8$##0!2I7!;-R4X$F:8^=B?AQ,#1W<CZ/P=.Y5&P!?*0O
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M3I&Q&^6?MO#0PD$G';P]BXKU:#>VU-&H/R]OUM%O;/ZN%S!_<9PWN&GN>76
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M@VT--;/%@.>K4_(*#-6\.G?I>43]I(OP<E9>:9P6,U=?N@BJ_>),ES4WM@!
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MV;=\N5R(1-  80&S4%7]( )!XLE?41P*3KT84;NJZWW#$P^[7HS=8%M;3;Q
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MX_68U0->#->NQ[N\03L/QRE;W%9,.M*WWQ_S2C>M+E6;^*1C[T[L:C;"-"6
MF9<Y:N=IY^'"1#N?(+NXY:T9;-696FP\VL^9=>+,7;[:C5_*-L/V:(.SC,9S
MYO2#[.QSXZ*#C[QYC>O[3U7YE#-%5/!'K2A=6A:#K4I&UZ36# 8R+&!9++P0
MBB3V(?))(B,"JO:"*(TH3D2$K&Y VZLP=<I,+WE0HNO/=@'!"%C-(H%IP;(;
M[BKE7"D#>FW4BN@GI1#(BY_!(1C!UUXMA_/^>$P<3?@C%)AUIA\/T.X4?T%+
MX_S3D;J//;UN$J689XA"P7 ,41!D,,.I@%Z8)4D4"$X)L_%%I\7-L@YIUIE"
MSW8^YPQ49O[%'0!VON14<5?GI,1F1CIR#F>$S>H(S S?'?2&;XT(WE5BG-[Y
MN"^7\I7/37']T!B'[P??GGB,MKE\ ZG@,V]65:%8'%>FY>M.V&X0TE]LMF50
M/])BNX#^I%'C0OK#3<X7U)\T:2NL/_WD2#*P'0['#8F*2IC?\/UIVL9;7JBJ
MV?4[G%?ZL&@AHWJ1X#" ./5#B&)UQ23V&4Q#&L=>B/P015;L81>I,_&@?K/B
M';-JPPOPK$1;$HY=!K;9U#P?A'8.PHCD5NG1'AI?K5D1KS21+=7GR6K#\(N<
M8I9\FS2QI[S51=U]SR%;FA,T7=&K7:;,O'QL3H#;(W!STZI]#/+V'\WS];>*
MU=?L;^^*S<:\81!RY/6IMQ%UOG![TEAO4_"_*\NF*&VV%H\A<#X4<6"\G:LQ
ML!M\=7JV8&#FJ.CD6)NSA2=GC!K&)^<>'4O[+[A<0+!;_+TEY=DL,\JZ?HVK
MZEE.'[JG%W)='_H9CR#RN*](G#.89BB A$8I#WB86I(N6LB>>"1OUKU+*1G0
MH6A;HGYS/,T"CHE0LHTN6B5T'9*>36RP6Z!0>VV$V@@.?&O[G1':FTN>F9W>
M&I)]JGG[)J8H+/*9XZ7BM%>L/ O&8\$])&"8<@Y1A*5O(2E5EWZ%XM"("+?*
M;S47/;%_^:U2 Z3J!(([*=':KQBC:.I6IL!F@C5+KXJFX)JKM,8A^V<ID[$E
M^ <J>7$($+OR%0=;&,N]U5=%VJ^(M/ZHN'O?\(=Z00GQ<.BE,/)9)EV)SR'.
M4 J9H(R$B>_YF54Y-1OA4Q]5\*I1O'2-G)3Q, Q_5"=#ND3H3UV)5,O<>2N$
MS1S.5+A9KETL"ZL-- -:M2MG.ZZ7 ..,X\M"],QD7_:@[+-^C6AC9*''GF>H
MHUL72/J<) X@9WX,44JY8OX3D%&$""-(>AVKHJP[[<^PL:&E659GW '!S"]<
M8)K]MH46- &K_!$C7!4_W&E]WKJ&ATW;*UEXY+&1]UO4W9GW=;WB[(V,)XJ[
M3[S*2Z:/9VK]Q^W+>9S)Q0/.0B'G^<SS$HC"E$#"$@)YFF*/9 3QP%L4_$YM
M=)L-.GLEC+Z\6?OE':IB_AWN)>D;<OI6W E"6E?0F@WDB>#Z4>XO\UHS?6J;
M'-XG&0V:JXLC]@K,>T-D-$![5T'&MV3GQ!Y8(X55*]JL*KS\"\>5HB*\5M7[
MZ)N\#<R[*3(FC,8H)) FOG1:D4<@]A,LG18/HH"AC!*C'0]SD1.'#ALE@-8"
M_!M^>/QWT&IBYJ@LX#OMF*8!Q=(1[>(A->C0 +T.Y^.1L?BPDJZ43].^;V:<
MMF3/C)>Q&[8WO76[\CWE2B,/!9%VIQ8-S>(^[0WKW>6(-T<FE:IUF)J<*WXO
MY^=UM>MV [J^?[<LO_V%LSO>,[:_XJ*L5!7LKJ(?;6_P%6H3>^%G"8E%@J 7
M102BQ%?G4HS+!1A1=.LT$G'<AW^W%JFH+I4<$1[>VKM@M;2]*_26J0Q8KF]>
MO[]J$\2%U!7<*V4M-Y_=]I19-#D_\.,R9O4NT9:>_<Y26RVBPUZI"[2^5\-:
M$E> :+7!KM[MW3W\W6&Z[12 NLK.=:K;O,F\4\"ZE_L[B9#1&0-YP=FK=E]9
M$6VK_[6'B+J^JJ+.4V'T*\W"_0FKB2-_Q$6S"%C$413(&#?.,KE$9YH&D< 4
M)QF37XHT"JV*H8Y79>H-M(?'9?G,.:!#+:PS"<;B;'H". =ZMB>"6B?0*:6I
M]5N"_776P99J:@VO_SK0SFGJP84(N<M$&*O(W(D)%P)V($_ATA;'IRV\+VH9
M"*M%S >I1'O8E:4H86F00)(J.O(DB&$64PI9["=I@%/A^U9\.4?D3.R@],G[
M1BSXJ@2W!UR6'#;'<#+U01=;;^M@1A@^*KG@A%D.,PD.29D];>"$J8=R!$X]
M;I\Z_!$_</;V.Z<K=:Q[(V2P(\?#B"3BLPU-/":U?+!6 /0:C,DF/@_*Z?'I
M' ^[47H>B@D2C(WM'95J?+[UV9*.C0T=IA^;O_0R?,TWJZ9NY*(Y+^Y.L71^
M+I?++K%Q@7":,>S%,$[5B6'"?9AQ1&!"$QQ@CV,<6RU'YC=A8H_TUX;] JZ?
M[GXQ9>G]47K6\,#RA^ZOESOP'-AUEK!Y$BJ)E^N8'X3&>80!_[]B=![?0:[)
MG2_09&P9N9K+E^ZO"_:&/_%EJ9-FWGY7NO/NV [1T/?3-(3<3S.(?,0@P5D
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M3IT3@!D>$3B!P?+P43H@'<VHN'C#Z?NI[ X$>CU4?;<6J[/@V)\.G+7;U6G
M<4'S[OZ?-7AOM__\&R,K(% Y#:WT8<%'WOQ15!POU06?3?Y]G[#4;32%&0G2
MA'HP#8,(H@PSF,4^EVMYCW+&9$P:&C'XCE5@8H^P4:#/+-19AG(D;!0:</A;
M5C^P!=O,;TP)H>5NW\WK]^I <:W/,$?S"A@50&C+PTV0USX6)E?U"VS%SUNQ
M8"0X>S4*QK8SNBI!WO /,DZ2$AKY5<SEEZF[UOQ05DW^3^TJNQNZZA3B]ENY
MX!GW4!8)&$G_)7T826$FLDRNH7V?48^3@-K6*+#78OK#R<2Z0,$(+,U<U.0(
MV?FI5AVH]0$;A5I:A2O-.:.),H:Z=0>74B^GU0S&P^*NML$('>:N=# >I@-U
M#RYHS/[<LJ4-9)\XKWZKRM7CNV+#V&MX;'FBB8F]2"<9*-% RU9W-,I&%=<S
M/[D\!<'Y@TM'UMMYB%.&.RYM8FCCJ./+4^W.=GII8-SP\-+D\9&IV&HW7Q_#
MJ0L<<GBW:5.;+?U7SYM'^@W_;[AB-X^:/>5FU=2*,C8O[O[*\[M[.45</_$*
MW_'/7*W%Y.>:-@'39H67*CDB6&"&XSA$*0Q2E0B%D@ 2*AB,!4^9\#$+L%6L
M\0(V3.QC>C5 IP=8*P(&F@"ERA48J&^9-OX"?6\6&_W@/6JYGS0X6AV:,SQ?
M!>3Y\!&L,DIV\6-'0SHP[ I8?$L<ILB_7->XRK9_ 0OF3=Q_N2[:NP/P@JJ,
MFQ!_SXM2)67*0)C+0=VTMY[ZNPIO>'>3)HMQ$L=I C.2A!#%/(1I*O^31#RE
M.(Z"D%F1)YJ)G26TU;S2A?RJ*6!+36D)RF^%;.X^?P1YIZ#E/I\AK&;3@WNP
M[#SZQVUP>C6N^HN(O2;@IUZ7X_E,U@[8SGA'/M-0Z*QNS@Z(7<]D^?;(HX1M
M D^.XS0F@0=91#*(,C^&)$$^9*$71#$+"$]CJX.".6E3K[]\>7O[Q7)W?PR!
MZ5PLI!,2AD[*^OF2U)UF_)M.230_\R9OL](4Y]ZM;*0[0?;#(([50$K#1/%F
MRA5D*CB&0J1)2J.4,6Q5Z.&8H(G'U49LRV.K!(\\;C\*E=G <P& W1 <9[OU
M<#QGF*.!>53,K$/TG+&[@_7L\V.'[1,O5EQ.JZ*L'M1)_>;F[QM>TRK7$?Z-
MN,T?9!"UX"A+?1J$BGQ.CF;BR7&=>A&D89;X/!)IX%LET%C*GWB0=X%A*=<N
MX-M]3N]!M5ZK/VY4W*(?5PGRO#]VD2$Y:?,Z6[91@&OYFS;1UD?8]8NIZY@,
M;5N/HA71H?@:U2%IP$ ;38.D]7'I:D8!X<P#V4F?V3&-@F;?7XUKQBU#G3JN
M7Q.58>%10:(,$DU3$J4J[3PB4*0>C8B@' N\:,H&+\U\EXE0*X>U%FT\CEIB
M,KI%3/;34F?_M,GF;NCBMF D6<HD7CX,0AQ!Y/LAS%+APRS+N!>$ <_L]E2<
MPVCO]P_!V"7KMVA. *.9QW8-CIV;-N"]FY.G[I#1$Q/-;8G\(9CB#H%@2O5V
M\-T+3B1?G=\R?K6[9?P.YY4JZJ4R%U8/[?YQG[;R)G_*&2^8RAA?X 03(I(8
M8NRK4)/'D(0Q@I2'/$2I%PO/BA%T<HTG=E*]*/"<<UMRX.E[R^+$\$?I@]G/
M!Y41NJ"ASM?JS1AD;:V[6)GB^#!P#M1='OU-JN_\!WUSP'_P6&\6P>/Y/M5.
MQH*$*(ACFLIX7/X'!1&"*<Y2Z&<$A6G@4Q((6XI/U?#4'KDGN%2R[&D\M>FG
M_>8E!MFY-S-;1K%S#A6_B)!3-S0[!^=0_4.TFUM_'UN!JLJ?=/7!_IA\L"LL
M(D(]187.6"J7K7[&849("&,:<Y0A(<+,ZCCJE+"I!\Q:]#KU9>0>^DG$S&(1
M5SA8CK,Q$(PH)W7>-F=5I$Z(FKEXU'FC]VM&&;PS=E"3YGU1-Y7V$OT!MIHV
MUU=D/W'Y)2D:?,<7"5=4<YX/,TXH1&$F8.:% @KAIXF72A] C#@11DF?>-@/
M[WZW>IP.<!W :>H")@+)UB>0!FSTN-J&Z0IL\-MHX])7C #!F?.PD3VS-QD!
MR[Y[&=/(6'^S6T[S6J7;53E>]C?7%C'V4YR@$%(D'0Q"*8($TP@F-)'_RC^D
M1(R@UC40;31Z''#J=F*!VK8%/]U)Z9:;MR8PFGH7-Z@X+-Z[7Z)777KM,1M<
M>9VR*N]1%":KM[LO\84KZ1Z%X'R-W..OCJTR]_"XDG[I2RD:N?;G.U?+NOO<
MG@B9$"B&(0X#B&B (?8] I'G49$$1/# :C/62.K$84FO Z@[)6P+KID 9^8J
MG,-AYRS62/3RK_;NEDY2KLW":&<EW$QDSES6S0*&_5)O-B^/\Q##FI=#EEP5
MW"Q\ZG,_C"/(%:$&8D*=UZA3&C_$& <D"XD5J\8I85-G_VQ5;652X/B"MGLX
MF?D!5];;#?]MPW_:" :E^%ES7TQ3G/:8A1/4HMT3]6*E9X\9?:K2[-%W[/D;
M;X20?J')B[LV_1<7[$..2;[4Q"8?9+#Q7M6<6(2(H SA".(P\R!*&(+8R^1_
M?!_Y849P&AEE>5C(G#K)8ZT%Z'+*5=6-@2+@JU(%:%T,MR-M$#WM 2;"R<X1
MO#1$YIR'$T UCM=P"(@F[#3 \%81!SD(I$8 <8*\T+2EV0@*+4T;DA#:OGKI
ML4W?^/.:E>Y&K#GI>DJZM]\;E8PC^_YM(;]I5?LM#S,?$9&J\D8R=D*$9_\?
M=^_:W#B.I O_%42<V'V[(X0^O("WW4^N*M=,G:BN\JFJGHF)_J# U>:.+'I(
MJ;H\O_X%0%*B98D"()!VGXW=7I<M,C,?"(G,1%Y@0:7*933*<91P%L=6]1$^
MF)KO&FC'XP*<:^CW^YY5,.#5^>+H@C6SO6":9R6<+Z*F7(0+KJXN1\W[%=<%
M++W05=CE()Z^,O/P;GL#5K4\Y[6F@!]X_2O^4=YO[]]4=5W]H>K,\0.FDJ4E
M*W!,XSB!+!;2@$UB!/.8<;FZ&0N$J@LG1G.<+&A.'Z_JN  /BHT%N&\9 :3G
M!-".%7/;S!3/\^;K!"A9A[%Z@&Y:@#H>P(X)\'8R@,R-UPF <C->O0!F9:Y:
MBCYBKIJ^:39SU5*TH;EJ^^C+-)&Z_J%X;)3S8MCE(UQ&.8JB(.$PC]0$;YXG
M$*,PA&%!D<@XB7EF-4WO!6286*M;-9$:L#]O$RF7M3>SDE_YBMJ=0#Z;2 T$
M^Y,VD;I@:5Y)$RD7"?Y43:0N6"+?3:0N8<5ACM']PZIZY+SYNJGH/V_D?KZ3
M?*D+]N[BEJ6<A!'/8(I40A[)(TA8RB#!&2*B0)AFQ@'P<\2FSK_KR(-&D0</
M'7WP(#]E,=3F'&+G/02?.-@IYAUEH$F#GG;;T.+LW;;#U\=\?(]'4-S<  C!
MIVK-?Y'_!4_> /B/LND&46WNR@;PE=[)OP (/<WE,11^;.C.N5?,-U''4)@G
MXW),G_%?&+\/Y%S_H*LM:Q6W_"*H3,6G#;8&TWK></EM4&-]EHA1$D=Q#A/$
MI&V?BQ@684H@YT$1\X30+.4.R803LCQ/$N)/*C/K9Z#X5<.M5KAI2E%*VZU<
M;ZJN?MI?0?FEJVAFI;_THDQ5OK[G71G<+?=@Q_[B6(_ Q7 ZV0(0+<=\!?">
MT)ZA;OY23E]-N;TGR&VJ]'V1=(P4T3O.MBNNLDT.\T^;=V5#5U6SE1M/7V0O
M@S 1><Q3&(LBD^< +6".,PS3,%;%+"P(4JL4,"OJ$YO./2_J.NQ82G4#!@R=
MO=GW +9A4&4J"&WO&)\CYB_]X2)A?048K&C/&QIP@>694^_TDLNT3B5&)IV\
MWVXDO2/S3C0'^^D<:9PD7 @$,5:3'KG L$BC& 8LHDDBHCP/C$K*IV!N1IUU
MW6S*>SW/K.4-7-W>UMJR?3(B"'1\+EHE=WK$D&4_::]+:J?ZYEXHRT#Q8(U&
M9SI)"[-?N2/KU2E3X'6LRY1(>E:[7EA[$:WL$]132MLK#8<0JRIW?*C+1MFP
M?+7B$J N.I:2E".,$I@F2 57,P;S)*(PY[FJ4(Q%&E'CX.I),E.'57>$P9ZR
M10CQ-#P&D50O0EO&4(_)ZQ([/2VX1=34"P".L\S=@+ +C)Z5;RPD>OKA^8*A
M9P5X$@8]_VD[!=34FV671]%]MS)$I=HAB50R<:!:%V-(XB"&+ Z3 D5!P@HC
MB_#9FR=6,QTML_WU7.QQ77*1,';JHT\M\K=/3C(_9F7(AP86AOS7WKIX_KY9
M=LM),?H-<OH#=GM"S:B[_M>VW#RJYE[M]>RNP=>[4@A>JWWG,.?1[JU3G\N:
M&;#C9M!L#^SY<1D':0G>^-:;%C?+H]T2L@D&2;I!X31;TI+4;.,FW2 83J!T
M?(-;O*:-5G_#/[YP)5RY*C51^0N5IU&N;R6YDC?+(%>YV%$,>:KBPX022$+$
M89IG:2[2%*$TM G%&-*=6,MT%TD;_ /0.UR/=.2Y"#RSH,<$D%@JD$&+)XV+
M)*V[%X&G'"WT'_9,/2Y47&.[]EAA;(F%IXB$*=59@PV64!S&$6P?O_2RZ<VV
M*=>\::ZH5&-M]4CSYG'PKQW9C?RI*5E73;(_<1E+Y!=1Y#"@-(0HX3DLDB*$
MF.*<(I&(A&*WJZB+>9LQZ/MTN=1OWO#;<JVS154QZK6>U C>X)6:RZ"J_/<[
M<@.>L*\,@8J6.H+\1[FY T/Y7>^Y+E]GVUNP65?//1+<L_D$994O//CWXO1:
MS1$,]HBE]RNXRSE[H0LZ;Y">OK[S1\)-RU_)M[-RM54VPE=.M[6NQ.Z3&U23
MB[:5C2;Z65SC6JFKYH;7;8OJQ^,ON/I1-LLX"6B6T1QB$JLIKZF .$D$S ,1
M<I06+(ZMBDPFY'7B4V!(&.PI@]\5;<N\A"E7S$Q_OY)UL-/GCDM@/[QR>G!\
M3<*<D--YQVI.#_FS&9TSD'14Z)0JOZVYP8_*ZGB[K6MY=BS#@J:%2#B,8U1
MI#+"BAQ1R((L"M4@4,Z,;O;&R4RM1CNBX*&E:JDXCR-CJ/,NEM=27?6B=@2E
M>=F2]*BI1D7RI62.$YE7/XP*^FQKCW_:_K[]:;/A3UMU4U");[5T\NYXLR0X
M8*%(,Q@BK'QCG$(B.($!BG(2<\Q18=3"\SRIB7=G2T[Y2YN.H/G=\QF,QO>H
M7\GM]NFS'N%[%+[Y1L'\%MX?&FXW\9>@8G4=;R;HR)7\F1?,=BUO)LCP:M[P
M"<?ZI%VCKD%_KH.\OR**TZ0@*8R3*) F!0E@D<0,%B*.L0@QBW!A-7#R/,T9
M@W6#?G$#=BSK@PQ0-#,_/&-CI^..0S%I6,M"7E\5,P84YZU\,8?@606+Q:.7
M7@X<GU2FJR:[ O(CUYZ'FR#*BR+AT@9*TX!"A.1_<AIG4!2")#EC),VLIJSX
M96]&K=-607><';WW=X[N>UDHVP#_W/"[Q_A'6G\\693%\569*<CO$T_O<7XO
MS+U0J-\GL*>C_5ZIN&GNCZHV\6W5;)91AL,TC3+(B>H!A5113AP0&(<Q)7%<
MI(@CF[GKNS=;Z4O[X>K?U".@>M W(=(F6>E"8"H)VZG&/1)F6LU)/CN%I$FH
MF\016:RUQS.^/6W\_7MGW;//Q#G<;L\_,/,H;55_IT)(*@S\*Z[_R3<W=4EY
MWT3BG9K+G)$P2P,209$5"*( !ZJ-C6K AGE"45P4V+X!VT3,3FS_?+OC@'5<
M@%KE)NEY!_>:&?!=SV66A^VN/0ZSGE$WZ4H:FD2O9'TL#:3+^Z;U_+>+VDH
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M C]K(''^B0N2496>^"S>EVN\IB5>W52-3@W?U_G$L4BX- 2H4'9!GF"8HT3
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M20Q%)G*(4ES (L]B>?2B+,U2'(O,:LC/"*VI;T3;1 9%'Q+- &AV'-@9[F.
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M93#(BU!UB^520:5*0_.D"#*19%@8I]!Y9&QB];:G#^B0 >DE]!Q8Y%OY7)!
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M0J7"]K<K4GE\D2>\NHA9TW)5]F5PTLO>RH^1%>]ZZ!\OF-,MW;,X2'C!I19
M6:!F8 8PSZ(,<L1$' BBAOU954E[9W'R-+6*_A,0724[K'*V+&3VOS)F>N=E
M\;;35CM>P<#V4.R"I_SJ6X\]Q_T<CL7QQDW#BN8;+BG[[! ^';R^BH_],SAO
M@?%D #\K(IZ.DGVP9;JY]G^1K]CLVC_U?1ZNVC8/\I<Z9"27YHK]S[;9M(4^
M(BR"1(0,YHBH7DT\@GF1!# A%!5I1H*\,$I$?G6237QV#(@"O*>JFP"R:J4Z
M;C_PNNT':-@.\-5!:!#V>E7\3G=\>6@OV K\9.Y?FWFUD3+OFP^V8N_[#"[
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MH2#&/?MF8GIBGTY%:<I]E.9.D;9PYF9;NLO"JB^U(-Z#JWM!AI$T\'D-!N*
M3A[0"@1:B18G(G+JMY^%OQBKUV7W$VE]J>6?+-[Z,E\#;V'7*=;#,?CJE957
M$8*= ES30.PDM!WG+DM7"JM>+1^Y-&R^*,/EL_BMX;I5YC)':<HRDD(<!@5$
MG'%(0AY 'H@HS:,X%9&1)6!$;>JPK*(&*P'5C#FL.X%:#B$>A<K,Y?,&@.61
MV9,%FNX"[,"0M-MVM!Y'Z9K(Z&N^[2BM>8?.FHC];!*LT4/V)7C7M=8]*DU
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MK6KSMMEN5AU$'%ZNNCSN9MY_JS'C][C^IZJ\T__XA.]YWSN1XP*A%*60LS2
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M33DDE&!/$K0[GA;3BH+,N0_RVN)B.8A_Y\5CB5^>,BI&<%J4S[5SF5:$/>%
MSRXV>G/B.;U2O^O,/ =\ZO;.5(S]]H=ZZA",%67;/\CKU<T\%#>,U;R(>".S
MD#_EM_@E$P%M?2Q.3IN6?N$-CR+_RLMO&>7WO,P*]J4IB9(7U(YMC2AC891$
M$(6<042<""8!"2")0P_1, XB)] J0II9X;D]DSR@;=OWT9YRFD5+<[\U-6?V
M,[T+S8."^T^WJ\L]J?O<]OMS2-F.IDXW[JEHL4IJ(1QMU5?-K>ZRE5D+@7]6
MT[647+.)H<Z;S62+Z7[?FL1C#N6$0R=)0HAB%\$D]$(81A'G.(UT&XE<E#*S
M"S[(!)44JN=Z+^-"_3@AS/4AHY&8ZKPH@<1/"8Q]3T 6.3CRT/H;+TFQ&#)]
M:6^*C=I<,ME>O0F@9^A</8\&+;+DBB_+6-1_#IIYZO2&+S9N2\_+LJ[![R6#
M?.;;/=UMX$783V,/!C'!$"$J1J<G/F', X=1'SNN;C/Z88DS>[!.?LWJT<LH
M4VRPJ Z<VM"U"H?>,-XC(>DW>L*;*K)Y&JDJ&FNO@_R(O*7[QJN9?Z%;O.*-
MIAFIQY2@XLE-]9A8-N^91+OO-28I<E@<P!0[OJ0!"F <1P%DA 8L35$8>EH<
M@SK"9_8-$VF%M6!4<P]S@:/G*2Z0!4L7\<M>%=#I\NLL?L,$!6OYHQJB%\X:
MU0?E/%?4X!GZ&:(/);LIRT\Y>\BV&R7G<'[7S$._EJ&>Y7EBT?!@GF:,WE!]
M*#$[:S,HQ&;?,K;#&S!LIU;RYF63C)(U3QZU6'+F91/ZR9A7KM ; U6Y7<L\
MVF*3,5F!75,#2W*K.O/20UX8X0CB.(Y%@$T<&#.Q_"5ABDC*/ =[2AUOAH3,
M/'CZ8D$G5ROO<A"AX=%ERVZ]<69DLO+P4K%I:((3]_<F-_'38;@-/GJ1@:=B
M7#<$E:XUJ#-W?PN]X+06-'#:79> ^RAR70(#-THABC 6(6Z<0M]UB._'%-%0
MF;5E6-3, [.6?;&@.' TZJN'T1H>GG8QT!ND0^:;U)D/XZ!19VX-#[.D'Z.O
MA5Z=N9*%0W7FPP]8KLY<R9"C.G.U.Z9S@4NJS'<\+4J^I\U\+_ZIMAF]R5E+
M87A":^UY& 5)[,(DH&+QSA$2GBV-H4>",(@C+XU#:DH1;J#/W ?&/7)L>0A4
MY/+$J*'*KHEG&W5[-+1R]ZLYTRQR\'_MRJQB&37(>9GXFM0V!Q8$7\_O'I.2
MU]B24Z17H-.OSC3J&#>7(BR?@-<,/.8FVKP9O?D$Z(98SZ<\UBH9^AI[GN^Q
M*(%N$C@0>22!./%\B",/1VX2$A=Y%HC.9W9^OY=%58%=GWQ;'GF05KH5ZO)U
MC)B+ \(@=W  4>!P2!P_AB&*HS2)**<17K_49^Q?M[C<+@;8J4Q;L &\%9\?
MLSR7NRS"OZ591?$&O')<VH$T04F2.#R&,4<4(I\E,$Y3# EE7D0#[ 01:B']
MD+.% >TDVH23RUJ/&8!4FT0M0*,W.5ZEPY^=X][R!'9-RL_ 37]MPAF[W&PB
MD;%ER9]X7F7?VMFKYL\3$OILX0_%9V%4D6^%@>)ICQVQ_9KX(O2F+!*Q./<@
M"IT0$C=(A2ME2<)=SL7_UCE_E#L@:@-^HD9*W_ZD^?;W]=+8/NOIU_79P"?,
MZOF1;ONF&YI3U]27H^9&E@#<<*.RCW0;?__RA_#*O^[I8NMP_)37_EC1?4<.
M>U[*$F26O-E4;1;U>I:@._6.MAZKWT/T-MN^WI0<WQ:,K]W$)5X<(>C&J8R
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M#!,/QWX4!BE&6K38&K+G/E#K9\/OU0)[O?2\A ZF:NYB)J0T5X@?;D$7D*^
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MG\@>C!>2CBP^W,P)W_.R[FPLT&AX%#J:J# (PA!AZ*2^I#Q(4X@C'$$O17[
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M@P*+*_BH;X9/M=I@-_P@<@5J!&RU0E&UR^)V^$4QB^^'#QE[:4-\\'JSH?K
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M[5"%\'H;F<H/_*"&9HLE)0#5UEW68=%THQTB]8>>!BN MX=4?$LM$8V,MM7
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MJKWXCFS:CO#KD+M1ZN(8BODN@0C[%"9>$,"8HB *_,1W0ZWJ:"M:S1VFMJH
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M8(JFXP2O19NU:1% <>'5B55=VWVE%ZG8DAXMM&TD][ R\R"RG>)RE]8J%&)
M)J?PATOCS1;R,"!,/\QAZ#'GT(9RS5E[D=BV<-D]/ND[Q#_5>0NOZ&ZE#1YI
MZ31YT27=7SQNME_D">,X#:HSG)8\(SG&<09Q$H<095$,\S0H8(8S%B1)Q%,[
MY_"4S$[M3Y:$E>_FR+%3MK2M0R.FFS*ST]?/,A%VBJGE&K1LZ,S2!>AQ#O[4
M:<0'WG7_XX[[_7N*_P7H9O0HZ_C]V(RZ!&!,#K6_"(WI6)T[A&-RT"_$>$Q/
MTVV3>%>NRRW_4'Y7$2A;N:1*LN*-6T/NZ/6V_.^^.^X_Y1GN7K527N*<")R'
M#&9AQB$B*NR-40SS,,1Q6L3R &O4"_!&/B96[7(=Y'8:W!5/,^4\ TIV>K=A
M"&J.P(&EQC'6^.>IOBGL<;< BC&@.?.G3&^$QI.>=.5B5A5X(U2GVNW6X6XK
M]_1AG]0FB@!E6&4&T3R#2"0Y))@(*"B-<(110(A5P^4S"A,KFXZ>0RW?ZZ"8
MZ96;1+73&'92.I=@.I/$<[FE#_,F[HV*=ZV,TOF#;LOM@RZFMW>0ZS)NFWZS
M\RCEL3S_)0RE$&&.(8X)@8&@N$@+D8@HL5E[P^0F7H@--;N5-X*/V3+T)[7=
MFFSH+GH76PUI\-<D(8UF8GI:L"/$9EV]9H*?+F7#M]S6M3Q2/%9K76JK*?3_
M:;?=R$U<U6M<1FD>,Q%@R*@((5)ERPC!#(JT8%$0%SF/K)P\0\0F7M,-Z280
M9P&J UW[1C9&T!4!2S..$,PR(J$KB@3FF52-C/.HP#EEE!;+IF_OURVNM_,"
M>$K8&,;7_*%<JQ;T@+0!ZM/ ER4%S6@>0TH1A2C'TJK+$)$[BXAH1A#.@K2%
M[^W:, [#+W@=66/HWC9?MVEQ,]MG?"%AM\NT2_!KLP0;PG+/.9#VM\.8".AI
M?QDD->ON8B+TZ=YB]([=SL)XN?RMO=_=J*RF^JFJ5:C2Z^<O*M>)2V$.AE$2
MH%RD*8(LRA/5/"& !4YCF(=)EN.,8HR0R19C177BO6;/!^@SH@H>[EDQ6_)V
M4 ZO_<D LG34CV/CV>IT$GS@FE&.U^@%^<-!'=A1F44O. G>*0BWE]ULT&/3
M5KF[ESD*<XR#&(8\4#%1\CQ)2"@/E20J* L)"C*KU.IS$E/'!9P4FZ>2I-T^
M?P$5L]W]-EGMEO/)B;$I[>IO'[\NBJ?=^P*!6??LZP*>[M0#3]J')G9)Q_?X
M1R]N]5!_[/WZZXYL2E;B6GZ^%#B*"E3DTOQF:5.YNHA) EE2Y&&11#%%B5E,
MM#UQH^_N33'1TN(I&9>&^:;< %:*;ANJ!-CT&#$/P;-$=WA53X38;24,5.V"
MHX#G R_R1_!U#MC, QBG@\\MCM$KC%8AC6Y(#$0V6@XX6X"CFZ#].$?'$7Q8
M0!V]YX]2T)UD8KU=HB0G>1@GD!9A"!''#!(6QBH9%R><145!K)H'C%*<V#Z2
MA&!+:9]Z\GR+@70)-!=[Z48H;C2?]M07X$!_*GMJ0-1)S*M+]%[0VAH0?]CX
M&GK1L12+:Y/>CSL5;-V6F]_<?<?E2I6B>%?5O\MWMTO,0A9F*(-I6!3J7H[#
M(BIB&!0918PD-"_RY7=>D\JX*LM$K-HLLC[#QFNM[9"-.\*Z#YK8;55)V0?%
M@4-/^\GGSTR#_0QS8J?X/+0^;WC7C6*:F;T[FEDM@,<R+!-#[*L>RU1LSEN8
M96*PSRJT3$W/5P!_^^,GLBH?-(_M![K1ZI)RD041%S#/,P814LH^IU+W)Y&(
M,T&C/$-VJ<N6'$Q^5N^(@2=)[=;0^F$PS33O% !Y#(#O?CMPL_^LZ8(\93"[
M$1*3Q:</4W_AD',C:,:CR,V&<0P,[PI/M9&<:]8[!K<Y2NS3^@M7%G!33T::
MPW7WZVOE3=OW9;_G]-NZ_->.;S[L(Q-9&(59E"1R,G$*48Q#:9J*%&9A4"0<
M(9SSPBJ"?&*&)SX0]\K)];M5OE\_[=H* WOFP(&[&V)%)Y]@,PWZ,TV;G<J=
M<L;LP]]G@M%7G/S4[,X;4#\3^&>1]W/1M;]A>KW;R%$VFSOZKUW9E#)L2MD^
MR#4B?U)7+DTYVWVKJM:P7O(@Y82'!&8,$XAHGJJ.J3D,\BC!210E#.?FMTWN
MC$QNS7ZV[EYW ZKCMTP3(^6D8SN>0(^IKD:V8@L<\;7H=<MK69L%6_.KJ'DP
M=KN6ZJ'ZN(>QZ["HJA^1;C+P@7NPE0?=#:8ZE?%7/[=4MX,T<&-UP^"SW5[=
M#D#_)LO#:(ZQY7CS[=VJ^OO?.7N0U-K",X)%*,Z2$&*:%2KBKX"8LQ0R6DC=
M3G,4%-@JJ/P2E8F-=443"$D4?)-4;7-%+N-B9B[?+*V=_M6"*GJ@)3A>D<@^
M6'=()%]1NA=IS!N>.R3F65SNX,.N[D2R_:ILOZ;6:\]9^16O^!>.5^5_2Q.F
MVFR6419@2K(,!H@+B%"$81&F%(HP(32G*,E"8NM)-"4^N=GU>RVI@+HE"5;R
M-]L5; &EJ1_1*SR.+D2R!0<F%H<+%2BJ&BI&%J!C!2A>?'H/;>7WYC@T)CRS
MS] 6D'-WH?4(CJFAE;0 I<6@1F_WLIA3GA>Q@%%$$HC2()/ZH^"0!)BE*"\X
MP5;1*N<D)M[@-4'04K3,!#V'PTP'W":DW5H_DF^"/?VZ++[2.L\)S)O*>57
ML_3-ZT_ZNA;\RNOO)6TCYY.$Q3FBL,@*#%%"53\>7D"2%@&*61*DH54F]B"U
MB5=A2\DA>'X8(]>[/4?)?=SD=5#XC:\W$G&R*[H^K1>^D+L@]OCUVZ67W);T
MY[JBG+/-.\GJ^\UFIS)$/^E]^I-H.H0OY?89Q8APN:2YW%)9AF#.L;3+DPA%
M:4@S0JRZ:XV3G'AQ=T15!(_$JESC^KF-OK);ZP;@F2UXOY#8K?J.-E#?5G#
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M;':/3]HE]*<J.(M75$>!KA_.JCE^P5O^2?1+TG8>IR4KXCB+<@9Y'G.(1!Q
M7.0$QIR2*"HPR8KXME ?+WQ.?:*1A-6-$^U7D"Y;VK=&"?F9*&-[ZJ7AMS;
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M6I.#L=?<UO8'+L?DGY[T?=[ZX8-*#MB?)%JWKRIP]Y\<U^_*[WR9)1G.:%+
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M78>JDN?P\%2@+(ER&-."0I3E&21I(N&A7%IL,4,)MRI<?CLXSNU35IZA,3/
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M/U0Y ]XRM>1".1BS&$8)SU2?G@AB3 @LPA1G*$4)-0MU-*0W^9%<OK369MU
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MZ<(?>M2E)F8O^:[U1$5%1'D<QY"QC$$4RX5(8LI@DJ2$Q7D>8V)DS%X9?_(
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M*'S(;Z<5G$2W5@!C<GE:[5?)S+JTQX0]7<>CS[LMVK9%I.X0^4'-D.I,I8Z
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M;@FW[LLE9ED1)SF#82I4]UM"8<XS>;(.(L:S!(4XM+KLMZ ]L:94^4CJ^OM
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MM62$J)@[<6OY*C*R8_GV("O9)(2[]Y_VPM7.M4R!EINO.>QCW6GULDFG-QH
MHT+8KM;7@!"P\[67&I-WQ[X&K%,=M*\:SSVZ^U;OMPR-_[-L7-^'DK)R;N@X
M6+VJ*%_-,A*G2D0<1C%#$"D50:JWBQ CGM%8\D0HJW1[&V%C^QU39VL??[P(
MS>40;4B#7;<I&\GMM@3\LA7^-_#71KY#-/8B&O8QV)"H^$5>KT7'*=QJ:^Y
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M8&9QSB$B6029I!R*N,!ZMA&.[)JJ.<@<>0+&OVJ!X*F5"&1Y_["")G$$&)U
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MX80:8@H,&<\8S"E''),4)\B*QO@Z-49VHRTO.N]K!<I&+?#+7"OVMQNPHC^
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ME"LP7]:U1T+7><#L9GXH&-PF_4:"J<Z2Y;-9CF[ FQ8(4^VQZ7D'?ODBGS7
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M@1R(IQ*3>IGK@#IT15>.YD&+-I_?+43Y7(HUG6\60EMRM!//CNP^M$C0D^G
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MH^/?@OJY &"%\WK7*#.U#PP W F/&&+4*Y@B/RX76TK4]K#4!0MGBG"51UC
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MR*]7:O3;\TXDF.]DNNT> @!OY\XF M/+Q6V$O)@67B<W%JTRX7Q7.#0"^;,
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M&$/E.R@,HRB.2<Y1*JQHJ WE3EV@L]="M^;+IL"C%@R*X]H=.T]BBJN9+YD
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M0E/ +#$7H7*1!&8Q53XR1@SF:<A@RJ($94FJXA>CT]@+]Y_Z:+:59I?N.<;
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M?*;,RE4(+B=3KE_JYB9>E8(7V[>$U>4?-S^+:DE2*4-$"4QPK&(./7$TS[F
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MM>,- 85N-_JF--J5^^WT9K\!7VE5W5_6%Y!U252XX#4R[=")G"IE<&S2) F
MO9!GW,X?&SJ\.3_YM/THZIL?I.1?OMW]N7XH]&'U%_%S^U+I]]^F ZDOWF#B
MY5K+!5^*;_IK^.?[C[>]$@SSF=27S1]>>=XLMUMX0T:#KUH!4&O@:4;U50N=
M)E5?ONML\ZJO&M:?6GW]PVXOTP-W0Y_=H4?R\?+QA-ZAUN7-SX>BR=&J=WNQ
MX4M$DTQ*$4/-P A1E#!(*),01Y)+G""!$JL#!V^:3>P##N)T'*WDV;US_3T
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M2.J*\[ ?G!HVMXU4IQ!H-*H9P[5.X*E2"] 'M5%,?W9Z4,T/IF< UY$R]%Z
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M:JX^69.9U_Z]'JI_1*>()<&6LX_-XKU%/&=90]T5\FDMB>J,>'#@09^V'\-
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M.G=0-FSO*H?5A+V@7&D[F?:(CIMZ[.]OI_7-S_5##WR[Q(O%2"D;9+6 3-@
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MJWIAS0H$3O_P4A6IG15L;^Q=PB*N5'ZUSGI7X62YN/Z=V^WU""G'FHGKSW[
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M@2G]R/?:4TP)%0S3]1XOU=C0>+*9B5-LB"XKD4A>[1O@W*[?;Y:H/4Z.ENT
M<+&Z<K@CDI$VRJZNMXQDM:,=(UZ01[*0RF%4*GK1R<W0'2KZ3>*TQ\B)<AX
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M@Z_MG(0(NC[[*R#)7(*2SH,S+D",UB)7SIGMAV\MP3:HV^YNM/\PQ$Y1Q0!
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M4]+OBX;!P;"!N@9@$5>/U>H=-TEN+<E?OU7SCB,GI!5,9RB&&9)(9."<$U5
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MW/N[JZZ3(^&$\*8@.!?JX 9.?H&(%K D;=!Y,MO-+XH?I:K?1U5#.#Z/5](
MCL^--/KMM(9W97,K"<S%<\^!JTAV&XT&5UP&CIFA8]H'T=QK>Y2J?A])]63K
M&BEI</9N@[_5_<T..8XL!4.>.]I-Y)_6GJ4.HC!8JS.3EH(EU?S)WA-)['>X
M2X^6L+7Z!F 6#Y?FB*2$*)6%(BT9?$FVWG-9F_@(+U+VK+UY/)RZGJ>N/#,H
M.]+: &[??BT%TY*<C&]D^Z?G^('L\+MI9;;^?W4]OI(30GOP Y(<QXFL]*I^
MLDY=VOR-C9\<"4-N2JQ1F*\NLK2NMOI!0%0)&1:1>>NZ[ [8Z#=]T]G]7=\*
M'X -/HG9W8-K;H8T;(IU+>H1"]$Q3 DBADS220I\] :BX2$F3Q)J;L>?E\-^
MLU"=[90!PV0 !\=I%B,)I5-Q$I"CK2V0,H3" C!M7"["%FY:]['J_C#H+ ,V
M3(@_28DG#IDA"<R7 \"MD$5YGPOH^AY>Z3H@+U'PH;00PFIK8F[]SJ=[W':6
M1!LH;I^BQ*%, +O\\F6R$F687(OR[;3,YA=K95X+-6G&<S$";-V-BCD+P6L%
MW!N)/,E@2^NN6 >2UF]>K3,D=J&8'EWDB[P<;;1P#=-\,[ QC/,--\8YQI 5
M<#'1OF'2D>M?+#@;;<@B&;E=LGYO8,UA*_4\-*0+Y<XZD_0 0JL-CBH;M3&"
M9S88C;(6Q-?Q%?4=>K8),LO)9]IWV/P1SGTJ^L%1%SJ^WZ'B%($/ C*W(JGD
M\Z)%]BS7=J@%E*KW7"YZ2$1_1.Y3\JW#Y2T2^JE$?!:P'"_JP4Y3^WAY<1'F
MWV?EX_A\.B[C5%_4KAL'K89F3L:IYJOOL''02+4#/]QFKMHQ7#0:KG9_F1NP
M<4R9.T;'&0L)5#'D*2L,D*//)J,S/K5^:/$P-2?[T/LD^XF$^<ND7GC*1&&K
M2AJ"(G:5J=V9D:RI$0)E9+HP[5J[T =1UO,\EC8HN><_MU?*8"W5!_R*TTL\
MPA1=_\TVMF8G'8V,R=6WZ^WMJSJ7F/#QM_'R\ZO+Q9).MOD-9EBT17I9&[9Y
MPDQ"!;$H!.D=4YZCC:ZU5W@@::?7C>Y=YA;3KA2+7-3>M9%B3V,4A&#(3[,Z
M4SCAE.6M'9U#:>O7U'2!H?O%I!UH:;"69]4 8C%>O:U_/5Y\F5W]-SF9;R[K
MKO] "X5:_C/-KTDRD]FJ&<G9?%XO*=9="IYNM5JLVL;B->>_D;6\[DST:G81
MQ]-P/5&LMN[?(/D&\)A=5CY&L+6'ND+!P=>1.LB4+-;FS)I;C*=1>*KM_!WG
MY[05-M5%JVUJC/X[36:+R_FF=R"\9SJ%  [K140=#1V"0\A.<LM0")=;/[@\
MCM)^[6J':-LVK\^@R,$:V]7%PV5:/Q^]'DYRC,^WXS.M',#'*&SF#6XLM+J3
MF=0ZSQW5628%+J,+8$5]FN8Y';."7/T<,&C/G!?-BR0.)NYTC_"1A6[WPNU6
MX,AC0,4A\\AJW2UMA104^.PS_4(DT;PM_S%T]NTI=H&O^[YBQ_H;K"F[*G ,
MD[?3*H)C'<&=GVECRAZGL)$IVVA(=0LJ+*Q8'J"H1,>5<AZ<B0H*,SH;[^D$
M;5T-L(.,4\W3+A'N0C3M'.D2@=F*S$'Q6FF=6( LT(1$@1#CK;VL TGK>T;(
M:<C8-C==Z&/H%H;LZFFQYN[O-+4Q^VAL9&3J<]9;5=^@*5OF.7G;$&)M@!<$
M(P=92,BZ"%=+5Z1JW7]]-R6G#_K=_.H&E*-TSG(#3J.H;]LTQ! #)&D$1O1>
MR]85XP^0TJ\I::#_^X-Y3Q?Y8*W':YR/O])GOJ[N2U]=$F'3]/VFN':\^/OO
M81K6._8(H_*DS[>Q-<=SU,P$71.P<?R0T_N?F,_OO'39@5/-/ 9/(.**D<^K
MC("@;81ZX(7();.N]5.Z$\@]W9@]>>G;[1<L&F8P@ZE#B97E&2+G=)8KE81G
MP0DQ %$-QBP^#R;OV\YGTO!@#>SF7+2GV\][4]5.-H\/TM,PRJO?_[X#24&C
MU-%+X-%G()>>SN,B4QTDY*QF+BG9.O[90\[I95?W/GV+71^8*6@\F( :5+1(
MFX8)2(:;&+Q+@L7N61V(]6F%B?O56(TT,%CK\9?9+/\YGDS(D[EJG[PD+V9<
M1[G52X=C3,JCGVQC9YY&>2/C<[WHV:KT[\YZ.Z#G>2Z*:0=,*@3E?0#GLH%@
M"I<R!0)"ZR=43R+P5 -UT&(;%4*V6!.3@M54 XJ1"D0AD4Y?#*@<%OJ=/L0Q
M$"/6';:VS5J'>ANLH;LSSB5L3KEYNH5[^%MM3-N!M#:R:0\.NKE-;J!Q2D8#
MA85:RI/JX$2.P&QFPOKL>/,G2X\2U: 'S>X%=NV J++F7%)<$E,=094EN!@2
MN* R]]*4)%HGOYY"7[]VJRU^=C2;Z49/@[54'S^3V#_/)J2UQ56?M:>;J!T?
M:50%_PAUC8S2JK/5G67JC/6->N8L2+%T)-5K8D*4@V"E AU8"DX[0R=3ZPKP
MO12=7/F^\^N[,.Z$SU%S"88"&E#%:@@\:TB*]I1,D4G6^D;S8.)Z?@O8#C/W
M:N [4<]P35!E]_U5LSER0,[^#/-<+?!1CW0>_E@CDW0@M:W2[S=:7[7A^X+3
MQ8KJJYJ35[/%<K&RDI'(R=<-TF[S$=:3/\TS2&01%+<6?&82;++6>I,C4ZSQ
M_CV-XI.3\(>N_LOFZK<[2B?4J(("IT6]1*^-Y.K8G,Q+9LZ&PE7KUSXGDMQS
M*O[Y\'DO&_^,JAZL\=QX(7I40O[V;[=*R#] 3[.$_-7W=V0I7/1!L^S ,56?
MW4M+JLT%;,!2$@]1B-9MB_>0T^SI_*Z#/W$>C/$(*IM$[H5AX!4%.2(I)#9%
M2J&S1_2#<\5:8>+!M_2G:F"PUN/7,)^.I^>U.]G*4AYA0NY]HHT=V4]9(V.R
MO<AM P_O!/TX!YZE!.69AY@T HM&FF -Q??-.U8^0,O)#3VWOKMQI:2$DLD6
MX(G7=EU9@D^R ./2,5UD-LVK51\DIE\#T@0']QIK-A'\8$W'!UR.YZNRHU]P
MBF6\/#9B>^!#K5ZV/$YE(V.RZ8*N'@5<K[SC5%(I"I^X!X;,T>&A#+CZ7+5(
M:PWFH'1I?9_^!/).SG;3.NM55G>E[\D1GV_K87<%LQ:(4D301#THX31$FSED
MR5EDAB//K2?I'$MKOP:K*ZS=RX<_AR8':^)^JRU:CS%I5W^QC0G;144CD[7^
M]&TPG@.7GE$LK!F=2UHQ"*PXB,7PP#+]2[6^>;M+P:F&IP[C1'SW!>>AM@U9
M?_P6E,9H$Z0@EUUB(;^]"*#PH(!D7DH")0NY]9O"_13U:T1.T/ZVG6@H^,%:
M@[.4+B\N5ZFEE3&L-GB.GZN%_(J_S1;'=41X[)NM^AT\B?96X=7J[N+V#50)
MB;FH*0 W=! 5;R#XF*!H(U*TZ.AD:!UOW*'@Y%;!FU);)P?JQ<S&<_6,*>82
M(#K-Z-1+&9S@ 83)0;H0M6I^<_\833T'5L<CX%Z+WY;"'ZR1J9.6QNNW@_6Y
MQVS5_@JG1W:LV_>U-H;E8'K;!5G7ZYUMK;?#]66<Z^PC1=;*TI'F+87O/"50
M1HN2,$G7OCOW4P@\V=^9U>8=UTMLU TO1CK%E(Q)P(,GUEE"VG16U0PHFF)D
M=JGU>Y*'J>D]6.H(,_?<H#;Z&*QU^HCGJ^;'T_P7G)W/PY?/X[31__B8Z_I'
MOMCHSOXI=+>J*5JO^0&_S.85$+<YQ<0M"2!!\G18T2%H(;),9V+VA21C#8^M
M<S\/T7)R'='6=W=E D16CCOM@?/:G[9X.J!E4;7O1LXR."NQ>?'4XV3U7#O4
M AOWJH8:*V.X5N@R+O ?E_2M7[\>V1W@WB=:->W=1UDKP[*UR.9 N\ACG317
M&"DWBP!>*@=2Q(3<I1QLZSOAAV@Y?;S%W>]NME_,SF<N0/OZ/$ I#LXQ!)LQ
MFL1,E+;U+.P'B>E[&$$#'-P?7]%"\,,U'>DSYLL)OGW[7V%RN?H>.07_[V68
MC,OWU0O>5<OAHTS*H9]N9&J.XN1$$[28+T<WRYWM6NZV_I65H+(GD(1:'&\H
MU/<!(^2"@JF@+#,'/8ZE)3?V*/WJ=G\>3LVQYJBN<"WH=V7_6KN.6]HDH0C:
M>B'51YLE*W V1'!<F,(M-RX=9)$?$<())/9CPCK"T;4Q>TZU#=?4'31 H/-Q
M"+V,1>AK/$**(26A!4C):U=Z"O*C50Q(;%Y;$Z).K4.[[L8CO)I-%_3)O%+3
MZN/?-[H9NFA=8!YDUA&4E,1IY :B%TKK5+(6K<ND]]$SV%$(3T'$_8QW(P4,
M8*C/^_EX-E_/0/V :1(6B]7F76DH_^_+=;N\U[A(\_&7^ILC7ZQ)'LF)C4Z!
M"FCH!' "#'*)R5N>L'6+LZ?2V,]8H(Y!UZFB!@#$OR[()?AUL1Q?A"4N1CY+
M'[)D54H.5*HC2VT1D)UPK'CA>6@=3MZEX" 0R1<&HA.$/ "(O"&7,$S6>V!D
MBT63/4()=90Y%Y+LK/5UQ*VQ(1G-4^N#;G/]?H?.=P2/HP4\ '!<#9/=GNZ]
M=3HKJUT)V8+*5H 2-D'0!'LM'9H0C)6A]9RL@PCK=S)[5WY2<Y4, &>W383O
M>7X8%<6@EL@7'I37&1QJ#6A+\;X@I_]OC*T'B>EW#'I'>&HC^@%@Z-,\9+RN
MW;U.>)!7A[1'X@37W(U,9$&%)"&E.NV8Q6J ':_RJCU_5" 1-L;3083U.ZJ\
M(VRU5\D <';3N&Y[OYCH4DA9@7>\=L,C9APWM&F4RR99\@M5ZWK^AVCI=]QX
MAY;J9,$/ $ /MMVY9X"+92Y1G!DEYW22>P8>O0#/,0>K;?3LV7I#'0,P_\(
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M1D^EN=_>MJT-][-JL&?C?<OKPQO069NMUH(.'U^'NQH!L40-+,5@10DH63S
MX!ZP5+]];%L:R=9R'7JN<'K>I(ICW]>:9@L?I[=1NK"&P3M&)UO-HRX106-M
MY1^=@U#J@W*=%6% )CQLYML3,Q7MYVK? OWCY]E\^8D.^KK01KR%&%%[!BF$
M3"BWF38/V48>R,5-.A'0FU?[/T)3O\G!!HAX^,1JH(1!^5"5C<V\_FW-+E?)
M^R* ,5]GZ918^WX[$,1+]1<=;]_/[%&J^LW@=0JL)HH8%+2NHF]RYMZ5WV;3
M\YM=<_>45E$Y64ARR=?*3!TI)F=>@DDJ,!O)G>/=E7,=1F._^;M.8=>!DH8
MPLLO7R9CG*^=$7P_GYW/P\463Y$KQ9,50!N,;#9/ 1Q& =*9(+R*%/BV3MX=
M0E>_2;HNP-9:&8/UU3>:NH5IOGZ<^NNW6H1\CA_&B[__'J9A[1,?[<(?L4@;
MS_Y4[IHY_-=D;!R79]/\GYC/5\-TK^M3=L#89<*2$@90DH>FZN WSV( 8926
MSD>72ONHX&AR6WIY.XBXOL=Y._U(>%BI[5VY*?9XC_,RFU_4';OAYBKD3AL'
MM5L2*.$8>(D*LG/:II"X4*U+3ILST7=P\CSHW>=H/C\6AN 2[!?  XS?NS>_
MG3(BG$\Y%@KQ9'U5%.DP]+40+181LV9)YNZRR$U8Z#N8&N1&Z!0'@]H&3ZT^
M7Y6;;WMMA4DKZ\!,53.L+C-PW'*0)8521) F=Q>[-6"@[\"N[RWPW!@8P 9X
M5PJQ6I\;K7G>?B=JDI!&($3I:3M;#."33>!+T-%EEW-HW49Q/T5]AX/]0+2A
ME@:%N8WMM<423UIX<J" ,6)$Q6# &4["TS%:+D1TS9]F'$!6OU45_:.OC;X&
MF["X'MHX/N$UU?UOM$DW/$);P]<&J[&5.R"$7!51&R0F%VN90>80T!70]&O&
MBQ59=O'JX %RVGE^-XNL<SCW<[T^850" L^$[!PL^&@D((N>3O;$;8</H_;3
MUO^K@Q98>=@?:ZB9P=J<ZW%VX6J@RO8,NZ,-T8$?;F.=CN&BD<G:,P]P!S -
M6N-LK9#RV8"2-D*P)59'W?-HM."J]6Y^$H'MS-KULIL%0,6@9@ZP,"0?P,7:
M6(]1I&(#!>D^1-[\AN=A<OHU7MVAYF%S=II&!N"X;T3*X^EXB;^1*WI/?-OE
MM,RC43P NL2 /% +%)1(8+Z.'I,^)]%ZRLT19/:;_.L#C-UH<% @?4NG2SF8
M3:^S+O6BE4N*6Y35BER6% $%&I:U%\)VZ><]@=1^TW1]@+4[30X(L+-]>_+-
MY;**]6(V7X[_N=+U5>/Q+=Y-BBQD6_/O5I&\,U*<[PO8I%DTR9-CW-4]3 OZ
M^TWO/3^TGUWG@XV#WL]K8_WE]]H)>GGU6.?+294ACWVQ3>3S)+H;A3QWUCS;
M6/,&FX'E;#%E<,(&4$DGB,+1/W)0B06=8O-<S:-$G3P3]J$%-A+A+D<A8P'#
M>6W8[ 1X+3FHXD/(04C#6Q>T/$Y5OX%.6ZS<FP;;5B>#M4X?E\3*^\O:/W-1
MGQ*>_1GF>=6T_FCS].@GV]BGIU'>JBCMYK1\5S8;_V\V,5JUQHYU-,#[\/WN
M*RB?HE=%1Y"Y$&1X9.!<3$"$L8 E1]U\3.!I%+>+63;7KHO6EX W,Q2NEMU\
M2G0V67U]U>IW]["%%>F_K';HEM]0I_L%H224VCQ2F2 A>G2@F<Y)EUA8[B[B
M>49&>RYQ>[Z]\'  -518#2C\VF3T6B+55JX,Z'IBR6U[27+0+R_6O[?=.\9%
M'ZTC9]R) DKK M%8#TC1)Y=2<)3=%<*UX*#G.K@A[)9G!\) M\&F C:YOZHT
M^+[=6E4%XA<+:.$T*,OKI'9.GA[Y?Y:'8N\]W.X$^D^CNN>:MV'!O4.%OP"(
MKUINCA/)?<7[7Z=C$G7=^0^P[Z0O2A'[/ALDZ0L+(4<$XV,H7G,>.RS_;\)"
MS]5TPP5_EU 8PD[8R?3&NX;5#ZPY_NNJH00^Q+E-DA7#$4JV<CW*V2D607GM
MD)<L"V_=7:X=]3W7\_6(_WX ,-C\SLV<Z9,J_[:_T:KR;R]MS2K_KE;9<=/!
M)5>Z=G*(-I**LW<0B]0@92)7-A09<OO*OP?):7E!7!?Y!0GT>+L@_6NQ'*>S
M:;X:J[H-^)RKOZ,ANU!]'5U[Y6D.S.@L19$\-R\A.I'DONL$VR!KW_5PUWH<
MPIE])YDSF]:SX)IU8O?J:O 7G&(9;U=*&I83"5> EH98#1(A&"L@9UXB-T5S
MV?R0/I[<OAL3=PW7;O4W**B^OB* &-SUINI^02^Y-+G440DD7N]C;:O!0 =4
M.82BK?(=/B)] JE]MS#N&J+=Z6U0\/RU%$SK!S57$OU GO?>9HLDWJ*UE" #
M3Z!2<>!DTF!T-+8@_9_N+NA_.KU]]SCN&J@=:W!0:*U-[-/L?%K;V!.C5T?%
MXL-L,B$/IX9JVREH*W,2%!PR']+5U;O'0@AC7ODBF>_PV'\JM7UW+.X:J9UJ
M;P@XO;RX"//O=UR:<'$U,VZC@1NB9+0^'18AV*O61E%%VGY>"_+((V\^W/-
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MW%1@?6+RB.-Z=3[I:&;NT)<,F'5M-> \>"%K35Y05L@L5/-AM2-M91"V[<^
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M$YS2)D2H/0!JUSCRC$()Y&&S4I@KV;K6-9Y/D#.M;SHMN Z12*?@DE?GQ*:
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M,>>T^HT8NNDW/$_;D_[CJ53<DRB4M,5+D#S'NDU+5U_T$)V1T3*9E6[=8?=
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M[A IVU,4B!LZF011!#I%)4APW&<H)5L5(D/;_,'U<4JF53+'2_@9R!S [@Y
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M-N@;33H36]Z/[>M#GI^NOWXLVV8@B_F)4C)@X;%VM;*@8J;+/Z $C%Q%YKW
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M=LV2>10*6 H?O2&6O*C%U;6D) J2&SJA@^!&"+/+-,P=/]=5 W!KX#22<D_
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MST*)OPN@FR%AYP+H(6KI %]/E^,&[00G 0#3==X,]P9\40Y,?12("3VZUI.
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MTXZ#-@%!%:\A1.D@T>]&(YF(S9\V3W=7\2#][[&K>(@R.L#74^MS#9K$@Y2
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MP=5$Y0]AU$S^/8#IBO9-EZQ(AC,7*=)@A8.*)D$L=/\+E^I\$2N]3ZW!<Y>
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MWBU?+SX3S9]POJ*_</6;;VK5YZK^]V_FEY\W5\29CE;9Q#TDYNAF\(4T$7,
MSW4*J21>7.M,V^A,]5&7/3K:)T! !R;QZO-B>3'[OS7MCP^ ,ZEBE"QR2'74
MGDI*@4M> *98=%3:^MCZ9?%YBG8"HSD-,#:4_<0/3Z]2PO-J 9A?8,IC1!V,
M@B"(,\5" 1^D!&FYXXY5OEYJ$ACTP9WP8OO&RW@2;@:;H\_)#,OEM]KBMQZ_
M3W^+Y'/Y^?+\H7P6C^0SXD#-@VDZTN3-MK*;I/T%4Q;&% &^J#K(IG Z&X,'
M[;VV)D;-Y6B=VL=M?[GCECS\[%5BUN1H@Y"\CO#2=1D/DJ_A;1V.*U,B]#K5
MNN-@=^KZ2$RVQ]3V)IFF^NK 07R&GQ^^_1K^9[%</SFM'S@QQ\(\Q7_,"T'\
M*0ZQ\ @9G>3"9AX?CN$[&(H#R.NE@Z4M0A;'45??2+QE[$[),7'ABS 1)'J2
M);( H59O:2^Q6)(MSZV32@-)G!:1HT%E=T@>K+<.8/GZ<G6QH/#_/:X]J$<L
M;HK5I=%9N 3K64R*<P\^<0G%:AEKJB#GU@_+.Q'6+00/A\9B;#U-''1?#SS)
M'S!]FB_.%Q^_D:/S&S$WOV$G!).<4Q*8O'HU=75X08'H2D")T7H;7@A[=OS4
MM(^"QP#2&#+OX/SZL P9/X?E?U;$R?I?JIRNF;$Z$?"5 5'W?2I#(O,A2O*1
M?7'968;8.M!ZEJ!I7P*/>5ZUTTL'('LR$;%A!85)$7D!Y[BK,TH]N&(+%)6-
M0"U3QM9O)L^0,^W;WC$!UDHG'<#K]J%R-W>6*4_,:0D!?5B7$$%@]*]*%&.-
M<[9]^F@@B;WTWXT:K(ZIMOY1^:1!T^E=N(D%@J'#77E&1SJW#$H][6TR2H;V
M\T,&DSGU"(4183,,H@?KL N8;K8]UD5\1,DG\C=^Q*]XOOA2W\"O1\<K44."
M#(E93X&1X.1KE A.A&RDR)&;]@ON=B"L:R@>#H]'<&RMJPX ^,P=<_MPJ@+R
M$'0 DTSMX_42HF0U64_VJTJ.OAPQM_S+H&+](S2R3954WD]!?8/NG\OU!,_
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M%OF*KS.2D[&92;"&%5"I> B\OJ\4B<IPU%*V?TM_B:K=('5".>;&BIC8$7K
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MT]AZ/'8SXJ<MESHB9I]I13BB^COP%NJ)5!>]7PVA8M$%EQ%0.8K+8JIM';:
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MSM@EO3OSV$<E+PNI"$9!GRL6*?SCF<*_H("<9Z:YI*",M4[V35S)N^^!L&E
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M-GYZ6 4K+/&,&FQ)&I35 KQADB1NE$:;C%.\L4&\2-1.N';=X;I-[K^MRCK
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MC-]6YC,^F/X:IK890QDQJUQD ,1"@F&D0X].@/$"$P_19=E-.=M0YD[4P(Z
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M7:ZNWH'K[>]J_I5T_8KK&7<*)=;B3^TX*(H8P&NV+;*26(KA:.,A$!LJR'X
M/.^GH--[K)\YFP\?:BN=W0R=X2[R %''RN!N#*5).D.)3"46R91\K!:;[R79
M#W_G_2K4T!<]IJS_MEJNUS.D4Y[+',&40LE0M RBY0YDU)EV]6)M'OUN>RO)
M?HAZI>\RPWW10<7W RT>6FN&WI,YT$%2CE&N;14XX<A*C-=\J?#@QFHV>$:L
M_;#V2A]$CO12%V-O'[/@+)H28[0"4-6W>!G(2EXZB,DYZ[+(C+7F(7E,COW
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MYWH%\/-B<_6>4$_U%+WT0A80U@900F5PGN)#M#+'$IUT;*^XF3[D#HCH;[<
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M%FEEL<J9'#E0,,*,$ZS.PSDE$/L+X(X&PA"8'>"5#H!&4N-Z,T]5H=V.+81
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M,-9Q3I6/*19)\J;:&)KH.RKD*/:BU:#?>@<D]+=;@'SW@>?$&G1(U'NX=7N
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MYS0.X:_L=<(1FK%NB 8#I0(7_K&!:BFOI[+=Y;-66#GBTNNW*B5F2$A&ERO
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M[VV K$!G+_SB\;)?_"2&3N.XX!-W,YJ,4F%**OU<K?F*$2LM0Q(8H^.J,*5
M:D.!0!)+IC1D-O?+H-TXJR)[/IPF#@!/%4KW4FR+?'(2UK)I] I:;8VE,4#'
M:6(,%E%BV 9@L=-*Q=59GKOG;0]+563MAU2S?(!4H%^/>:"G=\RNG$,$0J8
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M+$<@!,VI%-3B["6<FSFI8MC $6J24<X5:$NG:V?!B=(F'FTJB'3W;%P4F V
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MEWQ6OT]5#'SO&N,M:&,YB'>);?9QL$\&Z@$,7Z8YH["P$I7*X[D#R4>UPS;
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MTF,/IUQGMNYGF87*,DAJK.AW,K1!3F!^H J@I1)Q'07$J)!:%=5$>;W3(:4
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M=1DKVU2)0"(A+.M,A:U<\T:9>N/I64T5IX_0KH5D)F!K4S'.&FDL9AZJ74#
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MJ-Q)7'S#//(OSIS?J=Z?2RU,(F+_[TQ=L4.E\^I)M[Z!/^TN^+/7D^9;>?'
MM_+DP_;FZQ<OMEZS?C9Q5\79Q6CP[=Q_%+$#+GG""5#M/WNZ\V;W@(VU2LK8
M&I8 .U8R*34W+.KU>W@9+V62I*S8GI/N;,&137B/X:7L9-Z(C"+C(ZW*XCD;
MRACQ(-Z'C%]S#10 )W,N8TB8VX'[:V+G$*?2??C4[;O943XYQHOY")RA=<?0
M1$KYZ@HT#\,6C=3^D.T)E;MQ.U"ZP(MTX*[A2FDI2)C-0L>:7]EV+G9F%.+A
M>B&%/RD[<9>>J)P&7_4%L55\J+TI00&DMNZ%;H!><A.7&=?L0$[=L]P_RBFK
MM_G/V;_MQ_I1O@8Z_HRO\KXX82.15W,97M;T)NO2*A:5MM1PU[&!ES(=O\8<
M9+FTL^I]$>+!2VACM,>M-6R$^1B!&LW@MD C=0_L-8!T0.=@;&4^F:E64+"]
MWB5BQ&=@4] 9EPF%@Z$]H8QU1G+MH1(S9SB?/GNZ_7)[-P69").)&>M+)47.
M(J%G8 5>\N>E$TC!Q;RGV"]<L;4HY7*:<K'>>K'V82YB<-OA'G*'UB 5DL)V
M>,!U(M10FBJ4_=:!45BID4AUC#,W4P,;IR(31>&>@-X0ZTBE03B'S"_2!J11
MVB"?G8=&<Z#@VQ@,AFSH## Y*?UQ_LQ/SK\YD^M8W.1@,]"MNS)87UB$#KS5
M=9.JD@W2LOI1I*7P\W4YX59I=LHEGT*5HN8,L>?(QSH92ZS%?N)^2$1K<T>6
M%WZD!]:(='99^]&]A#V44LVKB/' &Y%.H>-RY-9I[&8WI5V5RD''_B1YE?#H
M[F>WS:I,LKNGZ;BT>YTT&#LA?C(.QXL(X<Y%(D"RM6H9NNOD-"MOV"*LQ8AT
MMM@[[NWNCDJ:,K-5\%> CD;G$GH_2<&(N7=O^Z1LSB*=X<7K-9)PF;1XC_#"
MC*Z%O:E/GDDAU5,W+[MI"GFV::N3$MPZ[)@=J\S+",%>6*1V &LQF0"7P?.!
M1FH+=ZF970ZKW+6 %X/4%N^!+W[@3&34D_*GTA@2&8DMUCJUJUUSL4_,;D,O
M(7:74UI*E*OB#AW#J@X3P(MY#W1>/I3!]F@5N.;E+U_UMM^XCRB4$54Y)^VF
M>BOF<*^FZO*%37FTS=5+^,2HK+3W7_+_*,-:_YGJ%9<I;$PT\-D&O[*@W_'L
MFB_,D[^@+&RH.O<'5)U#-O[N3#Q1[]G3[>T7NSW=RQ O+J/R"^035>HII;7E
M&'AFT]A;_D/IIB)9!2SX@C.:>V%=UWIPHN/1V?*OK0KDAB/%+5]K+]X>UWYS
MWU2[#+P12+W/.ZS7B"G?'LQK%]'Z"GS_.6[_#L51?9OWH;-.O,,']_%9&-E9
MF,11H_9^*9G@]^0U0DFQK?+9.MY:BYDOF>2].WCK2AD^RC 0QB'T+N'(K4E5
M"/$G,,!UG ;.*(2VG'_F!?Y0EDHD):I9%N.E27$#/!H'G@BDMCQ/N2RO>&S+
MJDCKD0:I)G<2T% ))U-]>46XR;UJFY/<SL[IT!_U1KT!XM67W&GB&'2)W#GI
M)9)"&@I-82>LQ9Q;P.^-C-PU\T+1LK?&=H&?;+\T5OL<4$ID(YY!2+/"(G6%
M]5H8T\9EX6[U1C0/]N*DY8O:J4RN.\G*:X5]Q25XLGNARVG)%\CWMXU*4F C
M,AET% VJ2Y"^713V0LJ/9LVA([O/Y\*PJ@4V.X)X5E<F(.# &/"%>P\V-%1:
MENP+/@$+VKU?4F\30D<:1&KWQ5187L?:@";@IR*W(3HHQ!=V[FYI7D#IKBH8
M6'BD'LQW DTT4@^%-I:-^!5?@+40ZGBA ^P^!KB$57WZO'"&AC5XZ9*)O3E4
M[EI\4[\OK&\,6,.&P\I21ES>FI:IW"'<Z2L1$"-2VT'<)A\$P(C4=@!?1'WT
M_0<&[AJNE)8DHC*.!N$, 2%54&XBYFS,XQF?.@&AP@(6J4=B[I/]\@9K&+)(
MI-[B&DX+$*F]31;W82Z9=-S;4"\%6,ES"I4&&ZD4$&M>I+ZCGGNF=JK8VA[7
M$YXHLXX=\E)H*&4<2AF'4L9_P0 \WOL'=MO^Q(>WQ3,*$9O'P+7][/8QV)D2
MVJ^U3.\4P M^%AQ2A\=14V2<1:#K;JP'TX43@)IP)9$HWA%,N%0^01%S0\Y&
M)5'&8SX3QG+)UIKT\77\T9M+S4201WR:B1D[%C<YV,R]C]^LL^A\B)?P>:EG
M0,&2'LI$<!\)9K62(J93 Z(23@*PA:GF/MI\.75[7Y"SK0T;I"+#7D.\TDB<
M\YV*XG5!<<PF&:UR A5> [%E!V?GP2."1NI0^J4X=A-T@7J*'EJ>T;"U:I[G
M$*?2?>9TP0;@QVXH[H)([0F74ZZ56E83&*@P):.1>@(RX5G&$I\]\T7$CJTW
MG_WO ]011K5:6H0O0<)-Z6[NYPXNY@6X%4J(+^Y=[YA+GI/ .3H>H$^@H+3
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M,6FJ!]SM?OD!MQ\JR03=FAU?2,C"PXS9S=8G_H_EA@I]J%DKF1;HRAH1G)V
M!C.#!+)<> L,,6B"!MAPXF;KG9U='WB&W/<1%5S0ZCAV/_)[;6@TAVP==_>:
M6B0QU!:FFOL3QV/@F4U9Y /@''KDG;EI^KT\;BVKH>W[C>'.H299D^@6X=9/
M$H8R%JV/@#Z'.)7N&J:+<&"!2.MCM#4/9U/(M'X=-8V9/*S8+>^Q!>Q=Z'P
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MB.2,[4%\2C(^*F"/CP?8YY&,-W%],*-MP?MP+CP8Y;@RIE(0>+DSFA/I<X?
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MX9+K1C-AUM'O+>S/+ -*S HB5+SYE8:[#U>BTC,@TB+1^#"2VILJJQ>@-:&
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MCJDE[.;B*--#8)SWN[/RD/=S^H7_A+_M7Y++3@R;?;,YM3W-4G)L2.ZH2?2
MZU%SVGV>>X36(2L#0?,#.$NZ3@)344L3S>&;9E (;KPPCMZGX:"RQA[1H9#*
M6W_CKORU^ O_DH02&T)Q*1@=A-%@I+E_&,;CZ8>C'7\M'BU5=:T;[^A])D0(
M'>M-$4QMV@E/6YI^_0$=,P(8L2P4Z1B#?M:A9G)1^(VD?H-VW*X)WZ,0.]*A
MMX 8:1@79?/YXT9>Z]P-H[PY> ]G3AO26'> O)F@N!,<:L1C-NI&@1/I"Y$^
M/]\5C?V>RLBV;'A'5G>_6.)0CG=7L3#YI01& $)8&C-NQ!EM*-/#ZRI"L%E
MF S++C/5&(5CTE$E*( Y-J=,D,%;9PD+Y,R$VLQP\HD#0YXZ -+@X$W)17/N
M2$0&38MD6G?>Y)\UJ9SD1'R$+JA)]!T702C,YK%HM$E#8X+5WC$U+6]T/,Q1
M287$94XMXY0\%SK4;K!I]*9^N<(B?@(L^N<+ ITYN\XX-\4KPZ6'J&96@&CW
M@#N4LW5;6&9I1(>) K#6T:AK(S_,V9"Z(7"AHJN7V!^ IL.3(]4651)0BL7#
M-JSGN&H5O@#?BH\>@K@[QFA'7.L]?RR1-+.X?BD-(D-Q4_--Q6O>S=V6R%I/
M,_ (_R-2K@^>JQWW7.UEEKS3I5)/J>A57DA0\22 #6P!Y;=AE!S+!+56NV6?
M>%]"A[_BIT/(!)L*!",E84S)GQR*.AT"'YM""A:>X4![!L<A^:(IAST8/VW&
MR?.R,7F3?5A'4\XY\F_5[  &8F,Q(P"0KLK$:Q$,(#XLJ<0N/<6;GC?X^"9W
M]K-W0EVCI-*/C&[DI**!/CJAN!?DNK5OKW<(L3#]?,WP,O-7[!EL%?OZ J7$
M.Q(_N$*YQART$T S);5-0>GAJ#V^YQ;Q?YQ-H@I.!(+?)E[&KQ##JKSMYF8B
MKW'/XF_%CF9*1 K5\$ 6)/*Y;+KN1%SX5F:+XSL5N[DM31DESV?9VYFE) @X
ME:WVHM\8TO;2)+IEENCNS689L<P;3FPR^^!%TD+=7_6*B@DM*PY>U8UB*3ID
M8?<.K*P"PK@F2XISBJAHL\)7(QB&L8B\U;;V,P'9T2_FS=:]EA*X#;I<L.2"
M#N\\$^#0Y9=4S<55"/(2.L+2+P@+WXU[>D^C?3N'V(ZL[9XF>R%_":Z!__ \
M.WB$+CUAB%!98W3.,LI*F,E?$RS_.>XK8N?KM1[TM6URL\9WI!22+#9<M6/.
M"=C/I7"8Y3GX\&!-M;\#I[O!VP:B+<?<8"4IE'US$6,OQ,ND"!P!CB7-+,S#
M=L]( A'%\EO,">OOR4:_6S_T7EOS7(ZA\$YFNT%CXT! ETKJGD'7.Z+*+$+,
M0_*C![R?GS:4!>HE+-H!,Q)6NI):A5+"RHJI.LBVX_#5M&PQQ8_<HZ!+(!<F
MENEG[M*[![+F"IL)A, ,3T.SU3I8@(ELL(7ZV,':28<UCFA_,5+O2'8P#H53
M;QLINE&O<D6BWFYN  S+"E*Z\+73$,9@[#FOFG?)J+R]P\F\H9P<!&9NQ3^0
MM/O791!3:1B(7]3$;+0S*.[GW'\O23]4!L$3A0/\$LDVQ]-)8THC<KFG'-,<
M>97X-^$)@PF$LQ](]]Z#HR53JYOC9DPKVK91$>N;6^2&)(SK@*U!ZHN)=4OB
M0FKR>A.5)Y)A:.TQFT@?#@1?PFAXO2A9ZR,MNCL,N4]OQ_USD6%!/__:X!KJ
M(8J,L=RHL,VMK3T_VBXU4%T6=\#K[X@<681Q2SC-.X(!LY ^=@U%.:P^_IAI
M<K)<">-Y"8=?NP^(7D \ST"3PH+CL$CY8J?6]LF,6L*E@$598>B"P**5 '9S
MV2@N/L%7B-@_7.-43P5JFV=JFN6VL4478"IN<V&*KE2@E(E!C&"K)34BMA#4
MD+J=:)B@ON^[X_V2H%GE[G'<074B9H4G#_-K"ZZB*+C74<>)JXW(V;E@(1NL
MM$26$"\=^Y=+3*P9TX]DWM9>S$>JKJ*M24G0R OY<U-\;KA[ 4^M*V(P+5-4
M/'Z_J>P09A$1YZ6(&V/,O7#%$%-P!1LXK(1-"P@1+]7$X!2T9O?V3OJ/Q?_[
M'I3]>D8@YS3,C;!W>A=<P1\3/S_$A+Z X'AI<W\,,@*3%FHJ;H/M!8 UI?+!
M/LB*7VV#IA&)$8>NSQC9S( E'D=>4I2D+9.@H>9'DFPQ<_%:UYLFK'T/-O9<
M5QVO/WGNJ.M,4&*'_5V\WZEV8XOWJUYB"F]E.3R/4H.4^\#<$A_PNL:$K'8O
MM)AW+F]RML]-1382EF1-XVGY#HT6BY0,@C3$H@">XP=/2%*9%PU['8* 1EF(
M:YE->I=1^'=80O2R;*O&SHU2H3!>0K/<-"FI%NY,FV#H(%EQ+RA0.@O]Q*Z8
MVM*A<7[LU!+N(D//.8<D0!8FE? 8K-R$8"-TB@&/DD"#%V YO9!*0[%1N5,#
M8AP;+Q.#VR'U<HWZ(052PM$++(8OE8RX]JM?GFJ6U? L/?8(1IA$EYC?-?Q2
M456YQ&C;8'TP7(MD@'8G3]!O.)8YPK]-[8A*>[\J(UTX,)2/R@GSH7S_G4FD
MS+4B;YV\?!+M _7\;%V2XR=K[&F&-4D 9RR1L[ 5*RE)N@LJV=QUP2_UJB*0
MH=3?1-RFK@[6V6F4@D9F@% 9A^?,SX<+&.Z3)XNL'.Z%8U$V< 9<TV=SDQPX
MI@9-!L4Y#9LN+%*^Z?D:UM8S/A%;OF\PDYWQ$5C:U'I1G+U*.>1" %X/5BRB
M /LD4@.TEZE7=UP6\N_(%#"7O>YTT 2C#UO9L(N+ OG!)[.0Z@P.&_0EB<!Z
M7UO/;:67;6%K"F+)%IVC#\X4:U)+?4Q%&HO2E[99S6G&?2\<V WAI+!4G]'[
MY.T;ST7J;G<?Z2?9D'&+WOZL:-D1R8[Y'2/SL1[*0*967_I!MF"?Y7"XHLZA
M#B#K3!!;L CF)@ZUF*'K0T[JV[+SN;F_"VSHK#_HI"4P 5-"A3^Y\7_A+K+[
M!?P *RSJ85^K.0%3$'04BVRJM&^H<IBHJJ*L@] -#-1]=),-S6*@9HM<[TET
MQW[C)%R=*%(0.A40V#ME@VR^P\_==,*W6HBC*%>],G^@HW 406^:5,R,G=Q;
M4^S4CMMH[C4BCUJ3B(9!'-W@A)N%43=$"AJD"P;MZB"*ZA4''2TJ0ICWM'68
M>2^1A2J>M,V=;9/VX"X&6LW&,_G$RDVW0+010J/>"5]Q"?0<IF#1=(3\S2_@
MA+ &$94GYQC\YC6:&J94-6;$=CQ]O-6;3,V)C2_<"QIYPV2>2%#WSDWTF?4H
M2*2/;:"X:B?B;^M AS?.9WZ\_T!0*^**B<Y6SK./# 3,MBP=>&2+VOH8+1'"
M$E<!+BQ$JXW< (L<,Q@\UE&W6 BU;>YN +%E9$X98^[$)K2JE%WVV*B2U3FP
M2%NUSBRO:[*9),^STT<I I+HUL7=-W4+:L>>-Y!2C8)F <[$+>&-KG.!2<KI
MR+V9UUM]&7-V,ORKUI03W3L78^]LW,4%(C;=/O8EZ!:[N@^W=_3@N1,$L,];
MCK4+?F53J44DDSG5>ZSX]/R3<STCQZHL/NIJ/0.]2CLP,GNV=W&=\:M(BIB;
M\MDSOM A\,@L?XW>B4HT.W0B*^LF)+L/U+M;$A-I6AFX*Q!%.R;R#[&;+V S
M_4];5J FH"#N&4Q[<&6WCNN#J6W58U&]NSZ-_D41G+:*?N==(N68&#/VMR(?
M-W'GL/@]_X+J^3 <D#OY8KWWM7G3&(9[V"*Z+T*[!\H6?F7=J@6L2->T2P)/
M*N"OIL6?FL5:W.EN*F##Y/P/%H8[-=-_M81*GDN#$N>N2<BSS*TW2OB030(Y
M99%?E9CH"D,VA11"\[O&2MPE\Y& -)I%@V(>:&'MC:'?\\0<Q)5P;KL#H-_L
M7''P'3'1L_#JH+[%22C8 [;?[TWP(,0':LFPJ*7M@NB:6.^2A*;Q$]C+](]
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M=>CHXJ1[%#V-[),=A9.* \=AV4Q6VW& 9>*+5KJJRZ+&T6X7*&D*A;>M;F$
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M^2R!V=3.P=]M&[CA8;@B"SS?@N*-7EMK3+'3;R9;8<*!R$@3L%92PC.2[$R
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ML5*#7/1-&8YW!*WHS#IASAYF.0SQN08=?A9CB(0VL*L@?9(_+#I!3BIB[4'
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MO="#.&]S*1937>NFZUSEVF/9]V]>16_>[ 5I_H"F$CF"?U2WNS7A+7005W[
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MYZ)B#@1J5%CL@-N$/TY;P%1GM-E*4,5!XA] DP6QDVNQ:Y@C?XJ5MCU+#-\
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MSB0W#NS!EUZCV*IAJP?J82885(GM@V'@9Z$<OI_R7J)SZ#FLCM\:CI:@NI=
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M=*]OKO&DO>]Y?US=7%[=]8BMY>;SQ]^N[C9,$RR-HV49FN 2-E=,EG"V6@V
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MUAQAU3EN(#2H_[',A\FT&A;5R_L2B)=M@WFFO*Z@"4]<7Y61# @]H@M(#85
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M#22U>J^"4(,1LVW=FZFE]#@Y-1R$B']P-!?%A>&3]_MHOV264=/XNF".U8"
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M"6ITR<BG@C$YV <: )XGN?"'ZB6<^YN7UT7Q);BTS-H.RM"*%1T-J^=X/Z&
MNTS*^E&6V*<H+SQC$G#R9<\C(O\R9B!]3]FU@8M<46T*4%8R9B)I%A<40=!0
MH1A2=)RE5G7;RDO'.PZ,D*;HE8.2RT%J^4,]V+"5+'WIB[HR5D!Z^K=L@;V3
M+LS;^N#9UZKDL7M%Q0YBE*/VLR(;MN?,03L%,/.?_#"RCC=]',Z#9<.6;]20
MSL\5HP(&2E[>$=?TSM%Q;5[?P2A8_0):YOGD%/\LU2Q8;?].["##DRN! NRN
MN0T5+)\-UB9%-^U0Q]GU\:%C'T9&8/.-*X@B/I!B?I)R(0T 3+*2PTF58WG
M0+PDTGTL-:#2X%T2PK *G.BY5)/@I88N_%<%@&MD1V=&E= T@)YR56*7J?NB
M=5/O-.M!L[^<<3"(#"#C3V,\I#SP6-M.3$)86@1K '8^MQ'3U5MLCGNVMQ_X
ML:Y*B#F:KC/-?MXP$BEA(T+\?=%M,ASM4!:_IC#!8@+8)!IMNV[##8T9>V)>
M"5MH7SC[P<\8J[G(EBAY,(I-3#_!0<YB;:=^M(31VDP[A!I5_-38I\ZG0@45
M\Y6Q6H[G)A8?N K]\L.*.!59$CVA489X,*G=IBD'.ZP]D\3FW.E9X+A:5"PC
M5WD>Z/8>5V7P,WJU"703)AG!C?!RGUJB9GG]L2AWK%R"1.T@.S1.IJ8>U99_
MP *'G+IST55PR%H9NQTD:R&$5<G/[55:.:/>$-ZXB(=X%-)-06WVSU1$O8I"
MT%'0.#0P+;T5)8RE<CY60'8ZZ*GQ7JKR$-$*["GZDGF?-9-!B)&6@/N7LF+*
M'&J'[;("\DD=(O%Q$:@NUS&.)4W@@"$UGP["G'BR$S;PPGPL0SVFCI.^9>;R
MF7AA]5#24K+$7DXFSP'6N,@ 0X*.AJ06E]  ]4@Z35 W#Q56GB=0%RO,,P8Z
M![@/5<)Q#6JADN;$A>E-Q!#/&N]?Q?!QHI-6>D9";IB:%9'D._>],0P!_A)@
M3 ?F< 3&,)\-.$$H9O;4YBD<7RHDAR=G&M(ZRC,-M'=$%B,- UD1POA)GE3\
MB_+XD+. "QC,@]$@DZ:>'Y>7[)E8^>D-9. H 4'CN(2&7?_%Y9QW-:NA49E3
ME<54'%7%.1\5:8R,/54 FAQQ.)3%OU(8U#S!0)X2[KL!_Z(91T^5#F9X2S0Z
M<$:X41W"36)X:3B41XZO4C--]7URS(21CMAIAKW(:58#2 6U&:'$<AC;QG;M
M&NPN!I-;JQ.E>XQ1S>$3ORYYZZ >&^MX7+3O\H(F]5ANABY8)1=6T*"GVM6W
M^J(-.>H=%;4FLUY(DN($U!JI2G0Q=A64V8TE*!><NJPP&%3M 3K,YRGFF^-^
M5H_?GJZF,/Z'Z_YH^UPJ('Z=LA9R'#-GF>>-5M#1%B<RW4H2YKI)"BSI6\)1
M*P,:?&[%'M3SU;,>G'>4[TX/1?4<.'4O;65C=;.]< "E&E#0FV.#E=RP2TJ.
MS>:'<:5=BF/CTCG8@KNTF[NZ7[@%CJSWPOI>/=(8?D25F)NDHXG^HF6A[S B
MT#G^-D#LE&$ H-B50]MDE%OSF2SI#DI>O46EJJLB';-:%VAETHC#-&M=)T*_
M/+^$P)%A,S\SI33E4G2"7:6$69,!P'KSPR(5801M\ZN0'2V4HS1_M$]Y*SFL
M*0;[FKL^<@0O<#2A$SG.A(&SV>K4='NLWM0U%I%=9:@[LMNG6GV,9H,5BNB2
M0B&KZ8K:.^'IQ$7]%?($VKRL-]AR^4\_+E \^SWO8+]_QH9/$D<O)4H\DW=F
M8)&N_GZD;FR("<T2I5[*(?4 ]1B&Y!:HMN9!A&7S [T[*X9=2F&4,:'L-H!O
M$N,-'1$5> M47@;JWK-= F)ZXARS=-GQ^EQB35*I*1P<K 362RJA6?Y$DR,H
M#2_R,95\A1/0XU'^'S^$$_]1_-?^8.]?T\<?O"P-*A\Y@<;^].LO[BX[!MF"
M^<_14Y/;BK83?RV#:N_WIU_?'@-'FTHO2P5P@24*">I^$( D8X(GHL+1\$M"
MSZ!\T:&D0D>U2I*_GU<4JP>G$<'$>PQE!;BM*!WGHE0:+I6HZ0..\288YI[W
M(?PBD""E)QNU=6 G6\W*9VSHIMGC\ ^%>JK;,)5Q@HK.H/6W8^W5C;X-L^LP
M^]GFA-E7I'C*IP99-THXV7_3__PNE=,6N+0,&W+4'1OR:&__D'(YU?RQ&V.U
M"7MDU)6/()59"$?LN<KB8P0N]JA67^ 0"(20)_"./<-6F87P>G[J!2E&_55-
M8BE$"P][*=E4O9KX=#E\1/N9,RIM2(81_EGB6L\L#EN^M/7+Q6'?LC)<](2^
M\4%-/1>9P*^VXHY/S)*F,FH^UG5IL/<W/E'*BM:8K@-1ZRE;=6@;[-L^=D<O
M6<&RS$1(32.)JG'L(( =H/V*2L]H3BV0O^W;:M\QF0A,CV,=(!)FUV;%R/"@
MD!C[H?K-J_GO%_FLQLB52]L>5C.#P]#!T%!6#G/3Z#^.!:4K;,M#1>K:!S5,
M%/%*:0JFE$[11XWE-33=D<.7X)FKJ1-1)G,/5L=X/^;=K_L<R_F&/?^8^JW\
M ,L^$596NDY/QQ(;\=7'1@:]NI6HJ610[J33 @!3W'[JD/>P'4HWB#AX<I_0
MKKW'IHZ2OW*NZ\B.R(H4%M!4OTCRZU2+LC54^C79V-,$7-P7,A J>L.60@P;
M4\U-3Y\DK%A8;EBG])K+"GKR-FMC('?AV)E90G?6E?-GGAZ-.IQ1IM[U[EA!
M4KWYZBFL35;(JN4WQT2DJVE*31@VU\[I9N&(U663B+9?*B3;-3QG3@C/K1^1
MR#:=5Y2K; CE.%<O%N3J7*N5[B!J\H&..XMK!S.4L-CN[BLS[MK,N0ITJ0)2
M'!9V.22H] W$H[4*].0(_VQJX=NI2JNCE?A"/6A'JF6<YD[^(J/3.C:&36NI
MV3;1K7V)DV>=\)FF88SV3^2-?,16D%=HHG@:"4M6;&=-S*7/^_^&.0.!?!2J
MLP'/5BWQRUS3KS56.,%*;F:_ W_DQ2PCFI5M3*-#_+/$=X957^64F[IY-J9]
MNQ]R76F\,G2)F-]<"AJ$>SLY)1Y@D5?X@>R;Z482[(#1LJ-YH0XB+/@(DR+#
MQ=6U$[*\?8//GF[B*R5MI)7'KG9? VF>8-%/GDBZ>2ZTP?6T]ATW6F-V!=W"
M3IUB< LV(L\SS?XN'V1=UF8='Q_@G\T.S8:["$;46JS*]8MSQX2) ;=.P_8R
MFC:*J;(26!(V'FW>:]21",@)A&S#EB*.EFBH*H0:%?HIO$3_L[^OJ:CP<_ZQ
MU41).17XJ\A_[FF8%[6KR"E67* H]2S$457H2.%3MR@IHAJ,'W)_IE3D+]5&
MOJL(HG!'C=A4V3FK@FN(!72@'ID<"C\()_(#MXEA3=\MZMO0U*'*ZEYHP96Q
MWP+)2J]\>^I?Z6#A)0R-"@<<()?%4^_+8A[U8XS12RN5;,W=FGHZ]CB^AI-B
M8M7-&$&&%\4>06L3+UFKHZ:#*->;I%.Z:@L;T;"1]YL.&UF^N;WPP2=K]P=I
M4L!M5'M9?? G?)8PVP JS5R6KS&?1*9$7U>+.%N+R@S91M#U:[*I&VPJT,<6
MG O<X"C$(8YDNR0XR0[WO0F\\SA[;0>YQ3VF$XC.T?Y!R],1^6G,@3K#H6IQ
MKLK_##-O??VP51KB>QM[+G</+,XNH&KB_"3BPG1,=:U8Z=!A!0<($NT1FVE=
M;C<+%E1OD*H&EK7GMGU>]X@WFI$EU ).#)GJ*RE2(L_[AXAC,86_7""7/"C5
MCR%\D"6YOQ7>[P2E]E!UE:RNX\KWD:W'V9_!?TC%R@TTL#?7,,P"<">E7:IS
MT2YY7S4A=JYZE^NF\[UJ:18;![XN%;#* S*-/4([."]2KH1F3 33IU %?$JG
M!9PE/IRH :IL]Z! _/6@8 UO7H7'9WMQHQ#3DX9EQ1Z6K$/*.&^D9DIS5JHC
M3R$R"+\B:R456E_V*>(#T>T?,'AQW[M48_9B& WTZ!JJW54;OF_,=;^1J5V?
MV3Z_>[B^^' %)L[;[*2Z491VTI[4*&"2GW^\NKF$__]P[YW?7'H/5W<?KV_.
M'ZX_W6P:L.!@KRT+UC5@ =AZPXY !V1_^1XY+([JP&]$G+'6<_K%X+>_)7[*
M)C[]=AP*..2_BJ"@XI9/W-B^IHD]_O->Q%CE_2<BXF]!PQ#C!/[V'P6\E7<'
M)WZ1!I@'=4M<_"(?)RF\HMU&;/88T3/S)\+"N_7J6$MZ'I6]OYCB:Z[(E&T\
M\;^L?[DL7ZVA5=A.25I=94 .G6Y*L.?=).:BGC=.GM'!T'ZC*0S*V_-< _RS
M1+$ W5X$8N4TL$^"_$%_@I8@>+\P+&EP-L >SV4#HIU$4OT\DY,'4YLEYO)R
M(VJ7=4+Z>#XM!)*D,2 -7.X)LJ" V0H?.A0%0\G(8L1A[%>YR? S'\0>Q$R6
M<:-DW8N42$M0U/ 78W8OT;90+\/!<C"8!Q%CWE<:%*^=!=H-. V[/8Q%6ZB_
MYI_KV6I+H0_QSQ+?9F5=G+@@DMNGVW2-4PX0O2!*/7X4LGX>-P()UJC  FUT
MF^@O;$SE= %#=)E,5K;:9HE'@^_1#V-.R45)AN#9:9%FA>Q_H@[0DU6N1%O*
M8.D+<6A'ET_W#IU3 (X&XO U%OC:9#?6PFA[(ZOY-8RVA[G:HKVMU88G&1PB
MDBU#-R!2[JHP=H@MU-]BZ>UYGQ$*5</((]EQL1UV$*2%'V6R.5.<I^&@D)7'
M8\Z0F@,A$.!VPLO4W]!T-*K81M(^64,;@8X^>P:7:RK,.*T-:9PL -%2 R;S
MU'\AJ]60DLC'9"KB[I0*X+#<LA-M%%,4P(X-X&\5 Q_#5TW4P^9=M81+GI5(
M+J=_6MM2F/:$_3 4*3/A/1UU@)DXQ_%'XJ<?^R?[O[S7Y3"I!>S&RY6R.MI_
M?[[F(8K#+H8H/E[?7UQ]^'!^<_7I\_VF'7"'ZQ25 /_TCP*T3BQU_Q4IMAE6
M^AN<=S<6::H_3*9,P"1#"1,?H[6Q77QOG1_4>ASV\E GZ^A8\CGN*/0+PG?Y
M,^I/U!_G(Z2=(O96"=2Q=!VZ\8@X?J0[,=$E]GL)U2,?.:OG7.2>SL1/*R^5
M:FX+75#0A8/]]8 N= :HP$+,!9&6Z/)I/Q4I$G9Y&9L/F<P#FM_UY \IY8%Y
M9XLD@^2U?%_,I8 SQ&7493&WC$Q&\>$NE:9?KG:&?3-[6Q@BR]+>P:]PFRMG
M3+UQ\QN&>?-KM7;N-(:S96!9:B))U0.5PM'/M=[]C?JNO^4QMD9^VIU TO^V
MALUO<&9AF%C:T$Y?'\ZB*12'+K\MM8%DZ&9[;?>+SJ:1A0U[XS%!PD$?!;UD
M$3>P.LJO]<W=O*?J7Y2 /_'HVQG^ZB$+#Z"D*[J0V<@XEU;EH4]A*#?6U=8!
MT(W\ZR0KS^D&[K W,LY?QU!$+J,5YZYPATE2)8- )DB 9"YHD5798)R9G-3G
M8_C7.V09>:+T-IY<E*@!&RH'<P-3X5,_'%*BC/O#@&1GN/U")B,9O%#G0/9?
MN6PSS'*Z&?Y&A140$Z")I24\F]JI)"6 74(YM%(*C2OZ$_<C$VJ A4P10!AA
MVY-L3,"]6/JUW!*[_G85]6,I&BOI)2=<SYD)S/CZSBK:8<\GG=8X"<3FNG%[
M]VB=]FX,LRFZ$,?$A*@F[_!?N,.[%:9LVL JAA,J1"UW]\ Z=_5B/3B)B'H0
MO-ELA%E6V*D@0YQZG1)TM.=%XND%D[ZY'XSY&RK""(K)(%7V'3[A2Q@/%9ZW
M>9OH,%4U?'B9P,3!9=Z=4'7<GU)XN0W<"L?KLQ7^">N$;/IP27<"^IC->Y8#
MX^"KWV!*&B(3.WJO-M(,G6Z &]9SF?Z6@Z<IPK'UX?. _Z0RH[F&-O/A,@G,
M 64_<T9B-2) %AD+MNV0;D]]WI"Y_U58DZ%N6J).I'%C0QA9+F((%[!B:?.V
M85LZMV/;\,*GB-ZJS4D[&T!VH9S,L?#Q;6122X[5DQV*)+E<B9G*(/AE(NP)
M2^WH0$&0I;$Z=1-)AQL/I?K9?^&Z4'"9TD(@!G5$]'>39 @2UV/\-1]8Q'K/
MF,H@F>I3RZE=4:=H)V#4JUCAS=OBI^NSQ<^-NOW@/Z_^L-5-<W$3RAI$#.+S
MX: -S4>$<,>*KVRH=^-01E-TH02=(MH!NL^E!Z2+%[1IZ 8UN*X8KV1U(L1D
MFIM\IGW/SS%EING6].'Y!"8@Z$99Q'8_O\9^7B-BM.OX"69S*'O$77 M(Y*C
M2>JQU>[PZY;S#^.E9 >&_ I<02PKDU%!]51O/?.&SB^8C- <WSY%0)JX$G);
MV50]64NA8 ]#?@:1CH<JWJGOAJ@/MA=$+ NRQ-!29R'';^.A9I28,C4YI4?P
M_E@MJAK/@(=J QMZ;BBL1M$AG>+&;;GWZ[/E;A+O$\G7^2.>$]VH'4!'3:.]
MF"L16Q%QP^6QRHN3-(5Y(1-^S//!CA@UGJ9:+K=.H*:_<U:)JW#ZGYNWR[BG
M3L9OH+#V][LBK4>SSP=PE/P -.6*3X)JV[!2""_$O),*F%#?673FK.0OZ'<_
M3+'W9.#+<KPPBF*,L5.M74"U*STG%()]Q615!V8,:NJX=<HMFR8%MH69PJ/I
M-D-LAQN,PP@3#2D=*7 D41[!!#DD98R$ME3X9;!+)-9!PBE1I-21^2L&B&1R
MG"KL\4U53LUIP"()"'QX"3@^_KN 74'YC,<":2=]J_R12XE3(4L$"9%"Q?QT
M0OG3:8+GT8+,D^NQ$SL#ZIJY$Z\B&'::Q&'@?40PZ(J17$F.2EQK?=@TC*6R
MT)YJMS!0"X.%6')NX3;I?# .91FO*0O->4<,A=4F@/@[Z.I %?(BIT81Z\9Z
M&EQ:BA[F_A<1<PIKZ"00!Y6VM4Z@<XOK,KBNOCL76US7;+['$HH#/C$ZOB8%
MB]U9J'^FQ']3U()%?R+R<4+.#O_-BH\KJ3;50RV/56F#$(Z^1SJPJD89GK+U
M&\SN+R/><=X\%Y&8CI&^E1L4(0C\!4X[9&8/40/$8$[J3^3Q=4T=:,0FPD#>
MJH[\%<Z62U!7% "X!//$E'I0G8B*"5P]D5Y^Q64Z/5@%70;HL-E3 >_K3,7&
MTH9TCUS]2E>(&/?3;N< &^N0^U>5S7_?N]=%)XQX%[5H%N,2--3FL&TQ=/8"
M:4.#8V!_V8D+<8=AS?]90_F$L9^9#_=VT*4XV/\E,]\[0Z&O^[_L&O;YB<Q(
M-?HF\HY#E&TQ=&Y'TR)OZ>U0U>^(2W%$E#SO2L\+2<O\S'2 I..$GM^K%E;V
M+(X69"RS"2T9;M7P:G5S)C'''"5C8-3C(U+G(ZB?,L0J2]8T7[1T;'NRTP0O
M@[]\3/WI&%YYMR=KQPRG:8.O5^[K/(\LV7V;FZ;?T*NIJ1(^>'--LV051/ -
M\;6R\*MD9G-0"';_%46BHYCHQ5>1!F$FR^20.HK%GJ #1*8@_RXBN?FD/>$
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ME$;6P^WE9V"L9G9Y$,83PZ'%1)R*H:$DD%P#^E8$G2'J1^,%R$16*%6>?,1
MD!YB6>YI7@][,ZDE/SMTS62T]U+D@@*KTQI57;9$[H?:?A<#!4,M)SQV!KL[
MAXYI7HVBQ)Y%"7B1,..Z*HG:W*A(;9'8O0HF2LN[(EK*_IX(/_ZKU2I=#R!V
M#_U$Q#Y\)LB3AO'8G*I45:^2Q5SRE_ O]*;H'^SX/_W8/SC^Q=D5A!"'P:O2
MW4MY-P4^NC6^UVZE#P^EICP_?Y>&V1>*;A:9[+\[4IVE]  .]ZFFTCR;,5$;
M*T4=!"198F3'*:@ '=,*W(;<IX)IY>B'.6C'?K]78O_4M#:R"DXG*_ CXAZ-
M_&=>8;3D-G:5NP<\(E?BX!V["Y7B)UFPQ$X*:0A8?5.!;=OA-DA!=QCWZA0$
M&,D]BZZ@?"%;P?47LD6?%=AF))107:W*0,L0UV6(, S+I<)#2-:6F$/_J*^9
MEUH.;U>XSIH$Y^#LP#\X6]DIW-8'^^3H[&B9(Y,'05LW[&5/3HM=YM@A'B-K
MS]H&NW1[:G-U6P>A>($4!Z%(4DHFR7=PXG0/.X>NF6Y1* 0UIWZ&XT N%@/5
MJO_;W"*YU!>UC:Q]F>J044>K=/<1+&A)]_SGVMY11T\V>;K,4NL4S'L*AP58
ME-SK?*OGOR<(I2L!IOC*IM,Z 8^V'.5A_6\1]\Q8K(.C=5NL#F+>+&QR&Q"Y
M?P+KI?M3F)+UJZ_!V(\?A7<>S %&RI/ISX>5ZN^],WO7I3QB_K I^UJ3G/RN
MD\-''4P.+WF1V[,G;[0<E5P)+<?]Q3^N+C]_N/+.OS7YTS;\97*7T? _<C]$
M;,P!QSSS%/^!O7?)-O^09&@<@+ZX)1)Q4/'7\9/(<C+W%)0*EPY__5$,)7OT
M!88F+N#AFI1,_A9_>ENMG<B\MC33"?W?$B>AC85LZ2MP2#-]NG?84TD/4%Q1
M"QMT1U.)]6^'A>4MLL-B-H?@T 'EL':9_B,DN I=]JB%-V+AY?XH(3V:#1/D
M#T8BXR35%1FA'EGFC8IXF%D,QP9(9<9Y[S_I-F_66YE649E%9BSJB!XS60-
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M;ZZY\QI1\,6E8"5Q\(ZOQ$Y_UY+OC@5]_\IFW]@%.]C=QCK7;]4.=VL$>-[
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M2P$"% ,4    " #%-=1:A]T$EV,C  "1JP$ $               @ %"Y@,
M;61T+3(P,C4P-#(U+GAS9%!+ 0(4 Q0    ( ,4UU%I_I[UQ%D$  %^K @ 4
M              "  =,)! !M9'0M,C R-3 T,C5?8V%L+GAM;%!+ 0(4 Q0
M   ( ,4UU%IO1JU(*?,  ,!+"P 4              "  1M+! !M9'0M,C R
M-3 T,C5?9&5F+GAM;%!+ 0(4 Q0    ( ,4UU%H%43^&[[$  +3<   3
M          "  78^!0!M9'0M,C R-3 T,C5?9S$N:G!G4$L! A0#%     @
MQ3746M>I,-V?N@  A]$  !0              ( !EO % &UD="TR,#(U,#0R
M-5]G,3 N:G!G4$L! A0#%     @ Q3746J@OTR<;BP  (*(  !0
M     ( !9ZL& &UD="TR,#(U,#0R-5]G,3$N:G!G4$L! A0#%     @ Q374
M6LW.#V>?BP  B*(  !0              ( !M#8' &UD="TR,#(U,#0R-5]G
M,3(N:G!G4$L! A0#%     @ Q3746M84OE6(C   KZ,  !0
M ( !A<(' &UD="TR,#(U,#0R-5]G,3,N:G!G4$L! A0#%     @ Q3746NS_
M/*=2BP  E:(  !0              ( !/T\( &UD="TR,#(U,#0R-5]G,30N
M:G!G4$L! A0#%     @ Q3746AJF'41T=@  %HX  !0              ( !
MP]H( &UD="TR,#(U,#0R-5]G,34N:G!G4$L! A0#%     @ Q3746H4W3>*_
M=0  <(T  !0              ( !:5$) &UD="TR,#(U,#0R-5]G,38N:G!G
M4$L! A0#%     @ Q3746NST-^:IE@  R?D  !0              ( !6L<)
M &UD="TR,#(U,#0R-5]G,3<N:G!G4$L! A0#%     @ Q3746CQ!$63?+@$
MXEP! !,              ( !-5X* &UD="TR,#(U,#0R-5]G,BYJ<&=02P$"
M% ,4    " #%-=1:S0HH60:;  #2KP  $P              @ %%C0L ;61T
M+3(P,C4P-#(U7V<S+FIP9U!+ 0(4 Q0    ( ,4UU%HA.4:;D/8  )H2 0 3
M              "  7PH# !M9'0M,C R-3 T,C5?9S0N:G!G4$L! A0#%
M  @ Q3746B <AEBA<   3X<  !,              ( !/1\- &UD="TR,#(U
M,#0R-5]G-2YJ<&=02P$"% ,4    " #%-=1:VX<C;L@. 0 E+ $ $P
M        @ $/D T ;61T+3(P,C4P-#(U7V<V+FIP9U!+ 0(4 Q0    ( ,4U
MU%IH=_$%U T! ,!' 0 3              "  0B?#@!M9'0M,C R-3 T,C5?
M9S<N:G!G4$L! A0#%     @ Q3746I?5S +T 0( I&\" !,
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M              "  =I5%@!M9'0M,C R-3$P:WAE>#(S+FAT;5!+ 0(4 Q0
M   ( ,4UU%HO.O8U[04  *HH   4              "  :I9%@!M9'0M,C R
M-3$P:WAE>#(T+FAT;5!+ 0(4 Q0    ( ,4UU%JSD:!WP@<  .,H   5
M          "  <E?%@!M9'0M,C R-3$P:WAE>#,Q,2YH=&U02P$"% ,4
M" #%-=1:X#PFSM,'   G*@  %0              @ &^9Q8 ;61T+3(P,C4Q
M,&MX97@S,3(N:'1M4$L! A0#%     @ Q3746C&Q^HDB!   4Q,  !4
M         ( !Q&\6 &UD="TR,#(U,3!K>&5X,S(Q+FAT;5!+ 0(4 Q0    (
M ,4UU%H=7H*!,@0  ) 3   5              "  1ET%@!M9'0M,C R-3$P
M:WAE>#,R,BYH=&U02P$"% ,4    " #%-=1:9>(1+/Y[   M3 , %0
M        @ %^>!8 ;61T+3(P,C4Q,&MX97@T,S N:'1M4$L! A0#%     @
MQ3746I:;Y1%&%@  ,X<  !0              ( !K_06 &UD="TR,#(U,3!K
M>&5X.3<N:'1M4$L! A0#%     @ Q3746E-96T9L;   ?LX# !<
M     ( !)PL7 &UD="TR,#(U,3!X:WAE>#$P.#$N:'1M4$L%!@     C ",
*_0@  ,AW%P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>mdt-20250425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mdt="http://www.medtronic.com/20250425"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mdt-20250425.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.250SeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.000SeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2.625SeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.125SeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.375SeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.000SeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.650SeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.625SeniorNotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.000SeniorNotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.125SeniorNotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A0.750SeniorNotesDue2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.375SeniorNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A3.875SeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2.250SeniorNotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.500SeniorNotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.375SeniorNotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4.150SeniorNotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.750SeniorNotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A1.625SeniorNotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A4.150SeniorNotesDue2053Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-10-25</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2025-06-17</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CardiacRhythmandHeartFailureDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:StructuralHeartAndAorticDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CoronaryAndPeripheralVascularDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:CranialAndSpinalTechnologiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SpecialtyTherapiesDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:SurgicalInnovationsDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">mdt:AcuteCareMonitoringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:TotalReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:VentilatorProductLineExitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">mdt:MozarcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mdt:MozarcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:RevenueMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdt:ProductDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:EnterpriseExcellenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mdt:SimplificationRestructuringProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2024-01-27</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:IncrementalDefinedBenefitDefinedContributionAndPostRetirementChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mdt:AssociatedAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdt:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20260250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20260.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20262.625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:A2015And2020CommercialPaperProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-26</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:AmendedandRestatedRevolvingCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20271125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20284.250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20293.000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20290375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20303.650PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20311625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20321000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20323.125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20330750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2023Due20334.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2022Due20353.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20354.375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20373.875PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:CIFSASeniorNotes2007Due20386.550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20392250PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2009Due20396500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20401500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2010Due20405550PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20411375PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2012Due20424500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2013Due20434000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20444.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2014Due20444625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20454625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2019Due20501750PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2020Due20511625PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2024Due20544.150PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:MedtronicLuxcoSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdt:MedtronicLuxcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2015Due20253.500PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdt:SeniorNotes2017Due20273.350PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mdt:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mdt:OtherAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TotalReturnSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mdt:RenalCareBusinessRCSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mdt:PurchasedTechnologyAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mdt:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:TwoThousandTwentyOneStockAwardAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mdt:EmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mdt:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:OtherPlanAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:PartnershipUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:RegisteredInvestmentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mdt:InsuranceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:ColibriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:HerniaMeshLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-28</instant>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mdt:DiabetesPumpRetainerRingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-28</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:NeuroscienceGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:MedicalSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mdt:DiabetesGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingUnitedStatesandIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mdt:TotalOtherCountriesExcludingIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2025-01-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-27</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-29</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>mdt:tranche</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="plaintiff">
        <measure>mdt:plaintiff</measure>
    </unit>
    <unit id="claim">
        <measure>mdt:claim</measure>
    </unit>
    <unit id="lawsuit">
        <measure>mdt:lawsuit</measure>
    </unit>
    <unit id="segment">
        <measure>mdt:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-92">0001613103</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-93">--04-25</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-94">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-95">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-96">2025</dei:DocumentFiscalYearFocus>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-97">H91 4K49</dei:EntityAddressPostalZipCode>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-72" id="f-513">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-709">http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet</us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-209" id="f-722">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-210" id="f-723">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-211" id="f-724">http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-212" id="f-728">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-213" id="f-729">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-214" id="f-730">http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentTerm contextRef="c-293" id="f-990">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-296" id="f-994">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-299" id="f-998">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-1005">http://fasb.org/us-gaap/2024#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-1006">http://fasb.org/us-gaap/2024#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentTerm contextRef="c-293" id="f-1024">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-296" id="f-1030">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-299" id="f-1036">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-312" id="f-1042">P8Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-315" id="f-1048">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-318" id="f-1054">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-321" id="f-1060">P8Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-324" id="f-1066">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-327" id="f-1072">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-330" id="f-1078">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-333" id="f-1084">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-336" id="f-1090">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-339" id="f-1096">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-342" id="f-1102">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-345" id="f-1108">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-348" id="f-1114">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-351" id="f-1120">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-354" id="f-1126">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-357" id="f-1132">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-360" id="f-1138">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-363" id="f-1144">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-366" id="f-1150">P20Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-369" id="f-1156">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-372" id="f-1162">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-375" id="f-1168">P19Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-378" id="f-1174">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-381" id="f-1180">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-384" id="f-1186">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-387" id="f-1192">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-390" id="f-1198">P29Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-1203">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-1204">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration contextRef="c-24" id="f-1251">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1261">http://fasb.org/us-gaap/2024#InterestExpenseNonoperating</us-gaap:DerivativeExcludedComponentGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-24" id="f-1350">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-24" id="f-1351">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-27" id="f-1352">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-27" id="f-1353">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-25" id="f-1490">http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2354">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-2355">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-2358">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2359">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-27" id="f-2362">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-2363">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-2725">Subsequent Events</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-04-25</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--04-25</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-36820</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Medtronic plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">98-1183488</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">Building Two, Parkmore Business Park West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Galway</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-12">IE</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-13">353</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-14">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">438-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Ordinary shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">MDT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-2" id="f-19">0.250% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-20">MDT/25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-21">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-22">0.000% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-23">MDT/25A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-24">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-25">2.625% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-26">MDT/25B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-27">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-28">1.125% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-29">MDT/27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-30">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-31">0.375% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-32">MDT/28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-33">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-34">3.000% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-35">MDT/28A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-36">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-8" id="f-37">3.650% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-8" id="f-38">MDT/29</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-8" id="f-39">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-9" id="f-40">1.625% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-9" id="f-41">MDT/31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-9" id="f-42">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-10" id="f-43">1.000% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-10" id="f-44">MDT/31A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-10" id="f-45">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-11" id="f-46">3.125% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-11" id="f-47">MDT/31B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-11" id="f-48">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-12" id="f-49">0.750% Senior Notes due 2032</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-12" id="f-50">MDT/32</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-12" id="f-51">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-13" id="f-52">3.375% Senior Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-13" id="f-53">MDT/34</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-13" id="f-54">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-14" id="f-55">3.875% Senior Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-14" id="f-56">MDT/36</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-14" id="f-57">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-15" id="f-58">2.250% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-15" id="f-59">MDT/39A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-15" id="f-60">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-16" id="f-61">1.500% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-16" id="f-62">MDT/39B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-16" id="f-63">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-17" id="f-64">1.375% Senior Notes due 2040</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-17" id="f-65">MDT/40A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-17" id="f-66">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-18" id="f-67">4.150% Senior Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-18" id="f-68">MDT/43A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-18" id="f-69">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-19" id="f-70">1.750% Senior Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-19" id="f-71">MDT/49</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-19" id="f-72">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-20" id="f-73">1.625% Senior Notes due 2050</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-20" id="f-74">MDT/50</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-20" id="f-75">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-21" id="f-76">4.150% Senior Notes due 2053</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-21" id="f-77">MDT/53</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-21" id="f-78">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-79">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-80">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-81">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-82">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-83">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-84">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-85">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-86">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-87">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-88">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-22" decimals="-8" id="f-89" unitRef="usd">116200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-23" decimals="INF" id="f-90" unitRef="shares">1281264703</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-91">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Portions of the registrant&#x2019;s Proxy Statement for its 2025 Annual General Meeting are incorporated by reference into Part III hereof.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-98">238</dei:AuditorFirmId>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-100">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity regulatory based risk assessments for the Company&#x2019;s systems and applications (where required),&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a formal incident response plan, in which &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;annual information security training program for all employees, including phishing awareness training,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity works closely with application development and infrastructure &amp;amp; operation teams to embed security considerations into the foundation of technology,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;engagement of third-party service providers to conduct assessment of the Company&#x2019;s cybersecurity risk management program, penetration testing, and vulnerability testing,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a third-party risk assessment process for service providers, suppliers, and vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risks from cybersecurity threats are integrated into Medtronic&#x2019;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#x2019;s business and operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#x2019;s business or operations. However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. See Item 1A. Risk Factors under, &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.&#x201d;&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-99">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have designed and implemented a cybersecurity risk management program to help us identify, assess, and mitigate cybersecurity risks relevant to our business, based on the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;dedicated cybersecurity professionals who analyze cybersecurity threats, define cybersecurity policy and requirements, implement protections, and monitor and respond to cybersecurity incidents,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity regulatory based risk assessments for the Company&#x2019;s systems and applications (where required),&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a formal incident response plan, in which &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incidents are classified based upon the severity, impact, and the potential harm that can be caused by the incident,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;annual information security training program for all employees, including phishing awareness training,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity works closely with application development and infrastructure &amp;amp; operation teams to embed security considerations into the foundation of technology,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;engagement of third-party service providers to conduct assessment of the Company&#x2019;s cybersecurity risk management program, penetration testing, and vulnerability testing,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a third-party risk assessment process for service providers, suppliers, and vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;given the smart technology within our devices, our product security includes design protocols and is supported by quality systems testing and use scanning tools to assess and detect vulnerabilities that could affect our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risks from cybersecurity threats are integrated into Medtronic&#x2019;s enterprise risk management (ERM) program. The ERM program establishes a risk management framework that seeks to identify, assess, and mitigate risks that could materially impact the Company&#x2019;s business and operation.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-101">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-102">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-103">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-104">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-109">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-108">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;/span&gt;&lt;/div&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-107">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors is engaged in the Company&#x2019;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#x2019;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#x2019;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#x2019;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-106">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors is engaged in the Company&#x2019;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#x2019;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#x2019;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#x2019;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-105">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cybersecurity risk management program is led by the Chief Information Security Officer (CISO). Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors is engaged in the Company&#x2019;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#x2019;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#x2019;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#x2019;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-110">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-111">Our CISO has over 29 years of experience assisting public and privately held companies in a variety of industries, leading several enterprise-wide transformation initiatives to adapt to changing cybersecurity threats. The CISO has held various executive level positions within Fortune 500 companies. Our CISO &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports to the Chief Information Officer (CIO), who leads the Global Information Technology (IT) organization and works closely with the Executive Committee to guide strategic direction and IT decisions to drive business outcomes.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-112">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors is engaged in the Company&#x2019;s ERM program and receives briefings on the outcomes of the ERM program and the steps the Company takes to mitigate risks that the program identifies. The Quality Committee of the Board oversees the Company&#x2019;s cybersecurity strategies, systems, and controls to ensure reliability and prevent unauthorized access. The Audit Committee discusses policies with respect to risk assessment and risk management, including risks associated with the reliability and security of the Company&#x2019;s information technology and security systems, and the steps management has undertaken to monitor and control such exposures. The Audit Committee receives regular updates on the Company&#x2019;s cybersecurity risk management program from the CISO and CIO, and our procedures specify escalation of certain cybersecurity events to the Audit Committee chair and full Audit Committee.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-113">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-24" decimals="-6" id="f-114" unitRef="usd">218000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-24" decimals="-6" id="f-115" unitRef="usd">199000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-24" decimals="-6" id="f-116" unitRef="usd">155000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-24" decimals="-6" id="f-117" unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-24" decimals="-6" id="f-118" unitRef="usd">100000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-24" decimals="-6" id="f-119" unitRef="usd">503000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <dei:AuditorName contextRef="c-1" id="f-120">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-121">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-122" unitRef="usd">33537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-123" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-124" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-125" unitRef="usd">11632000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-25" decimals="-6" id="f-126" unitRef="usd">11216000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-26" decimals="-6" id="f-127" unitRef="usd">10719000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-6" id="f-128" unitRef="usd">2732000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-25" decimals="-6" id="f-129" unitRef="usd">2735000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-26" decimals="-6" id="f-130" unitRef="usd">2696000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-131" unitRef="usd">10849000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-25" decimals="-6" id="f-132" unitRef="usd">10736000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-26" decimals="-6" id="f-133" unitRef="usd">10415000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-134" unitRef="usd">1807000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-25" decimals="-6" id="f-135" unitRef="usd">1693000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-26" decimals="-6" id="f-136" unitRef="usd">1698000000</us-gaap:AmortizationOfIntangibleAssets>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-1" decimals="-6" id="f-137" unitRef="usd">267000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-25" decimals="-6" id="f-138" unitRef="usd">226000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-26" decimals="-6" id="f-139" unitRef="usd">375000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-1" decimals="-6" id="f-140" unitRef="usd">317000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-25" decimals="-6" id="f-141" unitRef="usd">149000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-26" decimals="-6" id="f-142" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-6" id="f-143" unitRef="usd">23000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-25" decimals="-6" id="f-144" unitRef="usd">-464000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-26" decimals="-6" id="f-145" unitRef="usd">131000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-146" unitRef="usd">5955000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-25" decimals="-6" id="f-147" unitRef="usd">5144000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-26" decimals="-6" id="f-148" unitRef="usd">5485000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-149" unitRef="usd">402000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-25" decimals="-6" id="f-150" unitRef="usd">412000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-26" decimals="-6" id="f-151" unitRef="usd">515000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-6" id="f-152" unitRef="usd">729000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-25" decimals="-6" id="f-153" unitRef="usd">719000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-26" decimals="-6" id="f-154" unitRef="usd">636000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-155" unitRef="usd">5628000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-156" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-157" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-158" unitRef="usd">936000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-159" unitRef="usd">1133000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-160" unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-161" unitRef="usd">4691000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-162" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-163" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-164" unitRef="usd">29000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-165" unitRef="usd">28000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-166" unitRef="usd">26000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-167" unitRef="usd">4662000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-6" id="f-168" unitRef="usd">3676000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-6" id="f-169" unitRef="usd">3758000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-176" unitRef="shares">1285600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="-5" id="f-177" unitRef="shares">1327700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="-5" id="f-178" unitRef="shares">1329800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-179" unitRef="shares">1289900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="-5" id="f-180" unitRef="shares">1330200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="-5" id="f-181" unitRef="shares">1332800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-182" unitRef="usd">4691000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-183" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-184" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-185" unitRef="usd">149000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-6" id="f-186" unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-6" id="f-187" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-188" unitRef="usd">853000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-6" id="f-189" unitRef="usd">-848000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-6" id="f-190" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-1" decimals="-6" id="f-191" unitRef="usd">-1474000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-25" decimals="-6" id="f-192" unitRef="usd">633000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax contextRef="c-26" decimals="-6" id="f-193" unitRef="usd">-596000000</mdt:OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-194" unitRef="usd">110000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-25" decimals="-6" id="f-195" unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-26" decimals="-6" id="f-196" unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-6" id="f-197" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-25" decimals="-6" id="f-198" unitRef="usd">136000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-26" decimals="-6" id="f-199" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-200" unitRef="usd">-964000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-6" id="f-201" unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-6" id="f-202" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-203" unitRef="usd">3727000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-204" unitRef="usd">3883000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-205" unitRef="usd">2549000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-206" unitRef="usd">31000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-207" unitRef="usd">27000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-208" unitRef="usd">26000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-209" unitRef="usd">3696000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-25" decimals="-6" id="f-210" unitRef="usd">3856000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-26" decimals="-6" id="f-211" unitRef="usd">2524000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-24" decimals="-6" id="f-212" unitRef="usd">2218000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-6" id="f-213" unitRef="usd">1284000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-24" decimals="-6" id="f-214" unitRef="usd">6747000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-27" decimals="-6" id="f-215" unitRef="usd">6721000000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-24" decimals="-6" id="f-216" unitRef="usd">199000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-27" decimals="-6" id="f-217" unitRef="usd">173000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-24" decimals="-6" id="f-218" unitRef="usd">6515000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-27" decimals="-6" id="f-219" unitRef="usd">6128000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-24" decimals="-6" id="f-220" unitRef="usd">5476000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-27" decimals="-6" id="f-221" unitRef="usd">5217000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-24" decimals="-6" id="f-222" unitRef="usd">2858000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-27" decimals="-6" id="f-223" unitRef="usd">2584000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-24" decimals="-6" id="f-224" unitRef="usd">23814000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-27" decimals="-6" id="f-225" unitRef="usd">21935000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-24" decimals="-6" id="f-226" unitRef="usd">6837000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-6" id="f-227" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c-24" decimals="-6" id="f-228" unitRef="usd">41737000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-27" decimals="-6" id="f-229" unitRef="usd">40986000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-24" decimals="-6" id="f-230" unitRef="usd">11667000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-27" decimals="-6" id="f-231" unitRef="usd">13225000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-24" decimals="-6" id="f-232" unitRef="usd">4040000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-27" decimals="-6" id="f-233" unitRef="usd">3657000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-24" decimals="-6" id="f-234" unitRef="usd">3584000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-27" decimals="-6" id="f-235" unitRef="usd">4047000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-24" decimals="-6" id="f-236" unitRef="usd">91680000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-27" decimals="-6" id="f-237" unitRef="usd">89981000000</us-gaap:Assets>
    <us-gaap:DebtCurrent contextRef="c-24" decimals="-6" id="f-238" unitRef="usd">2874000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-27" decimals="-6" id="f-239" unitRef="usd">1092000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-24" decimals="-6" id="f-240" unitRef="usd">2449000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-27" decimals="-6" id="f-241" unitRef="usd">2410000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-24" decimals="-6" id="f-242" unitRef="usd">2514000000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-27" decimals="-6" id="f-243" unitRef="usd">2375000000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-24" decimals="-6" id="f-244" unitRef="usd">1358000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-27" decimals="-6" id="f-245" unitRef="usd">1330000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-24" decimals="-6" id="f-246" unitRef="usd">3683000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-247" unitRef="usd">3582000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-24" decimals="-6" id="f-248" unitRef="usd">12879000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-249" unitRef="usd">10789000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-24" decimals="-6" id="f-250" unitRef="usd">25642000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-27" decimals="-6" id="f-251" unitRef="usd">23932000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-24" decimals="-6" id="f-252" unitRef="usd">1158000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-27" decimals="-6" id="f-253" unitRef="usd">1101000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-24" decimals="-6" id="f-254" unitRef="usd">1574000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-27" decimals="-6" id="f-255" unitRef="usd">1859000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-24" decimals="-6" id="f-256" unitRef="usd">403000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-27" decimals="-6" id="f-257" unitRef="usd">515000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-24" decimals="-6" id="f-258" unitRef="usd">1769000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-27" decimals="-6" id="f-259" unitRef="usd">1365000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-24" decimals="-6" id="f-260" unitRef="usd">43424000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-27" decimals="-6" id="f-261" unitRef="usd">39561000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-24" id="f-262" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-27" id="f-263" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-264"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-265"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-266"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-267"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-268"
      unitRef="shares">1281934628</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-269"
      unitRef="shares">1281934628</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-270"
      unitRef="shares">1311337531</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-271"
      unitRef="shares">1311337531</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-24" decimals="-6" id="f-272" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-27" decimals="-6" id="f-273" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-24" decimals="-6" id="f-274" unitRef="usd">20833000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-27" decimals="-6" id="f-275" unitRef="usd">23129000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-24" decimals="-6" id="f-276" unitRef="usd">31476000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-27" decimals="-6" id="f-277" unitRef="usd">30403000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-6" id="f-278" unitRef="usd">-4284000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-6" id="f-279" unitRef="usd">-3318000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-6" id="f-280" unitRef="usd">48024000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-281" unitRef="usd">50214000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-24" decimals="-6" id="f-282" unitRef="usd">232000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-27" decimals="-6" id="f-283" unitRef="usd">206000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-284" unitRef="usd">48256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-285" unitRef="usd">50420000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-24" decimals="-6" id="f-286" unitRef="usd">91680000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-27" decimals="-6" id="f-287" unitRef="usd">89981000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-28" decimals="-6" id="f-288" unitRef="shares">1331000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-289" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-290" unitRef="usd">24566000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-291" unitRef="usd">30250000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-292" unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-293" unitRef="usd">52551000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-294" unitRef="usd">171000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-6" id="f-295" unitRef="usd">52722000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-35" decimals="-6" id="f-296" unitRef="usd">3758000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-36" decimals="-6" id="f-297" unitRef="usd">3758000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-6" id="f-298" unitRef="usd">26000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-299" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-6" id="f-300" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-6" id="f-301" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-6" id="f-302" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-26"
      decimals="INF"
      id="f-303"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-35" decimals="-6" id="f-304" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-36" decimals="-6" id="f-305" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-26" decimals="-6" id="f-306" unitRef="usd">3616000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-39" decimals="-6" id="f-307" unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-6" id="f-308" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-6" id="f-309" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-26" decimals="-6" id="f-310" unitRef="usd">236000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-39" decimals="-6" id="f-311" unitRef="shares">6000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-40" decimals="-6" id="f-312" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-36" decimals="-6" id="f-313" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-26" decimals="-6" id="f-314" unitRef="usd">571000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-40" decimals="-6" id="f-315" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-6" id="f-316" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-6" id="f-317" unitRef="usd">355000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-40" decimals="-6" id="f-318" unitRef="usd">5000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-36" decimals="-6" id="f-319" unitRef="usd">5000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-37" decimals="-6" id="f-320" unitRef="usd">-15000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-26" decimals="-6" id="f-321" unitRef="usd">-10000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-6" id="f-322" unitRef="shares">1331000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-6" id="f-323" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-324" unitRef="usd">24590000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-325" unitRef="usd">30392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-326" unitRef="usd">-3499000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-327" unitRef="usd">51483000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-328" unitRef="usd">182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-6" id="f-329" unitRef="usd">51665000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-48" decimals="-6" id="f-330" unitRef="usd">3676000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-49" decimals="-6" id="f-331" unitRef="usd">3676000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-50" decimals="-6" id="f-332" unitRef="usd">28000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-333" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-51" decimals="-6" id="f-334" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-49" decimals="-6" id="f-335" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-50" decimals="-6" id="f-336" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-6" id="f-337" unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-25"
      decimals="INF"
      id="f-338"
      unitRef="usdPerShare">2.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-48" decimals="-6" id="f-339" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-49" decimals="-6" id="f-340" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-25" decimals="-6" id="f-341" unitRef="usd">3666000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-52" decimals="-6" id="f-342" unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-53" decimals="-6" id="f-343" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-49" decimals="-6" id="f-344" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-25" decimals="-6" id="f-345" unitRef="usd">231000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-52" decimals="-6" id="f-346" unitRef="shares">25000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-53" decimals="-6" id="f-347" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-49" decimals="-6" id="f-348" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-25" decimals="-6" id="f-349" unitRef="usd">2084000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-53" decimals="-6" id="f-350" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-6" id="f-351" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-6" id="f-352" unitRef="usd">393000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-50" decimals="-6" id="f-353" unitRef="usd">-2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-25" decimals="-6" id="f-354" unitRef="usd">-2000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="-6" id="f-355" unitRef="shares">1311000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-6" id="f-356" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-6" id="f-357" unitRef="usd">23129000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-358" unitRef="usd">30403000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-6" id="f-359" unitRef="usd">-3318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-6" id="f-360" unitRef="usd">50214000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-6" id="f-361" unitRef="usd">206000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-362" unitRef="usd">50420000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-60" decimals="-6" id="f-363" unitRef="usd">4662000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-61" decimals="-6" id="f-364" unitRef="usd">4662000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-6" id="f-365" unitRef="usd">29000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-366" unitRef="usd">4691000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-63" decimals="-6" id="f-367" unitRef="usd">-966000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-61" decimals="-6" id="f-368" unitRef="usd">-966000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-62" decimals="-6" id="f-369" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-370" unitRef="usd">-964000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-371"
      unitRef="usdPerShare">2.80</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-60" decimals="-6" id="f-372" unitRef="usd">3589000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-61" decimals="-6" id="f-373" unitRef="usd">3589000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-374" unitRef="usd">3589000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-64" decimals="-6" id="f-375" unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-65" decimals="-6" id="f-376" unitRef="usd">440000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-61" decimals="-6" id="f-377" unitRef="usd">440000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-6" id="f-378" unitRef="usd">440000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-64" decimals="-6" id="f-379" unitRef="shares">38000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-65" decimals="-6" id="f-380" unitRef="usd">3166000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-61" decimals="-6" id="f-381" unitRef="usd">3166000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-1" decimals="-6" id="f-382" unitRef="usd">3166000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-65" decimals="-6" id="f-383" unitRef="usd">429000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-61" decimals="-6" id="f-384" unitRef="usd">429000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-385" unitRef="usd">429000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-62" decimals="-6" id="f-386" unitRef="usd">-6000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-1" decimals="-6" id="f-387" unitRef="usd">-6000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-66" decimals="-6" id="f-388" unitRef="shares">1282000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-6" id="f-389" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-6" id="f-390" unitRef="usd">20833000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-6" id="f-391" unitRef="usd">31476000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-6" id="f-392" unitRef="usd">-4284000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-6" id="f-393" unitRef="usd">48024000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-6" id="f-394" unitRef="usd">232000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-395" unitRef="usd">48256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-396" unitRef="usd">4691000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-6" id="f-397" unitRef="usd">3705000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-6" id="f-398" unitRef="usd">3784000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-399" unitRef="usd">2861000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-25" decimals="-6" id="f-400" unitRef="usd">2647000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-26" decimals="-6" id="f-401" unitRef="usd">2697000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-6" id="f-402" unitRef="usd">123000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-25" decimals="-6" id="f-403" unitRef="usd">90000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-26" decimals="-6" id="f-404" unitRef="usd">73000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-6" id="f-405" unitRef="usd">-316000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-25" decimals="-6" id="f-406" unitRef="usd">-508000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-26" decimals="-6" id="f-407" unitRef="usd">-226000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-408" unitRef="usd">429000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-25" decimals="-6" id="f-409" unitRef="usd">393000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-26" decimals="-6" id="f-410" unitRef="usd">355000000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-6" id="f-411" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-25" decimals="-6" id="f-412" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-26" decimals="-6" id="f-413" unitRef="usd">-53000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-414" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-25" decimals="-6" id="f-415" unitRef="usd">371000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-26" decimals="-6" id="f-416" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-6" id="f-417" unitRef="usd">-310000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-25" decimals="-6" id="f-418" unitRef="usd">-573000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-26" decimals="-6" id="f-419" unitRef="usd">-270000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-1" decimals="-6" id="f-420" unitRef="usd">433000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-25" decimals="-6" id="f-421" unitRef="usd">391000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable contextRef="c-26" decimals="-6" id="f-422" unitRef="usd">576000000</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-423" unitRef="usd">292000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-25" decimals="-6" id="f-424" unitRef="usd">139000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-26" decimals="-6" id="f-425" unitRef="usd">939000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-6" id="f-426" unitRef="usd">209000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-25" decimals="-6" id="f-427" unitRef="usd">391000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-26" decimals="-6" id="f-428" unitRef="usd">696000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-429" unitRef="usd">538000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-25" decimals="-6" id="f-430" unitRef="usd">345000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-26" decimals="-6" id="f-431" unitRef="usd">148000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-432" unitRef="usd">7044000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-25" decimals="-6" id="f-433" unitRef="usd">6787000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-26" decimals="-6" id="f-434" unitRef="usd">6039000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-435" unitRef="usd">98000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-25" decimals="-6" id="f-436" unitRef="usd">211000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-26" decimals="-6" id="f-437" unitRef="usd">1867000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-438" unitRef="usd">1859000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-25" decimals="-6" id="f-439" unitRef="usd">1587000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-26" decimals="-6" id="f-440" unitRef="usd">1459000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-6" id="f-441" unitRef="usd">8226000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-25" decimals="-6" id="f-442" unitRef="usd">7748000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-26" decimals="-6" id="f-443" unitRef="usd">7514000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-6" id="f-444" unitRef="usd">8495000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-25" decimals="-6" id="f-445" unitRef="usd">7441000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-26" decimals="-6" id="f-446" unitRef="usd">7343000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-447" unitRef="usd">249000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-25" decimals="-6" id="f-448" unitRef="usd">261000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-26" decimals="-6" id="f-449" unitRef="usd">-4000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-450" unitRef="usd">-1937000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-25" decimals="-6" id="f-451" unitRef="usd">-2366000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-26" decimals="-6" id="f-452" unitRef="usd">-3493000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-1" decimals="-6" id="f-453" unitRef="usd">-1070000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-25" decimals="-6" id="f-454" unitRef="usd">1073000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess contextRef="c-26" decimals="-6" id="f-455" unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-6" id="f-456" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-25" decimals="-6" id="f-457" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-26" decimals="-6" id="f-458" unitRef="usd">2284000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-6" id="f-459" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-25" decimals="-6" id="f-460" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-26" decimals="-6" id="f-461" unitRef="usd">2279000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-6" id="f-462" unitRef="usd">3209000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-25" decimals="-6" id="f-463" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-26" decimals="-6" id="f-464" unitRef="usd">5409000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-465" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-25" decimals="-6" id="f-466" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-26" decimals="-6" id="f-467" unitRef="usd">6012000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-468" unitRef="usd">3589000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-25" decimals="-6" id="f-469" unitRef="usd">3666000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-26" decimals="-6" id="f-470" unitRef="usd">3616000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-1" decimals="-6" id="f-471" unitRef="usd">508000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-25" decimals="-6" id="f-472" unitRef="usd">284000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-26" decimals="-6" id="f-473" unitRef="usd">308000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-474" unitRef="usd">3235000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-25" decimals="-6" id="f-475" unitRef="usd">2138000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-26" decimals="-6" id="f-476" unitRef="usd">645000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-477" unitRef="usd">-184000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-25" decimals="-6" id="f-478" unitRef="usd">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-26" decimals="-6" id="f-479" unitRef="usd">-409000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-480" unitRef="usd">-4361000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-25" decimals="-6" id="f-481" unitRef="usd">-4450000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-26" decimals="-6" id="f-482" unitRef="usd">-4960000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-6" id="f-483" unitRef="usd">188000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-6" id="f-484" unitRef="usd">-230000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-6" id="f-485" unitRef="usd">243000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-486" unitRef="usd">934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-25" decimals="-6" id="f-487" unitRef="usd">-259000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-26" decimals="-6" id="f-488" unitRef="usd">-2171000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-489" unitRef="usd">1284000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-6" id="f-490" unitRef="usd">1543000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-6" id="f-491" unitRef="usd">3714000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-6" id="f-492" unitRef="usd">2218000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-6" id="f-493" unitRef="usd">1284000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-6" id="f-494" unitRef="usd">1543000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-6" id="f-495" unitRef="usd">1819000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-25" decimals="-6" id="f-496" unitRef="usd">1622000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-26" decimals="-6" id="f-497" unitRef="usd">1548000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-498" unitRef="usd">762000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-25" decimals="-6" id="f-499" unitRef="usd">826000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-26" decimals="-6" id="f-500" unitRef="usd">606000000</us-gaap:InterestPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-501">Summary of Significant Accounting Policies &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Operations   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic plc (Medtronic or the Company)&#160;is the leading global healthcare technology company &#x2013; alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies to serve healthcare systems, physicians, clinicians, and patients. Medtronic was founded in 1949 and is headquartered in Galway, Ireland. In May 2025, the Company announced its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company. The separation is expected to be completed within 18 months of the initial announcement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible assets, equity investments, and liability valuations. Actual results may or may not differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year-End&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for each of the three fiscal years ended April&#160;25, 2025 (fiscal year 2025), April&#160;26, 2024 (fiscal year 2024), and April&#160;28, 2023 (fiscal year 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#x2019;s investment and are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Goodwill and Intangible Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#x2019;s net assets exceeds the estimated fair value of the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from &lt;span style="-sec-ix-hidden:f-513"&gt;three&lt;/span&gt; to 20 years. Amortization is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the asset group's carrying value to its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group is estimated by utilizing a discounted cash flow analysis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;amp;D with no alternative future use acquired outside of a business combination is expensed immediately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain of the Company&#x2019;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#x2019;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Self-Insurance  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#x2019; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Assumptions  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. Refer to Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency exchange rate contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#x2019;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other intangible assets, and IPR&amp;amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For certain of our capital equipment, control is transferred upon installation. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general, and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and were $322 million, $341 million, and $351 million in fiscal years 2025, 2024, and 2023, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#x2019;s tax return but has not yet been recognized as an expense in the consolidated statements of income.&#160;See Note 13 for more information on the Company's uncertain tax positions and tax policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating (Income) Expense, Net  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other operating (income) expense, net primarily includes royalty expense, currency remeasurement and derivative gains and losses, changes in fair value of contingent consideration, certain acquisition and divestiture-related items, income from funded research and development arrangements, Puerto Rico excise taxes, and commitments to the Medtronic Foundation and Medtronic LABS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Other Non-Operating Income, Net   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Currency Translation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplier Finance Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements but did require additional disclosures. Refer to Note 6 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company retrospectively adopted this guidance beginning in the fourth quarter of fiscal year 2025. The adoption of this standard did not have a material impact on the Company's consolidated financial statements but did require additional disclosures. Refer to Note 19 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-502">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation  &lt;/span&gt; The consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-503">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Amounts reported in millions within this annual report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-504">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, goodwill, intangible assets, equity investments, and liability valuations. Actual results may or may not differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FiscalPeriod contextRef="c-1" id="f-505">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year-End&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at April&#160;25, 2025 and April&#160;26, 2024 and for each of the three fiscal years ended April&#160;25, 2025 (fiscal year 2025), April&#160;26, 2024 (fiscal year 2024), and April&#160;28, 2023 (fiscal year 2023).&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company considers highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company invests in marketable debt and equity securities, investments for which the Company has elected the fair value option, investments that do not have readily determinable fair values, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable debt securities are classified and accounted for as available-for-sale. These investments are recorded at fair value in the consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. The classification of marketable debt securities as current or long-term is based on the nature of the securities and the availability for use in current operations consistent with the Company's management of its capital structure and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s investments in marketable equity securities and other securities are long-term, strategic investments in companies that are in various stages of development and are primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. Marketable equity securities are recorded at fair value in the consolidated balance sheets. The change in fair value of marketable equity securities is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. At each reporting period, the Company makes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. Equity method investments for which the Company has elected the fair value option are valued using a discounted cash flow methodology, taking into consideration various assumptions including discount rate and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Equity securities accounted for under the equity method are initially recorded at the amount of the Company&#x2019;s investment and are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividends paid. Securities accounted for under the equity method are reviewed quarterly for changes in circumstance or the occurrence of events that suggest other than temporary impairment has occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-508">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts and Credit Losses   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants credit to customers in the normal course of business and maintains an allowance for doubtful accounts for potential credit losses. When evaluating allowances for doubtful accounts, the Company considers various factors, including historical experience and customer-specific information. Uncollectible accounts are written-off against the allowance when it is deemed that a customer account is uncollectible.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-509">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories  &lt;/span&gt; Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Property, plant, and equipment is stated at cost and depreciated over the useful lives of the assets using the straight-line method. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. The Company assesses property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of asset groupings may not be recoverable. The cost of interest that is incurred in connection with significant ongoing construction projects is capitalized using a weighted average interest rate. These costs are included in property, plant, and equipment and amortized over the useful life of the related asset. Upon retirement or disposal of property, plant, and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts. The difference, if any, between the net asset value and the proceeds, is recognized in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-511">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Goodwill and Intangible Assets &lt;/span&gt;  Goodwill is the excess of the purchase price over the estimated fair value of identified net assets of acquired businesses. The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit&#x2019;s net assets exceeds the estimated fair value of the reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-512">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and in-process research and development (IPR&amp;amp;D). Intangible assets with a definite life are amortized on a straight-line basis with estimated useful lives typically ranging from &lt;span style="-sec-ix-hidden:f-513"&gt;three&lt;/span&gt; to 20 years. Amortization is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Intangible assets with a definite life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group, which includes intangible assets, may not be recoverable.&lt;/span&gt;&lt;/div&gt;When events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the asset group's carrying value to its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The fair value of an asset group is estimated by utilizing a discounted cash flow analysis.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-73" id="f-514">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-515">Acquired IPR&amp;amp;D represents the fair value assigned to those research and development projects that were primarily acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&amp;amp;D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. The fair value of IPR&amp;amp;D is determined by estimating the future cash flows of each project and discounting the net cash flows back to their present values. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a definite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&amp;amp;D, which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually in the third quarter of the fiscal year, prior to moving to definite-lived, and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset&#x2019;s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. IPR&amp;amp;D with no alternative future use acquired outside of a business combination is expensed immediately.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <mdt:ContingentConsiderationPolicyTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain of the Company&#x2019;s business combinations involve potential payment or receipt of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. The Company records contingent consideration at fair value at the date of acquisition or divestiture based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected revenues are based on the Company&#x2019;s most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Contingent consideration payments made or received soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made or received soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;statements of cash flows, and amounts paid or received in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</mdt:ContingentConsiderationPolicyTextBlock>
    <us-gaap:SelfInsuranceReservePolicyTextBlock contextRef="c-1" id="f-517">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Self-Insurance  &lt;/span&gt; The Company self-insures the majority of its insurable risks, including medical and dental costs, disability coverage, physical loss to property, business interruptions, workers&#x2019; compensation, comprehensive general, and product liability. Insurance coverage is obtained for risks required to be insured by law or contract. The Company uses claims data and historical experience, as applicable, to estimate liabilities associated with the exposures that the Company has self-insured.</us-gaap:SelfInsuranceReservePolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy contextRef="c-1" id="f-518">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Assumptions  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. Refer to Note 15 for assumptions used in determining pension and post-retirement benefit costs and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-519">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value in accordance with authoritative guidance on derivatives and hedging, and presents assets and liabilities associated with derivative financial instruments on a gross basis in the consolidated financial statements. For derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or hedges of net investments, based upon the exposure being hedged. See Note 7 for more information on the Company's derivative instruments and hedging programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-520">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability, based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Inputs are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets that are classified as Level 1 securities include highly liquid government bonds within U.S. government and agency securities, mutual funds, short-term investments, and equity securities for which quoted market prices are available. In addition, the Company classifies currency exchange rate contracts as Level 1 since they are valued using quoted market prices in active markets which have identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, government and agency securities, other asset-backed securities, and mortgage-backed securities whose value is determined using inputs that are observable in the market or may be derived principally from, or corroborated by, observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, total return swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Financial assets that are classified as Level 3 include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation, equity method investments for which the Company has elected the fair value option, and auction rate securities. The investment securities with limited market activity are valued using third-party pricing sources that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments by market participants. The fair value of auction rate securities is estimated by the Company using a discounted cash flow model, which incorporates significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the Company&#x2019;s auction rate securities are years to principal recovery and the illiquidity premium that is incorporated into the discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation techniques for investments valued using the fair value option are included in the "Investments" section above. For goodwill, other intangible assets, and IPR&amp;amp;D, inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are excluded from the fair value hierarchy. Financial assets for which the fair value is measured using the net asset value per share practical expedient include equity and fixed income commingled trusts, partnership units, and registered investment companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily sells its products through direct sales representatives and independent distributors. Additionally, a portion of the Company's revenue is generated from consignment inventory maintained at hospitals and royalty and intellectual property arrangements. The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is typically transferred upon shipment or upon delivery, based on the contract terms and legal requirements. For certain of our capital equipment, control is transferred upon installation. For consignment inventory, control is transferred when the product is used or implanted. Payment terms vary depending on the country of sale, type of customer, and type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis. In estimating rebates, the Company considers the lag time between the point of sale and the payment of the rebate claim, the stated rebate rates, and other relevant information. The Company records adjustments to rebates and returns reserves as increases or decreases of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue primarily represents remote monitoring services and equipment maintenance, for which consideration is received at the same time as consideration for the device or equipment. Revenue related to remote monitoring services and equipment maintenance is recognized over the service period as time elapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred to physically move product from the Company's premises to the customer's premises are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general, and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and were $322 million, $341 million, and $351 million in fiscal years 2025, 2024, and 2023, respectively. Other shipping and handling costs incurred to store, move, and prepare products for shipment are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-74" decimals="-6" id="f-522" unitRef="usd">322000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-75" decimals="-6" id="f-523" unitRef="usd">341000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-76" decimals="-6" id="f-524" unitRef="usd">351000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-525">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and license payments for technology not yet approved by regulators.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-526">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;  The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-527">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;  The Company has deferred taxes that arise as a result of the different treatment of transactions for U.S. GAAP and income tax accounting, known as temporary differences. The Company records the tax effect of these temporary differences as deferred tax assets and deferred tax liabilities. Deferred tax assets generally represent items that may be used as a tax deduction or credit in a tax return in future years for which the Company has already recognized the tax benefit in the consolidated statements of income. The Company establishes valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense for which payment has been deferred or expense has already been taken as a deduction on the Company&#x2019;s tax return but has not yet been recognized as an expense in the consolidated statements of income.</us-gaap:IncomeTaxPolicyTextBlock>
    <mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating (Income) Expense, Net  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Other operating (income) expense, net primarily includes royalty expense, currency remeasurement and derivative gains and losses, changes in fair value of contingent consideration, certain acquisition and divestiture-related items, income from funded research and development arrangements, Puerto Rico excise taxes, and commitments to the Medtronic Foundation and Medtronic LABS.&lt;/span&gt;&lt;/div&gt;</mdt:OtherOperatingIncomeExpenseNetPolicyTextBlock>
    <mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock contextRef="c-1" id="f-529">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Other Non-Operating Income, Net   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other non-operating income, net includes the non-service component of net periodic pension and post-retirement benefit cost, investment gains and losses, and interest income, which includes income on marketable debt securities and our global liquidity structures.&lt;/span&gt;&lt;/div&gt;</mdt:OtherNonoperatingIncomeExpenseNetPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Currency Translation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities of non-U.S. dollar functional currency entities are translated to U.S. dollars at period-end exchange rates, and the currency impacts arising from the translation of the assets and liabilities are recorded as a cumulative translation adjustment, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets. Elements of the consolidated statements of income are translated at the average monthly currency exchange rates in effect during the period. Currency transaction gains and losses are included in o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-531">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are expected to vest. The Company estimates pre-vesting forfeitures at the time of grant and revises the estimates in subsequent periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-532">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplier Finance Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-04, Liabilities&#x2014; Supplier Finance Programs (Subtopic 405-50), which requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program&#x2019;s nature, activity during the period, changes from period to period, and potential magnitude. The Company adopted this guidance on April 29, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements but did require additional disclosures. Refer to Note 6 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company retrospectively adopted this guidance beginning in the fourth quarter of fiscal year 2025. The adoption of this standard did not have a material impact on the Company's consolidated financial statements but did require additional disclosures. Refer to Note 19 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-533">Revenue &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiac Rhythm &amp;amp; Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Structural Heart &amp;amp; Aortic &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coronary &amp;amp; Peripheral Vascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cranial &amp;amp; Spinal Technologies &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical &amp;amp; Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acute Care &amp;amp; Monitoring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-0.01pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Includes operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At April&#160;25, 2025, $983&#160;million of rebates were classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$680&#160;million of reba&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tes were classified as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheet. At April&#160;26, 2024, $1.0 billion of rebates were classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $574 million of rebates were classified as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheet. During fiscal year 2025, adjustments to rebate and return reserves recorded in prior periods were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Revenue and Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue at April&#160;25, 2025 and April&#160;26, 2024 was $446&#160;million and $453&#160;million, respectively. At April&#160;25, 2025 and April&#160;26, 2024, $354&#160;million and $352&#160;million was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, and $92&#160;million and $101&#160;million was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. During the fiscal year ended&#160;April&#160;25, 2025, the Company recognized&#160;$320 million&#160;of revenue that was included in deferred revenue as of&#160;April&#160;26, 2024. During the fiscal year ended April&#160;26, 2024, the Company recognized $324 million of revenue that was included in deferred revenue at April&#160;28, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At April&#160;25, 2025, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.3&#160;billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below illustrates net sales by segment and division and by market geography for fiscal years 2025, 2024, and 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiac Rhythm &amp;amp; Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Structural Heart &amp;amp; Aortic &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coronary &amp;amp; Peripheral Vascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cranial &amp;amp; Spinal Technologies &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical &amp;amp; Endoscopy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acute Care &amp;amp; Monitoring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-0.01pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.774%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Includes operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-6" id="f-535" unitRef="usd">6392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-6" id="f-536" unitRef="usd">5995000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-6" id="f-537" unitRef="usd">5783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-6" id="f-538" unitRef="usd">3554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-6" id="f-539" unitRef="usd">3358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-6" id="f-540" unitRef="usd">3363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-6" id="f-541" unitRef="usd">2535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-6" id="f-542" unitRef="usd">2478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-6" id="f-543" unitRef="usd">2375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-6" id="f-544" unitRef="usd">12481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-6" id="f-545" unitRef="usd">11831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-6" id="f-546" unitRef="usd">11522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-6" id="f-547" unitRef="usd">4973000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-6" id="f-548" unitRef="usd">4756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-6" id="f-549" unitRef="usd">4451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-6" id="f-550" unitRef="usd">2940000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-6" id="f-551" unitRef="usd">2905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-6" id="f-552" unitRef="usd">2815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-6" id="f-553" unitRef="usd">1932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-6" id="f-554" unitRef="usd">1746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-6" id="f-555" unitRef="usd">1693000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-6" id="f-556" unitRef="usd">9846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-6" id="f-557" unitRef="usd">9406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-6" id="f-558" unitRef="usd">8959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-6" id="f-559" unitRef="usd">6498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-6" id="f-560" unitRef="usd">6508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-6" id="f-561" unitRef="usd">6152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-6" id="f-562" unitRef="usd">1909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-6" id="f-563" unitRef="usd">1908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-6" id="f-564" unitRef="usd">1837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-6" id="f-565" unitRef="usd">8407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-6" id="f-566" unitRef="usd">8417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-6" id="f-567" unitRef="usd">7989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-6" id="f-568" unitRef="usd">2755000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-6" id="f-569" unitRef="usd">2488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-6" id="f-570" unitRef="usd">2262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-6" id="f-571" unitRef="usd">33489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-6" id="f-572" unitRef="usd">32142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-6" id="f-573" unitRef="usd">30731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-6" id="f-574" unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-6" id="f-575" unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-6" id="f-576" unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-6" id="f-577" unitRef="usd">-90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-6" id="f-578" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-6" id="f-579" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-580" unitRef="usd">33537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-581" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-582" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-6" id="f-583" unitRef="usd">5804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-6" id="f-584" unitRef="usd">5597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-124" decimals="-6" id="f-585" unitRef="usd">5796000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-125" decimals="-6" id="f-586" unitRef="usd">6677000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-126" decimals="-6" id="f-587" unitRef="usd">6234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-127" decimals="-6" id="f-588" unitRef="usd">5725000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-128" decimals="-6" id="f-589" unitRef="usd">6713000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-129" decimals="-6" id="f-590" unitRef="usd">6305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-6" id="f-591" unitRef="usd">6018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-6" id="f-592" unitRef="usd">3133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-6" id="f-593" unitRef="usd">3101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-6" id="f-594" unitRef="usd">2941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-134" decimals="-6" id="f-595" unitRef="usd">3664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-135" decimals="-6" id="f-596" unitRef="usd">3717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-6" id="f-597" unitRef="usd">3549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-6" id="f-598" unitRef="usd">4744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-138" decimals="-6" id="f-599" unitRef="usd">4700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-6" id="f-600" unitRef="usd">4440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-140" decimals="-6" id="f-601" unitRef="usd">923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-6" id="f-602" unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-6" id="f-603" unitRef="usd">849000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-143" decimals="-6" id="f-604" unitRef="usd">1832000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-144" decimals="-6" id="f-605" unitRef="usd">1636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-145" decimals="-6" id="f-606" unitRef="usd">1413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-6" id="f-607" unitRef="usd">17104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-147" decimals="-6" id="f-608" unitRef="usd">16471000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-148" decimals="-6" id="f-609" unitRef="usd">16212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-149" decimals="-6" id="f-610" unitRef="usd">16386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-150" decimals="-6" id="f-611" unitRef="usd">15671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-151" decimals="-6" id="f-612" unitRef="usd">14519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-152" decimals="-6" id="f-613" unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-153" decimals="-6" id="f-614" unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-154" decimals="-6" id="f-615" unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-155" decimals="-6" id="f-616" unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-156" decimals="-6" id="f-617" unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-157" decimals="-6" id="f-618" unitRef="usd">335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-158" decimals="-6" id="f-619" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-159" decimals="-6" id="f-620" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-160" decimals="-6" id="f-621" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-6" id="f-622" unitRef="usd">-90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-162" decimals="-6" id="f-623" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-163" decimals="-6" id="f-624" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="-6" id="f-625" unitRef="usd">17171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="-6" id="f-626" unitRef="usd">16562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-6" id="f-627" unitRef="usd">16373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-167" decimals="-6" id="f-628" unitRef="usd">16365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-168" decimals="-6" id="f-629" unitRef="usd">15802000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-169" decimals="-6" id="f-630" unitRef="usd">14854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-170" decimals="-6" id="f-631" unitRef="usd">983000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-171" decimals="-6" id="f-632" unitRef="usd">680000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-172" decimals="-8" id="f-633" unitRef="usd">1000000000.0</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-173" decimals="-6" id="f-634" unitRef="usd">574000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-24" decimals="-6" id="f-635" unitRef="usd">446000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-27" decimals="-6" id="f-636" unitRef="usd">453000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-170" decimals="-6" id="f-637" unitRef="usd">354000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-172" decimals="-6" id="f-638" unitRef="usd">352000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-174" decimals="-6" id="f-639" unitRef="usd">92000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-175" decimals="-6" id="f-640" unitRef="usd">101000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-6" id="f-641" unitRef="usd">320000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-25" decimals="-6" id="f-642" unitRef="usd">324000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-24" decimals="-8" id="f-643" unitRef="usd">300000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming contextRef="c-1" id="f-644">three years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-645">Acquisitions, Dispositions, and Funded Research and Development Arrangements &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had acquisitions during fiscal years 2025 and 2024 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company&#x2019;s consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions during fiscal years 2025 and 2024 was not significant, either individually or in the aggregate, to the consolidated results of the Company. Purchase price allocation adjustments for fiscal years 2025 and 2024 business combinations were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair value of net assets acquired during fiscal year 2025 was $128&#160;million, consisting of $159 million of assets acquired and $31 million of liabilities assumed. Based on preliminary valuations, assets acquired were primarily comprised of $108&#160;million of goodwill and $50&#160;million of IPR&amp;amp;D. The goodwill is not deductible for tax purposes. The Company recognized $20&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2025, which comprised of other milestone-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair value of net assets acquired during fiscal year 2024 was $335&#160;million, consisting of $338&#160;million of assets acquired and $3&#160;million of liabilities assumed. Assets acquired were primarily comprised of $131&#160;million of goodwill, $150&#160;million of IPR&amp;amp;D, and $29&#160;million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, $51&#160;million of goodwill is deductible while $80&#160;million is not deductible. The IPR&amp;amp;D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized $30&#160;million of non-cash contingent consideration liabilities in connection with these business combinations during fiscal year 2024, which are comprised of revenue and product development milestone-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Disposal Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ventilator Product Line Exit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM). In connection with this decision, the Company recorded pre-tax charges of $439&#160;million, including $369&#160;million recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$70&#160;million recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income in fiscal year 2024. The charges included $371&#160;million of non-cash impairments and write-downs primarily related to $295&#160;million of long-lived asset impairments to write-down the value of related intangible assets to zero and $70&#160;million of inventory-write downs. The other charges primarily related to contract cancellation costs and severance. The Company will continue to honor existing ventilator contracts to serve the needs of its customers and their patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Renal Care Solutions (RCS) Disposition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company and DaVita Inc. (DaVita) entered into a definitive agreement for the Company to sell half of its RCS business, and on April 1, 2023, completed the transaction. This sale was part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (&#x201c;Mozarc Medical&#x201d; or "Mozarc") with equal equity ownership. At closing, the Company received $45&#160;million cash consideration, recorded non-cash contingent consideration receivables valued at $195&#160;million, made an additional cash investment of $224&#160;million, and retained a 50% non-controlling equity interest in Mozarc valued at $307&#160;million. For the contingent consideration receivables, the maximum consideration the Company could receive in the future is $300&#160;million based on the achievement of certain milestones, as further described below. The Company recorded non-cash pre-tax charges of $136&#160;million in fiscal year 2023, primarily related to impairment of goodwill and changes in the carrying amount of the disposal group, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Refer to Note 9 to the consolidated financial statements for additional information on the goodwill impairment. Refer to Note 5 to the consolidated financial statements for additional information on the Company&#x2019;s retained 50% equity investment in Mozarc as a result of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the sale of the RCS business did not meet the criteria to be classified as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of contingent consideration liabilities at April&#160;25, 2025 and April&#160;26, 2024 was $81 million and $149 million, respectively. At April&#160;25, 2025, $31 million was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $50 million was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. At April&#160;26, 2024, $96 million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $53 million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue and other performance-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5% - 28.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product development and other milestone-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the sale of our RCS business as further discussed above, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at April&#160;25, 2025 and April&#160;26, 2024 was $13 million and $58&#160;million,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, and was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Funded Research and Development Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. (collectively, "Blackstone") to receive funding related to the development of certain products within the Cardiovascular Portfolio and Diabetes Operating Unit. As there is substantive and genuine transfer of risk to Blackstone, the development funding is recognized by Medtronic as an obligation to perform contractual services. The Company recognizes the funding as income within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-709"&gt;other operating (income) expense, net&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as the research and development costs are incurred and funding payments become due. Under these arrangements, the Company recognized income of $181&#160;million, $174&#160;million, and $202&#160;million in fiscal years 2025, 2024, and 2023, respectively. As of April&#160;25, 2025, the Company is eligible to receive additional funding of $391&#160;million under these arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following potential U.S. regulatory approval and commercial launch of each product covered by the Blackstone agreements, Blackstone will be eligible to receive a combination of fixed regulatory and commercial milestone payments up to $1.2&#160;billion and royalties based on percent of sales of such products. Under certain termination provisions, the Company's payment obligation will survive, and in certain termination circumstances, a payment to Blackstone of a multiple of the funded amounts may be required. At the time of executing these contracts, the occurrence of such circumstances was deemed to be remote.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-176" decimals="-6" id="f-646" unitRef="usd">128000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-177" decimals="-6" id="f-647" unitRef="usd">159000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-177" decimals="-6" id="f-648" unitRef="usd">31000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill contextRef="c-177" decimals="-6" id="f-649" unitRef="usd">108000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-178" decimals="-6" id="f-650" unitRef="usd">50000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-177" decimals="-6" id="f-651" unitRef="usd">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-179" decimals="-6" id="f-652" unitRef="usd">335000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-180" decimals="-6" id="f-653" unitRef="usd">338000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-180" decimals="-6" id="f-654" unitRef="usd">3000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill contextRef="c-180" decimals="-6" id="f-655" unitRef="usd">131000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-181" decimals="-6" id="f-656" unitRef="usd">150000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-182" decimals="-6" id="f-657" unitRef="usd">29000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-182" id="f-658">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillImpairmentLossNetOfTax contextRef="c-179" decimals="-6" id="f-659" unitRef="usd">51000000</us-gaap:GoodwillImpairmentLossNetOfTax>
    <us-gaap:GoodwillNotAllocatedAmount contextRef="c-180" decimals="-6" id="f-660" unitRef="usd">80000000</us-gaap:GoodwillNotAllocatedAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-180" decimals="-6" id="f-661" unitRef="usd">30000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessExitCosts1 contextRef="c-183" decimals="-6" id="f-662" unitRef="usd">439000000</us-gaap:BusinessExitCosts1>
    <mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet contextRef="c-183" decimals="-6" id="f-663" unitRef="usd">369000000</mdt:DisposalGroupIncludingDiscontinuedOperationOtherOperatingIncomeExpenseNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-183" decimals="-6" id="f-664" unitRef="usd">70000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments contextRef="c-184" decimals="-6" id="f-665" unitRef="usd">371000000</mdt:DisposalGroupIncludingDiscontinuedOperationNonCashImpairments>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-185" decimals="-6" id="f-666" unitRef="usd">295000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InventoryWriteDown contextRef="c-183" decimals="-6" id="f-667" unitRef="usd">70000000</us-gaap:InventoryWriteDown>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-186" decimals="-6" id="f-668" unitRef="usd">45000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-187" decimals="-6" id="f-669" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-186" decimals="-6" id="f-670" unitRef="usd">224000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-188" decimals="2" id="f-671" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterest contextRef="c-189" decimals="-6" id="f-672" unitRef="usd">307000000</us-gaap:MinorityInterest>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-190" decimals="-6" id="f-673" unitRef="usd">300000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:AssetImpairmentCharges contextRef="c-191" decimals="-6" id="f-674" unitRef="usd">136000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-192" decimals="2" id="f-675" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-24" decimals="-6" id="f-676" unitRef="usd">81000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-27" decimals="-6" id="f-677" unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-170" decimals="-6" id="f-678" unitRef="usd">31000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-174" decimals="-6" id="f-679" unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-172" decimals="-6" id="f-680" unitRef="usd">96000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-175" decimals="-6" id="f-681" unitRef="usd">53000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c-1" id="f-682">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-27" decimals="-6" id="f-683" unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-47" decimals="-6" id="f-684" unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-1" decimals="-6" id="f-685" unitRef="usd">20000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:BusinessAcquisitionPriceContingentConsideration contextRef="c-25" decimals="-6" id="f-686" unitRef="usd">30000000</mdt:BusinessAcquisitionPriceContingentConsideration>
    <mdt:BusinessAcquisitionContingentConsiderationMilestonePayment contextRef="c-1" decimals="-6" id="f-687" unitRef="usd">86000000</mdt:BusinessAcquisitionContingentConsiderationMilestonePayment>
    <mdt:BusinessAcquisitionContingentConsiderationMilestonePayment contextRef="c-25" decimals="-6" id="f-688" unitRef="usd">104000000</mdt:BusinessAcquisitionContingentConsiderationMilestonePayment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-6" id="f-689" unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-25" decimals="-6" id="f-690" unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-24" decimals="-6" id="f-691" unitRef="usd">81000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-27" decimals="-6" id="f-692" unitRef="usd">149000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-693">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue and other performance-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5% - 28.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product development and other milestone-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.02pt"&gt;Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-193" decimals="-6" id="f-694" unitRef="usd">54000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-194" decimals="3" id="f-695" unitRef="number">0.165</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-195" decimals="3" id="f-696" unitRef="number">0.282</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-196" decimals="3" id="f-697" unitRef="number">0.231</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-197" decimals="-6" id="f-698" unitRef="usd">27000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-198" decimals="3" id="f-699" unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-199" decimals="3" id="f-700" unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-200" decimals="-6" id="f-701" unitRef="usd">13000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-27" decimals="-6" id="f-702" unitRef="usd">58000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-201" decimals="-6" id="f-703" unitRef="usd">58000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-202" decimals="-6" id="f-704" unitRef="usd">195000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue contextRef="c-203" decimals="-6" id="f-705" unitRef="usd">-45000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue contextRef="c-204" decimals="-6" id="f-706" unitRef="usd">-138000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-200" decimals="-6" id="f-707" unitRef="usd">13000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable contextRef="c-201" decimals="-6" id="f-708" unitRef="usd">58000000</mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-6" id="f-710" unitRef="usd">181000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-25" decimals="-6" id="f-711" unitRef="usd">174000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-26" decimals="-6" id="f-712" unitRef="usd">202000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:DeferredIncome contextRef="c-205" decimals="-6" id="f-713" unitRef="usd">391000000</us-gaap:DeferredIncome>
    <mdt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-205" decimals="-8" id="f-714" unitRef="usd">1200000000</mdt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-715">Restructuring Charges &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal years 2025 and 2024, the Company incurred $303 million and $389 million, respectively, of restructuring and associated costs primarily related to cost reduction initiatives, which predominantly included employee termination benefits, facility consolidations, and asset write-downs, and specifically for fiscal year 2025, contract terminations. In fiscal year 2023, restructuring costs primarily related to Enterprise Excellence and Simplification restructuring programs, both of which were substantially completed as of the end fiscal year 2023. Enterprise Excellence was designed to leverage the Company&#x2019;s global size and scale to focus on global operations, and functional and commercial optimization, and had total cumulative pre-tax charges of $1.8 billion. Simplification was designed to focus the organization on accelerating innovation, enhancing customer experience, driving revenue growth and winning market share, and had total cumulative pre-tax charges of $0.5 billion. In addition, in the fourth quarter of fiscal year 2023, the Company incurred $0.3 billion of restructuring charges primarily related to employee termination benefits to support cost reduction initiatives. These charges were incremental to charges incurred under our Enterprise Excellence and Simplification programs noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and, specifically for fiscal year 2023, voluntary early retirement benefits. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting fees, asset write-offs, and contract terminations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of restructuring costs in the consolidated statements of income: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-722"&gt;&lt;span style="-sec-ix-hidden:f-723"&gt;&lt;span style="-sec-ix-hidden:f-724"&gt;Cost of products sold&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-728"&gt;&lt;span style="-sec-ix-hidden:f-729"&gt;&lt;span style="-sec-ix-hidden:f-730"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the activity related to restructuring programs for fiscal years 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Associated and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCosts contextRef="c-1" decimals="-6" id="f-716" unitRef="usd">303000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-25" decimals="-6" id="f-717" unitRef="usd">389000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-206" decimals="-8" id="f-718" unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-207" decimals="-8" id="f-719" unitRef="usd">500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-208" decimals="-8" id="f-720" unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-721">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of restructuring costs in the consolidated statements of income: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-722"&gt;&lt;span style="-sec-ix-hidden:f-723"&gt;&lt;span style="-sec-ix-hidden:f-724"&gt;Cost of products sold&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-728"&gt;&lt;span style="-sec-ix-hidden:f-729"&gt;&lt;span style="-sec-ix-hidden:f-730"&gt;Selling, general, and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In fiscal year 2023, restructuring charges, net included $94&#160;million of incremental defined benefit, defined contribution, and post-retirement related expenses for employees that accepted voluntary early retirement packages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the activity related to restructuring programs for fiscal years 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Associated and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-211" decimals="-6" id="f-725" unitRef="usd">26000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-210" decimals="-6" id="f-726" unitRef="usd">55000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-209" decimals="-6" id="f-727" unitRef="usd">97000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-212" decimals="-6" id="f-731" unitRef="usd">10000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-214" decimals="-6" id="f-732" unitRef="usd">108000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-213" decimals="-6" id="f-733" unitRef="usd">173000000</us-gaap:RestructuringCharges>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-1" decimals="-6" id="f-734" unitRef="usd">267000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-25" decimals="-6" id="f-735" unitRef="usd">226000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact contextRef="c-26" decimals="-6" id="f-736" unitRef="usd">375000000</mdt:RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact>
    <us-gaap:RestructuringCosts contextRef="c-1" decimals="-6" id="f-737" unitRef="usd">303000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-25" decimals="-6" id="f-738" unitRef="usd">389000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-26" decimals="-6" id="f-739" unitRef="usd">647000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-215" decimals="-6" id="f-740" unitRef="usd">94000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-216" decimals="-6" id="f-741" unitRef="usd">204000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-217" decimals="-6" id="f-742" unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-47" decimals="-6" id="f-743" unitRef="usd">230000000</us-gaap:RestructuringReserve>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-218" decimals="-6" id="f-744" unitRef="usd">233000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-219" decimals="-6" id="f-745" unitRef="usd">163000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-25" decimals="-6" id="f-746" unitRef="usd">396000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <us-gaap:PaymentsForRestructuring contextRef="c-218" decimals="-6" id="f-747" unitRef="usd">292000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-219" decimals="-6" id="f-748" unitRef="usd">161000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-25" decimals="-6" id="f-749" unitRef="usd">453000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-218" decimals="-6" id="f-750" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-219" decimals="-6" id="f-751" unitRef="usd">16000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-25" decimals="-6" id="f-752" unitRef="usd">16000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-218" decimals="-6" id="f-753" unitRef="usd">-8000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-219" decimals="-6" id="f-754" unitRef="usd">0</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-25" decimals="-6" id="f-755" unitRef="usd">-8000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve contextRef="c-220" decimals="-6" id="f-756" unitRef="usd">136000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-221" decimals="-6" id="f-757" unitRef="usd">11000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-27" decimals="-6" id="f-758" unitRef="usd">147000000</us-gaap:RestructuringReserve>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-222" decimals="-6" id="f-759" unitRef="usd">240000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-223" decimals="-6" id="f-760" unitRef="usd">82000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <mdt:RestructuringChargesIncludingAccrualAdjustments contextRef="c-1" decimals="-6" id="f-761" unitRef="usd">322000000</mdt:RestructuringChargesIncludingAccrualAdjustments>
    <us-gaap:PaymentsForRestructuring contextRef="c-222" decimals="-6" id="f-762" unitRef="usd">225000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-223" decimals="-6" id="f-763" unitRef="usd">48000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-6" id="f-764" unitRef="usd">273000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-222" decimals="-6" id="f-765" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-223" decimals="-6" id="f-766" unitRef="usd">27000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-1" decimals="-6" id="f-767" unitRef="usd">27000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-222" decimals="-6" id="f-768" unitRef="usd">-19000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-223" decimals="-6" id="f-769" unitRef="usd">0</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-1" decimals="-6" id="f-770" unitRef="usd">-19000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve contextRef="c-224" decimals="-6" id="f-771" unitRef="usd">132000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-225" decimals="-6" id="f-772" unitRef="usd">18000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-24" decimals="-6" id="f-773" unitRef="usd">150000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-774">Financial Instruments &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;25, 2025 and April&#160;26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost of debt securities excludes accrued interest, which is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the gross unrealized losses and fair values of the Company&#x2019;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;25, 2025 and April&#160;26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes activity related to the Company&#x2019;s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of available-for-sale debt securities at April&#160;25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, which includes income on marketable debt securities and the global liquidity structures, is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the consolidated statements of income. For fiscal years 2025, 2024, and 2023 there was $511 million, $597&#160;million, and $386&#160;million of interest income, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities, Equity Method Investments, and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's equity and other investments at&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April&#160;25, 2025 and April&#160;26, 2024, which are classified as primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments with readily determinable fair value (marketable equity securities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments for which the fair value option has been elected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2025, there were $181&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;25, 2025. During fiscal year 2024, there were $291&#160;million of net unrealized losses on equity securities and other investments still held at April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mozarc Medical Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. During fiscal year 2025 and 2024, the Company recognized a loss of $171 million and $220&#160;million, respectively, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-775">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April&#160;25, 2025 and April&#160;26, 2024:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.904%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-226" decimals="-6" id="f-776" unitRef="usd">417000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-226" decimals="-6" id="f-777" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-226" decimals="-6" id="f-778" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-226" decimals="-6" id="f-779" unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-227" decimals="-6" id="f-780" unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-228" decimals="-6" id="f-781" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-229" decimals="-6" id="f-782" unitRef="usd">3540000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-229" decimals="-6" id="f-783" unitRef="usd">17000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-229" decimals="-6" id="f-784" unitRef="usd">36000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-229" decimals="-6" id="f-785" unitRef="usd">3521000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-230" decimals="-6" id="f-786" unitRef="usd">3521000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-231" decimals="-6" id="f-787" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-232" decimals="-6" id="f-788" unitRef="usd">835000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-232" decimals="-6" id="f-789" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-232" decimals="-6" id="f-790" unitRef="usd">20000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-232" decimals="-6" id="f-791" unitRef="usd">814000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-233" decimals="-6" id="f-792" unitRef="usd">814000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-234" decimals="-6" id="f-793" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-235" decimals="-6" id="f-794" unitRef="usd">948000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-235" decimals="-6" id="f-795" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-235" decimals="-6" id="f-796" unitRef="usd">29000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-235" decimals="-6" id="f-797" unitRef="usd">923000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-236" decimals="-6" id="f-798" unitRef="usd">923000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-237" decimals="-6" id="f-799" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-238" decimals="-6" id="f-800" unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-238" decimals="-6" id="f-801" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-238" decimals="-6" id="f-802" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-238" decimals="-6" id="f-803" unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-239" decimals="-6" id="f-804" unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-240" decimals="-6" id="f-805" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-241" decimals="-6" id="f-806" unitRef="usd">1044000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-241" decimals="-6" id="f-807" unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-241" decimals="-6" id="f-808" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-241" decimals="-6" id="f-809" unitRef="usd">1044000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-242" decimals="-6" id="f-810" unitRef="usd">1044000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-243" decimals="-6" id="f-811" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-244" decimals="-6" id="f-812" unitRef="usd">6373000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-244" decimals="-6" id="f-813" unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-244" decimals="-6" id="f-814" unitRef="usd">91000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-244" decimals="-6" id="f-815" unitRef="usd">6308000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-245" decimals="-6" id="f-816" unitRef="usd">6308000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-246" decimals="-6" id="f-817" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-247" decimals="-6" id="f-818" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-247" decimals="-6" id="f-819" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-247" decimals="-6" id="f-820" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-247" decimals="-6" id="f-821" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-248" decimals="-6" id="f-822" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-249" decimals="-6" id="f-823" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-24" decimals="-6" id="f-824" unitRef="usd">6826000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-24" decimals="-6" id="f-825" unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-24" decimals="-6" id="f-826" unitRef="usd">100000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-24" decimals="-6" id="f-827" unitRef="usd">6752000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-250" decimals="-6" id="f-828" unitRef="usd">6719000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-251" decimals="-6" id="f-829" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-252" decimals="-6" id="f-830" unitRef="usd">494000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-252" decimals="-6" id="f-831" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-252" decimals="-6" id="f-832" unitRef="usd">22000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-252" decimals="-6" id="f-833" unitRef="usd">472000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-253" decimals="-6" id="f-834" unitRef="usd">472000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-254" decimals="-6" id="f-835" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-255" decimals="-6" id="f-836" unitRef="usd">3953000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-255" decimals="-6" id="f-837" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-255" decimals="-6" id="f-838" unitRef="usd">125000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-255" decimals="-6" id="f-839" unitRef="usd">3832000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-256" decimals="-6" id="f-840" unitRef="usd">3832000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-257" decimals="-6" id="f-841" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-258" decimals="-6" id="f-842" unitRef="usd">847000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-258" decimals="-6" id="f-843" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-258" decimals="-6" id="f-844" unitRef="usd">43000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-258" decimals="-6" id="f-845" unitRef="usd">804000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-259" decimals="-6" id="f-846" unitRef="usd">804000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-260" decimals="-6" id="f-847" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-261" decimals="-6" id="f-848" unitRef="usd">692000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-261" decimals="-6" id="f-849" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-261" decimals="-6" id="f-850" unitRef="usd">50000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-261" decimals="-6" id="f-851" unitRef="usd">643000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-262" decimals="-6" id="f-852" unitRef="usd">643000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-263" decimals="-6" id="f-853" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-264" decimals="-6" id="f-854" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-264" decimals="-6" id="f-855" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-264" decimals="-6" id="f-856" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-264" decimals="-6" id="f-857" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-265" decimals="-6" id="f-858" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-266" decimals="-6" id="f-859" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-267" decimals="-6" id="f-860" unitRef="usd">941000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-267" decimals="-6" id="f-861" unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-267" decimals="-6" id="f-862" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-267" decimals="-6" id="f-863" unitRef="usd">934000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-268" decimals="-6" id="f-864" unitRef="usd">934000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-269" decimals="-6" id="f-865" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-270" decimals="-6" id="f-866" unitRef="usd">6438000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-270" decimals="-6" id="f-867" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-270" decimals="-6" id="f-868" unitRef="usd">227000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-270" decimals="-6" id="f-869" unitRef="usd">6218000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-271" decimals="-6" id="f-870" unitRef="usd">6218000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-272" decimals="-6" id="f-871" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-273" decimals="-6" id="f-872" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-273" decimals="-6" id="f-873" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-273" decimals="-6" id="f-874" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-273" decimals="-6" id="f-875" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-274" decimals="-6" id="f-876" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-275" decimals="-6" id="f-877" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-27" decimals="-6" id="f-878" unitRef="usd">6968000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-27" decimals="-6" id="f-879" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-27" decimals="-6" id="f-880" unitRef="usd">252000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-27" decimals="-6" id="f-881" unitRef="usd">6723000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-276" decimals="-6" id="f-882" unitRef="usd">6690000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-277" decimals="-6" id="f-883" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-884">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the gross unrealized losses and fair values of the Company&#x2019;s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April&#160;25, 2025 and April&#160;26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auction rate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-278" decimals="-6" id="f-885" unitRef="usd">702000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-278" decimals="-6" id="f-886" unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-278" decimals="-6" id="f-887" unitRef="usd">1235000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-278" decimals="-6" id="f-888" unitRef="usd">29000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-279" decimals="-6" id="f-889" unitRef="usd">110000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-279" decimals="-6" id="f-890" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-279" decimals="-6" id="f-891" unitRef="usd">641000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-279" decimals="-6" id="f-892" unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-280" decimals="-6" id="f-893" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-280" decimals="-6" id="f-894" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-280" decimals="-6" id="f-895" unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-280" decimals="-6" id="f-896" unitRef="usd">28000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-281" decimals="-6" id="f-897" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-281" decimals="-6" id="f-898" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-281" decimals="-6" id="f-899" unitRef="usd">469000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-281" decimals="-6" id="f-900" unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-282" decimals="-6" id="f-901" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-282" decimals="-6" id="f-902" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-282" decimals="-6" id="f-903" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-282" decimals="-6" id="f-904" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-24" decimals="-6" id="f-905" unitRef="usd">814000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-24" decimals="-6" id="f-906" unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-24" decimals="-6" id="f-907" unitRef="usd">2993000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-24" decimals="-6" id="f-908" unitRef="usd">91000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-283" decimals="-6" id="f-909" unitRef="usd">661000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-283" decimals="-6" id="f-910" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-283" decimals="-6" id="f-911" unitRef="usd">2448000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-283" decimals="-6" id="f-912" unitRef="usd">116000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-284" decimals="-6" id="f-913" unitRef="usd">177000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-284" decimals="-6" id="f-914" unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-284" decimals="-6" id="f-915" unitRef="usd">730000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-284" decimals="-6" id="f-916" unitRef="usd">61000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-285" decimals="-6" id="f-917" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-285" decimals="-6" id="f-918" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-285" decimals="-6" id="f-919" unitRef="usd">582000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-285" decimals="-6" id="f-920" unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-286" decimals="-6" id="f-921" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-286" decimals="-6" id="f-922" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-286" decimals="-6" id="f-923" unitRef="usd">502000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-286" decimals="-6" id="f-924" unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-287" decimals="-6" id="f-925" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-287" decimals="-6" id="f-926" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-287" decimals="-6" id="f-927" unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-287" decimals="-6" id="f-928" unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-27" decimals="-6" id="f-929" unitRef="usd">838000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-27" decimals="-6" id="f-930" unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-27" decimals="-6" id="f-931" unitRef="usd">4296000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-27" decimals="-6" id="f-932" unitRef="usd">238000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-933">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes activity related to the Company&#x2019;s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-6" id="f-934" unitRef="usd">8213000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-25" decimals="-6" id="f-935" unitRef="usd">7359000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-26" decimals="-6" id="f-936" unitRef="usd">7321000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-6" id="f-937" unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-25" decimals="-6" id="f-938" unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-26" decimals="-6" id="f-939" unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-6" id="f-940" unitRef="usd">19000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-25" decimals="-6" id="f-941" unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-26" decimals="-6" id="f-942" unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-943">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of available-for-sale debt securities at April&#160;25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-24" decimals="-6" id="f-944" unitRef="usd">1458000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-24" decimals="-6" id="f-945" unitRef="usd">1448000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-24" decimals="-6" id="f-946" unitRef="usd">3183000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-24" decimals="-6" id="f-947" unitRef="usd">3149000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c-24" decimals="-6" id="f-948" unitRef="usd">845000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-24" decimals="-6" id="f-949" unitRef="usd">843000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost contextRef="c-24" decimals="-6" id="f-950" unitRef="usd">1340000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-24" decimals="-6" id="f-951" unitRef="usd">1313000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-24" decimals="-6" id="f-952" unitRef="usd">6826000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-24" decimals="-6" id="f-953" unitRef="usd">6752000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-1" decimals="-6" id="f-954" unitRef="usd">511000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-25" decimals="-6" id="f-955" unitRef="usd">597000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-26" decimals="-6" id="f-956" unitRef="usd">386000000</us-gaap:InterestIncomeExpenseNet>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock contextRef="c-1" id="f-957">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's equity and other investments at&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April&#160;25, 2025 and April&#160;26, 2024, which are classified as primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments with readily determinable fair value (marketable equity securities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments for which the fair value option has been elected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestmentsTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-251" decimals="-6" id="f-958" unitRef="usd">17000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-277" decimals="-6" id="f-959" unitRef="usd">28000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-251" decimals="-6" id="f-960" unitRef="usd">140000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-277" decimals="-6" id="f-961" unitRef="usd">311000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-251" decimals="-6" id="f-962" unitRef="usd">705000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-277" decimals="-6" id="f-963" unitRef="usd">859000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-251" decimals="-6" id="f-964" unitRef="usd">89000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-277" decimals="-6" id="f-965" unitRef="usd">84000000</us-gaap:EquityMethodInvestments>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments contextRef="c-251" decimals="-6" id="f-966" unitRef="usd">951000000</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments>
    <mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments contextRef="c-277" decimals="-6" id="f-967" unitRef="usd">1282000000</mdt:EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueandEquityMethodInvestments>
    <mdt:ScheduleOfInvestmentsTableTextBlock contextRef="c-1" id="f-968">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:ScheduleOfInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-1" decimals="-6" id="f-969" unitRef="usd">308000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <mdt:GainOnInvestments contextRef="c-1" decimals="-6" id="f-970" unitRef="usd">108000000</mdt:GainOnInvestments>
    <mdt:LossOnInvestments contextRef="c-1" decimals="-6" id="f-971" unitRef="usd">204000000</mdt:LossOnInvestments>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="-6" id="f-972" unitRef="usd">135000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-288" decimals="-6" id="f-973" unitRef="usd">-181000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-289" decimals="-6" id="f-974" unitRef="usd">-291000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-188" decimals="2" id="f-975" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-1" decimals="-6" id="f-976" unitRef="usd">-171000000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-25" decimals="-6" id="f-977" unitRef="usd">-220000000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-978">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-27" decimals="-6" id="f-979" unitRef="usd">311000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-47" decimals="-6" id="f-980" unitRef="usd">531000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-1" decimals="-6" id="f-981" unitRef="usd">171000000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-25" decimals="-6" id="f-982" unitRef="usd">220000000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-24" decimals="-6" id="f-983" unitRef="usd">140000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-27" decimals="-6" id="f-984" unitRef="usd">311000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-985">Financing Arrangements &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt obligations consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-990"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-994"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-998"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;Current debt obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   In January 2015, Medtronic Global Holdings S.C.A. (Medtronic Luxco), an entity organized under the laws of Luxembourg, entered into various agreements pursuant to which Medtronic Luxco may issue United States Dollar-denominated unsecured commercial paper notes (the 2015 CP Program) on a private placement basis, and in January 2020, Medtronic Luxco entered into various agreements pursuant to which Medtronic Luxco may issue Euro-denominated unsecured commercial paper notes (the 2020 CP Program) on a private placement basis. The maximum aggregate amount outstanding at any time under the 2015 CP Program and the 2020 CP Program together may not exceed the equivalent of $3.5&#160;billion. The Company and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the 2015 CP Program and the 2020 CP Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no commercial paper outstanding at April&#160;25, 2025. During fiscal year 2025, the weighted average original maturity of the commercial paper outstanding was approximately 13 days and the weighted average interest rate was 5.02 percent. There was $1.1&#160;billion commercial paper outstanding at April&#160;26, 2024. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing credit facility, defined below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Line of Credit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   In October 2024, Medtronic Luxco, as borrower, entered into an amendment to its amended and restated credit agreement (Credit Facility), by and among Medtronic, Medtronic, Inc., Medtronic Luxco, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and issuing bank, extending the maturity date of the Credit Facility to December 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility provides for a $3.5 billion&#160;five-year unsecured revolving credit facility (Credit Facility). At each anniversary date of the Credit Facility, we can request a one-year extension of the maturity date. The Credit Facility provides the Company with the ability to increase its borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. The Company and Medtronic, Inc. have guaranteed the obligations of the borrowers under the Credit Facility, and Medtronic Luxco will also guarantee the obligations of any designated borrower. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At April&#160;25, 2025 and April&#160;26, 2024, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rates on advances on the Credit Facility are determined by a pricing matrix based on the Company&#x2019;s long-term debt ratings, assigned by Standard &amp;amp; Poor&#x2019;s Ratings Services and Moody&#x2019;s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with all covenants related to the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-1024"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-1030"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-1036"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125 percent &lt;span style="-sec-ix-hidden:f-1042"&gt;eight&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250 percent &lt;span style="-sec-ix-hidden:f-1048"&gt;five&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.000 percent &lt;span style="-sec-ix-hidden:f-1054"&gt;six&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.375 percent &lt;span style="-sec-ix-hidden:f-1060"&gt;eight&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.650 percent &lt;span style="-sec-ix-hidden:f-1066"&gt;five&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1072"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.000 percent &lt;span style="-sec-ix-hidden:f-1078"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125 percent &lt;span style="-sec-ix-hidden:f-1084"&gt;nine&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750 percent &lt;span style="-sec-ix-hidden:f-1090"&gt;twelve&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1096"&gt;ten&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375 percent &lt;span style="-sec-ix-hidden:f-1102"&gt;twelve&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375 percent &lt;span style="-sec-ix-hidden:f-1108"&gt;twenty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875 percent &lt;span style="-sec-ix-hidden:f-1114"&gt;twelve&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.550 percent &lt;span style="-sec-ix-hidden:f-1120"&gt;thirty&lt;/span&gt;-year 2007 CIFSA senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250 percent &lt;span style="-sec-ix-hidden:f-1126"&gt;twenty&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.500 percent &lt;span style="-sec-ix-hidden:f-1132"&gt;thirty&lt;/span&gt;-year 2009 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500 percent &lt;span style="-sec-ix-hidden:f-1138"&gt;twenty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.550 percent &lt;span style="-sec-ix-hidden:f-1144"&gt;thirty&lt;/span&gt;-year 2010 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375 percent &lt;span style="-sec-ix-hidden:f-1150"&gt;twenty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1156"&gt;thirty&lt;/span&gt;-year 2012 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000 percent &lt;span style="-sec-ix-hidden:f-1162"&gt;thirty&lt;/span&gt;-year 2013 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.150 percent &lt;span style="-sec-ix-hidden:f-1168"&gt;nineteen&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1174"&gt;thirty&lt;/span&gt;-year 2014 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1180"&gt;thirty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750 percent &lt;span style="-sec-ix-hidden:f-1186"&gt;thirty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1192"&gt;thirty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.150 percent &lt;span style="-sec-ix-hidden:f-1198"&gt;twenty-nine&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1203"&gt;&lt;span style="-sec-ix-hidden:f-1204"&gt;Finance lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Notes   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of &#x20ac;3.0&#160;billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2&#160;billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Loan Agreements   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to &#xa5;300&#160;billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of &#xa5;297&#160;billion, or approximately $2.3&#160;billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9&#160;billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9&#160;billion of total consideration, and $368&#160;million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376&#160;million of total consideration. The Company recognized a total loss on debt extinguishment of $53&#160;million within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income during fiscal year 2023, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. During the fourth quarter of fiscal year 2023, the Company repaid the term loan in full, including interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. For fiscal years 2025, 2024, and 2023, there was $913&#160;million, $916&#160;million, and $743&#160;million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025, the estimated fair value of the Company&#x2019;s Senior Notes was $26.2 billion compared to a principal value of $28.6 billion. At April&#160;26, 2024, the estimated fair value was $21.2 billion compared to a principal value of $24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplier Financing Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in a supplier financing program that provides participating suppliers the ability to finance payment obligations from the Company with third-party financial institutions in order to receive earlier payment. The Company&#x2019;s standard payment term is 90 days. The Company&#x2019;s outstanding payables to its suppliers, including amounts due and payment terms, are not affected by a supplier&#x2019;s participation in the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025 and April&#160;26, 2024, the Company had $100 million and $96 million of outstanding payables, respectively, associated with the supplier financing program recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a roll-forward of outstanding payables confirmed as valid associated with the program during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Invoices confirmed during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Confirmed invoices paid during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1251"&gt;Ending Balance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c-1" id="f-986">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt obligations consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-990"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-994"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-998"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;Current debt obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c-290" decimals="-6" id="f-987" unitRef="usd">13000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-291" decimals="-6" id="f-988" unitRef="usd">13000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-292"
      decimals="INF"
      id="f-989"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-292" decimals="-6" id="f-991" unitRef="usd">1142000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-294" decimals="-6" id="f-992" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-295"
      decimals="INF"
      id="f-993"
      unitRef="number">0.00000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-295" decimals="-6" id="f-995" unitRef="usd">1142000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-297" decimals="-6" id="f-996" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-298"
      decimals="INF"
      id="f-997"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-298" decimals="-6" id="f-999" unitRef="usd">571000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-300" decimals="-6" id="f-1000" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-24" decimals="-6" id="f-1001" unitRef="usd">6000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-27" decimals="-6" id="f-1002" unitRef="usd">6000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:CommercialPaper contextRef="c-24" decimals="-6" id="f-1003" unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper contextRef="c-27" decimals="-6" id="f-1004" unitRef="usd">1073000000</us-gaap:CommercialPaper>
    <us-gaap:DebtCurrent contextRef="c-24" decimals="-6" id="f-1007" unitRef="usd">2874000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-27" decimals="-6" id="f-1008" unitRef="usd">1092000000</us-gaap:DebtCurrent>
    <mdt:CommercialPaperMaximumBorrowingCapacity contextRef="c-301" decimals="-8" id="f-1009" unitRef="usd">3500000000</mdt:CommercialPaperMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent contextRef="c-302" decimals="INF" id="f-1010" unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c-303" id="f-1011">P13D</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="c-303"
      decimals="4"
      id="f-1012"
      unitRef="number">0.0502</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtCurrent contextRef="c-304" decimals="-8" id="f-1013" unitRef="usd">1100000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c-305" id="f-1014">P20D</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="c-306"
      decimals="4"
      id="f-1015"
      unitRef="number">0.0545</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-307" decimals="INF" id="f-1016" unitRef="usd">3500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-308" id="f-1017">P5Y</us-gaap:DebtInstrumentTerm>
    <mdt:LineOfCreditFacilityLengthOfExtension contextRef="c-308" id="f-1018">P1Y</mdt:LineOfCreditFacilityLengthOfExtension>
    <mdt:LineOfCreditFacilityAdditionalBorrowingCapacity contextRef="c-307" decimals="INF" id="f-1019" unitRef="usd">1000000000.0</mdt:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-309" decimals="INF" id="f-1020" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c-310" decimals="INF" id="f-1021" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1022">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except interest rates)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity by Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250 percent &lt;span style="-sec-ix-hidden:f-1024"&gt;six&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.000 percent &lt;span style="-sec-ix-hidden:f-1030"&gt;five&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625 percent &lt;span style="-sec-ix-hidden:f-1036"&gt;three&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.125 percent &lt;span style="-sec-ix-hidden:f-1042"&gt;eight&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.250 percent &lt;span style="-sec-ix-hidden:f-1048"&gt;five&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.000 percent &lt;span style="-sec-ix-hidden:f-1054"&gt;six&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.375 percent &lt;span style="-sec-ix-hidden:f-1060"&gt;eight&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.650 percent &lt;span style="-sec-ix-hidden:f-1066"&gt;five&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1072"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.000 percent &lt;span style="-sec-ix-hidden:f-1078"&gt;twelve&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125 percent &lt;span style="-sec-ix-hidden:f-1084"&gt;nine&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750 percent &lt;span style="-sec-ix-hidden:f-1090"&gt;twelve&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1096"&gt;ten&lt;/span&gt;-year 2023 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375 percent &lt;span style="-sec-ix-hidden:f-1102"&gt;twelve&lt;/span&gt;-year 2022 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375 percent &lt;span style="-sec-ix-hidden:f-1108"&gt;twenty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875 percent &lt;span style="-sec-ix-hidden:f-1114"&gt;twelve&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.550 percent &lt;span style="-sec-ix-hidden:f-1120"&gt;thirty&lt;/span&gt;-year 2007 CIFSA senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250 percent &lt;span style="-sec-ix-hidden:f-1126"&gt;twenty&lt;/span&gt;-year 2019&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.500 percent &lt;span style="-sec-ix-hidden:f-1132"&gt;thirty&lt;/span&gt;-year 2009 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.500 percent &lt;span style="-sec-ix-hidden:f-1138"&gt;twenty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.550 percent &lt;span style="-sec-ix-hidden:f-1144"&gt;thirty&lt;/span&gt;-year 2010 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375 percent &lt;span style="-sec-ix-hidden:f-1150"&gt;twenty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.500 percent &lt;span style="-sec-ix-hidden:f-1156"&gt;thirty&lt;/span&gt;-year 2012 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.000 percent &lt;span style="-sec-ix-hidden:f-1162"&gt;thirty&lt;/span&gt;-year 2013 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.150 percent &lt;span style="-sec-ix-hidden:f-1168"&gt;nineteen&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1174"&gt;thirty&lt;/span&gt;-year 2014 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625 percent &lt;span style="-sec-ix-hidden:f-1180"&gt;thirty&lt;/span&gt;-year 2015 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750 percent &lt;span style="-sec-ix-hidden:f-1186"&gt;thirty&lt;/span&gt;-year 2019 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.625 percent &lt;span style="-sec-ix-hidden:f-1192"&gt;thirty&lt;/span&gt;-year 2020 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.150 percent &lt;span style="-sec-ix-hidden:f-1198"&gt;twenty-nine&lt;/span&gt;-year 2024 senior notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1203"&gt;&lt;span style="-sec-ix-hidden:f-1204"&gt;Finance lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027-2054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-292"
      decimals="INF"
      id="f-1023"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-292" decimals="-6" id="f-1025" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-292"
      decimals="4"
      id="f-1026"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-294" decimals="-6" id="f-1027" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-294"
      decimals="4"
      id="f-1028"
      unitRef="number">0.0044</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-295"
      decimals="INF"
      id="f-1029"
      unitRef="number">0.00000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-295" decimals="-6" id="f-1031" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-295"
      decimals="4"
      id="f-1032"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-297" decimals="-6" id="f-1033" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-297"
      decimals="4"
      id="f-1034"
      unitRef="number">0.0023</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-298"
      decimals="INF"
      id="f-1035"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-298" decimals="-6" id="f-1037" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-298"
      decimals="4"
      id="f-1038"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-300" decimals="-6" id="f-1039" unitRef="usd">535000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-300"
      decimals="4"
      id="f-1040"
      unitRef="number">0.0286</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-311"
      decimals="INF"
      id="f-1041"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-311" decimals="-6" id="f-1043" unitRef="usd">1714000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-311"
      decimals="4"
      id="f-1044"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-313" decimals="-6" id="f-1045" unitRef="usd">1606000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-313"
      decimals="4"
      id="f-1046"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-314"
      decimals="INF"
      id="f-1047"
      unitRef="number">0.04250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-314" decimals="-6" id="f-1049" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-314"
      decimals="4"
      id="f-1050"
      unitRef="number">0.0442</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-316" decimals="-6" id="f-1051" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-316"
      decimals="4"
      id="f-1052"
      unitRef="number">0.0442</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-317"
      decimals="INF"
      id="f-1053"
      unitRef="number">0.03000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-317" decimals="-6" id="f-1055" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-317"
      decimals="4"
      id="f-1056"
      unitRef="number">0.0309</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-319" decimals="-6" id="f-1057" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-319"
      decimals="4"
      id="f-1058"
      unitRef="number">0.0310</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-320"
      decimals="INF"
      id="f-1059"
      unitRef="number">0.00375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-320" decimals="-6" id="f-1061" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-320"
      decimals="4"
      id="f-1062"
      unitRef="number">0.0051</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-322" decimals="-6" id="f-1063" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-322"
      decimals="4"
      id="f-1064"
      unitRef="number">0.0051</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-323"
      decimals="INF"
      id="f-1065"
      unitRef="number">0.03650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-323" decimals="-6" id="f-1067" unitRef="usd">971000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-323"
      decimals="4"
      id="f-1068"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-325" decimals="-6" id="f-1069" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-325"
      decimals="4"
      id="f-1070"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-326"
      decimals="INF"
      id="f-1071"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-326" decimals="-6" id="f-1073" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-326"
      decimals="4"
      id="f-1074"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-328" decimals="-6" id="f-1075" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-328"
      decimals="4"
      id="f-1076"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-329"
      decimals="INF"
      id="f-1077"
      unitRef="number">0.01000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-329" decimals="-6" id="f-1079" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-329"
      decimals="4"
      id="f-1080"
      unitRef="number">0.0106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-331" decimals="-6" id="f-1081" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-331"
      decimals="4"
      id="f-1082"
      unitRef="number">0.0106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-332"
      decimals="INF"
      id="f-1083"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-332" decimals="-6" id="f-1085" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-332"
      decimals="4"
      id="f-1086"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-334" decimals="-6" id="f-1087" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-334"
      decimals="4"
      id="f-1088"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-335"
      decimals="INF"
      id="f-1089"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-335" decimals="-6" id="f-1091" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-335"
      decimals="4"
      id="f-1092"
      unitRef="number">0.0081</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-337" decimals="-6" id="f-1093" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-337"
      decimals="4"
      id="f-1094"
      unitRef="number">0.0081</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-338"
      decimals="INF"
      id="f-1095"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-338" decimals="-6" id="f-1097" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-338"
      decimals="4"
      id="f-1098"
      unitRef="number">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-340" decimals="-6" id="f-1099" unitRef="usd">1000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-340"
      decimals="4"
      id="f-1100"
      unitRef="number">0.0462</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-341"
      decimals="INF"
      id="f-1101"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-341" decimals="-6" id="f-1103" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-341"
      decimals="4"
      id="f-1104"
      unitRef="number">0.0344</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-343" decimals="-6" id="f-1105" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-343"
      decimals="4"
      id="f-1106"
      unitRef="number">0.0344</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-344"
      decimals="INF"
      id="f-1107"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-344" decimals="-6" id="f-1109" unitRef="usd">1932000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-344"
      decimals="4"
      id="f-1110"
      unitRef="number">0.0447</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-346" decimals="-6" id="f-1111" unitRef="usd">1932000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-346"
      decimals="4"
      id="f-1112"
      unitRef="number">0.0447</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-347"
      decimals="INF"
      id="f-1113"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-347" decimals="-6" id="f-1115" unitRef="usd">971000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-347"
      decimals="4"
      id="f-1116"
      unitRef="number">0.0393</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-349" decimals="-6" id="f-1117" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-349"
      decimals="4"
      id="f-1118"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-350"
      decimals="INF"
      id="f-1119"
      unitRef="number">0.06550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-350" decimals="-6" id="f-1121" unitRef="usd">253000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-350"
      decimals="4"
      id="f-1122"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-352" decimals="-6" id="f-1123" unitRef="usd">253000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-352"
      decimals="4"
      id="f-1124"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-353"
      decimals="INF"
      id="f-1125"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-353" decimals="-6" id="f-1127" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-353"
      decimals="4"
      id="f-1128"
      unitRef="number">0.0234</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-355" decimals="-6" id="f-1129" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-355"
      decimals="4"
      id="f-1130"
      unitRef="number">0.0234</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-356"
      decimals="INF"
      id="f-1131"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-356" decimals="-6" id="f-1133" unitRef="usd">158000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-356"
      decimals="4"
      id="f-1134"
      unitRef="number">0.0656</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-358" decimals="-6" id="f-1135" unitRef="usd">158000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-358"
      decimals="4"
      id="f-1136"
      unitRef="number">0.0656</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-359"
      decimals="INF"
      id="f-1137"
      unitRef="number">0.01500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-359" decimals="-6" id="f-1139" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-359"
      decimals="4"
      id="f-1140"
      unitRef="number">0.0158</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-361" decimals="-6" id="f-1141" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-361"
      decimals="4"
      id="f-1142"
      unitRef="number">0.0158</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-362"
      decimals="INF"
      id="f-1143"
      unitRef="number">0.05550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-362" decimals="-6" id="f-1145" unitRef="usd">224000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-362"
      decimals="4"
      id="f-1146"
      unitRef="number">0.0558</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-364" decimals="-6" id="f-1147" unitRef="usd">224000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-364"
      decimals="4"
      id="f-1148"
      unitRef="number">0.0558</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-365"
      decimals="INF"
      id="f-1149"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-365" decimals="-6" id="f-1151" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-365"
      decimals="4"
      id="f-1152"
      unitRef="number">0.0146</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-367" decimals="-6" id="f-1153" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-367"
      decimals="4"
      id="f-1154"
      unitRef="number">0.0146</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-368"
      decimals="INF"
      id="f-1155"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-368" decimals="-6" id="f-1157" unitRef="usd">105000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-368"
      decimals="4"
      id="f-1158"
      unitRef="number">0.0454</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-370" decimals="-6" id="f-1159" unitRef="usd">105000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-370"
      decimals="4"
      id="f-1160"
      unitRef="number">0.0454</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-371"
      decimals="INF"
      id="f-1161"
      unitRef="number">0.04000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-371" decimals="-6" id="f-1163" unitRef="usd">305000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-371"
      decimals="4"
      id="f-1164"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-373" decimals="-6" id="f-1165" unitRef="usd">305000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-373"
      decimals="4"
      id="f-1166"
      unitRef="number">0.0409</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-374"
      decimals="INF"
      id="f-1167"
      unitRef="number">0.04150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-374" decimals="-6" id="f-1169" unitRef="usd">685000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-374"
      decimals="4"
      id="f-1170"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-376" decimals="-6" id="f-1171" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-376"
      decimals="4"
      id="f-1172"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-377"
      decimals="INF"
      id="f-1173"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-377" decimals="-6" id="f-1175" unitRef="usd">127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-377"
      decimals="4"
      id="f-1176"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-379" decimals="-6" id="f-1177" unitRef="usd">127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-379"
      decimals="4"
      id="f-1178"
      unitRef="number">0.0467</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-380"
      decimals="INF"
      id="f-1179"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-380" decimals="-6" id="f-1181" unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-380"
      decimals="4"
      id="f-1182"
      unitRef="number">0.0469</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-382" decimals="-6" id="f-1183" unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-382"
      decimals="4"
      id="f-1184"
      unitRef="number">0.0469</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-383"
      decimals="INF"
      id="f-1185"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-383" decimals="-6" id="f-1187" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-383"
      decimals="4"
      id="f-1188"
      unitRef="number">0.0187</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-385" decimals="-6" id="f-1189" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-385"
      decimals="4"
      id="f-1190"
      unitRef="number">0.0187</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-386"
      decimals="INF"
      id="f-1191"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-386" decimals="-6" id="f-1193" unitRef="usd">1142000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-386"
      decimals="4"
      id="f-1194"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-388" decimals="-6" id="f-1195" unitRef="usd">1070000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-388"
      decimals="4"
      id="f-1196"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-389"
      decimals="INF"
      id="f-1197"
      unitRef="number">0.04150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-389" decimals="-6" id="f-1199" unitRef="usd">800000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-389"
      decimals="4"
      id="f-1200"
      unitRef="number">0.0419</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-391" decimals="-6" id="f-1201" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-391"
      decimals="4"
      id="f-1202"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-24" decimals="-6" id="f-1205" unitRef="usd">52000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-24" decimals="4" id="f-1206" unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-27" decimals="-6" id="f-1207" unitRef="usd">55000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-27" decimals="4" id="f-1208" unitRef="number">0.1017</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-24" decimals="-6" id="f-1209" unitRef="usd">59000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-27" decimals="-6" id="f-1210" unitRef="usd">55000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-24" decimals="-6" id="f-1211" unitRef="usd">117000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-27" decimals="-6" id="f-1212" unitRef="usd">110000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-24" decimals="-6" id="f-1213" unitRef="usd">25642000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-27" decimals="-6" id="f-1214" unitRef="usd">23932000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <mdt:DebtInstrumentNumberofTranches
      contextRef="c-392"
      decimals="INF"
      id="f-1215"
      unitRef="tranche">4</mdt:DebtInstrumentNumberofTranches>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-392" decimals="-8" id="f-1216" unitRef="eur">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c-393" decimals="-8" id="f-1217" unitRef="usd">3200000000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-9" id="f-1218" unitRef="jpy">300000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c-395" id="f-1219">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-395"
      decimals="4"
      id="f-1220"
      unitRef="number">0.0040</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-395" decimals="-9" id="f-1221" unitRef="jpy">297000000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-395" decimals="-8" id="f-1222" unitRef="usd">2300000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-396" decimals="-8" id="f-1223" unitRef="usd">1900000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-397"
      decimals="INF"
      id="f-1224"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt contextRef="c-398" decimals="-8" id="f-1225" unitRef="usd">1900000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-399" decimals="-6" id="f-1226" unitRef="usd">368000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-400"
      decimals="INF"
      id="f-1227"
      unitRef="number">0.03350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt contextRef="c-401" decimals="-6" id="f-1228" unitRef="usd">376000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-395" decimals="-6" id="f-1229" unitRef="usd">-53000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1230">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt for the next five fiscal years and thereafter, excluding deferred financing costs and debt discount, net, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-24" decimals="-6" id="f-1231" unitRef="usd">2874000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-24" decimals="-6" id="f-1232" unitRef="usd">1721000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-24" decimals="-6" id="f-1233" unitRef="usd">1006000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-24" decimals="-6" id="f-1234" unitRef="usd">2290000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-24" decimals="-6" id="f-1235" unitRef="usd">977000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-24" decimals="-6" id="f-1236" unitRef="usd">19824000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-24" decimals="-6" id="f-1237" unitRef="usd">28691000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestExpenseBorrowings contextRef="c-1" decimals="-6" id="f-1238" unitRef="usd">913000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-25" decimals="-6" id="f-1239" unitRef="usd">916000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-26" decimals="-6" id="f-1240" unitRef="usd">743000000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:LongTermDebtFairValue contextRef="c-402" decimals="-8" id="f-1241" unitRef="usd">26200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-402" decimals="-8" id="f-1242" unitRef="usd">28600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtFairValue contextRef="c-403" decimals="-8" id="f-1243" unitRef="usd">21200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-403" decimals="-8" id="f-1244" unitRef="usd">24000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-24" decimals="-6" id="f-1245" unitRef="usd">100000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-27" decimals="-6" id="f-1246" unitRef="usd">96000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SupplierFinanceProgramTableTextBlock contextRef="c-1" id="f-1247">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a roll-forward of outstanding payables confirmed as valid associated with the program during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Invoices confirmed during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Confirmed invoices paid during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1251"&gt;Ending Balance&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplierFinanceProgramTableTextBlock>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-27" decimals="-6" id="f-1248" unitRef="usd">96000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SupplierFinanceProgramObligationIncrease contextRef="c-1" decimals="-6" id="f-1249" unitRef="usd">522000000</us-gaap:SupplierFinanceProgramObligationIncrease>
    <us-gaap:SupplierFinanceProgramObligationDecreaseSettlement contextRef="c-1" decimals="-6" id="f-1250" unitRef="usd">517000000</us-gaap:SupplierFinanceProgramObligationDecreaseSettlement>
    <us-gaap:SupplierFinanceProgramObligation contextRef="c-24" decimals="-6" id="f-1252" unitRef="usd">100000000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1253">Derivatives and Currency Exchange Risk Management &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of a fixed-rate debt obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Amounts excluded from the assessment of effectiveness are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on a straight-line basis over the term of the hedge and were not significant for the fiscal year ended April&#160;25, 2025. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception, foreign currency forward and option contracts are designated as a cash flow hedge. Changes in the fair value of these derivatives are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash flow hedges will mature within the subsequent two-year period. At April&#160;25, 2025 and April&#160;26, 2024, the Company had $149 million in after-tax unrealized losses and $229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company expects that $62 million of after-tax net unrealized losses at April&#160;25, 2025 will be recognized in the consolidated statements of income over the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For instruments that are designated as net investment hedges, the gains or losses are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a straight-line basis over the term of the instrument. For fiscal years 2025, 2024, and 2023, the Company recognized $198 million, $197 million, and $107 million, respectively, of after-tax unrealized gains related to excluded components in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1261"&gt;interest expense&lt;/span&gt;, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Undesignated Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency forward exchange contracts to offset the Company&#x2019;s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company&#x2019;s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Outstanding Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of the Company's outstanding instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undesignated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes derivative contracts with a notional value of &#x20ac;1.0 billion, or $1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes derivative contracts with a notional value of &#x20ac;5.0 billion, or $5.7 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#xa5;322 billion, or $2.3 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2026 through 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes &#x20ac;18.0 billion, or $20.6 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.704%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance Sheet Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;25, 2025 and April&#160;26, 2024. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total return swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1350"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1351"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1352"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1353"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total return swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, derivative contracts, and trade accounts receivable. Global concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of April&#160;25, 2025 the Company posted net cash collateral of $125 million to its counterparties. Cash collateral posted is recorded as a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with the offset recorded as an increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. As of April&#160;26, 2024, the Company received net cash collateral of $101 million from its counterparties. Cash collateral received is recorded as an increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the offset recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt; in the consolidated balance sheets.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="c-404" id="f-1254">P2Y</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-6" id="f-1255" unitRef="usd">-149000000</mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-6" id="f-1256" unitRef="usd">229000000</mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths contextRef="c-1" decimals="-6" id="f-1257" unitRef="usd">62000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-1" decimals="-6" id="f-1258" unitRef="usd">198000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-25" decimals="-6" id="f-1259" unitRef="usd">197000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-26" decimals="-6" id="f-1260" unitRef="usd">107000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1262">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the contractual amounts of the Company's outstanding instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Designation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undesignated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes derivative contracts with a notional value of &#x20ac;1.0 billion, or $1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes derivative contracts with a notional value of &#x20ac;5.0 billion, or $5.7 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of &#xa5;322 billion, or $2.3 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2026 through 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At April&#160;25, 2025, includes &#x20ac;18.0 billion, or $20.6 billion, of outstanding Euro-denominated debt designated as hedges of a portion our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.704%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain)&#160;Loss&#160;Recognized in Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net investment hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements for fiscal years 2025, 2024, and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of (Gain) Loss in Income Statement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-405" decimals="-8" id="f-1263" unitRef="usd">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-406" decimals="-8" id="f-1264" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-407" decimals="-8" id="f-1265" unitRef="usd">10600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-408" decimals="-8" id="f-1266" unitRef="usd">10400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-409" decimals="-8" id="f-1267" unitRef="usd">8000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-410" decimals="-8" id="f-1268" unitRef="usd">7400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-411" decimals="-8" id="f-1269" unitRef="usd">20600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-412" decimals="-8" id="f-1270" unitRef="usd">17100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-413" decimals="-8" id="f-1271" unitRef="usd">3900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-414" decimals="-8" id="f-1272" unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-405" decimals="-8" id="f-1273" unitRef="eur">1000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-405" decimals="-8" id="f-1274" unitRef="usd">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-415" decimals="-8" id="f-1275" unitRef="eur">5000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-415" decimals="-8" id="f-1276" unitRef="usd">5700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-416" decimals="-9" id="f-1277" unitRef="jpy">322000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-416" decimals="-8" id="f-1278" unitRef="usd">2300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-411" decimals="-8" id="f-1279" unitRef="eur">18000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-411" decimals="-8" id="f-1280" unitRef="usd">20600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-417" decimals="-6" id="f-1281" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-418" decimals="-6" id="f-1282" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-419" decimals="-6" id="f-1283" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax contextRef="c-417" decimals="-6" id="f-1284" unitRef="usd">59000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax contextRef="c-418" decimals="-6" id="f-1285" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax contextRef="c-419" decimals="-6" id="f-1286" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-420" decimals="-6" id="f-1287" unitRef="usd">-308000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-421" decimals="-6" id="f-1288" unitRef="usd">416000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-422" decimals="-6" id="f-1289" unitRef="usd">161000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-420" decimals="-6" id="f-1290" unitRef="usd">156000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-421" decimals="-6" id="f-1291" unitRef="usd">312000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-422" decimals="-6" id="f-1292" unitRef="usd">703000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-423" decimals="-6" id="f-1293" unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-424" decimals="-6" id="f-1294" unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-425" decimals="-6" id="f-1295" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-423" decimals="-6" id="f-1296" unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-424" decimals="-6" id="f-1297" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-425" decimals="-6" id="f-1298" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-426" decimals="-6" id="f-1299" unitRef="usd">-1276000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-427" decimals="-6" id="f-1300" unitRef="usd">431000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-428" decimals="-6" id="f-1301" unitRef="usd">-524000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-426" decimals="-6" id="f-1302" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-427" decimals="-6" id="f-1303" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-428" decimals="-6" id="f-1304" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-429" decimals="-6" id="f-1305" unitRef="usd">-247000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-430" decimals="-6" id="f-1306" unitRef="usd">202000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-431" decimals="-6" id="f-1307" unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-429" decimals="-6" id="f-1308" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-430" decimals="-6" id="f-1309" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-431" decimals="-6" id="f-1310" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-1" decimals="-6" id="f-1311" unitRef="usd">-1759000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-25" decimals="-6" id="f-1312" unitRef="usd">1173000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-26" decimals="-6" id="f-1313" unitRef="usd">-356000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-1" decimals="-6" id="f-1314" unitRef="usd">288000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-25" decimals="-6" id="f-1315" unitRef="usd">369000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-26" decimals="-6" id="f-1316" unitRef="usd">706000000</mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-432" decimals="-6" id="f-1317" unitRef="usd">91000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-433" decimals="-6" id="f-1318" unitRef="usd">-136000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-434" decimals="-6" id="f-1319" unitRef="usd">-31000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1320">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at April&#160;25, 2025 and April&#160;26, 2024. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total return swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-435" decimals="-6" id="f-1321" unitRef="usd">269000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-436" decimals="-6" id="f-1322" unitRef="usd">368000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-437" decimals="-6" id="f-1323" unitRef="usd">200000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-438" decimals="-6" id="f-1324" unitRef="usd">37000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-439" decimals="-6" id="f-1325" unitRef="usd">57000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-440" decimals="-6" id="f-1326" unitRef="usd">276000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-441" decimals="-6" id="f-1327" unitRef="usd">196000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-442" decimals="-6" id="f-1328" unitRef="usd">17000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-443" decimals="-6" id="f-1329" unitRef="usd">326000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-444" decimals="-6" id="f-1330" unitRef="usd">644000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-443" decimals="-6" id="f-1331" unitRef="usd">396000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-444" decimals="-6" id="f-1332" unitRef="usd">54000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-445" decimals="-6" id="f-1333" unitRef="usd">7000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-446" decimals="-6" id="f-1334" unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-447" decimals="-6" id="f-1335" unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-448" decimals="-6" id="f-1336" unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-449" decimals="-6" id="f-1337" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-450" decimals="-6" id="f-1338" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-451" decimals="-6" id="f-1339" unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-452" decimals="-6" id="f-1340" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-453" decimals="-6" id="f-1341" unitRef="usd">7000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-454" decimals="-6" id="f-1342" unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-453" decimals="-6" id="f-1343" unitRef="usd">21000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-454" decimals="-6" id="f-1344" unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-24" decimals="-6" id="f-1345" unitRef="usd">334000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-27" decimals="-6" id="f-1346" unitRef="usd">659000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-24" decimals="-6" id="f-1347" unitRef="usd">417000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-27" decimals="-6" id="f-1348" unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1349">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.600%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1350"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1351"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1352"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1353"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssets contextRef="c-455" decimals="-6" id="f-1354" unitRef="usd">334000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-455" decimals="-6" id="f-1355" unitRef="usd">401000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-456" decimals="-6" id="f-1356" unitRef="usd">659000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-456" decimals="-6" id="f-1357" unitRef="usd">66000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-244" decimals="-6" id="f-1358" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-244" decimals="-6" id="f-1359" unitRef="usd">16000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-270" decimals="-6" id="f-1360" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-270" decimals="-6" id="f-1361" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-24" decimals="-6" id="f-1362" unitRef="usd">334000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-24" decimals="-6" id="f-1363" unitRef="usd">417000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets contextRef="c-27" decimals="-6" id="f-1364" unitRef="usd">659000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-27" decimals="-6" id="f-1365" unitRef="usd">66000000</us-gaap:DerivativeLiabilities>
    <us-gaap:OffsettingAssetsTableTextBlock contextRef="c-1" id="f-1367">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total return swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OffsettingAssetsTableTextBlock>
    <us-gaap:OffsettingLiabilitiesTableTextBlock contextRef="c-1" id="f-1366">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total return swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount Not Offset on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amount of Recognized Assets (Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral (Received) Posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OffsettingLiabilitiesTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-457" decimals="-6" id="f-1368" unitRef="usd">334000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction contextRef="c-457" decimals="-6" id="f-1369" unitRef="usd">195000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash contextRef="c-457" decimals="-6" id="f-1370" unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral contextRef="c-457" decimals="-6" id="f-1371" unitRef="usd">139000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-457" decimals="-6" id="f-1372" unitRef="usd">401000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-457" decimals="-6" id="f-1373" unitRef="usd">195000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-457" decimals="-6" id="f-1374" unitRef="usd">125000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-457" decimals="-6" id="f-1375" unitRef="usd">82000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-458" decimals="-6" id="f-1376" unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-458" decimals="-6" id="f-1377" unitRef="usd">0</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-458" decimals="-6" id="f-1378" unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-458" decimals="-6" id="f-1379" unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-24" decimals="-6" id="f-1380" unitRef="usd">417000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-24" decimals="-6" id="f-1381" unitRef="usd">195000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-24" decimals="-6" id="f-1382" unitRef="usd">125000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-24" decimals="-6" id="f-1383" unitRef="usd">97000000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability contextRef="c-24" decimals="-6" id="f-1384" unitRef="usd">-84000000</mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability>
    <mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction contextRef="c-24" decimals="-6" id="f-1385" unitRef="usd">0</mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-24" decimals="-6" id="f-1386" unitRef="usd">-125000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet contextRef="c-24" decimals="-6" id="f-1387" unitRef="usd">42000000</us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-459" decimals="-6" id="f-1388" unitRef="usd">659000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction contextRef="c-459" decimals="-6" id="f-1389" unitRef="usd">66000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash contextRef="c-459" decimals="-6" id="f-1390" unitRef="usd">101000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral contextRef="c-459" decimals="-6" id="f-1391" unitRef="usd">492000000</us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-459" decimals="-6" id="f-1392" unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction contextRef="c-459" decimals="-6" id="f-1393" unitRef="usd">66000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash contextRef="c-459" decimals="-6" id="f-1394" unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral contextRef="c-459" decimals="-6" id="f-1395" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral>
    <mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability contextRef="c-27" decimals="-6" id="f-1396" unitRef="usd">593000000</mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability>
    <mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction contextRef="c-27" decimals="-6" id="f-1397" unitRef="usd">0</mdt:DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1398" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet contextRef="c-27" decimals="-6" id="f-1399" unitRef="usd">492000000</us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-24" decimals="-6" id="f-1400" unitRef="usd">-125000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash contextRef="c-27" decimals="-6" id="f-1401" unitRef="usd">101000000</mdt:DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-1402">Inventories &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-1403">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-24" decimals="-6" id="f-1404" unitRef="usd">3779000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-27" decimals="-6" id="f-1405" unitRef="usd">3668000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-24" decimals="-6" id="f-1406" unitRef="usd">744000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-27" decimals="-6" id="f-1407" unitRef="usd">642000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-24" decimals="-6" id="f-1408" unitRef="usd">953000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-27" decimals="-6" id="f-1409" unitRef="usd">907000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-24" decimals="-6" id="f-1410" unitRef="usd">5476000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-27" decimals="-6" id="f-1411" unitRef="usd">5217000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1412">Goodwill and Other Intangible Assets &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill by segment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any goodwill impairment charges during fiscal years 2025 or 2024. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208&#160;million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61&#160;million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any definite-lived intangible asset impairment charges during fiscal years 2025 and 2023. During fiscal year 2024, the Company recognized $295&#160;million of &lt;span style="-sec-ix-hidden:f-1490"&gt;definite-lived intangible asset impairment charges&lt;/span&gt; in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no indefinite-lived intangible asset impairment charges during fiscal year 2025. Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024 and 2023. Due to the nature of IPR&amp;amp;D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible asset amortization expense was $1.8 billion for fiscal year 2025, including $151&#160;million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $1.7 billion for fiscal years 2024 and 2023. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;25, 2025, excluding any possible future amortization associated with acquired IPR&amp;amp;D which has not met technological feasibility, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1413">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill by segment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill as a result of acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-460" decimals="-6" id="f-1414" unitRef="usd">7873000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-461" decimals="-6" id="f-1415" unitRef="usd">11718000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-462" decimals="-6" id="f-1416" unitRef="usd">19579000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-463" decimals="-6" id="f-1417" unitRef="usd">2255000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-47" decimals="-6" id="f-1418" unitRef="usd">41425000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-87" decimals="-6" id="f-1419" unitRef="usd">131000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-99" decimals="-6" id="f-1420" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-108" decimals="-6" id="f-1421" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-111" decimals="-6" id="f-1422" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-25" decimals="-6" id="f-1423" unitRef="usd">131000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-87" decimals="-6" id="f-1424" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-99" decimals="-6" id="f-1425" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-108" decimals="-6" id="f-1426" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-111" decimals="-6" id="f-1427" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-25" decimals="-6" id="f-1428" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-87" decimals="-6" id="f-1429" unitRef="usd">-33000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-99" decimals="-6" id="f-1430" unitRef="usd">-74000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-108" decimals="-6" id="f-1431" unitRef="usd">-458000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-111" decimals="-6" id="f-1432" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-25" decimals="-6" id="f-1433" unitRef="usd">-565000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-464" decimals="-6" id="f-1434" unitRef="usd">7966000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-465" decimals="-6" id="f-1435" unitRef="usd">11644000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-466" decimals="-6" id="f-1436" unitRef="usd">19121000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-467" decimals="-6" id="f-1437" unitRef="usd">2255000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-27" decimals="-6" id="f-1438" unitRef="usd">40986000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-86" decimals="-6" id="f-1439" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-98" decimals="-6" id="f-1440" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-107" decimals="-6" id="f-1441" unitRef="usd">108000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-110" decimals="-6" id="f-1442" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-6" id="f-1443" unitRef="usd">108000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-86" decimals="-6" id="f-1444" unitRef="usd">2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-98" decimals="-6" id="f-1445" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-107" decimals="-6" id="f-1446" unitRef="usd">-2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-110" decimals="-6" id="f-1447" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-6" id="f-1448" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-86" decimals="-6" id="f-1449" unitRef="usd">50000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-98" decimals="-6" id="f-1450" unitRef="usd">72000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-107" decimals="-6" id="f-1451" unitRef="usd">521000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-110" decimals="-6" id="f-1452" unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-6" id="f-1453" unitRef="usd">643000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-468" decimals="-6" id="f-1454" unitRef="usd">8017000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-469" decimals="-6" id="f-1455" unitRef="usd">11716000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-470" decimals="-6" id="f-1456" unitRef="usd">19748000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-471" decimals="-6" id="f-1457" unitRef="usd">2255000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-24" decimals="-6" id="f-1458" unitRef="usd">41737000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-1459" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-25" decimals="INF" id="f-1460" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-472" decimals="-6" id="f-1461" unitRef="usd">208000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-473" decimals="-6" id="f-1462" unitRef="usd">61000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1464">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1463">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gross carrying amount and accumulated amortization of intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Definite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased technology and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Indefinite-lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-474" decimals="-6" id="f-1465" unitRef="usd">16550000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-474" decimals="-6" id="f-1466" unitRef="usd">9650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-475" decimals="-6" id="f-1467" unitRef="usd">16518000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-475" decimals="-6" id="f-1468" unitRef="usd">8689000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-476" decimals="-6" id="f-1469" unitRef="usd">11600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-476" decimals="-6" id="f-1470" unitRef="usd">7514000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-477" decimals="-6" id="f-1471" unitRef="usd">11557000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-477" decimals="-6" id="f-1472" unitRef="usd">6868000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-478" decimals="-6" id="f-1473" unitRef="usd">421000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-478" decimals="-6" id="f-1474" unitRef="usd">283000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-479" decimals="-6" id="f-1475" unitRef="usd">424000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-479" decimals="-6" id="f-1476" unitRef="usd">274000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-480" decimals="-6" id="f-1477" unitRef="usd">355000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-480" decimals="-6" id="f-1478" unitRef="usd">101000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-481" decimals="-6" id="f-1479" unitRef="usd">256000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-481" decimals="-6" id="f-1480" unitRef="usd">84000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-24" decimals="-6" id="f-1481" unitRef="usd">28925000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-24" decimals="-6" id="f-1482" unitRef="usd">17547000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-27" decimals="-6" id="f-1483" unitRef="usd">28755000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-27" decimals="-6" id="f-1484" unitRef="usd">15915000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-482" decimals="-6" id="f-1485" unitRef="usd">289000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-483" decimals="-6" id="f-1486" unitRef="usd">385000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-6" id="f-1487" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-26" decimals="-6" id="f-1488" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-185" decimals="-6" id="f-1489" unitRef="usd">295000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-6" id="f-1491" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-25" decimals="-6" id="f-1492" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-26" decimals="-6" id="f-1493" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-8" id="f-1494" unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <mdt:AcceleratedAmortizationOfIntangibleAssets contextRef="c-86" decimals="-6" id="f-1495" unitRef="usd">151000000</mdt:AcceleratedAmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-25" decimals="-8" id="f-1496" unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-26" decimals="-8" id="f-1497" unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1498">Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April&#160;25, 2025, excluding any possible future amortization associated with acquired IPR&amp;amp;D which has not met technological feasibility, is as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-24" decimals="-6" id="f-1499" unitRef="usd">1677000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-24" decimals="-6" id="f-1500" unitRef="usd">1654000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-24" decimals="-6" id="f-1501" unitRef="usd">1582000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-24" decimals="-6" id="f-1502" unitRef="usd">1479000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-24" decimals="-6" id="f-1503" unitRef="usd">1343000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1504">Property, Plant, and Equipment &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment balances and corresponding estimated useful lives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generally 2-10, up to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense of $1.1 billion, $954 million, and $999 million was recognized in fiscal years 2025, 2024, and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1505">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment balances and corresponding estimated useful lives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives &lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generally 2-10, up to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-484" decimals="-6" id="f-1506" unitRef="usd">7156000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-485" decimals="-6" id="f-1507" unitRef="usd">6396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-486" id="f-1508">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-487" id="f-1509">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-484" id="f-1510">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-488" decimals="-6" id="f-1511" unitRef="usd">3295000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-489" decimals="-6" id="f-1512" unitRef="usd">2872000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-490" id="f-1513">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-491" decimals="-6" id="f-1514" unitRef="usd">160000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-492" decimals="-6" id="f-1515" unitRef="usd">159000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-493" id="f-1516">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-494" decimals="-6" id="f-1517" unitRef="usd">2685000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-495" decimals="-6" id="f-1518" unitRef="usd">2506000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-496" id="f-1519">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-497" decimals="-6" id="f-1520" unitRef="usd">2340000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-498" decimals="-6" id="f-1521" unitRef="usd">2119000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-6" id="f-1522" unitRef="usd">15636000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1523" unitRef="usd">14052000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-6" id="f-1524" unitRef="usd">8799000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1525" unitRef="usd">7922000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-6" id="f-1526" unitRef="usd">6837000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-27" decimals="-6" id="f-1527" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation contextRef="c-1" decimals="-8" id="f-1528" unitRef="usd">1100000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-6" id="f-1529" unitRef="usd">954000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-6" id="f-1530" unitRef="usd">999000000</us-gaap:Depreciation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1531">Shareholders&#x2019; Equity &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Capital   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic plc is authorized to issue 2.6 billion Ordinary Shares, $0.0001 par value; 40 thousand Euro Deferred Shares, &#x20ac;1.00 par value; 127.5 million Preferred Shares, $0.20 par value; and 500 thousand A Preferred Shares, $1.00 par value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Euro Deferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 40 thousand Euro Deferred Shares, with a par value of &#x20ac;1.00 per share. At April&#160;25, 2025, no&#160;Euro Deferred Shares were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 127.5 million of Preferred Shares, with a par value of $0.20 per share. At April&#160;25, 2025, no&#160;Preferred&#160;Shares were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A Preferred Shares   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authorized share capital of the Company includes 500 thousand A Preferred Shares, with a par value of $1.00 per share. At April&#160;25, 2025, no A Preferred Shares were outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Dividends   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing, declaration, and payment of future dividends to holders of the Company's ordinary shares falls within the discretion of the Company's Board of Directors and depends upon many factors, including the statutory requirements of Irish law, the Company's earnings and financial condition, the capital requirements of the Company's businesses, industry practice and any other factors the Board of Directors deems relevant.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ordinary Share Repurchase Program   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares are repurchased on occasion to support the Company&#x2019;s stock-based compensation programs and to return capital to shareholders. During fiscal years 2025 and 2024, the Company repurchased approximately 38 million and 25 million shares, respectively, at an average price of $83.36 and $83.04, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company's Board of Directors authorized $6.0&#160;billion for repurchase of the Company's ordinary shares. In March 2024, the Company's Board of Directors authorized an additional $5.0&#160;billion for repurchase of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations. At April&#160;25, 2025, the Company had used the $6.0&#160;billion authorized in March 2019 and $2.9 billion of the $5.0&#160;billion authorized in March 2024, leaving approximately $2.1 billion available for future repurchases. The Company accounts for repurchases of ordinary shares using the par value method and shares repurchased are cancelled.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1532"
      unitRef="shares">2600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-1533"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mdt:DeferredStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1534"
      unitRef="shares">40000</mdt:DeferredStockSharesAuthorized>
    <mdt:DeferredStockParorStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-1535"
      unitRef="eurPerShare">1.00</mdt:DeferredStockParorStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1536"
      unitRef="shares">127500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-1537"
      unitRef="usdPerShare">0.20</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-499"
      decimals="INF"
      id="f-1538"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-499"
      decimals="INF"
      id="f-1539"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <mdt:DeferredStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1540"
      unitRef="shares">40000</mdt:DeferredStockSharesAuthorized>
    <mdt:DeferredStockParorStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-1541"
      unitRef="eurPerShare">1.00</mdt:DeferredStockParorStatedValuePerShare>
    <mdt:DeferredStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-1542"
      unitRef="shares">0</mdt:DeferredStockSharesOutstanding>
    <mdt:DeferredStockSharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-1543"
      unitRef="shares">0</mdt:DeferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1544"
      unitRef="shares">127500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-1545"
      unitRef="usdPerShare">0.20</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-1546"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-1547"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-499"
      decimals="INF"
      id="f-1548"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-499"
      decimals="INF"
      id="f-1549"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-499"
      decimals="INF"
      id="f-1550"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-1" decimals="-6" id="f-1551" unitRef="shares">38000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-25"
      decimals="-6"
      id="f-1552"
      unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <mdt:StockRepurchaseProgramAveragePurchasePrice
      contextRef="c-1"
      decimals="2"
      id="f-1553"
      unitRef="usdPerShare">83.36</mdt:StockRepurchaseProgramAveragePurchasePrice>
    <mdt:StockRepurchaseProgramAveragePurchasePrice
      contextRef="c-25"
      decimals="2"
      id="f-1554"
      unitRef="usdPerShare">83.04</mdt:StockRepurchaseProgramAveragePurchasePrice>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-500" decimals="-8" id="f-1555" unitRef="usd">6000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-501" decimals="-8" id="f-1556" unitRef="usd">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-500" decimals="-8" id="f-1557" unitRef="usd">6000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="-8" id="f-1558" unitRef="usd">2900000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-501" decimals="-8" id="f-1559" unitRef="usd">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-24" decimals="-8" id="f-1560" unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1561">Stock Purchase and Award Plans &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal year 2025, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April&#160;25, 2025, there were approximately 67 million shares available for future grants under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Options are granted at the exercise price, which is equal to the closing price of the Company&#x2019;s ordinary shares on the grant date. The majority of the Company&#x2019;s options are non-qualified options with a ten-year life and a four-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company&#x2019;s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company&#x2019;s ordinary shares. Implied volatility is based on market traded options of the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions used:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to outstanding stock options at April&#160;25, 2025 was $66 million and is expected to be recognized over a weighted average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a four-year ratable vesting term or cliff vest after three years. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to restricted stock as of April&#160;25, 2025 was $414 million and is expected to be recognized over a weighted average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Share Units  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on invested capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance share unit activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per performance share units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to performance share units as of April&#160;25, 2025 was $90 million and is expected to be recognized over a weighted average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employees Stock Purchase Plan (ESPP)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Medtronic plc 2024 Employee Stock Purchase Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company&#x2019;s ESPP is equal to the 15 percent discount the employee receives. Employees purchased 3 million shares at an average price of $72.27 per share in fiscal year 2025. At April&#160;25, 2025, approximately 26 million ordinary shares were available for future purchase under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-502"
      decimals="-6"
      id="f-1562"
      unitRef="shares">67000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1563">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-503" decimals="-6" id="f-1564" unitRef="usd">66000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-504" decimals="-6" id="f-1565" unitRef="usd">76000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-505" decimals="-6" id="f-1566" unitRef="usd">77000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-506" decimals="-6" id="f-1567" unitRef="usd">216000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-507" decimals="-6" id="f-1568" unitRef="usd">184000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-508" decimals="-6" id="f-1569" unitRef="usd">166000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-509" decimals="-6" id="f-1570" unitRef="usd">111000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-510" decimals="-6" id="f-1571" unitRef="usd">97000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-511" decimals="-6" id="f-1572" unitRef="usd">74000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-512" decimals="-6" id="f-1573" unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-513" decimals="-6" id="f-1574" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-514" decimals="-6" id="f-1575" unitRef="usd">38000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1576" unitRef="usd">429000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-6" id="f-1577" unitRef="usd">393000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-6" id="f-1578" unitRef="usd">355000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-6" id="f-1579" unitRef="usd">46000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-210" decimals="-6" id="f-1580" unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-209" decimals="-6" id="f-1581" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-515" decimals="-6" id="f-1582" unitRef="usd">52000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-516" decimals="-6" id="f-1583" unitRef="usd">47000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-517" decimals="-6" id="f-1584" unitRef="usd">39000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-6" id="f-1585" unitRef="usd">331000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-6" id="f-1586" unitRef="usd">310000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-6" id="f-1587" unitRef="usd">280000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1588" unitRef="usd">429000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-6" id="f-1589" unitRef="usd">393000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-6" id="f-1590" unitRef="usd">355000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-1591" unitRef="usd">70000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-25" decimals="-6" id="f-1592" unitRef="usd">64000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-26" decimals="-6" id="f-1593" unitRef="usd">60000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-6" id="f-1594" unitRef="usd">358000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-25" decimals="-6" id="f-1595" unitRef="usd">329000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-26" decimals="-6" id="f-1596" unitRef="usd">295000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-503" id="f-1597">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-503" id="f-1598">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1599">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions used:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1600"
      unitRef="usdPerShare">16.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-25"
      decimals="2"
      id="f-1601"
      unitRef="usdPerShare">18.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-26"
      decimals="2"
      id="f-1602"
      unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-1603">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-25" id="f-1604">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-26" id="f-1605">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-1606" unitRef="number">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-25" decimals="4" id="f-1607" unitRef="number">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-26" decimals="4" id="f-1608" unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="4" id="f-1609" unitRef="number">0.2447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-25" decimals="4" id="f-1610" unitRef="number">0.2429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-26" decimals="4" id="f-1611" unitRef="number">0.2405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="4" id="f-1612" unitRef="number">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-25" decimals="4" id="f-1613" unitRef="number">0.0318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-26" decimals="4" id="f-1614" unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1615">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg. Remaining Contractual Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-518"
      decimals="-3"
      id="f-1616"
      unitRef="shares">32339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-518"
      decimals="2"
      id="f-1617"
      unitRef="usdPerShare">93.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-503"
      decimals="-3"
      id="f-1618"
      unitRef="shares">3414000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-503"
      decimals="2"
      id="f-1619"
      unitRef="usdPerShare">80.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-503"
      decimals="-3"
      id="f-1620"
      unitRef="shares">6058000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-503"
      decimals="2"
      id="f-1621"
      unitRef="usdPerShare">77.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-503"
      decimals="-3"
      id="f-1622"
      unitRef="shares">1928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-503"
      decimals="2"
      id="f-1623"
      unitRef="usdPerShare">96.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-519"
      decimals="-3"
      id="f-1624"
      unitRef="shares">27766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-519"
      decimals="2"
      id="f-1625"
      unitRef="usdPerShare">95.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-503" id="f-1626">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-519" decimals="-6" id="f-1627" unitRef="usd">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-519"
      decimals="-3"
      id="f-1628"
      unitRef="shares">7764000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-519"
      decimals="2"
      id="f-1629"
      unitRef="usdPerShare">88.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-503" id="f-1630">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-519" decimals="-6" id="f-1631" unitRef="usd">14000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-519"
      decimals="-3"
      id="f-1632"
      unitRef="shares">19467000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-519"
      decimals="2"
      id="f-1633"
      unitRef="usdPerShare">97.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-503" id="f-1634">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-519" decimals="-6" id="f-1635" unitRef="usd">7000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-503" decimals="-6" id="f-1636" unitRef="usd">305000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-504" decimals="-6" id="f-1637" unitRef="usd">78000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-505" decimals="-6" id="f-1638" unitRef="usd">77000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-503" decimals="-6" id="f-1639" unitRef="usd">66000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-504" decimals="-6" id="f-1640" unitRef="usd">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-505" decimals="-6" id="f-1641" unitRef="usd">42000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-503" decimals="-6" id="f-1642" unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-504" decimals="-6" id="f-1643" unitRef="usd">6000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-505" decimals="-6" id="f-1644" unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-519" decimals="-6" id="f-1645" unitRef="usd">66000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-503" id="f-1646">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-520" id="f-1647">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-521" id="f-1648">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-1649">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-522"
      decimals="-3"
      id="f-1650"
      unitRef="shares">6142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-522"
      decimals="2"
      id="f-1651"
      unitRef="usdPerShare">92.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-523"
      decimals="-3"
      id="f-1652"
      unitRef="shares">4207000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-523"
      decimals="2"
      id="f-1653"
      unitRef="usdPerShare">82.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-523"
      decimals="-3"
      id="f-1654"
      unitRef="shares">2068000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-523"
      decimals="2"
      id="f-1655"
      unitRef="usdPerShare">99.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-523"
      decimals="-3"
      id="f-1656"
      unitRef="shares">636000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-523"
      decimals="2"
      id="f-1657"
      unitRef="usdPerShare">88.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-524"
      decimals="-3"
      id="f-1658"
      unitRef="shares">7644000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-524"
      decimals="2"
      id="f-1659"
      unitRef="usdPerShare">85.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-523"
      decimals="2"
      id="f-1660"
      unitRef="usdPerShare">82.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-525"
      decimals="2"
      id="f-1661"
      unitRef="usdPerShare">82.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-526"
      decimals="2"
      id="f-1662"
      unitRef="usdPerShare">91.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-523" decimals="-6" id="f-1663" unitRef="usd">205000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-525" decimals="-6" id="f-1664" unitRef="usd">186000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-526" decimals="-6" id="f-1665" unitRef="usd">256000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-523" decimals="-6" id="f-1666" unitRef="usd">33000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-525" decimals="-6" id="f-1667" unitRef="usd">29000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-526" decimals="-6" id="f-1668" unitRef="usd">45000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-524" decimals="-6" id="f-1669" unitRef="usd">414000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-523" id="f-1670">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-509" id="f-1671">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-509" id="f-1672">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-527"
      decimals="INF"
      id="f-1673"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-528"
      decimals="INF"
      id="f-1674"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-1675">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance share unit activity during fiscal year 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Wtd. Avg.&lt;br/&gt;Grant&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per performance share units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit related to performance share units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-529"
      decimals="-3"
      id="f-1676"
      unitRef="shares">2422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-529"
      decimals="2"
      id="f-1677"
      unitRef="usdPerShare">106.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-509"
      decimals="-3"
      id="f-1678"
      unitRef="shares">1444000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-509"
      decimals="2"
      id="f-1679"
      unitRef="usdPerShare">98.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-509"
      decimals="-3"
      id="f-1680"
      unitRef="shares">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-509"
      decimals="2"
      id="f-1681"
      unitRef="usdPerShare">147.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments
      contextRef="c-509"
      decimals="-3"
      id="f-1682"
      unitRef="shares">256000</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustments>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments
      contextRef="c-509"
      decimals="2"
      id="f-1683"
      unitRef="usdPerShare">97.75</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAveragePerformanceAdjustments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-509"
      decimals="-3"
      id="f-1684"
      unitRef="shares">209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-509"
      decimals="2"
      id="f-1685"
      unitRef="usdPerShare">103.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-530"
      decimals="-3"
      id="f-1686"
      unitRef="shares">3141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-530"
      decimals="2"
      id="f-1687"
      unitRef="usdPerShare">100.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-509"
      decimals="2"
      id="f-1688"
      unitRef="usdPerShare">98.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-510"
      decimals="2"
      id="f-1689"
      unitRef="usdPerShare">104.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-511"
      decimals="2"
      id="f-1690"
      unitRef="usdPerShare">98.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-509" decimals="-6" id="f-1691" unitRef="usd">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-510" decimals="-6" id="f-1692" unitRef="usd">78000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-511" decimals="-6" id="f-1693" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-509" decimals="-6" id="f-1694" unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-510" decimals="-6" id="f-1695" unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-511" decimals="-6" id="f-1696" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-530" decimals="-6" id="f-1697" unitRef="usd">90000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-509" id="f-1698">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-531"
      decimals="INF"
      id="f-1699"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod
      contextRef="c-531"
      decimals="-6"
      id="f-1700"
      unitRef="shares">3000000</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeSharesPurchasedDuringPeriod>
    <mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare
      contextRef="c-531"
      decimals="2"
      id="f-1701"
      unitRef="usdPerShare">72.27</mdt:ShareBasedCompensationArrangementByShareBasedPaymentAwardAveragePurchasePricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-532"
      decimals="-6"
      id="f-1702"
      unitRef="shares">26000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1703">Income Taxes &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision is based on income before income taxes reported for financial statement purposes. The components of income before income taxes, based on tax jurisdiction, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax (benefit) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss, capital loss, and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state benefit on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on available-for-sale securities and derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,006&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reported as (after valuation allowance and jurisdictional netting):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No deferred taxes have been provided on the approximately $88.6 billion and $86.3 billion of undistributed earnings of the Company&#x2019;s subsidiaries at April&#160;25, 2025 and April&#160;26, 2024, respectively, since these earnings have been, and under current plans will continue to be, permanently reinvested in these subsidiaries. Due to the number of legal entities and jurisdictions involved, the complexity of the legal entity structure of the Company, and the complexity of the tax laws in the relevant jurisdictions, the Company believes it is not practicable to estimate, within any reasonable range, the amount of additional taxes which may be payable upon distribution of these undistributed earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025, the Company had approximately $10.8 billion of tax effected net operating loss carryforwards in certain non-U.S. jurisdictions, of which&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.8 billion have no expiration, and the remaining $6.0 billion will expire during fiscal years 2026 through 2045. Included in these net operating loss carryforwards are $3.9 billion of tax effected net operating losses generated in fiscal year 2008 as a result &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the receipt of a favorable tax ruling from certain non-U.S. taxing authorities; and $4.9&#160;billion of tax effected net operating losses generated during fiscal year 2023 as a result of an intercompany reorganization. The Company has recorded a full valuation allowance against these net operating losses, as management does not believe that it is more likely than not that these net operating losses will be utilized. Certain of the remaining non-U.S. net operating loss carryforwards of $2.0 billion have a valuation allowance recorded against the carryforwards, as management does not believe that it is more likely than not that these net operating losses will be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025, the Company had $53 million of tax effected U.S. federal net operating loss carryforwards, of which $35&#160;million have no expiration. The remaining loss carryforwards will expire during fiscal years 2026 through 2036. For U.S. state purposes, the Company had $84 million of tax effected net operating loss carryforwards at April&#160;25, 2025, $12&#160;million of which have no expiration. The remaining U.S. state loss carryforwards will expire during fiscal years 2026 through 2044.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025, the Company also had $313 million of tax credits available to reduce future income taxes payable, of which&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$136 million have no expiration. The remaining credits will expire during fiscal years 2026 through 2042. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has established valuation allowances of $12.7 billion and $13.3 billion at April&#160;25, 2025 and April&#160;26, 2024, respectively, primarily related to the uncertainty of the utilization of certain deferred tax assets which are primarily comprised of tax loss and credit carryforwards in various jurisdictions. The decrease in the valuation allowance during fiscal year 2025 is primarily related to a decrease in the Luxembourg tax rate applied to previously recorded deferred tax assets and associated valuation allowances and current year utilization of attributes with a full valuation allowance due to certain intercompany transactions. These valuation allowances would result in a reduction to the income tax provision in the consolidated statements of income if they are ultimately not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Base erosion anti-abuse tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign derived intangible income benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two Global Minimum Tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which were effective for Medtronic in fiscal year 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Israeli Central-Lod District Court issued its decision in Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office in June 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187&#160;million income tax charge during fiscal year 2024 and filed an appeal with the Supreme Court of Israel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2025, the cost from certain tax adjustments of $62&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income, relates to amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2024, the net cost from certain tax adjustments of $299&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income, included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $187&#160;million associated with a reserve adjustment related to the Israeli Central-Lod District Court decision with respect to a deemed taxable transfer of intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $124&#160;million related to a change in valuation allowance on previously recorded net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A benefit of $95&#160;million related to a Swiss Cantonal tax rate change on previously recorded deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $50&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $33&#160;million associated with a change in the Company&#x2019;s permanent reinvestment assertion on certain historical earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2023, the net benefit from certain tax adjustments of $910&#160;million, recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income, included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A net cost of $764&#160;million associated with the August 2022 U.S. Tax Court (Tax Court) Opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS&#x2019;s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Company has assumed the Tax Court findings will be applied for all years following fiscal year 2006. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $55&#160;million related to the disallowance of certain interest deductions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $30&#160;million related to the change in reporting currency for certain carryover attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A cost of $28&#160;million associated with the amortization of the previously established deferred tax assets from intercompany intellectual property transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A net cost of $33&#160;million primarily associated with the sale of half of the Company&#x2019;s RCS business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currently, the Company&#x2019;s operations in Puerto Rico, Singapore, Dominican Republic, Costa Rica, and China have various tax holidays and tax incentive grants. The tax reductions, inclusive of Pillar Two global minimum tax impacts, as compared to the local statutory rate favorably impacted earnings by $294&#160;million, $229 million, and $115 million in fiscal years 2025, 2024, and 2023, respectively, and diluted earnings per share by $0.23, $0.17, and $0.09, in fiscal years 2025, 2024, and 2023, respectively. The tax holidays are conditional upon the Company meeting certain thresholds required under statutory law. The tax incentive grants, unless extended, will expire between fiscal years 2026 and 2049. The tax incentive grants which expired during fiscal year 2025 did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $2.9 billion, $2.8 billion, and $2.7 billion of gross unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2025, 2024, and 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross increases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross decreases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation lapses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash advance paid to taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year, net of cash advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If all of the Company&#x2019;s unrecognized tax benefits at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023 were recognized, $2.7 billion, $2.7 billion, and $2.5 billion would impact the Company&#x2019;s effective tax rate, respectively. Although the Company believes that it has adequately reserved for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on the Company&#x2019;s effective tax rate in future periods. The Company has recorded gross unrecognized tax benefits, net of cash advance, of $1.9 billion as a noncurrent liability. The Company estimates that within the next 12 months it is reasonably possible that its uncertain tax positions, excluding interest, could decrease by as much as $17&#160;million, net as a result of statute of limitation lapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to income tax matters in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income and records the liability in the current or noncurrent &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accrued income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets, as appropriate. During fiscal years 2025, 2024, and 2023, the Company recognized gross interest expense of $55 million, $134 million, and $86 million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. The Company had $74 million, $19 million, and $61 million of accrued gross interest and penalties at April&#160;25, 2025, April&#160;26, 2024, and April&#160;28, 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. These reserves are subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or other tax authorities during future tax audits, could have a material impact on the Company&#x2019;s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and that it has meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Earliest Year Open&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - federal and state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dominican Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 for additional information regarding the status of current tax audits and proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1704">The components of income before income taxes, based on tax jurisdiction, are as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-6" id="f-1705" unitRef="usd">1037000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-25" decimals="-6" id="f-1706" unitRef="usd">750000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-26" decimals="-6" id="f-1707" unitRef="usd">1295000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-6" id="f-1708" unitRef="usd">4591000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-25" decimals="-6" id="f-1709" unitRef="usd">4087000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-26" decimals="-6" id="f-1710" unitRef="usd">4069000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1711" unitRef="usd">5628000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-1712" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-1713" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1714">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax (benefit) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1715" unitRef="usd">583000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1716" unitRef="usd">756000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1717" unitRef="usd">1303000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1718" unitRef="usd">692000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1719" unitRef="usd">905000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1720" unitRef="usd">530000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1721" unitRef="usd">1275000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1722" unitRef="usd">1661000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1723" unitRef="usd">1833000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1724" unitRef="usd">-322000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1725" unitRef="usd">-435000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1726" unitRef="usd">-336000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1727" unitRef="usd">-17000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1728" unitRef="usd">-93000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1729" unitRef="usd">83000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1730" unitRef="usd">-339000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1731" unitRef="usd">-528000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1732" unitRef="usd">-253000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1733" unitRef="usd">936000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-6" id="f-1734" unitRef="usd">1133000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-6" id="f-1735" unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1736">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax assets (liabilities), shown before jurisdictional netting of deferred tax assets (liabilities), are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss, capital loss, and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state benefit on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on available-for-sale securities and derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,006&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis difference of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and post-retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reported as (after valuation allowance and jurisdictional netting):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards contextRef="c-24" decimals="-6" id="f-1737" unitRef="usd">11252000000</mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards>
    <mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards contextRef="c-27" decimals="-6" id="f-1738" unitRef="usd">11775000000</mdt:DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-24" decimals="-6" id="f-1739" unitRef="usd">2800000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-27" decimals="-6" id="f-1740" unitRef="usd">2858000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization contextRef="c-24" decimals="-6" id="f-1741" unitRef="usd">1420000000</mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization contextRef="c-27" decimals="-6" id="f-1742" unitRef="usd">1255000000</mdt:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-24" decimals="-6" id="f-1743" unitRef="usd">450000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-27" decimals="-6" id="f-1744" unitRef="usd">404000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-24" decimals="-6" id="f-1745" unitRef="usd">363000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-27" decimals="-6" id="f-1746" unitRef="usd">374000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-24" decimals="-6" id="f-1747" unitRef="usd">149000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-27" decimals="-6" id="f-1748" unitRef="usd">147000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-24" decimals="-6" id="f-1749" unitRef="usd">144000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-27" decimals="-6" id="f-1750" unitRef="usd">138000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-24" decimals="-6" id="f-1751" unitRef="usd">213000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-27" decimals="-6" id="f-1752" unitRef="usd">172000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mdt:DeferredTaxAssetsLeaseObligations contextRef="c-24" decimals="-6" id="f-1753" unitRef="usd">165000000</mdt:DeferredTaxAssetsLeaseObligations>
    <mdt:DeferredTaxAssetsLeaseObligations contextRef="c-27" decimals="-6" id="f-1754" unitRef="usd">157000000</mdt:DeferredTaxAssetsLeaseObligations>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions contextRef="c-24" decimals="-6" id="f-1755" unitRef="usd">32000000</mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions>
    <mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions contextRef="c-27" decimals="-6" id="f-1756" unitRef="usd">21000000</mdt:DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions>
    <mdt:DeferredTaxAssetsInterestLimitation contextRef="c-24" decimals="-6" id="f-1757" unitRef="usd">479000000</mdt:DeferredTaxAssetsInterestLimitation>
    <mdt:DeferredTaxAssetsInterestLimitation contextRef="c-27" decimals="-6" id="f-1758" unitRef="usd">608000000</mdt:DeferredTaxAssetsInterestLimitation>
    <mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives contextRef="c-24" decimals="-6" id="f-1759" unitRef="usd">-56000000</mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives>
    <mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives contextRef="c-27" decimals="-6" id="f-1760" unitRef="usd">-13000000</mdt:DeferredTaxAssetsUnrealizedGainsOnTradingSecuritiesAndDerivatives>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-24" decimals="-6" id="f-1761" unitRef="usd">421000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-27" decimals="-6" id="f-1762" unitRef="usd">355000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-24" decimals="-6" id="f-1763" unitRef="usd">17946000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-27" decimals="-6" id="f-1764" unitRef="usd">18277000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-24" decimals="-6" id="f-1765" unitRef="usd">12668000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-6" id="f-1766" unitRef="usd">13271000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-24" decimals="-6" id="f-1767" unitRef="usd">5277000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-27" decimals="-6" id="f-1768" unitRef="usd">5006000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-24" decimals="-6" id="f-1769" unitRef="usd">1238000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-27" decimals="-6" id="f-1770" unitRef="usd">1406000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-24" decimals="-6" id="f-1771" unitRef="usd">67000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="c-27" decimals="-6" id="f-1772" unitRef="usd">70000000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-24" decimals="-6" id="f-1773" unitRef="usd">159000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-27" decimals="-6" id="f-1774" unitRef="usd">149000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-24" decimals="-6" id="f-1775" unitRef="usd">114000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-27" decimals="-6" id="f-1776" unitRef="usd">110000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries contextRef="c-24" decimals="-6" id="f-1777" unitRef="usd">71000000</mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries>
    <mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries contextRef="c-27" decimals="-6" id="f-1778" unitRef="usd">90000000</mdt:DeferredTaxLiabilitiesInvestmentInSubsidiaries>
    <mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits contextRef="c-24" decimals="-6" id="f-1779" unitRef="usd">35000000</mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits>
    <mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits contextRef="c-27" decimals="-6" id="f-1780" unitRef="usd">45000000</mdt:DeferredTaxLiabilitiesPensionAndPostRetirementBenefits>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-24" decimals="-6" id="f-1781" unitRef="usd">90000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-27" decimals="-6" id="f-1782" unitRef="usd">90000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-24" decimals="-6" id="f-1783" unitRef="usd">1773000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-27" decimals="-6" id="f-1784" unitRef="usd">1960000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:PrepaidTaxes contextRef="c-24" decimals="-6" id="f-1785" unitRef="usd">719000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-27" decimals="-6" id="f-1786" unitRef="usd">520000000</us-gaap:PrepaidTaxes>
    <us-gaap:IncomeTaxReceivable contextRef="c-24" decimals="-6" id="f-1787" unitRef="usd">464000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable contextRef="c-27" decimals="-6" id="f-1788" unitRef="usd">406000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-24" decimals="-6" id="f-1789" unitRef="usd">4687000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1790" unitRef="usd">3972000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <mdt:DeferredTaxAssetsNetofValuationAllowanceOther contextRef="c-24" decimals="-6" id="f-1791" unitRef="usd">1050000000</mdt:DeferredTaxAssetsNetofValuationAllowanceOther>
    <mdt:DeferredTaxAssetsNetofValuationAllowanceOther contextRef="c-27" decimals="-6" id="f-1792" unitRef="usd">830000000</mdt:DeferredTaxAssetsNetofValuationAllowanceOther>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-24" decimals="-6" id="f-1793" unitRef="usd">4040000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-27" decimals="-6" id="f-1794" unitRef="usd">3657000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-24" decimals="-6" id="f-1795" unitRef="usd">403000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1796" unitRef="usd">515000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-24" decimals="-6" id="f-1797" unitRef="usd">4687000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-27" decimals="-6" id="f-1798" unitRef="usd">3972000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-24" decimals="-8" id="f-1799" unitRef="usd">88600000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-27" decimals="-8" id="f-1800" unitRef="usd">86300000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:OperatingLossCarryforwards contextRef="c-533" decimals="-8" id="f-1801" unitRef="usd">10800000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-533" decimals="-8" id="f-1802" unitRef="usd">4800000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-533" decimals="-8" id="f-1803" unitRef="usd">6000000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-534" decimals="-8" id="f-1804" unitRef="usd">3900000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-24" decimals="-8" id="f-1805" unitRef="usd">4900000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c-533" decimals="-8" id="f-1806" unitRef="usd">2000000000.0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-535" decimals="-6" id="f-1807" unitRef="usd">53000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-535" decimals="-6" id="f-1808" unitRef="usd">35000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-536" decimals="-6" id="f-1809" unitRef="usd">84000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-536" decimals="-6" id="f-1810" unitRef="usd">12000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-24" decimals="-6" id="f-1811" unitRef="usd">313000000</us-gaap:TaxCreditCarryforwardAmount>
    <mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration contextRef="c-24" decimals="-6" id="f-1812" unitRef="usd">136000000</mdt:DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-24" decimals="-8" id="f-1813" unitRef="usd">12700000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-8" id="f-1814" unitRef="usd">13300000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1815">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate varied from the U.S. federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Base erosion anti-abuse tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign derived intangible income benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1816"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-25"
      decimals="INF"
      id="f-1817"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-26"
      decimals="INF"
      id="f-1818"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1819" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-25" decimals="3" id="f-1820" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-26" decimals="3" id="f-1821" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-1822" unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-25" decimals="3" id="f-1823" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-26" decimals="3" id="f-1824" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-1" decimals="3" id="f-1825" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-25" decimals="3" id="f-1826" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax contextRef="c-26" decimals="3" id="f-1827" unitRef="number">0.010</mdt:EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1828" unitRef="number">-0.065</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-25" decimals="3" id="f-1829" unitRef="number">-0.067</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-26" decimals="3" id="f-1830" unitRef="number">-0.080</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1831" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-25" decimals="3" id="f-1832" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-26" decimals="3" id="f-1833" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-1" decimals="3" id="f-1834" unitRef="number">0.014</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-25" decimals="3" id="f-1835" unitRef="number">0.013</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent contextRef="c-26" decimals="3" id="f-1836" unitRef="number">0.012</mdt:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-1" decimals="3" id="f-1837" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-25" decimals="3" id="f-1838" unitRef="number">0.003</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent contextRef="c-26" decimals="3" id="f-1839" unitRef="number">0</mdt:EffectiveIncomeTaxRateReconciliationBaseErosionAndAntiAbuseTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-1" decimals="3" id="f-1840" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-25" decimals="3" id="f-1841" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-26" decimals="3" id="f-1842" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1843" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-25" decimals="3" id="f-1844" unitRef="number">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-26" decimals="3" id="f-1845" unitRef="number">0.170</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-1" decimals="3" id="f-1846" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-25" decimals="3" id="f-1847" unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-26" decimals="3" id="f-1848" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1849" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-25" decimals="3" id="f-1850" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-26" decimals="3" id="f-1851" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1852" unitRef="number">0.166</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-25" decimals="3" id="f-1853" unitRef="number">0.234</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-26" decimals="3" id="f-1854" unitRef="number">0.295</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-25" decimals="-6" id="f-1855" unitRef="usd">187000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-6" id="f-1856" unitRef="usd">62000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-25" decimals="-6" id="f-1857" unitRef="usd">299000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets contextRef="c-25" decimals="-6" id="f-1858" unitRef="usd">187000000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-25" decimals="-6" id="f-1859" unitRef="usd">124000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-25" decimals="-6" id="f-1860" unitRef="usd">-95000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="c-25" decimals="-6" id="f-1861" unitRef="usd">50000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion contextRef="c-25" decimals="-6" id="f-1862" unitRef="usd">33000000</mdt:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentReinvestmentAssertion>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-26" decimals="-6" id="f-1863" unitRef="usd">910000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount contextRef="c-26" decimals="-6" id="f-1864" unitRef="usd">764000000</mdt:EffectiveIncomeTaxRateReconciliationTaxAdjustmentsForReservesAmount>
    <mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount contextRef="c-26" decimals="-6" id="f-1865" unitRef="usd">55000000</mdt:EffectiveIncomeTaxReconciliationDisallowanceOfInterestDeductionsAmount>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="c-47" decimals="-6" id="f-1866" unitRef="usd">30000000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="c-26" decimals="-6" id="f-1867" unitRef="usd">28000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets contextRef="c-26" decimals="-6" id="f-1868" unitRef="usd">33000000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-537" decimals="-6" id="f-1869" unitRef="usd">294000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-538" decimals="-6" id="f-1870" unitRef="usd">229000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxReconciliationTaxHolidays contextRef="c-539" decimals="-6" id="f-1871" unitRef="usd">115000000</us-gaap:IncomeTaxReconciliationTaxHolidays>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-537"
      decimals="2"
      id="f-1872"
      unitRef="usdPerShare">0.23</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-538"
      decimals="2"
      id="f-1873"
      unitRef="usdPerShare">0.17</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-539"
      decimals="2"
      id="f-1874"
      unitRef="usdPerShare">0.09</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-8" id="f-1875" unitRef="usd">2900000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-8" id="f-1876" unitRef="usd">2800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-47" decimals="-8" id="f-1877" unitRef="usd">2700000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1878">A reconciliation of the beginning and ending amount of unrecognized tax benefits for fiscal years 2025, 2024, and 2023 is as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross increases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross decreases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute of limitation lapses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash advance paid to taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of fiscal year, net of cash advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-6" id="f-1879" unitRef="usd">2824000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-47" decimals="-6" id="f-1880" unitRef="usd">2682000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-34" decimals="-6" id="f-1881" unitRef="usd">1661000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1882" unitRef="usd">13000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1883" unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1884" unitRef="usd">980000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1885" unitRef="usd">93000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1886" unitRef="usd">85000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1887" unitRef="usd">89000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1888" unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-25" decimals="-6" id="f-1889" unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-6" id="f-1890" unitRef="usd">12000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-6" id="f-1891" unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-25" decimals="-6" id="f-1892" unitRef="usd">55000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-26" decimals="-6" id="f-1893" unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-6" id="f-1894" unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-25" decimals="-6" id="f-1895" unitRef="usd">7000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-26" decimals="-6" id="f-1896" unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-6" id="f-1897" unitRef="usd">2902000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-6" id="f-1898" unitRef="usd">2824000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-47" decimals="-6" id="f-1899" unitRef="usd">2682000000</us-gaap:UnrecognizedTaxBenefits>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-1" decimals="-6" id="f-1900" unitRef="usd">934000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-25" decimals="-6" id="f-1901" unitRef="usd">934000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:CashAdvancePaidinConnectionWithProposedSettlements contextRef="c-26" decimals="-6" id="f-1902" unitRef="usd">918000000</mdt:CashAdvancePaidinConnectionWithProposedSettlements>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-24" decimals="-6" id="f-1903" unitRef="usd">1968000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-27" decimals="-6" id="f-1904" unitRef="usd">1890000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid contextRef="c-47" decimals="-6" id="f-1905" unitRef="usd">1764000000</mdt:UnrecognizedTaxBenefitsNetofCashAdvancePaid>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-24" decimals="-8" id="f-1906" unitRef="usd">2700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-27" decimals="-8" id="f-1907" unitRef="usd">2700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-47" decimals="-8" id="f-1908" unitRef="usd">2500000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent contextRef="c-24" decimals="-8" id="f-1909" unitRef="usd">1900000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-24" decimals="-6" id="f-1910" unitRef="usd">17000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-1" decimals="-6" id="f-1911" unitRef="usd">55000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-25" decimals="-6" id="f-1912" unitRef="usd">134000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <mdt:IncomeTaxExaminationInterestIncomeExpenseGross contextRef="c-26" decimals="-6" id="f-1913" unitRef="usd">86000000</mdt:IncomeTaxExaminationInterestIncomeExpenseGross>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-24" decimals="-6" id="f-1914" unitRef="usd">74000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-27" decimals="-6" id="f-1915" unitRef="usd">19000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-47" decimals="-6" id="f-1916" unitRef="usd">61000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SummaryOfIncomeTaxExaminationsTextBlock contextRef="c-1" id="f-1917">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major tax jurisdictions where the Company conducts business which remain subject to examination are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Earliest Year Open&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - federal and state&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2005&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dominican Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2010&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxExaminationsTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1918">Earnings Per Share&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of weighted average diluted shares outstanding excludes stock awards of approximately 26 million, 28 million, and 23 million ordinary shares in fiscal year 2025, 2024, and 2023, respectively because their effect would have been anti-dilutive on the Company&#x2019;s earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-1919">Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1920">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to ordinary shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted &#x2013; weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,332.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-1921" unitRef="usd">4662000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-6" id="f-1922" unitRef="usd">3676000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-6" id="f-1923" unitRef="usd">3758000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-1924" unitRef="shares">1285600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-25"
      decimals="-5"
      id="f-1925"
      unitRef="shares">1327700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-26"
      decimals="-5"
      id="f-1926"
      unitRef="shares">1329800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-503"
      decimals="-5"
      id="f-1927"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-504"
      decimals="-5"
      id="f-1928"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-505"
      decimals="-5"
      id="f-1929"
      unitRef="shares">1500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-506"
      decimals="-5"
      id="f-1930"
      unitRef="shares">2200000</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-507"
      decimals="-5"
      id="f-1931"
      unitRef="shares">1400000</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
      contextRef="c-508"
      decimals="-5"
      id="f-1932"
      unitRef="shares">1000000.0</us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-509"
      decimals="-5"
      id="f-1933"
      unitRef="shares">1500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-510"
      decimals="-5"
      id="f-1934"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-511"
      decimals="-5"
      id="f-1935"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-1936" unitRef="shares">1289900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-25"
      decimals="-5"
      id="f-1937"
      unitRef="shares">1330200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-26"
      decimals="-5"
      id="f-1938"
      unitRef="shares">1332800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1939"
      unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-1940"
      unitRef="usdPerShare">2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-1941"
      unitRef="usdPerShare">2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1942"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-1943"
      unitRef="usdPerShare">2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-1944"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-540"
      decimals="-6"
      id="f-1945"
      unitRef="shares">26000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-541"
      decimals="-6"
      id="f-1946"
      unitRef="shares">28000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-542"
      decimals="-6"
      id="f-1947"
      unitRef="shares">23000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1948">Retirement Benefit Plans &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net expense related to these plans was $466 million, $451 million, and $494 million in fiscal years 2025, 2024, and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company maintains qualified pension plans designed to provide guaranteed minimum retirement benefits to all eligible U.S. participants. Pension coverage for non-U.S. employees is provided, to the extent deemed appropriate, through separate plans. In addition to the benefits provided under the qualified pension plan, retirement benefits associated with wages in excess of the IRS allowable limits are provided to certain employees under a non-qualified plan. U.S. and Puerto Rico employees are also eligible to receive a medical benefit component, in addition to normal retirement benefits, through the Company&#x2019;s post-retirement benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At April&#160;25, 2025 and April&#160;26, 2024, the funded status of the Company&#x2019;s benefit plans was $440 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overfunded and $484 million overfunded, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2023, the Company offered certain eligible U.S. employees voluntary early retirement packages, resulting in charges of $94&#160;million, primarily related to U.S. pension benefits. The charges were recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;restructuring charges, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income. See Note 4 for additional information on restructuring charges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The change in benefit obligation and funded status of the Company&#x2019;s U.S. and Non-U.S. pension benefits are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated benefit obligation at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments, settlements, and amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial loss (gain)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over funded status of the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized on the consolidated&lt;br/&gt;balance sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized in accumulated other&lt;br/&gt;comprehensive loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In April 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain countries outside the U.S., fully funding pension plans is not a common practice, as funding provides no income tax benefit. Consequently, certain pension plans were partially funded at April&#160;25, 2025 and April&#160;26, 2024. U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost of the plans includes the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement and curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of net periodic benefit cost other than the service component are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other changes in plan assets and projected benefit obligations recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other comprehensive (loss) income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for fiscal year 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S.&lt;br/&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and settlement recognition of actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actuarial assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.24% - 5.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21% - 24.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53% - 5.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68% - 5.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12% - 4.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51% - 5.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.30% - 7.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes a full yield curve approach methodology to estimate the service and interest cost components of net periodic pension cost and net periodic post-retirement benefit cost for the Company&#x2019;s pension and other post-retirement benefits. The full yield curve approach applies specific spot rates along the yield curve to their underlying projected cash flows in estimation of the cost components. The current yield curves represent high quality, long-term fixed income instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets assumptions are determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Investment Strategy  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company sponsors trusts that hold the assets for U.S. pension plans and other U.S. post-retirement benefit plans, primarily retiree medical benefits. For investment purposes, the Medtronic U.S. pension and other U.S. post-retirement benefit plans employ similar investment strategies with different asset allocation targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a Qualified Plan Committee (the Plan Committee) that sets investment guidelines for U.S. pension plans and other U.S. post-retirement benefit plans with the assistance of external consultants. These guidelines are established based on market conditions, risk tolerance, funding requirements, and expected benefit payments. The Plan Committee also oversees the investment allocation process, selects the investment managers, and monitors asset performance. As pension liabilities are long-term in nature, the Company employs a long-term total return approach to maximize the long-term rate of return on plan assets for a prudent level of risk. An annual analysis on the risk versus the return of the investment portfolio is conducted to justify the expected long-term rate of return assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment portfolios contain a diversified allocation of investment categories, including equities, fixed income securities, hedge funds, and private equity. Securities are also diversified in terms of domestic and international, short- and long-term, growth and value styles, large cap and small cap stocks, and active and passive management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside the U.S., pension plan assets are typically managed by decentralized fiduciary committees. There is significant variation in policy asset allocation from country to country. Local regulations, funding rules, and financial and tax considerations are part of the funding and investment allocation process in each country. The weighted average target asset allocations at April&#160;25, 2025 for the plans are&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; equity securities, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; debt securities, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; other.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The plans did not hold any investments in the Company&#x2019;s ordinary shares at April&#160;25, 2025 or April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. plans target asset allocations at April&#160;25, 2025, compared to the U.S. plans actual asset allocations at April&#160;25, 2025 and April&#160;26, 2024 by asset category, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Strong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Asset Fair Values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Short-term investments include money market funds. These investments are valued at the closing price reported in the active markets in which the individual security is traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Mutual funds:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Comprised of investments in equity and fixed income securities held in pooled investment vehicles. The valuations of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity commingled trusts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Comprised of investments in equity securities held in pooled investment vehicles. The valuations of equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed income commingled trusts: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund, either daily or monthly depending on the investment, at market close. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the fund, less its liabilities.&#160;The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Partnership units:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Partnership units include investment partnerships that provide exposure to long/short equity, absolute return strategies, private equity investments, and real estate investments. The net asset values are reported by the investment manager based on the valuation of the underlying assets held by the partnerships, less its liabilities. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Registered investment companies:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance contracts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company&#x2019;s general portfolio and participate in the insurer&#x2019;s profit-sharing policy on an excess yield basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement using net asset value as a practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported net asset value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;25, 2025 and April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. pension benefit assets that are valued using significant unobservable inputs (Level 3) was $48&#160;million and $42&#160;million as of April&#160;25, 2025 and April&#160;26, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the fair value hierarchy classification on an annual basis. There were no transfers into or out of Level 3 for both the U.S. and non-U.S. pension plans during the fiscal years ended April&#160;25, 2025 and April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Retirement Benefit Plan Funding  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; It is the Company&#x2019;s policy to fund retirement costs within the limits of allowable tax deductions. During fiscal year 2025, the Company made discretionary contributions of approximately $31 million to the U.S. pension plan. Internationally, the Company contributed approximately $45 million for pension benefits during fiscal year 2025. The Company anticipates that it will make contributions of $29 million and $55 million to its U.S. pension benefit plans and non-U.S. pension benefit plans, respectively, in fiscal year 2026. Based on the guidelines under the U.S. Employee Retirement Income Security Act of 1974 and the various guidelines which govern the plans outside the U.S., the majority of anticipated fiscal year 2026 contributions will be discretionary. The Company believes that pension assets, returns on invested pension assets, and Company contributions will be able to meet its pension and other post-retirement obligations in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 &#x2013; 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Post-retirement Benefit Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The net periodic benefit cost associated with the Company&#x2019;s post-retirement benefit plans was income of $16 million, $16 million, and $11 million in fiscal years 2025, 2024, and 2023, respectively. The Company&#x2019;s projected benefit obligation for all post-retirement benefit plans was $231 million and $235 million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The Company&#x2019;s fair value of plan assets for all post-retirement benefit plans was $303 million and $308 million at April&#160;25, 2025 and April&#160;26, 2024, respectively. The post-retirement benefit plan assets at both April&#160;25, 2025 and April&#160;26, 2024 primarily comprised of equity and fixed commingled trusts, consistent with the U.S. retirement benefit plan assets outlined in the fair value leveling tables above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Defined Contribution Savings Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   The Company has defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security during retirement by providing employees with an incentive to make regular savings. Company contributions to the plans are based on employee contributions and Company performance. Expense recognized under these plans was $478 million, $471 million, and $390 million in fiscal years 2025, 2024, and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-1" decimals="-6" id="f-1949" unitRef="usd">466000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-25" decimals="-6" id="f-1950" unitRef="usd">451000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c-26" decimals="-6" id="f-1951" unitRef="usd">494000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-24" decimals="-6" id="f-1952" unitRef="usd">440000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-27" decimals="-6" id="f-1953" unitRef="usd">484000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits contextRef="c-26" decimals="-6" id="f-1954" unitRef="usd">94000000</mdt:DefinedBenefitAndContributionPlanCostOfProvidingSpecialAndContractualTerminationBenefits>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c-1" id="f-1955">The change in benefit obligation and funded status of the Company&#x2019;s U.S. and Non-U.S. pension benefits are as follows:&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated benefit obligation at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan curtailments, settlements, and amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial loss (gain)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funded status at end of year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over funded status of the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized on the consolidated&lt;br/&gt;balance sheets consist of:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts recognized in accumulated other&lt;br/&gt;comprehensive loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;In April 2020, the Company announced the freezing of the U.S. pension benefits beginning Plan year 2028. Employees will continue to earn benefits as required by the Medtronic Retirement Plan until April 30, 2027, after which date benefits will no longer be earned and employees will earn benefits through the Medtronic Savings and Investment Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). The actuarial gains and losses were primarily driven by increases and decreases in discount rates, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-543" decimals="-6" id="f-1956" unitRef="usd">3235000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-544" decimals="-6" id="f-1957" unitRef="usd">3144000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-545" decimals="-6" id="f-1958" unitRef="usd">1685000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-546" decimals="-6" id="f-1959" unitRef="usd">1513000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-544" decimals="-6" id="f-1960" unitRef="usd">3194000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-547" decimals="-6" id="f-1961" unitRef="usd">3451000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-546" decimals="-6" id="f-1962" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-548" decimals="-6" id="f-1963" unitRef="usd">1499000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-549" decimals="-6" id="f-1964" unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-550" decimals="-6" id="f-1965" unitRef="usd">61000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-551" decimals="-6" id="f-1966" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-552" decimals="-6" id="f-1967" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-549" decimals="-6" id="f-1968" unitRef="usd">174000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-550" decimals="-6" id="f-1969" unitRef="usd">162000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-551" decimals="-6" id="f-1970" unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-552" decimals="-6" id="f-1971" unitRef="usd">53000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-549" decimals="-6" id="f-1972" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-550" decimals="-6" id="f-1973" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-551" decimals="-6" id="f-1974" unitRef="usd">10000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-552" decimals="-6" id="f-1975" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-549" decimals="-6" id="f-1976" unitRef="usd">0</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-550" decimals="-6" id="f-1977" unitRef="usd">0</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-551" decimals="-6" id="f-1978" unitRef="usd">2000000</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation contextRef="c-552" decimals="-6" id="f-1979" unitRef="usd">10000000</mdt:DefinedBenefitPlanCurtailmentsandSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-549" decimals="-6" id="f-1980" unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-550" decimals="-6" id="f-1981" unitRef="usd">245000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-551" decimals="-6" id="f-1982" unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-552" decimals="-6" id="f-1983" unitRef="usd">-116000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-549" decimals="-6" id="f-1984" unitRef="usd">173000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-550" decimals="-6" id="f-1985" unitRef="usd">234000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-551" decimals="-6" id="f-1986" unitRef="usd">59000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-552" decimals="-6" id="f-1987" unitRef="usd">65000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-549" decimals="-6" id="f-1988" unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-550" decimals="-6" id="f-1989" unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-551" decimals="-6" id="f-1990" unitRef="usd">129000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-552" decimals="-6" id="f-1991" unitRef="usd">-41000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-543" decimals="-6" id="f-1992" unitRef="usd">3269000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-544" decimals="-6" id="f-1993" unitRef="usd">3194000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-545" decimals="-6" id="f-1994" unitRef="usd">1797000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-546" decimals="-6" id="f-1995" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-544" decimals="-6" id="f-1996" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-547" decimals="-6" id="f-1997" unitRef="usd">3398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-546" decimals="-6" id="f-1998" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-548" decimals="-6" id="f-1999" unitRef="usd">1614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-549" decimals="-6" id="f-2000" unitRef="usd">200000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-550" decimals="-6" id="f-2001" unitRef="usd">356000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-551" decimals="-6" id="f-2002" unitRef="usd">34000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-552" decimals="-6" id="f-2003" unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-549" decimals="-6" id="f-2004" unitRef="usd">31000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-550" decimals="-6" id="f-2005" unitRef="usd">32000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-551" decimals="-6" id="f-2006" unitRef="usd">45000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-552" decimals="-6" id="f-2007" unitRef="usd">40000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-549" decimals="-6" id="f-2008" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-550" decimals="-6" id="f-2009" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-551" decimals="-6" id="f-2010" unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-552" decimals="-6" id="f-2011" unitRef="usd">9000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-549" decimals="-6" id="f-2012" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-550" decimals="-6" id="f-2013" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-551" decimals="-6" id="f-2014" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-552" decimals="-6" id="f-2015" unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-549" decimals="-6" id="f-2016" unitRef="usd">173000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-550" decimals="-6" id="f-2017" unitRef="usd">234000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-551" decimals="-6" id="f-2018" unitRef="usd">59000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-552" decimals="-6" id="f-2019" unitRef="usd">65000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-549" decimals="-6" id="f-2020" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-550" decimals="-6" id="f-2021" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-551" decimals="-6" id="f-2022" unitRef="usd">138000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-552" decimals="-6" id="f-2023" unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-543" decimals="-6" id="f-2024" unitRef="usd">3610000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-544" decimals="-6" id="f-2025" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-545" decimals="-6" id="f-2026" unitRef="usd">1823000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-546" decimals="-6" id="f-2027" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-543" decimals="-6" id="f-2028" unitRef="usd">3610000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-544" decimals="-6" id="f-2029" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-545" decimals="-6" id="f-2030" unitRef="usd">1823000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-546" decimals="-6" id="f-2031" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-543" decimals="-6" id="f-2032" unitRef="usd">3269000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-544" decimals="-6" id="f-2033" unitRef="usd">3194000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-545" decimals="-6" id="f-2034" unitRef="usd">1797000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-546" decimals="-6" id="f-2035" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-543" decimals="-6" id="f-2036" unitRef="usd">341000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-544" decimals="-6" id="f-2037" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-545" decimals="-6" id="f-2038" unitRef="usd">27000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-546" decimals="-6" id="f-2039" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-543" decimals="-6" id="f-2040" unitRef="usd">341000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-544" decimals="-6" id="f-2041" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-545" decimals="-6" id="f-2042" unitRef="usd">27000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-546" decimals="-6" id="f-2043" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-543" decimals="-6" id="f-2044" unitRef="usd">591000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-544" decimals="-6" id="f-2045" unitRef="usd">617000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-545" decimals="-6" id="f-2046" unitRef="usd">322000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-546" decimals="-6" id="f-2047" unitRef="usd">296000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-543" decimals="-6" id="f-2048" unitRef="usd">29000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-544" decimals="-6" id="f-2049" unitRef="usd">30000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-545" decimals="-6" id="f-2050" unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-546" decimals="-6" id="f-2051" unitRef="usd">7000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-543" decimals="-6" id="f-2052" unitRef="usd">221000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-544" decimals="-6" id="f-2053" unitRef="usd">230000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-545" decimals="-6" id="f-2054" unitRef="usd">289000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-546" decimals="-6" id="f-2055" unitRef="usd">235000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-543" decimals="-6" id="f-2056" unitRef="usd">341000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-544" decimals="-6" id="f-2057" unitRef="usd">357000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-545" decimals="-6" id="f-2058" unitRef="usd">27000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-546" decimals="-6" id="f-2059" unitRef="usd">54000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-543" decimals="-6" id="f-2060" unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-544" decimals="-6" id="f-2061" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-545" decimals="-6" id="f-2062" unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-546" decimals="-6" id="f-2063" unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-543" decimals="-6" id="f-2064" unitRef="usd">-602000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-544" decimals="-6" id="f-2065" unitRef="usd">-534000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-545" decimals="-6" id="f-2066" unitRef="usd">-230000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-546" decimals="-6" id="f-2067" unitRef="usd">-161000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-543" decimals="-6" id="f-2068" unitRef="usd">588000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-544" decimals="-6" id="f-2069" unitRef="usd">517000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-545" decimals="-6" id="f-2070" unitRef="usd">226000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-546" decimals="-6" id="f-2071" unitRef="usd">158000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2072">U.S. and non-U.S. pension plans with accumulated benefit obligations in excess of plan assets consist of the following:&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-553" decimals="-6" id="f-2073" unitRef="usd">813000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-554" decimals="-6" id="f-2074" unitRef="usd">773000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-553" decimals="-6" id="f-2075" unitRef="usd">849000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-554" decimals="-6" id="f-2076" unitRef="usd">809000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-553" decimals="-6" id="f-2077" unitRef="usd">347000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-554" decimals="-6" id="f-2078" unitRef="usd">334000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2079">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and non-U.S. pension plans with projected benefit obligations in excess of plan assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c-553" decimals="-6" id="f-2080" unitRef="usd">1470000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation contextRef="c-554" decimals="-6" id="f-2081" unitRef="usd">1321000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets contextRef="c-553" decimals="-6" id="f-2082" unitRef="usd">924000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets contextRef="c-554" decimals="-6" id="f-2083" unitRef="usd">819000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock contextRef="c-1" id="f-2084">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost of the plans includes the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement and curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit (credit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-549" decimals="-6" id="f-2085" unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-550" decimals="-6" id="f-2086" unitRef="usd">61000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-555" decimals="-6" id="f-2087" unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-551" decimals="-6" id="f-2088" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-552" decimals="-6" id="f-2089" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-556" decimals="-6" id="f-2090" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-549" decimals="-6" id="f-2091" unitRef="usd">174000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-550" decimals="-6" id="f-2092" unitRef="usd">162000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-555" decimals="-6" id="f-2093" unitRef="usd">142000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-551" decimals="-6" id="f-2094" unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-552" decimals="-6" id="f-2095" unitRef="usd">53000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-556" decimals="-6" id="f-2096" unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-549" decimals="-6" id="f-2097" unitRef="usd">264000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-550" decimals="-6" id="f-2098" unitRef="usd">261000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-555" decimals="-6" id="f-2099" unitRef="usd">224000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-551" decimals="-6" id="f-2100" unitRef="usd">68000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-552" decimals="-6" id="f-2101" unitRef="usd">72000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-556" decimals="-6" id="f-2102" unitRef="usd">58000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-549" decimals="-6" id="f-2103" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-550" decimals="-6" id="f-2104" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-555" decimals="-6" id="f-2105" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-551" decimals="-6" id="f-2106" unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-552" decimals="-6" id="f-2107" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-556" decimals="-6" id="f-2108" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-549" decimals="-6" id="f-2109" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-550" decimals="-6" id="f-2110" unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-555" decimals="-6" id="f-2111" unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-551" decimals="-6" id="f-2112" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-552" decimals="-6" id="f-2113" unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-556" decimals="-6" id="f-2114" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-549" decimals="-6" id="f-2115" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-550" decimals="-6" id="f-2116" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-555" decimals="-6" id="f-2117" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-551" decimals="-6" id="f-2118" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-552" decimals="-6" id="f-2119" unitRef="usd">3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-556" decimals="-6" id="f-2120" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-549" decimals="-6" id="f-2121" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-550" decimals="-6" id="f-2122" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-555" decimals="-6" id="f-2123" unitRef="usd">74000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-551" decimals="-6" id="f-2124" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-552" decimals="-6" id="f-2125" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod contextRef="c-556" decimals="-6" id="f-2126" unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-549" decimals="-6" id="f-2127" unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-550" decimals="-6" id="f-2128" unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-555" decimals="-6" id="f-2129" unitRef="usd">89000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-551" decimals="-6" id="f-2130" unitRef="usd">28000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-552" decimals="-6" id="f-2131" unitRef="usd">18000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-556" decimals="-6" id="f-2132" unitRef="usd">26000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-2133">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other changes in plan assets and projected benefit obligations recognized in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other comprehensive (loss) income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for fiscal year 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S.&lt;br/&gt;Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and settlement recognition of actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-549" decimals="-6" id="f-2134" unitRef="usd">-85000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-551" decimals="-6" id="f-2135" unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-549" decimals="-6" id="f-2136" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-551" decimals="-6" id="f-2137" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax contextRef="c-549" decimals="-6" id="f-2138" unitRef="usd">16000000</mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax>
    <mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax contextRef="c-551" decimals="-6" id="f-2139" unitRef="usd">-1000000</mdt:OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax>
    <mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment contextRef="c-549" decimals="-6" id="f-2140" unitRef="usd">0</mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment>
    <mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment contextRef="c-551" decimals="-6" id="f-2141" unitRef="usd">16000000</mdt:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansForeignExchangeAdjustment>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-549" decimals="-6" id="f-2142" unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-551" decimals="-6" id="f-2143" unitRef="usd">69000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-549" decimals="-6" id="f-2144" unitRef="usd">47000000</mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-551" decimals="-6" id="f-2145" unitRef="usd">97000000</mdt:ComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-2146">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actuarial assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; projected benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.24% - 5.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21% - 24.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Critical assumptions &#x2013; net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.54% - 5.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23% - 4.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53% - 5.82%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68% - 5.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12% - 4.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51% - 5.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73% - 4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% - 4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40% - 26.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% - 10.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 25.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% - 8.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.30% - 7.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-557"
      decimals="4"
      id="f-2147"
      unitRef="number">0.0524</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-558"
      decimals="4"
      id="f-2148"
      unitRef="number">0.0576</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-559"
      decimals="4"
      id="f-2149"
      unitRef="number">0.0554</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-560"
      decimals="4"
      id="f-2150"
      unitRef="number">0.0575</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-561"
      decimals="4"
      id="f-2151"
      unitRef="number">0.0473</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-562"
      decimals="4"
      id="f-2152"
      unitRef="number">0.0499</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-563"
      decimals="4"
      id="f-2153"
      unitRef="number">0.0121</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-564"
      decimals="4"
      id="f-2154"
      unitRef="number">0.2440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-565"
      decimals="4"
      id="f-2155"
      unitRef="number">0.0140</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-566"
      decimals="4"
      id="f-2156"
      unitRef="number">0.2640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-567"
      decimals="4"
      id="f-2157"
      unitRef="number">0.0130</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-568"
      decimals="4"
      id="f-2158"
      unitRef="number">0.1070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-543"
      decimals="4"
      id="f-2159"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-544"
      decimals="4"
      id="f-2160"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-547"
      decimals="4"
      id="f-2161"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-545"
      decimals="4"
      id="f-2162"
      unitRef="number">0.0289</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-546"
      decimals="4"
      id="f-2163"
      unitRef="number">0.0285</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-548"
      decimals="4"
      id="f-2164"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-569"
      decimals="4"
      id="f-2165"
      unitRef="number">0.0554</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-570"
      decimals="4"
      id="f-2166"
      unitRef="number">0.0575</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-571"
      decimals="4"
      id="f-2167"
      unitRef="number">0.0473</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-572"
      decimals="4"
      id="f-2168"
      unitRef="number">0.0499</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-573"
      decimals="4"
      id="f-2169"
      unitRef="number">0.0423</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-574"
      decimals="4"
      id="f-2170"
      unitRef="number">0.0448</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-575"
      decimals="4"
      id="f-2171"
      unitRef="number">0.0140</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-576"
      decimals="4"
      id="f-2172"
      unitRef="number">0.2640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-577"
      decimals="4"
      id="f-2173"
      unitRef="number">0.0130</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-578"
      decimals="4"
      id="f-2174"
      unitRef="number">0.1070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-579"
      decimals="4"
      id="f-2175"
      unitRef="number">0.0060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-580"
      decimals="4"
      id="f-2176"
      unitRef="number">0.2540</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-569"
      decimals="4"
      id="f-2177"
      unitRef="number">0.0553</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-570"
      decimals="4"
      id="f-2178"
      unitRef="number">0.0582</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-571"
      decimals="4"
      id="f-2179"
      unitRef="number">0.0468</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-572"
      decimals="4"
      id="f-2180"
      unitRef="number">0.0507</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-573"
      decimals="4"
      id="f-2181"
      unitRef="number">0.0412</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-574"
      decimals="4"
      id="f-2182"
      unitRef="number">0.0451</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-575"
      decimals="4"
      id="f-2183"
      unitRef="number">0.0140</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-576"
      decimals="4"
      id="f-2184"
      unitRef="number">0.2640</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-577"
      decimals="4"
      id="f-2185"
      unitRef="number">0.0130</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-578"
      decimals="4"
      id="f-2186"
      unitRef="number">0.1070</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-579"
      decimals="4"
      id="f-2187"
      unitRef="number">0.0060</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate
      contextRef="c-580"
      decimals="4"
      id="f-2188"
      unitRef="number">0.2540</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostServiceCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-569"
      decimals="4"
      id="f-2189"
      unitRef="number">0.0551</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-570"
      decimals="4"
      id="f-2190"
      unitRef="number">0.0563</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-571"
      decimals="4"
      id="f-2191"
      unitRef="number">0.0473</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-572"
      decimals="4"
      id="f-2192"
      unitRef="number">0.0490</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-573"
      decimals="4"
      id="f-2193"
      unitRef="number">0.0390</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-574"
      decimals="4"
      id="f-2194"
      unitRef="number">0.0423</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-575"
      decimals="4"
      id="f-2195"
      unitRef="number">0.0140</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-576"
      decimals="4"
      id="f-2196"
      unitRef="number">0.2640</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-577"
      decimals="4"
      id="f-2197"
      unitRef="number">0.0130</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-578"
      decimals="4"
      id="f-2198"
      unitRef="number">0.1070</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-579"
      decimals="4"
      id="f-2199"
      unitRef="number">0.0060</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-580"
      decimals="4"
      id="f-2200"
      unitRef="number">0.2540</mdt:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-569"
      decimals="4"
      id="f-2201"
      unitRef="number">0.0640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-570"
      decimals="4"
      id="f-2202"
      unitRef="number">0.0810</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-571"
      decimals="4"
      id="f-2203"
      unitRef="number">0.0640</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-572"
      decimals="4"
      id="f-2204"
      unitRef="number">0.0810</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-573"
      decimals="4"
      id="f-2205"
      unitRef="number">0.0530</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-574"
      decimals="4"
      id="f-2206"
      unitRef="number">0.0720</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-551"
      decimals="4"
      id="f-2207"
      unitRef="number">0.0380</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-552"
      decimals="4"
      id="f-2208"
      unitRef="number">0.0407</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-556"
      decimals="4"
      id="f-2209"
      unitRef="number">0.0348</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-549"
      decimals="4"
      id="f-2210"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-550"
      decimals="4"
      id="f-2211"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-555"
      decimals="4"
      id="f-2212"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-551"
      decimals="4"
      id="f-2213"
      unitRef="number">0.0285</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-552"
      decimals="4"
      id="f-2214"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-556"
      decimals="4"
      id="f-2215"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-581"
      decimals="2"
      id="f-2216"
      unitRef="number">0.42</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-582"
      decimals="2"
      id="f-2217"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-583"
      decimals="2"
      id="f-2218"
      unitRef="number">0.23</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2219">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. plans target asset allocations at April&#160;25, 2025, compared to the U.S. plans actual asset allocations at April&#160;25, 2025 and April&#160;26, 2024 by asset category, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Target Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Actual Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;25, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April&#160;26, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Category:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-584"
      decimals="INF"
      id="f-2220"
      unitRef="number">0.34</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-584"
      decimals="2"
      id="f-2221"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-585"
      decimals="2"
      id="f-2222"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-586"
      decimals="INF"
      id="f-2223"
      unitRef="number">0.51</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-586"
      decimals="2"
      id="f-2224"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-587"
      decimals="2"
      id="f-2225"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-588"
      decimals="INF"
      id="f-2226"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-588"
      decimals="2"
      id="f-2227"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-589"
      decimals="2"
      id="f-2228"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-543"
      decimals="INF"
      id="f-2229"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-543"
      decimals="INF"
      id="f-2230"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-544"
      decimals="INF"
      id="f-2231"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock contextRef="c-1" id="f-2232">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information by level for the retirement benefit plan assets that are measured at fair value, as defined by U.S. GAAP. Certain investments for which the fair value is measured using the net asset value per share (or its equivalent) practical expedient are not presented within the fair value hierarchy. The fair value amounts presented for these investments are intended to permit reconciliation to the total fair value of plan assets at April&#160;25, 2025 and April&#160;26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income commingled trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partnership units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;br/&gt;Using Inputs Considered as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Registered investment companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:FairValueMeasurementsRetirementBenefitPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-590" decimals="-6" id="f-2233" unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-591" decimals="-6" id="f-2234" unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-592" decimals="-6" id="f-2235" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-593" decimals="-6" id="f-2236" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-594" decimals="-6" id="f-2237" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-595" decimals="-6" id="f-2238" unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-596" decimals="-6" id="f-2239" unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-597" decimals="-6" id="f-2240" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-598" decimals="-6" id="f-2241" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-599" decimals="-6" id="f-2242" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-600" decimals="-6" id="f-2243" unitRef="usd">1011000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-601" decimals="-6" id="f-2244" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-602" decimals="-6" id="f-2245" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-603" decimals="-6" id="f-2246" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-604" decimals="-6" id="f-2247" unitRef="usd">1011000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-605" decimals="-6" id="f-2248" unitRef="usd">1296000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-606" decimals="-6" id="f-2249" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-607" decimals="-6" id="f-2250" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-608" decimals="-6" id="f-2251" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-609" decimals="-6" id="f-2252" unitRef="usd">1296000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-610" decimals="-6" id="f-2253" unitRef="usd">1142000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-611" decimals="-6" id="f-2254" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-612" decimals="-6" id="f-2255" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-613" decimals="-6" id="f-2256" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-614" decimals="-6" id="f-2257" unitRef="usd">1142000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-543" decimals="-6" id="f-2258" unitRef="usd">3610000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-615" decimals="-6" id="f-2259" unitRef="usd">162000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-616" decimals="-6" id="f-2260" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-617" decimals="-6" id="f-2261" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-618" decimals="-6" id="f-2262" unitRef="usd">3448000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-619" decimals="-6" id="f-2263" unitRef="usd">80000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-620" decimals="-6" id="f-2264" unitRef="usd">80000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-621" decimals="-6" id="f-2265" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-622" decimals="-6" id="f-2266" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-623" decimals="-6" id="f-2267" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-624" decimals="-6" id="f-2268" unitRef="usd">106000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-625" decimals="-6" id="f-2269" unitRef="usd">106000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-626" decimals="-6" id="f-2270" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-627" decimals="-6" id="f-2271" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-628" decimals="-6" id="f-2272" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-629" decimals="-6" id="f-2273" unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-630" decimals="-6" id="f-2274" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-631" decimals="-6" id="f-2275" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-632" decimals="-6" id="f-2276" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-633" decimals="-6" id="f-2277" unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-634" decimals="-6" id="f-2278" unitRef="usd">1273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-635" decimals="-6" id="f-2279" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-636" decimals="-6" id="f-2280" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-637" decimals="-6" id="f-2281" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-638" decimals="-6" id="f-2282" unitRef="usd">1273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-639" decimals="-6" id="f-2283" unitRef="usd">1151000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-640" decimals="-6" id="f-2284" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-641" decimals="-6" id="f-2285" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-642" decimals="-6" id="f-2286" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-643" decimals="-6" id="f-2287" unitRef="usd">1151000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-544" decimals="-6" id="f-2288" unitRef="usd">3551000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-644" decimals="-6" id="f-2289" unitRef="usd">186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-645" decimals="-6" id="f-2290" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-646" decimals="-6" id="f-2291" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-647" decimals="-6" id="f-2292" unitRef="usd">3366000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-648" decimals="-6" id="f-2293" unitRef="usd">1775000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-649" decimals="-6" id="f-2294" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-650" decimals="-6" id="f-2295" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-651" decimals="-6" id="f-2296" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-652" decimals="-6" id="f-2297" unitRef="usd">1775000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-653" decimals="-6" id="f-2298" unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-654" decimals="-6" id="f-2299" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-655" decimals="-6" id="f-2300" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-656" decimals="-6" id="f-2301" unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-657" decimals="-6" id="f-2302" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-545" decimals="-6" id="f-2303" unitRef="usd">1823000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-658" decimals="-6" id="f-2304" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-659" decimals="-6" id="f-2305" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-660" decimals="-6" id="f-2306" unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-661" decimals="-6" id="f-2307" unitRef="usd">1775000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-662" decimals="-6" id="f-2308" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-663" decimals="-6" id="f-2309" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-664" decimals="-6" id="f-2310" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-665" decimals="-6" id="f-2311" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-666" decimals="-6" id="f-2312" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-667" decimals="-6" id="f-2313" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-668" decimals="-6" id="f-2314" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-669" decimals="-6" id="f-2315" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-670" decimals="-6" id="f-2316" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-671" decimals="-6" id="f-2317" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-546" decimals="-6" id="f-2318" unitRef="usd">1659000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-672" decimals="-6" id="f-2319" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-673" decimals="-6" id="f-2320" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-674" decimals="-6" id="f-2321" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-675" decimals="-6" id="f-2322" unitRef="usd">1617000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-660" decimals="-6" id="f-2323" unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-674" decimals="-6" id="f-2324" unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-549" decimals="-6" id="f-2325" unitRef="usd">31000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-551" decimals="-6" id="f-2326" unitRef="usd">45000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-543" decimals="-6" id="f-2327" unitRef="usd">29000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-545" decimals="-6" id="f-2328" unitRef="usd">55000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="c-1" id="f-2329">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Retiree benefit payments, which reflect expected future service, are anticipated to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.033%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031 &#x2013; 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-543" decimals="-6" id="f-2330" unitRef="usd">192000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-545" decimals="-6" id="f-2331" unitRef="usd">77000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-543" decimals="-6" id="f-2332" unitRef="usd">201000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-545" decimals="-6" id="f-2333" unitRef="usd">71000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-543" decimals="-6" id="f-2334" unitRef="usd">212000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-545" decimals="-6" id="f-2335" unitRef="usd">76000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-543" decimals="-6" id="f-2336" unitRef="usd">219000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-545" decimals="-6" id="f-2337" unitRef="usd">81000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-543" decimals="-6" id="f-2338" unitRef="usd">227000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-545" decimals="-6" id="f-2339" unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-543" decimals="-6" id="f-2340" unitRef="usd">1191000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-545" decimals="-6" id="f-2341" unitRef="usd">483000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-676" decimals="-6" id="f-2342" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-677" decimals="-6" id="f-2343" unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-678" decimals="-6" id="f-2344" unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-679" decimals="-6" id="f-2345" unitRef="usd">231000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-680" decimals="-6" id="f-2346" unitRef="usd">235000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-679" decimals="-6" id="f-2347" unitRef="usd">303000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-680" decimals="-6" id="f-2348" unitRef="usd">308000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-6" id="f-2349" unitRef="usd">478000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-25" decimals="-6" id="f-2350" unitRef="usd">471000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-26" decimals="-6" id="f-2351" unitRef="usd">390000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-2352">Leases &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;typically do not provide an implicit rate, the Company&#x2019;s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the leases that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for fiscal year 2025, 2024, and 2023 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases were not material to the consolidated financial statements at April&#160;25, 2025 or April&#160;26, 2024 or for fiscal year 2025, 2024 and 2023. Finance lease right-of-use assets are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;propert&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;y, plant, and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and finance lease liabilities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;current debt obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;25, 2025 and April&#160;26, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2354"&gt;&lt;span style="-sec-ix-hidden:f-2355"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2358"&gt;&lt;span style="-sec-ix-hidden:f-2359"&gt;Other accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2362"&gt;&lt;span style="-sec-ix-hidden:f-2363"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;25, 2025 and April&#160;26, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2025, 2024, and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's operating leases at April&#160;25, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total expected lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income and the Company's net investments in sales-type leases are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets. Lessor income for fiscal year 2025, 2024, and 2023 and the related assets and lease maturities at April&#160;25, 2025 and April&#160;26, 2024 were not material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mdt:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-2353">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at April&#160;25, 2025 and April&#160;26, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2354"&gt;&lt;span style="-sec-ix-hidden:f-2355"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2358"&gt;&lt;span style="-sec-ix-hidden:f-2359"&gt;Other accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2362"&gt;&lt;span style="-sec-ix-hidden:f-2363"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mdt:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-24" decimals="-6" id="f-2356" unitRef="usd">1100000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-27" decimals="-6" id="f-2357" unitRef="usd">1012000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-24" decimals="-6" id="f-2360" unitRef="usd">192000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-27" decimals="-6" id="f-2361" unitRef="usd">183000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-24" decimals="-6" id="f-2364" unitRef="usd">918000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-27" decimals="-6" id="f-2365" unitRef="usd">840000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-2366">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at April&#160;25, 2025 and April&#160;26, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2025, 2024, and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for fiscal year 2025, 2024, and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-24" id="f-2367">P8Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-27" id="f-2368">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-24" decimals="3" id="f-2369" unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-27" decimals="3" id="f-2370" unitRef="number">0.034</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-6" id="f-2371" unitRef="usd">232000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-25" decimals="-6" id="f-2372" unitRef="usd">232000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-26" decimals="-6" id="f-2373" unitRef="usd">211000000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-6" id="f-2374" unitRef="usd">66000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-25" decimals="-6" id="f-2375" unitRef="usd">41000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-26" decimals="-6" id="f-2376" unitRef="usd">62000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-6" id="f-2377" unitRef="usd">298000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-25" decimals="-6" id="f-2378" unitRef="usd">273000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-26" decimals="-6" id="f-2379" unitRef="usd">273000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-6" id="f-2380" unitRef="usd">233000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-25" decimals="-6" id="f-2381" unitRef="usd">232000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-26" decimals="-6" id="f-2382" unitRef="usd">210000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-2383" unitRef="usd">281000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-25" decimals="-6" id="f-2384" unitRef="usd">220000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-26" decimals="-6" id="f-2385" unitRef="usd">417000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-2386">&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's operating leases at April&#160;25, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:16pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total expected lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-24" decimals="-6" id="f-2387" unitRef="usd">218000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-24" decimals="-6" id="f-2388" unitRef="usd">199000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-24" decimals="-6" id="f-2389" unitRef="usd">155000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-24" decimals="-6" id="f-2390" unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-24" decimals="-6" id="f-2391" unitRef="usd">100000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-24" decimals="-6" id="f-2392" unitRef="usd">503000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-24" decimals="-6" id="f-2393" unitRef="usd">1294000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-24" decimals="-6" id="f-2394" unitRef="usd">185000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-24" decimals="-6" id="f-2395" unitRef="usd">1109000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-2396">Accumulated Other Comprehensive Loss &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Loss) Gain on Investment Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in Retirement Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain (Loss) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was an expense of $25 million, an expense of $4 million, and a benefit of $21&#160;million, respectively. During fiscal years 2025, 2024, and 2023, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $3 million, $5&#160;million and $9&#160;million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal years 2025, 2024, and 2023, the income tax on cumulative translation adjustment was an expense of $4 million, an expense of $3 million, and a benefit of $5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2025, the income tax on net investment hedges was a benefit of $47 million. During fiscal years 2024 and 2023, there were no tax impacts on net investment hedges. Refer to Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 resulted in a benefit of $32 million, an expense of $79&#160;million, and an expense of $6&#160;million, respectively. During fiscal years 2025, 2024, and 2023, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of&#160;$3 million, $2&#160;million, and $9&#160;million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-operating income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Refer to Note 15 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during fiscal years 2025, 2024, and 2023 was&#160;a benefit of $33 million, an expense&#160;$103&#160;million, and an expense of $56&#160;million, respectively. Amounts reclassified from AOCI related to cash flow hedges included income taxes of $52 million, $66&#160;million, and $133&#160;million for fiscal years 2025, 2024, and 2023, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; other operating (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cost of products sold. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-2397">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized (Loss) Gain on Investment Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in Retirement Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain (Loss) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-681" decimals="-6" id="f-2398" unitRef="usd">-209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-682" decimals="-6" id="f-2399" unitRef="usd">-2599000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-683" decimals="-6" id="f-2400" unitRef="usd">841000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-684" decimals="-6" id="f-2401" unitRef="usd">-773000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-685" decimals="-6" id="f-2402" unitRef="usd">474000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-2403" unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-686" decimals="-6" id="f-2404" unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-687" decimals="-6" id="f-2405" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-688" decimals="-6" id="f-2406" unitRef="usd">-596000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-689" decimals="-6" id="f-2407" unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-690" decimals="-6" id="f-2408" unitRef="usd">184000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-38" decimals="-6" id="f-2409" unitRef="usd">-704000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-686" decimals="-6" id="f-2410" unitRef="usd">-29000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-687" decimals="-6" id="f-2411" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-688" decimals="-6" id="f-2412" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-689" decimals="-6" id="f-2413" unitRef="usd">-6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-690" decimals="-6" id="f-2414" unitRef="usd">565000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-38" decimals="-6" id="f-2415" unitRef="usd">530000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-686" decimals="-6" id="f-2416" unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-687" decimals="-6" id="f-2417" unitRef="usd">-240000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-688" decimals="-6" id="f-2418" unitRef="usd">-596000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-689" decimals="-6" id="f-2419" unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-690" decimals="-6" id="f-2420" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-6" id="f-2421" unitRef="usd">-1234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-691" decimals="-6" id="f-2422" unitRef="usd">-258000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-692" decimals="-6" id="f-2423" unitRef="usd">-2839000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-693" decimals="-6" id="f-2424" unitRef="usd">245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-694" decimals="-6" id="f-2425" unitRef="usd">-741000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-695" decimals="-6" id="f-2426" unitRef="usd">93000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-2427" unitRef="usd">-3499000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-696" decimals="-6" id="f-2428" unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-697" decimals="-6" id="f-2429" unitRef="usd">-846000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-698" decimals="-6" id="f-2430" unitRef="usd">633000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-699" decimals="-6" id="f-2431" unitRef="usd">205000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-700" decimals="-6" id="f-2432" unitRef="usd">438000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-51" decimals="-6" id="f-2433" unitRef="usd">457000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-696" decimals="-6" id="f-2434" unitRef="usd">-17000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-697" decimals="-6" id="f-2435" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-698" decimals="-6" id="f-2436" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-699" decimals="-6" id="f-2437" unitRef="usd">-7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-700" decimals="-6" id="f-2438" unitRef="usd">302000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-51" decimals="-6" id="f-2439" unitRef="usd">278000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-696" decimals="-6" id="f-2440" unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-697" decimals="-6" id="f-2441" unitRef="usd">-846000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-698" decimals="-6" id="f-2442" unitRef="usd">633000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-699" decimals="-6" id="f-2443" unitRef="usd">212000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-700" decimals="-6" id="f-2444" unitRef="usd">136000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-51" decimals="-6" id="f-2445" unitRef="usd">180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-701" decimals="-6" id="f-2446" unitRef="usd">-212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-702" decimals="-6" id="f-2447" unitRef="usd">-3686000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-703" decimals="-6" id="f-2448" unitRef="usd">878000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-704" decimals="-6" id="f-2449" unitRef="usd">-529000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-705" decimals="-6" id="f-2450" unitRef="usd">229000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-6" id="f-2451" unitRef="usd">-3318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-706" decimals="-6" id="f-2452" unitRef="usd">135000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-707" decimals="-6" id="f-2453" unitRef="usd">851000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-708" decimals="-6" id="f-2454" unitRef="usd">-1474000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-709" decimals="-6" id="f-2455" unitRef="usd">-116000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-710" decimals="-6" id="f-2456" unitRef="usd">-204000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-63" decimals="-6" id="f-2457" unitRef="usd">-808000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-706" decimals="-6" id="f-2458" unitRef="usd">-14000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-707" decimals="-6" id="f-2459" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-708" decimals="-6" id="f-2460" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-709" decimals="-6" id="f-2461" unitRef="usd">-5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-710" decimals="-6" id="f-2462" unitRef="usd">177000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-63" decimals="-6" id="f-2463" unitRef="usd">158000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-706" decimals="-6" id="f-2464" unitRef="usd">149000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-707" decimals="-6" id="f-2465" unitRef="usd">851000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-708" decimals="-6" id="f-2466" unitRef="usd">-1474000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-709" decimals="-6" id="f-2467" unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-710" decimals="-6" id="f-2468" unitRef="usd">-381000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-63" decimals="-6" id="f-2469" unitRef="usd">-966000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-711" decimals="-6" id="f-2470" unitRef="usd">-63000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-712" decimals="-6" id="f-2471" unitRef="usd">-2835000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-713" decimals="-6" id="f-2472" unitRef="usd">-597000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-714" decimals="-6" id="f-2473" unitRef="usd">-640000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-715" decimals="-6" id="f-2474" unitRef="usd">-149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-6" id="f-2475" unitRef="usd">-4284000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-706" decimals="-6" id="f-2476" unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-696" decimals="-6" id="f-2477" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-686" decimals="-6" id="f-2478" unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-706" decimals="-6" id="f-2479" unitRef="usd">-3000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-696" decimals="-6" id="f-2480" unitRef="usd">5000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-686" decimals="-6" id="f-2481" unitRef="usd">9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-707" decimals="-6" id="f-2482" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-697" decimals="-6" id="f-2483" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-687" decimals="-6" id="f-2484" unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-708" decimals="-6" id="f-2485" unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-688" decimals="INF" id="f-2486" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-698" decimals="INF" id="f-2487" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-709" decimals="-6" id="f-2488" unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-699" decimals="-6" id="f-2489" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-689" decimals="-6" id="f-2490" unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-709" decimals="-6" id="f-2491" unitRef="usd">3000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-699" decimals="-6" id="f-2492" unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-689" decimals="-6" id="f-2493" unitRef="usd">9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-710" decimals="-6" id="f-2494" unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-700" decimals="-6" id="f-2495" unitRef="usd">103000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-690" decimals="-6" id="f-2496" unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-710" decimals="-6" id="f-2497" unitRef="usd">52000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-700" decimals="-6" id="f-2498" unitRef="usd">66000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-690" decimals="-6" id="f-2499" unitRef="usd">133000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-2500">Commitments and Contingencies &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder-related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries. With respect to intellectual property disputes, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. With respect to commercial disputes, antitrust and competition issues have gained increased prominence, enforcement and private litigation have increased globally, and the Company is involved in or at risk for antitrust litigation, investigations or enforcement actions regarding a range of commercial activities, including challenges to mergers and acquisition transactions, joint ventures, co-development or co-marketing arrangements, contracting practices, distribution agreements and employment agreements. The outcomes of legal actions are not within the Company&#x2019;s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek significant monetary damages and/or royalty payments, as well as other civil or criminal remedies (including injunctions barring or restricting the sale of products that are the subject of the proceeding, placing restrictions on competitive strategies or practices, or unwinding consummated transactions), any or all of which could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;certain litigation charges, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of income. During fiscal years 2025, 2024, and 2023, the Company recognized $317&#160;million of certain litigation charges, net, $149&#160;million of certain litigation charges, net, and $30&#160;million of certain litigation income, net, respectively. At April&#160;25, 2025 and April&#160;26, 2024, accrued litigation was approximately $0.4&#160;billion and $0.2&#160;billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intellectual Property Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Colibri&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company&#x2019;s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $106&#160;million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hernia Mesh Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of June 11, 2025, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 9,325 individual plaintiffs, and certain plaintiffs&#x2019; law firm&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s have advised the Company that they may file additional cases in the future. Approximately 6,950 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,875 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Diabetes Pump Retainer Ring Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of May 28, 2025, after a number of recent dismissals, there are nine lawsuits filed on behalf of 20 individuals. Plaintiffs&#x2019; firms previously notified the Company that they may file additional lawsuits in the future on behalf of several thousand additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Applied Medical&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation in the U.S. District Court for the Central District of California, alleging that the Company has engaged in anticompetitive and monopolistic conduct relating to its sales of advanced bipolar devices, including under contracts with group purchasing organizations. The Company has substantial legal and factual defenses and intends to defend itself vigorously. The court recently deferred trial from June 2025 until after it rules on the parties' summary judgment motions. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Anti-Corruption Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in other countries regarding certain activities in different global markets. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Italian Payback&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, &#x201c;payback&#x201d; legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy&#x2019;s medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by $90&#160;million during the three months ended July 26, 2024, as a reduction to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company&#x2019;s liability could differ from the amount currently accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Termination with Blackstone&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 3, the Company is party to various research and development funding arrangements with Blackstone, which are subject to certain termination provisions. During fiscal year 2025, the parties negotiated a contractual dispute resolution under one of the funding arrangements. As a result, the Company recognized certain litigation charges in connection with the resolution. The Company included this accrued litigation charge in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other accrued expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS&#x2019;s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. Oral argument for the Appeal occurred in May 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medtronic, Inc.&#x2019;s fiscal years 2017 through 2023 U.S. federal income tax returns are currently being audited by the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2021. Covidien LP&#x2019;s fiscal year 2023 federal income tax return is currently being audited by the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 13 for additional discussion of income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates&#x2019; products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company&#x2019;s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into standby letters of credit agreements, bank guarantees, and surety bonds with financial institutions to support various performance and other obligations, as well as ongoing tax matters. As of April 25, 2025, the aggregated amount outstanding under these instruments was approximately $0.9&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company&#x2019;s consolidated earnings, financial position, and/or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-1" decimals="-6" id="f-2501" unitRef="usd">317000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-25" decimals="-6" id="f-2502" unitRef="usd">149000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-26" decimals="-6" id="f-2503" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-24" decimals="-8" id="f-2504" unitRef="usd">400000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-27" decimals="-8" id="f-2505" unitRef="usd">200000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-716" decimals="-6" id="f-2506" unitRef="usd">106000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-717"
      decimals="0"
      id="f-2507"
      unitRef="plaintiff">9325</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-718"
      decimals="0"
      id="f-2508"
      unitRef="plaintiff">6950</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-719"
      decimals="0"
      id="f-2509"
      unitRef="plaintiff">500</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-720" decimals="0" id="f-2510" unitRef="claim">1875</us-gaap:LossContingencyPendingClaimsNumber>
    <mdt:LossContingencyLawsuitsNumber
      contextRef="c-720"
      decimals="INF"
      id="f-2511"
      unitRef="lawsuit">10</mdt:LossContingencyLawsuitsNumber>
    <mdt:LossContingencyLawsuitsNumber
      contextRef="c-721"
      decimals="INF"
      id="f-2512"
      unitRef="lawsuit">9</mdt:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-722"
      decimals="INF"
      id="f-2513"
      unitRef="plaintiff">20</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-723" decimals="-6" id="f-2514" unitRef="usd">90000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-24" decimals="-8" id="f-2515" unitRef="usd">900000000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-2516">Segment and Geographic Information &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The chief operating decision maker (CODM) is our Chief Executive Officer (CEO) and has chosen to organize the entity based upon therapy solutions provided by each segment. The four reportable segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Cardiovascular Portfolio segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products and services from which the Medical Surgical Portfolio segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, lungs, pelvic region, obesity, and other preventable complications. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary products from which the Diabetes Operating Unit segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM measures and evaluates segment performance and allocates resources based on net sales and segment operating profit. Net sales include end-customer revenues from products developed, manufactured, and distributed by the segments. Significant expense categories include cost of products sold excluding amortization of intangible assets, research and development expense, and selling, general, and administrative expenses. Segment operating profit excludes certain corporate and centralized expenses not allocated to the segments, including interest income and expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other operating (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. The CODM uses segment operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The CODM is not regularly provided with expenditures for additions to long-lived assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Operating Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;span id="i8b8636ab5d4d4004bd25d54153027b58_1-2-1-1-411492"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments to the Medtronic Foundation and Medtronic LABS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets and Depreciation Expense &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April&#160;25, 2025 and April&#160;26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other countries, excluding Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single customer represented over 10 percent of the Company&#x2019;s consolidated net sales in fiscal years 2025, 2024, or 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-2517"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-2518"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-2519">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Operating Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;span id="i8b8636ab5d4d4004bd25d54153027b58_1-2-1-1-411492"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold, excluding amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reportable segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit / (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-operating income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centralized distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and associated costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and divestiture-related items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certain litigation charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical device regulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments to the Medtronic Foundation and Medtronic LABS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements.</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-724" decimals="-6" id="f-2520" unitRef="usd">12481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-725" decimals="-6" id="f-2521" unitRef="usd">9846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-726" decimals="-6" id="f-2522" unitRef="usd">8407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-727" decimals="-6" id="f-2523" unitRef="usd">2755000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-728" decimals="-6" id="f-2524" unitRef="usd">33489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-729" decimals="-6" id="f-2525" unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherNonrecurringIncomeExpense contextRef="c-730" decimals="-6" id="f-2526" unitRef="usd">90000000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-2527" unitRef="usd">33537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-724" decimals="-6" id="f-2528" unitRef="usd">3967000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-725" decimals="-6" id="f-2529" unitRef="usd">2762000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-726" decimals="-6" id="f-2530" unitRef="usd">3142000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-727" decimals="-6" id="f-2531" unitRef="usd">1117000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-728" decimals="-6" id="f-2532" unitRef="usd">10987000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-724" decimals="-6" id="f-2533" unitRef="usd">931000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-725" decimals="-6" id="f-2534" unitRef="usd">542000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-726" decimals="-6" id="f-2535" unitRef="usd">606000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-727" decimals="-6" id="f-2536" unitRef="usd">400000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-728" decimals="-6" id="f-2537" unitRef="usd">2478000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-724" decimals="-6" id="f-2538" unitRef="usd">2824000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-725" decimals="-6" id="f-2539" unitRef="usd">2327000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-726" decimals="-6" id="f-2540" unitRef="usd">1600000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-727" decimals="-6" id="f-2541" unitRef="usd">791000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-728" decimals="-6" id="f-2542" unitRef="usd">7541000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-724" decimals="-6" id="f-2543" unitRef="usd">-41000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-725" decimals="-6" id="f-2544" unitRef="usd">31000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-726" decimals="-6" id="f-2545" unitRef="usd">18000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-727" decimals="-6" id="f-2546" unitRef="usd">-43000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-728" decimals="-6" id="f-2547" unitRef="usd">-36000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingIncomeLoss contextRef="c-724" decimals="-6" id="f-2548" unitRef="usd">4801000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-725" decimals="-6" id="f-2549" unitRef="usd">4183000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-726" decimals="-6" id="f-2550" unitRef="usd">3042000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-727" decimals="-6" id="f-2551" unitRef="usd">491000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-728" decimals="-6" id="f-2552" unitRef="usd">12518000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-729" decimals="-6" id="f-2553" unitRef="usd">49000000</us-gaap:OperatingIncomeLoss>
    <mdt:CorporateOverhead contextRef="c-730" decimals="-6" id="f-2554" unitRef="usd">1837000000</mdt:CorporateOverhead>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-730" decimals="-6" id="f-2555" unitRef="usd">-729000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-730" decimals="-6" id="f-2556" unitRef="usd">402000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-730" decimals="-6" id="f-2557" unitRef="usd">1807000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-730" decimals="-6" id="f-2558" unitRef="usd">429000000</us-gaap:ShareBasedCompensation>
    <mdt:CentralizedDistributionCosts contextRef="c-730" decimals="-6" id="f-2559" unitRef="usd">1650000000</mdt:CentralizedDistributionCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-730" decimals="-6" id="f-2560" unitRef="usd">3000000</mdt:ForeignCurrencyCosts>
    <us-gaap:RestructuringCharges contextRef="c-730" decimals="-6" id="f-2561" unitRef="usd">303000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-730" decimals="-6" id="f-2562" unitRef="usd">124000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-730" decimals="-6" id="f-2563" unitRef="usd">317000000</us-gaap:LossContingencyAccrualProvision>
    <mdt:MedicalDeviceRegulations contextRef="c-730" decimals="-6" id="f-2564" unitRef="usd">52000000</mdt:MedicalDeviceRegulations>
    <us-gaap:OtherNonrecurringIncomeExpense contextRef="c-730" decimals="-6" id="f-2565" unitRef="usd">90000000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-2566" unitRef="usd">5628000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-731" decimals="-6" id="f-2567" unitRef="usd">11831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-732" decimals="-6" id="f-2568" unitRef="usd">9406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-733" decimals="-6" id="f-2569" unitRef="usd">8417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-734" decimals="-6" id="f-2570" unitRef="usd">2488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-735" decimals="-6" id="f-2571" unitRef="usd">32142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-736" decimals="-6" id="f-2572" unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-2573" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-731" decimals="-6" id="f-2574" unitRef="usd">3731000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-732" decimals="-6" id="f-2575" unitRef="usd">2634000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-733" decimals="-6" id="f-2576" unitRef="usd">3057000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-734" decimals="-6" id="f-2577" unitRef="usd">963000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-735" decimals="-6" id="f-2578" unitRef="usd">10385000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-731" decimals="-6" id="f-2579" unitRef="usd">906000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-732" decimals="-6" id="f-2580" unitRef="usd">556000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-733" decimals="-6" id="f-2581" unitRef="usd">587000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-734" decimals="-6" id="f-2582" unitRef="usd">402000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-735" decimals="-6" id="f-2583" unitRef="usd">2452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-731" decimals="-6" id="f-2584" unitRef="usd">2748000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-732" decimals="-6" id="f-2585" unitRef="usd">2245000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-733" decimals="-6" id="f-2586" unitRef="usd">1594000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-734" decimals="-6" id="f-2587" unitRef="usd">778000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-735" decimals="-6" id="f-2588" unitRef="usd">7365000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-731" decimals="-6" id="f-2589" unitRef="usd">-28000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-732" decimals="-6" id="f-2590" unitRef="usd">30000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-733" decimals="-6" id="f-2591" unitRef="usd">9000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-734" decimals="-6" id="f-2592" unitRef="usd">-49000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-735" decimals="-6" id="f-2593" unitRef="usd">-39000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingIncomeLoss contextRef="c-731" decimals="-6" id="f-2594" unitRef="usd">4474000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-732" decimals="-6" id="f-2595" unitRef="usd">3940000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-733" decimals="-6" id="f-2596" unitRef="usd">3170000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-734" decimals="-6" id="f-2597" unitRef="usd">394000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-735" decimals="-6" id="f-2598" unitRef="usd">11979000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-736" decimals="-6" id="f-2599" unitRef="usd">10000000</us-gaap:OperatingIncomeLoss>
    <mdt:CorporateOverhead contextRef="c-737" decimals="-6" id="f-2600" unitRef="usd">1784000000</mdt:CorporateOverhead>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-737" decimals="-6" id="f-2601" unitRef="usd">-719000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-737" decimals="-6" id="f-2602" unitRef="usd">412000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-737" decimals="-6" id="f-2603" unitRef="usd">1693000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-737" decimals="-6" id="f-2604" unitRef="usd">393000000</us-gaap:ShareBasedCompensation>
    <mdt:CentralizedDistributionCosts contextRef="c-737" decimals="-6" id="f-2605" unitRef="usd">1609000000</mdt:CentralizedDistributionCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-737" decimals="-6" id="f-2606" unitRef="usd">-68000000</mdt:ForeignCurrencyCosts>
    <us-gaap:RestructuringCharges contextRef="c-737" decimals="-6" id="f-2607" unitRef="usd">389000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-737" decimals="-6" id="f-2608" unitRef="usd">777000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-737" decimals="-6" id="f-2609" unitRef="usd">149000000</us-gaap:LossContingencyAccrualProvision>
    <mdt:MedicalDeviceRegulations contextRef="c-737" decimals="-6" id="f-2610" unitRef="usd">119000000</mdt:MedicalDeviceRegulations>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-2611" unitRef="usd">4837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-738" decimals="-6" id="f-2612" unitRef="usd">11522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-739" decimals="-6" id="f-2613" unitRef="usd">8959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-740" decimals="-6" id="f-2614" unitRef="usd">7989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-741" decimals="-6" id="f-2615" unitRef="usd">2262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-742" decimals="-6" id="f-2616" unitRef="usd">30731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-743" decimals="-6" id="f-2617" unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-2618" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-738" decimals="-6" id="f-2619" unitRef="usd">3562000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-739" decimals="-6" id="f-2620" unitRef="usd">2411000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-740" decimals="-6" id="f-2621" unitRef="usd">2859000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-741" decimals="-6" id="f-2622" unitRef="usd">871000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-742" decimals="-6" id="f-2623" unitRef="usd">9704000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-738" decimals="-6" id="f-2624" unitRef="usd">815000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-739" decimals="-6" id="f-2625" unitRef="usd">573000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-740" decimals="-6" id="f-2626" unitRef="usd">543000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-741" decimals="-6" id="f-2627" unitRef="usd">392000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-742" decimals="-6" id="f-2628" unitRef="usd">2323000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-738" decimals="-6" id="f-2629" unitRef="usd">2653000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-739" decimals="-6" id="f-2630" unitRef="usd">2189000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-740" decimals="-6" id="f-2631" unitRef="usd">1549000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-741" decimals="-6" id="f-2632" unitRef="usd">705000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-742" decimals="-6" id="f-2633" unitRef="usd">7096000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-738" decimals="-6" id="f-2634" unitRef="usd">-31000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-739" decimals="-6" id="f-2635" unitRef="usd">74000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-740" decimals="-6" id="f-2636" unitRef="usd">-10000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-741" decimals="-6" id="f-2637" unitRef="usd">-90000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-742" decimals="-6" id="f-2638" unitRef="usd">-57000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingIncomeLoss contextRef="c-738" decimals="-6" id="f-2639" unitRef="usd">4522000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-739" decimals="-6" id="f-2640" unitRef="usd">3712000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-740" decimals="-6" id="f-2641" unitRef="usd">3048000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-741" decimals="-6" id="f-2642" unitRef="usd">383000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-742" decimals="-6" id="f-2643" unitRef="usd">11664000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-743" decimals="-6" id="f-2644" unitRef="usd">-89000000</us-gaap:OperatingIncomeLoss>
    <mdt:CorporateOverhead contextRef="c-744" decimals="-6" id="f-2645" unitRef="usd">1763000000</mdt:CorporateOverhead>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-744" decimals="-6" id="f-2646" unitRef="usd">-636000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-744" decimals="-6" id="f-2647" unitRef="usd">515000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-744" decimals="-6" id="f-2648" unitRef="usd">1698000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-744" decimals="-6" id="f-2649" unitRef="usd">355000000</us-gaap:ShareBasedCompensation>
    <mdt:CentralizedDistributionCosts contextRef="c-744" decimals="-6" id="f-2650" unitRef="usd">1558000000</mdt:CentralizedDistributionCosts>
    <mdt:ForeignCurrencyCosts contextRef="c-744" decimals="-6" id="f-2651" unitRef="usd">-465000000</mdt:ForeignCurrencyCosts>
    <us-gaap:RestructuringCharges contextRef="c-744" decimals="-6" id="f-2652" unitRef="usd">647000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-744" decimals="-6" id="f-2653" unitRef="usd">345000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-744" decimals="-6" id="f-2654" unitRef="usd">-30000000</us-gaap:LossContingencyAccrualProvision>
    <mdt:MedicalDeviceRegulations contextRef="c-744" decimals="-6" id="f-2655" unitRef="usd">150000000</mdt:MedicalDeviceRegulations>
    <mdt:CommitmentsToTheMedtronicFoundationAndMedtronicLABS contextRef="c-744" decimals="-6" id="f-2656" unitRef="usd">70000000</mdt:CommitmentsToTheMedtronicFoundationAndMedtronicLABS>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-2657" unitRef="usd">5364000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock contextRef="c-1" id="f-2658">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Assets and Depreciation Expense &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Surgical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets contextRef="c-745" decimals="-6" id="f-2659" unitRef="usd">16548000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-746" decimals="-6" id="f-2660" unitRef="usd">16128000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-724" decimals="-6" id="f-2661" unitRef="usd">225000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-731" decimals="-6" id="f-2662" unitRef="usd">199000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-738" decimals="-6" id="f-2663" unitRef="usd">209000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-747" decimals="-6" id="f-2664" unitRef="usd">18476000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-748" decimals="-6" id="f-2665" unitRef="usd">18270000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-725" decimals="-6" id="f-2666" unitRef="usd">282000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-732" decimals="-6" id="f-2667" unitRef="usd">252000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-739" decimals="-6" id="f-2668" unitRef="usd">267000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-749" decimals="-6" id="f-2669" unitRef="usd">33317000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-750" decimals="-6" id="f-2670" unitRef="usd">33586000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-726" decimals="-6" id="f-2671" unitRef="usd">205000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-733" decimals="-6" id="f-2672" unitRef="usd">194000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-740" decimals="-6" id="f-2673" unitRef="usd">203000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-751" decimals="-6" id="f-2674" unitRef="usd">4136000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-752" decimals="-6" id="f-2675" unitRef="usd">3996000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-727" decimals="-6" id="f-2676" unitRef="usd">112000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-734" decimals="-6" id="f-2677" unitRef="usd">94000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-741" decimals="-6" id="f-2678" unitRef="usd">80000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-753" decimals="-6" id="f-2679" unitRef="usd">72476000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-754" decimals="-6" id="f-2680" unitRef="usd">71980000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-728" decimals="-6" id="f-2681" unitRef="usd">823000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-735" decimals="-6" id="f-2682" unitRef="usd">739000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-742" decimals="-6" id="f-2683" unitRef="usd">759000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-755" decimals="-6" id="f-2684" unitRef="usd">296000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-756" decimals="-6" id="f-2685" unitRef="usd">547000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-116" decimals="-6" id="f-2686" unitRef="usd">1000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-117" decimals="-6" id="f-2687" unitRef="usd">0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-118" decimals="-6" id="f-2688" unitRef="usd">2000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-757" decimals="-6" id="f-2689" unitRef="usd">18906000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-758" decimals="-6" id="f-2690" unitRef="usd">17455000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-759" decimals="-6" id="f-2691" unitRef="usd">229000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-760" decimals="-6" id="f-2692" unitRef="usd">215000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-761" decimals="-6" id="f-2693" unitRef="usd">238000000</us-gaap:Depreciation>
    <us-gaap:Assets contextRef="c-24" decimals="-6" id="f-2694" unitRef="usd">91680000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-27" decimals="-6" id="f-2695" unitRef="usd">89981000000</us-gaap:Assets>
    <us-gaap:Depreciation contextRef="c-1" decimals="-6" id="f-2696" unitRef="usd">1054000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-6" id="f-2697" unitRef="usd">954000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-6" id="f-2698" unitRef="usd">999000000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c-1" id="f-2699">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April&#160;25, 2025 and April&#160;26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.766%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other countries, excluding Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-762" decimals="-6" id="f-2700" unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-763" decimals="-6" id="f-2701" unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-764" decimals="-6" id="f-2702" unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-765" decimals="-6" id="f-2703" unitRef="usd">291000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-766" decimals="-6" id="f-2704" unitRef="usd">252000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="-6" id="f-2705" unitRef="usd">17171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="-6" id="f-2706" unitRef="usd">16562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-6" id="f-2707" unitRef="usd">16373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-767" decimals="-6" id="f-2708" unitRef="usd">5133000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-768" decimals="-6" id="f-2709" unitRef="usd">4593000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-769" decimals="-6" id="f-2710" unitRef="usd">16250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-770" decimals="-6" id="f-2711" unitRef="usd">15689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-771" decimals="-6" id="f-2712" unitRef="usd">14756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-772" decimals="-6" id="f-2713" unitRef="usd">1414000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-773" decimals="-6" id="f-2714" unitRef="usd">1286000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-774" decimals="-6" id="f-2715" unitRef="usd">33421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-775" decimals="-6" id="f-2716" unitRef="usd">32251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-776" decimals="-6" id="f-2717" unitRef="usd">31129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-777" decimals="-6" id="f-2718" unitRef="usd">6547000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-778" decimals="-6" id="f-2719" unitRef="usd">5879000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-2720" unitRef="usd">33537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-6" id="f-2721" unitRef="usd">32364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-6" id="f-2722" unitRef="usd">31227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-24" decimals="-6" id="f-2723" unitRef="usd">6837000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-6" id="f-2724" unitRef="usd">6131000000</us-gaap:PropertyPlantAndEquipmentNet>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-779" id="f-2726">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-779" id="f-2727">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-779" id="f-2728">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-779" id="f-2729">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-2730">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-2731">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MEDTRONIC PLC AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II &#x2013; VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges to Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charges to Other Accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Changes (Debit) Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for doubtful accounts and credit losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax valuation allowance: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 25, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 26, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiscal year ended April 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.066%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:92.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(a) Primarily consists of uncollectible accounts written off, less recoveries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(b) Reflects the impact from acquisitions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c) Primarily reflects carryover attribute utilization and expiration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(d) Primarily reflects the effects of currency fluctuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(e) Primarily reflects the impacts from tax rate changes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-780" decimals="-6" id="f-2732" unitRef="usd">173000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-781" decimals="-6" id="f-2733" unitRef="usd">123000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-781" decimals="-6" id="f-2734" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-781" decimals="-6" id="f-2735" unitRef="usd">97000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-782" decimals="-6" id="f-2736" unitRef="usd">199000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-783" decimals="-6" id="f-2737" unitRef="usd">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-784" decimals="-6" id="f-2738" unitRef="usd">90000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-784" decimals="-6" id="f-2739" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-784" decimals="-6" id="f-2740" unitRef="usd">93000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-780" decimals="-6" id="f-2741" unitRef="usd">173000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-785" decimals="-6" id="f-2742" unitRef="usd">230000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-786" decimals="-6" id="f-2743" unitRef="usd">73000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-786" decimals="-6" id="f-2744" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-786" decimals="-6" id="f-2745" unitRef="usd">127000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-783" decimals="-6" id="f-2746" unitRef="usd">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-787" decimals="-6" id="f-2747" unitRef="usd">13271000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-788" decimals="-6" id="f-2748" unitRef="usd">151000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-788" decimals="-6" id="f-2749" unitRef="usd">9000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-788" decimals="-6" id="f-2750" unitRef="usd">195000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-789" decimals="-6" id="f-2751" unitRef="usd">12668000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-788" decimals="-6" id="f-2752" unitRef="usd">567000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-790" decimals="-6" id="f-2753" unitRef="usd">11311000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-791" decimals="-6" id="f-2754" unitRef="usd">1522000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-791" decimals="-6" id="f-2755" unitRef="usd">3000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-791" decimals="-6" id="f-2756" unitRef="usd">108000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-787" decimals="-6" id="f-2757" unitRef="usd">13271000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments contextRef="c-791" decimals="-6" id="f-2758" unitRef="usd">545000000</mdt:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToAdjustments>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet contextRef="c-791" decimals="-6" id="f-2759" unitRef="usd">-2000000</mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-792" decimals="-6" id="f-2760" unitRef="usd">6583000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-793" decimals="-6" id="f-2761" unitRef="usd">4779000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-793" decimals="-6" id="f-2762" unitRef="usd">39000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-793" decimals="-6" id="f-2763" unitRef="usd">63000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-790" decimals="-6" id="f-2764" unitRef="usd">11311000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet contextRef="c-793" decimals="-6" id="f-2765" unitRef="usd">1000000</mdt:SECSchedule1209ValuationAllowancesAndReservesChargesToOtherAccountsNet>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-793" decimals="-6" id="f-2766" unitRef="usd">27000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
